-DOCSTART- -X- -X- O

Naloxone	NN	B-NP	O
reverses	VBZ	B-VP	O
the	DT	B-NP	O
antihypertensive	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
unanesthetized	JJ	B-NP	O
,	,	I-NP	O
spontaneously	RB	I-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
intravenous	JJ	B-NP	O
clonidine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
inhibited	VBN	I-VP	O
or	CC	I-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
nalozone	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hypotensive	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
alpha	SYM	O	O
-	HYPH	O	O
methyldopa	NN	B-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
partially	RB	I-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
naloxone	NN	B-NP	O
.	.	O	O

Naloxone	NN	B-NP	O
alone	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
either	CC	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
or	CC	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
brain	NN	B-NP	O
membranes	NNS	I-NP	O
from	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
clonidine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
influence	VB	I-VP	O
stereoselective	JJ	B-NP	O
binding	NN	I-NP	O
of	IN	B-PP	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
naloxone	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
nM	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
naloxone	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
influence	VB	I-VP	O
clonidine	NN	B-NP	O
-	HYPH	B-NP	O
suppressible	JJ	I-NP	O
binding	NN	I-NP	O
of	IN	B-PP	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
dihydroergocryptine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
nM	NN	I-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
stimulation	NN	I-NP	O
involve	VBP	B-VP	O
activation	NN	B-NP	O
of	IN	B-PP	O
opiate	JJ	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
naloxone	NN	B-NP	O
and	CC	I-NP	O
clonidine	NN	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
interact	VB	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
receptor	NN	I-NP	O
site	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
observed	VBN	I-NP	O
functional	JJ	I-NP	O
antagonism	NN	I-NP	O
suggests	VBZ	B-VP	O
the	DT	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
endogenous	JJ	I-NP	O
opiate	NN	I-NP	O
by	IN	B-PP	O
clonidine	NN	B-NP	O
or	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
methyldopa	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
possible	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
opiate	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
sympathetic	JJ	B-NP	O
tone	NN	I-NP	O
.	.	O	O

Lidocaine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
asystole	NN	I-NP	I
.	.	O	O

Intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
bolus	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
profound	JJ	B-NP	O
depression	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sinoatrial	JJ	I-NP	O
and	CC	I-NP	O
atrioventricular	JJ	I-NP	O
nodal	JJ	I-NP	O
pacemakers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
apparent	JJ	I-NP	O
associated	VBN	I-NP	O
conditions	NNS	I-NP	O
which	WDT	B-NP	O
might	MD	B-VP	O
have	VB	I-VP	O
predisposed	VBN	I-VP	O
him	PRP	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
bradyarrhythmias	NNS	B-NP	B
;	:	O	O
and	CC	O	O
,	,	O	O
thus	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
probably	RB	I-NP	O
represented	VBN	I-NP	O
a	DT	B-NP	O
true	JJ	I-NP	O
idiosyncrasy	NN	I-NP	O
to	TO	B-PP	O
lidocaine	NN	B-NP	O
.	.	O	O

Suxamethonium	NN	B-NP	O
infusion	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
observed	VBN	B-NP	O
fasciculations	NNS	I-NP	B
.	.	O	O

A	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
response	NN	B-NP	O
study	NN	I-NP	O
.	.	O	O

Suxamethonium	NN	B-NP	O
chloride	NN	I-NP	O
(	(	O	O
Sch	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
i.v.	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
adult	JJ	I-NP	O
males	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
rates	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
s	SYM	B-NP	O
-	SYM	B-ADJP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
s	AFX	O	O
-	HYPH	O	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
either	CC	O	O
when	WRB	B-ADVP	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
muscular	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
tetanic	JJ	B-NP	B
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ulnar	JJ	I-NP	O
nerve	NN	I-NP	O
or	CC	O	O
when	WRB	B-ADVP	O
Sch	NNP	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
was	VBD	B-VP	O
exceeded	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
additional	JJ	I-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
i.v.	JJ	I-NP	O
bolus	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Fasciculations	NNS	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
body	NN	I-NP	O
were	VBD	B-VP	O
scored	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	O	O
summated	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
total	JJ	I-NP	O
fasciculation	NN	I-NP	B
score	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
times	NNS	I-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
fasciculation	NN	I-NP	B
,	,	O	O
twitch	NN	B-NP	B
suppression	NN	I-NP	O
and	CC	O	O
tetanus	NN	B-NP	B
suppression	NN	I-NP	O
were	VBD	B-VP	O
inversely	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
rates	NNS	I-NP	O
.	.	O	O

Fasciculations	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
areas	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
total	JJ	I-NP	O
fasciculation	NN	I-NP	B
score	NN	I-NP	O
were	VBD	B-VP	O
related	VBN	I-VP	O
directly	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
infusion	NN	B-NP	O
.	.	O	O

Total	JJ	B-NP	O
fasciculation	NN	I-NP	B
scores	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
bolus	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
s	AFX	O	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
s	AFX	O	O
-	HYPH	O	O
num	CD	B-NP	O
infusion	NN	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
significantly	RB	I-ADJP	O
different	JJ	I-ADJP	O
.	.	O	O

Galanthamine	NN	B-NP	O
hydrobromide	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
longer	RBR	I-NP	O
acting	VBG	I-NP	O
anticholinesterase	NN	I-NP	O
drug	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
(	(	O	O
Hyoscine	NN	B-NP	O
)	)	O	O
.	.	O	O

Galanthamine	NN	B-NP	O
hydrobromide	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
anticholinesterase	NN	I-NP	O
drug	NN	I-NP	O
capable	JJ	B-ADJP	O
of	IN	B-PP	O
penetrating	VBG	B-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
demonstrating	VBG	B-VP	O
central	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
(	(	O	O
hyoscine	NN	B-NP	O
)	)	O	O
overdosage	NN	B-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
longer	RB	I-VP	O
acting	VBG	I-VP	O
than	IN	B-PP	O
physostigmine	NN	B-NP	O
and	CC	O	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
anaesthesia	NN	B-NP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
depolarizing	VBG	B-VP	O
neuromuscular	JJ	B-NP	O
block	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
studies	NNS	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
necessary	JJ	B-ADJP	O
to	TO	B-PP	O
combating	VBG	B-VP	O
scopolamine	NN	B-NP	O
intoxication	NN	I-NP	O
are	VBP	B-VP	O
indicated	VBN	I-VP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
uninephrectomy	JJ	B-NP	O
and	CC	I-NP	O
high	JJ	I-NP	O
protein	NN	I-NP	O
feeding	NN	I-NP	O
on	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
chronic	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Rats	NNS	B-NP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
high	JJ	B-NP	O
protein	NN	I-NP	O
(	(	O	O
HP	NN	B-NP	O
)	)	O	O
feeding	NN	B-NP	O
,	,	O	O
uninephrectomy	NN	B-NP	O
(	(	O	O
NX	NN	B-NP	O
)	)	O	O
or	CC	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
,	,	O	O
in	IN	B-PP	O
an	DT	B-NP	O
attempt	NN	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
glomerular	JJ	B-NP	O
hyperfiltration	NN	I-NP	O
and	CC	O	O
further	JJ	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Newborn	JJ	B-NP	O
female	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
fed	VBN	I-VP	O
a	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
diet	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
then	RB	B-ADVP	O
randomized	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
diet	NN	I-NP	O
,	,	O	O
HP	NN	B-NP	O
diet	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
vs.	IN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
NX	NN	B-NP	O
or	CC	I-NP	O
HP+NX	NN	I-NP	O
for	IN	B-PP	O
another	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Corresponding	VBG	B-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
lithium	NN	I-NP	O
pretreated	VBN	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
generated	VBN	I-VP	O
.	.	O	O

When	WRB	B-ADVP	O
comparing	VBG	B-VP	O
all	DT	B-NP	O
lithium	NN	I-NP	O
treated	VBN	B-VP	O
versus	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
lithium	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
lithium	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
GFR	NN	B-NP	O
)	)	O	O
without	IN	B-PP	O
significant	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
effective	JJ	B-NP	O
renal	JJ	I-NP	O
plasma	NN	I-NP	O
flow	NN	I-NP	O
(	(	O	O
as	IN	B-SBAR	O
determined	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
marker	NN	I-NP	O
secreted	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
proximal	JJ	I-NP	O
tubules	NNS	I-NP	O
)	)	O	O
or	CC	O	O
lithium	NN	B-NP	O
clearance	NN	I-NP	O
.	.	O	O

Consequently	RB	B-ADVP	O
,	,	O	O
lithium	NN	B-NP	O
pretreatment	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
filtration	NN	B-NP	O
fraction	NN	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
fractional	JJ	B-NP	O
Li	NNP	I-NP	O
excretion	NN	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
also	RB	B-ADVP	O
caused	VBD	B-VP	O
proteinuria	NN	B-NP	B
and	CC	O	O
systolic	JJ	B-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
absence	NN	B-NP	O
of	IN	B-PP	O
glomerulosclerosis	NN	B-NP	B
.	.	O	O

HP	NN	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
accentuante	VB	I-VP	O
progression	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
and	CC	B-PP	O
in	IN	B-PP	O
fact	NN	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
GFR	NN	B-NP	O
and	CC	O	O
decrease	VB	B-VP	O
plasma	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
lithium	NN	B-NP	O
pretreated	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

NX	NN	B-NP	O
caused	VBD	B-VP	O
an	DT	B-NP	O
additive	JJ	I-NP	O
deterioration	NN	I-NP	O
in	IN	B-PP	O
GFR	NN	B-NP	O
which	WDT	B-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
was	VBD	B-VP	O
ameliorated	VBN	I-VP	O
by	IN	B-PP	O
HP	NN	B-NP	O
.	.	O	O

NX+HP	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
further	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
Li	NN	B-NP	O
-	HYPH	B-NP	O
pretreated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
Li	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
even	RB	B-ADVP	O
when	WRB	I-ADVP	O
the	DT	B-NP	O
GFR	NN	I-NP	O
is	VBZ	B-VP	O
only	RB	I-VP	O
modestly	RB	I-VP	O
reduced	VBN	I-VP	O
,	,	O	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
proteinuria	NN	B-NP	B
and	CC	O	O
arterial	JJ	B-NP	O
systolic	JJ	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
the	DT	B-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
GFR	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
corresponding	JJ	I-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
effective	JJ	B-NP	O
renal	JJ	I-NP	O
plasma	NN	I-NP	O
flow	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
functional	JJ	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
nonfiltrating	JJ	B-NP	O
atubular	JJ	I-NP	O
glomeruli	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
fractional	JJ	I-NP	O
reabsorption	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
fluid	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
proximal	JJ	I-NP	O
tubules	NNS	I-NP	O
is	VBZ	B-VP	O
reduced	VBN	I-VP	O
,	,	O	O
leaving	VBG	B-VP	O
the	DT	B-NP	O
distal	JJ	I-NP	O
delivery	NN	I-NP	O
unchanged.	JJ	B-ADJP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
Crohn	NN	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
with	IN	B-PP	O
fusidic	JJ	B-NP	O
acid	NN	I-NP	O
:	:	O	O
an	DT	B-NP	O
antibiotic	NN	I-NP	O
with	IN	B-PP	O
immunosuppressive	JJ	B-NP	O
properties	NNS	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
cyclosporin	NN	B-NP	O
.	.	O	O

Fusidic	JJ	B-NP	O
acid	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
antibiotic	NN	I-NP	O
with	IN	B-PP	O
T	NN	B-NP	O
-	HYPH	I-NP	O
cell	NN	I-NP	O
specific	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
effects	NNS	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
cyclosporin	NN	B-NP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
treatments	NNS	I-NP	O
for	IN	B-PP	O
Crohn	NN	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	I-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
pharmacodynamics	NNS	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
fusidic	JJ	B-NP	O
acid	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
active	JJ	I-NP	O
,	,	I-NP	O
therapy	NN	I-NP	O
-	HYPH	I-NP	O
resistant	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
Crohn	NN	I-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
.	.	O	O

Fusidic	JJ	B-NP	O
acid	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
orally	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
t.d.s.	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
planned	VBN	I-VP	O
to	TO	I-VP	O
last	VB	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
disease	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
primarily	RB	I-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
modified	VBN	I-NP	O
individual	JJ	I-NP	O
grading	NN	I-NP	O
score	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
improved	VBN	B-VP	O
during	IN	B-PP	O
fusidic	JJ	B-NP	O
acid	NN	I-NP	O
treatment	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
after	IN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
serious	JJ	I-NP	O
clinical	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
but	CC	O	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
was	VBD	B-VP	O
required	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
nausea	NN	B-NP	B
.	.	O	O

Biochemically	RB	B-ADVP	O
,	,	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
alkaline	NN	B-NP	O
phosphatases	NNS	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
greatest	JJS	I-NP	O
increases	NNS	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
elevated	VBN	I-VP	O
levels	NNS	B-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
reversed	VBD	B-VP	O
to	TO	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
levels	NNS	I-NP	O
after	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
fusidic	JJ	B-NP	O
acid	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
benefit	NN	B-NP	O
in	IN	B-PP	O
selected	VBN	B-NP	O
chronic	JJ	I-NP	O
active	JJ	I-NP	O
Crohn	NN	I-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
conventional	JJ	B-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

Because	IN	B-SBAR	O
there	EX	B-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
exist	VB	I-VP	O
a	DT	B-NP	O
scientific	JJ	I-NP	O
rationale	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
fusidic	JJ	B-NP	O
acid	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
cytokine	NN	I-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
inflammatory	JJ	B-NP	B
bowel	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
treatment	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
further	RBR	B-ADJP	O
investigated	VBN	I-ADJP	O
.	.	O	O

Electrocardiographic	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
psychiatrically	RB	B-NP	O
hospitalized	VBN	I-NP	O
cocaine	NN	I-NP	O
abusers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
electrocardiograms	NNS	I-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	O	O
abusing	VBG	B-VP	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
ECGs	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
schizophrenic	JJ	I-NP	B
controls	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cocaine	NN	I-NP	O
abusers	NNS	I-NP	O
and	CC	O	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
had	VBD	B-VP	O
ECG	NN	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
significant	JJ	B-NP	O
myocardial	JJ	I-NP	B
injury	NN	I-NP	I
defined	VBN	B-VP	O
as	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
,	,	O	O
ischemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
bundle	NN	B-NP	B
branch	NN	I-NP	I
block	NN	I-NP	I
.	.	O	O

Sulpiride	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tardive	NN	I-NP	B
dystonia	NN	I-NP	I
.	.	O	O

Sulpiride	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
D2	NN	I-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
with	IN	B-PP	O
antipsychotic	JJ	B-NP	O
and	CC	I-NP	O
antidepressant	JJ	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
initially	RB	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
free	JJ	B-ADJP	O
of	IN	B-PP	O
extrapyramidal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
sulpiride	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tardive	NN	I-NP	B
dyskinesia	NN	I-NP	I
and	CC	I-NP	O
parkinsonism	NN	I-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
occasionally	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
persistent	JJ	B-NP	O
segmental	JJ	I-NP	O
dystonia	NN	I-NP	B
within	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
sulpiride	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
find	VB	I-VP	O
any	DT	B-NP	O
previous	JJ	I-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
sulpiride	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tardive	NN	I-NP	B
dystonia	NN	I-NP	I
.	.	O	O

Ocular	JJ	B-NP	B
and	CC	I-NP	I
auditory	JJ	I-NP	I
toxicity	NN	I-NP	I
in	IN	B-PP	O
hemodialyzed	VBN	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
desferrioxamine	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
study	NN	B-NP	O
num	CD	I-NP	O
hemodialyzed	VBN	B-VP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
desferrioxamine	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
for	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
audiovisual	JJ	B-NP	B
toxicity	NN	I-NP	I
.	.	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
presented	VBD	B-VP	O
clinical	JJ	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	B
or	CC	I-NP	I
auditory	JJ	I-NP	I
toxicity	NN	I-NP	I
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
detailed	VBD	B-VP	O
ophthalmologic	JJ	B-NP	O
and	CC	I-NP	O
audiologic	JJ	I-NP	O
studies	NNS	I-NP	O
disclosed	VBD	B-VP	O
abnormalities	NNS	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
more	JJR	I-NP	O
asymptomatic	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Visual	JJ	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
of	IN	B-PP	O
retinal	JJ	B-NP	O
origin	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
tritan	NN	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
dyschromatopsy	NN	I-NP	B
,	,	O	O
sometimes	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	B
loss	NN	I-NP	I
of	IN	B-PP	I
visual	JJ	B-NP	I
acuity	NN	I-NP	I
and	CC	O	O
pigmentary	JJ	B-NP	B
retinal	JJ	I-NP	I
deposits	NNS	I-NP	I
.	.	O	O

Auditory	JJ	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
mid	NN	I-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
frequency	NN	I-NP	O
neurosensorial	JJ	I-NP	B
hearing	NN	I-NP	I
loss	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
lesion	NN	I-NP	O
was	VBD	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
cochlear	JJ	I-NP	O
type	NN	I-NP	O
.	.	O	O

Desferrioxamine	NN	B-NP	O
withdrawal	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
and	CC	O	O
partial	JJ	B-NP	O
recovery	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
a	DT	B-NP	O
complete	JJ	I-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
partial	JJ	B-NP	O
recovery	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

This	DT	B-NP	O
toxicity	NN	I-NP	B
appeared	VBD	B-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
desferrioxamine	NN	B-NP	O
or	CC	O	O
coincided	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
normalization	NN	I-NP	O
of	IN	B-PP	O
ferritin	NN	B-NP	O
or	CC	I-NP	O
aluminium	NN	I-NP	O
serum	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
audiovisual	JJ	B-NP	B
toxicity	NN	I-NP	I
is	VBZ	B-VP	O
not	RB	O	O
an	DT	B-NP	O
infrequent	JJ	I-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
hemodialyzed	VBN	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
desferrioxamine	NN	B-NP	O
.	.	O	O

Periodical	JJ	B-NP	O
audiovisual	JJ	I-NP	O
monitoring	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
hemodialyzed	VBN	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
detect	VB	I-VP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
as	RB	B-ADVP	O
early	RB	I-ADVP	O
as	IN	B-PP	O
possible	JJ	B-ADJP	O
.	.	O	O

Myasthenia	NNP	B-NP	B
gravis	VBZ	B-VP	I
presenting	VBG	I-VP	O
as	IN	B-PP	O
weakness	NN	B-NP	O
after	IN	B-PP	O
magnesium	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
prior	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
neuromuscular	JJ	B-NP	B
disease	NN	I-NP	I
who	WP	B-NP	O
became	VBD	B-VP	O
virtually	RB	B-ADJP	O
quadriplegic	JJ	I-ADJP	B
after	IN	B-PP	O
parenteral	JJ	B-NP	O
magnesium	NN	I-NP	O
administration	NN	I-NP	O
for	IN	B-PP	O
preeclampsia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
magnesium	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mEq	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
usually	RB	B-ADVP	O
well	RB	B-ADJP	O
tolerated	VBN	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
magnesium	NN	I-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
and	CC	O	O
she	PRP	B-NP	O
recovered	VBD	B-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
she	PRP	B-NP	O
was	VBD	B-VP	O
weak	JJ	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
Hz	NN	I-NP	O
repetitive	JJ	I-NP	O
stimulation	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
decrement	NN	I-NP	O
without	IN	B-PP	O
significant	JJ	B-NP	O
facilitation	NN	I-NP	O
at	IN	B-PP	O
rapid	JJ	B-NP	O
rates	NNS	I-NP	O
or	CC	B-PP	O
after	IN	B-PP	O
exercise	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
postsynaptic	JJ	B-NP	B
neuromuscular	JJ	I-NP	I
blockade	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
her	PRP$	B-NP	O
strength	NN	I-NP	O
returned	VBD	B-VP	O
,	,	O	O
repetitive	JJ	B-NP	O
stimulation	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
single	JJ	B-NP	O
fiber	NN	I-NP	O
EMG	NN	I-NP	O
revealed	VBD	B-VP	O
increased	VBN	B-NP	O
jitter	NN	I-NP	O
and	CC	I-NP	O
blocking	NN	I-NP	O
.	.	O	O

Her	PRP$	B-NP	O
acetylcholine	NN	I-NP	O
receptor	NN	I-NP	O
antibody	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
markedly	RB	B-ADJP	O
elevated	JJ	I-ADJP	O
.	.	O	O

Although	IN	B-SBAR	O
paralysis	NN	B-NP	B
after	IN	B-PP	O
magnesium	NN	B-NP	O
administration	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
known	VBN	B-NP	O
myasthenia	NN	I-NP	B
gravis	NN	I-NP	I
,	,	O	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
or	CC	I-NP	O
only	JJ	I-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
unusually	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
neuromuscular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
magnesium	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
suspected	VBN	I-VP	O
of	IN	B-PP	O
having	VBG	B-VP	O
an	DT	B-NP	O
underlying	VBG	I-NP	O
disorder	NN	I-NP	B
of	IN	B-PP	I
neuromuscular	JJ	B-NP	I
transmission	NN	I-NP	I
.	.	O	O

Chloroacetaldehyde	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
contribution	NN	I-NP	O
to	TO	B-PP	O
urotoxicity	NN	B-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
or	CC	I-NP	O
ifosfamide	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
experimental	JJ	I-NP	O
study	NN	I-NP	O
/	SYM	B-NP	O
short	JJ	I-NP	O
communication	NN	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
clinical	JJ	B-NP	O
data	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
chloroacetaldehyde	NN	B-NP	O
(	(	O	O
CAA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
metabolite	NN	I-NP	O
of	IN	B-PP	O
oxazaphosphorine	NN	B-NP	O
cytostatics	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
elucidate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
CAA	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
CAA	NN	B-NP	O
after	IN	B-PP	O
i.v.	JJ	B-NP	O
administration	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
bladder	NN	B-NP	B
damage	NN	I-NP	I
.	.	O	O

When	WRB	B-ADVP	O
instilled	VBN	B-VP	O
directly	RB	B-ADVP	O
into	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
,	,	O	O
CAA	NN	B-NP	O
exerts	VBZ	B-VP	O
urotoxic	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
susceptible	JJ	B-ADJP	O
to	TO	B-PP	O
detoxification	NN	B-NP	O
with	IN	B-PP	O
mesna	NN	B-NP	O
.	.	O	O

Source	NN	B-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
and	CC	O	O
primitive	JJ	B-NP	O
dysfunction	NN	I-NP	O
in	IN	B-PP	O
migraine	NN	B-NP	B
:	:	O	O
an	DT	B-NP	O
identical	JJ	I-NP	O
site	NN	I-NP	O
?	.	O	O
num	CD	B-NP	O
common	JJ	I-NP	O
migraine	NN	I-NP	B
patients	NNS	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
sided	JJ	I-NP	O
frontotemporal	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
nitroglycerin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
or	CC	O	O
placebo	NN	B-NP	O
ointment	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Early	JJ	B-NP	O
onset	NN	I-NP	O
migraine	NN	I-NP	B
attacks	NNS	I-NP	O
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
nitroglycerin	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
versus	IN	B-PP	O
no	DT	B-NP	O
patient	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Subsequently	RB	B-NP	O
num	CD	I-NP	O
migraine	NN	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
an	DT	B-NP	O
early	JJ	I-NP	O
onset	NN	I-NP	O
attack	NN	I-NP	O
with	IN	B-PP	O
frontotemporal	JJ	B-NP	O
nitroglycerin	NN	I-NP	O
,	,	O	O
received	VBD	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
second	JJ	I-NP	O
induction	NN	I-NP	O
test	NN	I-NP	O
at	IN	B-PP	O
other	JJ	B-NP	O
body	NN	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
early	JJ	I-NP	O
onset	NN	I-NP	O
migraine	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Thus	RB	B-ADVP	O
the	DT	B-NP	O
migraine	NN	I-NP	B
-	HYPH	O	O
inducing	VBG	B-VP	O
effect	NN	B-NP	O
of	IN	B-PP	O
nitroglycerin	NN	B-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
depend	VB	I-VP	O
on	IN	B-PP	O
direct	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
habitual	JJ	I-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
frontotemporal	JJ	I-NP	O
region	NN	I-NP	O
is	VBZ	B-VP	O
of	IN	B-PP	O
crucial	JJ	B-NP	O
importance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
migraine	NN	I-NP	B
crisis	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
a	DT	B-NP	O
CNS	NN	I-NP	O
origin	NN	I-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
attack	NN	I-NP	O
.	.	O	O

Clotiazepam	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
with	IN	B-PP	O
extensive	JJ	B-NP	B
hepatocellular	JJ	I-NP	I
necrosis	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
clotiazepam	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
thienodiazepine	NN	I-NP	O
derivative	NN	I-NP	O
.	.	O	O

Clotiazepam	NN	B-NP	O
withdrawal	NN	I-NP	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
prompt	JJ	B-NP	O
recovery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
benzodiazepines	NNS	I-NP	O
,	,	O	O
chemically	RB	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
clotiazepam	NN	B-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
interfere	VB	I-VP	O
with	IN	B-PP	O
recovery	NN	B-NP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
any	DT	B-NP	O
relapse	NN	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
observation	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
clotiazepam	NN	B-NP	O
can	MD	B-VP	O
induce	VB	I-VP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
and	CC	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
cross	JJ	I-NP	O
hepatotoxicity	NN	I-NP	B
between	IN	B-PP	O
clotiazepam	NN	B-NP	O
and	CC	O	O
several	JJ	B-NP	O
benzodiazepines	NNS	I-NP	O
.	.	O	O

Arterial	JJ	B-NP	O
hypertension	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
prolonged	JJ	B-NP	O
ketoconazole	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Cushing	NN	B-NP	B
s	VBZ	B-VP	I
syndrome	NN	B-NP	I
treated	VBN	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
basis	NN	I-NP	O
with	IN	B-PP	O
ketoconazole	NN	B-NP	O
developed	VBD	B-VP	O
sustained	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
cases	NNS	I-NP	O
normal	JJ	B-NP	O
plasma	NN	I-NP	O
and	CC	O	O
urinary	JJ	B-NP	O
free	JJ	I-NP	O
cortisol	NN	I-NP	O
levels	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
achieved	VBN	I-VP	O
following	VBG	B-PP	O
ketoconazole	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
yet	RB	B-NP	O
continuous	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
monitoring	NN	I-NP	O
demonstrated	VBD	B-VP	O
hypertension	NN	B-NP	B
num	CD	I-NP	O
(	(	O	O
patient	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
(	(	O	O
patient	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
after	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
patient	NN	B-NP	O
num	CD	I-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
deoxycorticosterone	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
deoxycortisol	NN	I-NP	O
were	VBD	B-VP	O
elevated	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
patient	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
both	CC	O	O
deoxycorticosterone	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
deoxycortisol	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
aldosterone	NN	I-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
raised	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
concomitant	JJ	I-NP	O
suppression	NN	I-NP	O
of	IN	B-PP	O
renin	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ketoconazole	NN	B-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
enzyme	NN	B-NP	O
blockade	NN	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
mineralocorticoid	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
Captopril	NNP	B-NP	O
)	)	O	O
on	IN	B-PP	O
pulmonary	JJ	B-NP	B
and	CC	I-NP	I
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
intravascular	JJ	B-NP	B
coagulation	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Induction	NN	B-NP	O
of	IN	B-PP	O
intravascular	JJ	B-NP	B
coagulation	NN	I-NP	I
and	CC	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
fibrinolysis	NN	B-NP	O
by	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
thrombin	NN	B-NP	O
and	CC	O	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
AMCA	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
gives	VBZ	B-VP	O
rise	NN	B-NP	O
to	TO	B-PP	O
pulmonary	JJ	B-NP	B
and	CC	I-NP	I
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
resembling	VBG	B-VP	O
that	IN	B-SBAR	O
occurring	VBG	B-VP	O
after	IN	B-PP	O
trauma	NN	B-NP	B
or	CC	I-NP	O
sepsis	NN	I-NP	B
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

Injection	NN	B-NP	O
of	IN	B-PP	O
Captopril	NNP	B-NP	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
,	,	O	O
reduced	VBD	B-VP	O
both	CC	O	O
pulmonary	JJ	B-NP	B
and	CC	I-NP	I
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
in	IN	B-PP	O
this	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
lung	NN	I-NP	O
weights	NNS	I-NP	O
were	VBD	B-VP	O
lower	JJR	B-ADJP	O
and	CC	O	O
PaO2	NN	B-NP	O
was	VBD	B-VP	O
improved	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-VP	O
this	DT	B-NP	O
enzyme	NN	I-NP	O
-	HYPH	O	O
blocking	VBG	B-VP	O
agent	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
contents	NNS	I-NP	O
of	IN	B-PP	O
albumin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lungs	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
changed	VBN	I-VP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
Captopril	NNP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
influence	VB	I-VP	O
the	DT	B-NP	O
extravasation	NN	I-NP	O
of	IN	B-PP	O
protein	NN	B-NP	O
.	.	O	O

Renal	JJ	B-NP	B
damage	NN	I-NP	I
as	IN	B-SBAR	O
reflected	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
urea	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
kidney	NN	B-NP	O
weight	NN	I-NP	O
was	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
Captopril	NNP	B-NP	O
.	.	O	O

The	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
fibrin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
considerably	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
which	WDT	B-NP	O
received	VBD	B-VP	O
thrombin	NN	B-NP	O
and	CC	I-NP	O
AMCA	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Captopril	NNP	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
lungs	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
vasodilatory	JJ	I-NP	O
effect	NN	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
circulating	VBG	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
Angiotension	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
prostacyclin	NN	B-NP	O
(	(	O	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
bradykinin	NN	B-NP	O
)	)	O	O
.	.	O	O

Captopril	NNP	B-NP	O
may	MD	B-VP	O
,	,	O	O
by	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
mechanism	NN	I-NP	O
,	,	O	O
reduce	VBP	B-VP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	B-VP	O
occur	VB	I-VP	O
after	IN	B-PP	O
an	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
thrombin	NN	B-NP	O
,	,	O	O
thereby	RB	B-VP	O
diminishing	VBG	I-VP	O
the	DT	B-NP	O
aggregation	NN	I-NP	O
of	IN	B-PP	O
fibrin	NN	B-NP	O
monomers	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
glomeruli	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
result	NN	I-NP	O
that	IN	B-SBAR	O
less	JJR	B-NP	O
fibrin	NN	I-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
deposited	VBN	I-VP	O
and	CC	O	O
thus	RB	O	O
less	JJR	B-NP	O
kidney	NN	I-NP	B
damage	NN	I-NP	I
will	MD	B-VP	O
be	VB	I-VP	O
produced	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
randomized	VBN	I-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
labetalol	NN	B-NP	O
and	CC	I-NP	O
nitroprusside	NN	I-NP	O
for	IN	B-PP	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
study	NN	I-NP	O
,	,	O	O
labetalol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
nitroprusside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
)	)	O	O
scheduled	VBN	B-VP	O
for	IN	B-PP	O
major	JJ	B-NP	O
orthopedic	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

Each	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
identical	JJ	I-NP	O
anesthetic	JJ	I-NP	O
protocol	NN	I-NP	O
and	CC	O	O
similar	JJ	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
reductions	NNS	I-NP	B
in	IN	B-PP	I
mean	JJ	B-NP	I
arterial	JJ	I-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mmHg	NN	I-NP	O
)	)	O	O
.	.	O	O

Nitroprusside	NN	B-NP	B
infusion	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	0
in	IN	B-PP	0
heart	NN	B-NP	B
rate	NN	I-NP	I
and	CC	O	I
cardiac	JJ	B-NP	B
output	NN	I-NP	I
;	:	O	O
rebound	NN	B-NP	O
hypertension	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
nitroprusside	NN	B-NP	O
.	.	O	O

Labetalol	NN	B-NP	O
administration	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Arterial	JJ	B-NP	O
PO2	NN	I-NP	O
decreased	VBD	B-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
labetalol	NN	B-NP	O
offers	VBZ	B-VP	O
advantages	NNS	B-NP	O
over	IN	B-PP	O
nitroprusside	NN	B-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
carbamazepine	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
:	:	O	O
efficacy	NN	B-NP	O
,	,	O	O
toxicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
effect	NN	B-NP	O
on	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	I-NP	O
tissue	NN	I-NP	O
folate	NN	I-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

Folate	JJ	B-NP	O
depletion	NN	I-NP	O
has	VBZ	B-VP	O
often	RB	I-VP	O
been	VBN	I-VP	O
a	DT	B-NP	O
problem	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
(	(	O	O
AED	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
.	.	O	O

Carbamazepine	NN	B-NP	O
(	(	O	O
CBZ	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
AED	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
to	TO	I-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
CBZ	NN	I-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
folate	JJ	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
this	DT	B-NP	O
model	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
common	JJ	I-NP	O
vehicle	NN	I-NP	O
,	,	O	O
propylene	NN	B-NP	O
glycol	NN	I-NP	O
,	,	O	O
by	IN	B-PP	O
itself	PRP	B-NP	O
in	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
exhibit	VB	I-VP	O
protective	JJ	B-NP	O
properties	NNS	I-NP	O
against	IN	B-PP	O
induced	VBN	B-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
inhibited	VBD	B-VP	O
weight	NN	B-NP	B
gain	NN	I-NP	I
.	.	O	O

Seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
hexafluorodiethyl	NN	B-NP	O
ether	NN	I-NP	O
(	(	O	O
HFDE	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
also	RB	I-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
sensitive	JJ	I-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
protection	NN	B-NP	O
by	IN	B-PP	O
CBZ	NN	B-NP	O
than	IN	B-PP	O
seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
maximal	JJ	B-NP	O
electroshock	NN	I-NP	O
(	(	O	O
MES	NN	B-NP	O
)	)	O	O
.	.	O	O

Oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
CBZ	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
aqueous	JJ	I-NP	O
suspension	NN	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
was	VBD	B-VP	O
continuously	RB	B-ADJP	O
protective	JJ	I-ADJP	O
against	IN	B-PP	O
HFDE	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
was	VBD	B-VP	O
minimally	RB	B-ADJP	O
toxic	JJ	I-ADJP	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
weight	NN	B-NP	B
gain	NN	I-NP	I
over	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
CBZ	NN	I-NP	O
levels	NNS	I-NP	O
measured	VBN	B-VP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
were	VBD	B-VP	O
below	IN	B-PP	O
those	DT	B-NP	O
normally	RB	B-VP	O
considered	VBN	I-VP	O
protective	JJ	B-ADJP	O
.	.	O	O

This	DT	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
CBZ	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
apparent	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
folate	JJ	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
,	,	O	O
and	CC	O	O
,	,	O	O
indeed	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
folate	JJ	I-NP	O
concentration	NN	I-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
liver	NN	B-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Inhibition	NN	B-NP	O
of	IN	B-PP	O
sympathoadrenal	JJ	B-NP	O
activity	NN	I-NP	O
by	IN	B-PP	O
atrial	JJ	B-NP	O
natriuretic	JJ	I-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
conscious	JJ	I-NP	O
,	,	I-NP	O
trained	JJ	I-NP	O
dogs	NNS	I-NP	O
,	,	O	O
maintained	VBN	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
sodium	NN	I-NP	O
intake	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mEq	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
sympathetic	JJ	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
release	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
and	CC	I-NP	O
epinephrine	NN	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
minute	JJ	I-NP	O
i.v.	JJ	I-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
atrial	JJ	I-NP	O
natriuretic	JJ	I-NP	O
factor	NN	I-NP	O
.	.	O	O

Mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
as	IN	B-PP	O
a	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
+	SYM	B-NP	O
/	SYM	B-VP	O
-	HYPH	B-NP	O
SEM	NN	I-NP	O
)	)	O	O
during	IN	B-PP	O
randomized	VBN	B-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
no	DT	B-NP	O
tachycardia	NN	I-NP	B
and	CC	O	O
no	DT	B-NP	O
augmentation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
norepinephrine	NN	I-NP	O
release	NN	I-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
comparable	JJ	B-NP	O
hypotension	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
hydralazine	NN	B-NP	O
or	CC	I-NP	O
nitroglycerin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
release	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
declined	VBD	B-VP	O
immediately	RB	B-ADVP	O
during	IN	B-PP	O
infusions	NNS	B-NP	O
of	IN	B-PP	O
atrial	JJ	B-NP	O
natriuretic	JJ	I-NP	O
factor	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
minimum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	B-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
p	NN	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
or	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
not	RB	O	O
significant	JJ	B-ADJP	O
)	)	O	O
during	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
.	.	O	O

Steady	JJ	B-NP	O
state	NN	I-NP	O
arterial	JJ	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
atrial	JJ	B-NP	O
natriuretic	JJ	I-NP	O
factor	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
during	IN	B-PP	O
infusions	NNS	B-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	B-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
factor.	NN	I-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Death	NN	B-NP	B
from	IN	B-PP	O
chemotherapy	NN	B-NP	O
in	IN	B-PP	O
gestational	JJ	B-NP	B
trophoblastic	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Multiple	JJ	B-NP	O
cytotoxic	JJ	I-NP	O
drug	NN	I-NP	O
administration	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
generally	RB	I-NP	O
accepted	VBN	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
choriocarcinoma	NN	B-NP	B
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
this	DT	B-NP	O
principle	NN	I-NP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
,	,	O	O
classified	VBN	B-VP	O
as	IN	B-PP	O
being	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
Goldstein	NNP	B-NP	O
and	CC	I-NP	O
Berkowitz	NNP	I-NP	O
score	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
multiple	JJ	B-NP	O
cytotoxic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
multiple	JJ	I-NP	O
drug	NN	I-NP	O
schema	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
:	:	O	O
Etoposide	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
Methotrexate	NN	B-NP	O
,	,	O	O
Cyclophosphamide	NN	B-NP	O
,	,	O	O
Actomycin	NN	B-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
,	,	O	O
and	CC	O	O
Cisplatin	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
schedule	NN	I-NP	O
,	,	O	O
moderate	JJ	B-NP	O
high	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
Methotrexate	NN	B-NP	O
,	,	I-NP	O
Etoposide	NN	I-NP	O
and	CC	I-NP	O
Cyclophosphamide	NN	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

Within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
died	VBD	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
picture	NN	I-NP	O
resembling	VBG	B-VP	O
massive	JJ	B-NP	O
pulmonary	JJ	I-NP	B
obstruction	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
choriocarcinomic	JJ	B-NP	O
tissue	NN	I-NP	O
plugs	NNS	I-NP	O
,	,	O	O
probably	RB	B-ADVP	O
originating	VBG	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
uterus	NN	I-NP	O
.	.	O	O

Formation	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
plugs	NNS	I-NP	O
was	VBD	B-VP	O
probably	RB	B-ADVP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
extensive	JJ	B-NP	O
tumor	NN	I-NP	B
necrosis	NN	I-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
walls	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
uterine	JJ	I-NP	O
veins	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
open	JJ	I-NP	O
exchange	NN	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
plugs	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
vascular	JJ	I-NP	O
spaces	NNS	I-NP	O
;	:	O	O
decrease	NN	B-NP	O
in	IN	B-PP	O
tumor	NN	B-NP	B
tissue	NN	I-NP	O
coherence	NN	I-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
chemotherapy	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
further	RBR	I-VP	O
contributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
emboli	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
view	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
close	JJ	I-NP	O
time	NN	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
acute	JJ	I-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
massive	JJ	B-NP	O
embolism	NN	I-NP	B
other	JJ	I-NP	O
explanations	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
spontaneous	JJ	B-NP	O
necrosis	NN	I-NP	B
,	,	O	O
must	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
less	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
large	JJ	B-NP	O
pelvic	JJ	I-NP	B
tumor	NN	I-NP	I
loads	NNS	I-NP	O
are	VBP	B-VP	O
,	,	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
existing	VBG	B-NP	O
classifications	NNS	I-NP	O
,	,	O	O
at	IN	B-PP	O
high	JJ	B-NP	O
risk	NN	I-NP	O
to	TO	B-VP	O
die	VB	I-VP	O
and	CC	O	O
to	TO	B-VP	O
develop	VB	I-VP	O
drug	NN	B-NP	O
resistance	NN	I-NP	O
.	.	O	O

Notwithstanding	IN	B-PP	O
these	DT	B-NP	O
facts	NNS	I-NP	O
our	PRP$	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
patients	NNS	I-NP	O
might	MD	B-VP	O
benefit	VB	I-VP	O
from	IN	B-PP	O
relatively	RB	B-NP	O
mild	JJ	I-NP	O
initial	JJ	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
especially	RB	B-ADJP	O
true	JJ	I-ADJP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
not	RB	B-VP	O
previously	RB	I-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Close	JJ	B-NP	O
observation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
response	NN	I-NP	O
status	NN	I-NP	O
both	CC	O	O
clinically	RB	B-ADVP	O
and	CC	O	O
with	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	O	O
hCG	NN	B-NP	O
values	NNS	I-NP	O
may	MD	B-VP	O
indicate	VB	I-VP	O
whether	IN	B-SBAR	O
and	CC	O	O
when	WRB	B-ADVP	O
more	RBR	B-NP	O
agressive	JJ	I-NP	O
combination	NN	I-NP	O
chemotherapy	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
started.	VBN	I-VP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Sexual	JJ	B-NP	B
dysfunction	NN	I-NP	I
among	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
arthritis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
relationship	NN	I-NP	O
of	IN	B-PP	O
arthritis	NN	B-NP	B
and	CC	O	O
sexual	JJ	B-NP	B
dysfunction	NN	I-NP	I
was	VBD	B-VP	O
investigated	VBN	I-VP	O
among	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
,	,	I-NP	O
osteoarthritis	NN	I-NP	B
and	CC	I-NP	O
spondyloarthropathy	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
were	VBD	B-VP	O
pair	NN	I-VP	O
-	HYPH	O	O
matched	VBN	B-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Assessments	NNS	B-NP	O
of	IN	B-PP	O
marital	JJ	B-NP	O
happiness	NN	I-NP	O
and	CC	O	O
depressed	JJ	B-NP	B
mood	NN	I-NP	I
were	VBD	B-VP	O
also	RB	I-VP	O
made	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
CES	NN	I-NP	O
-	HYPH	O	O
D	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
Azrin	NNP	I-NP	O
Marital	NNP	I-NP	O
Happiness	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
AMHS	NNP	B-NP	O
)	)	O	O
.	.	O	O

Sexual	JJ	B-NP	B
dysfunctions	NNS	I-NP	I
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
common	JJ	B-ADJP	O
among	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	I-NP	O
controls	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
majority	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
reporting	VBG	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
dysfunctions	NNS	I-NP	O
.	.	O	O

Impotence	NN	B-NP	B
was	VBD	B-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
among	IN	B-PP	O
male	JJ	B-NP	O
patients	NNS	I-NP	O
than	IN	B-PP	O
controls	NNS	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
morbidity	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
taking	NN	I-NP	O
of	IN	B-PP	O
methotrexate	NN	B-NP	O
.	.	O	O

Depressed	VBN	B-NP	B
mood	NN	I-NP	I
was	VBD	B-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
among	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
certain	JJ	B-NP	O
sexual	JJ	I-NP	O
difficulties	NNS	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	B-PP	O
with	IN	I-PP	O
impotence	NN	B-NP	B
.	.	O	O

Marital	JJ	B-NP	O
unhappiness	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
indicated	VBN	B-VP	O
by	IN	B-PP	O
AMHS	NN	B-NP	O
scores	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
arthritis	NN	B-NP	B
but	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
sexual	JJ	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
sexual	JJ	B-NP	O
dissatisfaction	NN	I-NP	O
and	CC	O	O
being	VBG	B-VP	O
female	JJ	B-ADJP	O
.	.	O	O

Does	NNP	B-NP	O
paracetamol	NN	I-NP	O
cause	VBP	B-VP	O
urothelial	JJ	B-NP	B
cancer	NN	I-NP	I
or	CC	O	O
renal	JJ	B-NP	B
papillary	JJ	I-NP	I
necrosis	NN	I-NP	I
?	.	O	O
The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
renal	JJ	B-NP	B
papillary	JJ	I-NP	I
necrosis	NN	I-NP	I
or	CC	I-NP	O
cancer	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
renal	JJ	I-NP	I
pelvis	NN	I-NP	I
,	,	I-NP	I
ureter	NN	I-NP	I
or	CC	I-NP	I
bladder	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
consumption	NN	B-NP	O
of	IN	B-PP	O
either	CC	O	O
phenacetin	NN	B-NP	O
or	CC	I-NP	O
paracetamol	NN	I-NP	O
was	VBD	B-VP	O
calculated	VBN	I-VP	O
from	IN	B-PP	O
data	NNS	B-NP	O
acquired	VBN	B-VP	O
by	IN	B-PP	O
questionnaire	NN	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
papillary	JJ	I-NP	I
necrosis	NN	I-NP	I
was	VBD	B-VP	O
increased	VBN	I-VP	O
nearly	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	B-VP	O
fold	RB	B-ADVP	O
by	IN	B-PP	O
consumption	NN	B-NP	O
of	IN	B-PP	O
phenacetin	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
also	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
cancer	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
renal	JJ	I-NP	I
pelvis	NN	I-NP	I
and	CC	I-NP	I
bladder	NN	I-NP	I
but	CC	B-PP	O
not	RB	B-PP	O
for	IN	I-PP	O
ureteric	JJ	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

By	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
were	VBD	B-VP	O
unable	JJ	B-ADJP	O
to	TO	B-VP	O
substantiate	VB	I-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
from	IN	B-PP	O
paracetamol	NN	B-NP	O
consumption	NN	I-NP	O
for	IN	B-PP	O
renal	JJ	B-NP	B
papillary	JJ	I-NP	I
necrosis	NN	I-NP	I
or	CC	O	O
any	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cancers	NNS	I-NP	B
although	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
suggestion	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
cancer	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
ureter	NN	I-NP	I
.	.	O	O

Dapsone	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
Heinz	NN	I-NP	O
body	NN	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
Cambodian	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
hemoglobin	NN	B-NP	O
E	NN	I-NP	O
trait	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
Cambodian	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
hemoglobin	NN	B-NP	O
E	NN	I-NP	O
trait	NN	I-NP	O
(	(	O	O
AE	NN	B-NP	O
)	)	O	O
and	CC	O	O
leprosy	NN	B-NP	B
developed	VBD	B-VP	O
a	DT	B-NP	O
Heinz	NNP	I-NP	O
body	NN	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
while	IN	B-SBAR	O
taking	VBG	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
dapsone	NN	B-NP	O
not	RB	B-VP	O
usually	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
hemolysis	NN	I-NP	B
.	.	O	O

Her	PRP$	B-NP	O
red	JJ	I-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
(	(	O	O
RBCs	NNS	B-NP	O
)	)	O	O
had	VBD	B-VP	O
increased	VBN	I-VP	O
incubated	VBN	B-VP	O
Heinz	NNP	B-NP	O
body	NN	I-NP	O
formation	NN	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
reduced	VBN	I-VP	O
glutathione	NN	B-NP	O
(	(	O	O
GSH	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
decreased	VBD	B-VP	O
GSH	NN	B-NP	O
stability	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pentose	NN	I-NP	O
phosphate	NN	I-NP	O
shunt	NN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dapsone	NN	I-NP	O
-	HYPH	B-VP	O
exposed	VBN	B-NP	O
AE	NN	I-NP	O
RBCs	NNS	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
RBCs	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
AE	NN	I-NP	O
RBCs	NNS	I-NP	O
from	IN	B-PP	O
an	DT	B-NP	O
individual	NN	I-NP	O
not	RB	B-VP	O
taking	VBG	I-VP	O
dapsone	NN	B-NP	O
had	VBD	B-VP	O
increased	VBN	I-VP	O
incubated	VBN	B-VP	O
Heinz	NNP	B-NP	O
body	NN	I-NP	O
formation	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
GSH	NN	I-NP	O
content	NN	I-NP	O
and	CC	O	O
GSH	NN	B-NP	O
stability	NN	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
pentose	NN	I-NP	O
phosphate	NN	I-NP	O
shunt	NN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
dapsone	NN	I-NP	O
-	HYPH	O	O
exposed	VBN	B-NP	O
AE	NN	I-NP	O
RBCs	NNS	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
RBCs	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
AE	NN	B-NP	O
RBCs	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
oxidant	JJ	B-NP	O
stress	NN	I-NP	O
both	CC	O	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
since	IN	B-SBAR	O
dapsone	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
at	IN	B-PP	O
this	DT	B-NP	O
dose	NN	I-NP	O
in	IN	B-PP	O
hematologically	RB	B-NP	O
normal	JJ	I-NP	O
individuals	NNS	I-NP	O
.	.	O	O

Given	VBN	B-PP	O
the	DT	B-NP	O
influx	NN	I-NP	O
of	IN	B-PP	O
Southeast	NNP	B-NP	O
Asians	NNPS	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
,	,	O	O
oxidant	JJ	B-NP	O
medications	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
caution	NN	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
if	IN	B-SBAR	O
an	DT	B-NP	O
infection	NN	I-NP	B
is	VBZ	B-VP	O
present	JJ	B-ADJP	O
,	,	O	O
in	IN	B-PP	O
individuals	NNS	B-NP	O
of	IN	B-PP	O
ethnic	JJ	B-NP	O
backgrounds	NNS	I-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
hemoglobin	NN	B-NP	O
E	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
antianginal	JJ	B-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
identified	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
poor	JJ	I-NP	O
metabolizer	NN	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
,	,	O	O
propafenone	NN	B-NP	O
,	,	O	O
diltiazem	NN	B-NP	O
,	,	O	O
and	CC	O	O
sparteine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
CCU	NN	I-NP	O
in	IN	B-PP	O
shock	NN	B-NP	B
with	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

AV	NN	B-NP	B
block	NN	I-NP	I
,	,	O	O
severe	JJ	B-NP	O
hypotension	NN	I-NP	B
,	,	O	O
and	CC	O	O
impairment	NN	B-NP	B
of	IN	B-PP	I
ventricular	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
week	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-VP	O
admission	NN	I-VP	O
a	DT	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
standard	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
initiated	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
before	IN	B-PP	O
admission	NN	B-NP	O
diltiazem	NN	I-NP	O
was	VBD	B-VP	O
prescribed	VBN	I-VP	O
in	IN	B-PP	O
addition	NN	B-NP	O
.	.	O	O

Analyses	NNS	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
blood	NN	I-NP	O
sample	NN	I-NP	O
revealed	VBD	B-VP	O
unusually	RB	B-NP	O
high	JJ	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
(	(	O	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
)	)	O	O
and	CC	O	O
diltiazem	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
following	VBG	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
antianginal	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
months	NNS	I-NP	O
later	RB	B-ADVP	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
,	,	O	O
diltiazem	NN	B-NP	O
,	,	O	O
propafenone	NN	B-NP	O
(	(	O	O
since	IN	B-SBAR	O
he	PRP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
this	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
past	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
sparteine	NN	B-NP	O
(	(	O	O
as	IN	B-PP	O
a	DT	B-NP	O
probe	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
debrisoquine	NN	I-NP	O
/	SYM	B-NP	O
sparteine	NN	I-NP	O
type	NN	I-NP	O
polymorphism	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
drug	NN	I-NP	O
metabolism	NN	I-NP	O
)	)	O	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
that	IN	B-SBAR	O
he	PRP	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
poor	JJ	I-NP	O
metabolizer	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
their	PRP$	B-NP	O
metabolism	NN	I-NP	O
is	VBZ	B-VP	O
under	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
genetic	JJ	I-NP	O
control	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
patients	NNS	B-NP	O
belonging	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
poor	JJ	I-NP	O
-	HYPH	I-NP	O
metabolizer	NN	I-NP	O
phenotype	NN	I-NP	O
of	IN	B-PP	O
sparteine	NN	B-NP	O
/	SYM	B-NP	O
debrisoquine	NN	I-NP	O
polymorphism	NN	I-NP	O
in	IN	B-PP	O
drug	NN	B-NP	O
metabolism	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
constitutes	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
German	JJ	I-NP	O
population	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
experience	VB	I-VP	O
adverse	JJ	B-NP	B
drug	NN	I-NP	I
reactions	NNS	I-NP	I
when	WRB	B-ADVP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
standard	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
coadministration	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
frequently	RB	I-NP	O
used	VBN	I-NP	O
drugs	NNS	I-NP	O
is	VBZ	B-VP	O
expected	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
especially	RB	B-ADJP	O
harmful	JJ	I-ADJP	O
in	IN	B-PP	O
this	DT	B-NP	O
subgroup	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Triazolam	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
brief	JJ	I-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
secondary	JJ	B-NP	O
mania	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
depressed	JJ	I-NP	B
patient	NN	I-NP	O
.	.	O	O

Large	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
triazolam	NN	B-NP	O
repeatedly	RB	B-ADVP	O
induced	VBD	B-VP	O
brief	JJ	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
mania	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
depressed	JJ	I-NP	B
elderly	JJ	I-NP	O
woman	NN	I-NP	O
.	.	O	O

Features	NNS	B-NP	O
of	IN	B-PP	O
organic	JJ	B-NP	B
mental	JJ	I-NP	I
disorder	NN	I-NP	I
(	(	O	O
delirium	NN	B-NP	B
)	)	O	O
were	VBD	B-VP	O
not	RB	O	O
present	JJ	B-ADJP	O
.	.	O	O

Manic	JJ	B-NP	B
excitement	NN	I-NP	O
was	VBD	B-VP	O
coincident	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
of	IN	B-PP	O
triazolam	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
triazolo	NN	I-NP	O
group	NN	I-NP	O
to	TO	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
affective	JJ	B-NP	O
status	NN	I-NP	O
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
tolerance	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
muscular	JJ	I-NP	B
rigidity	NN	I-NP	I
produced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
tolerance	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
muscular	JJ	I-NP	B
rigidity	NN	I-NP	I
produced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Saline	NN	B-NP	O
-	HYPH	B-NP	O
pretreated	VBN	I-NP	O
controls	NNS	I-NP	O
given	VBN	B-VP	O
a	DT	B-NP	O
test	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
pronounced	JJ	I-NP	O
rigidity	NN	I-NP	B
recorded	VBN	B-VP	O
as	IN	B-PP	O
tonic	JJ	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
electromyogram	NN	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
with	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	O	O
withdrawn	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
showed	VBD	B-VP	O
differences	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
tolerance	NN	B-NP	O
:	:	O	O
about	IN	B-NP	O
half	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
rigidity	NN	I-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
akinetic	JJ	B-ADJP	B
(	(	O	O
A	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
other	JJ	I-NP	O
rats	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rigidity	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
stereotyped	JJ	B-NP	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
licking	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
gnawing	VBG	B-VP	O
in	IN	B-PP	O
presence	NN	B-NP	O
of	IN	B-PP	O
akinetic	JJ	B-NP	B
or	CC	I-NP	O
hyperkinetic	JJ	I-NP	B
(	(	O	O
K	NN	B-NP	O
)	)	O	O
behaviour	NN	B-NP	O
(	(	O	O
AS	NN	B-NP	O
/	SYM	B-NP	O
KS	NN	I-NP	O
group	NN	I-NP	O
)	)	O	O
,	,	O	O
suggesting	VBG	B-VP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
dopaminergic	JJ	B-NP	O
activation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rigidity	NN	I-NP	B
was	VBD	B-VP	O
considerably	RB	I-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
s	VBZ	B-VP	O
treatment	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
further	JJ	I-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
experiments	NNS	B-NP	O
,	,	O	O
haloperidol	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
block	VB	I-VP	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
activation	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
real	JJ	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tolerance	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
rigidity	NN	I-NP	B
without	IN	B-PP	O
any	DT	B-NP	O
dopaminergic	JJ	I-NP	O
interference	NN	I-NP	O
.	.	O	O

Haloperidol	NN	B-NP	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
rigidity	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
A	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
AS	NN	I-NP	O
/	SYM	B-NP	O
KS	NN	I-NP	O
group	NN	I-NP	O
remained	VBD	B-VP	O
considerably	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
A	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
rigidity	NN	B-NP	B
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
assumed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
an	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
can	MD	B-VP	O
be	VB	I-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
another	DT	B-NP	O
process	NN	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
dopaminergic	JJ	B-NP	O
activation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
.	.	O	O

Nevertheless	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
occurs	VBZ	B-VP	O
some	DT	B-NP	O
real	JJ	I-NP	O
tolerance	NN	I-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rapid	JJ	I-NP	O
alternations	NNS	I-NP	O
of	IN	B-PP	O
rigidity	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
dopaminergic	JJ	B-NP	O
activation	NN	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
AS	NN	I-NP	O
/	SYM	B-NP	O
KS	NN	I-NP	O
group	NN	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
rapid	JJ	B-NP	O
shifts	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
predominance	NN	I-NP	O
of	IN	B-PP	O
various	JJ	B-NP	O
DA	NN	I-NP	O
-	HYPH	B-NP	O
innervated	VBN	I-NP	O
structures	NNS	I-NP	O
.	.	O	O

Compression	NN	B-NP	B
neuropathy	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
radial	JJ	I-NP	I
nerve	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
pentazocine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
fibrous	JJ	I-NP	B
myopathy	NN	I-NP	I
.	.	O	O

Fibrous	JJ	B-NP	B
myopathy	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
,	,	O	O
well	RB	B-ADVP	O
-	HYPH	B-NP	O
known	VBN	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
repeated	VBN	B-NP	O
pentazocine	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
compression	NN	B-NP	B
neuropathy	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
fibrotic	JJ	B-NP	O
muscle	NN	I-NP	O
affected	VBN	B-VP	O
by	IN	B-PP	O
pentazocine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myopathy	NN	I-NP	B
has	VBZ	B-VP	O
not	RB	I-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
documented	VBN	B-NP	O
pentazocine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
fibrous	JJ	I-NP	B
myopathy	NN	I-NP	I
of	IN	B-PP	O
triceps	NNS	B-NP	O
and	CC	O	O
deltoid	JJ	B-NP	O
muscles	NNS	I-NP	O
bilaterally	RB	B-ADVP	O
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
right	JJ	B-NP	O
wrist	NN	I-NP	O
drop	NN	I-NP	O
,	,	O	O
electrodiagnostic	JJ	B-NP	O
examination	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
but	CC	I-NP	O
partial	JJ	I-NP	O
lesion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
radial	JJ	I-NP	O
nerve	NN	I-NP	O
distal	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
branches	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
triceps	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
fibrous	JJ	I-NP	B
myopathy	NN	I-NP	I
.	.	O	O

Surgery	NNP	B-NP	O
revealed	VBD	B-VP	O
the	DT	B-NP	O
right	JJ	I-NP	O
radial	JJ	I-NP	O
nerve	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
severely	RB	I-VP	O
compressed	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
densely	RB	I-NP	O
fibrotic	JJ	I-NP	O
lateral	JJ	I-NP	O
head	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
triceps	NNS	I-NP	O
.	.	O	O

Decompression	NN	B-NP	O
and	CC	I-NP	O
neurolysis	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
good	JJ	B-NP	O
subsequent	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
function	NN	B-NP	O
.	.	O	O

Recurrent	JJ	B-NP	O
reversible	JJ	I-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
from	IN	B-PP	O
amphotericin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
cryptogenic	JJ	B-NP	O
cirrhosis	NN	I-NP	B
and	CC	O	O
disseminated	VBN	B-NP	O
sporotrichosis	NN	I-NP	B
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
immediately	RB	B-VP	O
following	VBG	I-VP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
occasions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
abruptness	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
reversibility	NN	I-NP	O
within	IN	B-PP	O
days	NNS	B-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
functional	JJ	I-NP	O
component	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
propose	VBP	B-VP	O
that	IN	B-SBAR	O
amphotericin	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
reduced	VBN	B-NP	O
effective	JJ	I-NP	O
arterial	JJ	I-NP	O
volume	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
activate	VB	I-VP	O
tubuloglomerular	JJ	B-NP	O
feedback	NN	I-NP	O
,	,	O	O
thereby	RB	B-VP	O
contributing	VBG	I-VP	O
to	TO	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Pneumonitis	NN	B-NP	O
with	IN	B-PP	O
pleural	JJ	B-NP	B
and	CC	I-NP	I
pericardial	JJ	I-NP	I
effusion	NN	I-NP	I
and	CC	I-NP	O
neuropathy	NN	I-NP	B
during	IN	B-PP	O
amiodarone	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
sinuatrial	JJ	B-NP	B
disease	NN	I-NP	I
and	CC	O	O
implanted	VBN	B-NP	O
pacemaker	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
amiodarone	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
for	IN	B-PP	O
control	NN	B-NP	O
of	IN	B-PP	O
supraventricular	JJ	B-NP	B
tachyarrhythmias	NNS	I-NP	I
.	.	O	O

He	PRP	B-NP	O
developed	VBD	B-VP	O
pneumonitis	NN	B-NP	B
,	,	O	O
pleural	JJ	B-NP	B
and	CC	I-NP	I
pericardial	JJ	I-NP	I
effusions	NNS	I-NP	I
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
predominantly	RB	I-NP	O
proximal	JJ	I-NP	B
motor	NN	I-NP	I
neuropathy	NN	I-NP	I
.	.	O	O

Immediate	JJ	B-NP	O
but	CC	I-NP	O
gradual	JJ	I-NP	O
improvement	NN	I-NP	O
followed	VBD	B-VP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
prednisolone	NN	B-NP	O
.	.	O	O

Review	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
and	CC	I-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
indicates	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
early	JJ	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
pneumonitis	NN	I-NP	B
,	,	O	O
immediate	JJ	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
,	,	O	O
and	CC	O	O
prompt	NN	B-NP	O
but	CC	O	O
continued	VBD	B-VP	O
steroid	JJ	B-NP	O
therapy	NN	I-NP	O
to	TO	B-VP	O
ensure	VB	I-VP	O
full	JJ	B-NP	O
recovery	NN	I-NP	O
.	.	O	O

Indomethacin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
insufficiency	NN	I-NP	I
:	:	O	O
recurrence	NN	B-NP	O
on	IN	B-PP	O
rechallenge	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
reported	VBN	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
oliguric	JJ	I-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
with	IN	B-PP	O
hyperkalemia	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
cirrhosis	NN	B-NP	B
,	,	O	O
ascites	NNS	B-NP	B
,	,	O	O
and	CC	O	O
cor	NN	B-NP	B
pulmonale	NN	I-NP	I
after	IN	B-PP	O
indomethacin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Prompt	JJ	B-NP	O
restoration	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
followed	VBD	B-VP	O
drug	NN	B-NP	O
withdrawal	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
re	AFX	B-NP	O
-	HYPH	I-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
indomethacin	NN	B-NP	O
caused	VBD	B-VP	O
recurrence	NN	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
reversible	JJ	I-NP	O
oliguria	NN	I-NP	B
.	.	O	O

Our	PRP$	B-NP	O
case	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
endogenous	JJ	B-NP	O
renal	JJ	I-NP	O
prostaglandins	NNS	I-NP	O
play	VBP	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
when	WRB	B-ADVP	O
circulating	VBG	B-VP	O
plasma	NN	B-NP	O
volume	NN	I-NP	O
is	VBZ	B-VP	O
diminished	VBN	I-VP	O
.	.	O	O

Since	IN	B-SBAR	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	B-NP	O
agents	NNS	I-NP	O
interfere	VBP	B-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
compensatory	JJ	I-NP	O
mechanism	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
cause	VB	I-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
they	PRP	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
caution	NN	B-NP	O
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subjective	JJ	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
following	VBG	B-PP	O
oral	JJ	B-NP	O
and	CC	I-NP	O
i.m.	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
flunitrazepam	NN	B-NP	O
in	IN	B-PP	O
volunteers	NNS	B-NP	O
.	.	O	O

Flunitrazepam	NNP	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
oral	JJ	I-NP	O
or	CC	I-NP	O
i.m.	JJ	I-NP	O
routes	NNS	I-NP	O
to	TO	B-PP	O
groups	NNS	B-NP	O
of	IN	B-PP	O
volunteers	NNS	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
effects	NNS	I-NP	O
compared	VBN	B-VP	O
.	.	O	O

Plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
were	VBD	B-VP	O
estimated	VBN	I-VP	O
by	IN	B-PP	O
gas	NN	B-NP	O
-	HYPH	I-NP	O
liquid	NN	I-NP	O
chromatography	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
smaller	JJR	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
striking	JJ	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
sedation	NN	B-NP	O
which	WDT	B-NP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
producing	VBG	B-VP	O
deep	JJ	B-NP	O
sleep	NN	I-NP	O
although	IN	B-SBAR	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
could	MD	B-VP	O
still	RB	I-VP	O
be	VB	I-VP	O
aroused	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
i.m.	JJ	B-NP	O
administration	NN	I-NP	O
were	VBD	B-VP	O
apparent	JJ	B-ADJP	O
earlier	RBR	B-ADVP	O
and	CC	O	O
sometimes	RB	B-VP	O
lasted	VBN	I-VP	O
longer	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
following	VBG	B-PP	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Dizziness	NN	B-NP	B
was	VBD	B-VP	O
less	RBR	B-ADJP	O
marked	JJ	I-ADJP	O
than	IN	B-PP	O
sedation	NN	B-NP	O
,	,	O	O
but	CC	O	O
increased	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
pain	NN	B-NP	B
on	IN	B-PP	O
i.m.	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
flunitrazepam	NN	B-NP	O
significantly	RB	B-ADVP	O
more	RBR	I-ADVP	O
often	RB	I-ADVP	O
than	IN	B-PP	O
with	IN	B-PP	O
isotonic	JJ	B-NP	O
saline	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
varied	VBD	B-VP	O
with	IN	B-PP	O
dose	NN	B-NP	O
and	CC	I-NP	O
route	NN	I-NP	O
and	CC	O	O
corresponded	VBD	B-VP	O
qualitatively	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
subjective	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
still	RB	B-ADVP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
measurable	JJ	B-NP	O
quantities	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
even	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
smallest	JJS	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
size	NN	I-NP	O
during	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
timolol	NN	I-NP	O
treatment	NN	I-NP	O
after	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
timolol	NN	I-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
heart	NN	B-NP	O
size	NN	I-NP	O
after	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
X	NN	B-NP	O
-	HYPH	B-NP	O
ray	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
including	VBG	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
placebo	NN	B-NP	O
num	CD	I-NP	O
timolol	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
period	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
timolol	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
small	JJ	I-NP	O
but	CC	I-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
size	NN	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
differences	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
timolol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
bradycardia	NN	I-NP	B
and	CC	O	O
a	DT	B-NP	O
compensatory	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
end	NN	B-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
volume	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
timolol	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
size	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
and	CC	I-NP	O
borderline	JJ	I-NP	O
heart	NN	I-NP	O
size	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cardiomegaly	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
size	NN	I-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
re	AFX	B-NP	O
-	HYPH	I-NP	O
infarction	NN	I-NP	B
,	,	O	O
heart	NN	B-NP	O
size	NN	I-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
timolol	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Vitamin	NN	B-NP	O
D3	NN	I-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
dairy	NN	B-NP	O
cows	NNS	I-NP	O
.	.	O	O

Large	JJ	B-NP	O
parenteral	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
IU	NN	I-NP	O
vitamin	NN	I-NP	O
D3	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
prolonged	JJ	B-NP	O
hypercalcemia	NN	I-NP	B
,	,	O	O
hyperphosphatemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
large	JJ	B-NP	O
increases	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
plasma	NN	I-NP	O
of	IN	B-PP	O
nonlactating	JJ	B-NP	O
nonpregnant	JJ	I-NP	O
and	CC	I-NP	O
pregnant	JJ	I-NP	O
Jersey	NNP	I-NP	O
cows	NNS	I-NP	O
.	.	O	O

Calcium	NN	B-NP	O
concentrations	NNS	I-NP	O
num	CD	B-NP	O
day	NN	I-NP	O
postpartum	NN	I-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
cows	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
about	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
prepartum	VBP	B-VP	O
than	IN	B-SBAR	O
in	IN	B-PP	O
control	NN	B-NP	O
cows	NNS	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cows	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
showed	VBD	B-VP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
milk	NN	B-NP	B
fever	NN	I-NP	I
during	IN	B-PP	O
the	DT	B-NP	O
peripartal	JJ	I-NP	O
period	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
cows	NNS	I-NP	O
developed	VBD	B-VP	O
clinical	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
milk	NN	B-NP	B
fever	NN	I-NP	I
during	IN	B-PP	O
this	DT	B-NP	O
period	NN	I-NP	O
.	.	O	O

Signs	NNS	B-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
toxicity	NN	I-NP	B
were	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
nonlactating	JJ	B-NP	O
nonpregnant	JJ	I-NP	O
cows	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
pregnant	JJ	B-NP	O
cows	NNS	I-NP	O
commonly	RB	B-ADVP	O
developed	VBD	B-VP	O
severe	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
toxicity	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cows	NNS	I-NP	O
died	VBD	B-VP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
widespread	JJ	B-NP	O
metastatic	JJ	I-NP	O
calcification	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cows	NNS	I-NP	O
that	WDT	B-NP	O
died	VBD	B-VP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
extreme	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
in	IN	B-PP	O
pregnant	JJ	B-NP	O
Jersey	NNP	I-NP	O
cows	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
low	JJ	I-NP	O
margin	NN	I-NP	O
of	IN	B-PP	O
safety	NN	B-NP	O
between	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
that	WDT	B-NP	O
prevent	VBP	B-VP	O
milk	NN	B-NP	B
fever	NN	I-NP	I
and	CC	I-NP	O
doses	NNS	I-NP	O
that	WDT	B-NP	O
induce	VBP	B-VP	O
milk	NN	B-NP	B
fever	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
concluded	VBD	B-VP	O
that	IN	B-SBAR	O
vitamin	NN	B-NP	O
D3	NN	I-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
practically	RB	B-ADVP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
milk	NN	B-NP	B
fever	NN	I-NP	I
when	WRB	B-ADVP	O
injected	VBN	B-VP	O
several	JJ	B-NP	O
weeks	NNS	I-NP	O
prepartum	NN	I-NP	O
.	.	O	O

Diseases	NNS	B-NP	B
of	IN	B-PP	I
peripheral	JJ	B-NP	I
nerves	NNS	I-NP	I
as	IN	B-SBAR	O
seen	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
Nigerian	JJ	I-NP	O
African	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
anatomical	JJ	I-NP	O
and	CC	I-NP	O
aetiological	JJ	I-NP	O
diagnoses	NNS	I-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	B
nerve	NN	I-NP	I
disease	NN	I-NP	I
excluding	VBG	B-PP	O
its	PRP$	B-NP	O
primary	JJ	I-NP	O
benign	JJ	I-NP	O
and	CC	I-NP	O
malignant	JJ	I-NP	O
disorders	NNS	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
seen	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
Nigerians	NNPS	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
male	JJ	I-NP	O
preponderance	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
peak	JJ	I-NP	O
incidence	NN	I-NP	O
is	VBZ	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
fourth	JJ	I-NP	O
decade	NN	I-NP	O
.	.	O	O

Sensori	AFX	B-NP	B
-	HYPH	I-NP	I
motor	NN	I-NP	I
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
the	DT	B-NP	O
commonest	JJS	I-NP	O
presentation	NN	I-NP	O
.	.	O	O

Guillain	NNP	B-NP	B
-	HYPH	I-NP	I
Barr	NNP	I-NP	I
syndrome	NN	I-NP	I
was	VBD	B-VP	O
the	DT	B-NP	O
commonest	JJS	I-NP	O
identifiable	JJ	I-NP	O
cause	NN	I-NP	O
,	,	O	O
accounting	VBG	B-VP	O
for	IN	B-PP	O
half	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
motor	NN	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
nutritional	JJ	B-NP	B
deficiency	NN	I-NP	I
of	IN	B-PP	O
thiamine	NN	B-NP	O
and	CC	I-NP	O
riboflavin	NN	I-NP	O
was	VBD	B-VP	O
common	JJ	B-ADJP	O
and	CC	O	O
presented	VBN	B-VP	O
mainly	RB	B-ADVP	O
as	IN	B-PP	O
sensory	JJ	B-ADJP	O
and	CC	O	O
sensori	AFX	B-NP	B
-	HYPH	I-NP	I
motor	NN	I-NP	I
neuropathy	NN	I-NP	I
.	.	O	O

Diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
was	VBD	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
autonomic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Isoniazid	NN	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequent	JJ	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neuropathy	NN	I-NP	B
.	.	O	O

Migraine	NN	B-NP	B
was	VBD	B-VP	O
not	RB	O	O
an	DT	B-NP	O
uncommon	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
cranial	JJ	B-NP	B
neuropathy	NN	I-NP	I
although	IN	B-SBAR	O
malignancies	NNS	B-NP	B
arising	VBG	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
reticuloendothelial	JJ	I-NP	O
system	NN	I-NP	O
or	CC	O	O
related	VBN	B-NP	O
structures	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
head	NN	I-NP	O
and	CC	I-NP	O
neck	NN	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
aetiology	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neuropathy	NN	I-NP	B
was	VBD	B-VP	O
undetermined	JJ	B-ADJP	O
.	.	O	O

Heredofamilial	JJ	B-NP	O
and	CC	I-NP	O
connective	JJ	I-NP	B
tissue	NN	I-NP	I
disorders	NNS	I-NP	I
were	VBD	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

Some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
factors	NNS	I-NP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
presentation	NN	I-NP	O
and	CC	I-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neuropathies	NNS	I-NP	B
are	VBP	B-VP	O
briefly	RB	I-VP	O
discussed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
dothiepin	NN	B-NP	O
hydrochloride	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
major	JJ	B-NP	O
depressive	JJ	I-NP	B
disorder	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
parallel	JJ	I-NP	O
treatment	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
dothiepin	NN	B-NP	O
and	CC	I-NP	O
amitriptyline	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
placebo	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
depressed	JJ	I-NP	B
outpatients	NNS	I-NP	O
.	.	O	O

Dothiepin	NN	B-NP	O
and	CC	I-NP	O
amitriptyline	NN	I-NP	O
were	VBD	B-VP	O
equally	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
alleviating	VBG	B-VP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
depressive	JJ	B-NP	B
illness	NN	I-NP	I
,	,	O	O
and	CC	O	O
both	DT	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
superior	JJ	I-ADJP	O
to	TO	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
blurred	JJ	B-NP	B
vision	NN	I-NP	I
,	,	O	O
dry	JJ	B-NP	B
mouth	NN	I-NP	I
,	,	O	O
and	CC	O	O
drowsiness	NN	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
with	IN	B-PP	O
dothiepin	NN	B-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
amitriptyline	NN	B-NP	O
.	.	O	O

Dothiepin	NNP	B-NP	O
also	RB	B-ADVP	O
produced	VBD	B-VP	O
fewer	JJR	B-NP	O
CNS	NN	I-NP	O
and	CC	I-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
clinically	RB	I-NP	O
important	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
laboratory	NN	B-NP	O
parameters	NNS	I-NP	O
.	.	O	O

Dothiepin	NNP	B-NP	O
thus	RB	B-ADVP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
antidepressant	NN	I-NP	O
drug	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
fewer	JJR	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
than	IN	B-PP	O
amitriptyline	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
depressed	JJ	B-NP	B
outpatients	NNS	I-NP	O
.	.	O	O

Behavioral	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
and	CC	I-NP	O
propranolol	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
panic	NN	B-NP	B
disorder	NN	I-NP	I
and	CC	I-NP	O
agoraphobia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
and	CC	I-NP	O
propranolol	NN	I-NP	O
on	IN	B-PP	O
psychological	JJ	B-NP	O
performance	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
panic	NN	B-NP	B
disorders	NNS	I-NP	I
and	CC	O	O
agoraphobia	NN	B-NP	B
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	O	O
randomized	VBN	B-VP	O
and	CC	O	O
crossover	NN	B-NP	O
design	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
drugs	NNS	I-NP	O
impaired	VBD	B-VP	B
immediate	JJ	B-NP	I
free	JJ	I-NP	I
recall	NN	I-NP	I
but	CC	O	O
the	DT	B-NP	O
decrease	NN	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
for	IN	B-PP	O
diazepam	NN	B-NP	O
than	IN	B-PP	O
propranolol	NN	B-NP	O
.	.	O	O

Delayed	VBN	B-NP	B
free	JJ	I-NP	I
recall	NN	I-NP	I
was	VBD	B-VP	I
also	RB	B-ADVP	I
impaired	JJ	B-ADJP	I
but	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
tapped	VBD	B-VP	O
faster	RBR	B-ADVP	O
after	IN	B-PP	O
propranolol	NN	B-NP	O
than	IN	B-PP	O
diazepam	NN	B-NP	O
and	CC	O	O
they	PRP	B-NP	O
were	VBD	B-VP	O
more	RBR	I-VP	O
sedated	VBN	I-VP	O
after	IN	B-PP	O
diazepam	NN	B-NP	O
than	IN	B-PP	O
propranolol	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
patients	NNS	B-NP	O
tested	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
medication	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
show	VB	I-VP	O
any	DT	B-NP	O
decrement	NN	I-NP	O
of	IN	B-PP	O
performance	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
previously	RB	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Accumulation	NN	B-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
reflected	VBN	I-VP	O
in	IN	B-PP	O
prolonged	JJ	B-NP	O
behavioral	JJ	I-NP	B
impairment	NN	I-NP	I
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
on	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
[	(	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
nitro	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
furyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
thiazolyl	NN	I-NP	O
]	)	O	O
-	HYPH	B-NP	O
formamide	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
epithelial	JJ	I-NP	O
proliferation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
and	CC	I-NP	O
forestomach	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
with	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
[	(	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
nitro	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
furyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
thiazolyl	NN	I-NP	O
]	)	O	O
-	HYPH	O	O
formamide	NN	B-NP	O
(	(	O	O
FANFT	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
rats	NNS	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
FANFT	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
bladder	NN	I-NP	B
carcinomas	NNS	I-NP	I
but	CC	O	O
a	DT	B-NP	O
concomitant	JJ	I-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
forestomach	NN	B-NP	B
tumors	NNS	I-NP	I
.	.	O	O

An	DT	B-NP	O
autoradiographic	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
male	JJ	B-NP	O
F	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
rats	NNS	I-NP	O
fed	VBN	B-VP	O
diet	NN	B-NP	O
containing	VBG	B-VP	O
FANFT	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
aspirin	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
FANFT	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
forestomach	NN	I-NP	O
and	CC	I-NP	O
bladder	NN	I-NP	O
.	.	O	O

FANFT	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
suppressed	VBN	I-VP	O
by	IN	B-PP	O
aspirin	NN	B-NP	O
co	AFX	O	O
-	HYPH	O	O
administration	NN	B-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
after	IN	I-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
forestomach	NN	I-NP	O
,	,	O	O
and	CC	O	O
also	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
,	,	O	O
aspirin	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
FANFT	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
labeling	VBG	B-VP	O
index	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
carcinogenicity	NN	I-NP	O
experiment	NN	I-NP	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
different	JJ	B-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
FANFT	NN	B-NP	O
carcinogenesis	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
and	CC	I-NP	O
forestomach	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
aspirin	NN	B-NP	O
s	VBZ	B-VP	O
effect	NN	B-NP	O
on	IN	B-PP	O
FANFT	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
forestomach	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
an	DT	B-NP	O
irritant	JJ	I-NP	O
effect	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
adaptation	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
ingestion	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
.	.	O	O

Provocation	NN	B-NP	O
of	IN	B-PP	O
postural	JJ	B-NP	O
hypotension	NN	I-NP	B
by	IN	B-PP	O
nitroglycerin	NN	B-NP	O
in	IN	B-PP	O
diabetic	JJ	B-NP	B
autonomic	JJ	I-NP	I
neuropathy	NN	I-NP	I
?	.	O	O
The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
nitroglycerin	NN	B-NP	O
on	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
normal	JJ	I-NP	O
subjects	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
diabetic	JJ	I-NP	B
subjects	NNS	I-NP	O
without	IN	B-PP	O
autonomic	JJ	B-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
diabetic	JJ	I-NP	B
subjects	NNS	I-NP	O
with	IN	B-PP	O
autonomic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
magnitude	NN	I-NP	O
and	CC	I-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
after	IN	B-PP	O
nitroglycerin	NN	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
and	CC	I-NP	O
diabetic	JJ	I-NP	B
subjects	NNS	I-NP	O
without	IN	B-PP	O
autonomic	JJ	B-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
whereas	IN	O	O
a	DT	B-NP	O
lesser	JJR	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
greater	JJR	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
diabetic	JJ	I-NP	B
subjects	NNS	I-NP	O
with	IN	B-PP	O
autonomic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
therefore	RB	I-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
caution	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
exercised	VBN	I-VP	O
when	WRB	B-ADVP	O
prescribing	VBG	B-VP	O
vasodilator	NN	B-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
diabetic	JJ	B-NP	B
patients	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
those	DT	B-NP	O
with	IN	B-PP	O
autonomic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Characterization	NN	B-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
adenohypophyseal	JJ	I-NP	B
tumors	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
Fischer	NNP	I-NP	O
num	CD	I-NP	O
rat	NN	I-NP	O
.	.	O	O

Pituitary	JJ	B-NP	B
tumors	NNS	I-NP	I
were	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
F344	NN	B-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
diethylstilbestrol	NN	B-NP	O
implanted	VBN	B-VP	O
subcutaneously	RB	B-ADVP	O
in	IN	B-PP	O
silastic	JJ	B-NP	O
capsules	NNS	I-NP	O
.	.	O	O

Over	IN	B-PP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
DES	NNP	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
pairs	NNS	B-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
and	CC	I-NP	O
DES	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
sacrificed	VBN	I-VP	O
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
pituitaries	NNS	I-NP	O
dissociated	VBN	B-VP	O
enzymatically	RB	B-ADVP	O
into	IN	B-PP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
cell	NN	I-NP	O
preparations	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
cell	NN	I-NP	O
populations	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
regarding	VBG	B-PP	O
total	JJ	B-NP	O
cell	NN	I-NP	O
recovery	NN	I-NP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
gland	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
intracellular	JJ	B-NP	O
prolactin	NN	I-NP	O
(	(	O	O
PRL	NN	B-NP	O
)	)	O	O
content	NN	B-NP	O
and	CC	O	O
subsequent	JJ	B-NP	O
release	NN	I-NP	O
in	IN	B-PP	O
primary	JJ	B-NP	O
culture	NN	I-NP	O
,	,	O	O
immunocytochemical	JJ	B-NP	O
PRL	NN	I-NP	O
staining	NN	I-NP	O
,	,	O	O
density	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
size	NN	B-NP	O
alterations	NNS	I-NP	O
via	IN	B-PP	O
separation	NN	B-NP	O
on	IN	B-PP	O
Ficoll	NN	B-NP	O
-	HYPH	I-NP	O
Hypaque	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
unit	NN	B-NP	O
gravity	NN	I-NP	O
sedimentation	NN	I-NP	O
,	,	O	O
and	CC	O	O
cell	NN	B-NP	O
cycle	NN	I-NP	O
analysis	NN	I-NP	O
,	,	O	O
after	IN	B-PP	O
acriflavine	NN	B-NP	O
DNA	NN	I-NP	O
staining	NN	I-NP	O
,	,	O	O
by	IN	B-PP	O
laser	NN	B-NP	O
flow	NN	I-NP	O
cytometry	NN	I-NP	O
.	.	O	O

Total	JJ	B-NP	O
cell	NN	I-NP	O
yields	NNS	I-NP	O
from	IN	B-PP	O
DES	NNP	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
pituitaries	NNS	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
control	VBP	B-VP	O
yields	NNS	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
control	VBP	B-VP	O
values	NNS	B-NP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Intracellular	JJ	B-NP	O
PRL	NN	I-NP	O
content	NN	I-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
control	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
and	CC	O	O
PRL	NN	B-NP	O
release	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
was	VBD	B-VP	O
significantly	RB	B-ADVP	O
and	CC	I-ADVP	O
consistently	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
after	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
DES	NNP	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

Beyond	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
DES	NNP	B-NP	O
exposure	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
immunochemically	RB	I-NP	O
PRL	NN	I-NP	O
-	HYPH	I-NP	O
positive	JJ	I-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
cells	NNS	B-NP	O
increased	VBN	B-VP	O
to	TO	B-PP	O
over	IN	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
population	NN	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
density	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
size	NN	B-NP	O
and	CC	I-NP	O
PRL	NN	I-NP	O
content	NN	I-NP	O
were	VBD	B-VP	O
indicated	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
PRL	NN	I-NP	O
cell	NN	I-NP	O
population	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
separation	NN	B-NP	O
protocols	NNS	I-NP	O
.	.	O	O

All	PDT	B-NP	O
these	DT	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
DES	NNS	B-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
among	IN	B-PP	O
previously	RB	B-NP	O
ovariectomized	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
extend	VBP	B-VP	O
the	DT	B-NP	O
findings	NNS	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
investigators	NNS	I-NP	O
,	,	O	O
further	RB	B-ADVP	O
establishing	VBG	B-VP	O
the	DT	B-NP	O
DES	NNP	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tumor	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
study	NN	B-NP	O
of	IN	B-PP	O
PRL	NN	B-NP	O
cellular	JJ	I-NP	O
control	NN	I-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

Triamterene	NN	B-NP	O
nephrolithiasis	NN	I-NP	B
complicating	VBG	B-VP	O
dyazide	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
triamterene	NN	B-NP	O
nephrolithiasis	NN	I-NP	B
is	VBZ	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
man	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
hydrochlorothiazide	NN	B-NP	O
-	HYPH	B-NP	O
triamterene	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
stone	NN	I-NP	O
passed	VBD	B-VP	O
spontaneously	RB	B-ADVP	O
and	CC	O	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
contain	VB	I-VP	O
a	DT	B-NP	O
triamterene	NN	I-NP	O
metabolite	NN	I-NP	O
admixed	VBN	B-VP	O
with	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
salts	NNS	I-NP	O
.	.	O	O

Factors	NNS	B-NP	O
affecting	VBG	B-VP	O
triamterene	NN	B-NP	O
nephrolithiasis	NN	I-NP	B
are	VBP	B-VP	O
discussed	VBN	I-VP	O
and	CC	O	O
num	CD	B-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

Metabolic	JJ	B-NP	O
involvement	NN	I-NP	O
in	IN	B-PP	O
adriamycin	NN	B-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
cardiotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
mammalian	JJ	B-NP	O
myocardial	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
culture	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

Adriamycin	NN	B-NP	O
inhibited	VBD	B-VP	O
cell	NN	B-NP	O
growth	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
rhythmic	JJ	I-NP	O
contractions	NNS	I-NP	O
characteristic	JJ	B-ADJP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
culture	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
possible	JJ	I-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
energy	NN	B-NP	O
metabolism	NN	I-NP	O
was	VBD	B-VP	O
suggested	VBN	I-VP	O
previously	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
the	DT	B-NP	O
adenylate	NN	I-NP	O
energy	NN	I-NP	O
charge	NN	I-NP	O
and	CC	I-NP	O
phosphorylcreatine	NN	I-NP	O
mole	NN	I-NP	O
fraction	NN	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
adriamycin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
adenylate	NN	I-NP	O
energy	NN	I-NP	O
charge	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
phophorylcreatine	NN	I-NP	O
mole	NN	I-NP	O
fraction	NN	I-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

Such	JJ	B-NP	O
disparity	NN	I-NP	O
suggests	VBZ	B-VP	O
an	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
creatine	NN	B-NP	O
phosphokinase	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
adenosine	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
cell	NN	I-NP	O
cultures	NNS	I-NP	O
markedly	RB	B-ADVP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
ATP	NN	I-NP	O
concentration	NN	I-NP	O
through	IN	B-PP	O
a	DT	B-NP	O
pathway	NN	I-NP	O
reportedly	RB	B-VP	O
leading	VBG	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
compartmentalized	VBN	I-NP	O
ATP	NN	I-NP	O
pool	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
adriamycin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
adenylate	NN	I-NP	O
charge	NN	I-NP	O
and	CC	O	O
,	,	O	O
concomitant	JJ	B-ADJP	O
with	IN	B-PP	O
this	DT	B-NP	O
inrcease	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
cells	NNS	I-NP	O
s	VBZ	B-VP	O
functional	JJ	B-NP	O
integrity	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
percentage	NN	B-NP	O
of	IN	B-PP	O
beating	VBG	B-VP	O
cells	NNS	B-NP	O
and	CC	O	O
rate	NN	B-NP	O
of	IN	B-PP	O
contractions	NNS	B-NP	O
,	,	O	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
.	.	O	O

Age	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
to	TO	B-PP	O
neurotoxic	JJ	B-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
streptomycin	NN	B-NP	O
.	.	O	O

Streptomycin	NN	B-NP	O
sulfate	NN	I-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
for	IN	B-PP	O
various	JJ	B-NP	O
periods	NNS	I-NP	O
into	IN	B-PP	O
preweanling	VBG	B-NP	O
rats	NNS	I-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
into	IN	B-PP	O
weanling	VBG	B-VP	O
rats	NNS	B-NP	O
.	.	O	O

Beginning	VBG	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
body	NN	B-NP	O
movement	NN	I-NP	O
and	CC	I-NP	O
hearing	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Abnormal	JJ	B-NP	B
movements	NNS	I-NP	I
and	CC	I-NP	O
deafness	NN	I-NP	B
occurred	VBD	B-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
preweaning	JJ	I-NP	O
period	NN	I-NP	O
;	:	O	O
within	IN	B-PP	O
this	DT	B-NP	O
period	NN	I-NP	O
the	DT	B-NP	O
greatest	JJS	I-NP	O
sensitivities	NNS	I-NP	O
for	IN	B-PP	O
these	DT	B-NP	O
abnormalities	NNS	I-NP	O
occurred	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
cochlea	NN	I-NP	O
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
streptomycin	NN	B-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
site	NN	I-NP	O
(	(	O	O
vestibular	JJ	B-ADJP	O
or	CC	I-ADJP	O
central	JJ	I-ADJP	O
)	)	O	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

Crescentic	JJ	B-NP	O
fibrillary	JJ	I-NP	O
glomerulonephritis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
intermittent	JJ	B-NP	O
rifampin	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
pulmonary	JJ	B-NP	B
tuberculosis	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
study	NN	I-NP	O
reveals	VBZ	B-VP	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
finding	NN	I-NP	O
of	IN	B-PP	O
rapidly	RB	B-NP	O
proliferative	JJ	I-NP	O
crescentic	JJ	I-NP	O
glomerulonephritis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
rifampin	NN	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
other	JJ	I-NP	O
identifiable	JJ	I-NP	O
causes	NNS	I-NP	O
for	IN	B-PP	O
developing	VBG	B-VP	O
this	DT	B-NP	O
disease	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
patient	NN	I-NP	O
underwent	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
regimen	NN	I-NP	O
of	IN	B-PP	O
rifampin	NN	B-NP	O
and	CC	I-NP	O
isoniazid	NN	I-NP	O
for	IN	B-PP	O
pulmonary	JJ	B-NP	B
tuberculosis	NN	I-NP	I
and	CC	O	O
was	VBD	B-VP	O
discovered	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
developed	VBN	I-VP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
completion	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Renal	JJ	B-NP	O
biopsy	NN	I-NP	O
revealed	VBD	B-VP	O
severe	JJ	B-NP	O
glomerulonephritis	NN	I-NP	B
with	IN	B-PP	O
crescents	NNS	B-NP	O
,	,	O	O
electron	NN	B-NP	O
dense	JJ	I-NP	O
fibrillar	JJ	I-NP	O
deposits	NNS	I-NP	O
and	CC	O	O
moderate	JJ	B-NP	O
lymphocytic	JJ	I-NP	O
interstitial	JJ	I-NP	O
infiltrate	NN	I-NP	O
.	.	O	O

Other	JJ	B-NP	O
possible	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
rapidly	RB	B-NP	O
progressive	JJ	I-NP	O
glomerulonephritis	NN	I-NP	B
were	VBD	B-VP	O
investigated	VBN	I-VP	O
and	CC	O	O
ruled	VBN	B-VP	O
out	RP	B-PRT	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
documents	VBZ	B-VP	O
the	DT	B-NP	O
unusual	JJ	I-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
rapidly	RB	B-NP	O
progressive	JJ	I-NP	O
glomerulonephritis	NN	I-NP	B
with	IN	B-PP	O
crescents	NNS	B-NP	O
and	CC	O	O
fibrillar	JJ	B-NP	O
glomerulonephritis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
rifampin	NN	B-NP	O
.	.	O	O

Time	NN	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
in	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
with	IN	B-PP	O
antioxidants	NNS	B-NP	O
significantly	RB	B-VP	O
reducing	VBG	I-VP	O
the	DT	B-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
temporal	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
and	CC	I-NP	O
proteinuria	NN	I-NP	B
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
hour	NN	I-NP	O
urine	NN	I-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
prior	RB	B-ADVP	O
to	TO	B-VP	O
sacrifice	VB	I-VP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
kidneys	NNS	I-NP	O
were	VBD	B-VP	O
removed	VBN	I-VP	O
,	,	O	O
flushed	VBN	B-VP	O
with	IN	B-PP	O
ice	NN	B-NP	O
cold	JJ	I-NP	O
TRIS	NN	I-NP	O
buffer	NN	I-NP	O
.	.	O	O

Kidney	NN	B-NP	O
cortices	NNS	I-NP	O
from	IN	B-PP	O
each	DT	B-NP	O
animal	NN	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
prepare	VB	I-VP	O
homogenates	NNS	B-NP	O
.	.	O	O

Tissue	NN	B-NP	O
lipid	NN	I-NP	O
peroxidation	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
whole	JJ	B-NP	O
homogenates	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
lipid	NN	B-NP	O
extracts	NNS	I-NP	O
from	IN	B-PP	O
homogenates	NNS	B-NP	O
as	IN	B-PP	O
thiobarbituric	JJ	B-NP	O
acid	NN	I-NP	O
reactive	JJ	I-NP	O
substances	NNS	I-NP	O
.	.	O	O

Proteinuria	NNP	B-NP	B
was	VBD	B-VP	O
evident	JJ	B-ADJP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
peaked	VBD	B-VP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
persisted	VBD	B-VP	O
to	TO	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
in	IN	B-PP	O
homogenates	NNS	B-NP	O
was	VBD	B-VP	O
maximal	JJ	B-ADJP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
declined	VBD	B-VP	O
rapidly	RB	B-ADVP	O
to	TO	B-PP	O
control	NN	B-NP	O
levels	NNS	I-NP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
in	IN	B-PP	O
mediating	VBG	B-VP	O
the	DT	B-NP	O
proteinuric	JJ	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
PAN	NN	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Clomipramine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
sleep	NN	I-NP	B
disturbance	NN	I-NP	I
does	VBZ	B-VP	O
not	RB	I-VP	O
impair	VB	I-VP	O
its	PRP$	B-NP	O
prolactin	NN	I-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
action	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	I-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
sleep	NN	B-NP	B
disturbance	NN	I-NP	I
,	,	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
clomipramine	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
secretory	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
prolactin	NN	B-NP	O
(	(	O	O
PRL	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
direct	JJ	I-NP	O
drug	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
supine	NN	B-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
under	IN	B-PP	O
placebo	NN	B-NP	O
-	HYPH	B-NP	O
controlled	VBN	I-NP	O
conditions	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
night	NN	I-NP	O
,	,	O	O
when	WRB	B-ADVP	O
sleeping	VBG	B-VP	O
and	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
at	IN	B-PP	O
daytime	NN	B-NP	O
,	,	O	O
when	WRB	B-ADVP	O
awake	NN	B-NP	O
.	.	O	O

Each	DT	B-NP	O
subject	NN	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
clomipramine	NN	B-NP	O
given	VBN	B-VP	O
orally	RB	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
before	IN	B-PP	O
blood	NN	B-NP	O
collection	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
PRL	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
intervals	NNS	I-NP	O
and	CC	O	O
underlying	VBG	B-VP	O
secretory	JJ	B-NP	O
rates	NNS	I-NP	O
calculated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
deconvolution	NN	I-NP	O
procedure	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
both	DT	B-NP	O
experiments	NNS	I-NP	O
the	DT	B-NP	O
drug	NN	I-NP	O
intake	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
PRL	NN	B-NP	O
secretion	NN	I-NP	O
,	,	O	O
acting	VBG	B-VP	O
preferentially	RB	B-ADVP	O
on	IN	B-PP	O
tonic	JJ	B-NP	O
secretion	NN	I-NP	O
as	IN	B-PP	O
pulse	NN	B-NP	O
amplitude	NN	I-NP	O
and	CC	O	O
frequency	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
from	IN	B-PP	O
corresponding	VBG	B-VP	O
control	NN	B-NP	O
values	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
night	NN	I-NP	O
clomipramine	NN	I-NP	O
ingestion	NN	I-NP	O
altered	VBD	B-VP	O
the	DT	B-NP	O
complete	JJ	I-NP	O
sleep	NN	I-NP	O
architecture	NN	I-NP	O
in	IN	B-PP	O
that	IN	B-NP	O
it	PRP	B-NP	O
suppressed	VBD	B-VP	O
REM	NN	B-NP	O
sleep	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
sleep	JJ	I-NP	O
cycles	NNS	I-NP	O
and	CC	O	O
induced	VBD	B-VP	O
increased	VBN	B-NP	O
wakefulness	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
the	DT	B-NP	O
relative	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
PRL	NN	B-NP	O
secretion	NN	I-NP	O
expressed	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mean	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
differ	VB	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
night	NN	I-NP	O
and	CC	I-NP	O
day	NN	I-NP	O
time	NN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
observed	VBN	I-NP	O
sleep	NN	I-NP	B
disturbance	NN	I-NP	I
did	VBD	B-VP	O
not	RB	I-VP	O
interfere	VB	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
action	NN	I-NP	O
per	FW	B-ADVP	O
se	FW	I-ADVP	O
.	.	O	O

The	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
REM	NN	B-NP	O
sleep	NN	I-NP	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
not	RB	O	O
to	TO	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
determining	VBG	I-NP	O
factor	NN	I-NP	O
either	CC	B-PP	O
for	IN	B-PP	O
secretory	JJ	B-NP	O
pulse	NN	I-NP	O
amplitude	NN	I-NP	O
and	CC	I-NP	O
frequency	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
,	,	O	O
for	IN	B-PP	O
both	DT	B-NP	O
,	,	O	O
mean	JJ	B-NP	O
nocturnal	JJ	I-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
with	IN	B-PP	O
and	CC	O	O
without	IN	B-PP	O
prior	JJ	B-NP	O
clomipramine	NN	I-NP	O
ingestion	NN	I-NP	O
.	.	O	O

Angioedema	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
with	IN	B-PP	O
flash	NN	B-NP	O
pulmonary	JJ	I-NP	B
edema	NN	I-NP	I
,	,	O	O
preceded	VBN	B-VP	O
by	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
,	,	O	O
requiring	VBG	B-VP	O
intubation	NN	B-NP	O
.	.	O	O

Her	PRP$	B-NP	O
medical	JJ	I-NP	O
history	NN	I-NP	O
included	VBD	B-VP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
with	IN	B-PP	O
previous	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarctions	NNS	I-NP	I
,	,	O	O
hypertension	NN	B-NP	B
,	,	O	O
and	CC	O	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
angioedema	NN	B-NP	B
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
lisinopril	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
elicited	VBN	I-VP	O
.	.	O	O

Current	JJ	B-NP	O
medications	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
include	VB	I-VP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitors	NNS	I-NP	O
or	CC	O	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
blockers	NNS	B-NP	O
.	.	O	O

She	PRP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
previous	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocking	VBG	B-VP	O
drug	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
hospitalization	NN	B-NP	O
(	(	O	O
while	IN	B-SBAR	O
intubated	VBN	B-VP	O
)	)	O	O
,	,	O	O
intravenous	JJ	B-NP	O
metoprolol	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
angioedema	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
angioedema	NN	I-NP	B
resolved	VBN	B-VP	O
after	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
steroids	NNS	I-NP	O
and	CC	O	O
diphenhydramine	NN	B-NP	O
hydrochloride	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
coniine	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
developing	VBG	I-NP	O
chick	NN	I-NP	O
embryo	NN	I-NP	O
.	.	O	O

Coniine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
alkaloid	NN	I-NP	O
from	IN	B-PP	O
Conium	NN	B-NP	O
maculatum	NN	I-NP	O
(	(	O	O
poison	NN	B-NP	O
hemlock	NN	I-NP	O
)	)	O	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
teratogenic	JJ	B-ADJP	O
in	IN	B-PP	O
livestock	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
major	JJ	I-NP	O
teratogenic	JJ	I-NP	O
outcome	NN	I-NP	O
is	VBZ	B-VP	O
arthrogryposis	NN	B-NP	B
,	,	O	O
presumably	RB	B-ADJP	O
due	JJ	I-ADJP	O
to	TO	B-PP	O
nicotinic	JJ	B-NP	O
receptor	NN	I-NP	O
blockade	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
coniine	NN	B-NP	O
has	VBZ	B-VP	O
failed	VBN	I-VP	O
to	TO	I-VP	O
produce	VB	I-VP	O
arthrogryposis	NN	B-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
or	CC	I-NP	O
mice	NNS	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
only	RB	B-ADJP	O
weakly	RB	I-ADJP	O
teratogenic	JJ	I-ADJP	O
in	IN	B-PP	O
rabbits	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
and	CC	I-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
coniine	NN	B-NP	O
and	CC	I-NP	O
nicotine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
developing	VBG	I-NP	O
chick	NN	I-NP	O
.	.	O	O

Concentrations	NNS	B-NP	O
of	IN	B-PP	O
coniine	NN	B-NP	O
and	CC	I-NP	O
nicotine	NN	I-NP	O
sulfate	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Both	DT	B-NP	O
compounds	NNS	I-NP	O
caused	VBD	B-VP	O
deformations	NNS	B-NP	B
and	CC	O	O
lethality	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
sulfate	NN	I-NP	O
caused	VBD	B-VP	O
some	DT	B-NP	O
lethality	NN	I-NP	O
but	CC	O	O
a	DT	B-NP	O
no	DT	I-NP	O
effect	NN	I-NP	O
level	NN	I-NP	O
for	IN	B-PP	O
coniine	NN	B-NP	O
lethality	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
deformations	NNS	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
both	CC	O	O
coniine	NN	B-NP	O
and	CC	O	O
nicotine	NN	B-NP	O
sulfate	NN	I-NP	O
were	VBD	B-VP	O
excessive	JJ	B-NP	B
flexion	NN	I-NP	I
or	CC	I-NP	I
extension	NN	I-NP	I
of	IN	B-PP	I
num	CD	B-NP	I
or	CC	I-NP	I
more	JJR	I-NP	I
toes	NNS	I-NP	I
.	.	O	O

No	DT	B-NP	O
histopathological	JJ	I-NP	O
alterations	NNS	I-NP	O
or	CC	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
bone	NN	B-NP	O
formation	NN	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
limbs	NNS	I-NP	O
or	CC	I-NP	O
toes	NNS	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
chicks	NNS	I-NP	O
from	IN	B-PP	O
any	DT	B-NP	O
group	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
extensive	JJ	B-NP	O
cranial	JJ	I-NP	B
hemorrhage	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
nicotine	NN	I-NP	O
sulfate	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
chicks	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
movement	NN	B-NP	O
in	IN	B-PP	O
coniine	NN	B-NP	O
and	CC	I-NP	O
nicotine	NN	I-NP	O
sulfate	NN	I-NP	O
treated	VBN	B-VP	O
chicks	NNS	B-NP	O
as	IN	B-SBAR	O
determined	VBN	B-VP	O
by	IN	B-PP	O
ultrasound	NN	B-NP	O
.	.	O	O

Control	NN	B-NP	O
chicks	NNS	I-NP	O
were	VBD	B-VP	O
in	IN	B-PP	O
motion	NN	B-NP	O
an	DT	B-NP	O
average	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
coniine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
chicks	NNS	I-NP	O
were	VBD	B-VP	O
only	RB	I-VP	O
moving	VBG	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
movement	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
for	IN	B-PP	O
nicotine	NN	B-NP	O
sulfate	NN	I-NP	O
treated	VBN	B-NP	O
chicks	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
summary	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
chick	NN	I-NP	O
embryo	NN	I-NP	O
provides	VBZ	B-VP	O
a	DT	B-NP	O
reliable	JJ	I-NP	O
and	CC	I-NP	O
simple	JJ	I-NP	O
experimental	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
coniine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
arthrogryposis	NN	I-NP	B
.	.	O	O

Data	NNS	B-NP	O
from	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
support	VBP	B-VP	O
a	DT	B-NP	O
mechanism	NN	I-NP	O
involving	VBG	B-VP	O
nicotinic	JJ	B-NP	O
receptor	NN	I-NP	O
blockade	NN	I-NP	O
with	IN	B-PP	O
subsequent	JJ	B-NP	O
decreased	VBN	I-NP	O
fetal	JJ	I-NP	O
movement	NN	I-NP	O
.	.	O	O

Epidural	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
during	IN	B-PP	O
prostaglandin	NN	B-NP	O
E1	NN	I-NP	O
or	CC	I-NP	O
trimethaphan	NN	I-NP	O
induced	VBD	B-VP	O
hypotension	NN	B-NP	B
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
E1	NN	I-NP	O
(	(	O	O
PGE1	NN	B-NP	O
)	)	O	O
or	CC	O	O
trimethaphan	NN	B-NP	O
(	(	O	O
TMP	NN	B-NP	O
)	)	O	O
induced	VBD	B-VP	O
hypotension	NN	B-NP	B
on	IN	B-PP	O
epidural	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
(	(	O	O
EBF	NN	B-NP	O
)	)	O	O
during	IN	B-PP	O
spinal	JJ	B-NP	O
surgery	NN	I-NP	O
,	,	O	O
EBF	NN	B-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
heat	NN	I-NP	O
clearance	NN	I-NP	O
method	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
postero	AFX	B-ADVP	O
-	HYPH	B-NP	O
lateral	JJ	I-NP	O
interbody	NN	I-NP	O
fusion	NN	I-NP	O
under	IN	B-PP	O
isoflurane	NN	B-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
initial	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microgram.kg	NN	I-NP	O
-	HYPH	B-NP	O
1.min	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
of	IN	B-PP	O
PGE1	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
micrograms.kg	NN	I-NP	O
-	HYPH	B-NP	O
1.min	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
of	IN	B-PP	O
TMP	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intravenously	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
dural	JJ	I-NP	O
opening	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
adjusted	VBN	I-VP	O
to	TO	B-VP	O
maintain	VB	I-VP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
at	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
mmHg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hypotensive	JJ	I-NP	B
drug	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
operative	JJ	I-NP	O
procedure	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
starting	VBG	B-VP	O
PGE1	NN	B-NP	O
or	CC	I-NP	O
TMP	NN	I-NP	O
,	,	I-NP	O
MAP	NN	I-NP	O
and	CC	I-NP	O
rate	NN	I-NP	O
pressure	NN	I-NP	O
product	NN	I-NP	O
(	(	O	O
RPP	NN	B-NP	O
)	)	O	O
decreased	VBD	B-VP	O
significantly	RB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
preinfusion	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
PGE1	NN	B-NP	O
remained	VBD	B-VP	O
constant	JJ	B-ADJP	O
until	IN	B-SBAR	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
its	PRP$	B-NP	O
discontinuation	NN	I-NP	O
.	.	O	O

Heart	NN	B-NP	O
rate	NN	I-NP	O
(	(	O	O
HR	NN	B-NP	O
)	)	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
in	IN	B-PP	O
either	DT	B-NP	O
group	NN	I-NP	O
.	.	O	O

EBFF	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
during	IN	B-PP	O
PGE1	NN	B-NP	O
infusion	NN	I-NP	O
whereas	IN	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
TMP	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
EBF	NN	B-NP	O
decreased	VBD	B-VP	O
significantly	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
TMP	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
PGE1	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
preferable	JJ	B-ADJP	O
to	TO	B-PP	O
TMP	NN	B-NP	O
for	IN	B-PP	O
hypotensive	JJ	B-NP	B
anaesthesia	NN	I-NP	O
in	IN	B-PP	O
spinal	JJ	B-NP	O
surgery	NN	I-NP	O
because	IN	B-SBAR	O
TMP	NN	B-NP	O
decreased	VBD	B-VP	O
EBF	NN	B-NP	O
.	.	O	O

Immunohistochemical	JJ	B-NP	O
studies	NNS	I-NP	O
with	IN	B-PP	O
antibodies	NNS	B-NP	O
to	TO	B-PP	O
neurofilament	NN	B-NP	O
proteins	NNS	I-NP	O
on	IN	B-PP	O
axonal	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
experimental	JJ	B-NP	O
focal	JJ	I-NP	O
lesions	NNS	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
.	.	O	O

Immunohistochemistry	NN	B-NP	O
with	IN	B-PP	O
monoclonal	JJ	B-NP	O
antibodies	NNS	I-NP	O
against	IN	B-PP	O
neurofilament	NN	B-NP	O
(	(	O	O
NF	NN	B-NP	O
)	)	O	O
proteins	NNS	B-NP	O
of	IN	B-PP	O
middle	JJ	B-NP	O
and	CC	I-NP	O
high	JJ	I-NP	O
molecular	JJ	I-NP	O
weight	NN	I-NP	O
class	NN	I-NP	O
,	,	O	O
NF	NN	B-NP	O
-	HYPH	B-NP	O
M	NN	I-NP	O
and	CC	I-NP	O
NF	NN	I-NP	O
-	HYPH	B-NP	O
H	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
study	VB	I-VP	O
axonal	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
borderzone	NN	I-NP	O
of	IN	B-PP	O
focal	JJ	B-NP	O
lesions	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Focal	JJ	B-NP	O
injury	NN	I-NP	B
in	IN	B-PP	I
the	DT	B-NP	I
cortex	NN	I-NP	I
was	VBD	B-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
infusion	NN	B-NP	O
of	IN	B-PP	O
lactate	NN	B-NP	O
at	IN	B-PP	O
acid	NN	B-NP	O
pH	NN	I-NP	O
or	CC	B-PP	O
by	IN	B-PP	O
stab	NN	B-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
needle	NN	B-NP	O
insertion	NN	I-NP	O
.	.	O	O

Infarcts	NNS	B-NP	B
in	IN	B-PP	I
substantia	NN	B-NP	I
nigra	NN	I-NP	I
pars	NNS	I-NP	I
reticulata	NNS	I-NP	I
were	VBD	B-VP	O
evoked	VBN	I-VP	O
by	IN	B-PP	O
prolonged	VBN	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

Immunohistochemical	JJ	B-NP	O
staining	NN	I-NP	O
for	IN	B-PP	O
NFs	NNS	B-NP	O
showed	VBD	B-VP	O
characteristic	JJ	B-NP	O
terminal	JJ	I-NP	O
clubs	NNS	I-NP	O
of	IN	B-PP	O
axons	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
borderzone	NN	I-NP	O
of	IN	B-PP	O
lesions	NNS	B-NP	O
.	.	O	O

Differences	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
labelling	NN	I-NP	O
pattern	NN	I-NP	O
occurred	VBD	B-VP	O
with	IN	B-PP	O
different	JJ	B-NP	O
antibodies	NNS	I-NP	O
which	WDT	B-NP	O
apparently	RB	B-ADVP	O
depended	VBD	B-VP	O
on	IN	B-PP	O
molecular	JJ	B-NP	O
weight	NN	I-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
NFs	NNS	B-NP	O
and	CC	O	O
phosphorylation	NN	B-NP	O
state	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
immunohistochemical	JJ	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
NFs	NNS	B-NP	O
can	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
marker	NN	I-NP	O
for	IN	B-PP	O
axonal	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
various	JJ	B-NP	O
experimental	JJ	I-NP	O
traumatic	JJ	I-NP	B
or	CC	I-NP	O
ischemic	JJ	I-NP	O
lesions	NNS	I-NP	O
.	.	O	O

Increase	NN	B-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
disability	NN	I-NP	I
after	IN	B-PP	O
fluoxetine	NN	B-NP	O
medication	NN	I-NP	O
.	.	O	O

Depression	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
clinical	JJ	I-NP	O
feature	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	B
disability	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
idiopathic	JJ	B-NP	B
Parkinson	NNP	I-NP	I
s	NN	I-NP	I
disease	NN	I-NP	I
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
antidepressant	NN	I-NP	O
fluoxetine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
clinically	RB	I-NP	O
relevant	JJ	I-NP	O
dopamine	NN	I-NP	O
-	HYPH	B-NP	O
antagonistic	JJ	I-NP	O
capacity	NN	I-NP	O
of	IN	B-PP	O
fluoxetine	NN	B-NP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
.	.	O	O

Acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Through	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
widespread	JJ	B-NP	O
use	NN	I-NP	O
,	,	O	O
acetaminophen	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
remarkably	RB	I-NP	O
safe	JJ	I-NP	O
medication	NN	I-NP	O
in	IN	B-PP	O
therapeutic	JJ	B-NP	O
dosages	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
acetaminophen	NN	B-NP	O
to	TO	B-VP	O
produce	VB	I-VP	O
cardiovascular	JJ	B-NP	B
toxicities	NNS	I-NP	I
is	VBZ	B-VP	O
very	RB	B-ADJP	O
low	JJ	I-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
acetaminophen	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
demonstrated	VBN	I-VP	O
to	TO	I-VP	O
produce	VB	I-VP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
anaphylaxis	NN	B-NP	B
,	,	O	O
including	VBG	B-PP	O
hypotension	NN	B-NP	B
,	,	O	O
in	IN	B-PP	O
sensitive	JJ	B-NP	O
individuals	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
article	NN	I-NP	O
describes	VBZ	B-VP	O
num	CD	B-NP	O
critically	RB	I-NP	B
ill	JJ	I-NP	I
patients	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
transient	JJ	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
reproducibly	RB	B-ADVP	O
developed	VBD	B-VP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
.	.	O	O

Other	JJ	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
allergic	JJ	B-NP	B
reactions	NNS	I-NP	I
were	VBD	B-VP	O
not	RB	O	O
clinically	RB	B-ADJP	O
detectable	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
hypotensive	JJ	I-NP	B
episodes	NNS	I-NP	O
were	VBD	B-VP	O
severe	JJ	B-ADJP	O
enough	RB	I-ADJP	O
to	TO	B-VP	O
require	VB	I-VP	O
vasopressor	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
reports	NNS	I-NP	O
illustrate	VBP	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-SBAR	O
clinicians	NNS	B-NP	O
to	TO	B-VP	O
consider	VB	I-VP	O
acetaminophen	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hypotension	NN	B-NP	B
of	IN	B-PP	O
unknown	JJ	B-NP	O
origin	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
,	,	O	O
autoimmune	JJ	B-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
,	,	O	O
and	CC	O	O
erythroblastocytopenia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
ceftriaxone	NN	B-NP	O
.	.	O	O

An	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yr	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
shortly	RB	B-ADVP	O
after	IN	B-PP	O
ingesting	VBG	B-VP	O
oral	JJ	B-NP	O
ceftriaxone	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
transaminases	NNS	I-NP	O
gradually	RB	B-ADVP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
after	IN	B-PP	O
withholding	VBG	B-VP	O
the	DT	B-NP	O
beta	NN	I-NP	O
lactam	NN	I-NP	O
antibiotic	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
gradual	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
bilirubin	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
hemoglobin	NN	B-NP	O
concentration	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
autoimmune	JJ	I-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
and	CC	I-NP	O
erythroblastocytopenia	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
responded	VBD	B-VP	O
to	TO	B-PP	O
systemic	JJ	B-NP	O
steroids	NNS	I-NP	O
and	CC	I-NP	O
immunoglobulins	NNS	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
the	DT	B-NP	O
widespread	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
this	DT	B-NP	O
triad	NN	I-NP	O
of	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
connection	NN	B-NP	O
with	IN	B-PP	O
beta	SYM	B-NP	O
lactam	NN	I-NP	O
antibiotics	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
atypical	JJ	I-NP	O
antipsychotics	NNS	I-NP	O
.	.	O	O

Collaborative	JJ	B-NP	O
Working	NNP	I-NP	O
Group	NNP	I-NP	O
on	IN	B-PP	O
Clinical	NNP	B-NP	O
Trial	NNP	I-NP	O
Evaluations	NNPS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
antipsychotics	NNS	B-NP	O
often	RB	B-ADVP	O
lead	VBP	B-VP	O
to	TO	B-PP	O
noncompliance	NN	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
clinicians	NNS	B-NP	O
should	MD	B-VP	O
address	VB	I-VP	O
patients	NNS	B-NP	O
s	VBZ	B-VP	O
concerns	NNS	B-NP	O
about	IN	B-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
and	CC	O	O
attempt	NN	B-NP	O
to	TO	B-VP	O
choose	VB	I-VP	O
medications	NNS	B-NP	O
that	WDT	B-NP	O
will	MD	B-VP	O
improve	VB	I-VP	O
their	PRP$	B-NP	O
patients	NNS	I-NP	O
s	VBZ	B-VP	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
overall	JJ	B-NP	O
health	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
profiles	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
atypical	JJ	I-NP	O
antipsychotics	NNS	I-NP	O
are	VBP	B-VP	O
more	RBR	B-ADJP	O
advantageous	JJ	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
neuroleptics	NNS	I-NP	O
.	.	O	O

Conventional	JJ	B-NP	O
agents	NNS	I-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
unwanted	JJ	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
(	(	O	O
EPS	NNS	B-NP	B
)	)	O	O
,	,	O	O
tardive	JJ	B-NP	B
dyskinesia	NN	I-NP	I
,	,	O	O
sedation	NN	B-NP	O
,	,	O	O
and	CC	O	O
possible	JJ	B-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
some	DT	B-NP	O
cognitive	JJ	I-NP	O
measures	NNS	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
cardiac	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
,	,	O	O
hepatic	JJ	B-NP	O
changes	NNS	I-NP	O
,	,	O	O
anticholinergic	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
sexual	JJ	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
and	CC	O	O
weight	NN	B-NP	B
gain	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
newer	JJR	I-NP	O
atypical	JJ	I-NP	O
agents	NNS	I-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
EPS	NNP	B-NP	B
,	,	O	O
but	CC	O	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
in	IN	B-PP	O
varying	VBG	B-NP	O
degrees	NNS	I-NP	O
with	IN	B-PP	O
sedation	NN	B-NP	O
,	,	O	O
cardiovascular	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
anticholinergic	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
weight	NN	B-NP	B
gain	NN	I-NP	I
,	,	O	O
sexual	JJ	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
hepatic	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
lowered	VBD	B-VP	O
seizure	NN	B-NP	B
threshold	NN	I-NP	O
(	(	O	O
primarily	RB	B-NP	O
clozapine	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
agranulocytosis	NN	B-NP	B
(	(	O	O
clozapine	NN	B-NP	O
only	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Since	IN	B-SBAR	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
specific	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
differ	VBP	B-VP	O
among	IN	B-PP	O
the	DT	B-NP	O
various	JJ	I-NP	O
atypicals	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
clinician	NN	I-NP	O
should	MD	B-VP	O
carefully	RB	I-VP	O
consider	VB	I-VP	O
which	WDT	B-NP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
most	RBS	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
individual	JJ	I-NP	O
s	NNS	I-NP	O
dissatisfaction	NN	I-NP	O
and	CC	I-NP	O
noncompliance	NN	I-NP	O
before	IN	B-PP	O
choosing	VBG	B-VP	O
an	DT	B-NP	O
antipsychotic	JJ	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
particular	JJ	I-NP	O
patient	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
tetrandrine	NN	B-NP	O
and	CC	I-NP	O
fangchinoline	NN	I-NP	O
on	IN	B-PP	O
experimental	JJ	B-NP	O
thrombosis	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
and	CC	O	O
human	JJ	B-NP	O
platelet	NN	I-NP	B
aggregation	NN	I-NP	I
.	.	O	O

Tetrandrine	NN	B-NP	O
(	(	O	O
TET	NN	B-NP	O
)	)	O	O
and	CC	O	O
fangchinoline	NN	B-NP	O
(	(	O	O
FAN	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
num	CD	B-NP	O
naturally	RB	I-NP	O
occurring	VBG	I-NP	O
analogues	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
bisbenzylisoquinoline	NN	I-NP	O
structure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
TET	NN	B-NP	O
and	CC	I-NP	O
FAN	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
thrombosis	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
collagen	NN	B-NP	O
plus	CC	O	O
epinephrine	NN	B-NP	O
(	(	O	O
EP	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
and	CC	O	O
platelet	NN	B-NP	B
aggregation	NN	I-NP	I
and	CC	O	O
blood	NN	B-NP	B
coagulation	NN	I-NP	I
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
TET	NN	B-NP	O
and	CC	I-NP	O
FAN	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
thrombosis	NN	B-NP	B
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
acetylsalicylic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
positive	JJ	I-NP	O
control	NN	I-NP	O
,	,	O	O
showed	VBD	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
inhibition	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
vitro	FW	I-NP	O
human	JJ	I-NP	O
platelet	NN	I-NP	B
aggregations	NNS	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
agonists	NNS	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
tests	NNS	B-NP	O
,	,	I-NP	O
TET	NN	I-NP	O
and	CC	I-NP	O
FAN	NN	I-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
inhibitions	NNS	I-NP	O
dose	NN	I-NP	O
dependently	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
neither	CC	O	O
TET	NN	B-NP	O
nor	CC	I-NP	O
FAN	NN	I-NP	O
showed	VBD	B-VP	O
any	DT	B-NP	O
anticoagulation	NN	I-NP	O
activities	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
measurement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
activated	VBN	I-NP	O
partial	JJ	I-NP	O
thromboplastin	NN	I-NP	O
time	NN	I-NP	O
(	(	O	O
APTT	NN	B-NP	O
)	)	O	O
,	,	O	O
prothrombin	NN	B-NP	O
time	NN	I-NP	O
(	(	O	O
PT	NN	B-NP	O
)	)	O	O
and	CC	O	O
thrombin	NN	B-NP	O
time	NN	I-NP	O
(	(	O	O
TT	NN	B-NP	O
)	)	O	O
using	VBG	B-VP	O
human	JJ	B-NP	O
-	HYPH	I-NP	O
citrated	VBN	I-NP	O
plasma	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
antithrombosis	NN	B-NP	O
of	IN	B-PP	O
TET	NN	B-NP	O
and	CC	I-NP	O
FAN	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
mainly	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
antiplatelet	JJ	I-NP	O
aggregation	NN	I-NP	O
activities	NNS	I-NP	O
.	.	O	O

Gemcitabine	NN	B-NP	O
plus	CC	I-NP	O
vinorelbine	NN	I-NP	O
in	IN	B-PP	O
nonsmall	JJ	B-NP	B
cell	NN	I-NP	I
lung	NN	I-NP	I
carcinoma	NN	I-NP	I
patients	NNS	I-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
or	CC	O	O
older	JJR	B-ADJP	O
or	CC	O	O
patients	NNS	B-NP	O
who	WP	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
receive	VB	I-VP	O
cisplatin	NN	B-NP	O
.	.	O	O

Oncopaz	NNP	B-NP	O
Cooperative	NNP	I-NP	O
Group	NNP	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
nonsmall	JJ	B-NP	B
cell	NN	I-NP	I
lung	NN	I-NP	I
carcinoma	NN	I-NP	I
(	(	O	O
NSCLC	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
high	JJ	B-ADJP	O
among	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
few	JJ	B-NP	O
data	NNS	I-NP	O
are	VBP	B-VP	O
available	JJ	B-ADJP	O
regarding	VBG	B-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Recent	JJ	B-NP	O
reports	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
single	JJ	B-NP	O
agent	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
vinorelbine	NN	B-NP	O
(	(	O	O
VNB	NN	B-NP	O
)	)	O	O
or	CC	O	O
gemcitabine	NN	B-NP	O
(	(	O	O
GEM	NN	B-NP	O
)	)	O	O
may	MD	B-VP	O
obtain	VB	I-VP	O
a	DT	B-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
acceptable	JJ	B-NP	O
toxicity	NN	I-NP	B
and	CC	I-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
symptoms	NNS	B-NP	O
and	CC	O	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
GEM	NN	B-NP	O
and	CC	I-NP	O
VNB	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
NSCLC	NN	I-NP	B
or	CC	O	O
those	DT	B-NP	O
with	IN	B-PP	O
some	DT	B-NP	O
contraindication	NN	I-NP	O
to	TO	B-PP	O
receiving	VBG	B-VP	O
cisplatin	NN	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
NSCLC	NN	I-NP	B
were	VBD	B-VP	O
included	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
were	VBD	B-VP	O
age	NN	I-VP	O
>	SYM	O	O
/	SYM	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
age	NN	B-NP	O
<	SYM	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
but	CC	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
some	DT	B-NP	O
contraindication	NN	I-NP	O
to	TO	B-PP	O
receiving	VBG	B-VP	O
cisplatin	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Treatment	NN	B-NP	O
was	VBD	B-VP	O
comprised	VBN	I-VP	O
of	IN	B-PP	O
VNB	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
,	,	O	O
plus	CC	B-PP	O
GEM	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
,	,	O	O
both	DT	O	O
on	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
minimum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
unless	IN	B-SBAR	O
progressive	JJ	B-NP	O
disease	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
courses	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
courses	NNS	I-NP	O
per	IN	B-PP	O
patient	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
attained	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
response	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

Eastern	NNP	B-NP	O
Cooperative	NNP	I-NP	O
Oncology	NNP	I-NP	O
Group	NNP	I-NP	O
performance	NN	I-NP	O
status	NN	I-NP	O
improved	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
initial	JJ	I-NP	O
value	NN	I-NP	O
>	SYM	B-NP	O
num	CD	B-NP	O
whereas	IN	B-PP	O
relief	NN	B-NP	O
of	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
symptom	NN	I-NP	O
without	IN	B-PP	O
worsening	VBG	B-VP	O
of	IN	B-PP	O
other	JJ	B-NP	O
symptoms	NNS	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
progression	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
survival	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Toxicity	NN	B-NP	B
was	VBD	B-VP	O
mild	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
World	NNP	B-NP	O
Health	NNP	I-NP	O
Organization	NNP	I-NP	O
Grade	NNP	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
Grade	NNP	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
thrombocytopenia	NN	I-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
Grade	NNP	B-NP	O
num	CD	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
neutropenia	NN	I-NP	B
died	VBD	B-VP	O
of	IN	B-PP	O
sepsis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
patients	NNS	I-NP	O
developing	VBG	B-VP	O
Grade	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
GEM	NN	B-NP	O
and	CC	I-NP	O
VNB	NN	I-NP	O
is	VBZ	B-VP	O
moderately	RB	B-ADJP	O
active	JJ	I-ADJP	O
and	CC	O	O
well	RB	B-VP	O
tolerated	VBN	I-VP	O
except	IN	B-PP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
age	NN	I-NP	O
>	SYM	O	O
/	SYM	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
age	NN	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
myelosuppression	NN	B-NP	B
.	.	O	O

Therefore	RB	B-ADVP	O
the	DT	B-NP	O
prophylactic	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
granulocyte	NN	B-NP	O
-	HYPH	B-NP	O
colony	NN	I-NP	O
stimulating	NN	I-NP	O
factor	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

New	JJ	B-NP	O
chemotherapy	NN	I-NP	O
combinations	NNS	I-NP	O
with	IN	B-PP	O
higher	JJR	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
lower	JJR	B-NP	O
toxicity	NN	I-NP	B
are	VBP	B-VP	O
needed	VBN	I-VP	O
for	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
advanced	JJ	B-NP	O
NSCLC	NN	I-NP	B
.	.	O	O

Warfarin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
artery	NN	I-NP	B
calcification	NN	I-NP	I
is	VBZ	B-VP	O
accelerated	VBN	I-VP	O
by	IN	B-PP	O
growth	NN	B-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
D	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
studies	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
growth	NN	B-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
D	NN	I-NP	O
treatment	NN	I-NP	O
enhance	VBP	B-VP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-VP	O
sufficient	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
Warfarin	NNP	B-NP	O
to	TO	B-VP	O
inhibit	VB	I-VP	O
gamma	NN	B-NP	O
-	HYPH	O	O
carboxylation	NN	B-NP	O
of	IN	B-PP	O
matrix	NN	B-NP	O
Gla	NN	I-NP	O
protein	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
calcification	NN	I-NP	B
inhibitor	NN	I-NP	O
known	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
expressed	VBN	I-VP	O
by	IN	B-PP	O
smooth	JJ	B-NP	O
muscle	NN	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
macrophages	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
artery	NN	I-NP	O
wall	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
experiments	NNS	B-NP	O
examined	VBN	B-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
and	CC	I-NP	O
growth	NN	I-NP	O
status	NN	I-NP	O
on	IN	B-PP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
in	IN	B-PP	O
Warfarin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
with	IN	B-PP	O
Warfarin	NN	B-NP	O
caused	VBD	B-VP	O
massive	JJ	B-NP	O
focal	JJ	I-NP	O
calcification	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
artery	NN	I-NP	I
media	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
rats	NNS	I-NP	O
and	CC	O	O
less	RBR	B-NP	O
extensive	JJ	I-NP	O
focal	JJ	I-NP	O
calcification	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
no	DT	B-NP	O
artery	NN	I-NP	B
calcification	NN	I-NP	I
could	MD	B-VP	O
be	VB	I-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
adult	JJ	I-NP	O
rats	NNS	I-NP	O
even	RB	B-ADVP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
Warfarin	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
directly	RB	I-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
growth	NN	B-NP	O
to	TO	B-PP	O
Warfarin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
artery	NN	I-NP	B
calcification	NN	I-NP	I
in	IN	B-PP	O
animals	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
age	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
fed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
either	CC	O	O
an	DT	B-NP	O
ad	NN	I-NP	O
libitum	NN	I-NP	O
diet	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
restricted	JJ	I-NP	O
diet	NN	I-NP	O
that	WDT	B-NP	O
maintains	VBZ	B-VP	O
weight	NN	B-NP	O
but	CC	O	O
prevents	VBZ	B-VP	O
growth	NN	B-NP	O
.	.	O	O

Concurrent	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
dietary	JJ	I-NP	O
groups	NNS	I-NP	O
with	IN	B-PP	O
Warfarin	NN	B-NP	O
produced	VBD	B-VP	O
massive	JJ	B-NP	O
focal	JJ	I-NP	O
calcification	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
artery	NN	I-NP	I
media	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ad	NN	I-NP	O
libitum	NN	I-NP	O
-	HYPH	B-NP	O
fed	VBN	I-NP	O
rats	NNS	I-NP	O
but	CC	O	O
no	DT	B-NP	O
detectable	JJ	I-NP	O
artery	NN	I-NP	B
calcification	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
restricted	JJ	I-NP	O
-	HYPH	I-NP	O
diet	NN	I-NP	O
,	,	O	O
growth	NN	B-NP	O
-	HYPH	B-VP	O
inhibited	VBN	B-NP	O
group	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
explanation	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
and	CC	O	O
growth	NN	B-NP	O
status	NN	I-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
determined	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
higher	JJR	B-NP	O
serum	NN	I-NP	O
phosphate	NN	I-NP	O
and	CC	O	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
higher	JJR	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
phosphate	NN	I-NP	O
in	IN	B-PP	O
young	JJ	B-NP	O
,	,	O	O
ad	NN	B-NP	O
libitum	NN	I-NP	O
-	HYPH	B-NP	O
fed	VBN	I-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
either	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
resistant	JJ	B-ADJP	O
to	TO	B-PP	O
Warfarin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
artery	NN	I-NP	B
calcification	NN	I-NP	I
,	,	O	O
ie	FW	B-NP	O
,	,	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
rats	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
restricted	JJ	I-NP	O
-	HYPH	I-NP	O
diet	NN	I-NP	O
,	,	O	O
growth	NN	B-NP	O
-	HYPH	O	O
inhibited	VBN	B-NP	O
young	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
observation	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
increased	VBN	B-NP	O
susceptibility	NN	I-NP	O
to	TO	B-PP	O
Warfarin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
artery	NN	I-NP	B
calcification	NN	I-NP	I
could	MD	B-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
higher	JJR	B-NP	O
serum	NN	I-NP	O
phosphate	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
set	NN	I-NP	O
of	IN	B-PP	O
experiments	NNS	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
synergy	NN	I-NP	O
between	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
and	CC	I-NP	O
Warfarin	NN	I-NP	O
in	IN	B-PP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
.	.	O	O

High	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
are	VBP	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
calcification	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
artery	NN	I-NP	I
media	NNS	I-NP	O
in	IN	B-PP	O
as	RB	B-NP	O
little	JJ	I-NP	O
as	IN	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

High	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
vitamin	NN	I-NP	O
K	NN	I-NP	O
antagonist	NN	I-NP	O
Warfarin	NN	I-NP	O
are	VBP	B-VP	O
also	RB	I-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
calcification	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
artery	NN	I-NP	I
media	NNS	I-NP	O
,	,	O	O
but	CC	O	O
at	IN	B-PP	O
treatment	NN	B-NP	O
times	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
or	CC	O	O
longer	JJR	B-ADJP	O
yet	CC	O	O
not	RB	O	O
at	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
synergy	NN	I-NP	O
between	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
treatments	NNS	I-NP	O
and	CC	O	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
concurrent	JJ	B-NP	O
Warfarin	NNP	I-NP	O
administration	NN	I-NP	O
dramatically	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
calcification	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
media	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
close	JJ	I-NP	O
parallel	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
dose	NN	I-NP	O
on	IN	B-PP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
dose	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
through	IN	B-PP	O
its	PRP$	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
Warfarin	NN	B-NP	O
treatment	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
synergy	NN	I-NP	O
between	IN	B-PP	O
Warfarin	NN	B-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
D	NN	I-NP	O
is	VBZ	B-VP	O
probably	RB	I-VP	O
best	RBS	I-VP	O
explained	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
Warfarin	NN	B-NP	O
inhibits	VBZ	B-VP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
matrix	NN	B-NP	O
Gla	NN	I-NP	O
protein	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
calcification	NN	I-NP	B
inhibitor	NN	I-NP	O
.	.	O	O

High	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
matrix	NN	B-NP	O
Gla	NN	I-NP	O
protein	NN	I-NP	O
are	VBP	B-VP	O
found	VBN	I-VP	O
at	IN	B-PP	O
sites	NNS	B-NP	O
of	IN	B-PP	O
artery	NN	B-NP	B
calcification	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
plus	CC	O	O
Warfarin	NN	B-NP	O
,	,	O	O
and	CC	O	O
chemical	NN	B-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
protein	NN	I-NP	O
that	WDT	B-NP	O
accumulated	VBD	B-VP	O
was	VBD	B-VP	O
indeed	RB	B-ADVP	O
not	RB	B-NP	O
gamma	NN	I-NP	O
-	HYPH	B-NP	O
carboxylated	VBN	B-VP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
although	IN	B-SBAR	O
the	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
carboxyglutamate	NN	I-NP	O
residues	NNS	I-NP	O
of	IN	B-PP	O
matrix	NN	B-NP	O
Gla	NN	I-NP	O
protein	NN	I-NP	O
are	VBP	B-VP	O
apparently	RB	I-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
its	PRP$	B-NP	O
function	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
calcification	NN	I-NP	B
inhibitor	NN	I-NP	O
,	,	O	O
they	PRP	B-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
its	PRP$	B-NP	O
accumulation	NN	I-NP	O
at	IN	B-PP	O
calcification	NN	B-NP	B
sites	NNS	I-NP	O
.	.	O	O

Antidepressant	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
mania	NN	I-NP	B
in	IN	B-PP	O
bipolar	JJ	B-NP	B
patients	NNS	I-NP	O
:	:	O	O
identification	NN	B-NP	O
of	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
.	.	O	O

Concerns	NNS	B-NP	O
about	IN	B-PP	O
possible	JJ	B-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
switching	VBG	B-VP	O
to	TO	B-PP	O
mania	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
antidepressants	NNS	B-NP	O
continue	VBP	B-VP	O
to	TO	I-VP	O
interfere	VB	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
establishment	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
optimal	JJ	I-NP	O
treatment	NN	I-NP	O
paradigm	NN	I-NP	O
for	IN	B-PP	O
bipolar	JJ	B-NP	B
depression	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
meeting	VBG	B-VP	O
DSM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
to	TO	B-PP	O
naturalistic	JJ	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Montgomery	NNP	I-NP	O
-	HYPH	I-NP	O
Asberg	NNP	I-NP	O
Depression	NNP	I-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Bech	NNP	I-NP	O
-	HYPH	I-NP	O
Rafaelson	NNP	I-NP	O
Mania	NNP	I-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
manic	JJ	I-NP	B
or	CC	I-NP	O
hypomanic	JJ	I-NP	B
switch	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	O	O
on	IN	B-PP	O
several	JJ	B-NP	O
variables	NNS	I-NP	O
including	VBG	B-PP	O
age	NN	B-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
diagnosis	NN	B-NP	O
(	(	O	O
DSM	NN	B-NP	B
-	HYPH	O	I
num	CD	B-NP	I
bipolar	JJ	I-NP	I
I	PRP	B-NP	I
vs.	IN	B-PP	O
bipolar	JJ	B-NP	B
num	CD	I-NP	I
)	)	O	O
,	,	O	O
number	NN	B-NP	O
of	IN	B-PP	O
previous	JJ	B-NP	O
manic	JJ	I-NP	B
episodes	NNS	I-NP	O
,	,	O	O
type	NN	B-NP	O
of	IN	B-PP	O
antidepressant	NN	B-NP	O
therapy	NN	I-NP	O
used	VBN	B-VP	O
(	(	O	O
electroconvulsive	JJ	B-NP	O
therapy	NN	I-NP	O
vs.	IN	B-PP	O
antidepressant	JJ	B-NP	O
drugs	NNS	I-NP	O
and	CC	O	O
,	,	O	O
more	RBR	B-ADVP	O
particularly	RB	I-ADVP	O
,	,	O	O
selective	JJ	B-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
[	(	O	O
SSRIs	NNS	B-NP	O
]	)	O	O
)	)	O	O
,	,	O	O
use	NN	B-NP	O
and	CC	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
mood	NN	B-NP	O
stabilizers	NNS	I-NP	O
(	(	O	O
lithium	NN	B-NP	O
vs.	IN	B-PP	O
anticonvulsants	NNS	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
temperament	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
assessed	VBN	B-VP	O
during	IN	B-PP	O
a	DT	B-NP	O
normothymic	JJ	I-NP	O
period	NN	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
hyperthymia	NN	I-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Semi	NN	I-NP	O
-	HYPH	O	O
structured	VBN	B-VP	O
Affective	JJ	B-NP	O
Temperament	NNP	I-NP	O
Interview	NNP	I-NP	O
.	.	O	O

Switches	NNS	B-NP	O
to	TO	B-PP	O
hypomania	NN	B-NP	B
or	CC	I-NP	O
mania	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subgroup	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
SSRIs	NNS	B-NP	O
[	(	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
]	)	O	O
)	)	O	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
experienced	VBD	B-VP	O
manic	JJ	B-NP	B
episodes	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
experienced	VBD	B-VP	O
hypomanic	JJ	B-NP	B
episodes	NNS	I-NP	O
.	.	O	O

Sex	NN	B-NP	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
diagnosis	NN	B-NP	O
(	(	O	O
bipolar	JJ	O	B
I	PRP	B-NP	I
vs.	IN	B-PP	O
bipolar	JJ	B-NP	B
num	CD	I-NP	I
)	)	O	O
,	,	O	O
and	CC	O	O
additional	JJ	B-NP	O
treatment	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
switching	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
mood	NN	B-NP	O
switches	NNS	I-NP	O
seemed	VBD	B-VP	O
not	RB	O	O
to	TO	B-VP	O
differ	VB	I-VP	O
between	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
an	DT	B-NP	O
anticonvulsant	NN	I-NP	O
and	CC	O	O
those	DT	B-NP	O
receiving	VBG	B-VP	O
no	DT	B-NP	O
mood	NN	I-NP	O
stabilizer	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
mood	NN	B-NP	O
switches	NNS	I-NP	O
were	VBD	B-VP	O
less	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
lithium	NN	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
not	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
previous	JJ	B-NP	O
manic	JJ	I-NP	B
episodes	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
probability	NN	I-NP	O
of	IN	B-PP	O
switching	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
a	DT	B-NP	O
high	JJ	I-NP	O
score	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
hyperthymia	NN	I-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Semistructured	JJ	I-NP	O
Affective	JJ	I-NP	O
Temperament	NN	I-NP	O
Interview	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
switching	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
mood	NN	B-NP	O
switching	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
antidepressant	NN	I-NP	O
therapy	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Particular	JJ	B-NP	O
attention	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
paid	VBN	I-VP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
hyperthymic	JJ	I-NP	O
temperament	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
mood	NN	B-NP	O
switches	NNS	I-NP	O
.	.	O	O

Caffeine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
arrhythmia	NN	I-NP	I
:	:	O	O
an	DT	B-NP	O
unrecognised	JJ	I-NP	O
danger	NN	I-NP	O
of	IN	B-PP	O
healthfood	NN	B-NP	O
products	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	B-VP	O
existing	VBG	B-NP	O
mitral	JJ	I-NP	B
valve	NN	I-NP	I
prolapse	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
intractable	JJ	B-NP	O
ventricular	JJ	I-NP	B
fibrillation	NN	I-NP	I
after	IN	B-PP	O
consuming	VBG	B-VP	O
a	DT	B-NP	O
natural	JJ	I-NP	O
energy	NN	I-NP	O
guarana	NN	I-NP	O
health	NN	I-NP	O
drink	NN	I-NP	O
containing	VBG	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
highlights	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
adequate	JJ	B-NP	O
labelling	NN	I-NP	O
and	CC	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
such	JJ	B-NP	O
products	NNS	I-NP	O
.	.	O	O

Bladder	NN	B-NP	O
retention	NN	I-NP	B
of	IN	B-PP	I
urine	NN	B-NP	I
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
continuous	JJ	B-NP	O
intravenous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
.	.	O	O

Sedation	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
commonly	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
neonate	NN	I-NP	O
to	TO	B-VP	O
decrease	VB	I-VP	O
the	DT	B-NP	O
stress	NN	I-NP	O
and	CC	I-NP	O
pain	NN	I-NP	B
from	IN	B-PP	O
the	DT	B-NP	O
noxious	JJ	I-NP	O
stimuli	NNS	I-NP	O
and	CC	O	O
invasive	JJ	B-NP	O
procedures	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
neonatal	JJ	I-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
to	TO	B-VP	O
facilitate	VB	I-VP	O
synchrony	NN	B-NP	O
between	IN	B-PP	O
ventilator	NN	B-NP	O
and	CC	O	O
spontaneous	JJ	B-NP	O
breaths	NNS	I-NP	O
.	.	O	O

Fentanyl	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
opioid	JJ	I-NP	O
analgesic	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
frequently	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
neonatal	JJ	I-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
setting	VBG	B-VP	O
for	IN	B-PP	O
these	DT	B-NP	O
very	JJ	I-NP	O
purposes	NNS	I-NP	O
.	.	O	O

Various	NNP	B-NP	O
reported	VBD	B-VP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
administration	NN	I-NP	O
include	VBP	B-VP	O
chest	NN	B-NP	B
wall	NN	I-NP	I
rigidity	NN	I-NP	I
,	,	O	O
hypotension	NN	B-NP	B
,	,	O	O
respiratory	JJ	B-NP	B
depression	NN	I-NP	I
,	,	O	O
and	CC	O	O
bradycardia	NN	B-NP	B
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	B
bladder	NN	I-NP	I
retention	NN	I-NP	I
leading	VBG	B-VP	O
to	TO	B-PP	O
renal	JJ	B-NP	O
pelvocalyceal	JJ	I-NP	O
dilatation	NN	I-NP	O
mimicking	VBG	B-VP	O
hydronephrosis	NN	B-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Combined	VBN	B-NP	O
antiretroviral	JJ	I-NP	O
therapy	NN	I-NP	O
causes	VBZ	B-VP	O
cardiomyopathy	NN	B-NP	B
and	CC	O	O
elevates	VBZ	B-VP	O
plasma	NN	B-NP	O
lactate	NN	I-NP	O
in	IN	B-PP	O
transgenic	JJ	B-NP	O
AIDS	NN	I-NP	B
mice	NNS	I-NP	O
.	.	O	O

Highly	RB	B-NP	O
active	JJ	I-NP	O
antiretroviral	JJ	I-NP	O
therapy	NN	I-NP	O
(	(	O	O
HAART	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
cardiomyopathy	NN	B-NP	B
(	(	O	O
CM	NN	B-NP	B
)	)	O	O
and	CC	O	O
in	IN	B-PP	O
elevated	VBN	B-NP	O
plasma	NN	I-NP	O
lactate	NN	I-NP	O
(	(	O	O
LA	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
AIDS	NN	B-NP	B
through	IN	B-PP	O
mechanisms	NNS	B-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
mitochondrial	JJ	B-NP	O
events	NNS	I-NP	O
from	IN	B-PP	O
HAART	NN	B-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
hemizygous	JJ	I-NP	O
transgenic	JJ	I-NP	O
AIDS	NN	I-NP	B
mice	NNS	I-NP	O
(	(	O	O
NL4	NN	B-NP	O
-	HYPH	B-NP	O
3Delta	SYM	I-NP	O
gag	NN	I-NP	O
/	SYM	I-NP	O
pol	NN	I-NP	O
;	:	O	O
TG	NN	B-NP	O
)	)	O	O
and	CC	O	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
FVB	NN	I-NP	O
/	SYM	B-NP	O
n	NN	I-NP	O
littermates	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
HAART	NN	I-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
zidovudine	NN	B-NP	O
,	,	O	O
lamivudine	NN	B-NP	O
,	,	O	O
and	CC	O	O
indinavir	NN	B-NP	O
or	CC	O	O
vehicle	NN	B-NP	O
control	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
or	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
termination	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experiments	NNS	I-NP	O
,	,	O	O
mice	NNS	B-NP	O
underwent	VBD	B-VP	O
echocardiography	NN	B-NP	O
,	,	O	O
quantitation	NN	B-NP	O
of	IN	B-PP	O
abundance	NN	B-NP	O
of	IN	B-PP	O
molecular	JJ	B-NP	O
markers	NNS	I-NP	O
of	IN	B-PP	O
CM	NN	B-NP	B
(	(	O	O
ventricular	JJ	B-NP	O
mRNA	NN	I-NP	O
encoding	VBG	B-VP	O
atrial	JJ	B-NP	O
natriuretic	JJ	I-NP	O
factor	NN	I-NP	O
[	(	O	O
ANF	NN	B-NP	O
]	)	O	O
and	CC	O	O
sarcoplasmic	JJ	B-NP	O
calcium	NN	I-NP	O
ATPase	NN	I-NP	O
[	(	O	O
SERCA2	NN	B-NP	O
]	)	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
determination	NN	B-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
LA	NN	I-NP	O
.	.	O	O

Myocardial	JJ	B-NP	O
histologic	JJ	I-NP	O
features	NNS	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
semiquantitatively	RB	B-ADVP	O
and	CC	O	O
results	NNS	B-NP	O
were	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
transmission	NN	B-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
TG	NN	I-NP	O
+	SYM	B-NP	O
HAART	NNP	I-NP	O
cohort	NN	I-NP	O
,	,	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
mass	NN	I-NP	O
increased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
echocardiography	NN	B-NP	O
.	.	O	O

Molecularly	RB	B-ADVP	O
,	,	O	O
ANF	NN	B-NP	O
mRNA	NN	I-NP	O
increased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
SERCA2	NN	I-NP	O
mRNA	NN	I-NP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Biochemically	RB	B-ADVP	O
,	,	O	O
LA	NN	B-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
.	.	O	O

Pathologically	RB	B-ADVP	O
,	,	O	O
granular	JJ	B-NP	O
cytoplasmic	JJ	I-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
myocytes	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
enlarged	VBN	I-VP	O
,	,	O	O
damaged	VBN	B-NP	O
mitochondria	NNS	I-NP	O
.	.	O	O

Findings	NNS	B-NP	O
were	VBD	B-VP	O
confirmed	VBN	I-VP	O
ultrastructurally	RB	B-ADVP	O
.	.	O	O

No	DT	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
other	JJ	B-NP	O
cohorts	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
only	RB	B-NP	O
ANF	NN	I-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
TG	NN	I-NP	O
+	SYM	B-NP	O
HAART	NNP	I-NP	O
cohort	JJ	B-ADJP	O
.	.	O	O

Results	NNS	B-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
cumulative	JJ	B-NP	O
HAART	NN	I-NP	O
caused	VBD	B-VP	O
mitochondrial	JJ	B-NP	O
CM	NN	I-NP	B
with	IN	B-PP	O
elevated	JJ	B-NP	O
LA	NN	I-NP	O
in	IN	B-PP	O
AIDS	NN	B-NP	B
transgenic	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

An	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	B-NP	O
all	DT	I-NP	O
,	,	O	O
studies	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
this	DT	B-NP	O
association	NN	I-NP	O
,	,	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
progestagen	NN	B-NP	O
included	VBN	B-VP	O
in	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
(	(	O	O
i.e.	FW	B-NP	O
,	,	O	O
desogestrel	NN	B-NP	O
or	CC	O	O
gestodene	NN	B-NP	O
)	)	O	O
and	CC	O	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
(	(	O	O
i.e.	FW	B-NP	O
,	,	O	O
levonorgestrel	NN	B-NP	O
)	)	O	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
or	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
prothrombotic	JJ	B-NP	O
mutations	NNS	I-NP	O
METHODS	NNS	I-NP	O
:	:	O	O
In	IN	B-PP	O
a	DT	B-NP	O
nationwide	JJ	I-NP	O
,	,	I-NP	O
population	NN	I-NP	O
-	HYPH	I-NP	O
based	VBN	B-VP	O
,	,	O	O
case	NN	B-NP	O
-	HYPH	I-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
identified	VBD	B-VP	O
and	CC	O	O
enrolled	VBD	B-VP	O
num	CD	B-NP	O
women	NNS	I-NP	O
num	CD	B-NP	O
through	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
had	VBN	I-VP	O
a	DT	B-NP	O
first	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
control	NN	I-NP	O
women	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
not	RB	I-VP	O
had	VBN	I-VP	O
a	DT	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
and	CC	O	O
who	WP	B-NP	O
were	VBD	B-VP	O
matched	VBN	I-VP	O
for	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
calendar	NN	B-NP	O
year	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
index	NN	I-NP	O
event	NN	I-NP	O
,	,	O	O
and	CC	O	O
area	NN	B-NP	O
of	IN	B-PP	O
residence	NN	B-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
supplied	VBD	B-VP	O
information	NN	B-NP	O
on	IN	B-PP	O
oral	JJ	B-NP	O
-	HYPH	I-NP	O
contraceptive	JJ	I-NP	O
use	NN	I-NP	O
and	CC	O	O
major	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
analysis	NN	I-NP	O
for	IN	B-PP	O
factor	NN	B-NP	O
V	NNP	I-NP	O
Leiden	NNP	I-NP	O
and	CC	O	O
the	DT	B-NP	O
G20210A	NN	I-NP	O
mutation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prothrombin	NN	I-NP	O
gene	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
RESULTS	NNS	I-NP	O
:	:	O	O
The	DT	B-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
for	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
among	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
any	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
combined	JJ	B-NP	O
oral	JJ	I-NP	O
contraceptive	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
nonusers	NNS	B-NP	O
,	,	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
adjusted	VBN	I-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
among	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
among	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
for	IN	B-PP	O
those	DT	B-NP	O
without	IN	B-PP	O
a	DT	B-NP	O
prothrombotic	JJ	I-NP	O
mutation	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
for	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
mutation	NN	I-NP	O
CONCLUSIONS	NNS	I-NP	O
:	:	O	O
The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
was	VBD	B-VP	O
increased	VBN	I-VP	O
among	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
were	VBD	B-VP	O
inconclusive	JJ	B-ADJP	O
but	CC	O	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
among	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
whether	IN	B-SBAR	O
or	CC	O	O
not	RB	O	O
they	PRP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
prothrombotic	JJ	I-NP	O
mutation	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT1B	NN	I-NP	O
receptor	NN	I-NP	O
ligands	NNS	I-NP	O
microinjected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
accumbal	JJ	I-NP	O
shell	NN	I-NP	O
or	CC	I-NP	O
core	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	B
hyperactivity	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT1B	NN	I-NP	O
receptor	NN	I-NP	O
ligands	NNS	I-NP	O
microinjected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
subregions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nucleus	NN	I-NP	O
accumbens	NN	I-NP	O
(	(	O	O
the	DT	B-NP	O
shell	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
core	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
the	DT	B-NP	O
locomotor	JJ	I-NP	B
hyperactivity	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
cocaine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
implanted	VBN	I-VP	O
bilaterally	RB	B-ADVP	O
with	IN	B-PP	O
cannulae	NNS	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
accumbens	NNS	I-NP	O
shell	NN	I-NP	O
or	CC	I-NP	O
core	NN	I-NP	O
,	,	O	O
and	CC	O	O
then	RB	O	O
were	VBD	B-VP	O
locally	RB	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
GR	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
an	DT	B-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT1B	NN	I-NP	O
receptors	NNS	I-NP	O
)	)	O	O
or	CC	O	O
CP	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
an	DT	B-NP	O
agonist	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT1B	NN	I-NP	O
receptors	NNS	I-NP	O
)	)	O	O
.	.	O	O

Given	VBN	B-VP	O
alone	RB	B-ADVP	O
to	TO	B-PP	O
any	DT	B-NP	O
accumbal	JJ	I-NP	O
subregion	NN	I-NP	O
,	,	O	O
GR	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
side	NN	I-NP	O
)	)	O	O
or	CC	O	O
CP	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
side	NN	I-NP	O
)	)	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
basal	JJ	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
cocaine	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

GR	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
side	NN	I-NP	O
)	)	O	O
,	,	O	O
administered	VBN	B-VP	O
intra	AFX	O	O
-	HYPH	O	O
accumbens	VBZ	B-VP	O
shell	NN	B-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
dependently	RB	B-ADVP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
psychostimulant	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	B
hyperactivity	NN	I-NP	I
.	.	O	O

Such	JJ	B-NP	O
attenuation	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
which	WDT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
GR	NN	B-NP	O
num	CD	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
accumbens	NNS	I-NP	O
core	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
injected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
accumbens	NNS	I-NP	O
shell	NN	I-NP	O
(	(	O	O
but	CC	B-CONJP	O
not	RB	I-CONJP	O
the	DT	B-NP	O
core	NN	I-NP	O
)	)	O	O
before	IN	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
CP	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
side	NN	I-NP	O
)	)	O	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
locomotor	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
;	:	O	O
the	DT	B-NP	O
maximum	NN	I-NP	O
effect	NN	I-NP	O
being	VBG	B-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
side	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
agonist	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
later	JJ	I-NP	O
enhancement	NN	I-NP	O
was	VBD	B-VP	O
attenuated	VBN	I-VP	O
after	IN	B-PP	O
intra	AFX	B-NP	O
-	HYPH	B-NP	O
accumbens	VBZ	B-VP	O
shell	NN	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
GR	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
side	NN	I-NP	O
)	)	O	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
cocaine	NN	B-NP	O
induced	JJ	I-NP	O
hyperlocomotion	NN	I-NP	B
is	VBZ	B-VP	O
modified	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT1B	NN	I-NP	O
receptor	NN	I-NP	O
ligands	NNS	I-NP	O
microinjected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
accumbens	NNS	I-NP	O
shell	NN	I-NP	O
,	,	B-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
core	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
modification	NN	I-NP	O
consisting	VBG	B-VP	O
in	IN	B-PP	O
inhibitory	JJ	B-NP	O
and	CC	I-NP	O
facilitatory	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT1B	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
(	(	O	O
GR	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
agonist	NN	B-NP	O
(	(	O	O
CP	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
other	JJ	B-NP	O
words	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
accumbal	JJ	I-NP	O
shell	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT1B	NN	I-NP	O
receptors	NNS	I-NP	O
play	VBP	B-VP	O
a	DT	B-NP	O
permissive	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
behavioural	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
psychostimulant	NN	I-NP	O
.	.	O	O

Ticlopidine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
ticlopidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
,	,	O	O
investigate	VB	B-VP	O
its	PRP$	B-NP	O
mechanism	NN	I-NP	O
,	,	O	O
and	CC	O	O
compare	VBP	B-VP	O
the	DT	B-NP	O
observed	VBN	I-NP	O
main	JJ	I-NP	O
characteristics	NNS	I-NP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
published	VBN	I-NP	O
cases	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
prolonged	JJ	B-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
after	IN	B-PP	O
receiving	VBG	B-VP	O
ticlopidine	NN	B-NP	O
following	VBG	B-PP	O
percutaneous	JJ	B-NP	O
coronary	JJ	I-NP	O
angioplasty	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
period	NN	B-NP	O
.	.	O	O

T	NN	B-NP	O
-	HYPH	I-NP	O
cell	NN	I-NP	O
stimulation	NN	I-NP	O
by	IN	B-PP	O
therapeutic	JJ	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
ticlopidine	NN	B-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	B-PP	O
in	IN	I-PP	O
healthy	JJ	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

Cholestatic	JJ	B-NP	B
hepatitis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antiplatelet	JJ	I-NP	O
agent	NN	I-NP	O
ticlopidine	NN	I-NP	O
;	:	O	O
several	JJ	B-NP	O
cases	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
but	CC	O	O
few	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
English	JJ	I-NP	O
literature	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
jaundice	NN	B-NP	B
following	VBG	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
ticlopidine	NN	B-NP	O
and	CC	O	O
showed	VBD	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
cholestatic	JJ	B-NP	B
hepatitis	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
resolved	VBD	B-VP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Hepatitis	NN	B-NP	B
may	MD	B-VP	O
develop	VB	I-VP	O
weeks	NNS	B-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
run	VB	I-VP	O
a	DT	B-NP	O
prolonged	VBN	I-NP	O
course	NN	I-NP	O
,	,	O	O
but	CC	O	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
objective	JJ	I-NP	O
causality	NN	I-NP	O
assessment	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
event	NN	I-NP	O
was	VBD	B-VP	O
probably	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
ticlopidine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
ticlopidine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
cholestasis	NN	I-NP	B
are	VBP	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

Immune	JJ	B-NP	O
mechanisms	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
s	NNS	I-NP	O
hepatotoxicity	NN	I-NP	B
,	,	O	O
as	IN	B-SBAR	O
suggested	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
T	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
stimulation	NN	I-NP	O
study	NN	I-NP	O
reported	VBD	B-VP	O
here	RB	B-ADVP	O
.	.	O	O

Cholestatic	JJ	B-NP	B
hepatitis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ticlopidine	NN	B-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
immune	JJ	B-ADJP	O
mediated	VBN	B-VP	O
.	.	O	O

Patients	NNS	B-NP	O
receiving	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
with	IN	B-PP	O
liver	NN	B-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
along	IN	B-PP	O
with	IN	B-PP	O
complete	JJ	B-NP	O
blood	NN	I-NP	O
cell	NN	I-NP	O
counts	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
complication	NN	I-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
observed	VBN	I-VP	O
even	RB	B-ADVP	O
less	RBR	I-ADVP	O
often	RB	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
future	NN	I-NP	O
as	IN	B-SBAR	O
ticlopidine	NN	B-NP	O
is	VBZ	B-VP	O
being	VBG	I-VP	O
replaced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
newer	JJR	I-NP	O
antiplatelet	JJ	I-NP	O
agent	NN	I-NP	O
clopidogrel	NN	I-NP	O
.	.	O	O

Epithelial	JJ	B-NP	O
sodium	NN	I-NP	O
channel	NN	I-NP	O
(	(	O	O
ENaC	NN	B-NP	O
)	)	O	O
subunit	NN	B-NP	O
mRNA	NN	I-NP	O
and	CC	O	O
protein	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
experimental	JJ	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
,	,	O	O
urinary	JJ	B-NP	O
sodium	NN	I-NP	O
excretion	NN	I-NP	O
is	VBZ	B-VP	O
decreased	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
molecular	JJ	I-NP	O
mechanism	NN	I-NP	O
(	(	I-NP	O
s	NNS	I-NP	O
)	)	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
salt	NN	B-NP	O
retention	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
completely	RB	B-ADJP	O
elucidated	VBN	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
rate	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
constituent	NN	B-NP	O
of	IN	B-PP	O
collecting	VBG	B-VP	O
duct	NN	B-NP	O
sodium	NN	I-NP	O
transport	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
epithelial	JJ	I-NP	O
sodium	NN	I-NP	O
channel	NN	I-NP	O
(	(	O	O
ENaC	NN	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
abundance	NN	I-NP	O
of	IN	B-PP	O
ENaC	NN	B-NP	O
subunit	NN	I-NP	O
mRNAs	NNS	I-NP	O
and	CC	I-NP	O
proteins	NNS	I-NP	O
in	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
time	NN	I-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	O
sodium	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
aldosterone	NN	I-NP	O
concentration	NN	I-NP	O
and	CC	I-NP	O
proteinuria	NN	I-NP	B
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
either	CC	O	O
PAN	NN	B-NP	O
or	CC	I-NP	O
vehicle	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
relative	JJ	I-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
alphaENaC	NN	B-NP	O
,	,	I-NP	O
betaENaC	NN	I-NP	O
and	CC	I-NP	O
gammaENaC	NN	I-NP	O
mRNAs	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
kidneys	NNS	B-NP	O
from	IN	B-PP	O
these	DT	B-NP	O
rats	NNS	I-NP	O
by	IN	B-PP	O
real	JJ	B-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
quantitative	JJ	B-NP	O
TaqMan	NNP	I-NP	O
PCR	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
proteins	NNS	B-NP	O
by	IN	B-PP	O
Western	JJ	B-NP	O
blot	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
kinetics	NNS	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	O
sodium	NN	I-NP	O
excretion	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
with	IN	B-PP	O
those	DT	B-NP	O
reported	VBN	B-VP	O
previously	RB	B-ADVP	O
.	.	O	O

Sodium	NN	B-NP	O
retention	NN	I-NP	O
occurred	VBD	B-VP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
after	IN	B-SBAR	O
PAN	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
up	RB	I-NP	O
-	HYPH	I-NP	O
regulation	NN	B-NP	O
of	IN	B-PP	O
alphaENaC	NN	B-NP	O
and	CC	I-NP	O
betaENaC	NN	I-NP	O
mRNA	NN	I-NP	O
abundance	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
preceded	JJ	I-NP	O
sodium	NN	I-NP	O
retention	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Conversely	RB	B-ADVP	O
,	,	O	O
down	RB	B-ADVP	O
-	HYPH	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
alphaENaC	NN	B-NP	O
,	,	O	O
betaENaC	NN	B-NP	O
and	CC	O	O
gammaENaC	NN	B-NP	O
mRNA	NN	I-NP	O
expression	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
aldosterone	NN	I-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
and	CC	O	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
return	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
excretion	NN	I-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
values	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
alphaENaC	NN	B-NP	O
,	,	I-NP	O
betaENaC	NN	I-NP	O
and	CC	I-NP	O
gammaENaC	NN	I-NP	O
proteins	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
increased	VBN	I-VP	O
during	IN	B-PP	O
PAN	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
sodium	NN	I-NP	O
retention	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
ENaC	NN	B-NP	O
mRNA	NN	I-NP	O
expression	NN	I-NP	O
,	,	O	O
especially	RB	B-NP	O
alphaENaC	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
very	RB	I-NP	O
early	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
PAN	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
but	CC	O	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
escape	VB	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
by	IN	B-PP	O
aldosterone	NN	B-NP	O
after	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

NO	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
:	:	O	O
strong	JJ	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
calcitonin	NN	I-NP	O
gene	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
peptide	NN	I-NP	O
(	(	O	O
CGRP	NN	B-NP	O
)	)	O	O
concentration	NN	B-NP	O
and	CC	O	O
negative	JJ	B-NP	O
correlation	NN	I-NP	O
with	IN	B-PP	O
platelet	NN	B-NP	O
serotonin	NN	I-NP	O
release	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
calcitonin	NN	I-NP	O
gene	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
peptide	NN	I-NP	O
(	(	O	O
CGRP	NN	B-NP	O
)	)	O	O
concentration	NN	B-NP	O
and	CC	O	O
platelet	NN	B-NP	O
serotonin	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytriptamine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
)	)	O	O
content	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
immediate	JJ	I-NP	O
headache	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
delayed	VBN	I-NP	O
genuine	JJ	I-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
provoked	VBN	B-VP	O
by	IN	B-PP	O
nitroglycerin	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
female	JJ	I-NP	O
migraineurs	NNS	I-NP	B
(	(	O	I
without	IN	B-PP	I
aura	NN	B-NP	I
)	)	O	I
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
participated	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Sublingual	JJ	B-NP	O
nitroglycerin	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

Blood	NN	B-NP	O
was	VBD	B-VP	O
collected	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
antecubital	JJ	I-NP	O
vein	NN	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
the	DT	B-NP	O
nitroglycerin	NN	I-NP	O
application	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
beginning	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
those	DT	B-NP	O
subjects	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
)	)	O	O
a	DT	B-NP	O
similar	JJ	I-NP	O
time	NN	I-NP	O
schedule	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

Plasma	NN	B-NP	O
CGRP	NN	I-NP	O
concentration	NN	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
during	IN	B-PP	O
the	DT	B-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
and	CC	O	O
returned	VBD	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
cessation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
migraine	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
both	CC	O	O
change	NN	B-NP	O
and	CC	I-NP	O
peak	NN	I-NP	O
,	,	O	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
positive	JJ	I-NP	O
correlations	NNS	I-NP	O
with	IN	B-PP	O
migraine	NN	B-NP	B
headache	NN	I-NP	B
intensity	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
plasma	NN	B-NP	O
CGRP	NN	I-NP	O
concentrations	NNS	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
change	VB	I-VP	O
during	IN	B-PP	O
immediate	JJ	B-NP	O
headache	NN	I-NP	B
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
.	.	O	O

Basal	JJ	B-NP	O
CGRP	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
and	CC	O	O
platelet	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
content	NN	I-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
.	.	O	O

Platelet	NN	B-NP	O
serotonin	NN	I-NP	O
content	NN	I-NP	O
decreased	VBD	B-VP	O
significantly	RB	B-ADVP	O
after	IN	B-PP	O
nitroglycerin	NN	B-NP	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
but	CC	O	O
no	DT	B-NP	O
consistent	JJ	I-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
migraine	NN	B-NP	B
attack	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
plasma	NN	B-NP	O
CGRP	NN	I-NP	O
concentration	NN	I-NP	O
correlates	VBZ	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
timing	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
migraine	NN	I-NP	B
headache	NN	I-NP	B
suggests	VBZ	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
CGRP	NN	B-NP	O
and	CC	I-NP	O
migraine	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
serotonin	NN	B-NP	O
release	NN	I-NP	O
from	IN	B-PP	O
platelets	NNS	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
provoke	VB	I-VP	O
migraine	NN	B-NP	B
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
even	RB	I-VP	O
counteract	VB	I-VP	O
the	DT	B-NP	O
headache	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
concomitant	JJ	I-NP	O
CGRP	NN	I-NP	O
release	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
.	.	O	O

Coronary	JJ	B-NP	B
aneurysm	NN	I-NP	I
after	IN	B-PP	O
implantation	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
paclitaxel	NN	I-NP	O
-	HYPH	O	O
eluting	VBG	B-VP	O
stent	NN	B-NP	O
.	.	O	O

Formation	NN	B-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
aneurysm	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
stenting	VBG	B-VP	O
with	IN	B-PP	O
bare	JJ	B-NP	O
metal	NN	I-NP	O
stents	NNS	I-NP	O
,	,	O	O
but	CC	O	O
based	VBN	B-PP	O
on	IN	B-PP	O
experimental	JJ	B-NP	O
studies	NNS	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
eluting	VBG	I-NP	O
stents	NNS	I-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
toxic	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
vessel	NN	I-NP	O
wall	NN	I-NP	O
with	IN	B-PP	O
incomplete	JJ	B-NP	O
stent	JJ	I-NP	O
apposition	NN	I-NP	O
,	,	O	O
aneurysm	NN	B-NP	B
formation	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
stent	JJ	B-NP	O
thrombosis	NN	I-NP	B
or	CC	O	O
vessel	NN	B-NP	B
rupture	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
coronary	JJ	I-NP	B
aneurysm	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
paclitaxel	NN	I-NP	O
-	HYPH	O	O
eluting	VBG	B-VP	O
stent	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
asymptomatic	JJ	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
aneurysm	NN	I-NP	B
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
routine	JJ	I-NP	O
control	NN	I-NP	O
.	.	O	O

Angiography	NN	B-NP	O
and	CC	I-NP	O
intracoronary	JJ	I-NP	O
ultrasound	NN	I-NP	O
demonstrated	VBD	B-VP	O
lack	NN	B-NP	O
of	IN	B-PP	O
contact	NN	B-NP	O
between	IN	B-PP	O
stent	NN	B-NP	O
and	CC	I-NP	O
vessel	NN	I-NP	O
wall	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mm	NN	I-NP	O
long	JJ	I-NP	O
segment	NN	I-NP	O
with	IN	B-PP	O
maximal	JJ	B-NP	O
aneurysm	NN	I-NP	B
diameter	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
successfully	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
graft	NN	I-NP	O
stent	NN	I-NP	O
.	.	O	O

Behavioral	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
urotensin	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
centrally	RB	B-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Urotensin	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
(	(	O	O
U	NN	B-NP	O
-	HYPH	O	O
num	CD	O	O
)	)	O	O
receptors	NNS	B-NP	O
are	VBP	B-VP	O
widely	RB	I-VP	O
distributed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Intracerebroventricular	JJ	O	O
(	(	O	O
i.c.v.	JJ	B-ADJP	O
)	)	O	O
injection	NN	B-NP	O
of	IN	B-PP	O
U	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
causes	NNS	I-NP	O
hypertension	NN	I-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
and	CC	O	O
stimulates	VBZ	B-VP	O
prolactin	NN	B-NP	O
and	CC	I-NP	O
thyrotropin	NN	I-NP	O
secretion	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
centrally	RB	B-NP	O
administered	VBN	I-NP	O
U	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
have	VBP	B-VP	O
received	VBN	I-VP	O
little	JJ	B-NP	O
attention	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
tested	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
i.c.v.	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
U	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
behavioral	JJ	B-NP	O
,	,	I-NP	O
metabolic	JJ	I-NP	O
,	,	O	O
and	CC	O	O
endocrine	JJ	B-NP	O
responses	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
graded	VBN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
U	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mouse	NN	I-NP	O
)	)	O	O
provoked	VBD	B-VP	O
:	:	O	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
head	NN	B-NP	O
dips	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hole	NN	I-NP	O
-	HYPH	I-NP	O
board	NN	I-NP	O
test	NN	I-NP	O
;	:	O	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
entries	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
white	JJ	I-NP	O
chamber	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
black	JJ	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
-	HYPH	I-NP	O
white	JJ	I-NP	O
compartment	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
entries	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
platform	NN	I-NP	O
and	CC	O	O
open	JJ	B-NP	O
arms	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plus	CC	I-NP	O
-	HYPH	I-NP	O
maze	NN	I-NP	O
test	NN	I-NP	O
;	:	O	O
and	CC	O	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
immobility	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
forced	VBN	I-NP	O
-	HYPH	I-NP	O
swimming	VBG	I-NP	O
test	NN	I-NP	O
and	CC	I-NP	O
tail	NN	I-NP	O
suspension	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Intracerebroventricular	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
U	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
also	RB	B-ADVP	O
caused	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
:	SYM	B-NP	O
food	NN	I-NP	O
intake	NN	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mouse	NN	I-NP	O
,	,	O	O
water	NN	B-NP	O
intake	NN	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mouse	NN	I-NP	O
,	,	O	O
and	CC	O	O
horizontal	JJ	B-NP	O
locomotion	NN	I-NP	O
activity	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mouse	NN	I-NP	O
.	.	O	O

Whatever	WDT	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
central	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
U	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
body	NN	B-NP	O
temperature	NN	I-NP	O
,	,	O	O
nociception	NN	B-NP	O
,	,	O	O
apomorphine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
penile	JJ	I-NP	B
erection	NN	I-NP	I
and	CC	O	O
climbing	VBG	B-VP	O
behavior	NN	B-NP	O
,	,	O	O
and	CC	O	O
stress	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
plasma	NN	I-NP	O
corticosterone	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

Taken	VBN	B-VP	O
together	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
central	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
U	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mouse	NN	I-NP	O
induces	VBZ	B-VP	O
anxiogenic	JJ	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
depressant	NN	I-NP	O
-	HYPH	O	O
like	JJ	B-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
mouse	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
U	NN	B-NP	O
-	HYPH	B-NP	O
II	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
aspects	NNS	I-NP	O
of	IN	B-PP	O
psychiatric	JJ	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

Recurrent	JJ	B-NP	O
dysphonia	NN	I-NP	B
and	CC	I-NP	O
acitretin	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
complaining	VBG	B-VP	O
of	IN	B-PP	O
dysphonia	NN	B-NP	B
while	IN	B-SBAR	O
she	PRP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
acitretin	NN	B-NP	O
.	.	O	O

Her	PRP$	B-NP	O
symptoms	NNS	I-NP	O
totally	RB	B-VP	O
regressed	VBN	I-VP	O
after	IN	B-PP	O
drug	NN	B-NP	O
withdrawal	NN	I-NP	O
and	CC	O	O
reappeared	VBD	B-VP	O
when	WRB	B-ADVP	O
acitretin	NN	B-NP	O
was	VBD	B-VP	O
reintroduced	VBN	I-VP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acitretin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dysphonia	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
pharmacological	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
on	IN	B-PP	O
mucous	JJ	B-NP	O
membranes	NNS	I-NP	O
.	.	O	O

Pharmacological	JJ	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
-	HYPH	B-NP	O
related	VBN	I-NP	O
brain	NN	I-NP	O
activity	NN	I-NP	O
during	IN	B-PP	O
normal	JJ	B-NP	O
and	CC	I-NP	O
central	JJ	I-NP	O
sensitization	NN	I-NP	O
states	NNS	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

Abnormal	JJ	B-NP	O
processing	NN	I-NP	O
of	IN	B-PP	O
somatosensory	JJ	B-NP	O
inputs	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
central	JJ	B-NP	O
sensitization	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
accounting	VBG	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
enhanced	VBN	I-NP	O
pain	NN	I-NP	B
sensitivity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
skin	NN	I-NP	O
surrounding	VBG	B-VP	O
tissue	NN	B-NP	B
injury	NN	I-NP	I
(	(	O	O
secondary	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
)	)	O	O
.	.	O	O

Secondary	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
shares	VBZ	B-VP	O
clinical	JJ	B-NP	O
characteristics	NNS	I-NP	O
with	IN	B-PP	O
neurogenic	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
neuropathic	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

Abnormal	JJ	B-NP	O
brain	NN	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
somatosensory	JJ	B-NP	O
stimuli	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hyperalgesia	NN	B-NP	B
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
subjects	NNS	I-NP	O
during	IN	B-PP	O
experimental	JJ	B-NP	O
central	JJ	I-NP	O
sensitization	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
gabapentin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
drug	NN	I-NP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
neuropathic	JJ	B-NP	B
pain	NN	I-NP	I
patients	NNS	I-NP	O
,	,	O	O
on	IN	B-PP	O
brain	NN	B-NP	O
processing	NN	I-NP	O
of	IN	B-PP	O
nociceptive	JJ	B-NP	O
information	NN	I-NP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
and	CC	I-NP	O
central	JJ	I-NP	O
sensitization	NN	I-NP	O
states	NNS	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
functional	JJ	B-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
fMRI	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
normal	JJ	B-NP	O
volunteers	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
gabapentin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
nociceptive	JJ	B-NP	O
mechanical	JJ	I-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
skin	NN	I-NP	O
and	CC	I-NP	O
capsaicin	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
secondary	JJ	I-NP	B
hyperalgesia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
gabapentin	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
os	NNS	B-NP	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
administration	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
(	(	B-LST	O
i	LS	I-LST	O
)	)	O	O
gabapentin	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
activations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
bilateral	JJ	I-NP	O
operculoinsular	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
independently	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
sensitization	NN	I-NP	O
;	:	O	O
(	(	B-LST	O
ii	LS	I-LST	O
)	)	O	O
gabapentin	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
activation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
,	,	O	O
only	RB	B-ADVP	O
during	IN	B-PP	O
central	JJ	B-NP	O
sensitization	NN	I-NP	O
;	:	O	O
(	(	B-LST	O
iii	LS	I-LST	O
)	)	O	O
gabapentin	NN	B-NP	O
suppressed	VBD	B-VP	O
stimulus	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
deactivations	NNS	I-NP	O
,	,	O	O
only	RB	B-ADVP	O
during	IN	B-PP	O
central	JJ	B-NP	O
sensitization	NN	I-NP	O
;	:	O	O
this	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
robust	JJ	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
brain	NN	B-NP	O
activation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
observed	VBN	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
baseline	NN	I-NP	O
fMRI	NN	I-NP	O
signal	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
gabapentin	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
measurable	JJ	I-NP	O
antinociceptive	JJ	I-NP	O
effect	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
stronger	JJR	I-NP	O
antihyperalgesic	JJ	I-NP	O
effect	NN	I-NP	O
most	RBS	B-ADJP	O
evident	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
areas	NNS	I-NP	O
undergoing	VBG	B-VP	O
deactivation	NN	B-NP	O
,	,	O	O
thus	RB	B-ADVP	O
supporting	VBG	B-VP	O
the	DT	B-NP	O
concept	NN	I-NP	O
that	IN	B-SBAR	O
gabapentin	NN	B-NP	O
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
modulating	VBG	B-VP	O
nociceptive	JJ	B-NP	O
transmission	NN	I-NP	O
when	WRB	B-ADVP	O
central	JJ	B-NP	O
sensitization	NN	I-NP	O
is	VBZ	B-VP	O
present	JJ	B-ADJP	O
.	.	O	O

MDMA	NN	B-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
show	VBP	B-VP	O
process	NN	B-NP	O
-	HYPH	O	O
specific	JJ	B-NP	O
central	JJ	I-NP	O
executive	NN	I-NP	O
impairments	NNS	I-NP	O
coupled	VBN	B-VP	O
with	IN	B-PP	O
impaired	VBN	B-NP	B
social	JJ	I-NP	I
and	CC	I-NP	I
emotional	JJ	I-NP	I
judgement	NN	I-NP	I
processes	NNS	I-NP	I
.	.	O	O

In	IN	B-PP	O
recent	JJ	B-NP	O
years	NNS	I-NP	O
working	VBG	B-VP	O
memory	NN	B-NP	B
deficits	NNS	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
MDMA	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methylenedioxymethamphetamine	NN	I-NP	O
,	,	O	O
ecstasy	JJ	B-ADJP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
MDMA	NN	B-NP	O
use	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
central	JJ	I-NP	O
executive	NN	I-NP	O
processes	NNS	I-NP	O
(	(	O	O
set	VBN	B-VP	O
shifting	NN	B-NP	O
,	,	I-NP	O
inhibition	NN	I-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
updating	VBG	B-VP	O
)	)	O	O
and	CC	O	O
also	RB	B-ADVP	O
on	IN	B-PP	O
prefrontal	JJ	B-NP	O
mediated	VBN	I-NP	O
social	JJ	I-NP	O
and	CC	I-NP	O
emotional	JJ	I-NP	O
judgement	NN	I-NP	O
processes	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
polydrug	NN	I-NP	O
ecstasy	JJ	I-NP	O
users	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
polydrug	NN	I-NP	O
non	AFX	O	O
-	HYPH	O	O
ecstasy	JJ	B-NP	O
user	NN	I-NP	O
controls	NNS	I-NP	O
completed	VBD	B-VP	O
a	DT	B-NP	O
general	JJ	I-NP	O
drug	NN	I-NP	O
use	NN	I-NP	O
questionnaire	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
Brixton	NNP	I-NP	O
Spatial	NNP	I-NP	O
Anticipation	NNP	I-NP	O
task	NN	I-NP	O
(	(	O	O
set	NN	B-NP	O
shifting	NN	I-NP	O
)	)	O	O
,	,	O	O
Backward	NNP	B-NP	O
Digit	NNP	I-NP	O
Span	NNP	I-NP	O
procedure	NN	I-NP	O
(	(	O	O
memory	NN	B-NP	O
updating	VBG	B-VP	O
)	)	O	O
,	,	O	O
Inhibition	NN	B-NP	O
of	IN	B-PP	O
Return	NN	B-NP	O
(	(	O	O
inhibition	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
emotional	JJ	I-NP	O
intelligence	NN	I-NP	O
scale	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
Tromso	NNP	I-NP	O
Social	NNP	I-NP	O
Intelligence	NNP	I-NP	O
Scale	NNP	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Dysexecutive	NN	I-NP	O
Questionnaire	NN	I-NP	O
(	(	O	O
DEX	NN	B-NP	O
)	)	O	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
MDMA	NN	B-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
polydrug	NN	I-NP	O
controls	NNS	I-NP	O
,	,	O	O
MDMA	NN	B-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
showed	VBD	B-VP	O
impairments	NNS	B-NP	O
in	IN	B-PP	O
set	NN	B-NP	O
shifting	NN	I-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
updating	VBG	B-ADJP	O
,	,	O	O
and	CC	O	O
also	RB	B-ADVP	O
in	IN	B-PP	O
social	JJ	B-NP	O
and	CC	I-NP	O
emotional	JJ	I-NP	O
judgement	NN	I-NP	O
processes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
latter	JJ	I-NP	O
num	CD	I-NP	O
deficits	NNS	I-NP	O
remained	VBD	B-VP	O
significant	JJ	B-ADJP	O
after	IN	B-PP	O
controlling	VBG	B-VP	O
for	IN	B-PP	O
other	JJ	B-NP	O
drug	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
lend	VBP	B-VP	O
further	JJ	B-NP	O
support	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
proposal	NN	I-NP	O
that	IN	B-SBAR	O
cognitive	JJ	B-NP	O
processes	NNS	I-NP	O
mediated	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
prefrontal	JJ	I-NP	O
cortex	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
impaired	VBN	I-VP	O
by	IN	B-PP	O
recreational	JJ	B-NP	O
ecstasy	JJ	I-NP	O
use	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
citrate	NN	I-NP	O
toxicity	NN	I-NP	B
complicating	VBG	B-VP	O
volunteer	NN	B-NP	O
apheresis	NN	I-NP	O
platelet	NN	I-NP	O
donation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
citrate	NN	I-NP	O
toxicity	NN	I-NP	B
during	IN	B-PP	O
volunteer	NN	B-NP	O
donor	NN	I-NP	O
apheresis	NN	I-NP	O
platelet	NN	I-NP	O
collection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
donor	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	JJ	I-NP	O
,	,	I-NP	O
first	JJ	I-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
apheresis	NN	I-NP	O
platelet	NN	I-NP	O
donor	NN	I-NP	O
.	.	O	O

Past	JJ	B-NP	O
medical	JJ	I-NP	O
history	NN	I-NP	O
was	VBD	B-VP	O
remarkable	JJ	B-ADJP	O
for	IN	B-PP	O
hypertension	NN	B-NP	B
,	,	O	O
hyperlipidemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
depression	NN	B-NP	B
.	.	O	O

Reported	VBN	B-NP	O
medications	NNS	I-NP	O
included	VBD	B-VP	O
bumetanide	NN	B-NP	O
,	,	O	O
pravastatin	NN	B-NP	O
,	,	O	O
and	CC	O	O
paroxetine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
minutes	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
donor	NN	I-NP	O
noted	VBD	B-VP	O
tingling	VBG	I-VP	O
around	IN	B-PP	O
the	DT	B-NP	O
mouth	NN	I-NP	O
,	,	O	O
hands	NNS	B-NP	O
,	,	O	O
and	CC	O	O
feet	NNS	B-NP	O
.	.	O	O

She	PRP	B-NP	O
then	RB	B-ADVP	O
very	RB	B-ADVP	O
rapidly	RB	I-ADVP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
facial	JJ	I-NP	O
and	CC	I-NP	O
extremity	NN	I-NP	O
tetany	NN	I-NP	B
.	.	O	O

Empirical	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
calcium	NN	I-NP	O
gluconate	NN	I-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
muscle	NN	B-NP	B
contractions	NNS	I-NP	I
slowly	RB	B-ADVP	O
subsided	VBD	B-VP	O
over	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
events	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
reaction	NN	I-NP	O
to	TO	B-PP	O
calcium	NN	B-NP	O
chelation	NN	I-NP	O
by	IN	B-PP	O
sodium	NN	B-NP	O
citrate	NN	I-NP	O
anticoagulant	NN	I-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
symptomatic	JJ	B-NP	O
systemic	JJ	I-NP	O
hypocalcemia	NN	I-NP	B
.	.	O	O

Upon	IN	B-PP	O
additional	JJ	B-NP	O
retrospective	JJ	I-NP	O
analysis	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
that	IN	B-SBAR	O
bumetanide	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
loop	NN	I-NP	O
diuretic	JJ	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
significant	JJ	B-NP	O
hypocalcemia	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
careful	JJ	B-NP	O
screening	NN	I-NP	O
for	IN	B-PP	O
medications	NNS	B-NP	O
and	CC	O	O
underlying	VBG	B-VP	O
conditions	NNS	B-NP	O
predisposing	VBG	B-VP	O
to	TO	B-PP	O
hypocalcemia	NN	B-NP	B
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
to	TO	I-VP	O
help	VB	I-VP	O
prevent	VB	I-VP	O
severe	JJ	B-NP	O
reactions	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-VP	O
citrate	VB	I-VP	O
toxicity	NN	B-NP	B
.	.	O	O

Laboratory	NN	B-NP	O
measurement	NN	I-NP	O
of	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
procedure	NN	I-NP	O
serum	NN	I-NP	O
calcium	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
selected	VBN	B-NP	O
donors	NNS	I-NP	O
may	MD	B-VP	O
identify	VB	I-VP	O
cases	NNS	B-NP	O
requiring	VBG	B-VP	O
heightened	VBN	B-NP	O
vigilance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
also	RB	B-ADVP	O
illustrates	VBZ	B-VP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
maintaining	VBG	B-VP	O
preparedness	NN	B-NP	O
for	IN	B-PP	O
managing	VBG	B-VP	O
rare	JJ	B-NP	O
but	CC	I-NP	O
serious	JJ	I-NP	O
reactions	NNS	I-NP	O
in	IN	B-PP	O
volunteer	NN	B-NP	O
apheresis	NN	I-NP	O
blood	NN	I-NP	O
donors	NNS	I-NP	O
.	.	O	O

Proteinuria	NN	B-NP	B
after	IN	B-PP	O
conversion	NN	B-NP	O
to	TO	B-PP	O
sirolimus	NN	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
.	.	O	O

Sirolimus	NN	B-NP	O
(	(	O	O
SRL	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
,	,	I-NP	O
potent	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

More	RBR	B-ADVP	O
recently	RB	I-ADVP	O
,	,	O	O
proteinuria	NN	B-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
has	VBZ	B-VP	O
remained	VBN	I-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
retrospectively	RB	B-ADVP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
renal	JJ	I-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
or	CC	I-VP	O
displayed	VBD	I-VP	O
increased	VBN	B-NP	O
proteinuria	NN	I-NP	B
after	IN	B-PP	O
SRL	NN	B-NP	O
conversion	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
cohort	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
)	)	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
SRL	NN	B-NP	O
as	IN	B-PP	O
conversion	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
due	JJ	B-PP	O
to	TO	B-PP	O
chronic	JJ	B-NP	B
allograft	NN	I-NP	I
nephropathy	NN	I-NP	I
(	(	O	O
CAN	NN	B-NP	B
)	)	O	O
neoplasia	NN	B-NP	B
;	:	O	O
Kaposi	NNP	B-NP	B
s	VBZ	B-VP	I
sarcoma	NN	B-NP	I
,	,	O	O
num	CD	B-NP	O
skin	NN	I-NP	B
cancers	NNS	I-NP	I
,	,	O	O
num	CD	B-NP	O
intestinal	JJ	I-NP	B
tumors	NNS	I-NP	I
,	,	O	O
num	CD	B-NP	O
renal	JJ	I-NP	B
cell	NN	I-NP	I
carsinom	NN	I-NP	I
)	)	O	O
or	CC	O	O
BK	NN	B-NP	O
virus	NN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

SRL	NN	B-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
mean	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	O	O
num	CD	B-NP	O
)	)	O	O
months	NNS	B-NP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
.	.	O	O

Mean	JJ	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
on	IN	B-PP	O
SRL	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	O	O
num	CD	O	O
)	)	O	O
months	NNS	B-NP	O
.	.	O	O

Proteinuria	NNP	B-NP	B
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	O	O
num	CD	O	O
)	)	O	O
g	NN	B-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
before	IN	B-PP	O
conversion	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	O	O
num	CD	B-NP	O
)	)	O	O
after	IN	B-PP	O
conversion	NN	B-NP	O
.	.	O	O

Before	IN	B-PP	O
conversion	NN	B-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
proteinuria	NN	I-NP	B
,	,	O	O
whereas	IN	O	O
afterwards	RB	O	O
all	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
proteinuria	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
proteinuria	NNS	I-NP	B
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
,	,	O	O
whereas	IN	O	O
it	PRP	B-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
it	PRP	B-NP	O
increased	VBD	B-VP	O
by	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
showed	VBD	B-VP	O
increased	VBN	B-NP	O
proteinuria	NN	I-NP	B
to	TO	B-PP	O
the	DT	B-NP	O
nephrotic	JJ	I-NP	B
range	NN	I-NP	O
.	.	O	O

Biopsies	NNS	B-NP	O
performed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
revealed	VBD	B-VP	O
new	JJ	B-NP	O
pathological	JJ	I-NP	O
changes	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
membranoproliferative	JJ	I-NP	B
glomerulopathy	NN	I-NP	I
and	CC	O	O
interstitial	JJ	B-NP	B
nephritis	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
persistently	RB	B-NP	O
good	JJ	I-NP	O
graft	NN	I-NP	O
function	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
creatinine	NN	I-NP	O
values	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
significantly	RB	B-ADVP	O
:	:	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
before	IN	B-PP	O
SRL	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
at	IN	B-PP	O
last	JJ	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
.	.	O	O

num	CD	B-NP	O
grafts	NNS	I-NP	O
were	VBD	B-VP	O
lost	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
dialysis	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
displayed	VBD	B-VP	O
CAN	NN	B-NP	B
and	CC	I-NP	O
Kaposi	NN	I-NP	B
s	NNS	I-NP	I
sarcoma	NN	I-NP	I
.	.	O	O

Mean	JJ	B-NP	O
urinary	JJ	I-NP	O
protein	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
dialysis	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	O	O
num	CD	O	O
)	)	O	O
g	NN	B-NP	O
/	SYM	B-VP	O
d	NN	B-NP	O
before	IN	B-PP	O
and	CC	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	O	O
num	CD	O	O
)	)	O	O
g	NN	B-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
after	IN	B-PP	O
conversion	NN	B-NP	O
.	.	O	O

Mean	JJ	B-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
level	NN	I-NP	O
before	IN	B-PP	O
conversion	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
and	CC	O	O
thereafter	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
.	.	O	O

Heavy	JJ	B-NP	O
proteinuria	NN	I-NP	B
was	VBD	B-VP	O
common	JJ	B-ADJP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
SRL	NN	B-NP	O
as	IN	B-PP	O
rescue	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
conversion	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
developed	VBN	I-VP	O
advanced	JJ	B-NP	O
CAN	NN	I-NP	B
and	CC	I-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
de	FW	B-NP	O
novo	FW	I-NP	O
glomerular	JJ	I-NP	O
pathology	NN	I-NP	O
under	IN	B-PP	O
SRL	NN	B-NP	O
treatment	NN	I-NP	O
requires	VBZ	B-VP	O
further	JJR	B-NP	O
investigation	NN	I-NP	O
by	IN	B-PP	O
renal	JJ	B-NP	O
biopsy	NN	I-NP	O
.	.	O	O

In	FW	B-NP	O
vitro	FW	I-NP	O
characterization	NN	I-NP	O
of	IN	B-PP	O
parasympathetic	JJ	B-NP	O
and	CC	I-NP	O
sympathetic	JJ	I-NP	O
responses	NNS	I-NP	O
in	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
,	,	O	O
detrusor	NN	B-NP	O
function	NN	I-NP	O
is	VBZ	B-VP	O
impaired	JJ	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
expression	NN	B-NP	O
and	CC	O	O
effects	NNS	B-NP	O
of	IN	B-PP	O
muscarinic	JJ	B-NP	O
receptors	NNS	I-NP	O
altered	VBN	B-VP	O
.	.	O	O

Whether	RB	B-ADVP	O
or	CC	O	O
not	RB	O	O
the	DT	B-NP	O
neuronal	JJ	I-NP	O
transmission	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
cystitis	NN	B-NP	B
was	VBD	B-VP	O
presently	RB	I-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Responses	NNS	B-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	O
strip	NN	I-NP	O
preparations	NNS	I-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
and	CC	I-NP	O
cyclophosphamide	NN	I-NP	O
-	HYPH	B-NP	O
pretreated	VBN	I-NP	O
rats	NNS	I-NP	O
to	TO	B-PP	O
electrical	JJ	B-NP	O
field	NN	I-NP	O
stimulation	NN	I-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
agonists	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
and	CC	I-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
muscarinic	JJ	B-NP	O
,	,	I-NP	O
adrenergic	JJ	I-NP	O
and	CC	I-NP	O
purinergic	JJ	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

Generally	RB	B-ADVP	O
,	,	O	O
atropine	NN	B-NP	O
reduced	VBD	B-VP	O
contractions	NNS	B-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
it	PRP	B-NP	O
also	RB	B-ADVP	O
reduced	VBD	B-VP	O
responses	NNS	B-NP	O
to	TO	B-PP	O
low	JJ	B-NP	O
electrical	JJ	I-NP	O
field	NN	I-NP	O
stimulation	NN	I-NP	O
intensity	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
Hz	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
inflamed	JJ	B-NP	O
preparations	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
types	NNS	I-NP	O
,	,	O	O
purinoceptor	NN	B-NP	O
desensitization	NN	I-NP	O
with	IN	B-PP	O
alpha	SYM	B-NP	O
,	,	O	O
beta	SYM	O	O
-	HYPH	O	O
methylene	NN	B-NP	O
adenosine	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
triphosphate	NN	I-NP	O
(	(	O	O
alpha	SYM	B-NP	O
,	,	O	O
beta	SYM	O	O
-	HYPH	O	O
meATP	NN	B-NP	O
)	)	O	O
caused	VBD	B-VP	O
further	JJ	B-NP	O
reductions	NNS	I-NP	O
at	IN	B-PP	O
low	JJ	B-NP	O
frequencies	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
muscarinic	JJ	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
atropine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
diphenylacetoxy	NN	I-NP	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	O	O
methylpiperidine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DAMP	NN	I-NP	O
)	)	O	O
(	(	O	O
'M	NN	B-NP	O
/	SYM	O	O
M	NN	B-NP	O
/	SYM	B-NP	O
M	NN	I-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
'	''	O	O
)	)	O	O
,	,	O	O
methoctramine	NN	B-NP	O
(	(	O	O
'M	NN	B-NP	O
-	HYPH	B-ADJP	O
selective	JJ	I-ADJP	O
'	''	O	O
)	)	O	O
and	CC	O	O
pirenzepine	NN	B-NP	O
(	(	O	O
'M	NN	B-NP	O
-	HYPH	B-ADJP	O
selective	JJ	I-ADJP	O
'	''	O	O
)	)	O	O
antagonized	VBD	B-VP	O
the	DT	B-NP	O
tonic	JJ	I-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
electrical	JJ	I-NP	O
field	NN	I-NP	O
stimulation	NN	I-NP	O
-	HYPH	O	O
evoked	VBN	B-VP	O
contractile	JJ	B-NP	O
response	NN	I-NP	O
more	RBR	B-ADVP	O
potently	RB	I-ADVP	O
than	IN	B-PP	O
the	DT	B-NP	O
phasic	JJ	I-NP	O
component.	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
DAMP	NN	I-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
tonic	JJ	I-NP	O
contractions	NNS	I-NP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
more	RBR	B-ADVP	O
potently	RB	I-ADVP	O
than	IN	B-PP	O
methoctramine	NN	B-NP	O
and	CC	I-NP	O
pirenzepine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
inflamed	JJ	B-NP	O
preparations	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
muscarinic	JJ	I-NP	O
receptor	NN	I-NP	O
antagonism	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
phasic	JJ	I-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
electrical	JJ	I-NP	O
field	NN	I-NP	O
stimulation	NN	I-NP	O
-	HYPH	B-VP	O
evoked	VBN	B-NP	O
contraction	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
pirenzepine	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
DAMP	NN	I-NP	O
antagonism	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
tonic	JJ	I-NP	O
component	NN	I-NP	O
was	VBD	B-VP	O
much	RB	B-ADJP	O
less	RBR	I-ADJP	O
efficient	JJ	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
methoctramine	NN	B-NP	O
increased	VBD	B-VP	O
-	SYM	B-NP	O
-	HYPH	B-NP	O
instead	RB	B-PP	O
of	IN	I-PP	O
decreased	VBN	B-NP	O
-	SYM	I-NP	O
-	HYPH	O	O
the	DT	B-NP	O
tonic	JJ	I-NP	O
responses	NNS	I-NP	O
at	IN	B-PP	O
high	JJ	B-NP	O
frequencies	NNS	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
contractions	NNS	B-NP	O
to	TO	B-PP	O
carbachol	NN	B-NP	O
and	CC	I-NP	O
ATP	NN	I-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
in	IN	B-PP	O
inflamed	JJ	B-ADJP	O
and	CC	O	O
in	IN	B-PP	O
control	NN	B-NP	O
strips	NNS	I-NP	O
when	WRB	B-ADVP	O
related	VBN	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
reference	NN	I-NP	O
potassium	NN	I-NP	O
response	NN	I-NP	O
,	,	O	O
isoprenaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
relaxations	NNS	I-NP	O
were	VBD	B-VP	O
smaller	JJR	B-ADJP	O
in	IN	B-PP	O
inflamed	JJ	B-NP	O
strips	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
cystitis	NN	B-NP	B
substantial	JJ	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
efferent	JJ	I-NP	O
functional	JJ	I-NP	O
responses	NNS	I-NP	O
occur	VBP	B-VP	O
.	.	O	O

While	IN	B-SBAR	O
postjunctional	JJ	B-ADJP	O
beta	SYM	O	O
-	HYPH	B-NP	O
adrenoceptor	NN	I-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
relaxations	NNS	I-NP	O
are	VBP	B-VP	O
reduced	VBN	I-VP	O
,	,	O	O
effects	NNS	B-NP	O
by	IN	B-PP	O
prejunctional	JJ	B-NP	O
inhibitory	JJ	I-NP	O
muscarinic	JJ	I-NP	O
receptors	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
increased	VBN	I-VP	O
.	.	O	O

Associations	NNS	B-NP	O
between	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
benzodiazepines	NNS	B-NP	O
or	CC	O	O
related	VBN	B-NP	O
drugs	NNS	I-NP	O
and	CC	I-NP	O
health	NN	I-NP	O
,	,	O	O
physical	JJ	B-NP	O
abilities	NNS	I-NP	O
and	CC	O	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
randomised	VBN	I-NP	O
clinical	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
.	.	O	O

To	TO	B-VP	O
describe	VB	I-VP	O
associations	NNS	B-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
benzodiazepines	NNS	B-NP	O
or	CC	O	O
related	VBN	B-NP	O
drugs	NNS	I-NP	O
(	(	O	O
BZDs	NNS	B-NP	O
/	SYM	B-NP	O
RDs	NNS	I-NP	O
)	)	O	O
and	CC	O	O
health	NN	B-NP	O
,	,	O	O
functional	JJ	B-NP	O
abilities	NNS	I-NP	O
and	CC	O	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
.	.	O	O

A	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	B-VP	O
randomised	VBN	I-VP	O
clinical	JJ	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
aged	VBN	B-VP	O
>	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
acute	JJ	B-NP	O
hospital	NN	I-NP	O
wards	NNS	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
month.	NN	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
admitted	VBN	I-VP	O
.	.	O	O

Of	IN	B-PP	O
these	DT	B-NP	O
,	,	O	O
nearly	RB	B-NP	O
half	NN	I-NP	O
had	VBD	B-VP	O
used	VBN	I-VP	O
BZDs	NNS	B-NP	O
/	SYM	O	O
RDs	NNS	B-NP	O
before	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
remainder	NN	I-NP	O
were	VBD	B-VP	O
non	AFX	B-ADJP	O
-	HYPH	B-NP	O
users	NNS	I-NP	O
.	.	O	O

Cognitive	JJ	B-NP	O
ability	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
Mini	NNP	I-NP	O
-	HYPH	I-NP	O
Mental	NNP	I-NP	O
State	NNP	I-NP	O
Examination	NNP	I-NP	O
(	(	O	O
MMSE	NN	B-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
scoring	VBG	B-VP	O
>	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
MMSE	NN	I-NP	O
sum	NN	I-NP	O
points	NNS	I-NP	O
were	VBD	B-VP	O
interviewed	VBN	I-VP	O
and	CC	O	O
questioned	VBN	B-VP	O
regarding	VBG	B-PP	O
symptoms	NNS	B-NP	O
and	CC	O	O
functional	JJ	B-NP	O
abilities	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
week	NN	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
admission	NN	B-NP	O
.	.	O	O

Data	NNS	B-NP	O
on	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
BZDs	NNS	B-NP	O
/	SYM	B-VP	O
RDs	NNS	B-NP	O
before	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
current	JJ	B-NP	O
medications	NNS	I-NP	O
and	CC	O	O
discharge	NN	B-NP	O
diagnoses	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
from	IN	B-PP	O
medical	JJ	B-NP	O
records	NNS	I-NP	O
.	.	O	O

Health	NNP	B-NP	O
,	,	O	O
physical	JJ	B-NP	O
abilities	NNS	I-NP	O
and	CC	O	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
between	IN	B-PP	O
BZD	NN	B-NP	O
/	SYM	I-NP	O
RD	NN	I-NP	O
users	NNS	I-NP	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
users	NNS	I-NP	O
,	,	O	O
and	CC	O	O
adjustments	NNS	B-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
for	IN	B-PP	O
confounding	VBG	B-VP	O
variables	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
residual	JJ	I-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
oxazepam	NN	B-NP	O
,	,	O	O
temazepam	NN	B-NP	O
and	CC	I-NP	O
zopiclone	NN	I-NP	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
mean	NN	I-NP	O
+	SYM	B-VP	O
/	SYM	B-NP	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
BZD	NN	B-NP	O
/	SYM	I-NP	O
RD	NN	I-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
BZDs	NNS	I-NP	O
/	SYM	I-NP	O
RDs	NNS	I-NP	O
were	VBD	B-VP	O
concomitantly	RB	I-VP	O
taken	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
users	NNS	B-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
female	JJ	B-NP	O
sex	NN	I-NP	O
and	CC	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
with	IN	B-PP	O
effects	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
CNS	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
diagnosed	VBN	B-NP	O
dementia	NN	I-NP	B
.	.	O	O

After	IN	B-PP	O
adjustment	NN	B-NP	O
for	IN	B-PP	O
these	DT	B-NP	O
variables	NNS	I-NP	O
as	IN	B-PP	O
confounders	NNS	B-NP	O
,	,	O	O
use	NN	B-NP	O
of	IN	B-PP	O
BZDs	NNS	B-NP	O
/	SYM	B-NP	O
RDs	NNS	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
MMSE	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
use	NN	B-NP	O
of	IN	B-PP	O
BZDs	NNS	B-NP	O
/	SYM	B-NP	O
RDs	NNS	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
dizziness	NN	B-NP	B
,	,	O	O
inability	NN	B-NP	B
to	TO	B-VP	I
sleep	VB	I-VP	I
after	IN	B-PP	O
awaking	VBG	B-VP	O
at	IN	B-PP	O
night	NN	B-NP	O
and	CC	I-NP	O
tiredness	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
mornings	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
week	NN	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
admission	NN	B-NP	O
and	CC	O	O
with	IN	B-PP	O
stronger	JJR	B-NP	O
depressive	JJ	I-NP	B
symptoms	NNS	I-NP	I
measured	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
beginning	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
stay	NN	I-NP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
BZDs	NNS	B-NP	O
/	SYM	B-NP	O
RDs	NNS	I-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
walk	VB	I-VP	O
and	CC	O	O
shorter	JJR	B-NP	O
night	NN	I-NP	O
-	HYPH	B-NP	O
time	NN	I-NP	O
sleep	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
week	NN	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
admission	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
higher	JJR	I-NP	O
residual	JJ	I-NP	O
serum	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
temazepam	NN	B-NP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
MMSE	NN	I-NP	O
sum	NN	I-NP	O
score	NN	I-NP	O
after	IN	B-PP	O
adjustment	NN	B-NP	O
for	IN	B-PP	O
confounding	VBG	B-VP	O
variables	NNS	B-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
and	CC	O	O
concomitant	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
BZD	NN	I-NP	O
/	SYM	B-NP	O
RD	NN	I-NP	O
were	VBD	B-VP	O
common	JJ	B-ADJP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
hospitalised	VBD	B-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
acute	JJ	B-NP	O
illnesses	NNS	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
daytime	NN	B-NP	O
and	CC	I-NP	O
night	NN	I-NP	O
-	HYPH	O	O
time	NN	B-NP	O
symptoms	NNS	I-NP	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
poorer	JJR	B-NP	O
health	NN	I-NP	O
and	CC	O	O
potentially	RB	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
vocal	JJ	I-NP	B
fold	JJ	I-NP	I
palsy	NN	I-NP	I
after	IN	B-PP	O
acute	JJ	B-NP	O
disulfiram	NN	I-NP	O
intoxication	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
disulfiram	NN	I-NP	O
overdose	NN	I-NP	B
is	VBZ	B-VP	O
very	RB	B-ADJP	O
rare	JJ	I-ADJP	O
and	CC	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
it	PRP	B-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
vocal	JJ	B-NP	B
fold	JJ	I-NP	I
palsy	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
was	VBD	B-VP	O
transferred	VBN	I-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
department	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
quadriparesis	NN	B-NP	B
,	,	O	O
lancinating	VBG	B-VP	O
pain	NN	B-NP	B
,	,	O	O
sensory	JJ	B-NP	B
loss	NN	I-NP	I
,	,	O	O
and	CC	O	O
paresthesia	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
distal	JJ	I-NP	O
limbs	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
month	NN	I-NP	O
previously	RB	B-ADVP	O
,	,	O	O
she	PRP	B-NP	O
had	VBD	B-VP	O
taken	VBN	I-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
disulfiram	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
tablets	NNS	I-NP	O
of	IN	B-PP	O
ALCOHOL	NNP	B-NP	O
STOP	NNP	I-NP	O
TAB	NNP	I-NP	O
,	,	O	O
Shin	NNP	B-NP	O
-	HYPH	B-NP	O
Poong	NNP	I-NP	O
Pharm	NNP	I-NP	O
.	.	O	O

Co.	NNP	B-NP	O
,	,	O	O
Ansan	NNP	B-NP	O
,	,	O	O
Korea	NNP	B-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
suicide	NN	I-NP	O
attempt	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
an	DT	B-NP	O
alcoholic	JJ	I-NP	O
.	.	O	O

For	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
few	JJ	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
ingestion	NN	B-NP	O
,	,	O	O
she	PRP	B-NP	O
was	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
confused	JJ	I-NP	O
state	NN	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
mild	JJ	B-ADJP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
ataxia	NN	I-NP	B
and	CC	I-NP	O
giddiness	NN	I-NP	B
.	.	O	O

She	PRP	B-NP	O
noticed	VBD	B-VP	O
hoarseness	NN	B-NP	B
and	CC	O	O
distally	RB	B-VP	O
accentuated	VBN	I-VP	O
motor	NN	B-NP	O
and	CC	O	O
sensory	JJ	B-NP	O
dysfunction	NN	I-NP	O
after	IN	B-SBAR	O
she	PRP	B-NP	O
had	VBD	B-VP	O
recovered	VBN	I-VP	O
from	IN	B-PP	O
this	DT	B-NP	O
state	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
nerve	NN	I-NP	O
conduction	NN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
sensorimotor	NN	I-NP	O
axonal	JJ	I-NP	O
polyneuropathy	NN	I-NP	B
.	.	O	O

Laryngeal	JJ	B-NP	O
electromyography	NN	I-NP	O
(	(	O	O
thyroarytenoid	NN	B-NP	O
muscle	NN	I-NP	O
)	)	O	O
showed	VBD	B-VP	O
ample	JJ	B-NP	O
denervation	NN	I-NP	O
potentials	NNS	I-NP	O
.	.	O	O

Laryngoscopy	NNP	B-NP	O
revealed	VBD	B-VP	O
asymmetric	JJ	B-NP	O
vocal	JJ	I-NP	O
fold	JJ	I-NP	O
movements	NNS	I-NP	O
during	IN	B-PP	O
phonation	NN	B-NP	O
.	.	O	O

Her	PRP$	B-NP	O
vocal	JJ	I-NP	O
change	NN	I-NP	O
and	CC	I-NP	O
weakness	NN	I-NP	O
began	VBD	B-VP	O
to	TO	I-VP	O
improve	VB	I-VP	O
spontaneously	RB	B-ADVP	O
about	IN	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
transfer	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
palsy	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
recurrent	JJ	I-NP	O
laryngeal	JJ	I-NP	O
nerve	NN	I-NP	O
and	CC	O	O
superimposed	VBN	B-VP	O
severe	JJ	B-NP	O
acute	JJ	I-NP	O
sensorimotor	NN	I-NP	O
axonal	JJ	I-NP	O
polyneuropathy	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
disulfiram	NN	I-NP	O
intoxication	NN	I-NP	O
.	.	O	O

Higher	JJR	B-NP	O
optical	JJ	I-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
antigen	NN	I-NP	O
assay	NN	I-NP	O
predicts	VBZ	B-VP	O
thrombosis	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
correlate	VB	I-VP	O
optical	JJ	B-NP	O
density	NN	I-NP	O
and	CC	I-NP	O
percent	NN	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
step	NN	I-NP	O
heparin	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
thrombocytopenia	NN	I-NP	B
(	(	O	O
HIT	NN	B-NP	B
)	)	O	O
antigen	NN	B-NP	O
assay	NN	I-NP	O
with	IN	B-PP	O
thrombosis	NN	B-NP	B
;	:	O	O
the	DT	B-NP	O
assay	NN	I-NP	O
utilizes	VBZ	B-VP	O
reaction	NN	B-NP	O
inhibition	NN	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
heparin	NN	I-NP	O
concentration	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
platelet	NN	B-NP	O
count	NN	I-NP	O
or	CC	O	O
thrombocytopenia	NN	B-NP	B
after	IN	B-SBAR	O
exposure	NN	B-NP	O
to	TO	B-PP	O
heparin	NN	B-NP	O
,	,	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
step	NN	I-NP	O
antigen	NN	I-NP	O
assay	NN	I-NP	O
[	(	O	O
optical	JJ	B-NP	O
density	NN	I-NP	O
(	(	O	O
OD	NN	B-NP	O
)	)	O	O
>	SYM	B-NP	O
num	CD	I-NP	O
and	CC	O	O
>	SYM	B-NP	O
num	CD	B-NP	O
inhibition	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
]	)	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
HIT	NN	I-NP	B
patients	NNS	I-NP	O
had	VBD	B-VP	O
thrombosis	NN	B-NP	B
at	IN	B-PP	O
diagnosis	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
isolated	VBN	I-VP	O
-	HYPH	B-NP	O
HIT	NN	I-NP	B
without	IN	B-PP	O
thrombosis	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
-	HYPH	I-NP	O
HIT	NN	I-NP	B
patients	NNS	I-NP	O
developed	VBD	B-VP	O
thrombosis	NN	B-NP	B
within	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
num	CD	I-NP	O
d	NN	I-NP	O
;	:	O	O
thus	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
thrombosis	NN	B-NP	B
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

At	IN	B-PP	O
diagnosis	NN	B-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
OD	NN	B-NP	O
between	IN	B-PP	O
HIT	NN	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
thrombosis	NN	B-NP	B
and	CC	O	O
those	DT	B-NP	O
with	IN	B-PP	O
isolated	VBN	B-NP	O
-	HYPH	I-NP	O
HIT	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
OD	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
thrombosis	NN	B-NP	B
,	,	O	O
including	VBG	B-PP	O
isolated	VBN	B-VP	O
-	HYPH	B-NP	O
HIT	NN	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
later	RB	B-ADVP	O
developed	VBD	B-VP	O
thrombosis	NN	B-NP	B
within	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
isolated	VBN	B-NP	O
-	HYPH	I-NP	O
HIT	NN	B-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
develop	VB	I-VP	O
thrombosis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
Receiver	NNP	I-NP	O
Operative	NNP	I-NP	O
Characteristic	NNP	I-NP	O
Curve	NNP	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
OD	NN	B-NP	O
>	SYM	B-VP	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
-	HYPH	I-NP	O
HIT	NN	I-NP	B
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
higher	JJR	I-NP	O
chance	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
thrombosis	NN	B-NP	B
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
groups	NNS	I-NP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
percent	NN	B-NP	O
inhibition	NN	I-NP	O
.	.	O	O

Multivariate	JJ	B-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
fold	RB	I-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
thrombosis	NN	B-NP	B
in	IN	B-PP	O
females	NNS	B-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
thrombotic	JJ	B-NP	B
risk	NN	I-NP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
age	NN	B-NP	O
and	CC	I-NP	O
OD	NN	I-NP	O
values	NNS	I-NP	O
.	.	O	O

Higher	JJR	B-NP	O
OD	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significant	JJ	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
subsequent	JJ	B-NP	O
thrombosis	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
isolated	VBN	B-NP	O
-	HYPH	I-NP	O
HIT	NN	I-NP	B
;	:	O	O
percent	NN	B-NP	O
inhibition	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
was	VBD	B-VP	O
not	RB	O	O
predictive	JJ	B-ADJP	O
.	.	O	O

Central	JJ	B-NP	O
retinal	JJ	I-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
clomiphene	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ovulation	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
retinal	JJ	I-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
clomiphene	NN	B-NP	O
citrate	NN	I-NP	O
(	(	O	O
CC	NN	B-NP	O
)	)	O	O
.	.	O	O

Case	NN	B-NP	O
study	NN	I-NP	O
.	.	O	O

Ophthalmology	NN	B-NP	O
clinic	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
academic	JJ	I-NP	O
hospital	NN	I-NP	O
.	.	O	O

PATIENT	NN	B-NP	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
:	:	O	O
A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
referred	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
infertility	NN	I-NP	B
clinic	NN	I-NP	O
for	IN	B-PP	O
blurred	JJ	B-NP	B
vision	NN	I-NP	I
.	.	O	O

INTERVENTION	NN	B-NP	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
:	:	O	O
Ophthalmic	JJ	B-NP	O
examination	NN	I-NP	O
after	IN	B-PP	O
CC	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

MAIN	NN	B-NP	O
OUTCOME	NN	I-NP	O
MEASURE	NN	I-NP	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
:	:	O	O
Central	JJ	B-NP	O
retinal	JJ	I-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
after	IN	B-PP	O
ovulation	NN	B-NP	O
induction	NN	I-NP	O
with	IN	B-PP	O
CC	NN	B-NP	O
.	.	O	O

RESULT	NN	B-NP	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
:	:	O	O
A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Chinese	JJ	I-NP	O
woman	NN	I-NP	O
developed	VBD	B-VP	O
central	JJ	B-NP	O
retinal	JJ	I-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
CC	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
search	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
thromboembolic	JJ	I-NP	B
complications	NNS	I-NP	O
of	IN	B-PP	O
CC	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
include	VB	I-VP	O
this	DT	B-NP	O
severe	JJ	I-NP	O
ophthalmic	JJ	I-NP	O
complication	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
mild	JJ	B-NP	O
visual	JJ	I-NP	B
disturbance	NN	I-NP	I
after	IN	B-PP	O
CC	NN	B-NP	O
intake	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
uncommon	JJ	B-ADJP	O
.	.	O	O

CONCLUSION	NN	B-NP	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
:	:	O	O
This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
retinal	JJ	I-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
CC	NN	B-NP	O
.	.	O	O

Extra	NNP	B-NP	O
caution	NN	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
in	IN	B-PP	O
treating	VBG	B-VP	O
infertility	NN	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
CC	NN	B-NP	O
,	,	O	O
and	CC	O	O
patients	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
well	RB	I-VP	O
informed	VBN	I-VP	O
of	IN	B-PP	O
this	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
before	IN	B-PP	O
commencement	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nystagmus	NN	I-NP	B
correlates	VBZ	B-VP	O
with	IN	B-PP	O
midpontine	JJ	B-NP	O
activation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pathomechanism	NN	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nystagmus	NN	I-NP	B
(	(	O	O
NIN	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
delineate	VB	I-VP	O
brain	NN	B-NP	O
structures	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
NIN	NN	B-NP	B
generation	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
volunteers	NNS	I-NP	O
inhaled	VBD	B-VP	O
nicotine	NN	B-NP	O
in	IN	B-PP	O
darkness	NN	B-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
functional	JJ	I-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
fMRI	NN	B-NP	O
)	)	O	O
experiment	NN	B-NP	O
;	:	O	O
eye	NN	B-NP	O
movements	NNS	I-NP	O
were	VBD	B-VP	O
registered	VBN	I-VP	O
using	VBG	B-VP	O
video	AFX	B-NP	O
-	HYPH	I-NP	O
oculography	NN	I-NP	O
.	.	O	O

NIN	NN	B-NP	B
correlated	VBD	B-VP	O
with	IN	B-PP	O
blood	NN	B-NP	O
oxygen	NN	I-NP	O
level	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
(	(	O	O
BOLD	NN	B-NP	O
)	)	O	O
activity	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
midpontine	JJ	I-NP	O
site	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
basis	NN	I-NP	O
pontis	NN	I-NP	O
.	.	O	O

NIN	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
midpontine	NN	I-NP	O
activation	NN	I-NP	O
may	MD	B-VP	O
correspond	VB	I-VP	O
to	TO	B-PP	O
activation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dorsomedial	JJ	I-NP	O
pontine	NN	I-NP	O
nuclei	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
nucleus	NN	I-NP	O
reticularis	NN	I-NP	O
tegmenti	NN	I-NP	O
pontis	NN	I-NP	O
,	,	O	O
structures	NNS	B-NP	O
known	VBN	B-VP	O
to	TO	B-VP	O
participate	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
generation	NN	I-NP	O
of	IN	B-PP	O
multidirectional	JJ	B-NP	O
saccades	NNS	I-NP	O
and	CC	O	O
smooth	JJ	B-NP	O
pursuit	NN	I-NP	O
eye	NN	I-NP	O
movements	NNS	I-NP	O
.	.	O	O

Protective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
on	IN	B-PP	O
gastric	JJ	B-NP	B
hemorrhagic	JJ	I-NP	I
ulcers	NNS	I-NP	B
in	IN	B-PP	O
severe	JJ	B-NP	O
atherosclerotic	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

Studies	NNS	B-NP	O
concerning	VBG	B-VP	O
with	IN	B-PP	O
pathogenesis	NN	B-NP	O
of	IN	B-PP	O
gastric	JJ	B-NP	B
hemorrhage	NN	I-NP	I
and	CC	O	O
mucosal	JJ	B-NP	O
ulceration	NN	I-NP	O
produced	VBN	B-VP	O
in	IN	B-PP	O
atherosclerotic	JJ	B-NP	B
rats	NNS	I-NP	O
are	VBP	B-VP	O
lacking	VBG	I-VP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
gastric	JJ	B-NP	O
acid	NN	I-NP	O
back	RB	B-ADVP	O
-	HYPH	B-NP	O
diffusion	NN	I-NP	O
,	,	O	O
mast	NN	B-NP	O
cell	NN	I-NP	O
histamine	NN	I-NP	O
release	NN	I-NP	O
,	,	O	O
lipid	NN	B-NP	O
peroxide	NN	I-NP	O
(	(	O	O
LPO	NN	B-NP	O
)	)	O	O
generation	NN	B-NP	O
and	CC	O	O
mucosal	JJ	B-NP	O
microvascular	JJ	I-NP	O
permeability	NN	I-NP	O
in	IN	B-PP	O
modulating	VBG	B-VP	O
gastric	JJ	B-NP	B
hemorrhage	NN	I-NP	I
and	CC	I-NP	O
ulcer	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
atherosclerosis	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
coadministration	NN	B-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D2	NN	I-NP	O
and	CC	I-NP	O
cholesterol	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
on	IN	B-PP	O
this	DT	B-NP	O
ulcer	NN	I-NP	B
model	NN	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
challenged	VBN	I-VP	O
intragastrically	RB	B-ADJP	O
once	RB	I-ADJP	O
daily	JJ	I-ADJP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
ml	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
of	IN	B-PP	O
corn	NN	B-NP	O
oil	NN	I-NP	O
containing	VBG	B-VP	O
vitamin	NN	B-NP	O
D2	NN	I-NP	O
and	CC	O	O
cholesterol	NN	B-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
atherosclerosis	NN	B-NP	B
.	.	O	O

Control	NN	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
corn	NN	B-NP	O
oil	NN	I-NP	O
only	RB	B-ADVP	O
.	.	O	O

After	IN	B-PP	O
gastric	JJ	B-NP	O
surgery	NN	I-NP	O
,	,	O	O
rat	NN	B-NP	O
stomachs	NNS	I-NP	O
were	VBD	B-VP	O
irrigated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
with	IN	B-PP	O
either	CC	O	O
simulated	VBN	B-VP	O
gastric	JJ	B-NP	O
juice	NN	I-NP	O
or	CC	O	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
.	.	O	O

Gastric	JJ	B-NP	O
acid	NN	I-NP	O
back	RB	B-ADVP	O
-	HYPH	B-NP	O
diffusion	NN	I-NP	O
,	,	O	O
mucosal	JJ	B-NP	O
LPO	NN	I-NP	O
generation	NN	I-NP	O
,	,	O	O
histamine	NN	B-NP	O
concentration	NN	I-NP	O
,	,	O	O
microvascular	JJ	B-NP	O
permeability	NN	I-NP	O
,	,	O	O
luminal	JJ	B-NP	O
hemoglobin	NN	I-NP	O
content	NN	I-NP	O
and	CC	I-NP	O
ulcer	NN	I-NP	B
areas	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

Elevated	JJ	B-NP	O
atherosclerotic	JJ	I-NP	B
parameters	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
cholesterol	NN	I-NP	O
and	CC	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
density	NN	I-NP	O
lipoprotein	NN	I-NP	O
concentration	NN	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
in	IN	B-PP	O
atherosclerotic	JJ	B-NP	B
rats	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
gastric	JJ	I-NP	O
ulcers	NNS	I-NP	B
accompanied	VBN	B-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
ulcerogenic	JJ	I-NP	O
factors	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
gastric	JJ	B-NP	O
acid	NN	I-NP	O
back	RB	B-ADVP	O
-	HYPH	B-NP	O
diffusion	NN	I-NP	O
,	,	O	O
histamine	NN	B-NP	O
release	NN	I-NP	O
,	,	O	O
LPO	NN	B-NP	O
generation	NN	I-NP	O
and	CC	O	O
luminal	JJ	B-NP	O
hemoglobin	NN	I-NP	O
content	NN	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
positive	JJ	I-NP	O
correlation	NN	I-NP	O
of	IN	B-PP	O
histamine	NN	B-NP	O
to	TO	B-PP	O
gastric	JJ	B-NP	B
hemorrhage	NN	I-NP	I
and	CC	B-PP	O
to	TO	B-PP	O
ulcer	NN	B-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
those	DT	B-NP	O
atherosclerotic	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
hemorrhagic	JJ	I-NP	B
ulcer	NN	I-NP	B
and	CC	O	O
various	JJ	B-NP	O
ulcerogenic	JJ	I-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	O	O
dependently	RB	B-VP	O
ameliorated	VBN	I-VP	O
by	IN	B-PP	O
daily	JJ	B-NP	O
intragastric	JJ	I-NP	O
verapamil	NN	I-NP	O
.	.	O	O

Atherosclerosis	NN	B-NP	B
could	MD	B-VP	O
produce	VB	I-VP	O
gastric	JJ	B-NP	B
hemorrhagic	JJ	I-NP	I
ulcer	NN	I-NP	B
via	IN	B-PP	O
aggravation	NN	B-NP	O
of	IN	B-PP	O
gastric	JJ	B-NP	O
acid	NN	I-NP	O
back	RB	B-ADVP	O
-	HYPH	B-NP	O
diffusion	NN	I-NP	O
,	,	O	O
LPO	NN	B-NP	O
generation	NN	I-NP	O
,	,	O	O
histamine	NN	B-NP	O
release	NN	I-NP	O
and	CC	O	O
microvascular	JJ	B-NP	O
permeability	NN	I-NP	O
that	WDT	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
ameliorated	VBN	I-VP	O
by	IN	B-PP	O
verapamil	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Adriamycin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
autophagic	JJ	I-NP	O
cardiomyocyte	NN	I-NP	O
death	NN	I-NP	B
plays	VBZ	B-VP	O
a	DT	B-NP	O
pathogenic	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
mechanisms	NNS	I-NP	O
underlying	VBG	B-VP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
adriamycin	NN	B-NP	O
are	VBP	B-VP	O
very	RB	B-ADJP	O
complicated	VBN	I-ADJP	O
and	CC	O	O
still	RB	B-ADJP	O
unclear	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
autophagy	NN	B-NP	O
was	VBD	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
adriamycin	NN	B-NP	O
,	,	O	O
so	IN	B-SBAR	O
that	IN	I-SBAR	O
we	PRP	B-NP	O
can	MD	B-VP	O
develop	VB	I-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
treatment	NN	I-NP	O
strategy	NN	I-NP	O
for	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
methyladenine	NN	I-NP	O
(	(	O	O
3MA	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
specific	JJ	I-NP	O
inhibitor	NN	I-NP	O
on	IN	B-PP	O
autophagy	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
model	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
adriamycin	NN	B-NP	O
.	.	O	O

Neonatal	JJ	B-NP	O
cardiomyocytes	NNS	I-NP	O
were	VBD	B-VP	O
isolated	VBN	I-VP	O
from	IN	B-PP	O
Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rat	NN	I-NP	O
hearts	NNS	I-NP	O
and	CC	O	O
randomly	RB	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
an	DT	B-NP	O
adriamycin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
3MA	NN	I-NP	O
plus	CC	I-NP	O
adriamycin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
then	RB	B-ADVP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
morphology	NN	I-NP	O
,	,	O	O
expression	NN	B-NP	O
of	IN	B-PP	O
beclin	NN	B-NP	O
num	CD	I-NP	O
gene	NN	I-NP	O
,	,	O	O
mitochondrial	JJ	B-NP	O
permeability	NN	I-NP	O
transition	NN	I-NP	O
(	(	O	O
MPT	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
Na+	NN	B-NP	O
-	HYPH	I-NP	O
K	NN	I-NP	O
+	SYM	I-NP	O
ATPase	NN	I-NP	O
activity	NN	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
assessed	VBD	B-VP	O
cell	NN	B-NP	O
viability	NN	I-NP	O
,	,	O	O
mitochondrial	JJ	B-NP	O
membrane	NN	I-NP	O
potential	NN	I-NP	O
changes	NNS	I-NP	O
and	CC	O	O
counted	VBD	B-VP	O
autophagic	JJ	B-NP	O
vacuoles	NNS	I-NP	O
in	IN	B-PP	O
cultured	VBN	B-NP	O
cardiomyocytes	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
analyzed	VBD	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
autophagy	NN	B-NP	O
associated	JJ	I-NP	O
gene	NN	I-NP	O
,	,	O	O
beclin	NN	B-NP	O
num	CD	I-NP	O
using	VBG	B-VP	O
RT	NN	B-NP	O
-	HYPH	I-NP	O
PCR	NN	I-NP	O
and	CC	I-NP	O
Western	NN	I-NP	O
blotting	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

3MA	NN	B-NP	O
significantly	RB	B-ADVP	O
improved	VBD	B-VP	O
cardiac	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
mitochondrial	JJ	I-NP	O
injury	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
adriamycin	NN	B-NP	O
induced	VBD	B-VP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
autophagic	JJ	B-NP	O
vacuoles	NNS	I-NP	O
,	,	O	O
and	CC	O	O
3MA	NN	B-NP	O
strongly	RB	B-ADVP	O
downregulated	VBD	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
beclin	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	I-VP	O
failing	VBG	B-VP	O
heart	NN	B-NP	O
and	CC	O	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
autophagic	JJ	B-NP	O
vacuoles	NNS	I-NP	O
.	.	O	O

Autophagic	JJ	B-NP	O
cardiomyocyte	NN	I-NP	O
death	NN	I-NP	B
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
adriamycin	NN	B-NP	O
.	.	O	O

Mitochondrial	JJ	B-NP	O
injury	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
adriamycin	NN	B-NP	O
via	IN	B-PP	O
the	DT	B-NP	O
autophagy	NN	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

Confusion	NN	B-NP	B
,	,	O	O
a	DT	B-NP	O
rather	RB	I-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
with	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
French	JJ	I-NP	O
Pharmacovigilance	NN	I-NP	O
database	NN	I-NP	O
.	.	O	O

Confusion	NN	B-NP	B
is	VBZ	B-VP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
frequently	RB	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

Some	DT	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
are	VBP	B-VP	O
published	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
but	CC	O	O
no	DT	B-NP	O
systematic	JJ	I-NP	O
study	NN	I-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
sample	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
published	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
this	DT	B-NP	O
study	NN	I-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
describe	VB	I-VP	O
the	DT	B-NP	O
main	JJ	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
the	DT	B-NP	O
French	JJ	I-NP	O
Pharmacovigilance	NN	I-NP	O
database	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
selected	VBD	B-VP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
confusion	NN	B-NP	B
reported	VBD	B-VP	O
since	IN	B-PP	O
num	CD	B-NP	O
with	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
confusion	NN	B-NP	B
were	VBD	B-VP	O
reported	VBN	I-VP	O
with	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
.	.	O	O

Confusion	NN	B-NP	B
mostly	RB	B-ADVP	O
occurred	VBD	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
first	JJ	I-NP	O
weeks	NNS	I-NP	O
following	VBG	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
exposure	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
serious	JJ	B-ADJP	O
for	IN	B-PP	O
almost	RB	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
outcome	NN	I-NP	O
favourable	JJ	B-ADJP	O
in	IN	B-PP	O
most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
ADR	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
aged	JJ	B-ADJP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
work	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
confusion	NN	B-NP	B
with	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
serious	JJ	I-NP	O
,	,	I-NP	O
rather	RB	I-NP	O
frequent	JJ	I-NP	O
but	CC	I-NP	O
reversible	JJ	I-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
occurs	VBZ	B-VP	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
and	CC	B-PP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Learning	NN	B-NP	B
and	CC	I-NP	I
memory	NN	I-NP	I
deficits	NNS	I-NP	I
in	IN	B-PP	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
and	CC	O	O
their	PRP$	B-NP	O
neural	JJ	I-NP	O
correlates	NNS	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
face	NN	I-NP	O
-	HYPH	O	O
learning	VBG	B-VP	O
task	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
consistently	RB	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
display	VBP	B-VP	O
impairments	NNS	B-NP	B
in	IN	B-PP	I
learning	NN	B-NP	I
and	CC	I-NP	I
memory	NN	I-NP	I
performance	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
working	VBG	B-VP	O
memory	NN	B-NP	O
processing	NN	I-NP	O
in	IN	B-PP	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
neural	JJ	B-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
hippocampal	JJ	O	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
cortical	JJ	B-NP	O
regions	NNS	I-NP	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
functional	JJ	B-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
fMRI	NN	B-NP	O
)	)	O	O
.	.	O	O

Using	VBG	B-VP	O
functional	JJ	B-NP	O
imaging	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
face	NN	I-NP	O
-	HYPH	O	O
learning	VBG	B-VP	O
task	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
neural	JJ	B-NP	O
correlates	NNS	I-NP	O
of	IN	B-PP	O
encoding	VBG	B-VP	O
and	CC	I-VP	O
recalling	VBG	I-VP	O
face	NN	B-NP	O
-	HYPH	B-NP	O
name	NN	I-NP	O
associations	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
recreational	JJ	I-NP	O
drug	NN	I-NP	O
users	NNS	I-NP	O
whose	WP$	B-NP	O
predominant	JJ	I-NP	O
drug	NN	I-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
ecstasy	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
address	VB	I-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
confounding	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cannabis	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ecstasy	NN	I-NP	O
using	VBG	B-VP	O
group	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
second	JJ	I-NP	O
analysis	NN	I-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
previously	RB	I-NP	O
tested	VBN	I-NP	O
cannabis	NN	I-NP	O
users	NNS	I-NP	O
(	(	O	O
Nestor	NNP	B-NP	O
,	,	O	O
L.	NNP	B-NP	O
,	,	O	O
Roberts	NNP	B-NP	O
,	,	O	O
G.	NNP	B-NP	O
,	,	O	O
Garavan	NNP	B-NP	O
,	,	O	O
H.	NNP	B-NP	O
,	,	O	O
Hester	NNP	B-NP	O
,	,	O	O
R.	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
.	.	O	O

Deficits	NNS	B-NP	B
in	IN	B-PP	I
learning	NN	B-NP	I
and	CC	I-NP	I
memory	NN	I-NP	I
:	:	O	O
parahippocampal	JJ	B-NP	O
hyperactivity	NN	I-NP	B
and	CC	O	O
frontocortical	JJ	B-NP	O
hypoactivity	NN	I-NP	O
in	IN	B-PP	O
cannabis	NN	B-NP	O
users	NNS	I-NP	O
.	.	O	O

Neuroimage	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
performed	VBD	B-VP	O
significantly	RB	B-ADJP	O
worse	JJR	I-ADJP	O
in	IN	B-PP	O
learning	NN	B-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
and	CC	O	O
cannabis	NN	B-NP	O
users	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
conjunction	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
encode	NN	I-NP	O
and	CC	I-NP	O
recall	NN	I-NP	O
phases	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
task	NN	I-NP	O
revealed	VBD	B-VP	O
ecstasy	JJ	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
hyperactivity	NN	I-NP	B
in	IN	B-PP	O
bilateral	JJ	B-NP	O
frontal	JJ	I-NP	O
regions	NNS	I-NP	O
,	,	O	O
left	VBD	B-VP	O
temporal	JJ	B-NP	O
,	,	I-NP	O
right	JJ	I-NP	O
parietal	JJ	I-NP	O
,	,	I-NP	O
bilateral	JJ	I-NP	O
temporal	JJ	I-NP	O
,	,	O	O
and	CC	O	O
bilateral	JJ	B-NP	O
occipital	NN	I-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
.	.	O	O

Ecstasy	NN	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
hypoactivity	NN	I-NP	O
was	VBD	B-VP	O
evident	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
dorsal	JJ	I-NP	O
anterior	JJ	I-NP	O
cingulated	VBN	I-NP	O
cortex	NN	I-NP	O
(	(	O	O
ACC	NN	B-NP	O
)	)	O	O
and	CC	O	O
left	VBD	B-VP	O
posterior	JJ	B-NP	O
cingulated	VBN	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
both	CC	O	O
ecstasy	JJ	B-NP	O
and	CC	I-NP	O
cannabis	NN	I-NP	O
groups	NNS	I-NP	O
brain	NN	I-NP	O
activation	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
medial	JJ	I-NP	O
frontal	JJ	I-NP	O
gyrus	NN	I-NP	O
,	,	O	O
left	VBD	B-VP	O
parahippocampal	JJ	B-NP	O
gyrus	NN	I-NP	O
,	,	O	O
left	VBD	B-VP	O
dorsal	JJ	B-NP	O
cingulate	NN	I-NP	O
gyrus	NN	I-NP	O
,	,	O	O
and	CC	O	O
left	VBD	B-VP	O
caudate	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
elucidated	VBD	B-VP	O
ecstasy	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
deficits	NNS	I-NP	O
,	,	O	O
only	RB	B-NP	O
some	DT	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
cannabis	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
ecstasy	AFX	I-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
effects	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
vulnerability	NN	I-NP	O
of	IN	B-PP	O
isocortical	JJ	B-NP	O
and	CC	I-NP	O
allocortical	JJ	I-NP	O
regions	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
neurotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
ecstasy	NN	B-NP	O
.	.	O	O

Prolonged	JJ	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
argatroban	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
cardiac	JJ	I-NP	O
transplant	NN	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
suspected	VBN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
with	IN	B-PP	O
thrombosis	NN	B-NP	B
.	.	O	O

Direct	JJ	B-NP	O
thrombin	NN	I-NP	O
inhibitors	NNS	I-NP	O
(	(	O	O
DTIs	NNS	B-NP	O
)	)	O	O
provide	VBP	B-VP	O
an	DT	B-NP	O
alternative	JJ	I-NP	O
method	NN	I-NP	O
of	IN	B-PP	O
anticoagulation	NN	B-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
(	(	O	O
HIT	NN	B-NP	B
)	)	O	O
or	CC	O	O
HIT	NN	B-NP	B
with	IN	B-PP	O
thrombosis	NN	B-NP	B
(	(	O	O
HITT	NN	B-NP	B
)	)	O	O
undergoing	VBG	B-VP	O
cardiopulmonary	JJ	B-NP	O
bypass	NN	I-NP	O
(	(	O	O
CPB	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
report	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
critically	RB	I-NP	B
ill	JJ	I-NP	I
patient	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
suspected	VBN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
HITT	NN	B-NP	B
was	VBD	B-VP	O
administered	VBN	I-VP	O
argatroban	NN	B-NP	O
for	IN	B-PP	O
anticoagulation	NN	B-NP	O
on	IN	B-PP	O
bypass	NN	B-NP	O
during	IN	B-PP	O
heart	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
required	VBD	B-VP	O
massive	JJ	B-NP	O
transfusion	NN	I-NP	O
support	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
units	NNS	I-NP	O
of	IN	B-PP	O
red	JJ	B-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
units	NNS	I-NP	O
of	IN	B-PP	O
fresh	JJ	B-NP	O
-	HYPH	I-NP	O
frozen	JJ	I-NP	O
plasma	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
units	NNS	I-NP	O
of	IN	B-PP	O
cryoprecipitate	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
units	NNS	I-NP	O
of	IN	B-PP	O
platelets	NNS	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
recombinant	JJ	B-NP	O
Factor	NN	I-NP	O
VIIa	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
severe	JJ	B-NP	O
intraoperative	JJ	I-NP	B
and	CC	I-NP	I
postoperative	JJ	I-NP	I
bleeding	NN	I-NP	I
.	.	O	O

Plasma	NN	B-NP	O
samples	NNS	I-NP	O
from	IN	B-PP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
CPB	NN	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
postoperatively	RB	B-ADVP	O
for	IN	B-PP	O
argatroban	JJ	B-NP	O
concentration	NN	I-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
modified	VBN	I-NP	O
ecarin	NN	I-NP	O
clotting	NN	I-NP	O
time	NN	I-NP	O
(	(	O	O
ECT	NN	B-NP	O
)	)	O	O
assay	NN	B-NP	O
.	.	O	O

Unexpectedly	RB	B-NP	O
high	JJ	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
argatroban	NN	B-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
samples	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
mL	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
prolonged	VBN	I-NP	O
plasma	NN	I-NP	O
argatroban	NN	I-NP	O
half	NN	I-NP	O
life	NN	I-NP	O
(	(	O	O
t	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Correlation	NN	B-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
argatroban	NN	I-NP	O
concentration	NN	I-NP	O
versus	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
coagulation	NN	B-NP	O
variables	NNS	I-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
course	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
prolonged	JJ	B-NP	O
elevated	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
argatroban	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
contributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
extended	JJ	B-NP	O
coagulopathy	NN	I-NP	B
.	.	O	O

Because	IN	B-SBAR	O
DTIs	NNS	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
reversal	JJ	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
surgical	JJ	B-NP	O
teams	NNS	I-NP	O
and	CC	O	O
transfusion	NN	B-NP	O
services	NNS	I-NP	O
should	MD	B-VP	O
remain	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
massive	JJ	B-NP	O
transfusion	NN	I-NP	O
events	NNS	I-NP	O
during	IN	B-PP	O
anticoagulation	NN	B-NP	O
with	IN	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
report	NN	I-NP	O
to	TO	B-VP	O
measure	VB	I-VP	O
plasma	NN	B-NP	O
argatroban	JJ	I-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
context	NN	I-NP	O
of	IN	B-PP	O
CPB	NN	B-NP	O
and	CC	O	O
extended	JJ	B-NP	O
coagulopathy	NN	I-NP	B
.	.	O	O

Antituberculosis	NN	B-NP	O
therapy	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
:	:	O	O
magnitude	NN	B-NP	O
,	,	O	O
profile	NN	B-NP	O
,	,	O	O
prognosis	NN	B-NP	O
,	,	O	O
and	CC	O	O
predictors	NNS	B-NP	O
of	IN	B-PP	O
outcome	NN	B-NP	O
.	.	O	O

Antituberculosis	NN	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
ATT	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
associated	VBN	B-VP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
ATT	NN	B-NP	O
-	HYPH	B-NP	O
ALF	NN	I-NP	B
)	)	O	O
is	VBZ	B-VP	O
the	DT	B-NP	O
commonest	JJS	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
in	IN	B-PP	O
South	NNP	B-NP	O
Asia	NNP	I-NP	O
.	.	O	O

Prospective	JJ	B-NP	O
studies	NNS	I-NP	O
on	IN	B-PP	O
ATT	NN	B-NP	O
-	HYPH	I-NP	O
ALF	NN	I-NP	B
are	VBP	B-VP	O
lacking	VBG	I-VP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
prospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
,	,	O	O
clinical	JJ	B-NP	O
course	NN	I-NP	O
,	,	O	O
outcome	NN	B-NP	O
,	,	O	O
and	CC	O	O
prognostic	JJ	B-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
ATT	NN	B-NP	O
-	HYPH	B-NP	O
ALF	NN	I-NP	B
.	.	O	O

From	IN	B-PP	O
January	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
January	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
ALF	NN	I-NP	B
patients	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
:	:	O	O
ATT	NN	B-NP	O
alone	RB	B-ADVP	O
was	VBD	B-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Another	DT	B-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
ATT	NN	B-NP	O
and	CC	O	O
simultaneous	JJ	B-NP	O
hepatitis	NN	I-NP	B
virus	NN	I-NP	I
infection	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
ATT	NN	B-NP	O
was	VBD	B-VP	O
prescribed	VBN	I-VP	O
empirically	RB	B-ADVP	O
without	IN	B-PP	O
definitive	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
tuberculosis	NN	B-NP	B
.	.	O	O

ATT	NN	B-NP	O
-	HYPH	O	O
ALF	NN	B-NP	B
patients	NNS	I-NP	O
were	VBD	B-VP	O
younger	JJR	B-ADJP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
were	VBD	B-VP	O
women	NNS	B-NP	O
.	.	O	O

Most	JJS	B-NP	O
had	VBD	B-VP	O
hyperacute	JJ	B-NP	O
presentation	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
icterus	NN	I-NP	B
encephalopathy	NN	I-NP	B
interval	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
ATT	NN	B-NP	O
before	IN	B-PP	O
ALF	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
presentation	NN	B-NP	O
,	,	O	O
advanced	VBD	B-VP	O
encephalopathy	NN	B-NP	B
and	CC	O	O
cerebral	JJ	B-NP	B
edema	NN	I-NP	I
were	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Gastrointestinal	JJ	B-NP	B
bleed	NN	I-NP	I
,	,	O	O
seizures	NNS	B-NP	B
,	,	O	O
infection	NN	B-NP	B
,	,	O	O
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
were	VBD	B-VP	O
documented	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
hepatitis	NN	B-NP	B
E	NN	I-NP	I
virus	NN	I-NP	O
(	(	O	O
HEV	NN	B-NP	O
)	)	O	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
A	NN	I-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
E	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
,	,	O	O
ATT	NN	B-NP	O
-	HYPH	O	O
ALF	NN	B-NP	B
patients	NNS	I-NP	O
had	VBD	B-VP	O
nearly	RB	B-NP	O
similar	JJ	I-NP	O
presentations	NNS	I-NP	O
except	IN	B-PP	O
for	IN	B-PP	O
older	JJR	B-NP	O
age	NN	I-NP	O
and	CC	O	O
less	JJR	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
enzymes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
among	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
ATT	NN	B-NP	O
-	HYPH	B-NP	O
ALF	NN	I-NP	B
was	VBD	B-VP	O
high	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
recovered	VBN	B-VP	O
with	IN	B-PP	O
medical	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
multivariate	JJ	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
factors	NNS	I-NP	O
independently	RB	B-ADVP	O
predicted	VBD	B-VP	O
mortality	NN	B-NP	O
:	:	O	O
serum	NN	B-NP	O
bilirubin	NN	I-NP	O
,	,	O	O
prothrombin	NN	B-NP	O
time	NN	I-NP	O
(	(	O	O
PT	NN	B-NP	O
)	)	O	O
prolongation	NN	B-NP	O
,	,	O	O
and	CC	O	O
grade	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
encephalopathy	NN	I-NP	B
at	IN	B-PP	O
presentation	NN	B-NP	O
.	.	O	O

ATT	NN	B-NP	O
-	HYPH	I-NP	O
ALF	NN	I-NP	B
constituted	VBN	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
ALF	NN	B-NP	B
at	IN	B-PP	O
our	PRP$	B-NP	O
center	NN	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
the	DT	B-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
is	VBZ	B-VP	O
so	RB	B-ADJP	O
high	JJ	I-ADJP	O
,	,	O	O
determining	VBG	B-VP	O
which	WDT	B-NP	O
factors	NNS	B-NP	O
are	VBP	B-VP	O
predictors	NNS	B-NP	O
is	VBZ	B-VP	O
less	RBR	B-ADJP	O
important	JJ	I-ADJP	O
.	.	O	O

A	DT	B-NP	O
high	JJ	I-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
consumed	VBN	I-VP	O
ATT	NNP	B-NP	O
empirically	RB	B-ADVP	O
,	,	O	O
which	WDT	B-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
prevented	VBN	I-VP	O
.	.	O	O

Central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
complications	NNS	I-NP	I
during	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
pediatric	JJ	I-NP	O
institution	NN	I-NP	O
.	.	O	O

Central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
(	(	O	I
CNS	NN	B-NP	I
)	)	O	I
complications	NNS	B-NP	I
during	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
childhood	NN	B-NP	O
acute	JJ	I-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
(	(	O	O
ALL	NN	B-NP	B
)	)	O	O
remain	VBP	B-VP	O
a	DT	B-NP	O
challenging	JJ	I-NP	O
clinical	JJ	I-NP	O
problem	NN	I-NP	O
.	.	O	O

Outcome	DT	B-NP	O
improvement	NN	I-NP	O
with	IN	B-PP	O
more	RBR	B-NP	O
intensive	JJ	I-NP	O
chemotherapy	NN	I-NP	O
has	VBZ	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
analyzed	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
neurological	JJ	B-NP	B
complications	NNS	I-NP	I
during	IN	B-PP	O
ALL	NN	B-NP	B
treatment	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
pediatric	JJ	I-NP	O
institution	NN	I-NP	O
,	,	O	O
focusing	VBG	B-VP	O
on	IN	B-PP	O
clinical	JJ	B-NP	O
,	,	I-NP	O
radiological	JJ	I-NP	O
,	,	O	O
and	CC	O	O
electrophysiological	JJ	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Exclusion	NN	B-NP	O
criteria	NNS	I-NP	O
included	VBD	B-VP	O
CNS	NN	B-NP	O
leukemic	JJ	I-NP	B
infiltration	NN	I-NP	I
at	IN	B-PP	O
diagnosis	NN	B-NP	O
,	,	O	O
therapy	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
late	JJ	B-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
encephalopathy	NN	I-NP	B
,	,	O	O
or	CC	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
neurocognitive	JJ	I-NP	B
defects	NNS	I-NP	I
.	.	O	O

During	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
retrospectively	RB	B-ADVP	O
collected	VBD	B-VP	O
num	CD	B-NP	O
neurological	JJ	I-NP	O
events	NNS	I-NP	O
in	IN	B-PP	O
as	RB	B-NP	O
many	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
from	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
enrolled	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
ALL	NN	I-NP	B
front	NN	I-NP	O
-	HYPH	B-NP	O
line	NN	I-NP	O
protocol	NN	I-NP	O
.	.	O	O

CNS	NN	B-NP	O
complications	NNS	I-NP	O
included	VBD	B-VP	O
posterior	JJ	B-NP	O
reversible	JJ	I-NP	O
leukoencephalopathy	NN	I-NP	B
syndrome	NN	I-NP	O
,	,	O	O
stroke	NN	B-NP	B
,	,	O	O
temporal	JJ	B-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
,	,	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methotrexate	NN	I-NP	O
toxicity	NN	I-NP	B
,	,	O	O
syndrome	NN	B-NP	O
of	IN	B-PP	O
inappropriate	JJ	B-NP	B
antidiuretic	JJ	I-NP	I
hormone	NN	I-NP	I
secretion	NN	I-NP	I
,	,	O	O
and	CC	O	O
other	JJ	B-NP	O
unclassified	JJ	I-NP	O
events	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
CNS	NN	B-NP	O
complications	NNS	I-NP	O
are	VBP	B-VP	O
frequent	JJ	B-NP	O
events	NNS	I-NP	O
during	IN	B-PP	O
ALL	NN	B-NP	B
therapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
require	VB	B-VP	O
rapid	JJ	B-NP	O
detection	NN	I-NP	O
and	CC	O	O
prompt	JJ	B-NP	O
treatment	NN	I-NP	O
to	TO	B-VP	O
limit	VB	I-VP	O
permanent	JJ	B-NP	O
damage	NN	I-NP	O
.	.	O	O

Safety	NN	B-NP	O
of	IN	B-PP	O
capecitabine	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
review	NN	I-NP	O
.	.	O	O

Fluoropyrimidines	NNS	B-NP	O
,	,	O	O
in	IN	B-PP	O
particular	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
,	,	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
the	DT	B-NP	O
mainstay	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
several	JJ	B-NP	O
solid	JJ	I-NP	O
tumors	NNS	I-NP	B
,	,	O	O
including	VBG	B-PP	O
colorectal	JJ	B-NP	B
,	,	I-NP	I
breast	NN	I-NP	I
and	CC	I-NP	I
head	NN	I-NP	I
and	CC	I-NP	I
neck	NN	I-NP	I
cancers	NNS	I-NP	I
,	,	O	O
for	IN	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
article	NN	I-NP	O
reviews	VBZ	B-VP	O
the	DT	B-NP	O
pharmacology	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
capecitabine	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
special	JJ	I-NP	O
emphasis	NN	I-NP	O
on	IN	B-PP	O
its	PRP$	B-NP	O
safety	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
reader	NN	I-NP	O
will	MD	B-VP	O
gain	VB	I-VP	O
better	JJR	B-NP	O
insight	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
capecitabine	NN	B-NP	O
in	IN	B-PP	O
special	JJ	B-NP	O
populations	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
renal	JJ	B-NP	B
and	CC	I-NP	I
kidney	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
explore	VBP	B-VP	O
different	JJ	B-NP	O
dosing	NN	I-NP	O
and	CC	O	O
schedules	NNS	B-NP	O
of	IN	B-PP	O
capecitabine	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Capecitabine	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
oral	JJ	I-NP	O
prodrug	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
to	TO	I-VP	O
fulfill	VB	I-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
more	RBR	I-NP	O
convenient	JJ	I-NP	O
therapy	NN	I-NP	O
and	CC	O	O
provide	VBP	B-VP	O
an	DT	B-NP	O
improved	VBN	I-NP	O
safety	NN	I-NP	O
/	SYM	I-NP	O
efficacy	NN	I-NP	O
profile	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
shown	VBN	I-VP	O
promising	JJ	B-NP	O
results	NNS	I-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
chemotherapeutic	JJ	I-NP	O
agents	NNS	I-NP	O
in	IN	B-PP	O
colorectal	JJ	B-NP	B
,	,	I-NP	I
breast	NN	I-NP	I
,	,	I-NP	I
pancreaticobiliary	JJ	I-NP	I
,	,	I-NP	I
gastric	JJ	I-NP	I
,	,	I-NP	I
renal	JJ	I-NP	I
cell	NN	I-NP	I
and	CC	O	I
head	NN	B-NP	I
and	CC	O	I
neck	NN	B-NP	I
cancers	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
commonly	RB	I-NP	O
reported	VBN	I-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
capecitabine	NN	B-NP	O
are	VBP	B-VP	O
diarrhea	NN	B-NP	B
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
vomiting	NN	B-NP	B
,	,	O	O
stomatitis	NN	B-NP	B
and	CC	I-NP	O
hand	NN	I-NP	B
-	HYPH	B-NP	I
foot	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Capecitabine	NNP	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
established	VBN	I-NP	O
safety	NN	I-NP	O
profile	NN	I-NP	O
and	CC	O	O
can	MD	B-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
safely	RB	B-ADVP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
hepatic	JJ	B-NP	B
and	CC	I-NP	I
renal	JJ	I-NP	I
dysfunctions	NNS	I-NP	I
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
pallidal	JJ	B-NP	O
neurotensin	NN	I-NP	O
on	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
parkinsonian	JJ	I-NP	B
catalepsy	NN	I-NP	I
:	:	O	O
behavioral	JJ	B-NP	O
and	CC	I-NP	O
electrophysiological	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
globus	NN	I-NP	O
pallidus	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
critical	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
movement	NN	B-NP	O
regulation	NN	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
indicated	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
globus	NN	I-NP	O
pallidus	NN	I-NP	O
receives	VBZ	B-VP	O
neurotensinergic	JJ	B-NP	O
innervation	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
and	CC	O	O
systemic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
neurotensin	NN	I-NP	O
analog	NN	I-NP	O
could	MD	B-VP	O
produce	VB	I-VP	O
antiparkinsonian	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
pallidal	JJ	B-NP	O
neurotensin	NN	I-NP	O
on	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
parkinsonian	JJ	I-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

Behavioral	JJ	B-NP	O
experiments	NNS	I-NP	O
and	CC	O	O
electrophysiological	JJ	B-NP	O
recordings	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
neurotensin	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
globus	NN	I-NP	O
pallidus	NN	I-NP	O
reversed	VBD	B-VP	O
haloperidol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
parkinsonian	JJ	I-NP	B
catalepsy	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Electrophysiological	JJ	B-NP	O
recordings	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
microinjection	NN	B-NP	O
of	IN	B-PP	O
neurotensin	NN	B-NP	O
induced	VBD	B-VP	O
excitation	NN	B-NP	O
of	IN	B-PP	O
pallidal	JJ	B-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	O
haloperidol	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
neurotensin	NN	I-NP	O
type	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
SR48692	NN	I-NP	O
blocked	VBD	B-VP	O
both	CC	O	O
the	DT	B-NP	O
behavioral	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
electrophysiological	JJ	I-NP	O
effects	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
neurotensin	NN	B-NP	O
.	.	O	O

Activation	NN	B-NP	O
of	IN	B-PP	O
pallidal	JJ	B-NP	O
neurotensin	NN	I-NP	O
receptors	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
neurotensin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
antiparkinsonian	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Antihypertensive	JJ	B-NP	O
drugs	NNS	I-NP	O
and	CC	I-NP	O
depression	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
reappraisal	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
new	JJ	I-NP	O
referral	JJ	I-NP	O
hypertensive	JJ	I-NP	B
out	RP	B-PRT	O
-	HYPH	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
new	JJ	I-NP	O
referral	JJ	I-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
hypertensive	JJ	I-NP	B
chronically	RB	B-VP	O
physically	RB	I-VP	O
ill	VB	I-VP	O
out	RP	B-PRT	O
-	HYPH	B-NP	O
patients	NNS	I-NP	O
completed	VBD	B-VP	O
a	DT	B-NP	O
mood	NN	I-NP	O
rating	NN	I-NP	O
scale	NN	I-NP	O
at	IN	B-PP	O
regular	JJ	B-NP	O
intervals	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
depression	NN	B-NP	B
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
preponderance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
group	NN	I-NP	O
.	.	O	O

Hypertensive	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
psychiatric	JJ	B-NP	B
histories	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
depression	NN	B-NP	B
than	IN	B-PP	O
the	DT	B-NP	O
comparison	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
accounted	VBN	I-VP	O
for	IN	B-PP	O
by	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
depressions	NNS	B-NP	B
occurring	VBG	B-VP	O
in	IN	B-PP	O
methyl	NN	B-NP	O
dopa	NN	I-NP	O
treated	VBN	B-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
psychiatric	JJ	B-NP	B
histories	NNS	I-NP	O
.	.	O	O

Pulmonary	JJ	B-NP	O
shunt	NN	I-NP	O
and	CC	O	O
cardiovascular	JJ	B-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
CPAP	NN	B-NP	O
during	IN	B-PP	O
nitroprusside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
continuous	JJ	B-NP	O
positive	JJ	I-NP	O
airway	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
CPAP	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
cardiovascular	JJ	B-NP	O
dynamics	NNS	I-NP	O
and	CC	O	O
pulmonary	JJ	B-NP	O
shunt	NN	I-NP	O
(	(	O	O
QS	NN	B-NP	O
/	SYM	B-NP	O
QT	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
during	IN	I-PP	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
infusion	NN	I-NP	O
that	WDT	B-NP	O
decreased	VBD	B-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
.	.	O	O

Before	IN	B-PP	O
nitroprusside	NN	B-NP	O
infusion	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
cm	NN	I-NP	O
H2O	NN	I-NP	O
CPAP	NN	I-NP	O
significantly	RB	B-ADVP	O
,	,	O	O
P	NN	B-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
decreased	VBD	B-VP	O
arterial	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
alter	VB	I-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
,	,	O	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
,	,	O	O
or	CC	O	O
QS	NN	B-NP	O
/	SYM	B-NP	O
QT	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cm	NN	I-NP	O
H2O	NN	I-NP	O
CPAP	NN	I-NP	O
before	IN	B-PP	O
nitroprusside	NN	B-NP	O
infusion	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
further	JJ	I-NP	O
decrease	NN	I-NP	B
in	IN	B-PP	I
arterial	JJ	B-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
and	CC	O	O
significantly	RB	B-VP	O
increased	VBD	I-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	B
cardiac	JJ	B-NP	I
output	NN	I-NP	I
and	CC	I-NP	O
QS	NN	I-NP	O
/	SYM	B-NP	O
QT	NN	I-NP	O
.	.	O	O

Nitroprusside	NNP	B-NP	O
caused	VBD	B-VP	O
significant	JJ	B-NP	O
decreases	NNS	I-NP	B
in	IN	B-PP	I
arterial	JJ	B-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
and	CC	O	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
and	CC	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
or	CC	I-NP	O
QS	NN	I-NP	O
/	SYM	B-NP	O
QT	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cm	NN	I-NP	O
H2O	NN	I-NP	O
CPAP	NN	I-NP	O
during	IN	B-PP	O
nitroprusside	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
further	RBR	I-VP	O
alter	VB	I-VP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
above	RB	I-NP	O
-	HYPH	I-NP	O
mentioned	VBN	I-NP	O
variables	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
cm	NN	I-NP	O
H2O	NN	I-NP	O
CPAP	NN	I-NP	O
decreased	VBD	B-VP	O
arterial	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
,	,	O	O
and	CC	O	O
QS	NN	B-NP	O
/	SYM	B-NP	O
QT	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
nitroprusside	NN	B-NP	O
infusion	NN	I-NP	O
rates	NNS	I-NP	O
that	WDT	B-NP	O
decrease	VBP	B-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
or	CC	I-NP	O
QS	NN	I-NP	O
/	SYM	B-NP	O
QT	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
nitroprusside	NN	B-NP	O
infusion	NN	I-NP	O
low	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
CPAP	NN	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
markedly	RB	I-VP	O
alter	VB	I-VP	O
cardiovascular	JJ	B-NP	O
dynamics	NNS	I-NP	O
,	,	O	O
but	CC	O	O
high	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
CPAP	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
cm	NN	I-NP	O
H2O	NN	I-NP	O
)	)	O	O
,	,	O	O
while	IN	B-SBAR	O
decreasing	VBG	B-VP	O
QS	NN	B-NP	O
/	SYM	B-NP	O
QT	NN	I-NP	O
,	,	O	O
produce	VBP	B-VP	O
marked	JJ	B-NP	O
decreases	NNS	I-NP	B
in	IN	B-PP	I
arterial	JJ	B-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
and	CC	O	I
cardiac	JJ	B-NP	I
output	NN	I-NP	I
.	.	O	O

Mediation	NN	B-NP	O
of	IN	B-PP	O
enhanced	VBN	B-NP	O
reflex	NN	I-NP	O
vagal	JJ	I-NP	O
bradycardia	NN	I-NP	B
by	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
dopa	NN	B-NP	O
via	IN	B-PP	O
central	JJ	B-NP	O
dopamine	NN	I-NP	O
formation	NN	I-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

L	NN	B-NP	O
-	HYPH	O	O
Dopa	NN	B-NP	O
decreased	VBD	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
after	IN	B-PP	O
extracerebral	JJ	B-NP	O
decarboxylase	NN	I-NP	O
inhibition	NN	I-NP	O
with	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
in	IN	B-PP	O
anesthetize	NN	B-NP	O
MAO	NN	I-NP	O
-	HYPH	B-NP	O
inhibited	VBN	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
reflex	NN	B-NP	O
bradycardia	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
injected	VBN	B-NP	O
norepinephrine	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
enhanced	VBN	I-VP	O
by	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
,	,	O	O
DL	NN	B-NP	O
-	HYPH	O	O
Threo	AFX	O	O
-	HYPH	O	O
dihydroxyphenylserine	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
or	CC	I-NP	O
reflex	NN	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
norepinephrine	NN	B-NP	O
.	.	O	O

FLA	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
dopamine	NN	I-NP	O
-	HYPH	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
oxidase	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
any	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
hypotension	NN	I-NP	B
,	,	I-NP	O
bradycardia	NN	I-NP	B
or	CC	I-NP	O
reflex	NN	I-NP	O
-	HYPH	O	O
enhancing	VBG	B-VP	O
effect	NN	B-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
dopa	NN	B-NP	O
.	.	O	O

Pimozide	NNP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
dopa	NN	B-NP	O
on	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
but	CC	O	O
completely	RB	B-VP	O
blocked	VBD	I-VP	O
the	DT	B-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
reflexes	NNS	B-NP	O
.	.	O	O

Removal	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
carotid	NN	I-NP	O
sinuses	NNS	I-NP	O
caused	VBD	B-VP	O
an	DT	B-NP	O
elevation	NN	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
abolished	VBD	B-VP	O
the	DT	B-NP	O
negative	JJ	I-NP	O
chronotropic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	O	O
dopa	NN	B-NP	O
restored	VBD	B-VP	O
the	DT	B-NP	O
bradycardia	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
norepinephrine	NN	B-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
decreasing	VBG	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
heart	NN	B-NP	O
rate.	NN	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HTP	NN	I-NP	O
decreased	VBD	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
reflex	NN	I-NP	O
bradycardia	NN	I-NP	B
to	TO	B-PP	O
norepinephrine	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
L	NN	B-NP	O
-	HYPH	O	O
dopa	NN	B-NP	O
enhances	VBZ	B-VP	O
reflex	NN	B-NP	O
bradycardia	NN	I-NP	B
through	IN	B-PP	O
central	JJ	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
stimulation	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
mediated	VBN	I-VP	O
through	IN	B-PP	O
dopamine	NN	B-NP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
norepinephrine	NN	B-NP	O
and	CC	O	O
do	VBP	B-VP	O
not	RB	I-VP	O
require	VB	I-VP	O
the	DT	B-NP	O
carotid	NN	I-NP	O
sinus	NN	I-NP	O
baroreceptors	NNS	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
:	:	O	O
clinical	JJ	B-NP	O
observations	NNS	I-NP	O
and	CC	O	O
pathogenetic	JJ	B-NP	O
considerations	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
and	CC	I-NP	O
experimental	JJ	I-NP	O
data	NNS	I-NP	O
published	VBN	B-VP	O
to	TO	B-PP	O
date	NN	B-NP	O
suggest	VBP	B-VP	O
several	JJ	B-NP	O
possible	JJ	I-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
cocaine	NN	B-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
acute	JJ	B-NP	B
myocardial	JJ	I-NP	I
infarction	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
individuals	NNS	B-NP	O
with	IN	B-PP	O
preexisting	JJ	B-NP	O
,	,	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
grade	NN	I-NP	O
coronary	JJ	I-NP	O
arterial	JJ	I-NP	O
narrowing	NN	I-NP	O
,	,	O	O
acute	JJ	B-NP	B
myocardial	JJ	I-NP	I
infarction	NN	I-NP	I
may	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
myocardial	JJ	B-NP	O
oxygen	NN	I-NP	O
demand	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
rate	NN	B-NP	O
-	HYPH	B-NP	O
pressure	NN	I-NP	O
product	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
other	JJ	B-NP	O
individuals	NNS	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
underlying	VBG	I-NP	O
atherosclerotic	JJ	I-NP	B
obstruction	NN	I-NP	I
,	,	O	O
coronary	JJ	B-NP	B
occlusion	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
spasm	NN	B-NP	B
,	,	O	O
thrombus	NN	B-NP	B
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
.	.	O	O

With	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
spasm	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
largely	RB	B-ADJP	O
circumstantial	JJ	I-ADJP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
locus	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasoconstriction	NN	I-NP	O
remains	VBZ	B-VP	O
speculative	JJ	B-ADJP	O
.	.	O	O

Although	IN	B-SBAR	O
certain	JJ	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
experimental	JJ	I-NP	O
findings	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
spasm	NN	B-NP	B
involves	VBZ	B-VP	O
the	DT	B-NP	O
epicardial	JJ	I-NP	O
,	,	I-NP	O
medium	JJ	I-NP	O
-	HYPH	I-NP	O
size	NN	I-NP	O
vessels	NNS	I-NP	O
,	,	O	O
other	JJ	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
intramural	JJ	B-NP	O
vasoconstriction	NN	I-NP	O
.	.	O	O

Diffuse	NN	B-NP	O
intramural	JJ	I-NP	O
vasoconstriction	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
reports	NNS	B-NP	O
of	IN	B-PP	O
segmental	JJ	B-NP	O
,	,	I-NP	O
discrete	JJ	I-NP	O
infarction	NN	I-NP	B
.	.	O	O

Whereas	IN	B-PP	O
certain	JJ	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
alpha	SYM	B-NP	O
-	HYPH	O	O
mediated	VBN	B-VP	O
,	,	O	O
other	JJ	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
the	DT	B-NP	O
opposite	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
finding	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasoconstriction	NN	I-NP	O
in	IN	B-PP	O
segments	NNS	B-NP	O
of	IN	B-PP	O
(	(	O	O
noninnervated	JJ	B-ADJP	O
)	)	O	O
human	JJ	B-NP	O
umbilical	JJ	I-NP	O
artery	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
presence	NN	I-NP	O
or	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
intact	JJ	B-NP	O
innervation	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
explain	VB	I-VP	O
the	DT	B-NP	O
discrepant	JJ	I-NP	O
data	NNS	I-NP	O
involving	VBG	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
primary	JJ	I-NP	O
,	,	I-NP	O
thrombotic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
excluded	VBN	I-VP	O
.	.	O	O

Rabbit	NN	B-NP	B
syndrome	NN	I-NP	I
,	,	O	O
antidepressant	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
and	CC	O	O
cerebral	JJ	B-NP	O
perfusion	NN	I-NP	O
SPECT	NN	I-NP	O
scan	NN	I-NP	O
findings	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
rabbit	NN	I-NP	B
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
an	DT	B-NP	O
extrapyramidal	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
neuroleptic	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Its	PRP$	B-NP	O
occurrence	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
imipramine	NN	B-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
,	,	O	O
representing	VBG	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
antidepressants	NNS	B-NP	O
.	.	O	O

Repeated	VBN	B-NP	O
cerebral	JJ	I-NP	O
perfusion	NN	I-NP	O
SPECT	NN	I-NP	O
scans	NNS	I-NP	O
revealed	VBD	B-VP	O
decreased	VBN	I-VP	B
basal	JJ	B-NP	I
ganglia	NN	I-NP	I
perfusion	NN	I-NP	I
while	IN	B-SBAR	O
the	DT	B-NP	O
movement	NN	I-NP	B
disorder	NN	I-NP	I
was	VBD	B-VP	O
present	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
return	NN	I-NP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
perfusion	NN	I-NP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
rabbit	NN	I-NP	B
syndrome	NN	I-NP	I
resolved	VBN	B-VP	O
.	.	O	O

Acute	JJ	B-NP	O
bronchodilating	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ipratropium	NN	B-NP	O
bromide	NN	I-NP	O
and	CC	I-NP	O
theophylline	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	B
obstructive	JJ	I-NP	I
pulmonary	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
bronchodilator	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
ipratropium	NN	B-NP	O
bromide	NN	I-NP	O
aerosol	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
)	)	O	O
and	CC	O	O
short	JJ	B-ADJP	O
-	HYPH	B-NP	O
acting	VBG	I-NP	O
theophylline	NN	I-NP	O
tablets	NNS	I-NP	O
(	(	O	O
dose	NN	B-NP	O
titrated	VBN	B-VP	O
to	TO	B-VP	O
produce	VB	I-VP	O
serum	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
crossover	NN	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
stable	JJ	B-NP	O
,	,	I-NP	O
chronic	JJ	I-NP	B
obstructive	JJ	I-NP	I
pulmonary	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Mean	JJ	B-NP	O
peak	JJ	I-NP	O
forced	VBN	I-NP	O
expiratory	JJ	I-NP	O
volume	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
second	JJ	I-NP	O
(	(	O	O
FEV1	NN	B-NP	O
)	)	O	O
increases	VBZ	B-VP	O
over	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
attaining	VBG	B-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
FEV1	NN	I-NP	O
(	(	O	O
responders	NNS	B-NP	O
)	)	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
for	IN	B-PP	O
ipratropium	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
for	IN	B-PP	O
theophylline	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
FEV1	NN	I-NP	O
increases	VBZ	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
ipratropium	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
theophylline	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
with	IN	B-PP	O
ipratropium	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
hours	NNS	I-NP	O
with	IN	B-PP	O
theophylline	NN	B-NP	O
.	.	O	O

While	IN	B-SBAR	O
side	NN	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
rare	JJ	B-ADJP	O
,	,	O	O
those	DT	B-NP	O
experienced	VBN	B-VP	O
after	IN	B-PP	O
theophylline	NN	B-NP	O
use	NN	I-NP	O
did	VBD	B-VP	O
involve	VB	I-VP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	B
and	CC	I-NP	I
gastrointestinal	JJ	I-NP	I
systems	NNS	I-NP	I
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
ipratropium	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
potent	JJ	I-NP	O
bronchodilator	NN	I-NP	O
than	IN	B-PP	O
oral	JJ	B-NP	O
theophylline	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
airflow	NN	I-NP	I
obstruction	NN	I-NP	I
.	.	O	O

Irreversible	JJ	B-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
medullary	JJ	I-NP	O
interstitium	NN	I-NP	O
in	IN	B-PP	O
experimental	JJ	B-NP	O
analgesic	JJ	I-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
F344	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	B
papillary	JJ	I-NP	I
necrosis	NN	I-NP	I
(	(	O	O
RPN	NN	B-NP	B
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
decreased	VBN	I-NP	O
urinary	JJ	I-NP	O
concentrating	VBG	I-NP	O
ability	NN	I-NP	O
developed	VBN	B-VP	O
during	IN	B-PP	O
continuous	JJ	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
aspirin	NN	B-NP	O
and	CC	I-NP	O
paracetamol	NN	I-NP	O
in	IN	B-PP	O
female	JJ	B-NP	O
Fischer	NNP	I-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
structure	NN	I-NP	O
and	CC	O	O
concentrating	VBG	B-NP	O
ability	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
recovery	NN	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
when	WRB	B-ADVP	O
no	DT	B-NP	O
analgesics	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
,	,	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
analgesic	JJ	I-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
reversible	JJ	B-ADJP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
repair	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
damaged	VBN	I-NP	O
medullary	JJ	I-NP	O
interstitial	JJ	I-NP	O
matrix	NN	I-NP	O
,	,	O	O
or	CC	O	O
proliferation	NN	B-NP	O
of	IN	B-PP	O
remaining	VBG	B-NP	O
undamaged	JJ	I-NP	O
type	NN	I-NP	O
num	CD	I-NP	O
medullary	JJ	I-NP	O
interstitial	JJ	I-NP	O
cells	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
recovery	NN	I-NP	O
period	NN	I-NP	O
following	VBG	B-PP	O
analgesic	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	O
concentrating	VBG	I-NP	O
ability	NN	I-NP	O
was	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
length	NN	I-NP	O
of	IN	B-PP	O
analgesic	JJ	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
resulting	VBG	I-NP	O
inner	JJ	I-NP	O
medullary	JJ	I-NP	O
structural	JJ	I-NP	O
damage	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
analgesic	JJ	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
concentrating	VBG	I-NP	O
ability	NN	I-NP	O
were	VBD	B-VP	O
reversible	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
after	IN	B-PP	O
prolonged	JJ	B-NP	O
analgesic	JJ	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
maximum	JJ	B-NP	O
urinary	JJ	I-NP	O
concentrating	VBG	I-NP	O
ability	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
recover	VB	I-VP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
prolonged	JJ	B-NP	O
analgesic	JJ	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
Fischer	NNP	B-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
causes	VBZ	B-VP	O
progressive	JJ	B-NP	O
and	CC	I-NP	O
irreversible	JJ	I-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
interstitial	JJ	I-NP	O
matrix	NN	I-NP	O
and	CC	I-NP	O
type	NN	I-NP	O
num	CD	I-NP	O
interstitial	JJ	I-NP	O
cells	NNS	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
RPN	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
associated	VBN	I-NP	O
urinary	JJ	I-NP	O
concentrating	VBG	I-NP	O
defect	NN	I-NP	O
is	VBZ	B-VP	O
reversible	JJ	B-ADJP	O
only	RB	B-ADVP	O
during	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
structural	JJ	B-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
inner	JJ	I-NP	O
medulla	NN	I-NP	O
.	.	O	O

Less	RBR	B-NP	O
frequent	JJ	I-NP	O
lithium	NN	I-NP	O
administration	NN	I-NP	O
and	CC	O	O
lower	JJR	B-NP	O
urine	NN	I-NP	O
volume	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
patients	NNS	B-NP	O
maintained	VBN	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
regimen	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
once	RB	I-NP	O
-	HYPH	I-NP	O
per	AFX	I-NP	O
-	HYPH	I-NP	O
day	NN	B-NP	O
schedule	NN	I-NP	O
have	VBP	B-VP	O
lower	JJR	B-NP	O
urine	NN	I-NP	O
volumes	NNS	I-NP	O
than	IN	B-SBAR	O
do	VBP	O	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
multiple	JJ	B-NP	O
doses	NNS	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
lithium	NN	I-NP	O
clinic	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
different	JJ	B-NP	O
dose	NN	I-NP	O
schedules	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
measurement	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
level	NN	I-NP	O
,	,	O	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
,	,	O	O
urine	NN	B-NP	O
volume	NN	I-NP	O
,	,	O	O
and	CC	O	O
maximum	JJ	B-NP	O
osmolality	NN	I-NP	O
.	.	O	O

Multiple	JJ	B-NP	O
daily	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
higher	JJR	B-NP	O
urine	NN	I-NP	O
volumes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
dosing	NN	I-NP	O
schedule	NN	I-NP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
and	CC	O	O
daily	JJ	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
maximum	JJ	B-NP	O
osmolality	NN	I-NP	O
or	CC	I-NP	O
creatinine	NN	I-NP	O
clearance	NN	I-NP	O
.	.	O	O

Urine	NN	B-NP	O
volume	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
giving	VBG	B-VP	O
lithium	NN	B-NP	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
by	IN	B-PP	O
lowering	VBG	B-VP	O
the	DT	B-NP	O
total	JJ	I-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polyuria	NN	I-NP	B
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
extrarenal	JJ	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
to	TO	B-PP	O
renal	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
whole	JJ	B-NP	O
body	NN	I-NP	O
hyperthermia	NN	I-NP	B
on	IN	B-PP	O
tumor	NN	B-NP	B
and	CC	O	O
normal	JJ	B-NP	O
tissues	NNS	I-NP	O
.	.	O	O

Thermal	JJ	B-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
Adriamycin	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-VP	O
antitumor	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
normal	JJ	B-NP	O
tissue	NN	I-NP	O
toxicities	NNS	I-NP	B
by	IN	B-PP	O
whole	JJ	B-NP	O
body	NN	I-NP	O
hyperthermia	NN	I-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
F344	NN	I-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

Antitumor	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
tumor	NN	I-NP	B
growth	NN	I-NP	O
delay	NN	I-NP	O
assay	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
normal	JJ	I-NP	O
tissue	NN	I-NP	O
toxicities	NNS	I-NP	B
(	(	O	O
i.e.	FW	B-NP	O
,	,	O	O
leukopenia	NN	B-NP	B
and	CC	O	O
thrombocytopenia	NN	B-NP	B
)	)	O	O
and	CC	O	O
late	JJ	B-NP	O
normal	JJ	I-NP	O
tissue	NN	I-NP	O
toxicities	NNS	I-NP	B
(	(	O	O
i.e.	FW	B-NP	O
,	,	O	O
myocardial	JJ	B-NP	B
and	CC	I-NP	I
kidney	NN	I-NP	I
injury	NN	I-NP	I
)	)	O	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
functional	JJ	B-NP	O
/	SYM	I-NP	O
physiological	JJ	I-NP	O
assays	NNS	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
morphological	JJ	B-NP	O
techniques	NNS	I-NP	O
.	.	O	O

Whole	JJ	B-NP	O
body	NN	I-NP	O
hyperthermia	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
min	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
C	NN	I-NP	O
)	)	O	O
enhanced	VBD	B-VP	O
both	CC	O	O
Adriamycin	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-VP	O
antitumor	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
toxic	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
thermal	JJ	I-NP	O
enhancement	NN	I-NP	O
ratio	NN	I-NP	O
calculated	VBN	B-VP	O
for	IN	B-PP	O
antitumor	JJ	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

Thermal	JJ	B-NP	O
enhancement	NN	I-NP	O
ratios	NNS	I-NP	O
estimated	VBN	B-VP	O
for	IN	B-PP	O
acute	JJ	B-NP	O
hematological	JJ	I-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
,	,	O	O
whereas	IN	O	O
those	DT	B-NP	O
estimated	VBN	B-VP	O
for	IN	B-PP	O
late	JJ	B-NP	O
damage	NN	I-NP	O
(	(	O	O
based	VBN	B-PP	O
on	IN	B-PP	O
morphological	JJ	B-NP	O
cardiac	JJ	I-NP	B
and	CC	I-NP	I
renal	JJ	I-NP	I
lesions	NNS	I-NP	I
)	)	O	O
varied	VBD	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
whole	JJ	B-NP	O
body	NN	I-NP	O
hyperthermia	NN	I-NP	B
enhances	VBZ	B-VP	O
Adriamycin	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
antitumor	NN	I-NP	O
effect	NN	I-NP	O
,	,	O	O
normal	JJ	B-NP	O
tissue	NN	I-NP	O
toxicity	NN	I-NP	B
is	VBZ	B-VP	O
also	RB	I-VP	O
increased	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
potential	JJ	I-NP	O
therapeutic	JJ	I-NP	O
gain	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
modality	NN	I-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
eroded	VBN	I-VP	O
.	.	O	O

Prazosin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
stress	NN	I-NP	B
incontinence	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
genuine	JJ	B-NP	O
stress	NN	I-NP	B
incontinence	NN	I-NP	I
due	IN	B-PP	O
to	TO	B-PP	O
prazosin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
common	JJ	I-NP	O
antihypertensive	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

Prazosin	NN	B-NP	O
exerts	VBZ	B-VP	O
its	PRP$	B-NP	O
antihypertensive	JJ	I-NP	O
effects	NNS	I-NP	O
through	IN	B-PP	O
vasodilatation	NN	B-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
selective	JJ	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
postsynaptic	JJ	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adrenergic	JJ	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

As	IN	B-PP	O
an	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
blocker	NN	B-NP	O
,	,	O	O
it	PRP	B-NP	O
also	RB	B-ADVP	O
exerts	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
relaxant	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
neck	NN	I-NP	O
and	CC	I-NP	O
urethra	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
clinical	JJ	B-NP	O
course	NN	I-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
and	CC	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
initial	JJ	B-NP	O
urodynamic	JJ	I-NP	O
studies	NNS	I-NP	O
while	IN	B-SBAR	O
on	IN	B-PP	O
prazosin	NN	B-NP	O
and	CC	O	O
subsequent	JJ	B-NP	O
studies	NNS	I-NP	O
while	IN	B-SBAR	O
taking	VBG	B-VP	O
verapamil	NN	B-NP	O
.	.	O	O

Her	PRP$	B-NP	O
incontinence	NN	I-NP	B
resolved	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
change	NN	I-NP	O
of	IN	B-PP	O
medication	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
restoration	NN	I-NP	O
of	IN	B-PP	O
continence	NN	B-NP	O
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
substantial	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
maximum	JJ	B-NP	O
urethral	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
maximum	JJ	B-NP	O
urethral	JJ	I-NP	O
closure	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
functional	JJ	B-NP	O
urethral	JJ	I-NP	O
length	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
present	VBP	B-VP	O
with	IN	B-PP	O
stress	NN	B-NP	B
incontinence	NN	I-NP	I
while	IN	B-SBAR	O
taking	VBG	B-VP	O
prazosin	NN	B-NP	O
should	MD	B-VP	O
change	VB	I-VP	O
their	PRP$	B-NP	O
antihypertensive	JJ	I-NP	O
medication	NN	I-NP	O
before	IN	B-PP	O
considering	VBG	B-VP	O
surgery	NN	B-NP	O
,	,	O	O
because	IN	B-SBAR	O
their	PRP$	B-NP	O
incontinence	NN	I-NP	B
may	MD	B-VP	O
resolve	VB	I-VP	O
spontaneously	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
drug	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
following	VBG	B-PP	O
sublingual	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
isosorbide	NN	B-NP	O
dinitrate	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-VP	O
old	JJ	B-ADJP	O
with	IN	B-PP	O
healed	VBN	B-NP	O
septal	JJ	I-NP	O
necrosis	NN	I-NP	B
suffered	VBD	B-VP	O
a	DT	B-NP	O
recurrent	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
wall	NN	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
isosorbide	NN	B-NP	O
dinitrate	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
sublingually	RB	B-ADVP	O
.	.	O	O

After	IN	B-PP	O
detailing	VBG	B-VP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
,	,	O	O
we	PRP	B-NP	O
discuss	VBP	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
paradoxical	JJ	B-NP	O
coronary	JJ	I-NP	O
spasm	NN	I-NP	B
and	CC	I-NP	O
hypotension	NN	I-NP	B
-	HYPH	O	O
mediated	VBN	B-VP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
occurring	VBG	B-VP	O
downstream	RB	B-ADVP	O
to	TO	B-PP	O
significant	JJ	B-NP	O
coronary	JJ	I-NP	B
arterial	JJ	I-NP	I
stenosis	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
coronary	JJ	I-NP	I
insufficiency	NN	I-NP	I
.	.	O	O

Fluoxetine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
:	:	O	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
theoretical	JJ	I-NP	O
implications	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
fluoxetine	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
obsessive	JJ	B-NP	B
compulsive	JJ	I-NP	I
disorder	NN	I-NP	I
or	CC	O	O
major	JJ	B-NP	B
depression	NN	I-NP	I
developed	VBD	B-VP	O
akathisia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
typical	JJ	I-NP	O
fluoxetine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
restlessness	NN	B-NP	O
,	,	O	O
constant	JJ	B-NP	O
pacing	NN	I-NP	O
,	,	O	O
purposeless	JJ	B-NP	O
movements	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
feet	NNS	I-NP	O
and	CC	I-NP	O
legs	NNS	I-NP	O
,	,	O	O
and	CC	O	O
marked	JJ	B-NP	O
anxiety	NN	I-NP	B
were	VBD	B-VP	O
indistinguishable	JJ	B-ADJP	O
from	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
experienced	VBN	I-VP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
past	NN	I-NP	O
reported	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
fluoxetine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
were	VBD	B-VP	O
identical	JJ	B-ADJP	O
,	,	O	O
although	IN	B-SBAR	O
somewhat	RB	B-ADJP	O
milder	JJR	I-ADJP	O
.	.	O	O

Akathisia	NNP	B-NP	B
appeared	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
fluoxetine	NN	B-NP	O
and	CC	O	O
generally	RB	B-VP	O
responded	VBD	I-VP	O
well	RB	I-VP	O
to	TO	I-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
antagonist	NN	I-NP	O
propranolol	NN	I-NP	O
,	,	O	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
fluoxetine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
serotonergically	RB	B-NP	O
mediated	VBN	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
dopaminergic	JJ	B-NP	O
neurotransmission	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
fluoxetine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
and	CC	O	O
tricyclic	JJ	B-NP	O
antidepressant	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
jitteriness	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
identical	JJ	B-ADJP	O
.	.	O	O

Chronic	JJ	B-NP	B
active	JJ	I-NP	I
hepatitis	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
diclofenac	NN	B-NP	O
sodium	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Diclofenac	NN	B-NP	O
sodium	NN	I-NP	O
(	(	O	O
Voltarol	NNP	B-NP	O
,	,	O	O
Geigy	NNP	B-NP	O
Pharmaceuticals	NNP	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
derivative	NN	I-NP	O
of	IN	B-PP	O
phenylacetic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
generally	RB	B-VP	O
well	RB	I-VP	O
-	HYPH	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
asymptomatic	JJ	B-NP	O
abnormalities	NNS	I-NP	B
of	IN	B-PP	I
liver	NN	B-NP	I
function	NN	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
recorded	VBN	I-VP	O
and	CC	O	O
,	,	O	O
less	RBR	B-ADVP	O
commonly	RB	I-ADVP	O
,	,	O	O
severe	JJ	B-NP	O
hepatitis	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
diclofenac	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
described	VBN	B-VP	O
developed	VBD	B-VP	O
chronic	JJ	B-NP	B
active	JJ	I-NP	I
hepatitis	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
diclofenac	NN	B-NP	O
sodium	NN	I-NP	O
which	WDT	B-NP	O
progressed	VBD	B-VP	O
despite	IN	B-PP	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
finding	NN	I-NP	O
not	RB	O	O
previously	RB	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Stroke	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	I-VP	O
stroke	VB	I-VP	B
and	CC	I-VP	O
review	VB	I-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
(	(	O	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
)	)	O	O
age	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
men	NNS	B-NP	O
.	.	O	O

Stroke	NNP	B-NP	B
followed	VBD	B-VP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
by	IN	B-PP	O
inhalation	NN	B-NP	O
,	,	O	O
intranasal	JJ	B-NP	O
,	,	I-NP	O
intravenous	JJ	I-NP	O
,	,	O	O
and	CC	O	O
intramuscular	JJ	B-NP	O
routes	NNS	I-NP	O
.	.	O	O

Intracranial	JJ	B-NP	B
aneurysms	NNS	I-NP	I
or	CC	O	O
arteriovenous	JJ	B-NP	B
malformations	NNS	I-NP	I
were	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
studied	VBN	B-VP	O
angiographically	RB	B-ADVP	O
or	CC	O	O
at	IN	B-PP	O
autopsy	NN	B-NP	O
;	:	O	O
cerebral	JJ	B-NP	B
vasculitis	NN	I-NP	I
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Cerebral	JJ	B-NP	B
infarction	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
subarachnoid	JJ	B-NP	B
hemorrhage	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
apparent	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
stroke	NN	B-NP	B
related	VBN	B-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
is	VBZ	B-VP	O
increasing	VBG	I-VP	O
;	:	O	O
cocaine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
stroke	NN	I-NP	B
occurs	VBZ	B-VP	O
primarily	RB	B-ADVP	O
in	IN	B-PP	O
young	JJ	B-NP	O
adults	NNS	I-NP	O
;	:	O	O
stroke	NN	B-NP	B
may	MD	B-VP	O
follow	VB	I-VP	O
any	DT	B-NP	O
route	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
administration	NN	I-NP	O
;	:	O	O
stroke	NN	B-NP	B
after	IN	B-SBAR	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
is	VBZ	B-VP	O
frequently	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
intracranial	JJ	B-NP	B
aneurysms	NNS	I-NP	I
and	CC	O	O
arteriovenous	JJ	B-NP	B
malformations	NNS	I-NP	I
;	:	O	O
and	CC	O	O
in	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
stroke	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
intracranial	JJ	B-NP	B
hemorrhage	NN	I-NP	I
exceeds	VBZ	B-VP	O
that	DT	B-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

Glyburide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
,	,	O	O
although	IN	B-SBAR	O
common	JJ	B-ADJP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
only	RB	B-ADVP	O
infrequently	RB	I-ADVP	O
with	IN	B-PP	O
sulfonylureas	NNS	B-NP	O
.	.	O	O

For	IN	B-PP	O
glyburide	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
second	JJ	I-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
sulfonylurea	NN	I-NP	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
brief	JJ	I-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
exist	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
type	NN	B-NP	B
num	CD	I-NP	I
diabetes	NNS	I-NP	I
mellitus	NN	I-NP	I
developed	VBD	B-VP	O
an	DT	B-NP	O
acute	JJ	I-NP	B
hepatitis	NN	I-NP	I
-	HYPH	B-NP	I
like	JJ	I-NP	I
syndrome	NN	I-NP	I
soon	RB	B-ADVP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
glyburide	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
serologic	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
viral	JJ	B-NP	B
infection	NN	I-NP	I
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
liver	NN	I-NP	O
biopsy	NN	I-NP	O
sample	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
histologic	JJ	I-NP	O
pattern	NN	I-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
drug	NN	B-NP	B
-	HYPH	B-NP	I
induced	VBN	I-NP	I
hepatitis	NN	I-NP	I
.	.	O	O

Both	DT	B-NP	O
patients	NNS	I-NP	O
recovered	VBD	B-VP	O
quickly	RB	B-ADVP	O
after	IN	B-PP	O
stopping	VBG	B-VP	O
glyburide	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
have	VBP	B-VP	O
remained	VBN	I-VP	O
well	RB	B-ADVP	O
for	IN	B-PP	O
a	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	O	O
up	RP	B-PRT	O
period	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
.	.	O	O

Glyburide	NN	B-NP	O
can	MD	B-VP	O
produce	VB	I-VP	O
an	DT	B-NP	O
acute	JJ	I-NP	B
hepatitis	NN	I-NP	I
-	HYPH	B-NP	I
like	JJ	I-NP	I
illness	NN	I-NP	I
in	IN	B-PP	O
some	DT	B-NP	O
persons	NNS	I-NP	O
.	.	O	O

Systolic	JJ	B-NP	O
pressure	NN	I-NP	O
variation	NN	I-NP	O
is	VBZ	B-VP	O
greater	JJR	B-ADJP	O
during	IN	B-PP	O
hemorrhage	NN	B-NP	B
than	IN	B-PP	O
during	IN	B-PP	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
ventilated	VBN	B-NP	O
dogs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
systolic	JJ	I-NP	O
pressure	NN	I-NP	O
variation	NN	I-NP	O
(	(	O	O
SPV	NN	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
maximal	JJ	I-NP	O
and	CC	I-NP	O
minimal	JJ	I-NP	O
values	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
after	IN	B-PP	O
num	CD	B-NP	O
positive	JJ	I-NP	O
-	HYPH	I-NP	O
pressure	NN	I-NP	O
breath	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
ventilated	VBN	B-NP	O
dogs	NNS	I-NP	O
subjected	VBN	B-VP	O
to	TO	B-PP	O
hypotension	NN	B-NP	B
.	.	O	O

Mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
either	CC	B-PP	O
by	IN	B-PP	O
hemorrhage	NN	B-NP	B
or	CC	B-PP	O
by	IN	B-PP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
HEM	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
the	DT	B-NP	O
cardiac	JJ	I-NP	O
output	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	B-NP	O
and	CC	I-NP	O
systemic	JJ	I-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
higher	JJR	B-ADJP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SNP	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
systemic	JJ	I-NP	O
,	,	I-NP	O
central	JJ	I-NP	O
venous	JJ	I-NP	O
,	,	I-NP	O
pulmonary	JJ	I-NP	O
capillary	JJ	I-NP	O
wedge	NN	I-NP	O
pressures	NNS	I-NP	O
,	,	O	O
and	CC	O	O
heart	NN	B-NP	O
rates	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
respiratory	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
waveform	NN	I-NP	O
enabled	VBD	B-VP	O
differentiation	NN	B-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
SPV	NN	I-NP	O
during	IN	B-PP	O
hypotension	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
HEM	NN	I-NP	B
group	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SNP	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
delta	SYM	I-NP	O
down	RP	B-PRT	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
decrease	NN	B-NP	O
of	IN	B-PP	O
SBP	NN	B-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
mechanical	JJ	I-NP	O
breath	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
HEM	NN	I-NP	B
and	CC	I-NP	O
SNP	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
during	IN	B-PP	O
hypotension	NN	B-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
increases	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SPV	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
delta	SYM	I-NP	O
down	RP	B-PRT	O
are	VBP	B-VP	O
characteristic	JJ	B-ADJP	O
of	IN	B-PP	O
a	DT	B-NP	O
hypotensive	JJ	I-NP	B
state	NN	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
predominant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
preload	NN	B-NP	O
.	.	O	O

They	PRP	B-NP	O
are	VBP	B-VP	O
thus	RB	B-ADJP	O
more	RBR	I-ADJP	O
important	JJ	I-ADJP	O
during	IN	B-PP	O
absolute	JJ	B-NP	O
hypovolemia	NN	I-NP	B
than	IN	B-PP	O
during	IN	B-PP	O
deliberate	JJ	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
arterial	JJ	I-NP	O
spasm	NN	I-NP	B
relieved	VBN	B-VP	O
by	IN	B-PP	O
lidocaine	NN	B-NP	O
.	.	O	O

Case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
major	JJ	B-NP	O
intracranial	JJ	I-NP	O
surgery	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
,	,	O	O
sodium	NN	B-NP	O
pentothal	NN	I-NP	O
was	VBD	B-VP	O
intravenously	RB	I-VP	O
infused	VBN	I-VP	O
to	TO	I-VP	O
minimize	VB	I-VP	O
cerebral	JJ	B-NP	B
ischaemia	NN	I-NP	I
.	.	O	O

Intense	JJ	B-NP	O
vasospasm	NN	I-NP	B
with	IN	B-PP	O
threatened	VBN	B-NP	O
gangrene	NN	I-NP	B
arose	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
arm	NN	I-NP	O
used	VBN	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
.	.	O	O

Since	IN	B-SBAR	O
the	DT	B-NP	O
cranial	JJ	I-NP	O
condition	NN	I-NP	O
precluded	VBD	B-VP	O
use	NN	B-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
usual	JJ	I-NP	O
methods	NNS	I-NP	O
,	,	O	O
lidocaine	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
intra	AFX	O	O
-	HYPH	O	O
arterially	RB	B-ADVP	O
,	,	O	O
with	IN	B-PP	O
careful	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
monitoring	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
counteract	VB	I-VP	O
the	DT	B-NP	O
vasospasm	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
rapidly	RB	B-ADJP	O
successful	JJ	I-ADJP	O
.	.	O	O

Cerebral	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
and	CC	I-NP	O
metabolism	NN	I-NP	O
during	IN	B-PP	O
isoflurane	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
subjected	VBN	B-VP	O
to	TO	B-PP	O
surgery	NN	B-NP	O
for	IN	B-PP	O
cerebral	JJ	B-NP	B
aneurysms	NNS	I-NP	I
.	.	O	O

Cerebral	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
and	CC	O	O
cerebral	JJ	B-NP	O
metabolic	JJ	I-NP	O
rate	NN	I-NP	O
for	IN	B-PP	O
oxygen	NN	B-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
during	IN	B-PP	O
isoflurane	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
subjected	VBN	B-VP	O
to	TO	B-PP	O
craniotomy	NN	B-NP	O
for	IN	B-PP	O
clipping	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
cerebral	JJ	I-NP	B
aneurysm	NN	I-NP	I
.	.	O	O

Flow	NN	B-NP	O
and	CC	I-NP	O
metabolism	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
subarachnoid	JJ	I-NP	B
haemorrhage	NN	I-NP	I
by	IN	B-PP	O
a	DT	B-NP	O
modification	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
classical	JJ	I-NP	O
Kety	NNP	I-NP	O
-	HYPH	I-NP	O
Schmidt	NNP	I-NP	O
technique	NN	I-NP	O
using	VBG	B-VP	O
xenon	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
i.v.	JJ	I-NP	O
Anaesthesia	NN	I-NP	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
inspired	JJ	I-NP	O
isoflurane	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
plus	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
nitrous	JJ	I-NP	O
oxide	NN	I-NP	O
in	IN	B-PP	O
oxygen	NN	B-NP	O
)	)	O	O
,	,	O	O
during	IN	B-PP	O
which	WDT	B-NP	O
CBF	NN	B-NP	O
and	CC	I-NP	O
CMRO2	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
g	NN	I-NP	O
min	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
g	NN	I-NP	O
min	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
at	IN	B-PP	O
PaCO2	NN	B-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
kPa	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
SEM	NN	B-NP	O
)	)	O	O
.	.	O	O

Controlled	JJ	B-NP	O
hypotension	NN	I-NP	B
to	TO	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
MAP	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
isoflurane	NN	B-NP	O
,	,	O	O
and	CC	O	O
maintained	VBD	B-VP	O
at	IN	B-PP	O
an	DT	B-NP	O
inspired	JJ	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
CMRO2	NN	B-NP	O
,	,	O	O
while	IN	B-SBAR	O
CBF	NN	B-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
clipping	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
aneurysm	NN	I-NP	B
the	DT	B-NP	O
isoflurane	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
CBF	NN	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
CMRO2	NN	B-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
hypotensive	JJ	I-NP	B
values	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
might	MD	B-VP	O
offer	VB	I-VP	O
protection	NN	B-NP	O
to	TO	B-PP	O
brain	NN	B-NP	O
tissue	NN	I-NP	O
during	IN	B-PP	O
periods	NNS	B-NP	O
of	IN	B-PP	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Allergic	JJ	B-NP	B
reaction	NN	I-NP	I
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
allergic	JJ	I-NP	B
reaction	NN	I-NP	I
consisting	VBG	B-VP	O
of	IN	B-PP	O
angioneurotic	JJ	B-NP	B
edema	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
carcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
oral	JJ	I-NP	I
cavity	NN	I-NP	I
,	,	O	O
cirrhosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
cisplatin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
impaired	JJ	I-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
reaction	NN	I-NP	O
occurred	VBD	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
sixth	JJ	I-NP	O
and	CC	I-NP	O
seventh	JJ	I-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
infusional	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Oral	JJ	B-NP	O
diphenhydramine	NN	I-NP	O
and	CC	I-NP	O
prednisone	NN	I-NP	O
were	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
the	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
allergic	JJ	I-NP	B
reaction	NN	I-NP	I
.	.	O	O

Discontinuance	NN	B-NP	O
of	IN	B-PP	O
effective	JJ	B-NP	O
chemotherapy	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
during	IN	B-PP	O
partial	JJ	B-NP	O
remission	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
fatal	JJ	B-NP	O
disease	NN	I-NP	O
progression	NN	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
sinoatrial	JJ	I-NP	B
block	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
sinoatrial	JJ	B-NP	B
block	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
chronic	JJ	B-NP	O
amiodarone	NN	I-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
boy	NN	I-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
,	,	O	O
Wolff	NNP	B-NP	B
-	HYPH	B-NP	I
Parkinson	NNP	I-NP	I
-	HYPH	I-NP	I
White	NNP	I-NP	I
syndrome	NN	I-NP	I
and	CC	I-NP	O
supraventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

Reduction	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sinoatrial	JJ	I-NP	B
block	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
persistence	NN	I-NP	O
of	IN	B-PP	O
asymptomatic	JJ	B-NP	O
sinus	NN	I-NP	B
bradycardia	NN	I-NP	I
.	.	O	O

Possible	JJ	B-NP	O
teratogenicity	NN	I-NP	O
of	IN	B-PP	O
sulphasalazine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
infants	NNS	I-NP	O
,	,	O	O
born	VBN	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
mothers	NNS	I-NP	O
with	IN	B-PP	O
inflammatory	JJ	B-NP	B
bowel	NN	I-NP	I
disease	NN	I-NP	I
who	WP	B-NP	O
received	VBD	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
sulphasalazine	NN	B-NP	O
throughout	IN	B-PP	O
pregnancy	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
major	JJ	B-NP	O
congenital	JJ	I-NP	B
anomalies	NNS	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
singleton	JJ	I-NP	O
pregnancy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mother	NN	I-NP	O
had	VBD	B-VP	O
ulcerative	JJ	B-NP	B
colitis	NN	I-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
infant	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
male	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
coarctation	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
aorta	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
ventricular	JJ	I-NP	B
septal	JJ	I-NP	I
defect	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
twin	NN	I-NP	O
pregnancy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mother	NN	I-NP	O
had	VBD	B-VP	O
Crohn	NN	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
twin	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
female	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
left	JJ	I-NP	O
Potter	NN	I-NP	B
-	HYPH	I-NP	I
type	NN	I-NP	I
IIa	NN	I-NP	I
polycystic	JJ	I-NP	I
kidney	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
rudimentary	JJ	I-NP	B
left	JJ	I-NP	I
uterine	JJ	I-NP	I
cornu	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
twin	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
male	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
some	DT	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
Potter	NNP	B-NP	B
s	VBZ	B-VP	I
facies	NNS	B-NP	I
,	,	O	O
hypoplastic	JJ	B-NP	B
lungs	NNS	I-NP	I
,	,	O	O
absent	JJ	B-NP	B
kidneys	NNS	I-NP	I
and	CC	I-NP	I
ureters	NNS	I-NP	I
,	,	O	O
and	CC	O	O
talipes	NNS	B-NP	B
equinovarus	NN	I-NP	I
.	.	O	O

Despite	IN	B-PP	O
reports	NNS	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
contrary	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
sulphasalazine	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
teratogenic	JJ	B-ADJP	O
.	.	O	O

Veno	AFX	B-NP	B
-	HYPH	I-NP	I
occlusive	JJ	B-NP	I
liver	NN	I-NP	I
disease	NN	I-NP	I
after	IN	B-PP	O
dacarbazine	NN	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
DTIC	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
melanoma	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
veno	AFX	B-NP	B
-	HYPH	I-NP	I
occlusive	JJ	I-NP	I
disease	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
with	IN	B-PP	O
fatal	JJ	B-NP	O
outcome	NN	I-NP	O
after	IN	B-PP	O
dacarbazine	NN	B-NP	O
(	(	O	O
DTIC	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
for	IN	B-PP	O
melanoma	NN	B-NP	B
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
fulminant	JJ	I-NP	O
clinical	JJ	I-NP	O
course	NN	I-NP	O
from	IN	B-PP	O
start	NN	B-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
until	IN	B-PP	O
death	NN	B-NP	B
.	.	O	O

At	IN	B-PP	O
autopsy	NN	B-NP	O
the	DT	B-NP	O
liver	NN	I-NP	O
was	VBD	B-VP	O
enlarged	VBN	I-VP	O
and	CC	O	O
firm	NN	B-NP	O
with	IN	B-PP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
congestion	NN	I-NP	I
.	.	O	O

Small	JJ	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
medium	NN	I-NP	O
-	HYPH	B-VP	O
sized	VBN	B-NP	O
hepatic	JJ	I-NP	O
veins	NNS	I-NP	O
were	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
thrombosis	NN	B-NP	B
.	.	O	O

Eosinophilic	JJ	B-NP	O
infiltrations	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
around	IN	B-PP	O
the	DT	B-NP	O
vessels	NNS	I-NP	O
.	.	O	O

Published	VBN	B-NP	O
cases	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
and	CC	O	O
pertinent	JJ	B-NP	O
features	NNS	I-NP	O
discussed	VBN	B-VP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
tardive	JJ	B-NP	B
dyskinesia	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
metoclopramide	NN	B-NP	O
.	.	O	O

Abnormal	JJ	B-NP	B
involuntary	JJ	I-NP	I
movements	NNS	I-NP	I
appeared	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mouth	NN	I-NP	O
,	,	I-NP	O
tongue	NN	I-NP	O
,	,	I-NP	O
neck	NN	I-NP	O
and	CC	I-NP	O
abdomen	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
patient	NN	I-NP	O
after	IN	B-SBAR	O
he	PRP	B-NP	O
took	VBD	B-VP	O
metoclopramide	NN	B-NP	O
for	IN	B-PP	O
gastrointestinal	JJ	B-NP	B
disorder	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
regimen	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
about	IN	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
symptoms	NNS	I-NP	O
exacerbated	VBN	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
maximum	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
month	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
the	DT	B-NP	O
metoclopramide	NN	I-NP	O
administration	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
abnormal	JJ	I-NP	B
movements	NNS	I-NP	I
gradually	RB	B-ADVP	O
improved	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
considerable	JJ	I-NP	O
extent	NN	I-NP	O
.	.	O	O

Attention	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
specific	JJ	B-NP	O
tardive	JJ	I-NP	B
dyskinesia	NN	I-NP	I
is	VBZ	B-VP	O
called	VBN	I-VP	O
for	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
observations	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
electrophysiologic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
amiodarone	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
of	IN	B-PP	O
a	DT	B-NP	O
reversible	JJ	I-NP	O
intra	AFX	I-NP	B
-	HYPH	I-NP	I
Hisian	JJ	I-NP	I
block	NN	I-NP	I
occurring	VBG	B-VP	O
under	IN	B-PP	O
amiodarone	NN	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
atrial	JJ	B-NP	B
tachycardia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
without	IN	B-PP	O
clear	JJ	B-NP	O
intraventricular	JJ	I-NP	B
conduction	NN	I-NP	I
abnormalities	NNS	I-NP	I
.	.	O	O

His	PRP$	B-NP	O
bundle	NN	I-NP	O
recordings	NNS	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
atrial	JJ	I-NP	B
tachycardia	NN	I-NP	I
with	IN	B-PP	O
intermittent	JJ	B-NP	O
exit	NN	I-NP	O
block	NN	I-NP	O
and	CC	O	O
greatly	RB	B-VP	O
prolonged	VBD	I-VP	O
BH	NN	B-NP	O
and	CC	I-NP	O
HV	NN	I-NP	O
intervals	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
msec	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
amiodarone	NN	B-NP	O
discontinuation	NN	I-NP	O
,	,	O	O
His	PRP$	B-NP	O
bundle	NN	I-NP	O
electrograms	NNS	I-NP	O
showed	VBD	B-VP	O
atrial	JJ	B-NP	B
flutter	NN	I-NP	I
without	IN	B-PP	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
Hisian	JJ	I-NP	O
or	CC	I-NP	O
infra	AFX	I-NP	O
-	HYPH	I-NP	O
Hisian	JJ	I-NP	O
delay	NN	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
caution	NN	B-NP	O
during	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
oral	JJ	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
clear	JJ	B-NP	O
intraventricular	JJ	I-NP	O
conduction	NN	I-NP	O
defects	NNS	I-NP	O
.	.	O	O

Busulfan	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
busulfan	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemorrhage	NN	I-NP	B
cystitis	NN	I-NP	I
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Spontaneous	JJ	B-NP	O
resolution	NN	I-NP	O
occurred	VBD	B-VP	O
following	VBG	I-VP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
similarity	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
histologic	JJ	I-NP	O
appearances	NNS	I-NP	O
of	IN	B-PP	O
busulfan	NN	B-NP	O
cystitis	NN	I-NP	B
and	CC	O	O
both	CC	O	O
radiation	NN	B-NP	O
and	CC	I-NP	O
cyclophosphamide	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
world	NN	I-NP	O
literature	NN	I-NP	O
reviewed	VBN	B-VP	O
.	.	O	O

In	IN	B-PP	O
view	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
known	JJ	I-NP	O
tendency	NN	I-NP	O
of	IN	B-PP	O
busulfan	NN	B-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
cellular	JJ	B-NP	O
atypia	NN	I-NP	O
and	CC	I-NP	O
carcinoma	NN	I-NP	B
in	IN	B-PP	O
other	JJ	B-NP	O
sites	NNS	I-NP	O
,	,	O	O
periodic	JJ	B-NP	O
urinary	JJ	I-NP	O
cytology	NN	I-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Rebound	VB	B-VP	O
hypertensive	JJ	B-ADJP	B
after	IN	B-PP	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
prevented	VBN	B-VP	O
by	IN	B-PP	O
saralasin	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
during	IN	B-PP	O
halothane	NN	B-NP	O
anesthesia	NN	I-NP	O
and	CC	O	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
(	(	O	O
SNP	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Control	NN	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
halothane	NN	B-NP	O
anesthesia	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
MAC	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
hour	NN	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
SNP	NN	B-NP	O
infusion	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
recovery	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
second	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
identically	RB	B-ADVP	O
and	CC	O	O
,	,	O	O
in	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
received	VBD	B-VP	O
an	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
saralasin	NN	B-NP	O
(	(	O	O
a	DT	B-NP	O
competitive	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
throughout	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
,	,	O	O
SNP	NN	B-NP	O
infusion	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
initial	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
torr	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
torr	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
to	TO	B-PP	O
num	CD	B-NP	O
torr	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
SNP	NN	I-NP	O
infusion	NN	I-NP	O
the	DT	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
progressive	JJ	I-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
blood	NN	B-NP	I
pressure	NN	I-NP	I
to	TO	B-PP	O
num	CD	B-NP	O
torr	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
saralasin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
SNP	NN	B-NP	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
rebounded	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
torr	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
torr	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
saralasin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
with	IN	B-PP	O
stable	JJ	B-NP	O
halothane	NN	I-NP	O
anesthesia	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
partial	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
during	IN	B-PP	O
SNP	NN	B-NP	O
infusion	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
SNP	NN	I-NP	O
rebound	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
completely	RB	I-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
saralasin	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
demonstrates	VBZ	B-VP	O
the	DT	B-NP	O
participation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
antagonizing	VBG	B-VP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
hypotensive	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
halothane	NN	B-NP	O
and	CC	I-NP	O
SNP	NN	I-NP	O
.	.	O	O

Toxic	JJ	B-NP	B
hepatitis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
antithyroid	JJ	B-NP	O
drugs	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
including	VBG	B-PP	O
num	CD	B-NP	O
with	IN	B-PP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
reactivity	NN	I-NP	O
between	IN	B-PP	O
carbimazole	NN	B-NP	O
and	CC	I-NP	O
benzylthiouracil	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
to	TO	I-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	B
adverse	JJ	I-NP	I
effects	NNS	I-NP	I
encountered	VBN	B-VP	O
with	IN	B-PP	O
antithyroid	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Retrospective	JJ	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
medical	JJ	B-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
hyperthyroidism	NN	B-NP	B
admitted	VBN	B-VP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
department	NN	I-NP	O
(	(	O	O
in	IN	B-PP	O
-	HYPH	B-NP	O
or	CC	O	O
out	RP	B-PRT	O
-	HYPH	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
with	IN	B-PP	O
toxic	JJ	B-NP	B
hepatitis	NN	I-NP	I
which	WDT	B-NP	O
could	MD	B-VP	O
reasonably	RB	I-VP	O
be	VB	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
antithyroid	JJ	B-NP	O
agent	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
carbimazole	NN	B-NP	O
(	(	O	O
N	NN	B-NP	O
omercazole	NN	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
others	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	O	O
mixed	JJ	O	O
(	(	O	O
cholestatic	JJ	B-NP	B
and	CC	I-NP	O
cytolytic	JJ	I-NP	O
)	)	I-NP	O
hepatitis	NN	I-NP	B
following	VBG	B-PP	O
carbimazole	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
latter	JJ	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
further	RBR	B-ADVP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
cytolytic	JJ	I-NP	O
hepatitis	NN	I-NP	B
which	WDT	B-NP	O
appeared	VBD	B-VP	O
after	IN	B-PP	O
Benzylthiouracil	NN	B-NP	O
(	(	O	O
Basd	NN	B-NP	O
ne	NN	I-NP	O
)	)	O	O
had	VBD	B-VP	O
replaced	VBN	I-VP	O
carbimazole	NN	B-NP	O
.	.	O	O

Biological	JJ	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
disappeared	VBD	B-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
cases	NNS	I-NP	O
after	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
incriminated	VBN	I-NP	O
drug	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
biliary	JJ	B-NP	O
,	,	I-NP	O
viral	JJ	I-NP	O
and	CC	I-NP	O
immunological	JJ	I-NP	O
searches	NNS	I-NP	O
were	VBD	B-VP	O
negative	JJ	B-ADJP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
mild	JJ	I-NP	O
or	CC	I-NP	O
severe	JJ	I-NP	O
neutropenia	NN	I-NP	B
.	.	O	O

Toxic	JJ	B-NP	B
hepatitis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
antithyroid	JJ	B-NP	O
drugs	NNS	I-NP	O
which	WDT	B-NP	O
warrants	NNS	B-NP	O
,	,	O	O
as	IN	B-PP	O
for	IN	B-PP	O
haematological	JJ	B-NP	O
disturbances	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
therapeutic	JJ	I-NP	O
determination	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
careful	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
relevant	JJ	B-NP	O
biological	JJ	I-NP	O
markers	NNS	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
hepatotoxicity	NN	B-NP	B
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
restricted	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
antithyroid	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

Study	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
B12	NN	I-NP	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
supplementation	NN	I-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
hematologic	JJ	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
zidovudine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
B12	NN	I-NP	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
supplementation	NN	I-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
zidovudine	NN	B-NP	O
(	(	O	O
ZDV	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
bone	NN	I-NP	B
marrow	NN	I-NP	I
suppression	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
human	JJ	I-NP	B
immunodeficiency	NN	I-NP	I
virus	NN	I-NP	I
(	(	O	I
HIV	NN	B-NP	I
)	)	O	I
-	HYPH	B-NP	I
infected	VBN	B-VP	I
patients	NNS	B-NP	O
with	IN	B-PP	O
CD4	NN	B-NP	O
+	SYM	B-VP	O
cell	NN	B-NP	O
counts	NNS	I-NP	O
<	SYM	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
mm3	NN	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
either	DT	B-NP	O
ZDV	NN	I-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
and	CC	O	O
intramascular	JJ	B-NP	O
vitamin	NN	I-NP	O
B12	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
monthly	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
excluded	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
(	(	O	O
noncompliance	NN	B-NP	O
num	CD	I-NP	O
death	NN	I-NP	B
num	CD	I-NP	O
)	)	O	O
;	:	O	O
thus	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
were	VBD	B-VP	O
eligible	JJ	B-ADJP	O
for	IN	B-PP	O
analysis	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
at	IN	B-PP	O
enrollment	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
vitamin	NN	B-NP	O
B12	NN	I-NP	O
and	CC	I-NP	O
folate	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
group	NN	B-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
hemoglobin	NN	B-NP	O
,	,	O	O
hematocrit	NN	B-NP	O
,	,	O	O
mean	JJ	B-NP	O
corpuscular	JJ	I-NP	O
volume	NN	I-NP	O
,	,	O	O
and	CC	O	O
white	JJ	B-NP	O
-	HYPH	I-NP	O
cell	NN	I-NP	O
,	,	I-NP	O
neutrophil	NN	I-NP	O
and	CC	I-NP	O
platelet	NN	I-NP	O
counts	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
hematologic	JJ	I-NP	O
toxicity	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
assigned	VBN	B-VP	O
to	TO	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
assigned	VBN	B-VP	O
to	TO	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
vitamin	NN	B-NP	O
B12	NN	I-NP	O
or	CC	O	O
folate	JJ	B-NP	O
levels	NNS	I-NP	O
and	CC	O	O
development	NN	B-NP	O
of	IN	B-PP	O
myelosuppression	NN	B-NP	B
.	.	O	O

Vitamin	NN	B-NP	O
B12	NN	I-NP	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
supplementation	NN	I-NP	O
of	IN	B-PP	O
ZDV	NN	B-NP	O
therapy	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
or	CC	I-VP	O
reducing	VBG	I-VP	O
ZDV	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myelotoxicity	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
overall	JJ	I-NP	O
treated	VBN	I-NP	O
population	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
a	DT	B-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
certain	JJ	B-NP	O
subgroups	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
excluded	VBN	I-VP	O
.	.	O	O

Acute	JJ	B-NP	O
confusion	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
combination	NN	B-NP	O
chemotherapy	NN	I-NP	O
incorporating	VBG	B-VP	O
cisplatinum	NN	B-NP	O
,	,	O	O
etoposide	NN	B-NP	O
,	,	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
inoperable	JJ	I-NP	O
gastric	JJ	I-NP	B
adenocarcinoma	NN	I-NP	I
.	.	O	O

He	PRP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
neurologic	JJ	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
mental	JJ	B-NP	O
confusion	NN	I-NP	B
,	,	I-NP	O
disorientation	NN	I-NP	B
and	CC	I-NP	O
irritability	NN	I-NP	B
,	,	O	O
and	CC	O	O
then	RB	B-ADVP	O
lapsed	VBD	B-VP	O
into	IN	B-PP	O
a	DT	B-NP	O
deep	JJ	I-NP	O
coma	NN	I-NP	B
,	,	O	O
lasting	VBG	B-VP	O
for	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
dose	NN	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
complication	NN	I-NP	O
reappeared	VBD	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
then	RB	B-ADVP	O
the	DT	B-NP	O
only	JJ	I-NP	O
drugs	NNS	I-NP	O
given	VBN	B-VP	O
.	.	O	O

Because	IN	B-SBAR	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
was	VBD	B-VP	O
unlikely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
condition	NN	I-NP	O
,	,	O	O
neurotoxicity	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
was	VBD	B-VP	O
highly	RB	I-VP	O
suspected	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
neurotoxicity	NN	I-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
Krebs	NNP	I-NP	O
cycle	NN	I-NP	O
blockade	NN	I-NP	O
by	IN	B-PP	O
fluoroacetate	NN	B-NP	O
and	CC	I-NP	O
fluorocitrate	NN	I-NP	O
,	,	O	O
thiamine	NN	B-NP	O
deficiency	NN	I-NP	O
,	,	O	O
or	CC	O	O
dihydrouracil	NN	B-NP	O
dehydrogenase	NN	I-NP	O
deficiency	NN	I-NP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
/	SYM	B-NP	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
infusion	NN	I-NP	O
therapy	NN	I-NP	O
has	VBZ	B-VP	O
recently	RB	I-VP	O
become	VBN	I-VP	O
a	DT	B-NP	O
popular	JJ	I-NP	O
regimen	NN	I-NP	O
for	IN	B-PP	O
various	JJ	B-NP	O
cancers	NNS	I-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
necessary	JJ	B-ADJP	O
that	IN	B-SBAR	O
both	CC	O	O
oncologists	NNS	B-NP	O
and	CC	I-NP	O
neurologists	NNS	I-NP	O
be	VB	B-VP	O
fully	RB	B-ADJP	O
aware	JJ	I-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
unusual	JJ	I-NP	O
complication	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
switching	VBG	B-VP	O
carbamazepine	NN	B-NP	O
to	TO	B-PP	O
oxcarbazepine	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
neuroleptics	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Carbamazepine	NN	B-NP	O
was	VBD	B-VP	O
switched	VBN	I-VP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
keto	NN	I-NP	O
analogue	NN	I-NP	O
oxcarbazepine	NN	I-NP	O
among	IN	B-PP	O
num	CD	B-NP	O
difficult	JJ	I-NP	O
-	HYPH	I-NP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
treat	NN	I-NP	O
schizophrenic	JJ	I-NP	B
or	CC	I-NP	O
organic	JJ	I-NP	B
psychotic	JJ	I-NP	I
patients	NNS	I-NP	O
using	VBG	B-VP	O
concomitantly	RB	B-NP	O
haloperidol	NN	I-NP	O
,	,	I-NP	O
chlorpromazine	NN	I-NP	O
or	CC	I-NP	O
clozapine	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
change	NN	I-NP	O
resulted	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
neuroleptics	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
any	DT	B-NP	O
clinical	JJ	I-NP	O
deteriotation	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
idea	NN	I-NP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
contrast	NN	B-NP	O
with	IN	B-PP	O
carbamazepine	NN	B-NP	O
oxcarbazepine	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
the	DT	B-NP	O
hepatic	JJ	I-NP	O
microsomal	JJ	I-NP	O
enzyme	NN	I-NP	O
systems	NNS	I-NP	O
regulating	VBG	B-VP	O
the	DT	B-NP	O
inactivation	NN	I-NP	O
of	IN	B-PP	O
antipsychotic	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Erythema	NN	B-NP	B
multiforme	JJ	I-NP	I
and	CC	I-NP	O
hypersensitivity	NN	I-NP	B
myocarditis	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
ampicillin	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
erythema	NN	B-NP	B
multiforme	NN	I-NP	I
and	CC	O	O
hypersensitivity	NN	B-NP	B
myocarditis	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
ampicillin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
boy	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
ampicillin	NN	B-NP	O
and	CC	I-NP	O
gentamicin	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
suspected	VBN	B-NP	O
septicemia	NN	I-NP	B
.	.	O	O

Medications	NNS	B-NP	O
were	VBD	B-VP	O
discontinued	VBN	I-VP	O
when	WRB	B-ADVP	O
erythema	NN	B-NP	B
multiforme	JJ	I-NP	I
and	CC	I-NP	O
congestive	JJ	I-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
myocarditis	NN	B-NP	B
occurred	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
methylprednisolone	NN	B-NP	O
and	CC	O	O
gradually	RB	B-VP	O
improved	VBN	I-VP	O
.	.	O	O

Macrophage	NN	B-NP	O
-	HYPH	I-NP	O
migration	NN	I-NP	O
inhibition	NN	I-NP	O
(	(	O	O
MIF	NN	B-NP	O
)	)	O	O
test	NN	B-NP	O
with	IN	B-PP	O
ampicillin	NN	B-NP	O
was	VBD	B-VP	O
positive	JJ	B-ADJP	O
.	.	O	O

After	IN	B-PP	O
most	JJS	B-NP	O
infections	NNS	I-NP	B
causing	VBG	B-VP	O
erythema	NN	B-NP	B
multiforme	JJ	I-NP	I
and	CC	O	O
myocarditis	NN	B-NP	B
were	VBD	B-VP	O
ruled	VBN	I-VP	O
out	RP	B-PRT	O
,	,	O	O
a	DT	B-NP	O
drug	NN	I-NP	B
-	HYPH	O	I
induced	VBN	B-NP	I
allergic	JJ	I-NP	I
reaction	NN	I-NP	I
was	VBD	B-VP	O
suspected	VBN	I-VP	O
.	.	O	O

Positive	JJ	B-NP	O
MIF	NN	I-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
ampicillin	NN	B-NP	O
showed	VBD	B-VP	O
sensitization	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
lymphocytes	NNS	B-NP	O
to	TO	B-PP	O
ampicillin	NN	B-NP	O
.	.	O	O

Hypersensitivity	NN	B-NP	B
myocarditis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
and	CC	I-NP	O
dangerous	JJ	I-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
allergy	NN	B-NP	B
to	TO	B-PP	O
penicillins	NNS	B-NP	O
.	.	O	O

Immediate	JJ	B-NP	O
allergic	JJ	I-NP	B
reactions	NNS	I-NP	I
to	TO	B-PP	O
amoxicillin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
large	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
suspected	VBN	B-NP	O
allergic	JJ	I-NP	B
reactions	NNS	I-NP	I
to	TO	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
lactam	NN	I-NP	O
antibiotics	NNS	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
detailed	JJ	I-NP	O
clinical	JJ	I-NP	O
history	NN	I-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
skin	NN	B-NP	O
tests	NNS	I-NP	O
,	,	O	O
RAST	NN	B-NP	O
(	(	O	O
radioallergosorbent	JJ	B-NP	O
test	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
controlled	VBN	B-NP	O
challenge	NN	I-NP	O
tests	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
establish	VB	I-VP	O
whether	IN	B-SBAR	O
patients	NNS	B-NP	O
allergic	JJ	B-ADJP	B
to	TO	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
lactam	NN	I-NP	O
antibiotics	NNS	I-NP	O
had	VBD	B-VP	O
selective	JJ	B-NP	O
immediate	JJ	I-NP	O
allergic	JJ	I-NP	B
responses	NNS	I-NP	O
to	TO	B-PP	O
amoxicillin	NN	B-NP	O
(	(	O	O
AX	NN	B-NP	O
)	)	O	O
or	CC	O	O
were	VBD	B-VP	O
cross	AFX	B-ADJP	O
-	HYPH	O	O
reacting	VBG	B-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
penicillin	NN	I-NP	O
derivatives	NNS	I-NP	O
.	.	O	O

Skin	NN	B-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
benzylpenicilloyl	NN	B-NP	O
-	HYPH	B-NP	O
poly	NN	I-NP	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	O	O
lysine	NN	B-NP	O
(	(	O	O
BPO	NN	B-NP	O
-	HYPH	B-NP	O
PLL	NN	I-NP	O
)	)	O	O
,	,	O	O
benzylpenicilloate	NN	B-NP	O
,	,	O	O
benzylpenicillin	NN	B-NP	O
(	(	O	O
PG	NN	B-NP	O
)	)	O	O
,	,	O	O
ampicillin	NN	B-NP	O
(	(	O	O
AMP	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
AX	NNP	B-NP	O
.	.	O	O

RAST	NN	B-NP	O
for	IN	B-PP	O
BPO	NN	B-NP	O
-	HYPH	B-NP	O
PLL	NN	I-NP	O
and	CC	I-NP	O
AX	NN	I-NP	O
-	HYPH	B-NP	O
PLL	NN	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
.	.	O	O

When	WRB	B-ADVP	O
both	CC	O	O
skin	NN	B-NP	O
test	NN	I-NP	O
and	CC	O	O
RAST	NN	B-NP	O
for	IN	B-PP	O
BPO	NN	B-NP	O
were	VBD	B-VP	O
negative	JJ	B-NP	O
,	,	I-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
challenge	NN	I-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
done	VBN	I-VP	O
to	TO	B-VP	O
ensure	VB	I-VP	O
tolerance	NN	B-NP	O
of	IN	B-PP	O
PG	NN	B-NP	O
or	CC	I-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
AX	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
diagnosed	VBN	I-VP	O
as	IN	B-PP	O
allergic	JJ	B-ADJP	B
to	TO	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
lactam	NN	I-NP	O
antibiotics	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
selected	VBD	B-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
immediate	JJ	B-NP	O
AX	NN	I-NP	O
allergy	NN	I-NP	B
with	IN	B-PP	O
good	JJ	B-NP	O
tolerance	NN	I-NP	O
of	IN	B-PP	O
PG	NN	B-NP	O
.	.	O	O

Anaphylaxis	NN	B-NP	B
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
having	VBG	I-NP	O
urticaria	NN	I-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
angioedema	NN	B-NP	B
.	.	O	O

All	PDT	B-NP	O
the	DT	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
skin	NN	B-NP	O
test	NN	I-NP	O
negative	JJ	B-ADJP	O
to	TO	B-PP	O
BPO	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
negative	JJ	B-ADJP	O
to	TO	B-PP	O
MDM	NN	B-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
PG	NN	B-NP	O
.	.	O	O

Skin	NN	B-NP	O
tests	NNS	I-NP	O
with	IN	B-PP	O
AX	NN	B-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

RAST	NN	B-NP	O
was	VBD	B-VP	O
positive	JJ	B-ADJP	O
for	IN	B-PP	O
AX	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
BPO	NN	B-NP	O
in	IN	B-PP	O
just	RB	B-NP	O
num	CD	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sera	NNS	I-NP	O
with	IN	B-PP	O
negative	JJ	B-NP	O
RAST	NN	I-NP	O
for	IN	B-PP	O
AX	NN	B-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
to	TO	B-PP	O
BPO	NN	B-NP	O
.	.	O	O

Challenge	NN	B-NP	O
tests	NNS	I-NP	O
with	IN	B-PP	O
AX	NN	B-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
to	TO	B-VP	O
establish	VB	I-VP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
immediate	JJ	B-NP	O
allergic	JJ	I-NP	B
reaction	NN	I-NP	I
to	TO	B-PP	O
AX	NN	B-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
both	CC	O	O
skin	NN	B-NP	O
test	NN	I-NP	O
and	CC	O	O
RAST	NN	B-NP	O
for	IN	B-PP	O
AX	NN	B-NP	O
were	VBD	B-VP	O
negative	JJ	B-ADJP	O
.	.	O	O

PG	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
by	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
largest	JJS	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
AX	NN	B-NP	O
-	HYPH	B-NP	O
allergic	JJ	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
tolerated	VBN	I-VP	O
PG	NN	B-NP	O
reported	VBN	B-VP	O
so	RB	B-ADVP	O
far	RB	I-ADVP	O
.	.	O	O

Diagnosis	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
achieved	VBN	I-VP	O
only	RB	B-ADVP	O
if	IN	B-SBAR	O
specific	JJ	B-NP	O
AX	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
reagents	NNS	I-NP	O
are	VBP	B-VP	O
employed	VBN	I-VP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
exact	JJ	I-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
problem	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
diagnostic	JJ	B-NP	O
methods	NNS	I-NP	O
.	.	O	O

Persistent	JJ	B-NP	O
paralysis	NN	I-NP	B
after	IN	B-PP	O
prolonged	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
atracurium	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
corticosteroids	NNS	B-NP	O
.	.	O	O

Neuromuscular	JJ	B-NP	O
blocking	VBG	I-NP	O
agents	NNS	I-NP	O
(	(	O	O
NMBAs	NNS	B-NP	O
)	)	O	O
are	VBP	B-VP	O
often	RB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
requiring	VBG	B-VP	O
prolonged	JJ	B-NP	O
mechanical	JJ	I-NP	O
ventilation	NN	I-NP	O
.	.	O	O

Reports	NNS	B-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
paralysis	NN	I-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
discontinuance	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
have	VBP	B-VP	O
most	RBS	I-VP	O
often	RB	I-VP	O
involved	VBN	B-NP	O
aminosteroid	NN	I-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
NMBAs	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
vecuronium	NN	B-NP	O
bromide	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
when	WRB	B-ADVP	O
used	VBN	B-VP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
corticosteroids	NNS	B-NP	O
.	.	O	O

Atracurium	NNP	B-NP	O
besylate	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	I-NP	O
benzylisoquinolinium	NN	I-NP	O
NMBA	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
eliminated	VBN	I-VP	O
independently	RB	B-ADVP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
or	CC	I-NP	O
hepatic	JJ	I-NP	O
function	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
persistent	JJ	B-NP	O
paralysis	NN	I-NP	B
,	,	O	O
but	CC	O	O
only	RB	O	O
when	WRB	B-ADVP	O
used	VBN	B-VP	O
with	IN	B-PP	O
corticosteroids	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
atracurium	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
paralysis	NN	I-NP	B
persisting	VBG	B-VP	O
for	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
corticosteroids	NNS	B-NP	O
.	.	O	O

Habitual	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
comparison	NN	I-NP	O
with	IN	B-PP	O
phenacetin	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
epidemiologic	JJ	I-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
and	CC	O	O
Europe	NNP	B-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
habitual	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
phenacetin	NN	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
and	CC	I-NP	O
end	NN	I-NP	B
-	HYPH	B-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
(	(	O	O
ESRD	NN	B-NP	B
)	)	O	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
relative	JJ	I-NP	O
risk	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
and	CC	I-NP	O
other	JJ	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
phenacetin	NN	B-NP	O
has	VBZ	B-VP	O
now	RB	I-VP	O
been	VBN	I-VP	O
withdrawn	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
market	NN	I-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
countries	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
case	NN	I-NP	O
control	NN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
each	DT	B-NP	O
in	IN	B-PP	O
North	NNP	B-NP	O
Carolina	NNP	I-NP	O
,	,	O	O
northern	JJ	B-NP	O
Maryland	NNP	I-NP	O
,	,	O	O
and	CC	O	O
West	NNP	B-NP	O
Berlin	NNP	I-NP	O
,	,	O	O
Germany	NNP	B-NP	O
,	,	O	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
habitual	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
is	VBZ	B-VP	O
also	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
and	CC	I-NP	O
ESRD	NN	I-NP	B
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
relative	JJ	I-NP	O
risk	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

These	DT	B-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
both	CC	O	O
phenacetin	NN	B-NP	O
and	CC	I-NP	O
acetaminophen	NN	I-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
burden	NN	I-NP	O
of	IN	B-PP	O
ESRD	NNP	B-NP	B
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
latter	JJ	I-NP	O
being	VBG	B-VP	O
somewhat	RB	B-ADJP	O
less	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
former	JJ	I-NP	O
.	.	O	O

This	DT	B-NP	O
apparent	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
risk	NN	B-NP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
differences	NNS	B-NP	O
in	IN	B-PP	O
nephrotoxic	JJ	B-NP	B
potential	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
themselves	PRP	B-NP	O
.	.	O	O

A	DT	B-NP	O
lower	JJR	I-NP	O
relative	JJ	I-NP	O
risk	NN	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
expected	VBN	I-VP	O
for	IN	B-PP	O
acetaminophen	NN	B-NP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
analgesics	NNS	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
either	DT	B-NP	O
agent	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
acetaminophen	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
both	CC	O	O
as	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
agent	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
analgesics	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
phenacetin	NN	B-NP	O
was	VBD	B-VP	O
available	JJ	B-ADJP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
combinations	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
habitual	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
alone	RB	B-ADVP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
ESRD	NNP	B-NP	B
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
clearly	RB	I-VP	O
demonstrated	VBN	I-VP	O
,	,	O	O
but	CC	O	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
dismissed	VBN	I-VP	O
.	.	O	O

Reduction	NN	B-NP	O
of	IN	B-PP	O
heparan	NN	B-NP	O
sulphate	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
anionic	JJ	B-NP	O
sites	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

Heparan	NN	B-NP	O
sulphate	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
anionic	JJ	B-NP	O
sites	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
diabetes	NN	B-NP	B
by	IN	B-PP	O
streptozotocin	NN	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
age	NN	B-NP	O
-	HYPH	O	O
adn	NN	B-NP	O
sex	NN	I-NP	O
-	HYPH	B-VP	O
matched	VBN	B-NP	O
control	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
employing	VBG	B-VP	O
the	DT	B-NP	O
cationic	JJ	I-NP	O
dye	NN	I-NP	O
cuprolinic	JJ	I-NP	O
blue	NN	I-NP	O
.	.	O	O

Morphometric	JJ	B-NP	O
analysis	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
ultrastructural	JJ	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
computerized	JJ	I-NP	O
image	NN	I-NP	O
processor	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
heparan	NN	I-NP	O
sulphate	NN	I-NP	O
specificity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cuprolinic	JJ	I-NP	O
blue	JJ	I-NP	O
staining	NN	I-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
by	IN	B-PP	O
glycosaminoglycan	NN	B-NP	O
-	HYPH	O	O
degrading	VBG	B-VP	O
enzymes	NNS	B-NP	O
,	,	O	O
showing	VBG	B-VP	O
that	IN	B-SBAR	O
pretreatment	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sections	NNS	I-NP	O
with	IN	B-PP	O
heparitinase	NN	B-NP	O
abolished	VBD	B-VP	O
all	DT	B-NP	O
staining	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
chondroitinase	NN	B-NP	O
ABC	NNP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
anionic	JJ	B-NP	O
sites	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
diabetic	JJ	B-ADJP	B
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
found	VBN	I-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
lamina	NN	I-NP	O
rara	NN	I-NP	O
externa	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
minority	NN	I-NP	O
of	IN	B-PP	O
anionic	JJ	B-NP	O
sites	NNS	I-NP	O
were	VBD	B-VP	O
scattered	VBN	I-VP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
lamina	NN	I-NP	O
densa	NN	I-NP	O
and	CC	O	O
lamina	NN	B-NP	O
rara	NN	I-NP	O
interna	NN	I-NP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
smaller	JJR	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lamina	NN	I-NP	O
rara	NN	I-NP	O
externa	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
.	.	O	O

Diabetic	JJ	B-NP	B
rats	NNS	I-NP	O
progressively	RB	B-ADVP	O
developed	VBD	B-VP	O
albuminuria	NN	B-NP	B
reaching	VBG	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
heparan	NN	B-NP	O
sulphate	NN	I-NP	O
anionic	JJ	I-NP	O
sites	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
total	JJ	I-NP	O
anionic	JJ	I-NP	O
site	NN	I-NP	O
surface	NN	I-NP	O
(	(	O	O
number	NN	B-NP	O
of	IN	B-PP	O
anionic	JJ	B-NP	O
sites	NNS	I-NP	O
x	VBP	B-VP	O
mean	JJ	B-NP	O
anionic	JJ	I-NP	O
site	NN	I-NP	O
surface	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
lamina	NN	I-NP	O
rara	NN	I-NP	O
externa	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Number	NN	B-NP	O
and	CC	O	O
total	JJ	B-NP	O
anionic	JJ	I-NP	O
site	NN	I-NP	O
surface	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
(	(	O	O
lamina	NN	B-NP	O
densa	NN	I-NP	O
and	CC	O	O
lamina	NN	B-NP	O
rara	NN	I-NP	O
interna	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
changed	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
diabetic	JJ	I-NP	B
rats	NNS	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
urinary	JJ	I-NP	O
albumin	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
heparan	NN	I-NP	O
sulphate	NN	I-NP	O
charge	NN	I-NP	O
barrier	NN	I-NP	O
/	SYM	B-NP	O
density	NN	I-NP	O
is	VBZ	B-VP	O
found	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
lamina	NN	I-NP	O
rara	NN	I-NP	O
externa	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
some	DT	B-NP	O
anticancer	JJ	I-NP	O
drugs	NNS	I-NP	O
and	CC	O	O
combined	JJ	B-NP	O
chemotherapy	NN	I-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	B
toxicity	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
nephrotoxic	JJ	I-NP	B
action	NN	I-NP	O
of	IN	B-PP	O
anticancer	JJ	B-NP	O
drugs	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
nitrogranulogen	NN	B-NP	O
(	(	O	O
NG	NN	B-NP	O
)	)	O	O
,	,	O	O
methotrexate	NN	B-NP	O
(	(	O	O
MTX	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
and	CC	O	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CY	NN	B-NP	O
)	)	O	O
administered	VBN	B-VP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
[	(	O	O
MTX	NN	B-NP	O
+	SYM	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
+	SYM	O	O
CY	NN	B-NP	O
(	(	O	O
CMF	NN	B-NP	O
)	)	O	O
]	)	O	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
experiments	NNS	B-NP	O
on	IN	B-PP	O
Wistar	NNP	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
drug	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
creatinine	NN	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
urine	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
.	.	O	O

Histopathologic	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
performed	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
MTX	NN	B-NP	O
administration	NN	I-NP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

After	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
NG	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
and	CC	I-NP	O
CY	NN	I-NP	O
neither	CC	O	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
creatinine	NN	B-NP	O
concentration	NN	I-NP	O
nor	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
receiving	VBG	B-VP	O
no	DT	B-NP	O
cytostatics	NNS	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
polytherapy	NN	B-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
CMF	NN	I-NP	O
regimen	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
,	,	O	O
but	CC	O	O
creatinine	NN	B-NP	O
concentration	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
increase	VB	I-VP	O
significantly	RB	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

CY	NN	B-NP	O
caused	VBD	B-VP	O
hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
this	DT	B-NP	O
complication	NN	I-NP	O
when	WRB	B-ADVP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
and	CC	I-NP	O
MTX	NN	I-NP	O
.	.	O	O

Histologic	JJ	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
rat	NN	B-NP	O
kidneys	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
MTX	NN	B-NP	O
,	,	I-NP	O
CY	NN	I-NP	O
and	CC	I-NP	O
NG	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
no	DT	B-NP	O
such	JJ	I-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
and	CC	O	O
joint	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
MTX	NN	B-NP	O
+	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
+	SYM	B-NP	O
CY	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
studies	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
nephrotoxicity	NN	B-NP	B
of	IN	B-PP	O
MTX	NN	B-NP	O
+	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
+	SYM	I-NP	O
CY	NN	I-NP	O
administered	VBN	B-VP	O
jointly	RB	B-ADVP	O
is	VBZ	B-VP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
monotherapy	NN	B-NP	O
.	.	O	O

Lithium	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
cognitive	JJ	I-NP	B
and	CC	I-NP	I
functional	JJ	I-NP	I
deficits	NNS	I-NP	I
reduced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
switch	NN	I-NP	O
to	TO	B-PP	O
divalproex	NN	B-NP	O
sodium	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
series	NN	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
remains	VBZ	B-VP	O
a	DT	B-NP	O
first	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
and	CC	I-NP	O
maintenance	NN	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
.	.	O	O

Although	IN	B-SBAR	O
much	JJ	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
written	VBN	I-VP	O
about	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
more	RBR	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
polyuria	NN	B-NP	B
and	CC	I-NP	O
tremor	NN	I-NP	B
,	,	O	O
more	RBR	B-NP	O
subtle	JJ	I-NP	O
lithium	NN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
,	,	O	O
loss	NN	B-NP	B
of	IN	B-PP	I
creativity	NN	B-NP	I
,	,	O	O
and	CC	O	O
functional	JJ	B-NP	B
impairments	NNS	I-NP	I
remain	VBP	B-VP	O
understudied	JJ	B-ADJP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
summarizes	VBZ	B-VP	O
our	PRP$	B-NP	O
experience	NN	I-NP	O
in	IN	B-PP	O
switching	VBG	B-VP	O
bipolar	JJ	B-NP	B
patients	NNS	I-NP	O
from	IN	B-PP	O
lithium	NN	B-NP	O
to	TO	B-PP	O
divalproex	NN	B-NP	O
sodium	NN	I-NP	O
to	TO	B-VP	O
alleviate	VB	I-VP	O
such	JJ	B-NP	O
cognitive	JJ	I-NP	B
and	CC	I-NP	I
functional	JJ	I-NP	I
impairments	NNS	I-NP	I
.	.	O	O

Open	NN	B-NP	O
,	,	O	O
case	NN	B-NP	O
series	NN	I-NP	O
design	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
where	WRB	B-ADVP	O
substitution	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
,	,	O	O
either	CC	O	O
fully	RB	B-ADVP	O
or	CC	I-ADVP	O
partially	RB	I-ADVP	O
,	,	O	O
with	IN	B-PP	O
divalproex	NN	B-NP	O
sodium	NN	I-NP	O
was	VBD	B-VP	O
extremely	RB	B-ADJP	O
helpful	JJ	I-ADJP	O
in	IN	B-PP	O
reducing	VBG	B-VP	O
the	DT	B-NP	O
cognitive	JJ	I-NP	B
,	,	I-NP	I
motivational	JJ	I-NP	I
,	,	I-NP	I
or	CC	I-NP	I
creative	JJ	I-NP	I
deficits	NNS	I-NP	I
attributed	VBN	B-VP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
bipolar	JJ	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
preliminary	JJ	I-NP	O
report	NN	I-NP	O
,	,	O	O
divalproex	NN	B-NP	O
sodium	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
superior	JJ	I-NP	O
alternative	NN	I-NP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
in	IN	B-PP	O
bipolar	JJ	B-NP	B
patients	NNS	I-NP	O
experiencing	VBG	B-VP	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
,	,	O	O
loss	NN	B-NP	B
of	IN	B-PP	I
creativity	NN	B-NP	I
,	,	O	O
and	CC	O	O
functional	JJ	B-NP	B
impairments	NNS	I-NP	I
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
previously	RB	B-NP	O
treated	VBN	I-NP	O
metastatic	JJ	I-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
by	IN	B-PP	O
mitoxantrone	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
continuous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
and	CC	I-NP	O
leucovorin	NN	I-NP	O
(	(	O	O
MFL	NN	B-NP	O
)	)	O	O
:	:	O	O
low	JJ	B-NP	O
palliative	JJ	I-NP	O
benefit	NN	I-NP	O
and	CC	O	O
high	JJ	B-NP	O
treatment	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

For	IN	B-PP	O
previously	RB	B-NP	O
treated	VBN	I-NP	O
advanced	JJ	I-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
standard	JJ	I-NP	O
second	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Combination	NN	B-NP	O
chemotherapy	NN	I-NP	O
with	IN	B-PP	O
mitoxantrone	NN	B-NP	O
,	,	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
and	CC	O	O
leucovorin	NN	B-NP	O
(	(	O	O
MFL	NN	B-NP	O
regimen	NN	I-NP	O
)	)	O	O
had	VBD	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
and	CC	I-NP	O
well	RB	I-NP	O
tolerated	VBN	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

From	IN	B-PP	O
October	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
we	PRP	B-NP	O
treated	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
previously	RB	B-NP	O
chemotherapy	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
metastatic	JJ	I-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
by	IN	B-PP	O
mitoxantrone	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
m2	NN	B-NP	O
,	,	O	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
m2	NN	B-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
leucovorin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

Each	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Most	JJS	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
metastatic	JJ	I-NP	O
sites	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
lung	NN	B-NP	O
metastasis	NN	I-NP	O
predominant	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
anthracycline	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
previously	RB	I-VP	O
received	VBN	I-VP	O
radiotherapy	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
hormone	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
courses	NNS	B-NP	O
of	IN	B-PP	O
MFL	NN	B-NP	O
regimen	NN	I-NP	O
given	VBN	B-VP	O
was	VBD	B-VP	O
num	CD	B-NP	O
and	CC	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
mitoxantrone	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
complete	JJ	B-NP	O
response	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
stable	JJ	B-NP	O
disease	NN	I-NP	O
,	,	O	O
none	NN	B-NP	O
had	VBD	B-VP	O
partial	JJ	B-NP	O
response	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
progressive	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
objective	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
period	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
survival	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
progression	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survival	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
complete	JJ	I-NP	O
responder	NN	I-NP	O
had	VBD	B-VP	O
relapse	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survival	NN	I-NP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Major	JJ	B-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
cardiotoxicity	NN	B-NP	B
and	CC	I-NP	O
leukopenia	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
dead	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
follow	VB	I-NP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
;	:	O	O
num	CD	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
died	VBD	B-VP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
MFL	NNP	I-NP	O
regimen	NN	I-NP	O
achieves	VBZ	B-VP	O
little	JJ	B-NP	O
palliative	JJ	I-NP	O
benefit	NN	I-NP	O
and	CC	O	O
induces	VBZ	B-VP	O
severe	JJ	B-NP	O
toxicity	NN	I-NP	B
at	IN	B-PP	O
a	DT	B-NP	O
fairly	RB	I-NP	O
high	JJ	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
regimen	NN	I-NP	O
to	TO	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
chemotherapy	NN	B-NP	O
and	CC	O	O
those	DT	B-NP	O
with	IN	B-PP	O
impaired	JJ	B-NP	B
heart	NN	I-NP	I
function	NN	I-NP	I
requires	VBZ	B-VP	O
careful	JJ	B-NP	O
attention	NN	I-NP	O
.	.	O	O

Upregulation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
vasopressin	NN	B-NP	O
gene	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
paraventricular	JJ	I-NP	O
and	CC	I-NP	O
supraoptic	JJ	I-NP	O
nuclei	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NN	I-NP	B
insipidus	NN	I-NP	I
rat	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
arginine	NN	B-NP	O
vasopressin	NN	I-NP	O
(	(	O	O
AVP	NN	B-NP	O
)	)	O	O
gene	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
paraventricular	JJ	I-NP	O
(	(	O	O
PVN	NN	B-NP	O
)	)	O	O
and	CC	O	O
supraoptic	JJ	B-NP	O
nuclei	NNS	I-NP	O
(	(	O	O
SON	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
(	(	O	O
Li	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polyuria	NN	I-NP	B
,	,	O	O
using	VBG	B-VP	O
in	FW	B-NP	O
situ	FW	I-NP	O
hybridization	NN	I-NP	O
histochemistry	NN	I-NP	O
and	CC	I-NP	O
radioimmunoassay	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
male	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
consuming	VBG	B-VP	O
a	DT	B-NP	O
diet	NN	I-NP	O
that	WDT	B-NP	O
contained	VBD	B-VP	O
LiCl	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
developed	VBD	B-VP	O
marked	JJ	B-NP	O
polyuria	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
Li	NNP	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
large	JJ	I-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
hypotonic	JJ	B-NP	O
urine	NN	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
ionic	JJ	I-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
sodium	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
slightly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
Li	NNP	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Plasma	NN	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
and	CC	I-NP	O
transcripts	NNS	I-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
gene	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PVN	NN	I-NP	O
and	CC	I-NP	O
SON	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
Li	NNP	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
dehydration	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
the	DT	B-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
visceral	JJ	B-NP	O
afferent	JJ	I-NP	O
inputs	NNS	I-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
AVP	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
upregulation	NN	I-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PVN	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
SON	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Li	NNP	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NN	I-NP	B
insipidus	NN	I-NP	I
rat	NN	I-NP	O
.	.	O	O

Suxamethonium	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
arrest	NN	I-NP	I
and	CC	I-NP	O
death	NN	I-NP	B
following	VBG	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
immobilization	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
and	CC	O	O
subsequent	JJ	B-NP	O
death	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
hyperkalaemia	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Malawian	JJ	I-NP	O
woman	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
meningitis	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
aspirated	VBD	B-VP	O
stomach	NN	B-NP	O
contents	NNS	I-NP	O
and	CC	O	O
needed	VBN	B-NP	O
endotracheal	JJ	I-NP	O
intubation	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
seconds	NNS	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
,	,	O	O
bradycardia	NN	B-NP	B
and	CC	O	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
occurred	VBD	B-VP	O
.	.	O	O

Attempts	NNS	B-NP	O
to	TO	B-VP	O
resuscitate	VB	I-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
successful	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
potassium	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
num	CD	B-NP	O
mequiv	NN	I-NP	O
L	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

Apart	RB	B-ADVP	O
from	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
level	NN	B-NP	O
of	IN	B-PP	O
consciousness	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
neurone	NN	I-NP	O
damage	NN	I-NP	O
or	CC	B-PP	O
of	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
known	VBN	I-NP	O
predisposing	VBG	I-NP	O
conditions	NNS	I-NP	O
for	IN	B-PP	O
hyperkalaemia	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
postulated	VBN	I-VP	O
that	IN	B-SBAR	O
her	PRP$	B-NP	O
death	NN	I-NP	B
was	VBD	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
hypersensitivity	NN	B-NP	B
to	TO	B-PP	O
suxamethonium	NN	B-NP	O
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
her	PRP	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
immobilization	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
unusual	JJ	I-NP	O
toxic	JJ	I-NP	O
reaction	NN	I-NP	O
to	TO	B-PP	O
axillary	JJ	B-NP	O
block	NN	I-NP	O
by	IN	B-PP	O
mepivacaine	NN	B-NP	O
with	IN	B-PP	O
adrenaline	NN	B-NP	O
.	.	O	O

An	DT	B-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
blood	NN	B-NP	I
pressure	NN	I-NP	I
,	,	O	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
,	,	O	O
agitation	NN	B-NP	B
,	,	O	O
incomprehensible	JJ	B-NP	B
shouts	NNS	I-NP	I
and	CC	O	O
loss	NN	B-NP	B
of	IN	B-PP	I
consciousness	NN	B-NP	I
,	,	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
elderly	JJ	I-NP	O
,	,	I-NP	O
ASA	NN	I-NP	O
classification	NN	I-NP	O
group	NN	I-NP	O
num	CD	I-NP	O
,	,	O	O
cardiovascularly	RB	B-NP	O
medicated	VBN	I-NP	O
male	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
performance	NN	B-NP	O
of	IN	B-PP	O
axillary	JJ	B-NP	O
block	NN	I-NP	O
with	IN	B-PP	O
mepivacaine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
containing	VBG	B-VP	O
adrenaline	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
correction	NN	B-NP	O
of	IN	B-PP	O
Dupuytren	NNP	B-NP	B
s	JJ	I-NP	I
contracture	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
labetalol	NN	B-NP	O
,	,	I-NP	O
metoprolol	NN	I-NP	O
and	CC	I-NP	O
midazolam	NN	I-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
condition	NN	I-NP	O
improved	VBD	B-VP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
later	RB	B-ADVP	O
he	PRP	B-NP	O
woke	VBD	B-VP	O
up	RP	B-PRT	O
.	.	O	O

The	DT	B-NP	O
block	NN	I-NP	O
was	VBD	B-VP	O
successful	JJ	B-ADJP	O
and	CC	O	O
surgery	NN	B-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
as	IN	B-SBAR	O
scheduled	VBN	B-VP	O
despite	IN	B-PP	O
persisting	VBG	B-VP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
.	.	O	O

Postoperatively	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
refused	VBD	B-VP	O
DC	NN	B-NP	O
cardioversion	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
medically	RB	B-ADVP	O
.	.	O	O

Both	CC	O	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
relationship	NN	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
and	CC	O	O
the	DT	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
systemic	JJ	I-NP	O
absorption	NN	I-NP	O
of	IN	B-PP	O
mepivacaine	NN	B-NP	O
with	IN	B-PP	O
adrenaline	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
interaction	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
cardiovascular	JJ	B-NP	O
medications	NNS	I-NP	O
were	VBD	B-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
perioperative	JJ	I-NP	O
complications	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
and	CC	I-NP	O
histopathologic	JJ	I-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
allografts	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
tacrolimus	NN	B-NP	O
(	(	O	O
FK506	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
clinically	RB	B-ADVP	O
and	CC	I-ADVP	O
pathologically	RB	I-ADVP	O
analyzed	VBN	B-VP	O
renal	JJ	B-NP	O
allografts	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
renal	JJ	I-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
tacrolimus	NN	B-NP	O
(	(	O	O
FK506	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
renal	JJ	I-NP	O
allograft	NN	I-NP	O
biopsy	NN	I-NP	O
specimens	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
renal	JJ	I-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
transplantations	NNS	B-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
biopsies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
from	IN	B-PP	O
stable	JJ	B-NP	O
functioning	VBG	I-NP	O
renal	JJ	I-NP	O
allografts	NNS	I-NP	O
with	IN	B-PP	O
informed	VBN	B-NP	O
consent	NN	I-NP	O
(	(	O	O
nonepisode	JJ	B-NP	O
biopsy	NN	I-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
from	IN	B-PP	O
dysfunctional	JJ	B-NP	O
renal	JJ	I-NP	O
allografts	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
indication	NN	I-NP	O
for	IN	B-PP	O
biopsy	NN	B-NP	O
(	(	O	O
episode	NN	B-NP	O
biopsy	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
pathologic	JJ	I-NP	O
diagnoses	NNS	I-NP	O
(	(	O	O
some	DT	B-NP	O
overlap	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
acute	JJ	B-NP	O
rejection	NN	I-NP	O
,	,	O	O
chronic	JJ	B-NP	O
rejection	NN	I-NP	O
,	,	O	O
AR+CR	NN	B-NP	O
,	,	O	O
recurrent	JJ	B-NP	O
IgA	NN	I-NP	B
nephropathy	NN	I-NP	I
,	,	O	O
normal	JJ	B-NP	O
findings	NNS	I-NP	O
,	,	O	O
minimal	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
chronic	JJ	I-NP	O
FK506	NN	I-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
and	CC	O	O
mild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
FK506	NN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
nonepisode	JJ	I-NP	O
biopsies	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
biopsies	NNS	I-NP	O
showed	VBD	B-VP	O
minimal	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
and	CC	I-NP	O
mild	JJ	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
chronic	JJ	I-NP	O
FK506	NN	I-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Chronic	JJ	B-NP	O
FK506	NN	I-NP	O
nephropathy	NN	I-NP	B
consisted	VBD	B-VP	O
of	IN	B-PP	O
rough	JJ	B-NP	O
and	CC	I-NP	O
foamy	JJ	I-NP	O
tubular	JJ	I-NP	O
vacuolization	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
biopsies	NNS	I-NP	O
)	)	O	O
,	,	O	O
arteriolopathy	NN	B-NP	O
(	(	O	O
angiodegeneration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arteriolar	JJ	I-NP	O
wall	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
biopsies	NNS	I-NP	O
)	)	O	O
,	,	O	O
focal	JJ	B-NP	B
segmental	JJ	I-NP	I
glomerulosclerosis	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
biopsies	NNS	I-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
striped	VBN	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
interstitial	JJ	B-NP	B
fibrosis	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
biopsies	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mild	JJ	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
chronic	JJ	I-NP	O
FK506	NN	I-NP	O
nephropathy	NN	I-NP	B
group	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
episode	NN	I-NP	O
biopsies	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
statistically	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
minimum	JJ	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
chronic	JJ	I-NP	O
FK506	NN	I-NP	O
-	HYPH	I-NP	O
nephropathy	NN	I-NP	B
group	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
chronic	JJ	B-NP	O
FK506	NN	I-NP	O
nephropathy	NN	I-NP	B
consists	VBZ	B-VP	O
primarily	RB	B-ADVP	O
of	IN	B-PP	O
arteriolopathy	NN	B-NP	O
manifesting	VBG	B-VP	O
as	IN	B-SBAR	O
insudative	JJ	B-NP	O
hyalinosis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arteriolar	JJ	I-NP	O
wall	NN	I-NP	O
,	,	O	O
and	CC	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
mild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
chronic	JJ	I-NP	O
FK506	NN	I-NP	O
nephropathy	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
condition	NN	I-NP	O
which	WDT	B-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
deterioration	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
allograft	NN	I-NP	O
function	NN	I-NP	O
.	.	O	O

Memory	NN	B-NP	O
facilitation	NN	I-NP	O
and	CC	I-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
endogenous	JJ	B-NP	O
nerve	NN	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
synthesis	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
acetylcholine	NN	I-NP	O
releaser	NN	I-NP	O
PG	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
PG	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
3alpha	NN	B-NP	O
-	HYPH	O	O
tropyl	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
p	NN	B-NP	O
-	HYPH	B-NP	O
bromophenyl	NN	I-NP	O
)	)	O	O
propionate	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
acetylcholine	NN	I-NP	O
releaser	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
memory	NN	B-NP	O
processes	NNS	I-NP	O
and	CC	O	O
nerve	NN	B-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
(	(	O	O
NGF	NN	B-NP	O
)	)	O	O
synthesis	NN	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
mouse	NN	I-NP	O
passive	JJ	I-NP	O
-	HYPH	I-NP	O
avoidance	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
PG	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
,	,	O	O
administered	VBN	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
training	NN	I-NP	O
session	NN	I-NP	O
,	,	O	O
prevented	VBD	B-VP	O
amnesia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
non	JJ	I-NP	O
selective	JJ	I-NP	O
antimuscarinic	JJ	I-NP	O
drug	NN	I-NP	O
scopolamine	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
M1	NN	I-NP	O
-	HYPH	B-NP	O
selective	JJ	I-NP	O
antagonist	NN	I-NP	O
S	NN	I-NP	O
-	HYPH	O	O
-	SYM	B-NP	O
ET	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
experimental	JJ	I-NP	O
conditions	NNS	I-NP	O
,	,	O	O
PG	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
per	IN	B-PP	O
mouse	NN	B-NP	O
,	,	O	O
i.c.v.	JJ	B-ADJP	O
)	)	O	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
antimuscarine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
,	,	O	O
demonstrating	VBG	B-VP	O
a	DT	B-NP	O
central	JJ	I-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
effective	JJ	I-NP	O
doses	NNS	I-NP	O
,	,	O	O
PG	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
any	DT	B-NP	O
collateral	JJ	I-NP	O
symptoms	NNS	I-NP	O
as	IN	B-SBAR	O
revealed	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
Irwin	NNP	I-NP	O
test	NN	I-NP	O
,	,	O	O
and	CC	O	O
it	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
modify	VB	I-VP	O
spontaneous	JJ	B-NP	O
motility	NN	I-NP	O
and	CC	I-NP	O
inspection	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
revealed	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
hole	NN	I-NP	O
-	HYPH	I-NP	O
board	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

PG	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
NGF	NN	B-NP	O
secreted	VBN	B-VP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
by	IN	B-PP	O
astrocytes	NNS	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
maximal	JJ	I-NP	O
NGF	NN	I-NP	O
contents	NNS	I-NP	O
obtained	VBN	B-VP	O
by	IN	B-PP	O
PG	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	B-ADVP	O
fold	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
value	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
culture	NN	B-NP	O
,	,	O	O
no	DT	B-NP	O
morphological	JJ	I-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
at	IN	B-PP	O
effective	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
PG	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
work	NN	I-NP	O
indicates	VBZ	B-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
PG	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
beneficial	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
cognitive	JJ	B-NP	O
processes	NNS	I-NP	O
and	CC	O	O
stimulate	VBP	B-VP	O
activity	NN	B-NP	O
of	IN	B-PP	O
NGF	NN	B-NP	O
synthesis	NN	I-NP	O
in	IN	B-PP	O
astroglial	JJ	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
PG	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
could	MD	B-VP	O
represent	VB	I-VP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
useful	JJ	I-NP	O
drug	NN	I-NP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
impaired	JJ	B-NP	O
cognitive	JJ	I-NP	O
processes	NNS	I-NP	O
.	.	O	O

Angioedema	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
ACE	NN	B-NP	O
inhibitors	NNS	I-NP	O
:	:	O	O
common	JJ	B-ADJP	O
and	CC	O	O
inadequately	RB	B-ADJP	O
diagnosed	VBN	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
estimated	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
angioedema	NN	B-NP	B
during	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
inhibitor	NN	B-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
potentially	RB	I-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
often	RB	I-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
minor	JJ	B-NP	O
manifestations	NNS	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
warning	NN	I-NP	O
.	.	O	O

Recurarization	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
recovery	NN	I-NP	O
room	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
recurarization	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
recovery	NN	I-NP	O
room	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Accumulation	NN	B-NP	O
of	IN	B-PP	O
atracurium	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
line	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
recurarization	NN	B-NP	O
after	IN	B-PP	O
flushing	VBG	B-VP	O
the	DT	B-NP	O
line	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
recovery	NN	I-NP	O
room	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
respiratory	JJ	I-NP	B
arrest	NN	I-NP	I
with	IN	B-PP	O
severe	JJ	B-NP	O
desaturation	NN	I-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
occurred	VBD	B-VP	O
.	.	O	O

Circumstances	NNS	B-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
event	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
enabling	VBG	B-VP	O
a	DT	B-NP	O
neuromuscular	JJ	I-NP	B
blockade	NN	I-NP	I
to	TO	B-VP	O
occur	VB	I-VP	O
,	,	O	O
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
small	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
relaxant	NN	B-NP	O
,	,	O	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Recurrent	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
newer	JJR	B-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
epidemiological	JJ	I-NP	O
studies	NNS	I-NP	O
that	WDT	B-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
(	(	O	O
VTE	NN	B-NP	B
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
newer	JJR	B-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
(	(	O	O
OC	NN	B-NP	O
)	)	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
distinguish	VB	I-VP	O
between	IN	B-PP	O
patterns	NNS	B-NP	O
of	IN	B-PP	O
OC	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
namely	RB	B-NP	O
first	JJ	I-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
users	NNS	I-NP	O
,	,	O	O
repeaters	NNS	B-NP	O
and	CC	I-NP	O
switchers	NNS	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
Transnational	JJ	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
for	IN	B-PP	O
the	DT	B-NP	O
latter	JJ	I-NP	O
patterns	NNS	I-NP	O
of	IN	B-PP	O
use	NN	B-NP	O
,	,	O	O
while	IN	B-SBAR	O
accounting	VBG	B-VP	O
for	IN	B-PP	O
duration	NN	B-NP	O
of	IN	B-PP	O
use	NN	B-NP	O
.	.	O	O

Over	IN	B-PP	O
the	DT	B-NP	O
period	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
were	VBD	B-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
Germany	NNP	B-NP	O
and	CC	O	O
the	DT	B-NP	O
UK	NNP	I-NP	O
along	IN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

Totals	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
for	IN	B-PP	O
repeat	NN	B-NP	O
use	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
for	IN	B-PP	O
switching	VBG	B-VP	O
patterns	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
adjusted	VBN	I-NP	O
rate	NN	I-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
for	IN	B-PP	O
repeat	NN	B-NP	O
users	NNS	I-NP	O
of	IN	B-PP	O
third	JJ	B-NP	O
generation	NN	I-NP	O
OC	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
relative	JJ	B-ADJP	O
to	TO	B-VP	O
repeat	VB	I-VP	O
users	NNS	B-NP	O
of	IN	B-PP	O
second	JJ	B-NP	O
generation	NN	I-NP	O
pills	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
for	IN	B-PP	O
switchers	NNS	B-NP	O
from	IN	B-PP	O
second	JJ	B-NP	O
to	TO	B-PP	O
third	JJ	B-NP	O
generation	NN	I-NP	O
pills	NNS	I-NP	O
relative	JJ	B-ADVP	O
to	TO	B-PP	O
switchers	NNS	B-NP	O
from	IN	B-PP	O
third	JJ	B-ADJP	O
to	TO	B-PP	O
second	JJ	B-NP	O
generation	NN	I-NP	O
pills	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
second	JJ	B-NP	O
and	CC	I-NP	O
third	JJ	I-NP	O
generation	NN	I-NP	O
agents	NNS	I-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
equivalent	JJ	B-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
when	WRB	B-ADVP	O
the	DT	B-NP	O
same	JJ	I-NP	O
agent	NN	I-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
repeatedly	RB	B-ADVP	O
after	IN	B-PP	O
interruption	NN	B-NP	O
periods	NNS	I-NP	O
or	CC	O	O
when	WRB	B-ADVP	O
users	NNS	B-NP	O
are	VBP	B-VP	O
switched	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
generations	NNS	I-NP	O
of	IN	B-PP	O
pills	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
analyses	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
higher	JJR	I-NP	O
risk	NN	I-NP	O
observed	VBN	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
newer	JJR	I-NP	O
OC	NN	I-NP	O
in	IN	B-PP	O
other	JJ	B-NP	O
studies	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
inadequate	JJ	B-NP	O
comparisons	NNS	I-NP	O
of	IN	B-PP	O
pill	NN	B-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
different	JJ	B-NP	O
patterns	NNS	I-NP	O
of	IN	B-PP	O
pill	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aggressive	JJ	I-NP	B
behavior	NN	I-NP	I
:	:	O	O
comparison	NN	B-NP	O
of	IN	B-PP	O
adult	JJ	B-NP	O
male	JJ	I-NP	O
and	CC	I-NP	O
female	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aggressive	JJ	I-NP	B
behavior	NN	I-NP	I
of	IN	B-PP	O
adult	JJ	B-NP	O
male	JJ	I-NP	O
and	CC	I-NP	O
female	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
obtained	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
breeder	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
sets	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
male	JJ	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
repeated	VBN	B-NP	O
apomorphine	NN	I-NP	O
treatment	NN	I-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
gradual	JJ	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
aggressive	JJ	B-NP	B
behavior	NN	I-NP	I
as	IN	B-SBAR	O
evidenced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
aggressiveness	NN	B-NP	B
and	CC	O	O
shortened	VBD	B-VP	O
latency	NN	B-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
attack	NN	I-NP	O
toward	IN	B-PP	O
the	DT	B-NP	O
opponent	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
only	RB	B-NP	O
a	DT	I-NP	O
weak	JJ	I-NP	O
tendency	NN	I-NP	O
toward	IN	B-PP	O
aggressiveness	NN	B-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
demonstrates	VBZ	B-VP	O
gender	NN	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
apomorphine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
aggressive	JJ	I-NP	B
behavior	NN	I-NP	I
and	CC	O	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
fill	VB	I-VP	O
the	DT	B-NP	O
validation	NN	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
use	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
method	NN	I-NP	O
.	.	O	O

Serotonergic	JJ	B-NP	O
antidepressants	NNS	I-NP	O
and	CC	O	O
urinary	JJ	B-NP	B
incontinence	NN	I-NP	I
.	.	O	O

Many	JJ	B-NP	O
new	JJ	I-NP	O
serotonergic	JJ	I-NP	O
antidepressants	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
introduced	VBN	I-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
past	JJ	I-NP	O
decade	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
urinary	JJ	B-NP	B
incontinence	NN	I-NP	I
is	VBZ	B-VP	O
listed	VBN	I-VP	O
as	IN	B-PP	O
num	CD	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
package	NN	I-NP	O
inserts	VBZ	B-VP	O
there	EX	B-NP	O
is	VBZ	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
report	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
concerns	VBZ	B-VP	O
num	CD	B-NP	O
male	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
incontinence	NN	B-NP	B
while	IN	B-SBAR	O
taking	VBG	B-VP	O
venlafaxine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
paper	NN	I-NP	O
the	DT	B-NP	O
authors	NNS	I-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
female	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
incontinence	NN	B-NP	B
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
paroxetine	NN	I-NP	O
and	CC	I-NP	O
sertraline	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
a	DT	B-NP	O
third	JJ	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
this	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
venlafaxine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
taking	VBG	I-VP	O
lithium	NN	B-NP	O
carbonate	NN	I-NP	O
and	CC	O	O
beta	SYM	O	O
-	HYPH	O	O
blockers	NNS	B-NP	O
,	,	O	O
both	DT	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
contributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
incontinence	NN	I-NP	B
.	.	O	O

Animal	JJ	B-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
incontinence	NN	B-NP	B
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
serotonergic	JJ	B-NP	O
antidepressants	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
5HT4	NN	I-NP	O
receptors	NNS	I-NP	O
found	VBN	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
research	NN	I-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
delineate	VB	I-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
troubling	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
and	CC	O	O
how	WRB	B-ADVP	O
best	JJS	O	O
to	TO	B-VP	O
treat	VB	I-VP	O
it	PRP	B-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
tizanidine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
angiotensin	NN	I-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Centrally	RB	B-ADVP	O
acting	VBG	B-VP	O
alpha	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
adrenergic	JJ	I-NP	O
agonists	NNS	I-NP	O
are	VBP	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
pharmacologic	JJ	I-NP	O
agents	NNS	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
spasticity	NN	B-NP	B
related	VBN	B-VP	O
to	TO	B-PP	O
disorders	NNS	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
central	JJ	I-NP	I
nervous	JJ	I-NP	I
system	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
spasticity	NN	B-NP	B
,	,	O	O
certain	JJ	B-NP	O
adverse	JJ	I-NP	O
cardiorespiratory	JJ	I-NP	O
effects	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Adults	NNS	B-NP	O
chronically	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
angiotensin	NN	B-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitors	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
limited	VBN	I-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
respond	VB	I-VP	O
to	TO	B-PP	O
hypotension	NN	B-NP	B
when	WRB	B-ADVP	O
the	DT	B-NP	O
sympathetic	JJ	I-NP	O
response	NN	I-NP	O
is	VBZ	B-VP	O
simultaneously	RB	I-VP	O
blocked	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
boy	NN	I-NP	O
chronically	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
lisinopril	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
angiotensin	NN	I-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
control	VB	I-VP	O
hypertension	NN	B-NP	B
who	WP	B-NP	O
developed	VBD	B-VP	O
hypotension	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
tizanidine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
spasticity	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
interaction	NN	I-NP	O
of	IN	B-PP	O
tizanidine	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
antihypertensive	JJ	I-NP	O
agents	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
kept	VBN	I-VP	O
in	IN	B-PP	O
mind	NN	B-NP	O
when	WRB	B-ADVP	O
prescribing	VBG	B-VP	O
therapy	NN	B-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
either	CC	O	O
hypertension	NN	B-NP	B
or	CC	I-NP	O
spasticity	NN	I-NP	B
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Peritubular	JJ	B-NP	O
capillary	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
reduplication	NN	I-NP	O
in	IN	B-PP	O
allografts	NNS	B-NP	O
and	CC	O	O
native	JJ	B-NP	O
kidney	NN	I-NP	B
disease	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
clinicopathologic	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
renal	JJ	I-NP	O
specimens	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
association	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
transplant	NN	B-NP	B
glomerulopathy	NN	I-NP	I
(	(	O	O
TG	NN	B-NP	B
)	)	O	O
and	CC	O	O
reduplication	NN	B-NP	O
of	IN	B-PP	O
peritubular	JJ	B-NP	O
capillary	JJ	I-NP	O
basement	NN	I-NP	O
membranes	NNS	I-NP	O
(	(	O	O
PTCR	NN	B-NP	O
)	)	O	O
.	.	O	O

Although	IN	B-SBAR	O
such	JJ	B-NP	O
an	DT	I-NP	O
association	NN	I-NP	O
is	VBZ	B-VP	O
of	IN	B-PP	O
practical	JJ	B-NP	O
and	CC	I-NP	O
theoretical	JJ	I-NP	O
importance	NN	I-NP	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
has	VBZ	B-VP	O
tried	VBN	I-VP	O
to	TO	I-VP	O
confirm	VB	I-VP	O
it	PRP	B-NP	O
.	.	O	O

We	PRP	B-NP	O
examined	VBD	B-VP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
renal	JJ	I-NP	O
specimens	NNS	I-NP	O
(	(	O	O
from	IN	B-PP	O
num	CD	B-NP	O
transplants	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
native	JJ	I-NP	O
kidneys	NNS	I-NP	O
)	)	O	O
for	IN	B-PP	O
ultrastructural	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
PTCR	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
renal	JJ	B-NP	O
allografts	NNS	I-NP	O
with	IN	B-PP	O
TG	NN	B-NP	B
,	,	O	O
we	PRP	B-NP	O
also	RB	B-ADVP	O
examined	VBD	B-VP	O
grafts	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
rejection	NN	I-NP	O
,	,	O	O
recurrent	JJ	B-NP	O
glomerulonephritis	NN	I-NP	B
,	,	O	O
chronic	JJ	B-NP	B
allograft	NN	I-NP	I
nephropathy	NN	I-NP	I
and	CC	O	O
stable	JJ	B-NP	O
grafts	NNS	I-NP	O
(	(	O	O
protocol	NN	B-NP	O
biopsies	NNS	I-NP	O
)	)	O	O
.	.	O	O

Native	JJ	B-NP	O
kidney	NN	I-NP	O
specimens	NNS	I-NP	O
included	VBD	B-VP	O
a	DT	B-NP	O
wide	JJ	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
glomerulopathies	NNS	B-NP	B
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
,	,	O	O
malignant	JJ	B-NP	B
hypertension	NN	I-NP	I
,	,	O	O
acute	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
,	,	O	O
and	CC	O	O
acute	JJ	B-NP	B
tubular	JJ	I-NP	I
necrosis	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
PTCR	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
TG	NN	B-NP	B
,	,	O	O
in	IN	B-PP	O
num	CD	B-NP	O
transplant	NN	I-NP	O
biopsy	NN	I-NP	O
specimens	NNS	I-NP	O
without	IN	B-PP	O
TG	NN	B-NP	B
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
native	JJ	I-NP	O
kidney	NN	I-NP	O
biopsy	NN	I-NP	O
specimens	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
num	CD	I-NP	O
included	VBN	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
malignant	JJ	B-NP	B
hypertension	NN	I-NP	I
,	,	O	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
,	,	O	O
lupus	NN	B-NP	B
nephritis	NN	I-NP	I
,	,	O	O
Henoch	NNP	B-NP	B
-	HYPH	I-NP	I
Schonlein	NNP	I-NP	I
nephritis	NN	I-NP	I
,	,	O	O
crescentic	JJ	B-NP	O
glomerulonephritis	NN	I-NP	B
,	,	O	O
and	CC	O	O
cocaine	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Mild	JJ	B-NP	O
PTCR	NN	I-NP	O
in	IN	B-PP	O
allografts	NNS	B-NP	O
without	IN	B-PP	O
TG	NN	B-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
predict	VB	I-VP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
or	CC	O	O
significant	JJ	B-NP	O
proteinuria	NN	I-NP	B
after	IN	B-SBAR	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
periods	NNS	B-NP	O
of	IN	B-PP	O
between	IN	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
year	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
transplants	NNS	B-NP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
well	RB	B-NP	O
-	HYPH	I-NP	O
developed	VBN	I-NP	O
PTCR	NN	I-NP	O
and	CC	I-NP	O
TG	NN	I-NP	B
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
significance	NN	I-NP	O
of	IN	B-PP	O
mild	JJ	B-NP	O
PTCR	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
predictive	JJ	I-NP	O
value	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
TG	NN	B-NP	B
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

PTCR	NN	B-NP	O
also	RB	B-ADVP	O
occurs	VBZ	B-VP	O
in	IN	B-PP	O
certain	JJ	B-NP	O
native	JJ	I-NP	O
kidney	NN	I-NP	B
diseases	NNS	I-NP	I
,	,	O	O
though	IN	B-SBAR	O
the	DT	B-NP	O
association	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
as	RB	B-ADJP	O
strong	JJ	I-ADJP	O
as	IN	B-PP	O
that	DT	B-NP	O
for	IN	B-PP	O
TG	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
repeated	VBN	B-NP	O
endothelial	JJ	I-NP	B
injury	NN	I-NP	I
,	,	O	O
including	VBG	B-PP	O
immunologic	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
lesion	NN	I-NP	O
both	CC	B-PP	O
in	IN	B-PP	O
allografts	NNS	B-NP	O
and	CC	O	O
native	JJ	B-NP	O
kidneys	NNS	I-NP	O
.	.	O	O

Conformationally	RB	B-NP	O
restricted	VBN	I-NP	O
analogs	NNS	I-NP	O
of	IN	B-PP	O
BD1008	NN	B-NP	O
and	CC	O	O
an	DT	B-NP	O
antisense	JJ	I-NP	O
oligodeoxynucleotide	NN	I-NP	O
targeting	VBG	B-VP	O
sigma1	NN	B-NP	O
receptors	NNS	I-NP	O
produce	VBP	B-VP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
cocaine	NN	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
s	VBZ	B-VP	O
ability	NN	B-NP	O
to	TO	B-VP	O
interact	VB	I-VP	O
with	IN	B-PP	O
sigma	SYM	B-NP	O
receptors	NNS	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
proteins	NNS	I-NP	O
mediate	VBP	B-VP	O
some	DT	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
novel	JJ	I-NP	O
sigma	NN	I-NP	O
receptor	NN	I-NP	O
ligands	NNS	I-NP	O
with	IN	B-PP	O
antagonist	NN	B-NP	O
activity	NN	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
Swiss	NNP	B-NP	O
Webster	NNP	I-NP	O
mice	NNS	I-NP	O
:	:	O	O
BD1018	NN	B-NP	O
(	(	O	O
3S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
[	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
(	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dichlorophenyl	NN	I-NP	O
)	)	O	O
ethyl	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
diazabicyclo	NN	I-NP	O
[	(	O	O
num	CD	O	O
]	)	O	O
nonane	NN	B-NP	O
)	)	O	O
,	,	O	O
BD1063	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	O	O
[	(	O	O
num	CD	O	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dichlorophenyl	NN	I-NP	O
)	)	O	O
ethyl	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methylpiperazine	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
LR132	NN	B-NP	O
(	(	O	O
1R	NN	B-NP	O
,	,	O	O
2S	NN	B-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
cis	NN	I-NP	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
[	(	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dichlorophenyl	NN	I-NP	O
)	)	O	O
ethyl	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
pyrrolidinyl	NN	I-NP	O
)	)	O	O
cyclohexylamine	NN	B-NP	O
)	)	O	O
.	.	O	O

Competition	NN	B-NP	O
binding	NN	I-NP	O
assays	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
all	DT	B-NP	O
num	CD	I-NP	O
compounds	NNS	I-NP	O
have	VBP	B-VP	O
high	JJ	B-NP	O
affinities	NNS	I-NP	O
for	IN	B-PP	O
sigma1	NN	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
compounds	NNS	I-NP	O
vary	VBP	B-VP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
affinities	NNS	I-NP	O
for	IN	B-PP	O
sigma2	NN	B-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
exhibit	VBP	B-VP	O
negligible	JJ	B-NP	O
affinities	NNS	I-NP	O
for	IN	B-PP	O
dopamine	NN	B-NP	O
,	,	O	O
opioid	NN	B-NP	O
,	,	O	O
GABA	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
and	CC	O	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
behavioral	JJ	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
BD1018	NN	B-NP	O
,	,	O	O
BD1063	NN	B-NP	O
,	,	O	O
or	CC	O	O
LR132	NN	B-NP	O
significantly	RB	B-ADVP	O
attenuated	VBD	B-VP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
and	CC	I-NP	O
lethality	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
LR132	NN	B-NP	O
prevented	VBD	B-VP	O
cocaine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
lethality	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
protection	NN	I-NP	O
provided	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
putative	JJ	I-NP	O
antagonists	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
characterized	VBN	I-NP	O
sigma	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
di	AFX	O	O
-	HYPH	O	O
o	AFX	O	O
-	HYPH	O	O
tolylguanidine	NN	B-NP	O
(	(	O	O
DTG	NN	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
novel	JJ	I-NP	O
sigma	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
BD1031	NN	I-NP	O
(	(	O	O
3R	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
[	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
(	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dichlorophenyl	NN	I-NP	O
)	)	O	O
ethyl	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
diazabicyclo	NN	I-NP	O
[	(	O	O
num	CD	O	O
]	)	O	O
nonane	NN	B-NP	O
)	)	O	O
each	DT	B-NP	O
worsened	VBD	B-VP	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

At	IN	B-PP	O
doses	NNS	B-NP	O
where	WRB	B-ADVP	O
alone	RB	I-ADVP	O
,	,	O	O
they	PRP	B-NP	O
produced	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
locomotion	NN	B-NP	O
,	,	O	O
BD1018	NN	B-NP	O
,	,	O	O
BD1063	NN	B-NP	O
and	CC	O	O
LR132	NN	B-NP	O
significantly	RB	B-ADVP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
locomotor	JJ	I-NP	O
stimulatory	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
further	RB	I-VP	O
validate	VB	I-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
cocaine	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
novel	JJ	I-NP	O
ligands	NNS	I-NP	O
involved	VBD	B-VP	O
antagonism	NN	B-NP	O
of	IN	B-PP	O
sigma	NN	B-NP	O
receptors	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
antisense	JJ	I-NP	O
oligodeoxynucleotide	NN	I-NP	O
against	IN	B-PP	O
sigma1	NN	B-NP	O
receptors	NNS	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
significantly	RB	I-VP	O
attenuate	VB	I-VP	O
the	DT	B-NP	O
convulsive	JJ	I-NP	B
and	CC	I-NP	O
locomotor	JJ	I-NP	O
stimulatory	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Together	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
data	NNS	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
functional	JJ	B-NP	O
antagonism	NN	I-NP	O
of	IN	B-PP	O
sigma	NN	B-NP	O
receptors	NNS	I-NP	O
is	VBZ	B-VP	O
capable	JJ	B-ADJP	O
of	IN	B-PP	O
attenuating	VBG	B-VP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
behaviors	NNS	I-NP	O
.	.	O	O

Pharmacokinetic	JJ	B-NP	O
/	SYM	I-NP	O
pharmacodynamic	JJ	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
E4031	NN	B-NP	O
,	,	O	O
cisapride	NN	B-NP	O
,	,	O	O
terfenadine	NN	B-NP	O
and	CC	I-NP	O
terodiline	NN	I-NP	O
on	IN	B-PP	O
monophasic	JJ	B-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
duration	NN	I-NP	O
in	IN	B-PP	O
dog.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Torsades	NNS	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
(	(	O	O
TDP	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
fatal	JJ	I-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
and	CC	O	O
monophasic	JJ	B-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
duration	NN	I-NP	O
(	(	O	O
MAPD	NN	B-NP	O
)	)	O	O
.	.	O	O

TDP	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
side	NN	I-NP	O
-	HYPH	I-NP	O
effect	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
led	VBN	I-VP	O
to	TO	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
drugs	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
market	NN	I-NP	O
(	(	O	O
e.g.	FW	B-NP	O
terfenadine	NN	I-NP	O
and	CC	O	O
terodiline	NN	B-NP	O
)	)	O	O
.	.	O	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
compounds	NNS	B-NP	O
to	TO	B-VP	O
cause	VB	I-VP	O
TDP	NN	B-NP	B
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
monitoring	VBG	B-VP	O
their	PRP$	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
MAPD	NN	B-NP	O
in	IN	B-PP	O
dog	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
compounds	NNS	I-NP	O
known	VBN	B-VP	O
to	TO	B-VP	O
increase	VB	I-VP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
and	CC	O	O
cause	NN	B-NP	O
TDP	NN	I-NP	B
were	VBD	B-VP	O
investigated	VBN	I-VP	O
:	:	O	O
terfenadine	NN	B-NP	O
,	,	I-NP	O
terodiline	NN	I-NP	O
,	,	I-NP	O
cisapride	NN	I-NP	O
and	CC	I-NP	O
E4031	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
that	IN	B-SBAR	O
only	RB	B-NP	O
free	JJ	I-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
systemic	JJ	I-NP	O
circulation	NN	I-NP	O
will	MD	B-VP	O
elicit	VB	I-VP	O
a	DT	B-NP	O
pharmacological	JJ	I-NP	O
response	NN	I-NP	O
target	NN	I-NP	O
,	,	O	O
free	JJ	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
were	VBD	B-VP	O
selected	VBN	I-VP	O
to	TO	I-VP	O
mimic	VB	I-VP	O
the	DT	B-NP	O
free	JJ	I-NP	O
drug	NN	I-NP	O
exposures	NNS	I-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

Infusion	NN	B-NP	O
regimens	NNS	I-NP	O
were	VBD	B-VP	O
designed	VBN	I-VP	O
that	WDT	B-NP	O
rapidly	RB	B-ADVP	O
achieved	VBD	B-VP	O
and	CC	O	O
maintained	VBD	B-VP	O
target	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	I-NP	O
data	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
free	JJ	B-NP	O
concentration	NN	I-NP	O
and	CC	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
MAPD	NN	B-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
for	IN	B-PP	O
these	DT	B-NP	O
compounds.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
free	JJ	I-NP	O
ED50	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
for	IN	B-PP	O
terfenadine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
nM	NN	I-NP	O
)	)	O	O
,	,	O	O
terodiline	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
nM	NN	I-NP	O
)	)	O	O
,	,	O	O
cisapride	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
nM	NN	I-NP	O
)	)	O	O
and	CC	O	O
E4031	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
nM	NN	I-NP	O
)	)	O	O
closely	RB	B-ADVP	O
correlate	VBP	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
free	JJ	I-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
causing	VBG	B-VP	O
QT	NN	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

For	IN	B-PP	O
compounds	NNS	B-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
TDP	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
clinic	NN	I-NP	O
(	(	O	O
terfenadine	NN	B-NP	O
,	,	O	O
terodiline	NN	B-NP	O
,	,	O	O
cisapride	NN	B-NP	O
)	)	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
little	JJ	B-NP	O
differentiation	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
dog	NN	I-NP	O
ED50	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
efficacious	JJ	I-NP	O
free	JJ	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
reflecting	VBG	B-VP	O
their	PRP$	B-NP	O
limited	VBN	I-NP	O
safety	NN	I-NP	O
margins	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
underline	VBP	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
maximize	VB	I-VP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
ratio	NN	I-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
TDP	NN	B-NP	B
in	IN	B-PP	O
potential	JJ	B-NP	O
development	NN	I-NP	O
candidates	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
using	VBG	B-VP	O
free	JJ	B-NP	O
drug	NN	I-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
pharmacokinetic	JJ	B-NP	O
/	SYM	I-NP	O
pharmacodynamic	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
myeloencephalopathy	NN	I-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
accidental	JJ	B-NP	O
intrathecal	JJ	I-NP	O
vincristin	NN	I-NP	O
administration	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
fatal	JJ	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
accidental	JJ	B-NP	O
intrathecal	JJ	I-NP	O
vincristine	NN	I-NP	O
instillation	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
girl	NN	I-NP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
acute	JJ	I-NP	B
lymphoblastic	JJ	I-NP	I
leucemia	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
lymphoblastic	JJ	B-NP	B
lymphoma	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
girl	NN	I-NP	O
died	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
man	NN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
intrathecal	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
.	.	O	O

Clinically	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
onset	NN	I-NP	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
opistothonus	NN	B-NP	B
,	,	O	I
sensory	NN	B-NP	I
and	CC	O	I
motor	NN	B-NP	I
dysfunction	NN	I-NP	I
and	CC	O	O
ascending	VBG	B-VP	O
paralysis	NN	B-NP	B
.	.	O	O

Histological	JJ	B-NP	O
and	CC	I-NP	O
immunohistochemical	JJ	I-NP	O
investigations	NNS	I-NP	O
(	(	O	O
HE	NN	B-NP	O
-	HYPH	O	O
LFB	NN	B-NP	O
,	,	O	O
CD	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
Neurofilament	NN	I-NP	O
)	)	O	O
revealed	VBD	B-VP	O
degeneration	NN	B-NP	B
of	IN	B-PP	I
myelin	NN	B-NP	I
and	CC	I-NP	I
axons	NNS	I-NP	I
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
pseudocystic	JJ	B-NP	B
transformation	NN	I-NP	I
in	IN	B-PP	O
areas	NNS	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
vincristine	NN	B-NP	O
,	,	O	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
secondary	JJ	B-NP	O
changes	NNS	I-NP	O
with	IN	B-PP	O
numerous	JJ	B-NP	O
prominent	JJ	I-NP	O
macrophages	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
course	NN	I-NP	O
and	CC	O	O
histopathological	JJ	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
is	VBZ	B-VP	O
given	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
better	JJR	I-NP	O
controlled	VBN	I-NP	O
regimen	NN	I-NP	O
for	IN	B-PP	O
administering	VBG	B-VP	O
vincristine	NN	B-NP	O
and	CC	O	O
intrathecal	JJ	B-NP	O
chemotherapy	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
.	.	O	O

Intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
prochlorperazine	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
infusion	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
bolus	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
akathisia	NN	B-NP	B
:	:	O	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
controlled	VBN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
akathisia	NN	B-NP	B
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
prochlorperazine	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
bolus	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
central	JJ	I-NP	O
-	HYPH	I-NP	O
city	NN	I-NP	O
teaching	NN	I-NP	O
hospital	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
aged	VBN	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
or	CC	O	O
older	JJR	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
prochlorperazine	NN	B-NP	O
for	IN	B-PP	O
headache	NN	B-NP	B
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
or	CC	O	O
vomiting	NN	B-NP	B
were	VBD	B-VP	O
eligible	JJ	B-ADJP	O
for	IN	B-PP	O
inclusion	NN	B-NP	O
.	.	O	O

Study	NN	B-NP	O
participants	NNS	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
prochlorperazine	NN	B-NP	O
administered	VBN	B-VP	O
intravenously	RB	B-ADVP	O
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
push	NN	I-NP	O
(	(	O	O
bolus	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
diluted	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
mL	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
solution	NN	I-NP	O
administered	VBN	B-VP	O
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
period	NN	I-NP	O
(	(	O	O
infusion	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
outcome	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
study	NN	B-NP	O
participants	NNS	I-NP	O
experiencing	VBG	B-VP	O
akathisia	NN	B-NP	B
within	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
.	.	O	O

Akathisia	NN	B-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
either	CC	O	O
a	DT	B-NP	O
spontaneous	JJ	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
restlessness	NN	B-NP	O
or	CC	I-NP	O
agitation	NN	I-NP	B
or	CC	O	O
a	DT	B-NP	O
change	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
-	HYPH	B-VP	O
reported	VBN	B-NP	O
akathisia	NN	I-NP	B
rating	NN	I-NP	O
scale	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
change	NN	I-NP	O
of	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
investigator	NN	I-NP	O
-	HYPH	B-VP	O
observed	VBN	B-NP	O
akathisia	NN	I-NP	B
rating	NN	I-NP	O
scale	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
headache	NN	B-NP	B
and	CC	I-NP	O
nausea	NN	I-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mm	NN	I-NP	O
visual	JJ	I-NP	O
analog	NN	I-NP	O
scale	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
study	NN	I-NP	O
participant	NN	I-NP	O
was	VBD	B-VP	O
excluded	VBN	I-VP	O
after	IN	B-PP	O
protocol	NN	B-NP	O
violation	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
participants	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
headache	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
nausea	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
bolus	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
akathisia	NN	B-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
bolus	NN	I-NP	O
and	CC	I-NP	O
infusion	NN	I-NP	O
groups	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
participants	NNS	B-NP	O
who	WP	B-NP	O
saw	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
headache	NN	I-NP	B
intensity	NN	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
nausea	NN	I-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
akathisia	NN	B-NP	B
when	WRB	B-ADVP	O
prochlorperazine	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
minute	JJ	I-NP	O
intravenous	JJ	I-NP	O
infusion	NN	I-NP	O
versus	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	JJ	I-NP	O
intravenous	JJ	I-NP	O
push	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
detected	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
prochlorperazine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
headache	NN	B-NP	B
and	CC	I-NP	O
nausea	NN	I-NP	B
likewise	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
no	DT	B-NP	O
formal	JJ	I-NP	O
statistical	JJ	I-NP	O
comparisons	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
.	.	O	O

Antithymocyte	NN	B-NP	O
globulin	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
antithymocyte	JJ	B-NP	O
globulin	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
D	NN	B-NP	O
-	HYPH	I-NP	O
penicillamine	NN	I-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

Bone	NN	B-NP	O
marrow	NN	I-NP	O
recovery	NN	I-NP	O
and	CC	O	O
peripheral	JJ	B-NP	O
blood	NN	I-NP	O
recovery	NN	I-NP	O
were	VBD	B-VP	O
complete	JJ	B-NP	O
num	CD	I-NP	O
month	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
after	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
and	CC	O	O
blood	NN	B-NP	O
transfusion	NN	I-NP	O
or	CC	O	O
other	JJ	B-NP	O
therapies	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
necessary	JJ	B-ADJP	O
in	IN	B-PP	O
a	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	I-NP	O
up	RP	B-PRT	O
period	NN	B-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
antithymocyte	JJ	B-NP	O
globulin	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
hippocampal	JJ	B-NP	O
acetylcholine	NN	I-NP	O
release	NN	I-NP	O
and	CC	O	O
cholinergic	JJ	B-NP	O
convulsant	JJ	I-NP	O
sensitivity	NN	I-NP	O
in	IN	B-PP	O
withdrawal	NN	B-NP	O
seizure	NN	I-NP	B
-	HYPH	B-NP	O
prone	NN	I-NP	O
and	CC	I-NP	O
withdrawal	NN	I-NP	O
seizure	NN	I-NP	B
-	HYPH	B-ADJP	O
resistant	JJ	B-NP	O
selected	VBN	I-NP	O
mouse	NN	I-NP	O
lines	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
septo	AFX	I-NP	O
-	HYPH	I-NP	O
hippocampal	JJ	I-NP	O
cholinergic	JJ	I-NP	O
pathway	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
epileptogenesis	NN	B-NP	O
,	,	O	O
and	CC	O	O
genetic	JJ	B-NP	O
factors	NNS	I-NP	O
influence	VBP	B-VP	O
the	DT	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
cholinergic	JJ	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
but	CC	O	O
limited	JJ	B-NP	O
data	NNS	I-NP	O
are	VBP	B-VP	O
available	JJ	B-ADJP	O
on	IN	B-PP	O
cholinergic	JJ	B-NP	O
involvement	NN	I-NP	O
in	IN	B-PP	O
alcohol	NN	B-NP	O
withdrawal	NN	I-NP	O
severity	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
cholinergic	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
responsiveness	NN	B-NP	O
and	CC	I-NP	O
alcohol	NN	I-NP	O
withdrawal	NN	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
genetic	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
ethanol	NN	B-NP	O
withdrawal	NN	I-NP	O
severity	NN	I-NP	O
.	.	O	O

Cholinergic	JJ	B-NP	O
convulsant	NN	I-NP	O
sensitivity	NN	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
alcohol	NN	B-NP	O
-	HYPH	B-NP	O
na	NN	I-NP	O
ve	NN	I-NP	O
Withdrawal	NN	I-NP	O
Seizure	NN	I-NP	B
-	HYPH	O	O
Prone	NN	B-NP	O
(	(	O	O
WSP	NN	B-NP	O
)	)	O	O
and	CC	O	O
-	HYPH	O	O
Resistant	JJ	O	O
(	(	O	O
WSR	JJ	B-ADJP	O
)	)	O	O
mice	NNS	B-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
nicotine	NN	B-NP	O
,	,	O	O
carbachol	NN	B-NP	O
,	,	O	O
or	CC	O	O
neostigmine	NN	B-NP	O
via	IN	B-PP	O
timed	VBN	B-NP	O
tail	NN	I-NP	O
vein	NN	I-NP	O
infusion	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
latencies	NNS	I-NP	O
to	TO	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
tremor	NN	B-NP	B
and	CC	I-NP	O
clonus	NN	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
and	CC	O	O
converted	VBN	B-VP	O
to	TO	B-VP	O
threshold	VB	I-VP	O
dose	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
used	VBD	B-VP	O
microdialysis	NN	B-NP	O
to	TO	B-VP	O
measure	VB	I-VP	O
basal	JJ	B-NP	O
and	CC	I-NP	O
potassium	NN	I-NP	O
-	HYPH	O	O
stimulated	VBN	B-VP	O
acetylcholine	NN	B-NP	O
(	(	O	O
ACh	NN	B-NP	O
)	)	O	O
release	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
CA1	NN	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
.	.	O	O

Potassium	NN	B-NP	O
was	VBD	B-VP	O
applied	VBN	I-VP	O
by	IN	B-PP	O
reverse	JJ	B-NP	O
dialysis	NN	I-NP	O
twice	RB	B-ADVP	O
,	,	O	O
separated	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

Hippocampal	JJ	B-NP	O
ACh	NN	I-NP	O
also	RB	B-ADVP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
during	IN	B-PP	O
testing	NN	B-NP	O
for	IN	B-PP	O
handling	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

Sensitivity	NN	B-NP	O
to	TO	B-PP	O
several	JJ	B-NP	O
convulsion	NN	I-NP	B
endpoints	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
nicotine	NN	B-NP	O
,	,	O	O
carbachol	NN	B-NP	O
,	,	O	O
and	CC	O	O
neostigmine	NN	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
in	IN	B-PP	O
WSR	NN	B-NP	O
versus	IN	B-PP	O
WSP	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
microdialysis	NN	B-NP	O
experiments	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
lines	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
in	IN	B-PP	O
basal	JJ	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
ACh	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mM	NN	I-NP	O
KCl	NN	I-NP	O
increased	VBD	B-VP	O
ACh	NN	B-NP	O
output	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
lines	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
release	NN	B-NP	O
of	IN	B-PP	O
ACh	NN	B-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
KCl	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
fold	RB	I-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
WSP	NN	B-NP	O
versus	IN	B-PP	O
WSR	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
hippocampal	JJ	B-NP	O
ACh	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
during	IN	B-PP	O
testing	NN	B-NP	O
for	IN	B-PP	O
handling	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
,	,	O	O
extracellular	JJ	B-NP	O
ACh	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
WSP	NN	B-NP	O
mice	NNS	I-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
nonsignificantly	RB	B-ADJP	O
elevated	JJ	I-ADJP	O
in	IN	B-PP	O
WSR	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
differences	NNS	B-NP	O
in	IN	B-PP	O
cholinergic	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
postsynaptic	JJ	B-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
cholinergic	JJ	B-NP	O
convulsants	NNS	I-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
ethanol	NN	B-NP	O
withdrawal	NN	I-NP	O
severity	NN	I-NP	O
and	CC	O	O
implicate	VBP	B-VP	O
cholinergic	JJ	B-NP	O
mechanisms	NNS	I-NP	O
in	IN	B-PP	O
alcohol	NN	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

Specifically	RB	B-ADVP	O
,	,	O	O
WSP	NN	B-NP	O
mice	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
lower	JJR	B-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
cholinergic	JJ	B-NP	O
convulsants	NNS	I-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
WSR	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
postsynaptic	JJ	B-NP	O
receptor	NN	I-NP	O
desensitization	NN	I-NP	O
brought	VBD	B-VP	O
on	RP	B-PRT	O
by	IN	B-PP	O
higher	JJR	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
cholinergic	JJ	B-NP	O
neurons	NNS	I-NP	O
.	.	O	O

Prenatal	JJ	B-NP	O
dexamethasone	NN	I-NP	O
programs	NNS	I-NP	O
hypertension	NN	I-NP	B
and	CC	O	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
is	VBZ	B-VP	O
frequently	RB	I-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
developing	VBG	I-NP	O
fetus	NN	I-NP	O
to	TO	B-VP	O
accelerate	VB	I-VP	O
pulmonary	JJ	B-NP	O
development	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
prenatal	JJ	B-NP	O
dexamethasone	NN	I-NP	O
programmed	VBD	B-VP	O
a	DT	B-NP	O
progressive	JJ	I-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
blood	NN	B-NP	I
pressure	NN	I-NP	I
and	CC	O	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
either	CC	O	O
vehicle	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
daily	JJ	I-NP	O
intraperitoneal	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
on	IN	B-PP	O
gestational	JJ	B-NP	O
days	NNS	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Offspring	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
administered	VBN	B-NP	O
dexamethasone	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
gestation	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	B
in	IN	B-PP	I
glomerular	JJ	B-NP	I
number	NN	I-NP	I
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
percent	NN	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
glomeruli	NNS	B-NP	O
measured	VBN	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
old	JJ	I-NP	O
rats	NNS	I-NP	O
receiving	VBG	B-VP	O
prenatal	JJ	B-NP	O
dexamethasone	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
glomeruli	NNS	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
rats	NNS	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
prenatal	JJ	B-NP	O
dexamethasone	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
had	VBD	B-VP	O
elevated	VBN	I-VP	B
blood	NN	B-NP	I
pressures	NNS	I-NP	I
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
;	:	O	O
the	DT	B-NP	O
latter	JJ	I-NP	O
group	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	B
in	IN	B-PP	I
glomerular	JJ	B-NP	I
number	NN	I-NP	I
.	.	O	O

Adult	JJ	B-NP	O
rats	NNS	I-NP	O
given	VBN	B-NP	O
dexamethasone	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
had	VBD	B-VP	O
more	RBR	B-ADJP	O
glomeruli	JJ	I-ADJP	O
with	IN	B-PP	O
glomerulosclerosis	NN	B-NP	B
than	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
prenatal	JJ	B-NP	O
dexamethasone	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	B
in	IN	B-PP	I
glomerular	JJ	B-NP	I
number	NN	I-NP	I
,	,	O	O
glomerulosclerosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
hypertension	NN	B-NP	B
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
at	IN	B-PP	O
specific	JJ	B-NP	O
points	NNS	I-NP	O
during	IN	B-PP	O
gestation	NN	B-NP	O
.	.	O	O

Hypertension	NN	B-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
glomeruli	NNS	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	B
in	IN	B-PP	I
glomerular	JJ	B-NP	I
number	NN	I-NP	I
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
reduction	NN	I-NP	B
in	IN	B-PP	I
glomerular	JJ	B-NP	I
number	NN	I-NP	I
is	VBZ	B-VP	O
not	RB	O	O
the	DT	B-NP	O
sole	JJ	I-NP	O
cause	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
in	IN	B-PP	O
women	NNS	B-NP	O
prescribed	VBD	B-VP	O
cyproterone	NN	B-NP	O
acetate	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
nested	JJ	I-NP	O
cohort	JJ	I-NP	O
analysis	NN	I-NP	O
and	CC	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Cyproterone	NN	B-NP	O
acetate	NN	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
(	(	O	O
CPA	NN	B-NP	O
/	SYM	B-NP	O
EE	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
licensed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
UK	NNP	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
acne	NN	B-NP	B
and	CC	I-NP	O
hirsutism	NN	I-NP	B
and	CC	O	O
is	VBZ	B-VP	O
also	RB	B-ADVP	O
a	DT	B-NP	O
treatment	NN	I-NP	O
option	NN	I-NP	O
for	IN	B-PP	O
polycystic	JJ	B-NP	B
ovary	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
PCOS	NN	B-NP	B
)	)	O	O
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
(	(	O	O
VTE	NN	B-NP	B
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
CPA	NN	B-NP	O
/	SYM	B-NP	O
EE	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
conventional	JJ	B-NP	O
combined	JJ	I-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
(	(	O	O
COCs	NNS	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
believe	VBP	B-VP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
studies	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
residual	JJ	B-NP	O
confounding	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
the	DT	B-NP	O
General	NNP	I-NP	O
Practice	NNP	I-NP	O
Research	NNP	I-NP	O
Database	NNP	I-NP	O
we	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
cohort	JJ	I-NP	O
analysis	NN	I-NP	O
and	CC	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
nested	VBD	B-VP	O
within	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
aged	JJ	B-ADJP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
with	IN	B-PP	O
acne	NN	B-NP	B
,	,	O	O
hirsutism	NN	B-NP	B
or	CC	O	O
PCOS	NN	B-NP	B
to	TO	B-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
CPA	NN	B-NP	O
/	SYM	I-NP	O
EE	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
age	NN	I-NP	O
-	HYPH	B-VP	O
adjusted	VBN	B-NP	O
incidence	NN	I-NP	O
rate	NN	I-NP	O
ratio	NN	I-NP	O
for	IN	B-PP	O
CPA	NN	B-NP	O
/	SYM	B-NP	O
EE	NN	I-NP	O
versus	IN	B-PP	O
conventional	JJ	B-NP	O
COCs	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
[	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
(	(	O	O
CI	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
]	)	O	O
.	.	O	O

Using	VBG	B-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
reference	NN	I-NP	O
group	NN	I-NP	O
women	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
using	VBG	I-VP	O
oral	JJ	B-NP	O
contraception	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
recent	JJ	I-NP	O
pregnancy	NN	I-NP	O
or	CC	I-NP	O
menopausal	JJ	I-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
analysis	NN	I-NP	O
gave	VBD	B-VP	O
an	DT	B-NP	O
adjusted	VBN	I-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
(	(	O	O
OR	NN	B-NP	O
(	(	O	O
adj	NN	B-NP	O
)	)	O	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
for	IN	B-PP	O
CPA	NN	B-NP	O
/	SYM	I-NP	O
EE	NN	I-NP	O
use	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
an	DT	B-NP	O
OR	NN	I-NP	O
(	(	O	O
adj	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
for	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
conventional	JJ	B-NP	O
COCs	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
CPA	NN	B-NP	O
/	SYM	B-NP	O
EE	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
acne	NN	B-NP	B
,	,	I-NP	O
hirsutism	NN	I-NP	B
or	CC	I-NP	O
PCOS	NN	I-NP	B
although	IN	B-SBAR	O
residual	JJ	B-NP	O
confounding	NN	I-NP	O
by	IN	B-PP	O
indication	NN	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
excluded	VBN	I-VP	O
.	.	O	O

Pseudoacromegaly	RB	B-ADVP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
minoxidil	NN	B-NP	O
.	.	O	O

Acromegaly	RB	B-ADVP	B
is	VBZ	B-VP	O
an	DT	B-NP	O
endocrine	JJ	I-NP	B
disorder	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
excessive	JJ	I-NP	O
growth	NN	I-NP	O
hormone	NN	I-NP	O
secretion	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
pituitary	JJ	I-NP	O
gland	NN	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
disfiguring	NN	I-NP	O
changes	NNS	I-NP	O
occur	VBP	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
bone	NN	B-NP	O
,	,	O	O
cartilage	NN	B-NP	O
,	,	O	O
and	CC	O	O
soft	JJ	B-NP	O
tissue	NN	I-NP	O
hypertrophy	NN	I-NP	B
,	,	O	O
including	VBG	B-PP	O
the	DT	B-NP	O
thickening	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
skin	NN	I-NP	O
,	,	O	O
coarsening	NN	B-NP	O
of	IN	B-PP	O
facial	JJ	B-NP	O
features	NNS	I-NP	O
,	,	O	O
and	CC	O	O
cutis	NN	B-NP	B
verticis	NN	I-NP	I
gyrata	NNS	I-NP	I
.	.	O	O

Pseudoacromegaly	RB	B-ADVP	B
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
similar	JJ	B-NP	O
acromegaloid	JJ	I-NP	O
features	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
elevated	JJ	B-NP	O
growth	NN	I-NP	O
hormone	NN	I-NP	O
or	CC	I-NP	O
insulin	NN	I-NP	O
-	HYPH	O	O
like	JJ	B-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
pseudoacromegaly	NN	B-NP	B
that	WDT	B-NP	O
resulted	VBD	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
minoxidil	NN	B-NP	O
at	IN	B-PP	O
an	DT	B-NP	O
unusually	RB	I-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
pseudoacromegaly	RB	B-ADVP	B
as	IN	B-PP	O
a	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
minoxidil	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Combined	VBN	B-NP	O
androgen	NN	I-NP	O
blockade	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
in	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
without	IN	B-PP	O
bone	NN	B-NP	O
involvement	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
and	CC	I-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
combined	VBN	B-NP	O
androgen	NN	I-NP	O
blockade	NN	I-NP	O
(	(	O	O
CAB	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
in	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
without	IN	B-PP	O
bone	NN	B-NP	O
involvement	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
biopsy	NN	B-NP	O
-	HYPH	O	O
proven	VBN	B-VP	O
prostatic	JJ	B-NP	B
adenocarcinoma	NN	I-NP	I
[	(	O	O
num	CD	B-NP	O
with	IN	B-PP	O
stage	NN	B-NP	O
C	NN	I-NP	O
(	(	O	O
T3N0M0	NN	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
stage	NN	B-NP	O
D1	NN	I-NP	O
(	(	O	O
T3N1M0	NN	B-NP	O
)	)	O	O
]	)	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
CAB	NN	B-NP	O
[	(	O	O
leuprolide	NN	B-NP	O
acetate	NN	I-NP	O
(	(	O	O
LHRH	NN	B-NP	O
-	HYPH	B-NP	O
A	NN	I-NP	O
)	)	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
intramuscularly	RB	B-ADVP	O
,	,	O	O
every	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
plus	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
flutamide	NN	I-NP	O
,	,	O	O
tid	NN	B-NP	O
,	,	O	O
per	IN	B-PP	O
Os	NNS	B-NP	O
]	)	O	O
and	CC	O	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
for	IN	B-PP	O
anemia	NN	B-NP	B
by	IN	B-PP	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
and	CC	I-NP	O
laboratory	NN	I-NP	O
tests	NNS	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
subsequent	JJ	I-NP	O
intervals	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
post	AFX	O	O
-	HYPH	O	O
CAB	NN	B-NP	O
)	)	O	O
.	.	O	O

Hb	NN	B-NP	O
,	,	I-NP	O
PSA	NN	I-NP	O
and	CC	I-NP	O
Testosterone	NN	I-NP	O
measurements	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
stage	NN	B-NP	O
D2	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
disease	NN	I-NP	O
,	,	O	O
abnormal	JJ	B-NP	O
hemoglobin	NN	I-NP	O
level	NN	I-NP	O
or	CC	O	O
renal	JJ	B-ADJP	O
and	CC	O	O
liver	NN	B-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
upper	JJ	I-NP	O
limits	NNS	I-NP	O
were	VBD	B-VP	O
excluded	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
hemoglobin	NN	I-NP	O
(	(	O	O
Hb	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
declined	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
CAB	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Severe	JJ	B-NP	O
and	CC	I-NP	O
clinically	RB	I-NP	O
evident	JJ	I-NP	O
anemia	NN	I-NP	B
of	IN	B-PP	O
Hb	NN	B-NP	O
<	SYM	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
symptoms	NNS	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
CAB	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
was	VBD	B-VP	O
normochromic	JJ	B-ADJP	O
and	CC	I-ADJP	O
normocytic	JJ	I-ADJP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
CAB	NN	B-NP	O
,	,	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
anemia	NN	I-NP	B
had	VBD	B-VP	O
a	DT	B-NP	O
Hb	NN	I-NP	O
mean	NN	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	B-NP	O
(	(	O	O
X	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
SE	NN	B-NP	O
)	)	O	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
mild	JJ	B-NP	O
anemia	NN	I-NP	B
with	IN	B-PP	O
Hb	NN	B-NP	O
mean	NN	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
X	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
SE	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
anemia	NN	I-NP	B
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
CAB	NN	B-NP	O
was	VBD	B-VP	O
predictable	JJ	B-ADJP	O
by	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
Hb	NN	B-NP	O
baseline	NN	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
CAB	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
CAB	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
anemia	NN	I-NP	B
in	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
T	NN	B-NP	O
baseline	NN	I-NP	O
values	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
and	CC	O	O
clinical	JJ	B-NP	O
stage	NN	I-NP	O
(	(	O	O
stage	NN	B-NP	O
C	NN	I-NP	O
versus	IN	B-PP	O
stage	NN	B-NP	O
D1	NN	I-NP	O
)	)	O	O
.	.	O	O

Severe	JJ	B-NP	O
and	CC	I-NP	O
clinically	RB	I-NP	O
evident	JJ	I-NP	O
anemia	NN	I-NP	B
was	VBD	B-VP	O
easily	RB	I-VP	O
corrected	VBN	I-VP	O
by	IN	B-PP	O
subcutaneous	JJ	B-NP	O
injections	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
/	SYM	I-NP	O
week	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
recombinant	JJ	B-NP	O
erythropoietin	NN	I-NP	O
(	(	O	O
rHuEPO	NN	B-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
)	)	O	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
rHuEPO	NN	B-NP	O
-	HYPH	B-NP	O
beta	NN	I-NP	O
correctable	JJ	I-NP	O
CAB	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
occurs	VBZ	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Reversible	JJ	B-NP	O
dilated	JJ	I-NP	B
cardiomyopathy	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
dilated	VBN	I-VP	B
cardiomyopathy	NN	B-NP	I
and	CC	O	O
clinical	JJ	B-NP	O
congestive	JJ	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
(	(	O	O
AmB	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
disseminated	VBN	B-NP	O
coccidioidomycosis	NN	I-NP	B
.	.	O	O

His	PRP$	B-NP	O
echocardiographic	JJ	I-NP	O
abnormalities	NNS	I-NP	O
and	CC	O	O
heart	NN	B-NP	B
failure	NN	I-NP	I
resolved	VBN	B-VP	O
after	IN	B-PP	O
posaconazole	NN	B-NP	O
was	VBD	B-VP	O
substituted	VBN	I-VP	O
for	IN	B-PP	O
AmB	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
recognize	VB	I-VP	O
the	DT	B-NP	O
rare	JJ	I-NP	O
and	CC	I-NP	O
potentially	RB	I-NP	O
reversible	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
AmB	NN	B-NP	O
.	.	O	O

Risks	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
consumption	NN	I-NP	O
of	IN	B-PP	O
beverages	NNS	B-NP	O
containing	VBG	B-VP	O
quinine	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
Food	NNP	I-NP	O
and	CC	I-NP	O
Drug	NNP	I-NP	O
Administration	NNP	I-NP	O
banned	VBD	B-VP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
for	IN	B-PP	O
nocturnal	JJ	B-NP	B
leg	NN	I-NP	I
cramps	NNS	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
lack	NN	B-NP	O
of	IN	B-PP	O
safety	NN	B-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
,	,	O	O
quinine	NN	B-NP	O
is	VBZ	B-VP	O
widely	RB	B-ADJP	O
available	JJ	I-ADJP	O
in	IN	B-PP	O
beverages	NNS	B-NP	O
including	VBG	B-PP	O
tonic	JJ	B-NP	O
water	NN	I-NP	O
and	CC	O	O
bitter	JJ	B-NP	O
lemon	NN	I-NP	O
.	.	O	O

Numerous	JJ	B-NP	O
anecdotal	JJ	I-NP	O
reports	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
products	NNS	B-NP	O
containing	VBG	B-VP	O
quinine	NN	B-NP	O
may	MD	B-VP	O
produce	VB	I-VP	O
neurological	JJ	B-NP	B
complications	NNS	I-NP	I
,	,	O	O
including	VBG	B-PP	O
confusion	NN	B-NP	B
,	,	O	O
altered	VBN	B-NP	O
mental	JJ	I-NP	O
status	NN	I-NP	O
,	,	O	O
seizures	NNS	B-NP	B
,	,	O	O
and	CC	O	O
coma	NN	B-NP	B
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
older	JJR	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Psychologists	NNS	B-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
inquire	VB	I-VP	O
about	IN	B-PP	O
consumption	NN	B-NP	O
of	IN	B-PP	O
quinine	NN	B-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
beverages	NNS	B-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
evaluation	NN	I-NP	O
process	NN	I-NP	O
.	.	O	O

Organophosphate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
and	CC	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
neuropathological	JJ	B-NP	B
damages	NNS	I-NP	I
.	.	O	O

Such	JJ	B-NP	O
organophosphorus	NN	I-NP	O
(	(	O	O
OP	NN	B-NP	O
)	)	O	O
compounds	NNS	B-NP	O
as	IN	B-PP	O
diisopropylfluorophosphate	NN	B-NP	O
(	(	O	O
DFP	NN	B-NP	O
)	)	O	O
,	,	O	O
sarin	NN	B-NP	O
and	CC	I-NP	O
soman	NN	I-NP	O
are	VBP	B-VP	O
potent	JJ	B-NP	O
inhibitors	NNS	I-NP	O
of	IN	B-PP	O
acetylcholinesterases	NNS	B-NP	O
(	(	O	O
AChEs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
butyrylcholinesterases	NNS	B-NP	O
(	(	O	O
BChEs	NNS	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
acute	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
OPs	NNS	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
irreversible	JJ	I-NP	O
binding	NN	I-NP	O
with	IN	B-PP	O
AChEs	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
elevates	VBZ	B-VP	O
acetylcholine	NN	B-NP	O
(	(	O	O
ACh	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
subcutaneously	RB	B-NP	O
(	(	O	O
SC	NN	B-NP	O
)	)	O	O
administered	VBN	B-NP	O
antidotes	NNS	I-NP	O
or	CC	O	O
their	PRP$	B-NP	O
combinations	NNS	I-NP	O
in	IN	B-PP	O
DFP	NN	B-NP	O
intoxication	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
weeks	NNS	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Han	NNP	I-NP	O
-	HYPH	B-NP	O
Wistar	NNP	I-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
AChE	NN	B-NP	O
reactivator	NN	I-NP	O
pralidoxime	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
chloride	NN	I-NP	O
(	(	O	O
2PAM	NN	B-NP	O
)	)	O	O
,	,	O	O
anticonvulsant	JJ	B-NP	O
diazepam	NN	I-NP	O
,	,	O	O
A	NN	B-NP	O
-	HYPH	I-NP	O
adenosine	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
cyclopentyl	NN	I-NP	O
adenosine	NN	I-NP	O
(	(	O	O
CPA	NN	B-NP	O
)	)	O	O
,	,	O	O
NMDA	NN	B-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
dizocilpine	NN	I-NP	O
maleate	NN	I-NP	O
or	CC	O	O
their	PRP$	B-NP	O
combinations	NNS	I-NP	O
with	IN	B-PP	O
cholinolytic	JJ	B-NP	O
drug	NN	I-NP	O
atropine	NN	I-NP	O
sulfate	NN	I-NP	O
immediately	RB	B-ADVP	O
or	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
single	JJ	I-NP	O
SC	NN	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
DFP	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
control	NN	I-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
atropine	NN	B-NP	O
sulfate	NN	I-NP	O
,	,	O	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
saline	NN	B-NP	O
and	CC	I-NP	O
olive	NN	I-NP	O
oil	NN	I-NP	O
instead	RB	B-PP	O
of	IN	I-PP	O
other	JJ	B-NP	O
antidotes	NNS	I-NP	O
and	CC	O	O
DFP	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

All	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
terminated	VBN	I-VP	O
either	CC	O	O
num	CD	B-NP	O
h	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
DFP	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rats	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
DFP	NN	B-NP	O
-	HYPH	O	O
atropine	NN	B-NP	O
showed	VBD	B-VP	O
severe	JJ	B-NP	O
typical	JJ	I-NP	O
OP	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
toxicity	NN	I-NP	B
signs	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
CPA	NN	B-NP	O
,	,	I-NP	O
diazepam	NN	I-NP	O
or	CC	I-NP	O
2PAM	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
DFP	NN	B-NP	O
-	HYPH	B-NP	O
atropine	NN	I-NP	O
,	,	O	O
these	DT	B-NP	O
treatments	NNS	I-NP	O
prevented	VBD	B-VP	O
,	,	O	O
delayed	VBD	B-VP	O
or	CC	I-VP	O
shortened	VBD	I-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
poisoning	NN	B-NP	B
.	.	O	O

Atropine	NN	B-NP	O
-	HYPH	O	O
MK801	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
offer	VB	I-VP	O
any	DT	B-NP	O
additional	JJ	I-NP	O
protection	NN	I-NP	O
against	IN	B-PP	O
DFP	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
CPA	NN	B-NP	O
,	,	O	O
diazepam	NN	B-NP	O
and	CC	I-NP	O
2PAM	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
atropine	NN	B-NP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
poisoning	NN	B-NP	B
and	CC	O	O
thus	RB	B-VP	O
reduced	VBD	I-VP	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
DFP	NN	B-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
.	.	O	O

Differential	JJ	B-NP	O
modulation	NN	I-NP	O
by	IN	B-PP	O
estrogen	NN	B-NP	O
of	IN	B-PP	O
alpha2	NN	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
and	CC	I-NP	O
I1	NN	I-NP	O
-	HYPH	O	O
imidazoline	NN	B-NP	O
receptor	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
recently	RB	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
estrogen	NN	B-NP	O
negatively	RB	B-ADVP	O
modulates	VBZ	B-VP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
(	(	O	O
mixed	VBN	B-NP	O
alpha2	NN	I-NP	O
-	HYPH	O	O
/	SYM	B-NP	O
I1	NN	I-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
and	CC	O	O
implicates	VBZ	B-VP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
autonomic	JJ	I-NP	O
control	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
interaction	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
whether	IN	B-SBAR	O
this	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
involves	VBZ	B-VP	O
interaction	NN	B-NP	O
with	IN	B-PP	O
alpha2	NN	B-NP	O
-	HYPH	O	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
I1	NN	B-NP	O
-	HYPH	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Changes	NNS	B-NP	O
evoked	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
intraperitoneal	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
rilmenidine	NN	B-NP	O
or	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
methyldopa	NN	B-NP	O
,	,	O	O
selective	JJ	B-NP	O
I1	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
alpha2	NN	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
hemodynamic	JJ	B-NP	O
variability	NN	I-NP	O
,	,	O	O
and	CC	O	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
radiotelemetered	VBN	B-NP	O
sham	NN	I-NP	O
-	HYPH	B-VP	O
operated	VBN	I-VP	O
and	CC	I-VP	O
ovariectomized	VBN	I-VP	O
(	(	O	O
Ovx	NN	B-NP	O
)	)	O	O
Sprague	NNP	B-NP	O
-	HYPH	B-NP	O
Dawley	NNP	I-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
estrogen	NN	I-NP	O
replacement	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
time	NN	I-NP	O
domain	NN	B-NP	O
indexes	NNS	I-NP	O
of	IN	B-PP	O
hemodynamic	JJ	B-NP	O
variability	NN	I-NP	O
were	VBD	B-VP	O
employed	VBN	I-VP	O
:	:	O	O
the	DT	B-NP	O
standard	JJ	I-NP	O
deviation	NN	I-NP	O
of	IN	B-PP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
variability	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
standard	JJ	I-NP	O
deviation	NN	I-NP	O
of	IN	B-PP	O
beat	NN	B-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
beat	JJ	I-NP	O
intervals	NNS	I-NP	O
(	(	O	O
SDRR	NN	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
root	NN	I-NP	O
mean	JJ	I-NP	O
square	NN	I-NP	O
of	IN	B-PP	O
successive	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
R	NN	B-NP	O
-	HYPH	B-NP	O
wave	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
R	NN	I-NP	O
-	HYPH	B-NP	O
wave	NN	I-NP	O
intervals	NNS	I-NP	O
as	IN	B-PP	O
measures	NNS	B-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
variability	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
sham	NN	B-NP	O
-	HYPH	B-NP	O
operated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
rilmenidine	NN	B-NP	O
or	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
methyldopa	NN	B-NP	O
elicited	VBD	B-VP	O
similar	JJ	B-NP	O
hypotension	NN	I-NP	B
that	WDT	B-NP	O
lasted	VBD	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
reductions	NNS	B-NP	O
in	IN	B-PP	O
standard	JJ	B-NP	O
deviation	NN	I-NP	O
of	IN	B-PP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
.	.	O	O

SDRR	NN	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
only	RB	B-ADVP	O
by	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
methyldopa	NN	B-NP	O
.	.	O	O

Ovx	NN	B-NP	O
significantly	RB	B-ADVP	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
response	NN	I-NP	O
to	TO	B-PP	O
alpha	SYM	O	O
-	HYPH	O	O
methyldopa	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
rilmenidine	NN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
enhanced	VBN	I-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
methyldopa	NN	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
Ovx	NN	B-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
paralleled	VBN	I-VP	O
with	IN	B-PP	O
further	JJ	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
SDRR	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	B
reduced	VBN	I-NP	I
locomotor	NN	I-NP	I
activity	NN	I-NP	I
.	.	O	O

Estrogen	NN	B-NP	O
replacement	NN	I-NP	O
(	(	O	O
17beta	NN	B-NP	O
-	HYPH	B-NP	O
estradiol	NN	I-NP	O
subcutaneous	JJ	I-NP	O
pellet	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
wk	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
Ovx	NN	B-NP	O
rats	NNS	I-NP	O
restored	VBD	B-VP	O
the	DT	B-NP	O
hemodynamic	JJ	I-NP	O
and	CC	I-NP	O
locomotor	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	O	O
methyldopa	NN	B-NP	O
to	TO	B-PP	O
sham	NN	B-NP	O
-	HYPH	B-NP	O
operated	VBN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
estrogen	NN	B-NP	O
downregulates	VBZ	B-VP	O
alpha2	NN	B-NP	O
-	HYPH	B-ADJP	O
but	CC	B-NP	O
not	RB	I-NP	O
I1	NN	B-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
hypotension	NN	I-NP	B
and	CC	O	O
highlight	VBP	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
autonomic	JJ	I-NP	O
control	NN	I-NP	O
in	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
methyldopa	NN	I-NP	O
-	HYPH	I-NP	O
estrogen	NN	I-NP	O
interaction	NN	I-NP	O
.	.	O	O

Cardioprotective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
tincture	NN	B-NP	O
of	IN	B-PP	O
Crataegus	NNP	B-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Tincture	NN	B-NP	O
of	IN	B-PP	O
Crataegus	NNP	B-NP	O
(	(	O	O
TCR	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
alcoholic	JJ	I-NP	O
extract	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
berries	NNS	I-NP	O
of	IN	B-PP	O
hawthorn	NN	B-NP	O
(	(	O	O
Crataegus	NNP	B-NP	O
oxycantha	NN	I-NP	O
)	)	O	O
,	,	O	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
herbal	JJ	B-NP	O
and	CC	I-NP	O
homeopathic	JJ	I-NP	O
medicine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
TCR	NN	B-NP	O
on	IN	B-PP	O
experimentally	RB	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
of	IN	B-PP	O
TCR	NN	B-NP	O
,	,	O	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mL	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
g	NN	I-NP	O
bodyweight	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
,	,	O	O
orally	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
and	CC	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
marker	NN	B-NP	O
enzymes	NNS	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

TCR	NN	B-NP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
isoproterenol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
antioxidant	JJ	B-NP	O
enzymes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
ADP	NN	B-NP	O
-	HYPH	B-NP	O
stimulated	VBN	I-NP	O
oxygen	NN	I-NP	O
uptake	NN	I-NP	O
and	CC	O	O
respiratory	JJ	B-NP	O
coupling	NN	I-NP	O
ratio	NN	I-NP	O
.	.	O	O

TCR	NN	B-NP	O
protected	VBD	B-VP	O
against	IN	B-PP	O
pathological	JJ	B-NP	O
changes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
heart	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
TCR	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
the	DT	B-NP	O
damage	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
heart	NN	I-NP	O
.	.	O	O

Safety	NN	B-NP	O
and	CC	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
raloxifene	NN	B-NP	O
:	:	O	O
multiple	JJ	B-NP	O
outcomes	NNS	I-NP	O
of	IN	B-PP	O
raloxifene	NN	B-NP	O
evaluation	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
raloxifene	NN	B-NP	O
on	IN	B-PP	O
major	JJ	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
that	WDT	B-NP	O
occur	VBP	B-VP	O
with	IN	B-PP	O
postmenopausal	JJ	B-NP	O
estrogen	NN	I-NP	O
therapy	NN	I-NP	O
or	CC	I-NP	O
tamoxifen	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
Multiple	NNP	I-NP	O
Outcomes	NNP	I-NP	O
of	IN	B-PP	O
Raloxifene	NNP	B-NP	O
Evaluation	NNP	I-NP	O
,	,	O	O
a	DT	B-NP	O
multicenter	NN	I-NP	O
,	,	O	O
randomized	VBN	B-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
,	,	O	O
enrolled	VBD	B-VP	O
num	CD	B-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
osteoporosis	NN	B-NP	B
.	.	O	O

Women	NNS	B-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
raloxifene	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

Outcomes	NNS	B-NP	O
included	VBD	B-VP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
,	,	O	O
cataracts	NNS	B-NP	B
,	,	O	O
gallbladder	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
endometrial	JJ	B-NP	B
hyperplasia	NN	I-NP	I
or	CC	I-NP	I
cancer	NN	I-NP	I
.	.	O	O

During	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
raloxifene	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
(	(	O	O
relative	JJ	B-NP	O
risk	NN	I-NP	O
[	(	O	O
RR	NN	B-NP	O
]	)	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
[	(	O	O
CI	NN	B-NP	O
]	)	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
excess	JJ	I-NP	O
event	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
woman	NN	I-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
number	NN	I-NP	O
needed	VBN	B-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
num	CD	B-NP	O
event	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
over	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Risk	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
raloxifene	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
but	CC	O	O
decreased	VBD	B-VP	O
to	TO	B-PP	O
about	IN	B-NP	O
the	DT	I-NP	O
same	JJ	I-NP	O
rate	NN	I-NP	O
as	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
thereafter	RB	B-ADVP	O
.	.	O	O

Raloxifene	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
increase	VB	I-VP	O
risk	NN	B-NP	O
for	IN	B-PP	O
cataracts	NNS	B-NP	B
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
gallbladder	NN	B-NP	B
disease	NN	I-NP	I
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
endometrial	JJ	B-NP	B
hyperplasia	NN	I-NP	I
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Raloxifene	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
,	,	O	O
but	CC	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
cataracts	NNS	B-NP	B
,	,	O	O
gallbladder	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
endometrial	JJ	B-NP	B
hyperplasia	NN	I-NP	I
,	,	O	O
or	CC	O	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

.	.	O	O

Ceftriaxone	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
biliary	JJ	B-NP	B
pseudolithiasis	NN	I-NP	I
in	IN	B-PP	O
paediatric	JJ	B-NP	O
surgical	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
well	RB	I-VP	O
known	VBN	I-VP	O
that	IN	B-SBAR	O
ceftriaxone	NN	B-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
pseudolithiasis	NN	B-NP	B
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
and	CC	I-NP	O
experimental	JJ	I-NP	O
studies	NNS	I-NP	O
also	RB	B-ADVP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
situations	NNS	B-NP	O
causing	VBG	B-VP	O
gallbladder	NN	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
fasting	VBG	B-VP	O
,	,	O	O
may	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
pseudolithiasis	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
prospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
pseudolithiasis	NN	B-NP	B
in	IN	B-PP	O
paediatric	JJ	B-NP	O
surgical	JJ	I-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
ceftriaxone	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
often	RB	B-ADVP	O
had	VBD	B-VP	O
to	TO	I-VP	O
fast	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
children	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
ceftriaxone	NN	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
serial	JJ	B-NP	O
abdominal	JJ	I-NP	O
sonograms	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
those	DT	B-NP	O
,	,	O	O
num	CD	B-NP	O
developed	VBD	B-VP	O
biliary	JJ	B-NP	O
pathology	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
pseudolithiasis	NN	B-NP	B
revealed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
age	NN	B-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
and	CC	I-NP	O
starvation	NN	I-NP	O
variables	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
pseudolithiasis	NN	B-NP	B
resolved	VBD	B-VP	O
spontaneously	RB	B-ADVP	O
within	IN	B-PP	O
a	DT	B-NP	O
short	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
pseudolithiasis	NN	B-NP	B
is	VBZ	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
fasting	VBG	B-VP	O
.	.	O	O

Evaluation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anticocaine	NN	I-NP	O
monoclonal	JJ	I-NP	O
antibody	NN	I-NP	O
GNC92H2	NN	I-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
immunotherapy	NN	I-NP	O
for	IN	B-PP	O
cocaine	NN	B-NP	B
overdose	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
illicit	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
continues	VBZ	B-VP	O
in	IN	B-PP	O
epidemic	JJ	B-NP	O
proportions	NNS	I-NP	O
and	CC	O	O
treatment	NN	B-NP	O
for	IN	B-PP	O
cocaine	NN	B-NP	B
overdose	NN	I-NP	I
remains	VBZ	B-VP	O
elusive	JJ	B-ADJP	O
.	.	O	O

Current	JJ	B-NP	O
protein	NN	I-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
technology	NN	I-NP	O
offers	VBZ	B-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
therapeutic	JJ	I-NP	O
venue	NN	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
antibodies	NNS	B-NP	O
bind	VBP	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
stream	NN	I-NP	O
,	,	O	O
inactivating	VBG	B-VP	O
its	PRP$	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
therapeutic	JJ	I-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anticocaine	NN	I-NP	O
antibody	NN	I-NP	O
GNC92H2	NN	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	B
overdose	NN	I-NP	I
.	.	O	O

Swiss	JJ	B-NP	O
albino	NN	I-NP	O
mice	NNS	I-NP	O
prepared	VBN	B-VP	O
with	IN	B-PP	O
intrajugular	JJ	B-NP	O
catheters	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
photocell	NN	B-NP	O
cages	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	B-NP	O
(	(	O	O
LD50	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
GNC92H2	NN	I-NP	O
infusions	NNS	I-NP	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
.	.	O	O

GNC92H2	NN	B-NP	O
was	VBD	B-VP	O
delivered	VBN	I-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-ADVP	O
,	,	O	O
concomitantly	RB	B-ADVP	O
or	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
cocaine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
toxicity	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
GNC92H2	NN	B-NP	O
,	,	O	O
where	WRB	B-ADVP	O
premorbid	JJ	B-NP	O
behaviors	NNS	I-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
seizures	VBZ	B-VP	B
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
death	NN	I-NP	B
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Importantly	RB	B-ADVP	O
,	,	O	O
GNC92H2	NN	B-NP	O
prevented	VBD	B-VP	O
death	NN	B-NP	B
even	RB	B-ADVP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
cocaine	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
important	JJ	I-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
GNC92H2	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
therapeutic	JJ	I-NP	O
tool	NN	I-NP	O
against	IN	B-PP	O
cocaine	NN	B-NP	B
overdose	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
raloxifene	NN	I-NP	O
therapy	NN	I-NP	O
on	IN	B-PP	O
fibrinolysis	NN	B-NP	O
markers	NNS	I-NP	O
:	:	O	O
TAFI	NN	B-NP	O
,	,	O	O
tPA	NN	B-NP	O
,	,	O	O
and	CC	O	O
PAI	NN	B-NP	O
-	SYM	O	O
num	CD	B-NP	O
.	.	O	O

Markers	NNS	B-NP	O
of	IN	B-PP	O
fibrinolysis	NN	B-NP	O
,	,	O	O
thrombin	NN	B-NP	O
-	HYPH	B-NP	O
activatable	JJ	I-NP	O
fibrinolysis	NN	I-NP	O
inhibitor	NN	I-NP	O
(	(	O	O
TAFI	NN	B-NP	O
)	)	O	O
,	,	O	O
tissue	NN	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
plasminogen	NN	I-NP	O
activator	NN	I-NP	O
(	(	O	O
tPA	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
plasminogen	NN	B-NP	O
activator	NN	I-NP	O
inhibitor	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
PAI	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
levels	NNS	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
raloxifene	NN	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
postmenopausal	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
osteopenia	NN	B-NP	B
or	CC	I-NP	O
osteoporosis	NN	I-NP	B
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
controlled	JJ	I-NP	O
clinical	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
women	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
raloxifene	NN	B-NP	O
hydrochloride	NN	I-NP	O
plus	CC	O	O
calcium	NN	B-NP	O
.	.	O	O

Age	NN	B-NP	O
-	HYPH	B-NP	O
matched	VBN	I-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
only	RB	B-NP	O
calcium	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
TAFI	NN	I-NP	O
,	,	O	O
tPA	NN	B-NP	O
,	,	O	O
and	CC	O	O
PAI	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
antigen	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
by	IN	B-PP	O
commercially	RB	B-NP	O
available	JJ	I-NP	O
ELISA	NN	I-NP	O
kits	NNS	I-NP	O
.	.	O	O

Variations	NNS	B-NP	O
of	IN	B-PP	O
individuals	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
Wilcoxon	NNP	B-NP	O
s	NNP	I-NP	O
test	NN	I-NP	O
.	.	O	O

Relationship	NN	B-NP	O
between	IN	B-PP	O
those	DT	B-NP	O
markers	NNS	I-NP	O
and	CC	O	O
demographic	JJ	B-NP	O
characteristics	NNS	I-NP	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
raloxifene	NN	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
TAFI	NN	I-NP	O
antigen	NN	I-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
tPA	NN	B-NP	O
antigen	NN	I-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
baseline	NN	B-NP	O
TAFI	NN	I-NP	O
antigen	NN	I-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
amenorrhea	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
raloxifene	NN	B-NP	O
treatment	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
increased	VBN	B-NP	O
tPA	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
TAFI	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

Ketoconazole	NN	B-NP	O
induced	VBD	B-VP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
without	IN	B-PP	O
concomitant	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
-	HYPH	O	O
prolonging	VBG	B-VP	O
drug	NN	B-NP	O
.	.	O	O

Ketoconazole	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
proarrhythmic	JJ	B-ADJP	O
without	IN	B-PP	O
concomitant	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
-	HYPH	O	O
prolonging	VBG	B-VP	O
drugs	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
markedly	RB	I-NP	O
prolonged	VBN	I-NP	B
QT	NN	I-NP	I
interval	NN	I-NP	I
and	CC	O	O
torsades	NNS	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
(	(	O	O
TdP	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
taking	VBG	B-VP	O
ketoconazole	NN	B-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
fungal	JJ	B-NP	B
infection	NN	I-NP	I
.	.	O	O

Her	PRP$	B-NP	O
QT	NN	I-NP	O
interval	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
upon	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
ketoconazole	NN	B-NP	O
.	.	O	O

Genetic	JJ	B-NP	O
study	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
find	VB	I-VP	O
any	DT	B-NP	O
mutation	NN	I-NP	O
in	IN	B-PP	O
her	PRP$	B-NP	O
genes	NNS	I-NP	O
that	WDT	B-NP	O
encode	VBP	B-VP	O
cardiac	JJ	B-NP	O
IKr	NN	I-NP	O
channel	NN	I-NP	O
proteins	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
postulate	VBP	B-VP	O
that	IN	B-SBAR	O
by	IN	B-PP	O
virtue	NN	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
direct	JJ	I-NP	O
blocking	VBG	I-NP	O
action	NN	I-NP	O
on	IN	B-PP	O
IKr	NN	B-NP	O
,	,	O	O
ketoconazole	NN	B-NP	O
alone	RB	B-ADVP	O
may	MD	B-VP	O
prolong	VB	I-VP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
and	CC	O	O
induce	VB	B-VP	O
TdP	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
calls	VBZ	B-VP	O
for	IN	B-PP	O
attention	NN	B-NP	O
when	WRB	B-ADVP	O
ketoconazole	NN	B-NP	O
is	VBZ	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
acquired	VBN	B-NP	O
long	JJ	I-NP	B
QT	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Pharmacological	JJ	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
Daucus	NN	B-NP	O
carota	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	B
dysfunctions	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
aimed	VBN	I-VP	O
at	IN	B-PP	O
investigating	VBG	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Daucus	NN	B-NP	O
carota	NN	I-NP	O
seeds	NNS	I-NP	O
on	IN	B-PP	O
cognitive	JJ	B-NP	O
functions	NNS	I-NP	O
,	,	O	O
total	JJ	B-NP	O
serum	NN	I-NP	O
cholesterol	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
brain	NN	B-NP	O
cholinesterase	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
ethanolic	JJ	I-NP	O
extract	NN	I-NP	O
of	IN	B-PP	O
Daucus	NN	B-NP	O
carota	NN	I-NP	O
seeds	NNS	I-NP	O
(	(	O	O
DCE	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
orally	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
successive	JJ	I-NP	O
days	NNS	I-NP	O
to	TO	B-PP	O
different	JJ	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
young	JJ	B-NP	O
and	CC	I-NP	O
aged	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Elevated	VBN	B-VP	O
plus	CC	O	O
maze	NN	B-NP	O
and	CC	O	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
apparatus	NN	I-NP	O
served	VBD	B-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
exteroceptive	JJ	I-NP	O
behavioral	JJ	I-NP	O
models	NNS	I-NP	O
for	IN	B-PP	O
testing	NN	B-NP	O
memory	NN	I-NP	O
.	.	O	O

Diazepam	NN	B-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
ageing	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
amnesia	NN	I-NP	B
served	VBD	B-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
interoceptive	JJ	I-NP	O
behavioral	JJ	I-NP	O
models	NNS	I-NP	O
.	.	O	O

DCE	NN	B-NP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
memory	NN	B-NP	O
scores	NNS	I-NP	O
of	IN	B-PP	O
young	JJ	B-NP	O
and	CC	I-NP	O
aged	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
memory	NN	B-NP	O
improvement	NN	I-NP	O
evoked	VBN	B-VP	O
by	IN	B-PP	O
DCE	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
in	IN	B-PP	O
young	JJ	B-NP	O
mice	NNS	I-NP	O
using	VBG	B-VP	O
elevated	VBN	B-VP	O
plus	CC	O	O
maze	NN	B-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
significant	JJ	B-NP	O
improvements	NNS	I-NP	O
in	IN	B-PP	O
memory	NN	B-NP	O
scores	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
using	VBG	B-VP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
apparatus	NN	I-NP	O
and	CC	O	O
aged	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
DCE	NN	B-NP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
amnesia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
.	.	O	O

Daucus	NN	B-NP	O
carota	NN	I-NP	O
extract	NN	I-NP	O
reduced	VBD	B-VP	O
significantly	RB	B-ADVP	O
the	DT	B-NP	O
brain	NN	I-NP	O
acetylcholinesterase	NN	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
cholesterol	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
young	JJ	B-NP	O
and	CC	I-NP	O
aged	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
cholinesterase	NN	I-NP	O
activity	NN	I-NP	O
evoked	VBN	B-VP	O
by	IN	B-PP	O
DCE	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
young	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
aged	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
remarkable	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
total	JJ	B-NP	O
cholesterol	NN	I-NP	O
level	NN	I-NP	O
as	RB	B-ADVP	O
well	RB	I-ADVP	O
,	,	O	O
to	TO	B-PP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
young	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
aged	JJ	B-NP	O
animals	NNS	I-NP	O
with	IN	B-PP	O
this	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
DCE	NN	B-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
DCE	NN	B-NP	O
may	MD	B-VP	O
prove	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
remedy	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	B
dysfunctions	NNS	I-NP	I
on	IN	B-PP	O
account	NN	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
multifarious	JJ	I-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
,	,	O	O
memory	NN	B-NP	O
improving	VBG	B-VP	O
property	NN	B-NP	O
,	,	O	O
cholesterol	NN	B-NP	O
lowering	VBG	B-VP	O
property	NN	B-NP	O
and	CC	I-NP	O
anticholinesterase	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Cauda	NNP	B-NP	B
equina	NNP	I-NP	I
syndrome	NN	I-NP	I
after	IN	B-PP	O
epidural	JJ	B-NP	O
steroid	NN	I-NP	O
injection	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Conventional	JJ	B-NP	O
treatment	NN	I-NP	O
methods	NNS	I-NP	O
of	IN	B-PP	O
lumbusacral	JJ	B-NP	O
radiculopathy	NN	I-NP	B
are	VBP	B-VP	O
physical	JJ	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
epidural	JJ	B-NP	O
steroid	NN	I-NP	O
injections	NNS	I-NP	O
,	,	O	O
oral	JJ	B-NP	O
medications	NNS	I-NP	O
,	,	O	O
and	CC	O	O
spinal	JJ	B-NP	O
manipulative	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Cauda	NNP	B-NP	B
equina	NNP	I-NP	I
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
epidural	JJ	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
following	VBG	I-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
cauda	NN	B-NP	B
equina	NN	I-NP	I
syndrome	NN	I-NP	I
possibly	RB	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
epidural	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
triamcinolone	NN	B-NP	O
and	CC	I-NP	O
bupivacaine	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	B
back	NN	I-NP	I
and	CC	O	I
right	JJ	B-NP	I
leg	NN	I-NP	I
pain	NN	I-NP	I
was	VBD	B-VP	O
scheduled	VBN	I-VP	O
for	IN	B-PP	O
epidural	JJ	B-NP	O
steroid	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
gauge	NN	I-NP	O
Touhy	NN	I-NP	O
needle	NN	I-NP	O
was	VBD	B-VP	O
inserted	VBN	I-VP	O
until	IN	B-PP	O
loss	NN	B-NP	O
of	IN	B-PP	O
resistance	NN	B-NP	O
occurred	VBD	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
L4	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
level	NN	I-NP	O
.	.	O	O

Spread	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
epidural	JJ	I-NP	O
space	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
radiographic	JJ	B-NP	O
imaging	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
verifying	VBG	B-VP	O
the	DT	B-NP	O
epidural	JJ	I-NP	O
space	NN	I-NP	O
,	,	O	O
bupivacaine	NN	B-NP	O
and	CC	I-NP	O
triamcinolone	NN	I-NP	O
diacetate	NN	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
radicular	JJ	B-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
she	PRP	B-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
perineal	JJ	B-NP	O
numbness	NN	I-NP	B
and	CC	O	O
lower	JJR	B-NP	B
extremity	NN	I-NP	I
weakness	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
neurologic	JJ	I-NP	O
evaluation	NN	I-NP	O
revealed	VBD	B-VP	O
loss	NN	B-NP	B
of	IN	B-PP	I
sensation	NN	B-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
saddle	JJ	I-NP	O
area	NN	I-NP	O
and	CC	O	O
medial	JJ	B-NP	O
aspect	NN	I-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
right	JJ	I-NP	O
leg	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
perception	NN	I-NP	O
of	IN	B-PP	O
pinprick	NN	B-NP	O
test	NN	I-NP	O
.	.	O	O

Deep	JJ	B-NP	O
-	HYPH	I-NP	O
tendon	NN	I-NP	O
reflexes	NNS	I-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
leg	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
unable	JJ	B-ADJP	O
to	TO	B-VP	O
urinate	VB	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
symptoms	NNS	I-NP	O
improved	VBD	B-VP	O
slightly	RB	B-ADVP	O
over	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
few	JJ	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

She	PRP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
gradual	JJ	I-NP	O
return	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
feeling	NN	B-NP	O
Foley	NNP	I-NP	O
catheter	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
were	VBD	B-VP	O
completely	RB	I-VP	O
resolved	VBN	I-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

Complications	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
epidural	JJ	B-NP	O
steroid	NN	I-NP	O
injections	NNS	I-NP	O
are	VBP	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

Clinical	JJ	B-NP	O
examination	NN	I-NP	O
and	CC	O	O
continued	JJ	B-NP	O
vigilance	NN	I-NP	O
for	IN	B-PP	O
neurologic	JJ	B-NP	B
deterioration	NN	I-NP	I
after	IN	B-PP	O
epidural	JJ	B-NP	O
steroid	NN	I-NP	O
injections	NNS	I-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
testosterone	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
atherosclerosis	NN	B-NP	B
in	IN	B-PP	O
postmenopausal	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
androgen	NN	B-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
atherosclerosis	NN	B-NP	B
in	IN	B-PP	O
postmenopausal	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
naturally	RB	I-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
aged	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
self	NN	B-NP	O
-	HYPH	B-VP	O
reported	VBN	I-VP	O
intramuscularly	RB	B-NP	O
administered	VBN	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
estrogen	NN	I-NP	O
-	HYPH	O	O
testosterone	NN	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
estradiol	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
testosterone	NN	I-NP	O
esters	NNS	I-NP	O
)	)	O	O
and	CC	O	O
aortic	JJ	B-NP	O
atherosclerosis	NN	I-NP	B
.	.	O	O

Aortic	JJ	B-NP	O
atherosclerosis	NN	I-NP	B
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
by	IN	B-PP	O
radiographic	JJ	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
calcified	VBN	B-NP	O
deposits	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
abdominal	JJ	I-NP	O
aorta	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
reflect	VB	I-VP	O
intima	NN	B-NP	O
atherosclerosis	NN	I-NP	B
.	.	O	O

Hormone	NN	B-NP	O
therapy	NN	I-NP	O
users	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
never	JJ	B-NP	O
users	NNS	I-NP	O
.	.	O	O

Intramuscular	JJ	B-NP	O
hormone	NN	I-NP	O
therapy	NN	I-NP	O
use	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
or	CC	I-NP	O
longer	NN	I-NP	O
was	VBD	B-VP	O
reported	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
almost	RB	B-NP	O
half	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
women	NNS	I-NP	O
severe	VBP	B-VP	O
atherosclerosis	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
aorta	NN	I-NP	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
,	,	O	O
while	IN	B-SBAR	O
in	IN	B-PP	O
women	NNS	B-NP	O
without	IN	B-PP	O
hormone	NN	B-NP	O
use	NN	I-NP	O
severe	JJ	I-NP	O
atherosclerosis	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
aorta	NN	I-NP	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
(	(	O	O
OR	NN	B-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	O	O
adjusted	VBN	B-VP	O
for	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
years	NNS	B-NP	O
since	IN	B-PP	O
menopause	NN	B-NP	O
,	,	O	O
smoking	NN	B-NP	O
,	,	O	O
and	CC	O	O
body	NN	B-NP	O
mass	NN	I-NP	O
index	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
remained	VBD	B-VP	O
after	IN	B-PP	O
additional	JJ	B-NP	O
adjustment	NN	I-NP	O
for	IN	B-PP	O
diabetes	NN	B-NP	B
,	,	O	O
cholesterol	NN	B-NP	O
level	NN	I-NP	O
,	,	O	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
or	CC	O	O
alcohol	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
association	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
for	IN	B-PP	O
hormone	NN	B-NP	O
use	NN	I-NP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
testosterone	NN	I-NP	O
therapy	NN	I-NP	O
may	MD	B-VP	O
adversely	RB	I-VP	O
affect	VB	I-VP	O
atherosclerosis	NN	B-NP	B
in	IN	B-PP	O
postmenopausal	JJ	B-NP	O
women	NNS	I-NP	O
and	CC	O	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
androgen	NN	B-NP	O
replacement	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
women	NNS	I-NP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
harmless	JJ	B-ADJP	O
.	.	O	O

Sirolimus	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
proteinuria	NN	I-NP	B
and	CC	O	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Sirolimus	NNP	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
immunosuppressant	NN	I-NP	O
with	IN	B-PP	O
potent	JJ	B-NP	O
antiproliferative	JJ	I-NP	O
actions	NNS	I-NP	O
through	IN	B-PP	O
its	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
inhibit	VB	I-VP	O
the	DT	B-NP	O
raptor	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
mammalian	JJ	B-NP	O
target	NN	I-NP	O
of	IN	B-PP	O
rapamycin	NN	B-NP	O
protein	NN	I-NP	O
kinase	NN	I-NP	O
.	.	O	O

Sirolimus	NNP	B-NP	O
represents	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
therapeutic	JJ	I-NP	O
advance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
renal	JJ	I-NP	O
allograft	NN	I-NP	O
rejection	NN	I-NP	O
and	CC	O	O
chronic	JJ	B-NP	O
allograft	NN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Its	PRP$	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
glomerulonephritis	NN	B-NP	B
,	,	O	O
autoimmunity	NN	B-NP	B
,	,	O	O
cystic	JJ	B-NP	B
renal	JJ	I-NP	I
diseases	NNS	I-NP	I
and	CC	O	O
renal	JJ	B-NP	B
cancer	NN	I-NP	I
is	VBZ	B-VP	O
under	IN	B-PP	O
investigation	NN	B-NP	O
.	.	O	O

Because	IN	B-SBAR	O
sirolimus	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
share	VB	I-VP	O
the	DT	B-NP	O
vasomotor	NN	I-NP	O
renal	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
exhibited	VBN	B-VP	O
by	IN	B-PP	O
calcineurin	NN	B-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
designated	VBN	I-VP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
nephrotoxic	JJ	I-NP	B
drug	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
clinical	JJ	B-NP	O
reports	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
under	IN	B-PP	O
some	DT	B-NP	O
circumstances	NNS	I-NP	O
,	,	O	O
sirolimus	NN	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
proteinuria	NN	B-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
common	JJ	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
presence	NN	B-NP	O
of	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	B-VP	O
existing	VBG	B-NP	O
chronic	JJ	I-NP	B
renal	JJ	I-NP	I
damage	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
proteinuria	NN	I-NP	B
are	VBP	B-VP	O
multifactorial	JJ	B-ADJP	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
glomerular	JJ	B-NP	O
capillary	JJ	I-NP	O
pressure	NN	I-NP	O
following	VBG	B-PP	O
calcineurin	NN	B-NP	O
inhibitor	NN	I-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
sirolimus	NN	B-NP	O
directly	RB	B-ADVP	O
causes	VBZ	B-VP	O
increased	VBN	I-VP	O
glomerular	JJ	B-NP	O
permeability	NN	I-NP	O
/	SYM	B-NP	O
injury	NN	I-NP	O
,	,	O	O
but	CC	O	O
evidence	NN	B-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
mechanism	NN	I-NP	O
is	VBZ	B-VP	O
currently	RB	B-ADJP	O
inconclusive	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
dysfunction	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
sirolimus	NN	B-NP	O
(	(	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
in	IN	B-PP	O
delayed	VBN	B-NP	O
graft	NN	I-NP	O
function	NN	I-NP	O
)	)	O	O
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
suppression	NN	B-NP	O
of	IN	B-PP	O
compensatory	JJ	B-NP	O
renal	JJ	I-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
and	CC	I-NP	O
survival	NN	I-NP	O
/	SYM	I-NP	O
repair	NN	I-NP	O
processes	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
these	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
occur	VBP	B-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
their	PRP$	B-NP	O
occurrence	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
minimised	VBN	I-VP	O
by	IN	B-PP	O
knowledge	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
in	IN	B-PP	O
appropriate	JJ	B-NP	O
patient	NN	I-NP	O
populations	NNS	I-NP	O
,	,	O	O
close	JJ	B-NP	O
monitoring	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
and	CC	O	O
renal	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
use	NN	B-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitors	NNS	I-NP	O
or	CC	O	O
angiotensin	NN	B-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
blockers	NNS	I-NP	O
if	IN	B-SBAR	O
proteinuria	NN	B-NP	B
occurs	VBZ	B-VP	O
and	CC	O	O
withdrawal	NN	B-NP	O
if	IN	B-SBAR	O
needed	VBN	B-VP	O
.	.	O	O

Further	RB	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
allograft	NN	I-NP	O
studies	NNS	I-NP	O
using	VBG	B-VP	O
sirolimus	NN	B-NP	O
as	IN	B-PP	O
de	FW	B-NP	O
novo	FW	I-NP	O
immunosuppression	NN	I-NP	O
along	IN	B-PP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
studies	NNS	I-NP	O
will	MD	B-VP	O
refine	VB	I-VP	O
these	DT	B-NP	O
issues	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
future	NN	I-NP	O
.	.	O	O

Progressive	JJ	B-NP	O
myopathy	NN	I-NP	B
with	IN	B-PP	O
up	RB	B-ADVP	O
-	HYPH	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
MHC	NN	B-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
statin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Statins	NNS	B-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
a	DT	B-NP	O
necrotizing	VBG	I-NP	O
myopathy	NN	I-NP	B
and	CC	I-NP	O
hyperCKaemia	NN	I-NP	B
which	WDT	B-NP	O
is	VBZ	B-VP	O
reversible	JJ	B-ADJP	O
on	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

What	WP	B-NP	O
is	VBZ	B-VP	O
less	RBR	I-VP	O
well	RB	I-VP	O
known	VBN	I-VP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
phenomenon	NN	I-NP	O
whereby	WRB	B-ADVP	O
statins	NNS	B-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
a	DT	B-NP	O
myopathy	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
persists	VBZ	B-VP	O
or	CC	O	O
may	MD	B-VP	O
progress	VB	I-VP	O
after	IN	B-PP	O
stopping	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
muscle	NN	I-NP	O
pathology	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
such	JJ	I-NP	O
cases	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
had	VBD	B-VP	O
myofibre	NN	B-NP	O
necrosis	NN	I-NP	B
but	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
inflammatory	JJ	I-NP	O
infiltrate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
cases	NNS	I-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
diffuse	JJ	B-ADJP	O
or	CC	I-ADJP	O
multifocal	JJ	I-ADJP	O
up	RB	B-ADVP	O
-	HYPH	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
MHC	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
expression	NN	I-NP	O
even	RB	B-ADVP	O
in	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
necrotic	JJ	I-NP	B
fibres	NNS	I-NP	O
.	.	O	O

Progressive	JJ	B-NP	O
improvement	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
after	IN	B-PP	O
commencement	NN	B-NP	O
of	IN	B-PP	O
prednisolone	NN	B-NP	O
and	CC	I-NP	O
methotrexate	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
case	NN	I-NP	O
spontaneously	RB	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
statins	NNS	B-NP	O
may	MD	B-VP	O
initiate	VB	I-VP	O
an	DT	B-NP	O
immune	JJ	I-NP	O
-	HYPH	I-NP	O
mediated	VBN	I-NP	O
myopathy	NN	I-NP	B
that	WDT	B-NP	O
persists	VBZ	B-VP	O
after	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
and	CC	O	O
responds	VBZ	B-VP	O
to	TO	B-PP	O
immunosuppressive	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
myopathy	NN	I-NP	B
is	VBZ	B-VP	O
uncertain	JJ	B-ADJP	O
but	CC	O	O
may	MD	B-VP	O
involve	VB	I-VP	O
the	DT	B-NP	O
induction	NN	I-NP	O
by	IN	B-PP	O
statins	NNS	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
endoplasmic	JJ	I-NP	O
reticulum	NN	I-NP	O
stress	NN	I-NP	O
response	NN	I-NP	O
with	IN	B-PP	O
associated	VBN	B-VP	O
up	RB	B-ADVP	O
-	HYPH	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
MHC	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
expression	NN	I-NP	O
and	CC	O	O
antigen	NN	B-NP	O
presentation	NN	I-NP	O
by	IN	B-PP	O
muscle	NN	B-NP	O
fibres	NNS	I-NP	O
.	.	O	O

Direct	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
hyperpolarization	NN	I-NP	O
-	HYPH	O	O
activated	VBN	B-VP	O
cyclic	JJ	B-NP	O
nucleotide	NN	I-NP	O
-	HYPH	B-VP	O
gated	VBN	B-NP	O
pacemaker	NN	I-NP	O
channels	NNS	I-NP	O
by	IN	B-PP	O
clonidine	NN	B-NP	O
.	.	O	O

Inhibition	NN	B-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
sympathetic	JJ	I-NP	O
tone	NN	I-NP	O
represents	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
strategy	NN	I-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
including	VBG	B-PP	O
arrhythmia	NN	B-NP	B
,	,	O	O
coronary	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
chronic	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
.	.	O	O

Activation	NN	B-NP	O
of	IN	B-PP	O
presynaptic	JJ	B-NP	O
alpha2	NN	I-NP	O
-	HYPH	B-NP	O
adrenoceptors	NNS	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
widely	RB	I-NP	O
accepted	VBN	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antisympathetic	JJ	I-NP	O
drug	NN	I-NP	O
clonidine	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
other	JJ	B-NP	O
target	NN	I-NP	O
proteins	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
postulated	VBN	I-VP	O
to	TO	I-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
test	VB	I-VP	O
whether	IN	B-SBAR	O
clonidine	NN	B-NP	O
elicits	VBZ	B-VP	O
pharmacological	JJ	B-NP	O
effects	NNS	I-NP	O
independent	JJ	B-ADJP	O
of	IN	B-PP	O
alpha2	NN	B-NP	O
-	HYPH	B-NP	O
adrenoceptors	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
have	VBP	B-VP	O
generated	VBN	I-VP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
targeted	VBN	I-NP	O
deletion	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
alpha2	NN	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
subtypes	NNS	I-NP	O
(	(	O	O
alpha2ABC	NN	B-NP	O
-	HYPH	O	O
/	SYM	B-NP	O
-	SYM	B-NP	O
)	)	O	O
.	.	O	O

Alpha2ABC	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
completely	RB	B-ADJP	O
unresponsive	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
hypnotic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
clonidine	NN	B-NP	O
significantly	RB	B-ADVP	O
lowered	VBD	B-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
alpha2ABC	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
by	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
bpm	NN	I-NP	O
.	.	O	O

Clonidine	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
bradycardia	NN	I-NP	B
in	IN	B-PP	O
conscious	JJ	B-NP	O
alpha2ABC	NN	I-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
similar	JJ	I-NP	O
bradycardic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
isolated	VBN	B-VP	O
spontaneously	RB	B-VP	O
beating	VBG	I-VP	O
right	JJ	B-NP	O
atria	NN	I-NP	O
from	IN	B-PP	O
alpha2ABC	NN	B-NP	O
-	HYPH	B-NP	O
knockout	NN	I-NP	O
and	CC	O	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Clonidine	NN	B-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
native	JJ	I-NP	O
pacemaker	NN	I-NP	O
current	NN	I-NP	O
(	(	O	O
I	NN	B-NP	O
(	(	O	O
f	NN	B-NP	O
)	)	O	O
)	)	O	O
in	IN	B-PP	O
isolated	VBN	B-NP	O
sinoatrial	JJ	I-NP	O
node	NN	I-NP	O
pacemaker	NN	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
I	NN	I-NP	O
(	(	O	O
f	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
generating	VBG	B-NP	O
hyperpolarization	NN	I-NP	O
-	HYPH	O	O
activated	VBN	B-VP	O
cyclic	JJ	B-NP	O
nucleotide	NN	I-NP	O
-	HYPH	B-VP	O
gated	VBN	I-VP	O
(	(	O	O
HCN	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
and	CC	O	O
HCN4	NN	B-NP	O
channels	NNS	I-NP	O
in	IN	B-PP	O
transfected	VBN	B-NP	O
HEK293	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
blocking	VBG	B-VP	O
I	NN	B-NP	O
(	(	O	O
f	NN	B-NP	O
)	)	O	O
,	,	O	O
clonidine	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
slope	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diastolic	JJ	I-NP	O
depolarization	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
pacemaker	NN	B-NP	O
potentials	NNS	I-NP	O
in	IN	B-PP	O
sinoatrial	JJ	B-NP	O
node	NN	I-NP	O
cells	NNS	I-NP	O
from	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
and	CC	I-NP	O
alpha2ABC	NN	I-NP	O
-	HYPH	B-NP	O
knockout	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Direct	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
HCN	NN	I-NP	O
pacemaker	NN	I-NP	O
channels	NNS	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
bradycardic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
gene	NN	I-NP	O
-	HYPH	B-NP	O
targeted	VBN	I-NP	O
mice	NNS	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
and	CC	O	O
thus	RB	O	O
,	,	O	O
clonidine	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
drugs	NNS	I-NP	O
represent	VBP	B-VP	O
novel	JJ	B-NP	O
structures	NNS	I-NP	O
for	IN	B-PP	O
future	JJ	B-NP	O
HCN	NN	I-NP	O
channel	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Influence	NN	B-NP	O
of	IN	B-PP	O
smoking	NN	B-NP	O
on	IN	B-PP	O
developing	VBG	B-VP	O
cochlea	NN	B-NP	O
.	.	O	O

Does	VBZ	O	O
smoking	NN	B-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
affect	VBP	B-VP	O
the	DT	B-NP	O
amplitudes	NNS	I-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
evoked	VBN	I-NP	O
otoacoustic	JJ	I-NP	O
emissions	NNS	I-NP	O
in	IN	B-PP	O
newborns	NNS	B-NP	O
?	.	O	O
OBJECTIVE	NN	B-NP	O
:	:	O	O
Maternal	JJ	B-NP	O
tobacco	NN	I-NP	O
smoking	NN	I-NP	O
has	VBZ	B-VP	O
negative	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
fetal	JJ	B-NP	O
growth	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
smoking	NN	B-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
developing	VBG	I-NP	O
cochlea	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
estimated	VBN	I-VP	O
,	,	O	O
although	IN	B-SBAR	O
smoking	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
positively	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
adults	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
maternal	JJ	B-NP	O
smoking	NN	I-NP	O
on	IN	B-PP	O
transient	JJ	B-NP	O
evoked	VBN	I-NP	O
otoacoustic	JJ	I-NP	O
emissions	NNS	I-NP	O
(	(	O	O
TEOAEs	NNS	B-NP	O
)	)	O	O
of	IN	B-PP	O
healthy	JJ	B-NP	O
neonates	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
neonatal	JJ	B-NP	O
screening	NN	I-NP	O
for	IN	B-PP	O
hearing	VBG	B-VP	B
impairment	NN	B-NP	I
and	CC	O	O
involved	VBD	B-VP	O
both	DT	B-NP	O
ears	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
newborns	NNS	I-NP	O
.	.	O	O

Newborns	NNS	B-NP	O
whose	WP$	B-NP	O
mothers	NNS	I-NP	O
reported	VBD	B-VP	O
smoking	NN	B-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
newborns	NNS	B-NP	O
,	,	O	O
whose	WP$	B-NP	O
mothers	NNS	I-NP	O
were	VBD	B-VP	O
non	AFX	B-ADJP	O
-	HYPH	B-NP	O
smokers	NNS	I-NP	O
.	.	O	O

Exposure	NN	B-NP	O
to	TO	B-PP	O
tobacco	NN	B-NP	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
as	IN	B-PP	O
low	JJ	B-ADJP	O
,	,	I-ADJP	O
moderate	JJ	I-ADJP	O
or	CC	I-ADJP	O
high	JJ	I-ADJP	O
.	.	O	O

In	IN	B-PP	O
exposed	VBN	B-NP	O
neonates	NNS	I-NP	O
,	,	O	O
TEOAEs	NNS	B-NP	O
mean	VBP	B-VP	O
response	NN	B-NP	O
(	(	O	O
across	IN	B-PP	O
frequency	NN	B-NP	O
)	)	O	O
and	CC	O	O
mean	JJ	B-NP	O
amplitude	NN	I-NP	O
at	IN	B-PP	O
4000Hz	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
exposed	VBN	B-NP	O
neonates	NNS	I-NP	O
.	.	O	O

Comparisons	NNS	B-NP	O
between	IN	B-PP	O
exposed	VBN	B-NP	O
newborns	NNS	I-NP	O
s	NNS	I-NP	O
subgroups	NNS	I-NP	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
by	IN	B-PP	O
comparing	VBG	B-VP	O
each	DT	B-NP	O
subgroup	NN	I-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
group	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
decreases	NNS	I-NP	B
of	IN	B-PP	I
TEOAEs	NNS	B-NP	I
amplitudes	NNS	I-NP	I
at	IN	B-PP	O
4000Hz	NNP	B-NP	O
for	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Mean	JJ	B-NP	O
TEOAEs	NNS	I-NP	O
responses	NNS	I-NP	O
of	IN	B-PP	O
highly	RB	B-NP	O
exposed	VBN	I-NP	O
newborns	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
utero	NN	B-NP	O
,	,	O	O
exposure	NN	B-NP	O
to	TO	B-PP	O
tobacco	NN	B-NP	O
smoking	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
small	JJ	I-NP	O
impact	NN	I-NP	O
on	IN	B-PP	O
outer	JJ	B-NP	O
hair	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
seem	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
equally	RB	B-ADJP	O
true	JJ	I-ADJP	O
for	IN	B-PP	O
all	DT	B-NP	O
exposed	VBN	I-NP	O
newborns	NNS	I-NP	O
,	,	O	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
exposure	NN	B-NP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
establish	VB	I-VP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
negative	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
maternal	JJ	B-NP	O
smoking	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
neonate	NN	I-NP	O
s	NN	I-NP	O
hearing	NN	I-NP	O
acuity	NN	I-NP	O
.	.	O	O

Neuroinflammation	NN	B-NP	B
and	CC	I-NP	O
behavioral	JJ	I-NP	B
abnormalities	NNS	I-NP	I
after	IN	B-PP	O
neonatal	JJ	B-NP	O
terbutaline	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
:	:	O	O
implications	NNS	B-NP	O
for	IN	B-PP	O
autism	NN	B-NP	B
.	.	O	O

Autism	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
neurodevelopmental	JJ	I-NP	B
disorder	NN	I-NP	I
presenting	VBG	B-VP	O
before	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
with	IN	B-PP	O
deficits	NNS	B-NP	B
in	IN	B-PP	I
communication	NN	B-NP	I
and	CC	O	I
social	JJ	B-NP	I
skills	NNS	I-NP	I
and	CC	O	O
repetitive	JJ	B-NP	B
behaviors	NNS	I-NP	I
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
genetic	JJ	B-NP	O
influences	NNS	I-NP	O
,	,	O	O
recent	JJ	B-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
prenatal	JJ	B-NP	O
drug	NN	I-NP	O
or	CC	I-NP	O
chemical	NN	I-NP	O
exposures	NNS	I-NP	O
are	VBP	B-VP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
autism	NN	B-NP	B
.	.	O	O

Terbutaline	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
beta2	NN	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
agonist	NN	I-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
arrest	VB	I-VP	O
preterm	JJ	B-NP	B
labor	NN	I-NP	I
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
concordance	NN	I-NP	O
for	IN	B-PP	O
autism	NN	B-NP	B
in	IN	B-PP	O
dizygotic	JJ	B-NP	O
twins	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
terbutaline	NN	B-NP	O
on	IN	B-PP	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
in	IN	B-PP	O
different	JJ	B-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
and	CC	O	O
behavioral	JJ	B-NP	O
outcomes	NNS	I-NP	O
in	IN	B-PP	O
developing	VBG	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Newborn	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
terbutaline	NN	B-NP	O
daily	RB	B-ADVP	O
on	IN	B-PP	O
postnatal	JJ	B-NP	O
days	NNS	I-NP	O
(	(	O	O
PN	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
or	CC	O	O
PN	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
and	CC	O	O
examined	VBD	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
dose	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
PN	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Immunohistochemical	JJ	B-NP	O
studies	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
administration	NN	B-NP	O
of	IN	B-PP	O
terbutaline	NN	B-NP	O
on	IN	B-PP	O
PN	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
robust	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
on	IN	B-PP	O
PN	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cerebral	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
cerebellar	JJ	B-NP	O
and	CC	I-NP	O
cerebrocortical	JJ	I-NP	O
white	JJ	I-NP	O
matter	NN	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
effects	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
given	VBN	B-VP	O
terbutaline	NN	B-NP	O
on	IN	B-PP	O
PN	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

In	IN	B-PP	O
behavioral	JJ	B-NP	O
tests	NNS	I-NP	O
,	,	O	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
terbutaline	NN	B-NP	O
on	IN	B-PP	O
PN	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
showed	VBD	B-VP	O
consistent	JJ	B-NP	O
patterns	NNS	I-NP	O
of	IN	B-PP	O
hyper	NN	B-NP	O
-	HYPH	B-NP	O
reactivity	NN	I-NP	O
to	TO	B-PP	O
novelty	NN	B-NP	O
and	CC	O	O
aversive	JJ	B-NP	O
stimuli	NNS	I-NP	O
when	WRB	B-ADVP	O
assessed	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
open	JJ	I-NP	O
field	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
the	DT	B-NP	O
acoustic	JJ	I-NP	O
startle	NN	I-NP	O
response	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
beta2	NN	B-NP	O
-	HYPH	B-NP	O
adrenoceptor	NN	I-NP	O
overstimulation	NN	I-NP	O
during	IN	B-PP	O
an	DT	B-NP	O
early	JJ	I-NP	O
critical	JJ	I-NP	O
period	NN	I-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
innate	JJ	B-NP	O
neuroinflammatory	JJ	I-NP	O
pathways	NNS	I-NP	O
and	CC	O	O
behavioral	JJ	B-NP	B
abnormalities	NNS	I-NP	I
,	,	O	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
described	VBN	B-VP	O
in	IN	B-PP	O
autism	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
provides	VBZ	B-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
understanding	VBG	B-VP	O
the	DT	B-NP	O
neuropathological	JJ	I-NP	O
processes	NNS	I-NP	O
underlying	VBG	B-VP	O
autism	NN	B-NP	B
spectrum	NN	I-NP	I
disorders	NNS	I-NP	I
.	.	O	O

Acute	JJ	B-NP	O
myocarditis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
clozapine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
myocarditis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
commencement	NN	I-NP	O
of	IN	B-PP	O
clozapine	NN	B-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
,	,	O	O
highlighting	VBG	B-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
,	,	O	O
course	NN	B-NP	O
and	CC	O	O
possible	JJ	B-NP	O
contributing	VBG	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
urgent	JJ	I-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
raise	VB	I-VP	O
awareness	NN	B-NP	O
about	IN	B-PP	O
this	DT	B-NP	O
potentially	RB	I-NP	O
fatal	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
clozapine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	NN	I-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
developed	VBD	B-VP	O
a	DT	B-NP	O
sudden	JJ	I-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
myocarditis	NN	B-NP	B
after	IN	B-PP	O
commencement	NN	B-NP	O
of	IN	B-PP	O
clozapine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
with	IN	B-PP	O
intensive	JJ	B-NP	O
medical	JJ	I-NP	O
support	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
symptoms	NNS	I-NP	O
occurred	VBD	B-VP	O
around	RB	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
clozapine	NN	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
inpatient	NN	I-NP	O
setting	NN	I-NP	O
.	.	O	O

Possible	JJ	B-NP	O
contributing	VBG	I-NP	O
factors	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
concomitant	JJ	B-NP	O
antidepressant	NN	I-NP	O
use	NN	I-NP	O
and	CC	O	O
unaccustomed	JJ	B-NP	O
physical	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Myocarditis	NN	B-NP	B
is	VBZ	B-VP	O
an	DT	B-NP	O
increasingly	RB	I-NP	O
recognized	VBN	I-NP	O
complication	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
clozapine	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
fatal	JJ	B-ADJP	O
if	IN	B-SBAR	O
not	RB	O	O
recognized	VBN	B-VP	O
and	CC	I-VP	O
treated	VBN	I-VP	O
early	RB	B-ADVP	O
.	.	O	O

Considering	VBG	B-VP	O
that	DT	B-NP	O
clozapine	NN	I-NP	O
remains	VBZ	B-VP	O
the	DT	B-NP	O
gold	JJ	I-NP	O
standard	NN	I-NP	O
in	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
resistant	JJ	B-NP	O
psychosis	NN	I-NP	B
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
urgent	JJ	I-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
raise	VB	I-VP	O
awareness	NN	B-NP	O
among	IN	B-PP	O
medical	JJ	B-NP	O
and	CC	I-NP	O
paramedical	JJ	I-NP	O
staff	NN	I-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
care	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
also	RB	B-ADVP	O
implications	NNS	B-NP	O
for	IN	B-PP	O
recommendations	NNS	B-NP	O
and	CC	I-NP	O
regulations	NNS	I-NP	O
regarding	VBG	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
clozapine	NN	B-NP	O
.	.	O	O

Encephalopathy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
levetiracetam	NN	B-NP	O
added	VBN	B-VP	O
to	TO	I-VP	O
valproate	VB	I-VP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
levetiracetam	NN	I-NP	O
(	(	O	O
LEV	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
idiopathic	JJ	B-NP	B
epilepsy	NN	I-NP	I
with	IN	B-PP	O
generalized	VBN	B-NP	O
seizures	NNS	I-NP	B
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
LEV	NN	B-NP	O
added	VBN	B-VP	O
to	TO	B-PP	O
valproate	NN	B-NP	O
(	(	O	O
VPA	NN	B-NP	O
)	)	O	O
.	.	O	O

Frequency	NN	B-NP	O
of	IN	B-PP	O
generalized	VBN	B-NP	O
tonic	JJ	I-NP	B
-	HYPH	I-NP	I
clonic	JJ	I-NP	I
seizures	NNS	I-NP	I
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
month	NN	B-NP	O
.	.	O	O

Neuropsychological	JJ	B-NP	O
testing	NN	I-NP	O
showed	VBD	B-VP	O
impaired	JJ	B-NP	B
word	NN	I-NP	I
fluency	NN	I-NP	I
,	,	O	I
psychomotor	NN	B-NP	I
speed	NN	I-NP	I
and	CC	O	I
working	VBG	B-NP	I
memory	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
interictal	JJ	I-NP	O
electroencephalogram	NN	I-NP	O
(	(	O	O
EEG	NN	B-NP	O
)	)	O	O
showed	VBD	B-VP	O
a	DT	B-NP	O
generalized	VBN	I-NP	O
slowing	VBG	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
second	JJ	B-NP	O
theta	NN	I-NP	O
rhythms	NNS	I-NP	O
with	IN	B-PP	O
bilateral	JJ	B-NP	O
generalized	VBN	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
amplitude	NN	I-NP	O
discharges	NNS	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
LEV	NN	B-NP	O
,	,	O	O
EEG	NN	B-NP	O
and	CC	O	O
neuropsychological	JJ	B-NP	O
findings	NNS	I-NP	O
improved	VBN	B-VP	O
and	CC	O	O
seizure	NN	B-NP	B
frequency	NN	I-NP	O
decreased	VBD	B-VP	O
.	.	O	O

Norepinephrine	NN	B-NP	O
signaling	NN	I-NP	O
through	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
receptors	NNS	I-NP	O
is	VBZ	B-VP	O
critical	JJ	B-ADJP	O
for	IN	B-PP	O
expression	NN	B-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anxiety	NN	I-NP	B
.	.	O	O

Cocaine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
widely	RB	I-NP	O
abused	JJ	I-NP	O
psychostimulant	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
both	CC	O	O
rewarding	JJ	B-NP	O
and	CC	I-NP	O
aversive	JJ	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
underlying	VBG	B-VP	O
cocaine	NN	B-NP	O
s	VBZ	B-VP	O
rewarding	JJ	B-NP	O
effects	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
studied	VBN	I-VP	O
extensively	RB	B-ADVP	O
,	,	O	O
less	JJR	B-NP	O
attention	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
paid	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
unpleasant	JJ	I-NP	O
behavioral	JJ	I-NP	O
states	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
anxiety	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
performance	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
beta	SYM	O	O
-	HYPH	O	O
hydroxylase	NN	B-NP	O
knockout	NN	I-NP	O
(	(	O	O
Dbh	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	SYM	O	O
)	)	O	O
mice	NNS	B-NP	O
,	,	O	O
which	WDT	B-NP	O
lack	VBP	B-VP	O
norepinephrine	NN	B-NP	O
(	(	O	O
NE	NN	B-NP	O
)	)	O	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
elevated	JJ	I-NP	O
plus	CC	O	O
maze	NN	B-NP	O
(	(	O	O
EPM	NN	B-NP	O
)	)	O	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
noradrenergic	JJ	B-NP	O
signaling	NN	I-NP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anxiety	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
cocaine	NN	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-VP	O
dependently	RB	I-VP	O
increased	VBN	B-NP	O
anxiety	NN	I-NP	B
-	HYPH	O	O
like	JJ	B-NP	O
behavior	NN	I-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
(	(	O	O
Dbh	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
)	)	O	O
mice	NNS	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
open	JJ	B-NP	O
arm	NN	I-NP	O
exploration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
Dbh	NN	I-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
had	VBD	B-VP	O
normal	JJ	B-NP	O
baseline	NN	I-NP	O
performance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
EPM	NN	I-NP	O
but	CC	O	O
were	VBD	B-VP	O
completely	RB	B-ADJP	O
resistant	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
anxiogenic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anxiety	NN	I-NP	B
was	VBD	B-VP	O
also	RB	I-VP	O
attenuated	VBN	I-VP	O
in	IN	B-PP	O
Dbh	NN	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	HYPH	B-NP	O
mice	NNS	I-NP	O
following	VBG	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
disulfiram	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
dopamine	NN	I-NP	O
beta	SYM	O	O
-	HYPH	O	O
hydroxylase	NN	B-NP	O
(	(	O	O
DBH	NN	B-NP	O
)	)	O	O
inhibitor	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
experiments	NNS	B-NP	O
using	VBG	B-VP	O
specific	JJ	B-NP	O
adrenergic	JJ	I-NP	O
antagonists	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
propranolol	NN	I-NP	O
blocked	VBD	B-VP	O
cocaine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
anxiety	NN	I-NP	B
-	HYPH	O	O
like	JJ	B-NP	O
behavior	NN	I-NP	O
in	IN	B-PP	O
Dbh	NN	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
wild	JJ	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
C57BL6	NN	I-NP	O
/	SYM	B-NP	O
J	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
alpha	NN	I-NP	O
antagonist	NN	I-NP	O
prazosin	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
alpha	NN	I-NP	O
antagonist	NN	I-NP	O
yohimbine	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
noradrenergic	JJ	B-NP	O
signaling	NN	I-NP	O
via	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
receptors	NNS	I-NP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anxiety	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Clonidine	NN	B-NP	O
for	IN	B-PP	O
attention	NN	B-NP	B
-	HYPH	I-NP	I
deficit	NN	I-NP	I
/	SYM	I-NP	I
hyperactivity	NN	I-NP	I
disorder	NN	I-NP	I
:	:	O	O
num	CD	B-NP	O
.	.	O	O

ECG	NN	B-NP	O
changes	NNS	I-NP	O
and	CC	O	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
used	VBN	B-VP	O
alone	RB	B-ADVP	O
or	CC	O	O
with	IN	B-PP	O
methylphenidate	NN	B-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
attention	NN	B-NP	B
-	HYPH	I-NP	I
deficit	NN	I-NP	I
/	SYM	O	I
hyperactivity	NN	B-NP	I
disorder	NN	I-NP	I
(	(	O	O
ADHD	NN	B-NP	B
)	)	O	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
multicenter	NN	I-NP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
ADHD	NN	B-NP	B
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
clonidine	NN	B-NP	O
,	,	I-NP	O
methylphenidate	NN	I-NP	O
,	,	I-NP	O
clonidine	NN	I-NP	O
and	CC	I-NP	O
methylphenidate	NN	I-NP	O
,	,	O	O
or	CC	O	O
placebo	NN	B-NP	O
.	.	O	O

Doses	NNS	B-NP	O
were	VBD	B-VP	O
flexibly	RB	I-VP	O
titrated	VBN	I-VP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
clonidine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
methylphenidate	NN	B-NP	O
(	(	O	O
both	DT	B-NP	O
with	IN	B-PP	O
divided	VBN	B-NP	O
dosing	NN	I-NP	O
)	)	O	O
.	.	O	O

Groups	NNS	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
regarding	VBG	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
and	CC	I-NP	O
changes	NNS	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
to	TO	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
electrocardiograms	NNS	B-NP	O
and	CC	O	O
vital	JJ	B-NP	O
signs	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
more	JJR	B-NP	O
incidents	NNS	I-NP	O
of	IN	B-PP	O
bradycardia	NN	B-NP	B
in	IN	B-PP	O
subjects	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
clonidine	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
not	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
clonidine	NN	B-NP	O
,	,	O	O
but	CC	O	O
no	DT	B-NP	O
other	JJ	I-NP	O
significant	JJ	I-NP	O
group	NN	I-NP	O
differences	NNS	I-NP	O
regarding	VBG	B-VP	O
electrocardiogram	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
suggestions	NNS	I-NP	O
of	IN	B-PP	O
interactions	NNS	B-NP	O
between	IN	B-PP	O
clonidine	NN	B-NP	O
and	CC	I-NP	O
methylphenidate	NN	I-NP	O
regarding	VBG	B-VP	O
cardiovascular	JJ	B-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

Moderate	JJ	B-NP	O
or	CC	I-NP	O
severe	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
on	IN	B-PP	O
clonidine	NN	B-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
higher	JJR	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
early	JJ	B-NP	O
study	NN	I-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

Drowsiness	NN	B-NP	B
was	VBD	B-VP	O
common	JJ	B-ADJP	O
on	IN	B-PP	O
clonidine	NN	B-NP	O
,	,	O	O
but	CC	O	O
generally	RB	B-VP	O
resolved	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Clonidine	NN	B-NP	O
,	,	O	O
used	VBN	B-VP	O
alone	RB	B-ADVP	O
or	CC	O	O
with	IN	B-PP	O
methylphenidate	NN	B-NP	O
,	,	O	O
appears	VBZ	B-VP	O
safe	JJ	B-ADJP	O
and	CC	O	O
well	RB	B-ADJP	O
tolerated	VBN	I-ADJP	O
in	IN	B-PP	O
childhood	NN	B-NP	O
ADHD	NN	I-NP	B
.	.	O	O

Physicians	NNS	B-NP	O
prescribing	VBG	B-VP	O
clonidine	NN	B-NP	O
should	MD	B-VP	O
monitor	VB	I-VP	O
for	IN	B-PP	O
bradycardia	NN	B-NP	B
and	CC	I-NP	O
advise	NN	I-NP	O
patients	NNS	I-NP	O
about	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
likelihood	NN	I-NP	O
of	IN	B-PP	O
initial	JJ	B-NP	O
drowsiness	NN	I-NP	B
.	.	O	O

Thalidomide	NN	B-NP	O
has	VBZ	B-VP	O
limited	VBN	I-VP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
agent	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
relapsed	JJ	B-NP	O
or	CC	I-NP	O
refractory	JJ	I-NP	O
indolent	JJ	I-NP	O
non	AFX	I-NP	B
-	HYPH	I-NP	I
Hodgkin	NN	I-NP	I
lymphomas	NNS	I-NP	I
:	:	O	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Cancer	NNP	I-NP	B
and	CC	I-NP	O
Leukemia	NNP	I-NP	B
Group	NNP	I-NP	O
B	NNP	I-NP	O
.	.	O	O

Thalidomide	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
immunomodulatory	JJ	I-NP	O
agent	NN	I-NP	O
with	IN	B-PP	O
demonstrated	VBN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
multiple	JJ	B-NP	B
myeloma	NN	I-NP	I
,	,	O	O
mantle	NN	B-NP	B
cell	NN	I-NP	I
lymphoma	NN	I-NP	I
and	CC	O	O
lymphoplasmacytic	JJ	B-NP	B
lymphoma	NN	I-NP	I
.	.	O	O

Its	PRP$	B-NP	O
activity	NN	I-NP	O
is	VBZ	B-VP	O
believed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
due	JJ	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tumour	NN	I-NP	B
milieu	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
downregulation	NN	B-NP	O
of	IN	B-PP	O
angiogenesis	NN	B-NP	O
and	CC	O	O
inflammatory	JJ	B-NP	O
cytokines	NNS	I-NP	O
.	.	O	O

Between	IN	B-PP	O
July	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
April	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
relapsed	VBN	B-NP	O
/	SYM	I-NP	O
refractory	JJ	I-NP	O
indolent	JJ	I-NP	O
lymphomas	NNS	I-NP	B
received	VBD	B-VP	O
thalidomide	IN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
daily	RB	B-ADVP	O
with	IN	B-PP	O
escalation	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
daily	RB	B-ADVP	O
every	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
as	IN	B-SBAR	O
tolerated	VBN	B-VP	O
,	,	O	O
up	IN	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
maximum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
daily	RB	B-ADVP	O
.	.	O	O

Patients	NNS	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
a	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
prior	JJ	B-NP	O
regimens	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
remission	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
remission	NN	I-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
progressed	VBD	B-VP	O
during	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Grade	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
included	VBD	B-VP	O
myelosuppression	NN	B-NP	B
,	,	O	O
fatigue	NN	B-NP	B
,	,	O	O
somnolence	NN	B-NP	B
/	SYM	B-NP	O
depressed	JJ	I-NP	B
mood	NN	I-NP	I
,	,	I-NP	O
neuropathy	NN	I-NP	B
and	CC	I-NP	O
dyspnea	NN	I-NP	B
.	.	O	O

Of	IN	B-PP	O
concern	NN	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
thromboembolic	JJ	I-NP	B
events	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
demonstrate	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
to	TO	B-PP	O
single	JJ	B-NP	O
agent	NN	I-NP	O
thalidomide	NN	I-NP	O
in	IN	B-PP	O
indolent	JJ	B-NP	O
lymphomas	NNS	I-NP	B
and	CC	O	O
contrast	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
activity	NN	I-NP	O
level	NN	I-NP	O
reported	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
generation	NN	I-NP	O
immunomodulatory	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
lenalidomide	NN	B-NP	O
.	.	O	O

Intracavernous	JJ	B-NP	O
epinephrine	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
minimally	RB	I-NP	O
invasive	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
priapism	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
.	.	O	O

Priapism	NN	B-NP	B
is	VBZ	B-VP	O
the	DT	B-NP	O
prolonged	VBN	I-NP	O
erection	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
penis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	O
arousal	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
admitted	VBN	I-NP	O
frequent	JJ	I-NP	O
cocaine	NN	I-NP	O
user	NN	I-NP	O
,	,	O	O
presented	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
Emergency	NNP	I-NP	O
Department	NNP	I-NP	O
(	(	O	O
ED	VBN	B-VP	O
)	)	O	O
on	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
occasions	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
priapism	NN	B-NP	B
after	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
management	NN	I-NP	O
options	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ED	NNP	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
exemplified	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
individual	JJ	I-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
particular	JJ	B-ADJP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
minimally	RB	I-NP	O
invasive	JJ	I-NP	O
method	NN	I-NP	O
of	IN	B-PP	O
intracorporal	JJ	B-NP	O
epinephrine	NN	I-NP	O
instillation	NN	I-NP	O
,	,	O	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
green	JJ	B-NP	O
tea	NN	I-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
E	NN	I-NP	O
combination	NN	I-NP	O
in	IN	B-PP	O
isoproterenol	NN	B-NP	O
induced	VBD	B-VP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
aimed	VBN	I-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
combined	VBN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
green	JJ	B-NP	O
tea	NN	I-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
E	NN	I-NP	O
on	IN	B-PP	O
heart	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
body	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
serum	NN	B-NP	O
marker	NN	I-NP	O
enzymes	NNS	I-NP	O
,	,	O	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
,	,	O	O
endogenous	JJ	B-NP	O
antioxidants	NNS	I-NP	O
and	CC	O	O
membrane	NN	B-NP	O
bound	VBD	B-VP	O
ATPases	NNS	B-NP	O
in	IN	B-PP	O
isoproterenol	NN	B-NP	O
(	(	O	O
ISO	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Adult	JJ	B-NP	O
male	JJ	I-NP	O
albino	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
ISO	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
at	IN	B-PP	O
an	DT	B-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
serum	NN	B-NP	O
marker	NN	I-NP	O
enzymes	NNS	I-NP	O
,	,	O	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
and	CC	I-NP	O
Ca+2	NN	I-NP	O
ATPase	NN	I-NP	O
level	NN	I-NP	O
whereas	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
endogenous	JJ	B-NP	O
antioxidants	NNS	I-NP	O
,	,	O	O
Na	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
K	NN	B-NP	O
+	SYM	I-NP	O
ATPase	NN	I-NP	O
and	CC	I-NP	O
Mg+2	NN	I-NP	O
ATPase	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
green	JJ	B-NP	O
tea	NN	I-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
E	NN	I-NP	O
together	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
and	CC	O	O
challenged	VBD	B-VP	O
with	IN	B-PP	O
ISO	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
day	NN	I-NP	O
29th	JJ	B-ADJP	O
and	CC	I-ADJP	O
30th	JJ	I-ADJP	O
,	,	O	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
serum	NN	B-NP	O
marker	NN	I-NP	O
enzymes	NNS	I-NP	O
,	,	O	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
,	,	O	O
Ca+2	NN	B-NP	O
ATPase	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
body	NN	I-NP	O
weight	NN	I-NP	O
,	,	O	O
endogenous	JJ	B-NP	O
antioxidants	NNS	I-NP	O
,	,	O	O
Na	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
K	NN	B-NP	O
+	SYM	I-NP	O
ATPase	NN	I-NP	O
and	CC	I-NP	O
Mg+2	NN	I-NP	O
ATPase	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
ISO	NN	B-NP	O
treated	JJ	I-NP	O
group	NN	I-NP	O
and	CC	O	O
green	JJ	B-NP	O
tea	NN	I-NP	O
or	CC	I-NP	O
vitamin	NN	I-NP	O
E	NN	I-NP	O
alone	RB	B-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
the	DT	B-NP	O
synergistic	JJ	I-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
green	JJ	B-NP	O
tea	NN	I-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
E	NN	I-NP	O
during	IN	B-PP	O
ISO	NN	B-NP	O
induced	VBD	B-VP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
ocular	JJ	B-NP	B
myasthenia	NN	I-NP	I
during	IN	B-PP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
experienced	JJ	I-NP	O
sudden	JJ	I-NP	O
diplopia	NN	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
(	(	O	O
IFN	NN	B-NP	O
)	)	O	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
2b	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
(	(	O	O
CHC	NN	B-NP	B
)	)	O	O
.	.	O	O

Ophthalmologic	JJ	B-NP	O
examinations	NNS	I-NP	O
showed	VBD	B-VP	O
ptosis	NN	B-NP	B
on	IN	B-PP	I
the	DT	B-NP	I
right	JJ	I-NP	I
upper	JJ	I-NP	I
lid	NN	I-NP	I
and	CC	O	O
restricted	JJ	B-NP	B
right	JJ	I-NP	I
eye	NN	I-NP	I
movement	NN	I-NP	I
without	IN	B-PP	O
any	DT	B-NP	O
other	JJ	I-NP	O
neurological	JJ	I-NP	O
signs	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
brain	NN	I-NP	O
imaging	NN	I-NP	O
study	NN	I-NP	O
and	CC	O	O
repetitive	JJ	B-NP	O
nerve	NN	I-NP	O
stimulation	NN	I-NP	O
test	NN	I-NP	O
indicated	VBD	B-VP	O
no	DT	B-NP	O
abnormality	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
acetylcholine	NN	I-NP	O
receptor	NN	I-NP	O
antibody	NN	I-NP	O
titer	NN	I-NP	O
and	CC	O	O
response	NN	B-NP	O
to	TO	B-PP	O
acetylcholinesterase	NN	B-NP	O
inhibitors	NNS	I-NP	O
were	VBD	B-VP	O
negative	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
thyroid	JJ	B-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
ophthalmological	JJ	B-NP	O
symptoms	NNS	I-NP	O
improved	VBD	B-VP	O
rapidly	RB	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
pegylated	VBN	B-NP	O
IFN	NN	I-NP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
2b	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ocular	JJ	I-NP	B
myasthenia	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
pegylated	VBN	B-NP	O
IFN	NN	I-NP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
2b	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
for	IN	B-PP	O
CHC	NN	B-NP	B
is	VBZ	B-VP	O
very	RB	B-VP	O
rarely	RB	I-VP	O
reported	VBN	I-VP	O
;	:	O	O
therefore	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
present	VBP	B-VP	O
this	DT	B-NP	O
case	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
various	JJ	I-NP	O
eye	NN	I-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
IFN	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
glycine	NN	I-NP	O
transporter	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
inhibitor	NN	I-NP	O
SSR103800	NN	I-NP	O
displays	VBZ	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
and	CC	I-NP	O
specific	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
profile	NN	I-NP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
and	CC	I-NP	O
transgenic	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Schizophrenia	NNP	B-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
initially	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
dysfunction	NN	B-NP	O
in	IN	B-PP	O
dopamine	NN	B-NP	O
neurotransmission	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
observation	NN	I-NP	O
that	IN	B-SBAR	O
antagonists	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glutamate	NN	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
aspartate	NN	I-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
produce	VBP	B-VP	O
schizophrenic	JJ	B-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
symptoms	NNS	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
has	VBZ	B-VP	O
led	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
idea	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
dysfunctioning	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glutamatergic	JJ	I-NP	O
system	NN	I-NP	O
via	IN	B-PP	O
its	PRP$	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
growing	VBG	I-NP	O
interest	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
pharmacological	JJ	B-NP	O
agents	NNS	I-NP	O
with	IN	B-PP	O
potential	JJ	B-NP	O
antipsychotic	JJ	I-NP	O
properties	NNS	I-NP	O
that	WDT	B-NP	O
enhance	VBP	B-VP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glutamatergic	JJ	I-NP	O
system	NN	I-NP	O
via	IN	B-PP	O
a	DT	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
them	PRP	B-NP	O
are	VBP	B-VP	O
glycine	NN	B-NP	O
transporter	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
GlyT1	NN	B-NP	O
)	)	O	O
inhibitors	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
SSR103800	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
indirectly	RB	B-ADVP	O
enhance	VBP	B-VP	O
NMDA	NN	B-NP	O
receptor	NN	I-NP	O
function	NN	I-NP	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
glycine	NN	I-NP	O
(	(	O	O
a	DT	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
agonist	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
)	)	O	O
levels	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
synapse	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
aimed	VBN	B-VP	O
at	IN	B-PP	O
investigating	VBG	B-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
SSR103800	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
particular	JJ	I-NP	O
focus	NN	I-NP	O
on	IN	B-PP	O
models	NNS	B-NP	O
of	IN	B-PP	O
hyperactivity	NN	B-NP	B
,	,	O	O
involving	VBG	B-VP	O
either	CC	O	O
drug	NN	B-NP	O
challenge	NN	I-NP	O
(	(	O	O
ie	FW	B-NP	O
,	,	I-NP	O
amphetamine	NN	I-NP	O
and	CC	I-NP	O
MK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
or	CC	O	O
transgenic	JJ	B-NP	O
mice	NNS	I-NP	O
(	(	O	O
ie	FW	B-NP	O
,	,	O	O
NMDA	NN	B-NP	O
Nr1	NN	I-NP	O
(	(	O	O
neo	AFX	O	O
-	HYPH	O	O
/	SYM	B-NP	O
-	SYM	B-NP	O
)	)	O	O
and	CC	O	O
DAT	NN	B-NP	O
)	)	O	O
.	.	O	O

Results	NNS	B-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
SSR103800	NN	B-NP	O
blocked	VBD	B-VP	O
hyperactivity	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
competitive	JJ	I-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
MK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
partially	RB	B-VP	O
reversed	VBD	I-VP	O
spontaneous	JJ	B-NP	O
hyperactivity	NN	I-NP	B
of	IN	B-PP	O
NMDA	NN	B-NP	O
Nr1	NN	I-NP	O
(	(	O	O
neo	AFX	O	O
-	HYPH	O	O
/	SYM	O	O
-	SYM	O	O
)	)	O	O
mice	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
SSR103800	NN	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
affect	VB	I-VP	O
hyperactivity	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
amphetamine	NN	B-NP	O
or	CC	O	O
naturally	RB	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
dopamine	NN	B-NP	O
transporter	NN	I-NP	O
(	(	O	O
DAT	NN	B-NP	O
)	)	O	O
knockout	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Importantly	RB	B-ADVP	O
,	,	O	O
both	DT	O	O
classical	JJ	O	O
(	(	O	O
haloperidol	NN	B-NP	O
)	)	O	O
and	CC	O	O
atypical	JJ	B-NP	O
(	(	O	O
olanzapine	NN	B-NP	O
,	,	O	O
clozapine	NN	B-NP	O
and	CC	O	O
aripiprazole	NN	B-NP	O
)	)	O	O
antipsychotics	NNS	B-NP	O
were	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
all	PDT	B-NP	O
these	DT	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
hyperactivity	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
unlike	IN	B-PP	O
these	DT	B-NP	O
latter	JJ	I-NP	O
,	,	O	O
SSR103800	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
catalepsy	NN	B-NP	B
(	(	O	O
retention	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
bar	NN	I-NP	O
test	NN	I-NP	O
)	)	O	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
p.o	NN	I-NP	O
.	.	O	O

Together	RB	B-ADVP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
GlyT1	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
SSR103800	NN	B-NP	O
,	,	O	O
produces	VBZ	B-VP	O
antipsychotic	JJ	B-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
differ	VBP	B-VP	O
from	IN	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
with	IN	B-PP	O
compounds	NNS	B-NP	O
primarily	RB	B-VP	O
targeting	VBG	I-VP	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
system	NN	I-NP	O
,	,	O	O
and	CC	O	O
has	VBZ	B-VP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
side	NN	I-NP	O
-	HYPH	I-NP	O
effect	NN	I-NP	O
potential	NN	I-NP	O
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
these	DT	B-NP	O
latter	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Phenylephrine	NN	B-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
ephedrine	NN	B-NP	O
reduces	VBZ	B-VP	B
frontal	JJ	B-NP	I
lobe	NN	I-NP	I
oxygenation	NN	I-NP	I
following	VBG	B-NP	O
anesthesia	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Vasopressor	NN	B-NP	O
agents	NNS	I-NP	O
are	VBP	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
correct	VB	I-VP	O
anesthesia	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
phenylephrine	NN	B-NP	O
and	CC	I-NP	O
ephedrine	NN	I-NP	O
on	IN	B-PP	O
frontal	JJ	B-NP	O
lobe	NN	I-NP	O
oxygenation	NN	I-NP	O
(	(	O	O
S	NN	B-NP	O
(	(	O	O
c	NN	B-NP	O
)	)	O	O
O	NN	B-NP	O
)	)	O	O
following	VBG	B-PP	O
anesthesia	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Following	VBG	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
by	IN	B-PP	O
fentanyl	NN	B-NP	O
and	CC	I-NP	O
propofol	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
phenylephrine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
ephedrine	NN	B-NP	O
to	TO	B-VP	O
restore	VB	I-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
.	.	O	O

Heart	NN	B-NP	O
rate	NN	I-NP	O
(	(	O	O
HR	NN	B-NP	O
)	)	O	O
,	,	O	O
MAP	NN	B-NP	O
,	,	O	O
stroke	NN	B-NP	B
volume	NN	I-NP	O
(	(	O	O
SV	NN	B-NP	O
)	)	O	O
,	,	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
(	(	O	O
CO	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
frontal	JJ	B-NP	O
lobe	NN	I-NP	O
oxygenation	NN	I-NP	O
(	(	O	O
S	NN	B-NP	O
(	(	O	O
c	NN	B-NP	O
)	)	O	O
O	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
registered	VBN	I-VP	O
.	.	O	O

Induction	NN	B-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	B
decrease	NN	I-NP	I
in	IN	B-PP	I
MAP	NN	B-NP	I
,	,	O	I
HR	NN	B-NP	I
,	,	O	I
SV	NN	B-NP	I
,	,	O	I
and	CC	O	I
CO	NN	B-NP	I
concomitant	JJ	B-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
S	NN	B-NP	O
(	(	O	O
c	NN	B-NP	O
)	)	O	O
O	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
phenylephrine	NN	B-NP	O
,	,	O	O
MAP	NN	B-NP	O
increased	VBD	B-VP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
S	NN	B-NP	O
(	(	O	O
c	NN	B-NP	O
)	)	O	O
O	NN	B-NP	O
followed	VBN	B-VP	O
with	IN	B-PP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
CO	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
MAP	NN	B-NP	O
,	,	O	O
restored	VBD	B-VP	O
CO	NN	B-NP	O
,	,	O	O
and	CC	O	O
preserved	VBN	B-VP	O
S	NN	B-NP	O
(	(	O	O
c	NN	B-NP	O
)	)	O	O
O	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
utilization	NN	I-NP	O
of	IN	B-PP	O
phenylephrine	NN	B-NP	O
to	TO	B-VP	O
correct	VB	I-VP	O
hypotension	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
anesthesia	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
negative	JJ	I-NP	O
impact	NN	I-NP	O
on	IN	B-PP	O
S	NN	B-NP	O
(	(	O	O
c	NN	B-NP	O
)	)	O	O
O	NN	B-NP	O
while	IN	B-SBAR	O
ephedrine	NN	B-NP	O
maintains	VBZ	B-VP	O
frontal	JJ	B-NP	O
lobe	NN	I-NP	O
oxygenation	NN	I-NP	O
potentially	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
CO	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
novel	JJ	I-NP	O
,	,	I-NP	O
multiple	JJ	I-NP	O
symptom	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
obsessive	JJ	B-NP	B
-	HYPH	I-NP	I
compulsive	JJ	I-NP	I
-	HYPH	I-NP	I
like	JJ	I-NP	I
behaviors	NNS	I-NP	I
in	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

Current	JJ	B-NP	O
animal	NN	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
obsessive	JJ	B-NP	B
-	HYPH	I-NP	I
compulsive	JJ	I-NP	I
disorder	NN	I-NP	I
(	(	O	O
OCD	NN	B-NP	B
)	)	O	O
typically	RB	B-ADVP	O
involve	VBP	B-VP	O
acute	JJ	B-NP	O
,	,	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
symptom	NN	I-NP	O
provocation	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
genetic	JJ	I-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
stereotypies	NNS	B-NP	O
or	CC	O	O
anxiety	NN	B-NP	B
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
current	JJ	I-NP	O
models	NNS	I-NP	O
demonstrate	VBP	B-VP	O
multiple	JJ	B-NP	O
OCD	NNP	I-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
behaviors	NNS	I-NP	O
.	.	O	O

Neonatal	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
tricyclic	JJ	I-NP	O
antidepressant	NN	I-NP	O
clomipramine	NN	I-NP	O
or	CC	I-NP	O
vehicle	NN	I-NP	O
between	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
twice	RB	I-NP	O
daily	RB	I-NP	O
and	CC	O	O
behaviorally	RB	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
adulthood	NN	B-NP	O
.	.	O	O

Clomipramine	NN	B-NP	O
exposure	NN	I-NP	O
in	IN	B-PP	O
immature	JJ	B-NP	O
rats	NNS	I-NP	O
produced	VBD	B-VP	O
significant	JJ	B-NP	O
behavioral	JJ	I-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
changes	NNS	I-NP	O
that	WDT	B-NP	O
include	VBP	B-VP	O
enhanced	VBN	I-VP	O
anxiety	NN	B-NP	B
(	(	O	O
elevated	VBN	B-VP	O
plus	CC	O	O
maze	NN	B-NP	O
and	CC	I-NP	O
marble	NN	I-NP	O
burying	NN	I-NP	O
)	)	O	O
,	,	O	O
behavioral	JJ	B-NP	B
inflexibility	NN	I-NP	I
(	(	O	O
perseveration	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
spontaneous	JJ	I-NP	O
alternation	NN	I-NP	O
task	NN	I-NP	O
and	CC	O	O
impaired	JJ	B-NP	O
reversal	NN	I-NP	O
learning	NN	I-NP	O
)	)	O	O
,	,	O	O
working	VBG	B-VP	O
memory	NN	B-NP	B
impairment	NN	I-NP	I
(	(	O	O
e.g.	FW	B-NP	O
,	,	O	O
win	NN	B-NP	O
-	HYPH	I-NP	O
shift	NN	I-NP	O
paradigm	NN	I-NP	O
)	)	O	O
,	,	O	O
hoarding	VBG	B-VP	B
,	,	O	O
and	CC	O	O
corticostriatal	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Dopamine	NN	B-NP	O
D2	NN	I-NP	O
receptors	NNS	I-NP	O
were	VBD	B-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
serotonin	NN	B-NP	O
2C	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
serotonin	NN	B-NP	O
1A	NN	I-NP	O
,	,	O	O
receptors	NNS	B-NP	O
were	VBD	B-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
orbital	JJ	I-NP	O
frontal	JJ	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
demonstration	NN	I-NP	O
of	IN	B-PP	O
multiple	JJ	B-NP	O
symptoms	NNS	I-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
OCD	NN	I-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
profile	NN	I-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
behaviors	NNS	I-NP	O
are	VBP	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
biochemical	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
regions	NNS	I-NP	O
previously	RB	B-VP	O
identified	VBN	I-VP	O
as	IN	B-PP	O
relevant	JJ	B-ADJP	O
to	TO	B-PP	O
OCD	NNP	B-NP	B
.	.	O	O

This	DT	B-NP	O
novel	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
OCD	NN	B-NP	B
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
drug	NN	B-NP	O
exposure	NN	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
sensitive	JJ	I-NP	O
period	NN	I-NP	O
can	MD	B-VP	O
program	VB	I-VP	O
disease	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
systems	NNS	I-NP	O
permanently	RB	B-ADVP	O
,	,	O	O
which	WDT	B-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
implications	NNS	B-NP	O
for	IN	B-PP	O
current	JJ	B-NP	O
and	CC	I-NP	O
future	JJ	I-NP	O
therapeutic	JJ	I-NP	O
strategies	NNS	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
psychiatric	JJ	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

Late	JJ	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
hemolytic	JJ	I-NP	B
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
hemolytic	JJ	I-NP	B
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
HUS	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
taking	VBG	B-VP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
,	,	I-NP	O
dipyridamole	NN	I-NP	O
and	CC	I-NP	O
hemodialysis	NN	I-NP	O
;	:	O	O
and	CC	O	O
after	IN	B-SBAR	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
,	,	O	O
her	PRP$	B-NP	O
urinary	JJ	I-NP	O
output	NN	I-NP	O
rose	VBD	B-VP	O
above	IN	B-PP	O
num	CD	B-NP	O
ml	NN	I-NP	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
anuria	NN	B-NP	B
,	,	O	O
dialysis	NN	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
emphasizes	VBZ	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
HUS	NN	B-NP	B
in	IN	B-PP	O
adults	NNS	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
invariably	RB	B-ADJP	O
irreversible	JJ	I-ADJP	O
and	CC	O	O
that	IN	B-SBAR	O
,	,	O	O
despite	IN	B-PP	O
prolonged	JJ	B-NP	O
oliguria	NN	I-NP	B
,	,	O	O
recovery	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
obtained	VBN	I-VP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
adult	JJ	B-NP	O
patients	NNS	I-NP	O
affected	VBN	B-VP	O
by	IN	B-PP	O
HUS	NN	B-NP	B
,	,	O	O
dialysis	NN	B-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
discontinued	VBN	I-VP	O
prematurely	RB	B-ADVP	O
;	:	O	O
moreover	RB	B-ADVP	O
,	,	O	O
bilateral	JJ	B-NP	O
nephrectomy	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hypertension	NN	I-NP	B
and	CC	O	O
microangiopathic	JJ	B-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
,	,	O	O
should	MD	B-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
caution	NN	B-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
acetylsalicylic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
dipyridamole	NN	B-NP	O
,	,	O	O
and	CC	O	O
hydrocortisone	NN	B-NP	O
on	IN	B-PP	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
reproducible	JJ	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
producing	VBG	B-VP	O
diffuse	JJ	B-NP	O
myocardial	JJ	I-NP	B
injury	NN	I-NP	I
(	(	O	O
epinephrine	NN	B-NP	O
infusion	NN	I-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
developed	VBN	I-VP	O
to	TO	I-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
cardioprotective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
agents	NNS	B-NP	O
or	CC	I-NP	O
maneuvers	NNS	I-NP	O
which	WDT	B-NP	O
might	MD	B-VP	O
alter	VB	I-VP	O
the	DT	B-NP	O
evolution	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

Infusions	NNS	B-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
increased	VBD	B-VP	O
radiocalcium	NN	B-NP	O
uptakes	VBZ	B-VP	O
into	IN	B-PP	O
intact	JJ	B-NP	O
myocardium	NN	I-NP	O
and	CC	O	O
each	DT	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
subcellular	JJ	I-NP	O
components	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
mitochondrial	JJ	I-NP	O
fraction	NN	I-NP	O
showing	VBG	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
consistent	JJ	I-NP	O
changes	NNS	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
saline	NN	B-NP	O
-	HYPH	O	O
infused	VBN	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
vs.	IN	I-NP	O
num	CD	I-NP	O
counts	NNS	I-NP	O
per	IN	B-PP	O
minute	NN	B-NP	O
per	IN	B-PP	O
gram	NN	B-NP	O
of	IN	B-PP	O
dried	VBN	B-NP	O
tissue	NN	I-NP	O
or	CC	I-NP	O
fraction	NN	I-NP	O
)	)	O	O
.	.	O	O

Myocardial	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
also	RB	B-ADVP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
.	.	O	O

Infusions	NNS	B-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
raise	VB	I-VP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
concentrations	NNS	I-NP	O
num	CD	B-NP	O
mEq.	NN	I-NP	O
per	IN	B-PP	O
liter	NN	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
calcium	NN	B-NP	O
influx	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
cell	NN	I-NP	O
.	.	O	O

Mitochondrial	JJ	B-NP	O
radiocalcium	NN	I-NP	O
uptakes	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
acetylsalicylic	JJ	B-NP	O
acid	NN	I-NP	O
or	CC	O	O
dipyridamole	NN	B-NP	O
or	CC	O	O
when	WRB	B-ADVP	O
hydrocortisone	NN	B-NP	O
was	VBD	B-VP	O
added	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
epinephrine	NN	I-NP	O
infusion	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
counts	NNS	I-NP	O
per	IN	B-PP	O
minute	NN	B-NP	O
per	IN	B-PP	O
gram	NN	B-NP	O
of	IN	B-PP	O
dried	VBN	B-NP	O
fraction	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Myocardial	JJ	B-NP	O
calcium	NN	I-NP	O
concentrations	NNS	I-NP	O
also	RB	B-ADVP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
being	VBG	B-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
.	.	O	O

Evidence	NN	B-NP	O
of	IN	B-PP	O
microscopic	JJ	B-NP	O
damage	NN	I-NP	O
was	VBD	B-VP	O
graded	VBN	I-VP	O
as	IN	B-PP	O
less	RBR	B-ADJP	O
severe	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Acetylsalicylic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
dipyridamole	NN	B-NP	O
,	,	O	O
and	CC	O	O
hydrocortisone	NN	B-NP	O
all	DT	O	O
appear	VBP	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
cardioprotective	JJ	B-NP	O
effects	NNS	I-NP	O
when	WRB	B-ADVP	O
tested	VBN	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
depressive	JJ	B-NP	B
status	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
topical	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

Depression	NN	B-NP	B
and	CC	I-NP	O
sexual	JJ	I-NP	B
dysfunction	NN	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
topical	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
preliminary	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
any	DT	B-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
a	DT	B-NP	O
non	JJ	I-NP	O
selective	JJ	I-NP	O
beta	SYM	O	O
-	HYPH	O	O
blocker	NN	B-NP	O
(	(	O	O
timolol	NN	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocker	NN	B-NP	O
(	(	O	O
betaxolol	NN	B-NP	O
)	)	O	O
regarding	VBG	B-VP	O
CNS	NN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
glaucomatous	JJ	I-NP	B
patients	NNS	I-NP	O
chronically	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
timolol	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
/	SYM	B-NP	O
12h	NN	I-NP	O
,	,	O	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
depression	NN	B-NP	B
diagnosed	VBN	B-VP	O
through	IN	B-PP	O
DMS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
R	NN	I-NP	O
criteria	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
follow	VB	B-VP	O
up	RP	B-PRT	O
,	,	O	O
depression	NN	B-NP	B
was	VBD	B-VP	O
quantified	VBN	I-VP	O
through	IN	B-PP	O
the	DT	B-NP	O
Beck	NNP	I-NP	O
and	CC	I-NP	O
Zung	NNP	I-NP	O
-	HYPH	O	O
Conde	NNP	B-NP	O
scales	VBZ	B-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
cross	AFX	O	O
-	HYPH	O	O
over	IN	B-PP	O
study	NN	B-NP	O
with	IN	B-PP	O
control	NN	B-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
under	IN	B-PP	O
timolol	NN	B-NP	O
treatment	NN	I-NP	O
presented	VBD	B-VP	O
higher	JJR	B-NP	O
depression	NN	I-NP	B
values	NNS	I-NP	O
measured	VBN	B-VP	O
through	IN	B-PP	O
the	DT	B-NP	O
Beck	NNP	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Zung	NNP	I-NP	O
-	HYPH	I-NP	O
Conde	NNP	I-NP	O
scales	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
betaxolol	NN	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
less	JJR	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
depression	NN	I-NP	B
-	HYPH	O	O
inducer	NN	B-NP	O
than	IN	B-PP	O
timolol	NN	B-NP	O
in	IN	B-PP	O
predisposed	VBN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
renal	JJ	I-NP	B
toxicity	NN	I-NP	I
in	IN	B-PP	O
children	NNS	B-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
malignant	JJ	B-NP	B
mesenchymal	JJ	I-NP	I
tumors	NNS	I-NP	I
:	:	O	O
an	DT	B-NP	O
International	NNP	I-NP	O
Society	NNP	I-NP	O
of	IN	B-PP	O
Pediatric	NNP	B-NP	O
Oncology	NNP	I-NP	O
report	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
malignant	JJ	B-NP	B
mesenchymal	JJ	I-NP	I
tumors	NNS	I-NP	I
in	IN	B-PP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
and	CC	O	O
who	WP	B-NP	O
have	VBP	B-VP	O
received	VBN	I-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
ifosfamide	NN	I-NP	O
chemotherapy	NN	I-NP	O
protocol	NN	I-NP	O
(	(	O	O
International	NNP	B-NP	O
Society	NNP	I-NP	O
of	IN	B-PP	O
Pediatric	NNP	B-NP	O
Oncology	NNP	I-NP	O
Malignant	NNP	I-NP	B
Mesenchymal	NNP	I-NP	I
Tumor	NNP	I-NP	I
Study	NNP	I-NP	O
num	CD	I-NP	O
[	(	O	O
SIOP	NN	B-NP	O
MMT	NN	I-NP	O
num	CD	I-NP	O
]	)	O	O
)	)	O	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
num	CD	B-NP	O
year	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Total	JJ	B-NP	O
cumulative	JJ	I-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
,	,	O	O
vincristine	NN	B-NP	O
,	,	O	O
and	CC	O	O
dactinomycin	NN	B-NP	O
[	(	O	O
IVA	NN	B-NP	O
]	)	O	O
)	)	O	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
cisplatin	NN	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Ages	NNS	B-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
males	NNS	B-NP	O
and	CC	O	O
num	CD	B-NP	O
females	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
primary	JJ	I-NP	O
tumor	NN	I-NP	B
site	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
head	NN	I-NP	O
and	CC	I-NP	O
neck	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
by	IN	B-PP	O
measuring	VBG	B-VP	O
plasma	NN	B-NP	O
and	CC	O	O
urinary	JJ	B-NP	O
electrolytes	NNS	I-NP	O
,	,	O	O
glucosuria	NN	B-NP	B
,	,	O	O
proteinuria	NN	B-NP	B
,	,	O	O
aminoaciduria	NN	B-NP	B
,	,	O	O
urinary	JJ	B-NP	O
pH	NN	I-NP	O
,	,	O	O
osmolarity	NN	B-NP	O
,	,	O	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
,	,	O	O
phosphate	NN	B-NP	O
tubular	JJ	I-NP	O
reabsorption	NN	I-NP	O
,	,	O	O
beta	SYM	B-NP	O
num	CD	B-NP	O
microglobulinuria	NNS	I-NP	O
,	,	O	O
and	CC	O	O
lysozymuria	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
normal	JJ	B-NP	O
renal	JJ	I-NP	O
tests	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
renal	JJ	B-NP	B
abnormalities	NNS	I-NP	I
.	.	O	O

num	CD	B-NP	O
subsets	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
from	IN	B-PP	O
this	DT	B-NP	O
latter	JJ	I-NP	O
group	NN	I-NP	O
:	:	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
population	NN	I-NP	O
)	)	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
major	JJ	B-NP	O
toxicity	NN	I-NP	B
resulting	VBG	B-VP	O
in	IN	B-PP	O
Fanconi	NNP	B-NP	B
s	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
TDFS	NN	B-NP	B
)	)	O	O
;	:	O	O
and	CC	O	O
the	DT	B-NP	O
second	JJ	I-NP	O
group	NN	I-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
elevated	VBN	B-NP	O
beta	SYM	I-NP	O
num	CD	I-NP	O
microglobulinuria	NNS	I-NP	O
and	CC	O	O
low	JJ	B-NP	O
phosphate	NN	I-NP	O
reabsorption	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
isolated	VBN	I-VP	O
beta	SYM	B-NP	O
num	CD	B-NP	O
microglobulinuria	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
toxicity	NN	I-NP	B
was	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
younger	JJR	I-NP	O
age	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
predominance	NN	I-NP	O
of	IN	B-PP	O
vesicoprostatic	JJ	B-NP	O
tumor	NN	I-NP	B
involvement	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
low	JJ	I-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
TDFS	NN	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
evaluated	VBN	I-VP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
mesenchymal	JJ	B-NP	B
tumors	NNS	I-NP	I
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

Evidence	NN	B-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
D1	NN	B-NP	O
and	CC	I-NP	O
D2	NN	I-NP	O
dopamine	NN	I-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
mediating	VBG	B-VP	O
nicotine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperactivity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
repeated	VBN	B-NP	O
exposure	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
or	CC	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
environment	NN	I-NP	O
is	VBZ	B-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
observe	VB	I-VP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
stimulation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
habituation	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
environment	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
stimulant	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
mediating	VBG	B-VP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
stimulation	NN	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
by	IN	B-PP	O
examining	VBG	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
selective	JJ	B-NP	O
D1	NN	I-NP	O
and	CC	I-NP	O
D2	NN	I-NP	O
dopamine	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
on	IN	B-PP	O
activity	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
nicotine	NN	B-NP	O
.	.	O	O

Locomotor	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
tested	VBN	B-VP	O
in	IN	B-PP	O
photocell	NN	B-NP	O
cages	NNS	I-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
locomotor	NN	B-NP	I
activity	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
habituated	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
environment	NN	I-NP	O
,	,	O	O
but	CC	O	O
had	VBD	B-VP	O
only	RB	B-NP	O
a	DT	I-NP	O
weak	JJ	I-NP	O
and	CC	I-NP	O
delayed	VBN	I-NP	O
stimulant	NN	I-NP	O
action	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
unfamiliar	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
environment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
stimulant	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
was	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nicotinic	JJ	I-NP	O
antagonist	NN	I-NP	O
mecamylamine	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
by	IN	I-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nicotinic	JJ	I-NP	O
blocker	NN	I-NP	O
hexamethonium	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
response	NN	I-NP	O
is	VBZ	B-VP	O
probably	RB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
central	JJ	B-NP	O
nicotinic	JJ	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
was	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
selective	JJ	I-NP	O
D1	NN	I-NP	O
antagonist	NN	I-NP	O
SCH	NN	I-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
selective	JJ	I-NP	O
D2	NN	I-NP	O
antagonist	NN	I-NP	O
raclopride	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
D1	NN	I-NP	O
/	SYM	B-NP	O
D2	NN	I-NP	O
antagonist	NN	I-NP	O
fluphenazine	NN	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
D2	NN	I-NP	O
agonist	NN	I-NP	O
PHNO	NN	I-NP	O
enhanced	VBD	B-VP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
D1	NN	I-NP	O
agonist	NN	I-NP	O
SKF	NN	I-NP	O
num	CD	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
acute	JJ	B-NP	O
nicotine	NN	I-NP	O
injection	NN	I-NP	O
induces	VBZ	B-VP	O
a	DT	B-NP	O
pronounced	JJ	I-NP	O
hyperactivity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
habituated	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
environment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
central	JJ	B-NP	O
nicotine	NN	I-NP	O
receptors	NNS	I-NP	O
,	,	O	O
possibly	RB	B-VP	O
located	VBN	I-VP	O
on	IN	B-PP	O
dopaminergic	JJ	B-NP	O
neurons	NNS	I-NP	O
,	,	O	O
and	CC	O	O
also	RB	B-VP	O
requires	VBZ	I-VP	O
the	DT	B-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
both	CC	O	O
D1	NN	B-NP	O
and	CC	O	O
D2	NN	B-NP	O
dopamine	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Neuropsychiatric	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
mefloquine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
describes	VBZ	B-VP	O
neuropsychiatric	JJ	B-NP	O
side	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
mefloquine	NN	B-NP	O
.	.	O	O

Reactions	NNS	B-NP	O
consisted	VBD	B-VP	O
mainly	RB	B-ADVP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
acute	JJ	B-NP	O
psychoses	NNS	I-NP	B
,	,	O	O
anxiety	NN	B-NP	B
neurosis	NN	I-NP	I
,	,	O	O
and	CC	O	O
major	JJ	B-NP	O
disturbances	NNS	I-NP	B
of	IN	B-PP	I
sleep	NN	B-NP	I
-	HYPH	B-NP	I
wake	NN	I-NP	I
rhythm	NN	I-NP	I
.	.	O	O

Side	NN	B-NP	O
effects	NNS	I-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
both	CC	B-NP	O
therapeutic	JJ	I-NP	O
and	CC	I-NP	O
prophylactic	JJ	I-NP	O
intake	NN	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
graded	VBN	I-VP	O
from	IN	B-PP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
risk	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
neuropsychiatric	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
Germany	NNP	B-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
estimated	VBN	I-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mefloquine	NN	I-NP	O
users	NNS	I-NP	O
suffers	VBZ	B-VP	O
from	IN	B-PP	O
such	JJ	B-NP	O
reactions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
calculation	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
therapeutic	JJ	I-NP	O
users	NNS	I-NP	O
had	VBD	B-VP	O
reactions	NNS	B-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prophylaxis	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
making	VBG	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
neuropsychiatric	JJ	B-NP	O
reactions	NNS	I-NP	O
after	IN	B-PP	O
mefloquine	NN	B-NP	O
treatment	NN	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
after	IN	B-PP	O
prophylaxis	NN	B-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
certain	JJ	B-NP	O
limitations	NNS	I-NP	O
for	IN	B-PP	O
malaria	NN	B-NP	B
prophylaxis	NN	I-NP	O
and	CC	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
mefloquine	NN	B-NP	O
are	VBP	B-VP	O
recommended	VBN	I-VP	O
.	.	O	O

Reduction	NN	B-NP	O
in	IN	B-PP	O
injection	NN	B-NP	O
pain	NN	I-NP	B
using	VBG	B-VP	O
buffered	VBN	B-NP	O
lidocaine	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
local	JJ	I-NP	O
anesthetic	NN	I-NP	O
before	IN	B-PP	O
cardiac	JJ	B-NP	O
catheterization	NN	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
pain	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
is	VBZ	B-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
acidic	JJ	I-NP	O
pH	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
solution	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
buffering	NN	I-NP	O
solution	NN	I-NP	O
to	TO	B-VP	O
adjust	VB	I-VP	O
the	DT	B-NP	O
pH	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
physiologic	JJ	I-NP	O
range	NN	I-NP	O
would	MD	B-VP	O
reduce	VB	I-VP	O
pain	NN	B-NP	B
during	IN	B-PP	O
injection	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
blinded	VBN	I-NP	O
randomized	VBN	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
cardiac	JJ	B-NP	O
catheterization	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
asked	VBN	I-VP	O
to	TO	B-VP	O
quantify	VB	I-VP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
after	IN	B-PP	O
receiving	VBG	B-VP	O
standard	JJ	B-NP	O
lidocaine	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
femoral	JJ	I-NP	O
area	NN	I-NP	O
and	CC	O	O
buffered	VBN	B-NP	O
lidocaine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
opposite	JJ	I-NP	O
femoral	JJ	I-NP	O
area	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
pain	NN	I-NP	B
score	NN	I-NP	O
for	IN	B-PP	O
buffered	VBN	B-NP	O
lidocaine	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
score	NN	I-NP	O
for	IN	B-PP	O
standard	JJ	B-NP	O
lidocaine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pH	NN	I-NP	O
adjustment	NN	I-NP	O
of	IN	B-PP	O
standard	JJ	B-NP	O
lidocaine	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
accomplished	VBN	I-VP	O
easily	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
catheterization	NN	I-NP	O
laboratory	NN	I-NP	O
before	IN	B-PP	O
injection	NN	B-NP	O
and	CC	O	O
results	VBZ	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pain	NN	I-NP	B
occurring	VBG	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
infiltration	NN	I-NP	O
of	IN	B-PP	O
tissues	NNS	B-NP	O
.	.	O	O

Randomized	VBN	B-VP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
mazindol	NN	B-NP	O
in	IN	B-PP	O
Duchenne	NNP	B-NP	B
dystrophy	NN	I-NP	I
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
evidence	NN	B-NP	O
that	IN	B-SBAR	O
growth	NN	B-NP	O
hormone	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
weakness	NN	B-NP	B
in	IN	B-PP	O
Duchenne	NNP	B-NP	B
dystrophy	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
controlled	VBD	B-VP	O
trial	NN	B-NP	O
of	IN	B-PP	O
mazindol	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
putative	JJ	I-NP	O
growth	NN	I-NP	O
hormone	NN	I-NP	O
secretion	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
num	CD	B-NP	O
boys	NNS	I-NP	O
with	IN	B-PP	O
Duchenne	JJ	B-NP	B
dystrophy	NN	I-NP	I
.	.	O	O

Muscle	NN	B-NP	O
strength	NN	I-NP	O
,	,	O	O
contractures	NNS	B-NP	O
,	,	O	O
functional	JJ	B-NP	O
ability	NN	I-NP	O
and	CC	O	O
pulmonary	JJ	B-NP	O
function	NN	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
mazindol	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
power	NN	I-NP	O
of	IN	B-PP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
to	TO	B-VP	O
detect	VB	I-VP	O
a	DT	B-NP	O
slowing	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
expected	VBN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
progression	NN	B-NP	O
of	IN	B-PP	O
weakness	NN	B-NP	B
at	IN	B-PP	O
P	NN	B-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Mazindol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
benefit	VB	I-VP	O
strength	NN	B-NP	O
at	IN	B-PP	O
any	DT	B-NP	O
point	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Side	NN	B-NP	O
effects	NNS	I-NP	O
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
mazindol	NN	B-NP	O
included	VBD	B-VP	O
decreased	VBN	I-VP	B
appetite	JJ	B-NP	I
,	,	I-NP	O
dry	JJ	I-NP	B
mouth	NN	I-NP	I
,	,	O	O
behavioral	JJ	B-NP	O
change	NN	I-NP	O
,	,	O	O
and	CC	O	O
gastrointestinal	JJ	B-NP	B
symptoms	NNS	I-NP	I
;	:	O	O
mazindol	NN	B-NP	O
dosage	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
mazindol	NN	B-NP	O
on	IN	B-PP	O
GH	NN	B-NP	O
secretion	NN	I-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
indirectly	RB	B-ADVP	O
by	IN	B-PP	O
comparing	VBG	B-VP	O
the	DT	B-NP	O
postabsorptive	JJ	I-NP	O
IGF	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
levels	NNS	I-NP	O
obtained	VBN	B-VP	O
following	VBG	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mazindol	NN	I-NP	O
treated	VBN	B-VP	O
to	TO	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
mazindol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
gained	VBD	B-VP	O
less	JJR	B-NP	O
weight	NN	I-NP	O
and	CC	I-NP	O
height	NN	I-NP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
no	DT	B-NP	O
significant	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
IGF	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
levels	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Mazindol	NN	B-NP	O
doses	NNS	I-NP	O
not	RB	O	O
slow	VB	B-VP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
weakness	NN	B-NP	B
in	IN	B-PP	O
Duchenne	NNP	B-NP	B
dystrophy	NN	I-NP	I
.	.	O	O

Pentoxifylline	NN	B-NP	O
(	(	O	O
Trental	JJ	B-ADJP	O
)	)	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
inhibit	VB	I-VP	O
dipyridamole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
coronary	JJ	I-NP	O
hyperemia	NN	I-NP	B
:	:	O	O
implications	NNS	B-NP	O
for	IN	B-PP	O
dipyridamole	NN	B-NP	O
-	HYPH	B-NP	O
thallium	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
myocardial	JJ	I-NP	O
imaging	NN	I-NP	O
.	.	O	O

Dipyridamole	NN	B-NP	O
-	HYPH	I-NP	O
thallium	NN	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
imaging	NN	I-NP	O
is	VBZ	B-VP	O
often	RB	I-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
unable	JJ	B-ADJP	O
to	TO	B-VP	O
exercise	VB	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
peripheral	JJ	B-NP	B
vascular	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Many	JJ	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
taking	VBG	I-VP	O
pentoxifylline	NN	B-NP	O
(	(	O	O
Trental	JJ	B-ADVP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
methylxanthine	NN	I-NP	O
derivative	NN	I-NP	O
which	WDT	B-NP	O
may	MD	B-VP	O
improve	VB	I-VP	O
intermittent	JJ	B-NP	B
claudication	NN	I-NP	I
.	.	O	O

Whether	IN	B-SBAR	O
pentoxifylline	NN	B-NP	O
inhibits	VBZ	B-VP	O
dipyridamole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
coronary	JJ	I-NP	O
hyperemia	NN	I-NP	B
like	IN	B-PP	O
other	JJ	B-NP	O
methylxanthines	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
theophylline	NN	B-NP	O
and	CC	O	O
should	MD	B-VP	O
be	VB	I-VP	O
stopped	VBN	I-VP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
dipyridamole	NN	B-NP	O
-	HYPH	B-NP	O
thallium	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
imaging	NN	I-NP	O
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
hyperemic	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
dipyridamole	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
chest	NN	I-NP	O
anesthetized	VBN	B-VP	O
dogs	NNS	B-NP	O
after	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
either	CC	O	O
pentoxifylline	NN	B-NP	O
or	CC	I-NP	O
theophylline	NN	I-NP	O
.	.	O	O

Baseline	NNP	B-NP	O
circumflex	NN	I-NP	O
coronary	JJ	I-NP	O
blood	NN	I-NP	O
flows	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
among	IN	B-PP	O
treatment	NN	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Dipyridamole	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
coronary	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
i.v.	JJ	I-NP	O
pentoxifylline	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
dose	NN	B-NP	O
of	IN	B-PP	O
pentoxifylline	NN	B-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
dipyridamole	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperemia	NN	I-NP	B
,	,	O	O
while	IN	B-SBAR	O
peak	NN	B-NP	O
coronary	JJ	I-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
after	IN	B-PP	O
theophylline	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
pentoxyifylline	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
inhibit	VB	I-VP	O
dipyridamole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
coronary	JJ	I-NP	O
hyperemia	NN	I-NP	B
even	RB	B-ADVP	O
at	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

Cause	NN	B-NP	O
of	IN	B-PP	O
death	NN	B-NP	B
among	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
rare	JJ	I-NP	O
mortality	NN	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
cerebral	JJ	B-NP	B
haemorrhage	NN	I-NP	I
.	.	O	O

Causes	NNS	B-NP	O
of	IN	B-PP	O
death	NN	B-NP	B
,	,	O	O
with	IN	B-PP	O
special	JJ	B-NP	O
reference	NN	I-NP	O
to	TO	B-PP	O
cerebral	JJ	B-NP	B
haemorrhage	NN	I-NP	I
,	,	O	O
among	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
pathologically	RB	B-NP	O
verified	VBN	I-NP	O
Parkinson	NNP	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
were	VBD	B-VP	O
investigated	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Annuals	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Pathological	JJ	I-NP	O
Autopsy	NN	I-NP	O
Cases	NNS	I-NP	O
in	IN	B-PP	O
Japan	NNP	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
leading	VBG	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
death	NN	B-NP	B
were	VBD	B-VP	O
pneumonia	NN	B-NP	B
and	CC	I-NP	O
bronchitis	NN	I-NP	B
,	,	O	O
malignant	JJ	B-NP	O
neoplasms	NNS	I-NP	B
,	,	O	O
heart	NN	B-NP	B
diseases	NNS	I-NP	I
,	,	O	O
cerebral	JJ	B-NP	B
infarction	NN	I-NP	I
and	CC	I-NP	O
septicaemia	NN	I-NP	B
.	.	O	O

Cerebral	JJ	B-NP	B
haemorrhage	NN	I-NP	I
was	VBD	B-VP	O
the	DT	B-NP	O
11th	JJ	I-NP	O
most	RBS	I-NP	O
frequent	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
death	NN	B-NP	B
,	,	O	O
accounting	VBG	B-VP	O
for	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
deaths	NNS	B-NP	B
among	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
5th	JJ	I-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
death	NN	B-NP	B
among	IN	B-PP	O
the	DT	B-NP	O
Japanese	JJ	I-NP	O
general	JJ	I-NP	O
population	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
low	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	B
haemorrhage	NN	I-NP	I
as	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
death	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	JJ	I-NP	I
disease	NN	I-NP	I
may	MD	B-VP	O
reflect	VB	I-VP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	O
hypotensive	JJ	I-NP	B
mechanism	NN	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
reduced	VBN	B-NP	O
noradrenaline	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
parkinsonian	JJ	I-NP	B
brain	NN	I-NP	O
.	.	O	O

Tolerance	NN	B-NP	O
and	CC	I-NP	O
antiviral	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Argentine	JJ	B-NP	B
hemorrhagic	JJ	I-NP	I
fever	NN	I-NP	I
.	.	O	O

Tolerance	NN	B-NP	O
and	CC	I-NP	O
antiviral	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Argentine	JJ	B-NP	B
hemorrhagic	JJ	I-NP	I
fever	NN	I-NP	I
(	(	O	O
AHF	NN	B-NP	B
)	)	O	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
evolution	NN	B-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
neutralization	NN	I-NP	O
of	IN	B-PP	O
viremia	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
drop	NN	I-NP	O
of	IN	B-PP	O
endogenous	JJ	B-NP	O
interferon	NN	I-NP	O
titers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
death	NN	B-NP	B
was	VBD	B-VP	O
delayed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
reversible	JJ	I-NP	O
anemia	NN	I-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
only	RB	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
observed	VBN	B-VP	O
.	.	O	O

From	IN	B-PP	O
these	DT	B-NP	O
results	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
ribavirin	NN	B-NP	O
has	VBZ	B-VP	O
an	DT	B-NP	O
antiviral	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
AHF	NN	B-NP	B
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
anemia	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
only	RB	I-NP	O
secondary	JJ	I-NP	O
reaction	NN	I-NP	O
observed	VBN	B-VP	O
,	,	O	O
can	MD	B-VP	O
be	VB	I-VP	O
easily	RB	I-VP	O
managed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
AHF	NN	B-NP	B
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Dipyridamole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
.	.	O	O

Angina	NNP	B-NP	B
and	CC	O	O
ischemic	JJ	B-NP	O
electrocardiographic	JJ	I-NP	O
changes	NNS	I-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
dipyridamole	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
awaiting	VBG	B-VP	O
urgent	JJ	B-NP	O
myocardial	JJ	I-NP	O
revascularization	NN	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
preoperative	JJ	B-NP	O
dipyridamole	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
dipyridamole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
demonstrated	VBN	I-VP	O
to	TO	I-VP	O
occur	VB	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
and	CC	I-NP	O
humans	NNS	I-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Epicardial	JJ	B-NP	O
coronary	JJ	I-NP	O
collateral	NN	I-NP	O
vessels	NNS	I-NP	O
were	VBD	B-VP	O
demonstrated	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
;	:	O	O
a	DT	B-NP	O
coronary	JJ	I-NP	O
steal	JJ	I-NP	O
phenomenon	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dipyridamole	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ischemia	NN	I-NP	B
observed	VBN	B-VP	O
.	.	O	O

Inhibition	NN	B-NP	O
of	IN	B-PP	O
immunoreactive	JJ	B-NP	O
corticotropin	NN	I-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
factor	NN	B-NP	O
secretion	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
hypophysial	JJ	I-NP	O
-	HYPH	I-NP	O
portal	JJ	I-NP	O
circulation	NN	I-NP	O
by	IN	B-PP	O
delayed	VBN	B-NP	O
glucocorticoid	NN	I-NP	O
feedback	NN	I-NP	O
.	.	O	O

Nitroprusside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
evokes	VBZ	B-VP	O
ACTH	NN	B-NP	O
secretion	NN	I-NP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
primarily	RB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
enhanced	VBN	B-NP	O
secretion	NN	I-NP	O
of	IN	B-PP	O
immunoreactive	JJ	B-NP	O
corticotropin	NN	I-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
factor	NN	B-NP	O
(	(	O	O
irCRF	NN	B-NP	O
)	)	O	O
into	IN	B-PP	O
the	DT	B-NP	O
hypophysial	JJ	I-NP	O
-	HYPH	I-NP	O
portal	JJ	I-NP	O
circulation	NN	I-NP	O
.	.	O	O

Portal	JJ	B-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
neither	CC	O	O
arginine	NN	B-NP	O
vasopressin	NN	I-NP	O
nor	CC	I-NP	O
oxytocin	NN	I-NP	O
are	VBP	B-VP	O
significantly	RB	I-VP	O
altered	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
paradigm	NN	I-NP	O
.	.	O	O

Application	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
delayed	VBN	I-NP	O
feedback	NN	I-NP	O
signal	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
systemic	JJ	I-NP	O
corticosterone	NN	I-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
urethane	NN	B-NP	O
-	HYPH	B-NP	O
anesthetized	VBN	I-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
pharmacological	JJ	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
glucocorticoid	NN	B-NP	O
synthesis	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
without	IN	B-PP	O
effect	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
resting	VBG	I-NP	O
secretion	NN	I-NP	O
of	IN	B-PP	O
arginine	NN	B-NP	O
vasopressin	NN	I-NP	O
and	CC	I-NP	O
oxytocin	NN	I-NP	O
at	IN	B-PP	O
any	DT	B-NP	O
corticosterone	NN	I-NP	O
feedback	NN	I-NP	O
dose	NN	I-NP	O
tested	VBN	B-VP	O
.	.	O	O

Resting	VBG	B-VP	O
irCRF	NN	B-NP	O
levels	NNS	I-NP	O
are	VBP	B-VP	O
suppressed	VBN	I-VP	O
only	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
corticosterone	NN	I-NP	O
infusion	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
systemic	JJ	B-NP	O
corticosterone	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
.	.	O	O

Suppression	NN	B-NP	O
of	IN	B-PP	O
irCRF	NN	B-NP	O
secretion	NN	I-NP	O
in	IN	B-PP	O
response	NN	I-PP	O
to	TO	I-PP	O
nitroprusside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
is	VBZ	B-VP	O
observed	VBN	I-VP	O
and	CC	O	O
occurs	VBZ	B-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
plasma	NN	I-NP	O
corticosterone	NN	I-NP	O
level	NN	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
studies	NNS	I-NP	O
provide	VBP	B-VP	O
further	JJ	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
central	JJ	I-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
delayed	VBN	I-NP	O
feedback	NN	I-NP	O
process	NN	I-NP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
modulation	NN	B-NP	O
of	IN	B-PP	O
irCRF	NN	B-NP	O
release	NN	I-NP	O
.	.	O	O

Noradrenergic	JJ	B-NP	O
involvement	NN	I-NP	O
in	IN	B-PP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
delta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydrocannabinol	NN	I-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
elucidate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
catecholaminergic	JJ	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cataleptogenic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
delta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydrocannabinol	NN	I-NP	O
(	(	O	O
THC	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxydopamine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
)	)	O	O
or	CC	O	O
with	IN	B-PP	O
desipramine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
and	CC	I-NP	O
lesions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
locus	NN	I-NP	O
coeruleus	NN	I-NP	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
cataleptogenic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
THC	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
lesions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
locus	NN	I-NP	O
coeruleus	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
desipramine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
contrary	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
cataleptogenic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
desipramine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
lesions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
locus	NN	I-NP	O
coeruleus	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
noradrenergic	JJ	B-NP	O
neurons	NNS	I-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
THC	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
dopaminergic	JJ	B-NP	O
neurons	NNS	I-NP	O
are	VBP	B-VP	O
important	JJ	B-ADJP	O
in	IN	B-PP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O

Intracranial	JJ	B-NP	O
pressure	NN	I-NP	O
increases	VBZ	B-VP	O
during	IN	B-PP	O
alfentanil	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rigidity	NN	I-NP	B
.	.	O	O

Intracranial	JJ	B-NP	O
pressure	NN	I-NP	O
(	(	O	O
ICP	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
during	IN	B-PP	O
alfentanil	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rigidity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
rats	NNS	I-NP	O
had	VBD	B-VP	O
arterial	JJ	B-NP	O
,	,	I-NP	O
central	JJ	I-NP	O
venous	JJ	I-NP	O
(	(	O	O
CVP	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
subdural	JJ	B-NP	O
cannulae	NNS	I-NP	O
inserted	VBN	B-VP	O
under	IN	B-PP	O
halothane	NN	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
mechanically	RB	I-VP	O
ventilated	VBN	I-VP	O
to	TO	I-VP	O
achieve	VB	I-VP	O
normocarbia	NN	B-NP	O
.	.	O	O

Following	VBG	B-PP	O
instrumentation	NN	B-NP	O
,	,	O	O
halothane	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
alfentanil	NN	B-NP	O
administered	VBN	B-VP	O
iv	NN	B-NP	O
during	IN	B-PP	O
emergence	NN	B-NP	O
from	IN	B-PP	O
halothane	NN	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
that	WDT	B-NP	O
developed	VBD	B-VP	O
somatic	JJ	B-NP	B
rigidity	NN	I-NP	I
,	,	I-NP	O
ICP	NN	I-NP	O
and	CC	I-NP	O
CVP	NN	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
above	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
variables	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
when	WRB	B-ADVP	O
rigidity	NN	B-NP	B
was	VBD	B-VP	O
abolished	VBN	I-VP	O
with	IN	B-PP	O
metocurine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
become	VBN	I-VP	O
rigid	JJ	B-NP	O
,	,	I-NP	O
ICP	NN	I-NP	O
and	CC	I-NP	O
CVP	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
following	VBG	B-PP	O
alfentanil	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
rigidity	NN	B-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
prevented	VBN	I-VP	O
when	WRB	B-ADVP	O
alfentanil	NN	B-NP	O
,	,	O	O
and	CC	O	O
,	,	O	O
presumably	RB	B-ADVP	O
,	,	O	O
other	JJ	B-NP	O
opiates	NNS	I-NP	O
,	,	O	O
are	VBP	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
ICP	NN	B-NP	O
problems	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
cardiac	JJ	I-NP	O
effects	NNS	I-NP	O
during	IN	B-PP	O
induction	NN	B-NP	O
chemotherapy	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
cis	NN	B-NP	O
-	HYPH	B-NP	O
platin	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
.	.	O	O

Survival	NN	B-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
head	NN	I-NP	B
and	CC	I-NP	I
neck	NN	I-NP	I
carcinoma	NN	I-NP	I
and	CC	O	O
esophageal	JJ	B-NP	B
carcinoma	NN	I-NP	I
is	VBZ	B-VP	O
poor	JJ	B-ADJP	O
with	IN	B-PP	O
radiotherapy	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
surgery	NN	B-NP	O
.	.	O	O

Obviously	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
effective	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
cis	NN	B-NP	O
-	HYPH	B-NP	O
platin	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
before	IN	B-PP	O
radiotherapy	NN	B-NP	O
and	CC	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
clarify	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
cardiac	JJ	I-NP	O
effects	NNS	I-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Before	IN	B-PP	O
treatment	NN	B-NP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
cardiac	JJ	I-NP	O
evaluation	NN	I-NP	O
and	CC	B-PP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
serial	JJ	I-NP	O
ECG	NN	I-NP	O
recordings	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
evaluation	NN	I-NP	O
,	,	O	O
signs	NNS	B-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
adverse	JJ	B-NP	O
cardiac	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
as	IN	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
was	VBD	B-VP	O
not	RB	O	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
than	IN	B-PP	O
in	IN	B-PP	O
those	DT	B-NP	O
without	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
evaluation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
were	VBD	B-VP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
,	,	O	O
ST	NN	B-NP	O
-	HYPH	I-NP	O
T	NN	I-NP	O
wave	NN	I-NP	O
changes	NNS	I-NP	O
and	CC	O	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
and	CC	O	O
sudden	JJ	B-NP	B
death	NN	I-NP	I
in	IN	B-PP	O
another	DT	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
patients	NNS	B-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
treatment	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
under	IN	B-PP	O
close	JJ	B-NP	O
supervision	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
treatment	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
discontinued	VBN	I-VP	O
if	IN	B-SBAR	O
chest	NN	B-NP	B
pain	NN	I-NP	I
or	CC	I-NP	O
tachyarrhythmia	NN	I-NP	B
is	VBZ	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Verapamil	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
carbamazepine	NN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
neurotoxicity	NN	I-NP	B
after	IN	B-PP	O
combined	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
verapamil	NN	B-NP	O
showed	VBD	B-VP	O
complete	JJ	B-NP	O
recovery	NN	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
calcium	NN	I-NP	O
entry	NN	I-NP	O
blocker	NN	I-NP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
carbamazepine	NN	B-NP	O
should	MD	B-VP	O
either	RB	I-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
or	CC	I-VP	O
prescribed	VBN	I-VP	O
only	RB	B-ADVP	O
with	IN	B-PP	O
appropriate	JJ	B-NP	O
adjustment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
carbamazepine	NN	I-NP	O
dose	NN	I-NP	O
(	(	O	O
usually	RB	B-ADVP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
carbamazepine	NN	I-NP	O
dose	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
half	NN	I-NP	O
)	)	O	O
.	.	O	O

Serial	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
auditory	JJ	B-NP	B
neurotoxicity	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
deferoxamine	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Visual	JJ	B-NP	B
and	CC	I-NP	I
auditory	JJ	I-NP	I
neurotoxicity	NN	I-NP	I
was	VBD	B-VP	O
previously	RB	I-VP	O
documented	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
transfusion	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
anemia	NN	I-NP	B
who	WP	B-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
iron	NN	B-NP	O
chelation	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
daily	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
deferoxamine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
affected	VBN	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
abnormal	JJ	B-NP	B
audiograms	NNS	I-NP	I
with	IN	B-PP	I
deficits	NNS	B-NP	I
mostly	RB	B-ADVP	I
in	IN	B-PP	I
the	DT	B-NP	I
high	JJ	I-NP	I
frequency	NN	I-NP	I
range	NN	I-NP	I
of	IN	B-PP	I
num	CD	B-NP	I
to	TO	I-NP	I
num	CD	I-NP	I
Hz	NN	I-NP	I
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
hearing	NN	I-NP	O
threshold	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
decibels	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
deferoxamine	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
serial	JJ	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
,	,	O	O
audiograms	NNS	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
reverted	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
or	CC	O	O
near	RB	B-ADJP	O
normal	JJ	I-ADJP	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
symptoms	NNS	B-NP	O
became	VBD	B-VP	O
asymptomatic	JJ	B-ADJP	O
.	.	O	O

Audiograms	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
remained	VBD	B-VP	O
abnormal	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
required	VBD	B-VP	O
hearing	NN	B-NP	O
aids	NNS	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
permanent	JJ	B-NP	B
disability	NN	I-NP	I
.	.	O	O

Since	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
initially	RB	I-VP	O
receiving	VBG	I-VP	O
deferoxamine	NN	B-NP	O
doses	NNS	I-NP	O
in	IN	B-PP	O
excess	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
commonly	RB	I-NP	O
recommended	VBN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
dose	NN	B-NP	O
,	,	O	O
therapy	NN	B-NP	O
was	VBD	B-VP	O
restarted	VBN	I-VP	O
with	IN	B-PP	O
lower	JJR	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
usually	RB	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
dose	NN	B-NP	O
or	CC	O	O
less	JJR	B-NP	O
depending	VBG	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
auditory	JJ	B-NP	B
abnormality	NN	I-NP	I
,	,	O	O
and	CC	O	O
with	IN	B-PP	O
the	DT	B-NP	O
exception	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
no	DT	B-NP	O
further	JJ	I-NP	O
toxicity	NN	I-NP	B
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
.	.	O	O

Auditory	JJ	B-NP	O
deterioration	NN	I-NP	O
and	CC	I-NP	O
improvement	NN	I-NP	O
,	,	O	O
demonstrated	VBD	B-VP	O
serially	RB	B-ADVP	O
in	IN	B-PP	O
individual	JJ	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
and	CC	O	O
not	RB	B-VP	O
receiving	VBG	I-VP	O
deferoxamine	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
provided	VBN	B-PP	O
convincing	VBG	B-VP	O
evidence	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
-	HYPH	I-NP	O
effect	NN	I-NP	O
relation	NN	I-NP	O
between	IN	B-PP	O
deferoxamine	NN	B-NP	O
administration	NN	I-NP	O
and	CC	I-NP	O
ototoxicity	NN	I-NP	B
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
these	DT	B-NP	O
data	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
plan	NN	I-NP	O
of	IN	B-PP	O
management	NN	B-NP	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
that	WDT	B-NP	O
allows	VBZ	B-VP	O
effective	JJ	B-NP	O
yet	RB	I-NP	O
safe	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
deferoxamine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
in	IN	B-PP	O
those	DT	B-NP	O
without	IN	B-PP	O
audiogram	NN	B-NP	O
abnormalities	NNS	I-NP	O
.	.	O	O

With	IN	B-PP	O
mild	JJ	B-NP	O
toxicity	NN	I-NP	B
,	,	O	O
a	DT	B-NP	O
reduction	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
dose	NN	B-NP	O
should	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
abnormal	JJ	I-NP	O
results	NNS	I-NP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
within	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Moderate	JJ	B-NP	O
abnormalities	NNS	I-NP	O
require	VBP	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
deferoxamine	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
dose	NN	B-NP	O
with	IN	B-PP	O
careful	JJ	B-NP	O
monitoring	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
drug	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
stopped	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
and	CC	O	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
audiogram	NN	I-NP	O
is	VBZ	B-VP	O
stable	JJ	B-ADJP	O
or	CC	I-ADJP	O
improved	JJ	I-ADJP	O
,	,	O	O
therapy	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
restarted	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
dose	NN	B-NP	O
.	.	O	O

Serial	JJ	B-NP	O
audiograms	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
in	IN	B-PP	O
those	DT	B-NP	O
without	IN	B-PP	O
problems	NNS	B-NP	O
and	CC	O	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
in	IN	B-PP	O
young	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
serum	NN	I-NP	O
ferritin	NN	I-NP	O
values	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
auditory	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Flurbiprofen	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
juvenile	JJ	B-NP	B
rheumatoid	JJ	I-NP	I
arthritis	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
juvenile	JJ	B-NP	B
rheumatoid	JJ	I-NP	I
arthritis	NN	I-NP	I
,	,	O	O
who	WP	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
flurbiprofen	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
maximum	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
decreases	NNS	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
arthritis	NN	I-NP	B
indices	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Improvements	NNS	B-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
tender	NN	B-NP	B
joints	NNS	I-NP	I
,	,	O	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
swelling	NN	B-NP	B
and	CC	I-NP	O
tenderness	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
walk	NN	B-NP	O
num	CD	B-NP	O
feet	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
morning	NN	B-NP	B
stiffness	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
circumference	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
knee	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
frequently	RB	I-NP	O
observed	VBN	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
fecal	JJ	B-NP	B
occult	JJ	I-NP	I
blood	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
)	)	O	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
other	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
gastrointestinal	JJ	B-NP	B
(	(	O	I
GI	NN	B-NP	I
)	)	O	I
bleeding	VBG	B-VP	I
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
prematurely	RB	I-VP	O
discontinued	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
for	IN	B-PP	O
severe	JJ	B-NP	O
headache	NN	I-NP	B
and	CC	O	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

Most	JJS	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
mild	JJ	B-ADJP	O
and	CC	O	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
GI	NN	I-NP	O
tract	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
neurotoxic	JJ	B-NP	B
esterase	NN	I-NP	O
inhibition	NN	I-NP	O
and	CC	I-NP	O
mipafox	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
neuropathic	JJ	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
neuropathic	JJ	B-NP	B
damage	NN	I-NP	I
and	CC	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
neurotoxic	JJ	B-NP	B
esterase	NN	I-NP	O
or	CC	I-NP	O
neuropathy	NN	I-NP	B
target	NN	I-NP	O
enzyme	NN	I-NP	O
(	(	O	O
NTE	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
acutely	RB	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
Mipafox	NNP	B-NP	O
(	(	O	O
N	NN	B-NP	O
,	,	O	O
N	NN	B-NP	O
'	SYM	O	O
-	HYPH	O	O
diisopropylphosphorodiamidofluoridate	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	B
neurotoxic	JJ	I-NP	O
organophosphate	NN	I-NP	O
.	.	O	O

Brain	NN	B-NP	O
and	CC	I-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
NTE	NN	I-NP	O
activities	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
Long	NNP	B-NP	O
-	HYPH	I-NP	O
Evans	NNP	I-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
num	CD	B-NP	O
hr	NN	I-NP	O
post	AFX	O	O
-	HYPH	O	O
exposure	NN	B-NP	O
to	TO	B-PP	O
various	JJ	B-NP	O
dosages	NNS	I-NP	O
of	IN	B-PP	O
Mipafox	NNP	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
were	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
histologically	RB	B-NP	O
scored	VBN	I-NP	O
cervical	JJ	I-NP	O
cord	NN	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
separate	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
similarly	RB	B-NP	O
dosed	VBN	I-NP	O
rats	NNS	I-NP	O
sampled	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
exposure	NN	I-NP	O
.	.	O	O

Those	DT	B-NP	O
dosages	NNS	I-NP	O
that	WDT	B-NP	O
inhibited	VBD	B-VP	O
mean	JJ	B-NP	O
NTE	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
values	NNS	I-NP	O
produced	VBD	B-VP	O
severe	JJ	B-ADJP	O
(	(	O	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
cervical	JJ	B-NP	O
cord	NN	I-NP	O
pathology	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
dosages	NNS	B-NP	O
of	IN	B-PP	O
Mipafox	NNP	B-NP	O
which	WDT	B-NP	O
inhibited	VBD	B-VP	O
mean	JJ	B-NP	O
NTE	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
spinal	JJ	B-NP	O
cord	NN	I-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
produced	VBD	B-VP	O
this	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
cord	NN	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
critical	JJ	I-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
NTE	NN	B-NP	O
inhibition	NN	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
and	CC	O	O
spinal	JJ	B-NP	O
cord	NN	I-NP	O
sampled	VBN	B-VP	O
shortly	RB	B-ADVP	O
after	IN	B-PP	O
Mipafox	NNP	B-NP	O
exposure	NN	I-NP	O
can	MD	B-VP	O
predict	VB	I-VP	O
neuropathic	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
several	JJ	B-NP	O
weeks	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Cerebral	JJ	B-NP	B
infarction	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
oral	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
phenylpropanolamine	NN	B-NP	O
.	.	O	O

Phenylpropanolamine	NN	B-NP	O
(	(	O	O
PPA	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
synthetic	JJ	I-NP	O
sympathomimetic	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
structurally	RB	B-ADJP	O
similar	JJ	I-ADJP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
available	JJ	B-ADJP	O
over	IN	B-PP	O
the	DT	B-NP	O
counter	NN	I-NP	O
in	IN	B-PP	O
anorectics	NNS	B-NP	O
,	,	O	O
nasal	JJ	B-NP	O
congestants	NNS	I-NP	O
,	,	O	O
and	CC	O	O
cold	JJ	B-NP	O
preparations	NNS	I-NP	O
.	.	O	O

Its	PRP$	B-NP	O
prolonged	JJ	I-NP	O
use	NN	I-NP	O
or	CC	I-NP	O
overuse	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
,	,	O	O
neuropsychiatric	JJ	B-NP	B
symptoms	NNS	I-NP	I
,	,	O	O
and	CC	O	O
nonhemorrhagic	JJ	B-NP	O
cerebral	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
young	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
suffered	VBD	B-VP	O
a	DT	B-NP	O
cerebral	JJ	I-NP	B
infarction	NN	I-NP	I
after	IN	B-PP	O
taking	VBG	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
oral	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
PPA	NN	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
psoriasis	NN	B-NP	B
with	IN	B-PP	O
azathioprine	NN	B-NP	O
.	.	O	O

Azathioprine	NN	B-NP	O
treatment	NN	I-NP	O
benefited	VBD	B-VP	O
num	CD	B-NP	O
out	IN	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
severe	JJ	B-NP	O
psoriasis	NN	I-NP	B
.	.	O	O

Haematological	JJ	B-NP	O
complications	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
troublesome	JJ	B-ADJP	O
and	CC	O	O
results	NNS	B-NP	O
of	IN	B-PP	O
biochemical	JJ	B-NP	O
liver	NN	I-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
remained	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

Minimal	JJ	B-NP	O
cholestasis	NN	I-NP	B
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
portal	JJ	B-NP	O
fibrosis	NN	I-NP	B
of	IN	B-PP	O
a	DT	B-NP	O
reversible	JJ	I-NP	O
degree	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Liver	NN	B-NP	O
biopsies	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
undertaken	VBN	I-VP	O
at	IN	B-PP	O
regular	JJ	B-NP	O
intervals	NNS	I-NP	O
if	IN	B-SBAR	O
azathioprine	NN	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
continued	VBN	I-VP	O
so	RB	B-SBAR	O
that	IN	I-SBAR	O
structural	JJ	B-NP	O
liver	NN	I-NP	B
damage	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
detected	VBN	I-VP	O
at	IN	B-PP	O
an	DT	B-NP	O
early	JJ	I-NP	O
and	CC	I-NP	O
reversible	JJ	I-NP	O
stage	NN	I-NP	O
.	.	O	O

Maternal	JJ	B-NP	O
lithium	NN	I-NP	O
and	CC	O	O
neonatal	JJ	B-NP	O
Ebstein	NN	I-NP	B
s	NNS	I-NP	I
anomaly	RB	B-ADVP	I
:	:	O	O
evaluation	NN	B-NP	O
with	IN	B-PP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

Cross	NN	B-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
echocardiography	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
num	CD	B-NP	O
neonates	NNS	I-NP	O
whose	WP$	B-NP	O
mothers	NNS	I-NP	O
ingested	VBD	B-VP	O
lithium	NN	B-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
infant	NN	I-NP	O
,	,	O	O
Ebstein	NNP	B-NP	B
s	VBZ	B-VP	I
anomaly	RB	B-ADVP	I
of	IN	B-PP	O
the	DT	B-NP	O
tricuspid	JJ	I-NP	O
valve	NN	I-NP	O
was	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
infant	NN	I-NP	O
cross	AFX	O	O
-	HYPH	O	O
sectional	JJ	B-NP	O
echocardiography	NN	I-NP	O
provided	VBD	B-VP	O
reassurance	NN	B-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
infant	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
Ebstein	NNP	B-NP	B
s	NNS	I-NP	I
anomaly	RB	B-ADVP	I
.	.	O	O

Cross	NN	B-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
echocardiographic	JJ	I-NP	O
screening	NN	I-NP	O
of	IN	B-PP	O
newborns	NNS	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
during	IN	B-PP	O
gestation	NN	B-NP	O
can	MD	B-VP	O
provide	VB	I-VP	O
highly	RB	B-NP	O
accurate	JJ	I-NP	O
,	,	I-NP	O
noninvasive	JJ	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
or	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
malformations	NNS	I-NP	I
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
training	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
aging	VBG	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
exercise	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
female	JJ	B-NP	O
albino	JJ	I-NP	O
rats	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
trained	VBN	I-VP	O
to	TO	I-VP	O
swim	VB	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
duration	NN	I-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
a	DT	B-NP	O
particular	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
infarcts	NNS	B-NP	B
were	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
histological	JJ	B-NP	O
methods	NNS	I-NP	O
.	.	O	O

Elevations	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
GOT	NN	I-NP	O
and	CC	I-NP	O
GPT	NN	I-NP	O
were	VBD	B-VP	O
maximum	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
sedentary	JJ	I-NP	O
-	HYPH	I-NP	O
isoproterenols	NNS	I-NP	O
and	CC	I-NP	O
minimum	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
exercise	NN	I-NP	O
-	HYPH	B-VP	O
controls	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
transaminases	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
corresponding	VBG	B-VP	O
depletions	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
GOT	NN	I-NP	O
and	CC	I-NP	O
GPT	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
age	NN	B-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
to	TO	I-VP	O
interfere	VB	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
responses	NNS	I-NP	O
exhibited	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
young	JJ	I-NP	O
and	CC	I-NP	O
old	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Studies	NNS	B-NP	O
dealing	VBG	B-VP	O
with	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
are	VBP	B-VP	O
more	RBR	B-ADJP	O
informative	JJ	I-ADJP	O
when	WRB	B-ADVP	O
dealt	NN	B-NP	O
with	IN	B-PP	O
age	NN	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
polyethylene	NN	B-NP	O
glycol	NN	I-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
adriamycin	NN	B-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
organic	JJ	I-NP	O
solvent	NN	I-NP	O
,	,	O	O
polyethylene	NN	B-NP	O
glycol	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
PEG	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
or	CC	I-NP	O
chronic	JJ	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
adriamycin	NN	B-NP	O
(	(	O	O
ADR	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

PEG	NN	B-NP	O
num	CD	I-NP	O
impressively	RB	B-ADVP	O
decreased	VBD	B-VP	O
both	CC	O	O
acute	JJ	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
and	CC	O	O
chronic	JJ	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
ADR	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
lethality	NN	I-NP	O
.	.	O	O

Light	NN	B-NP	O
microscopic	JJ	I-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
protection	NN	I-NP	O
against	IN	B-PP	O
ADR	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
morphological	JJ	I-NP	I
alterations	NNS	I-NP	I
.	.	O	O

Such	JJ	B-NP	O
treatment	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
diminish	VB	I-VP	O
the	DT	B-NP	O
ADR	NN	I-NP	O
antitumor	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
L1210	NN	B-NP	B
leukemia	NN	I-NP	I
and	CC	B-PP	O
in	IN	B-PP	O
Ehrlich	NNP	B-NP	B
ascites	NNS	I-NP	I
tumor	NN	I-NP	I
.	.	O	O

Intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	I-NP	O
BCNU	NN	I-NP	O
chemotherapy	NN	I-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
malignant	JJ	B-NP	B
gliomas	NNS	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
rapid	JJ	I-NP	O
systemic	JJ	I-NP	O
clearance	NN	I-NP	O
of	IN	B-PP	O
BCNU	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
bis	NN	I-NP	O
-	HYPH	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroethyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
nitrosourea	NN	I-NP	O
)	)	O	O
,	,	O	O
intra	AFX	O	O
-	HYPH	O	O
arterial	JJ	B-NP	O
administration	NN	I-NP	O
should	MD	B-VP	O
provide	VB	I-VP	O
a	DT	B-NP	O
substantial	JJ	I-NP	O
advantage	NN	I-NP	O
over	IN	B-PP	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
malignant	JJ	B-NP	B
gliomas	NNS	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
BCNU	NN	B-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
either	CC	O	O
by	IN	B-PP	O
transfemoral	JJ	B-NP	O
catheterization	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
internal	JJ	I-NP	O
carotid	NN	I-NP	O
or	CC	O	O
vertebral	JJ	B-NP	O
artery	NN	I-NP	O
or	CC	B-PP	O
through	IN	B-PP	O
a	DT	B-NP	O
fully	RB	I-NP	O
implantable	JJ	I-NP	O
intracarotid	JJ	I-NP	O
drug	NN	I-NP	O
delivery	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
beginning	VBG	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
sq	NN	I-NP	O
m	NN	I-NP	O
body	NN	I-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
astrocytomas	NNS	I-NP	B
were	VBD	B-VP	O
treated	VBN	I-VP	O
after	IN	B-PP	O
partial	JJ	B-NP	O
resection	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tumor	NN	I-NP	B
without	IN	B-PP	O
prior	JJ	B-NP	O
radiation	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
tumor	NN	B-NP	B
size	NN	I-NP	O
and	CC	O	O
surrounding	VBG	B-VP	O
edema	NN	B-NP	B
on	IN	B-PP	O
contrast	NN	B-NP	O
-	HYPH	O	O
enhanced	VBN	B-VP	O
computerized	VBN	B-NP	O
tomography	NN	I-NP	O
scans	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
responders	NNS	I-NP	O
,	,	O	O
median	JJ	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
response	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
operation	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
survival	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
)	)	O	O
,	,	O	O
with	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
survival	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
Grade	NN	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
astrocytomas	NNS	I-NP	B
,	,	O	O
whose	WP$	B-NP	O
resection	NN	I-NP	O
and	CC	I-NP	O
irradiation	NN	I-NP	O
therapy	NN	I-NP	O
had	VBD	B-VP	O
failed	VBN	I-VP	O
,	,	O	O
received	VBD	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	I-NP	O
BCNU	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
response	NN	I-NP	O
or	CC	O	O
were	VBD	B-VP	O
stable	JJ	B-ADJP	O
for	IN	B-PP	O
a	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
catheterization	NN	I-NP	O
procedure	NN	I-NP	O
is	VBZ	B-VP	O
safe	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
immediate	JJ	I-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
BCNU	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
delayed	VBN	I-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
unilateral	JJ	B-NP	O
loss	NN	I-NP	B
of	IN	B-PP	I
vision	NN	B-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
retinal	JJ	I-NP	B
vasculitis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	B
loss	NN	I-NP	I
decreased	VBD	B-VP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ethanol	NN	I-NP	O
diluent	NN	I-NP	O
was	VBD	B-VP	O
lowered	VBN	I-VP	O
.	.	O	O

Blood	NN	B-NP	O
pressure	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
chronic	JJ	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intrarenal	JJ	I-NP	O
noradrenaline	NN	I-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Sodium	NN	B-NP	O
chloride	NN	I-NP	O
solution	NN	I-NP	O
or	CC	I-NP	O
noradrenaline	NN	I-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
h	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
infused	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
,	,	O	O
either	CC	O	O
intrarenally	RB	B-ADVP	O
(	(	O	O
by	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
technique	NN	I-NP	O
)	)	O	O
or	CC	O	O
intravenously	RB	B-ADVP	O
into	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
kidney	NN	I-NP	O
removed	VBN	B-VP	O
.	.	O	O

Intrarenal	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
noradrenaline	NN	B-NP	O
caused	VBD	B-VP	O
hypertension	NN	B-NP	B
at	IN	B-PP	O
doses	NNS	B-NP	O
which	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
do	VB	I-VP	O
so	RB	B-ADVP	O
when	WRB	B-ADVP	O
infused	VBN	B-VP	O
intravenously	RB	B-ADVP	O
.	.	O	O

Intrarenal	JJ	B-ADJP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
noradrenaline	NN	B-NP	O
caused	VBD	B-VP	O
higher	JJR	B-NP	O
plasma	NN	I-NP	O
noradrenaline	NN	I-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
shift	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
noradrenaline	NN	I-NP	O
concentration	NN	I-NP	O
-	HYPH	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
effect	NN	I-NP	O
curve	NN	I-NP	O
towards	IN	B-PP	O
lower	JJR	B-NP	O
plasma	NN	I-NP	O
noradrenaline	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
hypertension	NN	B-NP	B
after	IN	B-PP	O
chronic	JJ	B-NP	O
intrarenal	JJ	I-NP	O
noradrenaline	NN	I-NP	O
infusion	NN	I-NP	O
is	VBZ	B-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
relatively	RB	B-NP	O
higher	JJR	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
circulating	VBG	B-VP	O
noradrenaline	NN	B-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
triggering	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
intrarenal	JJ	I-NP	O
pressor	NN	I-NP	O
mechanism	NN	I-NP	O
.	.	O	O

Age	NN	B-NP	O
and	CC	I-NP	O
renal	JJ	I-NP	O
clearance	NN	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
ages	NNS	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
yr	NN	I-NP	O
)	)	O	O
receiving	VBG	B-VP	O
cimetidine	NN	B-NP	O
therapeutically	RB	B-NP	O
num	CD	I-NP	O
serum	NN	I-NP	O
samples	NNS	I-NP	O
and	CC	O	O
all	DT	B-NP	O
urine	NN	I-NP	O
formed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
interim	NN	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
for	IN	B-PP	O
analysis	NN	B-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
by	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
pressure	NN	I-NP	O
liquid	NN	I-NP	O
chromatography	NN	I-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
creatinine	NN	B-NP	O
.	.	O	O

Cimetidine	NN	B-NP	O
clearance	NN	I-NP	O
decreased	VBD	B-VP	O
with	IN	B-PP	O
age	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
extrapolated	VBN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hr	NN	I-NP	O
serum	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
per	IN	B-PP	O
unit	NN	B-NP	O
dose	NN	I-NP	O
,	,	O	O
after	IN	B-PP	O
intravenous	JJ	B-NP	O
cimetidine	NN	I-NP	O
,	,	O	O
increased	VBD	B-VP	O
with	IN	B-PP	O
age	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
clearance	NN	I-NP	O
to	TO	B-PP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
(	(	O	O
Rc	NN	B-NP	O
)	)	O	O
averaged	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
,	,	O	O
indicating	VBG	B-VP	O
net	JJ	B-NP	O
tubular	JJ	I-NP	O
secretion	NN	I-NP	O
for	IN	B-PP	O
cimetidine	NN	B-NP	O
.	.	O	O

Rc	NN	B-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
independent	JJ	B-ADJP	O
of	IN	B-PP	O
age	NN	B-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
with	IN	B-PP	O
increasing	VBG	B-NP	O
serum	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
secretion	NN	B-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
saturable	JJ	I-NP	O
process	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
dementia	NN	B-NP	B
possibly	RB	B-ADVP	O
due	IN	B-PP	O
to	TO	B-PP	O
cimetidine	NN	B-NP	O
(	(	O	O
with	IN	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	B-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
liver	NN	B-NP	B
or	CC	I-NP	I
kidney	NN	I-NP	I
disease	NN	I-NP	I
who	WP	B-NP	O
had	VBD	B-VP	O
cimetidine	NN	B-NP	O
levels	NNS	I-NP	O
above	IN	B-PP	O
num	CD	B-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
high	JJ	B-NP	O
cimetidine	NN	I-NP	O
levels	NNS	I-NP	O
alone	RB	B-ADVP	O
do	VBP	B-VP	O
not	RB	I-VP	O
always	RB	I-VP	O
induce	VB	I-VP	O
dementia	NN	B-NP	B
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
clear	JJ	B-NP	B
cell	NN	I-NP	I
adenocarcinoma	NN	I-NP	I
in	IN	B-PP	O
DES	NNP	B-NP	O
-	HYPH	B-VP	O
exposed	VBN	B-NP	O
offspring	NN	I-NP	O
under	IN	B-PP	O
observation	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
clear	JJ	B-NP	B
cell	NN	I-NP	I
adenocarcinoma	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
vagina	NN	I-NP	I
detected	VBN	B-VP	O
at	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
in	IN	B-PP	O
young	JJ	B-NP	O
women	NNS	I-NP	O
exposed	VBN	B-VP	O
in	IN	B-PP	O
utero	NN	B-NP	O
to	TO	B-PP	O
diethylstilbestrol	NN	B-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
,	,	O	O
aged	VBN	B-ADJP	O
num	CD	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
followed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
before	IN	B-SBAR	O
carcinoma	NN	B-NP	B
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
;	:	O	O
the	DT	B-NP	O
second	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
aged	VBN	B-ADJP	O
num	CD	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
seen	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
regular	JJ	I-NP	O
basis	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
instances	NNS	I-NP	O
,	,	O	O
suspicion	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
carcinoma	NN	B-NP	B
was	VBD	B-VP	O
aroused	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
palpation	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
small	JJ	I-NP	O
nodule	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
vaginal	JJ	I-NP	O
fornix	NN	I-NP	O
.	.	O	O

Hysterosalpingography	NN	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
both	DT	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
,	,	O	O
in	IN	B-PP	O
num	CD	B-NP	O
instance	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
abnormal	JJ	I-NP	O
x	NN	I-NP	O
-	HYPH	B-NP	O
ray	NN	I-NP	O
film	NN	I-NP	O
was	VBD	B-VP	O
reflected	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
gross	JJ	I-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
uterine	JJ	I-NP	O
cavity	NN	I-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
surgical	JJ	I-NP	O
specimen	NN	I-NP	O
.	.	O	O

Phenobarbitone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
enlargement	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
:	:	O	O
its	PRP$	B-NP	O
relationship	NN	I-NP	O
to	TO	B-PP	O
carbon	NN	B-NP	O
tetrachloride	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cirrhosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
yield	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
cirrhosis	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
carbon	NN	B-NP	O
tetrachloride	NN	I-NP	O
given	VBN	B-VP	O
intragastrically	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
phenobarbitone	NN	I-NP	O
-	HYPH	B-VP	O
primed	VBN	B-NP	O
rat	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
giving	VBG	B-VP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
calibrating	VBG	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
carbon	NN	B-NP	O
tetrachloride	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
peak	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
phenobarbitone	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
enlargement	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
.	.	O	O

At	IN	B-PP	O
this	DT	B-NP	O
point	NN	I-NP	O
it	PRP	B-NP	O
was	VBD	B-VP	O
assumed	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
cytochrome	NN	I-NP	O
P450	NN	I-NP	O
/	SYM	B-NP	O
CCl4	NN	I-NP	O
toxic	JJ	I-NP	O
state	NN	I-NP	O
was	VBD	B-VP	O
both	CC	O	O
maximal	JJ	B-ADJP	O
and	CC	I-ADJP	O
stable	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
optimal	JJ	I-NP	O
rat	NN	I-NP	O
size	NN	I-NP	O
to	TO	B-VP	O
begin	VB	I-VP	O
phenobarbitone	NN	B-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
as	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
,	,	O	O
and	CC	O	O
this	DT	B-NP	O
size	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
maximum	JJ	I-NP	O
relative	JJ	I-NP	O
liver	NN	I-NP	O
weight	NN	I-NP	O
increase	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
normal	JJ	B-NP	O
rats	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
body	NN	I-NP	O
weight	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
optimal	JJ	I-NP	O
time	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
carbon	NN	B-NP	O
tetrachloride	NN	I-NP	O
was	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
on	IN	B-PP	O
phenobarbitone	NN	B-NP	O
.	.	O	O

Attenuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
diabetes	NN	I-NP	B
-	HYPH	B-NP	I
insipidus	NN	I-NP	I
-	HYPH	B-NP	I
like	JJ	I-NP	I
syndrome	NN	I-NP	I
by	IN	B-PP	O
amiloride	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
amiloride	NN	B-NP	O
on	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polydipsia	NN	I-NP	B
and	CC	I-NP	O
polyuria	NN	I-NP	B
and	CC	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
,	,	I-NP	O
brain	NN	I-NP	O
,	,	I-NP	O
kidney	NN	I-NP	O
,	,	I-NP	O
thyroid	NN	I-NP	O
and	CC	I-NP	O
red	JJ	I-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
chronically	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
LiCl	NN	B-NP	O
.	.	O	O

Amiloride	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
drinking	NN	I-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
subacute	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
experiment.	VBP	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
amiloride	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
reduction	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
medulla	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
organs	NNS	I-NP	O
studied	VBN	B-VP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
all	PDT	B-NP	O
the	DT	I-NP	O
tissues	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
slight	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
lithium	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
combined	JJ	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
marked	JJ	I-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	I-NP	O
tissue	NN	I-NP	O
lithium	NN	I-NP	O
levels	NNS	I-NP	O
accompanied	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
water	NN	B-NP	O
intake	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
experiments	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
attenuation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
diabetes	NN	I-NP	B
-	HYPH	B-NP	I
insipidus	NN	I-NP	I
-	HYPH	B-NP	I
like	JJ	I-NP	I
syndrome	NN	I-NP	I
by	IN	B-PP	O
amiloride	NN	B-NP	O
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ratio	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
medulla	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
and	CC	O	O
an	DT	B-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
potassium	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
acute	JJ	B-NP	O
amiloride	NN	I-NP	O
administration	NN	I-NP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
polydipsia	NN	B-NP	B
and	CC	I-NP	O
polyuria	NN	I-NP	B
might	MD	B-VP	O
relieve	VB	I-VP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
but	CC	O	O
prolonged	VBD	B-VP	O
amiloride	NN	B-NP	O
supplementation	NN	I-NP	O
would	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
elevated	JJ	B-NP	O
lithium	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
might	MD	B-VP	O
be	VB	I-VP	O
hazardous	JJ	B-ADJP	O
.	.	O	O

Safety	NN	B-NP	O
and	CC	I-NP	O
side	NN	I-NP	O
-	HYPH	O	O
effects	NNS	B-NP	O
of	IN	B-PP	O
alprazolam	NN	B-NP	O
.	.	O	O

Controlled	VBN	B-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
agoraphobia	NN	B-NP	B
with	IN	B-PP	O
panic	NN	B-NP	B
disorder	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
widespread	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
benzodiazepines	NNS	B-NP	O
has	VBZ	B-VP	O
led	VBN	I-VP	O
to	TO	B-PP	O
increasing	VBG	B-NP	O
recognition	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
unwanted	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
alprazolam	NN	B-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
in	IN	B-PP	O
panic	NN	B-NP	B
disorder	NN	I-NP	I
with	IN	B-PP	O
agoraphobia	NN	B-NP	B
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
side	NN	I-NP	O
-	HYPH	O	O
effect	NN	B-NP	O
and	CC	O	O
adverse	JJ	B-NP	O
effect	NN	I-NP	O
profiles	NNS	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
drug	NN	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
London	NNP	B-NP	O
and	CC	O	O
Toronto	NNP	B-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
met	VBD	B-VP	O
DSM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
panic	NN	B-NP	B
disorder	NN	I-NP	I
with	IN	B-PP	O
agoraphobia	NN	B-NP	B
were	VBD	B-VP	O
randomised	VBN	I-VP	O
to	TO	B-PP	O
alprazolam	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
drug	NN	I-NP	O
group	NN	I-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
either	CC	O	O
exposure	NN	B-NP	O
or	CC	I-NP	O
relaxation	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
was	VBD	B-VP	O
from	IN	B-PP	O
weeks	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
then	RB	I-VP	O
tapered	VBN	I-VP	O
from	IN	B-PP	O
weeks	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

Mean	JJ	B-NP	O
alprazolam	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
daily	RB	B-ADVP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
subjects	NNS	I-NP	O
,	,	O	O
alprazolam	NN	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
more	RBR	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
v.	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
depression	NN	B-NP	B
,	,	I-NP	O
enuresis	NN	I-NP	B
,	,	I-NP	O
disinhibition	NN	I-NP	O
and	CC	I-NP	O
aggression	NN	I-NP	B
;	:	O	O
and	CC	O	O
more	JJR	B-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
sedation	NN	B-NP	O
,	,	O	O
irritability	NN	B-NP	B
,	,	O	O
impaired	JJ	B-NP	B
memory	NN	I-NP	I
,	,	O	O
weight	NN	B-NP	B
loss	NN	I-NP	I
and	CC	I-NP	O
ataxia	NN	I-NP	B
.	.	O	O

Side	NN	B-NP	O
-	HYPH	I-NP	O
effects	NNS	I-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
diminish	VB	I-VP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
but	CC	O	O
remained	VBD	B-VP	O
significant	JJ	B-ADJP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
this	DT	B-NP	O
,	,	O	O
the	DT	B-NP	O
drop	VB	I-NP	O
-	HYPH	B-VP	O
out	RP	B-PRT	O
rate	NN	B-NP	O
was	VBD	B-VP	O
low	JJ	B-ADJP	O
.	.	O	O

Alprazolam	NN	B-NP	O
caused	VBD	B-VP	O
side	NN	B-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
and	CC	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
but	CC	O	O
many	JJ	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
willing	JJ	B-ADJP	O
to	TO	B-VP	O
accept	VB	I-VP	O
these	DT	B-NP	O
.	.	O	O

Dup	IN	B-PP	O
num	CD	B-NP	O
prevents	NNS	I-NP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndromes	NNS	I-NP	I
such	JJ	B-PP	O
as	IN	I-PP	O
proteinuria	NN	B-NP	B
,	,	O	O
hypoalbuminemia	NN	B-NP	B
,	,	O	O
hypercholesterolemia	NN	B-NP	B
and	CC	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
nitrogen	NN	I-NP	O
urea	NN	I-NP	O
,	,	O	O
induced	VBN	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
was	VBD	B-VP	O
markedly	RB	I-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
Dup	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
losartan	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
novel	JJ	I-NP	O
angiotensin	NN	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

Sodium	NN	B-NP	O
bicarbonate	NN	I-NP	O
alleviates	VBZ	B-VP	O
penile	JJ	B-NP	B
pain	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
intracavernous	JJ	B-NP	O
injections	NNS	I-NP	O
for	IN	B-PP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
an	DT	B-NP	O
attempt	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
penile	JJ	B-NP	B
pain	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
intracorporeal	JJ	B-NP	O
injections	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
acidity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
study	NN	I-NP	O
comparing	VBG	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
penile	JJ	B-NP	B
pain	NN	I-NP	I
following	VBG	B-PP	O
intracorporeal	JJ	B-NP	O
injections	NNS	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
bicarbonate	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
intracorporeal	JJ	I-NP	O
medications	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
presented	VBD	B-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
clinic	NN	I-NP	O
with	IN	B-PP	O
impotence	NN	B-NP	B
received	VBD	B-VP	O
num	CD	B-NP	O
ml.	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
drugs	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
mg.	NN	I-NP	O
papaverine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
micrograms.	NNS	I-NP	O
phentolamine	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
micrograms.	NNS	I-NP	O
prostaglandin	NN	I-NP	O
E1	NN	I-NP	O
with	IN	B-PP	O
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
or	CC	O	O
without	IN	B-PP	O
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
bicarbonate	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
mEq.	NN	I-NP	O
)	)	O	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
sodium	NN	B-NP	O
bicarbonate	NN	I-NP	O
added	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
num	CD	I-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
penile	JJ	B-NP	B
pain	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
men	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
sodium	NN	B-NP	O
bicarbonate	NN	I-NP	O
complained	VBN	B-VP	O
of	IN	B-PP	O
penile	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

From	IN	B-PP	O
these	DT	B-NP	O
data	NNS	I-NP	O
we	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
penile	JJ	I-NP	B
pain	NN	I-NP	I
following	VBG	B-PP	O
intracorporeal	JJ	B-NP	O
injections	NNS	I-NP	O
is	VBZ	B-VP	O
most	RBS	B-ADVP	O
likely	RB	I-ADVP	O
due	IN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
acidity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
overcome	VBN	I-VP	O
by	IN	B-PP	O
elevating	VBG	B-VP	O
the	DT	B-NP	O
pH	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
neutral	JJ	I-NP	O
level	NN	I-NP	O
.	.	O	O

Prospective	JJ	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
somatostatin	NN	B-NP	O
analog	NN	I-NP	O
(	(	O	O
octreotide	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
gallbladder	NN	B-NP	O
function	NN	I-NP	O
and	CC	O	O
gallstone	NN	B-NP	B
formation	NN	I-NP	O
in	IN	B-PP	O
Chinese	JJ	B-NP	O
acromegalic	JJ	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
article	NN	I-NP	O
reports	VBZ	B-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
gallbladder	NN	B-NP	O
function	NN	I-NP	O
examined	VBN	B-VP	O
by	IN	B-PP	O
ultrasonography	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
Chinese	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
active	JJ	B-NP	O
acromegaly	RB	B-VP	B
treated	VBN	I-VP	O
with	IN	B-PP	O
sc	NN	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
somatostatin	NN	I-NP	O
analog	NN	I-NP	O
octreotide	NN	I-NP	O
in	IN	B-PP	O
dosages	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
mean	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
octreotide	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
sludge	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
gallstones	NNS	B-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
cholecystitis	NN	I-NP	I
requiring	VBG	B-VP	O
surgery	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
examined	VBN	B-VP	O
acutely	RB	B-ADVP	O
,	,	O	O
gallbladder	NN	B-NP	O
contractility	NN	I-NP	O
was	VBD	B-VP	O
inhibited	VBN	I-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
injection	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
followed	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
gallbladder	NN	B-NP	O
contractility	NN	I-NP	O
remained	VBD	B-VP	O
depressed	JJ	B-ADJP	B
throughout	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
octreotide	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
gallstones	NNS	B-NP	B
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
assessed	VBN	B-VP	O
had	VBD	B-VP	O
return	NN	B-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
gallbladder	NN	I-NP	O
contractility	NN	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
gallstones	NNS	B-NP	B
during	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
gallbladder	NN	B-NP	O
contractility	NN	I-NP	O
normalized	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
has	VBZ	B-VP	O
disappearance	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
stones	NNS	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
remained	VBD	B-VP	O
depressed	VBN	I-VP	B
in	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
had	VBD	B-VP	O
stones	NNS	B-NP	O
present	JJ	B-ADJP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
suppression	NN	I-NP	O
of	IN	B-PP	O
gallbladder	NN	B-NP	O
contractility	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
successive	JJ	I-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
bile	NN	B-NP	O
sludge	NN	I-NP	O
,	,	O	O
gallstones	NNS	B-NP	B
,	,	O	O
and	CC	O	O
cholecystitis	NN	B-NP	B
during	IN	B-PP	O
octreotide	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
Chinese	JJ	B-NP	O
acromegalic	JJ	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
therefore	RB	B-ADVP	O
very	RB	B-ADJP	O
important	JJ	I-ADJP	O
to	TO	B-VP	O
follow	VB	I-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
gallbladder	NN	B-NP	O
function	NN	I-NP	O
during	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
octreotide	NN	I-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
acromegalic	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Improvement	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
by	IN	B-PP	O
propranolol	NN	B-NP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
with	IN	B-PP	O
severely	RB	B-ADVP	O
disabling	VBG	B-VP	O
dyskinesia	NN	B-NP	B
received	VBD	B-VP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
propranolol	NN	I-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
adjunct	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
currently	RB	I-NP	O
used	VBN	I-NP	O
medical	JJ	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dyskinesia	NN	I-NP	B
score	NN	I-NP	O
without	IN	B-PP	O
increase	NN	B-NP	O
of	IN	B-PP	O
parkinsonian	JJ	B-NP	B
motor	NN	I-NP	B
disability	NN	I-NP	I
.	.	O	O

Ballistic	JJ	B-NP	O
and	CC	I-NP	O
choreic	JJ	I-NP	O
dyskinesia	NN	I-NP	B
were	VBD	B-VP	O
markedly	RB	I-VP	O
ameliorated	VBN	I-VP	O
,	,	O	O
whereas	IN	O	O
dystonia	NN	B-NP	B
was	VBD	B-VP	O
not	RB	O	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
administration	NN	B-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
beta	SYM	O	O
-	HYPH	O	O
blockers	NNS	B-NP	O
may	MD	B-VP	O
improve	VB	I-VP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ballistic	JJ	I-NP	O
and	CC	I-NP	O
choreic	JJ	I-NP	O
dyskinesia	NN	I-NP	B
in	IN	B-PP	O
PD	NN	B-NP	B
.	.	O	O

Morphological	JJ	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
encephalopathy	NN	B-NP	B
after	IN	B-SBAR	O
chronic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
valproate	NN	I-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
transmission	NN	I-NP	O
electron	NN	I-NP	O
microscopic	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
capillaries	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cerebellar	JJ	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
intragastric	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
sodium	NN	I-NP	O
valproate	NN	I-NP	O
(	(	O	O
Vupral	JJ	B-NP	O
Polfa	NN	I-NP	O
)	)	O	O
at	IN	B-PP	O
the	DT	B-NP	O
effective	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
b.	NN	I-NP	O
w.	NN	I-NP	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
revealed	VBD	B-VP	O
neurological	JJ	B-NP	B
disorders	NNS	I-NP	I
indicating	VBG	B-VP	O
cerebellum	NN	B-NP	B
damage	NN	I-NP	I
(	(	O	O
valproate	NN	B-NP	O
encephalopathy	NN	I-NP	B
)	)	O	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
ultrastructural	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
structural	JJ	B-NP	O
elements	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	B-NP	O
brain	NN	I-NP	O
-	HYPH	O	O
barrier	NN	B-NP	O
(	(	O	O
BBB	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
cerebellar	JJ	I-NP	O
cortex	NN	I-NP	O
were	VBD	B-VP	O
detectable	JJ	B-ADJP	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experiment	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
became	VBD	B-VP	O
more	RBR	B-ADJP	O
severe	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
later	JJ	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experiment	NN	I-NP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
most	RBS	B-ADJP	O
severe	JJ	I-ADJP	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
located	JJ	B-ADJP	O
mainly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
layer	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cerebellar	JJ	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

Lesions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
capillary	NN	I-NP	O
included	VBD	B-VP	O
necrosis	NN	B-NP	B
of	IN	B-PP	O
endothelial	JJ	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

Organelles	NNS	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cells	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
particular	JJ	B-ADJP	O
the	DT	B-NP	O
mitochondria	NNS	I-NP	O
(	(	O	O
increased	VBN	B-NP	O
number	NN	I-NP	O
and	CC	I-NP	O
size	NN	I-NP	O
,	,	O	O
distinct	JJ	B-NP	O
degeneration	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
matrix	NN	I-NP	O
and	CC	I-NP	O
cristae	NN	I-NP	O
)	)	O	O
and	CC	O	O
Golgi	NNP	B-NP	O
apparatus	NN	I-NP	O
were	VBD	B-VP	O
altered	VBN	I-VP	O
.	.	O	O

Reduced	VBN	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
capillary	JJ	B-NP	O
lumen	NN	I-NP	O
and	CC	I-NP	O
occlusion	NN	I-NP	O
were	VBD	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
swollen	VBN	B-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
which	WDT	B-NP	O
had	VBD	B-VP	O
luminal	JJ	B-NP	O
protrusions	NNS	I-NP	O
and	CC	O	O
swollen	JJ	B-NP	O
microvilli	NNS	I-NP	O
.	.	O	O

Pressure	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
vessel	NN	I-NP	O
wall	NN	I-NP	O
was	VBD	B-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
enlarged	JJ	B-NP	O
perivascular	JJ	I-NP	O
astrocytic	JJ	I-NP	O
processes	NNS	I-NP	O
.	.	O	O

Fragments	NNS	B-NP	O
of	IN	B-PP	O
necrotic	JJ	B-NP	B
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
vascular	JJ	I-NP	O
lumens	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
these	DT	B-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
loosening	VBG	I-VP	O
and	CC	O	O
breaking	NN	B-NP	O
of	IN	B-PP	O
tight	JJ	B-NP	O
cellular	JJ	I-NP	O
junctions	NNS	I-NP	O
.	.	O	O

Damage	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
vascular	JJ	I-NP	O
basement	NN	I-NP	O
lamina	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
.	.	O	O

Damage	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
capillary	NN	I-NP	O
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
marked	JJ	B-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
neuroglial	JJ	B-NP	O
cells	NNS	I-NP	O
,	,	O	O
mainly	RB	B-ADVP	O
to	TO	B-PP	O
perivascular	JJ	B-NP	O
processes	NNS	I-NP	O
of	IN	B-PP	O
astrocytes	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
proliferation	NN	I-NP	O
of	IN	B-PP	O
astrocytes	NNS	B-NP	O
(	(	O	O
Bergmann	NNP	B-NP	O
s	NNS	I-NP	O
in	IN	B-PP	O
particular	JJ	B-ADJP	O
)	)	O	O
and	CC	O	O
occasionally	RB	B-ADVP	O
of	IN	B-PP	O
oligodendrocytes	NNS	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Alterations	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
structural	JJ	I-NP	O
elements	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
coexisted	VBD	B-VP	O
with	IN	B-PP	O
marked	JJ	B-NP	O
lesions	NNS	I-NP	O
of	IN	B-PP	O
neurons	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cerebellum	NN	I-NP	O
(	(	O	O
Purkinje	NN	B-NP	O
cells	NNS	I-NP	O
are	VBP	B-VP	O
earliest	JJS	B-ADJP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
electron	NN	B-NP	O
micrographs	NNS	I-NP	O
both	CC	O	O
luminal	JJ	B-NP	O
and	CC	I-NP	O
antiluminal	JJ	I-NP	O
sides	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
BBB	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cerebellar	JJ	I-NP	O
cortex	NN	I-NP	O
had	VBD	B-VP	O
similar	JJ	B-NP	O
lesions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hepatic	JJ	I-NP	B
damage	NN	I-NP	I
,	,	O	O
mainly	RB	B-NP	O
hyperammonemia	NN	I-NP	B
,	,	O	O
upon	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
valproate	NN	B-NP	O
encephalopathy	NN	I-NP	B
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Macula	NN	B-NP	O
toxicity	NN	I-NP	B
after	IN	B-PP	O
intravitreal	JJ	B-NP	O
amikacin	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
intravitreal	JJ	B-NP	O
aminoglycosides	NNS	I-NP	O
have	VBP	B-VP	O
substantially	RB	I-VP	O
improved	VBN	I-VP	O
visual	JJ	B-NP	O
prognosis	NN	I-NP	O
in	IN	B-PP	O
endophthalmitis	NN	B-NP	B
,	,	O	O
macular	JJ	B-NP	O
infarction	NN	I-NP	B
may	MD	B-VP	O
impair	VB	I-VP	O
full	JJ	B-NP	O
visual	JJ	I-NP	O
recovery	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
presumed	VBN	B-NP	O
amikacin	NN	I-NP	O
retinal	NN	I-NP	B
toxicity	NN	I-NP	I
following	VBG	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
amikacin	NN	B-NP	O
and	CC	I-NP	O
vancomycin	NN	I-NP	O
for	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
haemolytic	JJ	I-NP	O
streptococcal	JJ	I-NP	B
endophthalmitis	NN	I-NP	I
.	.	O	O

Endophthalmitis	NN	B-NP	B
resolved	VBN	B-VP	O
with	IN	B-PP	O
improvement	NN	B-NP	O
in	IN	B-PP	O
visual	JJ	B-NP	O
acuity	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Fundus	NN	B-NP	O
fluorescein	NN	I-NP	O
angiography	NN	I-NP	O
confirmed	VBD	B-VP	O
macular	JJ	B-NP	O
capillary	JJ	I-NP	O
closure	NN	I-NP	O
and	CC	I-NP	O
telangiectasis	NN	I-NP	B
.	.	O	O

Currently	RB	B-NP	O
accepted	VBN	I-NP	O
intravitreal	JJ	I-NP	O
antibiotic	JJ	I-NP	O
regimens	NNS	I-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
retinal	JJ	B-NP	B
toxicity	NN	I-NP	I
and	CC	O	O
macular	JJ	B-NP	O
ischaemia	NN	I-NP	B
.	.	O	O

Treatment	NN	B-NP	O
strategies	NNS	I-NP	O
aimed	VBN	B-VP	O
at	IN	B-PP	O
avoiding	VBG	B-VP	O
retinal	JJ	B-NP	B
toxicity	NN	I-NP	I
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Iatrogenically	RB	B-NP	O
induced	VBN	I-NP	O
intractable	JJ	I-NP	O
atrioventricular	JJ	I-NP	B
reentrant	JJ	I-NP	I
tachycardia	NN	I-NP	I
after	IN	B-PP	O
verapamil	NN	B-NP	O
and	CC	I-NP	O
catheter	NN	I-NP	O
ablation	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
Wolff	NNP	B-NP	B
-	HYPH	B-NP	I
Parkinson	NNP	I-NP	I
-	HYPH	I-NP	I
White	NNP	I-NP	I
syndrome	NN	I-NP	I
and	CC	I-NP	O
idiopathic	JJ	I-NP	B
dilated	JJ	I-NP	I
cardiomyopathy	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
WPW	NN	B-NP	B
syndrome	NN	I-NP	I
and	CC	O	O
idiopathic	JJ	B-NP	B
dilated	JJ	I-NP	I
cardiomyopathy	NN	I-NP	I
,	,	O	O
intractable	JJ	B-NP	O
atrioventricular	JJ	I-NP	B
reentrant	NN	I-NP	I
tachycardia	NN	I-NP	I
(	(	O	O
AVRT	NN	B-NP	B
)	)	O	O
was	VBD	B-VP	O
iatrogenically	RB	I-VP	O
induced	VBN	I-VP	O
.	.	O	O

QRS	NNS	B-NP	O
without	IN	B-PP	O
preexcitation	NN	B-NP	O
,	,	O	O
caused	VBN	B-VP	O
by	IN	B-PP	O
junctional	JJ	B-NP	O
escape	NN	I-NP	O
beats	NNS	I-NP	O
after	IN	B-PP	O
verapamil	NN	B-NP	O
or	CC	O	O
unidirectional	JJ	B-NP	O
antegrade	NN	I-NP	O
block	NN	I-NP	O
of	IN	B-PP	O
accessory	JJ	B-NP	O
pathway	NN	I-NP	O
after	IN	B-PP	O
catheter	NN	B-NP	O
ablation	NN	I-NP	O
,	,	O	O
established	VBN	B-VP	O
frequent	JJ	B-NP	O
AVRT	NN	I-NP	B
attack	NN	I-NP	O
.	.	O	O

Epidemic	JJ	B-NP	O
of	IN	B-PP	O
liver	NN	B-NP	B
disease	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
hydrochlorofluorocarbons	NNS	B-NP	O
used	VBN	B-VP	O
as	IN	B-PP	O
ozone	NN	B-NP	O
-	HYPH	O	O
sparing	VBG	B-VP	O
substitutes	NNS	B-NP	O
of	IN	B-PP	O
chlorofluorocarbons	NNS	B-NP	O
.	.	O	O

Hydrochlorofluorocarbons	NNS	B-NP	O
(	(	O	O
HCFCs	NNS	B-NP	O
)	)	O	O
are	VBP	B-VP	O
used	VBN	I-VP	O
increasingly	RB	B-ADVP	O
in	IN	B-PP	O
industry	NN	B-NP	O
as	IN	B-PP	O
substitutes	NNS	B-NP	O
for	IN	B-PP	O
ozone	NN	B-NP	O
-	HYPH	O	O
depleting	VBG	B-VP	O
chlorofluorocarbons	NNS	B-NP	O
(	(	O	O
CFCs	NNS	B-NP	O
)	)	O	O
.	.	O	O

Limited	JJ	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
indicate	VBP	B-VP	O
potential	JJ	B-NP	O
hepatotoxicity	NN	I-NP	B
of	IN	B-PP	O
some	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
compounds	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
an	DT	B-NP	O
epidemic	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
industrial	JJ	I-NP	O
workers	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
had	VBN	I-VP	O
repeated	VBN	I-VP	O
accidental	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
mixture	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	B-NP	O
dichloro	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
trifluoroethane	NN	I-NP	O
(	(	O	O
HCFC	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloro	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrafluoroethane	NN	I-NP	O
(	(	O	O
HCFC	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
exposed	VBN	I-NP	O
workers	NNS	I-NP	O
were	VBD	B-VP	O
affected	VBN	I-VP	O
to	TO	B-PP	O
various	JJ	B-NP	O
degrees	NNS	I-NP	O
.	.	O	O

Both	DT	B-NP	O
compounds	NNS	I-NP	O
are	VBP	B-VP	O
metabolised	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
way	NN	I-NP	O
as	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
bromo	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
chloro	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
trifluoroethane	NN	I-NP	O
(	(	O	O
halothane	NN	B-NP	O
)	)	O	O
to	TO	B-VP	O
form	VB	I-VP	O
reactive	JJ	B-NP	O
trifluoroacetyl	NN	I-NP	O
halide	NN	I-NP	O
intermediates	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hepatotoxicity	NN	I-NP	B
of	IN	B-PP	O
halothane	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
test	VB	I-VP	O
whether	IN	B-SBAR	O
HCFCs	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
can	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
serious	JJ	B-NP	O
liver	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

For	IN	B-PP	O
num	CD	B-NP	O
severely	RB	B-VP	O
affected	VBD	I-VP	O
worker	NN	B-NP	O
liver	NN	I-NP	O
biopsy	NN	I-NP	O
and	CC	O	O
immunohistochemical	JJ	B-NP	O
stainings	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
trifluoroacetyl	NN	B-NP	O
protein	NN	I-NP	O
adducts	NNS	I-NP	O
were	VBD	B-VP	O
done	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
affected	VBN	I-NP	O
workers	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
autoantibodies	NNS	B-NP	O
that	WDT	B-NP	O
react	VBP	B-VP	O
with	IN	B-PP	O
human	JJ	B-NP	O
liver	NN	I-NP	O
cytochrome	NN	I-NP	O
-	HYPH	B-NP	O
P450	NN	I-NP	O
2E1	NN	I-NP	O
(	(	O	O
P450	NN	B-NP	O
2E1	NN	I-NP	O
)	)	O	O
and	CC	O	O
P58	NN	B-NP	O
protein	NN	I-NP	O
disulphide	NN	I-NP	O
isomerase	NN	I-NP	O
isoform	NN	I-NP	O
(	(	O	O
P58	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
liver	NN	I-NP	O
biopsy	NN	I-NP	O
sample	NN	I-NP	O
showed	VBD	B-VP	O
hepatocellular	JJ	B-NP	O
necrosis	NN	I-NP	B
which	WDT	B-NP	O
was	VBD	B-VP	O
prominent	JJ	B-ADJP	O
in	IN	B-PP	O
perivenular	JJ	B-NP	O
zone	NN	I-NP	O
num	CD	I-NP	O
and	CC	O	O
extended	VBD	B-VP	O
focally	RB	B-ADVP	O
from	IN	B-PP	O
portal	JJ	B-NP	O
tracts	NNS	I-NP	O
to	TO	B-PP	O
portal	JJ	B-NP	O
tracts	NNS	I-NP	O
and	CC	O	O
centrilobular	JJ	B-NP	O
areas	NNS	I-NP	O
(	(	O	O
bridging	VBG	B-VP	O
necrosis	NN	B-NP	B
)	)	O	O
.	.	O	O

Trifluoroacetyl	NN	B-NP	O
-	HYPH	B-NP	O
adducted	VBN	I-NP	O
proteins	NNS	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
surviving	VBG	B-VP	O
hepatocytes	NNS	B-NP	O
.	.	O	O

Autoantibodies	NNS	B-NP	O
against	IN	B-PP	O
P450	NN	B-NP	O
2E1	NN	I-NP	O
or	CC	I-NP	O
P58	NN	I-NP	O
,	,	O	O
previously	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
halothane	NN	B-NP	B
hepatitis	NN	I-NP	I
,	,	O	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
affected	VBN	I-NP	O
workers	NNS	I-NP	O
.	.	O	O

Repeated	VBN	B-NP	O
exposure	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
beings	NNS	I-NP	O
to	TO	B-PP	O
HCFCs	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
can	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
serious	JJ	B-NP	O
liver	NN	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
large	JJ	I-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
exposed	VBN	I-NP	O
population	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
exact	JJ	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
of	IN	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
trifluoroacetyl	NN	B-NP	O
-	HYPH	B-VP	O
altered	VBN	B-NP	O
liver	NN	I-NP	O
proteins	NNS	I-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
view	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
potentially	RB	I-NP	O
widespread	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
compounds	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
urgent	JJ	I-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
develop	VB	I-VP	O
safer	JJR	B-NP	O
alternatives	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
different	JJ	B-NP	O
anaesthetic	JJ	I-NP	O
agents	NNS	I-NP	O
in	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
following	VBG	B-PP	O
spinal	JJ	B-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
after	IN	B-PP	O
spinal	JJ	B-NP	O
anaesthesia	NN	I-NP	O
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

Up	IN	B-PP	O
until	IN	B-PP	O
now	RB	B-NP	O
,	,	O	O
the	DT	B-NP	O
only	JJ	I-NP	O
factor	NN	I-NP	O
studied	VBN	B-ADJP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diameter	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
needle	NN	I-NP	O
on	IN	B-PP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
sensorineural	JJ	I-NP	B
hearing	NN	I-NP	I
loss	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
describe	VB	I-VP	O
this	DT	B-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
and	CC	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
other	JJ	B-NP	O
factors	NNS	I-NP	O
influencing	VBG	B-VP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
similar	JJ	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mL	NN	I-NP	O
prilocaine	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
and	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mL	NN	I-NP	O
bupivacaine	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
given	VBN	B-PP	O
prilocaine	NN	B-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
develop	VB	I-VP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
out	IN	B-ADVP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
than	IN	B-PP	O
those	DT	B-NP	O
given	VBN	I-NP	O
bupivacaine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
out	IN	B-ADVP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
for	IN	B-PP	O
speech	NN	B-NP	O
frequencies	NNS	I-NP	O
was	VBD	B-VP	O
about	RB	B-NP	O
num	CD	I-NP	O
dB	NN	I-NP	O
after	IN	B-PP	O
prilocaine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
dB	NN	I-NP	O
after	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
subjective	JJ	B-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
possible	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
transient	JJ	I-NP	O
neurological	JJ	I-NP	B
deficit	NN	I-NP	I
following	VBG	B-PP	O
intrathecal	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
hyperbaric	JJ	I-NP	O
bupivacaine	NN	I-NP	O
for	IN	B-PP	O
unilateral	JJ	B-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
neurological	JJ	I-NP	B
deficit	NN	I-NP	I
that	WDT	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
unilateral	JJ	B-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
hyperbaric	JJ	I-NP	O
bupivacaine	NN	I-NP	O
slowly	RB	B-VP	O
injected	VBN	I-VP	O
through	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
gauge	NN	I-NP	O
pencil	NN	I-NP	O
-	HYPH	B-NP	O
point	NN	I-NP	O
spinal	JJ	I-NP	O
needle	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
surgery	NN	I-NP	O
and	CC	I-NP	O
anaesthesia	NN	I-NP	O
were	VBD	B-VP	O
uneventful	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
reported	VBD	B-VP	O
an	DT	B-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
hypoaesthesia	NN	B-NP	O
over	IN	B-PP	O
L3	NN	B-NP	O
-	HYPH	B-NP	O
L4	NN	I-NP	O
dermatomes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
leg	NN	I-NP	O
which	WDT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
operated	VBN	I-VP	O
on	IN	B-PP	O
(	(	O	O
loss	NN	B-NP	B
of	IN	B-PP	I
pinprick	NN	B-NP	I
sensation	NN	I-NP	I
)	)	O	O
without	IN	B-PP	O
reduction	NN	B-NP	O
in	IN	B-PP	O
muscular	JJ	B-NP	O
strength	NN	I-NP	O
.	.	O	O

Sensation	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
area	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
over	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Prospective	JJ	B-NP	O
multicentre	JJ	I-NP	O
studies	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
large	JJ	I-NP	O
population	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
long	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
should	MD	B-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
unusual	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
low	JJ	I-NP	O
solution	NN	I-NP	O
concentration	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
preferred	VBN	I-VP	O
for	IN	B-PP	O
unilateral	JJ	B-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
hyperbaric	JJ	I-NP	O
anaesthetic	JJ	I-NP	O
solution	NN	I-NP	O
(	(	O	O
if	IN	B-SBAR	O
pencil	NN	B-NP	O
-	HYPH	B-NP	O
point	NN	I-NP	O
needle	NN	I-NP	O
and	CC	O	O
slow	JJ	B-NP	O
injection	NN	I-NP	O
rate	NN	I-NP	O
are	VBP	B-VP	O
employed	VBN	I-VP	O
)	)	O	O
,	,	O	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
minimize	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
localized	JJ	I-NP	O
high	JJ	I-NP	O
peak	NN	I-NP	O
anaesthetic	JJ	I-NP	O
concentration	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
might	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
neurological	JJ	I-NP	B
deficit	NN	I-NP	I
.	.	O	O

Pethidine	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
seizure	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
healthy	JJ	I-NP	O
adolescent	JJ	I-NP	O
receiving	VBG	I-NP	O
pethidine	NN	I-NP	O
for	IN	B-PP	O
postoperative	JJ	B-NP	B
pain	NN	I-NP	I
control	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
healthy	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
male	JJ	I-NP	O
received	VBN	I-NP	O
standard	JJ	I-NP	O
intermittent	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
pethidine	NN	B-NP	O
via	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-VP	O
analgesia	NN	B-NP	O
(	(	O	O
PCA	NN	B-NP	O
)	)	O	O
pump	NN	B-NP	O
for	IN	B-PP	O
management	NN	B-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
pain	NN	I-NP	I
control	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
postoperatively	RB	B-ADVP	O
he	PRP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
brief	JJ	I-NP	O
self	NN	I-NP	O
-	HYPH	B-VP	O
limited	VBN	B-NP	O
seizure	NN	I-NP	B
.	.	O	O

Both	CC	O	O
plasma	NN	B-NP	O
pethidine	NN	I-NP	O
and	CC	O	O
norpethidine	NN	B-NP	O
were	VBD	B-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
range	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
excitation	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
other	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
CNS	NN	B-NP	O
toxicity	NN	I-NP	B
were	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
method	NN	I-NP	O
allowed	VBD	B-VP	O
frequent	JJ	B-NP	O
self	AFX	I-NP	O
-	HYPH	I-NP	O
dosing	NN	B-NP	O
of	IN	B-PP	O
pethidine	NN	B-NP	O
at	IN	B-PP	O
short	JJ	B-NP	O
time	NN	I-NP	O
intervals	NNS	I-NP	O
and	CC	O	O
rapid	JJ	B-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
pethidine	NN	B-NP	O
and	CC	I-NP	O
norpethidine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
routine	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
pethidine	NN	B-NP	O
via	IN	B-PP	O
PCA	NN	B-NP	O
even	RB	B-ADVP	O
for	IN	B-PP	O
a	DT	B-NP	O
brief	JJ	I-NP	O
postoperative	JJ	I-NP	O
analgesia	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
reconsidered	VBN	I-VP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
acute	JJ	I-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
vanishing	VBG	B-VP	B
bile	NN	B-NP	I
duct	NN	I-NP	I
and	CC	O	O
Stevens	NNP	B-NP	B
-	HYPH	B-NP	I
Johnson	NNP	I-NP	I
syndromes	NNS	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
child	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
vanishing	VBG	I-NP	B
bile	NN	I-NP	I
duct	NN	I-NP	I
syndrome	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
but	CC	I-NP	O
established	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
progressive	JJ	B-NP	O
cholestasis	NN	I-NP	B
in	IN	B-PP	O
adults	NNS	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
most	RBS	B-ADVP	O
often	RB	I-ADVP	O
drug	NN	B-NP	O
or	CC	I-NP	O
toxin	NN	I-NP	O
related	VBN	B-ADJP	O
,	,	O	O
and	CC	O	O
is	VBZ	B-VP	O
of	IN	B-PP	O
unknown	JJ	B-NP	O
pathogenesis	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
previously	RB	B-ADVP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

Stevens	NNP	B-NP	B
-	HYPH	I-NP	I
Johnson	NNP	I-NP	I
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
recognized	VBN	B-VP	O
immune	JJ	B-NP	O
complex	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
hypersensitivity	NN	I-NP	B
reaction	NN	I-NP	O
that	WDT	B-NP	O
affects	VBZ	B-VP	O
all	DT	B-NP	O
age	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
drug	NN	B-NP	O
or	CC	I-NP	O
infection	NN	I-NP	B
induced	VBD	B-VP	O
,	,	O	O
and	CC	O	O
has	VBZ	B-VP	O
classic	JJ	B-NP	O
systemic	JJ	I-NP	O
,	,	I-NP	O
mucosal	JJ	I-NP	O
,	,	O	O
and	CC	O	O
dermatologic	JJ	B-NP	O
manifestations	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
previously	RB	I-NP	O
healthy	JJ	I-NP	O
child	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
,	,	I-NP	O
severe	JJ	I-NP	O
,	,	I-NP	O
rapidly	RB	I-NP	O
progressive	JJ	I-NP	O
vanishing	VBG	I-NP	B
bile	NN	I-NP	I
duct	NN	I-NP	I
syndrome	NN	I-NP	I
shortly	RB	B-ADVP	O
after	IN	B-PP	O
Stevens	NNP	B-NP	B
-	HYPH	I-NP	I
Johnson	NNP	I-NP	I
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
described	VBN	I-VP	O
;	:	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
temporally	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
ibuprofen	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
ursodeoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
prednisone	NN	B-NP	O
,	,	O	O
and	CC	O	O
then	RB	B-ADVP	O
tacrolimus	NN	B-NP	O
,	,	O	O
her	PRP$	B-NP	O
cholestatic	JJ	I-NP	B
disease	NN	I-NP	I
was	VBD	B-VP	O
unrelenting	VBG	I-VP	O
,	,	O	O
with	IN	B-PP	O
cirrhosis	NN	B-NP	B
shown	VBN	B-VP	O
by	IN	B-PP	O
biopsy	NN	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
presentation	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
documents	NNS	I-NP	O
acute	JJ	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	I-VP	O
vanishing	VBG	B-VP	B
bile	NN	B-NP	I
duct	NN	I-NP	I
syndrome	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
pediatric	JJ	I-NP	O
age	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
suggests	VBZ	B-VP	O
shared	VBN	I-VP	O
immune	JJ	B-NP	O
mechanisms	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
both	CC	O	O
Stevens	NNP	B-NP	B
-	HYPH	I-NP	I
Johnson	NNP	I-NP	I
syndrome	NN	I-NP	I
and	CC	O	O
vanishing	VBG	B-VP	B
bile	NN	B-NP	I
duct	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

High	JJ	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
appetite	JJ	B-NP	O
suppressants	NNS	I-NP	O
in	IN	B-PP	O
Belgium	NNP	B-NP	O
.	.	O	O

Primary	JJ	B-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
,	,	I-NP	O
progressive	JJ	I-NP	O
and	CC	I-NP	O
incurable	JJ	I-NP	O
disease	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
intake	NN	I-NP	O
of	IN	B-PP	O
appetite	JJ	B-NP	O
suppressant	NN	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
association	NN	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
Belgium	NNP	B-NP	O
while	IN	B-SBAR	O
this	DT	B-NP	O
country	NN	I-NP	O
still	RB	B-ADVP	O
had	VBD	B-VP	O
no	DT	B-NP	O
restriction	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
prescription	NN	I-NP	O
of	IN	B-PP	O
appetite	JJ	B-NP	O
suppressants	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
matched	VBN	I-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
recruited	VBN	I-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
in	IN	B-PP	O
Belgium	NNP	B-NP	O
.	.	O	O

Exposure	NN	B-NP	O
to	TO	B-VP	O
appetite	VB	I-VP	O
-	HYPH	B-NP	O
suppressants	NNS	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
hospital	NN	B-NP	O
records	NNS	I-NP	O
and	CC	O	O
standardized	JJ	B-NP	O
interview	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
previously	RB	I-VP	O
taken	VBN	I-VP	O
appetite	NN	B-NP	O
suppressants	NNS	I-NP	O
,	,	O	O
mainly	RB	B-NP	O
fenfluramines	NNS	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
interview	NN	I-NP	O
,	,	O	O
all	DT	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
had	VBD	B-VP	O
taken	VBN	I-VP	O
appetite	JJ	B-NP	O
suppressants	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
was	VBD	B-VP	O
uncertain	JJ	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
had	VBD	B-VP	O
taken	VBN	I-VP	O
appetite	JJ	B-NP	O
suppressants	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
exposed	VBN	I-VP	O
to	TO	I-VP	O
appetite	VB	I-VP	O
suppressants	NNS	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
on	IN	B-PP	O
average	NN	B-NP	O
more	RBR	B-ADJP	O
severely	RB	I-ADJP	O
ill	JJ	I-ADJP	O
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
shorter	JJR	I-NP	O
median	JJ	I-NP	O
delay	NN	I-NP	O
between	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
and	CC	I-NP	O
diagnosis	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
policy	NN	I-NP	O
of	IN	B-PP	O
unrestricted	JJ	B-NP	O
prescription	NN	I-NP	O
of	IN	B-PP	O
appetite	JJ	B-NP	O
suppressants	NNS	I-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
associated	VBN	B-NP	O
primary	JJ	I-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
.	.	O	O

Intake	NN	B-NP	O
of	IN	B-PP	O
appetite	JJ	B-NP	O
suppressants	NNS	I-NP	O
may	MD	B-VP	O
accelerate	VB	I-VP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
.	.	O	O

Choreoathetoid	JJ	B-NP	B
movements	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
rapid	JJ	B-NP	O
adjustment	NN	I-NP	O
to	TO	B-PP	O
methadone	NN	B-NP	O
.	.	O	O

Choreatiform	NN	B-NP	B
hyperkinesias	NNS	I-NP	I
are	VBP	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
occasional	JJ	B-NP	O
movement	NN	I-NP	B
abnormalities	NNS	I-NP	I
during	IN	B-PP	O
intoxications	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
opiates	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
euphoria	NN	B-NP	O
and	CC	O	O
choreoathetoid	JJ	B-NP	B
movements	NNS	I-NP	I
both	CC	O	O
transiently	RB	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
rapid	JJ	B-NP	O
adjustment	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
selective	JJ	I-NP	O
mu	SYM	I-NP	O
-	HYPH	I-NP	O
opioid	JJ	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
methadone	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
inpatient	NN	I-NP	O
previously	RB	B-NP	O
abusing	VBG	I-NP	O
heroine	NN	I-NP	O
and	CC	I-NP	O
cocaine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
minor	JJ	B-NP	O
EEG	NN	I-NP	O
abnormalities	NNS	I-NP	O
occurred	VBD	B-VP	O
.	.	O	O

Possible	JJ	B-NP	O
underlying	VBG	I-NP	O
neurobiological	JJ	I-NP	O
phenomena	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
mood	NN	I-NP	B
disorder	NN	I-NP	I
:	:	O	O
prevalence	NN	B-NP	O
rates	NNS	I-NP	O
and	CC	O	O
psychiatric	JJ	B-NP	B
symptoms	NNS	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
outpatient	NN	I-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
sample	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
paper	NN	I-NP	O
attempts	VBZ	B-VP	O
to	TO	I-VP	O
examine	VB	I-VP	O
and	CC	I-VP	O
compare	VB	I-VP	O
prevalence	NN	B-NP	O
rates	NNS	I-NP	O
and	CC	O	O
symptom	NN	B-NP	O
patterns	NNS	I-NP	O
of	IN	B-PP	O
DSM	NN	B-NP	O
substance	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
and	CC	I-NP	O
other	JJ	I-NP	O
mood	NN	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O
num	CD	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
outpatients	NNS	I-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
mood	NN	I-NP	B
disorder	NN	I-NP	I
(	(	O	O
CIMD	NN	B-NP	B
)	)	O	O
,	,	O	O
other	JJ	B-NP	O
mood	NN	I-NP	B
disorders	NNS	I-NP	I
,	,	O	O
or	CC	O	O
no	DT	B-NP	O
mood	NN	I-NP	B
disorder	NN	I-NP	I
were	VBD	B-VP	O
compared	VBN	I-VP	O
on	IN	B-PP	O
measures	NNS	B-NP	O
of	IN	B-PP	O
psychiatric	JJ	B-NP	B
symptoms	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
prevalence	NN	I-NP	O
rate	NN	I-NP	O
for	IN	B-PP	O
CIMD	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

Introduction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DSM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
CIMD	NN	B-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
substantially	RB	I-VP	O
affect	VB	I-VP	O
rates	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
depressive	JJ	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
CIMD	NN	B-NP	B
had	VBD	B-VP	O
symptom	NN	B-NP	O
severity	NN	I-NP	O
levels	NNS	I-NP	O
between	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
and	CC	I-PP	O
without	IN	I-PP	O
a	DT	B-NP	O
mood	NN	I-NP	B
disorder	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
some	DT	B-NP	O
validity	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
new	JJ	I-NP	O
DSM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
CIMD	NN	B-NP	B
,	,	O	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
requires	VBZ	B-VP	O
further	JJ	B-NP	O
specification	NN	I-NP	O
and	CC	I-NP	O
replication	NN	I-NP	O
.	.	O	O

Hemolysis	NN	B-NP	B
of	IN	B-PP	O
human	JJ	B-NP	O
erythrocytes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
tamoxifen	NN	B-NP	O
is	VBZ	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
disruption	NN	B-NP	O
of	IN	B-PP	O
membrane	NN	B-NP	O
structure	NN	I-NP	O
.	.	O	O

Tamoxifen	NN	B-NP	O
(	(	O	O
TAM	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
antiestrogenic	JJ	I-NP	O
drug	NN	I-NP	O
most	RBS	B-VP	O
widely	RB	I-VP	O
prescribed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
chemotherapy	NN	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
induces	VBZ	B-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
discoid	JJ	I-NP	O
shape	NN	I-NP	O
of	IN	B-PP	O
erythrocytes	NNS	B-NP	O
and	CC	O	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
work	NN	I-NP	O
evaluates	VBZ	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
TAM	NN	B-NP	O
on	IN	B-PP	O
isolated	VBN	B-NP	O
human	JJ	I-NP	O
erythrocytes	NNS	I-NP	O
,	,	O	O
attempting	VBG	B-VP	O
to	TO	I-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
mechanisms	NNS	I-NP	O
on	IN	B-PP	O
TAM	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
biomembranes	NNS	B-NP	O
in	IN	B-PP	O
its	PRP$	B-NP	O
cytostatic	JJ	I-NP	O
action	NN	I-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

TAM	NN	B-NP	O
induces	VBZ	B-VP	O
hemolysis	NN	B-NP	B
of	IN	B-PP	O
erythrocytes	NNS	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
concentration	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
extension	NN	I-NP	O
of	IN	B-PP	O
hemolysis	NN	B-NP	B
is	VBZ	B-VP	O
variable	JJ	B-ADJP	O
with	IN	B-PP	O
erythrocyte	NN	B-NP	O
samples	NNS	I-NP	O
,	,	O	O
but	CC	O	O
num	CD	B-NP	O
microM	NN	I-NP	O
TAM	NN	I-NP	O
induces	VBZ	B-VP	O
total	JJ	B-NP	O
hemolysis	NN	I-NP	B
of	IN	B-PP	O
all	DT	B-NP	O
tested	VBN	I-NP	O
suspensions	NNS	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
inducing	VBG	B-VP	O
extensive	JJ	B-NP	O
erythrocyte	NN	I-NP	O
lysis	NN	I-NP	O
,	,	O	O
TAM	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
shift	VB	I-VP	O
the	DT	B-NP	O
osmotic	JJ	I-NP	O
fragility	NN	I-NP	O
curves	NNS	I-NP	O
of	IN	B-PP	O
erythrocytes	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
hemolytic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
TAM	NN	B-NP	O
is	VBZ	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
low	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
alpha	SYM	O	O
-	HYPH	O	O
tocopherol	NN	B-NP	O
(	(	O	O
alpha	SYM	O	O
-	HYPH	O	O
T	NN	B-NP	O
)	)	O	O
and	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
tocopherol	NN	B-NP	O
acetate	NN	I-NP	O
(	(	O	O
alpha	SYM	O	O
-	HYPH	O	O
TAc	NN	B-NP	O
)	)	O	O
(	(	O	O
inactivated	VBN	B-VP	O
functional	JJ	B-NP	O
hydroxyl	NN	I-NP	O
)	)	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
TAM	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolysis	NN	I-NP	B
is	VBZ	B-VP	O
not	RB	O	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
oxidative	JJ	B-NP	O
membrane	NN	I-NP	O
damage	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
further	RB	I-VP	O
evidenced	VBN	I-VP	O
by	IN	B-PP	O
absence	NN	B-NP	O
of	IN	B-PP	O
oxygen	NN	B-NP	O
consumption	NN	I-NP	O
and	CC	O	O
hemoglobin	NN	B-NP	O
oxidation	NN	I-NP	O
both	CC	O	O
determined	VBN	B-VP	O
in	IN	B-PP	O
parallel	NN	B-NP	O
with	IN	B-PP	O
TAM	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolysis	NN	I-NP	B
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
that	IN	B-SBAR	O
TAM	NN	B-NP	O
inhibits	VBZ	B-VP	O
the	DT	B-NP	O
peroxidation	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
erythrocytes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
AAPH	NN	B-NP	O
,	,	O	O
thus	RB	B-ADVP	O
ruling	VBG	B-VP	O
out	RP	B-PRT	O
TAM	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cell	NN	I-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
.	.	O	O

Hemolysis	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
TAM	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
leakage	NN	I-NP	O
of	IN	B-PP	O
K	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
cells	NNS	I-NP	O
,	,	O	O
also	RB	B-ADVP	O
excluding	VBG	B-VP	O
a	DT	B-NP	O
colloid	JJ	I-NP	O
-	HYPH	I-NP	O
osmotic	JJ	I-NP	O
type	NN	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
hemolysis	NN	B-NP	B
,	,	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
osmotic	JJ	B-NP	O
fragility	NN	I-NP	O
curves	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
TAM	NN	B-NP	O
induces	VBZ	B-VP	O
release	NN	B-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	O
proteins	NNS	I-NP	O
of	IN	B-PP	O
membrane	NN	B-NP	O
-	HYPH	B-NP	O
cytoskeleton	NN	I-NP	O
and	CC	I-NP	O
cytosol	NN	I-NP	O
proteins	NNS	I-NP	O
essentially	RB	B-ADVP	O
bound	VBD	B-VP	O
to	TO	B-PP	O
band	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Either	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
T	NN	B-NP	O
or	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
TAc	NN	B-NP	O
increases	VBZ	B-VP	O
membrane	NN	B-NP	O
packing	NN	I-NP	O
and	CC	O	O
prevents	VBZ	B-VP	O
TAM	NN	B-NP	O
partition	NN	I-NP	O
into	IN	B-PP	O
model	NN	B-NP	O
membranes	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
protection	NN	I-NP	O
from	IN	B-PP	O
hemolysis	NN	B-NP	B
by	IN	B-PP	O
tocopherols	NNS	B-NP	O
is	VBZ	B-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
decreased	VBN	I-NP	O
TAM	NN	I-NP	O
incorporation	NN	I-NP	O
in	IN	B-PP	O
condensed	VBN	B-NP	O
membranes	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
structural	JJ	I-NP	O
damage	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
erythrocyte	NN	I-NP	O
membrane	NN	I-NP	O
is	VBZ	B-VP	O
consequently	RB	I-VP	O
avoided	VBN	I-VP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
TAM	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolysis	NN	I-NP	B
results	VBZ	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
structural	JJ	I-NP	O
perturbation	NN	I-NP	O
of	IN	B-PP	O
red	JJ	B-NP	O
cell	NN	I-NP	O
membrane	NN	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
framework	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
erythrocyte	NN	I-NP	O
membrane	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
cytoskeleton	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
its	PRP$	B-NP	O
high	JJ	I-NP	O
partition	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
membrane	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
defects	NNS	I-NP	O
explain	VBP	B-VP	O
the	DT	B-NP	O
abnormal	JJ	I-NP	O
erythrocyte	NN	I-NP	O
shape	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
mechanical	JJ	B-NP	O
stability	NN	I-NP	O
promoted	VBN	B-VP	O
by	IN	B-PP	O
TAM	NN	B-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
since	IN	B-SBAR	O
membrane	NN	B-NP	O
leakage	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
final	JJ	I-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
cytotoxicity	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
disruption	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
structural	JJ	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
biomembranes	NNS	B-NP	O
by	IN	B-PP	O
TAM	NN	B-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
multiple	JJ	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
anticancer	JJ	I-NP	O
action	NN	I-NP	O
.	.	O	O

Changes	NNS	B-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
and	CC	I-NP	O
ATP	NN	I-NP	O
affinities	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
(	(	O	O
Na	NN	B-NP	O
,	,	O	O
K	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
during	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
deficient	JJ	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
system	NN	I-NP	O
,	,	O	O
NO	NN	B-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
functions	NNS	B-NP	O
.	.	O	O

Inhibition	NN	B-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
synthesis	NN	I-NP	O
induces	VBZ	B-VP	O
sustained	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
several	JJ	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
,	,	O	O
elevation	NN	B-NP	O
of	IN	B-PP	O
intracellular	JJ	B-NP	O
sodium	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
documented	VBN	I-VP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
tissue	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
disturbances	NNS	B-NP	O
in	IN	B-PP	O
transmembraneous	JJ	B-NP	O
transport	NN	I-NP	O
of	IN	B-PP	O
Na+	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
(	(	O	O
Na	NN	B-NP	O
,	,	O	O
K	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
to	TO	B-PP	O
NO	NN	B-NP	O
-	HYPH	B-NP	O
deficient	JJ	I-NP	O
hypertension	NN	I-NP	B
induced	VBN	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
NO	NN	B-NP	O
-	HYPH	I-NP	O
synthase	NN	I-NP	O
inhibition	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	O	O
day	NN	B-NP	O
N	NN	I-NP	O
(	(	O	O
G	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
nitro	AFX	O	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	I-NP	O
arginine	NN	I-NP	O
methyl	NN	I-NP	O
ester	NN	I-NP	O
(	(	O	O
L	NN	B-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
increased	VBD	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
terminating	VBG	B-VP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
SBP	NN	I-NP	O
recovered	VBD	B-VP	O
to	TO	B-VP	O
control	VB	I-VP	O
value	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
activating	VBG	B-VP	O
the	DT	B-NP	O
(	(	O	O
Na	NN	B-NP	O
,	,	I-NP	O
K	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
with	IN	B-PP	O
its	PRP$	B-NP	O
substrate	NN	I-NP	O
ATP	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
Km	NN	B-NP	O
and	CC	I-NP	O
Vmax	NN	I-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
NO	NN	B-NP	O
-	HYPH	B-NP	O
deficient	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
activation	NN	B-NP	O
with	IN	B-PP	O
Na+	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
Vmax	NN	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
,	,	O	O
however	RB	B-ADVP	O
the	DT	B-NP	O
K	NN	I-NP	O
(	(	O	O
Na	NN	B-NP	O
)	)	O	O
increased	VBD	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
profound	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
affinity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Na+	NN	I-NP	O
-	HYPH	O	O
binding	VBG	B-VP	O
site	NN	B-NP	O
in	IN	B-PP	O
NO	NN	B-NP	O
-	HYPH	B-NP	O
deficient	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
recovery	NN	B-NP	O
from	IN	B-PP	O
hypertension	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
(	(	O	O
Na	NN	B-NP	O
,	,	O	O
K	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
increased	VBD	B-VP	O
,	,	O	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
higher	JJR	B-NP	O
affinity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ATP	NN	I-NP	O
-	HYPH	B-PP	O
binding	VBG	B-NP	O
site	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
revealed	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
lowered	JJ	I-NP	O
Km	NN	I-NP	O
value	NN	I-NP	O
for	IN	B-PP	O
ATP	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
K	NN	I-NP	O
(	(	O	O
Na	NN	B-NP	O
)	)	O	O
value	NN	B-NP	O
for	IN	B-PP	O
Na	NN	B-NP	O
+	SYM	B-NP	O
returned	VBD	B-VP	O
to	TO	I-VP	O
control	VB	I-VP	O
value	NN	B-NP	O
.	.	O	O

Inhibition	NN	B-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
-	HYPH	B-NP	O
synthase	NN	I-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
reversible	JJ	I-NP	O
hypertension	NN	I-NP	B
accompanied	VBN	B-VP	O
by	IN	B-PP	O
depressed	JJ	B-NP	B
Na+	NN	I-NP	O
-	HYPH	B-NP	O
extrusion	NN	I-NP	O
from	IN	B-PP	O
cardiac	JJ	B-NP	O
cells	NNS	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
deteriorated	VBN	B-NP	O
Na+	NN	I-NP	O
-	HYPH	O	O
binding	VBG	B-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
(	(	O	O
Na	NN	B-NP	O
,	,	I-NP	O
K	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
recovery	NN	B-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
extrusion	NN	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
+	SYM	B-NP	O
from	IN	B-PP	O
cardiac	JJ	B-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
normalized	VBN	I-VP	O
,	,	O	O
as	IN	B-SBAR	O
revealed	VBN	B-VP	O
by	IN	B-PP	O
restoration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
(	(	O	O
Na	NN	B-NP	O
,	,	I-NP	O
K	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
pretreatment	NN	I-NP	O
with	IN	B-PP	O
isoproterenol	NN	B-NP	O
on	IN	B-PP	O
bromocriptine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
in	IN	B-PP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
bromocriptine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
persisted	VBD	B-VP	O
after	IN	B-PP	O
adrenalectomy	NN	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
(	(	O	O
i	NN	B-NP	O
)	)	O	O
mediated	VBN	B-VP	O
by	IN	B-PP	O
central	JJ	B-NP	O
dopamine	NN	I-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
activation	NN	I-NP	O
and	CC	O	O
(	(	B-LST	O
ii	LS	I-LST	O
)	)	O	O
reduced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
isoproterenol	NN	I-NP	O
pretreatment	NN	I-NP	O
,	,	O	O
supporting	VBG	B-VP	O
therefore	RB	B-ADVP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
sympathetic	JJ	B-NP	O
outflow	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
to	TO	I-VP	O
examine	VB	I-VP	O
whether	IN	B-SBAR	O
prolonged	VBN	B-NP	O
pretreatment	NN	I-NP	O
with	IN	B-PP	O
isoproterenol	NN	B-NP	O
could	MD	B-VP	O
abolish	VB	I-VP	O
bromocriptine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
in	IN	B-PP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Isoproterenol	NN	B-NP	O
pretreatment	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
caused	VBD	B-VP	O
cardiac	JJ	B-NP	B
hypertrophy	NN	I-NP	I
without	IN	B-PP	O
affecting	VBG	B-VP	O
baseline	NN	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
intravenous	JJ	B-NP	O
bromocriptine	NN	I-NP	O
induced	VBD	B-VP	O
significant	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
tachycardia	NN	I-NP	B
.	.	O	O

Bromocriptine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
was	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
pretreatment	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
tachycardia	NN	B-NP	B
was	VBD	B-VP	O
reversed	VBN	I-VP	O
to	TO	B-PP	O
significant	JJ	B-NP	O
bradycardia	NN	I-NP	B
,	,	O	O
an	DT	B-NP	O
effect	NN	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
partly	RB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
i.v.	JJ	B-NP	O
domperidone	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
cardiac	JJ	B-NP	O
vagal	JJ	I-NP	O
nor	CC	I-NP	O
sympathetic	JJ	I-NP	O
tone	NN	I-NP	O
was	VBD	B-VP	O
altered	VBN	I-VP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
pretreatment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
isolated	VBN	B-NP	O
perfused	VBN	I-NP	O
heart	NN	B-NP	O
preparations	NNS	I-NP	O
from	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
pretreated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
isoproterenol	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
maximal	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
systolic	JJ	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
saline	NN	B-NP	O
-	HYPH	B-NP	O
pretreated	VBN	I-NP	O
rats	NNS	I-NP	O
(	(	O	O
the	DT	B-NP	O
EC50	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
isoproterenol	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
systolic	JJ	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
enhanced	VBN	I-VP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
isoproterenol	NN	I-NP	O
pretreatment	NN	I-NP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
abolished	VBD	B-VP	O
but	CC	I-VP	O
reversed	VBD	I-VP	O
bromocriptine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
to	TO	B-PP	O
bradycardia	NN	B-NP	B
,	,	O	O
an	DT	B-NP	O
effect	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
mainly	RB	I-VP	O
related	VBN	I-VP	O
to	TO	I-VP	O
further	VB	I-VP	O
cardiac	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
desensitization	NN	I-NP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
to	TO	B-PP	O
impairment	NN	B-NP	O
of	IN	B-PP	O
autonomic	JJ	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
in	IN	B-PP	O
normal	JJ	B-NP	O
conscious	JJ	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
central	JJ	I-NP	O
tachycardia	NN	I-NP	B
of	IN	B-PP	O
bromocriptine	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
predominate	VB	I-VP	O
and	CC	O	O
to	TO	B-VP	O
mask	VB	I-VP	O
the	DT	B-NP	O
bradycardia	NN	I-NP	B
of	IN	B-PP	O
this	DT	B-NP	O
agonist	NN	I-NP	O
at	IN	B-PP	O
peripheral	JJ	B-NP	O
dopamine	NN	I-NP	O
D2	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
developmental	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
s	VBZ	B-VP	O
effects	NNS	B-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
ultrasound	NN	I-NP	O
production	NN	I-NP	O
in	IN	B-PP	O
infant	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Under	IN	B-PP	O
controlled	VBN	B-NP	O
conditions	NNS	I-NP	O
,	,	O	O
infant	JJ	B-NP	O
rats	NNS	I-NP	O
emit	VBP	B-VP	O
ultrasonic	JJ	B-NP	O
vocalizations	NNS	I-NP	O
during	IN	B-PP	O
extreme	JJ	B-NP	O
cold	JJ	I-NP	O
exposure	NN	I-NP	O
and	CC	B-PP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
alpha	NN	I-NP	O
adrenoceptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
clonidine	NN	B-NP	O
.	.	O	O

Previous	JJ	B-NP	O
investigations	NNS	I-NP	O
have	VBP	B-VP	O
determined	VBN	I-VP	O
that	IN	B-SBAR	O
,	,	O	O
in	IN	B-PP	O
response	NN	I-PP	O
to	TO	I-PP	O
clonidine	NN	B-NP	O
,	,	O	O
ultrasound	NN	B-NP	O
production	NN	I-NP	O
increases	VBZ	B-VP	O
through	IN	B-PP	O
the	DT	B-NP	O
2nd	NN	I-NP	O
-	HYPH	B-NP	O
week	NN	I-NP	O
postpartum	NN	I-NP	O
and	CC	O	O
decreases	VBZ	B-VP	O
thereafter	RB	B-ADVP	O
.	.	O	O

Given	VBN	B-VP	O
that	IN	B-SBAR	O
sympathetic	JJ	B-NP	O
neural	JJ	I-NP	O
dominance	NN	I-NP	O
exhibits	VBZ	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
developmental	JJ	I-NP	O
pattern	NN	I-NP	O
,	,	O	O
and	CC	O	O
given	VBN	B-VP	O
that	IN	B-SBAR	O
clonidine	NN	B-NP	O
induces	VBZ	B-VP	O
sympathetic	JJ	B-NP	O
withdrawal	NN	I-NP	O
and	CC	I-NP	O
bradycardia	NN	I-NP	B
,	,	O	O
we	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
clonidine	NN	B-NP	O
s	VBZ	B-VP	O
developmental	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
ultrasound	NN	I-NP	O
production	NN	I-NP	O
would	MD	B-VP	O
mirror	VB	I-VP	O
each	DT	B-NP	O
other	JJ	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
experiment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
administration	NN	I-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
ultrasound	NN	I-NP	O
production	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Age	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
ultrasound	JJ	B-NP	O
production	NN	I-NP	O
corresponded	VBD	B-VP	O
with	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
cardiovascular	JJ	B-NP	O
variables	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
baseline	NN	B-NP	O
cardiac	JJ	I-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
clonidine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
bradycardia	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
experiment	NN	I-NP	O
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
ultrasound	JJ	B-NP	O
production	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
acoustic	NN	I-NP	O
by	IN	B-PP	O
-	HYPH	B-NP	O
product	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
physiological	JJ	I-NP	O
maneuver	NN	I-NP	O
that	WDT	B-NP	O
compensates	VBZ	B-VP	O
for	IN	B-PP	O
clonidine	NN	B-NP	O
s	VBZ	B-VP	O
detrimental	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
cardiovascular	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Differential	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
systemically	RB	B-NP	O
administered	VBN	I-NP	O
ketamine	NN	I-NP	O
and	CC	I-NP	O
lidocaine	NN	I-NP	O
on	IN	B-PP	O
dynamic	JJ	B-NP	O
and	CC	I-NP	O
static	JJ	I-NP	O
hyperalgesia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
intradermal	JJ	B-NP	O
capsaicin	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
examined	VBN	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
lidocaine	NN	I-NP	O
on	IN	B-PP	O
brush	NN	B-NP	O
-	HYPH	O	O
evoked	VBN	B-VP	O
(	(	O	O
dynamic	JJ	O	O
)	)	O	O
pain	NN	B-NP	B
and	CC	I-NP	O
punctate	NN	I-NP	O
-	HYPH	O	O
evoked	VBN	B-VP	O
(	(	O	O
static	JJ	O	O
)	)	O	O
hyperalgesia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
capsaicin	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
crossover	NN	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
num	CD	B-NP	O
volunteers	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
experiments	NNS	I-NP	O
.	.	O	O

Capsaicin	NN	B-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
intradermally	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
volar	JJ	I-NP	O
forearm	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
i.v.	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
,	,	O	O
lidocaine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
kg	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
or	CC	O	O
saline	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

Infusion	NN	B-NP	O
started	VBD	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
following	VBG	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
:	:	O	O
spontaneous	JJ	B-NP	O
pain	NN	I-NP	B
,	,	O	O
pain	NN	B-NP	B
evoked	VBN	B-VP	O
by	IN	B-PP	O
punctate	NN	B-NP	O
and	CC	I-NP	O
brush	NN	I-NP	O
stimuli	NNS	I-NP	O
(	(	O	O
VAS	NNS	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
areas	NNS	B-NP	O
of	IN	B-PP	O
brush	NN	B-NP	O
-	HYPH	B-NP	O
evoked	VBN	B-VP	O
and	CC	O	O
punctate	NN	B-NP	O
-	HYPH	O	O
evoked	VBN	B-NP	O
hyperalgesia	NN	I-NP	B
.	.	O	O

Ketamine	NN	B-NP	O
reduced	VBD	B-VP	O
both	CC	O	O
the	DT	B-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
brush	NN	B-NP	O
-	HYPH	B-NP	O
evoked	VBN	B-VP	O
and	CC	O	O
punctate	NN	B-NP	O
-	HYPH	O	O
evoked	VBN	B-NP	O
hyperalgesia	NN	I-NP	B
significantly	RB	B-ADVP	O
and	CC	O	O
it	PRP	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
reduce	VB	I-VP	O
brush	NN	B-NP	O
-	HYPH	O	O
evoked	VBN	B-NP	O
pain	NN	I-NP	B
.	.	O	O

Lidocaine	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
punctate	NN	B-NP	O
-	HYPH	O	O
evoked	VBN	B-NP	O
hyperalgesia	NN	I-NP	B
significantly	RB	B-ADVP	O
.	.	O	O

It	PRP	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
reduce	VB	I-VP	O
VAS	NNP	B-NP	O
scores	NNS	I-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
pain	NN	I-NP	B
but	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
evoked	VBN	B-NP	O
pain	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
differential	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
lidocaine	NN	I-NP	O
on	IN	B-PP	O
static	JJ	B-NP	O
and	CC	I-NP	O
dynamic	JJ	I-NP	O
hyperalgesia	NN	I-NP	B
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
num	CD	I-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
hyperalgesia	NN	B-NP	B
are	VBP	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
separate	JJ	B-NP	O
mechanisms	NNS	I-NP	O
and	CC	O	O
have	VBP	B-VP	O
a	DT	B-NP	O
distinct	JJ	I-NP	O
pharmacology	NN	I-NP	O
.	.	O	O

Cyclosporine	NN	B-NP	O
and	CC	I-NP	O
tacrolimus	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
(	(	O	O
TMA	NN	B-NP	B
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
well	RB	I-VP	O
documented	VBN	I-VP	O
.	.	O	O

Treatments	NNS	B-NP	O
have	VBP	B-VP	O
included	VBN	I-VP	O
discontinuation	NN	B-NP	O
or	CC	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
dose	NN	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
concurrent	JJ	B-NP	O
plasma	NN	I-NP	O
exchange	NN	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
infusion	NN	I-NP	O
,	,	O	O
anticoagulation	NN	B-NP	O
,	,	O	O
and	CC	O	O
intravenous	JJ	B-NP	O
immunoglobulin	NN	I-NP	O
G	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
for	IN	B-PP	O
recipients	NNS	B-NP	O
of	IN	B-PP	O
organ	NN	B-NP	O
transplantation	NN	I-NP	O
,	,	O	O
removing	VBG	B-VP	O
the	DT	B-NP	O
inciting	VBG	I-NP	O
agent	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
without	IN	B-PP	O
the	DT	B-NP	O
attendant	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
precipitating	VBG	B-VP	O
acute	JJ	B-NP	O
rejection	NN	I-NP	O
and	CC	I-NP	O
graft	NN	I-NP	O
loss	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
last	JJ	I-NP	O
decade	NN	I-NP	O
has	VBZ	B-VP	O
seen	VBN	I-VP	O
the	DT	B-NP	O
emergence	NN	I-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
agent	NN	I-NP	O
with	IN	B-PP	O
mechanisms	NNS	B-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
virtually	RB	B-ADJP	O
identical	JJ	I-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
,	,	O	O
switching	VBG	B-VP	O
to	TO	B-PP	O
tacrolimus	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
viable	JJ	I-NP	O
therapeutic	JJ	I-NP	O
option	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
TMA	NN	I-NP	B
.	.	O	O

With	IN	B-PP	O
the	DT	B-NP	O
more	RBR	I-NP	O
widespread	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
in	IN	B-PP	O
organ	NN	B-NP	O
transplantation	NN	I-NP	O
,	,	O	O
tacrolimus	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
TMA	NN	I-NP	B
has	VBZ	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
recognized	VBN	I-VP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
literature	NN	B-NP	O
regarding	VBG	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
TMA	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
exposed	VBN	B-VP	O
sequentially	RB	B-ADVP	O
to	TO	B-PP	O
cyclosporine	NN	B-NP	O
and	CC	I-NP	O
tacrolimus	NN	I-NP	O
is	VBZ	B-VP	O
limited	VBN	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
living	VBG	I-NP	O
donor	NN	I-NP	O
renal	JJ	I-NP	O
transplant	NN	I-NP	O
recipient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
cyclosporine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
TMA	NN	I-NP	B
that	WDT	B-NP	O
responded	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
plasmapheresis	NN	B-NP	O
and	CC	O	O
fresh	JJ	B-NP	O
frozen	JJ	I-NP	O
plasma	NN	I-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Introduction	NN	B-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
alternative	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
agent	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
TMA	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
subsequent	JJ	I-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
allograft	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
switched	VBN	I-VP	O
from	IN	B-PP	O
cyclosporine	NN	B-NP	O
to	TO	B-PP	O
tacrolimus	NN	B-NP	O
or	CC	I-NP	O
vice	NN	I-NP	O
versa	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
closely	RB	I-VP	O
monitored	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
signs	NNS	I-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
recurrent	JJ	B-NP	O
TMA	NN	I-NP	B
.	.	O	O

Repeated	VBN	B-NP	O
transient	JJ	I-NP	O
anuria	NN	I-NP	B
following	VBG	B-PP	O
losartan	NN	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
solitary	JJ	I-NP	O
kidney	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
hypertensive	JJ	I-NP	B
man	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
solitary	JJ	I-NP	O
kidney	NN	I-NP	O
and	CC	O	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
anuria	NN	I-NP	B
after	IN	B-PP	O
losartan	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
hospitalized	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
with	IN	B-PP	O
pulmonary	JJ	B-NP	B
edema	NN	I-NP	I
,	,	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
diuretics	NNS	I-NP	O
.	.	O	O

Due	JJ	B-PP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
systolic	JJ	I-NP	B
dysfunction	NN	I-NP	I
losartan	NN	I-NP	O
was	VBD	B-VP	O
prescribed	VBN	I-VP	O
.	.	O	O

Surprisingly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
losartan	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
sudden	JJ	I-NP	O
anuria	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
lasted	VBD	B-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
despite	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
furosemide	NN	I-NP	O
and	CC	O	O
amine	NN	B-NP	O
infusion	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
by	IN	B-PP	O
mistake	NN	B-NP	O
,	,	O	O
losartan	NN	B-NP	O
was	VBD	B-VP	O
prescribed	VBN	I-VP	O
again	RB	B-ADVP	O
and	CC	O	O
after	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
second	JJ	I-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
anuria	NN	I-NP	B
lasting	VBG	B-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
episodes	NNS	I-NP	O
,	,	O	O
his	PRP$	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
diminished	VBD	B-VP	O
but	CC	O	O
no	DT	B-NP	O
severe	JJ	I-NP	O
hypotension	NN	I-NP	B
was	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

Ultimately	RB	B-ADVP	O
,	,	O	O
an	DT	B-NP	O
arteriography	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
renal	JJ	I-NP	B
artery	NN	I-NP	I
stenosis	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
renal	JJ	B-NP	B
artery	NN	I-NP	I
stenosis	NN	I-NP	I
combined	VBN	B-VP	O
with	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
and	CC	O	O
diuretic	JJ	B-NP	O
therapy	NN	I-NP	O
certainly	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
(	(	O	O
RAS	NN	B-NP	O
)	)	O	O
.	.	O	O

Under	IN	B-PP	O
such	JJ	B-NP	O
conditions	NNS	I-NP	O
,	,	O	O
angiotensin	NN	B-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
blockade	NN	I-NP	O
by	IN	B-PP	O
losartan	NN	B-NP	O
probably	RB	B-ADVP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
critical	JJ	I-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
pressure	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
highlights	VBZ	B-VP	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
angiotensin	NN	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
losartan	NN	I-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
serious	JJ	B-NP	O
unexpected	JJ	I-NP	O
complications	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
renovascular	JJ	B-NP	B
disease	NN	I-NP	I
and	CC	O	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
extreme	JJ	B-NP	O
caution	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
setting	NN	I-NP	O
.	.	O	O

In	FW	B-NP	O
vivo	FW	I-NP	O
protection	NN	I-NP	O
of	IN	B-PP	O
dna	NN	B-NP	O
damage	NN	I-NP	O
associated	VBN	B-VP	O
apoptotic	JJ	B-NP	O
and	CC	I-NP	O
necrotic	JJ	I-NP	B
cell	NN	I-NP	O
deaths	NNS	I-NP	O
during	IN	B-PP	O
acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
,	,	O	O
amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lung	NN	I-NP	B
toxicity	NN	I-NP	I
and	CC	I-NP	O
doxorubicin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
by	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
IH636	NN	I-NP	O
grape	NN	I-NP	O
seed	NN	I-NP	O
proanthocyanidin	NN	I-NP	O
extract	NN	I-NP	O
.	.	O	O

Grape	NN	B-NP	O
seed	NN	I-NP	O
extract	NN	I-NP	O
,	,	O	O
primarily	RB	B-ADVP	O
a	DT	B-NP	O
mixture	NN	I-NP	O
of	IN	B-PP	O
proanthocyanidins	NNS	B-NP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
modulate	VB	I-VP	O
a	DT	B-NP	O
wide	JJ	I-NP	O
-	HYPH	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
biological	JJ	B-NP	O
,	,	I-NP	O
pharmacological	JJ	I-NP	O
and	CC	I-NP	O
toxicological	JJ	I-NP	O
effects	NNS	I-NP	O
which	WDT	B-NP	O
are	VBP	B-VP	O
mainly	RB	B-ADJP	O
cytoprotective	JJ	I-ADJP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
IH636	NN	B-NP	O
grape	NN	I-NP	O
seed	NN	I-NP	O
proanthocyanidin	NN	I-NP	O
extract	NN	I-NP	O
(	(	O	O
GSPE	NN	B-NP	O
)	)	O	O
to	TO	B-VP	O
prevent	VB	I-VP	O
acetaminophen	NN	B-NP	O
(	(	O	O
AAP	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
,	,	O	O
amiodarone	NN	B-NP	O
(	(	O	O
AMI	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lung	NN	I-NP	B
toxicity	NN	I-NP	I
,	,	O	O
and	CC	O	O
doxorubicin	NN	B-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Experimental	JJ	B-NP	O
design	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
control	NN	B-NP	O
(	(	O	O
vehicle	NN	B-NP	O
alone	RB	B-ADVP	O
)	)	O	O
,	,	O	O
GSPE	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
drug	NN	B-NP	O
alone	RB	B-ADVP	O
and	CC	O	O
GSPE+drug	NN	B-NP	O
.	.	O	O

For	IN	B-PP	O
the	DT	B-NP	O
cytoprotection	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
animals	NNS	B-NP	O
were	VBD	B-VP	O
orally	RB	I-VP	O
gavaged	VBN	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
Kg	NN	I-NP	O
GSPE	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
i.p.	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
organ	NN	B-NP	O
specific	JJ	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Parameters	NNS	B-NP	O
of	IN	B-PP	O
study	NN	B-NP	O
included	VBD	B-VP	O
analysis	NN	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
chemistry	NN	I-NP	O
(	(	O	O
ALT	NN	B-NP	O
,	,	O	O
BUN	NN	B-NP	O
and	CC	O	O
CPK	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
orderly	JJ	B-NP	O
fragmentation	NN	I-NP	O
of	IN	B-PP	O
genomic	JJ	B-NP	O
DNA	NN	I-NP	O
(	(	O	O
both	CC	O	O
endonuclease	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
and	CC	I-NP	O
independent	JJ	I-NP	O
)	)	O	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
microscopic	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
damage	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
protection	NN	B-NP	O
in	IN	B-PP	O
corresponding	VBG	B-VP	O
PAS	NN	B-NP	O
stained	VBD	B-VP	O
tissues	NNS	B-NP	O
.	.	O	O

Results	NNS	B-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
GSPE	NN	B-NP	O
preexposure	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
AAP	NN	B-NP	O
,	,	I-NP	O
AMI	NN	I-NP	O
and	CC	I-NP	O
DOX	NN	I-NP	O
,	,	O	O
provided	VBN	B-PP	O
near	IN	B-PP	O
complete	JJ	B-NP	O
protection	NN	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
chemistry	NN	I-NP	O
changes	NNS	I-NP	O
(	(	O	O
ALT	NN	B-NP	O
,	,	O	O
BUN	NN	B-NP	O
and	CC	O	O
CPK	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
significantly	RB	B-VP	O
reduced	VBD	I-VP	O
DNA	NN	B-NP	O
fragmentation	NN	I-NP	O
.	.	O	O

Histopathological	JJ	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	O
,	,	I-NP	O
heart	NN	I-NP	O
and	CC	I-NP	O
lung	NN	I-NP	O
sections	NNS	I-NP	O
revealed	VBD	B-VP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
massive	JJ	B-NP	O
tissue	NN	I-NP	B
damage	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
morphological	JJ	B-NP	O
aberrations	NNS	I-NP	O
by	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
GSPE	NN	B-NP	O
preexposure	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
its	PRP$	B-NP	O
presence	NN	I-NP	O
.	.	O	O

GSPE+drug	NN	B-NP	O
exposed	VBN	I-NP	O
tissues	NNS	I-NP	O
exhibited	VBD	B-VP	O
minor	JJ	B-NP	O
residual	JJ	I-NP	O
damage	NN	I-NP	O
or	CC	B-PP	O
near	IN	B-PP	O
total	JJ	B-NP	O
recovery	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
histopathological	JJ	B-NP	O
alterations	NNS	I-NP	O
mirrored	VBD	B-VP	O
both	CC	O	O
serum	NN	B-NP	O
chemistry	NN	I-NP	O
changes	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
DNA	NN	B-NP	O
fragmentation	NN	I-NP	O
.	.	O	O

Interestingly	RB	B-ADVP	O
,	,	O	O
all	PDT	B-NP	O
the	DT	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
,	,	O	O
AAP	NN	B-NP	O
,	,	O	O
AMI	NN	B-NP	O
and	CC	I-NP	O
DOX	NN	I-NP	O
induced	VBD	B-VP	O
apoptotic	JJ	B-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
necrosis	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
respective	JJ	I-NP	O
organs	NNS	I-NP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
very	RB	I-VP	O
effectively	RB	I-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
GSPE	NN	B-NP	O
.	.	O	O

Since	IN	B-PP	O
AAP	NN	B-NP	O
,	,	O	O
AMI	NN	B-NP	O
and	CC	I-NP	O
DOX	NN	I-NP	O
undergo	VBP	B-VP	O
biotransformation	NN	B-NP	O
and	CC	O	O
are	VBP	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
produce	VB	I-VP	O
damaging	JJ	B-NP	O
radicals	NNS	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
the	DT	B-NP	O
protection	NN	I-NP	O
by	IN	B-PP	O
GSPE	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
linked	VBN	I-VP	O
to	TO	B-PP	O
both	CC	O	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
metabolism	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
detoxification	NN	B-NP	O
of	IN	B-PP	O
cytotoxic	JJ	B-NP	O
radicals	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
its	PRP$	B-NP	O
s	NNS	I-NP	O
presumed	VBD	B-VP	O
contribution	NN	B-NP	O
to	TO	B-PP	O
DNA	NN	B-NP	O
repair	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
another	DT	B-NP	O
important	JJ	I-NP	O
attribute	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
played	VBD	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
chemoprevention	NN	I-NP	O
process	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
report	NN	I-NP	O
on	IN	B-PP	O
AMI	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
apoptotic	JJ	I-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lung	NN	I-NP	O
tissue	NN	I-NP	O
.	.	O	O

Taken	VBN	B-VP	O
together	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
events	NNS	I-NP	O
undoubtedly	RB	B-VP	O
establish	VBP	I-VP	O
GSPE	NN	B-NP	O
s	VBZ	B-VP	O
abundant	JJ	B-NP	O
bioavailability	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
power	NN	I-NP	O
to	TO	B-VP	O
defend	VB	I-VP	O
multiple	JJ	B-NP	O
target	NN	I-NP	O
organs	NNS	I-NP	O
from	IN	B-PP	O
toxic	JJ	B-NP	O
assaults	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
structurally	RB	B-NP	O
diverse	JJ	I-NP	O
and	CC	I-NP	O
functionally	RB	I-NP	O
different	JJ	I-NP	O
entities	NNS	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

Palpebral	JJ	B-NP	B
twitching	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
depressed	JJ	I-NP	B
adolescent	NN	I-NP	O
on	IN	B-PP	O
citalopram	NN	B-NP	O
.	.	O	O

Current	JJ	B-NP	O
estimates	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
between	IN	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
children	NNS	B-NP	O
and	CC	I-NP	O
adolescents	NNS	I-NP	O
are	VBP	B-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
major	JJ	B-NP	B
depression	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
favorable	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
citalopram	NN	B-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
boy	NN	I-NP	O
with	IN	B-PP	O
major	JJ	B-NP	B
depression	NN	I-NP	I
who	WP	B-NP	O
exhibited	VBD	B-VP	O
palpebral	JJ	B-NP	B
twitching	NN	I-NP	I
during	IN	B-PP	O
his	PRP$	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
a	DT	B-NP	O
side	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
citalopram	NN	B-NP	O
as	IN	B-SBAR	O
it	PRP	B-NP	O
remitted	VBD	B-VP	O
with	IN	B-PP	O
redistribution	NN	B-NP	O
of	IN	B-PP	O
doses	NNS	B-NP	O
.	.	O	O

Metamizol	NN	B-NP	O
potentiates	VBZ	B-VP	O
morphine	NN	B-NP	O
antinociception	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
constipation	NN	B-NP	B
after	IN	B-PP	O
chronic	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
work	NN	I-NP	O
evaluates	VBZ	B-VP	O
the	DT	B-NP	O
antinociceptive	JJ	I-NP	O
and	CC	I-NP	O
constipating	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
s.c.	JJ	I-NP	O
morphine	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
s.c.	JJ	I-NP	O
metamizol	NN	I-NP	O
in	IN	B-PP	O
acutely	RB	B-ADVP	O
and	CC	I-ADVP	O
chronically	RB	I-ADVP	O
treated	VBN	B-VP	O
(	(	O	O
once	RB	O	O
a	DT	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
rats	NNS	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
13th	JJ	I-NP	O
day	NN	I-NP	O
,	,	O	O
antinociceptive	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
nociception	NN	I-NP	O
,	,	O	O
pain	NN	B-NP	B
-	HYPH	O	O
induced	VBN	B-NP	O
functional	JJ	I-NP	O
impairment	NN	I-NP	O
model	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
charcoal	NN	I-NP	O
meal	JJ	I-NP	O
test	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
intestinal	JJ	I-NP	O
transit	NN	I-NP	O
.	.	O	O

Simultaneous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
with	IN	B-PP	O
metamizol	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
markedly	RB	I-NP	O
antinociceptive	JJ	I-NP	O
potentiation	NN	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increasing	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
units	NNS	I-NP	O
area	NN	I-NP	O
and	CC	O	O
repeated	VBN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Antinociceptive	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
chronically	RB	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
while	IN	B-SBAR	O
the	DT	B-NP	O
combination	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
antinociception	NN	I-NP	O
was	VBD	B-VP	O
remained	VBN	I-VP	O
similar	JJ	B-ADJP	O
as	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
antinociceptive	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
were	VBD	B-VP	O
partially	RB	I-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
naloxone	NN	I-NP	O
s.c.	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
partial	JJ	I-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
opioidergic	JJ	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
synergism	NN	I-NP	O
observed	VBN	B-VP	O
.	.	O	O

In	IN	B-PP	O
independent	JJ	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
morphine	NN	B-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
intestinal	JJ	I-NP	O
transit	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
after	IN	B-PP	O
acute	JJ	B-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
tolerance	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
develop	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
constipating	VBG	I-NP	B
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
inhibited	VBD	B-VP	O
intestinal	JJ	B-NP	O
transit	NN	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
metamizol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
potentiate	VB	I-VP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
constipation	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
show	VBP	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	I-NP	O
metamizol	NN	I-NP	O
in	IN	B-PP	O
chronically	RB	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
combination	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

Ifosfamide	NN	B-NP	O
encephalopathy	NN	I-NP	B
presenting	VBG	B-VP	O
with	IN	B-PP	O
asterixis	NN	B-NP	B
.	.	O	O

CNS	NN	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antineoplastic	JJ	I-NP	O
agent	NN	I-NP	O
ifosfamide	NN	I-NP	O
(	(	O	O
IFX	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
frequent	JJ	B-ADJP	O
and	CC	O	O
include	VBP	B-VP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
neurological	JJ	B-NP	O
symptoms	NNS	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
limit	VB	I-VP	O
drug	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
severe	JJ	B-ADJP	O
,	,	O	O
disabling	VBG	B-VP	O
negative	JJ	B-NP	O
myoclonus	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
upper	JJ	I-NP	O
and	CC	I-NP	O
lower	JJR	I-NP	O
extremities	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
for	IN	B-PP	O
plasmacytoma	NN	B-NP	B
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
awake	NN	B-NP	O
,	,	O	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
mental	JJ	B-NP	O
status	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
rest	NN	B-NP	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
further	JJ	I-NP	O
motor	NN	I-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

Cranial	JJ	B-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
and	CC	O	O
extensive	JJ	B-NP	O
laboratory	NN	I-NP	O
studies	NNS	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
reveal	VB	I-VP	O
structural	JJ	B-NP	B
lesions	NNS	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
brain	NN	I-NP	I
and	CC	I-NP	O
metabolic	JJ	I-NP	B
abnormalities	NNS	I-NP	I
.	.	O	O

An	DT	B-NP	O
electroencephalogram	NN	I-NP	O
showed	VBD	B-VP	O
continuous	JJ	B-ADJP	O
,	,	O	O
generalized	VBN	B-VP	O
irregular	JJ	B-NP	O
slowing	NN	I-NP	O
with	IN	B-PP	O
admixed	VBN	B-NP	O
periodic	JJ	I-NP	O
triphasic	JJ	I-NP	O
waves	NNS	I-NP	O
indicating	VBG	B-VP	O
symptomatic	JJ	B-NP	O
encephalopathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
the	DT	B-NP	O
asterixis	NN	I-NP	B
resolved	VBD	B-VP	O
completely	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
described	VBN	B-VP	O
,	,	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
asterixis	NN	B-NP	B
during	IN	B-PP	O
infusion	NN	B-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
,	,	O	O
normal	JJ	B-NP	O
laboratory	NN	I-NP	O
findings	NNS	I-NP	O
and	CC	O	O
imaging	NN	B-NP	O
studies	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
negative	JJ	B-NP	O
myoclonus	NN	I-NP	B
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
IFX	NN	B-NP	O
.	.	O	O

Sub	NN	B-NP	O
-	HYPH	I-NP	O
chronic	JJ	I-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
gamma	SYM	O	O
-	HYPH	O	O
vinyl	NN	B-NP	O
GABA	NN	I-NP	O
(	(	O	O
vigabatrin	NN	B-NP	O
)	)	O	O
inhibits	VBZ	B-VP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
nucleus	NN	B-NP	O
accumbens	NN	I-NP	O
dopamine	NN	I-NP	O
.	.	O	O

gamma	SYM	B-NP	O
-	:	O	O
Vinyl	NN	B-NP	O
GABA	NN	I-NP	O
(	(	O	O
GVG	NN	B-NP	O
)	)	O	O
irreversibly	RB	B-ADVP	O
inhibits	VBZ	B-VP	O
GABA	NN	B-NP	O
-	HYPH	I-NP	O
transaminase	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
mediated	VBN	I-NP	O
inhibition	NN	I-NP	O
requires	VBZ	B-VP	O
de	FW	B-NP	O
novo	FW	I-NP	O
synthesis	NN	I-NP	O
for	IN	B-PP	O
restoration	NN	B-NP	O
of	IN	B-PP	O
functional	JJ	B-NP	O
GABA	NN	I-NP	O
catabolism	NN	I-NP	O
.	.	O	O

Given	VBN	B-VP	O
its	PRP$	B-NP	O
preclinical	JJ	I-NP	O
success	NN	I-NP	O
for	IN	B-PP	O
treating	VBG	B-VP	O
substance	NN	B-NP	B
abuse	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	B
field	NN	I-NP	I
defects	NNS	I-NP	I
(	(	O	O
VFD	NN	B-NP	B
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
cumulative	JJ	B-NP	O
lifetime	NN	I-NP	O
exposure	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
explored	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
chronic	JJ	I-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
GVG	NN	I-NP	O
on	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
nucleus	NN	B-NP	O
accumbens	NN	I-NP	O
(	(	O	O
NAcc	NN	B-NP	O
)	)	O	O
dopamine	NN	B-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
.	.	O	O

Using	VBG	B-VP	O
in	FW	B-NP	O
vivo	FW	I-NP	O
microdialysis	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
compared	VBD	B-VP	O
acute	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
identical	JJ	I-NP	O
sub	AFX	I-NP	O
-	HYPH	I-NP	O
chronic	JJ	I-NP	O
exposure	NN	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
washout	NN	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
washout	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Sub	NN	B-NP	O
-	HYPH	I-NP	O
chronic	JJ	I-NP	O
GVG	NN	I-NP	O
exposure	NN	I-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
exceeded	VBD	B-VP	O
in	IN	B-PP	O
magnitude	NN	B-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
the	DT	B-NP	O
identical	JJ	I-NP	O
acute	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Sub	NN	B-NP	O
-	HYPH	I-NP	O
chronic	JJ	I-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
GVG	NN	I-NP	O
potentiates	VBZ	B-VP	O
and	CC	I-VP	O
extends	VBZ	I-VP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
dopamine	NN	B-NP	O
,	,	O	O
effectively	RB	B-VP	O
reducing	VBG	I-VP	O
cumulative	JJ	B-NP	O
exposures	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
VFDS	NN	B-NP	O
.	.	O	O

Amount	NN	B-NP	O
of	IN	B-PP	O
bleeding	NN	B-NP	B
and	CC	I-NP	O
hematoma	NN	I-NP	B
size	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
collagenase	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
intracerebral	JJ	I-NP	B
hemorrhage	NN	I-NP	I
rat	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aggravated	JJ	I-NP	O
risk	NN	I-NP	O
on	IN	B-PP	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
(	(	O	O
ICH	NN	B-NP	B
)	)	O	O
with	IN	B-PP	O
drugs	NNS	B-NP	O
used	VBN	B-VP	O
for	IN	B-PP	O
stroke	NN	B-NP	B
patients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
estimated	VBN	I-VP	O
carefully	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
established	VBD	B-VP	O
sensitive	JJ	B-NP	O
quantification	NN	I-NP	O
methods	NNS	I-NP	O
and	CC	O	O
provided	VBD	B-VP	O
a	DT	B-NP	O
rat	NN	I-NP	O
ICH	NN	I-NP	B
model	NN	I-NP	O
for	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
ICH	NN	B-NP	B
deterioration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
ICH	NN	B-NP	B
intrastriatally	RB	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
unit	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
unit	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
unit	NN	I-NP	O
collagenase	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
bleeding	NN	B-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
hemoglobin	NN	I-NP	O
assay	NN	I-NP	O
developed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
morphologically	RB	I-NP	O
determined	VBN	I-NP	O
hematoma	NN	I-NP	B
volume	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
blood	NN	I-NP	O
amounts	NNS	I-NP	O
and	CC	O	O
hematoma	NN	B-NP	B
volumes	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
correlated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
hematoma	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
unit	NN	I-NP	O
collagenase	NN	I-NP	O
was	VBD	B-VP	O
adequate	JJ	B-ADJP	O
to	TO	B-VP	O
detect	VB	I-VP	O
ICH	NN	B-NP	B
deterioration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
ICH	NN	B-NP	B
induction	NN	I-NP	O
using	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
unit	NN	I-NP	O
collagenase	NN	I-NP	O
,	,	O	O
heparin	NN	B-NP	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
hematoma	NN	I-NP	B
volume	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	B-VP	O
fold	RB	B-ADVP	O
over	IN	B-PP	O
that	DT	B-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
control	NN	B-NP	O
ICH	NN	I-NP	B
animals	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
bleeding	VBG	I-NP	B
num	CD	I-NP	O
-	HYPH	B-VP	O
fold	RB	B-ADVP	O
.	.	O	O

Data	NNS	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
sensitive	JJ	I-NP	O
hemoglobin	NN	I-NP	O
assay	NN	I-NP	O
is	VBZ	B-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
ICH	NN	B-NP	B
detection	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
a	DT	B-NP	O
model	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
small	JJ	I-NP	O
ICH	NN	I-NP	B
induced	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
collagenase	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
evaluation	NN	B-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
affect	VB	I-VP	O
ICH	NN	B-NP	B
.	.	O	O

Estradiol	NN	B-NP	O
reduces	VBZ	B-VP	O
seizure	NN	B-NP	B
-	HYPH	O	O
induced	VBN	B-NP	O
hippocampal	JJ	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
ovariectomized	VBN	B-NP	O
female	JJ	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Estrogens	NNS	B-NP	O
protect	VBP	B-VP	O
ovariectomized	VBN	I-VP	O
rats	NNS	B-NP	O
from	IN	B-PP	O
hippocampal	JJ	B-NP	B
injury	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
kainic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
(	(	O	O
SE	NN	B-NP	B
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
17beta	NN	B-NP	O
-	HYPH	B-NP	O
estradiol	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
male	JJ	I-NP	O
and	CC	I-NP	O
ovariectomized	VBN	I-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
subjected	VBN	B-VP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
SE	NN	I-NP	B
.	.	O	O

Rats	NNS	B-NP	O
received	VBD	B-VP	O
subcutaneous	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
17beta	NN	B-NP	O
-	HYPH	O	O
estradiol	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
rat	NN	I-NP	O
)	)	O	O
or	CC	O	O
oil	NN	B-NP	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

SE	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
injection	NN	I-NP	O
and	CC	O	O
terminated	VBN	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
silver	NN	B-NP	O
-	HYPH	B-NP	O
stained	VBN	I-NP	O
CA3	NN	I-NP	O
and	CC	I-NP	O
CA1	NN	I-NP	O
hippocampal	JJ	I-NP	O
neurons	NNS	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
SE	NN	B-NP	B
.	.	O	O
17beta	NN	B-NP	O
-	HYPH	O	O
Estradiol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
first	JJ	B-NP	O
clonus	NN	I-NP	O
in	IN	B-PP	O
ovariectomized	VBN	B-NP	O
rats	NNS	I-NP	O
but	CC	O	O
accelerated	VBD	B-VP	O
it	PRP	B-NP	O
in	IN	B-PP	O
males.	NN	B-NP	O
17beta	NN	I-NP	O
-	HYPH	B-NP	O
Estradiol	NN	I-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
argyrophilic	JJ	I-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
CA1	NN	I-NP	O
and	CC	I-NP	O
CA3	NN	I-NP	O
-	HYPH	I-NP	O
C	NN	I-NP	O
sectors	NNS	I-NP	O
of	IN	B-PP	O
ovariectomized	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
males	NNS	B-NP	O
,	,	O	O
estradiol	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
total	JJ	I-NP	O
damage	NN	I-NP	O
score	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
estradiol	NN	B-NP	O
on	IN	B-PP	O
seizure	NN	B-NP	B
threshold	NN	I-NP	O
and	CC	I-NP	O
damage	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
altered	VBN	I-VP	O
by	IN	B-PP	O
sex	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hormonal	JJ	I-NP	O
environment	NN	I-NP	O
.	.	O	O

Delirium	NN	B-NP	B
during	IN	B-PP	O
clozapine	NN	B-NP	O
treatment	NN	I-NP	O
:	:	O	O
incidence	NN	B-NP	O
and	CC	O	O
associated	VBN	B-VP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
.	.	O	O

Incidence	NN	B-NP	O
and	CC	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
delirium	NN	B-NP	B
during	IN	B-PP	O
clozapine	NN	B-NP	O
treatment	NN	I-NP	O
require	VBP	B-VP	O
further	JJR	B-NP	O
clarification	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
computerized	JJ	B-NP	O
pharmacy	NN	I-NP	O
records	NNS	I-NP	O
to	TO	B-VP	O
identify	VB	I-VP	O
all	DT	B-NP	O
adult	JJ	I-NP	O
psychiatric	JJ	I-NP	B
inpatients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
clozapine	NN	B-NP	O
,	,	O	O
reviewed	VBD	B-VP	O
their	PRP$	B-NP	O
medical	JJ	I-NP	O
records	NNS	I-NP	O
to	TO	B-VP	O
score	VB	I-VP	O
incidence	NN	B-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
delirium	NN	B-NP	B
,	,	O	O
and	CC	O	O
tested	VBN	B-VP	O
associations	NNS	B-NP	O
with	IN	B-PP	O
potential	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
women	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
,	,	O	O
aged	VBN	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
hospitalized	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
and	CC	O	O
given	VBN	B-VP	O
clozapine	NN	B-NP	O
,	,	O	O
gradually	RB	B-ADVP	O
increased	VBD	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Delirium	NN	B-NP	B
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
incidence	NN	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
/	SYM	B-NP	O
person	NN	I-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
exposure	NN	B-NP	O
)	)	O	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
were	VBD	B-VP	O
moderate	JJ	B-ADJP	O
or	CC	I-ADJP	O
severe	JJ	I-ADJP	O
.	.	O	O

Associated	VBN	B-NP	O
factors	NNS	I-NP	O
were	VBD	B-VP	O
co	AFX	O	O
-	HYPH	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
centrally	RB	I-NP	O
antimuscarinic	JJ	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
poor	JJ	B-NP	O
clinical	JJ	I-NP	O
outcome	NN	I-NP	O
,	,	O	O
older	JJR	B-NP	O
age	NN	I-NP	O
,	,	O	O
and	CC	O	O
longer	JJR	B-NP	O
hospitalization	NN	I-NP	O
(	(	O	O
by	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
increasing	VBG	B-VP	O
cost	NN	B-NP	O
)	)	O	O
;	:	O	O
sex	NN	B-NP	O
,	,	I-NP	O
diagnosis	NN	I-NP	O
or	CC	I-NP	O
medical	JJ	I-NP	O
co	AFX	O	O
-	HYPH	O	O
morbidity	NN	B-NP	O
,	,	O	O
and	CC	O	O
daily	JJ	B-NP	O
clozapine	NN	I-NP	O
dose	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
fell	VBD	B-VP	O
with	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
unrelated	JJ	B-ADJP	O
.	.	O	O

Delirium	NN	B-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
clozapine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
inpatients	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
other	JJ	B-NP	O
central	JJ	I-NP	O
anticholinergics	NNS	I-NP	O
.	.	O	O

Delirium	NN	B-NP	B
was	VBD	B-VP	O
inconsistently	RB	I-VP	O
recognized	VBN	I-VP	O
clinically	RB	B-ADVP	O
in	IN	B-PP	O
milder	JJR	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
length	NN	I-NP	O
-	HYPH	B-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
stay	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
costs	NNS	I-NP	O
,	,	O	O
and	CC	O	O
inferior	JJ	B-NP	O
clinical	JJ	I-NP	O
outcome	NN	I-NP	O
.	.	O	O

Ketoconazole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
neurologic	JJ	I-NP	B
sequelae	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
y	NN	I-NP	O
-	HYPH	I-NP	O
old	JJ	I-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
weakness	NN	B-NP	B
of	IN	B-PP	I
extremities	NNS	B-NP	I
,	,	O	O
legs	NNS	B-NP	B
paralysis	NN	I-NP	I
,	,	I-NP	O
dysarthria	NN	I-NP	B
and	CC	I-NP	O
tremor	NN	I-NP	B
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
ingestion	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
ketoconazole	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
in	IN	B-PP	O
his	PRP$	B-NP	O
life	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
complaints	NNS	I-NP	O
faded	VBD	B-VP	O
away	RB	B-ADVP	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

Few	JJ	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
used	VBD	B-VP	O
another	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
ketoconazole	NN	I-NP	O
tablet	NN	I-NP	O
,	,	O	O
and	CC	O	O
within	IN	B-PP	O
an	DT	B-NP	O
hour	NN	I-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
clinical	JJ	I-NP	O
picture	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
resolved	VBD	B-VP	O
again	RB	B-ADVP	O
spontaneously	RB	B-ADVP	O
within	IN	B-PP	O
hours	NNS	B-NP	O
.	.	O	O

Laboratory	NN	B-NP	O
evaluations	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
head	NN	B-NP	O
CT	NN	I-NP	O
scan	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
illustrates	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
close	JJ	B-NP	O
vigilance	NN	I-NP	O
in	IN	B-PP	O
adverse	JJ	B-NP	B
drug	NN	I-NP	I
reactions	NNS	I-NP	I
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
.	.	O	O

Noxious	JJ	B-NP	O
chemical	NN	I-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
rat	NN	B-NP	O
facial	JJ	I-NP	O
mucosa	NN	I-NP	O
increases	VBZ	B-VP	O
intracranial	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
through	IN	B-PP	O
a	DT	B-NP	O
trigemino	AFX	I-NP	O
-	HYPH	I-NP	O
parasympathetic	JJ	I-NP	O
reflex	NN	I-NP	O
-	HYPH	B-VP	O
-	HYPH	B-NP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
vascular	JJ	B-NP	B
dysfunctions	NNS	I-NP	I
in	IN	B-PP	O
cluster	NN	B-NP	B
headache	NN	I-NP	I
.	.	O	O

Cluster	NNP	B-NP	B
headache	PRP	B-NP	I
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
typical	JJ	B-NP	O
autonomic	JJ	I-NP	O
dysfunctions	NNS	I-NP	O
including	VBG	B-PP	O
facial	JJ	B-NP	O
and	CC	I-NP	O
intracranial	JJ	I-NP	B
vascular	JJ	I-NP	I
disturbances	NNS	I-NP	I
.	.	O	O

Both	CC	O	O
the	DT	B-NP	O
trigeminal	JJ	I-NP	O
and	CC	O	O
the	DT	B-NP	O
cranial	JJ	I-NP	O
parasympathetic	JJ	I-NP	O
systems	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
mediating	VBG	B-VP	O
these	DT	B-NP	O
dysfunctions	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
to	TO	B-VP	O
measure	VB	I-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
lacrimation	NN	B-NP	O
and	CC	O	O
intracranial	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
following	VBG	B-PP	O
noxious	JJ	B-NP	O
chemical	NN	I-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
facial	JJ	B-NP	O
mucosa	NN	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
flow	NN	I-NP	O
was	VBD	B-VP	O
monitored	VBN	I-VP	O
in	IN	B-PP	O
arteries	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
exposed	VBN	I-NP	O
cranial	JJ	I-NP	O
dura	NN	I-NP	O
mater	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
parietal	JJ	I-NP	O
cortex	NN	I-NP	O
using	VBG	B-VP	O
laser	NN	B-NP	O
Doppler	NNP	I-NP	O
flowmetry	NN	I-NP	O
.	.	O	O

Capsaicin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
)	)	O	O
applied	VBD	B-VP	O
to	TO	B-PP	O
oral	JJ	B-NP	O
or	CC	I-NP	O
nasal	JJ	I-NP	O
mucosa	NN	I-NP	O
induced	VBD	B-VP	O
increases	NNS	B-NP	B
in	IN	B-PP	I
dural	JJ	B-NP	I
and	CC	I-NP	I
cortical	JJ	I-NP	I
blood	NN	I-NP	I
flow	NN	I-NP	I
and	CC	O	O
provoked	JJ	B-NP	O
lacrimation	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
systemic	JJ	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
administration	NN	B-NP	O
of	IN	B-PP	O
hexamethonium	NN	B-NP	O
chloride	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
evoked	VBN	I-NP	O
increases	NNS	I-NP	B
in	IN	B-PP	I
dural	JJ	B-NP	I
blood	NN	I-NP	I
flow	NN	I-NP	I
were	VBD	B-VP	O
also	RB	I-VP	O
abolished	VBN	I-VP	O
by	IN	B-PP	O
topical	JJ	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
administration	NN	B-NP	O
of	IN	B-PP	O
atropine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
)	)	O	O
and	CC	O	O
[	(	O	O
Lys1	NN	B-NP	O
,	,	O	O
Pro2	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
,	,	O	O
Arg3	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
,	,	I-NP	O
Tyr6	NN	I-NP	O
]	)	O	O
-	HYPH	B-NP	O
VIP	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
vasoactive	JJ	I-NP	O
intestinal	JJ	I-NP	O
polypeptide	NN	I-NP	O
(	(	O	O
VIP	NN	B-NP	O
)	)	O	O
antagonist	NN	B-NP	O
,	,	O	O
onto	IN	B-PP	O
the	DT	B-NP	O
exposed	VBN	I-NP	O
dura	NN	I-NP	O
mater	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
noxious	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
facial	JJ	B-NP	O
mucosa	NN	I-NP	O
increases	VBZ	B-VP	O
intracranial	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
and	CC	I-NP	O
lacrimation	NN	I-NP	O
via	IN	B-PP	O
a	DT	B-NP	O
trigemino	AFX	I-NP	O
-	HYPH	I-NP	O
parasympathetic	JJ	I-NP	O
reflex	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
responses	NNS	I-NP	O
seem	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
acetylcholine	NN	B-NP	O
and	CC	I-NP	O
VIP	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
meninges	NNS	I-NP	O
.	.	O	O

Similar	JJ	B-NP	O
mechanisms	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
cluster	NN	B-NP	B
headache	NN	I-NP	I
.	.	O	O

Recurrent	JJ	B-NP	O
excitation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
murine	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
temporal	JJ	B-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
.	.	O	O

Similar	JJ	B-ADJP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
systemic	JJ	B-NP	O
pilocarpine	NN	I-NP	O
injection	NN	I-NP	O
causes	VBZ	B-VP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
(	(	O	O
SE	NN	B-NP	B
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
eventual	JJ	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
mossy	NN	B-NP	O
fiber	NN	I-NP	O
sprouting	VBG	B-VP	O
in	IN	B-PP	O
C57BL	NN	B-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
and	CC	O	O
CD1	NN	B-NP	O
mice	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
physiological	JJ	I-NP	O
correlates	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
events	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Population	NN	B-NP	O
responses	NNS	I-NP	O
in	IN	B-PP	O
granule	NN	B-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
transverse	JJ	B-NP	O
slices	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
hippocampus	NN	I-NP	O
from	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-ADVP	O
treated	VBN	B-NP	O
and	CC	I-NP	O
untreated	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
Mg	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
bathing	NN	I-NP	O
medium	NN	I-NP	O
containing	VBG	B-VP	O
bicuculline	NN	B-NP	O
,	,	O	O
conditions	NNS	B-NP	O
designed	VBN	B-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
excitability	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
slices	NNS	I-NP	O
,	,	O	O
electrical	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hilus	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
population	NN	I-NP	O
spike	NN	I-NP	O
in	IN	B-PP	O
granule	NN	B-NP	O
cells	NNS	I-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
mice	NNS	I-NP	O
and	CC	I-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
experience	VB	I-VP	O
SE	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
SE	NN	B-NP	B
survivors	NNS	I-NP	O
,	,	O	O
similar	JJ	B-NP	O
stimulation	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
spike	NN	I-NP	O
followed	VBD	B-VP	O
,	,	O	O
at	IN	B-PP	O
a	DT	B-NP	O
variable	JJ	I-NP	O
latency	NN	I-NP	O
,	,	O	O
by	IN	B-PP	O
negative	JJ	B-NP	O
DC	NN	I-NP	O
shifts	NNS	I-NP	O
and	CC	O	O
repetitive	JJ	B-NP	O
afterdischarges	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
duration	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
ionotropic	JJ	B-NP	O
glutamate	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

Focal	JJ	B-NP	O
glutamate	NN	I-NP	O
photostimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
layer	NN	I-NP	O
at	IN	B-PP	O
sites	NNS	B-NP	O
distant	JJ	B-ADJP	O
from	IN	B-PP	O
the	DT	B-NP	O
recording	VBG	I-NP	O
pipette	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
population	NN	B-NP	O
responses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
duration	NN	I-NP	O
in	IN	B-PP	O
slices	NNS	B-NP	O
from	IN	B-PP	O
SE	NN	B-NP	B
survivors	NNS	I-NP	O
but	CC	O	O
not	RB	O	O
other	JJ	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
SE	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
mossy	NN	I-NP	O
fiber	NN	I-NP	O
sprouting	VBG	B-VP	O
and	CC	O	O
synaptic	JJ	B-NP	O
reorganization	NN	I-NP	O
are	VBP	B-VP	O
relevant	JJ	B-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
development	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
murine	JJ	I-NP	O
strains	NNS	I-NP	O
,	,	O	O
resembling	VBG	B-VP	O
rat	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
temporal	JJ	I-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
alpha3	NN	I-NP	O
and	CC	I-NP	O
beta4	NN	I-NP	O
nicotinic	JJ	I-NP	O
acetylcholine	NN	I-NP	O
receptor	NN	I-NP	O
subunits	NNS	I-NP	O
are	VBP	B-VP	O
necessary	JJ	B-ADJP	O
for	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
hypolocomotion	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Binding	NN	B-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
to	TO	B-PP	O
nicotinic	JJ	B-NP	O
acetylcholine	NN	I-NP	O
receptors	NNS	I-NP	O
(	(	O	O
nAChRs	NNS	B-NP	O
)	)	O	O
elicits	VBZ	B-VP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
behaviors	NNS	I-NP	O
that	WDT	B-NP	O
go	VBP	B-VP	O
from	IN	B-PP	O
altered	VBN	B-NP	O
exploration	NN	I-NP	O
,	,	O	O
sedation	NN	B-NP	O
,	,	O	O
and	CC	O	O
tremors	NNS	B-NP	B
,	,	O	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
and	CC	I-NP	O
death	NN	I-NP	B
.	.	I-NP	O
nAChRs	NNS	I-NP	O
are	VBP	B-VP	O
pentameric	JJ	B-NP	O
ion	NN	I-NP	O
channels	NNS	I-NP	O
usually	RB	B-VP	O
composed	VBN	I-VP	O
of	IN	B-PP	O
alpha	NN	B-NP	O
and	CC	O	O
beta	NN	B-NP	O
subunits	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
gene	NN	I-NP	O
cluster	NN	I-NP	O
comprises	VBZ	B-VP	O
the	DT	B-NP	O
alpha3	NN	I-NP	O
,	,	I-NP	O
alpha5	NN	I-NP	O
and	CC	I-NP	O
beta4	NN	I-NP	O
subunits	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
coassemble	VBP	B-VP	O
to	TO	I-VP	O
form	VB	I-VP	O
functional	JJ	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
beta4	NN	I-NP	O
subunits	NNS	I-NP	O
in	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
hypolocomotion	NN	I-NP	B
in	IN	B-PP	O
beta4	NN	B-NP	O
homozygous	JJ	I-NP	O
null	NN	I-NP	O
(	(	O	O
beta4	NN	B-NP	O
-	HYPH	O	O
/	SYM	B-NP	O
-	SYM	B-NP	O
)	)	O	O
and	CC	O	O
alpha3	NN	B-NP	O
heterozygous	JJ	I-NP	O
mice.	NNS	I-NP	O
beta4	NN	I-NP	O
-	HYPH	B-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
less	RBR	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
both	CC	B-PP	O
at	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
measured	VBN	B-VP	O
as	IN	B-PP	O
decreased	VBN	B-NP	O
exploration	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
open	JJ	I-NP	O
field	NN	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
at	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
measured	VBN	B-VP	O
as	IN	B-PP	O
sensitivity	NN	B-NP	O
to	TO	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Using	VBG	B-VP	O
in	FW	B-NP	O
situ	FW	I-NP	O
hybridization	NN	I-NP	O
probes	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
alpha3	NN	I-NP	O
and	CC	I-NP	O
alpha5	NN	I-NP	O
subunits	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
alpha5	NN	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
are	VBP	B-VP	O
unchanged	JJ	B-ADJP	O
,	,	O	O
whereas	IN	O	O
alpha3	NN	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
are	VBP	B-VP	O
selectively	RB	I-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mitral	JJ	I-NP	O
cell	NN	I-NP	O
layer	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
olfactory	JJ	I-NP	O
bulb	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
inferior	JJ	I-NP	O
and	CC	O	O
the	DT	B-NP	O
superior	JJ	I-NP	O
colliculus	NN	I-NP	O
of	IN	B-PP	O
beta4	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
brains.	SYM	B-NP	O
alpha3	NN	I-NP	O
+	SYM	B-NP	O
/	SYM	B-VP	O
-	HYPH	B-ADVP	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
partially	RB	B-ADJP	O
resistant	JJ	I-ADJP	O
to	TO	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
littermates.	NN	I-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
alpha5	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
beta4	NN	I-NP	O
subunits	NNS	I-NP	O
were	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
alpha3	NN	B-NP	O
+	SYM	B-NP	O
/	SYM	B-VP	O
-	HYPH	B-ADVP	O
brains	NNS	B-NP	O
.	.	O	O

Together	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
beta4	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
alpha3	NN	I-NP	O
subunits	NNS	I-NP	O
are	VBP	B-VP	O
mediators	NNS	B-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
hypolocomotion	NN	I-NP	B
.	.	O	O

Recurrent	JJ	B-NP	O
acute	JJ	I-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
azithromycin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
girl	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
,	,	I-NP	O
azithromycin	NN	I-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
,	,	I-NP	O
acute	JJ	I-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
episode	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
severe	JJ	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
;	:	O	O
and	CC	O	O
although	IN	B-SBAR	O
both	DT	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intensive	JJ	B-NP	O
corticosteroid	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
renal	JJ	B-NP	O
function	NN	I-NP	O
remained	VBD	B-VP	O
impaired	JJ	B-ADJP	O
.	.	O	O

Although	IN	B-SBAR	O
most	JJS	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
antibiotic	NN	B-NP	O
induced	VBD	B-VP	O
acute	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
are	VBP	B-VP	O
benign	JJ	B-ADJP	O
and	CC	O	O
self	AFX	B-VP	O
-	HYPH	I-VP	O
limited	VBN	I-VP	O
,	,	O	O
some	DT	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
at	IN	B-PP	O
risk	NN	B-NP	O
for	IN	B-PP	O
permanent	JJ	B-NP	O
renal	JJ	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Valproate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
.	.	O	O

Valproate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
syndrome	NN	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
manifest	VB	I-VP	O
in	IN	B-PP	O
otherwise	RB	B-NP	O
normal	JJ	I-NP	O
epileptic	JJ	I-NP	B
individuals	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
may	MD	B-VP	O
even	RB	B-ADJP	O
present	JJ	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
tolerated	VBN	I-VP	O
this	DT	B-NP	O
medicine	NN	I-NP	O
well	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
past	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
usually	RB	I-VP	O
but	CC	I-VP	O
not	RB	I-VP	O
necessarily	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hyperammonemia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
EEG	NN	I-NP	O
shows	VBZ	B-VP	O
characteristic	JJ	B-NP	O
triphasic	JJ	I-NP	O
waves	NNS	I-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
valproate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
problems	NNS	I-NP	O
in	IN	B-PP	O
diagnosing	VBG	B-VP	O
this	DT	B-NP	O
condition	NN	I-NP	O
are	VBP	B-VP	O
subsequently	RB	I-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Nitro	AFX	B-NP	O
-	HYPH	I-NP	O
L	NN	I-NP	O
-	HYPH	I-NP	O
arginine	NN	I-NP	O
methyl	NN	I-NP	O
ester	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
potential	JJ	I-NP	O
protector	NN	I-NP	O
against	IN	B-PP	O
gentamicin	NN	B-NP	O
ototoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
inhibitor	NN	B-NP	O
nitro	NN	I-NP	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
methyl	NN	I-NP	O
ester	NN	I-NP	O
(	(	O	O
L	NN	B-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
)	)	O	O
may	MD	B-VP	O
act	VB	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
otoprotectant	NN	I-NP	O
against	IN	B-PP	O
high	JJ	B-NP	B
-	HYPH	I-NP	I
frequency	NN	I-NP	I
hearing	NN	I-NP	I
loss	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
gentamicin	NN	B-NP	O
,	,	O	O
but	CC	O	O
further	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
confirm	VB	I-VP	O
this.Aminoglycoside	NN	B-NP	O
antibiotics	NNS	I-NP	O
are	VBP	B-VP	O
still	RB	I-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
by	IN	B-PP	O
virtue	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
low	JJ	I-NP	O
cost	NN	I-NP	O
.	.	O	O

Their	PRP$	B-NP	O
ototoxicity	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
serious	JJ	I-NP	O
health	NN	I-NP	O
problem	NN	I-NP	O
and	CC	O	O
,	,	O	O
as	IN	B-SBAR	O
their	PRP$	B-NP	O
ototoxic	JJ	I-NP	B
mechanism	NN	I-NP	O
involves	VBZ	B-VP	O
the	DT	B-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
inhibitors	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
aminoglycoside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
sensorineural	JJ	I-NP	B
hearing	NN	I-NP	I
loss	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
experimental	JJ	I-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
used	VBD	B-VP	O
num	CD	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
had	VBD	B-VP	O
gentamicin	NN	B-NP	O
instilled	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
middle	JJ	I-NP	O
ear	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
otoprotectant	JJ	I-NP	O
L	NN	I-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
topically	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

Its	PRP$	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
attenuation	NN	B-NP	O
of	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
,	,	O	O
measured	VBN	B-VP	O
by	IN	B-PP	O
shifts	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
auditory	JJ	I-NP	O
brainstem	NN	I-NP	O
response	NN	I-NP	O
threshold	NN	I-NP	O
.	.	O	O

L	NN	B-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
reduced	VBD	B-VP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
frequency	NN	I-NP	O
range	NN	I-NP	O
,	,	O	O
but	CC	O	O
gave	VBD	B-VP	O
no	DT	B-NP	O
protection	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
middle	JJ	I-NP	O
or	CC	I-NP	O
low	JJ	I-NP	O
frequencies	NNS	I-NP	O
.	.	O	O

Cerebral	JJ	B-NP	B
vasculitis	NN	I-NP	I
following	VBG	B-PP	O
oral	JJ	B-NP	O
methylphenidate	NN	I-NP	O
intake	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
adult	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Methylphenidate	NN	B-NP	O
is	VBZ	B-VP	O
structurally	RB	B-ADJP	O
and	CC	I-ADJP	O
functionally	RB	I-ADJP	O
similar	JJ	I-ADJP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

Cerebral	JJ	B-NP	B
vasculitis	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
amphetamine	NN	B-NP	B
abuse	NN	I-NP	I
is	VBZ	B-VP	O
well	RB	I-VP	O
documented	VBN	I-VP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
rare	JJ	B-NP	O
cases	NNS	I-NP	O
ischaemic	JJ	B-NP	B
stroke	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
after	IN	B-PP	O
methylphenidate	NN	B-NP	O
intake	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
female	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
methylphenidate	NN	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
hyperactivity	NN	B-NP	B
and	CC	O	O
suffered	VBD	B-VP	O
from	IN	B-PP	O
multiple	JJ	B-NP	O
ischaemic	JJ	I-NP	B
strokes	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
consider	VBP	B-VP	O
drug	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cerebral	JJ	I-NP	B
vasculitis	NN	I-NP	I
as	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
likely	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
recurrent	JJ	B-NP	O
ischaemic	JJ	I-NP	B
strokes	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
pathological	JJ	I-NP	O
findings	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
diagnostic	JJ	I-NP	O
work	NN	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
methylphenidate	NN	B-NP	O
mediated	VBN	I-NP	O
vasculitis	NN	I-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
neurological	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
methylphenidate	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
potential	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
,	,	O	O
though	IN	B-SBAR	O
very	RB	B-ADJP	O
rare	JJ	I-ADJP	O
,	,	O	O
represents	VBZ	B-VP	O
num	CD	B-NP	O
more	JJR	I-NP	O
reason	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
very	RB	B-ADJP	O
restrictive	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
methylphenidate	NN	B-NP	O
.	.	O	O

Cerebral	JJ	B-NP	B
haemorrhage	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
,	,	I-NP	O
severity	NN	I-NP	O
and	CC	I-NP	O
preventability	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cerebral	JJ	I-NP	B
haemorrhages	NNS	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
warfarin	NN	B-NP	O
and	CC	I-NP	O
warfarin	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
living	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
county	NN	I-NP	O
of	IN	B-PP	O
Osterg	NNP	B-NP	O
tland	NNP	I-NP	O
,	,	O	O
Sweden	NNP	B-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
diagnosed	VBN	I-NP	O
cerebral	JJ	I-NP	B
haemorrhage	NN	I-NP	I
at	IN	B-PP	O
num	CD	B-NP	O
hospitals	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
period	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

Medical	JJ	B-NP	O
records	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
retrospectively	RB	B-ADVP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
whether	IN	B-SBAR	O
warfarin	NN	B-NP	O
and	CC	I-NP	O
warfarin	NN	I-NP	O
-	HYPH	O	O
drug	NN	B-NP	O
interactions	NNS	I-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
caused	VBN	I-VP	O
the	DT	B-NP	O
cerebral	JJ	I-NP	B
haemorrhage	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
possibly	RB	B-NP	O
avoidable	JJ	I-NP	O
cases	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
drug	NN	B-NP	O
interactions	NNS	I-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
.	.	O	O

Among	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cerebral	JJ	B-NP	B
haemorrhage	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
as	IN	B-SBAR	O
related	VBN	B-VP	O
to	TO	B-PP	O
warfarin	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
imply	VBP	B-VP	O
an	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
fatal	JJ	I-NP	O
outcome	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
to	TO	B-PP	O
num	CD	B-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
warfarin	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
warfarin	NN	I-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
contributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
haemorrhage	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
warfarin	NN	I-NP	O
patients	NNS	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
the	DT	I-NP	O
bleeding	VBG	I-NP	B
complication	NN	I-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
being	VBG	B-VP	O
possible	JJ	B-ADJP	O
to	TO	B-VP	O
avoid	VB	I-VP	O
.	.	O	O

Warfarin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cerebral	JJ	I-NP	B
haemorrhages	NNS	I-NP	I
are	VBP	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
clinical	JJ	I-NP	O
problem	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
fatality	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Almost	RB	B-NP	O
half	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
was	VBD	B-VP	O
related	VBN	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
warfarin	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
cerebral	JJ	I-NP	B
haemorrhages	NNS	I-NP	I
might	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
prevented	VBN	I-VP	O
if	IN	B-SBAR	O
greater	JJR	B-NP	O
caution	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taken	VBN	I-VP	O
when	WRB	B-ADVP	O
prescribing	VBG	B-VP	O
drugs	NNS	B-NP	O
known	VBN	B-VP	O
to	TO	B-VP	O
interact	VB	I-VP	O
with	IN	B-PP	O
warfarin	NN	B-NP	O
.	.	O	O

Side	NN	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
and	CC	I-NP	O
gentamicin	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
sub	AFX	I-NP	O
-	HYPH	I-NP	O
Tenon	NN	I-NP	O
s	NNS	I-NP	O
space	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
emetic	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
and	CC	I-NP	O
gentamicin	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
sub	AFX	I-NP	O
-	HYPH	I-NP	O
Tenon	NN	I-NP	O
s	VBZ	B-VP	O
space	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
routine	JJ	B-NP	O
cataract	NN	I-NP	B
surgery	NN	I-NP	O
.	.	O	O

St	NN	B-NP	O
.	.	O	O

Luke	NNP	B-NP	O
s	VBZ	B-VP	O
Hospital	NNP	B-NP	O
,	,	O	O
Gwardamangia	NNP	B-NP	O
,	,	O	O
Malta	NNP	B-NP	O
.	.	O	O

A	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
armed	JJ	I-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
comprised	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
uneventful	JJ	B-NP	O
sutureless	JJ	I-NP	O
phacoemulsification	NN	I-NP	O
under	IN	B-PP	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
Tenon	NN	I-NP	O
s	VBZ	B-VP	O
local	JJ	B-NP	O
infiltration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mL	NN	I-NP	O
of	IN	B-PP	O
plain	JJ	B-NP	O
lignocaine	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
,	,	O	O
Group	NN	B-NP	O
A	NN	I-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mL	NN	I-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mL	NN	I-NP	O
of	IN	B-PP	O
gentamicin	NN	B-NP	O
injected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
sub	AFX	I-NP	O
-	HYPH	I-NP	O
Tenon	NN	I-NP	O
s	NNS	I-NP	O
space	NN	I-NP	O
and	CC	I-NP	O
Group	NN	I-NP	O
B	NN	I-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
combination	NN	I-NP	O
injected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
sub	AFX	I-NP	O
-	HYPH	I-NP	O
Tenon	NN	I-NP	O
s	NNS	I-NP	O
space	NN	I-NP	O
.	.	O	O

Postoperatively	RB	B-ADVP	O
,	,	O	O
all	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
for	IN	B-PP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
nausea	NN	B-NP	B
,	,	O	I
vomiting	NN	B-NP	I
,	,	O	O
and	CC	O	O
headache	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
chi	AFX	I-NP	O
-	HYPH	I-NP	O
square	NN	I-NP	O
test	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
statistical	JJ	I-NP	O
significance	NN	I-NP	O
of	IN	B-PP	O
results	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
percent	NN	I-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
A	NN	I-NP	O
developed	VBD	B-VP	O
postoperative	JJ	B-NP	B
emetic	JJ	I-NP	I
symptoms	NNS	I-NP	I
,	,	O	O
headache	NN	B-NP	B
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
;	:	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
B	NN	I-NP	O
developed	VBD	B-VP	O
symptoms	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
and	CC	I-NP	O
gentamicin	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
sub	AFX	I-NP	O
-	HYPH	I-NP	O
Tenon	NN	I-NP	O
s	NNS	I-NP	O
space	NN	I-NP	O
was	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
including	VBG	B-PP	O
nausea	NN	B-NP	B
,	,	O	I
vomiting	NN	B-NP	I
,	,	O	O
and	CC	O	O
headache	NN	B-NP	B
.	.	O	O

All	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
self	AFX	B-ADJP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
.	.	O	O

Cardiac	JJ	B-NP	O
Angiography	NN	I-NP	O
in	IN	B-PP	O
Renally	RB	B-NP	O
Impaired	JJ	I-NP	O
Patients	NNS	I-NP	O
(	(	O	O
CARE	NN	B-NP	O
)	)	O	O
study	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
contrast	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
kidney	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

No	DT	B-NP	O
direct	JJ	I-NP	O
comparisons	NNS	I-NP	O
exist	VBP	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
osmolality	NN	I-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
iopamidol	NN	I-NP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
iso	AFX	I-NP	O
-	HYPH	I-NP	O
osmolality	NN	I-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
iodixanol	NN	I-NP	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
multicenter	NN	I-NP	O
,	,	O	O
randomized	VBN	B-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
iopamidol	NN	B-NP	O
and	CC	I-NP	O
iodixanol	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
kidney	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
estimated	VBN	B-NP	O
glomerular	JJ	I-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mL	NN	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
)	)	O	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
cardiac	JJ	B-NP	O
angiography	NN	I-NP	O
or	CC	O	O
percutaneous	JJ	B-NP	O
coronary	JJ	I-NP	O
interventions	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
creatinine	NN	I-NP	O
(	(	O	O
SCr	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
and	CC	O	O
estimated	VBN	B-NP	O
glomerular	JJ	I-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
medications	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
outcome	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
postdose	JJ	I-NP	O
SCr	NN	I-NP	O
increase	NN	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
)	)	O	O
over	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

Secondary	JJ	B-NP	O
outcomes	NNS	I-NP	O
were	VBD	B-VP	O
a	DT	B-NP	O
postdose	JJ	I-NP	O
SCr	NN	I-NP	O
increase	NN	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
postdose	JJ	I-NP	O
estimated	VBN	I-NP	O
glomerular	JJ	I-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
>	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
peak	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
SCr	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
contrast	NN	B-NP	O
volume	NN	I-NP	O
,	,	O	O
presence	NN	B-NP	O
of	IN	B-PP	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
,	,	O	O
use	NN	B-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
acetylcysteine	NN	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
baseline	NN	I-NP	O
SCr	NN	I-NP	O
,	,	O	O
and	CC	O	O
estimated	VBN	B-NP	O
glomerular	JJ	I-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

SCr	NN	B-NP	O
increases	VBZ	B-VP	O
>	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
after	IN	B-PP	O
iopamidol	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
after	IN	B-PP	O
iodixanol	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
rates	NNS	B-NP	O
of	IN	B-PP	O
SCr	NN	B-NP	O
increases	VBZ	B-VP	O
>	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
diabetes	NN	B-NP	B
,	,	O	O
SCr	NN	B-NP	O
increases	VBZ	B-VP	O
>	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
iopamidol	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
iodixanol	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
SCr	NN	B-NP	O
increases	VBZ	B-VP	O
>	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Mean	JJ	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
SCr	NN	I-NP	O
increases	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
with	IN	B-PP	O
iopamidol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
contrast	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
defined	VBN	B-VP	O
by	IN	B-PP	O
multiple	JJ	B-NP	O
end	NN	I-NP	O
points	NNS	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
not	RB	O	O
statistically	RB	B-ADJP	O
different	JJ	I-ADJP	O
after	IN	B-PP	O
the	DT	B-NP	O
intraarterial	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
iopamidol	NN	B-NP	O
or	CC	I-NP	O
iodixanol	NN	I-NP	O
to	TO	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
.	.	O	O

Any	DT	B-NP	O
true	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
agents	NNS	I-NP	O
is	VBZ	B-VP	O
small	JJ	B-ADJP	O
and	CC	O	O
not	RB	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
clinically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

A	DT	B-NP	O
novel	JJ	I-NP	O
compound	NN	I-NP	O
,	,	O	O
maltolyl	NN	B-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
coumarate	NN	I-NP	O
,	,	O	O
attenuates	VBZ	B-VP	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
and	CC	O	O
shows	VBZ	B-VP	O
neuroprotective	JJ	B-NP	O
effects	NNS	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-NP	O
vivo	FW	I-NP	O
dementia	NN	I-NP	B
models	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
develop	VB	I-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
and	CC	I-NP	O
effective	JJ	I-NP	O
drug	NN	I-NP	O
that	WDT	B-NP	O
could	MD	B-VP	O
enhance	VB	I-VP	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
neuroprotection	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
newly	RB	B-ADVP	O
synthesized	VBD	B-VP	O
maltolyl	NN	B-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
coumarate	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
esterification	NN	I-NP	O
of	IN	B-PP	O
maltol	NN	B-NP	O
and	CC	I-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
coumaric	JJ	I-NP	O
acid	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
whether	IN	B-SBAR	O
maltolyl	NN	B-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
coumarate	NN	I-NP	O
could	MD	B-VP	O
improve	VB	I-VP	O
cognitive	JJ	B-NP	B
decline	NN	I-NP	I
in	IN	B-PP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
injected	VBN	I-NP	O
rats	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
amyloid	JJ	B-NP	O
beta	SYM	I-NP	O
peptide	NN	I-NP	O
-	HYPH	B-NP	O
infused	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Maltolyl	JJ	B-NP	O
p	NN	I-NP	O
-	HYPH	O	O
coumarate	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
attenuate	VB	I-VP	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
rat	NN	I-NP	O
models	NNS	I-NP	O
using	VBG	B-VP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
test	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
reduce	VB	I-VP	O
apoptotic	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
amyloid	NN	I-NP	O
beta	SYM	B-NP	O
peptide	NN	I-NP	O
-	HYPH	B-NP	O
infused	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
neuroprotective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
maltolyl	NN	B-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
coumarate	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
using	VBG	B-VP	O
SH	NN	B-NP	O
-	HYPH	I-NP	O
SY5Y	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

Cells	NNS	B-NP	O
were	VBD	B-VP	O
pretreated	VBN	I-VP	O
with	IN	B-PP	O
maltolyl	NN	B-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
coumarate	NN	I-NP	O
,	,	O	O
before	IN	B-SBAR	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
amyloid	JJ	B-NP	O
beta	NN	I-NP	O
peptide	NN	I-NP	O
,	,	O	O
glutamate	NN	B-NP	O
or	CC	I-NP	O
H2O2	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
maltolyl	NN	B-NP	O
p	NN	I-NP	O
-	HYPH	O	O
coumarate	NN	B-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	O
apoptotic	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
reactive	JJ	I-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
,	,	O	O
cytochrome	NN	B-NP	O
c	NN	I-NP	O
release	NN	I-NP	O
,	,	O	O
and	CC	O	O
caspase	NN	B-NP	O
num	CD	I-NP	O
activation	NN	I-NP	O
.	.	O	O

Taking	VBG	B-VP	O
these	DT	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
and	CC	O	O
in	FW	B-NP	O
vivo	FW	I-NP	O
results	NNS	I-NP	O
together	RB	B-ADVP	O
,	,	O	O
our	PRP$	B-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
maltolyl	NN	B-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
coumarate	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
effective	JJ	I-NP	O
candidate	NN	I-NP	O
against	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
that	WDT	B-NP	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
wide	JJ	B-NP	O
spread	NN	I-NP	O
neuronal	JJ	I-NP	B
death	NN	I-NP	I
and	CC	O	O
progressive	JJ	B-NP	O
decline	NN	I-NP	B
of	IN	B-PP	I
cognitive	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

Interaction	NN	B-NP	O
between	IN	B-PP	O
warfarin	NN	B-NP	O
and	CC	I-NP	O
levofloxacin	NN	I-NP	O
:	:	O	O
case	NN	B-NP	O
series	NN	I-NP	O
.	.	O	O

Warfarin	NNP	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
oral	JJ	I-NP	O
anticoagulant	NN	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
indicated	VBN	I-VP	O
for	IN	B-PP	O
many	JJ	B-NP	O
clinical	JJ	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Levofloxacin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
fluoroquinolone	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
commonly	RB	I-NP	O
prescribed	VBN	I-NP	O
antibiotics	NNS	I-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
practice	NN	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
against	IN	B-PP	O
Gram	NN	B-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
,	,	I-NP	O
Gram	NN	I-NP	O
-	HYPH	I-NP	O
negative	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
atypical	JJ	B-NP	O
bacteria	NNS	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
small	JJ	B-NP	O
prospective	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
revealed	VBN	I-VP	O
any	DT	B-NP	O
significant	JJ	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
warfarin	NN	B-NP	O
and	CC	I-NP	O
levofloxacin	NN	I-NP	O
,	,	O	O
several	JJ	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
indicated	VBN	I-VP	O
that	IN	B-SBAR	O
levofloxacin	NN	B-NP	O
may	MD	B-VP	O
significantly	RB	I-VP	O
potentiate	VB	I-VP	O
the	DT	B-NP	O
anticoagulation	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
bleeding	VBG	I-NP	B
complications	NNS	I-NP	O
that	WDT	B-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
warfarin	NN	B-NP	O
and	CC	I-NP	O
levofloxacin	NN	I-NP	O
.	.	O	O

Physicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
potential	JJ	I-NP	O
interaction	NN	I-NP	O
and	CC	I-NP	O
use	NN	I-NP	O
caution	NN	I-NP	O
when	WRB	B-ADVP	O
prescribing	VBG	B-VP	O
levofloxacin	NN	B-NP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
warfarin	NN	B-NP	O
.	.	O	O

Mutations	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
lamivudine	NN	B-NP	O
-	HYPH	B-NP	O
resistance	NN	I-NP	O
in	IN	B-PP	O
therapy	NN	B-NP	O
-	HYPH	B-NP	O
na	NN	I-NP	O
ve	NN	I-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
virus	NN	I-NP	I
(	(	O	I
HBV	NN	B-NP	I
)	)	O	I
infected	JJ	B-NP	I
patients	NNS	I-NP	O
with	IN	B-PP	O
and	CC	I-PP	O
without	IN	I-PP	O
HIV	NN	B-NP	B
co	AFX	O	I
-	HYPH	B-NP	I
infection	NN	I-NP	I
:	:	O	O
implications	NNS	B-NP	O
for	IN	B-PP	O
antiretroviral	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
HBV	NN	B-NP	B
and	CC	I-NP	I
HIV	NN	I-NP	I
co	AFX	O	I
-	HYPH	O	I
infected	VBN	B-VP	I
South	JJ	B-NP	O
African	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
an	DT	B-NP	O
exploratory	JJ	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
lamivudine	NN	B-NP	O
-	HYPH	B-NP	O
resistant	JJ	I-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
(	(	O	O
HBV	NN	B-NP	O
)	)	O	O
strains	NNS	B-NP	O
in	IN	B-PP	O
selected	VBN	B-NP	O
lamivudine	NN	I-NP	O
-	HYPH	I-NP	O
na	NN	I-NP	O
ve	NN	I-NP	O
HBV	NN	I-NP	O
carriers	NNS	I-NP	O
with	IN	B-PP	O
and	CC	O	O
without	IN	B-PP	O
human	JJ	B-NP	B
immunodeficiency	NN	I-NP	I
virus	NN	I-NP	I
(	(	O	I
HIV	NN	B-NP	I
)	)	O	I
co	AFX	O	I
-	HYPH	B-NP	I
infection	NN	I-NP	I
in	IN	B-PP	O
South	JJ	B-NP	O
African	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
lamivudine	NN	I-NP	O
-	HYPH	I-NP	O
na	NN	I-NP	O
ve	NN	I-NP	O
HBV	NN	I-NP	B
infected	JJ	B-NP	I
patients	NNS	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
HIV	NN	B-NP	B
co	AFX	O	I
-	HYPH	B-NP	I
infection	NN	I-NP	I
were	VBD	B-VP	O
studied	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
chronic	JJ	I-NP	O
HBV	NN	I-NP	B
mono	AFX	O	I
-	HYPH	B-NP	I
infected	VBN	B-NP	I
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
HBV	NN	I-NP	B
-	HYPH	B-NP	I
HIV	NN	I-NP	I
co	AFX	O	I
-	HYPH	B-NP	I
infected	VBN	B-NP	I
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
latter	JJ	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
further	JJ	B-ADJP	O
sub	AFX	O	O
-	HYPH	O	O
divided	VBN	B-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
occult	JJ	I-NP	O
HBV	NN	I-NP	O
(	(	O	O
HBsAg	NN	B-NP	O
-	HYPH	O	O
negative	JJ	B-ADJP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
overt	JJ	I-NP	O
HBV	NN	I-NP	O
(	(	O	O
HBsAg	NN	B-NP	O
-	HYPH	O	O
positive	JJ	O	O
)	)	O	O
patients	NNS	B-NP	O
.	.	O	O

HBsAg	NN	B-NP	O
,	,	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
HBs	NNS	I-NP	O
,	,	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
HBc	NN	B-NP	O
,	,	O	O
and	CC	O	O
anti	AFX	O	O
-	HYPH	O	O
HIV	NN	B-NP	O
num	CD	I-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
routine	JJ	B-NP	O
diagnosis	NN	I-NP	O
using	VBG	B-VP	O
Axsym	NN	B-NP	O
assays	NNS	I-NP	O
(	(	O	O
Abbott	NNP	B-NP	O
Laboratories	NNP	I-NP	O
,	,	O	O
North	NNP	B-NP	O
Chicago	NNP	I-NP	O
,	,	O	O
IL	NNP	B-NP	O
)	)	O	O
.	.	O	O

Serum	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
PCR	NN	B-NP	O
amplified	VBN	B-VP	O
with	IN	B-PP	O
HBV	NN	B-NP	O
reverse	JJ	I-NP	O
transcriptase	NN	I-NP	O
(	(	O	O
RT	NN	B-NP	O
)	)	O	O
primers	NNS	B-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
direct	JJ	B-NP	O
sequencing	NN	I-NP	O
across	IN	B-PP	O
the	DT	B-NP	O
tyrosine	NN	I-NP	O
-	HYPH	B-NP	O
methionine	NN	I-NP	O
-	HYPH	B-NP	O
aspartate	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
YMDD	NN	B-NP	O
)	)	O	O
motif	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
catalytic	JJ	I-NP	O
region	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
C	NN	I-NP	O
domain	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
HBV	NN	I-NP	O
RT	NN	I-NP	O
enzyme	NN	I-NP	O
.	.	O	O

HBV	NN	B-NP	O
viral	JJ	I-NP	O
load	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
Amplicor	NNP	B-NP	O
HBV	NNP	I-NP	O
Monitor	NNP	I-NP	O
test	NN	I-NP	O
v2.0	NN	I-NP	O
(	(	O	O
Roche	NNP	B-NP	O
Diagnostics	NNP	I-NP	O
,	,	O	O
Penzberg	NNP	B-NP	O
,	,	O	O
Germany	NNP	B-NP	O
)	)	O	O
.	.	O	O

HBV	NN	B-NP	O
lamivudine	NN	I-NP	O
-	HYPH	O	O
resistant	JJ	B-NP	O
strains	NNS	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mono	AFX	I-NP	O
-	HYPH	I-NP	O
infected	VBN	I-NP	O
chronic	JJ	I-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
HBV	NN	I-NP	B
-	HYPH	I-NP	I
HIV	NN	I-NP	I
co	AFX	O	I
-	HYPH	B-NP	I
infected	VBN	B-NP	I
patients	NNS	I-NP	O
.	.	O	O

To	TO	B-PP	O
the	DT	B-NP	O
best	JJS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
constitutes	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
lamivudine	NN	I-NP	O
-	HYPH	O	O
resistant	JJ	B-NP	O
strains	NNS	I-NP	O
in	IN	B-PP	O
therapy	NN	B-NP	O
-	HYPH	B-NP	O
na	NN	I-NP	O
ve	NN	I-NP	O
HBV	NN	I-NP	B
-	HYPH	B-NP	I
HIV	NN	I-NP	I
co	AFX	O	I
-	HYPH	B-NP	I
infected	VBN	B-NP	I
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
HBV	NN	I-NP	O
viral	JJ	I-NP	O
loads	NNS	I-NP	O
for	IN	B-PP	O
mono	AFX	B-NP	O
-	HYPH	I-NP	O
infected	VBN	B-VP	O
and	CC	O	O
co	AFX	O	O
-	HYPH	B-NP	O
infected	VBN	B-NP	O
patients	NNS	I-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
x	CC	I-NP	O
num	CD	I-NP	O
and	CC	O	O
<	SYM	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
copies	NNS	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

It	PRP	B-NP	O
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
seen	VBN	I-VP	O
whether	IN	B-SBAR	O
such	JJ	B-NP	O
pre	AFX	I-NP	O
-	HYPH	B-PP	O
existing	VBG	B-NP	O
antiviral	JJ	I-NP	O
mutations	NNS	I-NP	O
could	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
widespread	JJ	B-NP	O
emergence	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
resistant	JJ	I-NP	O
strains	NNS	I-NP	O
when	WRB	B-ADVP	O
lamivudine	NN	B-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
highly	RB	B-NP	O
active	JJ	I-NP	O
antiretroviral	JJ	I-NP	O
(	(	O	O
ARV	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
(	(	O	O
HAART	NN	B-NP	O
)	)	O	O
regimens	NNS	B-NP	O
become	VBP	B-VP	O
widely	RB	I-VP	O
applied	VBN	I-VP	O
in	IN	B-PP	O
South	NNP	B-NP	O
Africa	NNP	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
this	DT	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
potential	JJ	B-NP	O
implications	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	B
-	HYPH	B-NP	I
HIV	NN	I-NP	I
co	AFX	O	I
-	HYPH	B-NP	I
infected	VBN	B-NP	I
patients	NNS	I-NP	O
.	.	O	O

Sex	NN	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
NMDA	NN	B-NP	O
antagonist	NN	I-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
antihyperalgesia	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
capsaicin	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
pain	NN	I-NP	B
:	:	O	O
comparisons	NNS	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
acute	JJ	B-NP	B
pain	NN	I-NP	I
models	NNS	I-NP	O
,	,	O	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
antagonists	NNS	B-NP	O
enhance	VBP	B-VP	O
the	DT	B-NP	O
antinociceptive	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
extent	NN	I-NP	O
in	IN	B-PP	O
males	NNS	B-NP	O
than	IN	B-PP	O
females	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
investigation	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
extend	VB	I-VP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
persistent	JJ	I-NP	O
pain	NN	I-NP	B
model	NN	I-NP	O
which	WDT	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
distinguished	VBN	I-VP	O
from	IN	B-PP	O
acute	JJ	B-NP	B
pain	NN	I-NP	I
models	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nociceptive	JJ	I-NP	O
fibers	NNS	I-NP	O
activated	VBN	B-VP	O
,	,	O	O
neurochemical	JJ	B-NP	O
substrates	NNS	I-NP	O
,	,	O	O
and	CC	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nociceptive	JJ	I-NP	O
stimulus	NN	I-NP	O
.	.	O	O

To	TO	B-PP	O
this	DT	B-NP	O
end	NN	I-NP	O
,	,	O	O
persistent	JJ	B-NP	O
hyperalgesia	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
tail	NN	I-NP	O
of	IN	B-PP	O
gonadally	RB	B-NP	O
intact	JJ	I-NP	O
F344	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
following	VBG	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
tail	NN	I-NP	O
was	VBD	B-VP	O
immersed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
mildly	RB	I-NP	O
noxious	JJ	I-NP	O
thermal	JJ	I-NP	O
stimulus	NN	I-NP	O
,	,	O	O
and	CC	O	O
tail	NN	B-NP	O
-	HYPH	B-NP	O
withdrawal	NN	I-NP	O
latencies	NNS	I-NP	O
measured	VBN	B-VP	O
.	.	O	O

For	IN	B-PP	O
comparison	NN	B-NP	O
,	,	O	O
tests	NNS	B-NP	O
were	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
acute	JJ	I-NP	B
pain	NN	I-NP	I
models	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
hotplate	NN	I-NP	O
and	CC	I-NP	O
warm	JJ	I-NP	O
water	NN	I-NP	O
tail	NN	I-NP	O
-	HYPH	B-NP	O
withdrawal	NN	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
males	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
competitive	JJ	I-NP	O
NMDA	NN	I-NP	O
antagonist	NN	I-NP	O
dextromethorphan	NN	I-NP	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
antihyperalgesic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
and	CC	O	O
time	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

Across	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
and	CC	O	O
pretreatment	NN	B-NP	O
times	NNS	I-NP	O
examined	VBN	B-VP	O
,	,	O	O
enhancement	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
females	NNS	B-NP	O
.	.	O	O

Enhancement	NN	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
antinociception	NN	I-NP	O
by	IN	B-PP	O
dextromethorphan	NN	B-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
both	CC	B-NP	O
males	NNS	I-NP	O
and	CC	I-NP	O
females	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	B
pain	NN	I-NP	I
models	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
effect	NN	I-NP	O
being	VBG	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
males	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
demonstrate	VBP	B-VP	O
a	DT	B-NP	O
sexually	RB	I-NP	O
-	HYPH	I-NP	O
dimorphic	JJ	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
NMDA	NN	B-NP	O
antagonists	NNS	I-NP	O
and	CC	O	O
morphine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
persistent	JJ	I-NP	O
pain	NN	I-NP	B
model	NN	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
distinguished	VBN	I-VP	O
from	IN	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
acute	JJ	B-NP	B
pain	NN	I-NP	I
models	NNS	I-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
after	IN	B-PP	O
switch	NN	B-NP	O
to	TO	B-PP	O
sirolimus	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
immunosuppression	NN	I-NP	O
in	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
cardiac	JJ	I-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Calcineurin	NN	B-NP	O
-	HYPH	I-NP	O
inhibitor	NN	I-NP	O
therapy	NN	I-NP	O
can	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
heart	NN	B-NP	O
transplantation	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
novel	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
(	(	O	O
IS	NN	B-NP	O
)	)	O	O
drug	NN	B-NP	O
sirolmus	NN	I-NP	O
(	(	O	O
Srl	NN	B-NP	O
)	)	O	O
lacks	VBZ	B-VP	O
nephrotoxic	JJ	B-NP	B
effects	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
proteinuria	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
Srl	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
following	VBG	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
cardiac	JJ	B-NP	O
transplantation	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
Srl	NN	B-NP	O
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
cardiac	JJ	I-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
switched	VBN	I-VP	O
from	IN	B-PP	O
cyclosporine	NN	B-NP	O
to	TO	B-PP	O
Srl	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
IS	NN	I-NP	O
.	.	O	O

Concomitant	JJ	B-NP	O
IS	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
mycophenolate	NN	B-NP	O
mofetil	NN	I-NP	O
+	SYM	B-NP	O
/	SYM	B-VP	O
-	HYPH	B-ADVP	O
steroids	NNS	B-NP	O
.	.	O	O

Proteinuria	NNP	B-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
from	IN	B-PP	O
a	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
preswitch	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
postswitch	VBP	B-VP	O
.	.	O	O

Before	IN	B-PP	O
the	DT	B-NP	O
switch	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
grade	NN	I-NP	O
proteinuria	NN	I-NP	B
;	:	O	O
this	DT	B-NP	O
increased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
postswitch	NN	I-NP	O
.	.	O	O

ACE	NN	B-NP	O
inhibitor	NN	I-NP	O
and	CC	I-NP	O
angiotensin	NN	I-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
blocker	NN	B-NP	O
(	(	O	O
ARB	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
reduced	VBD	B-VP	O
proteinuria	NN	B-NP	B
development	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
without	IN	B-PP	O
proteinuria	NN	B-NP	B
had	VBD	B-VP	O
increased	VBN	I-VP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
patients	NNS	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
grade	NN	I-NP	O
proteinuria	NN	I-NP	B
showed	VBD	B-VP	O
decreased	VBN	I-VP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
proteinuria	NN	B-NP	B
may	MD	B-VP	O
develop	VB	I-VP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
after	IN	B-PP	O
switch	NN	B-NP	O
to	TO	B-PP	O
Srl	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Srl	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
ACEi	NN	B-NP	O
/	SYM	I-NP	O
ARB	NN	I-NP	O
therapy	NN	I-NP	O
and	CC	O	O
patients	NNS	B-NP	O
monitored	VBN	B-VP	O
for	IN	B-PP	O
proteinuria	NN	B-NP	B
and	CC	O	O
increased	VBD	B-VP	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Synthesis	NN	B-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
pyrimidinyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
phenoxyacetamides	NNS	I-NP	O
as	IN	B-PP	O
adenosine	NN	B-NP	O
A2A	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
pyrimidinyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
phenoxyacetamide	NN	I-NP	O
adenosine	NN	I-NP	O
A	NN	I-NP	O
(	(	O	O
2A	NN	B-NP	O
)	)	O	O
antagonists	NNS	B-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

SAR	NN	B-NP	O
studies	NNS	I-NP	O
led	VBD	B-VP	O
to	TO	I-VP	O
compound	VB	I-VP	O
num	CD	B-NP	O
with	IN	B-PP	O
excellent	JJ	B-NP	O
potency	NN	I-NP	O
(	(	O	O
K	NN	B-NP	O
,	,	O	O
selectivity	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
/	SYM	I-NP	O
A	NN	I-NP	O
,	,	O	O
and	CC	O	O
efficacy	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
haloperidol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
model	NN	I-NP	O
for	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Methamphetamine	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
neurotoxicity	NN	I-NP	B
and	CC	O	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
fractalkine	NN	B-NP	O
receptor	NN	I-NP	O
signaling	NN	I-NP	O
.	.	O	O

Methamphetamine	NN	B-NP	O
(	(	O	O
METH	NN	B-NP	O
)	)	O	O
damages	NNS	B-NP	O
dopamine	NN	I-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
nerve	NN	B-NP	O
endings	NNS	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
process	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
linked	VBN	I-VP	O
to	TO	B-PP	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
but	CC	O	O
the	DT	B-NP	O
signaling	NN	I-NP	O
pathways	NNS	I-NP	O
that	WDT	B-NP	O
mediate	VBP	B-VP	O
this	DT	B-NP	O
response	NN	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
yet	RB	I-VP	O
been	VBN	I-VP	O
delineated	VBN	I-VP	O
.	.	O	O

Cardona	NNP	B-NP	O
et	FW	I-NP	O
al.	FW	I-NP	O
[	(	O	O
Nat	NNP	B-NP	O
.	.	O	O

Neurosci.	NNP	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
]	)	O	O
recently	RB	B-ADVP	O
identified	VBD	B-VP	O
the	DT	B-NP	O
microglial	JJ	I-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
fractalkine	NN	I-NP	O
receptor	NN	I-NP	O
(	(	O	O
CX3CR1	NN	B-NP	O
)	)	O	O
as	IN	B-PP	O
an	DT	B-NP	O
important	JJ	I-NP	O
mediator	NN	I-NP	O
of	IN	B-PP	O
MPTP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurodegeneration	NN	I-NP	B
of	IN	B-PP	O
DA	NN	B-NP	O
neurons	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
the	DT	B-NP	O
CNS	NN	I-NP	B
damage	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
METH	NN	B-NP	O
and	CC	I-NP	O
MPTP	NN	I-NP	O
is	VBZ	B-VP	O
highly	RB	B-ADJP	O
selective	JJ	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
DA	NN	I-NP	O
neuronal	JJ	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
mouse	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
neurotoxicity	NN	B-NP	B
,	,	O	O
we	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
CX3CR1	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
METH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
and	CC	O	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
.	.	O	O

Mice	NNS	B-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
CX3CR1	NN	I-NP	O
gene	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
deleted	VBN	I-VP	O
and	CC	O	O
replaced	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
cDNA	NN	I-NP	O
encoding	NN	I-NP	O
enhanced	VBD	B-VP	O
green	JJ	B-NP	O
fluorescent	JJ	I-NP	O
protein	NN	I-NP	O
(	(	O	O
eGFP	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
METH	NN	B-NP	O
and	CC	O	O
examined	VBN	B-VP	O
for	IN	B-PP	O
striatal	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

METH	NN	B-NP	O
depleted	VBD	B-VP	O
DA	NNP	B-NP	O
,	,	O	O
caused	VBD	B-VP	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
,	,	O	O
and	CC	O	O
increased	VBD	B-VP	O
body	NN	B-NP	O
temperature	NN	I-NP	O
in	IN	B-PP	O
CX3CR1	NN	B-NP	O
knockout	NN	I-NP	O
mice	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
extent	NN	I-NP	O
and	CC	O	O
over	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
in	IN	B-PP	O
CX3CR1	NN	B-NP	O
knockout	NN	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
gender	NN	B-NP	O
-	HYPH	B-ADJP	O
dependent	JJ	I-ADJP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
extend	VB	I-VP	O
beyond	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
.	.	O	O

Striatal	JJ	B-NP	O
microglia	NNS	I-NP	O
expressing	VBG	B-VP	O
eGFP	NN	B-NP	O
constitutively	RB	B-VP	O
show	VBP	I-VP	O
morphological	JJ	B-NP	O
changes	NNS	I-NP	O
after	IN	B-PP	O
METH	NN	B-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
characteristic	JJ	B-ADJP	O
of	IN	B-PP	O
activation	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
restricted	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
and	CC	O	O
contrasted	VBN	B-VP	O
sharply	RB	B-ADVP	O
with	IN	B-PP	O
unresponsive	JJ	B-NP	O
eGFP	NN	I-NP	O
-	HYPH	B-NP	O
microglia	NN	I-NP	O
in	IN	B-PP	O
surrounding	VBG	B-VP	O
brain	NN	B-NP	O
areas	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
damaged	VBN	I-VP	O
by	IN	B-PP	O
METH	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
from	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
that	IN	B-NP	O
CX3CR1	NN	B-NP	O
signaling	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
modulate	VB	I-VP	O
METH	NN	B-NP	O
neurotoxicity	NN	I-NP	B
or	CC	O	O
microglial	JJ	B-NP	O
activation	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
appears	VBZ	B-VP	O
that	IN	B-SBAR	O
striatal	JJ	B-NP	O
-	HYPH	I-NP	O
resident	JJ	I-NP	O
microglia	NNS	I-NP	O
respond	VBP	B-VP	O
to	TO	B-PP	O
METH	NN	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
activation	NN	I-NP	O
cascade	NN	I-NP	O
and	CC	O	O
then	RB	B-VP	O
return	VB	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
surveying	VBG	I-NP	O
state	NN	I-NP	O
without	IN	B-PP	O
undergoing	VBG	B-VP	O
apoptosis	NN	B-NP	O
or	CC	I-NP	O
migration	NN	I-NP	O
.	.	O	O

Recovery	NN	B-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
brachial	JJ	I-NP	B
neuritis	NN	I-NP	I
after	IN	B-PP	O
conversion	NN	B-NP	O
to	TO	B-PP	O
everolimus	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
pediatric	JJ	I-NP	O
renal	JJ	I-NP	O
transplant	NN	I-NP	O
recipient	NN	I-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
and	CC	O	O
review	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

TAC	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
solid	JJ	B-NP	O
organ	NN	I-NP	O
transplantation	NN	I-NP	O
in	IN	B-PP	O
pediatrics	NNS	B-NP	O
.	.	O	O

Neurotoxicity	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
serious	JJ	I-NP	O
toxic	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
encephalopathy	NN	B-NP	B
,	,	O	O
headaches	NNS	B-NP	B
,	,	O	O
seizures	NNS	B-NP	B
,	,	O	O
or	CC	O	O
neurological	JJ	B-NP	B
deficits	NNS	I-NP	I
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
-	HYPH	I-NP	O
a	SYM	B-NP	O
-	HYPH	I-NP	O
half	JJ	I-NP	O
-	HYPH	I-NP	O
yr	NN	I-NP	O
-	HYPH	I-NP	O
old	JJ	I-NP	O
male	JJ	I-NP	O
renal	JJ	I-NP	O
transplant	NN	I-NP	O
recipient	NN	I-NP	O
with	IN	B-PP	O
right	JJ	B-NP	O
BN	NN	I-NP	O
.	.	O	O

MRI	NN	B-NP	O
demonstrated	VBD	B-VP	O
hyperintense	JJ	B-NP	O
T2	NN	I-NP	O
signals	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cervical	JJ	I-NP	O
cord	NN	I-NP	O
and	CC	O	O
right	JJ	B-NP	O
brachial	JJ	I-NP	O
plexus	NN	I-NP	O
roots	NNS	I-NP	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
both	CC	O	O
myelitis	NN	B-NP	B
and	CC	O	O
right	JJ	B-NP	O
brachial	JJ	I-NP	B
plexitis	NN	I-NP	I
.	.	O	O

Symptoms	NNS	B-NP	O
persisted	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
despite	IN	B-PP	O
TAC	NN	B-NP	O
dose	NN	I-NP	O
reduction	NN	I-NP	O
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
IVIG	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
pulse	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Improvement	NN	B-NP	O
and	CC	O	O
eventually	RB	B-ADVP	O
full	JJ	B-NP	O
recovery	NN	I-NP	O
only	RB	B-ADVP	O
occurred	VBD	B-VP	O
after	IN	B-SBAR	O
TAC	NN	B-NP	O
was	VBD	B-VP	O
completely	RB	I-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
successfully	RB	B-VP	O
replaced	VBN	I-VP	O
by	IN	B-PP	O
everolimus	NN	B-NP	O
.	.	O	O

Valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
pergolide	NN	B-NP	O
.	.	O	O

Course	NN	B-NP	O
following	VBG	B-PP	O
treatment	NN	B-NP	O
modifications	NNS	I-NP	O
.	.	O	O

Valvular	JJ	B-NP	B
heart	NN	I-NP	I
abnormalities	NNS	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
pergolide	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
abnormalities	NNS	I-NP	O
vary	VBP	B-VP	O
from	IN	B-PP	O
study	NN	B-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
and	CC	O	O
their	PRP$	B-NP	O
course	NN	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
withdrawal	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
systematically	RB	I-VP	O
assessed	VBN	I-VP	O
.	.	O	O

To	TO	B-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
abnormality	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
possible	JJ	I-NP	O
reversibility	NN	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
withdrawal	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
PD	NN	I-NP	B
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Amiens	NNP	I-NP	O
area	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
pergolide	NN	B-NP	O
were	VBD	B-VP	O
invited	VBN	I-VP	O
to	TO	B-VP	O
attend	VB	I-VP	O
a	DT	B-NP	O
cardiologic	JJ	I-NP	O
assessment	NN	I-NP	O
including	VBG	B-PP	O
transthoracic	JJ	B-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
PD	NN	I-NP	B
patients	NNS	I-NP	O
participated	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
second	JJ	I-NP	O
echocardiography	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
(	(	O	O
median	JJ	B-NP	O
interval	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
after	IN	B-PP	O
pergolide	NN	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

Controls	NNS	B-NP	O
were	VBD	B-VP	O
age	NN	B-NP	O
-	HYPH	B-ADJP	O
and	CC	O	O
sex	NN	B-NP	O
-	HYPH	O	O
matched	VBN	B-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
PD	NN	B-NP	B
patients	NNS	I-NP	O
referred	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
cardiology	NN	I-NP	O
department	NN	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
aortic	JJ	B-NP	B
regurgitation	NN	I-NP	I
(	(	O	O
OR	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
IC	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
mitral	JJ	B-NP	B
regurgitation	NN	I-NP	I
(	(	O	O
OR	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
IC	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
in	IN	B-PP	O
PD	NN	B-NP	B
patients	NNS	I-NP	O
(	(	O	O
tricuspid	NN	B-NP	O
:	:	O	O
NS	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
affected	VBN	B-NP	O
valves	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
sum	NN	I-NP	O
of	IN	B-PP	O
regurgitation	NN	B-NP	O
grades	NNS	I-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
pergolide	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Severity	NN	B-NP	O
of	IN	B-PP	O
regurgitation	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
pergolide	NN	B-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
restrictive	JJ	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
valvular	JJ	B-NP	B
regurgitation	NN	I-NP	I
,	,	O	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
pergolide	NN	B-NP	O
,	,	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
including	VBG	B-PP	O
num	CD	B-NP	O
with	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Pergolide	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
regurgitation	NN	I-NP	O
grade	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
transthoracic	JJ	I-NP	O
echocardiography	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
returned	VBD	B-VP	O
to	TO	B-PP	O
nearly	RB	B-NP	O
normal	JJ	I-NP	O
clinical	JJ	I-NP	O
examination	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
high	JJ	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
restrictive	JJ	B-NP	O
valve	NN	I-NP	B
regurgitation	NN	I-NP	I
in	IN	B-PP	O
PD	NN	B-NP	B
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
pergolide	NN	B-NP	O
and	CC	O	O
reveals	VBZ	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
significant	JJ	I-NP	O
improvement	NN	I-NP	O
is	VBZ	B-VP	O
usual	JJ	B-ADJP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
converted	VBN	I-VP	O
to	TO	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
ergot	NN	I-NP	O
dopamine	NN	I-NP	O
agonists	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
topical	JJ	B-NP	O
papaverine	NN	I-NP	O
on	IN	B-PP	O
auditory	JJ	B-NP	O
nerve	NN	I-NP	O
function	NN	I-NP	O
.	.	O	O

Papaverine	NN	B-NP	O
hydrochloride	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	I-NP	O
vasodilator	NN	I-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
manage	VB	I-VP	O
vasospasm	NN	B-NP	B
during	IN	B-PP	O
various	JJ	B-NP	O
neurosurgical	JJ	I-NP	O
operations	NNS	I-NP	O
.	.	O	O

Transient	JJ	B-NP	O
cranial	JJ	I-NP	B
nerve	NN	I-NP	I
dysfunction	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
topical	JJ	B-NP	O
papaverine	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
supports	VBZ	B-VP	O
previous	JJ	B-NP	O
reports	NNS	I-NP	O
and	CC	O	O
provides	VBZ	B-VP	O
neurophysiological	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
auditory	JJ	I-NP	O
nerve	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
microvascular	JJ	I-NP	O
decompression	NN	I-NP	O
operations	NNS	I-NP	O
and	CC	O	O
studied	VBN	B-VP	O
those	DT	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
topical	JJ	B-NP	O
papaverine	NN	I-NP	O
for	IN	B-PP	O
vasospasm	NN	B-NP	B
.	.	O	O

Topical	JJ	B-NP	O
papaverine	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
therapeutic	JJ	I-NP	O
action	NN	I-NP	O
to	TO	B-VP	O
manage	VB	I-VP	O
vasospasm	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
timing	NN	I-NP	O
of	IN	B-PP	O
papaverine	NN	B-NP	O
application	NN	I-NP	O
and	CC	O	O
ongoing	JJ	B-NP	O
operative	JJ	I-NP	O
events	NNS	I-NP	O
was	VBD	B-VP	O
reviewed	VBN	I-VP	O
relative	JJ	B-ADVP	O
to	TO	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
neurophysiological	JJ	B-NP	O
recordings	NNS	I-NP	O
.	.	O	O

Brainstem	NN	B-NP	O
auditory	JJ	I-NP	O
evoked	JJ	I-NP	O
potentials	NNS	I-NP	O
(	(	O	O
BAEPs	NNS	B-NP	O
)	)	O	O
were	VBD	B-VP	O
routinely	RB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
monitor	VB	I-VP	O
cochlear	JJ	B-NP	O
nerve	NN	I-NP	O
function	NN	I-NP	O
during	IN	B-PP	O
these	DT	B-NP	O
operations	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
temporal	JJ	I-NP	O
relationship	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
topical	JJ	B-NP	O
papaverine	NN	I-NP	O
and	CC	I-NP	O
BAEP	NN	I-NP	O
changes	NNS	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
complete	JJ	B-NP	O
waveform	NN	I-NP	O
loss	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
temporal	JJ	I-NP	O
delay	NN	I-NP	O
between	IN	B-PP	O
papaverine	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
BAEP	NN	I-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
BAEP	NN	B-NP	O
waves	VBZ	B-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
V	NN	I-NP	O
completely	RB	B-ADVP	O
disappeared	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
papaverine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
complete	JJ	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
BAEP	NN	B-NP	O
waveforms	NNS	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
later	JJ	B-NP	O
waves	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
delayed	VBN	I-NP	O
profound	JJ	I-NP	O
sensorineural	JJ	I-NP	B
hearing	NN	I-NP	I
loss	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
recovery	NN	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
BAEP	NN	B-NP	O
waveforms	NNS	I-NP	O
to	TO	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
papaverine	NN	I-NP	O
baseline	NN	I-NP	O
values	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

Topical	JJ	B-NP	O
papaverine	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
vasospasm	NN	B-NP	B
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
disturbance	NN	I-NP	O
in	IN	B-PP	O
neurophysiological	JJ	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ascending	VBG	I-NP	O
auditory	JJ	I-NP	O
brainstem	NN	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
complete	JJ	I-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
BAEP	NN	B-NP	O
waveforms	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
consistent	JJ	I-NP	O
temporal	JJ	I-NP	O
delay	NN	I-NP	O
suggests	VBZ	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
adverse	JJ	I-NP	B
effect	NN	I-NP	I
on	IN	B-PP	I
the	DT	B-NP	I
proximal	JJ	I-NP	I
eighth	JJ	I-NP	I
nerve	NN	I-NP	I
.	.	O	O

Recommendations	NNS	B-NP	O
to	TO	B-VP	O
avoid	VB	I-VP	O
potential	JJ	B-NP	O
cranial	JJ	I-NP	B
nerve	NN	I-NP	I
deficits	NNS	I-NP	I
from	IN	B-PP	O
papaverine	NN	B-NP	O
are	VBP	B-VP	O
provided	VBN	I-VP	O
.	.	O	O

Massive	JJ	B-NP	O
proteinuria	NN	I-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
after	IN	B-PP	O
oral	JJ	B-NP	O
bisphosphonate	NN	I-NP	O
(	(	O	O
alendronate	NN	B-NP	O
)	)	O	O
administration	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
focal	JJ	B-NP	B
segmental	JJ	I-NP	I
glomerulosclerosis	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Japanese	JJ	I-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
focal	JJ	B-NP	B
segmental	JJ	I-NP	I
glomerulosclerosis	NN	I-NP	I
was	VBD	B-VP	O
initially	RB	I-VP	O
responding	VBG	I-VP	O
well	RB	B-ADVP	O
to	TO	B-PP	O
steroid	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
urinary	JJ	I-NP	O
protein	NN	I-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
.	.	O	O

Within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
oral	JJ	I-NP	O
bisphosphonate	NN	I-NP	O
(	(	O	O
alendronate	NN	B-NP	O
sodium	NN	I-NP	O
)	)	O	O
administration	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
urinary	JJ	I-NP	O
protein	NN	I-NP	O
increased	VBD	B-VP	O
rapidly	RB	B-ADVP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
discontinuing	VBG	B-VP	O
the	DT	B-NP	O
oral	JJ	I-NP	O
alendronate	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
underwent	VBD	B-VP	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
hemodialysis	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
LDL	NN	B-NP	O
apheresis	NN	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
volume	NN	I-NP	O
and	CC	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
recovered	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
range	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
urinary	JJ	B-NP	O
protein	NN	I-NP	O
disappearing	VBG	B-VP	O
completely	RB	B-ADVP	O
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
intravenous	JJ	B-ADJP	O
,	,	O	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
oral	JJ	B-NP	O
bisphosphonates	NNS	I-NP	O
can	MD	B-VP	O
aggravate	VB	I-VP	O
proteinuria	NN	B-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Serum	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
glucocorticoid	NN	I-NP	O
-	HYPH	I-NP	O
inducible	JJ	I-NP	O
kinase	NN	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
leads	VBZ	B-VP	O
to	TO	B-PP	O
epithelial	JJ	B-NP	O
sodium	NN	I-NP	O
channel	NN	I-NP	O
(	(	O	O
ENaC	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
volume	NN	I-NP	B
retention	NN	I-NP	I
and	CC	O	O
renal	JJ	B-NP	O
fibrosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
aldosterone	NN	I-NP	O
-	HYPH	O	O
sensitive	JJ	B-NP	O
serum	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
glucocorticoid	NN	I-NP	O
-	HYPH	I-NP	O
inducible	JJ	I-NP	O
kinase	NN	I-NP	O
SGK1	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
participate	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
ENaC	NN	B-NP	O
and	CC	O	O
to	TO	B-VP	O
mediate	VB	I-VP	O
renal	JJ	B-NP	O
fibrosis	NN	I-NP	B
following	VBG	B-PP	O
mineralocorticoid	NN	B-NP	O
and	CC	I-NP	O
salt	NN	I-NP	O
excess	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	I-VP	O
elucidate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
SGK1	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
volume	NN	I-NP	B
retention	NN	I-NP	I
and	CC	I-NP	O
fibrosis	NN	I-NP	B
during	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

To	TO	B-PP	O
this	DT	B-NP	O
end	NN	I-NP	O
,	,	O	O
doxorubicin	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
intravenously	RB	B-ADVP	O
into	IN	B-PP	O
gene	NN	B-NP	O
-	HYPH	B-NP	O
targeted	VBN	I-NP	O
mice	NNS	I-NP	O
lacking	VBG	B-VP	O
SGK1	NN	B-NP	O
(	(	O	O
sgk1	NN	B-NP	O
)	)	O	O
and	CC	O	O
their	PRP$	B-NP	O
wild	JJ	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
littermates	NNS	I-NP	O
(	(	O	O
sgk1	NN	B-NP	O
)	)	O	O
.	.	O	O

Doxorubicin	NN	B-NP	O
treatment	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
heavy	JJ	B-NP	O
proteinuria	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
sgk1	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
with	IN	B-PP	O
ascites	NNS	B-NP	B
,	,	O	O
lipidemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
hypoalbuminemia	NN	B-NP	B
in	IN	B-PP	O
both	DT	B-NP	O
genotypes	NNS	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
aldosterone	NN	I-NP	O
levels	NNS	I-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
nephrotic	JJ	B-NP	B
mice	NNS	I-NP	O
of	IN	B-PP	O
both	CC	O	O
genotypes	NNS	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
increased	VBN	B-NP	O
SGK1	NN	I-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
sodium	NN	I-NP	O
excretion	NN	I-NP	O
reached	VBD	B-VP	O
signficantly	RB	B-NP	O
lower	JJR	I-NP	O
values	NNS	I-NP	O
in	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
higher	JJR	I-NP	O
body	NN	I-NP	O
weight	NN	I-NP	B
gain	NN	I-NP	I
in	IN	B-PP	O
sgk1	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
,	,	O	O
serum	NN	B-NP	O
urea	NN	I-NP	O
concentrations	NNS	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADJP	O
faster	JJR	I-ADJP	O
in	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
uremia	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
median	NN	I-NP	O
survival	NN	I-NP	O
in	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
vs.	IN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
sgk1	NN	B-NP	O
mice	NNS	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
gene	NN	B-NP	O
-	HYPH	O	O
targeted	VBN	B-NP	O
mice	NNS	I-NP	O
lacking	VBG	B-VP	O
SGK1	NN	B-NP	O
showed	VBD	B-VP	O
blunted	JJ	B-NP	O
volume	NN	I-NP	B
retention	NN	I-NP	I
,	,	O	O
yet	RB	O	O
were	VBD	B-VP	O
not	RB	I-VP	O
protected	VBN	I-VP	O
against	IN	B-PP	O
renal	JJ	B-NP	O
fibrosis	NN	I-NP	B
during	IN	B-PP	O
experimental	JJ	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Severe	JJ	B-NP	O
and	CC	I-NP	O
long	JJ	I-NP	O
lasting	JJ	I-NP	O
cholestasis	NN	I-NP	B
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
co	AFX	O	O
-	HYPH	B-NP	O
trimoxazole	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
Pneumocystis	NN	B-NP	B
pneumonia	NN	I-NP	I
in	IN	B-PP	O
HIV	NN	B-NP	B
-	HYPH	O	I
infected	VBN	B-NP	I
patients	NNS	I-NP	O
-	SYM	O	O
-	HYPH	O	O
a	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Pneumocystis	NN	B-NP	B
pneumonia	NN	I-NP	I
(	(	O	O
PCP	NN	B-NP	B
)	)	O	O
,	,	O	O
a	DT	B-NP	O
common	JJ	I-NP	O
opportunistic	JJ	I-NP	B
infection	NN	I-NP	I
in	IN	B-PP	O
HIV	NN	B-NP	B
-	HYPH	B-NP	I
infected	VBN	I-NP	I
individuals	NNS	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
generally	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
trimoxazole	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
treatment	NN	B-NP	O
is	VBZ	B-VP	O
often	RB	I-VP	O
limited	VBN	I-VP	O
by	IN	B-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
severely	RB	B-NP	O
immunocompromised	VBN	I-NP	O
HIV	NN	I-NP	B
-	HYPH	B-NP	I
infected	VBN	I-NP	I
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
severe	JJ	B-NP	O
intrahepatic	JJ	I-NP	B
cholestasis	NN	I-NP	I
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
lesions	NNS	I-NP	O
mimicking	VBG	B-VP	O
liver	NN	B-NP	B
abscess	NN	I-NP	I
formation	NN	I-NP	O
on	IN	B-PP	O
radiologic	JJ	B-NP	O
exams	NNS	I-NP	O
,	,	O	O
during	IN	B-PP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
trimoxazole	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
PCP	NN	B-NP	B
.	.	O	O

Whereas	IN	B-SBAR	O
patient	NN	B-NP	O
num	CD	I-NP	O
showed	VBD	B-VP	O
lesions	NNS	B-NP	O
of	IN	B-PP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
cm	NN	I-NP	O
readily	RB	B-ADJP	O
detectable	JJ	I-ADJP	O
on	IN	B-PP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
under	IN	B-PP	O
prolonged	JJ	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
trimoxazole	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
therapy	NN	B-NP	O
of	IN	B-PP	O
patient	NN	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
switched	VBN	I-VP	O
early	RB	B-ADVP	O
.	.	O	O

Clinically	RB	B-NP	O
significant	JJ	I-NP	O
proteinuria	NN	I-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
to	TO	B-PP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
.	.	O	O

Sirolimus	NNP	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
latest	JJS	I-NP	O
immunosuppressive	JJ	I-NP	O
agent	NN	I-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
rejection	NN	B-NP	O
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
have	VB	I-VP	O
less	JJR	B-NP	O
nephrotoxicity	NN	I-NP	B
than	IN	B-PP	O
calcineurin	NN	B-NP	O
inhibitor	NN	I-NP	O
(	(	O	O
CNI	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
regimens	NNS	I-NP	O
.	.	O	O

To	TO	B-PP	O
date	NN	B-NP	O
there	EX	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
little	JJ	B-NP	O
documentation	NN	I-NP	O
of	IN	B-PP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
proteinuria	NN	I-NP	B
linked	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
encountered	VBN	I-VP	O
several	JJ	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
substantial	JJ	B-NP	O
proteinuria	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
sirolimus	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
each	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
close	JJ	I-NP	O
temporal	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
commencement	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	I-NP	O
proteinuria	NN	I-NP	B
implicated	VBD	B-VP	O
sirolimus	NN	B-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
likely	JJ	I-NP	O
etiology	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
analyzed	VBD	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
information	NN	I-NP	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
transplanted	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
Washington	NNP	I-NP	O
Hospital	NNP	I-NP	O
Center	NNP	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
for	IN	B-PP	O
whom	WP	B-NP	O
sirolimus	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
immunosuppressant	JJ	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
on	IN	B-PP	O
morning	NN	B-NP	O
urine	NN	I-NP	O
samples	NNS	I-NP	O
by	IN	B-PP	O
turbidometric	JJ	B-NP	O
measurement	NN	I-NP	O
or	CC	O	O
random	JJ	B-NP	O
urine	NN	I-NP	O
protein	NN	I-NP	O
:	:	O	O
creatinine	NN	B-NP	O
ratios	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
estimate	NN	I-NP	O
of	IN	B-PP	O
grams	NNS	B-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

Laboratory	NN	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
between	IN	B-PP	O
prior	JJ	B-NP	O
,	,	O	O
during	IN	B-PP	O
and	CC	O	O
following	VBG	B-PP	O
sirolimus	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
increased	VBN	B-NP	O
proteinuria	NN	I-NP	B
from	IN	B-PP	O
baseline	NN	B-NP	O
during	IN	B-PP	O
their	PRP$	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
transplantation	NN	I-NP	O
course	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
an	DT	B-NP	O
alternative	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
was	VBD	B-VP	O
either	CC	O	O
obvious	JJ	B-NP	O
or	CC	I-NP	O
insufficient	JJ	I-NP	O
data	NNS	I-NP	O
was	VBD	B-VP	O
available	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
conclusive	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
striking	JJ	I-NP	O
temporal	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
nephrotic	JJ	B-NP	B
-	HYPH	I-NP	O
range	NN	I-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

Proteinuria	NNP	B-NP	B
correlated	VBD	B-VP	O
most	RBS	B-ADVP	O
strongly	RB	I-ADVP	O
with	IN	B-PP	O
sirolimus	NN	B-NP	O
therapy	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
other	JJ	B-NP	O
demographic	JJ	I-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
variables	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
resolution	NN	B-NP	O
,	,	O	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
.	.	O	O

Sirolimus	NN	B-NP	O
induces	VBZ	B-VP	O
or	CC	I-VP	O
aggravates	VBZ	I-VP	O
pre	AFX	B-NP	O
-	HYPH	B-PP	O
existing	VBG	B-NP	O
proteinuria	NN	I-NP	B
in	IN	B-PP	O
an	DT	B-NP	O
unpredictable	JJ	I-NP	O
subset	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
allograft	NN	I-NP	O
recipients	NNS	I-NP	O
.	.	O	O

Proteinuria	NNP	B-NP	B
may	MD	B-VP	O
improve	VB	I-VP	O
,	,	O	O
but	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
resolve	VB	I-VP	O
,	,	O	O
when	WRB	B-ADVP	O
sirolimus	NN	B-NP	O
is	VBZ	B-VP	O
withdrawn	VBN	I-VP	O
.	.	O	O

Comparative	JJ	B-NP	O
cognitive	JJ	I-NP	O
and	CC	I-NP	O
subjective	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
immediate	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
oxycodone	NN	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
middle	JJ	I-NP	O
-	HYPH	I-NP	O
aged	JJ	I-NP	O
and	CC	I-NP	O
older	JJR	I-NP	O
adults	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
measured	VBD	B-VP	O
the	DT	B-NP	O
objective	JJ	I-NP	O
and	CC	I-NP	O
subjective	JJ	I-NP	O
neurocognitive	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
immediate	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
oxycodone	NN	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
,	,	O	O
older	JJR	B-ADJP	O
,	,	O	O
and	CC	O	O
middle	JJ	B-ADJP	O
-	HYPH	O	O
aged	JJ	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
adults	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
suffering	VBG	I-VP	O
from	IN	B-PP	O
chronic	JJ	B-NP	O
or	CC	I-NP	O
significant	JJ	I-NP	O
daily	JJ	I-NP	O
pain	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
participants	NNS	I-NP	O
completed	VBD	B-VP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
study	NN	I-NP	O
days	NNS	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
blind	JJ	B-ADJP	O
to	TO	B-PP	O
medication	NN	B-NP	O
condition	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
oxycodone	NN	I-NP	O
concentration	NN	I-NP	O
peaked	VBD	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
postdose	NN	I-NP	O
and	CC	I-NP	O
pupil	NN	I-NP	O
size	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
indication	NN	I-NP	O
of	IN	B-PP	O
physiological	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
,	,	O	O
peaked	VBD	B-VP	O
at	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
postdose	VBP	B-VP	O
.	.	O	O

Significant	JJ	B-NP	O
declines	NNS	I-NP	B
in	IN	B-PP	I
simple	JJ	B-NP	I
and	CC	I-NP	I
sustained	JJ	I-NP	I
attention	NN	I-NP	I
,	,	O	I
working	VBG	B-VP	I
memory	NN	B-NP	I
,	,	O	I
and	CC	O	I
verbal	JJ	B-NP	I
memory	NN	I-NP	I
were	VBD	B-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
hour	NN	I-NP	O
postdose	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
for	IN	B-PP	O
both	DT	B-NP	O
age	NN	I-NP	O
groups	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
trend	NN	I-NP	O
toward	IN	B-PP	O
return	NN	B-NP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
postdose	VBP	B-VP	O
.	.	O	O

For	IN	B-PP	O
almost	RB	B-NP	O
all	DT	I-NP	O
cognitive	JJ	I-NP	O
measures	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
medication	NN	I-NP	O
by	IN	B-PP	O
age	NN	B-NP	O
-	HYPH	I-NP	O
interaction	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
num	CD	I-NP	O
age	NN	I-NP	O
groups	NNS	I-NP	O
exhibited	VBD	B-VP	O
similar	JJ	B-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
challenge	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
for	IN	B-PP	O
healthy	JJ	B-NP	O
older	JJR	I-NP	O
adults	NNS	I-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
suffering	VBG	I-VP	O
from	IN	B-PP	O
chronic	JJ	B-NP	B
pain	NN	I-NP	I
,	,	O	O
neurocognitive	JJ	B-NP	O
and	CC	I-NP	O
pharmacodynamic	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
immediate	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
oxycodone	NN	I-NP	O
are	VBP	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
for	IN	B-PP	O
middle	JJ	B-NP	O
-	HYPH	I-NP	O
aged	JJ	I-NP	O
adults	NNS	I-NP	O
.	.	O	O

Study	NN	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
metabolism	NN	I-NP	O
,	,	O	O
neurocognitive	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
and	CC	O	O
physical	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
oxycodone	NN	I-NP	O
are	VBP	B-VP	O
similar	JJ	B-ADJP	O
for	IN	B-PP	O
healthy	JJ	B-NP	O
middle	JJ	I-NP	O
-	HYPH	I-NP	O
aged	JJ	I-NP	O
and	CC	I-NP	O
older	JJR	I-NP	O
adults	NNS	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
clinicians	NNS	B-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
avoid	VB	I-VP	O
prescribing	VBG	I-VP	O
oral	JJ	B-NP	O
opioids	NNS	I-NP	O
to	TO	B-PP	O
older	JJR	B-NP	O
adults	NNS	I-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
belief	NN	I-NP	O
that	IN	B-SBAR	O
older	JJR	B-NP	O
adults	NNS	I-NP	O
are	VBP	B-VP	O
at	IN	B-PP	O
higher	JJR	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
than	IN	B-PP	O
younger	JJR	B-NP	O
adults	NNS	I-NP	O
.	.	O	O

Normalizing	VBG	B-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
modafinil	NN	B-NP	O
on	IN	B-PP	O
sleep	NN	B-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
morning	NN	B-NP	O
-	HYPH	O	O
dosed	VBN	B-NP	O
modafinil	NN	I-NP	O
on	IN	B-PP	O
sleep	NN	B-NP	O
and	CC	I-NP	O
daytime	NN	I-NP	B
sleepiness	NN	I-NP	I
in	IN	B-PP	O
chronic	JJ	B-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
participants	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
modafinil	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
or	CC	O	O
placebo	NN	B-NP	O
every	DT	B-NP	O
morning	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
:	SYM	I-NP	O
num	CD	I-NP	O
a.m.	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
inpatient	NN	I-NP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
randomized	VBN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

Participants	NNS	B-NP	O
underwent	VBD	B-VP	O
polysomnographic	JJ	B-NP	O
sleep	NN	I-NP	O
recordings	NNS	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	B-NP	O
(	(	O	O
first	JJ	B-ADVP	O
,	,	O	O
second	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
third	JJ	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
abstinence	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
Multiple	JJ	I-NP	O
Sleep	NN	I-NP	O
Latency	NN	I-NP	O
Test	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
:	SYM	I-NP	O
num	CD	I-NP	O
a.m.	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
:	SYM	O	O
num	CD	B-NP	O
p.m.	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
:	SYM	O	O
num	CD	B-NP	O
p.m.	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
.	.	O	O

For	IN	B-PP	O
comparison	NN	B-NP	O
of	IN	B-PP	O
sleep	JJ	B-NP	O
architecture	NN	I-NP	O
variables	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
comparison	NN	I-NP	O
participants	NNS	I-NP	O
underwent	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
night	NN	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
polysomnography	NN	I-NP	O
that	WDT	B-NP	O
followed	VBD	B-VP	O
num	CD	B-NP	O
night	NN	I-NP	O
of	IN	B-PP	O
accommodation	NN	B-NP	O
polysomnography	NN	I-NP	O
.	.	O	O

Progressive	JJ	B-NP	O
abstinence	NN	I-NP	O
from	IN	B-PP	O
cocaine	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
worsening	VBG	B-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
measured	VBN	I-NP	O
polysomnographic	JJ	I-NP	O
sleep	NN	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
modafinil	NN	B-NP	O
decreased	VBD	B-VP	O
nighttime	RB	I-VP	O
sleep	VB	I-VP	O
latency	NN	B-NP	O
and	CC	O	O
increased	VBD	B-VP	O
slow	JJ	B-NP	O
-	HYPH	I-NP	O
wave	NN	I-NP	O
sleep	NN	I-NP	O
time	NN	I-NP	O
in	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
participants	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
modafinil	NN	B-NP	O
interacted	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
abstinence	NN	I-NP	O
week	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
longer	JJR	B-NP	O
total	JJ	I-NP	O
sleep	NN	I-NP	O
time	NN	I-NP	O
and	CC	O	O
shorter	JJR	B-NP	O
REM	NN	I-NP	O
sleep	NN	I-NP	O
latency	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
abstinence	NN	B-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
slow	JJ	B-NP	O
-	HYPH	I-NP	O
wave	NN	I-NP	O
sleep	NN	I-NP	O
time	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
sleep	NN	I-NP	O
time	NN	I-NP	O
,	,	O	O
and	CC	O	O
sleep	VB	B-VP	O
latency	NN	B-NP	O
in	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
and	CC	I-NP	O
healthy	JJ	I-NP	O
participants	NNS	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
normalizing	VBG	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
modafinil	NN	B-NP	O
in	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
participants	NNS	I-NP	O
.	.	O	O

Modafinil	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
daytime	NN	I-NP	O
sleep	NN	I-NP	O
latency	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
Multiple	NNP	I-NP	O
Sleep	NNP	I-NP	O
Latency	NNP	I-NP	O
Test	NNP	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
nearly	RB	I-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
subjective	JJ	B-NP	O
daytime	NN	I-NP	B
sleepiness	NN	I-NP	I
.	.	O	O

Morning	NN	B-NP	O
-	HYPH	B-PP	O
dosed	VBN	B-NP	O
modafinil	NN	I-NP	O
promotes	VBZ	B-VP	O
nocturnal	JJ	B-NP	O
sleep	NN	I-NP	O
,	,	O	O
normalizes	VBZ	B-VP	O
sleep	NN	B-NP	O
architecture	NN	I-NP	O
,	,	O	O
and	CC	O	O
decreases	VBZ	B-VP	O
daytime	NN	B-NP	B
sleepiness	NN	I-NP	I
in	IN	B-PP	O
abstinent	JJ	B-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
relevant	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
dependence	NN	I-NP	O
.	.	O	O

Efficacy	NN	B-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
asenapine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-VP	O
trial	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
exacerbation	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

Asenapine	NN	B-NP	O
is	VBZ	B-VP	O
approved	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
Food	NNP	I-NP	O
and	CC	I-NP	O
Drugs	NNP	I-NP	O
Administration	NNP	I-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
for	IN	B-PP	O
acute	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
or	CC	B-PP	O
of	IN	B-PP	O
manic	JJ	B-NP	B
or	CC	I-NP	O
mixed	JJ	I-NP	O
episodes	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
bipolar	JJ	B-NP	B
I	NN	I-NP	I
disorder	NN	I-NP	I
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
psychotic	JJ	B-NP	B
features	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
trial	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
schizophrenia	NN	I-NP	B
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
fixed	VBN	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
asenapine	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
twice	RB	B-ADVP	O
daily	RB	O	O
(	(	O	O
BID	NN	B-NP	O
)	)	O	O
,	,	O	O
asenapine	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
BID	NN	I-NP	O
,	,	O	O
placebo	NN	B-NP	O
,	,	O	O
or	CC	O	O
haloperidol	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
BID	NN	I-NP	O
(	(	O	O
to	TO	B-VP	O
verify	VB	I-VP	O
assay	NN	B-NP	O
sensitivity	NN	I-NP	O
)	)	O	O
.	.	O	O

With	IN	B-PP	O
last	JJ	B-NP	O
observations	NNS	I-NP	O
carried	VBD	B-VP	O
forward	JJ	B-ADJP	O
(	(	O	O
LOCF	NN	B-NP	O
)	)	O	O
,	,	O	O
mean	JJ	B-NP	O
Positive	JJ	I-NP	O
and	CC	I-NP	O
Negative	JJ	I-NP	O
Syndrome	NN	I-NP	O
Scale	NN	I-NP	O
total	JJ	I-NP	O
score	NN	I-NP	O
reductions	NNS	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
to	TO	B-VP	O
endpoint	VB	I-VP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
with	IN	B-PP	O
asenapine	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
BID	NN	I-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
;	:	O	O
using	VBG	B-VP	O
mixed	VBN	B-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
repeated	VBN	B-NP	O
measures	NNS	I-NP	O
(	(	O	O
MMRM	NN	B-NP	O
)	)	O	O
,	,	O	O
changes	NNS	B-NP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
with	IN	B-PP	O
asenapine	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
BID	NN	I-NP	O
(	(	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
and	CC	O	O
haloperidol	NN	B-NP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
Positive	JJ	I-NP	O
and	CC	I-NP	O
Negative	JJ	I-NP	O
Syndrome	NN	I-NP	O
Scale	NN	I-NP	O
positive	JJ	I-NP	O
subscale	NN	I-NP	O
,	,	O	O
all	DT	B-NP	O
treatments	NNS	I-NP	O
were	VBD	B-VP	O
superior	JJ	B-ADJP	O
to	TO	B-PP	O
placebo	NN	B-NP	O
with	IN	B-PP	O
LOCF	NN	B-NP	O
and	CC	I-NP	O
MMRM	NN	I-NP	O
;	:	O	O
asenapine	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
BID	NN	I-NP	O
was	VBD	B-VP	O
superior	JJ	B-ADJP	O
to	TO	B-VP	O
placebo	VB	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
negative	JJ	I-NP	O
subscale	NN	I-NP	O
with	IN	B-PP	O
MMRM	NN	B-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
general	JJ	I-NP	O
psychopathology	NN	I-NP	O
subscale	NN	I-NP	O
with	IN	B-PP	O
LOCF	NN	B-NP	O
and	CC	I-NP	O
MMRM	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
(	(	O	O
AEs	NNS	B-NP	O
)	)	O	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
asenapine	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
BID	NN	I-NP	O
,	,	O	O
haloperidol	NN	B-NP	O
,	,	O	O
and	CC	O	O
placebo	NN	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
reported	VBN	B-VP	O
as	IN	B-SBAR	O
AEs	NNS	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
asenapine	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
BID	NN	I-NP	O
,	,	O	O
haloperidol	NN	B-NP	O
,	,	O	O
and	CC	O	O
placebo	NN	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Across	IN	B-PP	O
all	DT	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
no	DT	B-NP	O
more	JJR	I-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
weight	NN	I-NP	O
change	NN	I-NP	O
.	.	O	O

Post	JJ	B-NP	O
hoc	NN	I-NP	O
analyses	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
efficacy	NN	B-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
with	IN	B-PP	O
asenapine	NN	B-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
;	:	O	O
greater	JJR	B-NP	O
contrasts	NNS	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
AEs	NNS	B-NP	O
,	,	O	O
especially	RB	B-NP	O
extrapyramidal	JJ	I-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

Permeability	NN	B-NP	O
,	,	O	O
ultrastructural	JJ	B-NP	O
changes	NNS	I-NP	O
,	,	O	O
and	CC	O	O
distribution	NN	B-NP	O
of	IN	B-PP	O
novel	JJ	B-NP	O
proteins	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
barrier	NN	I-NP	O
in	IN	B-PP	O
early	JJ	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
unclear	JJ	B-ADJP	O
what	WP	B-NP	O
happens	VBZ	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
glomerulus	NN	I-NP	O
when	WRB	B-ADVP	O
proteinuria	NN	B-NP	B
starts	VBZ	B-VP	O
.	.	O	O

Using	VBG	B-VP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
nephrosis	NN	I-NP	B
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
early	RB	B-NP	O
ultrastructural	JJ	I-NP	O
and	CC	I-NP	O
permeability	NN	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
relation	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
podocyte	NN	I-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
molecules	NNS	I-NP	O
nephrin	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
-	HYPH	I-NP	O
actinin	NN	I-NP	O
,	,	O	O
dendrin	NN	B-NP	O
,	,	O	O
and	CC	O	O
plekhh2	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
only	RB	B-VP	O
recently	RB	I-VP	O
discovered	VBN	I-VP	O
in	IN	B-PP	O
podocytes	NNS	B-NP	O
.	.	O	O

Using	VBG	B-VP	O
immune	JJ	B-NP	O
stainings	NNS	I-NP	O
,	,	O	O
semiquantitative	JJ	B-NP	O
measurement	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
under	IN	B-PP	O
the	DT	B-NP	O
electron	NN	I-NP	O
microscope	NN	I-NP	O
.	.	O	O

Permeability	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
isolated	VBN	B-NP	O
kidney	NN	I-NP	O
perfusion	NN	I-NP	O
with	IN	B-PP	O
tracers	NNS	B-NP	O
.	.	O	O

Possible	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ACE	NN	B-NP	O
inhibition	NN	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
.	.	O	O

By	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
some	DT	B-NP	O
patchy	JJ	I-NP	O
foot	NN	I-NP	O
process	NN	I-NP	O
effacement	NN	I-NP	O
,	,	O	O
but	CC	O	O
no	DT	B-NP	O
proteinuria	NN	I-NP	B
,	,	O	O
appeared	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
nephrin	NN	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
both	CC	B-NP	O
diseased	JJ	I-NP	O
and	CC	I-NP	O
normal	JJ	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
other	JJ	I-NP	O
proteins	NNS	I-NP	O
showed	VBD	B-VP	O
few	JJ	B-NP	O
changes	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
limited	VBN	I-VP	O
to	TO	B-PP	O
diseased	JJ	B-NP	O
areas	NNS	I-NP	O
.	.	O	O

By	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
foot	NN	I-NP	O
process	NN	I-NP	O
effacement	NN	I-NP	O
was	VBD	B-VP	O
complete	JJ	B-ADJP	O
and	CC	O	O
proteinuria	NN	B-NP	B
appeared	VBD	B-VP	O
in	IN	B-PP	O
parallel	NN	B-NP	O
with	IN	B-PP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
size	NN	B-NP	O
barrier	NN	I-NP	O
damage	NN	I-NP	O
.	.	O	O

Nephrin	NN	B-NP	O
decreased	VBD	B-VP	O
further	RBR	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
dendrin	NN	B-NP	O
and	CC	I-NP	O
plekhh2	NN	I-NP	O
also	RB	B-ADVP	O
decreased	VBD	B-VP	O
but	CC	O	O
a	DT	O	O
-	:	O	O
actinin	NN	B-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

ACE	NN	B-NP	O
inhibition	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

PAN	NN	B-NP	O
glomeruli	NNS	I-NP	O
already	RB	B-ADVP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
pathology	NN	I-NP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
despite	IN	B-PP	O
relatively	RB	B-NP	O
mild	JJ	I-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
altered	VBN	B-NP	O
nephrin	NN	I-NP	O
expression	NN	I-NP	O
,	,	O	O
supporting	VBG	B-VP	O
its	PRP$	B-NP	O
pivotal	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
podocyte	NN	B-NP	O
morphology	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
novel	JJ	I-NP	O
proteins	NNS	I-NP	O
dendrin	NN	I-NP	O
and	CC	I-NP	O
plekhh2	NN	I-NP	O
were	VBD	B-VP	O
both	DT	O	O
reduced	VBN	B-VP	O
,	,	O	O
suggesting	VBG	B-VP	O
roles	NNS	B-NP	O
in	IN	B-PP	O
PAN	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
a	DT	B-NP	O
-	HYPH	I-NP	O
actinin	NN	I-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
preterm	JJ	I-NP	O
neonates	NNS	I-NP	O
with	IN	B-PP	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
lopinavir	NN	B-NP	O
/	SYM	O	O
ritonavir	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
twin	JJ	B-NP	O
neonates	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
born	VBN	I-VP	O
prematurely	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
mother	NN	I-NP	O
with	IN	B-PP	O
human	JJ	B-NP	B
immunodeficiency	NN	I-NP	I
virus	NN	I-NP	I
infection	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
twins	NNS	I-NP	O
developed	VBD	B-VP	O
complete	JJ	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
and	CC	O	O
dilated	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
lopinavir	NN	B-NP	O
/	SYM	B-NP	O
ritonavir	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
boosted	VBN	I-NP	O
protease	NN	I-NP	O
-	HYPH	I-NP	O
inhibitor	NN	I-NP	O
agent	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
other	JJ	I-NP	O
twin	NN	I-NP	O
developed	VBD	B-VP	O
mild	JJ	B-NP	O
bradycardia	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
recommend	VBP	B-VP	O
caution	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
lopinavir	NN	B-NP	O
/	SYM	B-NP	O
ritonavir	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
immediate	JJ	I-NP	O
neonatal	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

Learning	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
under	IN	B-PP	O
amnesia	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
pentobarbital	NN	B-NP	O
.	.	O	O

Dissociated	VBN	B-NP	O
learning	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
state	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
state	NN	I-NP	O
of	IN	B-PP	O
amnesia	NN	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pentobarbital	NN	B-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
trained	VBN	I-VP	O
to	TO	I-VP	O
approach	VB	I-VP	O
a	DT	B-NP	O
shelf	NN	I-NP	O
where	WRB	B-ADVP	O
they	PRP	B-NP	O
received	VBD	B-VP	O
food	NN	B-NP	O
reinforcement	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
trained	VBN	I-VP	O
under	IN	B-PP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
pentobarbital	NN	B-NP	O
to	TO	B-VP	O
run	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
shelf	NN	I-NP	O
as	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
state	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
trained	VBN	I-VP	O
to	TO	I-VP	O
approach	VB	I-VP	O
different	JJ	B-NP	O
shelves	NNS	I-NP	O
in	IN	B-PP	O
different	JJ	B-NP	O
drug	NN	I-NP	O
states	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
memory	NN	B-NP	B
dissociation	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Differences	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
parameters	NNS	I-NP	O
of	IN	B-PP	O
training	NN	B-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
pentobarbital	NN	B-NP	O
between	IN	B-PP	O
Groups	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
revealed	VBN	I-VP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
brain	NN	I-NP	O
-	HYPH	O	O
dissociated	VBN	B-NP	O
state	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
pentobarbital	NN	B-NP	O
is	VBZ	B-VP	O
formed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
participation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
information	NN	B-NP	O
perception	NN	I-NP	O
.	.	O	O

Angiosarcoma	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
diethylstilbestrol	NN	B-NP	O
.	.	O	O

Angiosarcoma	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
differentiated	VBN	I-NP	O
adenocarcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
with	IN	B-PP	O
diethylstilbestrol	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Angiosarcoma	NN	B-NP	B
was	VBD	B-VP	O
also	RB	B-ADVP	O
present	JJ	B-ADJP	O
within	IN	B-PP	O
pulmonary	JJ	B-NP	O
and	CC	I-NP	O
renal	JJ	I-NP	O
arteries	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
intraarterial	JJ	I-NP	B
lesions	NNS	I-NP	I
might	MD	B-VP	O
represent	VB	I-VP	O
independent	JJ	B-NP	O
primary	JJ	I-NP	O
tumors	NNS	I-NP	B
is	VBZ	B-VP	O
considered	VBN	I-VP	O
.	.	O	O

Role	NN	B-NP	O
of	IN	B-PP	O
xanthine	NN	B-NP	O
oxidase	NN	I-NP	O
in	IN	B-PP	O
dexamethasone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
rats.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Glucocorticoid	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
(	(	O	O
GC	NN	B-NP	O
-	HYPH	B-NP	O
HT	NN	I-NP	B
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
-	HYPH	B-NP	O
redox	NN	I-NP	O
imbalance.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
xanthine	NN	B-NP	O
oxidase	NN	I-NP	O
(	(	O	O
XO	NN	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
dexamethasone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
(	(	O	O
dex	NN	B-NP	O
-	HYPH	B-NP	O
HT	NN	I-NP	B
)	)	O	O
.	.	O	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
male	JJ	I-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
randomly	RB	B-ADVP	O
into	IN	B-PP	O
num	CD	B-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
:	:	O	O
saline	NN	B-NP	O
,	,	O	O
dexamethasone	NN	B-NP	O
(	(	O	O
dex	NN	B-NP	O
)	)	O	O
,	,	O	O
allopurinol	NN	B-NP	O
plus	CC	O	O
saline	NN	B-NP	O
,	,	O	O
and	CC	O	O
allopurinol	NN	B-NP	O
plus	CC	O	O
dex.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressures	NNS	I-NP	O
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
and	CC	O	O
bodyweights	NNS	B-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
each	DT	B-NP	O
alternate	JJ	I-NP	O
day	NN	I-NP	O
.	.	O	O

Thymus	NN	B-NP	O
weight	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
glucocorticoid	NN	B-NP	O
activity	NN	I-NP	O
,	,	O	O
and	CC	O	O
serum	NN	B-NP	O
urate	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
XO	NN	B-NP	O
inhibition.	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Dex	NN	B-NP	O
increased	VBD	B-VP	B
SBP	NN	B-NP	I
and	CC	O	O
decreased	VBD	B-VP	B
thymus	NN	B-NP	I
and	CC	I-NP	I
bodyweights	NNS	I-NP	I
.	.	O	O

Allopurinol	NN	B-NP	O
decreased	VBD	B-VP	O
serum	NN	B-NP	O
urate	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
in	IN	B-PP	O
saline	NN	B-NP	O
and	CC	B-PP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
in	IN	B-PP	O
dex	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
groups.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Allopurinol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
dex	NN	B-NP	O
-	HYPH	B-NP	O
HT	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
our	PRP$	B-NP	O
previous	JJ	I-NP	O
findings	NNS	I-NP	O
that	IN	B-SBAR	O
allopurinol	NN	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
prevent	VB	I-VP	O
adrenocorticotrophic	JJ	B-NP	O
hormone	NN	I-NP	O
induced	VBD	B-VP	O
hypertension	NN	B-NP	B
,	,	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
XO	NN	B-NP	O
activity	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
a	DT	B-NP	O
major	JJ	I-NP	O
determinant	NN	I-NP	O
of	IN	B-PP	O
GC	NN	B-NP	O
-	HYPH	B-NP	O
HT	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Extrapyramidal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
at	IN	B-PP	O
comparable	JJ	B-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
occupancy	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Risperidone	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
antipsychotic	JJ	I-NP	O
drug	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
affinity	NN	I-NP	O
at	IN	B-PP	O
dopamine	NN	B-NP	O
D2	NN	I-NP	O
and	CC	O	O
serotonin	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT2	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
proposed	VBN	I-VP	O
that	IN	B-SBAR	O
risperidone	NN	B-NP	O
s	VBZ	B-VP	O
pharmacologic	JJ	B-NP	O
profile	NN	I-NP	O
may	MD	B-VP	O
produce	VB	I-VP	O
improved	JJ	B-NP	O
efficacy	NN	I-NP	O
for	IN	B-PP	O
negative	JJ	B-NP	O
psychotic	JJ	I-NP	B
symptoms	NNS	I-NP	I
and	CC	O	O
decreased	VBD	B-VP	O
propensity	NN	B-NP	O
for	IN	B-PP	O
extrapyramidal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
;	:	O	O
features	NNS	B-NP	O
shared	VBN	B-VP	O
by	IN	B-PP	O
so	RB	O	O
-	HYPH	O	O
called	VBN	B-VP	O
atypical	JJ	B-NP	O
neuroleptics	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
routine	JJ	B-NP	O
risperidone	NN	I-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
unique	JJ	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
D2	NN	B-NP	O
receptor	NN	I-NP	O
occupancy	NN	I-NP	O
and	CC	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
used	VBD	B-VP	O
[	(	B-LST	O
123I	LS	I-LST	O
]	)	O	O
IBZM	NN	B-NP	O
SPECT	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
D2	NN	B-NP	O
occupancy	NN	I-NP	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
routine	JJ	B-NP	O
clinical	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
or	CC	I-NP	O
haloperidol	NN	I-NP	O
.	.	O	O

Both	CC	O	O
risperidone	NN	B-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
produced	VBD	B-VP	O
D2	NN	B-NP	O
occupancy	NN	I-NP	O
levels	NNS	I-NP	O
between	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
standard	JJ	B-NP	O
clinical	JJ	I-NP	O
doses	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
occupancy	NN	B-NP	O
levels	NNS	I-NP	O
obtained	VBN	B-VP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
or	CC	I-NP	O
risperidone	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	B
-	HYPH	B-NP	I
induced	VBN	I-NP	I
parkinsonism	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
occupancy	NN	B-NP	O
levels	NNS	I-NP	O
above	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
these	DT	B-NP	O
observations	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT2	NN	I-NP	O
blockade	NN	I-NP	O
obtained	VBN	B-VP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
at	IN	B-PP	O
D2	NN	B-NP	O
occupancy	NN	I-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
above	IN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
protect	VB	I-VP	O
against	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
extrapyramidal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Simvastatin	NN	B-NP	O
-	HYPH	B-NP	O
ezetimibe	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hepatic	JJ	I-NP	B
failure	NN	I-NP	I
necessitating	VBG	B-VP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Abstract	NN	B-NP	O
Serum	NN	I-NP	O
aminotransferase	NN	I-NP	O
elevations	NNS	I-NP	O
are	VBP	B-VP	O
a	DT	B-NP	O
commonly	RB	I-NP	O
known	VBN	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methylglutaryl	NN	I-NP	O
coenzyme	NN	I-NP	O
A	NN	I-NP	O
reductase	NN	I-NP	O
inhibitor	NN	I-NP	O
(	(	O	O
statin	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
hepatotoxic	JJ	B-NP	B
events	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
widely	RB	I-VP	O
published	VBN	I-VP	O
with	IN	B-PP	O
ezetimibe	NN	B-NP	O
or	CC	O	O
the	DT	B-NP	O
combination	NN	I-NP	O
agent	NN	I-NP	O
simvastatin	NN	I-NP	O
-	HYPH	B-NP	O
ezetimibe	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Hispanic	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
necessitating	VBG	B-VP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
conversion	NN	B-NP	O
from	IN	B-PP	O
simvastatin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
to	TO	B-PP	O
simvastatin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
-	HYPH	O	O
ezetimibe	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
lipid	NN	I-NP	O
panel	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
maintained	VBN	I-VP	O
with	IN	B-PP	O
simvastatin	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
before	IN	B-SBAR	O
the	DT	B-NP	O
conversion	NN	I-NP	O
without	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
routine	JJ	I-NP	O
laboratory	NN	I-NP	O
work	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-SBAR	O
conversion	NN	B-NP	O
revealed	VBD	B-VP	O
elevated	JJ	B-NP	O
serum	NN	I-NP	O
aminotransferase	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Simvastatinezetimibe	NN	B-NP	O
and	CC	I-NP	O
escitalopram	NN	I-NP	O
(	(	O	O
which	WDT	B-NP	O
she	PRP	B-NP	O
was	VBD	B-VP	O
taking	VBG	I-VP	O
for	IN	B-PP	O
depression	NN	B-NP	B
)	)	O	O
were	VBD	B-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
and	CC	O	O
other	JJ	B-NP	O
potential	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
were	VBD	B-VP	O
excluded	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
repeat	NN	I-NP	O
work	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
revealed	VBD	B-VP	O
further	JJ	B-NP	O
elevations	NNS	I-NP	O
in	IN	B-PP	O
aminotransferase	NN	B-NP	O
levels	NNS	I-NP	O
,	,	O	O
and	CC	O	O
liver	NN	B-NP	O
biopsy	NN	I-NP	O
revealed	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
moderate	JJ	B-NP	O
-	HYPH	I-NP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
severe	JJ	I-NP	O
drug	NN	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

She	PRP	B-NP	O
underwent	VBD	B-VP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
uneventful	JJ	I-NP	O
postoperative	JJ	I-NP	O
course	NN	I-NP	O
.	.	O	O

Her	PRP$	B-NP	O
aminotransferase	NN	I-NP	O
levels	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
by	IN	B-PP	O
postoperative	JJ	B-NP	O
day	NN	I-NP	O
num	CD	I-NP	O
and	CC	O	O
her	PRP	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
showed	VBD	B-VP	O
no	DT	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
.	.	O	O

Ezetimibe	NNP	B-NP	O
undergoes	VBZ	B-VP	O
extensive	JJ	B-NP	O
glucuronidation	NN	I-NP	O
by	IN	B-PP	O
uridine	NN	B-NP	O
diphosphate	NN	I-NP	O
glucoronosyltransferases	NNS	I-NP	O
(	(	O	O
UGT	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
intestine	NN	I-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
have	VB	I-VP	O
inhibited	VBN	I-VP	O
the	DT	B-NP	O
glucuronidation	NN	I-NP	O
of	IN	B-PP	O
simvastatin	NN	B-NP	O
hydroxy	NN	I-NP	O
acid	NN	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
increased	VBN	B-NP	O
simvastatin	NN	I-NP	O
exposure	NN	I-NP	O
and	CC	O	O
subsequent	JJ	B-NP	O
hepatotoxicity	NN	I-NP	B
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
simvastatin	NN	B-NP	O
-	HYPH	B-NP	O
ezetimibe	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
failure	NN	I-NP	I
that	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
postulate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
simvastatinezetimibe	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
simvastatin	NN	I-NP	O
exposure	NN	I-NP	O
by	IN	B-PP	O
ezetimibe	NN	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
UGT	NN	B-NP	O
enzymes	NNS	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
potential	JJ	B-NP	O
hepatotoxicity	NN	I-NP	B
with	IN	B-PP	O
simvastatin	NN	B-NP	O
-	HYPH	B-NP	O
ezetimibe	NN	I-NP	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
should	MD	B-VP	O
carefully	RB	I-VP	O
monitor	VB	I-VP	O
serum	NN	B-NP	O
aminotransferase	NN	I-NP	O
levels	NNS	I-NP	O
when	WRB	B-ADVP	O
starting	VBG	B-VP	O
therapy	NN	B-NP	O
and	CC	O	O
titrating	VBG	B-VP	O
the	DT	B-NP	O
dosage	NN	I-NP	O
.	.	O	O

Oral	JJ	B-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
meth	NN	B-NP	B
mouth	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
documentation	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
clinical	JJ	I-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
make	VB	I-VP	O
clinicians	NNS	B-NP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
meth	NN	B-NP	B
mouth	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
medical	JJ	I-NP	O
risks	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
serious	JJ	I-NP	O
condition	NN	I-NP	O
.	.	O	O

Methamphetamine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
very	RB	I-NP	O
addictive	JJ	I-NP	O
,	,	I-NP	O
powerful	JJ	I-NP	O
stimulant	NN	I-NP	O
that	WDT	B-NP	O
increases	VBZ	B-VP	O
wakefulness	NN	B-NP	O
and	CC	O	O
physical	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
can	MD	B-VP	O
produce	VB	I-VP	O
other	JJ	B-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
cardiac	JJ	B-NP	B
dysrhythmias	NNS	I-NP	I
,	,	O	O
hypertension	NN	B-NP	B
,	,	O	O
hallucinations	NNS	B-NP	B
,	,	O	O
and	CC	O	O
violent	JJ	B-NP	B
behavior	NN	I-NP	I
.	.	O	O

Dental	JJ	B-NP	O
patients	NNS	I-NP	O
abusing	VBG	B-VP	O
methamphetamine	NN	B-NP	O
can	MD	B-VP	O
present	VB	I-VP	O
with	IN	B-PP	O
poor	JJ	B-NP	O
oral	JJ	I-NP	O
hygiene	NN	I-NP	O
,	,	O	O
xerostomia	NN	B-NP	B
,	,	O	O
rampant	JJ	B-NP	O
caries	NNS	I-NP	B
(	(	O	O
meth	NN	B-NP	B
mouth	NN	I-NP	I
)	)	O	O
,	,	O	O
and	CC	O	O
excessive	JJ	B-NP	O
tooth	NN	I-NP	B
wear	NN	I-NP	I
.	.	O	O

Oral	JJ	B-NP	O
rehabilitation	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
using	VBG	B-VP	O
methamphetamine	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
challenging	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Caucasian	JJ	I-NP	O
woman	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
dental	JJ	B-NP	O
pain	NN	I-NP	B
,	,	O	O
bad	JJ	B-NP	B
breath	NN	I-NP	I
,	,	O	O
and	CC	O	O
self	NN	B-NP	O
-	HYPH	B-VP	O
reported	VBN	B-NP	O
poor	JJ	I-NP	O
esthetics	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
comprehensive	JJ	I-NP	O
examination	NN	I-NP	O
including	VBG	B-PP	O
her	PRP$	B-NP	O
medical	JJ	I-NP	O
history	NN	I-NP	O
,	,	O	O
panoramic	JJ	B-NP	O
radiograph	NN	I-NP	O
,	,	O	O
and	CC	O	O
intraoral	JJ	B-NP	O
examination	NN	I-NP	O
revealed	VBD	B-VP	O
num	CD	B-NP	O
carious	JJ	I-NP	B
lesions	NNS	I-NP	I
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
very	RB	B-ADJP	O
common	JJ	I-ADJP	O
for	IN	B-PP	O
a	DT	B-NP	O
healthy	JJ	I-NP	O
adult	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
reported	VBD	B-VP	O
her	PRP$	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
not	RB	I-VP	O
experienced	VBN	I-VP	O
any	DT	B-NP	O
major	JJ	I-NP	O
carious	JJ	I-NP	B
episodes	NNS	I-NP	I
before	IN	B-SBAR	O
she	PRP	B-NP	O
started	VBD	B-VP	O
using	VBG	I-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
medical	JJ	B-NP	O
and	CC	I-NP	O
dental	JJ	I-NP	O
histories	NNS	I-NP	O
along	IN	B-PP	O
with	IN	B-PP	O
radiographic	JJ	B-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
findings	NNS	I-NP	O
lead	VBP	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
meth	NN	B-NP	B
mouth	NN	I-NP	I
.	.	O	O
Although	IN	B-SBAR	O
num	CD	B-NP	O
different	JJ	I-NP	O
dental	JJ	I-NP	O
treatment	NN	I-NP	O
modalities	NNS	I-NP	O
(	(	O	O
either	CC	O	O
conventional	JJ	O	O
or	CC	O	O
implant	NN	B-NP	O
-	HYPH	B-VP	O
supported	VBN	I-VP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
offered	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
since	IN	B-PP	O
August	NNP	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
has	VBZ	B-VP	O
yet	RB	I-VP	O
to	TO	I-VP	O
initiate	VB	I-VP	O
any	DT	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
clinical	JJ	I-NP	O
case	NN	I-NP	O
showing	VBG	B-VP	O
oral	JJ	B-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
meth	NN	B-NP	B
mouth	NN	I-NP	I
was	VBD	B-VP	O
presented	VBN	I-VP	O
to	TO	I-VP	O
help	VB	I-VP	O
dental	JJ	B-NP	O
practitioners	NNS	I-NP	O
recognize	VBP	B-VP	O
and	CC	I-VP	O
manage	VBP	I-VP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
abusing	VBG	I-VP	O
methamphetamines	NNS	B-NP	O
.	.	O	O

Dental	JJ	B-NP	O
practitioners	NNS	I-NP	O
also	RB	B-ADVP	O
may	MD	B-VP	O
be	VB	I-VP	O
skeptical	JJ	B-ADJP	O
about	IN	B-PP	O
the	DT	B-NP	O
reliability	NN	I-NP	O
of	IN	B-PP	O
appointment	NN	B-NP	O
keeping	NN	I-NP	O
by	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
they	PRP	B-NP	O
frequently	RB	B-ADVP	O
miss	VBP	B-VP	O
their	PRP$	B-NP	O
appointments	NNS	I-NP	O
without	IN	B-PP	O
reasonable	JJ	B-NP	O
justification	NN	I-NP	O
.	.	O	O

Thyroxine	NN	B-NP	O
abuse	NN	I-NP	O
:	:	O	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
thyrotoxicosis	NN	B-NP	B
in	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

Eating	VBG	B-NP	B
disorders	NNS	I-NP	I
and	CC	O	O
the	DT	B-NP	O
associated	VBN	I-NP	O
behavioural	JJ	I-NP	O
problems	NNS	I-NP	O
and	CC	I-NP	O
drug	NN	I-NP	B
abuse	NN	I-NP	I
are	VBP	B-VP	O
uncommon	JJ	B-ADJP	O
in	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
they	PRP	B-NP	O
do	VBP	B-VP	O
occur	VB	I-VP	O
they	PRP	B-NP	O
are	VBP	B-VP	O
often	RB	B-ADVP	O
unrecognized	JJ	B-ADJP	O
because	IN	B-PP	O
of	IN	I-PP	O
denial	NN	B-NP	O
but	CC	O	O
when	WRB	B-ADVP	O
significant	JJ	B-NP	O
may	MD	B-VP	O
pose	VB	I-VP	O
a	DT	B-NP	O
risk	NN	I-NP	O
to	TO	B-PP	O
both	CC	O	O
the	DT	B-NP	O
mother	NN	I-NP	O
and	CC	O	O
her	PRP$	B-NP	O
fetus	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
illustrates	VBZ	B-VP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
problems	NNS	B-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
encountered	VBN	I-VP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
eating	VBG	B-VP	B
disorders	NNS	B-NP	I
in	IN	B-PP	O
pregnancy	NN	B-NP	O
,	,	O	O
including	VBG	B-PP	O
prolonged	JJ	B-NP	O
and	CC	I-NP	O
recurrent	JJ	I-NP	O
metabolic	JJ	I-NP	O
disturbances	NNS	I-NP	O
and	CC	O	O
diuretic	JJ	B-NP	O
abuse	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
particular	JJ	B-NP	O
it	PRP	B-NP	O
illustrates	VBZ	B-VP	O
the	DT	B-NP	O
derangements	NNS	I-NP	O
of	IN	B-PP	O
thyroid	NN	B-NP	O
function	NN	I-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
pregnant	JJ	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
eating	VBG	B-NP	B
disorders	NNS	I-NP	I
and	CC	O	O
reminds	VBZ	B-VP	O
us	PRP	B-NP	O
that	IN	B-SBAR	O
when	WRB	B-ADVP	O
a	DT	B-NP	O
cause	NN	I-NP	O
for	IN	B-PP	O
thyrotoxicosis	NN	B-NP	B
remains	VBZ	B-VP	O
obscure	JJ	B-ADJP	O
,	,	O	O
thyroxine	NN	B-NP	O
abuse	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
and	CC	I-VP	O
explored	VBN	I-VP	O
.	.	O	O

Attenuation	NN	B-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nigrostriatal	JJ	I-NP	O
dopaminergic	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
by	IN	B-PP	O
lipopolysaccharide	NN	B-NP	O
pretreatment	NN	I-NP	O
.	.	O	O

Immunological	JJ	B-NP	O
activation	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
to	TO	I-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dopaminergic	JJ	I-NP	B
terminal	JJ	I-NP	I
damage	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
roles	NNS	I-NP	O
of	IN	B-PP	O
lipopolysaccharide	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
pro	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
and	CC	I-NP	O
inflammatory	JJ	I-NP	O
factor	NN	I-NP	O
,	,	O	O
treatment	NN	B-NP	O
in	IN	B-PP	O
modulating	VBG	B-VP	O
the	DT	B-NP	O
methamphetamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nigrostriatal	JJ	I-NP	O
dopamine	NN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Lipopolysaccharide	NN	B-NP	O
pretreatment	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
body	NN	I-NP	O
temperature	NN	I-NP	O
or	CC	I-NP	O
methamphetamine	NN	I-NP	O
-	HYPH	O	O
elicited	VBN	B-NP	O
hyperthermia	NN	I-NP	B
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Such	JJ	B-NP	O
systemic	JJ	I-NP	O
lipopolysaccharide	NN	I-NP	O
treatment	NN	I-NP	O
mitigated	VBD	B-VP	O
methamphetamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
striatal	JJ	I-NP	O
dopamine	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydroxyphenylacetic	JJ	I-NP	O
acid	NN	I-NP	O
depletions	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
the	DT	B-NP	O
most	RBS	I-NP	O
potent	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
lipopolysaccharide	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
day	NN	I-NP	O
before	IN	B-PP	O
or	CC	I-PP	O
after	IN	I-PP	O
the	DT	B-NP	O
methamphetamine	NN	I-NP	O
dosing	NN	I-NP	O
regimen	NN	I-NP	O
,	,	O	O
methamphetamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
striatal	JJ	I-NP	O
dopamine	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydroxyphenylacetic	JJ	I-NP	O
acid	NN	I-NP	O
depletions	NNS	I-NP	O
remained	VBD	B-VP	O
unaltered	JJ	B-ADJP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
systemic	JJ	B-NP	O
lipopolysaccharide	NN	I-NP	O
pretreatment	NN	I-NP	O
attenuated	VBD	B-VP	O
local	JJ	B-NP	O
methamphetamine	NN	I-NP	O
infusion	NN	I-NP	O
-	HYPH	B-NP	O
produced	VBN	I-NP	O
dopamine	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydroxyphenylacetic	JJ	I-NP	O
acid	NN	I-NP	O
depletions	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
lipopolysaccharide	NN	B-NP	O
is	VBZ	B-VP	O
less	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
due	IN	B-PP	O
to	TO	B-PP	O
interrupted	JJ	B-NP	O
peripheral	JJ	I-NP	O
distribution	NN	I-NP	O
or	CC	I-NP	O
metabolism	NN	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
concluded	VBD	B-VP	O
a	DT	B-NP	O
critical	JJ	I-NP	O
time	NN	I-NP	O
window	NN	I-NP	O
for	IN	B-PP	O
systemic	JJ	B-NP	O
lipopolysaccharide	NN	I-NP	O
pretreatment	NN	I-NP	O
in	IN	B-PP	O
exerting	VBG	B-VP	O
effective	JJ	B-NP	O
protection	NN	I-NP	O
against	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nigrostriatal	JJ	I-NP	O
dopamine	NN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibition	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
converting	VBG	I-NP	O
enzyme	NN	I-NP	O
inhibitor	NN	I-NP	O
(	(	O	O
CEI	NN	B-NP	O
)	)	O	O
enalapril	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
Munich	NNP	B-NP	O
-	HYPH	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
established	VBN	B-NP	O
adriamycin	NN	I-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
month	NN	I-NP	O
later	RB	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
matched	VBN	B-VP	O
for	IN	B-PP	O
albuminuria	NN	B-NP	B
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
plasma	NN	B-NP	O
albumin	NN	I-NP	O
concentration	NN	I-NP	O
.	.	O	O

Groups	NNS	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
remained	VBD	B-VP	O
untreated	JJ	B-ADJP	O
while	IN	B-SBAR	O
groups	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
received	VBD	B-VP	O
enalapril	NN	B-NP	O
.	.	O	O

Groups	NNS	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
underwent	VBD	B-VP	O
micropuncture	NN	B-NP	O
studies	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
studies	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
enalapril	NN	B-NP	O
reduced	VBD	B-VP	O
arterial	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
glomerular	JJ	B-NP	O
capillary	JJ	I-NP	O
pressure	NN	I-NP	O
without	IN	B-PP	O
reducing	VBG	B-VP	O
albuminuria	NN	B-NP	B
or	CC	I-NP	O
GFR	NN	I-NP	O
.	.	O	O

Groups	NNS	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
enalapril	NN	B-NP	O
on	IN	B-PP	O
progression	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
adriamycin	NN	B-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

Chronic	JJ	B-NP	O
enalapril	NN	I-NP	O
treatment	NN	I-NP	O
reduced	VBD	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
without	IN	B-PP	O
reducing	VBG	B-VP	O
albuminuria	NN	B-NP	B
in	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Untreated	JJ	B-NP	O
group	NN	I-NP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
progressive	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
GFR	NN	B-NP	O
.	.	O	O

Enalapril	NNP	B-NP	O
treatment	NN	I-NP	O
blunted	VBD	B-VP	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
reduction	NN	B-NP	O
in	IN	B-PP	O
GFR	NN	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Reduction	NN	B-NP	O
in	IN	B-PP	O
GFR	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	B
sclerosis	NN	I-NP	I
in	IN	B-PP	O
both	CC	B-NP	O
treated	VBN	I-NP	O
and	CC	I-NP	O
untreated	JJ	I-NP	O
rats.	NNS	I-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Butyrylcholinesterase	NN	B-NP	O
gene	NN	I-NP	O
mutations	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
prolonged	JJ	B-NP	O
apnea	NN	I-NP	B
after	IN	B-PP	O
succinylcholine	NN	B-NP	O
for	IN	B-PP	O
electroconvulsive	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
electroconvulsive	JJ	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
ECT	NN	B-NP	O
)	)	O	O
often	RB	B-ADVP	O
receive	VBP	B-VP	O
succinylcholine	NN	B-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
procedure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
prolonged	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
genetic	JJ	B-NP	O
variants	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
butyrylcholinesterase	NN	I-NP	O
enzyme	NN	I-NP	O
(	(	O	O
BChE	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
being	VBG	B-VP	O
the	DT	B-NP	O
K	NN	I-NP	O
-	HYPH	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
A	NN	I-NP	O
-	HYPH	I-NP	O
variants	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
significance	NN	I-NP	O
of	IN	B-PP	O
genetic	JJ	B-NP	O
variants	NNS	I-NP	O
in	IN	B-PP	O
butyrylcholinesterase	NN	B-NP	O
gene	NN	I-NP	O
(	(	O	O
BCHE	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
suspected	VBN	I-NP	O
prolonged	VBN	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
after	IN	B-PP	O
ECT	NN	B-NP	O
.	.	O	O

a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
referred	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
Danish	NNP	I-NP	O
Cholinesterase	NNP	I-NP	O
Research	NNP	I-NP	O
Unit	NNP	I-NP	O
after	IN	B-PP	O
ECT	NN	B-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
determined	VBD	B-VP	O
the	DT	B-NP	O
BChE	NN	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
BCHE	NN	I-NP	O
genotype	NN	I-NP	O
using	VBG	B-VP	O
molecular	JJ	B-NP	O
genetic	JJ	I-NP	O
methods	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
apnea	NN	B-NP	B
,	,	O	O
time	NN	B-NP	O
to	TO	B-PP	O
sufficient	JJ	B-NP	O
spontaneous	JJ	I-NP	O
ventilation	NN	I-NP	O
and	CC	O	O
whether	IN	B-SBAR	O
neuromuscular	JJ	B-NP	O
monitoring	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
apnea	NN	B-NP	B
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
published	VBN	B-NP	O
data	NNS	I-NP	O
on	IN	B-PP	O
normal	JJ	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
mutations	NNS	B-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
BCHE	NN	I-NP	O
gene	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
variant	NN	I-NP	O
being	VBG	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequent	JJ	I-NP	O
.	.	O	O

The	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
apnea	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
distress	NN	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
recovery	NN	I-NP	O
phase	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Neuromuscular	JJ	B-NP	O
monitoring	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
prolonged	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
had	VBD	B-VP	O
mutations	NNS	B-NP	O
in	IN	B-PP	O
BCHE	NN	B-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
reason	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
prolonged	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
apnea	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
recommend	VBP	B-VP	O
objective	JJ	B-NP	O
neuromuscular	JJ	I-NP	O
monitoring	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
ECT	NN	I-NP	O
.	.	O	O

Ketamine	NN	B-NP	O
sedation	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
children	NNS	B-NP	O
s	VBZ	B-VP	O
fractures	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
recently	RB	B-ADVP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
a	DT	B-NP	O
resurgence	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
utilization	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
unique	JJ	I-NP	O
anesthetic	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
emergency	NN	B-NP	O
-	HYPH	I-NP	O
department	NN	I-NP	O
procedures	NNS	I-NP	O
requiring	VBG	B-VP	O
sedation	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
for	IN	B-PP	O
sedation	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
children	NNS	B-NP	O
s	VBZ	B-VP	O
fractures	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
(	(	O	O
average	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
;	:	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
closed	VBN	B-VP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
isolated	VBN	I-NP	O
fracture	NN	I-NP	B
or	CC	I-NP	O
dislocation	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
level	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
trauma	NN	I-NP	B
center	NN	I-NP	O
were	VBD	B-VP	O
prospectively	RB	I-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Ketamine	NN	B-NP	O
hydrochloride	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intravenously	RB	B-ADVP	O
(	(	O	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
milligrams	NNS	I-NP	O
per	IN	B-PP	O
kilogram	NN	B-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
intramuscularly	RB	B-ADVP	O
(	(	O	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
milligrams	NNS	I-NP	O
per	IN	B-PP	O
kilogram	NN	B-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
.	.	O	O

A	DT	B-NP	O
board	NN	I-NP	O
-	HYPH	B-VP	O
certified	VBN	B-NP	O
emergency	NN	I-NP	O
physician	NN	I-NP	O
skilled	VBN	B-VP	O
in	IN	B-PP	O
airway	NN	B-NP	O
management	NN	I-NP	O
supervised	VBD	B-VP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
registered	VBN	I-NP	O
nurse	NN	I-NP	O
.	.	O	O

Any	DT	B-NP	O
pain	NN	I-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
was	VBD	B-VP	O
rated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
orthopaedic	JJ	I-NP	O
surgeon	NN	I-NP	O
treating	VBG	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Hospital	NNP	B-NP	O
of	IN	B-PP	O
Eastern	NNP	B-NP	O
Ontario	NNP	I-NP	O
Pain	NNP	I-NP	B
Scale	NNP	I-NP	O
(	(	O	O
CHEOPS	NNP	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
time	NN	I-NP	O
from	IN	B-PP	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
to	TO	B-PP	O
manipulation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
fracture	NN	I-NP	B
or	CC	I-NP	O
dislocation	NN	I-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
minute	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
seconds	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
seconds	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
average	JJ	I-NP	O
time	NN	I-NP	O
from	IN	B-PP	O
intramuscular	JJ	B-NP	O
administration	NN	I-NP	O
to	TO	B-PP	O
manipulation	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
and	CC	I-NP	O
forty	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
seconds	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
sixty	JJ	B-NP	O
seconds	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
score	NN	I-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Hospital	NNP	B-NP	O
of	IN	B-PP	O
Eastern	NNP	B-NP	O
Ontario	NNP	I-NP	O
Pain	NNP	I-NP	B
Scale	NNP	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
points	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
points	NNS	I-NP	O
)	)	O	O
,	,	O	O
reflecting	VBG	B-VP	O
minimal	JJ	B-NP	O
or	CC	I-NP	O
no	DT	I-NP	O
pain	NN	I-NP	B
during	IN	B-PP	O
fracture	NN	B-NP	B
reduction	NN	I-NP	O
.	.	O	O

Adequate	JJ	B-NP	O
fracture	NN	I-NP	B
reduction	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
children	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
parents	NNS	I-NP	O
present	JJ	B-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
were	VBD	B-VP	O
pleased	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
sedation	NN	I-NP	O
and	CC	O	O
would	MD	B-VP	O
allow	VB	I-VP	O
it	PRP	B-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
again	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
situation	NN	I-NP	O
.	.	O	O

Patency	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
airway	NN	I-NP	O
and	CC	O	O
independent	JJ	B-NP	O
respiration	NN	I-NP	O
were	VBD	B-VP	O
maintained	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
remained	VBD	B-VP	O
stable	JJ	B-ADJP	O
.	.	O	O

Minor	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
included	VBD	B-VP	O
nausea	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
emesis	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
nausea	NN	B-NP	B
)	)	O	O
,	,	O	O
clumsiness	NN	B-NP	B
(	(	O	O
evident	JJ	B-ADJP	O
as	IN	B-PP	O
ataxic	JJ	B-NP	B
movements	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
dysphoric	JJ	B-NP	B
reaction	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
)	)	O	O
.	.	O	O

No	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
sequelae	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
hallucinations	NNS	B-NP	B
or	CC	I-NP	O
nightmares	NNS	I-NP	O
.	.	O	O

Ketamine	NN	B-NP	O
reliably	RB	B-ADVP	O
,	,	O	O
safely	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
quickly	RB	B-VP	O
provided	VBD	I-VP	O
adequate	JJ	B-NP	O
sedation	NN	I-NP	O
to	TO	B-VP	O
effectively	RB	I-VP	O
facilitate	VB	I-VP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
children	NNS	B-NP	O
s	VBZ	B-VP	O
fractures	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
at	IN	B-PP	O
our	PRP$	B-NP	O
institution	NN	I-NP	O
.	.	O	O

Ketamine	NN	B-NP	O
should	MD	B-VP	O
only	RB	I-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
environment	NN	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
,	,	O	O
where	WRB	B-ADVP	O
proper	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	B-ADVP	O
on	IN	B-PP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
monitoring	NN	I-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
and	CC	O	O
board	NN	B-NP	O
-	HYPH	B-NP	O
certified	VBN	I-NP	O
physicians	NNS	I-NP	O
skilled	VBD	B-VP	O
in	IN	B-PP	O
airway	NN	B-NP	O
management	NN	I-NP	O
are	VBP	B-VP	O
directly	RB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
care	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

Prophylactic	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
immunosuppressive	JJ	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
rheumatologic	JJ	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	I-VP	O
report	VB	I-VP	O
our	PRP$	B-NP	O
experience	NN	I-NP	O
concerning	VBG	B-VP	O
the	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
prophylactic	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
in	IN	B-PP	O
hepatitis	NN	B-NP	O
B	NN	I-NP	O
virus	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
HBs	NNS	B-NP	O
Ag	NN	I-NP	O
)	)	O	O
positive	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
rheumatologic	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

From	IN	B-PP	O
June	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
October	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
HBs	NNS	I-NP	O
Ag	NN	I-NP	O
positive	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
rheumatologic	JJ	B-NP	B
diseases	NNS	I-NP	I
,	,	O	O
who	WP	B-NP	O
were	VBD	B-VP	O
on	IN	B-PP	O
both	CC	B-NP	O
immunosuppressive	JJ	I-NP	O
and	CC	I-NP	O
prophylactic	JJ	I-NP	O
lamivudine	NN	I-NP	O
therapies	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
retrospectively	RB	I-VP	O
assessed	VBN	I-VP	O
.	.	O	O

Liver	NN	B-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
,	,	O	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
(	(	O	O
HBV	NN	B-NP	O
)	)	O	O
serologic	JJ	B-NP	O
markers	NNS	I-NP	O
,	,	O	O
and	CC	O	O
HBV	NN	B-NP	O
DNA	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
during	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	B-PRT	O
up	RP	B-PRT	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
hospital	NN	B-NP	O
file	NN	I-NP	O
records	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
male	JJ	I-NP	O
)	)	O	O
with	IN	B-PP	O
median	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
median	JJ	B-NP	O
disease	NN	I-NP	O
duration	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
median	JJ	B-VP	O
follow	VB	I-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
period	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Lamivudine	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
immunosuppressive	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Baseline	NN	B-NP	O
,	,	O	O
liver	NN	B-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
fourth	JJ	B-NP	O
patient	NN	I-NP	O
:	:	O	O
ALT	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
,	,	O	O
AST	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
,	,	O	O
tenth	NN	B-NP	O
patient	NN	I-NP	O
:	:	O	O
ALT	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
,	,	O	O
AST	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
minimal	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
biopsy	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
)	)	O	O
.	.	O	O

Shortly	RB	B-ADVP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
their	PRP$	B-NP	O
tests	NNS	I-NP	O
normalized	VBN	B-VP	O
and	CC	O	O
during	IN	B-VP	O
follow	VB	I-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
period	NN	B-NP	O
none	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
abnormal	JJ	B-NP	B
liver	NN	I-NP	I
function	NN	I-NP	I
tests	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
HBV	NN	I-NP	O
DNA	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
normal	JJ	B-ADJP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
normalized	VBN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
others	NNS	I-NP	O
increased	VBD	B-VP	O
later	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
additional	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
HBV	NN	B-NP	O
DNA	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
during	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
significant	JJ	B-NP	O
clinical	JJ	I-NP	O
sings	NNS	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
activation	NN	I-NP	O
.	.	O	O

Lamivudine	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
was	VBD	B-VP	O
continued	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Prophylactic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
required	VBD	B-VP	O
immunosuppressive	JJ	B-NP	O
therapy	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
safe	JJ	B-ADJP	O
,	,	O	O
well	RB	B-ADJP	O
tolerated	VBN	I-ADJP	O
and	CC	O	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
HBV	NN	B-NP	O
reactivation	NN	I-NP	O
.	.	O	O

Safety	NN	B-NP	O
of	IN	B-PP	O
transesophageal	JJ	B-NP	O
echocardiography	NN	I-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
:	:	O	O
study	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
multidisciplinary	JJ	I-NP	O
hospital	NN	I-NP	O
.	.	O	O

TEE	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
semi	AFX	I-NP	O
-	HYPH	I-NP	O
invasive	JJ	I-NP	O
tool	NN	I-NP	O
broadly	RB	B-VP	O
used	VBN	I-VP	O
and	CC	O	O
its	PRP$	B-NP	O
utilization	NN	I-NP	O
associated	VBN	B-VP	O
to	TO	B-PP	O
sedatives	NNS	B-NP	O
drugs	NNS	I-NP	O
might	MD	B-VP	O
to	TO	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
safety	NN	I-NP	O
.	.	O	O

to	TO	B-VP	O
analyze	VB	I-VP	O
aspects	NNS	B-NP	O
of	IN	B-PP	O
TEE	NN	B-NP	O
safety	NN	I-NP	O
associated	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
Midazolan	NN	B-NP	O
(	(	O	O
MZ	NN	B-NP	O
)	)	O	O
and	CC	O	O
Flumazenil	NN	B-NP	O
(	(	O	O
FL	NN	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
variables	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
event	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

prospective	JJ	B-NP	O
study	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
that	WDT	B-NP	O
underwent	VBD	B-VP	O
TEE	NN	B-NP	O
with	IN	B-PP	O
MZ	NN	B-NP	O
associated	VBN	B-VP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
sedation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
analyzed	VBD	B-VP	O
the	DT	B-NP	O
following	JJ	I-NP	O
events	NNS	I-NP	O
:	:	O	O
complications	NNS	B-NP	O
related	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
topical	JJ	I-NP	O
anesthesia	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
MZ	NN	B-NP	O
use	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
.	.	O	O

Uni	NNP	B-NP	O
-	:	O	O
and	CC	O	O
multivariate	JJ	B-NP	O
analyses	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
variables	NNS	I-NP	O
:	:	O	O
age	NN	B-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
stroke	NN	B-NP	B
,	,	O	O
myocardiopathy	NN	B-NP	B
(	(	O	O
MP	NN	B-NP	B
)	)	O	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
,	,	O	O
mitral	JJ	B-NP	B
regurgitation	NN	I-NP	I
(	(	O	O
MR	NN	B-NP	B
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
MZ	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
finished	VBD	B-VP	O
the	DT	B-NP	O
examination	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
MZ	NN	B-NP	O
and	CC	I-NP	O
FL	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
examination	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
(	(	O	O
EF	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Mild	JJ	B-NP	O
hypoxia	NN	I-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
event	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
;	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
presented	VBD	B-VP	O
transient	JJ	B-NP	O
hypoxia	NN	I-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
upper	JJ	B-NP	O
airway	NN	I-NP	B
obstruction	NN	I-NP	I
by	IN	B-PP	O
probe	NN	B-NP	O
introduction	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
hypoxia	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
MZ	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Transient	JJ	B-NP	O
hypotension	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
multivariate	JJ	I-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
severe	JJ	B-NP	O
MR	NN	I-NP	B
,	,	O	O
MP	NN	B-NP	B
and	CC	O	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
MZ	NN	B-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
events	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
EF	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
with	IN	B-PP	O
MP	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
MR	NN	I-NP	B
and	CC	O	O
it	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
factor	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
events	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
group	NN	I-NP	O
.	.	O	O

TEE	NN	B-NP	O
with	IN	B-PP	O
sedation	NN	B-NP	O
presents	VBZ	B-VP	O
a	DT	B-NP	O
low	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
severe	JJ	I-NP	O
events	NNS	I-NP	O
and	CC	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
interrupt	VB	I-VP	O
the	DT	B-NP	O
examinations	NNS	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
on	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
on	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

For	IN	B-PP	O
each	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
tested	VBN	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
(	(	O	O
diltiazem	NN	B-NP	O
,	,	O	O
verapamil	NN	B-NP	O
and	CC	O	O
bepridil	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
doses	NNS	I-NP	O
,	,	O	O
i.e.	FW	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
i.p.	NN	I-NP	O
,	,	O	O
or	CC	O	O
an	DT	B-NP	O
equal	JJ	I-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
all	PDT	B-NP	O
the	DT	I-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
i.p.	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
convulsant	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
latency	NN	B-NP	O
to	TO	B-PP	O
convulse	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
local	JJ	I-NP	O
anesthetic	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
mortality	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
different	JJ	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
convulsant	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
modified	VBN	I-VP	O
but	CC	O	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
latency	NN	B-NP	O
to	TO	B-VP	O
obtain	VB	I-VP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
;	:	O	O
this	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
less	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
with	IN	B-PP	O
bepridil	NN	B-NP	O
.	.	O	O

Selegiline	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
postural	JJ	I-NP	B
hypotension	NN	I-NP	I
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
longitudinal	JJ	I-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
United	NNP	I-NP	O
Kingdom	NNP	I-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Research	NNP	I-NP	O
Group	NNP	I-NP	O
(	(	O	O
UKPDRG	NNP	O	O
)	)	O	O
trial	NN	B-NP	O
found	VBD	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
randomized	VBD	B-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
selegiline	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
and	CC	O	O
L	NN	B-NP	O
-	HYPH	O	O
dopa	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
taking	VBG	I-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
therapy	NN	B-NP	O
with	IN	B-PP	O
selegiline	NN	B-NP	O
and	CC	I-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
selective	JJ	B-NP	O
systolic	JJ	I-NP	B
orthostatic	JJ	I-NP	I
hypotension	NN	I-NP	I
which	WDT	B-NP	O
was	VBD	B-VP	O
abolished	VBN	I-VP	O
by	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
selegiline	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
unwanted	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
postural	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
underlying	VBG	B-VP	O
autonomic	JJ	B-NP	O
failure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aims	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
to	TO	I-VP	O
confirm	VB	I-VP	O
our	PRP$	B-NP	O
previous	JJ	I-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
separate	JJ	I-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
consequences	NNS	I-NP	O
of	IN	B-PP	O
stopping	VBG	B-VP	O
selegiline	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
expectation	NN	I-NP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
might	MD	B-VP	O
shed	VB	I-VP	O
light	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
drug	NN	I-NP	O
causes	VBZ	B-VP	O
orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
cardiovascular	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-VP	O
standing	VB	I-VP	O
and	CC	I-VP	O
head	VB	I-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
tilt	NN	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
repeatedly	RB	B-ADVP	O
in	IN	B-PP	O
PD	NN	B-NP	B
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
selegiline	NN	B-NP	O
and	CC	B-PP	O
as	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
withdrawn	VBN	I-VP	O
.	.	O	O

Head	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
tilt	NN	B-NP	O
caused	VBD	B-VP	O
systolic	JJ	B-NP	B
orthostatic	JJ	I-NP	I
hypotension	NN	I-NP	I
which	WDT	B-NP	O
was	VBD	B-VP	O
marked	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
PD	NN	I-NP	B
patients	NNS	I-NP	O
on	IN	B-PP	O
selegiline	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
lost	VBD	B-VP	O
consciousness	NN	B-NP	O
with	IN	B-PP	O
unrecordable	JJ	B-NP	O
blood	NN	I-NP	O
pressures	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
lesser	JJR	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
occurred	VBD	B-VP	O
with	IN	B-PP	O
standing	NN	B-NP	O
.	.	O	O

Orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
was	VBD	B-VP	O
ameliorated	VBN	I-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
selegiline	NN	B-NP	O
and	CC	O	O
totally	RB	B-VP	O
abolished	VBD	I-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Stopping	VBG	B-VP	O
selegiline	NN	B-NP	O
also	RB	B-ADVP	O
significantly	RB	B-VP	O
reduced	VBD	I-VP	B
the	DT	B-NP	I
supine	NN	I-NP	I
systolic	JJ	I-NP	I
and	CC	I-NP	I
diastolic	JJ	I-NP	I
blood	NN	I-NP	I
pressures	NNS	I-NP	I
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
a	DT	B-NP	O
previously	RB	I-NP	O
undescribed	JJ	I-NP	O
supine	NN	I-NP	O
pressor	NN	I-NP	O
action	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
confirms	VBZ	B-VP	O
our	PRP$	B-NP	O
previous	JJ	I-NP	O
finding	NN	I-NP	O
that	IN	B-SBAR	O
selegiline	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
dopa	NN	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
selective	JJ	B-NP	O
orthostatic	JJ	I-NP	B
hypotension	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
possibilities	NNS	I-NP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
cardiovascular	JJ	I-NP	O
findings	NNS	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
monoamine	NN	B-NP	O
oxidase	NN	I-NP	O
or	CC	B-PP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
and	CC	I-NP	O
metamphetamine	NN	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Explicit	JJ	B-NP	O
episodic	JJ	I-NP	O
memory	NN	I-NP	O
for	IN	B-PP	O
sensory	NN	B-NP	O
-	HYPH	B-NP	O
discriminative	JJ	I-NP	O
components	NNS	I-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
pain	NN	I-NP	B
:	:	O	O
immediate	JJ	B-NP	O
and	CC	I-NP	O
delayed	VBN	I-NP	O
ratings	NNS	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
memory	NN	I-NP	O
is	VBZ	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
affect	VB	I-VP	O
future	JJ	B-NP	O
pain	NN	I-NP	B
sensitivity	NN	I-NP	O
and	CC	O	O
thus	RB	B-ADVP	O
contribute	VBP	B-VP	O
to	TO	B-PP	O
clinical	JJ	B-NP	O
pain	NN	I-NP	B
conditions	NNS	I-NP	O
.	.	O	O

Systematic	JJ	B-NP	O
investigations	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
capacity	NN	I-NP	O
to	TO	B-VP	O
remember	VB	I-VP	O
sensory	JJ	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
pain	NN	I-NP	B
are	VBP	B-VP	O
sparse	JJ	B-ADJP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
address	VB	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
pain	NN	I-NP	B
memory	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
male	JJ	I-NP	O
volunteers	NNS	I-NP	O
received	VBD	B-VP	O
intradermal	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
,	,	O	O
separated	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
breaks	NNS	I-NP	O
)	)	O	O
,	,	O	O
each	DT	B-NP	O
given	VBN	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
balanced	JJ	I-NP	O
design	NN	I-NP	O
across	IN	B-PP	O
num	CD	B-NP	O
sessions	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
rating	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
computerized	JJ	I-NP	O
visual	JJ	I-NP	O
analogue	NN	I-NP	O
scale	NN	I-NP	O
digitized	VBN	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
s	NN	I-NP	O
,	,	O	O
either	CC	O	O
immediately	RB	B-ADVP	O
online	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
hour	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
also	RB	B-ADVP	O
recalled	VBD	B-VP	O
their	PRP$	B-NP	O
pains	NNS	I-NP	B
num	CD	B-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Capsaicin	NN	B-NP	O
injection	NN	I-NP	O
reliably	RB	B-ADVP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
flare	NN	I-NP	O
without	IN	B-PP	O
any	DT	B-NP	O
difference	NN	I-NP	O
within	IN	B-PP	O
or	CC	I-PP	O
across	IN	I-PP	O
sessions	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
strong	JJ	I-NP	O
burning	VBG	I-NP	O
pain	NN	I-NP	B
decayed	VBD	B-VP	O
exponentially	RB	B-ADVP	O
within	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
minutes	NNS	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
were	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
reliably	RB	I-VP	O
discriminate	VB	I-VP	O
pain	NN	B-NP	B
magnitude	NN	I-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
across	IN	B-PP	O
capsaicin	NN	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
whether	IN	B-SBAR	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
ratings	NNS	I-NP	O
were	VBD	B-VP	O
requested	VBN	I-VP	O
immediately	RB	B-ADVP	O
,	,	O	O
after	IN	B-SBAR	O
num	CD	B-NP	O
hour	NN	I-NP	O
or	CC	O	O
after	IN	B-PP	O
num	CD	B-NP	O
day	NN	I-NP	O
.	.	O	O

Pain	NNP	B-NP	B
recall	VBP	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
was	VBD	B-VP	O
similarly	RB	B-ADJP	O
precise	JJ	I-ADJP	O
.	.	O	O

Correlation	NN	B-NP	O
with	IN	B-PP	O
rating	NN	B-NP	O
recall	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
was	VBD	B-VP	O
best	RBS	B-ADVP	O
when	WRB	B-ADVP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
ratings	NNS	I-NP	O
were	VBD	B-VP	O
requested	VBN	I-VP	O
as	IN	B-PP	O
late	RB	B-NP	O
as	IN	I-NP	O
num	CD	B-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
both	CC	O	O
rating	NN	B-NP	O
retrievals	NNS	I-NP	O
utilized	VBD	B-VP	O
similar	JJ	B-NP	O
memory	NN	I-NP	O
traces	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
a	DT	B-NP	O
reliable	JJ	I-NP	O
memory	NN	I-NP	O
for	IN	B-PP	O
magnitude	NN	B-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
experimentally	RB	B-NP	O
induced	VBN	I-NP	O
pain	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
further	RB	B-ADVP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
consolidation	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
memory	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
interim	JJ	I-NP	O
stage	NN	I-NP	O
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
take	VB	I-VP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
day	NN	I-NP	O
.	.	O	O

Reversibility	NN	B-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
renal	JJ	I-NP	B
insufficiency	NN	I-NP	I
after	IN	B-PP	O
prolonged	JJ	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
renovascular	JJ	B-NP	B
hypertension	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hypertension	NN	I-NP	B
with	IN	B-PP	O
an	DT	B-NP	O
occluded	VBN	I-NP	O
renal	JJ	I-NP	O
artery	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
solitary	JJ	I-NP	O
kidney	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
sudden	JJ	B-NP	B
deterioration	NN	I-NP	I
of	IN	B-PP	I
renal	JJ	B-NP	I
function	NN	I-NP	I
following	VBG	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
captopril	NN	B-NP	O
.	.	O	O

His	PRP$	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
remained	VBD	B-VP	O
impaired	JJ	B-ADJP	O
but	CC	I-ADJP	O
stable	JJ	I-ADJP	O
during	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
s	VBZ	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
captopril	NN	B-NP	O
but	CC	O	O
returned	VBD	B-VP	O
to	TO	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
levels	NNS	I-NP	O
soon	RB	B-ADVP	O
after	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
indicates	VBZ	B-VP	O
reversibility	NN	B-NP	O
in	IN	B-PP	O
captopril	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
even	RB	B-ADVP	O
after	IN	B-PP	O
its	PRP$	B-NP	O
prolonged	JJ	I-NP	O
use	NN	I-NP	O
and	CC	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
no	DT	B-NP	O
organic	JJ	I-NP	O
damage	NN	I-NP	O
occurs	VBZ	B-VP	O
to	TO	B-PP	O
glomerular	JJ	B-NP	O
arterioles	NNS	I-NP	O
following	VBG	B-PP	O
chronic	JJ	B-NP	O
ACE	NN	I-NP	O
inhibition	NN	I-NP	O
.	.	O	O

Liver	NN	B-NP	B
disease	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
propylthiouracil	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
presents	VBZ	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
,	,	I-NP	O
laboratory	NN	I-NP	O
,	,	O	O
and	CC	O	O
light	NN	B-NP	O
and	CC	I-NP	O
electron	NN	I-NP	O
microscopic	JJ	I-NP	O
observations	NNS	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
active	JJ	I-NP	I
(	(	O	I
aggressive	JJ	B-ADJP	I
)	)	O	I
hepatitis	NN	B-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
propylthiouracil	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
addition	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
list	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
liver	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

Capsaicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
pain	NN	I-NP	I
alters	VBZ	B-VP	O
the	DT	B-NP	O
excitability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
jaw	NN	I-NP	O
-	HYPH	I-NP	O
stretch	NN	I-NP	O
reflex	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
painful	JJ	B-NP	O
temporomandibular	JJ	I-NP	B
disorders	NNS	I-NP	I
is	VBZ	B-VP	O
not	RB	I-VP	O
fully	RB	I-VP	O
understood	VBN	I-VP	O
,	,	O	O
but	CC	O	O
evidence	NN	B-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
muscle	NN	B-NP	B
pain	NN	I-NP	I
modulates	VBZ	B-VP	O
motor	NN	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
characteristic	JJ	B-NP	O
ways	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
tested	VBD	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
activation	NN	B-NP	O
of	IN	B-PP	O
nociceptive	JJ	B-NP	B
muscle	NN	I-NP	I
afferent	JJ	I-NP	O
fibers	NNS	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
linked	VBN	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
excitability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
jaw	NN	I-NP	O
-	HYPH	I-NP	O
stretch	NN	I-NP	O
reflex	NN	I-NP	O
and	CC	O	O
whether	IN	B-SBAR	O
this	DT	B-NP	O
process	NN	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
sensitive	JJ	B-ADJP	O
to	TO	B-PP	O
length	NN	B-NP	O
and	CC	I-NP	O
velocity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
stretch	NN	I-NP	O
.	.	O	O

Capsaicin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micro	NN	I-NP	O
g	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
masseter	NN	I-NP	O
muscle	NN	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
pain	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

Short	JJ	B-NP	O
-	HYPH	I-NP	O
latency	NN	I-NP	O
reflex	NN	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
evoked	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
masseter	NN	I-NP	O
and	CC	I-NP	O
temporalis	NN	I-NP	O
muscles	NNS	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
stretch	NN	I-NP	O
device	NN	I-NP	O
with	IN	B-PP	O
different	JJ	B-NP	O
velocities	NNS	I-NP	O
and	CC	I-NP	O
displacements	NNS	I-NP	O
before	RB	B-ADVP	O
,	,	O	O
during	IN	B-ADVP	O
,	,	O	O
and	CC	O	O
after	IN	B-PP	O
the	DT	B-NP	O
pain	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
normalized	JJ	I-NP	O
reflex	NN	I-NP	O
amplitude	NN	I-NP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
velocity	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
given	VBN	I-NP	O
displacement	NN	I-NP	O
,	,	O	O
but	CC	O	O
remained	VBD	B-VP	O
constant	JJ	B-ADJP	O
with	IN	B-PP	O
different	JJ	B-NP	O
displacements	NNS	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
given	VBN	I-NP	O
velocity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
normalized	JJ	I-NP	O
reflex	NN	I-NP	O
amplitude	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
during	IN	B-PP	O
pain	NN	B-NP	B
,	,	O	O
but	CC	O	O
only	RB	B-ADVP	O
at	IN	B-PP	O
faster	JJR	B-NP	O
stretches	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
painful	JJ	I-NP	B
muscle	NN	I-NP	I
.	.	O	O

Increased	VBN	B-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
fusimotor	NN	I-NP	O
system	NN	I-NP	O
during	IN	B-PP	O
acute	JJ	B-NP	O
muscle	NN	I-NP	B
pain	NN	I-NP	I
could	MD	B-VP	O
be	VB	I-VP	O
num	CD	B-NP	O
likely	JJ	I-NP	O
mechanism	NN	I-NP	O
to	TO	B-VP	O
explain	VB	I-VP	O
the	DT	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Repetitive	JJ	B-NP	O
transcranial	JJ	I-NP	O
magnetic	JJ	I-NP	O
stimulation	NN	I-NP	O
for	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
-	HYPH	B-VP	O
controlled	VBN	I-VP	O
,	,	O	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
blinded	VBN	B-VP	O
,	,	O	O
crossover	NN	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
real	JJ	B-NP	O
repetitive	JJ	I-NP	O
transcranial	JJ	I-NP	O
magnetic	JJ	I-NP	O
stimulation	NN	I-NP	O
(	(	O	O
rTMS	NN	B-NP	O
)	)	O	O
versus	IN	B-PP	O
sham	NN	B-NP	O
rTMS	NN	I-NP	O
(	(	O	O
placebo	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
peak	NN	B-NP	O
dose	NN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
PD	NN	B-NP	B
and	CC	O	O
prominent	JJ	B-NP	O
dyskinesias	NNS	I-NP	B
had	VBD	B-VP	O
rTMS	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
pulses	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
Hz	NN	I-NP	O
rate	NN	I-NP	O
)	)	O	O
delivered	VBN	B-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
motor	NN	I-NP	O
cortex	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
twice	RB	B-ADVP	O
,	,	O	O
once	RB	B-ADVP	O
real	JJ	B-NP	O
stimuli	NNS	I-NP	O
and	CC	O	O
once	RB	B-ADVP	O
sham	NN	B-NP	O
stimulation	NN	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
;	:	O	O
evaluations	NNS	B-NP	O
were	VBD	B-VP	O
done	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
baseline	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
series	NN	I-NP	O
.	.	O	O

Direct	JJ	B-NP	O
comparison	NN	I-NP	O
between	IN	B-PP	O
sham	NN	B-NP	O
and	CC	O	O
real	JJ	B-NP	O
rTMS	NN	I-NP	O
effects	NNS	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
clinician	NN	B-NP	O
-	HYPH	B-NP	O
assessed	VBN	I-NP	O
dyskinesia	NN	I-NP	B
severity	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
comparison	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
baseline	NN	I-NP	O
showed	VBD	B-VP	O
small	JJ	B-NP	O
but	CC	I-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
dyskinesia	NN	B-NP	B
severity	NN	I-NP	O
following	VBG	B-PP	O
real	JJ	B-NP	O
rTMS	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
placebo	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
major	JJ	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
on	IN	B-PP	O
dystonia	NN	B-NP	B
subscore	NN	I-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
patient	NN	B-NP	O
diaries	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
both	DT	B-NP	O
treatments	NNS	I-NP	O
caused	VBD	B-VP	O
reduction	NN	B-NP	O
in	IN	B-PP	O
subjective	JJ	B-NP	O
dyskinesia	NN	I-NP	B
scores	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
intervention	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
sustained	JJ	B-ADJP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
intervention	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
real	JJ	I-NP	O
rTMS	NN	I-NP	O
only	RB	B-ADVP	O
.	.	O	O

Following	VBG	B-PP	O
rTMS	NN	B-NP	O
,	,	O	O
no	DT	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
no	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
motor	NN	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
PD	NN	I-NP	B
symptoms	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
the	DT	B-NP	O
existence	NN	I-NP	O
of	IN	B-PP	O
residual	JJ	B-NP	O
beneficial	JJ	I-NP	O
clinical	JJ	I-NP	O
aftereffects	NNS	I-NP	O
of	IN	B-PP	O
consecutive	JJ	B-NP	O
daily	JJ	I-NP	O
applications	NNS	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
frequency	NN	I-NP	O
rTMS	NN	I-NP	O
on	IN	B-PP	O
dyskinesias	NNS	B-NP	B
in	IN	B-PP	O
PD	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
further	RBR	B-ADJP	O
exploited	VBN	I-ADJP	O
for	IN	B-PP	O
potential	JJ	B-NP	O
therapeutic	JJ	I-NP	O
uses	NNS	I-NP	O
.	.	O	O

Disulfiram	NN	B-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
syndrome	NN	I-NP	O
after	IN	B-PP	O
hydrogen	NN	B-NP	O
cyanamide	NN	I-NP	O
professional	JJ	I-NP	O
skin	NN	I-NP	O
exposure	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
in	IN	B-PP	O
France	NNP	B-NP	O
.	.	O	O

Hydrogen	NN	B-NP	O
cyanamide	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
plant	NN	I-NP	O
growth	NN	I-NP	O
regulator	NN	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
agriculture	NN	B-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
bud	NN	B-NP	O
break	NN	I-NP	O
in	IN	B-PP	O
fruit	NN	B-NP	O
trees	NNS	I-NP	O
.	.	O	O

Contact	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
skin	NN	I-NP	O
can	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
percutaneous	JJ	B-NP	O
absorption	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
substance	NN	I-NP	O
that	WDT	B-NP	O
inhibits	VBZ	B-VP	O
aldehyde	NN	B-NP	O
dehydrogenase	NN	I-NP	O
and	CC	O	O
can	MD	B-VP	O
induce	VB	I-VP	O
acetaldehyde	NN	B-NP	O
syndrome	NN	I-NP	O
in	IN	B-PP	O
case	NN	B-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
describe	VB	I-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
disulfiram	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
syndrome	NN	I-NP	O
following	VBG	B-PP	O
occupational	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
hydrogen	NN	B-NP	O
cyanamide	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
involved	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
Dormex	NNP	B-NP	O
,	,	O	O
which	WDT	B-NP	O
contains	VBZ	B-VP	O
hydrogen	NN	B-NP	O
cyanamide	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
protection	NN	B-NP	O
after	IN	B-PP	O
consuming	VBG	B-VP	O
a	DT	B-NP	O
large	JJ	I-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
meal	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
hour	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
ingestion	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
,	,	O	O
he	PRP	B-NP	O
developed	VBD	B-VP	O
malaise	NN	B-NP	O
with	IN	B-PP	O
flushing	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
face	NN	I-NP	I
,	,	O	O
tachycardia	NN	B-NP	B
,	,	O	O
and	CC	O	O
dyspnea	NN	B-NP	B
.	.	O	O

Manifestations	NNS	B-NP	O
regressed	VBD	B-VP	O
spontaneously	RB	B-ADVP	O
under	IN	B-PP	O
surveillance	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
case	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
farmer	NN	I-NP	O
following	VBG	B-PP	O
cutaneous	JJ	B-NP	O
contact	NN	I-NP	O
with	IN	B-PP	O
Dormex	NNP	B-NP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
,	,	O	O
he	PRP	B-NP	O
developed	VBD	B-VP	O
disulfiram	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
syndrome	NN	I-NP	O
with	IN	B-PP	O
flushing	NN	B-NP	B
,	,	O	O
tachycardia	NN	B-NP	B
,	,	O	O
and	CC	O	O
arterial	JJ	B-NP	B
hypotension	NN	I-NP	I
after	IN	B-PP	O
consuming	VBG	B-VP	O
num	CD	B-NP	O
glasses	NNS	I-NP	O
of	IN	B-PP	O
wine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
spontaneously	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
under	IN	B-PP	O
surveillance	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
cases	NNS	I-NP	O
confirm	VBP	B-VP	O
the	DT	B-NP	O
necessity	NN	I-NP	O
of	IN	B-PP	O
avoiding	VBG	B-VP	O
alcohol	NN	B-NP	O
consumption	NN	I-NP	O
as	IN	B-SBAR	O
recommended	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
instructions	NNS	I-NP	O
for	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
Dormex	NNP	B-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
preventing	VBG	B-VP	O
cutaneous	JJ	B-NP	O
contact	NN	I-NP	O
during	IN	B-PP	O
use	NN	B-NP	O
.	.	O	O

Repeated	VBN	B-NP	O
trimipramine	NN	I-NP	O
induces	VBZ	B-VP	O
dopamine	NN	B-NP	O
D2	NN	I-NP	O
/	SYM	B-NP	O
D3	NN	I-NP	O
and	CC	I-NP	O
alpha1	NN	I-NP	O
-	HYPH	O	O
adrenergic	JJ	B-ADJP	O
up	RB	B-ADVP	O
-	HYPH	B-NP	O
regulation	NN	I-NP	O
.	.	O	O

Trimipramine	NN	B-NP	O
(	(	O	O
TRI	NN	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
shows	VBZ	B-VP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
antidepressant	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
chemically	RB	B-ADJP	O
related	VBN	I-ADJP	O
to	TO	B-PP	O
imipramine	NN	B-NP	O
but	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
inhibit	VB	I-VP	O
the	DT	B-NP	O
reuptake	NN	I-NP	O
of	IN	B-PP	O
noradrenaline	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytryptamine	NN	I-NP	O
,	,	O	O
nor	CC	O	O
does	VBZ	O	O
it	PRP	B-NP	O
induce	VB	B-VP	O
beta	SYM	B-NP	O
-	HYPH	O	O
adrenergic	JJ	B-ADJP	O
down	RB	B-ADVP	O
-	HYPH	B-NP	O
regulation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
antidepressant	NN	I-NP	O
activity	NN	I-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
unknown	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
find	VB	I-VP	O
out	RP	B-PRT	O
whether	IN	B-SBAR	O
TRI	NN	B-NP	O
given	VBN	B-VP	O
repeatedly	RB	B-ADVP	O
was	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
induce	VB	I-VP	O
adaptive	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
and	CC	I-NP	O
alpha1	NN	I-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
systems	NNS	I-NP	O
,	,	O	O
demonstrated	VBN	B-VP	O
by	IN	B-PP	O
us	PRP	B-NP	O
previously	RB	B-ADVP	O
for	IN	B-PP	O
various	JJ	B-NP	O
antidepressants	NNS	I-NP	O
.	.	O	O

TRI	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
and	CC	O	O
male	JJ	B-NP	O
Albino	NNP	I-NP	O
Swiss	JJ	I-NP	O
mice	NNS	I-NP	O
perorally	RB	B-ADVP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
experiment	NN	I-NP	O
TRI	NN	I-NP	O
(	(	O	O
given	VBN	B-VP	O
i.p.	RB	B-ADVP	O
)	)	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
antagonize	VB	I-VP	O
the	DT	B-NP	O
reserpine	NN	I-NP	O
hypothermia	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
and	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
potentiate	VB	I-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxytryptophan	NN	I-NP	O
head	NN	I-NP	O
twitches	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

TRI	NN	B-NP	O
given	VBN	B-VP	O
repeatedly	RB	B-ADVP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
locomotor	JJ	I-NP	O
hyperactivity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	O	O
amphetamine	NN	B-NP	O
,	,	O	O
quinpirole	NN	B-NP	O
and	CC	O	O
-	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
-	HYPH	O	O
dipropyloaminotetralin	NN	B-NP	O
(	(	O	O
dopamine	NN	B-NP	O
D2	NN	I-NP	O
and	CC	O	O
D3	NN	B-NP	O
effects	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
stereotypies	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
amphetamine	NN	I-NP	O
or	CC	I-NP	O
apomorphine	NN	I-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
potentiated	VBN	I-VP	O
by	IN	B-PP	O
TRI	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
behaviour	NN	I-NP	O
stimulation	NN	I-NP	O
evoked	VBN	B-VP	O
by	IN	B-PP	O
phenylephrine	NN	B-NP	O
(	(	O	O
given	VBN	B-VP	O
intraventricularly	RB	B-ADVP	O
)	)	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
evaluated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
open	JJ	I-NP	O
field	NN	I-NP	O
test	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
aggressiveness	NN	I-NP	B
evoked	VBN	B-VP	O
by	IN	B-PP	O
clonidine	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
both	DT	B-NP	O
these	DT	B-NP	O
effects	NNS	I-NP	O
being	VBG	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
alpha1	NN	I-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
,	,	O	O
like	IN	B-PP	O
other	JJ	B-NP	O
tricyclic	JJ	I-NP	O
antidepressants	NNS	I-NP	O
studied	VBN	B-VP	O
previously	RB	B-ADVP	O
,	,	O	O
TRI	NN	B-NP	O
given	VBN	B-VP	O
repeatedly	RB	B-ADVP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
responsiveness	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
dopamine	NN	I-NP	O
D2	NN	I-NP	O
and	CC	O	O
D3	NN	B-NP	O
(	(	O	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
but	CC	B-CONJP	O
not	RB	I-CONJP	O
stereotypy	JJ	B-ADJP	O
)	)	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
alpha1	NN	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
receptors	NNS	I-NP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
agonists	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
question	NN	I-NP	O
arises	VBZ	B-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
reuptake	NN	I-NP	O
inhibition	NN	I-NP	O
is	VBZ	B-VP	O
of	IN	B-PP	O
any	DT	B-NP	O
importance	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
adaptive	JJ	I-NP	O
changes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
repeated	VBN	B-NP	O
antidepressants	NNS	I-NP	O
,	,	O	O
suggested	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
antidepressant	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Ranitidine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
cadaveric	JJ	I-NP	O
renal	JJ	I-NP	O
allograft	NN	I-NP	O
.	.	O	O

Ranitidine	NN	B-NP	O
frequently	RB	B-ADVP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
preventing	VBG	B-VP	O
peptic	JJ	B-NP	O
ulceration	NN	I-NP	O
after	IN	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
drug	NN	I-NP	O
occasionally	RB	B-ADVP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
in	IN	B-PP	O
native	JJ	B-NP	O
kidneys	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
no	DT	B-NP	O
similar	JJ	I-NP	O
reports	NNS	I-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
ranitidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
recipient	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
cadaveric	JJ	I-NP	O
renal	JJ	I-NP	O
allograft	NN	I-NP	O
presenting	VBG	B-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
allograft	NN	I-NP	O
dysfunction	NN	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
biopsy	NN	I-NP	O
specimen	NN	I-NP	O
showed	VBD	B-VP	O
pathognomonic	JJ	B-NP	O
features	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
eosinophilic	JJ	B-NP	O
infiltration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
interstitial	JJ	I-NP	O
compartment	NN	I-NP	O
.	.	O	O

Allograft	NN	B-NP	O
function	NN	I-NP	O
improved	VBD	B-VP	O
rapidly	RB	B-ADVP	O
and	CC	O	O
returned	VBD	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
after	IN	B-PP	O
stopping	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Late	RB	B-ADVP	O
,	,	O	O
late	JJ	B-NP	O
doxorubicin	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
complication	NN	I-NP	O
which	WDT	B-NP	O
limits	VBZ	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
chemotherapeutic	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Cardiomyopathy	NNP	B-NP	B
is	VBZ	B-VP	O
frequent	JJ	B-ADJP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
exceeds	VBZ	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
and	CC	O	O
occurs	VBZ	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
progressive	JJ	B-NP	O
cardiomyopathy	NN	I-NP	B
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
half	NN	I-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
which	WDT	B-NP	O
apparently	RB	B-ADVP	O
represents	VBZ	B-VP	O
late	JJ	B-NP	O
,	,	I-NP	O
late	JJ	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Acetazolamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrolithiasis	NN	I-NP	B
:	:	O	O
implications	NNS	B-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
neuromuscular	JJ	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

Carbonic	JJ	B-NP	O
anhydrase	NN	I-NP	O
inhibitors	NNS	I-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
nephrolithiasis	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
carbonic	JJ	I-NP	O
anhydrase	NN	I-NP	O
inhibitor	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
periodic	JJ	B-NP	O
paralysis	NN	I-NP	B
and	CC	I-NP	O
myotonia	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
on	IN	B-PP	O
acetazolamide	NN	B-NP	O
developed	VBD	B-VP	O
renal	JJ	B-NP	B
calculi	NNS	I-NP	I
.	.	O	O

Extracorporeal	JJ	B-NP	O
lithotripsy	NN	I-NP	O
successfully	RB	B-VP	O
removed	VBD	I-VP	O
a	DT	B-NP	O
renal	JJ	I-NP	B
calculus	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
and	CC	O	O
surgery	NN	B-NP	O
removed	VBD	B-VP	O
a	DT	B-NP	O
staghorn	JJ	I-NP	O
calculus	NN	I-NP	B
in	IN	B-PP	O
another	DT	B-NP	O
,	,	O	O
permitting	VBG	B-VP	O
continued	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
function	NN	I-NP	O
remained	VBD	B-VP	O
normal	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Nephrolithiasis	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
acetazolamide	NN	B-NP	O
but	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
preclude	VB	I-VP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
.	.	O	O

Is	VBZ	O	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
scabies	NNS	B-NP	B
hazardous	JJ	B-ADJP	O
?	.	O	O
Treatment	NN	B-NP	O
for	IN	B-PP	O
scabies	NNS	B-NP	B
is	VBZ	B-VP	O
usually	RB	I-VP	O
initiated	VBN	I-VP	O
by	IN	B-PP	O
general	JJ	B-NP	O
practitioners	NNS	I-NP	O
;	:	O	O
most	RBS	B-NP	O
consider	JJ	I-NP	O
lindane	NN	I-NP	O
(	(	O	O
gamma	NN	B-NP	O
benzene	NN	I-NP	O
hexachloride	NN	I-NP	O
)	)	O	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
.	.	O	O

Lindane	NN	B-NP	O
is	VBZ	B-VP	O
also	RB	B-ADVP	O
widely	RB	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
agricultural	JJ	I-NP	O
and	CC	I-NP	O
industrial	JJ	I-NP	O
pesticide	NN	I-NP	O
,	,	O	O
and	CC	O	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
insecticide	NN	I-NP	O
is	VBZ	B-VP	O
well	RB	I-VP	O
understood	VBN	I-VP	O
.	.	O	O

Evidence	NN	B-NP	O
is	VBZ	B-VP	O
accumulating	VBG	I-VP	O
that	DT	B-NP	O
lindane	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
toxic	JJ	B-ADJP	B
to	TO	B-PP	I
the	DT	B-NP	I
central	JJ	I-NP	I
nervous	JJ	I-NP	I
system	NN	I-NP	I
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
aplastic	JJ	B-NP	B
anaemia	NN	I-NP	I
.	.	O	O

Preparations	NNS	B-NP	O
containing	VBG	B-VP	O
lindane	NN	B-NP	O
continue	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
sold	VBN	I-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
counter	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
represent	VB	I-VP	O
a	DT	B-NP	O
hazard	NN	I-NP	O
to	TO	B-PP	O
poorly	RB	B-NP	O
informed	VBN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
literature	NN	I-NP	O
review	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
general	JJ	B-NP	O
practitioners	NNS	I-NP	O
should	MD	B-VP	O
prescribe	VB	I-VP	O
scabicides	NNS	B-NP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
caution	NN	I-NP	O
for	IN	B-PP	O
certain	JJ	B-NP	O
at	IN	B-PP	O
-	HYPH	B-NP	O
risk	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
and	CC	O	O
give	VB	B-VP	O
adequate	JJ	B-NP	O
warnings	NNS	I-NP	O
regarding	VBG	B-VP	O
potential	JJ	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Anaesthetists	NNS	B-NP	O
s	NNS	I-NP	O
nightmare	NN	I-NP	O
:	:	O	O
masseter	NN	B-NP	B
spasm	NN	I-NP	I
after	IN	B-PP	O
induction	NN	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
undiagnosed	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
myotonia	NN	B-NP	B
congenita	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
an	DT	B-NP	O
undiagnosed	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
myotonia	NN	B-NP	B
congenita	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
previously	RB	I-NP	O
healthy	JJ	I-NP	O
primigravida	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
life	NN	B-NP	O
threatening	JJ	I-NP	O
masseter	NN	I-NP	B
spasm	NN	I-NP	I
following	VBG	B-PP	O
a	DT	B-NP	O
standard	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
suxamethonium	NN	I-NP	O
for	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anaesthesia	NN	B-NP	O
.	.	O	O

Neither	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
nor	CC	O	O
the	DT	B-NP	O
anaesthetist	NN	I-NP	O
was	VBD	B-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
before	IN	B-PP	O
this	DT	B-NP	O
potentially	RB	I-NP	O
lethal	JJ	I-NP	O
complication	NN	I-NP	O
occurred	VBD	B-VP	O
.	.	O	O

Toxicity	NN	B-NP	B
in	IN	B-PP	O
rhesus	NN	B-NP	O
monkeys	NNS	I-NP	O
following	VBG	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
aminoquinoline	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
[	(	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
amino	JJ	I-NP	O
-	HYPH	I-NP	O
l	NN	I-NP	O
-	HYPH	I-NP	O
methylbutyl	NN	I-NP	O
)	)	O	O
amino	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
l	NN	B-NP	O
-	HYPH	I-NP	O
hexyloxy	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methoxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methylquinoline	NN	I-NP	O
(	(	O	O
WR242511	NN	B-NP	O
)	)	O	O
.	.	O	O

Many	JJ	B-NP	O
substances	NNS	I-NP	O
that	WDT	B-NP	O
form	VBP	B-VP	O
methemoglobin	NN	B-NP	O
(	(	O	O
MHb	NN	B-NP	O
)	)	O	O
effectively	RB	B-VP	O
counter	VBP	I-VP	O
cyanide	NN	B-NP	O
(	(	O	O
CN	NN	B-NP	O
)	)	O	O
toxicity	NN	B-NP	B
.	.	O	O

Although	IN	B-SBAR	O
MHb	NN	B-NP	O
formers	NNS	I-NP	O
are	VBP	B-VP	O
generally	RB	I-VP	O
applied	VBN	I-VP	O
as	IN	B-PP	O
treatments	NNS	B-NP	O
for	IN	B-PP	O
CN	NN	B-NP	O
poisoning	NN	I-NP	B
,	,	O	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
stable	JJ	I-NP	O
,	,	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	I-NP	O
MHb	NN	I-NP	O
former	JJ	B-ADJP	O
could	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
CN	NN	I-NP	O
pretreatment	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
this	DT	B-NP	O
rationale	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
aminoquinoline	NN	I-NP	O
WR242511	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
potent	JJ	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
lasting	VBG	B-VP	O
MHb	NN	B-NP	O
former	JJ	B-ADJP	O
in	IN	B-PP	O
rodents	NNS	B-NP	O
and	CC	O	O
beagle	NN	B-NP	O
dogs	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
rhesus	NN	I-NP	O
monkey	NN	I-NP	O
for	IN	B-PP	O
advanced	VBN	B-NP	O
development	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
CN	NN	I-NP	O
pretreatment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
WR242511	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intravenously	RB	B-ADVP	O
(	(	O	O
num	CD	B-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
female	JJ	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
male	JJ	I-NP	O
rhesus	NN	I-NP	O
monkeys	NNS	I-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
;	:	O	O
a	DT	B-NP	O
single	JJ	I-NP	O
male	NN	I-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
WR242511	NN	B-NP	O
orally	RB	B-ADVP	O
(	(	O	O
PO	NN	B-NP	O
)	)	O	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Health	NNP	B-NP	O
status	NN	I-NP	O
and	CC	I-NP	O
MHb	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
following	VBG	B-PP	O
exposure	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
selected	VBN	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
WR242511	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
produced	VBD	B-VP	O
significant	JJ	B-NP	O
methemoglobinemia	NN	I-NP	B
in	IN	B-PP	O
beagle	NN	B-NP	O
dogs	NNS	I-NP	O
in	IN	B-PP	O
earlier	JJR	B-NP	O
studies	NNS	I-NP	O
conducted	VBN	B-VP	O
elsewhere	RB	B-ADVP	O
,	,	O	O
produced	VBD	B-VP	O
very	RB	B-NP	O
little	JJ	I-NP	O
MHb	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rhesus	NN	I-NP	O
monkey	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
transient	JJ	B-NP	O
hemoglobinuria	NN	I-NP	B
was	VBD	B-VP	O
noted	VBN	I-VP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
postinjection	NN	I-NP	O
of	IN	B-PP	O
WR242511	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
lethalities	NNS	I-NP	O
occurred	VBD	B-VP	O
(	(	O	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	O	O
num	CD	B-NP	O
PO	NN	I-NP	O
)	)	O	O
following	VBG	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Myoglobinuria	NN	B-NP	B
was	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
following	VBG	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Histopathology	NN	B-NP	O
analyses	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
animals	NNS	I-NP	O
that	WDT	B-NP	O
died	VBD	B-VP	O
revealed	VBN	B-NP	O
liver	NN	I-NP	B
and	CC	I-NP	I
kidney	NN	I-NP	I
toxicity	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
greater	JJR	B-NP	O
severity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
orally	RB	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
animal	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
demonstrate	VBP	B-VP	O
direct	JJ	B-ADJP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
indirect	JJ	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
WR242511	NN	B-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
pursued	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
pretreatment	NN	I-NP	O
for	IN	B-PP	O
CN	NN	B-NP	O
poisoning	VBG	B-VP	B
unless	IN	B-SBAR	O
the	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
CN	NN	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
compound	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
successfully	RB	I-VP	O
dissociated	VBN	I-VP	O
from	IN	B-PP	O
those	DT	B-NP	O
producing	VBG	B-VP	O
undesirable	JJ	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Neuroplasticity	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
adult	JJ	I-NP	O
primate	JJ	I-NP	O
auditory	JJ	I-NP	O
cortex	NN	I-NP	O
following	VBG	B-PP	O
cochlear	JJ	B-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
.	.	O	O

Tonotopic	JJ	B-NP	O
organization	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
essential	JJ	I-NP	O
feature	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
auditory	JJ	I-NP	O
area	NN	I-NP	O
(	(	O	O
A1	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
primate	JJ	B-NP	O
cortex	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
A1	NN	B-NP	O
of	IN	B-PP	O
macaque	NN	B-NP	O
monkeys	NNS	I-NP	O
,	,	O	O
low	JJ	B-NP	O
frequencies	NNS	I-NP	O
are	VBP	B-VP	O
represented	VBN	I-VP	O
rostrolaterally	RB	B-ADVP	O
and	CC	O	O
high	JJ	B-NP	O
frequencies	NNS	I-NP	O
are	VBP	B-VP	O
represented	VBN	I-VP	O
caudomedially	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
changes	NNS	B-NP	O
occur	VBP	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
tonotopic	JJ	I-NP	O
organization	NN	I-NP	O
following	VBG	B-PP	O
cochlear	JJ	B-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
.	.	O	O

Under	IN	B-PP	O
anesthesia	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
superior	JJ	I-NP	O
temporal	JJ	I-NP	O
gyrus	NN	I-NP	O
of	IN	B-PP	O
adult	JJ	B-NP	O
macaque	NN	I-NP	O
monkeys	NNS	I-NP	O
was	VBD	B-VP	O
exposed	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
tonotopic	JJ	I-NP	O
organization	NN	I-NP	O
of	IN	B-PP	O
A1	NN	B-NP	O
was	VBD	B-VP	O
mapped	VBN	I-VP	O
using	VBG	B-VP	O
conventional	JJ	B-NP	O
microelectrode	NN	I-NP	O
recording	NN	I-NP	O
techniques	NNS	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
recovery	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
monkeys	NNS	I-NP	O
were	VBD	B-VP	O
selectively	RB	I-VP	O
deafened	VBN	I-VP	O
for	IN	B-PP	O
high	JJ	B-NP	O
frequencies	NNS	I-NP	O
using	VBG	B-VP	O
kanamycin	NN	B-NP	O
and	CC	I-NP	O
furosemide	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
actual	JJ	I-NP	O
frequencies	NNS	I-NP	O
deafened	VBN	B-VP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
tone	NN	B-NP	O
-	HYPH	B-NP	O
burst	NN	I-NP	O
elicited	VBD	B-VP	O
auditory	JJ	B-NP	O
brainstem	NN	I-NP	O
responses	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
deafening	NN	B-NP	O
,	,	O	O
A1	NN	B-NP	O
was	VBD	B-VP	O
remapped	VBN	I-VP	O
.	.	O	O

Postmortem	JJ	B-NP	O
cytoarchitectural	JJ	I-NP	O
features	NNS	I-NP	O
identifying	VBG	B-VP	O
A1	NN	B-NP	O
were	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
electrophysiologic	JJ	I-NP	O
data	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
deprived	VBN	I-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
A1	NN	B-NP	O
undergoes	VBZ	B-VP	O
extensive	JJ	B-NP	O
reorganization	NN	I-NP	O
and	CC	O	O
becomes	VBZ	B-VP	O
responsive	JJ	B-ADJP	O
to	TO	B-PP	O
intact	JJ	B-NP	O
cochlear	JJ	I-NP	O
frequencies	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
cortex	NN	B-NP	O
that	WDT	B-NP	O
represents	VBZ	B-VP	O
the	DT	B-NP	O
low	JJ	I-NP	O
frequencies	NNS	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
obviously	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
cochlear	JJ	I-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
common	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
sumatriptan	NN	B-NP	O
.	.	O	O

Atypical	JJ	B-NP	B
sensations	NNS	I-NP	I
following	VBG	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
subcutaneous	JJ	B-NP	O
sumatriptan	NN	I-NP	O
are	VBP	B-VP	O
common	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
of	IN	B-PP	O
uncertain	JJ	B-NP	O
origin	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
are	VBP	B-VP	O
almost	RB	B-ADJP	O
always	RB	I-ADJP	O
benign	JJ	I-ADJP	O
,	,	O	O
but	CC	O	O
can	MD	B-VP	O
be	VB	I-VP	O
mistaken	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
with	IN	B-PP	O
tingling	VBG	B-VP	B
or	CC	I-VP	I
burning	VBG	I-VP	I
sensations	NNS	B-NP	I
limited	VBN	B-VP	O
to	TO	B-PP	O
areas	NNS	B-NP	O
of	IN	B-PP	O
heat	NN	B-NP	O
exposure	NN	I-NP	O
or	CC	I-NP	O
sunburn	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
individuals	NNS	I-NP	O
,	,	O	O
side	NN	B-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
most	RBS	I-VP	O
likely	RB	I-VP	O
generated	VBN	I-VP	O
superficially	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
skin	NN	I-NP	O
.	.	O	O

Tremor	NN	B-NP	B
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
salbutamol	NN	B-NP	O
,	,	O	O
quantified	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
laser	NN	I-NP	O
pointer	NN	I-NP	O
technique	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
study	VB	I-VP	O
tremor	NN	B-NP	B
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
salbutamol	NN	B-NP	O
an	DT	B-NP	O
easily	RB	I-NP	O
applicable	JJ	I-NP	O
,	,	I-NP	O
quick	JJ	I-NP	O
and	CC	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
priced	VBN	I-NP	O
method	NN	I-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
new	JJ	I-NP	O
method	NN	I-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
commercially	RB	I-NP	O
available	JJ	B-ADJP	O
,	,	O	O
pen	NN	B-NP	O
-	HYPH	B-VP	O
shaped	VBN	B-NP	O
laser	NN	I-NP	O
pointer	NN	I-NP	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
.	.	O	O

Aim	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
sensitivity	NN	B-NP	O
,	,	O	O
reproducibility	NN	B-NP	O
,	,	O	O
reference	NN	B-NP	O
values	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
agreement	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
questionnaire	NN	I-NP	O
.	.	O	O

Tremor	NN	B-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
laser	NN	I-NP	O
pointer	NN	I-NP	O
technique	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
sensitivity	NN	B-NP	O
we	PRP	B-NP	O
assessed	VBD	B-VP	O
tremor	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
obstructive	JJ	B-NP	B
lung	NN	I-NP	I
disease	NN	I-NP	I
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
cumulative	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
salbutamol	NN	B-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
were	VBD	B-VP	O
asked	VBN	I-VP	O
to	TO	B-VP	O
aim	VB	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
centre	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
target	NN	I-NP	O
,	,	O	O
subdivided	VBN	B-VP	O
in	IN	B-PP	O
concentric	JJ	B-NP	O
circles	NNS	I-NP	O
,	,	O	O
from	IN	B-PP	O
num	CD	B-NP	O
m	NN	I-NP	O
distance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
circle	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
participant	NN	I-NP	O
succeeded	VBD	B-VP	O
to	TO	B-PP	O
aim	NN	B-NP	O
was	VBD	B-VP	O
recorded	VBN	I-VP	O
in	IN	B-PP	O
millimetres	NNS	B-NP	O
radius	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
another	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
measurements	NNS	B-NP	O
,	,	O	O
reproducibility	NN	B-NP	O
and	CC	I-NP	O
reference	NN	I-NP	O
values	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tremor	NN	I-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
sessions	NNS	I-NP	O
,	,	O	O
at	IN	B-PP	O
num	CD	B-NP	O
a.m.	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
p.m.	RB	I-NP	O
and	CC	O	O
num	CD	B-NP	O
a.m.	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Postural	JJ	B-NP	O
tremor	NN	I-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
arm	NN	I-NP	O
horizontally	RB	B-ADVP	O
outstretched	VBD	B-VP	O
rest	NN	B-NP	O
tremor	NN	I-NP	B
with	IN	B-PP	O
the	DT	B-NP	O
arm	NN	I-NP	O
supported	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
armrest	NN	I-NP	O
and	CC	O	O
finally	RB	B-ADVP	O
tremor	NN	B-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
after	IN	B-PP	O
holding	VBG	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
kg	NN	I-NP	O
weight	NN	I-NP	O
until	IN	B-PP	O
exhaustion	NN	B-NP	O
.	.	O	O

Inter	AFX	B-NP	O
-	HYPH	I-NP	O
observer	NN	I-NP	O
variability	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Tremor	NN	B-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
by	IN	B-PP	O
num	CD	B-NP	O
independent	JJ	I-NP	O
observers	NNS	I-NP	O
.	.	O	O

Salbutamol	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
tremor	NN	B-NP	B
severity	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
way	NN	I-NP	O
.	.	O	O

Within	IN	B-PP	O
healthy	JJ	B-NP	O
adults	NNS	I-NP	O
no	DT	B-NP	O
age	NN	I-NP	O
-	HYPH	B-NP	O
dependency	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
found	VBN	I-VP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
agreement	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
questionnaire	NN	I-NP	O
and	CC	I-NP	O
tremor	NN	I-NP	B
severity	NN	I-NP	O
.	.	O	O

Postural	JJ	B-NP	O
tremor	NN	I-NP	B
showed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
and	CC	I-NP	O
third	JJ	I-NP	O
session	NN	I-NP	O
.	.	O	O

Support	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arm	NN	I-NP	O
decreased	VBD	B-VP	O
tremor	NN	B-NP	B
severity	NN	I-NP	O
,	,	O	O
exhaustion	NN	B-NP	O
increased	VBD	B-VP	O
tremor	NN	B-NP	B
severity	NN	I-NP	O
significantly	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
good	JJ	I-NP	O
agreement	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
independent	JJ	I-NP	O
observers	NNS	I-NP	O
(	(	O	O
interclass	NN	B-NP	O
correlation	NN	I-NP	O
coefficient	JJ	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Quantifying	VBG	B-VP	O
tremor	NN	B-NP	B
by	IN	B-PP	O
using	VBG	B-VP	O
an	DT	B-NP	O
inexpensive	JJ	I-NP	O
laser	NN	I-NP	O
pointer	NN	I-NP	O
is	VBZ	B-VP	O
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
exception	NN	I-NP	O
of	IN	B-PP	O
children	NNS	B-NP	O
a	DT	B-NP	O
sensitive	JJ	I-NP	O
and	CC	I-NP	O
reproducible	JJ	I-NP	O
method	NN	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
with	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
docetaxel	NN	B-NP	O
and	CC	I-NP	O
thalidomide	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
metastatic	JJ	B-NP	O
androgen	NN	I-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
(	(	O	O
VTE	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
androgen	NN	I-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
who	WP	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
docetaxel	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
thalidomide	NN	B-NP	O
.	.	O	O

Retrospective	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
.	.	O	O

National	NNP	B-NP	O
Institutes	NNPS	I-NP	O
of	IN	B-PP	O
Health	NNP	B-NP	O
clinical	JJ	B-NP	O
research	NN	I-NP	O
center	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
men	NNS	I-NP	O
,	,	O	O
aged	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
androgen	NN	I-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Each	DT	B-NP	O
patient	NN	I-NP	O
received	VBD	B-VP	O
either	CC	O	O
intravenous	JJ	B-NP	O
docetaxel	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	B-NP	O
week	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
off	RB	B-ADVP	O
,	,	O	O
or	CC	O	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
continuous	JJ	B-NP	O
oral	JJ	I-NP	O
thalidomide	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
every	DT	B-NP	O
evening	NN	I-NP	O
plus	CC	O	O
the	DT	B-NP	O
same	JJ	I-NP	O
docetaxel	NN	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
cycle	NN	I-NP	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
until	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
excessive	JJ	B-NP	O
toxicity	NN	I-NP	B
or	CC	I-NP	O
disease	NN	I-NP	O
progression	NN	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
docetaxel	NN	B-NP	O
alone	RB	B-ADVP	O
developed	VBD	B-VP	O
VTE	NNP	B-NP	B
,	,	O	O
whereas	IN	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
docetaxel	NN	B-NP	O
plus	CC	I-NP	O
thalidomide	NN	I-NP	O
developed	VBD	B-VP	O
VTE	NNP	B-NP	B
.	.	O	O

The	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
to	TO	B-PP	O
docetaxel	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
significantly	RB	B-ADVP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
potential	JJ	I-NP	O
complication	NN	I-NP	O
when	WRB	B-ADVP	O
adding	VBG	B-VP	O
thalidomide	NN	B-NP	O
to	TO	B-PP	O
chemotherapeutic	JJ	B-NP	O
regimens	NNS	I-NP	O
.	.	O	O

Sublingual	JJ	B-NP	O
absorption	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
quaternary	JJ	I-NP	O
ammonium	NN	I-NP	O
antiarrhythmic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
UM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
.	.	O	O

UM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
N	NN	B-NP	O
,	,	O	O
N	NN	B-NP	O
-	HYPH	B-NP	O
dimethylpropranolol	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
quaternary	JJ	I-NP	O
antiarrhythmic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
sublingually	RB	B-ADVP	O
to	TO	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
ouabain	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ventricular	JJ	I-NP	B
tachycardias	NNS	I-NP	I
.	.	O	O

Both	CC	O	O
anti	AFX	O	O
-	HYPH	B-NP	O
arrhythmic	JJ	I-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
bioavailability	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
oral	JJ	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Sublingual	JJ	B-NP	O
UM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
converted	VBD	B-VP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
to	TO	B-PP	O
sinus	NN	B-NP	O
rhythm	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
time	NN	I-NP	O
curve	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
num	CD	I-ADJP	O
times	NNS	I-ADJP	O
greater	JJR	I-ADJP	O
than	IN	B-PP	O
for	IN	B-PP	O
oral	JJ	B-NP	O
drug	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
existence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
absorption	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
process	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
intestine	NN	I-NP	O
,	,	O	O
and	CC	O	O
providing	VBG	B-VP	O
an	DT	B-NP	O
alternate	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
for	IN	B-PP	O
quaternary	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
thrombocytopenia	NN	I-NP	B
and	CC	O	O
haemolytic	JJ	B-NP	B
anaemia	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
with	IN	B-PP	O
fatal	JJ	B-NP	O
outcome	NN	I-NP	O
.	.	O	O

Haematological	JJ	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
fatal	JJ	B-NP	O
outcome	NN	I-NP	O
are	VBP	B-VP	O
rare	JJ	B-ADJP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
Caucasian	JJ	I-NP	O
man	NN	I-NP	O
reported	VBN	B-VP	O
with	IN	B-PP	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
and	CC	I-NP	O
jaundice	NN	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
ciprofloxacin	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
suspect	NN	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	B
tract	NN	I-NP	I
infection	NN	I-NP	I
.	.	O	O

Clinical	JJ	B-NP	O
evaluations	NNS	I-NP	O
suggested	VBD	B-VP	O
an	DT	B-NP	O
initial	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
thrombocytopenia	NN	I-NP	B
and	CC	I-NP	O
haemolysis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
progressively	RB	B-ADVP	O
developed	VBD	B-VP	O
petechiae	NN	B-NP	B
and	CC	I-NP	O
purpura	NN	I-NP	B
on	IN	B-PP	O
thorax	NN	B-NP	O
and	CC	O	O
lower	JJR	B-NP	O
limbs	NNS	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
pharmacological	JJ	B-NP	O
and	CC	I-NP	O
supportive	JJ	I-NP	O
interventions	NNS	I-NP	O
,	,	O	O
laboratory	NN	B-NP	O
parameters	NNS	I-NP	O
worsened	VBD	B-VP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
died	VBD	B-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
admission	NN	B-NP	O
.	.	O	O

An	DT	B-NP	O
accurate	JJ	I-NP	O
autopsy	NN	I-NP	O
revealed	VBD	B-VP	O
most	JJS	B-NP	O
organs	NNS	I-NP	O
with	IN	B-PP	O
diffuse	JJ	B-NP	O
petechial	JJ	I-NP	O
haemorrhages	NNS	I-NP	B
.	.	O	O

No	DT	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
bone	NN	B-NP	B
marrow	NN	I-NP	I
depression	NN	I-NP	I
were	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

No	DT	B-NP	O
thrombi	NN	I-NP	B
or	CC	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
microangiopathies	NNS	B-NP	B
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
arterial	JJ	B-NP	O
vessels	NNS	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
cultures	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
show	VB	I-VP	O
any	DT	B-NP	O
bacterial	JJ	I-NP	O
growth	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
ciprofloxacin	NN	B-NP	O
may	MD	B-VP	O
precipitate	VB	I-VP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
thrombocytopenia	NN	B-NP	B
and	CC	O	O
haemolytic	JJ	B-NP	B
anaemia	NN	I-NP	I
,	,	O	O
even	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
phases	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
and	CC	O	O
without	IN	B-PP	O
apparent	JJ	B-NP	O
previous	JJ	I-NP	O
exposures	NNS	I-NP	O
.	.	O	O

Simvastatin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
bilateral	JJ	I-NP	O
leg	NN	I-NP	O
compartment	NN	I-NP	B
syndrome	NN	I-NP	I
and	CC	I-NP	O
myonecrosis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
hypothyroidism	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
hypothyroid	NN	I-NP	B
male	JJ	B-NP	O
taking	VBG	I-NP	O
thyroxine	NN	I-NP	O
and	CC	I-NP	O
simvastatin	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
bilateral	JJ	B-NP	O
leg	NN	I-NP	O
compartment	NN	I-NP	B
syndrome	NN	I-NP	I
and	CC	I-NP	O
myonecrosis	NN	I-NP	B
.	.	O	O

Urgent	JJ	B-NP	O
fasciotomies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
made	VBD	B-VP	O
an	DT	B-NP	O
uneventful	JJ	I-NP	O
recovery	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
simvastatin	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
complication	NN	I-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
seen	VBN	I-VP	O
more	RBR	B-ADVP	O
often	RB	I-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
worldwide	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
approval	NN	I-NP	O
for	IN	B-PP	O
all	DT	B-NP	O
arteriopathic	JJ	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

Bile	NN	B-NP	B
duct	NN	I-NP	I
hamartoma	NN	I-NP	I
occurring	VBG	B-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
danazol	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
bile	NN	B-NP	B
duct	NN	I-NP	I
hamartoma	NN	I-NP	I
which	WDT	B-NP	O
developed	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
on	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
danazol	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Such	JJ	B-NP	O
patients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
under	IN	B-PP	O
close	JJ	B-ADJP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
,	,	O	O
preferably	RB	B-ADVP	O
with	IN	B-PP	O
periodic	JJ	B-NP	O
ultrasound	NN	I-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
.	.	O	O

If	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
develops	VBZ	B-VP	O
a	DT	B-NP	O
liver	NN	I-NP	B
mass	NN	I-NP	I
,	,	O	O
because	IN	B-PP	O
of	IN	I-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
clinical	JJ	I-NP	O
features	NNS	I-NP	O
and	CC	O	O
imaging	NN	B-NP	O
appearances	NNS	I-NP	O
,	,	O	O
biopsy	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
only	JJ	I-NP	O
way	NN	I-NP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
a	DT	B-NP	O
definitive	JJ	I-NP	O
diagnosis	NN	I-NP	O
.	.	O	O

Granulomatous	JJ	B-NP	B
hepatitis	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
combination	NN	B-NP	O
of	IN	B-PP	O
amoxicillin	NN	B-NP	O
and	CC	O	O
clavulanic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
amoxicillin	NN	B-NP	O
-	HYPH	O	O
clavulanic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
hepatitis	NN	I-NP	B
with	IN	B-PP	O
histologic	JJ	B-NP	O
multiple	JJ	I-NP	O
granulomas	NNS	I-NP	B
.	.	O	O

This	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
lesion	NN	B-NP	O
broadens	VBZ	B-VP	O
the	DT	B-NP	O
spectrum	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	B
injury	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
combination	NN	I-NP	O
,	,	O	O
mainly	RB	B-VP	O
represented	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
benign	JJ	I-NP	O
cholestatic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
of	IN	B-PP	O
granulomas	NNS	B-NP	B
and	CC	O	O
eosinophilia	NN	B-NP	B
favor	VBP	B-VP	O
an	DT	B-NP	O
immunoallergic	JJ	I-NP	O
mechanism	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
penicillin	NN	B-NP	O
derivatives	NNS	I-NP	O
and	CC	O	O
amoxicillin	NN	B-NP	O
alone	RB	B-ADVP	O
are	VBP	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
induce	VB	I-VP	O
such	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
lesions	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
amoxicillin	NN	I-NP	O
component	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
a	DT	B-NP	O
potentiating	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
clavulanic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
might	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
.	.	O	O

Intracranial	JJ	B-NP	B
aneurysms	NNS	I-NP	I
and	CC	O	O
cocaine	NN	B-NP	B
abuse	NN	I-NP	I
:	:	O	O
analysis	NN	B-NP	O
of	IN	B-PP	O
prognostic	JJ	B-NP	O
indicators	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
outcome	NN	I-NP	O
of	IN	B-PP	O
subarachnoid	JJ	B-NP	B
hemorrhage	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
cocaine	NN	B-NP	B
abuse	NN	I-NP	I
is	VBZ	B-VP	O
reportedly	RB	B-ADJP	O
poor	JJ	I-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
has	VBZ	B-VP	O
reported	VBN	I-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
statistical	JJ	I-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
analyze	VB	I-VP	O
the	DT	B-NP	O
variables	NNS	I-NP	O
that	WDT	B-NP	O
influence	VBP	B-VP	O
outcome	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
admissions	NNS	B-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
revealed	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
aneurysms	NNS	I-NP	B
.	.	O	O

This	DT	B-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
ruptured	JJ	B-NP	B
aneurysms	NNS	I-NP	I
and	CC	O	O
no	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	B
abuse	NN	I-NP	I
.	.	O	O

Age	NN	B-NP	O
at	IN	B-PP	O
presentation	NN	B-NP	O
,	,	O	O
time	NN	B-NP	O
of	IN	B-PP	O
ictus	NN	B-NP	O
after	IN	B-PP	O
intoxication	NN	B-NP	O
,	,	O	O
Hunt	NNP	B-NP	O
and	CC	I-NP	O
Hess	NNP	I-NP	O
grade	NN	I-NP	O
of	IN	B-PP	O
subarachnoid	JJ	B-NP	B
hemorrhage	NN	I-NP	I
,	,	O	O
size	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
aneurysm	NN	I-NP	B
,	,	O	O
location	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
aneurysm	NN	I-NP	B
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
Glasgow	NNP	I-NP	O
Outcome	NNP	I-NP	O
Scale	NNP	I-NP	O
score	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
and	CC	O	O
compared	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
younger	JJR	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
all	DT	B-NP	O
aneurysms	NNS	I-NP	B
were	VBD	B-VP	O
located	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
circulation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
aneurysms	NNS	I-NP	B
were	VBD	B-VP	O
smaller	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
mortality	NN	B-NP	O
and	CC	I-NP	O
morbidity	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
significant	JJ	B-ADJP	O
.	.	O	O

Hunt	NNP	B-NP	O
and	CC	I-NP	O
Hess	NNP	I-NP	O
grade	NN	I-NP	O
and	CC	I-NP	O
age	NN	I-NP	O
were	VBD	B-VP	O
significant	JJ	B-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
outcome	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
aneurysms	NNS	I-NP	B
.	.	O	O

Cocaine	NN	B-NP	O
use	NN	I-NP	O
predisposed	VBD	B-VP	O
aneurysmal	JJ	B-NP	B
rupture	NN	I-NP	I
at	IN	B-PP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
earlier	JJR	I-NP	O
age	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
much	RB	B-NP	O
smaller	JJR	I-NP	O
aneurysms	NNS	I-NP	B
.	.	O	O

Contrary	JJ	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
published	VBN	I-NP	O
literature	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
group	NN	I-NP	O
did	VBD	B-VP	O
reasonably	RB	B-ADVP	O
well	RB	I-ADVP	O
with	IN	B-PP	O
aggressive	JJ	B-NP	O
management	NN	I-NP	O
.	.	O	O

Anti	AFX	B-NP	O
-	HYPH	I-NP	O
epileptic	JJ	B-NP	B
drugs	NNS	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
absence	NN	I-NP	B
seizures	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
present	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
de	FW	B-NP	O
novo	FW	I-NP	O
absence	NN	I-NP	B
epilepsy	NN	I-NP	I
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
and	CC	I-NP	O
vigabatrin	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
diseases	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
prognosis	NN	I-NP	O
for	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
absence	NN	I-NP	B
seizure	NN	I-NP	I
is	VBZ	B-VP	O
good	JJ	B-ADJP	O
because	IN	B-SBAR	O
it	PRP	B-NP	O
subsides	VBZ	B-VP	O
rapidly	RB	B-ADVP	O
after	IN	B-PP	O
discontinuing	VBG	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
offending	VBG	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
gamma	NN	I-NP	O
-	HYPH	O	O
aminobutyric	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
transmitted	VBN	B-VP	O
thalamocortical	JJ	B-NP	O
circuitry	NN	I-NP	O
accounts	VBZ	B-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
major	JJ	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
neurophysiology	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	B
epilepsy	NN	I-NP	I
.	.	O	O

Because	IN	B-SBAR	O
drug	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
absence	NN	I-NP	B
seizure	NN	I-NP	I
is	VBZ	B-VP	O
rare	JJ	B-ADJP	O
,	,	O	O
pro	AFX	O	O
-	HYPH	O	O
absence	NN	B-NP	O
drugs	NNS	I-NP	O
can	MD	B-VP	O
only	RB	I-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
a	DT	B-NP	O
promoting	VBG	I-NP	O
factor	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
underlying	VBG	I-NP	O
epileptogenecity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
or	CC	O	O
the	DT	B-NP	O
synergistic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
accompanying	VBG	I-NP	O
drugs	NNS	I-NP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
to	TO	I-VP	O
trigger	VB	I-VP	O
the	DT	B-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
absence	NN	I-NP	B
seizure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aggravation	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
whenever	WRB	B-ADVP	O
an	DT	B-NP	O
unexpected	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
seizure	NN	B-NP	B
frequency	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
new	JJ	B-NP	O
seizure	NN	I-NP	B
types	NNS	I-NP	O
appear	VBP	B-VP	O
following	VBG	I-VP	O
a	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
understanding	VBG	B-VP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
absence	NN	B-NP	B
epilepsy	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
can	MD	B-VP	O
avoid	VB	I-VP	O
the	DT	B-NP	O
inappropriate	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
anticonvulsants	NNS	B-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
epilepsy	NN	B-NP	B
and	CC	O	O
prevent	VBP	B-VP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
absence	NN	I-NP	B
seizures	NNS	I-NP	I
.	.	O	O

Procainamide	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
polymorphous	JJ	I-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
procainamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polymorphous	JJ	I-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
are	VBP	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
polymorphous	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
appeared	VBD	B-VP	O
after	IN	B-SBAR	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
procainamide	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
sustained	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
procainamide	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
orally	RB	B-ADVP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
premature	JJ	I-NP	B
ventricular	JJ	I-NP	I
contractions	NNS	I-NP	I
or	CC	O	O
atrial	JJ	B-NP	B
flutter	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
Q	NN	B-NP	B
-	HYPH	I-NP	I
T	NN	I-NP	I
prolongation	NN	I-NP	I
and	CC	O	O
recurrent	JJ	B-NP	O
syncope	NN	I-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
polymorphous	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
was	VBD	B-VP	O
rapidly	RB	I-VP	O
diagnosed	VBN	I-VP	O
and	CC	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
disappearance	NN	B-NP	O
of	IN	B-PP	O
further	JJ	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
degenerated	VBD	B-VP	O
into	IN	B-PP	O
irreversible	JJ	B-NP	O
ventricular	JJ	I-NP	B
fibrillation	NN	I-NP	I
and	CC	O	O
both	DT	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
seventh	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
permanent	JJ	I-NP	O
ventricular	JJ	I-NP	O
pacemaker	NN	I-NP	O
was	VBD	B-VP	O
inserted	VBN	I-VP	O
and	CC	O	O
,	,	O	O
despite	IN	B-PP	O
continuation	NN	B-NP	O
of	IN	B-PP	O
procainamide	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
polymorphous	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
did	VBD	B-VP	O
not	RB	I-VP	O
reoccur	VB	I-VP	O
.	.	O	O

These	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
procainamide	NN	B-NP	O
can	MD	B-VP	O
produce	VB	I-VP	O
an	DT	B-NP	O
acquired	VBN	I-NP	O
prolonged	VBN	I-NP	B
Q	NN	I-NP	I
-	HYPH	I-NP	I
T	NN	I-NP	I
syndrome	NN	I-NP	I
with	IN	B-PP	O
polymorphous	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

Role	NN	B-NP	O
of	IN	B-PP	O
activation	NN	B-NP	O
of	IN	B-PP	O
bradykinin	NN	B-NP	O
B2	NN	I-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
disruption	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
during	IN	B-PP	O
acute	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Cellular	JJ	B-NP	O
mechanisms	NNS	I-NP	O
which	WDT	B-NP	O
account	VBP	B-VP	O
for	IN	B-PP	O
disruption	NN	B-NP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
during	IN	B-PP	O
acute	JJ	B-NP	O
hypertension	NN	I-NP	B
are	VBP	B-VP	O
not	RB	O	O
clear	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
synthesis	NN	B-NP	O
/	SYM	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
bradykinin	NN	B-NP	O
to	TO	B-VP	O
activate	VB	I-VP	O
B2	NN	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
disruption	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
during	IN	B-PP	O
acute	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Permeability	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
was	VBD	B-VP	O
quantitated	VBN	I-VP	O
by	IN	B-PP	O
clearance	NN	B-NP	O
of	IN	B-PP	O
fluorescent	NN	B-NP	O
-	HYPH	O	O
labeled	VBN	B-VP	O
dextran	NN	B-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
during	IN	I-PP	O
phenylephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
vehicle	NN	B-NP	O
and	CC	I-NP	O
Hoe	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
microM	NN	I-NP	O
)	)	O	O
.	.	O	O

Phenylephrine	NN	B-NP	O
infusion	NN	I-NP	O
increased	VBD	B-VP	O
arterial	JJ	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
arteriolar	JJ	B-NP	O
diameter	NN	I-NP	O
and	CC	I-NP	O
clearance	NN	I-NP	O
of	IN	B-PP	O
fluorescent	JJ	B-NP	O
dextran	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
magnitude	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
disruption	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
during	IN	B-PP	O
acute	JJ	B-NP	O
hypertension	NN	I-NP	B
is	VBZ	B-VP	O
not	RB	O	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
synthesis	NN	I-NP	O
/	SYM	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
bradykinin	NN	B-NP	O
to	TO	B-VP	O
activate	VB	I-VP	O
B2	NN	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
azacytidine	NN	I-NP	O
potentiates	VBZ	B-VP	O
initiation	NN	B-NP	B
induced	VBN	B-VP	I
by	IN	B-PP	I
carcinogens	NNS	B-NP	I
in	IN	B-PP	O
rat	NN	B-NP	O
liver	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
validity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
hypomethylation	NN	B-NP	O
of	IN	B-PP	O
DNA	NN	B-NP	O
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	B
of	IN	B-PP	I
carcinogenic	JJ	B-NP	I
process	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
azacytidine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
AzC	NN	I-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
DNA	NN	B-NP	O
methylation	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
repair	NN	B-NP	O
synthesis	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
carcinogens	NNS	I-NP	O
,	,	O	O
benzo	NN	B-NP	O
[	(	O	O
a	DT	O	O
]	)	O	O
-	HYPH	B-NP	O
pyrene	NN	I-NP	O
,	,	O	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
nitrosourea	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dimethylhydrazine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DMH	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
initiated	VBN	I-NP	O
hepatocytes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
were	VBD	B-VP	O
assayed	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
glutamyltransferase	NN	I-NP	O
(	(	O	O
gamma	SYM	B-NP	O
-	HYPH	I-NP	O
GT	NN	I-NP	O
)	)	I-NP	O
positive	JJ	I-NP	O
foci	NNS	I-NP	O
formed	VBN	B-VP	O
following	VBG	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
selection	NN	I-NP	O
regimen	NN	I-NP	O
consisting	VBG	B-VP	O
of	IN	B-PP	O
dietary	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
acetylaminofluorene	NN	I-NP	O
coupled	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
necrogenic	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
CCl4	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
obtained	VBN	B-VP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
with	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
carcinogens	NNS	I-NP	O
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
AzC	NN	I-NP	O
during	IN	B-PP	O
repair	NN	B-NP	O
synthesis	NN	I-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
initiated	VBN	B-NP	O
hepatocytes	NNS	I-NP	O
,	,	O	O
for	IN	B-PP	O
example	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
foci	NNS	I-NP	O
/	SYM	B-NP	O
cm2	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
AzC	NN	I-NP	O
and	CC	I-NP	O
carcinogen	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
foci	NNS	I-NP	O
/	SYM	B-NP	O
cm2	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
carcinogen	NN	B-NP	O
only	RB	B-ADVP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
azadeoxycytidine	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
repair	NN	I-NP	O
synthesis	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DMH	NN	I-NP	O
further	RB	B-ADVP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
mol	NN	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
cytosine	NN	B-NP	O
residues	NNS	I-NP	O
in	IN	B-PP	O
DNA	NN	B-NP	O
were	VBD	B-VP	O
substituted	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
analogue	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
incorporation	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
AzC	NN	I-NP	O
occurs	VBZ	B-VP	O
during	IN	B-PP	O
repair	NN	B-NP	O
synthesis	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
carcinogen	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
AzC	NN	I-NP	O
given	VBN	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
thirds	NNS	I-NP	O
partial	JJ	I-NP	O
hepatectomy	NN	I-NP	O
,	,	O	O
when	WRB	B-ADVP	O
its	PRP$	B-NP	O
incorporation	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
maximum	JJ	B-ADJP	O
,	,	O	O
failed	VBD	B-VP	O
to	TO	I-VP	O
induce	VB	I-VP	O
any	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
GT	NN	I-NP	O
positive	JJ	I-NP	O
foci	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
hypomethylation	NN	B-NP	O
of	IN	B-PP	O
DNA	NN	B-NP	O
per	FW	B-ADVP	O
se	FW	I-ADVP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
sufficient	JJ	B-ADJP	O
for	IN	B-PP	O
initiation	NN	B-NP	O
.	.	O	O

Perhaps	RB	B-ADVP	O
num	CD	B-NP	O
events	NNS	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
necessary	JJ	B-ADJP	O
for	IN	B-PP	O
initiation	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
carcinogen	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
second	JJ	I-NP	O
involving	VBG	I-NP	O
hypomethylation	NN	I-NP	O
of	IN	B-PP	O
DNA	NN	B-NP	O
.	.	O	O

Withdrawal	NN	B-NP	B
-	HYPH	I-NP	I
emergent	JJ	I-NP	I
rabbit	NN	I-NP	I
syndrome	NN	I-NP	I
during	IN	B-PP	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

Rabbit	NN	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
RS	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
extrapyramidal	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
prolonged	JJ	B-NP	O
neuroleptic	JJ	I-NP	O
medication	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
withdrawal	NN	B-NP	B
-	HYPH	B-NP	I
emergent	JJ	I-NP	I
RS	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
kind	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
RS	NN	B-NP	B
during	IN	B-PP	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
symptom	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
successfully	RB	B-ADVP	O
with	IN	B-PP	O
trihexyphenidyl	NN	B-NP	O
anticholinergic	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
underlying	VBG	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
withdrawal	NN	B-NP	B
-	HYPH	B-NP	I
emergent	JJ	I-NP	I
RS	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
case	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
pharmacological	JJ	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
serotonin	NN	I-NP	O
-	HYPH	I-NP	O
dopamine	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
pathophysiologic	JJ	I-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
serotonin	NN	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
RS	NN	B-NP	B
.	.	O	O

Verapamil	NN	B-NP	O
withdrawal	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
hypertensive	JJ	I-NP	B
woman	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
coronary	JJ	I-NP	O
angiogram	NN	I-NP	O
.	.	O	O

Verapamil	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
and	CC	O	O
relatively	RB	B-ADJP	O
-	HYPH	I-ADJP	O
safe	JJ	B-NP	O
antihypertensive	JJ	I-NP	O
drug	NN	I-NP	O
.	.	O	O

Serious	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
uncommon	JJ	B-ADJP	O
and	CC	O	O
mainly	RB	B-VP	O
have	VBP	I-VP	O
been	VBN	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
depression	NN	I-NP	B
of	IN	B-PP	O
cardiac	JJ	B-NP	O
contractility	NN	I-NP	O
and	CC	I-NP	O
conduction	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
combined	VBN	I-VP	O
with	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-PP	O
blocking	VBG	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
coincided	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
previously	RB	I-NP	O
asymptomatic	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Possible	JJ	B-NP	O
mechanisms	NNS	I-NP	O
that	WDT	B-NP	O
involve	VBP	B-VP	O
a	DT	B-NP	O
verapamil	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
platelet	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
vascular	JJ	B-NP	O
alpha	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoreceptor	NN	I-NP	O
affinity	NN	I-NP	O
for	IN	B-PP	O
catecholamines	NNS	B-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Remission	NN	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
meningeal	JJ	B-NP	B
leukemia	NN	I-NP	I
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
methotrexate	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
meningeal	JJ	B-NP	B
disease	NN	I-NP	I
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
methotrexate	NN	I-NP	O
regimen	NN	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
and	CC	I-VP	O
maintain	VB	I-VP	O
CSF	NN	B-NP	O
methotrexate	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
without	IN	B-PP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
concomitant	JJ	B-NP	O
intrathecal	JJ	I-NP	O
dosing	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
methotrexate	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
loading	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
hour	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	B-NP	O
h	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

Leucovorin	NN	B-NP	O
rescue	NN	I-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
loading	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
and	CC	O	O
then	RB	B-ADVP	O
every	DT	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
until	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
methotrexate	NN	I-NP	O
level	NN	I-NP	O
decreased	VBD	B-VP	O
to	TO	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
X	SYM	I-NP	O
num	CD	I-NP	O
mol	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
steady	JJ	I-NP	O
-	HYPH	I-NP	O
state	NN	I-NP	O
plasma	NN	I-NP	O
and	CC	I-NP	O
CSF	NN	I-NP	O
methotrexate	NN	I-NP	O
concentrations	NNS	I-NP	O
achieved	VBN	B-VP	O
were	VBD	B-VP	O
num	CD	B-NP	O
X	SYM	O	O
num	CD	B-NP	O
mol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
X	SYM	I-NP	O
num	CD	I-NP	O
mol	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
responded	VBD	B-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
regimen	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
remission	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
obtained	VBD	B-VP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
remission	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
toxicities	NNS	I-NP	B
encountered	VBN	B-VP	O
were	VBD	B-VP	O
transient	JJ	B-NP	O
serum	NN	I-NP	O
transaminase	NN	I-NP	O
and	CC	I-NP	O
bilirubin	NN	I-NP	O
elevations	NNS	I-NP	O
,	,	O	O
neutropenia	NN	B-NP	B
,	,	O	O
and	CC	O	O
mucositis	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
focal	JJ	B-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
transient	JJ	B-NP	B
hemiparesis	NN	I-NP	I
but	CC	O	O
recovered	VBD	B-VP	O
completely	RB	B-ADVP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
methotrexate	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
remission	NN	B-NP	O
after	IN	B-PP	O
meningeal	JJ	B-NP	O
relapse	NN	I-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
.	.	O	O

Hypersensitivity	NN	B-NP	B
to	TO	B-PP	O
carbamazepine	NN	B-NP	O
presenting	VBG	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
leukemoid	JJ	I-NP	B
reaction	NN	I-NP	I
,	,	O	O
eosinophilia	NN	B-NP	B
,	,	O	O
erythroderma	NN	B-NP	B
,	,	O	O
and	CC	O	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
hypersensitivity	NN	B-NP	B
to	TO	B-PP	O
carbamazepine	NN	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
generalized	VBN	B-NP	O
erythroderma	NN	I-NP	B
,	,	O	O
a	DT	B-NP	O
severe	JJ	I-NP	O
leukemoid	JJ	I-NP	B
reaction	NN	I-NP	I
,	,	O	O
eosinophilia	NN	B-NP	B
,	,	O	O
hyponatremia	NN	B-NP	B
,	,	O	O
and	CC	O	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
such	JJ	B-NP	O
an	DT	I-NP	O
unusual	JJ	I-NP	O
reaction	NN	I-NP	O
to	TO	B-PP	O
carbamazepine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
interpeduncular	JJ	I-NP	O
nucleus	NN	I-NP	O
regulates	VBZ	B-VP	O
nicotine	NN	B-NP	O
s	NN	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
free	JJ	B-NP	O
-	HYPH	I-NP	O
field	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Partial	JJ	B-NP	O
lesions	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
with	IN	B-PP	O
kainic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
interpeduncular	JJ	I-NP	O
nucleus	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
midbrain	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
sham	NN	B-NP	O
-	HYPH	B-NP	O
operated	VBN	I-NP	O
controls	NNS	I-NP	O
,	,	O	O
lesions	NNS	B-NP	O
significantly	RB	B-VP	O
blunted	VBD	I-VP	O
the	DT	B-NP	O
early	JJ	I-NP	O
free	JJ	I-NP	O
-	HYPH	I-NP	O
field	NN	I-NP	O
locomotor	NN	I-NP	B
hypoactivity	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
nicotine	NN	B-NP	O
,	,	O	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
later	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
)	)	I-NP	O
nicotine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
,	,	O	O
and	CC	O	O
raised	VBD	B-VP	O
spontaneous	JJ	B-NP	O
nocturnal	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Lesions	NNS	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
immunohistological	JJ	B-NP	O
staining	NN	I-NP	O
for	IN	B-PP	O
choline	NN	B-NP	O
acetyltransferase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
interpeduncular	JJ	I-NP	O
nucleus	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
for	IN	B-PP	O
tyrosine	NN	B-NP	O
hydroxylase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
surrounding	VBG	I-NP	O
catecholaminergic	JJ	I-NP	O
A10	NN	I-NP	O
region	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
interpeduncular	JJ	I-NP	O
nucleus	NN	I-NP	O
mediates	VBZ	B-VP	O
nicotinic	JJ	B-NP	O
depression	NN	I-NP	B
of	IN	B-PP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
dampens	VBZ	B-VP	O
nicotinic	JJ	B-NP	O
arousal	JJ	I-NP	O
mechanisms	NNS	I-NP	O
located	VBN	B-VP	O
elsewhere	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Assessment	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
invasive	JJ	I-NP	O
index	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
performance	NN	I-NP	O
for	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
dobutamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
.	.	O	O

Electrocardiography	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
very	RB	I-NP	O
low	JJ	I-NP	O
sensitivity	NN	I-NP	O
in	IN	B-PP	O
detecting	VBG	B-VP	O
dobutamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
added	VBN	I-NP	O
diagnostic	JJ	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
cardiac	JJ	I-NP	O
performance	NN	I-NP	O
index	NN	I-NP	O
(	(	O	O
dP	NN	B-NP	O
/	SYM	B-NP	O
dtejc	NN	I-NP	O
)	)	O	O
measurement	NN	B-NP	O
,	,	O	O
based	VBN	B-PP	O
on	IN	B-PP	O
brachial	JJ	B-NP	O
artery	NN	I-NP	O
flow	NN	I-NP	O
changes	NNS	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-VP	O
standard	VB	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
lead	NN	I-NP	O
ECG	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
detecting	VBG	B-VP	O
dobutamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
,	,	O	O
using	VBG	B-VP	O
Tc99m	NN	B-NP	O
-	HYPH	B-NP	O
Sestamibi	NN	I-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
photon	NN	I-NP	O
emission	NN	I-NP	O
computed	VBD	B-VP	O
tomography	NN	B-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
gold	JJ	I-NP	O
standard	NN	I-NP	O
of	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
or	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
ischemia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
group	NN	I-NP	O
comprised	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
Sestamibi	NN	B-NP	O
-	HYPH	B-NP	O
SPECT	NN	I-NP	O
/	SYM	I-NP	O
dobutamine	NN	I-NP	O
stress	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Simultaneous	JJ	B-NP	O
measurements	NNS	I-NP	O
of	IN	B-PP	O
ECG	NN	B-NP	O
and	CC	O	O
brachial	JJ	B-NP	O
artery	NN	I-NP	O
dP	NN	I-NP	O
/	SYM	B-NP	O
dtejc	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
at	IN	B-PP	O
each	DT	B-NP	O
dobutamine	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
perfusion	NN	I-NP	O
defects	NNS	I-NP	O
compatible	JJ	B-ADJP	O
with	IN	B-PP	O
ischemia	NN	B-NP	B
were	VBD	B-VP	O
detected	VBN	I-VP	O
on	IN	B-PP	O
SPECT	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
dP	NN	B-NP	O
/	SYM	B-NP	O
dtejc	NN	I-NP	O
during	IN	B-PP	O
infusion	NN	B-NP	O
of	IN	B-PP	O
dobutamine	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
severely	RB	B-ADJP	O
impaired	JJ	I-ADJP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
ischemic	JJ	I-NP	O
group.	NN	I-NP	O
dP	NN	I-NP	O
/	SYM	B-NP	O
dtejc	NN	I-NP	O
outcome	NN	I-NP	O
was	VBD	B-VP	O
combined	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
ECG	NN	I-NP	O
results	NNS	I-NP	O
,	,	O	O
giving	VBG	B-VP	O
an	DT	B-NP	O
ECG	NN	I-NP	O
-	HYPH	B-NP	O
enhanced	VBN	I-NP	O
value	NN	I-NP	O
,	,	O	O
and	CC	O	O
compared	VBN	B-VP	O
to	TO	B-PP	O
ECG	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
sensitivity	NN	I-NP	O
improved	VBD	B-VP	O
dramatically	RB	B-ADVP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
positive	JJ	B-NP	O
predictive	JJ	I-NP	O
value	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
negative	JJ	I-NP	O
predictive	JJ	I-NP	O
value	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
specificity	NN	B-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

If	IN	B-SBAR	O
ECG	NN	B-NP	O
alone	RB	B-ADVP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
specificity	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
combination	NN	I-NP	O
with	IN	B-PP	O
dP	NN	B-NP	O
/	SYM	I-NP	O
dtejc	NN	I-NP	O
improved	VBD	B-VP	O
the	DT	B-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
and	CC	O	O
could	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
cost	NN	I-NP	O
-	HYPH	B-NP	O
savings	NNS	I-NP	O
alternative	JJ	B-ADJP	O
to	TO	B-PP	O
cardiac	JJ	B-NP	O
imaging	NN	I-NP	O
or	CC	I-NP	O
perfusion	NN	I-NP	O
studies	NNS	I-NP	O
to	TO	B-VP	O
detect	VB	I-VP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
unable	JJ	B-ADJP	O
to	TO	B-VP	O
exercise	VB	I-VP	O
.	.	O	O

Acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
regular	JJ	B-NP	O
alcohol	NN	I-NP	O
consumption	NN	I-NP	O
ingesting	VBG	B-VP	O
paracetamol	NN	B-NP	O
at	IN	B-PP	O
therapeutic	JJ	B-NP	O
dosage	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
therapeutic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
paracetamol	NN	B-NP	O
(	(	O	O
acetaminophen	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
currently	RB	I-VP	O
debated	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
regular	JJ	B-NP	O
consumers	NNS	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
and	CC	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
liver	NN	B-NP	B
failure	NN	I-NP	I
within	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
hospitalization	NN	B-NP	O
and	CC	O	O
stopping	VBG	B-VP	O
alcohol	NN	B-NP	O
consumption	NN	I-NP	O
while	IN	B-SBAR	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
paracetamol	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
paracetamol	NN	I-NP	O
serum	NN	I-NP	O
level	NN	I-NP	O
obtained	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
in	IN	B-PP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
range	NN	I-NP	O
.	.	O	O

Possible	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
therapeutic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
paracetamol	NN	B-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
,	,	O	O
e.g.	FW	B-NP	O
regular	JJ	I-NP	O
consumption	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
,	,	O	O
liver	NN	B-NP	B
failure	NN	I-NP	I
is	VBZ	B-VP	O
possible	JJ	B-ADJP	O
when	WRB	B-ADVP	O
therapeutic	JJ	B-NP	O
doses	NNS	I-NP	O
are	VBP	B-VP	O
ingested	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
propose	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
paracetamol	NN	I-NP	O
dose	NN	I-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
exceed	VB	I-VP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
their	PRP$	B-NP	O
liver	NN	I-NP	O
function	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
closely	RB	B-ADVP	O
while	IN	B-SBAR	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
paracetamol	NN	B-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
related	JJ	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
:	:	O	O
are	VBP	B-VP	O
we	PRP	B-NP	O
seeing	VBG	B-VP	O
the	DT	B-NP	O
tip	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
iceberg	NN	I-NP	O
?	.	O	O
The	DT	B-NP	O
recreational	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
is	VBZ	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
increase	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
emergency	NN	I-NP	O
nurse	NN	I-NP	O
ought	MD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
familiar	JJ	B-ADJP	O
with	IN	B-PP	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
consequences	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
particular	JJ	B-NP	O
,	,	O	O
the	DT	B-NP	O
tendency	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
to	TO	B-VP	O
produce	VB	I-VP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
ought	MD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mind	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
nurse	NN	I-NP	O
when	WRB	B-ADVP	O
faced	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
young	JJ	I-NP	O
victim	NN	I-NP	O
of	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
who	WP	B-NP	O
is	VBZ	B-VP	O
otherwise	RB	B-ADVP	O
at	IN	B-PP	O
low	JJ	B-NP	O
risk	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
and	CC	O	O
treatment	NN	B-NP	O
dilemmas	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
moral	JJ	B-NP	O
issues	NNS	I-NP	O
relating	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
testing	NN	I-NP	O
of	IN	B-PP	O
potential	JJ	B-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
addressed	VBN	I-VP	O
.	.	O	O

Severe	JJ	B-NP	O
rhabdomyolysis	NN	I-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
concomitant	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
simvastatin	NN	B-NP	O
,	,	O	O
amiodarone	NN	B-NP	O
,	,	O	O
and	CC	O	O
atazanavir	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
simvastatin	NN	B-NP	O
,	,	O	O
amiodarone	NN	B-NP	O
,	,	O	O
and	CC	O	O
atazanavir	NN	B-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
white	JJ	I-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
underlying	VBG	B-VP	O
human	JJ	B-NP	B
immunodeficiency	NN	I-NP	I
virus	NN	I-NP	I
,	,	O	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
,	,	O	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
hyperlipidemia	NN	B-NP	B
presented	VBD	B-VP	O
with	IN	B-PP	O
generalized	VBN	B-NP	O
pain	NN	I-NP	B
,	,	O	O
fatigue	NN	B-NP	B
,	,	O	O
and	CC	O	O
dark	JJ	B-NP	O
orange	JJ	I-NP	O
urine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
taking	VBG	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
simvastatin	NN	I-NP	O
at	IN	B-PP	O
bedtime	NN	B-NP	O
(	(	O	O
initiated	VBN	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
earlier	RBR	B-ADVP	O
)	)	O	O
;	:	O	O
amiodarone	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
then	RB	B-ADVP	O
num	CD	B-NP	O
mg	NN	I-NP	O
daily	JJ	I-NP	O
(	(	O	O
initiated	VBN	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
earlier	RBR	B-ADVP	O
)	)	O	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
atazanavir	NN	I-NP	O
daily	JJ	I-NP	O
(	(	O	O
initiated	VBN	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
previously	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Laboratory	NN	B-NP	O
evaluation	NN	I-NP	O
revealed	VBD	B-VP	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
creatine	NN	I-NP	O
kinase	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
blood	NN	I-NP	O
urea	NN	I-NP	O
nitrogen	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
creatinine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
aspartate	NN	I-NP	O
aminotransferase	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
alanine	NN	I-NP	O
aminotransferase	NN	I-NP	O
.	.	O	O

Simvastatin	NN	B-NP	O
,	,	O	O
amiodarone	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
human	JJ	B-NP	B
immunodeficiency	NN	I-NP	I
virus	NN	I-NP	I
medications	NNS	I-NP	O
were	VBD	B-VP	O
all	DT	B-NP	O
temporarily	RB	I-NP	O
discontinued	VBN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
forced	VBN	B-NP	O
alkaline	NN	I-NP	O
diuresis	NN	I-NP	O
and	CC	O	O
started	VBN	B-VP	O
on	IN	B-PP	O
dialysis	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
creatine	NN	I-NP	O
kinase	NN	I-NP	O
had	VBD	B-VP	O
dropped	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	B-NP	O
and	CC	I-NP	O
creatinine	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
discharged	VBN	I-VP	O
and	CC	O	O
continued	VBN	B-NP	O
outpatient	NN	I-NP	O
dialysis	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
until	IN	B-PP	O
his	PRP$	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
recovered	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
is	VBZ	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
concomitant	JJ	B-NP	O
drugs	NNS	I-NP	O
that	WDT	B-NP	O
inhibit	VBP	B-VP	O
simvastatin	NN	B-NP	O
metabolism	NN	I-NP	O
.	.	O	O

Simvastatin	NN	B-NP	O
is	VBZ	B-VP	O
metabolized	VBN	I-VP	O
by	IN	B-PP	O
CYP3A4	NN	B-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
and	CC	I-NP	O
atazanavir	NN	I-NP	O
are	VBP	B-VP	O
recognized	VBN	I-VP	O
CYP3A4	NN	B-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Pharmacokinetic	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
statins	NNS	B-NP	O
are	VBP	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
consideration	NN	I-NP	O
for	IN	B-PP	O
assessing	VBG	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
potential	JJ	B-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
requiring	VBG	B-VP	O
the	DT	B-NP	O
concurrent	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
statins	NNS	B-NP	O
and	CC	O	O
CYP3A4	NN	B-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
pravastatin	NN	B-NP	O
,	,	O	O
fluvastatin	NN	B-NP	O
,	,	O	O
and	CC	O	O
rosuvastatin	NN	B-NP	O
carry	VBP	B-VP	O
the	DT	B-NP	O
lowest	JJS	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
interactions	NNS	I-NP	O
;	:	O	O
atorvastatin	NN	B-NP	O
carries	VBZ	B-VP	O
moderate	JJ	B-NP	O
risk	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
simvastatin	NN	B-NP	O
and	CC	I-NP	O
lovastatin	NN	I-NP	O
have	VBP	B-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
risk	NN	I-NP	O
and	CC	O	O
should	MD	B-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
concomitant	JJ	B-NP	O
CYP3A4	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Phase	NN	B-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
vinorelbine	NN	B-NP	O
in	IN	B-PP	O
metastatic	JJ	B-NP	O
squamous	JJ	I-NP	B
cell	NN	I-NP	I
esophageal	JJ	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

European	NNP	B-NP	O
Organization	NNP	I-NP	O
for	IN	B-PP	O
Research	NNP	B-NP	O
and	CC	I-NP	O
Treatment	NNP	I-NP	O
of	IN	B-PP	O
Cancer	NNP	B-NP	B
Gastrointestinal	NNP	I-NP	O
Treat	NNP	I-NP	O
Cancer	NNP	I-NP	B
Cooperative	NNP	I-NP	O
Group	NNP	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
toxic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
vinorelbine	NN	B-NP	O
(	(	O	O
VNB	NN	B-NP	O
)	)	O	O
administered	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
metastatic	JJ	B-NP	O
squamous	JJ	I-NP	B
cell	NN	I-NP	I
esophageal	JJ	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
eligible	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
measurable	JJ	B-NP	O
lesions	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
and	CC	O	O
were	VBD	B-VP	O
stratified	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
previous	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
prior	JJ	B-NP	O
chemotherapy	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
cisplatin	NN	B-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
chemotherapy	NN	I-NP	O
were	VBD	B-VP	O
assessable	JJ	B-ADJP	O
for	IN	B-PP	O
toxicity	NN	B-NP	B
and	CC	I-NP	O
response	NN	I-NP	O
.	.	O	O

VNB	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
weekly	RB	B-ADVP	O
as	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
short	JJ	B-NP	O
intravenous	JJ	I-NP	O
(	(	O	O
i.v.	JJ	B-ADJP	O
)	)	O	O
infusion	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
prior	JJ	B-NP	O
chemotherapy	NN	I-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
(	(	O	O
PR	NN	B-NP	O
)	)	O	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
[	(	O	O
CI	NN	B-NP	O
]	)	O	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
prior	JJ	B-NP	O
chemotherapy	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
response	NN	I-NP	O
(	(	O	O
CR	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
s	NNS	I-NP	O
duration	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
World	NNP	B-NP	O
Health	NNP	I-NP	O
Organization	NNP	I-NP	O
[	(	O	O
WHO	WP	B-NP	O
]	)	O	O
criteria	NNS	B-NP	O
)	)	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
CR	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
PR	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
intensity	NN	B-NP	O
(	(	O	O
DI	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	I-NP	O
wk	NN	I-NP	O
.	.	O	O

VNB	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
num	CD	B-NP	O
instances	NNS	I-NP	O
of	IN	B-PP	O
WHO	NN	B-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
nonhematologic	JJ	I-NP	O
toxicity	NN	I-NP	B
occurred	VBD	B-VP	O
.	.	O	O

At	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
granulocytopenia	NN	I-NP	B
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
infection	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
but	CC	O	O
no	DT	B-NP	O
toxic	JJ	I-NP	O
deaths	NNS	I-NP	B
occurred	VBD	B-VP	O
.	.	O	O

Other	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
rare	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
peripheral	JJ	B-NP	B
neurotoxicity	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
minor	JJ	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
VNB	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
active	JJ	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
metastatic	JJ	B-NP	O
esophageal	JJ	I-NP	B
squamous	JJ	I-NP	I
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

Given	VBN	B-VP	O
its	PRP$	B-NP	O
excellent	JJ	I-NP	O
tolerance	NN	I-NP	O
profile	NN	I-NP	O
and	CC	O	O
low	JJ	B-NP	O
toxicity	NN	I-NP	B
,	,	O	O
further	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
VNB	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Paclitaxel	NN	B-NP	O
,	,	O	O
cisplatin	NN	B-NP	O
,	,	O	O
and	CC	O	O
gemcitabine	NN	B-NP	O
combination	NN	I-NP	O
chemotherapy	NN	I-NP	O
within	IN	B-PP	O
a	DT	B-NP	O
multidisciplinary	JJ	I-NP	O
therapeutic	JJ	I-NP	O
approach	NN	I-NP	O
in	IN	B-PP	O
metastatic	JJ	B-NP	O
nonsmall	JJ	I-NP	B
cell	NN	I-NP	I
lung	NN	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

Cisplatin	NN	B-NP	O
-	HYPH	B-PP	O
based	VBN	B-NP	O
chemotherapy	NN	I-NP	O
combinations	NNS	I-NP	O
improve	VBP	B-VP	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
and	CC	I-NP	O
survival	NN	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
nonsmall	JJ	I-NP	B
cell	NN	I-NP	I
lung	NN	I-NP	I
carcinoma	NN	I-NP	I
(	(	O	O
NSCLC	NN	B-NP	B
)	)	O	O
.	.	O	O

The	DT	B-NP	O
emergence	NN	I-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
active	JJ	I-NP	O
drugs	NNS	I-NP	O
might	MD	B-VP	O
translate	VB	I-VP	O
into	IN	B-PP	O
more	RBR	B-NP	O
effective	JJ	I-NP	O
regimens	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
disease	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
feasibility	NN	I-NP	O
,	,	O	O
response	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
and	CC	O	O
toxicity	NN	B-NP	B
of	IN	B-PP	O
a	DT	B-NP	O
paclitaxel	NN	I-NP	O
,	,	O	O
cisplatin	NN	B-NP	O
,	,	O	O
and	CC	O	O
gemcitabine	NN	B-NP	O
combination	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
metastatic	JJ	B-NP	O
NSCLC	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
chemotherapy	NN	I-NP	O
-	HYPH	O	O
naive	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Stage	NN	B-NP	O
num	CD	I-NP	O
NSCLC	NN	I-NP	B
and	CC	O	O
an	DT	B-NP	O
Eastern	NNP	I-NP	O
Cooperative	NNP	I-NP	O
Oncology	NNP	I-NP	O
Group	NNP	I-NP	O
performance	NN	I-NP	O
status	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
on	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
cisplatin	NN	I-NP	O
on	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
gemcitabine	NN	B-NP	O
on	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
responding	VBG	B-VP	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
scheduled	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
consolidation	NN	B-NP	O
radiotherapy	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
preplanned	VBN	I-VP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
chemotherapy	NN	I-NP	O
after	IN	B-PP	O
disease	NN	B-NP	O
progression	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
response	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
rates	NNS	I-NP	O
reported	VBN	B-VP	O
refer	VBP	B-VP	O
only	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
chemotherapy	NN	I-NP	O
regimen	NN	I-NP	O
given	VBN	B-VP	O
.	.	O	O

All	PDT	B-NP	O
the	DT	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
toxicity	NN	B-NP	B
;	:	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
examinable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
.	.	O	O

An	DT	B-NP	O
objective	JJ	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
[	(	O	O
CI	NN	B-NP	O
]	)	O	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
complete	JJ	I-NP	O
responses	NNS	I-NP	O
.	.	O	O

According	VBG	B-PP	O
to	TO	B-PP	O
intention	NN	B-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
treat	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
53.	LS	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
dose	NN	I-NP	O
intensity	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
for	IN	B-PP	O
paclitaxel	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
for	IN	B-PP	O
cisplatin	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
for	IN	B-PP	O
gemcitabine	NN	B-NP	O
.	.	O	O

World	NNP	B-NP	O
Health	NNP	I-NP	O
Organization	NNP	I-NP	O
Grade	NNP	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
treatment	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
death	NN	I-NP	B
.	.	O	O

Nonhematologic	JJ	B-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
mild	JJ	B-ADJP	O
.	.	O	O

After	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
progression	NN	I-NP	O
free	JJ	I-NP	O
survival	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
survival	NN	I-NP	O
time	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
,	,	O	O
cisplatin	NN	B-NP	O
,	,	O	O
and	CC	O	O
gemcitabine	NN	B-NP	O
is	VBZ	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
shows	VBZ	B-VP	O
high	JJ	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
metastatic	JJ	B-NP	O
NSCLC	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
treatment	NN	I-NP	O
merits	VBZ	B-VP	O
further	JJR	B-NP	O
comparison	NN	I-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
cisplatin	NN	I-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
regimens	NNS	I-NP	O
.	.	O	O

Evaluation	NN	B-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
of	IN	B-PP	O
aponidine	NN	B-NP	O
hydrochloride	NN	I-NP	O
ophthalmic	JJ	I-NP	O
solution	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
prospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
of	IN	B-PP	O
apraclonidine	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
normal	JJ	I-NP	O
volunteers	NNS	I-NP	O
by	IN	B-PP	O
instilling	VBG	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
drop	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
apraclonidine	NN	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
right	JJ	I-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Examinations	NNS	B-NP	O
,	,	O	O
including	VBG	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
pulse	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
conjunctiva	NN	B-NP	O
and	CC	I-NP	O
cornea	NN	I-NP	O
,	,	O	O
intraocular	JJ	B-NP	O
pressure	NN	I-NP	O
(	(	O	O
IOP	NN	B-NP	O
)	)	O	O
,	,	O	O
pupil	NN	B-NP	O
diameter	NN	I-NP	O
,	,	O	O
basal	JJ	B-NP	O
tear	NN	I-NP	O
secretion	NN	I-NP	O
and	CC	O	O
margin	NN	B-NP	O
reflex	NN	I-NP	O
distance	NN	I-NP	O
of	IN	B-PP	O
both	CC	B-NP	O
upper	JJ	I-NP	O
and	CC	I-NP	O
lower	JJR	I-NP	O
eyelids	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
entry	NN	B-NP	O
and	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
instillation	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
ocular	JJ	I-NP	B
hypotensive	JJ	I-NP	I
effects	NNS	I-NP	O
were	VBD	B-VP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
for	IN	B-PP	O
apraclonidine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
eyes	NNS	I-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
and	CC	O	O
also	RB	B-ADVP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
for	IN	B-PP	O
contralateral	JJ	B-NP	O
eyes	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
topical	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
apraclonidine	NN	I-NP	O
.	.	O	O

Decreases	NNS	B-NP	B
in	IN	B-PP	I
systolic	JJ	B-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
were	VBD	B-VP	O
statistically	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
clinically	RB	B-ADVP	O
,	,	O	O
significant	JJ	B-ADJP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
diastolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
pulse	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
basal	JJ	B-NP	O
tear	NN	I-NP	O
secretion	NN	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

Conjunctival	JJ	B-NP	B
blanching	NN	I-NP	I
and	CC	I-NP	O
mydriasis	NN	I-NP	B
were	VBD	B-VP	O
commonly	RB	I-VP	O
found	VBN	I-VP	O
.	.	O	O

Upper	IN	B-PP	O
lid	JJ	B-NP	O
retraction	NN	I-NP	O
was	VBD	B-VP	O
frequently	RB	I-VP	O
noted	VBN	I-VP	O
.	.	O	O

While	IN	B-SBAR	O
the	DT	B-NP	O
elevations	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
upper	JJ	I-NP	O
lid	JJ	I-NP	O
margin	NN	I-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
noticeable	JJ	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
appearance	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
subject	NN	I-NP	O
suffered	VBD	B-VP	O
from	IN	B-PP	O
mechanical	JJ	B-NP	O
entropion	NN	I-NP	B
and	CC	O	O
marked	JJ	B-NP	O
corneal	JJ	I-NP	B
abrasion	NN	I-NP	I
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
instillation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
may	MD	B-VP	O
well	RB	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
particularly	RB	I-NP	O
notable	JJ	I-NP	O
finding	NN	I-NP	O
in	IN	B-PP	O
Asian	JJ	B-NP	O
people	NNS	I-NP	O
.	.	O	O

Carmofur	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
organic	JJ	I-NP	B
mental	JJ	I-NP	I
disorders	NNS	I-NP	I
.	.	O	O

Organic	JJ	B-NP	B
mental	JJ	I-NP	I
disorder	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prognostic	JJ	I-NP	O
period	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
carmofur	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
leukoencephalopathy	NN	I-NP	B
.	.	O	O

Symptoms	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
euphoria	NN	B-NP	O
,	,	O	O
emotional	JJ	B-NP	O
lability	NN	I-NP	O
and	CC	O	O
puerile	JJ	B-NP	O
attitude	NN	I-NP	O
noted	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
were	VBD	B-VP	O
diagnosed	VBN	I-VP	O
as	IN	B-PP	O
organic	JJ	B-NP	B
personality	NN	I-NP	I
syndrome	NN	I-NP	I
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
criteria	NNS	I-NP	O
defined	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
DSM	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
R	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
referred	VBN	I-VP	O
to	TO	B-PP	O
as	IN	B-PP	O
a	DT	B-NP	O
frontal	JJ	I-NP	B
lobe	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Brain	NN	B-NP	O
CT	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
periventricular	JJ	I-NP	O
low	JJ	I-NP	O
density	NN	I-NP	O
area	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
frontal	JJ	I-NP	O
white	JJ	I-NP	O
matter	NN	I-NP	O
and	CC	O	O
moderate	JJ	B-NP	O
dilatation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
ventricles	NNS	I-NP	O
especially	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
bilateral	JJ	I-NP	O
anterior	JJ	I-NP	O
horns	NNS	I-NP	O
.	.	O	O

Consequently	RB	B-ADVP	O
,	,	O	O
carmofur	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
leukoencephalopathy	NN	I-NP	B
may	MD	B-VP	O
uncommonly	RB	I-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
organic	JJ	B-NP	B
personality	NN	I-NP	I
syndrome	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
residual	JJ	I-NP	O
state	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
structural	JJ	I-NP	B
damage	NN	I-NP	I
to	TO	B-PP	I
the	DT	B-NP	I
frontal	JJ	I-NP	I
lobe	NN	I-NP	I
.	.	O	O

International	JJ	B-NP	O
mexiletine	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
antiarrhythmic	JJ	I-NP	O
coronary	JJ	I-NP	O
trial	NN	I-NP	O
:	:	O	O
I	LS	B-LST	O
.	.	O	O

Report	NN	B-NP	O
on	IN	B-PP	O
arrhythmia	NN	B-NP	B
and	CC	O	O
other	JJ	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Impact	NNP	B-NP	O
Research	NNP	I-NP	O
Group	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
antiarrhythmic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sustained	JJ	I-NP	O
release	NN	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
mexiletine	NN	B-NP	O
(	(	O	O
Mexitil	NN	B-NP	O
-	HYPH	B-NP	O
Perlongets	NNPS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
placebo	NN	I-NP	O
trial	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
recent	JJ	B-NP	O
documented	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
response	NN	I-NP	O
variable	JJ	I-NP	O
was	VBD	B-VP	O
based	VBN	I-VP	O
on	IN	B-PP	O
central	JJ	B-NP	O
reading	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
hour	NN	I-NP	O
ambulatory	JJ	I-NP	O
electrocardiographic	JJ	I-NP	O
recordings	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
single	JJ	I-NP	O
premature	JJ	I-NP	O
ventricular	JJ	I-NP	O
complexes	NNS	I-NP	O
in	IN	B-PP	O
any	DT	B-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
num	CD	I-NP	O
minute	NN	I-NP	O
blocks	NNS	I-NP	O
or	CC	O	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
runs	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
premature	JJ	I-NP	O
ventricular	JJ	I-NP	O
complexes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
num	CD	I-NP	O
hour	NN	I-NP	O
electrocardiographic	JJ	I-NP	O
recording	NN	I-NP	O
.	.	O	O

Large	JJ	B-NP	O
differences	NNS	I-NP	O
,	,	O	O
regarded	VBN	B-VP	O
as	IN	B-PP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
,	,	O	O
between	IN	B-PP	O
the	DT	B-NP	O
mexiletine	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
that	DT	B-NP	O
end	NN	I-NP	O
point	NN	I-NP	O
at	IN	B-PP	O
months	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
but	CC	O	O
only	RB	B-NP	O
trends	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
month	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

These	DT	B-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
even	RB	B-SBAR	O
though	IN	I-SBAR	O
the	DT	B-NP	O
serum	NN	I-NP	O
mexiletine	NN	I-NP	O
levels	NNS	I-NP	O
obtained	VBN	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
generally	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
studies	NNS	B-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
used	VBN	I-VP	O
the	DT	B-NP	O
regular	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
more	JJR	B-NP	O
deaths	NNS	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
mexiletine	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	O
events	NNS	I-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Previously	RB	B-NP	O
recognized	VBN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
particularly	RB	B-NP	O
tremor	NN	I-NP	B
and	CC	O	O
gastrointestinal	JJ	B-NP	B
problems	NNS	I-NP	I
,	,	O	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
mexiletine	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Regional	JJ	B-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antagonism	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
by	IN	B-PP	O
intracerebral	JJ	B-NP	O
calcitonin	NN	I-NP	O
injections	NNS	I-NP	O
.	.	O	O

Calcitonin	NN	B-NP	O
receptors	NNS	I-NP	O
are	VBP	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
,	,	O	O
and	CC	O	O
intracerebral	JJ	B-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
calcitonin	NN	B-NP	O
can	MD	B-VP	O
produce	VB	I-VP	O
behavioral	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
these	DT	B-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
food	NN	B-NP	O
intake	NN	I-NP	O
and	CC	O	O
decreases	VBZ	B-VP	O
in	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
previous	JJ	B-NP	O
experiments	NNS	I-NP	O
we	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
food	NN	B-NP	O
intake	NN	I-NP	O
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
local	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
calcitonin	NN	B-NP	O
into	IN	B-PP	O
several	JJ	B-NP	O
hypothalamic	JJ	I-NP	O
sites	NNS	I-NP	O
and	CC	B-PP	O
into	IN	B-PP	O
the	DT	B-NP	O
nucleus	NN	I-NP	O
accumbens	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
experiment	NN	I-NP	O
calcitonin	NN	I-NP	O
decreased	VBD	B-VP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
when	WRB	B-ADVP	O
locally	RB	B-VP	O
injected	VBN	I-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
sites	NNS	I-NP	O
where	WRB	B-ADVP	O
it	PRP	B-NP	O
decreases	VBZ	B-VP	O
food	NN	B-NP	O
intake	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
areas	NNS	I-NP	O
where	WRB	B-ADVP	O
calcitonin	NN	B-NP	O
is	VBZ	B-VP	O
most	RBS	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
decreasing	VBG	B-VP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
are	VBP	B-VP	O
located	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
hypothalamus	NN	I-NP	O
and	CC	I-NP	O
nucleus	NN	I-NP	O
accumbens	NNS	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
areas	NNS	I-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
sites	NNS	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
of	IN	B-PP	O
calcitonin	NN	B-NP	O
in	IN	B-PP	O
inhibiting	VBG	B-VP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
intracranial	JJ	I-NP	B
bleeding	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
prehospital	NN	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
paramedic	JJ	B-NP	O
misjudgment	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
execution	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
protocol	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
allergic	JJ	B-NP	B
reaction	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
pulmonary	JJ	B-NP	B
edema	NN	I-NP	I
with	IN	B-PP	O
wheezing	VBG	B-NP	B
.	.	O	O

The	DT	B-NP	O
sudden	JJ	I-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	B
distress	NN	I-NP	I
,	,	O	O
rash	NN	B-NP	B
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
medicine	NN	I-NP	O
led	VBD	B-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
paramedics	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
scene	NN	I-NP	O
to	TO	B-VP	O
administer	VB	I-VP	O
subcutaneous	JJ	B-NP	O
epinephrine	NN	I-NP	O
.	.	O	O

Subsequently	RB	B-ADVP	O
,	,	O	O
acute	JJ	B-NP	O
cardiac	JJ	I-NP	B
arrest	NN	I-NP	I
and	CC	O	O
fatal	JJ	B-NP	O
subarachnoid	JJ	I-NP	B
hemorrhage	NN	I-NP	I
occurred	VBD	B-VP	O
.	.	O	O

Epinephrine	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
proven	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
in	IN	B-PP	O
prehospital	NN	B-NP	O
care	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
use	NN	B-NP	O
by	IN	B-PP	O
paramedics	NNS	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
suspected	VBN	B-NP	O
allergic	JJ	I-NP	B
reaction	NN	I-NP	I
and	CC	O	O
severe	JJ	B-NP	O
hypertension	NN	I-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
viewed	VBN	I-VP	O
with	IN	B-PP	O
caution	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
massive	JJ	B-NP	O
rhabdomyolysis	NN	I-NP	B
following	VBG	B-PP	O
molindone	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Rhabdomyolysis	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
lethal	JJ	I-NP	O
syndrome	NN	I-NP	O
that	IN	B-NP	O
psychiatric	JJ	B-NP	B
patients	NNS	I-NP	O
seem	VBP	B-VP	O
predisposed	VBN	I-VP	O
to	TO	I-VP	O
develop	VB	I-VP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
signs	NNS	I-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
typical	JJ	B-NP	O
laboratory	NN	I-NP	O
features	NNS	I-NP	O
,	,	O	O
and	CC	O	O
complications	NNS	B-NP	O
of	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
are	VBP	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
schizophrenic	JJ	I-NP	B
patient	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
illustrate	VB	I-VP	O
massive	JJ	B-NP	O
rhabdomyolysis	NN	I-NP	B
and	CC	O	O
subsequent	JJ	B-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
following	VBG	B-PP	O
molindone	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Physicians	NNS	B-NP	O
who	WP	B-NP	O
prescribe	VBP	B-VP	O
molindone	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
reaction	NN	I-NP	O
.	.	O	O

Cardiovascular	JJ	B-NP	B
alterations	NNS	I-NP	I
in	IN	B-PP	O
rat	NN	B-NP	O
fetuses	NNS	I-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

Preclinical	JJ	B-NP	O
toxicologic	JJ	I-NP	O
investigation	NN	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
new	JJ	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
Ro	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
induced	VBD	B-VP	O
cardiovascular	JJ	B-NP	B
alterations	NNS	I-NP	I
in	IN	B-PP	O
rat	NN	B-NP	O
fetuses	NNS	I-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
agent	NN	I-NP	O
during	IN	B-PP	O
organogenesis	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
in	IN	B-PP	O
general	JJ	B-NP	O
induce	VBP	B-VP	O
cardiovascular	JJ	B-NP	B
malformations	NNS	I-NP	I
indicating	VBG	B-VP	O
a	DT	B-NP	O
pharmacologic	JJ	I-NP	O
class	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
num	CD	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
of	IN	B-PP	O
different	JJ	B-NP	O
structure	NN	I-NP	O
,	,	O	O
nifedipine	NN	B-NP	O
,	,	O	O
diltiazem	NN	B-NP	O
,	,	O	O
and	CC	O	O
verapamil	NN	B-NP	O
,	,	O	O
along	IN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
new	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
morphogenesis	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
offspring	NN	I-NP	O
examined	VBN	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
for	IN	B-PP	O
cardiovascular	JJ	B-NP	B
malformations	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
low	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
malformations	NNS	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
each	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
,	,	O	O
but	CC	O	O
this	DT	B-NP	O
incidence	NN	I-NP	O
was	VBD	B-VP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
only	RB	B-ADVP	O
for	IN	B-PP	O
verapamil	NN	B-NP	O
and	CC	I-NP	O
nifedipine	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
agents	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
aortic	JJ	B-NP	O
arch	NN	I-NP	O
branching	NN	I-NP	O
variants	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
significantly	RB	B-ADJP	O
increased	VBN	I-ADJP	O
only	RB	B-ADVP	O
for	IN	B-PP	O
Ro	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
verapamil	NN	I-NP	O
.	.	O	O

Differential	JJ	B-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
immune	JJ	B-NP	O
escape	NN	I-NP	O
mutations	NNS	I-NP	O
G145R	NN	I-NP	O
and	CC	I-NP	O
P120T	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
replication	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
-	HYPH	B-NP	O
resistant	JJ	I-NP	O
hepatitis	NN	I-NP	O
B	NN	I-NP	O
virus	NN	I-NP	O
e	NN	I-NP	O
antigen	NN	I-NP	O
-	HYPH	O	O
positive	JJ	B-NP	O
and	CC	I-NP	O
-	HYPH	I-NP	O
negative	JJ	I-NP	O
strains	NNS	I-NP	O
.	.	O	O

Immune	JJ	B-NP	O
escape	NN	I-NP	O
variants	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
(	(	O	O
HBV	NN	B-NP	O
)	)	O	O
represent	VBP	B-VP	O
an	DT	B-NP	O
emerging	VBG	I-NP	O
clinical	JJ	I-NP	O
challenge	NN	I-NP	O
,	,	O	O
because	IN	B-SBAR	O
they	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
vaccine	NN	B-NP	O
escape	NN	I-NP	O
,	,	O	O
HBV	NN	B-NP	O
reactivation	NN	I-NP	O
,	,	O	O
and	CC	O	O
failure	NN	B-NP	O
of	IN	B-PP	O
diagnostic	JJ	B-NP	O
tests	NNS	I-NP	O
.	.	O	O

Recent	JJ	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
preferential	JJ	I-NP	O
selection	NN	I-NP	O
of	IN	B-PP	O
immune	JJ	B-NP	O
escape	NN	I-NP	O
mutants	NNS	I-NP	O
in	IN	B-PP	O
distinct	JJ	B-NP	O
peripheral	JJ	I-NP	O
blood	NN	I-NP	O
leukocyte	NN	I-NP	O
compartments	NNS	I-NP	O
of	IN	B-PP	O
infected	JJ	B-NP	O
individuals	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
systematically	RB	B-ADVP	O
analyzed	VBD	B-VP	O
the	DT	B-NP	O
functional	JJ	I-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
prevalent	JJ	I-NP	O
immune	JJ	I-NP	O
escape	NN	I-NP	O
variants	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
sG145R	NN	I-NP	O
and	CC	I-NP	O
sP120T	NN	I-NP	O
mutants	NNS	I-NP	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
viral	JJ	I-NP	O
replication	NN	I-NP	O
efficacy	NN	I-NP	O
and	CC	O	O
antiviral	JJ	B-NP	O
drug	NN	I-NP	O
susceptibility	NN	I-NP	O
of	IN	B-PP	O
common	JJ	B-NP	O
treatment	NN	I-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
mutants	NNS	I-NP	O
with	IN	B-PP	O
resistance	NN	B-NP	O
to	TO	B-PP	O
lamivudine	NN	B-NP	O
(	(	O	O
LAM	NN	B-NP	O
)	)	O	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
HBeAg	NN	B-NP	O
negativity	NN	I-NP	O
.	.	O	O

Replication	NN	B-NP	O
-	HYPH	I-NP	O
competent	JJ	I-NP	O
HBV	NN	I-NP	O
strains	NNS	I-NP	O
with	IN	B-PP	O
sG145R	NN	B-NP	O
or	CC	O	O
sP120T	NN	B-NP	O
and	CC	O	O
LAM	NN	B-NP	O
resistance	NN	I-NP	O
(	(	O	O
rtM204I	NN	B-NP	O
or	CC	O	O
rtL180M	NN	B-NP	O
/	SYM	B-NP	O
rtM204V	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
generated	VBN	I-VP	O
on	IN	B-PP	O
an	DT	B-NP	O
HBeAg	NN	I-NP	O
-	HYPH	B-VP	O
positive	JJ	B-ADJP	O
and	CC	O	O
an	DT	B-NP	O
HBeAg	NN	I-NP	O
-	HYPH	B-NP	O
negative	JJ	I-NP	O
background	NN	I-NP	O
with	IN	B-PP	O
precore	NN	B-NP	O
(	(	O	O
PC	NN	B-NP	O
)	)	O	O
and	CC	O	O
basal	JJ	B-NP	O
core	NN	I-NP	O
promoter	NN	I-NP	O
(	(	O	O
BCP	NN	B-NP	O
)	)	O	O
mutants	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
sG145R	NN	I-NP	O
mutation	NN	I-NP	O
strongly	RB	B-ADVP	O
reduced	VBD	B-VP	O
HBsAg	NN	B-NP	O
levels	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
fully	RB	I-VP	O
restore	VB	I-VP	O
the	DT	B-NP	O
impaired	JJ	I-NP	O
replication	NN	I-NP	O
of	IN	B-PP	O
LAM	NN	B-NP	O
-	HYPH	B-NP	O
resistant	JJ	I-NP	O
HBV	NN	I-NP	O
mutants	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
HBV	NN	I-NP	O
,	,	O	O
and	CC	O	O
PC	NN	B-NP	O
or	CC	I-NP	O
BCP	NN	I-NP	O
mutations	NNS	I-NP	O
further	RBR	B-ADVP	O
enhanced	VBD	B-VP	O
viral	JJ	B-NP	O
replication	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
sP120T	NN	I-NP	O
substitution	NN	I-NP	O
also	RB	B-ADVP	O
impaired	VBD	B-VP	O
HBsAg	NN	B-NP	O
secretion	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
enhance	VB	I-VP	O
the	DT	B-NP	O
replication	NN	I-NP	O
of	IN	B-PP	O
LAM	NN	B-NP	O
-	HYPH	B-NP	O
resistant	JJ	I-NP	O
clones	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
concomitant	JJ	I-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
HBeAg	NN	B-NP	O
negativity	NN	I-NP	O
(	(	O	O
PC	NN	B-NP	O
/	SYM	O	O
BCP	NN	B-NP	O
)	)	O	O
,	,	O	O
sP120T	NN	B-NP	O
,	,	O	O
and	CC	O	O
LAM	NN	B-NP	O
resistance	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
restoration	NN	I-NP	O
of	IN	B-PP	O
replication	NN	B-NP	O
to	TO	B-PP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
HBV	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
clones	NNS	I-NP	O
with	IN	B-PP	O
combined	JJ	B-NP	O
immune	JJ	I-NP	O
escape	NN	I-NP	O
and	CC	I-NP	O
LAM	NN	I-NP	O
resistance	NN	I-NP	O
mutations	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
nucleotide	NN	I-NP	O
analogues	NNS	I-NP	O
adefovir	NN	I-NP	O
and	CC	I-NP	O
tenofovir	NN	I-NP	O
remained	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
suppressing	VBG	B-VP	O
viral	JJ	B-NP	O
replication	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
reveal	VBP	B-VP	O
the	DT	B-NP	O
differential	JJ	I-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
immune	JJ	B-NP	O
escape	NN	I-NP	O
variants	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
replication	NN	I-NP	O
and	CC	I-NP	O
drug	NN	I-NP	O
susceptibility	NN	I-NP	O
of	IN	B-PP	O
complex	JJ	B-NP	O
HBV	NN	I-NP	O
mutants	NNS	I-NP	O
,	,	O	O
supporting	VBG	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
of	IN	B-PP	O
close	JJ	B-NP	O
surveillance	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
adjustment	NN	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
selection	NN	I-NP	O
of	IN	B-PP	O
distinct	JJ	B-NP	O
mutational	JJ	I-NP	O
patterns	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
sevoflurane	NN	B-NP	O
on	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
sevoflurane	NN	B-NP	O
on	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
cats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
convulsive	JJ	I-NP	B
threshold	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg.	NN	I-NP	O
l	NN	I-NP	O
with	IN	B-PP	O
lidocaine	NN	B-NP	O
infusion	NN	I-NP	O
,	,	O	O
increasing	VBG	B-VP	O
significantly	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg.	NN	I-NP	O
l	NN	I-NP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
tidal	JJ	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
sevoflurane	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
threshold	NN	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
sevoflurane	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
significant	JJ	B-ADJP	O
from	IN	B-PP	O
that	DT	B-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
sevoflurane	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
celling	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
convulsive	JJ	I-NP	B
threshold	NN	I-NP	O
between	IN	B-PP	O
sevoflurane	NN	B-NP	O
and	CC	I-NP	O
enflurane	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
became	VBD	B-VP	O
less	RBR	B-ADJP	O
marked	JJ	I-ADJP	O
when	WRB	B-ADVP	O
higher	JJR	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
sevoflurane	NN	B-NP	O
or	CC	I-NP	O
enflurane	NN	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
at	IN	B-PP	O
convulsions	NNS	B-NP	B
decreased	VBD	B-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
sevoflurane	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
enflurane	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lidocaine	NN	I-NP	O
concentrations	NNS	I-NP	O
measured	VBN	B-VP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
became	VBD	B-VP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
.	.	O	O

Apamin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
blocker	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
potassium	NN	I-NP	O
channels	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intracerebroventricularly	RB	B-ADVP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
anesthetized	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
sevoflurane	NN	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anticonvulsive	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Apamin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
ng	NN	I-NP	O
)	)	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
tendency	NN	I-NP	O
to	TO	B-VP	O
decrease	VB	I-VP	O
the	DT	B-NP	O
convulsive	JJ	I-NP	B
threshold	NN	I-NP	O
but	CC	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
sevoflurane	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
convulsive	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
toxicity	NN	I-NP	B
but	CC	O	O
carries	VBZ	B-VP	O
some	DT	B-NP	O
risk	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
circulatory	JJ	B-NP	O
depression	NN	I-NP	B
.	.	O	O

Anti	AFX	B-NP	O
-	HYPH	I-NP	O
oxidant	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
atorvastatin	NN	B-NP	O
in	IN	B-PP	O
dexamethasone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
(	(	O	O
Dex	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
endothelial	JJ	B-NP	O
dysfunction	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
deficiency	NN	B-NP	O
and	CC	O	O
increased	VBN	B-NP	O
superoxide	NN	I-NP	O
(	(	O	O
O2	NN	B-NP	O
-	HYPH	O	O
)	)	O	O
production	NN	B-NP	O
.	.	O	O

Atorvastatin	NN	B-NP	O
(	(	O	O
Ato	NN	B-NP	O
)	)	O	O
possesses	VBZ	B-VP	O
pleiotropic	JJ	B-NP	O
properties	NNS	I-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
improve	VB	I-VP	O
endothelial	JJ	B-NP	O
function	NN	I-NP	O
through	IN	B-PP	O
increased	VBN	B-NP	O
availability	NN	I-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
O2	NN	I-NP	O
-	HYPH	B-NP	O
production	NN	I-NP	O
in	IN	B-PP	O
various	JJ	B-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
whether	IN	B-SBAR	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
,	,	O	O
p.o.	FW	B-NP	O
,	,	O	O
Ato	NNP	B-NP	O
could	MD	B-VP	O
prevent	VB	I-VP	O
endothelial	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
(	(	O	O
eNOS	NN	B-NP	O
)	)	O	O
downregulation	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
O2	NN	B-NP	O
-	HYPH	B-ADJP	O
in	IN	B-PP	O
Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
(	(	O	O
SD	NNP	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
,	,	O	O
thereby	RB	B-ADVP	O
reducing	VBG	B-VP	O
blood	NN	B-NP	O
pressure.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
SD	NN	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
Ato	NN	B-NP	O
or	CC	I-NP	O
tap	NN	I-NP	O
water	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
Ato	NNP	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
and	CC	O	O
continued	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

Systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
on	IN	B-PP	O
alternate	JJ	B-NP	O
days	NNS	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
tail	NN	I-NP	O
-	HYPH	I-NP	O
cuff	NN	I-NP	O
method	NN	I-NP	O
.	.	O	O

Endothelial	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
acetylcholine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasorelaxation	NN	I-NP	O
and	CC	I-NP	O
phenylephrine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasoconstriction	NN	I-NP	O
in	IN	B-PP	O
aortic	JJ	B-NP	O
segments	NNS	I-NP	O
.	.	O	O

Vascular	JJ	B-NP	O
eNOS	NN	I-NP	O
mRNA	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
semi	AFX	B-NP	O
-	HYPH	I-NP	O
quantitative	JJ	I-NP	O
reverse	JJ	I-NP	O
transcription	NN	I-NP	O
-	HYPH	B-NP	O
polymerase	NN	I-NP	O
chain	NN	I-NP	O
reaction.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

In	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
Dex	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
SBP	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
on	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	O	O
Day	NN	B-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
Ato	NNP	I-NP	O
+	CC	I-NP	O
Dex	NNP	I-NP	O
group	NN	I-NP	O
,	,	O	O
SBP	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
on	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
respectively	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
SBP	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
Dex	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Endothelial	JJ	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
relaxation	NN	I-NP	O
and	CC	I-NP	O
eNOS	NN	I-NP	O
mRNA	NN	I-NP	O
expression	NN	I-NP	O
were	VBD	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
Dex	NNP	I-NP	O
+	SYM	I-NP	O
Ato	NNP	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
Dex	NN	I-NP	O
only	RB	B-NP	O
group	NN	I-NP	O
.	.	O	O

Aortic	JJ	B-NP	O
superoxide	NN	I-NP	O
production	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
Dex	NNP	I-NP	O
+	SYM	I-NP	O
Ato	NNP	I-NP	O
group	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
Dex	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O
num	CD	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
Ato	NNP	B-NP	O
improved	VBD	B-VP	O
endothelial	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
reduced	VBD	B-VP	O
superoxide	NN	B-NP	O
production	NN	I-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
SBP	NN	I-NP	O
in	IN	B-PP	O
Dex	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
SD	NN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

99mTc	NN	B-NP	O
-	HYPH	I-NP	O
glucarate	NN	I-NP	O
for	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Infarct	NN	B-NP	B
-	HYPH	I-NP	O
avid	JJ	I-NP	O
radiopharmaceuticals	NNS	I-NP	O
are	VBP	B-VP	O
necessary	JJ	B-ADJP	O
for	IN	B-PP	O
rapid	JJ	B-NP	O
and	CC	I-NP	O
timely	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
produce	VB	I-VP	O
infarction	NN	B-NP	B
implies	VBZ	B-VP	O
artery	NN	B-NP	O
ligation	NN	I-NP	O
but	CC	O	O
chemical	JJ	B-NP	O
induction	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
easily	RB	I-VP	O
obtained	VBN	I-VP	O
with	IN	B-PP	O
isoproterenol	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
new	JJ	I-NP	O
infarct	NN	I-NP	B
-	HYPH	I-NP	O
avid	NN	I-NP	O
radiopharmaceutical	NN	I-NP	O
based	VBN	B-VP	O
on	IN	B-PP	O
glucaric	JJ	B-NP	O
acid	NN	I-NP	O
was	VBD	B-VP	O
prepared	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
radiopharmacy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
INCMNSZ.	NNP	I-NP	O
99mTc	NN	I-NP	O
-	HYPH	O	O
glucarate	NN	B-NP	O
was	VBD	B-VP	O
easy	JJ	B-ADJP	O
to	TO	B-VP	O
prepare	VB	I-VP	O
,	,	O	O
stable	JJ	B-ADJP	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
study	VB	I-VP	O
its	PRP$	B-NP	O
biodistribution	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

Histological	JJ	B-NP	O
studies	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
rats	NNS	I-NP	O
developed	VBD	B-VP	O
an	DT	B-NP	O
infarct	NN	I-NP	B
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
isoproterenol	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rat	NN	I-NP	O
biodistribution	NN	I-NP	O
studies	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
blood	NN	I-NP	O
clearance	NN	I-NP	O
via	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
99mTc	NN	B-NP	O
-	HYPH	B-NP	O
glucarate	NN	I-NP	O
administration	NN	I-NP	O
the	DT	B-NP	O
standardised	JJ	I-NP	O
heart	NN	I-NP	O
uptake	NN	I-NP	O
value	NN	I-NP	O
S	NN	I-NP	O
(	(	O	O
h	NN	B-NP	O
)	)	O	O
UV	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
in	IN	B-PP	O
infarcted	VBN	B-NP	O
rat	NN	I-NP	O
heart	NN	I-NP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
num	CD	B-ADJP	O
times	NNS	I-ADJP	O
more	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

ROIs	NNS	B-NP	O
drawn	VBN	B-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
gamma	NN	I-NP	O
camera	NN	I-NP	O
images	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
high	JJ	I-NP	O
image	NN	I-NP	O
quality	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
high	JJ	B-NP	O
contrast	NN	I-NP	O
images	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
obtained	VBN	I-VP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
and	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
stability	NN	I-NP	O
makes	VBZ	B-VP	O
it	PRP	B-NP	O
an	DT	B-NP	O
ideal	JJ	I-NP	O
agent	NN	I-NP	O
to	TO	B-VP	O
detect	VB	I-VP	O
,	,	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
early	JJ	B-NP	O
cardiac	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
comparison	NN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
for	IN	B-PP	O
psychosis	NN	B-NP	B
and	CC	O	O
disruptive	JJ	B-NP	B
behaviors	NNS	I-NP	I
in	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
psychosis	NN	B-NP	B
and	CC	O	O
disruptive	JJ	B-NP	B
behaviors	NNS	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
random	JJ	I-NP	O
-	HYPH	I-NP	O
assignment	NN	I-NP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
trial	NN	B-NP	O
(	(	O	O
phase	NN	B-NP	O
A	NN	I-NP	O
)	)	O	O
,	,	O	O
haloperidol	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
standard	JJ	B-NP	O
dose	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
haloperidol	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
low	JJ	B-NP	O
dose	NN	I-NP	O
)	)	O	O
,	,	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
outpatients	NNS	I-NP	O
with	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

For	IN	B-PP	O
the	DT	B-NP	O
subsequent	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
crossover	NN	I-NP	O
phase	NN	I-NP	O
(	(	O	O
phase	NN	B-NP	O
B	NN	I-NP	O
)	)	O	O
,	,	O	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
standard	JJ	B-NP	O
-	HYPH	I-NP	O
or	CC	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
haloperidol	NN	I-NP	O
were	VBD	B-VP	O
switched	VBN	I-VP	O
to	TO	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
and	CC	O	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
placebo	NN	B-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
standard	JJ	B-NP	O
-	HYPH	I-NP	O
or	CC	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
haloperidol	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
completed	VBD	B-VP	O
phase	NN	B-NP	O
A	NN	I-NP	O
,	,	O	O
standard	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
haloperidol	NN	I-NP	O
was	VBD	B-VP	O
efficacious	JJ	B-ADJP	O
and	CC	I-ADJP	O
superior	JJ	I-ADJP	O
to	TO	B-PP	O
both	CC	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
haloperidol	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
for	IN	B-PP	O
scores	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Brief	NNP	I-NP	O
Psychiatric	NNP	I-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
psychosis	NN	I-NP	B
factor	NN	I-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
psychomotor	NN	B-NP	B
agitation	NN	I-NP	I
.	.	O	O

Response	NN	B-NP	O
rates	NNS	I-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
num	CD	B-NP	O
sets	NNS	I-NP	O
of	IN	B-PP	O
criteria	NNS	B-NP	O
were	VBD	B-VP	O
greater	JJR	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
dose	NN	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
advantage	NN	I-NP	O
of	IN	B-PP	O
standard	JJ	B-NP	O
dose	NN	I-NP	O
over	IN	B-PP	O
low	JJ	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
replicated	VBN	I-VP	O
in	IN	B-PP	O
phase	NN	B-NP	O
B	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
phase	NN	B-NP	O
A	NN	I-NP	O
,	,	O	O
extrapyramidal	JJ	B-NP	B
signs	NNS	I-NP	I
tended	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
greater	JJR	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
dose	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
conditions	NNS	I-NP	O
,	,	O	O
primarily	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
subgroup	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
signs	NNS	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
haloperidol	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
from	IN	B-PP	O
placebo	NN	B-NP	O
on	IN	B-PP	O
any	DT	B-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
efficacy	NN	B-NP	O
or	CC	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicated	VBD	B-VP	O
a	DT	B-NP	O
favorable	JJ	I-NP	O
therapeutic	JJ	I-NP	O
profile	NN	I-NP	O
for	IN	B-PP	O
haloperidol	NN	B-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
a	DT	B-NP	O
subgroup	NN	I-NP	O
developed	VBD	B-VP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
extrapyramidal	JJ	I-NP	B
signs	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
starting	VBG	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
with	IN	B-PP	O
gradual	JJ	B-NP	O
,	,	I-NP	O
upward	JJ	I-NP	O
dose	NN	I-NP	O
titration	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
narrow	JJ	I-NP	O
therapeutic	JJ	I-NP	O
window	NN	I-NP	O
observed	VBN	B-VP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
apply	VB	I-VP	O
to	TO	B-PP	O
other	JJ	B-NP	O
neuroleptics	NNS	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
with	IN	B-PP	O
psychosis	NN	B-NP	B
and	CC	O	O
disruptive	JJ	B-NP	B
behaviors	NNS	I-NP	I
.	.	O	O

Individual	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
ACE	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
rats	NNS	I-NP	O
predict	VBP	B-VP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
damage	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
man	NN	B-NP	O
,	,	O	O
differences	NNS	B-NP	O
in	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
,	,	O	O
related	VBN	B-VP	O
to	TO	B-PP	O
ACE	NN	B-NP	O
(	(	O	O
I	NN	B-NP	O
/	SYM	B-NP	O
D	NN	I-NP	O
)	)	O	O
genotype	NN	B-NP	O
,	,	O	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
renal	JJ	B-NP	O
prognosis	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
raises	VBZ	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
individual	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
ACE	NN	I-NP	O
activity	NN	I-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
susceptibility	NN	I-NP	O
to	TO	B-PP	O
inflicted	VBN	B-NP	O
damage	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
predictive	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
ACE	NN	I-NP	O
activity	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Renal	JJ	B-NP	O
ACE	NN	I-NP	O
activity	NN	I-NP	O
(	(	O	O
Hip	NN	B-NP	O
-	HYPH	B-NP	O
His	NN	I-NP	O
-	HYPH	B-NP	O
Leu	NN	I-NP	O
cleavage	NN	I-NP	O
by	IN	B-PP	O
cortical	JJ	B-NP	O
homogenates	NNS	I-NP	O
)	)	O	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
renal	JJ	B-NP	O
biopsy	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
adult	JJ	I-NP	O
male	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
recovery	NN	B-NP	O
,	,	O	O
proteinuria	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
adriamycin	NN	B-NP	O
[	(	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
intravenously	RB	B-ADVP	O
(	(	O	O
i.v.	RB	O	O
)	)	O	O
n	NN	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
;	:	O	O
controls	NNS	B-NP	O
,	,	O	O
saline	NN	B-NP	O
i.v.	JJ	I-NP	O
n	NN	I-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
]	)	O	O
.	.	O	O

Proteinuria	NNP	B-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
sacrificed	VBN	I-VP	O
and	CC	O	O
their	PRP$	B-NP	O
kidneys	NNS	I-NP	O
harvested	VBN	B-VP	O
.	.	O	O

As	IN	B-SBAR	O
anticipated	VBN	B-VP	O
,	,	O	O
adriamycin	NN	B-NP	O
elicited	VBD	B-VP	O
nephrotic	JJ	B-NP	B
range	NN	I-NP	O
proteinuria	NN	I-NP	B
,	,	O	O
renal	JJ	B-NP	B
interstitial	JJ	I-NP	I
damage	NN	I-NP	I
and	CC	O	O
mild	JJ	B-NP	O
focal	JJ	I-NP	B
glomerulosclerosis	NN	I-NP	I
.	.	O	O

Baseline	NN	B-NP	O
renal	JJ	I-NP	O
ACE	NN	I-NP	O
positively	RB	B-ADVP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
relative	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
proteinuria	NN	B-NP	B
after	IN	B-PP	O
adriamycin	NN	B-NP	O
,	,	O	O
renal	JJ	B-NP	O
interstitial	JJ	I-NP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
actin	NN	I-NP	O
,	,	O	O
interstitial	JJ	B-NP	O
macrophage	NN	I-NP	O
influx	NN	I-NP	O
,	,	O	O
interstitial	JJ	B-NP	O
collagen	NN	I-NP	O
num	CD	I-NP	O
,	,	O	O
glomerular	JJ	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
actin	NN	I-NP	O
and	CC	O	O
glomerular	JJ	B-NP	O
desmin	NN	I-NP	O
.	.	O	O

Baseline	NN	B-NP	O
renal	JJ	I-NP	O
ACE	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
focal	JJ	B-NP	B
glomerulosclerosis	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
no	DT	B-NP	O
predictive	JJ	I-NP	O
values	NNS	I-NP	O
for	IN	B-PP	O
renal	JJ	B-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Individual	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
ACE	NN	I-NP	O
activity	NN	I-NP	O
predict	VBP	B-VP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
this	DT	B-NP	O
outbred	JJ	I-NP	O
rat	NN	I-NP	O
strain	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
assumption	NN	I-NP	O
that	IN	B-SBAR	O
differences	NNS	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
ACE	NN	I-NP	O
activity	NN	I-NP	O
predispose	VBP	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
less	RBR	I-NP	O
favourable	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
.	.	O	O

Clinical	JJ	B-NP	O
nephrotoxicity	NN	I-NP	B
of	IN	B-PP	O
tobramycin	NN	B-NP	O
and	CC	I-NP	O
gentamicin	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Nearly	RB	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
people	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
country	NN	I-NP	O
receive	VBP	B-VP	O
aminoglycoside	NN	B-NP	O
antibiotics	NNS	I-NP	O
annually	RB	B-ADVP	O
.	.	O	O

Gentamicin	NN	B-NP	O
sulfate	NN	I-NP	O
and	CC	O	O
tobramycin	NN	B-NP	O
sulfate	NN	I-NP	O
continue	VBP	B-VP	O
to	TO	I-VP	O
demonstrate	VB	I-VP	O
ototoxicity	NN	B-NP	B
and	CC	I-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
both	CC	B-NP	O
animal	JJ	I-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
confirmed	VBN	B-NP	O
initial	JJ	I-NP	O
normal	JJ	I-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
and	CC	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
gentamicin	NN	B-NP	O
sulfate	NN	I-NP	O
or	CC	O	O
tobramycin	NN	B-NP	O
sulfate	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
minimum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
up	RP	B-PRT	O
prospectively	RB	B-ADVP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
aminoglycoside	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
,	,	O	O
defined	VBN	B-VP	O
as	IN	B-PP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
third	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
no	DT	B-NP	O
other	JJ	I-NP	O
causes	NNS	I-NP	O
for	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
could	MD	B-VP	O
be	VB	I-VP	O
identified	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tobramycin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
gentamicin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
gentamicin	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
as	RB	I-NP	O
often	RB	I-NP	O
as	IN	I-NP	O
was	VBD	B-VP	O
tobramycin	NN	B-NP	O
.	.	O	O

Neuroprotective	JJ	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
MPEP	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
mGluR5	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dopaminergic	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
dopamine	NN	B-NP	O
outflow	NN	I-NP	O
and	CC	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
hyperthermia	NN	B-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
metabotropic	JJ	B-NP	O
glutamate	NN	I-NP	O
receptor	NN	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
on	IN	B-PP	O
dopaminergic	JJ	B-NP	O
neurones	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Methamphetamine	NN	B-NP	O
,	,	O	O
administered	VBN	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
,	,	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
in	IN	B-PP	O
striatal	JJ	B-NP	O
tissue	NN	I-NP	O
when	WRB	B-ADVP	O
measured	VBN	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
injection	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
selective	JJ	I-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
mGluR5	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
(	(	I-NP	O
phenylethynyl	NN	I-NP	O
)	)	O	O
pyridine	NN	B-NP	O
,	,	O	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
immediately	RB	B-ADVP	O
before	IN	B-SBAR	O
each	DT	B-NP	O
methamphetamine	NN	I-NP	O
injection	NN	I-NP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
above	RB	I-NP	O
-	HYPH	I-NP	O
mentioned	VBN	I-NP	O
methamphetamine	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
MPEP	NN	I-NP	O
injection	NN	I-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
extracellular	JJ	I-NP	O
dopamine	NN	I-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
dopamine	NN	B-NP	O
release	NN	I-NP	O
stimulated	VBD	B-VP	O
either	CC	O	O
by	IN	B-PP	O
methamphetamine	NN	B-NP	O
or	CC	B-PP	O
by	IN	B-PP	O
intrastriatally	RB	B-NP	O
administered	VBN	I-NP	O
veratridine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
microM	NN	I-NP	O
)	)	O	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
transiently	RB	B-ADVP	O
diminished	VBD	B-VP	O
the	DT	B-NP	O
methamphetamine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
hyperthermia	NN	I-NP	B
and	CC	O	O
reduced	VBN	B-NP	O
basal	JJ	I-NP	O
body	NN	I-NP	O
temperature	NN	I-NP	O
.	.	O	O

MPEP	NN	B-NP	O
administered	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
at	IN	B-PP	O
high	JJ	B-NP	O
concentrations	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
microM	NN	I-NP	O
)	)	O	O
increased	VBD	B-VP	O
extracellular	JJ	B-NP	O
dopamine	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
lower	JJR	B-NP	O
concentrations	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microM	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
devoid	JJ	B-ADJP	O
of	IN	B-PP	O
any	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
mGluR5	NN	B-NP	O
by	IN	B-PP	O
MPEP	NN	B-NP	O
may	MD	B-VP	O
protect	VB	I-VP	O
dopaminergic	JJ	B-NP	O
neurones	NNS	I-NP	O
against	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Neuroprotection	NN	B-NP	O
rendered	VBN	B-VP	O
by	IN	B-PP	O
MPEP	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
methamphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dopamine	NN	I-NP	O
efflux	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
extrastriatal	JJ	B-NP	O
mGluR5	NN	I-NP	O
,	,	O	O
and	CC	O	O
with	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
hyperthermia	NN	B-NP	B
.	.	O	O

Pharmacokinetics	NNS	B-NP	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
HCl	NN	I-NP	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
with	IN	B-PP	O
cinacalcet	NN	B-NP	O
HCl	NN	I-NP	O
.	.	O	O

In	FW	B-NP	O
vitro	FW	I-NP	O
work	NN	I-NP	O
has	VBZ	B-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
cinacalcet	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
cytochrome	NN	B-NP	O
P450	NN	I-NP	O
isoenzyme	NN	I-NP	O
(	(	O	O
CYP	NN	B-NP	O
)	)	O	O
2D6	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
cinacalcet	NN	B-NP	O
on	IN	B-PP	O
CYP2D6	NN	B-NP	O
activity	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
desipramine	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
probe	NN	I-NP	O
substrate	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
subjects	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
genotyped	VBN	I-VP	O
as	IN	B-PP	O
CYP2D6	NN	B-NP	O
extensive	JJ	I-NP	O
metabolizers	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
,	,	O	O
crossover	NN	B-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
receive	VB	I-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
oral	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
occasions	NNS	I-NP	O
,	,	O	O
once	RB	B-ADVP	O
alone	RB	I-ADVP	O
and	CC	I-ADVP	O
once	RB	I-ADVP	O
after	IN	B-SBAR	O
multiple	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
cinacalcet	NN	B-NP	O
.	.	O	O

Blood	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
predose	RB	B-ADVP	O
and	CC	I-ADVP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
postdose	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
subjects	NNS	I-NP	O
completed	VBD	B-VP	O
both	CC	O	O
treatment	NN	B-NP	O
arms	NNS	I-NP	O
.	.	O	O

Relative	JJ	B-ADJP	O
to	TO	B-PP	O
desipramine	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
mean	JJ	B-NP	O
AUC	NN	I-NP	O
and	CC	O	O
C	NN	B-NP	O
(	(	O	O
max	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
increased	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
when	WRB	B-ADVP	O
coadministered	VBN	B-VP	O
with	IN	B-PP	O
cinacalcet	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
t	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
z	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
was	VBD	B-VP	O
longer	JJR	B-ADJP	O
when	WRB	B-ADVP	O
desipramine	NN	B-NP	O
was	VBD	B-VP	O
coadministered	VBN	I-VP	O
with	IN	B-PP	O
cinacalcet	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
versus	IN	I-NP	O
num	CD	I-NP	O
hs	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
t	NN	I-NP	O
(	(	O	O
max	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
regimens	NNS	I-NP	O
.	.	O	O

Fewer	JJR	B-NP	O
subjects	NNS	I-NP	O
reported	VBD	B-VP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
following	VBG	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
desipramine	NN	B-NP	O
alone	RB	B-ADVP	O
than	IN	B-PP	O
when	WRB	B-ADVP	O
receiving	VBG	B-VP	O
desipramine	NN	B-NP	O
with	IN	B-PP	O
cinacalcet	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
versus	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequent	JJ	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
(	(	O	O
nausea	NN	B-NP	B
and	CC	O	O
headache	NN	B-NP	B
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
either	CC	O	O
desipramine	NN	B-NP	O
or	CC	I-NP	O
cinacalcet	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
cinacalcet	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
CYP2D6	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
during	IN	B-PP	O
concomitant	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
cinacalcet	NN	B-NP	O
,	,	O	O
dose	NN	B-NP	O
adjustment	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
necessary	JJ	B-ADJP	O
for	IN	B-PP	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
demonstrate	VBP	B-VP	O
a	DT	B-NP	O
narrow	JJ	I-NP	O
therapeutic	JJ	I-NP	O
index	NN	I-NP	O
and	CC	O	O
are	VBP	B-VP	O
metabolized	VBN	I-VP	O
by	IN	B-PP	O
CYP2D6	NN	B-NP	O
.	.	O	O

Proteomic	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
striatal	JJ	B-NP	O
proteins	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
.	.	O	O

L	NN	B-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
dyskinesia	NN	I-NP	B
(	(	O	O
LID	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
among	IN	B-PP	O
the	DT	B-NP	O
motor	NN	I-NP	O
complications	NNS	I-NP	O
that	WDT	B-NP	O
arise	VBP	B-VP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
patients	NNS	B-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
prolonged	VBN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
.	.	O	O

To	TO	B-PP	O
this	DT	B-NP	O
day	NN	I-NP	O
,	,	O	O
transcriptome	NN	B-NP	O
analysis	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
LID	NN	B-NP	B
[	(	O	O
Neurobiol	NN	B-NP	O
.	.	O	O

Dis.	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
]	)	O	O
but	CC	O	O
information	NN	B-NP	O
regarding	VBG	B-VP	O
the	DT	B-NP	O
proteome	NN	I-NP	O
is	VBZ	B-VP	O
still	RB	I-VP	O
lacking	VBG	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
occurring	VBG	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
protein	NN	I-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
striatal	JJ	B-NP	O
samples	NNS	I-NP	O
obtained	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
unilaterally	RB	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxydopamine	NN	I-NP	O
-	HYPH	I-NP	O
lesion	NN	I-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
PD	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
or	CC	I-NP	O
bromocriptine	NN	I-NP	O
using	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dimensional	JJ	I-NP	O
difference	NN	I-NP	O
gel	NN	I-NP	O
electrophoresis	NN	I-NP	O
and	CC	O	O
mass	NN	B-NP	O
spectrometry	NN	I-NP	O
(	(	O	O
MS	NN	B-NP	O
)	)	O	O
.	.	O	O

Rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
were	VBD	B-VP	O
allocated	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
or	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
LID	NN	B-NP	B
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
spots	NNS	I-NP	O
compared	VBN	B-VP	O
for	IN	B-PP	O
statistical	JJ	B-NP	O
difference	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
spots	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
changed	VBN	I-VP	O
in	IN	B-PP	O
abundance	NN	B-NP	O
and	CC	O	O
identified	VBN	B-VP	O
using	VBG	B-VP	O
matrix	NN	B-NP	O
-	HYPH	I-NP	O
assisted	VBN	I-NP	O
laser	NN	I-NP	O
desorption	NN	I-NP	O
/	SYM	B-VP	O
ionization	NN	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
flight	NN	I-NP	O
MS	NN	I-NP	O
,	,	O	O
atmospheric	JJ	B-NP	O
pressure	NN	I-NP	O
matrix	NN	I-NP	O
-	HYPH	B-VP	O
assisted	VBN	B-NP	O
laser	NN	I-NP	O
desorption	NN	I-NP	O
/	SYM	B-NP	O
ionization	NN	I-NP	O
and	CC	I-NP	O
HPLC	NN	I-NP	O
coupled	VBN	B-VP	O
tandem	JJ	B-NP	O
MS	NN	I-NP	O
(	(	O	O
LC	NN	B-NP	O
/	SYM	B-NP	O
MS	NN	I-NP	O
/	SYM	I-NP	O
MS	NN	I-NP	O
)	)	O	O
.	.	O	O

Out	IN	B-PP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
proteins	NNS	I-NP	O
,	,	O	O
LID	NNP	B-NP	B
significantly	RB	B-ADVP	O
changed	VBD	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
proteins	NNS	I-NP	O
:	:	O	O
alphabeta	NN	B-NP	O
-	HYPH	B-NP	O
crystalin	NN	I-NP	O
,	,	O	O
gamma	SYM	O	O
-	HYPH	O	O
enolase	NN	B-NP	O
,	,	O	O
guanidoacetate	NN	B-NP	O
methyltransferase	NN	I-NP	O
,	,	O	O
vinculin	NN	B-NP	O
,	,	O	O
and	CC	O	O
proteasome	NN	B-NP	O
alpha	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
subunit	NN	I-NP	O
.	.	O	O

Complementary	JJ	B-NP	O
techniques	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
western	JJ	B-NP	O
immunoblotting	NN	I-NP	O
and	CC	I-NP	O
immunohistochemistry	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
validity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
data	NNS	I-NP	O
obtained	VBN	B-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
proteomic	JJ	I-NP	O
approach	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
study	NN	I-NP	O
provides	VBZ	B-VP	O
new	JJ	B-NP	O
insights	NNS	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
protein	NN	I-NP	O
changes	NNS	I-NP	O
occurring	VBG	B-VP	O
in	IN	B-PP	O
LID	NNP	B-NP	B
.	.	O	O

Pseudo	AFX	B-NP	O
-	HYPH	I-NP	O
allergic	JJ	B-NP	B
reactions	NNS	I-NP	I
to	TO	B-PP	O
corticosteroids	NNS	B-NP	O
:	:	O	O
diagnosis	NN	B-NP	O
and	CC	I-NP	O
alternatives	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
parenteral	JJ	B-NP	O
paramethasone	NN	I-NP	O
(	(	O	O
Triniol	NN	B-NP	O
)	)	O	O
and	CC	O	O
dexamethasone	NN	B-NP	O
(	(	O	O
Sedionbel	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
described	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
few	JJ	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
they	PRP	B-NP	O
presented	VBD	B-VP	O
urticaria	NN	B-NP	B
(	(	O	O
patients	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
conjunctivitis	NN	B-NP	B
(	(	O	O
patient	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
s	VBZ	B-VP	O
reactions	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
immunological	JJ	I-NP	O
mechanisms	NNS	I-NP	O
involved	VBN	B-VP	O
and	CC	O	O
whether	IN	B-SBAR	O
these	DT	B-NP	O
patients	NNS	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
tolerate	VB	I-VP	O
any	DT	B-NP	O
kind	NN	I-NP	O
of	IN	B-PP	O
corticoid	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
examinations	NNS	I-NP	O
and	CC	I-NP	O
skin	NN	I-NP	O
,	,	O	O
oral	JJ	B-NP	O
and	CC	I-NP	O
parenteral	JJ	I-NP	O
challenges	NNS	I-NP	O
with	IN	B-PP	O
different	JJ	B-NP	O
corticosteroids	NNS	I-NP	O
and	CC	O	O
ELISA	NN	B-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
skin	NN	B-NP	O
and	CC	I-NP	O
ELISA	NN	I-NP	O
tests	NNS	I-NP	O
with	IN	B-PP	O
paramethasone	NN	B-NP	O
were	VBD	B-VP	O
negative	JJ	B-ADJP	O
,	,	O	O
as	IN	B-SBAR	O
was	VBD	B-VP	O
the	DT	B-NP	O
prick	NN	I-NP	O
test	NN	I-NP	O
with	IN	B-PP	O
each	DT	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
excipients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
parenteral	JJ	I-NP	O
challenge	NN	I-NP	O
with	IN	B-PP	O
Triniol	NN	B-NP	O
was	VBD	B-VP	O
positive	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
patients	NNS	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ml	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
,	,	O	O
and	CC	O	O
negative	JJ	B-ADJP	O
with	IN	B-PP	O
its	PRP$	B-NP	O
excipients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
carried	VBD	B-VP	O
out	RP	B-PRT	O
oral	JJ	B-NP	O
and	CC	I-NP	O
parenteral	JJ	I-NP	O
challenges	NNS	I-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
corticosteroids	NNS	I-NP	O
and	CC	O	O
found	VBN	B-VP	O
intolerance	NN	B-NP	O
to	TO	B-PP	O
some	DT	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
paramethasone	NN	B-NP	O
caused	VBD	B-VP	O
pseudoallergic	JJ	B-NP	O
reactions	NNS	I-NP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Corticosteroids	NNS	B-NP	O
different	JJ	B-ADJP	O
from	IN	B-PP	O
paramethasone	NN	B-NP	O
also	RB	B-ADVP	O
produced	VBD	B-VP	O
hypersensitivity	NN	B-NP	B
reactions	NNS	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
few	JJ	I-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
were	VBD	B-VP	O
tolerated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
basic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
reactions	NNS	I-NP	O
are	VBP	B-VP	O
not	RB	O	O
yet	RB	B-ADVP	O
fully	RB	B-ADJP	O
understood	VBN	I-ADJP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
pseudo	AFX	I-NP	O
-	HYPH	I-NP	O
allergy	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
paramethasone	NN	B-NP	O
.	.	O	O

Valproic	JJ	B-NP	O
acid	NN	I-NP	O
induced	VBN	B-NP	O
encephalopathy	NN	I-NP	B
-	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
new	JJ	I-NP	O
cases	NNS	I-NP	O
in	IN	B-PP	O
Germany	NNP	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
-	:	O	O
a	DT	B-NP	O
side	JJ	I-NP	O
effect	NN	I-NP	O
associated	VBN	B-VP	O
to	TO	B-PP	O
VPA	NN	B-NP	O
-	HYPH	I-NP	O
therapy	NN	I-NP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
in	IN	B-PP	O
young	JJ	B-NP	O
children	NNS	I-NP	O
.	.	O	O

Valproic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
VPA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
broad	JJ	I-NP	O
-	HYPH	I-NP	O
spectrum	NN	I-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
usually	RB	B-ADVP	O
well	RB	B-ADVP	O
-	HYPH	B-NP	O
tolerated	VBN	B-VP	O
.	.	O	O

Rare	NN	B-NP	O
serious	JJ	I-NP	O
complications	NNS	I-NP	O
may	MD	B-VP	O
occur	VB	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
haemorrhagic	JJ	B-NP	O
pancreatitis	NN	I-NP	B
,	,	O	O
bone	NN	B-NP	B
marrow	NN	I-NP	I
suppression	NN	I-NP	I
,	,	O	O
VPA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
and	CC	I-NP	O
VPA	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
typical	JJ	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
VPA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
are	VBP	B-VP	O
impaired	JJ	B-NP	B
consciousness	NN	I-NP	I
,	,	O	O
sometimes	RB	B-NP	O
marked	JJ	I-NP	O
EEG	NN	I-NP	O
background	NN	I-NP	O
slowing	VBG	B-VP	O
,	,	O	O
increased	VBN	B-NP	O
seizure	NN	I-NP	B
frequency	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
hyperammonemia	NN	B-NP	B
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
no	DT	B-NP	O
proof	NN	I-NP	O
of	IN	B-PP	O
causative	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
VPA	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
encephalopathy	NN	B-NP	B
,	,	O	O
but	CC	O	O
only	RB	B-ADVP	O
of	IN	B-PP	O
an	DT	B-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
assumed	VBN	I-NP	O
causal	JJ	I-NP	O
relation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
VPA	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
encephalopathy	NN	I-NP	B
in	IN	B-PP	O
Germany	NNP	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
years	NNS	I-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
none	NN	I-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
published	VBN	I-VP	O
previously	RB	B-ADVP	O
.	.	O	O

Haemolytic	JJ	B-NP	B
-	HYPH	I-NP	I
uraemic	JJ	I-NP	I
syndrome	NN	I-NP	I
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
metronidazole	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
paper	NN	I-NP	O
describes	VBZ	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
the	DT	B-NP	O
haemolytic	JJ	I-NP	B
-	HYPH	I-NP	I
uraemic	JJ	I-NP	I
syndrome	NN	I-NP	I
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
metronidazole	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
children	NNS	I-NP	O
were	VBD	B-VP	O
older	JJR	B-ADJP	O
and	CC	O	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
undergone	VBN	I-VP	O
recent	JJ	B-NP	O
bowel	NN	I-NP	O
surgery	NN	I-NP	O
than	IN	B-SBAR	O
are	VBP	B-VP	O
other	JJ	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
this	DT	B-NP	O
condition	NN	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
metronidazole	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
aetiology	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
haemolytic	JJ	I-NP	B
-	HYPH	I-NP	I
uraemic	JJ	I-NP	I
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
not	RB	I-VP	O
established	VBN	I-VP	O
firmly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
sensitizing	VBG	B-VP	O
tissues	NNS	B-NP	O
to	TO	B-PP	O
oxidation	NN	B-NP	O
injury	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
reported	VBN	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
oxidation	NN	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
haemolytic	JJ	I-NP	B
-	HYPH	I-NP	I
uraemic	JJ	I-NP	I
syndrome	NN	I-NP	I
suggest	VBP	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
link	NN	I-NP	O
between	IN	B-PP	O
metronidazole	NN	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
some	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
haemolytic	JJ	I-NP	B
-	HYPH	I-NP	I
uraemic	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Risk	NN	B-NP	O
factors	NNS	I-NP	O
of	IN	B-PP	O
sensorineural	JJ	B-NP	B
hearing	NN	I-NP	I
loss	NN	I-NP	I
in	IN	B-PP	O
preterm	JJ	B-NP	O
infants	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
num	CD	B-NP	O
preterm	JJ	I-NP	O
infants	NNS	I-NP	O
of	IN	B-PP	O
<	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
gestation	NN	I-NP	O
born	VBN	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
developed	VBD	B-VP	O
severe	JJ	B-NP	O
progressive	JJ	I-NP	O
and	CC	I-NP	O
bilateral	JJ	I-NP	O
sensorineural	JJ	I-NP	B
hearing	NN	I-NP	I
loss	NN	I-NP	I
.	.	O	O

Perinatal	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
of	IN	B-PP	O
infants	NNS	B-NP	O
with	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
matched	VBN	B-VP	O
for	IN	B-PP	O
gestation	NN	B-NP	O
and	CC	I-NP	O
birth	NN	I-NP	O
weight	NN	I-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
perinatal	JJ	B-NP	O
complications	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
observations	NNS	I-NP	O
demonstrated	VBD	B-VP	O
an	DT	B-NP	O
association	NN	I-NP	O
of	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
perinatal	JJ	B-NP	O
complications	NNS	I-NP	O
.	.	O	O

Ototoxicity	NN	B-NP	B
appeared	VBD	B-VP	O
closely	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
prolonged	VBN	I-NP	O
administration	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
ototoxic	JJ	B-NP	B
drugs	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
aminoglycosides	IN	B-ADVP	O
and	CC	O	O
furosemide	NN	B-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
strongly	RB	B-ADVP	O
recommend	VBP	B-VP	O
to	TO	B-PP	O
prospectively	RB	B-VP	O
and	CC	I-VP	O
regularly	RB	I-VP	O
perform	VB	I-VP	O
audiologic	JJ	B-NP	O
assessment	NN	I-NP	O
in	IN	B-PP	O
sick	JJ	B-NP	O
preterm	JJ	I-NP	O
children	NNS	I-NP	O
as	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
is	VBZ	B-VP	O
of	IN	B-PP	O
delayed	VBN	B-NP	O
onset	NN	I-NP	O
and	CC	O	O
in	IN	B-PP	O
most	JJS	B-NP	O
cases	NNS	I-NP	O
bilateral	JJ	B-ADJP	O
and	CC	I-ADJP	O
severe	JJ	I-ADJP	O
.	.	O	O

Pharmacokinetic	JJ	B-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cimetidine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
mental	JJ	I-NP	O
confusion	NN	I-NP	B
.	.	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
mental	JJ	I-NP	O
confusion	NN	I-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
order	NN	B-NP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
investigated	VBN	I-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
mental	JJ	B-NP	O
status	NN	I-NP	O
(	(	O	O
M.S.	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
serum	NN	B-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
and	CC	I-NP	O
hepatic	JJ	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
M.S.	NNP	I-NP	O
change	NN	I-NP	O
on	IN	B-PP	O
cimetidine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
changes	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
both	CC	B-NP	O
renal	JJ	I-NP	B
and	CC	O	I
liver	NN	B-NP	I
dysfunction	NN	I-NP	I
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
cimetidine	NN	B-NP	O
trough	NN	I-NP	O
-	HYPH	O	O
concentrations	NNS	B-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
M.S.	NNP	B-NP	O
changes	NNS	I-NP	O
increased	VBD	B-VP	O
as	IN	B-PP	O
trough	NN	B-NP	O
-	HYPH	O	O
concentrations	NNS	B-NP	O
rose	VBD	B-VP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
lumbar	JJ	B-NP	O
puncture	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cerebrospinal	JJ	I-NP	O
fluid	NN	I-NP	O
:	:	O	O
serum	NN	B-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
concentrations	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
:	SYM	O	O
num	CD	B-NP	O
and	CC	O	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
cimetidine	NN	B-NP	O
passes	VBZ	B-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
;	:	O	O
it	PRP	B-NP	O
also	RB	B-ADVP	O
raises	VBZ	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
M.S.	NNP	B-NP	O
changes	NNS	I-NP	O
are	VBP	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
blockade	NN	B-NP	O
of	IN	B-PP	O
histamine	NN	B-NP	O
H2	NN	I-NP	O
-	HYPH	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
both	CC	O	O
raised	VBN	B-NP	O
trough	NN	I-NP	O
-	HYPH	B-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
mental	JJ	B-NP	O
confusion	NN	I-NP	B
are	VBP	B-VP	O
those	DT	B-NP	O
with	IN	B-PP	O
both	CC	O	O
severe	JJ	B-NP	O
renal	JJ	I-NP	B
and	CC	I-NP	I
hepatic	JJ	I-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

They	PRP	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
closely	RB	I-VP	O
observed	VBN	I-VP	O
and	CC	O	O
should	MD	B-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
reduced	VBN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
.	.	O	O

Different	JJ	B-NP	O
lobular	JJ	I-NP	O
distributions	NNS	I-NP	O
of	IN	B-PP	O
altered	JJ	B-NP	O
hepatocyte	NN	I-NP	O
tight	JJ	I-NP	O
junctions	NNS	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
intrahepatic	JJ	B-NP	B
and	CC	I-NP	I
extrahepatic	JJ	I-NP	I
cholestasis	NN	I-NP	I
.	.	O	O

Hepatocyte	NN	B-NP	O
tight	JJ	I-NP	O
junctions	NNS	I-NP	O
(	(	O	O
TJs	NNS	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
only	RB	I-NP	O
intercellular	JJ	I-NP	O
barrier	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
sinusoidal	JJ	I-NP	O
and	CC	O	O
the	DT	B-NP	O
canalicular	JJ	I-NP	O
spaces	NNS	I-NP	O
,	,	O	O
play	VBP	B-VP	O
a	DT	B-NP	O
key	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
bile	NN	B-NP	O
formation	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
hepatocyte	NN	B-NP	O
TJs	NNS	I-NP	O
are	VBP	B-VP	O
impaired	JJ	B-ADJP	O
in	IN	B-PP	O
cholestasis	NN	B-NP	B
,	,	O	O
attempts	VBZ	B-VP	O
to	TO	I-VP	O
localize	VB	I-VP	O
the	DT	B-NP	O
precise	JJ	I-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
hepatocyte	NN	B-NP	O
TJ	NN	I-NP	O
damage	NN	I-NP	O
by	IN	B-PP	O
freeze	NN	B-NP	O
-	HYPH	B-NP	O
fracture	NN	I-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
have	VBP	B-VP	O
produced	VBN	I-VP	O
limited	JJ	B-NP	O
information	NN	I-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
several	JJ	B-NP	O
TJ	NN	I-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
proteins	NNS	I-NP	O
like	IN	B-PP	O
ZO	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
identified	VBN	I-VP	O
and	CC	O	O
characterized	VBN	B-VP	O
.	.	O	O

Immunolocalization	NN	B-NP	O
of	IN	B-PP	O
7H6	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
closely	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
paracellular	JJ	B-NP	O
permeability	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
rat	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
intrahepatic	JJ	B-NP	B
cholestasis	NN	I-NP	I
by	IN	B-PP	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
(	(	O	O
EE	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
and	CC	O	O
extrahepatic	JJ	B-NP	B
cholestasis	NN	I-NP	I
by	IN	B-PP	O
bile	NN	B-NP	O
duct	NN	I-NP	O
ligation	NN	I-NP	O
(	(	O	O
BDL	NN	B-NP	O
)	)	O	O
to	TO	B-VP	O
precisely	RB	I-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
TJ	NN	B-NP	O
damage	NN	I-NP	O
.	.	O	O

Alterations	NNS	B-NP	O
in	IN	B-PP	O
hepatocyte	NN	B-NP	O
TJs	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
immunolabeling	NN	I-NP	O
for	IN	B-PP	O
7H6	NN	B-NP	O
and	CC	I-NP	O
ZO	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
confocal	JJ	I-NP	O
laser	NN	I-NP	O
scanning	NN	I-NP	O
microscope	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
immunostaining	NN	B-NP	O
for	IN	B-PP	O
7H6	NN	B-NP	O
and	CC	I-NP	O
ZO	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
colocalized	VBD	B-VP	O
to	TO	I-VP	O
outline	VB	I-VP	O
bile	NN	B-NP	O
canaliculi	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
continuous	JJ	I-NP	O
fashion	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
7H6	NN	B-NP	O
and	CC	I-NP	O
ZO	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
immunostaining	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
discontinuous	JJ	I-ADJP	O
,	,	O	O
outlining	VBG	B-VP	O
the	DT	B-NP	O
bile	NN	I-NP	O
canaliculi	NNS	I-NP	O
after	IN	B-PP	O
BDL	NN	B-NP	O
.	.	O	O

Immunostaining	NN	B-NP	O
for	IN	B-PP	O
7H6	NN	B-NP	O
,	,	O	O
not	RB	B-NP	O
ZO	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
decreased	VBN	B-VP	O
and	CC	O	O
predominantly	RB	B-VP	O
appeared	VBD	I-VP	O
as	IN	B-PP	O
discrete	JJ	B-NP	O
signals	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
submembranous	JJ	I-NP	O
cytoplasm	NN	I-NP	O
of	IN	B-PP	O
periportal	JJ	B-NP	O
hepatocytes	NNS	I-NP	O
after	IN	B-PP	O
BDL	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
EE	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
changes	NNS	B-NP	O
in	IN	B-PP	O
immunostaining	NN	B-NP	O
for	IN	B-PP	O
7H6	NN	B-NP	O
and	CC	I-NP	O
ZO	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
periportal	JJ	B-NP	O
hepatocytes	NNS	I-NP	O
after	IN	B-PP	O
BDL	NN	B-NP	O
,	,	O	O
but	CC	O	O
distributed	VBD	B-VP	O
more	RBR	B-ADVP	O
diffusely	RB	I-ADVP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
lobule	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
to	TO	B-VP	O
demonstrate	VB	I-VP	O
that	IN	B-SBAR	O
impairment	NN	B-NP	O
of	IN	B-PP	O
hepatocyte	NN	B-NP	O
TJs	NNS	I-NP	O
occurs	VBZ	B-VP	O
heterogenously	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
lobule	NN	I-NP	O
after	IN	B-PP	O
BDL	NN	B-NP	O
and	CC	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
BDL	NN	B-NP	O
and	CC	I-NP	O
EE	NN	I-NP	O
treatments	NNS	I-NP	O
produce	VBP	B-VP	O
different	JJ	B-NP	O
lobular	JJ	I-NP	O
distributions	NNS	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
paracellular	JJ	I-NP	O
permeability	NN	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
term	NN	I-NP	O
audiological	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
beta	SYM	B-NP	B
-	HYPH	O	I
thalassemic	JJ	B-NP	I
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
monitor	VB	I-VP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
hearing	NN	B-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
children	NNS	B-NP	O
and	CC	O	O
young	JJ	B-NP	O
adults	NNS	I-NP	O
with	IN	B-PP	O
beta	SYM	B-NP	B
-	HYPH	I-NP	I
thalassemia	NN	I-NP	I
major	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
aged	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
participated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
regular	JJ	I-NP	O
transfusion	NN	I-NP	O
-	HYPH	B-NP	O
chelation	NN	I-NP	O
program	NN	I-NP	O
maintaining	VBG	B-VP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
hemoglobin	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
gr	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
desferrioxamine	NN	B-NP	O
(	(	O	O
DFO	NN	B-NP	O
)	)	O	O
chelation	NN	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
a	DT	B-NP	O
week	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
then	RB	I-VP	O
reduced	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
frequency	NN	I-NP	O
sensorineural	JJ	I-NP	B
hearing	NN	I-NP	I
loss	NN	I-NP	I
(	(	O	O
SNHL	NN	B-NP	B
)	)	O	O
,	,	O	O
either	CC	O	O
unilateral	JJ	B-ADJP	O
or	CC	I-ADJP	O
bilateral	JJ	I-ADJP	O
.	.	O	O

No	DT	B-NP	O
ototoxic	JJ	I-NP	B
factor	NN	I-NP	O
,	,	O	O
other	JJ	B-ADJP	O
than	IN	B-PP	O
DFO	NNP	B-NP	O
,	,	O	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
SNHL	NN	B-NP	B
presented	VBD	B-VP	O
with	IN	B-PP	O
relatively	RB	B-NP	O
lower	JJR	I-NP	O
serum	NN	I-NP	O
ferritin	NN	I-NP	O
levels	NNS	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
hearing	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Subjects	NNS	B-NP	O
with	IN	B-PP	O
SNHL	NN	B-NP	B
were	VBD	B-VP	O
submitted	VBN	I-VP	O
to	TO	B-PP	O
DFO	NN	B-NP	O
reduction	NN	I-NP	O
or	CC	O	O
temporary	JJ	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
intervention	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
out	IN	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
affected	VBN	I-NP	O
patients	NNS	I-NP	O
recovered	VBD	B-VP	O
,	,	O	O
num	CD	B-NP	O
remained	VBD	B-VP	O
stable	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
demonstrated	VBD	B-VP	O
aggravation	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
DFO	NN	B-NP	O
s	NNS	I-NP	O
contributing	VBG	B-VP	O
role	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hearing	VBG	B-VP	B
impairment	NN	B-NP	I
.	.	O	O

Regular	JJ	B-NP	O
audiologic	JJ	I-NP	O
evaluation	NN	I-NP	O
is	VBZ	B-VP	O
imperative	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
thalassemic	JJ	I-NP	B
patients	NNS	I-NP	O
so	IN	B-SBAR	O
that	IN	I-SBAR	O
early	JJ	B-NP	O
changes	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
recognized	VBN	I-VP	O
and	CC	O	O
treatment	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
judiciously	RB	I-VP	O
adjusted	VBN	I-VP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
prevent	VB	I-VP	O
or	CC	I-VP	O
reverse	VB	I-VP	O
hearing	VBG	B-NP	B
impairment	NN	I-NP	I
.	.	O	O

Design	NN	B-NP	O
and	CC	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
HYPREN	NN	I-NP	O
-	HYPH	B-NP	O
trial	NN	I-NP	O
:	:	O	O
safety	NN	B-NP	O
of	IN	B-PP	O
enalapril	NN	B-NP	O
and	CC	I-NP	O
prazosin	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
treatment	NN	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Since	IN	B-SBAR	O
the	DT	B-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
inhibitors	NNS	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
adjunctive	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
,	,	O	O
cases	NNS	B-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hypotension	NN	I-NP	B
,	,	O	O
especially	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
have	VBP	B-VP	O
occasionally	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ACE	NN	I-NP	O
inhibitor	NN	I-NP	O
enalapril	VBP	B-VP	O
a	DT	B-NP	O
multicenter	NN	I-NP	O
,	,	O	O
randomized	VBN	B-VP	O
,	,	O	O
prazosin	NN	B-NP	O
-	HYPH	B-VP	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
that	WDT	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
symptomatic	JJ	B-NP	O
hypotension	NN	I-NP	B
on	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Trial	JJ	B-NP	O
medication	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
enalapril	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
prazosin	NN	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
inpatients	NNS	I-NP	O
with	IN	B-PP	O
New	NNP	B-NP	O
York	NNP	I-NP	O
Heart	NNP	I-NP	O
Association	NNP	I-NP	O
(	(	O	O
NYHA	NNP	B-NP	O
)	)	O	O
functional	JJ	B-NP	O
class	NN	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
enalapril	NN	B-NP	O
experienced	VBD	B-VP	O
clinically	RB	B-ADVP	O
and	CC	I-ADVP	O
statistically	RB	B-NP	O
significantly	RB	I-NP	O
less	RBR	I-NP	O
symptomatic	JJ	I-NP	O
hypotension	NN	I-NP	B
than	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
prazosin	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
recovered	VBD	B-VP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
treatment	NN	B-NP	O
with	IN	B-PP	O
enalapril	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
,	,	O	O
therefore	RB	B-ADVP	O
,	,	O	O
unreasonable	JJ	B-ADJP	O
to	TO	B-VP	O
restrict	VB	I-VP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
enalapril	NN	B-NP	O
to	TO	B-PP	O
inpatients	NNS	B-NP	O
.	.	O	O

Antagonism	NN	B-NP	O
between	IN	B-PP	O
interleukin	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
erythropoietin	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
azidothymidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
and	CC	B-PP	O
in	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

Azidothymidine	NN	B-NP	O
(	(	O	O
AZT	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
IGF	NN	B-NP	O
-	HYPH	B-NP	O
IL	NN	I-NP	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
fusion	NN	B-NP	O
protein	NN	I-NP	O
of	IN	B-PP	O
insulin	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
IGF	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
interleukin	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Although	IN	B-SBAR	O
interleukin	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
IL	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
and	CC	O	O
erythropoietin	NN	B-NP	O
(	(	O	O
EPO	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
act	VB	I-VP	O
synergistically	RB	B-ADVP	O
on	IN	B-PP	O
hematopoietic	JJ	B-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
,	,	O	O
injection	NN	B-NP	O
of	IN	B-PP	O
IGF	NN	B-NP	O
-	HYPH	B-NP	O
IL	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
EPO	NN	B-NP	O
in	IN	B-PP	O
AZT	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
red	JJ	B-NP	O
cells	NNS	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
EPO	NN	I-NP	O
levels	NNS	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
IGF	NN	B-NP	O
-	HYPH	B-NP	O
IL	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
EPO	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
tested	VBD	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
antagonistic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
IL	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
EPO	NN	B-NP	O
on	IN	B-PP	O
erythroid	JJ	B-NP	O
cells	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
endothelial	JJ	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

Bovine	JJ	B-NP	O
liver	NN	I-NP	O
erythroid	JJ	I-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
cultured	VBN	I-VP	O
on	IN	B-PP	O
monolayers	NNS	B-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
previously	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
EPO	NN	B-NP	O
and	CC	I-NP	O
IGF	NN	I-NP	O
-	HYPH	B-NP	O
IL	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
thymidine	NN	B-NP	O
incorporation	NN	I-NP	O
into	IN	B-PP	O
both	CC	O	O
erythroid	JJ	B-NP	O
and	CC	I-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
cultures	NNS	B-NP	O
pre	AFX	O	O
-	HYPH	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
IGF	NN	B-NP	O
-	HYPH	B-NP	O
IL	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
EPO	NNP	B-NP	O
.	.	O	O

Endothelial	JJ	B-NP	O
cell	NN	I-NP	O
culture	NN	I-NP	O
supernatants	NNS	I-NP	O
separated	VBN	B-VP	O
by	IN	B-PP	O
ultrafiltration	NN	B-NP	O
and	CC	I-NP	O
ultracentrifugation	NN	I-NP	O
from	IN	B-PP	O
cells	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
EPO	NN	B-NP	O
and	CC	I-NP	O
IL	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
thymidine	NN	B-NP	O
incorporation	NN	I-NP	O
into	IN	B-PP	O
erythroid	JJ	B-NP	O
cells	NNS	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
identical	JJ	B-NP	O
fractions	NNS	I-NP	O
obtained	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
media	NNS	I-NP	O
of	IN	B-PP	O
cells	NNS	B-NP	O
cultured	VBN	B-VP	O
with	IN	B-PP	O
EPO	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
endothelial	JJ	B-NP	O
cells	NNS	I-NP	O
treated	VBN	B-VP	O
simultaneously	RB	B-ADVP	O
with	IN	B-PP	O
EPO	NN	B-NP	O
and	CC	I-NP	O
IL	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
negative	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
erythroid	JJ	B-NP	O
cell	NN	I-NP	O
production	NN	I-NP	O
.	.	O	O

Interactive	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
variations	NNS	B-NP	O
in	IN	B-PP	O
[	(	B-NP	O
Na	NN	I-NP	O
]	)	I-NP	O
o	NN	I-NP	O
and	CC	O	O
[	(	B-NP	O
Ca	NN	I-NP	O
]	)	I-NP	O
o	NN	I-NP	O
on	IN	B-PP	O
rat	NN	B-NP	O
atrial	JJ	I-NP	O
spontaneous	JJ	I-NP	O
frequency	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
varying	VBG	B-VP	O
the	DT	B-NP	O
extracellular	JJ	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
and	CC	I-NP	O
Ca	NN	I-NP	O
(	(	O	O
[	(	O	O
Na	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
and	CC	O	O
[	(	O	O
Ca	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
both	CC	O	O
,	,	O	O
the	DT	B-NP	O
spontaneous	JJ	I-NP	O
beating	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
negative	JJ	I-NP	O
chronotropic	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
rat	NN	I-NP	O
atria	NN	I-NP	O
.	.	O	O

Basal	JJ	B-NP	O
frequency	NN	I-NP	O
(	(	O	O
BF	NN	B-NP	O
)	)	O	O
evaluated	VBN	B-VP	O
by	IN	B-PP	O
surface	NN	B-NP	O
electrogram	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
min.	NN	I-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
Krebs	NNS	I-NP	O
-	HYPH	B-NP	O
Ringer	NN	I-NP	O
containing	VBG	B-VP	O
num	CD	B-NP	O
mM	NN	I-NP	O
Na	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mM	NN	I-NP	O
Ca	NN	I-NP	O
(	(	O	O
N	NN	B-NP	O
)	)	O	O
.	.	O	O

It	PRP	B-NP	O
decreased	VBD	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
lowering	VBG	B-VP	O
[	(	O	O
Na	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
(	(	O	O
LNa	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
lowering	VBG	B-VP	O
simultaneously	RB	B-ADVP	O
[	(	O	O
Na	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
and	CC	O	O
[	(	B-NP	O
Ca	NN	I-NP	O
]	)	I-NP	O
o	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
(	(	O	O
LNa+LCa	NN	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
lowering	VBG	B-VP	O
[	(	O	O
Na	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
plus	CC	O	O
increasing	VBG	B-VP	O
[	(	O	O
Ca	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
(	(	O	O
LNa+HCa	NN	B-NP	O
)	)	O	O
.	.	O	O

At	IN	B-PP	O
normal	JJ	B-NP	O
[	(	O	O
Na	NN	O	O
]	)	O	O
o	NN	B-NP	O
,	,	O	O
decrease	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
mM	NN	I-NP	O
)	)	O	O
or	CC	O	O
increase	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
mM	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
[	(	O	O
Ca	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
modify	VB	I-VP	O
BF	NN	B-NP	O
;	:	O	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
mM	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
[	(	I-NP	O
Ca	NN	I-NP	O
]	)	I-NP	O
o	NN	I-NP	O
was	VBD	B-VP	O
effective	JJ	B-ADJP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
BF	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
negative	JJ	I-NP	O
chronotropic	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
BF	NN	B-NP	O
-	HYPH	B-VP	O
dependent	JJ	B-ADJP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
bradycardia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
verapamil	NN	B-NP	O
was	VBD	B-VP	O
potentiated	VBN	I-VP	O
by	IN	B-PP	O
LNa	NN	B-NP	O
,	,	O	O
LCa	NN	B-NP	O
,	,	O	O
and	CC	O	O
HCa	NN	B-NP	O
.	.	O	O

Independent	JJ	B-ADJP	O
but	CC	I-ADJP	O
not	RB	I-ADJP	O
additive	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
and	CC	I-NP	O
Ca	NN	I-NP	O
are	VBP	B-VP	O
shown	VBN	I-VP	O
by	IN	B-PP	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
values	NNS	I-NP	O
of	IN	B-PP	O
[	(	B-NP	O
verapamil	NN	I-NP	O
]	)	I-NP	O
o	NN	I-NP	O
needed	VBN	B-VP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
BF	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
IC30	NN	B-NP	O
)	)	O	O
with	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
order	NN	I-NP	O
of	IN	B-PP	O
inhibitory	JJ	B-NP	O
potency	NN	I-NP	O
:	:	O	O
LNa	NN	B-NP	O
>	SYM	B-NP	O
LCa	NN	I-NP	O
>	SYM	I-NP	O
HCa	NN	I-NP	O
>	SYM	I-NP	O
N	NN	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
LNa+HCa	NN	B-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
LNa	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
[	(	I-NP	O
verapamil	NN	I-NP	O
]	)	I-NP	O
o	NN	I-NP	O
that	WDT	B-NP	O
arrested	VBD	B-VP	O
atrial	JJ	B-NP	O
beating	NN	I-NP	O
(	(	O	O
AC	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
also	RB	I-VP	O
potentiated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
order	NN	I-NP	O
LNa	NN	I-NP	O
=	SYM	B-VP	O
LNa+LCa	NN	B-NP	O
=	SYM	B-VP	O
LNa+HCa	NN	B-NP	O
=	SYM	B-VP	O
LCa	NN	B-NP	O
>	SYM	B-NP	O
HCa	NN	I-NP	O
=	SYM	B-VP	O
N	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
rat	NN	B-NP	O
atrial	JJ	I-NP	O
spontaneous	JJ	I-NP	O
beating	NN	I-NP	O
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
dependent	JJ	I-ADJP	O
on	IN	B-PP	O
[	(	O	O
Na	NN	B-NP	O
]	)	I-NP	O
o	NN	I-NP	O
than	IN	B-PP	O
on	IN	B-PP	O
[	(	B-NP	O
Ca	NN	I-NP	O
]	)	I-NP	O
o	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
normal	JJ	I-NP	O
concentration	NN	I-NP	O
.	.	O	O

Also	RB	B-ADVP	O
the	DT	B-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
atrial	JJ	B-NP	O
beating	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
at	IN	B-PP	O
LNa	NN	B-NP	O
than	IN	B-PP	O
at	IN	B-PP	O
LCa.	NNP	B-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Sodium	NN	B-NP	O
status	NN	I-NP	O
influences	VBZ	B-VP	O
chronic	JJ	B-NP	O
amphotericin	NN	I-NP	O
B	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
nephrotoxic	JJ	I-NP	B
potential	NN	I-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
depleted	VBN	I-NP	O
,	,	I-NP	O
normal	JJ	I-NP	O
-	HYPH	I-NP	O
salt	NN	I-NP	O
,	,	O	O
and	CC	O	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
loaded	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
depleted	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
decreased	VBD	B-VP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
linearly	RB	B-ADVP	O
with	IN	B-PP	O
time	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
by	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
normal	JJ	B-NP	O
-	HYPH	I-NP	O
salt	NN	I-NP	O
rats	NNS	I-NP	O
creatinine	NN	I-NP	O
clearance	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
but	CC	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
lesser	JJR	I-NP	O
extent	NN	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
and	CC	O	O
in	IN	B-PP	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
loaded	VBN	I-NP	O
rats	NNS	I-NP	O
creatinine	NN	I-NP	O
clearance	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

All	DT	B-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
sodium	NN	I-NP	O
-	HYPH	B-VP	O
depleted	VBN	B-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
histopathological	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
patchy	JJ	B-NP	O
tubular	JJ	I-NP	O
cytoplasmic	JJ	I-NP	O
degeneration	NN	I-NP	O
in	IN	B-PP	O
tubules	NNS	B-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
any	DT	B-NP	O
normal	JJ	I-NP	O
-	HYPH	I-NP	O
salt	NN	I-NP	O
or	CC	I-NP	O
salt	NN	I-NP	O
-	HYPH	O	O
loaded	VBN	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Concentrations	NNS	B-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
significantly	RB	I-ADJP	O
different	JJ	I-ADJP	O
among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
at	IN	B-PP	O
any	DT	B-NP	O
time	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
salt	NN	B-NP	O
-	HYPH	O	O
depleted	VBN	B-NP	O
and	CC	I-NP	O
normal	JJ	I-NP	O
-	HYPH	I-NP	O
salt	NN	I-NP	O
rats	NNS	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
loaded	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
plasma	NN	B-NP	O
/	SYM	B-VP	O
kidney	NN	B-NP	O
ratios	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
depleted	VBN	I-NP	O
,	,	I-NP	O
normal	JJ	I-NP	O
-	HYPH	I-NP	O
salt	NN	I-NP	O
,	,	O	O
and	CC	O	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
loaded	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
reductions	NNS	B-NP	O
in	IN	B-PP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
amphotericin	NN	I-NP	O
B	NN	I-NP	O
accumulation	NN	I-NP	O
after	IN	B-PP	O
chronic	JJ	B-NP	O
amphotericin	NN	I-NP	O
B	NN	I-NP	O
administration	NN	I-NP	O
were	VBD	B-VP	O
enhanced	VBN	I-VP	O
by	IN	B-PP	O
salt	NN	B-NP	O
depletion	NN	I-NP	O
and	CC	O	O
attenuated	VBN	B-VP	O
by	IN	B-PP	O
sodium	NN	B-NP	O
loading	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Reversible	JJ	B-NP	O
inferior	JJ	I-NP	B
colliculus	NN	I-NP	I
lesion	NN	I-NP	I
in	IN	B-PP	O
metronidazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
:	:	O	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
findings	NNS	I-NP	O
on	IN	B-PP	O
diffusion	NN	B-NP	O
-	HYPH	O	O
weighted	VBN	B-VP	O
and	CC	O	O
fluid	NN	B-NP	O
attenuated	VBD	B-VP	O
inversion	NN	B-NP	O
recovery	NN	I-NP	O
imaging	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
present	VB	I-VP	O
reversible	JJ	B-NP	O
inferior	JJ	I-NP	B
colliculus	NN	I-NP	I
lesions	NNS	I-NP	I
in	IN	B-PP	O
metronidazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
,	,	O	O
to	TO	B-VP	O
focus	VB	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
diffusion	NN	I-NP	O
-	HYPH	O	O
weighted	VBN	B-VP	O
imaging	NN	B-NP	O
(	(	O	O
DWI	NN	B-NP	O
)	)	O	O
and	CC	O	O
fluid	NN	B-NP	O
attenuated	VBD	B-VP	O
inversion	NN	B-NP	O
recovery	NN	I-NP	O
(	(	O	O
FLAIR	NN	B-NP	O
)	)	O	O
imaging	NN	B-NP	O
.	.	O	O

From	IN	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
September	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
diagnosed	VBN	I-VP	O
as	IN	B-PP	O
having	VBG	B-VP	O
metronidazole	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
encephalopathy	NN	I-NP	B
(	(	O	O
age	NN	B-NP	O
range	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
.	.	O	O

They	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taking	VBG	I-VP	O
metronidazole	NN	B-NP	O
(	(	O	O
total	JJ	B-NP	O
dosage	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
;	:	O	O
duration	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
to	TO	B-VP	O
treat	VB	I-VP	O
the	DT	B-NP	O
infection	NN	I-NP	B
in	IN	B-PP	O
various	JJ	B-NP	O
organs	NNS	I-NP	O
.	.	O	O

Initial	JJ	B-NP	O
brain	NN	I-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
MRI	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
hospitalization	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
DWI	NN	B-NP	O
,	,	O	O
apparent	JJ	B-NP	O
diffusion	NN	I-NP	O
coefficient	NN	I-NP	O
(	(	O	O
ADC	NN	B-NP	O
)	)	O	O
map	NN	B-NP	O
,	,	O	O
FLAIR	NN	B-NP	O
,	,	O	O
and	CC	O	O
T2	NN	B-NP	O
-	HYPH	O	O
weighted	VBN	B-NP	O
image	NN	I-NP	O
.	.	O	O

Follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
MRIs	NNS	B-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
from	IN	B-PP	O
third	JJ	B-ADJP	O
to	TO	B-PP	O
14th	JJ	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
metronidazole	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Findings	NNS	B-NP	O
of	IN	B-PP	O
initial	JJ	B-NP	O
and	CC	O	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
MRIs	NNS	B-NP	O
were	VBD	B-VP	O
retrospectively	RB	I-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
neuroradiologists	NNS	I-NP	O
by	IN	B-PP	O
consensus	NN	B-NP	O
,	,	O	O
to	TO	B-VP	O
analyze	VB	I-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
signal	NN	I-NP	O
intensities	NNS	I-NP	O
,	,	O	O
their	PRP$	B-NP	O
locations	NNS	I-NP	O
,	,	O	O
and	CC	O	O
signal	NN	B-NP	O
changes	NNS	I-NP	O
on	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
images	NNS	B-NP	O
.	.	O	O

Initial	JJ	B-NP	O
MRIs	NNS	I-NP	O
showed	VBD	B-VP	O
abnormal	JJ	B-NP	O
high	JJ	I-NP	O
signal	NN	I-NP	O
intensities	NNS	I-NP	O
on	IN	B-PP	O
DWI	NN	B-NP	O
and	CC	I-NP	O
FLAIR	NN	I-NP	O
(	(	O	O
or	CC	O	O
T2	NN	B-NP	O
-	HYPH	O	O
weighted	VBN	B-NP	O
image	NN	I-NP	O
)	)	O	O
at	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
nucleus	NN	I-NP	O
,	,	O	O
inferior	JJ	B-NP	O
colliculus	NN	I-NP	O
,	,	O	O
corpus	NN	B-NP	O
callosum	NN	I-NP	O
,	,	O	O
pons	NNS	B-NP	O
,	,	O	O
medulla	NN	B-NP	O
,	,	O	O
and	CC	O	O
bilateral	JJ	B-NP	O
cerebral	JJ	I-NP	O
white	JJ	I-NP	O
matter	NN	I-NP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
signal	NN	I-NP	O
intensity	NN	I-NP	O
lesions	NNS	I-NP	O
on	IN	B-PP	O
DWI	NN	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
show	VB	I-VP	O
low	JJ	B-NP	O
signal	NN	I-NP	O
intensity	NN	I-NP	O
on	IN	B-PP	O
ADC	NN	B-NP	O
map	NN	I-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
,	,	O	O
high	JJ	B-NP	O
signal	NN	I-NP	O
intensity	NN	I-NP	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
at	IN	B-PP	O
bilateral	JJ	B-NP	O
dentate	NN	I-NP	O
nuclei	NNS	I-NP	O
on	IN	B-PP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
DWI	NN	B-NP	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
ADC	NN	B-NP	O
map	NN	I-NP	O
.	.	O	O

All	PDT	B-NP	O
the	DT	I-NP	O
lesions	NNS	I-NP	O
in	IN	B-PP	O
dentate	NN	B-NP	O
,	,	O	O
inferior	JJ	B-NP	O
colliculus	NN	I-NP	O
,	,	O	O
pons	NNS	B-NP	O
,	,	O	O
and	CC	O	O
medullas	NNS	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
resolved	VBN	I-VP	O
completely	RB	B-ADVP	O
on	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
MRIs	NNS	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
,	,	O	O
corpus	VBZ	B-VP	O
callosal	JJ	B-NP	B
lesion	NN	I-NP	I
persisted	VBD	B-VP	O
.	.	O	O

Reversible	JJ	B-NP	O
inferior	JJ	I-NP	B
colliculus	NN	I-NP	I
lesions	NNS	I-NP	I
could	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-SBAR	O
the	DT	B-NP	O
characteristic	NN	I-NP	O
for	IN	B-PP	O
metronidazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
,	,	O	O
next	JJ	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
nucleus	NN	I-NP	O
involvement	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
respiratory	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
i.v.	JJ	B-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	O	O
regional	JJ	B-NP	O
analgesia	NN	I-NP	O
by	IN	B-PP	O
extradural	JJ	B-NP	O
block	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
respiratory	JJ	I-NP	O
apnoea	NN	I-NP	B
was	VBD	B-VP	O
compared	VBN	I-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
continuous	JJ	I-NP	O
i.v.	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
continuous	JJ	I-NP	O
extradural	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
bupivacaine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
period	NN	I-NP	O
following	VBG	B-PP	O
upper	JJ	B-NP	O
abdominal	JJ	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

Monitoring	NNP	B-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
airflow	NN	B-NP	O
detection	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
carbon	NN	I-NP	O
dioxide	NN	I-NP	O
analyser	NN	I-NP	O
,	,	O	O
chest	NN	B-NP	O
wall	NN	I-NP	O
movement	NN	I-NP	O
detected	VBN	B-VP	O
by	IN	B-PP	O
pneumatic	JJ	B-NP	O
capsules	NNS	I-NP	O
,	,	O	O
and	CC	O	O
continuous	JJ	B-NP	O
electrocardiograph	NN	I-NP	O
recorded	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
Holter	NNP	I-NP	O
ambulatory	JJ	I-NP	O
monitor	NN	I-NP	O
.	.	O	O

Both	CC	O	O
obstructive	JJ	B-NP	B
and	CC	I-NP	I
central	JJ	I-NP	I
apnoea	NN	I-NP	I
occurred	VBD	B-VP	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
morphine	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
tachyarrhythmias	NNS	B-NP	B
and	CC	O	O
ventricular	JJ	B-NP	B
ectopic	JJ	I-NP	I
beats	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
morphine	NN	I-NP	O
infusion	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
volumetry	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cerebellum	NN	I-NP	O
in	IN	B-PP	O
epileptic	JJ	B-NP	B
patients	NNS	I-NP	O
after	IN	B-PP	O
phenytoin	NN	B-NP	O
overdosages	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
phenytoin	NN	B-NP	O
medication	NN	I-NP	O
and	CC	O	O
cerebellar	JJ	B-NP	B
atrophy	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
experienced	VBN	I-VP	O
clinical	JJ	B-NP	O
intoxication	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
females	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
males	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
T	NN	I-NP	O
whole	JJ	I-NP	O
-	HYPH	I-NP	O
body	NN	I-NP	O
system	NN	I-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
circular	JJ	I-NP	O
polarized	VBN	I-NP	O
head	NN	I-NP	O
coil	NN	I-NP	O
.	.	O	O

Conventional	JJ	B-NP	O
spin	NN	I-NP	O
echo	NN	I-NP	O
images	NNS	I-NP	O
were	VBD	B-VP	O
acquired	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
sagittal	JJ	I-NP	O
and	CC	I-NP	O
transverse	JJ	I-NP	O
orientation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
resolution	NN	I-NP	O
3D	NN	I-NP	O
gradient	NN	I-NP	O
echo	NN	I-NP	O
,	,	O	O
T1	NN	B-NP	O
-	HYPH	O	O
weighted	VBN	B-VP	O
sequences	NNS	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mm	NN	I-NP	O
slice	NN	I-NP	O
thickness	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
images	NNS	I-NP	O
were	VBD	B-VP	O
subsequently	RB	I-VP	O
processed	VBN	I-VP	O
to	TO	B-VP	O
obtain	VB	I-VP	O
volumetric	JJ	B-NP	O
data	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
cerebellum	NN	I-NP	O
.	.	O	O

Cerebellar	JJ	B-NP	O
volume	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
group	NN	I-NP	O
ranged	VBD	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
ml	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	I-NP	O
ml	NN	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
3D	NN	I-NP	O
gradient	NN	I-NP	O
echo	JJ	I-NP	O
data	NNS	I-NP	O
sets	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
male	JJ	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
healthy	JJ	I-NP	O
female	JJ	I-NP	O
age	NN	I-NP	O
-	HYPH	B-NP	O
matched	VBN	I-NP	O
volunteers	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
compare	VB	I-VP	O
cerebellar	JJ	B-NP	O
volumes	NNS	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
linear	JJ	B-NP	O
regression	NN	I-NP	O
we	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
no	DT	B-NP	O
correlation	NN	I-NP	O
exists	VBZ	B-VP	O
between	IN	B-PP	O
seizure	NN	B-NP	B
duration	NN	I-NP	O
,	,	O	O
elevation	NN	B-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
serum	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
cerebellar	JJ	B-NP	O
volume	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
multiple	JJ	B-NP	O
regression	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
daily	JJ	I-NP	O
dosage	NN	I-NP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
cerebellar	JJ	B-NP	O
volume	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
correlation	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
parameters	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
phenytoin	NN	B-NP	O
overdosage	NN	I-NP	B
does	VBZ	B-VP	O
not	RB	I-VP	O
necessarily	RB	I-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
cerebellar	JJ	B-NP	B
atrophy	NN	I-NP	I
and	CC	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
unlikely	JJ	B-ADJP	O
that	IN	B-SBAR	O
phenytoin	NN	B-NP	O
medication	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
only	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
cerebellar	JJ	B-NP	B
atrophy	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Quantitative	JJ	B-NP	O
morphometric	JJ	I-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cerebellum	NN	I-NP	O
provide	VBP	B-VP	O
valuable	JJ	B-NP	O
insights	NNS	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
cerebellar	JJ	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

Evaluation	NN	B-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
troponin	NN	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
T	NN	I-NP	O
levels	NNS	I-NP	O
as	IN	B-PP	O
markers	NNS	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
rats	NNS	I-NP	O
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
relationship	NN	I-NP	O
with	IN	B-PP	O
echocardiographic	JJ	B-NP	O
and	CC	I-NP	O
histological	JJ	I-NP	O
findings	NNS	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
troponins	NNS	I-NP	O
I	NN	I-NP	O
(	(	O	O
cTnI	NN	B-NP	O
)	)	O	O
and	CC	O	O
T	NN	B-NP	O
(	(	O	O
cTnT	NN	B-NP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
highly	RB	B-NP	O
sensitive	JJ	I-NP	O
and	CC	I-NP	O
specific	JJ	I-NP	O
markers	NNS	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
cell	NN	I-NP	I
injury	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
diagnostic	JJ	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
cTnI	NN	B-NP	O
and	CC	I-NP	O
cTnT	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
,	,	O	O
and	CC	O	O
we	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
serial	JJ	B-NP	O
cTnI	NN	I-NP	O
and	CC	I-NP	O
cTnT	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
disorders	NNS	I-NP	I
monitored	VBN	B-VP	O
by	IN	B-PP	O
echocardiography	NN	B-NP	O
and	CC	O	O
histological	JJ	B-NP	O
examinations	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
DOX	NN	I-NP	O
,	,	O	O
i.v.	JJ	B-ADJP	O
,	,	O	O
weekly	RB	B-ADVP	O
for	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
total	JJ	I-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
BW	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
saline	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
control	NN	I-NP	O
group.	NN	I-NP	O
cTnI	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
with	IN	B-PP	O
Access	NN	B-NP	O
(	(	O	O
R	NN	B-NP	O
)	)	O	O
(	(	O	O
ng	NN	B-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
research	NN	I-NP	O
immunoassay	NN	I-NP	O
(	(	O	O
pg	NN	B-NP	O
/	SYM	O	O
ml	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
cTnT	NN	B-NP	O
,	,	O	O
CK	NN	B-NP	O
-	HYPH	I-NP	O
MB	NN	I-NP	O
mass	NN	I-NP	O
and	CC	I-NP	O
CK	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
using	VBG	B-VP	O
transthoracic	JJ	B-NP	O
echocardiography	NN	I-NP	O
,	,	O	O
anterior	JJ	B-NP	O
and	CC	I-NP	O
posterior	JJ	I-NP	O
wall	NN	I-NP	O
thickness	NN	I-NP	O
,	,	O	O
LV	NN	B-NP	O
diameters	NNS	I-NP	O
and	CC	O	O
LV	NN	B-NP	O
fractional	JJ	I-NP	O
shortening	NN	I-NP	O
(	(	O	O
FS	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
rats	NNS	I-NP	O
before	IN	B-PP	O
DOX	NN	B-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
at	IN	B-PP	O
weeks	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
surviving	VBG	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Histology	NN	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
DOX	NN	B-NP	O
-	HYPH	B-NP	O
rats	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
DOX	NN	I-NP	O
dose	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
all	DT	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DOX	NN	I-NP	O
rats	NNS	I-NP	O
died	VBD	B-VP	O
prematurely	RB	B-ADVP	O
of	IN	B-PP	O
general	JJ	B-NP	O
toxicity	NN	I-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

End	NN	B-NP	O
-	HYPH	O	O
diastolic	JJ	O	O
(	(	O	O
ED	JJ	B-ADJP	O
)	)	O	O
and	CC	O	O
end	NN	B-ADJP	O
-	HYPH	I-ADJP	O
systolic	JJ	I-ADJP	O
(	(	O	O
ES	NN	B-NP	O
)	)	O	O
LV	NN	B-NP	O
diameters	NNS	I-NP	O
/	SYM	O	O
BW	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
,	,	O	O
whereas	IN	O	O
LV	NN	B-NP	O
FS	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
DOX	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
parameters	NNS	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Histological	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
hearts	NNS	B-NP	O
from	IN	B-PP	O
all	DT	B-NP	O
rats	NNS	I-NP	O
given	VBN	B-VP	O
DOX	NN	B-NP	O
revealed	VBD	B-VP	O
significant	JJ	B-NP	O
slight	JJ	I-NP	O
degrees	NNS	I-NP	O
of	IN	B-PP	O
perivascular	JJ	B-NP	O
and	CC	I-NP	O
interstitial	JJ	I-NP	O
fibrosis	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
,	,	I-NP	O
degeneration	NN	I-NP	O
and	CC	I-NP	O
myocyte	NN	I-NP	O
vacuolisation	NN	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
exhibited	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
very	RB	B-NP	O
slight	JJ	I-NP	O
perivascular	JJ	I-NP	O
fibrosis	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
cTnT	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
DOX	NN	B-NP	O
rats	NNS	I-NP	O
after	IN	B-PP	O
cumulative	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
in	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O
cTnT	NN	B-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
found	VBN	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
DOX	NN	I-NP	O
.	.	O	O

Maximal	JJ	B-NP	O
cTnI	NN	I-NP	O
(	(	O	O
pg	NN	B-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
and	CC	O	O
cTnT	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
DOX	NN	B-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O
cTnI	NN	B-NP	O
(	(	O	O
ng	NN	B-NP	O
/	SYM	O	O
ml	NN	B-NP	O
)	)	O	O
,	,	O	O
CK	NN	B-NP	O
-	HYPH	B-NP	O
MB	NN	I-NP	O
mass	NN	I-NP	O
and	CC	I-NP	O
CK	NN	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
DOX	NN	B-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

All	DT	B-NP	O
markers	NNS	I-NP	O
remained	VBD	B-VP	O
stable	JJ	B-ADJP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
data	NNS	B-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
maximal	JJ	B-NP	O
cTnT	NN	I-NP	O
and	CC	I-NP	O
ED	NN	I-NP	O
and	CC	I-NP	O
ES	NN	I-NP	O
LV	NN	I-NP	O
diameters	NNS	I-NP	O
/	SYM	B-NP	O
BW	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
relationship	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
maximal	JJ	B-NP	O
cTnT	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	O
morphological	JJ	I-NP	O
changes	NNS	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
between	IN	B-PP	O
LV	NN	B-NP	O
diameters	NNS	I-NP	O
/	SYM	B-NP	O
BW	NN	I-NP	O
and	CC	O	O
histological	JJ	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
markers	NNS	B-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	B
injury	NN	I-NP	I
after	IN	B-PP	O
DOX	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
cTnT	NN	B-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
greatest	JJS	I-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
detect	VB	I-VP	O
myocardial	JJ	B-NP	B
damage	NN	I-NP	I
assessed	VBN	B-VP	O
by	IN	B-PP	O
echocardiographic	JJ	B-NP	O
detection	NN	I-NP	O
and	CC	O	O
histological	JJ	B-NP	O
changes	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
discrepancy	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
cTnI	NN	B-NP	O
and	CC	I-NP	O
cTnT	NN	I-NP	O
after	IN	B-PP	O
DOX	NN	B-NP	O
,	,	O	O
probably	RB	B-ADVP	O
due	IN	B-PP	O
to	TO	B-PP	O
heterogeneity	NN	B-NP	O
in	IN	B-PP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
reactivities	NNS	I-NP	O
of	IN	B-PP	O
mAbs	NNS	B-NP	O
to	TO	B-PP	O
various	JJ	B-NP	O
cTnI	NN	I-NP	O
and	CC	I-NP	O
cTnT	NN	I-NP	O
forms	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
that	IN	B-SBAR	O
cTnT	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
after	IN	B-SBAR	O
DOX	NN	B-NP	O
indicates	VBZ	B-VP	O
cell	NN	B-NP	O
damage	NN	I-NP	O
determined	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
injury	NN	B-NP	O
induced	VBN	B-VP	O
and	CC	O	O
that	IN	B-SBAR	O
cTnT	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
marker	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
prediction	NN	I-NP	O
of	IN	B-PP	O
experimentally	RB	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
and	CC	O	O
possibly	RB	B-ADVP	O
for	IN	B-PP	O
cardioprotective	JJ	B-NP	O
experiments	NNS	I-NP	O
.	.	O	O

Calcineurin	NN	B-NP	O
-	HYPH	I-NP	O
inhibitor	NN	I-NP	O
induced	VBN	I-NP	O
pain	NN	I-NP	B
syndrome	NN	I-NP	O
(	(	O	O
CIPS	NN	B-NP	B
)	)	O	O
:	:	O	O
a	DT	B-NP	O
severe	JJ	I-NP	O
disabling	VBG	I-NP	O
complication	NN	I-NP	O
after	IN	B-PP	O
organ	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Bone	NN	B-NP	O
pain	NN	I-NP	B
after	IN	B-SBAR	O
transplantation	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
frequent	JJ	I-NP	O
complication	NN	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
several	JJ	B-NP	O
diseases	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
strategies	NNS	I-NP	O
depend	VBP	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
correct	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pain	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
pain	NN	I-NP	B
in	IN	B-PP	O
their	PRP$	B-NP	O
feet	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
registered	VBN	I-VP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Bone	NN	B-NP	O
scans	NNS	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
tracer	NN	I-NP	O
uptake	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
foot	NN	I-NP	O
bones	NNS	I-NP	O
.	.	O	O

Magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
demonstrated	VBD	B-VP	O
bone	NN	B-NP	B
marrow	NN	I-NP	I
oedema	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
painful	JJ	I-NP	O
bones	NNS	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
was	VBD	B-VP	O
not	RB	I-VP	O
explained	VBN	I-VP	O
by	IN	B-PP	O
other	JJ	B-NP	O
diseases	NNS	I-NP	O
causing	VBG	B-VP	O
foot	NN	B-NP	O
pain	NN	I-NP	B
,	,	O	O
like	IN	B-PP	O
reflex	NN	B-NP	B
sympathetic	JJ	I-NP	I
dystrophy	NN	I-NP	I
,	,	O	O
polyneuropathy	NN	B-NP	B
,	,	O	O
Morton	NNP	B-NP	B
s	VBZ	B-VP	I
neuralgia	NN	B-NP	I
,	,	O	O
gout	NN	B-NP	B
,	,	O	O
osteoporosis	NN	B-NP	B
,	,	O	O
avascular	JJ	B-NP	B
necrosis	NN	I-NP	I
,	,	O	O
intermittent	JJ	B-NP	B
claudication	NN	I-NP	I
,	,	O	O
orthopaedic	JJ	B-NP	O
foot	NN	I-NP	B
deformities	NNS	I-NP	I
,	,	O	O
stress	NN	B-NP	B
fractures	NNS	I-NP	I
,	,	O	O
and	CC	O	O
hyperparathyroidism	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
-	HYPH	B-NP	O
or	CC	O	O
tacrolimus	NN	B-NP	O
trough	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
relief	NN	B-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
Calcineurin	NN	I-NP	O
-	HYPH	I-NP	O
inhibitor	NN	I-NP	O
Induced	VBN	I-NP	O
Pain	NN	I-NP	B
Syndrome	NN	I-NP	O
(	(	O	O
CIPS	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
but	CC	I-NP	O
severe	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
or	CC	I-NP	O
tacrolimus	NN	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
accurately	RB	I-VP	O
diagnosed	VBN	I-VP	O
by	IN	B-PP	O
its	PRP$	B-NP	O
typical	JJ	I-NP	O
presentation	NN	I-NP	O
,	,	O	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
scans	NNS	I-NP	O
.	.	O	O

Incorrect	JJ	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
syndrome	NN	I-NP	O
will	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
quality	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
CIPS	NNP	B-NP	B
.	.	O	O

The	DT	B-NP	O
haemodynamic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
ephedrine	NN	B-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
ASA	NN	B-NP	O
groups	NNS	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
marked	JJ	I-NP	O
vasodilator	NN	I-NP	O
and	CC	O	O
negative	JJ	B-NP	O
inotropic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
are	VBP	B-VP	O
disadvantages	NNS	B-NP	O
in	IN	B-PP	O
frail	NN	B-NP	O
elderly	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
adding	VBG	B-VP	O
different	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
to	TO	B-PP	O
propofol	NN	B-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
obtund	VB	I-VP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
response	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
haemodynamic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
adding	VBG	B-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	I-VP	O
control	VB	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
ASA	NN	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
presenting	VBG	B-VP	O
for	IN	B-PP	O
genito	AFX	B-NP	O
-	HYPH	I-NP	O
urinary	JJ	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
to	TO	B-PP	O
propofol	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
method	NN	I-NP	O
of	IN	B-PP	O
obtunding	VBG	B-VP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
response	NN	I-NP	O
to	TO	B-PP	O
propofol	NN	B-NP	O
at	IN	B-PP	O
all	DT	B-NP	O
doses	NNS	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
marked	JJ	B-NP	O
tachycardia	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
occasionally	RB	B-ADVP	O
reaching	VBG	B-VP	O
high	JJ	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
individual	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Due	JJ	B-PP	O
to	TO	I-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
tachycardia	NN	I-NP	B
inducing	VBG	B-VP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
would	MD	B-VP	O
not	RB	I-VP	O
recommend	VB	I-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ephedrine	NN	I-NP	O
/	SYM	B-NP	O
propofol	NN	I-NP	O
/	SYM	O	O
mixtures	NNS	B-NP	O
studied	VBN	B-VP	O
.	.	O	O

Neurotoxicity	NN	B-NP	B
of	IN	B-PP	O
halogenated	VBN	B-NP	O
hydroxyquinolines	NNS	I-NP	O
:	:	O	O
clinical	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
reported	VBN	B-VP	O
outside	IN	B-PP	O
Japan	NNP	B-NP	O
.	.	O	O

An	DT	B-NP	O
analysis	NN	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
possible	JJ	B-NP	O
neurotoxic	JJ	I-NP	B
reactions	NNS	I-NP	O
to	TO	B-PP	O
halogenated	VBN	B-NP	O
hydroxyquinolines	NNS	I-NP	O
reported	VBN	B-VP	O
from	IN	B-PP	O
outside	IN	B-PP	O
Japan	NNP	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
insufficient	JJ	B-NP	O
information	NN	I-NP	O
was	VBD	B-VP	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
adequate	JJ	B-NP	O
comment	NN	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
a	DT	B-NP	O
relationship	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
clioquinol	NN	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
excluded	VBN	I-VP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
remainder	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
relationship	NN	I-NP	O
to	TO	B-PP	O
clioquinol	NN	B-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
probable	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
possible	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
probable	JJ	I-NP	O
cases	NNS	I-NP	O
the	DT	B-NP	O
neurological	JJ	I-NP	B
disturbance	NN	I-NP	I
consisted	VBD	B-VP	O
of	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
reversible	JJ	I-NP	O
encephalopathy	NN	I-NP	B
usually	RB	B-ADVP	O
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
ingestion	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
clioquinol	NN	B-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
short	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
manifestation	NN	I-NP	O
,	,	O	O
observed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
further	JJ	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
isolated	VBN	I-VP	O
optic	JJ	B-NP	B
atrophy	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
most	RBS	I-VP	O
frequently	RB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
,	,	O	O
many	DT	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
clioquinol	NN	B-NP	O
as	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
acrodermatitis	NN	B-NP	B
enteropathica	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
myelopathy	JJ	B-NP	B
,	,	I-NP	O
visual	JJ	I-NP	B
disturbance	NN	I-NP	I
,	,	O	O
and	CC	O	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
manifestation	NN	I-NP	O
.	.	O	O

Isolated	VBN	B-NP	O
myelopathy	JJ	I-NP	B
or	CC	I-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
or	CC	O	O
these	DT	B-NP	O
manifestations	NNS	I-NP	O
occurring	VBG	B-VP	O
together	RB	B-ADVP	O
,	,	O	O
were	VBD	B-VP	O
infrequent	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
manifestations	NNS	I-NP	O
(	(	O	O
except	IN	B-PP	O
toxic	JJ	B-NP	O
encephalopathy	NN	I-NP	B
)	)	O	O
was	VBD	B-VP	O
usually	RB	B-ADVP	O
subacute	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
subsequent	JJ	B-NP	O
partial	JJ	I-NP	O
recovery	NN	I-NP	O
.	.	O	O

Older	JJR	B-NP	O
subjects	NNS	I-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
display	VB	I-VP	O
more	RBR	B-NP	O
side	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
full	JJ	I-NP	O
syndrome	NN	I-NP	O
of	IN	B-PP	O
subacute	JJ	B-NP	O
myelo	AFX	I-NP	B
-	HYPH	I-NP	I
optic	JJ	I-NP	I
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
more	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
in	IN	B-PP	O
women	NNS	B-NP	O
,	,	O	O
but	CC	O	O
they	PRP	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
taken	VBN	I-VP	O
greater	JJR	B-NP	O
quantities	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Epileptic	JJ	B-NP	B
seizures	NNS	I-NP	I
following	VBG	B-PP	O
cortical	JJ	B-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
fibrin	NN	B-NP	O
sealants	NNS	I-NP	O
containing	VBG	B-VP	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Fibrin	NN	B-NP	O
sealants	NNS	I-NP	O
(	(	O	O
FS	NNS	B-NP	O
)	)	O	O
derived	VBN	B-VP	O
from	IN	B-PP	O
human	JJ	B-NP	O
plasma	NN	I-NP	O
are	VBP	B-VP	O
frequently	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
neurosurgery	NN	B-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
increase	VB	I-VP	O
clot	NN	B-NP	O
stability	NN	I-NP	O
,	,	O	O
FS	NN	B-NP	O
typically	RB	B-ADVP	O
contain	VBP	B-VP	O
aprotinin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
natural	JJ	I-NP	O
fibrinolysis	NN	I-NP	O
inhibitor	NN	I-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
synthetic	JJ	B-NP	O
fibrinolysis	NN	I-NP	O
inhibitors	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
tAMCA	NN	B-NP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
substitutes	NNS	B-NP	O
for	IN	B-PP	O
aprotinin	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
tAMCA	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
epileptic	JJ	B-NP	B
seizures	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
wanted	VBD	B-VP	O
to	TO	I-VP	O
study	VB	I-VP	O
whether	IN	B-SBAR	O
tAMCA	NN	B-NP	O
retains	VBZ	B-VP	O
its	PRP$	B-NP	O
convulsive	JJ	I-NP	B
action	NN	I-NP	O
if	IN	B-SBAR	O
incorporated	VBN	B-VP	O
into	IN	B-PP	O
a	DT	B-NP	O
FS	NN	I-NP	O
.	.	O	O

FS	NN	B-NP	O
containing	VBG	B-VP	O
aprotinin	NN	B-NP	O
or	CC	O	O
different	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
tAMCA	NN	B-NP	O
were	VBD	B-VP	O
applied	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
pial	JJ	I-NP	O
surface	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
of	IN	B-PP	O
anaesthetized	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
using	VBG	B-VP	O
electroencephalography	NN	B-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
monitoring	VBG	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
behaviour	NN	I-NP	O
during	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
recovery	NN	B-NP	O
from	IN	B-PP	O
anaesthesia	NN	B-NP	O
.	.	O	O

FS	NN	B-NP	O
containing	VBG	B-VP	O
tAMCA	NN	B-NP	O
caused	VBD	B-VP	O
paroxysmal	JJ	B-NP	O
brain	NN	I-NP	O
activity	NN	I-NP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
distinct	JJ	B-NP	O
convulsive	JJ	I-NP	B
behaviours	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
seizures	NNS	I-NP	B
increased	VBD	B-VP	O
with	IN	B-PP	O
increasing	VBG	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
tAMCA	NN	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
FS	NN	B-NP	O
containing	VBG	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
tAMCA	NN	I-NP	O
evoked	VBD	B-VP	O
generalized	VBN	B-NP	B
seizures	NNS	I-NP	I
in	IN	B-PP	O
all	DT	B-NP	O
tested	VBN	I-NP	O
rats	NNS	I-NP	O
while	IN	B-SBAR	O
the	DT	B-NP	O
lowest	JJS	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
tAMCA	NN	B-NP	O
only	RB	B-ADVP	O
evoked	VBD	B-VP	O
brief	JJ	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
jerk	NN	B-NP	O
-	HYPH	O	O
correlated	VBN	B-NP	O
convulsive	JJ	I-NP	B
potentials	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
FS	NN	B-NP	O
containing	VBG	B-VP	O
aprotinin	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
evoke	VB	I-VP	O
any	DT	B-NP	O
paroxysmal	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
retains	VBZ	B-VP	O
its	PRP$	B-NP	O
convulsive	JJ	I-NP	B
action	NN	I-NP	O
within	IN	B-PP	O
FS	NN	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
use	NN	B-NP	O
of	IN	B-PP	O
FS	NN	B-NP	O
containing	VBG	B-VP	O
tAMCA	NN	B-NP	O
for	IN	B-PP	O
surgery	NN	B-NP	O
within	IN	B-PP	O
or	CC	O	O
close	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
CNS	NN	I-NP	O
may	MD	B-VP	O
pose	VB	I-VP	O
a	DT	B-NP	O
substantial	JJ	I-NP	O
risk	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
diet	NN	I-NP	O
promoting	VBG	B-VP	O
sugar	NN	B-NP	B
dependency	NN	I-NP	I
causes	VBZ	B-VP	O
behavioral	JJ	B-NP	B
cross	AFX	I-NP	I
-	HYPH	I-NP	I
sensitization	NN	I-NP	I
to	TO	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

Previous	JJ	B-NP	O
research	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
laboratory	NN	I-NP	O
has	VBZ	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
diet	NN	I-NP	O
of	IN	B-PP	O
intermittent	JJ	B-NP	O
excessive	JJ	I-NP	O
sugar	NN	I-NP	O
consumption	NN	I-NP	O
produces	VBZ	B-VP	O
a	DT	B-NP	O
state	NN	I-NP	O
with	IN	B-PP	O
neurochemical	JJ	B-NP	O
and	CC	I-NP	O
behavioral	JJ	I-NP	O
similarities	NNS	I-NP	O
to	TO	B-PP	O
drug	NN	B-NP	B
dependency	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
examined	VBD	B-VP	O
whether	IN	B-SBAR	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
on	IN	B-PP	O
various	JJ	B-NP	O
regimens	NNS	I-NP	O
of	IN	B-PP	O
sugar	NN	B-NP	O
access	NN	I-NP	O
would	MD	B-VP	O
show	VB	I-VP	O
behavioral	JJ	B-ADJP	B
cross	AFX	B-NP	I
-	HYPH	I-NP	I
sensitization	NN	I-NP	I
to	TO	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
baseline	NN	I-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
animals	NNS	B-NP	O
were	VBD	B-VP	O
maintained	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
cyclic	JJ	I-NP	O
diet	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
deprivation	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
access	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
sucrose	NN	I-NP	O
solution	NN	I-NP	O
and	CC	I-NP	O
chow	NN	I-NP	O
pellets	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
h	NN	I-NP	O
access	NN	I-NP	O
starting	VBG	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dark	JJ	I-NP	O
period	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Locomotor	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
again	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
beginning	NN	I-NP	O
of	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
sugar	NN	B-NP	O
access	NN	I-NP	O
.	.	O	O

Beginning	VBG	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
all	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
maintained	VBN	I-VP	O
on	IN	B-PP	O
ad	NN	B-NP	O
libitum	NN	I-NP	O
chow	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
animals	NNS	I-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
experienced	VBN	I-VP	O
cyclic	JJ	B-NP	O
sucrose	NN	I-NP	O
and	CC	I-NP	O
chow	NN	I-NP	O
were	VBD	B-VP	O
hyperactive	JJ	B-ADJP	B
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
(	(	O	O
ad	NN	B-NP	O
libitum	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
sucrose	NN	I-NP	O
and	CC	I-NP	O
chow	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
amphetamine	NN	B-NP	O
injection	NN	I-NP	O
,	,	O	O
cyclic	JJ	B-NP	O
chow	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
amphetamine	NN	B-NP	O
injection	NN	I-NP	O
,	,	O	O
ad	NN	B-NP	O
libitum	NN	I-NP	O
chow	NN	I-NP	O
with	IN	B-PP	O
amphetamine	NN	B-NP	O
,	,	O	O
or	CC	O	O
cyclic	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
sucrose	NN	I-NP	O
and	CC	I-NP	O
chow	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
saline	NN	I-NP	O
injection	NN	I-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
diet	NN	I-NP	O
comprised	VBN	B-VP	O
of	IN	B-PP	O
alternating	VBG	B-VP	O
deprivation	NN	B-NP	O
and	CC	I-NP	O
access	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
sugar	NN	I-NP	O
solution	NN	I-NP	O
and	CC	I-NP	O
chow	NN	I-NP	O
produces	VBZ	B-VP	O
bingeing	VBG	I-VP	O
on	IN	B-PP	O
sugar	NN	B-NP	O
that	WDT	B-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
lasting	JJ	I-NP	O
state	NN	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
,	,	O	O
possibly	RB	B-ADVP	O
due	JJ	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
lasting	JJ	I-NP	O
alteration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dopamine	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
angiopathy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
aortic	JJ	B-NP	O
permeability	NN	I-NP	O
to	TO	B-PP	O
albumin	NN	B-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
ultrastructure	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
vessel	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	O	O
penicillamine	NN	B-NP	O
(	(	O	O
D	NN	B-NP	O
-	HYPH	B-NP	O
pen	NN	I-NP	O
)	)	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

Pair	NN	B-NP	O
fed	VBN	I-NP	O
rats	NNS	I-NP	O
served	VBD	B-VP	O
as	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
aortic	JJ	B-NP	O
morphology	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
by	IN	B-PP	O
light	NN	B-NP	O
-	HYPH	O	O
and	CC	O	O
transmission	NN	B-NP	O
-	HYPH	O	O
electron	NN	B-NP	O
microscopy	NN	I-NP	O
(	(	O	O
TEM	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
endothelial	JJ	I-NP	O
permeability	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
penetration	NN	I-NP	O
through	IN	B-PP	O
the	DT	B-NP	O
aortic	JJ	I-NP	O
wall	NN	I-NP	O
of	IN	B-PP	O
albumin	NN	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
i.	JJ	B-NP	O
v.	NN	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
serum	NN	I-NP	O
131I	NN	I-NP	O
-	HYPH	B-NP	O
albumin	NN	I-NP	O
(	(	O	O
131I	NN	B-NP	O
-	HYPH	B-NP	O
HSA	NN	I-NP	O
)	)	O	O
.	.	O	O

TEM	NN	B-NP	O
revealed	VBD	B-VP	O
extensive	JJ	B-NP	O
elastolysis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
arterial	JJ	I-NP	O
wall	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
pen	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
crosslink	NN	B-NP	O
formation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
excess	JJ	B-NP	O
deposition	NN	I-NP	O
of	IN	B-PP	O
collagen	NN	B-NP	O
and	CC	I-NP	O
glycoaminoglycans	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
subendothelial	JJ	I-NP	O
and	CC	I-NP	O
medial	JJ	I-NP	O
layer	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
aortic	JJ	I-NP	O
wall	NN	I-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
prominent	JJ	B-NP	O
basal	JJ	I-NP	O
membrane	NN	I-NP	O
substance	NN	I-NP	O
around	IN	B-PP	O
aortic	JJ	B-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aorta	NN	I-NP	O
/	SYM	B-NP	O
serum	NN	I-NP	O
-	HYPH	B-NP	O
ratio	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
radioactive	JJ	I-NP	O
build	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
131I	NN	B-NP	O
-	HYPH	B-NP	O
HSA	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
pen	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
an	DT	B-NP	O
impeded	JJ	I-NP	O
transmural	JJ	I-NP	O
transport	NN	I-NP	O
of	IN	B-PP	O
tracer	NN	B-NP	O
which	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
steric	JJ	I-NP	O
exclusion	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
abundant	JJ	B-NP	O
hyaluronate	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
endothelial	JJ	I-NP	O
ultrastructure	NN	I-NP	O
was	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
by	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	I-NP	O
pen	NN	I-NP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
aortic	JJ	B-NP	O
131I	NN	I-NP	O
-	HYPH	B-NP	O
HSA	NN	I-NP	O
radioactivity	NN	I-NP	O
or	CC	I-NP	O
aorta	NN	I-NP	O
/	SYM	B-NP	O
serum	NN	I-NP	O
-	HYPH	B-NP	O
ratio	NN	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
between	IN	B-PP	O
experimental	JJ	B-NP	O
and	CC	I-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
tracer	NN	B-NP	O
injection	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
permeability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
endothelial	JJ	I-NP	O
barrier	NN	I-NP	O
to	TO	B-PP	O
albumin	NN	B-NP	O
remained	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
by	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
pen	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
treatment	NN	B-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
pen	NN	I-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
a	DT	B-NP	O
fibroproliferative	JJ	I-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
aorta	NN	I-NP	O
,	,	O	O
possibly	RB	B-ADVP	O
by	IN	B-PP	O
an	DT	B-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
linking	VBG	I-NP	O
of	IN	B-PP	O
collagen	NN	B-NP	O
and	CC	I-NP	O
elastin	NN	I-NP	O
.	.	O	O

Brain	NN	B-NP	O
natriuretic	JJ	I-NP	O
peptide	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
predictor	NN	I-NP	O
of	IN	B-PP	O
anthracycline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Anthracyclines	NNS	B-NP	O
are	VBP	B-VP	O
effective	JJ	B-NP	O
antineoplastic	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
but	CC	O	O
they	PRP	B-NP	O
frequently	RB	B-ADVP	O
cause	VBP	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
cardiotoxicity	NN	I-NP	B
of	IN	B-PP	O
conventional	JJ	B-NP	O
anthracycline	NN	I-NP	O
therapy	NN	I-NP	O
highlights	VBZ	B-VP	O
a	DT	B-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
search	VB	I-VP	O
for	IN	B-PP	O
methods	NNS	B-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
highly	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
and	CC	I-ADJP	O
capable	JJ	I-ADJP	O
of	IN	B-PP	O
predicting	VBG	B-VP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
measured	VBD	B-VP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
natriuretic	JJ	I-NP	O
peptide	NN	I-NP	O
(	(	O	O
BNP	NN	B-NP	O
)	)	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
BNP	NN	B-NP	O
might	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
simple	JJ	I-NP	O
diagnostic	JJ	I-NP	O
indicator	NN	I-NP	O
of	IN	B-PP	O
anthracycline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
leukemia	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
daunorubicin	NN	I-NP	O
(	(	O	O
DNR	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
containing	VBG	B-VP	O
regimen	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
leukemia	NN	I-NP	I
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
DNR	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
regimen	NN	B-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
functions	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
with	IN	B-PP	O
radionuclide	NN	B-NP	O
angiography	NN	I-NP	O
before	IN	B-PP	O
chemotherapies	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
atrial	JJ	B-NP	O
natriuretic	JJ	I-NP	O
peptide	NN	I-NP	O
(	(	O	O
ANP	NN	B-NP	O
)	)	O	O
and	CC	O	O
BNP	NN	B-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
radionuclide	NN	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
after	IN	B-PP	O
the	DT	B-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
diagnosed	VBN	I-VP	O
as	IN	B-PP	O
having	VBG	B-VP	O
subclinical	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
after	IN	B-PP	O
the	DT	B-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
BNP	NN	B-NP	O
in	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
subclinical	JJ	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
increased	VBD	B-VP	O
above	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
limit	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
before	IN	B-PP	O
the	DT	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
or	CC	I-NP	O
subclinical	JJ	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
by	IN	B-PP	O
radionuclide	NN	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
BNP	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
increase	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
given	VBN	B-PP	O
DNR	NN	B-NP	O
,	,	O	O
even	RB	B-ADVP	O
at	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
plasma	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
ANP	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
always	RB	I-VP	O
increase	VB	I-VP	O
in	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
subclinical	JJ	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
preliminary	JJ	I-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
BNP	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
as	IN	B-PP	O
an	DT	B-NP	O
early	JJ	I-NP	O
and	CC	I-NP	O
sensitive	JJ	I-NP	O
indicator	NN	I-NP	O
of	IN	B-PP	O
anthracycline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Antibacterial	JJ	B-NP	O
medication	NN	I-NP	O
use	NN	I-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
and	CC	O	O
risk	NN	B-NP	O
of	IN	B-PP	O
birth	NN	B-NP	B
defects	NNS	I-NP	I
:	:	O	O
National	NNP	B-NP	O
Birth	NNP	I-NP	B
Defects	NNPS	I-NP	I
Prevention	NNP	I-NP	O
Study	NNP	I-NP	O
.	.	O	O

To	TO	B-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
antibacterial	JJ	B-NP	O
medications	NNS	I-NP	O
and	CC	O	O
selected	VBN	B-NP	O
birth	NN	I-NP	B
defects	NNS	I-NP	I
.	.	O	O

DESIGN	NN	B-NP	O
,	,	O	O
SETTING	NN	B-NP	O
,	,	O	O
AND	CC	O	O
PARTICIPANTS	NNS	B-NP	O
:	:	O	O
Population	NN	B-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
,	,	I-NP	O
multisite	JJ	I-NP	O
,	,	I-NP	O
case	NN	I-NP	O
-	HYPH	I-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
pregnancies	NNS	B-NP	O
affected	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
eligible	JJ	I-NP	O
major	JJ	I-NP	O
birth	NN	I-NP	B
defects	NNS	I-NP	I
identified	VBN	B-VP	O
via	IN	B-PP	O
birth	NN	B-NP	B
defect	NN	I-NP	I
surveillance	NN	I-NP	O
programs	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
states	NNS	I-NP	O
and	CC	O	O
control	NN	B-NP	O
women	NNS	I-NP	O
randomly	RB	B-VP	O
selected	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
geographical	JJ	I-NP	O
regions	NNS	I-NP	O
.	.	O	O

Reported	VBN	B-NP	O
maternal	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
antibacterials	NNS	B-NP	O
(	(	O	O
num	CD	B-NP	O
month	NN	I-NP	O
before	IN	B-PP	O
pregnancy	NN	B-NP	O
through	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
trimester	NN	I-NP	O
)	)	O	O
.	.	O	O

Odds	NNS	B-NP	O
ratios	NNS	I-NP	O
(	(	O	O
ORs	NNS	B-NP	O
)	)	O	O
measuring	VBG	B-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
antibacterial	JJ	B-NP	O
use	NN	I-NP	O
and	CC	O	O
selected	VBN	B-NP	O
birth	NN	I-NP	B
defects	NNS	I-NP	I
adjusted	VBN	B-VP	O
for	IN	B-PP	O
potential	JJ	B-NP	O
confounders	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
reported	VBN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
antibacterials	NNS	B-NP	O
increased	VBD	B-VP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
,	,	O	O
peaking	VBG	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
month	NN	I-NP	O
.	.	O	O

Sulfonamides	NNS	B-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
anencephaly	RB	B-ADVP	B
,	,	O	O
hypoplastic	JJ	B-NP	B
left	JJ	I-NP	I
heart	NN	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
coarctation	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
aorta	NN	I-NP	I
,	,	O	O
choanal	JJ	B-NP	B
atresia	NN	I-NP	I
,	,	O	O
transverse	JJ	B-NP	B
limb	NN	I-NP	I
deficiency	NN	I-NP	I
,	,	O	O
and	CC	O	O
diaphragmatic	JJ	B-NP	B
hernia	NN	I-NP	I
.	.	O	O

Nitrofurantoins	NNS	B-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
anophthalmia	NN	B-NP	B
or	CC	I-NP	O
microphthalmos	NNS	I-NP	B
,	,	O	O
hypoplastic	JJ	B-NP	B
left	JJ	I-NP	I
heart	NN	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
atrial	JJ	B-NP	B
septal	JJ	I-NP	I
defects	NNS	I-NP	I
,	,	O	O
and	CC	O	O
cleft	NN	B-NP	B
lip	NN	I-NP	I
with	IN	B-PP	O
cleft	NN	B-NP	B
palate	NN	I-NP	I
.	.	O	O

Other	JJ	B-NP	O
antibacterial	JJ	I-NP	O
agents	NNS	I-NP	O
that	WDT	B-NP	O
showed	VBD	B-VP	O
associations	NNS	B-NP	O
included	VBD	B-VP	O
erythromycins	NNS	B-NP	O
(	(	O	O
num	CD	B-NP	O
defects	NNS	I-NP	O
)	)	O	O
,	,	O	O
penicillins	NNS	B-NP	O
(	(	O	O
num	CD	B-NP	O
defect	NN	I-NP	O
)	)	O	O
,	,	O	O
cephalosporins	NNS	B-NP	O
(	(	O	O
num	CD	B-NP	O
defect	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
quinolones	NNS	B-NP	O
(	(	O	O
num	CD	B-NP	O
defect	NN	I-NP	O
)	)	O	O
.	.	O	O

Reassuringly	RB	B-ADVP	O
,	,	O	O
penicillins	NNS	B-NP	O
,	,	O	O
erythromycins	NNS	B-NP	O
,	,	O	O
and	CC	O	O
cephalosporins	NNS	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
used	VBN	B-VP	O
commonly	RB	B-ADVP	O
by	IN	B-PP	O
pregnant	JJ	B-NP	O
women	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
many	JJ	B-NP	O
birth	NN	I-NP	B
defects	NNS	I-NP	I
.	.	O	O

Sulfonamides	NNS	B-NP	O
and	CC	I-NP	O
nitrofurantoins	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
several	JJ	B-NP	O
birth	NN	I-NP	B
defects	NNS	I-NP	I
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
additional	JJ	B-NP	O
scrutiny	NN	I-NP	O
.	.	O	O

Incidence	NN	B-NP	O
of	IN	B-PP	O
neoplasms	NNS	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
exposed	VBN	B-VP	O
to	TO	B-PP	O
different	JJ	B-NP	O
treatment	NN	I-NP	O
regimens	NNS	I-NP	O
.	.	O	O

Immunosuppressive	JJ	B-NP	O
drugs	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
in	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
rheumatoid	JJ	I-NP	B
arthritis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
drugs	NNS	I-NP	O
commonly	RB	B-VP	O
used	VBN	I-VP	O
are	VBP	B-VP	O
cyclophosphamide	NN	B-NP	O
and	CC	O	O
chlorambucil	NN	B-NP	O
(	(	O	O
alkylating	VBG	B-NP	O
agents	NNS	I-NP	O
)	)	O	O
,	,	O	O
azathioprine	NN	B-NP	O
(	(	O	O
purine	NN	B-NP	O
analogue	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
methotrexate	NN	B-NP	O
(	(	O	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
analogue	NN	I-NP	O
)	)	O	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
evidence	NN	B-NP	O
that	IN	B-SBAR	O
all	DT	B-NP	O
num	CD	I-NP	O
immunosuppressive	JJ	I-NP	O
drugs	NNS	I-NP	O
can	MD	B-VP	O
reduce	VB	I-VP	O
synovitis	NN	B-NP	B
,	,	O	O
but	CC	O	O
disease	NN	B-NP	O
activity	NN	I-NP	O
almost	RB	B-ADVP	O
always	RB	I-ADVP	O
recurs	VBZ	B-VP	O
after	IN	B-SBAR	O
therapy	NN	B-NP	O
is	VBZ	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

Since	IN	B-SBAR	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
are	VBP	B-VP	O
frequent	JJ	B-ADJP	O
,	,	O	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
are	VBP	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
continue	VB	I-VP	O
a	DT	B-NP	O
particular	JJ	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
.	.	O	O

Since	IN	B-SBAR	O
it	PRP	B-NP	O
takes	VBZ	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
maximal	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
those	DT	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
unable	JJ	B-ADJP	O
to	TO	B-VP	O
continue	VB	I-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
receive	VB	B-VP	O
little	JJ	B-NP	O
benefit	NN	I-NP	O
from	IN	B-PP	O
it	PRP	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
alkylating	VBG	B-NP	O
agents	NNS	I-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
nonlymphocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
,	,	O	O
and	CC	O	O
both	DT	B-NP	O
alkylating	VBG	I-NP	O
agents	NNS	I-NP	O
and	CC	O	O
azathioprine	NN	B-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
non	AFX	B-NP	B
-	HYPH	I-NP	I
Hodgkin	NNP	I-NP	I
s	NN	I-NP	I
lymphoma	NN	I-NP	I
.	.	O	O

Cyclophosphamide	NN	B-NP	O
therapy	NN	I-NP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
carcinoma	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
bladder	NN	I-NP	I
.	.	O	O

There	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
several	JJ	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
azathioprine	NN	B-NP	O
and	CC	I-NP	O
cyclophosphamide	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
common	JJ	I-NP	O
cancers	NNS	I-NP	B
is	VBZ	B-VP	O
not	RB	I-VP	O
increased	VBN	I-VP	O
.	.	O	O

Data	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
malignancy	NN	B-NP	B
in	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
are	VBP	B-VP	O
still	RB	I-VP	O
being	VBG	I-VP	O
collected	VBN	I-VP	O
,	,	O	O
and	CC	O	O
until	IN	B-SBAR	O
further	JJ	B-NP	O
information	NN	I-NP	O
is	VBZ	B-VP	O
available	JJ	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
immunosuppressive	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
alkylating	VBG	B-VP	O
agents	NNS	B-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
should	MD	B-VP	O
be	VB	I-VP	O
reserved	VBN	I-VP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
progressive	JJ	I-NP	O
disease	NN	I-NP	O
or	CC	O	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
complications	NNS	B-NP	O
.	.	O	O

Patterns	NNS	B-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	B
injury	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
methyldopa	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
liver	NN	B-NP	B
disease	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
methyldopa	NN	B-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Illness	NN	B-NP	O
occurred	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
commencement	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
having	VBG	B-VP	O
received	VBN	I-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
before	IN	B-PP	O
experiencing	VBG	B-VP	O
symptoms	NNS	B-NP	O
.	.	O	O

Jaundice	NN	B-NP	B
with	IN	B-PP	O
tender	NN	B-NP	O
hepatomegaly	NN	I-NP	B
,	,	O	O
usually	RB	B-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
malaise	NN	B-NP	O
,	,	I-NP	O
anorexia	NN	I-NP	B
,	,	I-NP	O
nausea	NN	I-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
,	,	O	O
and	CC	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
upper	JJ	B-NP	O
abdominal	JJ	I-NP	B
pain	NN	I-NP	I
,	,	O	O
was	VBD	B-VP	O
an	DT	B-NP	O
invariable	JJ	I-NP	O
finding	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Biochemical	JJ	B-NP	O
liver	NN	I-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
indicated	VBD	B-VP	O
hepatocellular	JJ	B-NP	O
necrosis	NN	I-NP	B
and	CC	O	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
histopathological	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
spectrum	NN	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
fatty	JJ	B-NP	B
change	NN	I-NP	I
and	CC	O	O
focal	JJ	B-NP	O
hepatocellular	JJ	I-NP	O
necrosis	NN	I-NP	B
to	TO	B-PP	O
massive	JJ	B-NP	B
hepatic	JJ	I-NP	I
necrosis	NN	I-NP	I
.	.	O	O

Most	JJS	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
acute	JJ	I-NP	B
hepatitis	NN	I-NP	I
or	CC	O	O
chronic	JJ	B-NP	B
active	JJ	I-NP	I
hepatitis	NN	I-NP	I
with	IN	B-PP	O
associated	VBN	B-NP	O
cholestasis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
withdrawn	VBN	I-VP	O
on	IN	B-PP	O
presentation	NN	B-NP	O
to	TO	B-PP	O
hospital	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
rapid	JJ	B-NP	O
clinical	JJ	I-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
died	VBD	B-VP	O
,	,	O	O
having	VBG	B-VP	O
presented	VBN	I-VP	O
in	IN	B-PP	O
hepatic	JJ	B-NP	B
failure	NN	I-NP	I
,	,	O	O
and	CC	O	O
another	DT	B-NP	O
,	,	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taking	VBG	I-VP	O
methyldopa	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
showed	VBD	B-VP	O
slower	JJR	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
resolution	NN	I-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
remaining	VBG	I-NP	O
patient	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
series	NN	I-NP	O
developed	VBD	B-VP	O
fulminant	JJ	B-NP	B
hepatitis	NN	I-NP	I
when	WRB	B-ADVP	O
the	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
accidentally	RB	I-VP	O
recommenced	VBN	I-VP	O
num	CD	B-NP	O
year	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
prior	JJ	I-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
methyldopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
latter	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
others	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
causal	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
methyldopa	NN	B-NP	O
and	CC	O	O
hepatic	JJ	B-NP	B
dysfunction	NN	I-NP	I
was	VBD	B-VP	O
proved	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
within	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
re	AFX	B-NP	O
-	HYPH	I-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
plus	CC	I-NP	O
cisplatin	NN	I-NP	O
as	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
head	NN	B-NP	B
and	CC	I-NP	I
neck	NN	I-NP	I
cancers	NNS	I-NP	I
:	:	O	O
preliminary	JJ	B-NP	O
results	NNS	I-NP	O
.	.	O	O

Improved	VBN	B-NP	O
outcomes	NNS	I-NP	O
among	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
head	NN	B-NP	B
and	CC	I-NP	I
neck	NN	I-NP	I
carcinomas	NNS	I-NP	I
require	VBP	B-VP	O
investigations	NNS	B-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
drugs	NNS	I-NP	O
for	IN	B-PP	O
induction	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Preliminary	JJ	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
Eastern	NNP	I-NP	O
Cooperative	NNP	I-NP	O
Oncology	NNP	I-NP	O
Group	NNP	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
agent	NN	I-NP	O
paclitaxel	NN	I-NP	O
(	(	O	O
Taxol	NN	B-NP	O
;	:	O	O
Bristol	NNP	B-NP	O
-	:	O	O
Myers	NNP	B-NP	O
Squibb	NNP	I-NP	O
Company	NNP	I-NP	O
,	,	O	O
Princeton	NNP	B-NP	O
,	,	O	O
NJ	NNP	B-NP	O
)	)	O	O
reported	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
head	NN	B-NP	B
and	CC	O	I
neck	NN	B-NP	I
cancer	NN	I-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
paclitaxel	NN	I-NP	O
/	SYM	B-NP	O
cisplatin	NN	I-NP	O
combination	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
successfully	RB	B-ADVP	O
and	CC	O	O
has	VBZ	B-VP	O
significantly	RB	I-VP	O
improved	VBN	I-VP	O
median	JJ	B-NP	O
response	NN	I-NP	O
duration	NN	I-NP	O
in	IN	B-PP	O
ovarian	JJ	B-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
initiated	VBD	B-VP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
response	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
escalating	VBG	B-VP	O
paclitaxel	NN	B-NP	O
doses	NNS	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
fixed	VBN	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cisplatin	NN	I-NP	O
with	IN	B-PP	O
granulocyte	NN	B-NP	O
colony	NN	I-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
factor	NN	B-NP	O
support	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
untreated	JJ	B-NP	O
locally	RB	I-NP	O
advanced	JJ	I-NP	O
inoperable	JJ	I-NP	O
head	NN	I-NP	B
and	CC	I-NP	I
neck	NN	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

To	TO	B-PP	O
date	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
good	JJ	B-NP	O
performance	NN	I-NP	O
status	NN	I-NP	O
have	VBP	B-VP	O
entered	VBN	I-VP	O
the	DT	B-NP	O
trial	NN	I-NP	O
.	.	O	O

Primary	JJ	B-NP	O
tumor	NN	I-NP	B
sites	NNS	I-NP	O
were	VBD	B-VP	O
oropharynx	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
;	:	O	O
hypopharynx	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
larynx	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
oral	JJ	B-NP	O
cavity	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
unknown	JJ	B-NP	O
primary	JJ	I-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
and	CC	O	O
nasal	JJ	B-NP	O
cavity	NN	I-NP	O
and	CC	I-NP	O
parotid	NN	I-NP	O
gland	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
each	DT	B-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
toxicity	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
stage	NN	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
stage	NN	B-NP	O
num	CD	I-NP	O
disease	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
,	,	O	O
given	VBN	B-PP	O
every	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
maximum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
,	,	O	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
followed	VBD	B-VP	O
the	DT	B-NP	O
next	JJ	I-NP	O
day	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
levels	NNS	I-NP	O
incorporate	JJ	B-ADJP	O
escalating	VBG	B-VP	O
paclitaxel	NN	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
and	CC	O	O
intrapatient	JJ	B-NP	O
escalations	NNS	I-NP	O
within	IN	B-PP	O
a	DT	B-NP	O
given	VBN	I-NP	O
dose	NN	I-NP	O
level	NN	I-NP	O
are	VBP	B-VP	O
permitted	VBN	I-VP	O
if	IN	B-SBAR	O
toxicity	NN	B-NP	B
permits	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
writing	NN	I-NP	O
,	,	O	O
dose	NN	B-NP	O
level	NN	I-NP	O
num	CD	I-NP	O
is	VBZ	B-VP	O
being	VBG	I-VP	O
evaluated	VBN	I-VP	O
;	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
from	IN	B-PP	O
this	DT	B-NP	O
level	NN	I-NP	O
are	VBP	B-VP	O
evaluable	JJ	B-ADJP	O
.	.	O	O

With	IN	B-PP	O
paclitaxel	NN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
,	,	I-NP	O
granulocyte	NN	I-NP	O
colony	NN	I-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
factor	NN	B-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
is	VBZ	B-VP	O
given	VBN	I-VP	O
(	(	O	O
days	NNS	B-NP	O
num	CD	B-NP	O
through	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
response	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
and	CC	I-NP	O
disease	NN	I-NP	O
progressed	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
responding	VBG	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
subsequent	JJ	B-NP	O
surgery	NN	I-NP	O
/	SYM	B-NP	O
radiotherapy	NN	B-NP	O
or	CC	O	O
radical	JJ	B-NP	O
radiotherapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
pathologic	JJ	I-NP	O
complete	JJ	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
achieved	VBN	I-VP	O
clinical	JJ	B-NP	O
complete	JJ	I-NP	O
responses	NNS	I-NP	O
.	.	O	O

Alopecia	NNP	B-NP	B
,	,	O	O
paresthesias	NNS	B-NP	B
,	,	O	O
and	CC	O	O
arthralgias	NNS	B-NP	B
/	SYM	B-NP	O
myalgias	NNS	I-NP	B
have	VBP	B-VP	O
occurred	VBN	I-VP	O
frequently	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
with	IN	B-PP	O
num	CD	B-NP	O
exception	NN	I-NP	O
(	(	O	O
a	DT	B-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
myalgia	NN	I-NP	B
)	)	O	O
they	PRP	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
grade	NN	B-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

No	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
hematologic	JJ	B-NP	O
toxicity	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
seen	VBN	I-VP	O
.	.	O	O

Paclitaxel	NN	B-NP	O
/	SYM	I-NP	O
cisplatin	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
first	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
regimen	NN	I-NP	O
for	IN	B-PP	O
locoregionally	RB	B-NP	O
advanced	JJ	I-NP	O
head	NN	I-NP	B
and	CC	I-NP	I
neck	NN	I-NP	I
cancer	NN	I-NP	I
and	CC	O	O
continued	JJ	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Results	NNS	B-NP	O
thus	RB	B-ADVP	O
far	RB	B-VP	O
suggest	VBP	I-VP	O
no	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
effect	NN	I-NP	O
for	IN	B-PP	O
paclitaxel	NN	B-NP	O
doses	NNS	I-NP	O
above	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydropyranyladriamycin	NN	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
pharmacology	NN	I-NP	O
and	CC	I-NP	O
pharmacokinetics	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
Phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
(	(	O	O
num	CD	O	O
)	)	O	O
bolus	NN	B-NP	O
num	CD	I-NP	O
'	SYM	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydropyranyladriamycin	NN	I-NP	O
(	(	O	O
Pirarubicin	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
done	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
good	JJ	B-NP	O
performance	NN	I-NP	O
status	NN	I-NP	O
with	IN	B-PP	O
refractory	JJ	B-NP	B
tumors	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
minimal	JJ	B-NP	O
prior	JJ	I-NP	O
therapy	NN	I-NP	O
(	(	O	O
good	JJ	B-NP	O
risk	NN	I-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
extensive	JJ	B-NP	O
prior	JJ	I-NP	O
therapy	NN	I-NP	O
(	(	O	O
poor	JJ	B-NP	O
risk	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
renal	JJ	B-ADJP	B
and	CC	O	I
/	SYM	B-NP	I
or	CC	O	I
hepatic	JJ	B-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
were	VBD	B-VP	O
evaluable	JJ	B-ADJP	O
.	.	O	O

Maximum	JJ	B-NP	O
tolerated	VBN	I-NP	O
dose	NN	I-NP	O
in	IN	B-PP	O
good	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
poor	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
toxic	JJ	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
transient	JJ	B-NP	O
noncumulative	JJ	I-NP	O
granulocytopenia	NN	I-NP	B
.	.	O	O

Granulocyte	NN	B-NP	O
nadir	NN	I-NP	O
was	VBD	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Less	RBR	B-NP	O
frequent	JJ	I-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
included	VBD	B-VP	O
thrombocytopenia	NN	B-NP	B
,	,	O	O
anemia	NN	B-NP	B
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
mild	JJ	B-NP	O
alopecia	NN	I-NP	B
,	,	O	O
phlebitis	NN	B-NP	B
,	,	O	O
and	CC	O	O
mucositis	NN	B-NP	B
.	.	O	O

Myelosuppression	NN	B-NP	B
was	VBD	B-VP	O
more	JJR	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hepatic	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Pharmacokinetic	JJ	B-NP	O
analyses	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
revealed	VBD	B-VP	O
Pirarubicin	NN	B-NP	O
plasma	NN	I-NP	O
T	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
alpha	SYM	O	O
(	(	O	O
+	SYM	B-NP	O
/	SYM	O	O
-	HYPH	B-NP	O
SE	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
,	,	O	O
T	NN	B-NP	O
beta	SYM	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
,	,	O	O
and	CC	O	O
T	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
gamma	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
curve	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
x	SYM	B-NP	O
hours	NNS	I-NP	O
,	,	O	O
volume	NN	B-NP	O
of	IN	B-PP	O
distribution	NN	B-NP	O
(	(	O	O
Vd	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
l	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
,	,	O	O
and	CC	O	O
total	JJ	B-NP	O
clearance	NN	I-NP	O
(	(	O	O
ClT	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	I-NP	O
num	CD	I-NP	O
l	NN	I-NP	O
/	SYM	B-NP	O
hour	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
.	.	O	O

Adriamycinol	NN	B-NP	O
,	,	O	O
doxorubicin	NN	B-NP	O
,	,	O	O
adriamycinone	NN	B-NP	O
,	,	O	O
and	CC	O	O
tetrahydropyranyladriamycinol	NN	B-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
metabolites	NNS	I-NP	O
detected	VBN	B-VP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
metabolites	NNS	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
Pirarubicin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Activity	NN	B-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
mesothelioma	NN	B-NP	B
,	,	O	O
leiomyosarcoma	NN	B-NP	B
,	,	O	O
and	CC	O	O
basal	JJ	B-NP	B
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
recommended	VBN	I-NP	O
starting	NN	I-NP	O
dose	NN	I-NP	O
for	IN	B-PP	O
Phase	NN	B-NP	O
num	CD	I-NP	O
trials	NNS	I-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	B-NP	O
num	CD	I-NP	O
bolus	NN	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Differential	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
gamma	SYM	O	O
-	HYPH	O	O
hexachlorocyclohexane	NN	B-NP	O
(	(	O	O
lindane	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
pharmacologically	RB	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Gamma	NN	B-NP	O
-	HYPH	I-NP	O
hexachlorocyclohexane	NN	I-NP	O
(	(	O	O
gamma	SYM	O	O
-	HYPH	O	O
HCH	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
active	JJ	I-NP	O
ingredient	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
insecticide	NN	I-NP	O
lindane	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
decrease	VB	I-VP	O
seizure	NN	B-NP	B
threshold	NN	I-NP	O
to	TO	B-PP	O
pentylenetrazol	NN	B-NP	O
(	(	O	O
PTZ	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
HCH	NN	I-NP	O
and	CC	O	O
conversely	RB	B-VP	O
increase	VBP	I-VP	O
threshold	NN	B-NP	O
to	TO	B-PP	O
PTZ	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
HCH	NN	I-NP	O
(	(	O	O
Vohland	NNP	B-NP	O
et	FW	I-NP	O
al.	FW	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
other	JJ	B-NP	O
seizure	NN	I-NP	B
-	HYPH	B-VP	O
inducing	VBG	B-NP	O
agents	NNS	I-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-SBAR	O
intraperitoneal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
gamma	SYM	O	O
-	HYPH	O	O
HCH	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
hour	NN	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	O	O
HCH	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
-	HYPH	O	O
inducing	VBG	B-NP	O
agents	NNS	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
,	,	O	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
mechanism	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
HCH	NN	I-NP	O
a	DT	B-NP	O
differential	JJ	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Seizure	NN	B-NP	B
activity	NN	I-NP	O
due	IN	B-PP	O
to	TO	B-PP	O
PTZ	NN	B-NP	O
and	CC	I-NP	O
picrotoxin	NN	I-NP	O
(	(	O	O
PTX	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
seizure	NN	B-NP	B
activity	NN	I-NP	O
due	IN	B-PP	O
to	TO	I-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
mercaptopropionic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
MPA	NN	B-NP	O
)	)	O	O
,	,	O	O
bicuculline	NN	B-NP	O
(	(	O	O
BCC	NN	B-NP	O
)	)	O	O
,	,	O	O
methyl	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dimethoxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
ethyl	NN	I-NP	O
-	HYPH	B-NP	O
B	NN	I-NP	O
-	HYPH	B-NP	O
carboline	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
carboxylate	NN	I-NP	O
(	(	O	O
DMCM	NN	B-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
strychnine	NN	B-NP	O
(	(	O	O
STR	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
not	RB	O	O
different	JJ	B-ADJP	O
from	IN	B-PP	O
control	NN	B-NP	O
.	.	O	O

In	FW	B-ADVP	O
vitro	FW	I-ADVP	O
,	,	O	O
gamma	SYM	B-NP	O
-	HYPH	I-NP	O
HCH	NN	I-NP	O
,	,	I-NP	O
pentylenetetrazol	NN	I-NP	O
and	CC	I-NP	O
picrotoxin	NN	I-NP	O
were	VBD	B-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
inhibit	VB	I-VP	O
3H	NN	B-NP	O
-	HYPH	B-NP	O
TBOB	NN	I-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
mouse	NN	B-NP	O
whole	JJ	I-NP	O
brain	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
IC50	NN	B-NP	O
values	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
microM	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

MPA	NN	B-NP	O
,	,	O	O
BCC	NN	B-NP	O
,	,	O	O
DMCM	NN	B-NP	O
,	,	O	O
and	CC	O	O
STR	NN	B-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
3H	NN	B-NP	O
-	HYPH	B-NP	O
TBOB	NN	I-NP	O
(	(	O	O
t	NN	B-NP	O
-	HYPH	B-NP	O
butyl	NN	I-NP	O
bicyclo	AFX	O	O
-	HYPH	B-NP	O
orthobenzoate	NN	I-NP	O
)	)	O	O
binding	NN	B-NP	O
at	IN	B-PP	O
concentrations	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
micron	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pharmacological	JJ	I-NP	O
challenge	NN	I-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
tolerance	NN	B-NP	O
may	MD	B-VP	O
occur	VB	I-VP	O
to	TO	B-PP	O
seizure	NN	B-NP	B
activity	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
PTZ	NN	B-NP	O
and	CC	I-NP	O
PTX	NN	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
HCH	NN	I-NP	O
,	,	O	O
since	IN	B-SBAR	O
the	DT	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
only	RB	B-NP	O
these	DT	I-NP	O
num	CD	I-NP	O
seizure	NN	I-NP	B
-	HYPH	B-VP	O
inducing	VBG	B-NP	O
agents	NNS	I-NP	O
is	VBZ	B-VP	O
decreased	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
site	NN	I-NP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
seizure	NN	B-NP	B
activity	NN	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
gamma	SYM	O	O
-	HYPH	O	O
HCH	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
GABA	NN	I-NP	O
-	HYPH	O	O
A	NN	B-NP	O
receptor	NN	I-NP	O
-	HYPH	B-VP	O
linked	VBN	B-NP	O
chloride	NN	I-NP	O
channel	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
ocular	JJ	I-NP	B
and	CC	I-NP	I
orbital	JJ	I-NP	I
toxicity	NN	I-NP	I
after	IN	B-PP	O
intracarotid	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
for	IN	B-PP	O
recurrent	JJ	B-NP	O
glioblastomas	NNS	I-NP	B
.	.	O	O

Glioblastoma	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
malignant	JJ	I-NP	B
tumor	NN	I-NP	I
that	WDT	B-NP	O
occurs	VBZ	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cerebrum	NN	I-NP	O
during	IN	B-PP	O
adulthood	NN	B-NP	O
.	.	O	O

With	IN	B-PP	O
current	JJ	B-NP	O
treatment	NN	I-NP	O
regimens	NNS	I-NP	O
including	VBG	B-PP	O
combined	VBN	B-NP	O
surgery	NN	I-NP	O
,	,	I-NP	O
radiation	NN	I-NP	O
and	CC	I-NP	O
chemotherapy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
average	JJ	I-NP	O
life	NN	I-NP	O
expectancy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
is	VBZ	B-VP	O
limited	VBN	I-VP	O
to	TO	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
glioblastoma	NN	B-NP	B
sometimes	RB	B-ADVP	O
have	VBP	B-VP	O
intracarotid	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
carcinostatics	NNS	B-NP	O
added	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

Generally	RB	B-ADVP	O
,	,	O	O
carboplatin	NN	B-NP	O
is	VBZ	B-VP	O
said	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
milder	JJR	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
than	IN	B-PP	O
cisplatin	NN	B-NP	O
,	,	O	O
whose	WP$	B-NP	O
ocular	JJ	I-NP	B
and	CC	I-NP	I
orbital	JJ	I-NP	I
toxicity	NN	I-NP	I
are	VBP	B-VP	O
well	RB	B-ADJP	O
known	VBN	I-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
ocular	JJ	I-NP	B
and	CC	I-NP	I
orbital	JJ	I-NP	I
toxicity	NN	I-NP	I
after	IN	B-PP	O
intracarotid	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
infrequently	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
received	VBD	B-VP	O
an	DT	B-NP	O
intracarotid	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
for	IN	B-PP	O
recurrent	JJ	B-NP	O
glioblastomas	NNS	I-NP	B
in	IN	B-PP	O
his	PRP$	B-NP	O
left	JJ	I-NP	O
temporal	JJ	I-NP	O
lobe	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
pain	NN	B-NP	B
and	CC	O	I
visual	JJ	B-NP	I
disturbance	NN	I-NP	I
in	IN	B-PP	I
the	DT	B-NP	I
ipsilateral	JJ	I-NP	I
eye	NN	I-NP	I
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
.	.	O	O

Various	JJ	B-NP	O
ocular	JJ	I-NP	O
symptoms	NNS	I-NP	O
and	CC	I-NP	O
findings	NNS	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
carboplatin	NN	B-NP	O
toxicity	NN	I-NP	B
were	VBD	B-VP	O
seen	VBN	I-VP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
corticosteroids	NNS	B-NP	O
and	CC	O	O
glycerin	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
intraocular	JJ	I-NP	O
pressure	NN	I-NP	O
elevation	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
secondary	JJ	B-NP	O
acute	JJ	I-NP	O
angle	JJ	I-NP	O
-	HYPH	I-NP	O
closure	NN	I-NP	O
glaucoma	NN	I-NP	B
decreased	VBD	B-VP	O
and	CC	O	O
ocular	JJ	B-NP	B
pain	NN	I-NP	I
diminished	VBD	B-VP	O
,	,	O	O
inexorable	JJ	B-NP	O
papilledema	NN	I-NP	B
and	CC	O	O
exudative	JJ	B-NP	O
retinal	JJ	I-NP	B
detachment	NN	I-NP	I
continued	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
diffuse	JJ	B-NP	O
chorioretinal	JJ	I-NP	B
atrophy	NN	I-NP	I
with	IN	B-PP	O
optic	JJ	B-NP	B
atrophy	NN	I-NP	I
occurred	VBD	B-VP	O
and	CC	O	O
the	DT	B-NP	O
vision	NN	I-NP	O
in	IN	B-PP	O
his	PRP$	B-NP	O
left	JJ	I-NP	O
eye	NN	I-NP	O
was	VBD	B-VP	O
lost	VBN	I-VP	O
.	.	O	O

When	WRB	B-ADVP	O
performing	VBG	B-VP	O
intracarotid	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
potentially	RB	I-NP	O
blinding	VBG	I-NP	O
ocular	JJ	B-NP	B
toxicity	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
that	IN	B-SBAR	O
further	JJ	B-NP	O
studies	NNS	I-NP	O
and	CC	I-NP	O
investigations	NNS	I-NP	O
are	VBP	B-VP	O
undertaken	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
effort	NN	I-NP	O
to	TO	B-VP	O
minimize	VB	I-VP	O
such	JJ	B-NP	O
severe	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Phase	NN	B-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
amsacrine	NN	I-NP	O
analogue	NN	I-NP	O
CI	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
NSC	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
in	IN	B-PP	O
non	AFX	B-NP	B
-	HYPH	I-NP	I
small	JJ	B-NP	I
cell	NN	I-NP	I
lung	NN	I-NP	I
cancer	NN	I-NP	I
.	.	O	O

CI	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
NSC	NNP	B-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	O	O
[	(	O	O
[	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methoxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
[	(	O	O
(	(	O	O
methylsulphonyl	NN	B-NP	O
)	)	O	O
amino	NN	B-NP	O
]	)	O	O
phenyl	NN	B-NP	O
]	)	O	O
amino	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
N	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dimethyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
acridinecarboxamide	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
topoisomerase	NN	I-NP	O
num	CD	I-NP	O
poison	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
experimental	JJ	I-NP	O
antitumour	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
infusion	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
non	AFX	O	B
-	HYPH	O	I
small	JJ	B-NP	I
cell	NN	I-NP	I
lung	NN	I-NP	I
cancer	NN	I-NP	I
(	(	O	O
NSCLC	NN	B-NP	B
)	)	O	O
(	(	O	O
num	CD	B-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
prior	JJ	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
relapse	NN	B-NP	O
following	VBG	B-PP	O
surgery	NN	B-NP	O
/	SYM	B-NP	O
radiotherapy	NN	I-NP	O
)	)	O	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
determined	VBN	B-VP	O
by	IN	B-PP	O
phase	NN	B-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
median	JJ	I-NP	O
performance	NN	I-NP	O
status	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
WHO	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
median	JJ	B-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
histology	NN	I-NP	O
comprised	VBD	B-VP	O
squamous	JJ	B-NP	B
carcinoma	NN	I-NP	I
,	,	O	O
adenocarcinoma	NN	B-NP	B
,	,	O	O
mixed	JJ	B-NP	O
histology	NN	I-NP	O
,	,	O	O
bronchio	AFX	B-NP	B
-	HYPH	I-NP	I
alveolar	JJ	B-NP	I
carcinoma	NN	I-NP	I
and	CC	O	O
large	JJ	B-NP	O
cell	NN	I-NP	O
undifferentiated	JJ	I-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

Neutropenia	NNP	B-NP	B
grade	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
infections	NNS	B-NP	B
with	IN	B-PP	O
recovery	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
grand	JJ	B-NP	O
mal	JJ	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
.	.	O	O

Grade	NN	B-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
nausea	NN	I-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
courses	NNS	I-NP	O
and	CC	O	O
phlebitis	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
arm	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
squamous	JJ	B-NP	B
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
achieved	VBD	B-VP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
lasting	VBG	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
testing	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
tumour	NN	I-NP	B
types	NNS	I-NP	O
using	VBG	B-VP	O
multiple	JJ	B-NP	O
daily	JJ	I-NP	O
schedules	NNS	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Alpha	NN	B-NP	O
-	HYPH	I-NP	O
lipoic	JJ	I-NP	O
acid	NN	I-NP	O
prevents	VBZ	B-VP	O
mitochondrial	JJ	B-NP	B
damage	NN	I-NP	I
and	CC	I-NP	O
neurotoxicity	NN	I-NP	B
in	IN	B-PP	O
experimental	JJ	B-NP	O
chemotherapy	NN	I-NP	O
neuropathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
investigates	VBZ	B-VP	O
if	IN	B-SBAR	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
lipoic	JJ	B-NP	O
acid	NN	I-NP	O
is	VBZ	B-VP	O
neuroprotective	JJ	B-ADJP	O
against	IN	B-PP	O
chemotherapy	NN	B-NP	O
induced	VBD	B-VP	O
neurotoxicity	NN	B-NP	B
,	,	O	O
if	IN	B-SBAR	O
mitochondrial	JJ	B-NP	B
damage	NN	I-NP	I
plays	VBZ	B-VP	O
a	DT	B-NP	O
critical	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
toxic	JJ	B-NP	B
neurodegenerative	JJ	I-NP	I
cascade	NN	I-NP	I
,	,	O	O
and	CC	O	O
if	IN	B-SBAR	O
neuroprotective	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
lipoic	JJ	I-NP	O
acid	NN	I-NP	O
depend	VBP	B-VP	O
on	IN	B-PP	O
mitochondria	NNS	B-NP	O
protection	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
an	DT	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
induced	JJ	I-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
that	WDT	B-NP	O
closely	RB	B-ADVP	O
mimic	VBP	B-VP	O
the	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
condition	NN	I-NP	O
by	IN	B-PP	O
exposing	VBG	B-VP	O
primary	JJ	B-NP	O
cultures	NNS	I-NP	O
of	IN	B-PP	O
dorsal	JJ	B-NP	O
root	NN	I-NP	O
ganglion	NN	I-NP	O
(	(	O	O
DRG	NN	B-NP	O
)	)	O	O
sensory	JJ	B-NP	O
neurons	NNS	I-NP	O
to	TO	B-PP	O
paclitaxel	NN	B-NP	O
and	CC	I-NP	O
cisplatin	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
and	CC	O	O
highly	RB	B-NP	O
effective	JJ	I-NP	O
chemotherapeutic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
approach	NN	I-NP	O
allowed	VBD	B-VP	O
investigating	VBG	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	O	O
lipoic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
axonal	JJ	B-NP	B
damage	NN	I-NP	I
and	CC	I-NP	O
apoptosis	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
ultrastructural	JJ	I-NP	O
morphology	NN	I-NP	O
of	IN	B-PP	O
mitochondria	NNS	B-NP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
toxic	JJ	B-NP	O
agents	NNS	I-NP	O
and	CC	O	O
alpha	SYM	B-NP	O
-	HYPH	O	O
lipoic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
both	CC	O	O
cisplatin	NN	B-NP	O
and	CC	I-NP	O
paclitaxel	NN	I-NP	O
cause	VBP	B-VP	O
early	JJ	B-NP	O
mitochondrial	JJ	I-NP	B
impairment	NN	I-NP	I
with	IN	B-PP	O
loss	NN	B-NP	O
of	IN	B-PP	O
membrane	NN	B-NP	O
potential	NN	I-NP	O
and	CC	O	O
induction	NN	B-NP	O
of	IN	B-PP	O
autophagic	JJ	B-NP	O
vacuoles	NNS	I-NP	O
in	IN	B-PP	O
neurons	NNS	B-NP	O
.	.	O	O

Alpha	NN	B-NP	O
-	HYPH	I-NP	O
lipoic	JJ	I-NP	O
acid	NN	I-NP	O
exerts	VBZ	B-VP	O
neuroprotective	JJ	B-NP	O
effects	NNS	I-NP	O
against	IN	B-PP	O
chemotherapy	NN	B-NP	O
induced	VBD	B-VP	O
neurotoxicity	NN	B-NP	B
in	IN	B-PP	O
sensory	JJ	B-NP	O
neurons	NNS	I-NP	O
:	:	O	O
it	PRP	B-NP	O
rescues	VBZ	B-VP	O
the	DT	B-NP	O
mitochondrial	JJ	I-NP	B
toxicity	NN	I-NP	I
and	CC	O	O
induces	VBZ	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
frataxin	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
essential	JJ	I-NP	O
mitochondrial	JJ	I-NP	O
protein	NN	I-NP	O
with	IN	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
oxidant	JJ	I-NP	O
and	CC	I-NP	O
chaperone	NN	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
mitochondrial	JJ	I-NP	B
toxicity	NN	I-NP	I
is	VBZ	B-VP	O
an	DT	B-NP	O
early	JJ	I-NP	O
common	JJ	I-NP	O
event	NN	I-NP	O
both	CC	B-PP	O
in	IN	B-PP	O
paclitaxel	NN	B-NP	O
and	CC	I-NP	O
cisplatin	NN	I-NP	O
induced	VBD	B-VP	O
neurotoxicity	NN	B-NP	B
.	.	O	O

Alpha	NN	B-NP	O
-	HYPH	I-NP	O
lipoic	JJ	I-NP	O
acid	NN	I-NP	O
protects	VBZ	B-VP	O
sensory	JJ	B-NP	O
neurons	NNS	I-NP	O
through	IN	B-PP	O
its	PRP$	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
oxidant	JJ	I-NP	O
and	CC	I-NP	O
mitochondrial	JJ	I-NP	O
regulatory	JJ	I-NP	O
functions	NNS	I-NP	O
,	,	O	O
possibly	RB	B-ADVP	O
inducing	VBG	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
frataxin	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
lipoic	JJ	B-NP	O
acid	NN	I-NP	O
might	MD	B-VP	O
reduce	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
peripheral	JJ	B-NP	B
nerve	NN	I-NP	I
toxicity	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
chemotherapy	NN	B-NP	O
and	CC	O	O
encourage	VB	B-VP	O
further	JJ	B-NP	O
confirmatory	JJ	I-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

Optimising	VBG	B-VP	O
stroke	JJ	B-NP	B
prevention	NN	I-NP	O
in	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
valvular	JJ	I-NP	O
atrial	JJ	I-NP	B
fibrillation	NN	I-NP	I
.	.	O	O

Atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
substantial	JJ	B-NP	O
morbidity	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
.	.	O	O

Pooled	VBN	B-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
trials	NNS	B-NP	O
comparing	VBG	B-VP	O
antithrombotic	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
warfarin	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
stroke	NN	B-NP	B
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
aspirin	NN	B-NP	O
alone	RB	B-ADVP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
warfarin	NN	B-NP	O
is	VBZ	B-VP	O
superior	JJ	B-ADJP	O
to	TO	B-PP	O
aspirin	NN	B-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
strokes	NNS	B-NP	B
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
relative	JJ	I-NP	O
risk	NN	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Ximelagatran	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
oral	JJ	I-NP	O
direct	JJ	I-NP	O
thrombin	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
as	RB	B-ADJP	O
efficient	JJ	I-ADJP	O
as	IN	B-PP	O
vitamin	NN	B-NP	O
K	NN	I-NP	O
antagonist	NN	I-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
embolic	JJ	B-NP	B
events	NNS	I-NP	I
,	,	O	O
but	CC	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
recently	RB	I-VP	O
withdrawn	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
abnormal	JJ	B-NP	B
liver	NN	I-NP	I
function	NN	I-NP	I
tests	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
ACTIVE	NN	I-NP	O
-	HYPH	I-NP	O
W	NN	I-NP	O
(	(	O	O
Atrial	JJ	B-NP	B
Fibrillation	NN	I-NP	I
Clopidogrel	NN	I-NP	O
Trial	NN	I-NP	O
with	IN	B-PP	O
Irbesartan	NN	B-NP	O
for	IN	B-PP	O
Prevention	NN	B-NP	O
of	IN	B-PP	O
Vascular	JJ	B-NP	O
Events	NNS	I-NP	O
)	)	O	O
study	NN	B-NP	O
has	VBZ	B-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
warfarin	NN	B-NP	O
is	VBZ	B-VP	O
superior	JJ	B-ADJP	O
to	TO	B-PP	O
platelet	NN	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
clopidogrel	NN	B-NP	O
plus	CC	O	O
aspirin	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
af	IN	B-PP	O
embolic	JJ	B-NP	B
events	NNS	I-NP	I
.	.	O	O

Idraparinux	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
Factor	NN	I-NP	O
Xa	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
being	VBG	I-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
.	.	O	O

Angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitors	NNS	I-NP	O
and	CC	O	O
angiotensin	NN	B-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
-	HYPH	O	O
blocking	VBG	B-VP	O
drugs	NNS	B-NP	O
hold	VBP	B-VP	O
promise	NN	B-NP	O
in	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
through	IN	B-PP	O
cardiac	JJ	B-NP	B
remodelling	NN	I-NP	I
.	.	O	O

Preliminary	JJ	B-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
statins	NNS	B-NP	O
could	MD	B-VP	O
interfere	VB	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
recurrence	NN	B-NP	O
after	IN	B-PP	O
electrical	JJ	B-NP	O
cardioversion	NN	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
percutaneous	JJ	B-NP	O
methods	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
exclusion	NN	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
atrial	JJ	I-NP	O
appendage	NN	I-NP	O
are	VBP	B-VP	O
under	IN	B-PP	O
investigation	NN	B-NP	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Interaction	NN	B-NP	O
of	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
with	IN	B-PP	O
antineoplastic	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
synergistic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
etoposide	NN	B-NP	O
and	CC	O	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
T	NN	I-NP	I
-	HYPH	B-NP	I
lymphocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
in	IN	B-PP	O
relapse	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
concomitant	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
etoposide	NN	B-NP	O
and	CC	O	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
eradication	NN	B-NP	O
of	IN	B-PP	O
hitherto	NN	B-NP	O
refractory	JJ	I-NP	O
leukemic	JJ	I-NP	B
infiltration	NN	I-NP	I
of	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
mental	JJ	B-NP	O
confusion	NN	I-NP	B
and	CC	O	O
progressive	JJ	B-NP	O
hyperbilirubinemia	NN	I-NP	B
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
point	NN	B-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
enhancement	NN	I-NP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
of	IN	B-PP	O
antineoplastic	JJ	B-NP	O
effects	NNS	I-NP	O
but	CC	O	O
also	RB	B-ADVP	O
of	IN	B-PP	O
toxicity	NN	B-NP	B
in	IN	B-PP	O
normal	JJ	B-NP	O
tissues	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
demonstrates	VBZ	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
that	IN	B-ADVP	O
the	DT	B-NP	O
pharmacodynamic	JJ	I-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
confined	VBN	I-VP	O
strictly	RB	B-ADVP	O
to	TO	B-PP	O
suppression	NN	B-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
T	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
functions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
hematologic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cefonicid	NN	B-NP	O
and	CC	I-NP	O
cefazedone	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dog	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
potential	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
cephalosporin	NN	B-NP	O
hematotoxicity	NN	I-NP	B
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

Cephalosporin	NN	B-NP	O
antibiotics	NNS	I-NP	O
cause	VBP	B-VP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
hematologic	JJ	B-NP	B
disturbances	NNS	I-NP	I
in	IN	B-PP	O
man	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
pathogeneses	NNS	I-NP	O
and	CC	I-NP	O
hematopathology	NN	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
remain	VBP	B-VP	O
poorly	RB	B-ADJP	O
characterized	VBN	I-ADJP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
defined	VBN	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
these	DT	B-NP	O
blood	NN	I-NP	B
dyscrasias	NNS	I-NP	I
can	MD	B-VP	O
be	VB	I-VP	O
studied	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
subacute	JJ	I-NP	O
toxicity	NN	I-NP	B
studies	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
cefonicid	NN	B-NP	O
or	CC	I-NP	O
cefazedone	NN	I-NP	O
to	TO	B-PP	O
beagle	NN	B-NP	O
dogs	NNS	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
anemia	NN	B-NP	B
,	,	O	O
neutropenia	NN	B-NP	B
,	,	O	O
and	CC	O	O
thrombocytopenia	NN	B-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
nonregenerative	JJ	I-NP	O
anemia	NN	I-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
compromising	JJ	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cytopenias	NNS	I-NP	B
and	CC	O	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
dogs	NNS	B-NP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
cefonicid	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
cefazedone	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
cytopenias	NNS	I-NP	B
were	VBD	B-VP	O
completely	RB	B-ADJP	O
reversible	JJ	I-ADJP	O
following	VBG	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
;	:	O	O
the	DT	B-NP	O
time	NN	I-NP	O
required	VBN	B-VP	O
for	IN	B-PP	O
recovery	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
erythron	NN	I-NP	O
(	(	O	O
approximately	RB	B-NP	O
num	CD	I-NP	O
month	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
considerably	RB	B-ADVP	O
longer	RBR	I-ADVP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
granulocytes	NNS	I-NP	O
and	CC	I-NP	O
platelets	NNS	I-NP	O
(	(	O	O
hours	NNS	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
days	NNS	I-NP	O
)	)	O	O
.	.	O	O

Upon	IN	B-PP	O
rechallenge	NN	B-NP	O
with	IN	B-PP	O
either	CC	O	O
cephalosporin	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
hematologic	JJ	I-NP	B
syndrome	NN	I-NP	I
was	VBD	B-VP	O
reproduced	VBN	I-VP	O
in	IN	B-PP	O
most	JJS	B-NP	O
dogs	NNS	I-NP	O
tested	VBN	B-VP	O
;	:	O	O
cefonicid	NN	B-NP	O
(	(	O	O
but	CC	O	O
not	RB	O	O
cefazedone	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
dogs	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
substantially	RB	I-NP	O
reduced	VBN	I-NP	O
induction	NN	I-NP	O
period	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
observation	NN	I-NP	O
,	,	O	O
along	IN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
rapid	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
decline	NN	B-NP	O
in	IN	B-PP	O
red	JJ	B-NP	O
cell	NN	I-NP	O
mass	NN	I-NP	O
parameters	NNS	I-NP	O
of	IN	B-PP	O
affected	VBN	B-NP	O
dogs	NNS	I-NP	O
,	,	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
hemolytic	JJ	I-NP	B
component	NN	I-NP	O
complicated	VBD	B-VP	O
the	DT	B-NP	O
red	JJ	I-NP	O
cell	NN	I-NP	O
production	NN	I-NP	O
problem	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
multiple	JJ	B-NP	O
toxicologic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
contributed	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
cytopenia	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
cefonicid	NN	B-NP	O
or	CC	I-NP	O
cefazedone	NN	I-NP	O
to	TO	B-PP	O
dogs	NNS	B-NP	O
can	MD	B-VP	O
induce	VB	I-VP	O
hematotoxicity	NN	B-NP	B
similar	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
cephalosporin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
blood	NN	I-NP	B
dyscrasias	NNS	I-NP	I
described	VBN	B-VP	O
in	IN	B-PP	O
man	NN	B-NP	O
and	CC	O	O
thus	RB	B-VP	O
provides	VBZ	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
studying	VBG	B-VP	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
disorders	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
pyridoxine	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
behavioral	JJ	I-NP	B
disorder	NN	I-NP	I
unmasked	JJ	B-ADJP	O
by	IN	B-PP	O
isoniazid	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
girl	NN	I-NP	O
had	VBD	B-VP	O
behavioral	JJ	B-NP	B
deterioration	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
hyperkinesis	NN	B-NP	B
,	,	O	O
irritability	NN	B-NP	B
,	,	O	O
and	CC	O	O
sleeping	VBG	B-VP	B
difficulties	NNS	B-NP	I
after	IN	B-PP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
isoniazid	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
pharmacologic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
pyridoxine	NN	B-NP	O
hydrochloride	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
.	.	O	O

After	IN	B-PP	O
discontinuing	VBG	B-VP	O
isoniazid	NN	B-NP	O
therapy	NN	I-NP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
behavior	NN	B-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
controlled	VBN	I-VP	O
by	IN	B-PP	O
pyridoxine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
placebo	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
,	,	O	O
but	CC	O	O
niacinamide	NN	B-NP	O
was	VBD	B-VP	O
as	RB	B-ADJP	O
effective	JJ	I-ADJP	O
as	IN	B-PP	O
pyridoxine	NN	B-NP	O
.	.	O	O

Periodic	JJ	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
pyridoxine	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
return	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hyperkinesis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
pyridoxal	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
periods	NNS	I-NP	O
of	IN	B-PP	O
relapse	NN	B-NP	O
.	.	O	O

Metabolic	JJ	B-NP	O
studies	NNS	I-NP	O
suggested	VBD	B-VP	O
a	DT	B-NP	O
block	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kynurenine	NN	I-NP	O
pathway	NN	I-NP	O
of	IN	B-PP	O
tryptophan	NN	B-NP	O
metabolism	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
followed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
has	VBZ	B-VP	O
required	VBN	I-VP	O
pharmacologic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
pyridoxine	NN	B-NP	O
to	TO	B-VP	O
control	VB	I-VP	O
her	PRP$	B-NP	O
behavior	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
selective	JJ	I-NP	O
dopamine	NN	I-NP	O
D4	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
NRA0160	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
preclinical	JJ	I-NP	O
neuropharmacological	JJ	I-NP	O
profile	NN	I-NP	O
.	.	O	O

NRA0160	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	O	O
[	(	O	O
num	CD	O	O
-	HYPH	O	O
(	(	O	O
num	CD	O	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorobenzylidene	NN	I-NP	O
)	)	O	O
piperidin	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yl	NN	I-NP	O
)	)	O	O
ethyl	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorophenyl	NN	I-NP	O
)	)	O	O
thiazole	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
carboxamide	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
affinity	NN	I-NP	O
for	IN	B-PP	O
human	JJ	B-NP	O
cloned	VBN	I-NP	O
dopamine	NN	I-NP	O
D4.2	NN	I-NP	O
,	,	I-NP	O
D4.4	NN	I-NP	O
and	CC	I-NP	O
D4.7	NN	I-NP	O
receptors	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
Ki	NN	B-NP	O
values	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
nM	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

NRA0160	NN	B-NP	O
is	VBZ	B-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
000fold	RB	B-ADJP	O
more	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
at	IN	B-PP	O
the	DT	B-NP	O
dopamine	NN	I-NP	O
D4.2	NN	I-NP	O
receptor	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
cloned	VBN	I-NP	O
dopamine	NN	I-NP	O
D2L	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

NRA0160	NN	B-NP	O
has	VBZ	B-VP	O
negligible	JJ	B-NP	O
affinity	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
cloned	VBN	I-NP	O
dopamine	NN	I-NP	O
D3	NN	I-NP	O
receptor	NN	I-NP	O
,	,	O	O
rat	NN	B-NP	O
serotonin	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
)	)	O	O
2A	NN	B-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
rat	NN	B-NP	O
alpha1	NN	I-NP	O
adrenoceptor	NN	I-NP	O
.	.	O	O

NRA0160	NN	B-NP	O
and	CC	I-NP	O
clozapine	NN	I-NP	O
antagonized	VBD	B-VP	O
locomotor	NN	B-NP	O
hyperactivity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
methamphetamine	NN	B-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

NRA0160	NN	B-NP	O
and	CC	I-NP	O
clozapine	NN	I-NP	O
antagonized	VBD	B-VP	O
MAP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
stereotyped	VBN	I-NP	O
behavior	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
their	PRP$	B-NP	O
effects	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
exceed	VB	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
inhibition	NN	I-NP	O
,	,	O	O
even	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
dose	NN	I-NP	O
given	VBN	B-VP	O
.	.	O	O

NRA0160	NN	B-NP	O
and	CC	I-NP	O
clozapine	NN	I-NP	O
significantly	RB	B-ADVP	O
induced	VBD	B-VP	O
catalepsy	NN	B-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
their	PRP$	B-NP	O
effects	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
exceed	VB	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
induction	NN	I-NP	O
even	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
dose	NN	I-NP	O
given	VBN	B-VP	O
.	.	O	O

NRA0160	NN	B-NP	O
and	CC	I-NP	O
clozapine	NN	I-NP	O
significantly	RB	B-ADVP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
disruption	NN	I-NP	O
of	IN	B-PP	O
prepulse	NN	B-NP	O
inhibition	NN	I-NP	O
(	(	O	O
PPI	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
apomorphine	NN	B-NP	O
.	.	O	O

NRA0160	NN	B-NP	O
and	CC	I-NP	O
clozapine	NN	I-NP	O
significantly	RB	B-ADVP	O
shortened	VBD	B-VP	O
the	DT	B-NP	O
phencyclidine	NN	I-NP	O
(	(	O	O
PCP	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-VP	O
prolonged	VBN	I-VP	O
swimming	VBG	B-VP	O
latency	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
water	NN	I-NP	O
maze	NN	I-NP	O
task	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
NRA0160	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
unique	JJ	B-NP	O
antipsychotic	JJ	I-NP	O
activities	NNS	I-NP	O
without	IN	B-PP	O
the	DT	B-NP	O
liability	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
typical	JJ	B-ADJP	O
of	IN	B-PP	O
classical	JJ	B-NP	O
antipsychotics	NNS	I-NP	O
.	.	O	O

Prolonged	JJ	B-NP	O
cholestasis	NN	I-NP	B
after	IN	B-PP	O
troleandomycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
troleandomycin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatitis	NN	I-NP	B
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
prolonged	JJ	B-NP	O
anicteric	JJ	I-NP	O
cholestasis	NN	I-NP	B
.	.	O	O

Jaundice	NNP	B-NP	B
occurred	VBD	B-VP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
troleandomycin	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hypereosinophilia	NN	B-NP	B
.	.	O	O

Jaundice	NNP	B-NP	B
disappeared	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
but	CC	O	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
prolonged	JJ	B-NP	O
anicteric	JJ	I-NP	O
cholestasis	NN	I-NP	B
marked	VBN	B-VP	O
by	IN	B-PP	O
pruritus	NN	B-NP	B
and	CC	O	O
high	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
alkaline	NN	B-NP	O
phosphatase	NN	I-NP	O
and	CC	I-NP	O
gammaglutamyltransferase	NN	I-NP	O
activities	NNS	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
pruritus	NN	B-NP	B
disappeared	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
and	CC	O	O
liver	NN	B-NP	O
tests	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
observation	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
prolonged	VBN	B-NP	O
cholestasis	NN	I-NP	B
can	MD	B-VP	O
follow	VB	I-VP	O
troleandomycin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

HMG	NN	B-NP	O
CoA	NN	I-NP	O
reductase	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Current	JJ	B-NP	O
clinical	JJ	I-NP	O
experience	NN	I-NP	O
.	.	O	O

Lovastatin	NN	B-NP	O
and	CC	I-NP	O
simvastatin	NN	I-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
best	JJS	I-NP	O
-	HYPH	I-NP	O
known	VBN	I-NP	O
members	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
hypolipidaemic	JJ	B-NP	O
agents	NNS	I-NP	O
known	VBN	B-VP	O
as	IN	B-PP	O
HMG	NN	B-NP	O
CoA	NN	I-NP	O
reductase	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
experience	NN	I-NP	O
with	IN	B-PP	O
lovastatin	NN	B-NP	O
includes	VBZ	B-VP	O
over	IN	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
,	,	O	O
and	CC	O	O
experience	NN	B-NP	O
with	IN	B-PP	O
simvastatin	NN	B-NP	O
includes	VBZ	B-VP	O
over	IN	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
of	IN	B-PP	O
whom	WP	B-NP	O
num	CD	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
.	.	O	O

Lovastatin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
marketed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
for	IN	B-PP	O
over	IN	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Both	DT	B-NP	O
agents	NNS	I-NP	O
show	VBP	B-VP	O
substantial	JJ	B-NP	O
clinical	JJ	I-NP	O
efficacy	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
reductions	NNS	B-NP	O
in	IN	B-PP	O
total	JJ	B-NP	O
cholesterol	NN	I-NP	O
of	IN	B-PP	O
over	IN	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
LDL	NN	B-NP	O
-	HYPH	B-NP	O
cholesterol	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Modest	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
HDL	NN	B-NP	O
-	HYPH	B-NP	O
cholesterol	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
are	VBP	B-VP	O
also	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Clinical	JJ	B-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
agents	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
good	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
fewer	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
withdrawn	VBN	B-VP	O
from	IN	B-PP	O
treatment	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
clinical	JJ	B-NP	O
adverse	JJ	I-NP	O
experiences	NNS	I-NP	O
.	.	O	O

Ophthalmological	JJ	B-NP	O
examinations	NNS	I-NP	O
in	IN	B-PP	O
over	IN	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
or	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
agent	NN	I-NP	O
have	VBP	B-VP	O
revealed	VBN	I-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
significant	JJ	B-NP	O
short	JJ	I-NP	O
term	NN	I-NP	O
(	(	O	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
cataractogenic	JJ	B-NP	O
potential	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
have	VBP	B-VP	O
elevations	NNS	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
transaminases	NNS	I-NP	O
to	TO	B-PP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
limit	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
.	.	O	O

These	DT	B-NP	O
episodes	NNS	I-NP	O
are	VBP	B-VP	O
asymptomatic	JJ	B-ADJP	O
and	CC	I-ADJP	O
reversible	JJ	I-ADJP	O
when	WRB	B-ADVP	O
therapy	NN	B-NP	O
is	VBZ	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

Minor	JJ	B-NP	O
elevations	NNS	I-NP	O
of	IN	B-PP	O
creatine	NN	B-NP	O
kinase	NN	I-NP	O
levels	NNS	I-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Myopathy	NN	B-NP	B
,	,	O	O
associated	VBN	B-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
myoglobinuria	NN	B-NP	B
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
transient	JJ	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
rarely	RB	I-VP	O
reported	VBN	I-VP	O
with	IN	B-PP	O
lovastatin	NN	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
concomitantly	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
cyclosporin	NN	B-NP	O
,	,	I-NP	O
gemfibrozil	NN	I-NP	O
or	CC	I-NP	O
niacin	NN	I-NP	O
.	.	O	O

Lovastatin	NN	B-NP	O
and	CC	I-NP	O
simvastatin	NN	I-NP	O
are	VBP	B-VP	O
both	DT	O	O
effective	JJ	B-ADJP	O
and	CC	O	O
well	RB	B-ADJP	O
-	HYPH	I-ADJP	O
tolerated	VBN	B-NP	O
agents	NNS	I-NP	O
for	IN	B-PP	O
lowering	VBG	B-VP	O
elevated	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
cholesterol	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
wider	JJR	B-NP	O
use	NN	I-NP	O
confirms	VBZ	B-VP	O
their	PRP$	B-NP	O
safety	NN	I-NP	O
profile	NN	I-NP	O
,	,	O	O
they	PRP	B-NP	O
will	MD	B-VP	O
gain	VB	I-VP	O
increasing	VBG	B-NP	O
importance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
hypercholesterolaemia	NN	B-NP	B
and	CC	O	O
its	PRP$	B-NP	O
consequences	NNS	I-NP	O
.	.	O	O

Sulfasalazine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lupus	NN	I-NP	B
erythematosus	NN	I-NP	I
.	.	O	O

Pneumonitis	NN	B-NP	B
,	,	O	O
bilateral	JJ	B-NP	O
pleural	JJ	I-NP	B
effusions	NNS	I-NP	I
,	,	O	O
echocardiographic	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
tamponade	NN	I-NP	I
,	,	O	O
and	CC	O	O
positive	JJ	B-NP	O
autoantibodies	NNS	I-NP	O
developed	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
was	VBD	B-VP	O
receiving	VBG	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
sulfasalazine	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	O
ulcerative	JJ	I-NP	B
colitis	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sulfasalazine	NN	I-NP	O
and	CC	I-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
corticosteroids	NNS	B-NP	O
,	,	O	O
these	DT	B-NP	O
problems	NNS	I-NP	O
resolved	VBN	B-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
sulfasalazine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lupus	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
manifested	VBD	B-VP	O
with	IN	B-PP	O
serositis	NN	B-NP	B
and	CC	O	O
pulmonary	JJ	B-NP	O
parenchymal	JJ	I-NP	O
involvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
joint	JJ	B-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

Physicians	NNS	B-NP	O
who	WP	B-NP	O
use	VBP	B-VP	O
sulfasalazine	NN	B-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
inflammatory	JJ	B-NP	B
bowel	NN	I-NP	I
disease	NN	I-NP	I
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
sulfasalazine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lupus	NN	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Optimization	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
single	JJ	I-NP	O
correct	JJ	I-NP	O
starting	NN	I-NP	O
dose	NN	I-NP	O
for	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
many	JJ	B-NP	O
individuals	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
started	VBN	I-VP	O
on	IN	B-PP	O
either	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
or	CC	O	O
controlled	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
formula	NN	I-NP	O
,	,	O	O
following	VBG	B-PP	O
the	DT	B-NP	O
general	JJ	I-NP	O
rule	NN	I-NP	O
not	RB	O	O
to	TO	B-VP	O
attempt	VB	I-VP	O
to	TO	I-VP	O
titrate	VB	I-VP	O
carbidopa	NN	B-NP	O
-	HYPH	O	O
levodopa	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
point	NN	I-NP	O
of	IN	B-PP	O
normality	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
can	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
toxicity	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
physician	NN	I-NP	O
should	MD	B-VP	O
also	RB	I-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
proper	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
adjunctive	JJ	I-NP	O
medications	NNS	I-NP	O
;	:	O	O
such	JJ	B-NP	O
combined	JJ	I-NP	O
therapy	NN	I-NP	O
has	VBZ	B-VP	O
become	VBN	I-VP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Following	VBG	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
emerging	VBG	B-VP	O
difficulties	NNS	B-NP	O
require	VBP	B-VP	O
a	DT	B-NP	O
reassessment	NN	I-NP	O
of	IN	B-PP	O
therapeutic	JJ	B-NP	O
approaches	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
dosage	NN	B-NP	O
adjustment	NN	I-NP	O
or	CC	I-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
dopamine	NN	I-NP	O
agonist	NN	I-NP	O
.	.	O	O

Other	JJ	B-NP	O
possible	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
-	HYPH	O	O
-	HYPH	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
gastrointestinal	JJ	B-NP	B
disorders	NNS	I-NP	I
,	,	O	O
orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
,	,	O	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
,	,	O	O
sleep	NN	B-NP	B
disturbances	NNS	I-NP	I
or	CC	I-NP	O
parasomnias	NNS	I-NP	B
,	,	O	O
or	CC	O	O
drug	NN	B-NP	O
interactions	NNS	I-NP	O
-	:	O	O
-	HYPH	B-NP	O
also	RB	B-ADVP	O
require	VBP	B-VP	O
carefully	RB	I-VP	O
monitored	VBN	I-VP	O
individual	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Nonpharmacologic	JJ	B-NP	O
concerns	NNS	I-NP	O
can	MD	B-VP	O
help	VB	I-VP	O
the	DT	B-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patient	NN	I-NP	O
achieve	NN	I-NP	O
and	CC	O	O
maintain	VBP	B-VP	O
optimal	JJ	B-NP	O
functioning	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
daily	JJ	B-NP	O
exercise	NN	I-NP	O
,	,	O	O
physical	JJ	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
involvement	NN	B-NP	O
with	IN	B-PP	O
support	NN	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Alpha	NN	B-NP	O
and	CC	I-NP	O
beta	NN	I-NP	O
coma	NN	I-NP	B
in	IN	B-PP	O
drug	NN	B-NP	O
intoxication	NN	I-NP	O
uncomplicated	VBN	B-VP	O
by	IN	B-PP	O
cerebral	JJ	B-NP	B
hypoxia	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
rendered	VBN	I-VP	O
comatose	NN	B-NP	B
or	CC	O	O
stuporous	JJ	B-ADJP	B
by	IN	B-PP	O
drug	NN	B-NP	O
intoxication	NN	I-NP	O
,	,	O	O
but	CC	O	O
who	WP	B-NP	O
were	VBD	B-VP	O
not	RB	O	O
hypoxic	JJ	B-ADJP	O
,	,	O	O
are	VBP	B-VP	O
described	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
chlormethiazole	NN	B-NP	O
for	IN	B-PP	O
alcohol	NN	B-NP	O
withdrawal	NN	I-NP	B
symptoms	NNS	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
took	VBD	B-VP	O
a	DT	B-NP	O
suicidal	JJ	I-NP	O
overdose	NN	I-NP	B
of	IN	B-PP	O
nitrazepam	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
nitrazepam	NN	B-NP	O
overdose	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
chlormethiazole	NN	B-NP	O
intoxication	NN	I-NP	O
conformed	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
criteria	NNS	I-NP	O
of	IN	B-PP	O
alpha	NN	B-NP	O
coma	NN	I-NP	B
,	,	O	O
showing	VBG	B-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
reactive	JJ	I-NP	O
generalized	VBN	B-VP	O
or	CC	O	O
frontally	RB	B-NP	O
predominant	JJ	I-NP	O
alpha	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
EEG	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
fourth	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
unconscious	JJ	B-ADJP	O
after	IN	B-SBAR	O
chlormethiazole	NN	B-NP	O
administration	NN	I-NP	O
exhibite	NN	I-NP	O
generalized	VBN	B-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
reactive	JJ	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
slow	JJ	I-NP	O
beta	NN	I-NP	O
range	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
recovered	VBD	B-VP	O
completely	RB	B-ADVP	O
without	IN	B-PP	O
neurological	JJ	B-NP	B
sequelae	NNS	I-NP	I
following	VBG	B-PP	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
offending	VBG	I-NP	O
agents	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
similarities	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
structural	JJ	B-NP	O
lesions	NNS	I-NP	O
and	CC	O	O
pharmacological	JJ	B-NP	O
depression	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
stem	NN	I-NP	O
reticular	JJ	I-NP	O
formation	NN	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
both	DT	B-NP	O
situations	NNS	I-NP	O
disturbed	VBD	B-VP	O
reticulo	AFX	B-NP	O
-	HYPH	I-NP	O
thalamic	JJ	B-NP	O
interactions	NNS	I-NP	O
are	VBP	B-VP	O
important	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
alpha	NN	B-NP	O
coma	NN	I-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
when	WRB	B-ADVP	O
this	DT	B-NP	O
electroencephalographic	JJ	I-NP	O
and	CC	I-NP	O
behavioural	JJ	I-NP	O
picture	NN	I-NP	O
is	VBZ	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
drug	NN	B-NP	O
intoxication	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
significant	JJ	B-NP	O
hypoxaemia	NN	I-NP	B
,	,	O	O
a	DT	B-NP	O
favourable	JJ	I-NP	O
outcome	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
anticipated	VBN	I-VP	O
.	.	O	O

Omitting	VBG	B-VP	O
fentanyl	NN	B-NP	O
reduces	VBZ	B-VP	O
nausea	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
,	,	O	O
without	IN	B-PP	O
increasing	VBG	B-VP	O
pain	NN	B-NP	B
,	,	O	O
after	IN	B-PP	O
sevoflurane	NN	B-NP	O
for	IN	B-PP	O
day	NN	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
advantages	NNS	B-NP	O
of	IN	B-PP	O
induction	NN	B-NP	O
and	CC	I-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
anaesthesia	NN	B-NP	O
with	IN	B-PP	O
sevoflurane	NN	B-NP	O
,	,	O	O
postoperative	JJ	B-NP	B
nausea	NN	I-NP	I
and	CC	I-NP	I
vomiting	NN	I-NP	I
occurs	VBZ	B-VP	O
frequently	RB	B-ADVP	O
.	.	O	O

Fentanyl	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
supplement	NN	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
it	PRP	B-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
improve	VB	I-VP	O
analgesia	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
nausea	NN	I-NP	I
and	CC	I-NP	I
vomiting	NN	I-NP	I
and	CC	I-NP	O
pain	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
sevoflurane	NN	B-NP	O
anaesthesia	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
adult	JJ	I-NP	O
day	NN	I-NP	O
surgery	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	B-PP	O
either	CC	O	O
receive	VB	B-VP	O
or	CC	O	O
not	RB	B-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
fentanyl	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
a	DT	B-NP	O
third	JJ	I-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
dexamethasone	NN	B-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
fentanyl	NN	B-NP	O
.	.	O	O

Omission	NN	B-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reduce	VB	I-VP	O
the	DT	B-NP	O
overall	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
nausea	NN	I-NP	I
and	CC	I-NP	I
vomiting	NN	I-NP	I
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
reduce	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
vomiting	VBG	B-VP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
nausea	NN	I-NP	B
prior	JJ	B-ADJP	O
to	TO	B-VP	O
discharge	VB	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
fentanyl	NN	B-NP	O
and	CC	I-NP	O
fentanyl	NN	I-NP	O
-	HYPH	O	O
dexamethasone	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Antiemetic	JJ	B-NP	O
requirements	NNS	I-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
or	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
nausea	NN	I-NP	I
and	CC	I-NP	I
vomiting	NN	I-NP	I
.	.	O	O

Combining	VBG	B-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
fentanyl	NN	I-NP	O
groups	NNS	I-NP	O
revealed	VBD	B-VP	O
further	JJ	B-NP	O
significant	JJ	I-NP	O
benefits	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
avoidance	NN	I-NP	O
of	IN	B-PP	O
opioids	NNS	B-NP	O
,	,	O	O
reducing	VBG	B-VP	O
postoperative	JJ	B-NP	B
nausea	NN	I-NP	I
and	CC	I-NP	I
vomiting	NN	I-NP	I
and	CC	I-NP	O
nausea	NN	I-NP	B
prior	JJ	B-ADJP	O
to	TO	B-VP	O
discharge	VB	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
nausea	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
severity	NN	I-NP	O
and	CC	O	O
analgesic	JJ	B-NP	O
requirements	NNS	I-NP	O
were	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
by	IN	B-PP	O
the	DT	B-NP	O
omission	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
.	.	O	O

Fentanyl	NN	B-NP	O
did	VBD	B-VP	O
reduce	VB	I-VP	O
minor	JJ	B-NP	O
intraoperative	JJ	I-NP	O
movement	NN	I-NP	O
but	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
sevoflurane	NN	I-NP	O
-	HYPH	O	O
sparing	VBG	B-VP	O
effect	NN	B-NP	O
and	CC	O	O
increased	VBD	B-VP	O
respiratory	JJ	B-NP	B
depression	NN	I-NP	I
,	,	O	O
hypotension	NN	B-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
.	.	O	O

As	IN	B-SBAR	O
fentanyl	NN	B-NP	O
exacerbated	JJ	I-NP	O
postoperative	JJ	I-NP	B
nausea	NN	I-NP	I
and	CC	I-NP	I
vomiting	NN	I-NP	I
without	IN	B-PP	O
an	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
postoperative	JJ	B-NP	B
pain	NN	I-NP	I
and	CC	O	O
also	RB	B-ADVP	O
had	VBD	B-VP	O
adverse	JJ	B-NP	O
cardiorespiratory	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
unnecessary	JJ	I-NP	O
and	CC	I-NP	O
possibly	RB	I-NP	O
detrimental	JJ	I-NP	O
supplement	NN	I-NP	O
to	TO	B-PP	O
sevoflurane	NN	B-NP	O
in	IN	B-PP	O
day	NN	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	B
Fanconi	NNP	I-NP	I
syndrome	NN	I-NP	I
and	CC	I-NP	O
myopathy	NN	I-NP	B
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
:	:	O	O
drug	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
mitochondrial	JJ	I-NP	B
cytopathy	NN	I-NP	I
?	.	O	O
Advances	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
field	NN	I-NP	O
of	IN	B-PP	O
transplantation	NN	B-NP	O
provide	VBP	B-VP	O
a	DT	B-NP	O
better	JJR	I-NP	O
quality	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
and	CC	O	O
allow	VB	B-VP	O
more	RBR	B-NP	O
favorable	JJ	I-NP	O
conditions	NNS	I-NP	O
for	IN	B-PP	O
growth	NN	B-NP	O
and	CC	I-NP	O
development	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
combinations	NNS	B-NP	O
of	IN	B-PP	O
different	JJ	B-NP	O
therapeutic	JJ	I-NP	O
regimens	NNS	I-NP	O
require	VBP	B-VP	O
consideration	NN	B-NP	O
of	IN	B-PP	O
potential	JJ	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yr	NN	I-NP	O
-	HYPH	I-NP	O
old	JJ	I-NP	O
girl	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
orthotopic	JJ	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
Wilson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Tacrolimus	NN	B-NP	O
,	,	O	O
MMF	NN	B-NP	O
,	,	O	O
and	CC	O	O
steroids	NNS	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
as	IN	B-PP	O
immunosuppressant	NN	B-NP	O
.	.	O	O

Lamivudine	NN	B-NP	O
was	VBD	B-VP	O
added	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
de	FW	B-NP	O
nova	FW	I-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
infection	NN	I-NP	I
during	IN	B-PP	O
her	PRP	B-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
.	.	O	O

num	CD	B-NP	O
yr	NN	I-NP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
she	PRP	B-NP	O
developed	VBD	B-VP	O
renal	JJ	B-NP	B
Fanconi	NNP	I-NP	I
syndrome	NN	I-NP	I
with	IN	B-PP	O
severe	JJ	B-NP	O
metabolic	JJ	I-NP	B
acidosis	NN	I-NP	I
,	,	O	O
hypophosphatemia	NN	B-NP	B
,	,	O	O
glycosuria	NN	B-NP	B
,	,	O	O
and	CC	O	O
aminoaciduria	NN	B-NP	B
.	.	O	O

Although	IN	B-SBAR	O
tacrolimus	NN	B-NP	O
was	VBD	B-VP	O
suspected	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
late	JJ	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
transplant	NN	I-NP	O
renal	JJ	I-NP	O
acidosis	NN	I-NP	B
and	CC	O	O
was	VBD	B-VP	O
replaced	VBN	I-VP	O
by	IN	B-PP	O
sirolimus	NN	B-NP	O
,	,	O	O
acidosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
electrolyte	NN	B-NP	O
imbalance	NN	I-NP	O
got	VBD	B-VP	O
worse	JJR	B-ADJP	O
.	.	O	O

Proximal	JJ	B-NP	O
muscle	NN	I-NP	B
weakness	NN	I-NP	I
has	VBZ	B-VP	O
developed	VBN	I-VP	O
during	IN	B-PP	O
her	PRP	B-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
.	.	O	O

Fanconi	NNP	B-NP	B
syndrome	NN	I-NP	I
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
myopathy	NN	B-NP	B
,	,	O	O
is	VBZ	B-VP	O
well	RB	I-VP	O
recognized	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mitochondrial	JJ	B-NP	B
disorders	NNS	I-NP	I
and	CC	O	O
caused	VBN	B-VP	O
by	IN	B-PP	O
depletion	NN	B-NP	O
of	IN	B-PP	O
mtDNA	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
tubular	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	I-NP	O
myopathy	NN	I-NP	B
may	MD	B-VP	O
have	VB	I-VP	O
resulted	VBN	I-VP	O
from	IN	B-PP	O
mitochondrial	JJ	B-NP	B
dysfunction	NN	I-NP	I
which	WDT	B-NP	O
is	VBZ	B-VP	O
triggered	VBN	I-VP	O
by	IN	B-PP	O
tacrolimus	NN	B-NP	O
and	CC	O	O
augmented	VBN	B-VP	O
by	IN	B-PP	O
lamivudine	NN	B-NP	O
.	.	O	O

Antipsychotic	JJ	B-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
thioperamide	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
H3	NN	I-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Experimental	JJ	B-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
evidence	NN	I-NP	O
points	VBZ	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
histaminergic	JJ	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
histamine	NN	B-NP	O
H	NN	I-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
ligands	NNS	I-NP	O
on	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
apomorphine	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	I-VP	O
climbing	VBG	B-VP	O
behavior	NN	B-NP	O
and	CC	I-NP	O
amphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
activities	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Catalepsy	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
,	,	O	O
while	IN	B-SBAR	O
apomorphine	NN	B-NP	O
and	CC	I-NP	O
amphetamine	NN	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
studying	VBG	B-VP	O
climbing	VBG	I-VP	O
behavior	NN	B-NP	O
and	CC	I-NP	O
locomotor	NN	I-NP	O
activities	NNS	I-NP	O
,	,	O	O
respectively.	NN	B-NP	O
(	(	O	O
R	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
alpha	SYM	O	O
-	HYPH	O	O
methylhistamine	NN	B-NP	O
(	(	O	O
RAMH	NN	B-NP	O
)	)	O	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
i.c.v.	NN	I-NP	O
)	)	O	O
and	CC	O	O
thioperamide	NN	B-NP	O
(	(	O	O
THP	NN	B-NP	O
)	)	O	O
,	,	O	O
per	FW	B-ADVP	O
se	FW	I-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
catalepsy	NN	B-NP	B
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
THP	NN	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
haloperidol	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
times	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
RAMH	NN	B-NP	O
significantly	RB	B-ADVP	O
reversed	VBD	B-VP	O
such	PDT	B-NP	O
an	DT	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
THP	NN	B-NP	O
.	.	O	O

RAMH	NN	B-NP	O
per	FW	B-ADVP	O
se	FW	I-ADVP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
locomotor	NN	B-NP	O
time	NN	I-NP	O
,	,	O	O
distance	NN	B-NP	O
traveled	VBN	B-VP	O
and	CC	O	O
average	JJ	B-NP	O
speed	NN	I-NP	O
but	CC	O	O
THP	NN	B-NP	O
per	FW	B-ADVP	O
se	FW	I-ADVP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
these	DT	B-NP	O
parameters	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
,	,	O	O
THP	NN	B-NP	O
reduced	VBD	B-VP	O
locomotor	NN	B-NP	O
time	NN	I-NP	O
,	,	O	O
distance	NN	B-NP	O
traveled	VBN	B-VP	O
and	CC	O	O
average	JJ	B-NP	O
speed	NN	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
RAMH	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
i.c.v.	NN	I-NP	O
)	)	O	O
could	MD	B-VP	O
partially	RB	I-VP	O
reverse	VB	I-VP	O
such	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
THP	NN	B-NP	O
.	.	O	O

Climbing	VBG	B-VP	O
behavior	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
apomorphine	NN	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
THP	NN	B-NP	O
.	.	O	O

Such	PDT	B-NP	O
an	DT	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
reversed	VBN	B-VP	O
in	IN	B-PP	O
presence	NN	B-NP	O
of	IN	B-PP	O
RAMH	NN	B-NP	O
.	.	O	O

THP	NN	B-NP	O
exhibited	VBD	B-VP	O
an	DT	B-NP	O
antipsychotic	JJ	I-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
profile	NN	I-NP	O
by	IN	B-PP	O
potentiating	VBG	B-VP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
reducing	VBG	B-VP	O
amphetamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperactivity	NN	I-NP	B
and	CC	O	O
reducing	VBG	B-VP	O
apomorphine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
climbing	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Such	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
THP	NN	B-NP	O
were	VBD	B-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
RAMH	NN	B-NP	O
indicating	VBG	B-VP	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
histamine	NN	B-NP	O
H	NN	I-NP	O
-	HYPH	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Findings	NNS	B-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
H	NN	B-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
in	IN	B-PP	O
improving	VBG	B-VP	O
the	DT	B-NP	O
refractory	JJ	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

Transient	JJ	B-NP	O
platypnea	NN	I-NP	B
-	HYPH	B-NP	I
orthodeoxia	NN	I-NP	I
-	HYPH	I-NP	I
like	JJ	I-NP	I
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
propafenone	NN	B-NP	O
overdose	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
young	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
Ebstein	NNP	B-NP	B
s	VBZ	B-VP	I
anomaly	RB	B-ADVP	I
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
white	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
Ebstein	NNP	B-NP	B
s	NNS	I-NP	I
anomaly	RB	B-ADVP	I
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
syndrome	NN	I-NP	O
called	VBN	B-VP	O
platypnea	NN	B-NP	B
-	HYPH	B-NP	I
orthodeoxia	NN	I-NP	I
,	,	O	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
massive	JJ	B-NP	O
right	JJ	I-NP	O
-	HYPH	I-NP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
left	JJ	I-NP	O
interatrial	JJ	I-NP	O
shunting	NN	I-NP	O
with	IN	B-PP	O
transient	JJ	B-NP	O
profound	JJ	I-NP	O
hypoxia	NN	I-NP	B
and	CC	I-NP	O
cyanosis	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
shunt	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
via	IN	B-PP	O
a	DT	B-NP	O
patent	NN	I-NP	B
foramen	NNS	I-NP	I
ovale	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
pulmonary	JJ	I-NP	O
artery	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
was	VBD	B-VP	O
probably	RB	I-VP	O
precipitated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
propafenone	NN	I-NP	O
overdose	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
drug	NN	I-NP	O
caused	VBD	B-VP	O
biventricular	JJ	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
due	IN	B-PP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
negative	JJ	I-NP	O
inotropic	JJ	I-NP	O
effect	NN	I-NP	O
,	,	O	O
and	CC	O	O
hypotension	NN	B-NP	B
,	,	O	O
due	IN	B-PP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
peripheral	JJ	I-NP	O
vasodilatory	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
gave	VBD	B-VP	O
rise	NN	B-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
atrial	JJ	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
num	CD	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
consequent	JJ	I-NP	O
stretching	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
foramen	NNS	I-NP	O
ovale	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
creation	NN	I-NP	O
of	IN	B-PP	O
massive	JJ	B-NP	O
right	JJ	I-NP	O
-	HYPH	I-NP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
left	JJ	I-NP	O
shunting	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
case	NN	I-NP	O
this	DT	B-NP	O
interatrial	JJ	I-NP	O
shunt	NN	I-NP	O
was	VBD	B-VP	O
very	RB	I-VP	O
accurately	RB	I-VP	O
detected	VBN	I-VP	O
at	IN	B-PP	O
bubble	NN	B-NP	O
contrast	NN	I-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
Phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
plus	CC	I-NP	O
WR	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
amifostine	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
carcinoma	NN	I-NP	I
:	:	O	O
an	DT	B-NP	O
Eastern	NNP	I-NP	O
Cooperative	NNP	I-NP	O
Oncology	NNP	I-NP	O
Group	NNP	I-NP	O
Study	NNP	I-NP	O
(	(	O	O
E8188	NN	B-NP	O
)	)	O	O
.	.	O	O

Cisplatin	NN	B-NP	O
has	VBZ	B-VP	O
minimal	JJ	B-NP	O
antitumor	JJ	I-NP	O
activity	NN	I-NP	O
when	WRB	B-ADVP	O
used	VBN	B-VP	O
as	IN	B-PP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
or	CC	I-NP	O
third	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

Older	JJR	B-NP	O
reports	NNS	I-NP	O
suggest	VBP	B-VP	O
an	DT	B-NP	O
objective	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
when	WRB	B-ADVP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
is	VBZ	B-VP	O
administered	VBN	I-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
effect	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
cisplatin	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
toxicities	NNS	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
cisplatin	NN	B-NP	O
(	(	O	O
e.g.	FW	B-NP	O
,	,	O	O
nephrotoxicity	NN	B-NP	B
,	,	O	O
ototoxicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
neurotoxicity	NN	B-NP	B
)	)	O	O
have	VBP	B-VP	O
limited	VBN	I-VP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
breast	NN	B-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

WR	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
or	CC	O	O
amifostine	NN	B-NP	O
initially	RB	B-ADVP	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
to	TO	I-VP	O
protect	VB	I-VP	O
military	JJ	B-NP	O
personnel	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
event	NN	I-NP	O
of	IN	B-PP	O
nuclear	JJ	B-NP	O
war	NN	I-NP	O
.	.	O	O

Amifostine	NN	B-NP	O
subsequently	RB	B-ADVP	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
protect	VB	I-VP	O
normal	JJ	B-NP	O
tissues	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
alkylating	VBG	B-NP	O
agents	NNS	I-NP	O
and	CC	O	O
cisplatin	NN	B-NP	O
without	IN	B-PP	O
decreasing	VBG	B-VP	O
the	DT	B-NP	O
antitumor	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Early	JJ	B-NP	O
trials	NNS	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
and	CC	I-NP	O
amifostine	NN	I-NP	O
also	RB	B-ADVP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
,	,	O	O
ototoxicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
neuropathy	NN	B-NP	B
were	VBD	B-VP	O
reduced	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
Phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
plus	CC	I-NP	O
amifostine	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
progressive	JJ	B-NP	O
metastatic	JJ	I-NP	O
breast	NN	I-NP	B
carcinoma	NN	I-NP	I
who	WP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
num	CD	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
chemotherapy	NN	I-NP	O
regimen	NN	I-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
received	VBD	B-VP	O
amifostine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
intravenously	RB	B-ADVP	O
over	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
completion	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
amifostine	NN	I-NP	O
infusion	NN	I-NP	O
,	,	O	O
cisplatin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
hydration	NN	I-NP	O
and	CC	I-NP	O
mannitol	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
cisplatin	NN	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
until	IN	B-SBAR	O
disease	NN	B-NP	O
progression	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
num	CD	B-NP	O
were	VBD	B-VP	O
ineligible	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
eligible	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
partial	JJ	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
for	IN	B-PP	O
an	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Most	JJS	B-NP	O
patients	NNS	I-NP	O
stopped	VBD	B-VP	O
treatment	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
disease	NN	B-NP	O
progression	NN	I-NP	O
.	.	O	O

Neurologic	JJ	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
different	JJ	I-NP	O
life	NN	I-NP	O
-	HYPH	B-VP	O
threatening	VBG	B-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
and	CC	I-NP	O
amifostine	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
a	DT	B-NP	O
tumor	NN	I-NP	B
-	HYPH	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
nor	CC	O	O
reduced	JJ	B-NP	O
toxicity	NN	I-NP	B
to	TO	B-PP	O
normal	JJ	B-NP	O
tissues	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
amifostine	NN	B-NP	O
to	TO	B-PP	O
cisplatin	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
trial	NN	I-NP	O
.	.	O	O

Warfarin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
iliopsoas	NNS	I-NP	O
hemorrhage	NN	I-NP	B
with	IN	B-PP	O
subsequent	JJ	B-NP	O
femoral	JJ	I-NP	B
nerve	NN	I-NP	I
palsy	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
on	IN	B-PP	O
chronic	JJ	B-NP	O
warfarin	NN	I-NP	O
therapy	NN	I-NP	O
who	WP	B-NP	O
sustained	VBD	B-VP	O
a	DT	B-NP	O
minor	JJ	I-NP	O
muscle	NN	I-NP	B
tear	NN	I-NP	I
and	CC	O	O
developed	VBD	B-VP	O
increasing	VBG	I-VP	O
pain	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
flexure	NN	I-NP	O
contracture	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
hip	NN	I-NP	O
.	.	O	O

Surgical	JJ	B-NP	O
exploration	NN	I-NP	O
revealed	VBD	B-VP	O
an	DT	B-NP	O
iliopsoas	JJ	I-NP	O
hematoma	NN	I-NP	B
and	CC	O	O
femoral	JJ	B-NP	O
nerve	NN	I-NP	B
entrapment	NN	I-NP	I
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
femoral	JJ	I-NP	B
nerve	NN	I-NP	I
palsy	NN	I-NP	I
and	CC	O	O
partial	JJ	B-NP	B
loss	NN	I-NP	I
of	IN	B-PP	I
quadriceps	NNS	B-NP	I
functions	NNS	I-NP	I
.	.	O	O

Anticoagulant	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
femoral	JJ	I-NP	B
nerve	NN	I-NP	I
palsy	NN	I-NP	I
represents	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
;	:	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
severe	JJ	B-NP	O
pain	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
inguinal	JJ	I-NP	O
region	NN	I-NP	O
,	,	O	O
varying	VBG	B-VP	O
degrees	NNS	B-NP	O
of	IN	B-PP	O
motor	NN	B-NP	B
and	CC	O	I
sensory	JJ	B-NP	I
impairment	NN	I-NP	I
,	,	O	O
and	CC	O	O
flexure	NN	B-NP	O
contracture	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
involved	VBN	I-NP	O
extremity	NN	I-NP	O
.	.	O	O

Myasthenia	NN	B-NP	B
gravis	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
penicillamine	NN	B-NP	O
and	CC	I-NP	O
chloroquine	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
described	VBN	I-VP	O
a	DT	B-NP	O
unique	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
reversible	JJ	B-NP	O
and	CC	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
myasthenia	NN	I-NP	B
gravis	NN	I-NP	I
after	IN	B-PP	O
penicillamine	NN	B-NP	O
and	CC	I-NP	O
chloroquine	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
.	.	O	O

Although	IN	B-SBAR	O
acetylcholine	NN	B-NP	O
receptor	NN	I-NP	O
antibodies	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
detectable	JJ	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
was	VBD	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
autoimmune	JJ	I-NP	O
process	NN	I-NP	O
.	.	O	O

Nephrotoxicity	NN	B-NP	B
of	IN	B-PP	O
combined	VBN	B-NP	O
cephalothin	JJ	I-NP	O
-	HYPH	I-NP	O
gentamicin	NN	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
tubular	JJ	I-NP	I
necrosis	NN	I-NP	I
,	,	O	O
characterized	VBN	B-VP	O
clinically	RB	B-ADVP	O
by	IN	B-PP	O
acute	JJ	B-NP	O
oliguric	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
while	IN	B-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
cephalothin	JJ	B-NP	O
sodium	NN	I-NP	O
and	CC	I-NP	O
gentamicin	NN	I-NP	O
sulfate	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
given	VBN	I-VP	O
this	DT	B-NP	O
drug	NN	I-NP	O
regimen	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
observed	VBN	I-VP	O
very	RB	B-ADVP	O
carefully	RB	I-ADVP	O
for	IN	B-PP	O
early	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

High	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
antibiotic	JJ	I-NP	O
combination	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
should	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
this	DT	B-NP	O
regimen	NN	I-NP	O
.	.	O	O

Components	NNS	B-NP	O
of	IN	B-PP	O
lemon	NN	B-NP	O
essential	JJ	I-NP	O
oil	NN	I-NP	O
attenuate	NN	I-NP	O
dementia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
dementia	NN	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
s	AFX	B-NP	O
-	HYPH	I-NP	O
limonene	NN	I-NP	O
and	CC	O	O
s	AFX	B-NP	O
-	HYPH	I-NP	O
perillyl	NN	I-NP	O
alcohol	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
test	NN	I-NP	O
(	(	O	O
PA	NN	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
open	JJ	I-NP	O
field	NN	I-NP	O
habituation	NN	I-NP	O
test	NN	I-NP	O
(	(	O	O
OFH	NN	B-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
lemon	JJ	I-NP	O
essential	JJ	I-NP	O
oils	NNS	I-NP	O
showed	VBD	B-VP	O
strong	JJ	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
improve	VB	I-VP	O
memory	NN	B-NP	B
impaired	VBN	B-VP	I
by	IN	B-PP	O
scopolamine	NN	B-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
s	AFX	B-NP	O
-	HYPH	I-NP	O
perillyl	NN	I-NP	O
alcohol	NN	I-NP	O
relieved	VBD	B-VP	O
the	DT	B-NP	O
deficit	NN	I-NP	B
of	IN	B-PP	I
associative	JJ	B-NP	I
memory	NN	I-NP	I
in	IN	B-PP	O
PA	NN	B-NP	O
only	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
improve	VB	I-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
associative	JJ	B-NP	O
memory	NN	I-NP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
OFH	NN	B-NP	O
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
neurotransmitter	NN	B-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
day	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
dopamine	NN	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
vehicle	NN	I-NP	O
/	SYM	B-NP	O
scopolamine	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
vehicle	NN	I-NP	O
/	SYM	I-NP	O
vehicle	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
but	CC	O	O
this	DT	B-NP	O
phenomenon	NN	I-NP	O
was	VBD	B-VP	O
reversed	VBN	I-VP	O
when	WRB	B-ADVP	O
s	AFX	O	O
-	HYPH	O	O
limonene	NN	B-NP	O
or	CC	O	O
s	AFX	B-NP	O
-	HYPH	I-NP	O
perillyl	NN	I-NP	O
alcohol	NN	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
.	.	O	O

Simultaneously	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
num	CD	I-NP	O
lemon	NN	I-NP	O
essential	JJ	I-NP	O
oil	NN	I-NP	O
components	NNS	I-NP	O
could	MD	B-VP	O
inhibit	VB	I-VP	O
acetylcholinesterase	NN	B-NP	O
activity	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Ellman	NNP	I-NP	O
method	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
selective	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT6	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
Ro4368554	NN	I-NP	O
restores	VBZ	B-VP	O
memory	NN	B-NP	O
performance	NN	I-NP	O
in	IN	B-PP	O
cholinergic	JJ	B-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
memory	NN	B-NP	B
deficiency	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Antagonists	NNS	B-NP	O
at	IN	B-PP	O
serotonin	NN	B-NP	O
type	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
)	)	O	O
receptors	NNS	B-NP	O
show	VBP	B-VP	O
activity	NN	B-NP	O
in	IN	B-PP	O
models	NNS	B-NP	O
of	IN	B-PP	O
learning	NN	B-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
mechanism	NN	I-NP	O
(	(	I-NP	O
s	NNS	I-NP	O
)	)	O	O
are	VBP	B-VP	O
not	RB	I-VP	O
well	RB	I-VP	O
understood	VBN	I-VP	O
,	,	O	O
these	DT	B-NP	O
effects	NNS	I-NP	O
may	MD	B-VP	O
involve	VB	I-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
acetylcholine	NN	B-NP	O
(	(	O	O
ACh	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
characterize	VB	I-VP	O
the	DT	B-NP	O
cognitive	JJ	I-NP	O
-	HYPH	I-NP	O
enhancing	VBG	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
antagonist	NN	I-NP	O
Ro4368554	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
benzenesulfonyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
(	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
piperazin	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yl	NN	I-NP	O
)	)	I-NP	O
1H	NN	I-NP	O
-	HYPH	O	O
indole	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
object	NN	I-NP	O
recognition	NN	I-NP	O
task	NN	I-NP	O
employing	VBG	B-VP	O
a	DT	B-NP	O
cholinergic	JJ	I-NP	O
(	(	O	O
scopolamine	NN	B-NP	O
pretreatment	NN	I-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
serotonergic	JJ	I-NP	O
-	HYPH	I-NP	O
(	(	O	O
tryptophan	NN	B-NP	O
(	(	O	O
TRP	NN	B-NP	O
)	)	O	O
depletion	NN	B-NP	O
)	)	O	O
deficient	JJ	B-NP	O
model	NN	I-NP	O
,	,	O	O
and	CC	O	O
compared	VBD	B-VP	O
its	PRP$	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
acetylcholinesterase	NN	I-NP	O
inhibitor	NN	I-NP	O
metrifonate	NN	I-NP	O
.	.	O	O

Initial	JJ	B-NP	O
testing	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
forgetting	VBG	I-NP	O
task	NN	I-NP	O
employing	VBG	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
delay	NN	I-NP	O
between	IN	B-PP	O
training	NN	B-NP	O
and	CC	I-NP	O
testing	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
metrifonate	NN	B-NP	O
improved	VBD	B-VP	O
object	NN	B-NP	O
recognition	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
Ro4368554	NN	B-NP	O
was	VBD	B-VP	O
inactive	JJ	B-ADJP	O
.	.	O	O

Both	CC	O	O
,	,	O	O
Ro4368554	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
intraperitoneally	RB	B-ADVP	O
(	(	O	O
i.p.	RB	B-ADVP	O
)	)	O	O
)	)	O	O
and	CC	O	O
metrifonate	NN	B-NP	O
reversed	VBD	B-VP	O
memory	NN	B-NP	B
deficits	NNS	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
and	CC	I-NP	O
TRP	NN	I-NP	O
depletion	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
Ro4368554	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
improve	VB	I-VP	O
a	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
retention	NN	I-NP	O
deficit	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
reversed	VBD	B-VP	O
a	DT	B-NP	O
cholinergic	JJ	I-NP	O
and	CC	O	O
a	DT	B-NP	O
serotonergic	JJ	I-NP	O
memory	NN	I-NP	B
deficit	NN	I-NP	I
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
both	DT	B-NP	O
mechanisms	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
facilitation	NN	I-NP	O
of	IN	B-PP	O
object	NN	B-NP	O
memory	NN	I-NP	O
by	IN	B-PP	O
Ro4368554	NN	B-NP	O
and	CC	O	O
,	,	O	O
possibly	RB	B-ADVP	O
,	,	O	O
other	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

Lone	NN	B-NP	O
atrial	JJ	I-NP	B
fibrillation	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
creatine	NN	B-NP	O
monohydrate	NN	I-NP	O
supplementation	NN	I-NP	O
.	.	O	O

Atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
in	IN	B-PP	O
young	JJ	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
structural	JJ	B-NP	O
heart	NN	I-NP	B
disease	NN	I-NP	I
is	VBZ	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
is	VBZ	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
this	DT	B-NP	O
population	NN	I-NP	O
,	,	O	O
reversible	JJ	B-NP	O
causes	NNS	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
identified	VBN	I-VP	O
and	CC	O	O
resolved	VBN	B-VP	O
.	.	O	O

Thyroid	JJ	B-NP	B
disorders	NNS	I-NP	I
,	,	O	O
illicit	JJ	B-NP	O
drug	NN	I-NP	O
or	CC	I-NP	O
stimulant	NN	I-NP	O
use	NN	I-NP	O
,	,	O	O
and	CC	O	O
acute	JJ	B-NP	B
alcohol	NN	I-NP	I
intoxication	NN	I-NP	I
are	VBP	B-VP	O
among	IN	B-PP	O
these	DT	B-NP	O
causes	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Caucasian	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
came	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
in	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
with	IN	B-PP	O
rapid	JJ	B-NP	O
ventricular	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

His	PRP$	B-NP	O
medical	JJ	I-NP	O
history	NN	I-NP	O
was	VBD	B-VP	O
unremarkable	JJ	B-ADJP	O
,	,	O	O
except	IN	B-PP	O
for	IN	B-PP	O
minor	JJ	B-NP	O
fractures	NNS	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
fingers	NNS	I-NP	O
and	CC	I-NP	O
foot	NN	I-NP	O
.	.	O	O

Thyroid	NN	B-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
hormone	NN	B-NP	O
,	,	O	O
magnesium	NN	B-NP	O
,	,	O	O
and	CC	O	O
potassium	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
within	IN	B-PP	O
normal	JJ	B-NP	O
limits	NNS	I-NP	O
,	,	O	O
urine	NN	B-NP	O
drug	NN	I-NP	O
screen	NN	I-NP	O
was	VBD	B-VP	O
negative	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
alcohol	NN	B-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
denied	VBN	I-VP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
questioned	VBN	I-VP	O
about	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
herbal	JJ	B-NP	O
products	NNS	I-NP	O
and	CC	I-NP	O
supplements	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
creatine	NN	B-NP	O
monohydrate	NN	I-NP	O
was	VBD	B-VP	O
revealed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
,	,	O	O
anticoagulated	VBN	B-VP	O
with	IN	B-PP	O
unfractionated	JJ	B-NP	O
heparin	NN	I-NP	O
,	,	O	O
and	CC	O	O
given	VBN	B-VP	O
intravenous	JJ	B-NP	O
diltiazem	NN	I-NP	O
for	IN	B-PP	O
rate	NN	B-NP	O
control	NN	I-NP	O
and	CC	O	O
intravenous	JJ	B-NP	O
amiodarone	NN	I-NP	O
for	IN	B-PP	O
rate	NN	B-NP	O
and	CC	I-NP	O
rhythm	NN	I-NP	O
control	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
discharged	VBN	B-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
receiving	VBG	I-VP	O
metoprolol	NN	B-NP	O
and	CC	I-NP	O
aspirin	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
plans	NNS	B-NP	O
for	IN	B-PP	O
echocardiography	NN	B-NP	O
and	CC	O	O
nuclear	JJ	B-NP	O
imaging	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
perfusion	NN	B-NP	O
.	.	O	O

Exogenous	JJ	B-NP	O
creatine	NN	I-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
by	IN	B-PP	O
athletes	NNS	B-NP	O
to	TO	B-VP	O
theoretically	RB	I-VP	O
improve	VB	I-VP	O
exercise	NN	B-NP	O
performance	NN	I-NP	O
.	.	O	O

Vegetarians	NNS	B-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
take	VB	I-VP	O
creatine	NN	B-NP	O
to	TO	B-VP	O
replace	VB	I-VP	O
what	WP	B-NP	O
they	PRP	B-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
consuming	VBG	I-VP	O
from	IN	B-PP	O
meat	NN	B-NP	O
,	,	O	O
fish	NN	B-NP	O
,	,	O	O
and	CC	O	O
other	JJ	B-NP	O
animal	NN	I-NP	O
products	NNS	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
anecdotal	JJ	I-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
linked	VBN	I-VP	O
creatine	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
arrhythmia	NN	B-NP	B
.	.	O	O

Clinicians	NNS	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
diligent	JJ	B-ADJP	O
when	WRB	B-ADVP	O
interviewing	VBG	B-VP	O
patients	NNS	B-NP	O
about	IN	B-PP	O
their	PRP$	B-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
histories	NNS	I-NP	O
and	CC	O	O
include	VBP	B-VP	O
questions	NNS	B-NP	O
about	IN	B-PP	O
their	PRP$	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
herbal	JJ	B-NP	O
products	NNS	I-NP	O
and	CC	O	O
dietary	JJ	B-NP	O
supplements	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
report	VB	I-VP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
frequently	RB	B-NP	O
consumed	VBN	I-NP	O
supplements	NNS	I-NP	O
and	CC	O	O
herbal	JJ	B-NP	O
products	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
Food	NNP	I-NP	O
and	CC	I-NP	O
Drug	NNP	I-NP	O
Administration	NNP	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
developmental	JJ	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
selective	JJ	B-NP	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
selective	JJ	B-NP	O
cyclooxygenase	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitors	NNS	I-NP	O
in	IN	B-PP	O
CRL	NN	B-NP	O
:	:	O	O
(	(	B-LST	O
WI	LS	I-LST	O
)	)	O	O
WUBR	NNP	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
-	SYM	B-NP	O
-	HYPH	I-NP	O
DFU	NN	I-NP	O
and	CC	I-NP	O
piroxicam	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Cyclooxygenase	NN	B-NP	O
(	(	O	O
COX	NN	B-NP	O
)	)	O	O
inhibitors	NNS	B-NP	O
are	VBP	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	O	O
most	RBS	B-ADVP	O
often	RB	I-ADVP	O
ingested	VBN	B-VP	O
drugs	NNS	B-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

Unlike	IN	B-PP	O
general	JJ	B-NP	O
toxicity	NN	I-NP	B
data	NNS	I-NP	O
,	,	O	O
their	PRP$	B-NP	O
prenatal	JJ	I-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
extensively	RB	I-VP	O
studied	VBN	I-VP	O
before	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experiment	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
developmental	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
(	(	O	O
piroxicam	NN	B-NP	O
)	)	O	O
and	CC	O	O
selective	JJ	B-NP	O
(	(	O	O
DFU	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dimethyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
(	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorophenyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methylsulphonyl	NN	I-NP	O
)	)	I-NP	O
phenyl	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
5H	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
furanon	NN	I-NP	O
)	)	O	O
COX	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Drugs	NNS	B-NP	O
were	VBD	B-VP	O
separately	RB	B-ADVP	O
,	,	O	O
orally	RB	B-ADVP	O
once	RB	I-ADVP	O
daily	RB	B-ADVP	O
dosed	VBN	B-VP	O
to	TO	B-PP	O
pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

Doses	NNS	B-NP	O
were	VBD	B-VP	O
set	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
piroxicam	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
DFU	NN	B-NP	O
.	.	O	O

Fetuses	NNS	B-NP	O
were	VBD	B-VP	O
delivered	VBN	I-VP	O
on	IN	B-PP	O
GD	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
routinely	RB	B-VP	O
examined	VBN	I-VP	O
.	.	O	O

Comprehensive	JJ	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
developmental	JJ	I-NP	O
measurements	NNS	I-NP	O
were	VBD	B-VP	O
done	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
pooled	JJ	I-NP	O
statistical	JJ	I-NP	O
analysis	NN	I-NP	O
for	IN	B-PP	O
ventricular	JJ	B-NP	B
septal	JJ	I-NP	I
(	(	O	I
VSD	NN	B-NP	I
)	)	O	I
and	CC	O	I
midline	NN	B-NP	I
(	(	O	I
MD	NN	B-NP	I
)	)	O	I
defects	NNS	B-NP	I
was	VBD	B-VP	O
performed	VBN	I-VP	O
for	IN	B-PP	O
rat	NN	B-NP	O
fetuses	NNS	I-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
piroxicam	NN	B-NP	O
,	,	O	O
selective	JJ	B-ADJP	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
selective	JJ	B-NP	O
COX	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitor	NN	I-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
present	JJ	B-NP	O
and	CC	I-NP	O
historic	JJ	I-NP	O
data	NNS	I-NP	O
.	.	O	O

Maternal	JJ	B-NP	O
toxicity	NN	I-NP	B
,	,	O	O
intrauterine	JJ	B-NP	B
growth	NN	I-NP	I
retardation	NN	I-NP	I
,	,	O	O
and	CC	O	O
increase	NN	B-NP	B
of	IN	B-PP	I
external	JJ	B-NP	I
and	CC	I-NP	I
skeletal	JJ	I-NP	I
variations	NNS	I-NP	I
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
piroxicam	NN	B-NP	O
.	.	O	O

Decrease	NN	B-NP	O
of	IN	B-PP	O
fetal	JJ	B-NP	O
length	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
only	JJ	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DFU	NN	I-NP	O
developmental	JJ	I-NP	O
toxicity	NN	I-NP	B
observed	VBN	B-VP	O
in	IN	B-PP	O
pups	NNS	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
compound	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Lack	NN	B-NP	O
of	IN	B-PP	O
teratogenicity	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
piroxicam	NN	B-NP	O
and	CC	I-NP	O
DFU	NN	I-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Prenatal	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
COX	NN	I-NP	O
inhibitors	NNS	I-NP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VSD	NN	B-NP	O
and	CC	I-NP	O
MD	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
historic	JJ	B-NP	O
control	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
with	IN	I-PP	O
selective	JJ	B-NP	O
COX	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Both	CC	O	O
selective	JJ	B-ADJP	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
selective	JJ	B-NP	O
COX	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
inhibitors	NNS	I-NP	O
were	VBD	B-VP	O
toxic	JJ	B-ADJP	O
for	IN	B-PP	O
rats	NNS	B-NP	O
fetuses	NNS	I-NP	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Unlike	IN	B-PP	O
DFU	NN	B-NP	O
,	,	O	O
piroxicam	NN	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
highly	RB	B-ADJP	O
toxic	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
dams	NNS	I-NP	O
.	.	O	O

Prenatal	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
selective	JJ	B-NP	O
COX	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitors	NNS	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
septal	JJ	I-NP	I
and	CC	I-NP	I
midline	NN	I-NP	I
defects	NNS	I-NP	I
in	IN	B-PP	O
rat	NN	B-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
selective	JJ	B-NP	O
drugs	NNS	I-NP	O
and	CC	O	O
historic	JJ	B-NP	O
control	NN	I-NP	O
.	.	O	O

Protective	JJ	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
neuroactive	JJ	B-NP	O
steroids	NNS	I-NP	O
against	IN	B-PP	O
cocaine	NN	B-NP	O
kindled	VBD	B-VP	O
-	HYPH	B-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Neuroactive	JJ	B-NP	O
steroids	NNS	I-NP	O
demonstrate	VBP	B-VP	O
pharmacological	JJ	B-NP	O
actions	NNS	I-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
relevance	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
host	NN	I-NP	O
of	IN	B-PP	O
neurological	JJ	B-NP	B
and	CC	I-NP	I
psychiatric	JJ	I-NP	I
disorders	NNS	I-NP	I
.	.	O	O

They	PRP	B-NP	O
offer	VBP	B-VP	O
protection	NN	B-NP	O
against	IN	B-PP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
models	NNS	B-NP	O
and	CC	O	O
seem	VBP	B-VP	O
to	TO	I-VP	O
inhibit	VB	I-VP	O
certain	JJ	B-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	B
dependence	NN	I-NP	I
in	IN	B-PP	O
preclinical	JJ	B-NP	O
assessments	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
num	CD	B-NP	O
endogenous	JJ	I-NP	O
and	CC	O	O
num	CD	B-NP	O
synthetic	JJ	I-NP	O
neuroactive	JJ	I-NP	O
steroid	NN	I-NP	O
that	WDT	B-NP	O
positively	RB	B-ADVP	O
modulate	VBP	B-VP	O
the	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
aminobutyric	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
GABA	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
)	)	O	O
receptor	NN	B-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
sensitivity	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
convulsant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
engendered	VBN	B-VP	O
by	IN	B-PP	O
repeated	VBN	B-NP	O
cocaine	NN	I-NP	O
administration	NN	I-NP	O
(	(	O	O
seizure	NN	B-NP	B
kindling	NN	I-NP	O
)	)	O	O
.	.	O	O

Allopregnanolone	NN	B-NP	O
(	(	O	O
3alpha	NN	B-NP	O
-	HYPH	B-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
5alpha	NN	I-NP	O
-	HYPH	B-NP	O
pregnan	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
pregnanolone	NN	B-NP	O
(	(	O	O
3alpha	NN	B-NP	O
-	HYPH	B-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
5beta	NN	I-NP	O
-	HYPH	B-NP	O
pregnan	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
ganaxolone	NN	B-NP	O
(	(	O	O
a	DT	B-NP	O
synthetic	JJ	I-NP	O
derivative	NN	I-NP	O
of	IN	B-PP	O
allopregnanolone	NN	B-NP	O
3alpha	NN	I-NP	O
-	HYPH	B-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
3beta	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
5alpha	NN	I-NP	O
-	HYPH	B-NP	O
pregnan	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
suppress	VB	I-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
(	(	O	O
anticonvulsant	JJ	B-NP	O
effect	NN	I-NP	O
)	)	O	O
and	CC	O	O
development	NN	B-NP	O
(	(	O	O
antiepileptogenic	JJ	B-NP	O
effect	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
kindled	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
male	JJ	B-NP	O
,	,	I-NP	O
Swiss	JJ	I-NP	O
-	HYPH	I-NP	O
Webster	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Kindled	VBN	B-NP	O
seizures	NNS	I-NP	B
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
daily	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
cocaine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
positive	JJ	I-NP	O
GABA	NN	I-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
modulators	NNS	B-NP	O
suppressed	VBD	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
kindled	JJ	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
whereas	IN	O	O
only	RB	B-NP	O
allopregnanolone	NN	I-NP	O
and	CC	I-NP	O
ganaxolone	NN	I-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
kindling	NN	B-NP	O
.	.	O	O

Allopregnanolone	NN	B-NP	O
and	CC	I-NP	O
pregnanolone	NN	I-NP	O
,	,	B-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
ganaxolone	NN	B-NP	O
,	,	O	O
also	RB	B-ADVP	O
reduced	VBD	B-VP	O
cumulative	JJ	B-NP	O
lethality	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
kindling	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
some	DT	B-NP	O
neuroactive	JJ	I-NP	O
steroids	NNS	I-NP	O
attenuate	VBP	B-VP	O
convulsant	NN	B-NP	O
and	CC	O	O
sensitizing	VBG	B-VP	O
properties	NNS	B-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	O	O
add	VB	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
growing	VBG	I-NP	O
literature	NN	I-NP	O
on	IN	B-PP	O
their	PRP$	B-NP	O
potential	JJ	I-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
of	IN	B-PP	O
abuse	NN	B-NP	O
.	.	O	O

Kidney	NN	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
morphology	NN	I-NP	O
after	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
cyclosporine	NN	B-NP	O
A	NN	I-NP	O
,	,	O	O
tacrolimus	NN	B-NP	O
and	CC	I-NP	O
sirolimus	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Sirolimus	NN	B-NP	O
(	(	O	O
SRL	NN	B-NP	O
)	)	O	O
may	MD	B-VP	O
supplement	VB	I-VP	O
calcineurin	NN	B-NP	O
inhibitors	NNS	I-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
organ	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
are	VBP	B-VP	O
nephrotoxic	JJ	B-ADJP	B
,	,	O	O
but	CC	O	O
SRL	NN	B-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
act	VB	I-VP	O
differently	RB	B-ADVP	O
displaying	VBG	B-VP	O
only	RB	B-NP	O
minor	JJ	I-NP	O
nephrotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
this	DT	B-NP	O
question	NN	I-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
open	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
protocols	NNS	I-NP	O
where	WRB	B-ADVP	O
SRL	NN	B-NP	O
was	VBD	B-VP	O
combined	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
calcineurin	NN	I-NP	O
inhibitor	NN	I-NP	O
indications	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
synergistic	JJ	I-NP	O
nephrotoxic	JJ	I-NP	B
effect	NN	I-NP	O
were	VBD	B-VP	O
described	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
further	RBR	B-ADVP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
morphological	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
of	IN	B-PP	O
male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
either	CC	O	O
cyclosporine	NN	B-NP	O
A	NN	I-NP	O
(	(	O	O
CsA	NN	B-NP	O
)	)	O	O
,	,	O	O
tacrolimus	NN	B-NP	O
(	(	O	O
FK506	NN	B-NP	O
)	)	O	O
or	CC	O	O
SRL	NN	B-NP	O
as	IN	B-PP	O
monotherapies	NNS	B-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
different	JJ	B-NP	O
combinations	NNS	I-NP	O
.	.	O	O

For	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
CsA	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
given	VBN	B-VP	O
orally	RB	B-ADVP	O
)	)	O	O
,	,	O	O
FK506	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
given	VBN	B-VP	O
orally	RB	B-ADVP	O
)	)	O	O
or	CC	O	O
SRL	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
given	VBN	B-VP	O
intraperitoneally	RB	B-ADVP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
once	RB	B-ADVP	O
a	DT	B-NP	O
day	NN	I-NP	O
as	IN	B-PP	O
these	DT	B-NP	O
doses	NNS	I-NP	O
have	VBP	B-VP	O
earlier	RBR	I-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
achieve	VB	I-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
conscious	JJ	I-NP	O
catheterized	VBN	I-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
GFR	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
clearance	NN	I-NP	O
of	IN	B-PP	O
Cr	NN	B-NP	O
(	(	O	O
EDTA	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
morphological	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
included	VBD	B-VP	O
a	DT	B-NP	O
semi	AFX	I-NP	O
-	HYPH	I-NP	O
quantitative	JJ	I-NP	O
scoring	NN	I-NP	O
system	NN	I-NP	O
analysing	VBG	B-VP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
striped	VBN	B-NP	O
fibrosis	NN	I-NP	B
,	,	O	O
subcapsular	JJ	B-NP	O
fibrosis	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
basophilic	JJ	B-NP	O
tubules	NNS	I-NP	O
,	,	O	O
plus	CC	B-PP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
stereological	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
grade	NN	I-NP	O
of	IN	B-PP	O
fibrosis	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
stained	VBD	B-VP	O
with	IN	B-PP	O
Sirius	NNP	B-NP	O
Red	NNP	I-NP	O
.	.	O	O

CsA	NN	B-NP	O
,	,	I-NP	O
FK506	NN	I-NP	O
and	CC	I-NP	O
SRL	NN	I-NP	O
all	RB	B-ADVP	O
significantly	RB	I-ADVP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
GFR	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
further	JJ	I-NP	O
deterioration	NN	I-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
when	WRB	B-ADVP	O
CsA	NN	B-NP	O
was	VBD	B-VP	O
combined	VBN	I-VP	O
with	IN	B-PP	O
either	CC	O	O
FK506	NN	B-NP	O
or	CC	O	O
SRL	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
GFR	NN	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
FK506	NN	B-NP	O
plus	CC	O	O
SRL	NN	B-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
single	JJ	I-NP	O
substances	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
morphological	JJ	I-NP	O
changes	NNS	I-NP	O
presented	VBD	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
pattern	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
semi	AFX	I-NP	O
-	HYPH	I-NP	O
quantitative	JJ	I-NP	O
scoring	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
worst	JJS	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
CsA	NN	B-NP	O
plus	CC	I-NP	O
SRL	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
grade	NN	I-NP	O
of	IN	B-PP	O
fibrosis	NN	B-NP	B
also	RB	B-ADVP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
proportion	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
group	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
FK506	NN	I-NP	O
plus	CC	I-NP	O
SRL	NN	I-NP	O
combination	NN	I-NP	O
showed	VBD	B-VP	O
only	RB	B-NP	O
a	DT	I-NP	O
marginally	RB	I-NP	O
higher	JJR	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
fibrosis	NN	B-NP	B
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
rat	NN	I-NP	O
study	NN	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
synergistic	JJ	I-NP	O
nephrotoxic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
CsA	NN	B-NP	O
plus	CC	I-NP	O
SRL	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
FK506	NN	B-NP	O
plus	CC	O	O
SRL	NN	B-NP	O
was	VBD	B-VP	O
better	RBR	B-ADJP	O
tolerated	VBN	I-ADJP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
fucoidan	NN	B-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
collagenase	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
intracerebral	JJ	I-NP	B
hemorrhage	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Inflammatory	JJ	B-NP	O
cells	NNS	I-NP	O
are	VBP	B-VP	O
postulated	VBN	I-VP	O
to	TO	I-VP	O
mediate	VB	I-VP	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	B
damage	NN	I-NP	I
following	VBG	B-PP	O
ischemic	JJ	B-NP	B
stroke	NN	I-NP	I
.	.	O	O

Intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
more	JJR	B-NP	O
inflammation	NN	I-NP	B
than	IN	B-PP	O
ischemic	JJ	B-NP	B
stroke	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
tested	VBD	B-VP	O
the	DT	B-NP	O
sulfated	JJ	I-NP	O
polysaccharide	NN	I-NP	O
fucoidan	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
reduce	VB	I-VP	O
inflammatory	JJ	B-NP	O
brain	NN	I-NP	B
damage	NN	I-NP	I
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
bacterial	JJ	B-NP	O
collagenase	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
caudate	JJ	I-NP	O
nucleus	NN	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
day	NN	I-NP	O
intravenous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
fucoidan	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
h	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
or	CC	O	O
vehicle	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
hematoma	NN	I-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
by	IN	B-PP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
.	.	O	O

Motor	NNP	B-NP	O
behavior	NN	I-NP	O
,	,	O	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
,	,	O	O
and	CC	O	O
skilled	VBD	B-VP	O
forelimb	NN	B-NP	O
function	NN	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
repeatedly	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Fucoidan	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
exhibited	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
impaired	JJ	B-NP	B
blood	NN	I-NP	I
clotting	NN	I-NP	I
and	CC	I-NP	O
hemodilution	NN	I-NP	B
,	,	O	O
had	VBD	B-VP	O
larger	JJR	B-NP	O
hematomas	NNS	I-NP	B
,	,	O	O
and	CC	O	O
tended	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
less	JJR	B-NP	O
inflammation	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
vicinity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hematoma	NN	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

They	PRP	B-NP	O
showed	VBD	B-VP	O
significantly	RB	B-NP	O
more	RBR	I-NP	O
rapid	JJ	I-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
week	NN	I-NP	O
following	VBG	B-PP	O
hemorrhage	NN	B-NP	B
and	CC	O	O
better	JJR	B-NP	O
memory	NN	I-NP	O
retention	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
white	JJ	I-NP	B
matter	NN	I-NP	I
edema	NN	I-NP	I
and	CC	O	O
eventual	JJ	B-NP	O
neuronal	JJ	I-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
adjacent	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
hematoma	NN	I-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Investigation	NN	B-NP	O
of	IN	B-PP	O
more	RBR	B-NP	O
specific	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
agents	NNS	I-NP	O
and	CC	O	O
hemodiluting	VBG	B-NP	O
agents	NNS	I-NP	O
are	VBP	B-VP	O
warranted	VBN	I-VP	O
in	IN	B-PP	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
.	.	O	O

Paracetamol	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
coma	NN	I-NP	B
,	,	O	O
metabolic	JJ	B-NP	B
acidosis	NN	I-NP	I
,	,	O	O
renal	JJ	B-NP	B
and	CC	I-NP	I
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
metabolic	JJ	B-NP	B
acidosis	NN	I-NP	I
,	,	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
and	CC	O	I
hepatic	JJ	B-NP	I
failure	NN	I-NP	I
following	VBG	B-PP	O
paracetamol	NN	B-NP	O
ingestion	NN	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
diagnostic	JJ	I-NP	O
difficulty	NN	I-NP	O
at	IN	B-PP	O
presentation	NN	B-NP	O
is	VBZ	B-VP	O
highlighted	VBN	I-VP	O
.	.	O	O

Continuous	JJ	B-NP	O
arteriovenous	JJ	I-NP	O
haemofiltration	NN	I-NP	O
proved	VBD	B-VP	O
a	DT	B-NP	O
valuable	JJ	I-NP	O
means	NNS	I-NP	O
of	IN	B-PP	O
maintaining	VBG	B-VP	O
fluid	NN	B-NP	O
and	CC	I-NP	O
electrolyte	NN	I-NP	O
balance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
.	.	O	O

Hepatic	JJ	B-NP	O
reactions	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
ketoconazole	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
Kingdom	NNP	I-NP	O
.	.	O	O

Ketoconazole	NN	B-NP	O
was	VBD	B-VP	O
introduced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
Kingdom	NNP	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

By	IN	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
Committee	NNP	I-NP	O
on	IN	B-PP	O
Safety	NNP	B-NP	O
of	IN	B-PP	O
Medicines	NNP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
num	CD	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
possible	JJ	B-NP	O
hepatotoxicity	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
deaths	NNS	I-NP	B
.	.	O	O

An	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
adequately	RB	I-VP	O
followed	VBN	I-VP	O
up	RP	B-PRT	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
including	VBG	B-PP	O
num	CD	B-NP	O
deaths	NNS	I-NP	B
,	,	O	O
were	VBD	B-VP	O
probably	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
remainder	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
possibly	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
unlikely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
so	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
unclassifiable	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
probable	JJ	I-NP	O
cases	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
,	,	O	O
with	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
being	VBG	B-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
in	IN	B-PP	O
women	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
jaundice	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
well	RB	I-NP	O
validated	VBN	I-NP	O
cases	NNS	I-NP	O
occurred	VBD	B-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
liver	NN	I-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
suggested	VBD	B-VP	O
hepatocellular	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
;	:	O	O
the	DT	B-NP	O
rest	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
mixed	VBN	I-NP	O
pattern	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
histological	JJ	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
often	RB	B-ADVP	O
showed	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
cholestasis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
.	.	O	O

Allergic	JJ	B-NP	O
manifestations	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
rash	NN	B-NP	B
and	CC	I-NP	O
eosinophilia	NN	I-NP	B
were	VBD	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

Hepatitis	NN	B-NP	B
was	VBD	B-VP	O
usually	RB	B-ADVP	O
reversible	JJ	B-ADJP	O
when	WRB	B-ADVP	O
treatment	NN	B-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
returning	VBG	B-VP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
after	IN	B-PP	O
an	DT	B-NP	O
average	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
deaths	NNS	I-NP	B
probably	RB	B-ADVP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
ketoconazole	NN	B-NP	O
treatment	NN	I-NP	O
the	DT	B-NP	O
drug	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
continued	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
jaundice	NN	B-NP	B
and	CC	O	O
other	JJ	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
.	.	O	O

Clinical	JJ	B-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
monitoring	NN	I-NP	O
at	IN	B-PP	O
regular	JJ	B-NP	O
intervals	NNS	I-NP	O
for	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
is	VBZ	B-VP	O
advised	VBN	I-VP	O
during	IN	B-PP	O
long	JJ	B-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
ketoconazole	NN	B-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
possible	JJ	B-NP	O
serious	JJ	I-NP	O
hepatic	JJ	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Combined	VBN	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
prolonged	VBN	B-NP	O
prostaglandin	NN	I-NP	O
E1	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
haemodilution	NN	I-NP	B
on	IN	B-PP	O
human	JJ	B-NP	O
hepatic	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

Combined	VBN	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
prolonged	VBN	B-NP	O
prostaglandin	NN	I-NP	O
E1	NN	I-NP	O
(	(	O	O
PGE1	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
haemodilution	NN	I-NP	B
on	IN	B-PP	O
hepatic	JJ	B-NP	O
function	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
hip	NN	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
;	:	O	O
those	DT	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
A	NN	I-NP	O
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
controlled	VBN	B-NP	O
hypotension	NN	I-NP	B
alone	RB	B-ADVP	O
,	,	O	O
those	DT	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
B	NN	I-NP	O
to	TO	B-PP	O
haemodilution	NN	B-NP	B
alone	RB	B-ADVP	O
and	CC	O	O
those	DT	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
C	NN	I-NP	O
to	TO	B-PP	O
both	CC	O	O
controlled	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
haemodilution	NN	I-NP	B
.	.	O	O

Haemodilution	NN	B-NP	B
in	IN	B-PP	O
groups	NNS	B-NP	O
B	NN	B-NP	O
and	CC	O	O
C	NN	B-NP	O
was	VBD	B-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
withdrawing	VBG	B-VP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
mL	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
and	CC	O	O
replacing	VBG	B-VP	O
it	PRP	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
dextran	NN	B-NP	O
solution	NN	I-NP	O
,	,	O	O
and	CC	O	O
final	JJ	B-NP	O
haematocrit	NN	I-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

Controlled	VBN	B-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
groups	NNS	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
C	NN	I-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
with	IN	B-PP	O
PGE1	NN	B-NP	O
to	TO	B-VP	O
maintain	VB	I-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

Measurements	NNS	B-NP	O
included	VBD	B-VP	O
arterial	JJ	B-NP	O
ketone	NN	I-NP	O
body	NN	I-NP	O
ratio	NN	I-NP	O
(	(	O	O
AKBR	NN	B-NP	O
,	,	O	O
aceto	AFX	B-NP	O
-	HYPH	I-NP	O
acetate	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxybutyrate	NN	I-NP	O
)	)	O	O
and	CC	O	O
clinical	JJ	B-NP	O
hepatic	JJ	I-NP	O
function	NN	I-NP	O
parameters	NNS	I-NP	O
.	.	O	O

AKBR	NN	B-NP	O
and	CC	I-NP	O
biological	JJ	I-NP	O
hepatic	JJ	I-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
in	IN	B-PP	O
groups	NNS	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
B	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
group	NN	B-NP	O
C	NN	I-NP	O
,	,	O	O
AKBR	NN	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
and	CC	B-PP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
recovery	NN	B-NP	O
of	IN	B-PP	O
normotension	NN	B-NP	O
,	,	O	O
and	CC	O	O
SGOT	NN	B-NP	O
,	,	O	O
SGPT	NN	B-NP	O
,	,	O	O
LDH	NN	B-NP	O
and	CC	O	O
total	JJ	B-NP	O
bilirubin	NN	I-NP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
increases	NNS	I-NP	O
after	IN	B-PP	O
operation	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
prolonged	VBN	I-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
PGE1	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
moderate	JJ	I-NP	O
haemodilution	NN	I-NP	B
would	MD	B-VP	O
cause	VB	I-VP	O
impairment	NN	B-NP	B
of	IN	B-PP	I
hepatic	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
:	:	O	O
filling	VBG	B-VP	O
the	DT	B-NP	O
bench	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
bedside	NN	I-NP	O
gap	NN	I-NP	O
.	.	O	O

Levodopa	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
effective	JJ	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
dopamine	NN	I-NP	O
precursor	NN	I-NP	O
is	VBZ	B-VP	O
complicated	VBN	I-VP	O
by	IN	B-PP	O
highly	RB	B-VP	O
disabling	VBG	I-VP	O
fluctuations	NNS	B-NP	O
and	CC	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

Although	IN	B-SBAR	O
preclinical	JJ	B-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
pulsatile	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
striatal	JJ	B-NP	O
postsynaptic	JJ	I-NP	O
receptors	NNS	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
key	JJ	I-NP	O
mechanism	NN	I-NP	O
underlying	VBG	I-NP	O
levodopa	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
,	,	O	O
their	PRP$	B-NP	O
pathogenesis	NN	I-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
unclear	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
recent	JJ	B-NP	O
years	NNS	I-NP	O
,	,	O	O
evidence	NN	B-NP	O
from	IN	B-PP	O
animal	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
has	VBZ	B-VP	O
provided	VBN	I-VP	O
important	JJ	B-NP	O
information	NN	I-NP	O
to	TO	B-VP	O
understand	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
specific	JJ	B-NP	O
receptor	NN	I-NP	O
and	CC	O	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
molecular	JJ	I-NP	O
mechanisms	NNS	I-NP	O
underlying	VBG	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
dyskinetic	JJ	B-NP	B
movements	NNS	I-NP	I
.	.	O	O

Recent	JJ	B-NP	O
preclinical	JJ	I-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
promising	JJ	B-NP	O
lines	NNS	I-NP	O
of	IN	B-PP	O
research	NN	B-NP	O
focus	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
differential	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
presynaptic	JJ	B-NP	O
versus	IN	B-PP	O
postsynaptic	JJ	B-NP	O
mechanisms	NNS	I-NP	O
,	,	O	O
dopamine	NN	B-NP	O
receptor	NN	I-NP	O
subtypes	NNS	I-NP	O
,	,	O	O
ionotropic	JJ	B-NP	O
and	CC	I-NP	O
metabotropic	JJ	I-NP	O
glutamate	NN	I-NP	O
receptors	NNS	I-NP	O
,	,	O	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
dopaminergic	JJ	I-NP	O
neurotransmitter	NN	I-NP	O
systems	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

Prevention	NN	B-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
and	CC	O	O
reorganization	NN	B-NP	O
of	IN	B-PP	O
hippocampal	JJ	B-NP	O
functions	NNS	I-NP	O
by	IN	B-PP	O
transplantation	NN	B-NP	O
of	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
epilepsy	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
mononuclear	JJ	I-NP	O
cells	NNS	I-NP	O
(	(	O	O
BMCs	NNS	B-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

BMCs	NNS	B-NP	O
obtained	VBN	B-VP	O
from	IN	B-PP	O
green	JJ	B-NP	O
fluorescent	JJ	I-NP	O
protein	NN	I-NP	O
(	(	O	O
GFP	NN	B-NP	O
)	)	O	O
transgenic	JJ	B-NP	O
mice	NNS	I-NP	O
or	CC	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
transplanted	VBN	I-VP	O
intravenously	RB	B-ADVP	O
after	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
(	(	O	O
SE	NN	B-NP	B
)	)	O	O
.	.	O	O

Spontaneous	JJ	B-NP	B
recurrent	JJ	I-NP	I
seizures	NNS	I-NP	I
(	(	O	O
SRS	NNS	B-NP	B
)	)	O	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
using	VBG	B-VP	O
Racine	NN	B-NP	O
s	VBZ	B-VP	O
seizure	NN	B-NP	B
severity	NN	I-NP	O
scale	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
saline	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
epileptic	JJ	B-NP	B
control	NN	I-NP	O
group	NN	I-NP	O
developed	VBD	B-VP	O
SRS	NN	B-NP	B
,	,	O	O
whereas	IN	O	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
BMC	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
epileptic	JJ	B-NP	B
animals	NNS	I-NP	O
had	VBD	B-VP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
short	JJ	I-NP	O
term	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
)	)	O	O
,	,	O	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
BMC	NN	I-NP	O
source	NN	I-NP	O
.	.	O	O

Over	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
chronic	JJ	I-NP	O
phase	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
)	)	O	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
BMC	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
epileptic	JJ	B-NP	B
animals	NNS	I-NP	O
had	VBD	B-VP	O
seizures	NNS	B-NP	B
,	,	O	O
but	CC	O	O
with	IN	B-PP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
epileptic	JJ	I-NP	B
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
hippocampal	JJ	B-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brains	NNS	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
BMCs	NNS	B-NP	O
was	VBD	B-VP	O
markedly	RB	I-VP	O
preserved	VBN	I-VP	O
.	.	O	O

At	IN	B-PP	O
hippocampal	JJ	B-NP	O
Schaeffer	NNP	I-NP	O
collateral	NN	I-NP	O
-	HYPH	B-NP	O
CA1	NN	I-NP	O
synapses	NNS	I-NP	O
,	,	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
potentiation	NN	I-NP	O
was	VBD	B-VP	O
preserved	VBN	I-VP	O
in	IN	B-PP	O
BMC	NN	B-NP	O
-	HYPH	B-NP	O
transplanted	VBN	I-NP	O
rats	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
epileptic	JJ	B-NP	B
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
donor	NN	I-NP	O
-	HYPH	B-VP	O
derived	VBN	B-NP	O
GFP	NN	I-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
rarely	RB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
brains	NNS	I-NP	O
of	IN	B-PP	O
transplanted	VBN	B-NP	O
epileptic	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
BMCs	NNS	B-NP	O
can	MD	B-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
reduce	VB	B-VP	O
neuronal	JJ	B-NP	B
loss	NN	I-NP	I
,	,	O	O
and	CC	O	O
influence	VB	B-VP	O
the	DT	B-NP	O
reorganization	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
neuronal	JJ	I-NP	O
network	NN	I-NP	O
.	.	O	O

Cardioprotective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
salvianolic	JJ	B-NP	O
acid	NN	I-NP	O
A	NN	I-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
cardioprotective	JJ	I-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
salvianolic	JJ	B-NP	O
acid	NN	I-NP	O
A	NN	I-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Hemodynamic	JJ	B-NP	O
parameters	NNS	I-NP	O
and	CC	O	O
lead	VBP	B-VP	O
num	CD	B-NP	O
electrocardiograph	NN	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
and	CC	O	O
recorded	VBN	B-VP	O
continuously	RB	B-ADVP	O
.	.	O	O

Cardiac	JJ	B-NP	O
marker	NN	I-NP	O
enzymes	NNS	I-NP	O
and	CC	O	O
antioxidative	JJ	B-NP	O
parameters	NNS	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
tissues	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
.	.	O	O

Assay	NN	B-NP	O
for	IN	B-PP	O
mitochondrial	JJ	B-NP	O
respiratory	JJ	I-NP	O
function	NN	I-NP	O
and	CC	O	O
histopathological	JJ	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
tissues	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

Isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
lactate	NN	B-NP	O
dehydrogenase	NN	I-NP	O
,	,	O	O
aspartate	NN	B-NP	O
transaminase	NN	I-NP	O
,	,	O	O
creatine	NN	B-NP	O
kinase	NN	I-NP	O
and	CC	I-NP	O
malondialdehyde	NN	I-NP	O
and	CC	O	O
significant	JJ	B-NP	O
decreases	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
superoxide	NN	B-NP	O
dismutase	NN	I-NP	O
,	,	O	O
catalase	NN	B-NP	O
and	CC	O	O
glutathione	NN	B-NP	O
peroxidase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
rats	NNS	I-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
declines	NNS	B-NP	O
in	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
systolic	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
maximum	NN	B-NP	O
and	CC	I-NP	O
minimum	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
developed	VBN	B-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
elevation	NN	B-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
ST	NN	I-NP	O
-	HYPH	I-NP	O
segment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
mitochondrial	JJ	B-NP	O
respiratory	JJ	I-NP	B
dysfunction	NN	I-NP	I
characterized	VBN	B-VP	O
by	IN	B-PP	O
decreased	VBN	B-NP	O
respiratory	JJ	I-NP	O
control	NN	I-NP	O
ratio	NN	I-NP	O
and	CC	I-NP	O
ADP	NN	I-NP	O
/	SYM	B-NP	O
O	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
salvianolic	JJ	B-NP	O
acid	NN	I-NP	O
A	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
significantly	RB	B-ADVP	O
attenuated	VBD	B-VP	O
isoproterenol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
myocardial	JJ	B-NP	B
injury	NN	I-NP	I
and	CC	O	O
improved	VBN	B-NP	O
mitochondrial	JJ	I-NP	O
respiratory	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
salvianolic	JJ	B-NP	O
acid	NN	I-NP	O
A	NN	I-NP	O
against	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
damage	NN	I-NP	I
was	VBD	B-VP	O
further	RBR	I-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
histopathological	JJ	B-NP	O
examination	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
salvianolic	JJ	B-NP	O
acid	NN	I-NP	O
A	NN	I-NP	O
possessing	VBG	B-VP	O
antioxidant	JJ	B-NP	O
activity	NN	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
against	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

Acute	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
propylpentanoyl	NN	I-NP	O
)	)	O	O
urea	NN	B-NP	O
on	IN	B-PP	O
hippocampal	JJ	B-NP	O
amino	JJ	I-NP	O
acid	NN	I-NP	O
neurotransmitters	NNS	I-NP	O
in	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizure	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
anticonvulsant	JJ	I-NP	O
activity	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
hippocampal	JJ	B-NP	O
amino	JJ	I-NP	O
acid	NN	I-NP	O
neurotransmitters	NNS	I-NP	O
(	(	O	O
glutamate	NN	B-NP	O
,	,	O	O
aspartate	NN	B-NP	O
,	,	O	O
glycine	NN	B-NP	O
and	CC	O	O
GABA	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
propylpentanoyl	NN	I-NP	O
)	)	O	O
urea	NN	B-NP	O
(	(	O	O
VPU	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
parent	NN	I-NP	O
compound	NN	I-NP	O
,	,	O	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
VPA	NN	B-NP	O
)	)	O	O
.	.	O	O

VPU	NN	B-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
VPA	NN	B-NP	O
,	,	O	O
exhibiting	VBG	B-VP	O
the	DT	B-NP	O
median	JJ	I-NP	O
effective	JJ	I-NP	O
dose	NN	I-NP	O
(	(	O	O
ED	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
in	IN	B-PP	O
protecting	VBG	B-VP	O
rats	NNS	B-NP	O
against	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizure	NN	I-NP	B
whereas	IN	B-PP	O
the	DT	B-NP	O
corresponding	JJ	I-NP	O
value	NN	I-NP	O
for	IN	B-PP	O
VPA	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

In	FW	B-NP	O
vivo	FW	I-NP	O
microdialysis	NN	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
intraperitoneal	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
pronounced	JJ	I-NP	O
increment	NN	I-NP	O
of	IN	B-PP	O
hippocampal	JJ	B-NP	O
glutamate	NN	I-NP	O
and	CC	I-NP	O
aspartate	NN	I-NP	O
whereas	IN	B-PP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
glycine	NN	B-NP	O
and	CC	I-NP	O
GABA	NN	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
either	CC	O	O
VPU	NN	B-NP	O
or	CC	O	O
VPA	NN	B-NP	O
completely	RB	B-ADVP	O
abolished	VBD	B-VP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
evoked	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
extracellular	JJ	B-NP	O
glutamate	NN	I-NP	O
and	CC	I-NP	O
aspartate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
GABA	NN	B-NP	O
and	CC	I-NP	O
glycine	NN	I-NP	O
but	CC	O	O
less	JJR	B-NP	O
than	IN	B-PP	O
a	DT	B-NP	O
drastic	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
and	CC	I-NP	O
aspartate	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
finding	NN	I-NP	O
that	IN	B-SBAR	O
VPU	NN	B-NP	O
and	CC	I-NP	O
VPA	NN	I-NP	O
could	MD	B-VP	O
protect	VB	I-VP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
against	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizure	NN	I-NP	B
it	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
inhibitory	JJ	B-NP	O
amino	JJ	I-NP	O
acid	NN	I-NP	O
neurotransmitters	NNS	I-NP	O
was	VBD	B-VP	O
comparatively	RB	B-ADJP	O
minor	JJ	I-ADJP	O
and	CC	O	O
offset	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
pronounced	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
and	CC	I-NP	O
aspartate	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
like	IN	B-PP	O
VPA	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
finding	NN	I-NP	O
that	IN	B-SBAR	O
VPU	NN	B-NP	O
could	MD	B-VP	O
drastically	RB	I-VP	O
reduce	VB	I-VP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
glutamate	NN	B-NP	O
and	CC	I-NP	O
aspartate	NN	I-NP	O
should	MD	B-VP	O
account	VB	I-VP	O
,	,	O	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
partly	RB	B-ADVP	O
,	,	O	O
for	IN	B-PP	O
its	PRP$	B-NP	O
anticonvulsant	JJ	I-NP	O
activity	NN	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizure	NN	I-NP	B
in	IN	B-PP	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

Some	DT	B-NP	O
other	JJ	I-NP	O
mechanism	NN	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
being	VBG	B-VP	O
reported	VBN	I-VP	O
herein	RB	B-ADVP	O
should	MD	B-VP	O
be	VB	I-VP	O
further	RBR	B-ADJP	O
investigated	VBN	I-ADJP	O
.	.	O	O

Acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
attack	NN	I-NP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
telithromycin	NN	B-NP	O
.	.	O	O

Antibiotic	JJ	B-NP	O
-	HYPH	I-NP	O
associated	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

With	IN	B-PP	O
widespread	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
antimicrobial	JJ	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
hepatic	JJ	B-NP	B
injury	NN	I-NP	I
occurs	VBZ	B-VP	O
frequently	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
among	IN	B-PP	O
adverse	JJ	B-NP	B
drug	NN	I-NP	I
reactions	NNS	I-NP	I
,	,	O	O
idiosyncratic	JJ	B-NP	O
reactions	NNS	I-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
serious	JJ	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
height	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cm	NN	I-NP	O
and	CC	I-NP	O
weight	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
kg	NN	I-NP	O
presented	VBN	B-VP	O
to	TO	B-PP	O
Marmara	NNP	B-NP	O
University	NNP	I-NP	O
Hospital	NNP	I-NP	O
Emergency	NNP	I-NP	O
Department	NNP	I-NP	O
,	,	O	O
Istanbul	NNP	B-NP	O
,	,	O	O
Turkey	NNP	B-NP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
s	VBZ	B-VP	O
history	NN	B-NP	O
of	IN	B-PP	O
jaundice	NN	B-NP	B
,	,	O	O
malaise	NN	B-NP	O
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
and	CC	O	O
vomiting	NN	B-NP	B
.	.	O	O

He	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
prescribed	VBN	I-VP	O
telithromycin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
PO	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
an	DT	B-NP	O
upper	JJ	I-NP	B
respiratory	JJ	I-NP	I
tract	NN	I-NP	I
infection	NN	I-NP	I
num	CD	B-NP	O
days	NNS	I-NP	O
prior	RB	B-ADVP	O
.	.	O	O

Admission	NN	B-NP	O
laboratory	NN	I-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
as	IN	B-SBAR	O
follows	VBZ	B-VP	O
:	:	O	O
alanine	NN	B-NP	O
aminotransferase	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	B-NP	O
(	(	O	O
reference	NN	B-NP	O
range	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
U	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
;	:	O	O
aspartate	NN	B-NP	O
aminotransferase	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
U	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
;	:	O	O
alkaline	NN	B-NP	O
phosphatase	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
U	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
;	:	O	O
gamma	SYM	B-NP	O
-	HYPH	I-NP	O
glutamyltransferase	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
U	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
;	:	O	O
amylase	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
U	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
;	:	O	O
total	JJ	B-NP	O
bilirubin	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
;	:	O	O
direct	JJ	B-NP	O
bilirubin	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
;	:	O	O
and	CC	O	O
albumin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
toxin	NN	I-NP	O
,	,	O	O
alcohol	NN	B-NP	O
,	,	O	O
or	CC	O	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
suffered	VBN	I-VP	O
a	DT	B-NP	O
previous	JJ	I-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
of	IN	B-PP	O
unknown	JJ	B-NP	O
origin	NN	I-NP	O
,	,	O	O
that	WDT	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
telithromycin	NN	B-NP	O
usage	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
incidents	NNS	I-NP	O
occurred	VBD	B-VP	O
within	IN	B-PP	O
a	DT	B-NP	O
year	NN	I-NP	O
.	.	O	O

Telithromycin	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ketolide	NN	I-NP	O
antibacterials	NNS	I-NP	O
to	TO	B-VP	O
receive	VB	I-VP	O
US	NNP	B-NP	O
Food	NNP	I-NP	O
and	CC	I-NP	O
Drug	NNP	I-NP	O
Administration	NNP	I-NP	O
approval	NN	I-NP	O
for	IN	B-PP	O
clinical	JJ	B-NP	O
use	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
infrequent	JJ	B-NP	O
and	CC	I-NP	O
usually	RB	I-NP	O
reversible	JJ	I-NP	O
severe	JJ	I-NP	O
hepatic	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
a	DT	B-NP	O
score	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
adverse	JJ	I-NP	B
drug	NN	I-NP	I
reaction	NN	I-NP	I
probability	NN	I-NP	O
scale	NN	I-NP	O
,	,	O	O
telithromycin	NN	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
probable	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
and	CC	O	O
pathological	JJ	B-NP	O
findings	NNS	I-NP	O
suggested	VBD	B-VP	O
drug	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
toxic	JJ	I-NP	B
hepatitis	NN	I-NP	I
.	.	O	O

Recurrence	NN	B-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
attack	NN	I-NP	O
might	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
avoided	VBN	I-VP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
initial	JJ	I-NP	O
incident	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
communicated	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
attending	VBG	I-NP	O
physician	NN	I-NP	O
who	WP	B-NP	O
prescribed	VBD	B-VP	O
telithromycin	NN	B-NP	O
the	DT	B-NP	O
second	JJ	I-NP	O
time	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
probably	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
telithromycin	NN	B-NP	O
.	.	O	O

Spironolactone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
insufficiency	NN	I-NP	I
and	CC	I-NP	O
hyperkalemia	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
previous	JJ	I-NP	O
randomized	VBN	I-NP	O
controlled	VBN	I-NP	O
trial	NN	I-NP	O
evaluating	VBG	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
spironolactone	NN	B-NP	O
in	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
patients	NNS	I-NP	O
reported	VBD	B-VP	O
a	DT	B-NP	O
low	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
hyperkalemia	NN	B-NP	B
and	CC	O	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
.	.	O	O

Because	IN	B-SBAR	O
treatments	NNS	B-NP	O
for	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
have	VBP	B-VP	O
changed	VBN	I-VP	O
since	IN	B-PP	O
the	DT	B-NP	O
benefits	NNS	I-NP	O
of	IN	B-PP	O
spironolactone	NN	B-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
complications	NNS	I-NP	O
may	MD	B-VP	O
differ	VB	I-VP	O
in	IN	B-PP	O
current	JJ	B-NP	O
clinical	JJ	I-NP	O
practice	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
associations	NNS	I-NP	O
of	IN	B-PP	O
hyperkalemia	NN	B-NP	B
and	CC	O	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
in	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
spironolactone	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
spironolactone	NN	B-NP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
clinical	JJ	I-NP	O
practice	NN	I-NP	O
.	.	O	O

Cases	NNS	B-NP	O
were	VBD	B-VP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
hyperkalemia	NN	B-NP	B
or	CC	O	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
,	,	O	O
and	CC	O	O
they	PRP	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
randomly	RB	I-NP	O
selected	VBN	I-NP	O
controls	NNS	I-NP	O
per	IN	B-PP	O
case	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
characteristics	NNS	I-NP	O
,	,	O	O
medications	NNS	B-NP	O
,	,	O	O
and	CC	O	O
serum	NN	B-NP	O
chemistries	NNS	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
time	NN	B-NP	O
periods	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
required	VBD	B-VP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
spironolactone	NN	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
hyperkalemia	NN	B-NP	B
or	CC	I-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
hyperkalemia	NN	B-NP	B
were	VBD	B-VP	O
older	JJR	B-ADJP	O
and	CC	O	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
diabetes	NNS	B-NP	B
,	,	O	O
had	VBD	B-VP	O
higher	JJR	B-NP	O
baseline	NN	I-NP	O
serum	NN	I-NP	O
potassium	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
lower	JJR	B-NP	O
baseline	NN	I-NP	O
potassium	NN	I-NP	O
supplement	NN	I-NP	O
doses	NNS	I-NP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
blockers	NNS	B-NP	O
than	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
had	VBD	B-VP	O
lower	JJR	B-NP	O
baseline	NN	I-NP	O
body	NN	I-NP	O
weight	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
baseline	NN	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
,	,	O	O
required	VBD	B-VP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
loop	NN	B-NP	O
diuretics	NNS	I-NP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
thiazide	NN	B-NP	O
diuretics	NNS	I-NP	O
than	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Spironolactone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperkalemia	NN	I-NP	B
and	CC	I-NP	O
renal	JJ	I-NP	B
insufficiency	NN	I-NP	I
are	VBP	B-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
clinical	JJ	I-NP	O
experience	NN	I-NP	O
than	IN	B-SBAR	O
reported	VBN	B-VP	O
previously	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
difference	NN	I-NP	O
is	VBZ	B-VP	O
explained	VBN	I-VP	O
by	IN	B-PP	O
patient	NN	B-NP	O
comorbidities	NNS	I-NP	O
and	CC	O	O
more	RBR	B-NP	O
frequent	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
blockers	NNS	B-NP	O
.	.	O	O

End	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
(	(	O	O
ESRD	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
orthotopic	JJ	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
(	(	O	O
OLTX	NN	B-NP	O
)	)	O	O
using	VBG	B-VP	O
calcineurin	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
immunotherapy	NN	I-NP	O
:	:	O	O
risk	NN	B-NP	O
of	IN	B-PP	O
development	NN	B-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
calcineurin	NN	I-NP	O
inhibitors	NNS	I-NP	O
cyclosporine	NN	I-NP	O
and	CC	I-NP	O
tacrolimus	NN	I-NP	O
are	VBP	B-VP	O
both	DT	O	O
known	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
nephrotoxic	JJ	B-ADJP	B
.	.	O	O

Their	PRP$	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
orthotopic	JJ	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
(	(	O	O
OLTX	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
dramatically	RB	I-VP	O
improved	VBN	B-NP	O
success	NN	I-NP	O
rates	NNS	I-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
have	VBP	B-VP	O
had	VBN	I-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
presenting	VBG	I-VP	O
after	IN	B-PP	O
OLTX	NN	B-NP	O
with	IN	B-PP	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
(	(	O	O
ESRD	NN	B-NP	B
)	)	O	O
.	.	O	O

This	DT	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
examines	VBZ	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
ESRD	NN	B-NP	B
and	CC	O	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
(	(	O	O
CRF	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
OLTX	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
receiving	VBG	B-VP	O
an	DT	B-NP	O
OLTX	NN	I-NP	O
only	RB	B-ADVP	O
from	IN	B-PP	O
June	NNP	B-NP	O
num	CD	I-NP	O
through	IN	B-PP	O
December	NNP	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
who	WP	B-NP	O
survived	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
postoperatively	RB	B-ADVP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

Our	PRP$	B-NP	O
prospectively	RB	I-NP	O
collected	VBN	I-NP	O
database	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
source	NN	I-NP	O
of	IN	B-PP	O
information	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
Controls	NNS	B-NP	O
,	,	O	O
no	DT	B-NP	O
CRF	NN	I-NP	B
or	CC	I-NP	O
ESRD	NN	I-NP	B
,	,	O	O
n=748	NN	B-NP	O
;	:	O	O
CRF	NN	B-NP	B
,	,	O	O
sustained	VBD	B-VP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
>	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
dl	NN	B-NP	O
,	,	O	O
n=41	NN	B-NP	O
;	:	O	O
and	CC	O	O
ESRD	NNP	B-NP	B
,	,	O	O
n=45	NN	B-NP	O
.	.	O	O

Groups	NNS	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
for	IN	B-PP	O
preoperative	JJ	B-NP	O
laboratory	NN	I-NP	O
variables	NNS	I-NP	O
,	,	O	O
diagnosis	NN	B-NP	O
,	,	O	O
postoperative	JJ	B-NP	O
variables	NNS	I-NP	O
,	,	O	O
survival	NN	B-NP	O
,	,	O	O
type	NN	B-NP	O
of	IN	B-PP	O
ESRD	NN	B-NP	B
therapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
survival	NN	B-NP	O
from	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
ESRD	NNP	B-NP	B
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
OLTX	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
renal	JJ	I-NP	B
dysfunction	NN	I-NP	I
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
CRF	NN	B-NP	B
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
ESRD	NN	B-NP	B
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
CRF	NN	B-NP	B
and	CC	O	O
ESRD	NN	B-NP	B
patients	NNS	I-NP	O
had	VBD	B-VP	O
higher	JJR	B-NP	O
preoperative	JJ	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
greater	JJR	I-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hepatorenal	JJ	B-NP	B
syndrome	NN	I-NP	I
,	,	O	O
higher	JJR	B-NP	O
percentage	NN	I-NP	O
requirement	NN	I-NP	O
for	IN	B-PP	O
dialysis	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
postoperatively	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
higher	JJR	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
.	.	O	O

Multivariate	JJ	B-NP	O
stepwise	JJ	I-NP	O
logistic	JJ	I-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
using	VBG	B-VP	O
preoperative	JJ	B-NP	O
and	CC	I-NP	O
postoperative	JJ	I-NP	O
variables	NNS	I-NP	O
identified	VBN	B-VP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
average	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
postoperatively	RB	B-ADVP	O
were	VBD	B-VP	O
independent	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
CRF	NN	B-NP	B
or	CC	I-NP	O
ESRD	NN	I-NP	B
with	IN	B-PP	O
odds	NNS	B-NP	O
ratios	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Overall	JJ	B-NP	O
survival	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
OLTX	NN	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
,	,	O	O
but	CC	O	O
by	IN	B-PP	O
year	NN	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
survival	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
ESRD	NN	B-NP	B
was	VBD	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
developing	VBG	B-VP	O
ESRD	NNP	B-NP	B
had	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
survival	NN	I-NP	O
after	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
ESRD	NN	B-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
hemodialysis	NN	B-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
developing	VBG	B-VP	O
ESRD	NN	B-NP	B
who	WP	B-NP	O
subsequently	RB	B-VP	O
received	VBD	I-VP	O
kidney	NN	B-NP	O
transplants	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
post	AFX	O	O
-	HYPH	O	O
OLTX	NN	B-NP	O
have	VBP	B-VP	O
CRF	NN	B-NP	B
and	CC	I-NP	O
ESRD	NN	I-NP	B
at	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
rate	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
ESRD	NN	B-NP	B
decreases	VBZ	B-VP	O
survival	NN	B-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
those	DT	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
dialysis	NN	B-NP	O
only	RB	B-ADVP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
develop	VBP	B-VP	O
ESRD	NNP	B-NP	B
have	VBP	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
preoperative	JJ	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
and	CC	O	O
are	VBP	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
hepatorenal	JJ	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
at	IN	B-PP	O
various	JJ	B-NP	O
times	NNS	I-NP	O
postoperatively	RB	B-ADVP	O
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
predictive	JJ	I-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
CRF	NN	B-NP	B
or	CC	I-NP	O
ESRD	NN	I-NP	B
.	.	O	O

New	JJ	B-NP	O
strategies	NNS	I-NP	O
for	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
immunosuppression	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
decrease	VB	I-VP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
nimodipine	NN	I-NP	O
on	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
outcome	NN	I-NP	O
after	IN	B-PP	O
acute	JJ	B-NP	B
stroke	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
Intravenous	NNP	I-NP	O
Nimodipine	NNP	I-NP	O
West	NNP	I-NP	O
European	NNP	I-NP	O
Stroke	NNP	I-NP	B
Trial	NNP	I-NP	O
(	(	O	O
INWEST	NN	B-NP	O
)	)	O	O
found	VBD	B-VP	O
a	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
nimodipine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
reduction	NN	I-NP	B
in	IN	B-PP	I
blood	NN	B-NP	I
pressure	NN	I-NP	I
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
and	CC	O	O
an	DT	B-NP	O
unfavorable	JJ	I-NP	O
outcome	NN	I-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	B
stroke	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
confirm	VB	I-VP	O
this	DT	B-NP	O
correlation	NN	I-NP	O
with	IN	B-PP	O
and	CC	B-PP	O
without	IN	B-PP	O
adjustment	NN	B-NP	O
for	IN	B-PP	O
prognostic	JJ	B-NP	O
variables	NNS	I-NP	O
and	CC	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
outcome	NN	B-NP	O
in	IN	B-PP	O
subgroups	NNS	B-NP	O
with	IN	B-PP	O
increasing	VBG	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
BP	NN	B-NP	B
reduction	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	B
stroke	NN	I-NP	I
(	(	O	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
consecutively	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
placebo	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
h	NN	I-NP	O
(	(	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
)	)	O	O
nimodipine	NN	B-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
h	NN	I-NP	O
(	(	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
)	)	O	O
nimodipine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
average	JJ	B-NP	O
BP	NN	I-NP	O
change	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
outcome	NN	I-NP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

Nimodipine	NN	B-NP	O
treatment	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	B
in	IN	B-PP	I
systolic	JJ	B-NP	I
BP	NN	I-NP	I
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
and	CC	O	O
diastolic	JJ	B-NP	O
BP	NN	I-NP	O
(	(	O	O
DBP	NN	B-NP	O
)	)	O	O
from	IN	B-PP	O
baseline	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
few	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
multivariate	JJ	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
DBP	NN	B-NP	B
reduction	NN	I-NP	I
and	CC	O	O
worsening	VBG	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
neurological	JJ	I-NP	O
score	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
DBP	NN	I-NP	B
reduction	NN	I-NP	I
of	IN	B-PP	O
>	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
increased	VBN	I-NP	O
adjusted	VBN	I-NP	O
OR	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
compound	NN	I-NP	O
outcome	NN	I-NP	O
variable	JJ	I-NP	O
death	NN	I-NP	B
or	CC	I-NP	O
dependency	NN	I-NP	O
and	CC	I-NP	O
death	NN	I-NP	B
alone	RB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
all	DT	B-NP	O
placebo	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
SBP	NN	B-NP	O
change	NN	I-NP	O
and	CC	I-NP	O
outcome	NN	I-NP	O
.	.	O	O

DBP	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
SBP	NN	B-NP	O
,	,	O	O
reduction	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
neurological	JJ	B-NP	O
worsening	VBG	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
nimodipine	NN	I-NP	O
after	IN	B-PP	O
acute	JJ	B-NP	B
stroke	NN	I-NP	I
.	.	O	O

For	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
nimodipine	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
conclusive	JJ	B-ADJP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
confirm	VB	I-VP	O
or	CC	I-VP	O
exclude	VB	I-VP	O
a	DT	B-NP	O
neuroprotective	JJ	I-NP	O
property	NN	I-NP	O
of	IN	B-PP	O
nimodipine	NN	B-NP	O
.	.	O	O

Transient	JJ	B-NP	B
neurologic	JJ	I-NP	I
symptoms	NNS	I-NP	I
after	IN	B-PP	O
spinal	JJ	B-NP	O
anesthesia	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
lower	JJR	I-NP	O
incidence	NN	I-NP	O
with	IN	B-PP	O
prilocaine	NN	B-NP	O
and	CC	I-NP	O
bupivacaine	NN	I-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
lidocaine	NN	B-NP	O
.	.	O	O

Recent	JJ	B-NP	O
evidence	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
transient	JJ	B-NP	B
neurologic	JJ	I-NP	I
symptoms	NNS	I-NP	I
(	(	O	O
TNSs	NNS	B-NP	B
)	)	O	O
frequently	RB	B-ADVP	O
follow	VBP	B-VP	O
lidocaine	NN	B-NP	O
spinal	JJ	I-NP	O
anesthesia	NN	I-NP	O
but	CC	O	O
are	VBP	B-VP	O
infrequent	JJ	B-ADJP	O
with	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
identification	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	B-VP	O
local	JJ	B-NP	O
anesthetic	NN	I-NP	O
to	TO	B-VP	O
substitute	VB	I-VP	O
for	IN	B-PP	O
lidocaine	NN	B-NP	O
for	IN	B-PP	O
brief	JJ	B-NP	O
surgical	JJ	I-NP	O
procedures	NNS	I-NP	O
remains	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
goal	NN	I-NP	O
.	.	O	O

Prilocaine	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
amide	NN	I-NP	O
local	JJ	I-NP	O
anesthetic	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
.	.	O	O

Accordingly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
,	,	I-NP	O
prospective	JJ	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
compares	VBZ	B-VP	O
prilocaine	NN	B-NP	O
with	IN	B-PP	O
lidocaine	NN	B-NP	O
and	CC	I-NP	O
bupivacaine	NN	I-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
duration	NN	B-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
and	CC	O	O
relative	JJ	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
TNSs	NNS	B-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
classified	VBN	B-VP	O
as	IN	B-PP	O
American	NNP	B-NP	O
Society	NNP	I-NP	O
of	IN	B-PP	O
Anesthesiologists	NNPS	B-NP	O
physical	JJ	I-NP	O
status	NN	I-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
scheduled	VBN	I-VP	O
for	IN	B-PP	O
short	JJ	B-NP	O
gynecologic	JJ	I-NP	O
procedures	NNS	I-NP	O
under	IN	B-PP	O
spinal	JJ	B-NP	O
anesthesia	NN	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
ml	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
lidocaine	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
glucose	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
prilocaine	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
glucose	NN	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
bupivacaine	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
glucose	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
solutions	NNS	I-NP	O
were	VBD	B-VP	O
provided	VBN	I-VP	O
in	IN	B-PP	O
blinded	JJ	B-NP	O
vials	NNS	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
pharmacy	NN	I-NP	O
.	.	O	O

Details	NNS	B-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	O
puncture	NN	I-NP	O
,	,	O	O
extension	NN	B-NP	O
and	CC	I-NP	O
regression	NN	I-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	O
block	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
times	NNS	I-NP	O
to	TO	B-VP	O
reach	VB	I-VP	O
discharge	NN	B-NP	O
criteria	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
evening	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
day	NN	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
for	IN	B-PP	O
TNSs	NNS	B-NP	B
by	IN	B-PP	O
a	DT	B-NP	O
physician	NN	I-NP	O
unaware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
administered	VBN	B-VP	O
and	CC	O	O
the	DT	B-NP	O
details	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
procedure	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
lidocaine	NN	B-NP	O
experienced	JJ	I-NP	O
TNSs	NNS	I-NP	B
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
prilocaine	NN	B-NP	O
had	VBD	B-VP	O
them	PRP	B-NP	O
,	,	O	O
and	CC	O	O
none	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
bupivacaine	NN	B-NP	O
had	VBD	B-VP	O
TNSs	NNS	B-NP	B
.	.	O	O

Times	NNS	B-NP	O
to	TO	B-VP	O
ambulate	VB	I-VP	O
and	CC	O	O
to	TO	B-PP	O
void	NN	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
after	IN	B-PP	O
lidocaine	NN	B-NP	O
and	CC	O	O
prilocaine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
vs.	IN	I-NP	O
num	CD	B-NP	O
min	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
but	CC	O	O
prolonged	VBD	B-VP	O
after	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

Prilocaine	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
preferable	JJ	B-ADJP	O
to	TO	B-PP	O
lidocaine	NN	B-NP	O
for	IN	B-PP	O
short	JJ	B-NP	O
surgical	JJ	I-NP	O
procedures	NNS	I-NP	O
because	IN	B-SBAR	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
but	CC	O	O
a	DT	B-NP	O
lower	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
TNSs	NNS	B-NP	B
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
in	IN	B-PP	O
smoking	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
cardiovascular	JJ	I-NP	B
disease	NN	I-NP	I
.	.	O	O

Nicotine	NN	B-NP	O
activates	VBZ	B-VP	O
the	DT	B-NP	O
sympathetic	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
this	DT	B-NP	O
way	NN	I-NP	O
could	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Animal	NN	B-NP	O
studies	NNS	I-NP	O
and	CC	O	O
mechanistic	JJ	B-NP	O
studies	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
nicotine	NN	B-NP	O
could	MD	B-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
accelerating	VBG	B-NP	O
atherosclerosis	NN	I-NP	B
,	,	O	O
but	CC	O	O
evidence	NN	B-NP	O
among	IN	B-PP	O
humans	NNS	B-NP	O
is	VBZ	B-VP	O
too	RB	B-ADJP	O
inadequate	JJ	I-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
definitive	JJ	B-ADJP	O
about	IN	B-PP	O
such	JJ	B-NP	O
an	DT	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Almost	RB	B-ADVP	O
certainly	RB	I-ADVP	O
,	,	O	O
nicotine	NN	B-NP	O
via	IN	B-PP	O
its	PRP$	B-NP	O
hemodynamic	JJ	I-NP	O
effects	NNS	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
acute	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
events	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
current	JJ	B-NP	O
evidence	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
are	VBP	B-VP	O
much	RB	B-ADJP	O
less	RBR	I-ADJP	O
important	JJ	I-ADJP	O
than	IN	B-SBAR	O
are	VBP	B-VP	O
the	DT	B-NP	O
prothrombotic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cigarette	NN	B-NP	O
smoking	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
carbon	NN	B-NP	O
monoxide	NN	I-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
enhance	VB	I-VP	O
thrombosis	NN	B-NP	B
among	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
pipe	NN	B-NP	O
smokers	NNS	I-NP	O
and	CC	O	O
people	NNS	B-NP	O
using	VBG	B-VP	O
transdermal	JJ	B-NP	O
nicotine	NN	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
idea	NN	I-NP	O
that	IN	B-SBAR	O
toxins	NNS	B-NP	O
other	JJ	B-ADJP	O
than	IN	B-PP	O
nicotine	NN	B-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
important	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
events	NNS	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
response	NN	I-NP	O
for	IN	B-PP	O
cardiovascular	JJ	B-NP	O
events	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
flat	JJ	B-ADJP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
if	IN	B-SBAR	O
nicotine	NN	B-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
,	,	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
seen	VBN	I-VP	O
with	IN	B-PP	O
relatively	RB	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
level	NN	I-NP	O
cigarette	NN	I-NP	O
exposures	NNS	I-NP	O
.	.	O	O

Seizure	NN	B-NP	B
resulting	VBG	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
venlafaxine	NN	I-NP	O
overdose	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
venlafaxine	NN	B-NP	O
overdose	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
major	JJ	B-NP	B
depression	NN	I-NP	I
took	VBD	B-VP	O
an	DT	B-NP	O
overdose	NN	I-NP	B
of	IN	B-PP	O
venlafaxine	NN	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
apparent	JJ	I-NP	O
suicide	NN	I-NP	O
attempt	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
ingestion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
venlafaxine	NN	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
tablets	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
witnessed	VBN	I-NP	O
generalized	VBN	I-NP	O
seizure	NN	I-NP	B
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
,	,	O	O
venlafaxine	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
further	JJ	I-NP	O
sequelae	NNS	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
venlafaxine	NN	B-NP	O
overdose	NN	I-NP	B
that	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
generalized	VBN	I-NP	O
seizure	NN	I-NP	B
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
nonoverdose	JJ	B-NP	O
pharmacokinetics	NNS	I-NP	O
and	CC	I-NP	O
pharmacodynamics	NNS	I-NP	O
of	IN	B-PP	O
venlafaxine	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
potential	JJ	I-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
available	JJ	B-NP	O
interventions	NNS	I-NP	O
,	,	O	O
no	DT	B-NP	O
emergent	JJ	I-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
instituted	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
venlafaxine	NN	I-NP	O
overdose	NN	I-NP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
generalized	VBN	B-NP	O
seizure	NN	I-NP	B
but	CC	O	O
elicited	VBD	B-VP	O
no	DT	B-NP	O
further	JJ	I-NP	O
sequelae	NNS	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
nifedipine	NN	B-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
receiving	VBG	B-VP	O
tacrolimus	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
nifedipine	NN	B-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
tacrolimus	NN	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
between	IN	B-PP	O
January	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
January	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
tacrolimus	NN	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
group	NN	I-NP	O
comprising	VBG	B-VP	O
hypertensive	JJ	B-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
nifedipine	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
comprising	JJ	I-NP	O
nonhypertensive	JJ	I-NP	O
patients	NNS	I-NP	O
not	RB	B-VP	O
receiving	VBG	I-VP	O
nifedipine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
time	NN	I-NP	O
from	IN	B-PP	O
transplant	NN	B-NP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Nifedipine	NN	B-NP	O
significantly	RB	B-ADVP	O
improved	VBD	B-VP	O
kidney	NN	B-NP	O
function	NN	I-NP	O
as	IN	B-SBAR	O
indicated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
lowering	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
observed	VBN	I-NP	O
positive	JJ	I-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
nifedipine	NN	B-NP	O
on	IN	B-PP	O
reducing	VBG	B-VP	O
the	DT	B-NP	O
nephrotoxicity	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
tacrolimus	NN	B-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
selecting	VBG	B-VP	O
an	DT	B-NP	O
agent	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
hypertension	NN	B-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
population	NN	I-NP	O
.	.	O	O

Sinus	NN	B-NP	B
arrest	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
continuous	JJ	B-NP	O
-	HYPH	I-NP	O
infusion	NN	I-NP	O
cimetidine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
intermittent	JJ	B-NP	O
intravenous	JJ	I-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
is	VBZ	B-VP	O
infrequently	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
bradyarrhythmias	NNS	B-NP	B
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
leukemia	NN	B-NP	B
and	CC	O	O
no	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
disease	NN	I-NP	I
developed	VBD	B-VP	O
recurrent	JJ	B-NP	O
,	,	I-NP	O
brief	JJ	I-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
apparent	JJ	B-NP	O
sinus	NN	I-NP	B
arrest	NN	I-NP	I
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
continuous	JJ	B-NP	O
-	HYPH	I-NP	O
infusion	NN	I-NP	O
cimetidine	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
hour	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
arrhythmias	NNS	I-NP	B
were	VBD	B-VP	O
temporally	RB	B-ADJP	O
related	VBN	I-ADJP	O
to	TO	B-PP	O
cimetidine	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
disappeared	VBD	B-VP	O
after	IN	B-PP	O
dechallenge	NN	B-NP	O
,	,	O	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
recur	VB	I-VP	O
during	IN	B-PP	O
ranitidine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
sinus	NN	B-NP	B
arrest	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
continuous	JJ	B-NP	O
-	HYPH	I-NP	O
infusion	NN	I-NP	O
cimetidine	NN	I-NP	O
.	.	O	O

Composition	NN	B-NP	O
of	IN	B-PP	O
gall	NN	B-NP	B
bladder	NN	I-NP	I
stones	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
octreotide	NN	B-NP	O
:	:	O	O
response	NN	B-NP	O
to	TO	B-PP	O
oral	JJ	B-NP	O
ursodeoxycholic	JJ	I-NP	O
acid	NN	I-NP	O
.	.	O	O

Octreotide	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
acromegaly	RB	B-NP	B
,	,	O	O
induces	VBZ	B-VP	O
gall	NN	B-NP	B
bladder	NN	I-NP	I
stones	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Because	IN	B-SBAR	O
knowledge	NN	B-NP	O
of	IN	B-PP	O
stone	NN	B-NP	O
composition	NN	I-NP	O
is	VBZ	B-VP	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
studies	NNS	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
pathogenesis	NN	I-NP	O
,	,	O	O
treatment	NN	B-NP	O
,	,	O	O
and	CC	O	O
prevention	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
by	IN	B-PP	O
direct	JJ	B-NP	O
and	CC	I-NP	O
indirect	JJ	I-NP	O
methods	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
octreotide	NN	I-NP	O
treated	VBN	B-VP	O
acromegalic	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
gall	NN	B-NP	B
stones	NNS	I-NP	I
.	.	O	O

Chemical	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
gall	NN	B-NP	B
stones	NNS	I-NP	I
retrieved	VBD	B-VP	O
at	IN	B-PP	O
cholecystectomy	NN	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
they	PRP	B-NP	O
contained	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
cholesterol	NN	I-NP	O
by	IN	B-PP	O
weight	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
localised	JJ	B-NP	O
computed	VBN	I-NP	O
tomography	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
gall	NN	I-NP	O
bladder	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
had	VBD	B-VP	O
stones	NNS	B-NP	O
with	IN	B-PP	O
maximum	JJ	B-NP	O
attenuation	NN	I-NP	O
scores	NNS	I-NP	O
of	IN	B-PP	O
<	SYM	B-NP	O
num	CD	I-NP	O
Hounsfield	NNP	I-NP	O
units	NNS	I-NP	O
.	.	O	O

Gall	NN	B-NP	O
bladder	NN	I-NP	O
bile	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
by	IN	B-PP	O
ultrasound	JJ	B-NP	O
guided	VBN	I-NP	O
,	,	I-NP	O
fine	JJ	I-NP	O
needle	NN	I-NP	O
puncture	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
supersaturated	VBN	I-VP	O
bile	NN	B-NP	O
(	(	O	O
mean	NN	B-NP	O
(	(	O	O
SEM	NN	B-NP	O
)	)	O	O
cholesterol	NN	B-NP	O
saturation	NN	I-NP	O
index	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
)	)	O	O
and	CC	O	O
all	DT	B-NP	O
had	VBD	B-VP	O
abnormally	RB	B-NP	O
rapid	JJ	I-NP	O
cholesterol	NN	I-NP	O
microcrystal	NN	I-NP	O
nucleation	NN	I-NP	O
times	NNS	I-NP	O
(	(	O	O
<	SYM	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
)	)	O	O
,	,	O	O
whilst	IN	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
the	DT	B-NP	O
bile	NN	I-NP	O
contained	VBD	B-VP	O
cholesterol	NN	B-NP	O
microcrystals	NNS	I-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
sampling	VBG	B-VP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
considered	VBN	B-VP	O
for	IN	B-PP	O
oral	JJ	B-NP	O
ursodeoxycholic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
UDCA	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
blocked	VBN	I-NP	O
cystic	JJ	I-NP	O
duct	NN	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
not	RB	I-VP	O
started	VBN	I-VP	O
on	IN	B-PP	O
UDCA	NN	B-NP	O
while	IN	B-SBAR	O
num	CD	B-NP	O
was	VBD	B-VP	O
lost	VBN	I-VP	O
to	TO	I-VP	O
follow	VB	I-VP	O
up	RP	B-PRT	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
either	CC	O	O
partial	JJ	B-NP	O
or	CC	I-NP	O
complete	JJ	I-NP	O
gall	NN	I-NP	B
stone	NN	I-NP	I
dissolution	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
their	PRP$	B-NP	O
stones	NNS	I-NP	O
were	VBD	B-VP	O
cholesterol	NN	B-ADJP	O
rich	JJ	I-ADJP	O
.	.	O	O

This	DT	B-NP	O
corresponds	VBZ	B-VP	O
,	,	O	O
by	IN	B-PP	O
actuarial	JJ	B-ADJP	O
(	(	O	O
life	NN	B-NP	O
table	NN	I-NP	O
)	)	O	O
analysis	NN	B-NP	O
,	,	O	O
to	TO	B-PP	O
a	DT	B-NP	O
combined	JJ	I-NP	O
gall	NN	I-NP	B
stone	NN	I-NP	I
dissolution	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
octreotide	NN	B-NP	O
induced	VBD	B-VP	O
gall	NN	B-NP	B
stones	NNS	I-NP	I
are	VBP	B-VP	O
generally	RB	B-ADVP	O
small	JJ	B-NP	O
,	,	I-NP	O
multiple	JJ	I-NP	O
,	,	O	O
and	CC	O	O
cholesterol	NN	B-NP	O
rich	JJ	B-ADJP	O
although	IN	B-SBAR	O
,	,	O	O
in	IN	B-PP	O
common	JJ	B-ADJP	O
with	IN	B-PP	O
spontaneous	JJ	B-NP	O
gall	NN	I-NP	B
stone	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
at	IN	B-PP	O
presentation	NN	B-NP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
will	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
blocked	VBN	I-NP	O
cystic	JJ	I-NP	O
duct	NN	I-NP	O
and	CC	O	O
some	DT	B-NP	O
gall	JJ	I-NP	B
stones	NNS	I-NP	I
containing	VBG	B-VP	O
calcium	NN	B-NP	O
.	.	O	O

Cardiovascular	JJ	B-NP	B
complications	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
terbutaline	NN	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
preterm	JJ	B-NP	B
labor	NN	I-NP	I
.	.	O	O

Severe	JJ	B-NP	O
cardiovascular	JJ	I-NP	B
complications	NNS	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
terbutaline	NN	B-NP	O
for	IN	B-PP	O
preterm	JJ	B-NP	B
labor	NN	I-NP	I
.	.	O	O

Associated	VBN	B-NP	O
corticosteroid	NN	I-NP	O
therapy	NN	I-NP	O
and	CC	I-NP	O
twin	NN	I-NP	O
gestations	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
predisposing	VBG	I-VP	O
factors	NNS	B-NP	O
.	.	O	O

Potential	JJ	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
are	VBP	B-VP	O
briefly	RB	I-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Neurologic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
subarachnoid	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroprocaine	NN	I-NP	O
-	HYPH	O	O
CE	NN	B-NP	O
,	,	O	O
bupivacaine	NN	B-NP	O
,	,	O	O
and	CC	O	O
low	JJ	B-NP	O
pH	NN	I-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
neurologic	JJ	I-NP	O
consequences	NNS	I-NP	O
of	IN	B-PP	O
deliberate	JJ	B-NP	O
subarachnoid	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
large	JJ	B-NP	O
volumes	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroprocaine	NN	I-NP	O
-	HYPH	I-NP	O
CE	NN	I-NP	O
in	IN	B-PP	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
pH	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
total	JJ	B-NP	O
volume	NN	I-NP	O
as	IN	B-PP	O
potential	JJ	B-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
causing	VBG	B-VP	O
neurotoxicity	NN	B-NP	B
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
received	VBD	B-VP	O
injections	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
subarachnoid	JJ	I-NP	O
space	NN	I-NP	O
as	IN	B-SBAR	O
follows	VBZ	B-VP	O
:	:	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
ml	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroprocaine	NN	I-NP	O
-	HYPH	I-NP	O
CE	NN	I-NP	O
,	,	O	O
low	JJ	B-NP	O
pH	NN	I-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
animals	NNS	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
subarachnoid	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroprocaine	NN	I-NP	O
-	HYPH	O	O
CE	NN	B-NP	O
num	CD	I-NP	O
developed	VBD	B-VP	O
hind	NN	B-NP	O
-	HYPH	B-NP	O
limb	NN	I-NP	O
paralysis	NN	I-NP	B
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
bupivacaine	NN	B-NP	O
,	,	O	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
,	,	O	O
or	CC	O	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
titrated	VBN	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
pH	NN	I-NP	O
num	CD	I-NP	O
developed	VBD	B-VP	O
hind	NN	B-NP	O
-	HYPH	B-NP	O
limb	NN	I-NP	O
paralysis	NN	I-NP	B
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
spinal	JJ	I-NP	O
cords	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroprocaine	NN	I-NP	O
-	HYPH	I-NP	O
CE	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
showed	VBD	B-VP	O
subpial	JJ	B-NP	B
necrosis	NN	I-NP	I
;	:	O	O
the	DT	B-NP	O
nerve	NN	I-NP	O
roots	NNS	I-NP	O
and	CC	O	O
subarachnoid	JJ	B-NP	O
vessels	NNS	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
spinal	JJ	I-NP	O
cords	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
bupivacaine	NN	B-NP	O
,	,	O	O
low	JJ	B-NP	O
pH	NN	I-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
show	VB	I-VP	O
abnormal	JJ	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Early	RB	B-NP	O
adjuvant	JJ	I-NP	O
adriamycin	NN	I-NP	O
in	IN	B-PP	O
superficial	JJ	B-NP	O
bladder	NN	I-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
multicenter	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
superficial	JJ	B-NP	O
transitional	JJ	I-NP	O
cell	NN	I-NP	O
carcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
bladder	NN	I-NP	I
.	.	O	O

Adriamycin	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intravesically	RB	B-ADVP	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
transurethral	JJ	B-NP	O
resection	NN	I-NP	O
of	IN	B-PP	O
TA	NN	B-NP	O
-	HYPH	B-NP	O
T1	NN	I-NP	O
(	(	O	O
O	NN	B-NP	O
-	HYPH	B-NP	O
A	NN	I-NP	O
)	)	O	O
bladder	NN	B-NP	B
tumors	NNS	I-NP	I
.	.	O	O

Instillation	NN	B-NP	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
twice	RB	B-ADVP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
week	NN	I-NP	O
,	,	O	O
then	RB	B-ADVP	O
weekly	RB	I-ADVP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
month	NN	I-NP	O
and	CC	O	O
afterwards	RB	B-ADJP	O
monthly	JJ	I-ADJP	O
for	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
tolerance	NN	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
local	JJ	B-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
chemical	NN	I-NP	O
cystitis	NN	I-NP	B
was	VBD	B-VP	O
severe	JJ	B-ADJP	O
enough	RB	I-ADJP	O
for	IN	B-SBAR	O
them	PRP	B-NP	O
to	TO	B-VP	O
drop	VB	I-VP	O
out	IN	B-PP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
systemic	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Recurrence	NN	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
followed	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
studied	VBN	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
primary	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
recurrent	JJ	I-NP	O
disease	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
show	VB	I-VP	O
any	DT	B-NP	O
recurrence	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
num	CD	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
recurrences	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
these	DT	B-NP	O
recurrences	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
T1	NN	B-NP	O
tumors	NNS	I-NP	B
while	IN	B-SBAR	O
num	CD	B-NP	O
progressed	VBD	B-VP	O
to	TO	B-PP	O
more	RBR	B-ADVP	O
highly	RB	I-ADVP	O
invasive	JJ	B-NP	O
lesions	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
free	JJ	B-ADJP	O
of	IN	B-PP	O
recurrence	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
remained	VBD	B-VP	O
tumor	NN	B-NP	B
-	HYPH	B-ADJP	O
free	JJ	I-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
period	NN	B-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
developing	VBG	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
recurrences	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
year	NN	I-NP	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
further	JJ	B-NP	O
recurrence	NN	I-NP	O
once	IN	B-SBAR	O
the	DT	B-NP	O
instillations	NNS	I-NP	O
were	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
Adriamycin	NN	B-NP	O
appears	VBZ	B-VP	O
obvious	JJ	B-ADJP	O
and	CC	O	O
might	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
itself	PRP	B-NP	O
,	,	O	O
the	DT	B-NP	O
early	JJ	I-NP	O
and	CC	I-NP	O
repeated	JJ	I-NP	O
instillations	NNS	I-NP	O
after	IN	B-PP	O
TUR	NN	B-NP	O
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
.	.	O	O

Hyperkalemia	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
sulindac	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Hyperkalemia	NN	B-NP	B
has	VBZ	B-VP	O
recently	RB	I-VP	O
been	VBN	I-VP	O
recognized	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
antiinflammatory	JJ	I-NP	O
agents	NNS	I-NP	O
(	(	O	O
NSAID	NN	B-NP	O
)	)	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
indomethacin	NN	B-NP	O
.	.	O	O

Several	JJ	B-NP	O
recent	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
stressed	VBN	I-VP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
sparing	VBG	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
sulindac	NN	B-NP	O
,	,	O	O
owing	VBG	B-VP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
interference	NN	B-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	O
prostacyclin	NN	I-NP	O
synthesis	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
hyperkalemia	NN	B-NP	B
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mEq	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
developed	VBN	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
sulindac	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
normal	JJ	B-NP	O
serum	NN	I-NP	O
potassium	NN	I-NP	O
levels	NNS	I-NP	O
reached	VBN	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
stopping	VBG	B-VP	O
sulindac	NN	B-NP	O
.	.	O	O

As	IN	B-SBAR	O
no	DT	B-NP	O
other	JJ	I-NP	O
medications	NNS	I-NP	O
known	VBN	B-VP	O
to	TO	B-VP	O
effect	VB	I-VP	O
serum	NN	B-NP	O
potassium	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
given	VBN	I-VP	O
concomitantly	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
is	VBZ	B-VP	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
-	HYPH	I-NP	O
effect	NN	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
sulindac	NN	B-NP	O
and	CC	I-NP	O
hyperkalemia	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
initial	JJ	B-NP	O
hopes	NNS	I-NP	O
that	IN	B-SBAR	O
sulindac	NN	B-NP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
renal	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
NSAID	NN	I-NP	O
are	VBP	B-VP	O
probably	RB	B-ADVP	O
not	RB	O	O
justified	JJ	B-ADJP	O
.	.	O	O

Ventricular	JJ	B-NP	B
tachyarrhythmias	NNS	I-NP	I
during	IN	B-PP	O
cesarean	JJ	B-NP	O
section	NN	I-NP	O
after	IN	B-PP	O
ritodrine	NN	B-NP	O
therapy	NN	I-NP	O
:	:	O	O
interaction	NN	B-NP	O
with	IN	B-PP	O
anesthetics	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
illustrates	VBZ	B-VP	O
that	IN	B-SBAR	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
ritodrine	NN	B-NP	O
for	IN	B-PP	O
preterm	JJ	B-NP	B
labor	NN	I-NP	I
may	MD	B-VP	O
risk	VB	I-VP	O
interactions	NNS	B-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
residual	JJ	I-NP	O
betamimetic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ritodrine	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
anesthetics	NNS	B-NP	O
during	IN	B-PP	O
cesarean	JJ	B-NP	O
section	NN	I-NP	O
.	.	O	O

Such	JJ	B-NP	O
interactions	NNS	I-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
serious	JJ	B-NP	O
cardiovascular	JJ	I-NP	B
complications	NNS	I-NP	I
even	RB	B-ADVP	O
after	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
ritodrine	NN	B-NP	O
.	.	O	O

Preoperative	JJ	B-NP	O
assessment	NN	I-NP	O
should	MD	B-VP	O
focus	VB	I-VP	O
on	IN	B-PP	O
cardiovascular	JJ	B-NP	O
status	NN	I-NP	O
and	CC	O	O
serum	NN	B-NP	O
potassium	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

Delaying	VBG	B-VP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
whenever	WRB	B-ADJP	O
possible	JJ	I-ADJP	O
.	.	O	O

Careful	JJ	B-NP	O
fluid	NN	I-NP	O
administration	NN	I-NP	O
and	CC	O	O
cautious	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
titrated	VBN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
are	VBP	B-VP	O
advised	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
delivery	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
infant	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
no	DT	B-NP	O
contraindication	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
vasopressor	NN	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
phenylephrine	NN	B-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
hypotensive	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
tachycardia	NN	B-NP	B
.	.	O	O

Immunohistochemical	JJ	B-NP	O
,	,	I-NP	O
electron	NN	I-NP	O
microscopic	JJ	I-NP	O
and	CC	I-NP	O
morphometric	JJ	I-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rat	NN	I-NP	O
prolactinomas	NNS	I-NP	B
after	IN	B-PP	O
bromocriptine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
clarify	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
bromocriptine	NN	B-NP	O
on	IN	B-PP	O
prolactinoma	NN	B-NP	B
cells	NNS	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
immunohistochemical	JJ	B-NP	O
,	,	I-NP	O
ultrastructural	JJ	I-NP	O
and	CC	I-NP	O
morphometrical	JJ	I-NP	O
analyses	NNS	I-NP	O
were	VBD	B-VP	O
applied	VBN	I-VP	O
to	TO	B-PP	O
estrogen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rat	NN	I-NP	O
prolactinoma	NN	I-NP	B
cells	NNS	I-NP	O
num	CD	B-NP	O
h	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
bromocriptine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
serum	NN	B-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
decreased	VBD	B-VP	O
markedly	RB	B-ADVP	O
.	.	O	O

Electron	NN	B-NP	O
microscopy	NN	I-NP	O
disclosed	VBD	B-VP	O
many	JJ	B-NP	O
secretory	JJ	I-NP	O
granules	NNS	I-NP	O
,	,	O	O
slightly	RB	B-NP	O
distorted	JJ	I-NP	O
rough	JJ	I-NP	O
endoplasmic	JJ	I-NP	O
reticulum	NN	I-NP	O
,	,	O	O
and	CC	O	O
partially	RB	B-NP	O
dilated	JJ	I-NP	O
Golgi	NNP	I-NP	O
cisternae	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prolactinoma	NN	I-NP	B
cells	NNS	I-NP	O
.	.	O	O

Morphometric	JJ	B-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
volume	NN	I-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
secretory	JJ	B-NP	O
granules	NNS	I-NP	O
increased	VBD	B-VP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
volume	NN	I-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
cytoplasmic	JJ	B-NP	O
microtubules	NNS	I-NP	O
decreased	VBD	B-VP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
lowered	VBN	B-NP	O
serum	NN	I-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
bromocriptine	NN	B-NP	O
treatment	NN	I-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
an	DT	B-NP	O
impaired	JJ	I-NP	O
secretion	NN	I-NP	O
of	IN	B-PP	O
prolactin	NN	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
decreasing	VBG	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
cytoplasmic	JJ	B-NP	O
microtubules	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
,	,	O	O
serum	NN	B-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
still	RB	B-ADVP	O
considerably	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
prolactinoma	NN	I-NP	B
cells	NNS	I-NP	O
at	IN	B-PP	O
this	DT	B-NP	O
time	NN	I-NP	O
were	VBD	B-VP	O
well	RB	I-VP	O
granulated	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
vesiculated	VBN	B-NP	O
rough	JJ	I-NP	O
endoplasmic	JJ	I-NP	O
reticulum	NN	I-NP	O
and	CC	O	O
markedly	RB	B-VP	O
dilated	VBD	I-VP	O
Golgi	NNP	B-NP	O
cisternae	NNS	I-NP	O
.	.	O	O

Electron	NN	B-NP	O
microscopical	JJ	I-NP	O
immunohistochemistry	NN	I-NP	O
revealed	VBD	B-VP	O
positive	JJ	B-NP	O
reaction	NN	I-NP	O
products	NNS	I-NP	O
noted	VBN	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
secretory	JJ	I-NP	O
granules	NNS	I-NP	O
,	,	O	O
Golgi	NNP	B-NP	O
cisternae	NNS	I-NP	O
,	,	O	O
and	CC	O	O
endoplasmic	JJ	B-NP	O
reticulum	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
untreated	JJ	I-NP	O
rat	NN	I-NP	O
prolactinoma	NN	I-NP	B
cells	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
only	RB	B-NP	O
secretory	JJ	I-NP	O
granules	NNS	I-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
positive	JJ	I-NP	O
reaction	NN	I-NP	O
products	NNS	I-NP	O
for	IN	B-PP	O
prolactin	NN	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
bromocriptine	NN	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
adenoma	NN	I-NP	B
cells	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
volume	NN	I-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
secretory	JJ	B-NP	O
granules	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
volume	NN	I-NP	O
densities	NNS	I-NP	O
of	IN	B-PP	O
rough	JJ	B-NP	O
endoplasmic	JJ	I-NP	O
reticulum	NN	I-NP	O
and	CC	I-NP	O
microtubules	NNS	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
morphometric	JJ	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
bromocriptine	NN	B-NP	O
inhibits	VBZ	B-VP	O
protein	NN	B-NP	O
synthesis	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
bringing	VBG	B-VP	O
about	IN	B-PP	O
a	DT	B-NP	O
disturbance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
prolactin	NN	I-NP	O
secretion	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
num	CD	B-NP	O
paradoxical	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	O	O
effects	NNS	B-NP	O
of	IN	B-PP	O
prednisolone	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
ribosomal	JJ	B-NP	O
RNA	NN	I-NP	O
biosyntheses	NNS	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
.	.	O	O

Liver	NN	B-NP	B
enlargement	NN	I-NP	I
and	CC	O	O
muscle	NN	B-NP	B
wastage	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
Wistar	NNP	B-NP	O
rats	NNS	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
subcutaneous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
prednisolone	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
both	CC	O	O
the	DT	B-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
RNA	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
biosynthesis	NN	I-NP	O
of	IN	B-PP	O
ribosomal	JJ	B-NP	O
RNA	NN	I-NP	O
increased	VBD	B-VP	O
while	IN	B-SBAR	O
both	CC	O	O
the	DT	B-NP	O
RNA	NN	I-NP	O
content	NN	I-NP	O
and	CC	O	O
ribosomal	JJ	B-NP	O
RNA	NN	I-NP	O
biosynthesis	NN	I-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
gastrocnemius	NN	I-NP	O
muscle	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
drug	NN	I-NP	O
acted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
and	CC	I-NP	O
tissue	NN	I-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
manner	NN	I-NP	O
to	TO	B-VP	O
enhance	VB	I-VP	O
ribosomal	JJ	B-NP	O
RNA	NN	I-NP	O
synthesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
and	CC	O	O
depress	VBP	B-VP	O
such	JJ	B-NP	O
synthesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
muscle	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
view	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
contention	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
liver	NN	I-NP	O
and	CC	I-NP	O
muscle	NN	I-NP	O
are	VBP	B-VP	O
independent	JJ	B-NP	O
sites	NNS	I-NP	O
of	IN	B-PP	O
prednisolone	JJ	B-NP	O
action	NN	I-NP	O
.	.	O	O

Possible	JJ	B-NP	O
intramuscular	JJ	I-NP	O
midazolam	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
cardiorespiratory	JJ	B-NP	B
arrest	NN	I-NP	I
and	CC	I-NP	O
death	NN	I-NP	B
.	.	O	O

Midazolam	NN	B-NP	O
hydrochloride	NN	I-NP	O
is	VBZ	B-VP	O
commonly	RB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
dental	JJ	B-NP	O
or	CC	I-NP	O
endoscopic	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
generally	RB	B-ADVP	O
consisted	VBN	B-VP	O
safe	JJ	B-ADJP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
intramuscularly	RB	B-ADVP	O
,	,	O	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
respiratory	JJ	B-NP	B
and	CC	I-NP	I
cardiovascular	JJ	I-NP	I
depression	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
published	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
cardiorespiratory	JJ	B-NP	B
arrest	NN	I-NP	I
and	CC	I-NP	O
death	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
intramuscular	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
midazolam	NN	B-NP	O
.	.	O	O

Information	NN	B-NP	O
regarding	VBG	B-VP	O
midazolam	NN	B-NP	O
use	NN	I-NP	O
is	VBZ	B-VP	O
reviewed	VBN	I-VP	O
to	TO	I-VP	O
provide	VB	I-VP	O
recommendation	NN	B-NP	O
for	IN	B-PP	O
safe	JJ	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Serial	JJ	B-NP	O
epilepsy	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
levodopa	NN	B-NP	O
/	SYM	O	O
carbidopa	NN	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
on	IN	B-PP	O
hemodialysis	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
similar	JJ	B-NP	O
clinical	JJ	I-NP	O
features	NNS	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
:	:	O	O
both	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
on	IN	B-PP	O
hemodialysis	NN	B-NP	O
for	IN	B-PP	O
many	JJ	B-NP	O
years	NNS	I-NP	O
but	CC	O	O
recently	RB	B-VP	O
begun	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
flux	NN	I-NP	O
dialyzer	NN	I-NP	O
;	:	O	O
both	DT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
receiving	VBG	I-VP	O
a	DT	B-NP	O
carbidopa	NN	I-NP	O
/	SYM	B-NP	O
levodopa	NN	I-NP	O
preparation	NN	I-NP	O
;	:	O	O
and	CC	O	O
both	DT	B-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
hallucinosis	NN	B-NP	B
and	CC	O	O
recurrent	JJ	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
refractory	JJ	B-ADJP	O
to	TO	B-PP	O
anticonvulsants	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
patient	NN	I-NP	O
died	VBD	B-VP	O
without	IN	B-PP	O
a	DT	B-NP	O
diagnosis	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
second	JJ	I-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
dramatic	JJ	I-NP	O
recovery	NN	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
B6	NN	I-NP	O
.	.	O	O

Neither	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
renal	JJ	I-NP	O
state	NN	I-NP	O
sufficiently	RB	B-ADJP	O
severe	JJ	I-ADJP	O
enough	RB	B-ADVP	O
to	TO	B-VP	O
explain	VB	I-VP	O
their	PRP$	B-NP	O
presentation	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
glyceryl	NN	I-NP	O
-	HYPH	O	O
phosphorylcholine	NN	B-NP	O
on	IN	B-PP	O
amnesia	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
to	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	O	O
-	HYPH	O	O
glycerylphosphorylcholine	NN	B-NP	O
(	(	O	O
L	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	O	O
-	HYPH	O	O
GFC	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
memory	NN	B-NP	B
impairment	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
healthy	JJ	I-NP	O
young	JJ	I-NP	O
volunteers	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

They	PRP	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
day	NN	I-NP	O
pretreatment	NN	I-NP	O
with	IN	B-PP	O
either	CC	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
GFC	NN	I-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
,	,	O	O
p.o.	NN	B-NP	O
,	,	B-PP	O
and	CC	I-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
eleventh	JJ	I-NP	O
day	NN	I-NP	O
either	CC	O	O
scopolamine	NN	B-NP	O
or	CC	O	O
placebo	NN	B-NP	O
,	,	O	O
i.m	RB	B-ADVP	O
.	.	O	O

Before	IN	B-ADVP	O
and	CC	O	O
num	CD	B-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
attention	NN	B-NP	O
and	CC	O	O
mnemonic	JJ	B-NP	O
tests	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
antagonize	VB	I-VP	O
impairment	NN	B-NP	B
of	IN	B-PP	I
attention	NN	B-NP	I
and	CC	I-NP	I
memory	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
.	.	O	O

Seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
cocaine	NN	I-NP	O
metabolite	NN	I-NP	O
benzoylecgonine	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
half	NN	I-NP	O
-	HYPH	O	O
life	NN	B-NP	O
(	(	O	O
t1	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
)	)	O	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
is	VBZ	B-VP	O
relatively	RB	B-ADJP	O
short	JJ	I-ADJP	O
,	,	O	O
but	CC	O	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
consequences	NNS	I-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
seizures	NNS	B-NP	B
and	CC	I-NP	O
strokes	NNS	I-NP	B
,	,	O	O
can	MD	B-VP	O
occur	VB	I-VP	O
hours	NNS	B-NP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
led	VBD	B-VP	O
us	PRP	B-NP	O
to	TO	B-VP	O
hypothesize	VB	I-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
metabolite	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
some	DT	B-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
delayed	VBN	I-NP	O
sequelae	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
metabolite	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
benzoylecgonine	NN	B-NP	O
(	(	O	O
BE	NN	B-NP	O
)	)	O	O
,	,	O	O
to	TO	B-VP	O
cause	VB	I-VP	O
seizures	NNS	B-NP	B
.	.	O	O

num	CD	B-NP	O
separate	JJ	I-NP	O
equimolar	JJ	I-NP	O
doses	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mumol	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
either	CC	O	O
cocaine	NN	B-NP	O
or	CC	I-NP	O
BE	NN	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
ventricularly	RB	B-ADVP	O
in	IN	B-PP	O
unanesthetized	JJ	B-NP	O
juvenile	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Treated	VBN	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
evaluated	VBN	I-VP	O
for	IN	B-PP	O
incidence	NN	B-NP	O
,	,	O	O
latency	NN	B-NP	O
,	,	O	O
and	CC	O	O
seizure	NN	B-NP	B
pattern	NN	I-NP	O
or	CC	B-PP	O
for	IN	B-PP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
without	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

BE	NN	B-NP	O
-	HYPH	B-NP	O
Induced	VBN	I-NP	O
seizures	NNS	I-NP	B
occurred	VBD	B-VP	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
and	CC	O	O
had	VBD	B-VP	O
significantly	RB	B-NP	O
longer	JJR	I-NP	O
latencies	NNS	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
equimolar	JJ	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Whereas	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
were	VBD	B-VP	O
best	RBS	I-VP	O
characterized	VBN	I-VP	O
as	IN	B-PP	O
brief	NN	B-NP	O
,	,	O	O
generalized	VBN	B-VP	O
,	,	O	O
and	CC	O	O
tonic	JJ	B-ADJP	O
and	CC	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
death	NN	B-NP	B
,	,	O	O
those	DT	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
BE	NN	B-NP	O
were	VBD	B-VP	O
prolonged	JJ	B-ADJP	O
,	,	O	O
often	RB	B-ADVP	O
multiple	JJ	B-ADJP	O
and	CC	O	O
mixed	JJ	B-ADJP	O
in	IN	B-PP	O
type	NN	B-NP	O
,	,	O	O
and	CC	O	O
rarely	RB	B-VP	O
resulted	VBD	I-VP	O
in	IN	B-PP	O
death	NN	B-NP	B
.	.	O	O

Electrical	JJ	B-NP	O
recordings	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
rhythmic	JJ	I-NP	O
progression	NN	I-NP	O
in	IN	B-PP	O
EEG	NN	B-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
voltage	NN	I-NP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
seizure	NN	I-NP	B
expression	NN	I-NP	O
.	.	O	O

BE	NN	B-NP	O
-	HYPH	B-NP	O
Injected	VBN	I-NP	O
rats	NNS	I-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
seizures	NNS	B-NP	B
had	VBD	B-VP	O
significantly	RB	B-NP	O
more	RBR	I-NP	O
locomotor	JJ	I-NP	O
activity	NN	I-NP	O
than	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
injected	VBN	I-NP	O
animals	NNS	I-NP	O
without	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

The	DT	B-NP	O
finding	NN	I-NP	O
that	IN	B-SBAR	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
BE	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
seizures	NNS	I-NP	B
differ	VBP	B-VP	O
in	IN	B-PP	O
several	JJ	B-NP	O
respects	NNS	I-NP	O
suggests	VBZ	B-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mechanism	NN	I-NP	O
for	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
emphasizes	VBZ	B-VP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
cocaine	NN	I-NP	O
metabolite	NN	I-NP	O
,	,	O	O
BE	NN	B-NP	O
.	.	O	O

Protection	NN	B-NP	O
against	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
toward	IN	B-PP	O
striatal	JJ	B-NP	O
dopamine	NN	I-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
rodents	NNS	B-NP	O
by	IN	B-PP	O
LY274614	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
excitatory	JJ	I-NP	O
amino	NN	I-NP	O
acid	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

LY274614	NN	B-NP	O
,	,	O	O
3SR	NN	B-NP	O
,	,	O	O
4aRS	NN	B-NP	O
,	,	O	O
6SR	NN	B-NP	O
,	,	O	O
8aRS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
[	(	I-NP	O
phosphonomethyl	NN	I-NP	O
]	)	O	O
decahydr	NN	B-NP	O
oisoquinoline	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
carboxylic	JJ	I-NP	O
acid	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
subtype	NN	B-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
receptor	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
its	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
antagonize	VB	I-VP	O
the	DT	B-NP	O
prolonged	VBN	I-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
by	IN	B-PP	O
amphetamine	NN	B-NP	O
in	IN	B-PP	O
iprindole	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
(	(	B-LST	O
i.p.	LS	I-LST	O
)	)	O	O
dose	NN	B-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
amphetamine	NN	I-NP	O
hemisulfate	NN	I-NP	O
,	,	O	O
given	VBN	B-PP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
iprindole	NN	B-NP	O
,	,	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
persistent	JJ	B-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
num	CD	I-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
prolonged	JJ	I-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
was	VBD	B-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
dizocilpine	NN	B-NP	O
(	(	O	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
competitive	JJ	I-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
)	)	O	O
or	CC	O	O
by	IN	B-PP	O
LY274614	NN	B-NP	O
(	(	O	O
a	DT	B-NP	O
competitive	JJ	I-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
LY274614	NN	B-NP	O
was	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-PP	O
dependent	JJ	B-ADJP	O
,	,	O	O
being	VBG	B-VP	O
maximum	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mgkg	NN	I-NP	O
(	(	O	O
i.p.	RB	B-ADVP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
LY274614	NN	B-NP	O
was	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
antagonizing	VBG	B-VP	O
the	DT	B-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
as	RB	B-ADVP	O
long	RB	I-ADVP	O
as	IN	B-SBAR	O
num	CD	B-NP	O
hr	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
but	CC	O	O
not	RB	O	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
num	CD	B-NP	O
hr	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

Depletion	NN	B-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
antagonized	VBN	I-VP	O
when	WRB	B-ADVP	O
LY274614	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
;	:	O	O
LY274614	NN	B-NP	O
protected	VBD	B-VP	O
when	WRB	B-ADVP	O
given	VBN	B-PP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
but	CC	O	O
not	RB	O	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
prolonged	VBN	I-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
given	VBN	B-PP	O
multiple	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
,	,	O	O
was	VBD	B-VP	O
also	RB	I-VP	O
antagonized	VBN	I-VP	O
dose	NN	B-NP	O
-	HYPH	O	O
dependently	RB	B-ADVP	O
and	CC	I-ADVP	O
completely	RB	I-ADVP	O
by	IN	B-PP	O
LY274614	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
strengthen	VBP	B-VP	O
the	DT	B-NP	O
evidence	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
neurotoxic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
and	CC	I-NP	O
related	VBN	I-NP	O
compounds	NNS	I-NP	O
toward	IN	B-PP	O
nigrostriatal	JJ	B-NP	O
dopamine	NN	I-NP	O
neurons	NNS	I-NP	O
involves	VBZ	B-VP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
LY274614	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
with	IN	B-PP	O
long	RB	B-ADVP	O
-	HYPH	B-NP	O
lasting	VBG	B-VP	O
in	FW	B-NP	O
vivo	FW	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Neonatal	JJ	B-NP	O
pyridoxine	NN	I-NP	O
responsive	JJ	I-NP	O
convulsions	NNS	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
isoniazid	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
infant	NN	I-NP	O
on	IN	B-PP	O
isoniazid	NN	B-NP	O
therapy	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
daily	RB	B-ADVP	O
from	IN	B-PP	O
birth	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
maternal	JJ	B-NP	O
tuberculosis	NN	I-NP	B
was	VBD	B-VP	O
admitted	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
clonic	JJ	B-NP	B
fits	NNS	I-NP	I
.	.	O	O

No	DT	B-NP	O
underlying	VBG	I-NP	O
infective	JJ	I-NP	O
or	CC	I-NP	O
biochemical	JJ	I-NP	O
cause	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
found	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
fits	NNS	I-NP	B
ceased	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
administering	VBG	B-VP	O
intramuscular	JJ	B-NP	O
pyridoxine	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
an	DT	B-NP	O
aetiology	NN	I-NP	O
of	IN	B-PP	O
pyridoxine	NN	B-NP	O
deficiency	NN	I-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
isoniazid	NN	B-NP	O
medication	NN	I-NP	O
.	.	O	O

Reversal	NN	B-NP	O
by	IN	B-PP	O
phenylephrine	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
nitroglycerin	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
myocardial	JJ	I-NP	I
infarction	NN	I-NP	I
.	.	O	O

Nitroglycerin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
reduce	VB	I-VP	O
ST	NN	B-NP	O
-	HYPH	I-NP	O
segment	NN	I-NP	O
elevation	NN	I-NP	O
during	IN	B-PP	O
acute	JJ	B-NP	B
myocardial	JJ	I-NP	I
infarction	NN	I-NP	I
,	,	O	O
an	DT	B-NP	O
effect	NN	I-NP	O
potentiated	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
dog	NN	I-NP	O
by	IN	B-PP	O
agents	NNS	B-NP	O
that	WDT	B-NP	O
reverse	VBP	B-VP	O
nitroglycerin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Our	PRP$	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
combined	VBN	B-NP	O
nitroglycerin	NN	I-NP	O
and	CC	I-NP	O
phenylephrine	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
transmural	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarctions	NNS	I-NP	I
received	VBD	B-VP	O
intravenous	JJ	B-NP	O
nitroglycerin	NN	I-NP	O
,	,	O	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
.	.	O	O

Left	VBN	B-NP	O
ventricular	JJ	I-NP	O
filling	NN	I-NP	O
pressure	NN	I-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
.	.	O	O

SigmaST	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
sum	NN	I-NP	O
of	IN	B-PP	O
ST	NN	B-NP	O
-	HYPH	I-NP	O
segment	NN	I-NP	O
elevations	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
precordial	JJ	I-NP	O
leads	NNS	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
nitroglycerin	NN	I-NP	O
.	.	O	O

Subsequent	JJ	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
phenylephrine	NN	B-NP	O
infusion	NN	I-NP	O
,	,	O	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
re	VB	I-VP	O
-	HYPH	O	O
elevate	VB	B-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
,	,	O	O
increased	VBN	B-VP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
filling	NN	I-NP	O
pressure	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
and	CC	O	O
also	RB	B-ADVP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
sigmaST	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
addition	NN	B-NP	O
of	IN	B-PP	O
phenylephrine	NN	B-NP	O
to	TO	B-PP	O
nitroglycerin	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
beneficial	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
myocardial	JJ	I-NP	I
infarction	NN	I-NP	I
.	.	O	O

Elevation	NN	B-NP	O
of	IN	B-PP	O
ADAM10	NN	B-NP	O
,	,	O	O
ADAM17	NN	B-NP	O
,	,	O	O
MMP	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
MMP	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
expression	NN	I-NP	O
with	IN	B-PP	O
media	NNS	B-NP	O
degeneration	NN	I-NP	O
features	VBZ	B-VP	O
CaCl2	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
thoracic	JJ	I-NP	B
aortic	JJ	I-NP	I
aneurysm	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
establish	VB	I-VP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
thoracic	JJ	B-NP	B
aortic	JJ	I-NP	I
aneurysm	NN	I-NP	I
(	(	O	O
TAA	NN	B-NP	B
)	)	O	O
by	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
(	(	O	O
CaCl	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
arterial	JJ	I-NP	B
injury	NN	I-NP	I
and	CC	O	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
disintegrin	NN	I-NP	O
and	CC	I-NP	O
metalloproteinase	NN	I-NP	O
(	(	O	O
ADAM	NN	B-NP	O
)	)	O	O
,	,	O	O
matrix	NN	B-NP	O
metalloproteinases	NNS	I-NP	O
(	(	O	O
MMPs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
their	PRP$	B-NP	O
endogenous	JJ	I-NP	O
inhibitors	NNS	I-NP	O
(	(	O	O
TIMPs	NNS	B-NP	O
)	)	O	O
in	IN	B-PP	O
TAA	NN	B-NP	B
formation	NN	I-NP	O
.	.	O	O

Thoracic	JJ	B-NP	O
aorta	NN	I-NP	O
of	IN	B-PP	O
male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
0.5M	NN	B-NP	O
CaCl	NN	I-NP	O
or	CC	O	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
(	(	O	O
NaCl	NN	B-NP	O
)	)	O	O
.	.	O	O

After	IN	B-PP	O
12weeks	NNS	B-NP	O
,	,	O	O
animals	NNS	B-NP	O
were	VBD	B-VP	O
euthanized	VBN	I-VP	O
,	,	O	O
and	CC	O	O
CaCl	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
,	,	O	O
CaCl	NN	B-NP	O
-	HYPH	B-NP	O
untreated	JJ	I-NP	O
and	CC	I-NP	O
NaCl	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
aortic	JJ	I-NP	O
segments	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
for	IN	B-PP	O
histological	JJ	B-NP	O
and	CC	I-NP	O
molecular	JJ	I-NP	O
assessments	NNS	I-NP	O
.	.	O	O

MMP	NN	B-NP	O
-	HYPH	I-NP	O
TIMP	NN	I-NP	O
and	CC	I-NP	O
ADAM	NN	I-NP	O
mRNAs	NNS	I-NP	O
were	VBD	B-VP	O
semi	AFX	O	O
-	HYPH	O	O
quantitatively	RB	B-VP	O
analyzed	VBN	I-VP	O
and	CC	O	O
protein	NN	B-NP	O
expressions	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
immunohistochemistry	NN	B-NP	O
.	.	O	O

Despite	IN	B-PP	O
similar	JJ	B-NP	O
external	JJ	I-NP	O
diameters	NNS	I-NP	O
among	IN	B-PP	O
CaCl	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
,	,	O	O
non	AFX	O	O
-	HYPH	B-NP	O
CaCl	NN	I-NP	O
-	HYPH	B-VP	O
treated	VBN	I-VP	O
and	CC	O	O
NaCl	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
segments	NNS	I-NP	O
,	,	O	O
aneurymal	JJ	B-NP	O
alteration	NN	I-NP	O
,	,	O	O
media	NNS	B-NP	O
degeneration	NN	I-NP	O
with	IN	B-PP	O
regional	JJ	B-NP	O
disruption	NN	I-NP	O
,	,	O	O
fragmentation	NN	B-NP	O
of	IN	B-PP	O
elastic	JJ	B-NP	O
fiber	NN	I-NP	O
,	,	O	O
and	CC	O	O
increased	VBD	B-VP	O
collagen	NN	B-NP	O
deposition	NN	I-NP	O
were	VBD	B-VP	O
demonstrated	VBN	I-VP	O
in	IN	B-PP	O
CaCl	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
segments	NNS	I-NP	O
.	.	O	O

MMP	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
MMP	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
ADAM	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
ADAM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
CaCl	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
segments	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
trends	NNS	B-NP	O
of	IN	B-PP	O
elevation	NN	B-NP	O
in	IN	B-PP	O
CaCl	NN	B-NP	O
-	HYPH	B-NP	O
untreated	JJ	I-NP	O
segments	NNS	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
NaCl	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
segments	NNS	I-NP	O
.	.	O	O

Immunohistochemistry	NN	B-NP	O
displayed	VBD	B-VP	O
significantly	RB	B-NP	O
increased	VBN	I-NP	O
expressions	NNS	I-NP	O
of	IN	B-PP	O
MMP	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
MMP	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
ADAM	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
ADAM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
in	IN	B-PP	O
intima	NNS	B-NP	O
and	CC	I-NP	O
media	NNS	I-NP	O
for	IN	B-PP	O
CaCl	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
segments	NNS	I-NP	O
.	.	O	O

TIMP	NN	B-NP	O
mRNA	NN	I-NP	O
and	CC	I-NP	O
tissue	NN	I-NP	O
levels	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
obviously	RB	B-ADVP	O
among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
aortic	JJ	I-NP	O
segments	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
establishes	VBZ	B-VP	O
a	DT	B-NP	O
TAA	NN	I-NP	B
model	NN	I-NP	O
by	IN	B-PP	O
periarterial	JJ	B-NP	O
CaCl	NN	I-NP	O
exposure	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
and	CC	O	O
demonstrates	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
expression	NN	B-NP	O
of	IN	B-PP	O
MMP	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
MMP	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ADAM10	NN	I-NP	O
and	CC	I-NP	O
ADAM17	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
vascular	JJ	B-NP	O
remodeling	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
drugs	NNS	B-NP	O
disappear	VBP	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
:	:	O	O
elimination	NN	B-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
medication	NN	I-NP	O
by	IN	B-PP	O
hemodiafiltration	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
heart	NN	B-NP	O
transplantation	NN	I-NP	O
,	,	O	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
acute	JJ	B-NP	O
right	JJ	I-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
requiring	VBG	B-VP	O
continuous	JJ	B-NP	O
venovenous	JJ	I-NP	O
hemodiafiltration	NN	I-NP	O
(	(	O	O
CVVHDF	NN	B-NP	O
)	)	O	O
.	.	O	O

Increasing	VBG	B-VP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
catecholamines	NNS	B-NP	O
,	,	O	O
sedatives	NNS	B-NP	O
,	,	O	O
and	CC	O	O
muscle	NN	B-NP	O
relaxants	NNS	I-NP	O
administered	VBN	B-VP	O
through	IN	B-PP	O
a	DT	B-NP	O
central	JJ	I-NP	O
venous	JJ	I-NP	O
catheter	NN	I-NP	O
were	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
bolus	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
injected	VBN	B-VP	O
through	IN	B-PP	O
an	DT	B-NP	O
alternative	JJ	I-NP	O
catheter	NN	I-NP	O
provoked	VBD	B-VP	O
a	DT	B-NP	O
hypertensive	JJ	I-NP	B
crisis	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
interference	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
venous	JJ	I-NP	O
infusion	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
dialysis	NN	I-NP	O
catheter	NN	I-NP	O
was	VBD	B-VP	O
suspected	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
catheters	NNS	I-NP	O
were	VBD	B-VP	O
changed	VBN	I-VP	O
,	,	O	O
and	CC	O	O
hemodynamics	NNS	B-NP	O
stabilized	VBD	B-VP	O
at	IN	B-PP	O
lower	JJR	B-NP	O
catecholamine	NN	I-NP	O
doses	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
drugs	NNS	I-NP	O
are	VBP	B-VP	O
inadequate	JJ	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
CVVHDF	NN	B-NP	O
,	,	O	O
interference	NN	B-NP	O
with	IN	B-PP	O
adjacent	JJ	B-NP	O
catheters	NNS	I-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
elimination	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
by	IN	B-PP	O
CVVHDF	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
suspected	VBN	I-VP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
glutamate	NN	I-NP	O
supplementation	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
protect	VB	I-VP	O
against	IN	B-PP	O
peripheral	JJ	B-NP	B
neurotoxicity	NN	I-NP	I
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
.	.	O	O

Toxic	JJ	B-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
is	VBZ	B-VP	O
still	RB	B-ADVP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
limiting	VBG	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
chemotherapy	NN	B-NP	O
with	IN	B-PP	O
paclitaxel	NN	B-NP	O
(	(	O	O
PAC	NN	B-NP	O
)	)	O	O
,	,	O	O
although	IN	B-SBAR	O
glutamate	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
closely	RB	I-NP	O
related	JJ	I-NP	O
amino	JJ	I-NP	O
acid	NN	I-NP	O
glutamine	NN	I-NP	O
were	VBD	B-VP	O
claimed	VBN	I-VP	O
to	TO	B-VP	O
ameliorate	VB	I-VP	O
PAC	NN	B-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
pilot	NN	I-NP	O
trial	NN	I-NP	O
aimed	VBN	B-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
supplementation	NN	I-NP	O
for	IN	B-PP	O
preventing	VBG	B-VP	O
PAC	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blinded	VBN	B-VP	O
clinical	JJ	B-ADJP	O
and	CC	O	O
electro	AFX	B-NP	O
-	HYPH	I-NP	O
diagnostic	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ovarian	JJ	I-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
were	VBD	B-VP	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
analysis	NN	B-NP	O
following	VBG	B-PP	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
PAC	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
regimen	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
supplemented	VBN	I-VP	O
by	IN	B-PP	O
glutamate	NN	B-NP	O
all	DT	O	O
along	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
a	DT	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
(	(	O	O
group	NN	B-NP	O
G	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
(	(	O	O
group	NN	B-NP	O
P	NN	I-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
neurological	JJ	B-NP	O
examinations	NNS	I-NP	O
,	,	O	O
questionnaires	NNS	B-NP	O
and	CC	O	O
sensory	JJ	B-NP	O
-	HYPH	I-NP	O
motor	NN	I-NP	O
nerve	NN	I-NP	O
conduction	NN	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
signs	NNS	B-NP	O
or	CC	I-NP	O
symptoms	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
although	IN	B-SBAR	O
neurotoxicity	NN	B-NP	B
symptoms	NNS	I-NP	O
presented	VBN	B-VP	O
mostly	RB	B-ADVP	O
with	IN	B-PP	O
lower	JJR	B-NP	O
scores	NNS	I-NP	O
of	IN	B-PP	O
severity	NN	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
G	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
difference	NN	I-NP	O
reached	VBD	B-VP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
only	RB	B-ADVP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
reported	VBN	B-NP	O
pain	NN	I-NP	B
sensation	NN	I-NP	O
.	.	O	O

Also	RB	B-ADVP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
electro	AFX	I-NP	O
-	HYPH	I-NP	O
diagnostic	JJ	I-NP	O
findings	NNS	I-NP	O
showed	VBD	B-VP	O
similarity	NN	B-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
conclusion	NN	I-NP	O
that	IN	B-SBAR	O
glutamate	NN	B-NP	O
supplementation	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
chosen	VBN	I-NP	O
regimen	NN	I-NP	O
fails	VBZ	B-VP	O
to	TO	I-VP	O
protect	VB	I-VP	O
against	IN	B-PP	O
peripheral	JJ	B-NP	B
neurotoxicity	NN	I-NP	I
of	IN	B-PP	O
PAC	NN	B-NP	O
.	.	O	O

Attentional	JJ	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
perceived	VBN	B-NP	O
pain	NN	I-NP	B
intensity	NN	I-NP	O
in	IN	B-PP	O
capsaicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
secondary	JJ	I-NP	O
hyperalgesia	NN	I-NP	B
.	.	O	O

Perceived	VBN	B-NP	O
pain	NN	I-NP	B
intensity	NN	I-NP	O
is	VBZ	B-VP	O
modulated	VBN	I-VP	O
by	IN	B-PP	O
attention	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
that	IN	B-SBAR	O
how	WRB	B-ADVP	O
pain	JJ	B-NP	B
intensity	NN	I-NP	O
ratings	NNS	I-NP	O
are	VBP	B-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
attention	NN	B-NP	O
in	IN	B-PP	O
capsaicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
secondary	JJ	I-NP	O
hyperalgesia	NN	I-NP	B
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
perceived	VBN	B-NP	O
pain	NN	I-NP	B
intensity	NN	I-NP	O
in	IN	B-PP	O
secondary	JJ	B-NP	O
hyperalgesia	NN	I-NP	B
is	VBZ	B-VP	O
decreased	VBN	I-VP	O
when	WRB	B-ADVP	O
attention	NN	B-NP	O
is	VBZ	B-VP	O
distracted	VBN	I-VP	O
away	RB	B-ADVP	O
from	IN	B-PP	O
the	DT	B-NP	O
painful	JJ	I-NP	O
pinprick	NN	I-NP	O
stimulus	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
visual	JJ	I-NP	O
task	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
attentional	JJ	B-NP	O
modulation	NN	I-NP	O
in	IN	B-PP	O
secondary	JJ	B-NP	O
hyperalgesia	NN	I-NP	B
is	VBZ	B-VP	O
very	RB	B-ADJP	O
similar	JJ	I-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
-	HYPH	B-NP	O
untreated	JJ	I-NP	O
,	,	I-NP	O
control	JJ	I-NP	O
condition	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
,	,	O	O
showing	VBG	B-VP	O
no	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
capsaicin	NN	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
attentional	JJ	B-NP	O
modulation	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
capsaicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
secondary	JJ	I-NP	O
hyperalgesia	NN	I-NP	B
and	CC	I-NP	O
attention	NN	I-NP	O
might	MD	B-VP	O
affect	VB	I-VP	O
mechanical	JJ	B-NP	O
pain	NN	I-NP	B
through	IN	B-PP	O
independent	JJ	B-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

Testosterone	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
hypertension	NN	I-NP	B
and	CC	I-NP	O
upregulation	NN	I-NP	O
of	IN	B-PP	O
intrarenal	JJ	B-NP	O
angiotensinogen	NN	I-NP	O
in	IN	B-PP	O
Dahl	NN	B-NP	O
salt	NN	I-NP	O
-	HYPH	B-NP	O
sensitive	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
pressure	NN	I-NP	O
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
more	JJR	B-NP	O
salt	NN	I-NP	O
sensitive	JJ	B-ADJP	O
in	IN	B-PP	O
men	NNS	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
premenopausal	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
Dahl	NN	B-NP	O
salt	NN	I-NP	O
-	HYPH	B-NP	O
sensitive	JJ	I-NP	O
rats	NNS	I-NP	O
(	(	O	O
DS	NN	B-NP	O
)	)	O	O
,	,	O	O
high	JJ	B-ADJP	O
-	HYPH	O	O
salt	NN	B-NP	O
(	(	O	O
HS	NN	B-NP	O
)	)	O	O
diet	NN	B-NP	O
increases	VBZ	B-VP	O
BP	NN	B-NP	O
more	JJR	I-NP	O
in	IN	B-PP	O
males	NNS	B-NP	O
than	IN	B-PP	O
females	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
systemic	JJ	I-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
suppressed	VBN	I-VP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
HS	NN	B-NP	O
in	IN	B-PP	O
male	JJ	B-NP	O
DS	NN	I-NP	O
,	,	O	O
intrarenal	JJ	B-NP	O
angiotensinogen	NN	I-NP	O
expression	NN	I-NP	O
is	VBZ	B-VP	O
increased	VBN	I-VP	O
,	,	O	O
and	CC	O	O
intrarenal	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
ANG	NN	B-NP	O
num	CD	I-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
suppressed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
that	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
sexual	JJ	I-NP	O
dimorphism	NN	I-NP	O
in	IN	B-PP	O
HS	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
upregulation	NN	I-NP	O
of	IN	B-PP	O
intrarenal	JJ	B-NP	O
angiotensinogen	NN	I-NP	O
mediated	VBN	B-VP	O
by	IN	B-PP	O
testosterone	NN	B-NP	O
that	WDT	B-NP	O
also	RB	B-ADVP	O
causes	VBZ	B-VP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
BP	NN	B-NP	O
and	CC	O	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
.	.	O	O

On	IN	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
salt	NN	I-NP	O
(	(	O	O
LS	NN	B-NP	O
)	)	O	O
diet	NN	B-NP	O
,	,	O	O
male	JJ	B-NP	O
DS	NN	I-NP	O
had	VBD	B-VP	O
higher	JJR	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
intrarenal	JJ	B-NP	O
angiotensinogen	NN	I-NP	O
mRNA	NN	I-NP	O
than	IN	B-PP	O
females	NNS	B-NP	O
.	.	O	O

HS	NN	B-NP	O
diet	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
wk	NN	I-NP	O
increased	VBD	B-VP	O
renal	JJ	B-NP	O
cortical	JJ	I-NP	O
angiotensinogen	NN	I-NP	O
mRNA	NN	I-NP	O
and	CC	I-NP	O
protein	NN	I-NP	O
only	RB	B-PP	O
in	IN	I-PP	O
male	JJ	B-NP	O
DS	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
castration	NN	B-NP	O
.	.	O	O

Ovariectomy	NN	B-NP	O
of	IN	B-PP	O
female	JJ	B-NP	O
DS	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
intrarenal	JJ	B-NP	O
angiotensinogen	NN	I-NP	O
expression	NN	I-NP	O
on	IN	B-PP	O
either	DT	B-NP	O
diet	NN	I-NP	O
.	.	O	O

Radiotelemetric	JJ	B-NP	O
BP	NN	I-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
between	IN	B-PP	O
males	NNS	B-NP	O
and	CC	O	O
castrated	VBN	B-VP	O
rats	NNS	B-NP	O
on	IN	B-PP	O
LS	NN	B-NP	O
diet	NN	I-NP	O
.	.	O	O

HS	NN	B-NP	O
diet	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
wk	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
progressive	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
BP	NN	B-NP	O
,	,	O	O
protein	NN	B-NP	O
and	CC	O	O
albumin	NN	B-NP	O
excretion	NN	I-NP	O
,	,	O	O
and	CC	O	O
glomerular	JJ	B-NP	B
sclerosis	NN	I-NP	I
in	IN	B-PP	O
male	JJ	B-NP	O
DS	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
attenuated	VBN	I-VP	O
by	IN	B-PP	O
castration	NN	B-NP	O
.	.	O	O

Testosterone	NN	B-NP	O
replacement	NN	I-NP	O
in	IN	B-PP	O
castrated	VBN	B-NP	O
DS	NN	I-NP	O
rats	NNS	I-NP	O
increased	VBD	B-VP	O
BP	NN	B-NP	O
,	,	O	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
and	CC	O	O
upregulation	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
angiotensinogen	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
HS	NN	B-NP	O
diet	NN	I-NP	O
.	.	O	O

Testosterone	NN	B-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
and	CC	O	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
male	JJ	B-NP	O
DS	NN	I-NP	O
rats	NNS	I-NP	O
on	IN	B-PP	O
HS	NN	B-NP	O
diet	NN	I-NP	O
possibly	RB	B-ADVP	O
through	IN	B-PP	O
upregulation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
intrarenal	JJ	I-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

Prenatal	JJ	B-NP	O
protein	NN	I-NP	O
deprivation	NN	I-NP	O
alters	VBZ	B-VP	O
dopamine	NN	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
behaviors	NNS	I-NP	O
and	CC	O	O
dopaminergic	JJ	B-NP	O
and	CC	I-NP	O
glutamatergic	JJ	I-NP	O
receptor	NN	I-NP	O
binding	NN	I-NP	O
.	.	O	O

Epidemiological	JJ	B-NP	O
evidence	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
prenatal	JJ	B-NP	O
nutritional	JJ	I-NP	O
deprivation	NN	I-NP	O
may	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
was	VBD	B-VP	O
to	TO	I-VP	O
use	VB	I-VP	O
an	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
prenatal	JJ	B-NP	O
protein	NN	I-NP	O
deprivation	NN	I-NP	O
on	IN	B-PP	O
behaviors	NNS	B-NP	O
and	CC	O	O
receptor	NN	B-NP	O
binding	NN	I-NP	O
with	IN	B-PP	O
relevance	NN	B-NP	O
to	TO	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
that	IN	B-SBAR	O
prenatally	RB	B-NP	O
protein	NN	I-NP	O
deprived	VBN	B-VP	O
(	(	O	O
PD	NN	B-NP	O
)	)	O	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
stereotypic	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
apomorphine	NN	B-NP	O
and	CC	O	O
an	DT	B-NP	O
increased	VBN	I-NP	O
locomotor	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
in	IN	B-PP	O
adulthood	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
during	IN	B-PP	O
puberty	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
or	CC	I-NP	O
MK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
locomotion	NN	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
following	VBG	B-PP	O
PD	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
PD	NN	B-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
showed	VBD	B-VP	O
increased	VBN	B-NP	O
H	NN	I-NP	O
-	HYPH	B-NP	O
MK	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
and	CC	I-NP	O
hippocampus	NN	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
.	.	O	O

PD	NN	B-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
increased	VBN	B-NP	O
H	NN	I-NP	O
-	HYPH	B-NP	O
haloperidol	NN	I-NP	O
binding	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
dopamine	NN	B-NP	O
transporter	NN	I-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
striatum	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
behavior	NN	B-NP	O
or	CC	I-NP	O
receptor	NN	I-NP	O
binding	NN	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
PD	NN	B-NP	O
males	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
exception	NN	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
H	NN	I-NP	O
-	HYPH	B-NP	O
MK	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
cortex	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
prenatal	JJ	B-NP	O
nutritional	JJ	I-NP	B
deficiency	NN	I-NP	I
enhances	VBZ	B-VP	O
risk	NN	B-NP	O
for	IN	B-PP	O
schizophrenia	NN	B-NP	B
in	IN	B-PP	O
humans	NNS	B-NP	O
and	CC	O	O
may	MD	B-VP	O
also	RB	I-VP	O
have	VB	I-VP	O
implications	NNS	B-NP	O
for	IN	B-PP	O
developmental	JJ	B-NP	O
processes	NNS	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
differential	JJ	B-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
drugs	NNS	B-NP	O
of	IN	B-PP	O
abuse	NN	B-NP	O
.	.	O	O

mToR	NN	B-NP	O
inhibitors	NNS	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
proteinuria	NN	I-NP	B
:	:	O	O
mechanisms	NNS	B-NP	O
,	,	O	O
significance	NN	B-NP	O
,	,	O	O
and	CC	O	O
management	NN	B-NP	O
.	.	O	O

Massive	JJ	B-NP	O
urinary	JJ	I-NP	O
protein	NN	I-NP	O
excretion	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
conversion	NN	B-NP	O
from	IN	B-PP	O
calcineurin	NN	B-NP	O
inhibitors	NNS	I-NP	O
to	TO	B-PP	O
mammalian	JJ	B-NP	O
target	NN	I-NP	O
of	IN	B-PP	O
rapamycin	NN	B-NP	O
(	(	O	O
mToR	NN	B-NP	O
)	)	O	O
inhibitors	NNS	B-NP	O
,	,	O	O
especially	RB	B-NP	O
sirolimus	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
allograft	NN	I-NP	I
nephropathy	NN	I-NP	I
.	.	O	O

Because	IN	B-SBAR	O
proteinuria	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
predictive	JJ	I-NP	O
factor	NN	I-NP	O
of	IN	B-PP	O
poor	JJ	B-NP	O
transplantation	NN	I-NP	O
outcome	NN	I-NP	O
,	,	O	O
many	JJ	B-NP	O
studies	NNS	I-NP	O
focused	VBN	B-VP	O
on	IN	B-PP	O
this	DT	B-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
past	JJ	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Whether	IN	B-SBAR	O
proteinuria	NN	B-NP	B
was	VBD	B-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
sirolimus	NN	B-NP	O
or	CC	O	O
only	RB	B-NP	O
a	DT	I-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
calcineurin	NN	B-NP	O
inhibitors	NNS	I-NP	O
withdrawal	NN	I-NP	O
remained	VBD	B-VP	O
unsolved	JJ	B-ADJP	O
until	IN	B-SBAR	O
high	JJ	B-NP	O
range	NN	I-NP	O
proteinuria	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
during	IN	B-PP	O
sirolimus	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
islet	NN	B-NP	O
transplantation	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
sirolimus	FW	B-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
.	.	O	O

Podocyte	NN	B-NP	O
injury	NN	I-NP	O
and	CC	O	O
focal	JJ	B-NP	O
segmental	JJ	I-NP	O
glomerulosclerosis	NN	I-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
mToR	NN	B-NP	O
inhibition	NN	I-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
pathways	NNS	I-NP	O
underlying	VBG	B-VP	O
these	DT	B-NP	O
lesions	NNS	I-NP	O
remain	VBP	B-VP	O
hypothetic	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
discuss	VBP	B-VP	O
herein	RB	B-ADVP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
mechanisms	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
significance	NN	I-NP	O
of	IN	B-PP	O
mToR	NN	B-NP	O
blockade	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

Hypothalamic	JJ	B-NP	O
prolactin	NN	I-NP	O
receptor	NN	I-NP	O
messenger	NN	I-NP	O
ribonucleic	JJ	I-NP	O
acid	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
prolactin	NN	B-NP	O
signaling	NN	I-NP	O
,	,	O	O
and	CC	O	O
hyperprolactinemic	JJ	B-NP	B
inhibition	NN	I-NP	O
of	IN	B-PP	O
pulsatile	JJ	B-NP	O
luteinizing	NN	I-NP	O
hormone	NN	I-NP	O
secretion	NN	I-NP	O
are	VBP	B-VP	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
estradiol	NN	B-NP	O
.	.	O	O

Hyperprolactinemia	NN	B-NP	B
can	MD	B-VP	O
reduce	VB	I-VP	O
fertility	NN	B-NP	O
and	CC	I-NP	O
libido	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
central	JJ	B-NP	O
prolactin	NN	I-NP	O
actions	NNS	I-NP	O
are	VBP	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
,	,	O	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
poorly	RB	I-VP	O
understood	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
first	RB	B-ADVP	O
tested	VBD	B-VP	O
whether	IN	B-SBAR	O
chronic	JJ	B-NP	O
hyperprolactinemia	NN	I-NP	B
inhibited	VBD	B-VP	O
num	CD	B-NP	O
neuroendocrine	JJ	I-NP	O
parameters	NNS	I-NP	O
necessary	JJ	B-ADJP	O
for	IN	B-PP	O
female	JJ	B-NP	O
fertility	NN	I-NP	O
:	:	O	O
pulsatile	JJ	B-NP	O
LH	NN	I-NP	O
secretion	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
estrogen	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
LH	NN	I-NP	O
surge	NN	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
hyperprolactinemia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
dopamine	NN	I-NP	O
antagonist	NN	I-NP	O
sulpiride	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
LH	NN	I-NP	O
pulse	NN	I-NP	O
frequency	NN	I-NP	O
in	IN	B-PP	O
ovariectomized	VBN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
but	CC	O	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
low	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
estradiol	NN	B-NP	O
.	.	O	O

Sulpiride	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
steroid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
LH	NN	I-NP	O
surge	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
GnRH	NN	B-NP	O
neurons	NNS	I-NP	O
activated	VBN	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
surge	NN	I-NP	O
.	.	O	O

Estradiol	NN	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
influence	VB	I-VP	O
expression	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
prolactin	NN	B-NP	O
receptors	NNS	I-NP	O
(	(	O	O
PRL	NN	B-NP	O
-	HYPH	B-NP	O
R	NN	I-NP	O
)	)	O	O
and	CC	O	O
components	NNS	B-NP	O
of	IN	B-PP	O
prolactin	NN	B-NP	O
s	VBZ	B-VP	O
signaling	NN	B-NP	O
pathway	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
estrogen	NN	B-NP	O
increases	VBZ	B-VP	O
PRL	NN	B-NP	O
-	HYPH	I-NP	O
R	NN	I-NP	O
expression	NN	I-NP	O
and	CC	O	O
sensitivity	NN	B-NP	O
to	TO	B-PP	O
prolactin	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
next	RB	B-ADVP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
estradiol	NN	B-NP	O
greatly	RB	B-ADVP	O
augments	VBZ	B-VP	O
prolactin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
STAT5	NN	I-NP	O
activation	NN	I-NP	O
.	.	O	O

Lastly	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
measured	VBD	B-VP	O
PRL	NN	B-NP	O
-	HYPH	B-NP	O
R	NN	I-NP	O
and	CC	I-NP	O
suppressor	NN	I-NP	O
of	IN	B-PP	O
cytokine	NN	B-NP	O
signaling	NN	I-NP	O
(	(	O	O
SOCS	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	O	O
CIS	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
reflect	VBP	B-VP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
prolactin	NN	B-NP	O
signaling	NN	I-NP	O
)	)	O	O
mRNAs	NNS	B-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
sulpiride	NN	B-NP	O
and	CC	I-NP	O
estradiol	NN	I-NP	O
.	.	O	O

Sulpiride	NN	B-NP	O
induced	VBD	B-VP	O
only	RB	B-NP	O
SOCS	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
medial	JJ	I-NP	O
preoptic	JJ	I-NP	O
area	NN	I-NP	O
,	,	O	O
where	WRB	B-ADVP	O
GnRH	NN	B-NP	O
neurons	NNS	I-NP	O
are	VBP	B-VP	O
regulated	VBN	I-VP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
arcuate	JJ	I-NP	O
nucleus	NN	I-NP	O
and	CC	O	O
choroid	JJ	B-NP	O
plexus	NN	I-NP	O
,	,	O	O
PRL	NN	B-NP	O
-	HYPH	B-NP	O
R	NN	I-NP	O
,	,	O	O
SOCS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
CIS	NN	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
induced	VBN	I-VP	O
.	.	O	O

Estradiol	NN	B-NP	O
enhanced	VBD	B-VP	O
these	DT	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
SOCS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
CIS	NN	I-NP	O
.	.	O	O

Interestingly	RB	B-ADVP	O
,	,	O	O
estradiol	NN	B-NP	O
also	RB	B-ADVP	O
induced	VBD	B-VP	O
PRL	NN	B-NP	O
-	HYPH	B-NP	O
R	NN	I-NP	O
,	,	O	O
SOCS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
CIS	NN	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
independently	RB	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
GnRH	NN	B-NP	O
pulse	NN	I-NP	O
frequency	NN	I-NP	O
is	VBZ	B-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
hyperprolactinemia	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
steroid	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
also	RB	B-ADVP	O
provide	VBP	B-VP	O
evidence	NN	B-NP	O
for	IN	B-PP	O
estradiol	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
region	NN	I-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
PRL	NN	B-NP	O
-	HYPH	B-NP	O
R	NN	I-NP	O
expression	NN	I-NP	O
and	CC	O	O
signaling	NN	B-NP	O
responses	NNS	I-NP	O
by	IN	B-PP	O
prolactin	NN	B-NP	O
.	.	O	O

Estrogen	NN	B-NP	O
prevents	VBZ	B-VP	O
cholesteryl	NN	B-NP	O
ester	NN	I-NP	O
accumulation	NN	I-NP	O
in	IN	B-PP	O
macrophages	NNS	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
HIV	NN	I-NP	O
protease	NN	I-NP	O
inhibitor	NN	I-NP	O
ritonavir	NN	I-NP	O
.	.	O	O

Individuals	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	O
can	MD	B-VP	O
now	RB	I-VP	O
live	VB	I-VP	O
long	JJ	B-NP	O
lives	NNS	I-NP	O
with	IN	B-PP	O
drug	NN	B-NP	O
therapy	NN	I-NP	O
that	WDT	B-NP	O
often	RB	B-ADVP	O
includes	VBZ	B-VP	O
protease	NN	B-NP	O
inhibitors	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
ritonavir	NN	B-NP	O
.	.	O	O

Many	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
develop	VBP	B-VP	O
negative	JJ	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
premature	JJ	B-NP	B
atherosclerosis	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
previously	RB	I-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
ritonavir	NN	B-NP	O
treatment	NN	I-NP	O
increases	VBZ	B-VP	O
atherosclerotic	JJ	B-NP	B
lesion	NN	I-NP	I
formation	NN	I-NP	O
in	IN	B-PP	O
male	JJ	B-NP	O
mice	NNS	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
extent	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
female	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
peripheral	JJ	B-NP	O
blood	NN	I-NP	O
monocytes	NNS	I-NP	O
isolated	VBN	B-VP	O
from	IN	B-PP	O
ritonavir	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
females	NNS	I-NP	O
had	VBD	B-VP	O
less	JJR	B-NP	O
cholesteryl	NN	I-NP	O
ester	NN	I-NP	O
accumulation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
have	VBP	B-VP	O
investigated	VBN	I-VP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
female	JJ	B-NP	O
hormones	NNS	I-NP	O
influence	VBP	B-VP	O
cholesterol	NN	B-NP	O
metabolism	NN	I-NP	O
in	IN	B-PP	O
macrophages	NNS	B-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
HIV	NN	I-NP	O
protease	NN	I-NP	O
inhibitor	NN	I-NP	O
ritonavir	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
utilized	VBN	I-VP	O
the	DT	B-NP	O
human	JJ	I-NP	O
monocyte	NN	I-NP	O
cell	NN	I-NP	O
line	NN	I-NP	O
,	,	O	O
THP	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
address	VB	I-VP	O
this	DT	B-NP	O
question	NN	I-NP	O
.	.	O	O

Briefly	RB	B-ADVP	O
,	,	O	O
cells	NNS	B-NP	O
were	VBD	B-VP	O
differentiated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
nM	NN	I-NP	O
PMA	NN	I-NP	O
to	TO	B-VP	O
obtain	VB	I-VP	O
a	DT	B-NP	O
macrophage	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
phenotype	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
or	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
nM	NN	I-NP	O
17beta	NN	I-NP	O
-	HYPH	O	O
estradiol	NN	B-NP	O
(	(	O	O
E2	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
nM	NN	I-NP	O
progesterone	NN	I-NP	O
or	CC	O	O
vehicle	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
ethanol	NN	I-NP	O
)	)	O	O
.	.	O	O

Cells	NNS	B-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	O	O
ml	NN	B-NP	O
ritonavir	NN	I-NP	O
or	CC	I-NP	O
vehicle	NN	I-NP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
aggregated	JJ	B-NP	O
LDL	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

Cell	NN	B-NP	O
extracts	NNS	I-NP	O
were	VBD	B-VP	O
harvested	VBN	I-VP	O
,	,	O	O
and	CC	O	O
lipid	NN	B-NP	O
or	CC	O	O
total	JJ	B-NP	O
RNA	NN	I-NP	O
was	VBD	B-VP	O
isolated	VBN	I-VP	O
.	.	O	O

E2	NN	B-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
cholesteryl	NN	B-NP	O
esters	NNS	I-NP	O
in	IN	B-PP	O
macrophages	NNS	B-NP	O
following	VBG	B-PP	O
ritonavir	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Ritonavir	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
scavenger	NN	I-NP	O
receptor	NN	I-NP	O
,	,	O	O
CD36	NN	B-NP	O
mRNA	NN	I-NP	O
,	,	O	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
uptake	NN	I-NP	O
of	IN	B-PP	O
LDL	NN	B-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
ritonavir	NN	B-NP	O
treatment	NN	I-NP	O
selectively	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
relative	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
PPARgamma	NN	B-NP	O
mRNA	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
transcription	NN	I-NP	O
factor	NN	I-NP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
CD36	NN	B-NP	O
mRNA	NN	I-NP	O
expression	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
E2	NN	B-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
failed	VBD	B-VP	O
to	TO	I-VP	O
prevent	VB	I-VP	O
these	DT	B-NP	O
increases	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
mRNA	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

E2	NN	B-NP	O
did	VBD	B-VP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
significantly	RB	B-ADVP	O
suppress	VBP	B-VP	O
CD36	NN	B-NP	O
protein	NN	I-NP	O
levels	NNS	I-NP	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
fluorescent	JJ	B-NP	O
immunocytochemistry	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
data	NNS	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
E2	NN	B-NP	O
modifies	VBZ	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
CD36	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
protein	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
monocyte	NN	B-NP	O
-	HYPH	O	O
derived	VBN	B-VP	O
macrophages	NNS	B-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
reduced	VBN	B-NP	O
cholesteryl	NN	I-NP	O
ester	NN	I-NP	O
accumulation	NN	I-NP	O
following	VBG	B-PP	O
ritonavir	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Upregulation	NN	B-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
P	NN	B-NP	O
-	HYPH	B-NP	O
glycoprotein	NN	I-NP	O
in	IN	B-PP	O
MRP2	NN	B-NP	O
-	HYPH	B-NP	O
deficient	JJ	I-NP	O
TR	NN	I-NP	O
rats	NNS	I-NP	O
resembles	VBZ	B-VP	O
seizure	NN	B-NP	B
-	HYPH	O	O
induced	VBN	B-VP	O
up	RB	B-ADVP	O
-	HYPH	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
efflux	NN	I-NP	O
transporter	NN	I-NP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
multidrug	JJ	I-NP	O
resistance	NN	I-NP	O
protein	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
MRP2	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
drug	NN	I-NP	O
efflux	NN	I-NP	O
transporter	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
expressed	VBN	I-VP	O
predominantly	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
apical	JJ	I-NP	O
domain	NN	I-NP	O
of	IN	B-PP	O
hepatocytes	NNS	B-NP	O
but	CC	O	O
seems	VBZ	B-VP	O
also	RB	B-ADVP	O
to	TO	B-VP	O
be	VB	I-VP	O
expressed	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
apical	JJ	I-NP	O
membrane	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
capillary	JJ	I-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
that	WDT	B-NP	O
form	VBP	B-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
(	(	O	O
BBB	NN	B-NP	O
)	)	O	O
.	.	O	O

MRP2	NN	B-NP	O
is	VBZ	B-VP	O
absent	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
transport	NN	I-NP	O
-	HYPH	B-NP	O
deficient	JJ	I-NP	O
(	(	O	O
TR	NN	B-NP	O
)	)	O	O
Wistar	NNP	B-NP	O
rat	NN	I-NP	O
mutant	NN	I-NP	O
,	,	O	O
so	IN	B-SBAR	O
that	IN	I-SBAR	O
this	DT	B-NP	O
rat	NN	I-NP	O
strain	NN	I-NP	O
was	VBD	B-VP	O
very	RB	B-ADJP	O
helpful	JJ	I-ADJP	O
in	IN	B-PP	O
defining	VBG	B-VP	O
substrates	NNS	B-NP	O
of	IN	B-PP	O
MRP2	NN	B-NP	O
by	IN	B-PP	O
comparing	VBG	B-VP	O
tissue	NN	B-NP	O
concentrations	NNS	I-NP	O
or	CC	O	O
functional	JJ	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
compounds	NNS	B-NP	O
in	IN	B-PP	O
MRP2	NN	B-NP	O
-	HYPH	B-NP	O
deficient	JJ	I-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
transport	NN	B-NP	O
-	HYPH	B-NP	O
competent	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

By	IN	B-PP	O
using	VBG	B-VP	O
this	DT	B-NP	O
strategy	NN	I-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
MRP2	NN	B-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
access	NN	I-NP	O
of	IN	B-PP	O
antiepileptic	JJ	B-NP	O
drugs	NNS	I-NP	O
(	(	O	O
AEDs	NNS	B-NP	O
)	)	O	O
,	,	O	O
we	PRP	B-NP	O
recently	RB	B-ADVP	O
reported	VBD	B-VP	O
that	IN	B-SBAR	O
phenytoin	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
substrate	NN	I-NP	O
for	IN	B-PP	O
MRP2	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
drawback	NN	I-NP	O
of	IN	B-PP	O
such	JJ	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
genetically	RB	B-NP	O
deficient	JJ	I-NP	O
rats	NNS	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
compensatory	JJ	B-NP	O
changes	NNS	I-NP	O
with	IN	B-PP	O
upregulation	NN	B-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
transporters	NNS	I-NP	O
can	MD	B-VP	O
occur	VB	I-VP	O
.	.	O	O

This	DT	B-NP	O
prompted	VBD	B-VP	O
us	PRP	B-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
brain	NN	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
P	NN	B-NP	O
-	HYPH	O	O
glycoprotein	NN	B-NP	O
(	(	O	O
Pgp	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
major	JJ	I-NP	O
drug	NN	I-NP	O
efflux	NN	I-NP	O
transporter	NN	I-NP	O
in	IN	B-PP	O
many	JJ	B-NP	O
tissues	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
,	,	O	O
in	IN	B-PP	O
TR	NN	B-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
nonmutant	JJ	O	O
(	(	O	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
)	)	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
MRP2	NN	B-NP	O
and	CC	I-NP	O
Pgp	NN	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
sections	NNS	I-NP	O
of	IN	B-PP	O
TR	NN	B-NP	O
rats	NNS	I-NP	O
and	CC	O	O
normal	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
with	IN	B-PP	O
immunohistochemistry	NN	B-NP	O
,	,	O	O
by	IN	B-PP	O
using	VBG	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
,	,	I-NP	O
highly	RB	I-NP	O
selective	JJ	I-NP	O
monoclonal	JJ	I-NP	O
MRP2	NN	I-NP	O
antibody	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
monoclonal	JJ	I-NP	O
Pgp	NN	I-NP	O
antibody	NN	I-NP	O
C219	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Immunofluorescence	NN	B-NP	O
staining	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
MRP2	NN	I-NP	O
antibody	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
label	VB	I-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
microvessels	NNS	B-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
such	JJ	B-NP	O
labeling	NN	I-NP	O
was	VBD	B-VP	O
absent	JJ	B-ADJP	O
in	IN	B-PP	O
TR	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

TR	NN	B-NP	O
rats	NNS	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
up	RB	B-ADVP	O
-	HYPH	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
Pgp	NN	B-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
capillary	JJ	I-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
such	JJ	I-NP	O
obvious	JJ	I-NP	O
upregulation	NN	I-NP	O
of	IN	B-PP	O
Pgp	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
liver	NN	B-NP	O
sections	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
comparable	JJ	I-NP	O
overexpression	NN	I-NP	O
of	IN	B-PP	O
Pgp	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BBB	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
after	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Experiments	NNS	B-NP	O
with	IN	B-PP	O
systemic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Pgp	NN	I-NP	O
substrate	NN	I-NP	O
phenobarbital	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
selective	JJ	I-NP	O
Pgp	NN	I-NP	O
inhibitor	NN	I-NP	O
tariquidar	NN	I-NP	O
in	IN	B-PP	O
TR	NN	B-NP	O
rats	NNS	I-NP	O
substantiated	VBD	B-VP	O
that	IN	B-SBAR	O
Pgp	NN	B-NP	O
is	VBZ	B-VP	O
functional	JJ	B-ADJP	O
and	CC	O	O
compensates	NNS	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
MRP2	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
on	IN	B-PP	O
TR	NN	B-NP	O
rats	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
Pgp	NN	B-NP	O
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
compensation	NN	I-NP	O
of	IN	B-PP	O
MRP2	NN	B-NP	O
deficiency	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
such	PDT	B-NP	O
a	DT	I-NP	O
compensatory	JJ	I-NP	O
mechanism	NN	I-NP	O
most	RBS	B-ADVP	O
likely	RB	I-ADVP	O
occurs	VBZ	B-VP	O
to	TO	I-VP	O
reduce	VB	I-VP	O
injury	NN	B-NP	B
to	TO	B-PP	I
the	DT	B-NP	I
brain	NN	I-NP	I
from	IN	B-PP	O
cytotoxic	JJ	B-NP	O
compounds	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
data	NNS	I-NP	O
substantiate	VBP	B-VP	O
the	DT	B-NP	O
concept	NN	I-NP	O
that	IN	B-SBAR	O
MRP2	NN	B-NP	O
performs	VBZ	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
our	PRP$	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
TR	NN	B-NP	O
rats	NNS	I-NP	O
are	VBP	B-VP	O
an	DT	B-NP	O
interesting	JJ	I-NP	O
tool	NN	I-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
consequences	NNS	B-NP	O
of	IN	B-PP	O
overexpression	NN	B-NP	O
of	IN	B-PP	O
Pgp	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BBB	NN	I-NP	O
on	IN	B-PP	O
access	NN	B-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
the	DT	B-NP	O
need	NN	I-NP	O
of	IN	B-PP	O
inducing	VBG	B-VP	O
seizures	NNS	B-NP	B
or	CC	O	O
other	JJ	B-NP	O
Pgp	NN	I-NP	O
-	HYPH	B-NP	O
enhancing	VBG	B-VP	O
events	NNS	B-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
purpose	NN	I-NP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
chromosome	NN	B-NP	O
substitution	NN	I-NP	O
strains	NNS	I-NP	O
to	TO	B-VP	O
identify	VB	I-VP	O
seizure	NN	B-NP	B
susceptibility	NN	I-NP	O
loci	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Seizure	NN	B-NP	B
susceptibility	NN	I-NP	O
varies	VBZ	B-VP	O
among	IN	B-PP	O
inbred	JJ	B-NP	O
mouse	NN	I-NP	O
strains	NNS	I-NP	O
.	.	O	O

Chromosome	NN	B-NP	O
substitution	NN	I-NP	O
strains	NNS	I-NP	O
(	(	O	O
CSS	NN	B-NP	O
)	)	O	O
,	,	O	O
in	IN	B-PP	O
which	WDT	B-NP	O
a	DT	B-NP	O
single	JJ	I-NP	O
chromosome	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
inbred	JJ	I-NP	O
strain	NN	I-NP	O
(	(	O	O
donor	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
transferred	VBN	I-VP	O
onto	IN	B-PP	O
a	DT	B-NP	O
second	JJ	I-NP	O
strain	NN	I-NP	O
(	(	O	O
host	NN	B-NP	O
)	)	O	O
by	IN	B-PP	O
repeated	VBN	B-NP	O
backcrossing	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
identify	VB	I-VP	O
quantitative	JJ	B-NP	O
trait	NN	I-NP	O
loci	NNS	I-NP	O
(	(	O	O
QTLs	NNS	B-NP	O
)	)	O	O
that	WDT	B-NP	O
contribute	VBP	B-VP	O
to	TO	I-VP	O
seizure	VB	I-VP	B
susceptibility	NN	B-NP	O
.	.	O	O

QTLs	NNS	B-NP	O
for	IN	B-PP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
,	,	O	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
temporal	JJ	B-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
,	,	O	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
,	,	O	O
and	CC	O	O
CSS	NN	B-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
localize	VB	I-VP	O
seizure	NN	B-NP	B
susceptibility	NN	I-NP	O
genes	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
QTLs	NNS	B-NP	O
identified	VBN	B-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
B6	NN	I-NP	O
(	(	O	O
host	NN	B-NP	O
)	)	O	O
x	NN	B-NP	O
A	NN	I-NP	O
/	SYM	O	O
J	NN	B-NP	O
(	(	O	O
donor	NN	B-NP	O
)	)	O	O
CSS	NN	B-NP	O
panel	NN	I-NP	O
to	TO	B-VP	O
localize	VB	I-VP	O
genes	NNS	B-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adult	JJ	I-NP	O
male	JJ	I-NP	O
CSS	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
B6	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
A	NN	I-NP	O
/	SYM	I-NP	O
J	NN	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Highest	JJ	B-NP	O
stage	NN	I-NP	O
reached	VBD	B-VP	O
and	CC	O	O
latency	NN	B-NP	O
to	TO	B-PP	O
each	DT	B-NP	O
stage	NN	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
for	IN	B-PP	O
all	DT	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

B6	NN	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
resistant	JJ	B-ADJP	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
and	CC	O	O
slower	JJR	B-ADJP	O
to	TO	B-VP	O
reach	VB	I-VP	O
stages	NNS	B-NP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
A	NN	B-NP	O
/	SYM	I-NP	O
J	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
CSS	NN	I-NP	O
for	IN	B-PP	O
Chromosomes	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
progressed	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
severe	JJ	I-NP	O
stages	NNS	I-NP	O
,	,	O	O
diverging	VBG	B-VP	O
dramatically	RB	B-ADVP	O
from	IN	B-PP	O
the	DT	B-NP	O
B6	NN	I-NP	O
phenotype	NN	I-NP	O
.	.	O	O

Latencies	NNS	B-NP	O
to	TO	B-PP	O
stages	NNS	B-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
significantly	RB	B-ADJP	O
shorter	JJR	I-ADJP	O
for	IN	B-PP	O
CSS10	NN	B-NP	O
and	CC	I-NP	O
CSS18	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

CSS	NN	B-NP	O
mapping	NN	I-NP	O
suggests	VBZ	B-VP	O
seizure	NN	B-NP	B
susceptibility	NN	I-NP	O
loci	NNS	I-NP	O
on	IN	B-PP	O
mouse	NN	B-NP	O
Chromosomes	NNS	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

This	DT	B-NP	O
approach	NN	I-NP	O
provides	VBZ	B-VP	O
a	DT	B-NP	O
framework	NN	I-NP	O
for	IN	B-PP	O
identifying	VBG	B-VP	O
potentially	RB	B-NP	O
novel	JJ	I-NP	O
homologous	JJ	I-NP	O
candidate	NN	I-NP	O
genes	NNS	I-NP	O
for	IN	B-PP	O
human	JJ	B-NP	O
temporal	JJ	I-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
.	.	O	O

Investigation	NN	B-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	O
involvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
.	.	O	O

Mitochondrial	JJ	B-NP	B
abnormalities	NNS	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
several	JJ	B-NP	O
aspects	NNS	I-NP	O
of	IN	B-PP	O
epileptogenesis	NN	B-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
energy	NN	B-NP	O
generation	NN	I-NP	O
,	,	O	O
control	NN	B-NP	O
of	IN	B-PP	O
cell	NN	B-NP	O
death	NN	I-NP	B
,	,	O	O
neurotransmitter	NN	B-NP	O
synthesis	NN	I-NP	O
,	,	O	O
and	CC	O	O
free	JJ	B-NP	O
radical	NN	I-NP	O
(	(	O	O
FR	NN	B-NP	O
)	)	O	O
production	NN	B-NP	O
.	.	O	O

Increased	VBN	B-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
FRs	NNS	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
mtDNA	NN	B-NP	O
damage	NN	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
decreased	VBN	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
phosphorylation	NN	I-NP	O
complexes	NNS	I-NP	O
containing	VBG	B-VP	O
mtDNA	NN	B-NP	O
-	HYPH	B-NP	O
encoded	VBN	I-NP	O
subunits	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
whether	IN	B-SBAR	O
increased	VBN	B-NP	O
generation	NN	I-NP	O
of	IN	B-PP	O
FR	NN	B-NP	O
during	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
would	MD	B-VP	O
be	VB	I-VP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
provoke	VB	I-VP	O
abnormalities	NNS	B-NP	O
in	IN	B-PP	O
mtDNA	NN	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
expression	NN	B-NP	O
and	CC	O	O
activity	NN	B-NP	O
of	IN	B-PP	O
cytochrome	NN	B-NP	O
c	NN	I-NP	O
oxidase	NN	I-NP	O
(	(	O	O
CCO	NN	B-NP	O
)	)	O	O
,	,	O	O
complex	NN	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
respiratory	JJ	I-NP	O
chain	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
temporal	JJ	B-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
.	.	O	O

DNA	NN	B-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
low	JJ	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
kb	NN	I-NP	O
mtDNA	NN	I-NP	O
deletion	NN	I-NP	O
but	CC	B-PP	O
with	IN	B-PP	O
no	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
frequency	NN	B-NP	O
or	CC	I-NP	O
quantity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
and	CC	I-NP	O
experimental	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
find	VB	I-VP	O
abnormalities	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
expression	NN	B-NP	O
and	CC	O	O
distribution	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
mtDNA	NN	I-NP	O
-	HYPH	B-VP	O
encoded	VBN	B-NP	O
subunit	NN	I-NP	O
of	IN	B-PP	O
CCO	NN	B-NP	O
(	(	O	O
CCO	NN	B-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
)	)	O	O
or	CC	O	O
a	DT	B-NP	O
relative	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
CCO	NN	B-NP	O
-	HYPH	O	O
I	PRP	B-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
nuclear	JJ	B-NP	O
-	HYPH	I-NP	O
encoded	VBN	I-NP	O
subunits	NNS	I-NP	O
(	(	O	O
CCO	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
SDH	NN	I-NP	O
-	HYPH	B-NP	O
fp	NN	I-NP	O
)	)	O	O
.	.	O	O

No	DT	B-NP	O
abnormality	NN	I-NP	O
in	IN	B-PP	O
CCO	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
through	IN	B-PP	O
histochemistry	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
evidences	NNS	B-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	B
abnormalities	NNS	I-NP	I
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
previously	RB	B-NP	O
published	VBN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
our	PRP$	B-NP	O
results	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
suggest	VB	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
FRs	NNS	I-NP	O
,	,	O	O
generated	VBN	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
phase	NN	I-NP	O
,	,	O	O
determined	VBN	B-VP	O
important	JJ	B-NP	O
abnormalities	NNS	I-NP	O
in	IN	B-PP	O
mtDNA	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
expression	NN	B-NP	O
of	IN	B-PP	O
CCO	NN	B-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
CCO	NN	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Causes	NNS	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
thrombotic	JJ	I-NP	B
microangiopathy	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
kidney	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
known	VBN	I-NP	O
problem	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
following	VBG	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
postrenal	JJ	B-NP	O
transplantation	NN	I-NP	O
,	,	O	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
is	VBZ	B-VP	O
often	RB	B-ADVP	O
a	DT	B-NP	O
reflection	NN	I-NP	O
of	IN	B-PP	O
hemolytic	JJ	B-NP	B
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
recipients	NNS	I-NP	O
and	CC	O	O
discuss	VBP	B-VP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
from	IN	B-PP	O
June	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
June	NNP	B-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
King	NNP	I-NP	O
Fahad	NNP	I-NP	O
National	NNP	I-NP	O
Guard	NNP	I-NP	O
Hospital	NNP	I-NP	O
in	IN	B-PP	O
Riyadh	NNP	B-NP	O
,	,	O	O
Saudi	NNP	B-NP	O
Arabia	NNP	I-NP	O
,	,	O	O
by	IN	B-PP	O
reviewing	VBG	B-VP	O
the	DT	B-NP	O
slides	NNS	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
transplant	NN	I-NP	O
biopsies	NNS	I-NP	O
performed	VBN	B-VP	O
during	IN	B-PP	O
this	DT	B-NP	O
interval	NN	I-NP	O
.	.	O	O

Pre	NN	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
posttransplant	NN	I-NP	O
crossmatching	NN	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
when	WRB	B-ADVP	O
possible	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
were	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
transplantations	NNS	I-NP	O
performed	VBN	B-VP	O
at	IN	B-PP	O
King	NNP	B-NP	O
Fahad	NNP	I-NP	O
National	NNP	I-NP	O
Guard	NNP	I-NP	O
Hospital	NNP	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
transplantations	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
performed	VBN	I-VP	O
abroad	RB	B-ADVP	O
and	CC	O	O
were	VBD	B-VP	O
referred	VBN	I-VP	O
to	TO	B-PP	O
us	PRP	B-NP	O
for	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	B-PRT	O
up	RP	B-PRT	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
cyclosporine	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
case	NN	I-NP	O
was	VBD	B-VP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
both	CC	O	O
cyclosporine	NN	B-NP	O
and	CC	I-NP	O
tacrolimus	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
fifth	JJ	I-NP	O
case	NN	I-NP	O
had	VBD	B-VP	O
features	NNS	B-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
antiphospholipid	JJ	I-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
systemic	JJ	B-NP	B
lupus	NN	I-NP	I
erythematosus	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
most	JJS	I-NP	O
-	HYPH	I-NP	O
frequent	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
hemolytic	JJ	B-NP	B
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
following	VBG	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
is	VBZ	B-VP	O
recurrence	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hemolytic	JJ	I-NP	B
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Other	JJ	B-NP	O
causes	NNS	I-NP	O
include	VBP	B-VP	O
drug	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-ADJP	O
(	(	O	O
cyclosporine	NN	B-NP	O
,	,	O	O
tacrolimus	NN	B-NP	O
)	)	O	O
toxicity	NN	B-NP	B
,	,	O	O
procoagulant	JJ	B-NP	O
status	NN	I-NP	O
,	,	O	O
and	CC	O	O
antibody	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
rejection	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
most	JJS	I-NP	O
-	HYPH	I-NP	O
frequent	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
was	VBD	B-VP	O
drug	NN	B-NP	O
related	VBN	B-ADJP	O
,	,	O	O
secondary	JJ	B-ADJP	O
mainly	RB	I-ADJP	O
to	TO	B-PP	O
cyclosporine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
percentage	NN	I-NP	O
reported	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
reversible	JJ	I-NP	O
left	JJ	I-NP	B
ventricular	JJ	I-NP	I
systolic	JJ	I-NP	I
and	CC	I-NP	I
diastolic	JJ	I-NP	I
dysfunction	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
accidental	JJ	B-NP	O
iatrogenic	JJ	I-NP	O
epinephrine	NN	I-NP	O
overdose	NN	I-NP	B
.	.	O	O

Catecholamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
chronic	JJ	B-NP	O
excess	NN	I-NP	O
of	IN	B-PP	O
endogenous	JJ	B-NP	O
catecholamines	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
recognized	VBN	I-VP	O
for	IN	B-PP	O
decades	NNS	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
phenomenon	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
reports	NNS	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
dysfunction	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
acute	JJ	B-NP	O
iatrogenic	JJ	I-NP	O
overdose	NN	I-NP	B
are	VBP	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
whose	WP$	B-NP	O
cervix	NN	I-NP	O
uteri	NNS	I-NP	O
was	VBD	B-VP	O
inadvertently	RB	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
developed	VBD	B-VP	O
myocardial	JJ	B-NP	B
stunning	NN	I-NP	I
that	WDT	B-NP	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
severe	JJ	B-NP	O
hemodynamic	JJ	I-NP	O
compromise	NN	I-NP	O
,	,	O	O
profound	NN	B-NP	O
,	,	O	O
albeit	IN	B-PP	O
transient	JJ	B-ADJP	O
,	,	O	O
left	VBD	B-VP	B
ventricular	JJ	B-NP	I
systolic	JJ	I-NP	I
and	CC	I-NP	I
diastolic	JJ	I-NP	I
dysfunction	NN	I-NP	I
,	,	O	O
and	CC	O	O
only	RB	B-NP	O
modestly	RB	I-NP	O
elevated	JJ	I-NP	O
biochemical	JJ	I-NP	O
markers	NNS	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
necrosis	NN	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
case	NN	I-NP	O
illustrates	VBZ	B-VP	O
the	DT	B-NP	O
serious	JJ	I-NP	O
consequences	NNS	I-NP	O
of	IN	B-PP	O
medical	JJ	B-NP	O
errors	NNS	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
through	IN	B-PP	O
improved	VBN	B-NP	O
medication	NN	I-NP	O
labeling	NN	I-NP	O
and	CC	I-NP	O
staff	NN	I-NP	O
supervision	NN	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	B
bladder	NN	I-NP	I
cancer	NN	I-NP	I
in	IN	B-PP	O
Wegener	NNP	B-NP	B
s	NNS	I-NP	I
granulomatosis	NN	I-NP	I
:	:	O	O
risks	NNS	B-NP	O
and	CC	O	O
relation	NN	B-NP	O
to	TO	B-PP	O
cyclophosphamide	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
and	CC	I-VP	O
characterise	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
and	CC	O	O
its	PRP$	B-NP	O
relation	NN	I-NP	O
to	TO	B-PP	O
cyclophosphamide	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Wegener	NN	B-NP	B
s	NN	I-NP	I
granulomatosis	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
population	NN	I-NP	O
based	VBN	B-VP	O
,	,	O	O
nationwide	JJ	B-NP	O
Swedish	NNP	I-NP	O
Inpatient	NNP	I-NP	O
Register	NNP	I-NP	O
a	DT	B-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Wegener	NN	B-NP	B
s	NNS	I-NP	I
granulomatosis	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

Through	IN	B-PP	O
linkage	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
Swedish	NNP	I-NP	O
Cancer	NNP	I-NP	B
Register	NNP	I-NP	O
,	,	O	O
all	DT	B-NP	O
subjects	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
cohort	NN	I-NP	O
diagnosed	VBN	B-VP	O
with	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
were	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

Nested	VBN	B-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
cohort	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
matched	VBN	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	I-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
and	CC	I-NP	O
bladder	NN	I-NP	B
cancer	NN	I-NP	I
using	VBG	B-VP	O
odds	NNS	B-NP	O
ratios	NNS	I-NP	O
(	(	O	O
ORs	NNS	B-NP	O
)	)	O	O
as	IN	B-PP	O
relative	JJ	B-NP	O
risk	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
cohort	NN	I-NP	O
the	DT	B-NP	O
cumulative	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
after	IN	B-PP	O
Wegener	NN	B-NP	B
s	NNS	I-NP	I
granulomatosis	NN	I-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
relative	JJ	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
diagnosis	NN	B-NP	O
of	IN	B-PP	O
Wegener	NNP	B-NP	B
s	NN	I-NP	I
granulomatosis	NN	I-NP	I
,	,	O	O
were	VBD	B-VP	O
also	RB	I-VP	O
estimated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
cumulative	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
among	IN	B-PP	O
cases	NNS	B-NP	O
and	CC	I-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
g	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
doubled	VBD	B-VP	O
for	IN	B-PP	O
every	DT	B-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
increment	NN	I-NP	O
in	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
OR	NN	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
(	(	O	O
CI	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

Treatment	NN	B-NP	O
duration	NN	I-NP	O
longer	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
eightfold	RB	I-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
absolute	JJ	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
cohort	JJ	I-NP	O
reached	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
diagnosis	NN	B-NP	O
of	IN	B-PP	O
Wegener	NNP	B-NP	B
s	NN	I-NP	I
granulomatosis	NN	I-NP	I
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
was	VBD	B-VP	O
(	(	O	O
non	AFX	O	O
-	HYPH	O	O
significantly	RB	O	O
)	)	O	O
twice	RB	B-ADJP	O
as	RB	I-ADJP	O
common	JJ	I-ADJP	O
as	IN	B-SBAR	O
expected	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
diagnosis	NN	B-NP	O
of	IN	B-PP	O
Wegener	NNP	B-NP	B
s	JJ	I-NP	I
granulomatosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
high	JJ	B-NP	O
cumulative	JJ	I-NP	O
risks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
cohort	NN	I-NP	O
,	,	O	O
and	CC	O	O
also	RB	B-ADVP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
operating	VBG	B-VP	O
even	RB	B-ADVP	O
before	IN	B-PP	O
Wegener	NNP	B-NP	B
s	JJ	I-NP	I
granulomatosis	NN	I-NP	I
.	.	O	O

L	NN	B-NP	O
-	HYPH	I-NP	O
arginine	NN	I-NP	O
transport	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
with	IN	B-PP	O
cortisol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
deficient	JJ	I-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
-	HYPH	I-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
system	NN	I-NP	O
is	VBZ	B-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
cortisol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
investigate	VBP	B-VP	O
whether	IN	B-SBAR	O
abnormalities	NNS	B-NP	O
in	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
uptake	NN	I-NP	O
contribute	VBP	B-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
deficiency	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
men	NNS	I-NP	O
were	VBD	B-VP	O
recruited	VBN	I-VP	O
.	.	O	O

Hydrocortisone	NN	B-NP	O
acetate	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
orally	RB	B-NP	O
every	DT	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
fixed	VBN	B-VP	O
-	HYPH	B-NP	O
salt	NN	I-NP	O
diet	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
mmol	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
)	)	O	O
.	.	O	O

Crossover	NN	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
apart	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
milliliters	NNS	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
for	IN	B-PP	O
isolation	NN	B-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	O
blood	NN	I-NP	O
mononuclear	JJ	I-NP	O
cells	NNS	I-NP	O
after	IN	B-PP	O
each	DT	B-NP	O
treatment	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

L	NN	B-NP	O
-	HYPH	I-NP	O
arginine	NN	I-NP	O
uptake	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
mononuclear	JJ	B-NP	O
cells	NNS	I-NP	O
incubated	VBN	B-VP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
arginine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micromol	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
,	,	O	O
incorporating	VBG	B-VP	O
num	CD	B-NP	O
nmol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	B-NP	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
l	NN	I-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
C	JJ	B-ADJP	O
.	.	O	O

Forearm	NN	B-NP	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
extraction	NN	I-NP	O
was	VBD	B-VP	O
calculated	VBN	I-VP	O
after	IN	B-PP	O
infusion	NN	B-NP	O
of	IN	B-PP	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	O	O
arginine	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
brachial	JJ	I-NP	O
artery	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
nCi	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
.	.	O	O

Deep	JJ	B-NP	O
forearm	NN	I-NP	O
venous	JJ	I-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
for	IN	B-PP	O
determination	NN	B-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
extraction	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
cortisol	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
raised	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
active	JJ	I-NP	O
phase	NN	I-NP	O
.	.	O	O

Systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
average	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
L	NN	B-NP	O
-	HYPH	I-NP	O
arginine	NN	I-NP	O
transport	NN	I-NP	O
into	IN	B-PP	O
mononuclear	JJ	B-NP	O
cells	NNS	I-NP	O
nor	CC	O	O
L	NN	B-NP	O
-	HYPH	I-NP	O
arginine	NN	I-NP	O
extraction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
forearm	NN	I-NP	O
was	VBD	B-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
cortisol	NN	B-NP	O
treatment	NN	I-NP	O
;	:	O	O
ie	FW	B-NP	O
,	,	O	O
that	IN	B-SBAR	O
L	NN	B-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
uptake	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
cortisol	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
cortisol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increases	NNS	I-NP	B
in	IN	B-PP	I
blood	NN	B-NP	I
pressure	NN	I-NP	I
are	VBP	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
abnormalities	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
l	NN	I-NP	O
-	HYPH	I-NP	O
arginine	NN	I-NP	O
transport	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

MR	NN	B-NP	O
imaging	NN	I-NP	O
with	IN	B-PP	O
quantitative	JJ	B-NP	O
diffusion	NN	I-NP	O
mapping	NN	I-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
in	IN	B-PP	O
organ	NN	B-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
objective	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
brain	NN	B-NP	O
MR	NN	I-NP	O
imaging	NN	I-NP	O
findings	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
diffusion	NN	B-NP	O
-	HYPH	O	O
weighted	VBN	B-VP	O
(	(	O	O
DW	NN	B-NP	O
)	)	O	O
imaging	NN	B-NP	O
in	IN	B-PP	O
organ	NN	B-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
neurologic	JJ	B-NP	O
symptoms	NNS	I-NP	O
during	IN	B-PP	O
tacrolimus	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Brain	NN	B-NP	O
MR	NN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
DW	NN	B-NP	O
imaging	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
prospectively	RB	I-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
organ	NN	I-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
tacrolimus	NN	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
neurologic	JJ	B-NP	B
complications	NNS	I-NP	I
.	.	O	O

In	IN	B-PP	O
each	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
abnormalities	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
MR	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	O	O
up	RP	B-PRT	O
MR	NN	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
num	CD	B-NP	O
month	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Apparent	JJ	B-NP	O
diffusion	NN	I-NP	O
coefficient	NN	I-NP	O
(	(	O	O
ADC	NN	B-NP	O
)	)	O	O
values	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
MR	NN	I-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
reversibility	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lesions	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
white	JJ	B-NP	B
matter	NN	I-NP	I
abnormalities	NNS	I-NP	I
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
putaminal	JJ	B-NP	B
hemorrhage	NN	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
normal	JJ	B-NP	O
findings	NNS	I-NP	O
on	IN	B-PP	O
initial	JJ	B-NP	O
MR	NN	I-NP	O
images	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
white	JJ	B-NP	B
matter	NN	I-NP	I
abnormalities	NNS	I-NP	I
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
higher	JJR	B-ADVP	O
than	IN	B-PP	O
normal	JJ	B-NP	O
ADC	NN	I-NP	O
values	NNS	I-NP	O
on	IN	B-PP	O
initial	JJ	B-NP	O
MR	NN	I-NP	O
images	NNS	I-NP	O
,	,	O	O
and	CC	O	O
all	DT	B-NP	O
showed	VBD	B-VP	O
complete	JJ	B-NP	O
resolution	NN	I-NP	O
on	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
images	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
showed	VBD	B-VP	O
lower	JJR	B-ADVP	O
than	IN	B-PP	O
normal	JJ	B-NP	O
ADC	NN	I-NP	O
value	NN	I-NP	O
and	CC	O	O
showed	VBD	B-VP	O
incomplete	JJ	B-NP	O
resolution	NN	I-NP	O
with	IN	B-PP	O
cortical	JJ	B-NP	B
laminar	JJ	I-NP	I
necrosis	NN	I-NP	I
.	.	O	O

Diffusion	NN	B-NP	O
-	HYPH	B-PP	O
weighted	VBN	B-NP	O
imaging	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
predicting	VBG	B-VP	O
the	DT	B-NP	O
outcomes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lesions	NNS	I-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Octreotide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypoxemia	NN	I-NP	B
and	CC	I-NP	O
pulmonary	JJ	I-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
premature	JJ	B-NP	O
neonates	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
premature	JJ	B-NP	O
neonates	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
enterocutaneous	JJ	B-NP	O
fistula	NN	I-NP	B
complicating	VBG	B-VP	O
necrotizing	VBG	B-NP	B
enterocolitis	NN	I-NP	I
.	.	O	O

Pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
developed	VBN	B-VP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
somatostatin	NN	I-NP	O
analogue	NN	I-NP	O
,	,	O	O
octreotide	NN	B-NP	O
,	,	O	O
to	TO	B-VP	O
enhance	VB	I-VP	O
resolution	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
fistula	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
discuss	VBP	B-VP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
and	CC	O	O
recommend	VB	B-VP	O
caution	NN	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
premature	JJ	I-NP	O
neonates	NNS	I-NP	O
.	.	O	O

Sequential	JJ	B-NP	O
observations	NNS	I-NP	O
of	IN	B-PP	O
exencephaly	RB	B-NP	B
and	CC	O	O
subsequent	JJ	B-NP	O
morphological	JJ	I-NP	O
changes	NNS	I-NP	O
by	IN	B-PP	O
mouse	NN	B-NP	O
exo	NN	I-NP	O
utero	NN	I-NP	O
development	NN	I-NP	O
system	NN	I-NP	O
:	:	O	O
analysis	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
transformation	NN	B-NP	O
from	IN	B-PP	O
exencephaly	RB	B-ADVP	B
to	TO	B-PP	O
anencephaly	RB	B-NP	B
.	.	O	O

Anencephaly	RB	B-ADVP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
to	TO	I-VP	O
develop	VB	I-VP	O
from	IN	B-PP	O
exencephaly	RB	B-NP	B
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
little	JJ	B-NP	O
direct	JJ	I-NP	O
experimental	JJ	I-NP	O
evidence	NN	I-NP	O
to	TO	B-VP	O
support	VB	I-VP	O
this	DT	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
transformation	NN	B-NP	O
remains	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
examined	VBD	B-VP	O
this	DT	B-NP	O
theory	NN	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
exo	NN	I-NP	O
utero	NN	I-NP	O
development	NN	I-NP	O
system	NN	I-NP	O
that	WDT	B-NP	O
allows	VBZ	B-VP	O
direct	JJ	B-NP	O
and	CC	I-NP	O
sequential	JJ	I-NP	O
observations	NNS	I-NP	O
of	IN	B-PP	O
mid	NN	B-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
late	JJ	B-NP	O
-	HYPH	I-NP	O
gestation	NN	I-NP	O
mouse	NN	I-NP	O
embryos	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
the	DT	B-NP	O
exencephaly	RB	I-NP	B
induced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
azacytidine	NN	I-NP	O
at	IN	B-PP	O
embryonic	JJ	B-NP	O
day	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
E13.5	NN	B-NP	O
)	)	O	O
,	,	O	O
let	VBD	B-VP	O
the	DT	B-NP	O
embryos	NNS	I-NP	O
develop	VBP	B-VP	O
exo	NN	B-NP	O
utero	NN	I-NP	O
until	IN	B-PP	O
E18.5	NN	B-NP	O
,	,	O	O
and	CC	O	O
re	NN	B-NP	O
-	HYPH	O	O
observed	VBN	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
embryos	NNS	I-NP	O
at	IN	B-PP	O
E18.5	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
confirmed	VBD	B-VP	O
several	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
transformation	NN	B-NP	O
from	IN	B-PP	O
exencephaly	RB	B-ADVP	B
to	TO	B-PP	O
anencephaly	RB	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
many	JJ	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
exencephalic	JJ	I-NP	B
brain	NN	I-NP	O
tissue	NN	I-NP	O
was	VBD	B-VP	O
preserved	VBN	I-VP	O
with	IN	B-PP	O
more	JJR	B-NP	O
or	CC	I-NP	O
less	JJR	I-NP	O
reduction	NN	I-NP	O
during	IN	B-PP	O
this	DT	B-NP	O
period	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
analyze	VB	I-VP	O
the	DT	B-NP	O
transformation	NN	I-NP	O
patterns	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
classified	VBD	B-VP	O
the	DT	B-NP	O
exencephaly	NN	I-NP	B
by	IN	B-PP	O
size	NN	B-NP	O
and	CC	I-NP	O
shape	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
exencephalic	JJ	I-NP	B
tissue	NN	I-NP	O
into	IN	B-PP	O
several	JJ	B-NP	O
types	NNS	I-NP	O
at	IN	B-PP	O
E13.5	NN	B-NP	O
and	CC	I-NP	O
E18.5	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
transformation	NN	I-NP	O
of	IN	B-PP	O
exencephalic	JJ	B-NP	B
tissue	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
simply	RB	B-ADVP	O
size	NN	B-NP	O
-	HYPH	B-VP	O
dependent	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
all	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
anencephaly	RB	B-ADVP	B
at	IN	B-PP	O
E18.5	NN	B-NP	O
resulted	VBD	B-VP	O
from	IN	B-PP	O
embryos	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
large	JJ	I-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
exencephalic	JJ	B-NP	B
tissue	NN	I-NP	O
at	IN	B-PP	O
E13.5	NN	B-NP	O
.	.	O	O

Microscopic	JJ	B-NP	O
observation	NN	I-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
configuration	NN	I-NP	O
of	IN	B-PP	O
exencephaly	RB	B-ADVP	B
at	IN	B-PP	O
E13.5	NN	B-NP	O
,	,	O	O
frequent	JJ	B-NP	O
hemorrhaging	NN	I-NP	B
and	CC	I-NP	O
detachment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neural	JJ	I-NP	O
plate	NN	I-NP	O
from	IN	B-PP	O
surface	NN	B-NP	O
ectoderm	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
exencephalic	JJ	I-NP	B
head	NN	I-NP	O
at	IN	B-PP	O
E15.5	NN	B-NP	O
,	,	O	O
and	CC	O	O
multiple	JJ	B-NP	O
modes	NNS	I-NP	O
of	IN	B-PP	O
reduction	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
exencephalic	JJ	I-NP	B
tissue	NN	I-NP	O
at	IN	B-PP	O
E18.5	NN	B-NP	O
.	.	O	O

From	IN	B-PP	O
observations	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
vasculature	NN	I-NP	O
,	,	O	O
altered	JJ	B-NP	O
distribution	NN	I-NP	O
patterns	NNS	I-NP	O
of	IN	B-PP	O
vessels	NNS	B-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
exencephalic	JJ	I-NP	B
head	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
overgrowth	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
exencephalic	JJ	I-NP	B
neural	JJ	I-NP	O
tissue	NN	I-NP	O
causes	VBZ	B-VP	O
the	DT	B-NP	O
altered	VBN	I-NP	O
distribution	NN	I-NP	O
patterns	NNS	I-NP	O
of	IN	B-PP	O
vessels	NNS	B-NP	O
,	,	O	O
subsequent	JJ	B-NP	O
peripheral	JJ	I-NP	O
circulatory	JJ	I-NP	B
failure	NN	I-NP	I
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
hemorrhaging	NN	B-NP	B
in	IN	B-PP	O
various	JJ	B-NP	O
parts	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
exencephalic	JJ	I-NP	B
head	NN	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
multiple	JJ	I-NP	O
modes	NNS	I-NP	O
of	IN	B-PP	O
tissue	NN	B-NP	O
reduction	NN	I-NP	O
during	IN	B-PP	O
transformation	NN	B-NP	O
from	IN	B-PP	O
exencephaly	RB	B-ADVP	B
to	TO	B-PP	O
anencephaly	RB	B-NP	B
.	.	O	O

Acute	JJ	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
:	:	O	O
differential	JJ	B-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
inbred	JJ	I-NP	O
mouse	NN	I-NP	O
strains	NNS	I-NP	O
.	.	O	O

Mature	JJ	B-NP	O
male	JJ	I-NP	O
and	CC	I-NP	O
female	JJ	I-NP	O
mice	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
inbred	JJ	I-NP	O
stains	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
behavioral	JJ	B-NP	O
seizures	NNS	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
ip	RB	B-ADVP	O
over	IN	B-PP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
doses	NNS	B-NP	O
and	CC	I-NP	O
behavior	NN	I-NP	O
was	VBD	B-VP	O
monitored	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
.	.	O	O

Seizure	NN	B-NP	B
end	NN	I-NP	O
points	NNS	I-NP	O
included	VBD	B-VP	O
latency	NN	B-NP	O
to	TO	B-PP	O
forelimb	NN	B-NP	O
or	CC	I-NP	O
hindlimb	NN	I-NP	O
clonus	NN	I-NP	O
,	,	O	O
latency	NN	B-NP	O
to	TO	B-PP	O
clonic	JJ	B-NP	O
running	VBG	I-NP	O
seizure	NN	I-NP	B
and	CC	I-NP	O
latency	NN	I-NP	O
to	TO	B-PP	O
jumping	VBG	B-VP	O
bouncing	VBG	B-NP	O
seizure	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
strain	NN	B-NP	O
specific	JJ	I-NP	O
sensitivities	NNS	I-NP	O
was	VBD	B-VP	O
documented	VBN	I-VP	O
with	IN	B-PP	O
A	NN	B-NP	O
/	SYM	I-NP	O
J	NN	I-NP	O
and	CC	I-NP	O
SJL	NN	I-NP	O
mice	NNS	I-NP	O
being	VBG	B-VP	O
most	RBS	B-NP	O
sensitive	JJ	I-NP	O
and	CC	I-NP	O
C57BL	NN	I-NP	O
/	SYM	I-NP	O
6J	NN	I-NP	O
most	RBS	B-ADJP	O
resistant	JJ	I-ADJP	O
.	.	O	O

DBA	NN	B-NP	O
/	SYM	I-NP	O
2J	NN	I-NP	O
,	,	O	O
BALB	NN	B-NP	O
/	SYM	B-NP	O
cByJ	NN	I-NP	O
and	CC	I-NP	O
NZW	NN	I-NP	O
/	SYM	B-NP	O
LacJ	NN	B-NP	O
strains	NNS	I-NP	O
exhibited	VBD	B-VP	O
intermediate	JJ	B-NP	O
sensitivity	NN	I-NP	O
.	.	O	O

EEG	NN	B-NP	O
recordings	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
in	IN	B-PP	O
SJL	NN	B-NP	O
,	,	O	O
A	NN	B-NP	O
/	SYM	I-NP	O
J	NN	I-NP	O
and	CC	I-NP	O
C57BL	NN	I-NP	O
/	SYM	B-NP	O
6J	NN	B-NP	O
mice	NNS	I-NP	O
revealing	VBG	B-VP	O
a	DT	B-NP	O
close	JJ	I-NP	O
correspondence	NN	I-NP	O
between	IN	B-PP	O
electrical	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	I-NP	O
behavior	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
levels	NNS	B-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
determined	VBN	B-VP	O
in	IN	B-PP	O
hippocampus	NN	B-NP	O
and	CC	I-NP	O
cortex	NN	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
different	JJ	I-ADJP	O
between	IN	B-PP	O
sensitive	JJ	B-NP	O
and	CC	I-NP	O
resistant	JJ	I-NP	O
strains	NNS	I-NP	O
.	.	O	O

Additional	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
murine	JJ	I-NP	O
strains	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
investigating	VBG	B-VP	O
genetic	JJ	B-NP	O
influences	NNS	I-NP	O
on	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Microangiopathic	JJ	B-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
complicating	VBG	B-VP	O
FK506	NN	B-NP	O
(	(	O	O
tacrolimus	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
microangiopathic	JJ	B-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
(	(	O	O
MAHA	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
solid	JJ	I-NP	O
organ	NN	I-NP	O
recipients	NNS	I-NP	O
under	IN	B-PP	O
FK506	NN	B-NP	O
(	(	O	O
tacrolimus	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
FK506	NN	B-NP	O
and	CC	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
plasma	NN	B-NP	O
exchange	NN	I-NP	O
,	,	O	O
fresh	JJ	B-NP	O
frozen	VBN	I-NP	O
plasma	NN	I-NP	O
replacement	NN	I-NP	O
,	,	O	O
corticosteroids	NNS	B-NP	O
,	,	O	O
aspirin	NN	B-NP	O
,	,	O	O
and	CC	O	O
dipyridamole	NN	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
resolution	NN	B-NP	O
of	IN	B-PP	O
MAHA	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
,	,	O	O
reintroduction	NN	B-NP	O
of	IN	B-PP	O
FK506	NN	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
rapid	JJ	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
MAHA	NN	B-NP	B
.	.	O	O

FK506	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
MAHA	NN	I-NP	B
is	VBZ	B-VP	O
probably	RB	B-ADVP	O
rare	JJ	B-ADJP	O
but	CC	O	O
physicians	NNS	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
severe	JJ	I-NP	O
complication	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
experience	NN	I-NP	O
and	CC	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
FK506	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
to	TO	B-PP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
react	NN	I-NP	O
with	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
(	(	O	O
CyA	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
immuno	AFX	I-NP	O
-	HYPH	I-NP	O
suppressive	JJ	I-NP	O
drug	NN	I-NP	O
already	RB	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
induce	VB	I-VP	O
MAHA	NN	B-NP	B
.	.	O	O

Variant	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
in	IN	B-PP	O
desipramine	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
variant	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
desipramine	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Unusual	JJ	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
are	VBP	B-VP	O
repetitive	JJ	B-NP	O
group	NN	I-NP	O
beating	NN	I-NP	O
,	,	O	O
progressive	JJ	B-NP	O
shortening	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
R	NN	I-NP	O
-	HYPH	B-NP	O
R	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
progressive	JJ	B-NP	O
widening	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
QRS	NN	I-NP	O
complex	NN	I-NP	O
with	IN	B-PP	O
eventual	JJ	B-NP	O
failure	NN	I-NP	O
of	IN	B-PP	O
intraventricular	JJ	B-NP	O
conduction	NN	I-NP	O
,	,	O	O
and	CC	O	O
changes	NNS	B-NP	O
in	IN	B-PP	O
direction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
QRS	NNP	I-NP	O
axis	NN	I-NP	O
.	.	O	O

Recognition	NN	B-NP	O
of	IN	B-PP	O
variant	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
because	IN	B-SBAR	O
therapy	NN	B-NP	O
differs	VBZ	B-VP	O
from	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
classic	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

Desipramine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
delirium	NN	I-NP	B
at	IN	B-PP	O
subtherapeutic	JJ	B-NP	O
concentrations	NNS	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
elderly	JJ	I-NP	O
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
low	JJ	B-NP	O
dose	NN	I-NP	O
Desipramine	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
delirium	NN	I-NP	B
while	IN	B-SBAR	O
her	PRP$	B-NP	O
plasma	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
subtherapeutic	JJ	I-NP	O
range	NN	I-NP	O
.	.	O	O

Delirium	NNP	B-NP	B
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
tricyclic	JJ	B-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
,	,	O	O
can	MD	B-VP	O
be	VB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
tricyclics	NNS	B-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
anticholinergic	JJ	I-NP	O
potency	NN	I-NP	O
.	.	O	O

Therapeutic	JJ	B-NP	O
ranges	NNS	I-NP	O
for	IN	B-PP	O
antidepressants	NNS	B-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
derived	VBN	I-VP	O
from	IN	B-PP	O
general	JJ	B-NP	O
adult	JJ	I-NP	O
population	NN	I-NP	O
studies	NNS	I-NP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
appropriate	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
specifically	RB	B-NP	O
elderly	JJ	I-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
now	RB	I-VP	O
required	VBN	I-VP	O
to	TO	I-VP	O
establish	VB	I-VP	O
safer	JJR	B-NP	O
and	CC	I-NP	O
more	RBR	I-NP	O
appropriate	JJ	I-NP	O
guidelines	NNS	I-NP	O
for	IN	B-PP	O
drug	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Mouse	NN	B-NP	O
strain	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
amantadine	NN	B-NP	O
on	IN	B-PP	O
motility	NN	B-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
biogenic	JJ	I-NP	O
amines	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
amantadine	NN	B-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
injected	VBN	B-VP	O
i.p.	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
increments	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
each	DT	B-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
hr	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
mouse	NN	B-NP	O
motility	NN	I-NP	O
and	CC	O	O
whole	JJ	B-NP	O
brain	NN	I-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
selected	VBN	B-NP	O
biogenic	JJ	I-NP	O
amines	NNS	I-NP	O
and	CC	O	O
major	JJ	B-NP	O
metabolites	NNS	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
strains	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
albino	JJ	I-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
ICR	NN	I-NP	O
and	CC	I-NP	O
BALB	NN	I-NP	O
/	SYM	B-NP	O
C	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
black	JJ	I-NP	O
C57BL	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
and	CC	O	O
the	DT	B-NP	O
brown	VBN	I-NP	O
CDF	NN	I-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
mouse	NN	I-NP	O
strains	NNS	I-NP	O
.	.	O	O

Amantadine	NN	B-NP	O
treatment	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
biphasic	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
mouse	NN	B-NP	O
motility	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
initial	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
amantadine	NN	B-NP	O
depressed	VBD	B-VP	B
locomotor	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
mouse	NN	I-NP	O
strains	NNS	I-NP	O
studied	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
BALB	NN	I-NP	O
/	SYM	B-VP	O
C	NN	B-NP	O
mice	NNS	I-NP	O
being	VBG	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
sensitive	JJ	I-NP	O
.	.	O	O

Subsequent	JJ	B-NP	O
amantadine	NN	I-NP	O
treatments	NNS	I-NP	O
produced	VBD	B-VP	O
enhancement	NN	B-NP	O
of	IN	B-PP	O
motility	NN	B-NP	O
from	IN	B-PP	O
corresponding	VBG	B-VP	O
control	NN	B-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
mouse	NN	I-NP	O
strains	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
BALB	NN	I-NP	O
/	SYM	B-VP	O
C	NN	B-NP	O
mice	NNS	I-NP	O
being	VBG	B-VP	O
the	DT	B-NP	O
least	JJS	I-NP	O
sensitive	JJ	I-NP	O
.	.	O	O

The	DT	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
from	IN	B-PP	O
corresponding	VBG	B-VP	O
controls	NNS	B-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
strains	NNS	I-NP	O
studied	VBN	B-VP	O
,	,	O	O
except	IN	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
ICR	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
during	IN	B-PP	O
an	DT	B-NP	O
overnight	JJ	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
period	NN	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
fourth	JJ	I-NP	O
amantadine	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Readministration	NN	B-NP	O
of	IN	B-PP	O
amantadine	NN	B-NP	O
,	,	O	O
after	IN	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
overnight	JJ	I-NP	O
period	NN	I-NP	O
,	,	O	O
increased	VBD	B-VP	O
motility	NN	B-NP	O
from	IN	B-PP	O
respective	JJ	B-NP	O
saline	NN	I-NP	O
control	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
strains	NNS	I-NP	O
with	IN	B-PP	O
exception	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
BALB	NN	I-NP	O
/	SYM	B-NP	O
C	NN	I-NP	O
mice	NNS	I-NP	O
where	WRB	B-ADVP	O
suppression	NN	B-NP	B
of	IN	B-PP	I
motility	NN	B-NP	I
occurred	VBD	B-VP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
amantadine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
whole	JJ	B-NP	O
brain	NN	I-NP	O
dopamine	NN	I-NP	O
levels	NNS	I-NP	O
but	CC	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dihydroxyphenylacetic	JJ	I-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BALB	NN	I-NP	O
/	SYM	B-NP	O
C	NN	I-NP	O
mice	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
saline	NN	B-NP	O
control	NN	I-NP	O
.	.	O	O

Conversely	RB	B-ADVP	O
,	,	O	O
brain	NN	B-NP	O
normetanephrine	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
saline	NN	B-NP	O
control	NN	I-NP	O
by	IN	B-PP	O
amantadine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BALB	NN	I-NP	O
/	SYM	B-NP	O
C	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
strain	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
amantadine	NN	B-NP	O
on	IN	B-PP	O
motility	NN	B-NP	O
and	CC	O	O
indicate	VBP	B-VP	O
a	DT	B-NP	O
differential	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
and	CC	I-NP	O
multiple	JJ	I-NP	O
dose	NN	I-NP	O
regimens	NNS	I-NP	O
used	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
BALB	NN	I-NP	O
/	SYM	I-NP	O
C	NN	I-NP	O
mouse	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
sensitive	JJ	I-NP	O
strain	NN	I-NP	O
and	CC	O	O
could	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
strain	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
for	IN	B-PP	O
evaluating	VBG	B-VP	O
the	DT	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
amantadine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
biochemical	JJ	I-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
biogenic	JJ	I-NP	O
amines	NNS	I-NP	O
of	IN	B-PP	O
BALB	NN	B-NP	O
/	SYM	I-NP	O
C	NN	I-NP	O
mouse	NN	I-NP	O
strain	NN	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
probable	JJ	I-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
catecholamine	NN	B-NP	O
turnover	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
metabolism	NN	B-NP	O
by	IN	B-PP	O
monoamine	NN	B-NP	O
oxidase	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
resulting	VBG	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
O	NN	B-NP	O
-	HYPH	B-NP	O
methylation	NN	I-NP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
which	WDT	B-NP	O
may	MD	B-VP	O
account	VB	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
behavioral	JJ	I-NP	B
depression	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
amantadine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BALB	NN	I-NP	O
/	SYM	B-NP	O
C	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
enhancement	NN	I-NP	O
by	IN	B-PP	O
phenobarbital	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hepatocarcinogenicity	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
choline	NN	I-NP	O
-	HYPH	B-NP	O
devoid	JJ	I-NP	O
diet	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
experiment	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	I-VP	O
test	VB	I-VP	O
whether	IN	B-SBAR	O
inclusion	NN	B-NP	O
of	IN	B-PP	O
phenobarbital	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
choline	NN	I-NP	O
-	HYPH	B-NP	O
devoid	JJ	I-NP	O
diet	NN	I-NP	O
would	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
hepatocarcinogenicity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diet	NN	I-NP	O
.	.	O	O

Groups	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
old	JJ	I-NP	O
male	JJ	I-NP	O
Fischer	NNP	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
fed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
semipurified	VBD	B-VP	O
choline	NN	B-NP	O
-	HYPH	B-NP	O
devoid	JJ	I-NP	O
or	CC	I-NP	O
choline	NN	I-NP	O
-	HYPH	B-NP	O
supplemented	VBN	I-NP	O
diets	NNS	I-NP	O
,	,	O	O
containing	VBG	B-VP	O
or	CC	O	O
not	RB	O	O
num	CD	B-NP	O
%	NN	I-NP	O
phenobarbital	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
hepatic	JJ	I-NP	O
preneoplastic	JJ	I-NP	O
nodules	NNS	I-NP	O
or	CC	O	O
hepatocellular	JJ	B-NP	B
carcinomas	NNS	I-NP	I
developed	VBN	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
fed	VBN	B-VP	O
the	DT	B-NP	O
plain	JJ	I-NP	O
choline	NN	I-NP	O
-	HYPH	B-VP	O
supplemented	VBN	B-NP	O
diet	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
num	CD	B-NP	O
preneoplastic	JJ	I-NP	O
nodule	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
hepatocellular	JJ	I-NP	B
carcinoma	NN	I-NP	I
developed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
fed	VBN	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
diet	NN	I-NP	O
containing	VBG	B-VP	O
phenobarbital	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
preneoplastic	JJ	B-NP	O
nodules	NNS	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
hepatocellular	JJ	B-NP	B
carcinomas	NNS	I-NP	I
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
fed	VBN	B-VP	O
the	DT	B-NP	O
plain	JJ	I-NP	O
choline	NN	I-NP	O
-	HYPH	B-NP	O
devoid	JJ	I-NP	O
diet	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
fed	VBN	B-VP	O
the	DT	B-NP	O
phenobarbital	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
choline	NN	B-NP	O
-	HYPH	B-NP	O
devoid	JJ	I-NP	O
diet	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
evinced	VBD	B-VP	O
no	DT	B-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hepatocarcinogenicity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
choline	NN	I-NP	O
-	HYPH	B-NP	O
devoid	JJ	I-NP	O
diet	NN	I-NP	O
by	IN	B-PP	O
phenobarbital	NN	B-NP	O
.	.	O	O

Sporadic	JJ	B-NP	O
neoplastic	JJ	I-NP	O
lesions	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
organs	NNS	B-NP	O
other	JJ	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
of	IN	B-PP	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
irrespective	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
diet	NN	I-NP	O
fed	VBN	B-VP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
direct	JJ	B-NP	O
intracoronary	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
methylergonovine	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
and	CC	O	O
without	IN	B-PP	O
variant	JJ	B-NP	B
angina	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
intracoronary	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
methylergonovine	NN	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
variant	JJ	B-NP	B
angina	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
atypical	JJ	B-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
and	CC	B-PP	O
in	IN	B-PP	O
others	NNS	B-NP	O
without	IN	B-PP	O
angina	NN	B-NP	B
pectoris	NN	I-NP	I
(	(	O	O
control	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
.	.	O	O

Methylergonovine	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
continuously	RB	B-ADVP	O
at	IN	B-PP	O
a	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	O	O
min	NN	B-NP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
variant	JJ	B-NP	B
angina	NN	I-NP	I
,	,	O	O
coronary	JJ	B-NP	B
spasm	NN	I-NP	I
was	VBD	B-VP	O
provoked	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
SD	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
neither	CC	O	O
ischemic	JJ	B-NP	O
ST	NN	I-NP	O
change	NN	I-NP	O
nor	CC	O	O
localized	JJ	B-NP	O
spasm	NN	I-NP	B
occurred	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
basal	JJ	I-NP	O
tone	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
vasoconstriction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
spasm	NN	B-NP	B
provocation	NN	I-NP	O
tests	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
use	VBP	B-VP	O
an	DT	B-NP	O
intracoronary	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
relatively	RB	I-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
methylergonovine	NN	B-NP	O
,	,	O	O
have	VBP	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
sensitivity	NN	I-NP	O
in	IN	B-PP	O
variant	JJ	B-NP	B
angina	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
vasoreactivity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
coronary	JJ	I-NP	O
arteries	NNS	I-NP	O
.	.	O	O

Dobutamine	NN	B-NP	O
stress	NN	I-NP	O
echocardiography	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
sensitive	JJ	I-NP	O
indicator	NN	I-NP	O
of	IN	B-PP	O
diminished	VBN	B-NP	O
myocardial	JJ	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
asymptomatic	JJ	B-NP	O
doxorubicin	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
survivors	NNS	I-NP	O
of	IN	B-PP	O
childhood	NN	B-NP	O
cancer	NN	I-NP	B
.	.	O	O

Doxorubicin	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
anticancer	JJ	I-NP	O
chemotherapeutic	JJ	I-NP	O
agent	NN	I-NP	O
known	VBN	B-VP	O
to	TO	B-VP	O
cause	VB	I-VP	O
acute	JJ	B-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
develop	VB	I-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
sensitive	JJ	I-NP	O
echocardiographic	JJ	I-NP	O
screening	NN	I-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
cardiac	JJ	B-NP	B
damage	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
doxorubicin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
cohort	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
using	VBG	B-VP	O
dobutamine	NN	B-NP	O
infusion	NN	I-NP	O
to	TO	B-VP	O
differentiate	VB	I-VP	O
asymptomatic	JJ	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
survivors	NNS	I-NP	O
of	IN	B-PP	O
childhood	NN	B-NP	O
cancer	NN	I-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
doxorubicin	NN	B-NP	O
from	IN	B-PP	O
healthy	JJ	B-NP	O
control	NN	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Echocardiographic	JJ	B-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
(	(	O	O
median	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
before	IN	B-SBAR	O
this	DT	B-NP	O
study	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
echocardiographic	JJ	B-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
normal	JJ	I-NP	O
age	NN	I-NP	O
-	HYPH	B-VP	O
matched	VBN	B-NP	O
control	NN	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Graded	VBN	B-NP	O
dobutamine	NN	I-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
min	NN	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

Echocardiographic	JJ	B-NP	O
Doppler	NNP	I-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
before	IN	B-PP	O
infusion	NN	B-NP	O
and	CC	O	O
after	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
infusion	NN	B-NP	O
at	IN	B-PP	O
each	DT	B-NP	O
rate	NN	I-NP	O
.	.	O	O

Dobutamine	NN	B-NP	O
infusion	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
min	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
studies	NNS	I-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
incidence	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
important	JJ	I-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
that	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
values	NNS	B-NP	O
in	IN	B-PP	O
control	JJ	B-NP	O
subjects	NNS	I-NP	O
,	,	O	O
end	NN	B-NP	O
-	HYPH	I-NP	O
systolic	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
posterior	JJ	I-NP	O
wall	NN	I-NP	O
dimension	NN	I-NP	O
and	CC	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
posterior	JJ	I-NP	O
wall	NN	I-NP	O
thickening	VBG	B-VP	O
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
study	NN	I-NP	O
and	CC	O	O
these	DT	B-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
more	RBR	I-VP	O
clearly	RB	I-VP	O
delineated	VBN	I-VP	O
with	IN	B-PP	O
dobutamine	NN	B-NP	O
stimulation	NN	I-NP	O
.	.	O	O

End	NN	B-NP	O
-	HYPH	I-NP	O
systolic	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
posterior	JJ	I-NP	O
wall	NN	I-NP	O
dimension	NN	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
doxorubicin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
for	IN	B-PP	O
control	NN	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

End	NN	B-NP	O
-	HYPH	I-NP	O
systolic	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
posterior	JJ	I-NP	O
wall	NN	I-NP	O
dimension	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
min	NN	B-NP	O
dobutamine	NN	I-NP	O
infusion	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
doxorubicin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
for	IN	B-PP	O
control	NN	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
aminophylline	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
initiating	VBG	B-VP	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
during	IN	B-PP	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Cardiac	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
have	VBP	B-VP	O
frequently	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
additive	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
pharmacologic	JJ	B-NP	O
agents	NNS	I-NP	O
in	IN	B-PP	O
precipitating	VBG	B-VP	O
cardiac	JJ	B-NP	B
disturbances	NNS	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
has	VBZ	B-VP	O
only	RB	I-VP	O
recently	RB	I-VP	O
been	VBN	I-VP	O
emphasized	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
aminophylline	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
ventricular	JJ	I-NP	B
fibrillation	NN	I-NP	I
threshold	NN	I-NP	O
during	IN	B-PP	O
normal	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
base	NN	I-NP	O
conditions	NNS	I-NP	O
and	CC	B-PP	O
during	IN	B-PP	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
open	JJ	I-NP	O
chest	NN	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
ventricular	JJ	I-NP	B
fibrillation	NN	I-NP	I
threshold	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
passing	VBG	B-VP	O
a	DT	B-NP	O
gated	VBN	I-NP	O
train	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
constant	JJ	I-NP	O
current	JJ	I-NP	O
pulses	NNS	I-NP	O
through	IN	B-PP	O
the	DT	B-NP	O
ventricular	JJ	I-NP	O
myocardium	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
vulnerable	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
cycle	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
aminophylline	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
ventricular	JJ	I-NP	B
fibrillation	NN	I-NP	I
threshold	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
when	WRB	B-ADVP	O
pH	NN	B-NP	O
and	CC	I-NP	O
partial	JJ	I-NP	O
pressures	NNS	I-NP	O
of	IN	B-PP	O
oxygen	NN	B-NP	O
(	(	O	O
PO2	NN	B-NP	O
)	)	O	O
and	CC	O	O
carbon	NN	B-NP	O
dioxide	NN	I-NP	O
(	(	O	O
CO2	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
kept	VBN	I-VP	O
within	IN	B-PP	O
normal	JJ	B-NP	O
limits	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
was	VBD	B-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
hypoventilation	NN	B-NP	B
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
;	:	O	O
PC02	NN	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
:	:	O	O
P02	NN	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
)	)	O	O
,	,	O	O
infusion	NN	B-NP	O
of	IN	B-PP	O
aminophylline	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
even	RB	I-NP	O
greater	JJR	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
threshold	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
experiments	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
although	IN	B-SBAR	O
many	JJ	B-NP	O
factors	NNS	I-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
in	IN	B-PP	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
,	,	O	O
pharmacologic	JJ	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
aminophylline	NN	B-NP	O
,	,	O	O
may	MD	B-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
role	NN	I-NP	O
.	.	O	O

Case	NN	B-NP	O
report	NN	I-NP	O
:	:	O	O
acute	JJ	B-NP	O
unintentional	JJ	I-NP	O
carbachol	NN	I-NP	O
intoxication	NN	I-NP	O
.	.	O	O

Intoxications	NNS	B-NP	O
with	IN	B-PP	O
carbachol	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
muscarinic	JJ	I-NP	O
cholinergic	JJ	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
are	VBP	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
an	DT	B-NP	O
interesting	JJ	I-NP	O
case	NN	I-NP	O
investigating	VBG	B-VP	O
a	DT	O	O
(	(	O	O
near	IN	O	O
)	)	O	O
fatal	JJ	B-NP	O
poisoning	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
son	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	NN	I-NP	O
discovered	VBD	B-VP	O
a	DT	B-NP	O
newspaper	NN	I-NP	O
report	NN	I-NP	O
stating	VBG	B-VP	O
clinical	JJ	B-NP	O
success	NN	I-NP	O
with	IN	B-PP	O
plant	NN	B-NP	O
extracts	NNS	I-NP	O
in	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
mode	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
was	VBD	B-VP	O
said	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
synthetic	JJ	I-NP	O
compound	NN	I-NP	O
carbamylcholin	NN	I-NP	O
;	:	O	O
that	DT	B-NP	O
is	VBZ	B-VP	O
,	,	O	O
carbachol	NN	B-NP	O
.	.	O	O

He	PRP	B-NP	O
bought	VBD	B-VP	O
num	CD	B-NP	O
g	NN	I-NP	O
of	IN	B-PP	O
carbachol	NN	B-NP	O
as	IN	B-PP	O
pure	JJ	B-NP	O
substance	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
pharmacy	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
father	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

Carbachol	NN	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
hospital	NN	B-NP	O
admission	NN	I-NP	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
by	IN	B-PP	O
HPLC	NN	B-NP	O
-	HYPH	I-NP	O
mass	NN	I-NP	O
spectrometry	NN	I-NP	O
.	.	O	O

Minutes	NNS	B-NP	O
after	IN	B-PP	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
nausea	NN	B-NP	B
,	,	I-NP	O
sweating	NN	I-NP	O
and	CC	I-NP	O
hypotension	NN	I-NP	B
,	,	O	O
and	CC	O	O
finally	RB	B-VP	O
collapsed	VBD	I-VP	O
.	.	O	O

Bradycardia	NNP	B-NP	B
,	,	O	O
cholinergic	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
asystole	NN	B-NP	B
occurred	VBD	B-VP	O
.	.	O	O

Initial	JJ	B-NP	O
cardiopulmonary	JJ	I-NP	O
resuscitation	NN	I-NP	O
and	CC	O	O
immediate	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
adrenaline	NN	B-NP	O
(	(	O	O
epinephrine	NN	B-NP	O
)	)	O	O
,	,	O	O
atropine	NN	B-NP	O
and	CC	I-NP	O
furosemide	NN	I-NP	O
was	VBD	B-VP	O
successful	JJ	B-ADJP	O
.	.	O	O

On	IN	B-PP	O
hospital	NN	B-NP	O
admission	NN	I-NP	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
intubated	JJ	I-NP	O
,	,	I-NP	O
bradyarrhythmic	JJ	I-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mmHg	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
signs	NNS	I-NP	O
were	VBD	B-VP	O
hyperhidrosis	NN	B-NP	B
,	,	O	O
hypersalivation	NN	B-NP	B
,	,	O	O
bronchorrhoea	NN	B-NP	B
,	,	O	O
and	CC	O	O
severe	JJ	B-NP	O
miosis	NN	I-NP	B
;	:	O	O
the	DT	B-NP	O
electrocardiographic	JJ	I-NP	O
finding	NN	I-NP	O
was	VBD	B-VP	O
atrio	AFX	B-ADJP	B
-	HYPH	B-NP	I
ventricular	JJ	I-NP	I
dissociation	NN	I-NP	I
.	.	O	O

High	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
atropine	NN	B-NP	O
,	,	I-NP	O
adrenaline	NN	I-NP	O
and	CC	I-NP	O
dopamine	NN	I-NP	O
were	VBD	B-VP	O
necessary	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
extubated	VBN	I-VP	O
num	CD	B-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
increased	VBN	B-NP	O
dyspnoea	NN	I-NP	B
and	CC	I-NP	O
bronchospasm	NN	I-NP	B
necessitated	VBD	B-VP	O
reintubation	NN	B-NP	O
.	.	O	O

Respiratory	JJ	B-NP	B
insufficiency	NN	I-NP	I
was	VBD	B-VP	O
further	RBR	I-VP	O
worsened	VBN	I-VP	O
by	IN	B-PP	O
Proteus	NNP	B-NP	B
mirabilis	NN	I-NP	I
infection	NN	I-NP	I
and	CC	O	O
severe	JJ	B-NP	O
bronchoconstriction	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
again	RB	I-VP	O
extubated	VBN	I-VP	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
was	VBD	B-VP	O
transferred	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
peripheral	JJ	I-NP	O
ward	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
day	NN	I-NP	O
he	PRP	B-NP	O
died	VBD	B-VP	O
,	,	O	O
probably	RB	B-ADVP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Serum	NN	B-NP	O
samples	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
and	CC	I-NP	O
second	JJ	I-NP	O
days	NNS	I-NP	O
contained	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
carbachol	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
corresponding	VBG	I-NP	O
urine	NN	I-NP	O
concentrations	NNS	I-NP	O
amounted	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
l	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
started	VBD	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
media	NNS	I-NP	O
report	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
popular	JJ	I-NP	O
newspaper	NN	I-NP	O
,	,	O	O
initiated	VBN	B-VP	O
by	IN	B-PP	O
published	VBN	B-VP	O
,	,	O	O
peer	NN	B-NP	O
-	HYPH	O	O
reviewed	VBN	B-VP	O
research	NN	B-NP	O
on	IN	B-PP	O
herbals	NNS	B-NP	O
,	,	O	O
and	CC	O	O
involved	VBN	B-VP	O
human	JJ	B-NP	O
failure	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
history	NN	I-NP	O
,	,	O	O
medical	JJ	B-NP	O
examination	NN	I-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
analytical	JJ	I-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
determination	NN	I-NP	O
of	IN	B-PP	O
carbachol	NN	B-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
developed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
analysed	VBN	I-NP	O
carbachol	NN	I-NP	O
concentration	NN	I-NP	O
exceeded	VBD	B-VP	O
the	DT	B-NP	O
supposed	VBN	I-NP	O
serum	NN	I-NP	O
level	NN	I-NP	O
resulting	VBG	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
therapeutic	JJ	I-NP	O
dose	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
factor	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

Especially	RB	B-ADVP	O
in	IN	B-PP	O
old	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
intensivists	NNS	B-NP	O
should	MD	B-VP	O
consider	VB	I-VP	O
intoxications	NNS	B-NP	O
(	(	O	O
with	IN	B-PP	O
cholinergics	NNS	B-NP	O
)	)	O	O
as	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
cardiovascular	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Crossover	NN	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
efficacy	NN	B-NP	O
and	CC	I-NP	O
preference	NN	I-NP	O
for	IN	B-PP	O
rizatriptan	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
versus	IN	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
in	IN	B-PP	O
migraine	NN	B-NP	B
.	.	O	O

Rizatriptan	NNP	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
(	(	O	O
1B	NN	B-NP	O
/	SYM	B-NP	O
1D	NN	I-NP	O
)	)	O	O
receptor	NN	B-NP	O
agonist	NN	I-NP	O
with	IN	B-PP	O
rapid	JJ	B-NP	O
oral	JJ	I-NP	O
absorption	NN	I-NP	O
and	CC	O	O
early	JJ	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
randomized	VBD	B-VP	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
crossover	NN	I-NP	O
outpatient	NN	I-NP	O
study	NN	I-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
preference	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
rizatriptan	NN	I-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
tablet	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
ergotamine	NN	I-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
caffeine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
tablets	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treating	VBG	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
with	IN	B-PP	O
each	DT	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
patients	NNS	B-NP	O
expressing	VBG	B-VP	O
a	DT	B-NP	O
preference	NN	I-NP	O
,	,	O	O
more	JJR	B-NP	O
than	IN	I-NP	O
twice	RB	I-NP	O
as	RB	I-NP	O
many	JJ	I-NP	O
preferred	VBN	I-NP	O
rizatriptan	NN	I-NP	O
to	TO	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
.	.	O	O

Faster	NN	B-NP	O
relief	NN	I-NP	O
of	IN	B-PP	O
headache	NN	B-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
important	JJ	I-NP	O
reason	NN	I-NP	O
for	IN	B-PP	O
preference	NN	B-NP	O
,	,	O	O
cited	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
preferring	VBG	B-VP	O
rizatriptan	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
preferred	VBD	B-VP	O
ergotamine	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
primary	JJ	I-NP	O
endpoint	NN	I-NP	O
of	IN	B-PP	O
being	VBG	B-VP	O
pain	NN	B-NP	B
free	JJ	B-ADJP	O
at	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
in	IN	B-PP	O
favor	NN	B-NP	O
of	IN	B-PP	O
rizatriptan	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
pain	NN	B-NP	B
free	JJ	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
rizatriptan	NN	B-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	I-NP	O
caffeine	NN	I-NP	O
,	,	O	O
rizatriptan	NN	B-NP	O
being	VBG	B-VP	O
superior	JJ	B-ADJP	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Headache	NN	B-NP	B
relief	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
rizatriptan	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	I-NP	O
caffeine	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
rizatriptan	NN	B-NP	O
being	VBG	B-VP	O
superior	JJ	B-ADJP	O
to	TO	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
dosing	NN	B-NP	O
.	.	O	O

Almost	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
rizatriptan	NN	B-NP	O
were	VBD	B-VP	O
pain	NN	B-NP	B
free	JJ	B-ADJP	O
at	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
recurrence	NN	I-NP	O
or	CC	I-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
additional	JJ	B-NP	O
medication	NN	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	I-NP	O
caffeine	NN	I-NP	O
.	.	O	O

Rizatriptan	NN	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
superior	JJ	B-ADJP	O
to	TO	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
proportions	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
nausea	NN	I-NP	B
,	,	I-NP	O
vomiting	NN	I-NP	B
,	,	I-NP	O
phonophobia	NN	I-NP	B
or	CC	I-NP	O
photophobia	NN	I-NP	B
and	CC	B-PP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
function	NN	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
intake	NN	I-NP	O
.	.	O	O

More	JJR	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
(	(	O	O
completely	RB	B-ADVP	O
,	,	O	O
very	RB	B-ADVP	O
or	CC	I-ADVP	O
somewhat	RB	I-ADVP	O
)	)	O	O
satisfied	VBD	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
rizatriptan	NN	B-NP	O
than	IN	B-PP	O
at	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
.	.	O	O

Recurrence	NN	B-NP	O
rates	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
rizatriptan	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
ergotamine	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
active	JJ	I-NP	O
treatments	NNS	I-NP	O
were	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
after	IN	B-PP	O
rizatriptan	NN	B-NP	O
and	CC	I-NP	O
ergotamine	NN	I-NP	O
/	SYM	O	O
caffeine	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
were	VBD	B-VP	O
dizziness	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
nausea	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
and	CC	O	O
somnolence	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
and	CC	O	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
antineoplastic	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
carcinoma	NN	B-NP	B
developed	VBD	B-VP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
(	(	O	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
,	,	O	O
microangiopathic	JJ	B-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
,	,	O	O
and	CC	O	O
usually	RB	B-ADVP	O
thrombocytopenia	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
cisplatin	NN	B-NP	O
,	,	O	O
bleomycin	NN	B-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
vinca	NN	I-NP	O
alkaloid	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
thrombotic	JJ	B-NP	B
thrombocytopenic	JJ	I-NP	I
purpura	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
the	DT	B-NP	O
hemolytic	JJ	I-NP	B
-	HYPH	I-NP	I
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
an	DT	B-NP	O
apparent	JJ	I-NP	O
forme	NN	I-NP	O
fruste	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
disorders	NNS	I-NP	O
.	.	O	O

Histologic	JJ	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
tissue	NN	I-NP	O
showed	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
intravascular	JJ	B-NP	B
coagulation	NN	I-NP	I
,	,	O	O
primarily	RB	B-ADVP	O
affecting	VBG	B-VP	O
the	DT	B-NP	O
small	JJ	I-NP	O
arteries	NNS	I-NP	O
,	,	O	O
arterioles	NNS	B-NP	O
,	,	O	O
and	CC	O	O
glomeruli	NNS	B-NP	O
.	.	O	O

Because	IN	B-SBAR	O
each	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
tumor	NN	B-NP	B
-	HYPH	B-PP	O
free	JJ	B-ADJP	O
or	CC	O	O
had	VBD	B-VP	O
only	RB	B-NP	O
a	DT	I-NP	O
small	JJ	I-NP	O
tumor	NN	I-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
thrombotic	JJ	I-NP	B
microangiopathy	NN	I-NP	I
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

Diagnosis	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
potentially	RB	I-NP	O
fatal	JJ	I-NP	O
complication	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
delayed	VBN	I-VP	O
or	CC	I-VP	O
missed	VBN	I-VP	O
if	IN	B-SBAR	O
renal	JJ	B-NP	O
tissue	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
blood	NN	I-NP	O
smear	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
examined	VBN	I-VP	O
,	,	O	O
because	IN	B-SBAR	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
ascribed	VBN	I-VP	O
to	TO	B-PP	O
cisplatin	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
anemia	NN	I-NP	B
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
to	TO	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
bone	NN	I-NP	B
marrow	NN	I-NP	I
suppression	NN	I-NP	I
.	.	O	O

Salvage	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
nelarabine	NN	B-NP	O
,	,	O	O
etoposide	NN	B-NP	O
,	,	O	O
and	CC	O	O
cyclophosphamide	NN	B-NP	O
in	IN	B-PP	O
relapsed	VBN	B-NP	O
/	SYM	I-NP	O
refractory	JJ	I-NP	O
paediatric	JJ	I-NP	O
T	NN	I-NP	B
-	HYPH	I-NP	I
cell	NN	I-NP	I
lymphoblastic	JJ	I-NP	I
leukaemia	NN	I-NP	I
and	CC	I-NP	I
lymphoma	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
of	IN	B-PP	O
nelarabine	NN	B-NP	O
(	(	O	O
AraG	NN	B-NP	O
)	)	O	O
with	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
of	IN	B-PP	O
etoposide	NN	B-NP	O
(	(	O	O
VP	NN	B-NP	O
)	)	O	O
and	CC	O	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CPM	NN	B-NP	O
)	)	O	O
and	CC	O	O
prophylactic	JJ	B-NP	O
intrathecal	JJ	I-NP	O
chemotherapy	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
salvage	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
refractory	JJ	B-NP	O
or	CC	I-NP	O
relapsed	VBN	I-NP	O
T	NN	I-NP	B
-	HYPH	I-NP	I
cell	NN	I-NP	I
leukaemia	NN	I-NP	I
or	CC	I-NP	I
lymphoma	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
AraG	NNP	I-NP	O
included	VBD	B-VP	O
Grade	NNP	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
sensory	JJ	I-NP	O
and	CC	I-NP	O
motor	NN	I-NP	O
neuropathy	NN	I-NP	B
and	CC	O	O
musculoskeletal	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

Haematological	JJ	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
than	IN	B-PP	O
AraG	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
although	IN	B-SBAR	O
median	JJ	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
neutrophil	NN	B-NP	O
and	CC	I-NP	O
platelet	NN	I-NP	O
recovery	NN	I-NP	O
was	VBD	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
other	JJ	B-NP	O
salvage	NN	I-NP	O
therapies	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
some	DT	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
therapy	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
went	VBD	B-VP	O
into	IN	B-PP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
AraG	NN	B-NP	O
/	SYM	B-NP	O
VP	NN	I-NP	O
/	SYM	B-NP	O
CPM	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
experience	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
giving	VBG	B-VP	O
AraG	NN	B-NP	O
as	IN	B-PP	O
salvage	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
synchrony	NN	B-NP	O
with	IN	B-PP	O
etoposide	NN	B-NP	O
and	CC	I-NP	O
cyclophosphamide	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
neurological	JJ	B-NP	B
toxicity	NN	I-NP	I
must	MD	B-VP	O
be	VB	I-VP	O
closely	RB	I-VP	O
monitored	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
sulphasalazine	NN	I-NP	O
syndrome	NN	I-NP	O
strikes	VBZ	B-VP	O
again	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
lady	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
constellation	NN	I-NP	O
of	IN	B-PP	O
dermatitis	NN	B-NP	B
,	,	I-NP	O
fever	NN	I-NP	B
,	,	I-NP	O
lymphadenopathy	NN	I-NP	B
and	CC	I-NP	O
hepatitis	NN	I-NP	B
,	,	O	O
beginning	VBG	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
17th	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
sulphasalazine	NN	I-NP	O
for	IN	B-PP	O
sero	AFX	B-NP	O
-	HYPH	I-NP	O
negative	JJ	I-NP	O
rheumatoid	JJ	I-NP	B
arthritis	NN	I-NP	I
.	.	O	O

Cervical	JJ	B-NP	O
and	CC	I-NP	O
inguinal	JJ	I-NP	O
lymph	NN	I-NP	O
node	NN	I-NP	O
biopsies	NNS	I-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
necrotising	NN	I-NP	O
lymphadenitis	NN	I-NP	B
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
erythrophagocytosis	NN	B-NP	O
and	CC	O	O
prominent	JJ	B-NP	O
eosinophilic	JJ	I-NP	O
infiltrates	NNS	I-NP	O
,	,	O	O
without	IN	B-PP	O
viral	JJ	B-NP	O
inclusion	NN	I-NP	O
bodies	NNS	I-NP	O
,	,	O	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
an	DT	B-NP	O
adverse	JJ	I-NP	B
drug	NN	I-NP	I
reaction	NN	I-NP	I
.A	NN	I-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
fulminant	JJ	B-NP	O
drug	NN	I-NP	B
-	HYPH	B-NP	I
induced	VBN	I-NP	I
hepatitis	NN	I-NP	I
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
nuclear	JJ	I-NP	O
autoantibodies	NNS	I-NP	O
(	(	O	O
but	CC	B-PP	O
not	RB	B-PP	O
with	IN	I-PP	O
other	JJ	B-NP	O
markers	NNS	I-NP	O
of	IN	B-PP	O
autoimmunity	NN	B-NP	B
)	)	O	O
,	,	O	O
and	CC	O	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
multi	AFX	B-NP	B
-	HYPH	I-NP	I
organ	NN	I-NP	I
failure	NN	I-NP	I
and	CC	I-NP	O
sepsis	NN	I-NP	B
,	,	O	O
supervened	VBD	B-VP	O
.	.	O	O

She	PRP	B-NP	O
subsequently	RB	B-ADVP	O
died	VBD	B-VP	O
some	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
commencement	NN	I-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
drug	NN	I-NP	O
therapy.Post	NN	I-NP	O
-	HYPH	B-NP	O
mortem	NN	I-NP	O
examination	NN	I-NP	O
showed	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
massive	JJ	B-NP	B
hepatocellular	JJ	I-NP	I
necrosis	NN	I-NP	I
,	,	O	O
acute	JJ	B-NP	O
hypersensitivity	NN	I-NP	O
myocarditis	NN	I-NP	B
,	,	O	O
focal	JJ	B-NP	O
acute	JJ	I-NP	O
tubulo	AFX	B-NP	O
-	HYPH	I-NP	O
interstitial	JJ	I-NP	O
nephritis	NN	I-NP	B
and	CC	O	O
extensive	JJ	B-NP	O
bone	NN	I-NP	B
marrow	NN	I-NP	I
necrosis	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
malignancy	NN	B-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
thought	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
clinico	AFX	I-NP	O
-	HYPH	I-NP	O
pathological	JJ	I-NP	O
features	NNS	I-NP	O
and	CC	O	O
chronology	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
bore	VBD	B-VP	O
the	DT	B-NP	O
hallmarks	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
so	RB	I-NP	O
-	HYPH	I-NP	O
called	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
sulphasalazine	NN	I-NP	O
syndrome	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
rare	JJ	I-NP	O
,	,	O	O
but	CC	O	O
often	RB	B-NP	O
fatal	JJ	I-NP	O
,	,	I-NP	O
immunoallergic	JJ	I-NP	O
reaction	NN	I-NP	O
to	TO	B-PP	O
sulphasalazine	NN	B-NP	O
.	.	O	O

Bupropion	NN	B-NP	O
(	(	O	O
Zyban	NN	B-NP	O
)	)	O	O
toxicity	NN	B-NP	B
.	.	O	O

Bupropion	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
monocyclic	JJ	I-NP	O
antidepressant	NN	I-NP	O
structurally	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

Zyban	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
sustained	JJ	I-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
formulation	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
recently	RB	I-VP	O
released	VBN	I-VP	O
in	IN	B-PP	O
Ireland	NNP	B-NP	O
,	,	O	O
as	IN	B-PP	O
a	DT	B-NP	O
smoking	NN	I-NP	O
cessation	NN	I-NP	O
aid	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
since	IN	B-SBAR	O
it	PRP	B-NP	O
s	VBZ	B-VP	O
introduction	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
overdose	JJ	I-NP	B
cases	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	B-PP	O
The	DT	B-NP	O
National	NNP	I-NP	O
Poisons	NNP	I-NP	O
Information	NNP	I-NP	O
Centre.	NNP	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
toxicity	NN	B-NP	B
.	.	O	O

Common	JJ	B-NP	O
features	NNS	I-NP	O
included	VBD	B-VP	O
tachycardia	NN	B-NP	B
,	,	I-NP	O
drowsiness	NN	I-NP	O
,	,	I-NP	O
hallucinations	NNS	I-NP	B
and	CC	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
severe	JJ	B-NP	O
cardiac	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
,	,	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
resuscitated	VBN	I-VP	O
following	VBG	B-PP	O
a	DT	B-NP	O
cardiac	JJ	I-NP	B
arrest	NN	I-NP	I
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
recovered	VBD	B-VP	O
without	IN	B-PP	O
sequelae	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
female	NN	I-NP	O
who	WP	B-NP	O
required	VBD	B-VP	O
admission	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
Intensive	JJ	I-NP	O
Care	NNP	I-NP	O
Unit	NNP	I-NP	O
for	IN	B-PP	O
ventilation	NN	B-NP	O
and	CC	O	O
full	JJ	B-NP	O
supportive	JJ	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
following	VBG	B-PP	O
ingestion	NN	B-NP	O
of	IN	B-PP	O
13.5g	NN	B-NP	O
bupropion	NN	I-NP	O
.	.	O	O

Recurrent	JJ	B-NP	O
seizures	NNS	I-NP	B
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
diazepam	NN	B-NP	O
and	CC	O	O
broad	JJ	B-NP	O
complex	JJ	I-NP	O
tachycardia	NN	I-NP	B
was	VBD	B-VP	O
successfully	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
adenosine	NN	B-NP	O
.	.	O	O

Zyban	NNP	B-NP	O
caused	VBD	B-VP	O
significant	JJ	B-NP	O
neurological	JJ	I-NP	B
and	CC	I-NP	I
cardiovascular	JJ	I-NP	I
toxicity	NN	I-NP	I
in	IN	B-PP	O
overdose	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
potential	JJ	I-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
when	WRB	B-ADVP	O
prescribing	VBG	B-VP	O
it	PRP	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
smoking	NN	I-NP	O
cessation	NN	I-NP	O
aid	NN	I-NP	O
.	.	O	O

Survey	NN	B-NP	O
of	IN	B-PP	O
complications	NNS	B-NP	O
of	IN	B-PP	O
indocyanine	NN	B-NP	O
green	JJ	I-NP	O
angiography	NN	I-NP	O
in	IN	B-PP	O
Japan	NNP	B-NP	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
indocyanine	NN	B-NP	O
green	NN	I-NP	O
for	IN	B-PP	O
use	NN	B-NP	O
in	IN	B-PP	O
fundus	NN	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
sent	VBD	B-VP	O
a	DT	B-NP	O
questionnaire	NN	I-NP	O
concerning	VBG	B-VP	O
complications	NNS	B-NP	O
of	IN	B-PP	O
indocyanine	NN	B-NP	O
green	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
institutions	NNS	I-NP	O
in	IN	B-PP	O
Japan	NNP	B-NP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
selected	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
client	NN	I-NP	O
list	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
Topcon	NNP	I-NP	O
Company	NNP	I-NP	O
,	,	O	O
which	WDT	B-NP	O
manufactures	VBZ	B-VP	O
the	DT	B-NP	O
indocyanine	NN	I-NP	O
green	JJ	I-NP	O
fundus	NN	I-NP	O
camera	NN	I-NP	O
.	.	O	O

Ophthalmologists	NNS	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
institutions	NNS	I-NP	O
responded	VBD	B-VP	O
,	,	O	O
reporting	VBG	B-VP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
indocyanine	NN	I-NP	O
green	JJ	I-NP	O
angiograms	NNS	I-NP	O
performed	VBN	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
between	IN	B-PP	O
June	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
September	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

Before	IN	B-PP	O
angiography	NN	B-NP	O
,	,	O	O
intradermal	JJ	B-NP	O
or	CC	I-NP	O
intravenous	JJ	I-NP	O
indocyanine	NN	I-NP	O
green	JJ	I-NP	O
testing	NN	I-NP	O
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
institutions	NNS	I-NP	O
.	.	O	O

For	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
decision	NN	I-NP	O
was	VBD	B-VP	O
made	VBN	I-VP	O
not	RB	O	O
to	TO	B-VP	O
proceed	VB	I-VP	O
with	IN	B-PP	O
angiography	NN	B-NP	O
after	IN	B-PP	O
positive	JJ	B-NP	O
preangiographic	JJ	I-NP	O
testing	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
indocyanine	NN	B-NP	O
green	JJ	B-NP	O
used	VBN	B-VP	O
for	IN	B-PP	O
angiography	NN	B-NP	O
varied	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
,	,	O	O
depending	VBG	B-VP	O
upon	IN	B-PP	O
the	DT	B-NP	O
institution	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
mild	JJ	B-NP	O
reactions	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
nausea	NN	B-NP	B
,	,	O	O
exanthema	NN	B-NP	B
,	,	O	O
urtication	NN	B-NP	B
,	,	O	O
itchiness	NN	B-NP	B
,	,	O	O
and	CC	O	O
urgency	NN	B-NP	O
to	TO	B-VP	O
defecate	VB	I-VP	O
,	,	O	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
require	VB	I-VP	O
treatment	NN	B-NP	O
.	.	O	O

Also	RB	B-VP	O
recorded	VBN	I-VP	O
were	VBD	B-VP	O
num	CD	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
vein	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
required	VBD	B-VP	O
treatment	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
hypotensive	JJ	I-NP	B
patients	NNS	I-NP	O
required	VBD	B-VP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
shock	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
frequency	NN	B-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-VP	O
indocyanine	VB	I-VP	O
green	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
such	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
fluorescein	NN	B-NP	O
sodium	NN	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
indocyanine	NN	B-NP	O
green	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
safe	NN	I-NP	O
as	IN	B-PP	O
fluorescein	NN	B-NP	O
for	IN	B-PP	O
use	NN	B-NP	O
in	IN	B-PP	O
angiography	NN	B-NP	O
.	.	O	O

Bradykinin	NN	B-NP	O
receptors	NNS	I-NP	O
antagonists	NNS	I-NP	O
and	CC	O	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
inhibitors	NNS	I-NP	O
in	IN	B-PP	O
vincristine	NN	B-NP	O
and	CC	I-NP	O
streptozotocin	NN	I-NP	O
induced	VBD	B-VP	O
hyperalgesia	NN	B-NP	B
in	IN	B-PP	O
chemotherapy	NN	B-NP	O
and	CC	O	O
diabetic	JJ	B-NP	B
neuropathy	JJ	I-NP	I
rat	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
irreversible	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
constitutive	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
relatively	RB	I-NP	O
selective	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
inducible	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
relatively	RB	I-NP	O
specific	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
neuronal	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
antihyperalgesic	JJ	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
selective	JJ	B-NP	O
antagonists	NNS	I-NP	O
of	IN	B-PP	O
B2	NN	B-NP	O
and	CC	I-NP	O
B1	NN	I-NP	O
receptors	NNS	I-NP	O
:	:	O	O
D	NN	B-NP	O
-	HYPH	B-NP	O
Arg	NN	I-NP	O
-	HYPH	O	O
[	(	O	O
Hyp3	NN	B-NP	O
,	,	O	O
Thi5	NN	B-NP	O
,	,	O	O
D	NN	B-NP	O
-	HYPH	B-NP	O
Tic7	NN	I-NP	O
,	,	O	O
Oic8	NN	B-NP	O
]	)	O	O
bradykinin	NN	B-NP	O
or	CC	O	O
des	VBZ	B-VP	O
Arg10	NNP	B-NP	O
HOE	NNP	I-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
model	NN	B-NP	O
of	IN	B-PP	O
diabetic	JJ	B-NP	B
(	(	O	I
streptozotocin	NN	B-NP	I
-	HYPH	B-VP	I
induced	VBN	I-VP	I
)	)	O	I
and	CC	O	I
toxic	JJ	B-NP	I
(	(	O	I
vincristine	NN	B-NP	I
-	HYPH	B-VP	I
induced	VBN	I-VP	I
)	)	O	I
neuropathy	NN	B-NP	I
was	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
pain	NN	B-NP	B
thresholds	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
using	VBG	B-VP	O
mechanical	JJ	B-NP	O
stimuli	NNS	I-NP	O
-	HYPH	O	O
-	HYPH	O	O
the	DT	B-NP	O
modification	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
classic	JJ	I-NP	O
paw	NN	I-NP	O
withdrawal	NN	I-NP	O
test	NN	I-NP	O
described	VBN	B-VP	O
by	IN	B-PP	O
Randall	NNP	B-NP	O
-	HYPH	I-NP	O
Selitto	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
paper	NN	I-NP	O
confirm	VBP	B-VP	O
that	IN	B-SBAR	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
bradykinin	NN	B-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
inducible	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
but	CC	B-CONJP	O
not	RB	I-CONJP	O
neuronal	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
activity	NN	I-NP	O
reduces	VBZ	B-VP	O
diabetic	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
NOArg	NN	I-NP	O
and	CC	I-NP	O
L	NN	I-NP	O
-	HYPH	O	O
NIL	NN	B-NP	O
but	CC	B-PP	O
not	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
NI	NN	I-NP	O
,	,	O	O
significantly	RB	B-VP	O
increases	VBZ	I-VP	O
antihyperalgesic	JJ	B-NP	O
activity	NN	I-NP	O
both	DT	O	O
HOE	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
des	VBZ	B-VP	O
Arg10	NNP	B-NP	O
HOE	NNP	I-NP	O
num	CD	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
both	DT	B-NP	O
products	NNS	I-NP	O
of	IN	B-PP	O
inducible	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
and	CC	O	O
neuronal	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
activation	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
bradykinin	NN	B-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
hyperalgesia	NN	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
vincristine	NN	B-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	O	O
NOArg	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
NI	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
L	NN	B-NP	O
-	HYPH	O	O
NIL	NN	B-NP	O
intensify	VBP	B-VP	O
antihyperalgesic	JJ	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
HOE	NN	B-NP	O
num	CD	I-NP	O
or	CC	O	O
des	AFX	O	O
-	HYPH	O	O
Arg10HOE	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
toxic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Results	NNS	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
B1	NN	B-NP	O
and	CC	I-NP	O
B2	NN	I-NP	O
receptors	NNS	I-NP	O
are	VBP	B-VP	O
engaged	VBN	I-VP	O
in	IN	B-PP	O
transmission	NN	B-NP	O
of	IN	B-PP	O
nociceptive	JJ	B-NP	O
stimuli	NNS	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
diabetic	JJ	I-NP	B
and	CC	I-NP	I
toxic	JJ	I-NP	I
neuropathy	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperalgesia	NN	I-NP	B
,	,	O	O
inducible	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
participates	VBZ	B-VP	O
in	IN	B-PP	O
pronociceptive	JJ	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
bradykinin	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
in	IN	B-PP	O
vincristine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperalgesia	NN	I-NP	B
bradykinin	NN	I-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
activate	VB	I-VP	O
neuronal	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
concomitant	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
small	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
bradykinin	NN	B-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
and	CC	O	O
NO	NN	B-NP	O
synthase	NN	I-NP	O
inhibitors	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
alleviation	NN	B-NP	O
of	IN	B-PP	O
neuropathic	JJ	B-NP	B
pain	NN	I-NP	I
,	,	O	O
even	RB	B-ADVP	O
in	IN	B-PP	O
hospital	NN	B-NP	O
care	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
observed	VBN	B-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cyclophosphamide	NN	I-NP	O
-	HYPH	B-VP	O
based	VBN	B-NP	O
chemotherapy	NN	I-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Cyclophosphamide	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
alkylating	VBG	I-NP	O
agent	NN	I-NP	O
given	VBN	B-VP	O
frequently	RB	B-ADVP	O
as	IN	B-PP	O
a	DT	B-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
many	JJ	B-NP	O
conditioning	VBG	I-NP	O
regimens	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
nonhematological	JJ	I-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
toxicity	NN	B-NP	B
is	VBZ	B-VP	O
cardiomyopathy	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
combined	VBD	B-VP	O
paclitaxel	NN	B-NP	O
,	,	O	O
melphalan	NN	B-NP	O
and	CC	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cyclophosphamide	NN	I-NP	O
,	,	O	O
thiotepa	NN	B-NP	O
,	,	O	O
and	CC	O	O
carboplatin	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
triple	JJ	I-NP	O
sequential	JJ	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
regimen	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Analysis	NN	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
chemotherapy	NN	B-NP	O
-	HYPH	B-NP	O
responsive	JJ	I-NP	O
metastatic	JJ	I-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
receiving	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
infusional	JJ	I-NP	O
cyclophosphamide	NN	I-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
triple	JJ	I-NP	O
sequential	JJ	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
regimen	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
association	NN	B-NP	O
between	IN	B-PP	O
presence	NN	B-NP	O
of	IN	B-PP	O
peritransplant	NN	B-NP	O
congestive	JJ	I-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
CHF	NN	B-NP	B
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
following	VBG	I-NP	O
pretreatment	NN	I-NP	O
characteristics	NNS	I-NP	O
:	:	O	O
presence	NN	B-NP	O
of	IN	B-PP	O
electrocardiogram	NN	B-NP	O
(	(	O	O
EKG	NN	B-NP	O
)	)	O	O
abnormalities	NNS	B-NP	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
hypertension	NN	B-NP	B
,	,	O	O
prior	JJ	B-NP	O
cardiac	JJ	I-NP	O
history	NN	I-NP	O
,	,	O	O
smoking	NN	B-NP	O
,	,	O	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
,	,	O	O
prior	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
anthracyclines	NNS	B-NP	O
,	,	O	O
and	CC	O	O
left	JJ	B-NP	O
-	HYPH	I-NP	O
sided	JJ	I-NP	O
chest	NN	I-NP	O
irradiation	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
developed	VBD	B-VP	O
clinically	RB	B-NP	O
reversible	JJ	I-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
CHF	NN	I-NP	B
following	VBG	B-PP	O
infusional	JJ	B-NP	O
cyclophosphamide	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
percent	NN	I-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
ejection	NN	B-NP	O
fraction	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Incidence	NN	B-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
cyclophosphamide	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
cardiac	JJ	I-NP	B
toxicity	NN	I-NP	I
is	VBZ	B-VP	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
previous	JJ	B-NP	O
recorded	VBN	I-NP	O
literature	NN	I-NP	O
.	.	O	O

Older	JJR	B-NP	O
age	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
CHF	NN	I-NP	B
development	NN	I-NP	O
;	:	O	O
with	IN	B-PP	O
median	JJ	B-NP	O
ages	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
group	NN	I-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
developing	VBG	B-VP	O
CHF	NN	B-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

No	DT	B-NP	O
association	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
pretreatment	NN	I-NP	O
characteristics	NNS	I-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
,	,	O	O
oncologists	NNS	B-NP	O
should	MD	B-VP	O
carefully	RB	I-VP	O
monitor	VB	I-VP	O
fluid	NN	B-NP	O
balance	NN	I-NP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Routine	NN	B-NP	O
EKG	NN	I-NP	O
monitoring	NN	I-NP	O
during	IN	B-PP	O
infusional	JJ	B-NP	O
cyclophosphamide	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
predict	VB	I-VP	O
CHF	NN	B-NP	B
development	NN	I-NP	O
.	.	O	O

Inappropriate	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
and	CC	I-NP	O
vigabatrin	NN	I-NP	O
in	IN	B-PP	O
typical	JJ	B-NP	O
absence	NN	I-NP	B
seizures	NNS	I-NP	I
.	.	O	O

Carbamazepine	NN	B-NP	O
and	CC	I-NP	O
vigabatrin	NN	I-NP	O
are	VBP	B-VP	O
contraindicated	VBN	I-VP	O
in	IN	B-PP	O
typical	JJ	B-NP	O
absence	NN	I-NP	B
seizures	NNS	I-NP	I
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
referrals	NNS	I-NP	O
of	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
resistant	JJ	B-NP	O
typical	JJ	I-NP	O
absences	NNS	I-NP	O
only	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
erroneously	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
carbamazepine	NN	B-NP	O
either	CC	B-PP	O
as	IN	B-PP	O
monotherapy	NN	B-NP	O
or	CC	B-PP	O
as	IN	B-PP	O
an	DT	B-NP	O
add	NN	I-NP	O
-	HYPH	B-ADVP	O
on	RP	I-ADVP	O
.	.	O	O

Vigabatrin	NN	B-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
.	.	O	O

Frequency	NN	B-NP	O
of	IN	B-PP	O
absences	NNS	B-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
carbamazepine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
developed	VBN	I-NP	O
myoclonic	JJ	I-NP	B
jerks	NNS	I-NP	I
,	,	O	O
which	WDT	B-NP	O
resolved	VBD	B-VP	O
on	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
.	.	O	O

Absences	NNS	B-NP	O
were	VBD	B-VP	O
aggravated	VBN	I-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
cases	NNS	I-NP	O
where	WRB	B-ADVP	O
vigabatrin	NN	B-NP	O
was	VBD	B-VP	O
added	VBN	I-VP	O
on	RP	B-PRT	O
to	TO	B-PP	O
concurrent	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Optimal	JJ	B-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
absences	NNS	I-NP	O
was	VBD	B-VP	O
achieved	VBN	I-VP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
valproate	NN	I-NP	O
,	,	O	O
lamotrigine	NN	B-NP	O
,	,	O	O
or	CC	O	O
ethosuximide	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
.	.	O	O

Hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
omeprazole	NN	B-NP	O
.	.	O	O

Omeprazole	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
drug	NN	I-NP	O
designed	VBN	B-VP	O
to	TO	I-VP	O
block	VB	I-VP	O
the	DT	B-NP	O
final	JJ	I-NP	O
step	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
acid	NN	I-NP	O
secretory	JJ	I-NP	O
process	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
parietal	JJ	I-NP	O
cell	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
extremely	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
peptic	JJ	B-NP	B
ulcer	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
reflux	NN	B-NP	B
esophagitis	NN	I-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
Zollinger	NN	I-NP	B
-	HYPH	I-NP	I
Ellison	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Although	IN	B-SBAR	O
clinical	JJ	B-NP	O
experience	NN	I-NP	O
with	IN	B-PP	O
omeprazole	NN	B-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
limited	JJ	B-ADJP	O
,	,	O	O
many	JJ	B-NP	O
controlled	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
established	VBN	I-VP	O
the	DT	B-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
serious	JJ	I-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
adverse	JJ	I-NP	O
reaction	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
omeprazole	NN	B-NP	O
:	:	O	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
weakness	NN	B-NP	O
,	,	O	O
lethargy	NN	B-NP	B
,	,	O	O
and	CC	O	O
shortness	NN	B-NP	B
of	IN	B-PP	I
breath	NN	B-NP	I
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
omeprazole	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
her	PRP$	B-NP	O
hematocrit	NN	I-NP	O
had	VBD	B-VP	O
decreased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
she	PRP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
direct	JJ	I-NP	O
Coombs	NNS	I-NP	O
antiglobulin	NN	I-NP	O
test	NN	I-NP	O
and	CC	O	O
an	DT	B-NP	O
elevated	VBN	I-NP	O
indirect	JJ	I-NP	O
bilirubin	NN	I-NP	O
.	.	O	O

After	IN	B-SBAR	O
she	PRP	B-NP	O
discontinued	VBD	B-VP	O
the	DT	B-NP	O
omeprazole	NN	I-NP	O
,	,	O	O
her	PRP$	B-NP	O
hemoglobin	NN	I-NP	O
and	CC	I-NP	O
hematocrit	NN	I-NP	O
gradually	RB	B-ADVP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
omeprazole	NN	B-NP	O
caused	VBD	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
is	VBZ	B-VP	O
uncertain	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
physicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
alerted	VBN	I-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
possible	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
didanosine	NN	B-NP	O
(	(	O	O
ddI	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
HIV	NN	B-NP	B
antibody	NN	I-NP	I
-	HYPH	B-NP	I
positive	JJ	I-NP	I
individuals	NNS	I-NP	O
intolerant	JJ	B-ADJP	O
to	TO	B-PP	O
zidovudine	NN	B-NP	O
(	(	O	O
AZT	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
intolerant	JJ	B-ADJP	O
to	TO	B-PP	O
zidovudine	NN	B-NP	O
(	(	O	O
AZT	NN	B-NP	O
)	)	O	O
received	VBD	B-VP	O
didanosine	NN	B-NP	O
(	(	O	O
ddI	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
a	DT	B-NP	O
maximum	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

Patient	NN	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
CD4	NN	B-NP	O
+	SYM	B-NP	O
lymphocyte	NN	I-NP	O
subset	NN	I-NP	O
count	NN	I-NP	O
,	,	O	O
HIV	NN	B-NP	O
p24	NN	I-NP	O
antigen	NN	I-NP	O
,	,	O	O
weight	NN	B-NP	O
,	,	O	O
and	CC	O	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
major	JJ	B-NP	O
opportunistic	JJ	I-NP	B
infections	NNS	I-NP	I
whilst	IN	B-PP	O
on	IN	B-PP	O
therapy	NN	B-NP	O
;	:	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
AIDS	NNP	I-NP	B
diagnosis	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Only	RB	B-NP	O
minor	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
CD4	NN	B-NP	O
+	SYM	B-NP	O
lymphocyte	NN	I-NP	O
subset	NN	I-NP	O
count	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
AIDS	NN	B-NP	B
patients	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
a	DT	B-NP	O
more	RBR	I-NP	O
significant	JJ	I-NP	O
rise	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
earlier	JJR	B-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
disease	NN	B-NP	O
.	.	O	O

Of	IN	B-PP	O
those	DT	B-NP	O
positive	JJ	B-ADJP	O
for	IN	B-PP	O
p24	NN	B-NP	O
antigen	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
commencement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
response	NN	I-NP	O
,	,	O	O
and	CC	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
most	RBS	B-ADVP	O
likely	RB	I-ADVP	O
in	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
CD4	NN	B-NP	O
+	SYM	I-NP	O
lymphocyte	NN	I-NP	O
subset	NN	I-NP	O
counts	NNS	I-NP	O
above	IN	B-PP	O
num	CD	B-NP	O
mm3	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
positive	JJ	I-NP	O
weight	NN	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Most	JJS	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
improvement	NN	B-NP	O
in	IN	B-PP	O
individual	JJ	B-NP	O
parameters	NNS	I-NP	O
and	CC	O	O
global	JJ	B-NP	O
score	NN	I-NP	O
of	IN	B-PP	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
possibly	RB	B-ADJP	O
attributable	JJ	I-ADJP	O
to	TO	B-PP	O
didanosine	NN	B-NP	O
were	VBD	B-VP	O
common	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
diarrhoea	NN	B-NP	B
,	,	O	O
which	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
individuals	NNS	I-NP	O
.	.	O	O

Peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	I-NP	O
pancreatitis	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
raised	VBN	I-NP	O
serum	NN	I-NP	O
amylase	NN	I-NP	O
without	IN	B-PP	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
glucose	NN	B-NP	B
tolerance	NN	I-NP	I
curves	NNS	I-NP	I
characteristic	JJ	B-ADJP	O
of	IN	B-PP	O
diabetes	NN	B-NP	B
but	CC	O	O
these	DT	B-NP	O
were	VBD	B-VP	O
mild	JJ	B-ADJP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
require	VB	I-VP	O
treatment	NN	B-NP	O
and	CC	O	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
on	IN	B-PP	O
ceasing	VBG	B-VP	O
didanosine	NN	B-NP	O
.	.	O	O

Can	MD	O	O
angiogenesis	NN	B-NP	O
be	VB	B-VP	O
a	DT	B-NP	O
target	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
ribavirin	NN	B-NP	O
associated	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
?	.	O	O
BACKGROUND	NN	B-NP	O
/	SYM	B-NP	O
AIMS	NNS	I-NP	O
:	:	O	O
Recently	RB	B-NP	O
ribavirin	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
inhibit	VB	I-VP	O
angiogenesis	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
angiogenesis	NN	B-NP	O
inhibitors	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
sunitinib	NN	B-NP	O
and	CC	I-NP	O
sorafenib	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
acute	JJ	B-NP	O
hemolysis	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
relation	NN	I-NP	O
between	IN	B-PP	O
hemoglobin	NN	B-NP	O
,	,	O	O
haptoglobin	NN	B-NP	O
and	CC	O	O
angiogenesis	NN	B-NP	O
soluble	JJ	I-NP	O
markers	NNS	I-NP	O
which	WDT	B-NP	O
are	VBP	B-VP	O
modifiable	JJ	B-ADJP	O
and	CC	O	O
can	MD	B-VP	O
help	VB	I-VP	O
in	IN	B-PP	O
developing	VBG	B-VP	O
strategies	NNS	B-NP	O
against	IN	B-PP	O
anemia	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
chronically	RB	B-VP	B
infected	VBN	I-VP	I
with	IN	B-PP	I
hepatitis	NN	B-NP	I
C	NN	I-NP	I
virus	NN	I-NP	I
were	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
alpha	NN	I-NP	O
2a	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
hemoglobin	NN	I-NP	O
,	,	O	O
haptoglobin	NN	B-NP	O
and	CC	I-NP	O
angiogenesis	NN	I-NP	O
markers	NNS	I-NP	O
of	IN	B-PP	O
vascular	JJ	B-NP	O
endothelial	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
and	CC	I-NP	O
angiopoetin	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
therapy	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
haptoglobin	NN	B-NP	O
levels	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Hemoglobin	NN	B-NP	O
levels	NNS	I-NP	O
also	RB	B-ADVP	O
decreased	VBD	B-VP	O
but	CC	O	O
insignificantly	RB	B-ADVP	O
by	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
serum	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
angiogenesis	NN	B-NP	O
factors	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
significantly	RB	B-ADVP	O
by	IN	B-PP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
no	DT	B-NP	O
correlation	NN	I-NP	O
of	IN	B-PP	O
angiogenesis	NN	B-NP	O
soluble	JJ	I-NP	O
markers	NNS	I-NP	O
with	IN	B-PP	O
either	CC	O	O
hemoglobin	NN	B-NP	O
or	CC	I-NP	O
haptoglobin	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
investigating	VBG	B-VP	O
a	DT	B-NP	O
link	NN	I-NP	O
between	IN	B-PP	O
angiogenesis	NN	B-NP	O
soluble	JJ	I-NP	O
markers	NNS	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
induced	VBD	B-VP	O
anemia	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hepatitis	NN	B-NP	B
C	NN	I-NP	I
and	CC	O	O
we	PRP	B-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
find	VB	I-VP	O
any	DT	B-NP	O
relation	NN	I-NP	O
.	.	O	O

Future	JJ	B-NP	O
research	NN	I-NP	O
with	IN	B-PP	O
larger	JJR	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
to	TO	I-VP	O
find	VB	I-VP	O
out	RP	B-PRT	O
modifiable	JJ	B-NP	O
factors	NNS	I-NP	O
that	WDT	B-NP	O
will	MD	B-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
causes	VBZ	B-VP	O
memory	NN	B-NP	B
and	CC	I-NP	I
learning	NN	I-NP	I
impairments	NNS	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
:	:	O	O
involvement	NN	B-NP	O
of	IN	B-PP	O
nuclear	JJ	B-NP	O
factor	NN	I-NP	O
kappa	NN	I-NP	O
B	NN	I-NP	O
and	CC	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
,	,	O	O
and	CC	O	O
prevention	NN	B-NP	O
by	IN	B-PP	O
topiramate	NN	B-NP	O
.	.	O	O

Different	JJ	B-NP	O
mechanisms	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
for	IN	B-PP	O
cocaine	NN	B-NP	O
toxicity	NN	I-NP	B
including	VBG	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
but	CC	O	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
oxidative	JJ	B-NP	O
status	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
and	CC	I-NP	O
cocaine	NN	I-NP	O
induced	VBN	B-VP	O
-	HYPH	B-NP	O
behaviour	NN	I-NP	O
is	VBZ	B-VP	O
poorly	RB	B-ADJP	O
understood	VBN	I-ADJP	O
.	.	O	O

Nuclear	JJ	B-NP	O
factor	NN	I-NP	O
kappa	NN	I-NP	O
B	NN	I-NP	O
(	(	O	O
NFkappaB	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
sensor	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
participates	VBZ	B-VP	O
in	IN	B-PP	O
memory	NN	B-NP	O
formation	NN	I-NP	O
that	WDT	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
drug	NN	B-NP	O
toxicity	NN	I-NP	B
and	CC	O	O
addiction	NN	B-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

Therefore	RB	B-NP	O
NFkappaB	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
,	,	O	O
neuronal	JJ	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
(	(	O	O
nNOS	NN	B-NP	O
)	)	O	O
activity	NN	B-NP	O
,	,	O	O
spatial	JJ	B-NP	O
learning	NN	I-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
topiramate	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
previously	RB	I-NP	O
proposed	VBN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
cocaine	NN	B-NP	B
addiction	NN	I-NP	I
,	,	O	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

NFkappaB	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
frontal	JJ	I-NP	O
cortex	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
GSH	NN	B-NP	O
concentration	NN	I-NP	O
and	CC	O	O
glutathione	NN	B-NP	O
peroxidase	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
nNOS	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
.	.	O	O

Memory	NN	B-NP	O
retrieval	NN	I-NP	O
of	IN	B-PP	O
experiences	NNS	B-NP	O
acquired	VBN	B-VP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
administration	NN	I-NP	O
was	VBD	B-VP	O
impaired	JJ	B-ADJP	O
and	CC	O	O
negatively	RB	B-VP	O
correlated	VBD	I-VP	O
with	IN	B-PP	O
NFkappaB	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
frontal	JJ	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
learning	VBG	B-VP	O
of	IN	B-PP	O
new	JJ	B-NP	O
tasks	NNS	I-NP	O
was	VBD	B-VP	O
enhanced	VBN	I-VP	O
and	CC	O	O
correlated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
nNOS	NN	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
glutathione	NN	B-NP	O
peroxidase	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
evidence	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
mechanistic	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
and	CC	I-NP	O
nitrosative	JJ	I-NP	O
stress	NN	I-NP	O
and	CC	I-NP	O
NFkappaB	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
alterations	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Topiramate	NN	B-NP	O
prevented	VBD	B-VP	O
all	PDT	B-NP	O
the	DT	I-NP	O
alterations	NNS	I-NP	O
observed	VBN	B-VP	O
,	,	O	O
showing	VBG	B-VP	O
novel	JJ	B-NP	O
neuroprotective	JJ	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

Antinociceptive	JJ	B-NP	O
and	CC	I-NP	O
antiamnesic	JJ	I-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
presynaptic	JJ	I-NP	O
cholinergic	JJ	I-NP	O
amplifier	NN	I-NP	O
PG	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
antinociceptive	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
tropyl	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
p	NN	B-NP	O
-	HYPH	B-NP	O
bromophenyl	NN	I-NP	O
)	)	O	O
propionate	NN	B-NP	O
[	(	O	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
]	)	O	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
rats	NNS	B-NP	O
and	CC	O	O
guinea	NN	B-NP	O
pigs	NNS	I-NP	O
by	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hot	JJ	I-NP	O
-	HYPH	I-NP	O
plate	NN	I-NP	O
,	,	O	O
abdominal	JJ	B-NP	O
-	HYPH	I-NP	O
constriction	NN	I-NP	O
,	,	O	O
tail	NN	B-NP	O
-	HYPH	I-NP	O
flick	NN	I-NP	O
and	CC	I-NP	O
paw	NN	I-NP	O
-	HYPH	O	O
pressure	NN	B-NP	O
tests.	NN	I-NP	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	SYM	O	O
num	CD	B-NP	O
antinociception	NN	I-NP	O
peaked	VBD	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
and	CC	O	O
then	RB	B-VP	O
slowly	RB	I-VP	O
diminished	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
antinociception	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	SYM	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
unselective	JJ	I-NP	O
muscarinic	JJ	I-NP	O
antagonist	NN	I-NP	O
atropine	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
M1	NN	I-NP	O
-	HYPH	B-NP	O
selective	JJ	I-NP	O
antagonists	NNS	I-NP	O
pirenzepine	NN	I-NP	O
and	CC	I-NP	O
dicyclomine	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
acetylcholine	NN	I-NP	O
depletor	NN	I-NP	O
hemicholinium	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
by	IN	I-PP	O
the	DT	B-NP	O
opioid	JJ	I-NP	O
antagonist	NN	I-NP	O
naloxone	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
aminobutyric	JJ	I-NP	O
acidB	NN	I-NP	O
antagonist	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
aminopropyl	NN	I-NP	O
-	HYPH	B-NP	O
diethoxy	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	O	O
phosphinic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
H3	NN	I-NP	O
agonist	NN	I-NP	O
R	NN	I-NP	O
-	HYPH	O	O
(	(	O	O
alpha	SYM	O	O
)	)	O	O
-	HYPH	B-NP	O
methylhistamine	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
D2	NN	I-NP	O
antagonist	NN	I-NP	O
quinpirole	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxytryptamine4	NN	I-NP	O
antagonist	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methoxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
amino	JJ	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
chlorobenzoic	JJ	I-NP	O
acid	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
diethylamino	NN	B-NP	O
)	)	O	O
ethyl	NN	B-NP	O
ester	NN	I-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxytryptamin1A	NN	I-NP	O
antagonist	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methoxyphenyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
[	(	O	O
num	CD	O	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
phthalimido	NN	I-NP	O
)	)	O	O
butyl	NN	B-NP	O
]	)	O	O
piperazine	NN	B-NP	O
hydrobromide	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
polyamines	NNS	I-NP	O
depletor	NN	I-NP	O
reserpine	NN	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
these	DT	B-NP	O
data	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
postulated	VBN	I-VP	O
that	IN	B-SBAR	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
exerted	VBD	B-VP	O
an	DT	B-NP	O
antinociceptive	JJ	I-NP	O
effect	NN	I-NP	O
mediated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
central	JJ	I-NP	O
potentiation	NN	I-NP	O
of	IN	B-PP	O
cholinergic	JJ	B-NP	O
transmission.	NN	I-NP	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
amnesia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
and	CC	I-NP	O
dicyclomine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mouse	NN	I-NP	O
passive	JJ	I-NP	O
-	HYPH	I-NP	O
avoidance	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Affinity	NN	B-NP	O
profiles	NNS	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
for	IN	B-PP	O
muscarinic	JJ	B-NP	O
receptor	NN	I-NP	O
subtypes	NNS	I-NP	O
,	,	O	O
determined	VBN	B-VP	O
by	IN	B-PP	O
functional	JJ	B-NP	O
studies	NNS	I-NP	O
(	(	O	O
rabbit	NN	B-NP	O
vas	NN	I-NP	O
deferens	NNS	I-NP	O
for	IN	B-PP	O
M1	NN	B-NP	O
,	,	O	O
guinea	NN	B-NP	O
pig	NN	I-NP	O
atrium	NN	I-NP	O
for	IN	B-PP	O
M2	NN	B-NP	O
,	,	O	O
guinea	NN	B-NP	O
pig	NN	I-NP	O
ileum	NN	I-NP	O
for	IN	B-PP	O
M3	NN	B-NP	O
and	CC	O	O
immature	JJ	B-NP	O
guinea	NN	I-NP	O
pig	NN	I-NP	O
uterus	NN	I-NP	O
for	IN	B-PP	O
putative	JJ	B-NP	O
M4	NN	I-NP	O
)	)	O	O
,	,	O	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
an	DT	B-NP	O
M4	NN	I-NP	O
/	SYM	B-VP	O
M1	NN	B-NP	O
selectivity	NN	I-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
that	WDT	B-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
antinociception	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
amnesic	JJ	I-NP	B
effect	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
through	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
acetylcholine	NN	B-NP	O
extracellular	JJ	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
antinociceptive	JJ	I-NP	O
and	CC	I-NP	O
antiamnesic	JJ	I-NP	O
dose	NN	I-NP	O
range	NN	I-NP	O
,	,	O	O
-	HYPH	B-NP	O
PG	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
impair	VB	I-VP	O
mouse	NN	B-NP	O
performance	NN	I-NP	O
evaluated	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
rota	NN	I-NP	O
-	HYPH	B-NP	O
rod	NN	I-NP	O
test	NN	I-NP	O
and	CC	O	O
Animex	NNP	B-NP	O
apparatus	NN	I-NP	O
.	.	O	O

Hyperbaric	JJ	B-NP	O
oxygen	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
control	NN	B-NP	O
of	IN	B-PP	O
intractable	JJ	B-NP	O
cyclophosphamide	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
intractable	JJ	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
cyclophosphamide	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
Wegener	NNP	B-NP	B
s	JJ	I-NP	I
granulomatosis	NN	I-NP	I
.	.	O	O

Conservative	JJ	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
bladder	NN	B-NP	O
irrigation	NN	I-NP	O
with	IN	B-PP	O
physiological	JJ	B-NP	O
saline	NN	I-NP	O
and	CC	I-NP	O
instillation	NN	I-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
F2	NN	I-NP	O
alpha	NN	I-NP	O
,	,	O	O
failed	VBD	B-VP	O
to	TO	I-VP	O
totally	RB	I-VP	O
control	VB	I-VP	O
hemorrhage	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
then	RB	B-ADVP	O
used	VBD	B-VP	O
hyperbaric	JJ	B-NP	O
oxygen	NN	I-NP	O
at	IN	B-PP	O
an	DT	B-NP	O
absolute	JJ	I-NP	O
pressure	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
atm	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
a	DT	B-NP	O
week	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
bleeding	VBG	I-NP	B
ceased	VBN	B-VP	O
completely	RB	B-ADVP	O
by	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
remained	VBD	B-VP	O
free	JJ	B-ADJP	O
of	IN	B-PP	O
hematuria	NN	B-NP	B
thereafter	RB	B-ADVP	O
.	.	O	O

No	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
future	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
can	MD	B-VP	O
offer	VB	I-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
alternative	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
on	IN	B-PP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
irrigation	NN	B-NP	O
solutions	NNS	I-NP	O
on	IN	B-PP	O
rat	NN	B-NP	O
bladders	NNS	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
certain	JJ	B-NP	O
irrigating	VBG	I-NP	O
fluids	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
bladder	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
degradation	NN	I-NP	O
product	NN	I-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
choloroaniline	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
chlorhexidine	NN	B-NP	O
-	HYPH	B-NP	O
digluconate	NN	I-NP	O
associated	VBN	B-VP	O
erosive	JJ	B-NP	O
cystitis	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
high	JJ	I-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
kanamycin	NN	B-NP	O
-	HYPH	B-NP	O
colistin	NN	I-NP	O
and	CC	I-NP	O
povidone	NN	I-NP	O
-	HYPH	B-NP	O
iodine	NN	I-NP	O
irrigations	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
erosive	JJ	B-NP	O
cystitis	NN	I-NP	B
and	CC	O	O
suggested	VBD	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
complication	NN	I-NP	O
with	IN	B-PP	O
human	JJ	B-NP	O
usage	NN	I-NP	O
.	.	O	O

Picloxydine	NN	B-NP	O
irrigations	NNS	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
erosive	JJ	B-NP	O
cystitis	NN	I-NP	B
but	CC	O	O
further	JJ	B-NP	O
studies	NNS	I-NP	O
would	MD	B-VP	O
have	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
before	IN	B-SBAR	O
it	PRP	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
recommended	VBN	I-VP	O
for	IN	B-PP	O
use	NN	B-NP	O
in	IN	B-PP	O
urological	JJ	B-NP	O
procedures	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
experiences	NNS	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
open	JJ	I-NP	O
and	CC	O	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
sixty	JJ	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
trated	VBN	I-VP	O
with	IN	B-PP	O
bromperidol	NN	B-NP	O
first	RB	B-ADVP	O
in	IN	B-PP	O
open	JJ	B-NP	O
conditions	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
then	RB	B-ADVP	O
on	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
basis	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
reference	NN	I-NP	O
substance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
open	JJ	I-NP	O
study	NN	I-NP	O
lasted	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
;	:	O	O
the	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
administrated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
tablets	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
always	RB	I-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
finished	VBD	B-VP	O
the	DT	B-NP	O
trial	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
result	NN	I-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
very	RB	B-ADJP	O
good	JJ	I-ADJP	O
to	TO	B-PP	O
good	JJ	B-ADJP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
statistical	JJ	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
exhibited	VBD	B-VP	O
mild	JJ	B-ADJP	O
to	TO	B-VP	O
moderate	VB	I-VP	O
extrapyramidal	JJ	B-NP	B
concomitant	JJ	I-NP	I
symptoms	NNS	I-NP	I
;	:	O	O
no	DT	B-NP	O
other	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
detailed	JJ	B-NP	O
laboratory	NN	I-NP	O
tests	NNS	I-NP	O
and	CC	I-NP	O
evaluations	NNS	I-NP	O
of	IN	B-PP	O
various	JJ	B-NP	O
quantitative	JJ	I-NP	O
and	CC	I-NP	O
qualitative	JJ	I-NP	O
tolerability	NN	I-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
toxic	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
,	,	O	O
both	DT	B-NP	O
substances	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
highly	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
psychotic	JJ	B-NP	B
syndromes	NNS	I-NP	I
belonging	VBG	B-VP	I
predominantly	RB	B-ADVP	I
to	TO	B-PP	I
the	DT	B-NP	I
schizophrenia	NN	I-NP	I
group	NN	I-NP	I
.	.	O	O

Certain	JJ	B-NP	O
clues	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
,	,	O	O
seem	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
superiority	NN	I-NP	O
of	IN	B-PP	O
bromperidol	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
and	CC	O	O
general	JJ	B-NP	O
tolerability	NN	I-NP	O
.	.	O	O

Curcumin	NN	B-NP	O
ameliorates	VBZ	B-VP	O
cognitive	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
oxidative	JJ	B-NP	O
damage	NN	I-NP	O
in	IN	B-PP	O
phenobarbitone	NN	B-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
administered	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
antiepileptic	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	I-NP	O
phenobarbitone	NN	I-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
are	VBP	B-VP	O
well	RB	I-VP	O
known	VBN	I-VP	O
to	TO	B-VP	O
cause	VB	I-VP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
on	IN	B-PP	O
chronic	JJ	B-NP	O
use	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
free	JJ	B-NP	O
radical	NN	I-NP	O
generation	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
as	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
important	JJ	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
by	IN	B-PP	O
antiepileptic	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Curcumin	NN	B-NP	O
has	VBZ	B-VP	O
shown	VBN	I-VP	O
antioxidant	JJ	B-ADJP	O
,	,	O	O
anti	AFX	O	O
-	HYPH	O	O
inflammatory	JJ	B-ADJP	O
and	CC	O	O
neuro	AFX	B-NP	O
-	HYPH	I-NP	O
protective	JJ	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
curcumin	NN	I-NP	O
administration	NN	I-NP	O
on	IN	B-PP	O
phenobarbitone	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cognitive	JJ	I-NP	B
impairment	NN	I-NP	I
and	CC	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Pharmacokinetic	JJ	B-NP	O
interactions	NNS	I-NP	O
of	IN	B-PP	O
curcumin	NN	B-NP	O
with	IN	B-PP	O
phenobarbitone	NN	B-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
studied	VBN	I-VP	O
.	.	O	O

Vehicle	NN	B-NP	O
/	SYM	I-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
21days	NNS	B-NP	O
to	TO	B-PP	O
male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Passive	JJ	B-NP	O
avoidance	NN	I-NP	O
paradigm	NN	I-NP	O
and	CC	O	O
elevated	VBN	B-VP	O
plus	CC	O	O
maze	NN	B-NP	O
test	NN	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
study	NN	B-NP	O
period	NN	I-NP	O
,	,	O	O
serum	NN	B-NP	O
phenobarbitone	NN	I-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
,	,	O	O
whole	JJ	B-NP	O
brain	NN	I-NP	O
malondialdehyde	NN	I-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
glutathione	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
estimated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
phenobarbitone	NN	B-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
for	IN	B-PP	O
21days	NNS	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
impairment	NN	I-NP	B
of	IN	B-PP	I
learning	NN	B-NP	I
and	CC	I-NP	I
memory	NN	I-NP	I
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
.	.	O	O

Concomitant	JJ	B-NP	O
curcumin	NN	I-NP	O
administration	NN	I-NP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
cognitive	JJ	I-NP	B
impairment	NN	I-NP	I
and	CC	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
these	DT	B-NP	O
antiepileptic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Curcumin	NN	B-NP	O
co	AFX	O	O
-	HYPH	O	O
administration	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
any	DT	B-NP	O
significant	JJ	I-NP	O
alteration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
phenobarbitone	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
carbamazepine	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
curcumin	NN	B-NP	O
has	VBZ	B-VP	O
beneficial	JJ	B-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
mitigating	VBG	B-VP	O
the	DT	B-NP	O
deterioration	NN	I-NP	B
of	IN	B-PP	I
cognitive	JJ	B-NP	I
functions	NNS	I-NP	I
and	CC	O	O
oxidative	JJ	B-NP	O
damage	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
phenobarbitone	NN	B-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
without	IN	B-PP	O
significantly	RB	B-VP	O
altering	VBG	I-VP	O
their	PRP$	B-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
curcumin	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
safe	JJ	I-NP	O
and	CC	I-NP	O
effective	JJ	I-NP	O
adjuvant	JJ	I-NP	O
to	TO	B-PP	O
phenobarbitone	NN	B-NP	O
and	CC	I-NP	O
carbamazepine	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Pyrrolidine	NN	B-NP	O
dithiocarbamate	NN	I-NP	O
protects	VBZ	B-VP	O
the	DT	B-NP	O
piriform	JJ	I-NP	O
cortex	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
model	NN	I-NP	O
.	.	O	O

Pyrrolidine	NN	B-NP	O
dithiocarbamate	NN	I-NP	O
(	(	O	O
PDTC	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
a	DT	B-NP	O
dual	JJ	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
antioxidant	NN	I-NP	O
and	CC	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
transcription	NN	I-NP	O
factor	NN	I-NP	O
kappa	NN	I-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
.	.	O	O

Both	CC	O	O
,	,	O	O
production	NN	B-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
activation	NN	B-NP	O
of	IN	B-PP	O
NF	NN	B-NP	O
-	HYPH	B-NP	O
kappaB	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
neuronal	JJ	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
different	JJ	B-NP	O
sub	AFX	I-NP	O
-	HYPH	I-NP	O
regions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
the	DT	B-NP	O
surrounding	VBG	I-NP	O
cortices	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
PDTC	NN	B-NP	O
on	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
-	HYPH	B-VP	O
associated	VBN	B-NP	O
cell	NN	I-NP	O
loss	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
and	CC	I-NP	O
piriform	NN	I-NP	O
cortex	NN	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
fractionated	VBD	B-VP	O
pilocarpine	NN	B-NP	O
model	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
PDTC	NN	I-NP	O
before	IN	B-PP	O
and	CC	O	O
following	VBG	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
PDTC	NN	I-NP	O
(	(	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
)	)	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
exert	VB	I-VP	O
major	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
or	CC	O	O
the	DT	B-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
vehicle	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
caused	VBD	B-VP	O
pronounced	JJ	B-NP	O
neuronal	JJ	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
piriform	NN	I-NP	O
cortex	NN	I-NP	O
comprising	VBG	B-VP	O
both	CC	O	O
pyramidal	JJ	B-NP	O
cells	NNS	I-NP	O
and	CC	I-NP	O
interneurons	NNS	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
PDTC	NN	I-NP	O
treatment	NN	I-NP	O
almost	RB	B-VP	O
completely	RB	I-VP	O
protected	VBN	I-VP	O
from	IN	B-PP	O
lesions	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
piriform	NN	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
neuronal	JJ	B-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
hilar	JJ	I-NP	O
formation	NN	I-NP	O
was	VBD	B-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
vehicle	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
PDTC	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
following	VBG	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
NF	NN	I-NP	O
-	HYPH	B-NP	O
kappaB	NN	I-NP	O
inhibitor	NN	I-NP	O
and	CC	O	O
antioxidant	JJ	B-NP	O
PDTC	NN	I-NP	O
protected	VBD	B-VP	O
the	DT	B-NP	O
piriform	NN	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
it	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
hilar	JJ	B-NP	O
neuronal	JJ	I-NP	B
loss	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
might	MD	B-VP	O
indicate	VB	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
generation	NN	I-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
and	CC	O	O
activation	NN	B-NP	O
of	IN	B-PP	O
NF	NN	B-NP	O
-	HYPH	B-NP	O
kappaB	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
central	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
seizure	NN	B-NP	B
-	HYPH	O	O
associated	VBN	B-NP	O
neuronal	JJ	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
cortex	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
hilus	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
future	JJ	B-NP	O
investigations	NNS	I-NP	O
are	VBP	B-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
exactly	RB	I-VP	O
analyze	VB	I-VP	O
the	DT	B-NP	O
biochemical	JJ	I-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
PDTC	NN	B-NP	O
exerted	VBD	B-VP	O
its	PRP$	B-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
piriform	NN	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

Safety	NN	B-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
nicotine	NN	I-NP	O
lozenge	NN	I-NP	O
compared	VBN	B-VP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
gum	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
smokers	NNS	I-NP	O
with	IN	B-PP	O
underlying	VBG	B-VP	O
medical	JJ	B-NP	O
conditions	NNS	I-NP	O
:	:	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
randomized	VBN	B-NP	O
,	,	I-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
polacrilex	NN	I-NP	O
lozenges	VBZ	B-VP	O
deliver	VB	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
more	JJR	B-NP	O
nicotine	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
equivalent	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
polacrilex	NN	I-NP	O
gum	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
increased	VBN	I-NP	O
nicotine	NN	I-NP	O
exposure	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
lozenge	NN	I-NP	O
has	VBZ	B-VP	O
raised	VBN	I-VP	O
questions	NNS	B-NP	O
about	IN	B-PP	O
the	DT	B-NP	O
relative	JJ	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lozenge	NN	I-NP	O
and	CC	I-NP	O
gum	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
profiles	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
nicotine	NN	I-NP	O
lozenge	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
nicotine	NN	I-NP	O
gum	NN	I-NP	O
in	IN	B-PP	O
smokers	NNS	B-NP	O
with	IN	B-PP	O
selected	VBN	B-NP	O
label	NN	I-NP	O
-	HYPH	B-NP	O
restricted	VBN	I-NP	O
diseases	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
multicenter	NN	I-NP	O
,	,	O	O
randomized	VBN	B-NP	O
,	,	I-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
smokers	NNS	I-NP	O
with	IN	B-PP	O
heart	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
hypertension	NN	B-NP	B
not	RB	B-VP	O
controlled	VBN	I-VP	O
by	IN	B-PP	O
medication	NN	B-NP	O
,	,	O	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
:	SYM	I-NP	O
num	CD	I-NP	O
ratio	NN	I-NP	O
to	TO	B-VP	O
receive	VB	I-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
nicotine	NN	I-NP	O
lozenge	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
nicotine	NN	I-NP	O
gum	NN	I-NP	O
.	.	O	O

Safety	NN	B-NP	O
assessments	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
product	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
lozenge	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
gum	NN	I-NP	O
(	(	O	O
safety	NN	B-NP	O
population	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
majority	NN	I-NP	O
were	VBD	B-VP	O
women	NNS	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
s	VBZ	B-VP	O
mean	JJ	B-NP	O
age	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
their	PRP$	B-NP	O
mean	JJ	I-NP	O
weight	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
pounds	NNS	I-NP	O
,	,	O	O
and	CC	O	O
they	PRP	B-NP	O
smoked	VBD	B-VP	O
a	DT	B-NP	O
mean	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cigarettes	NNS	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
taking	VBG	B-VP	O
the	DT	B-NP	O
lozenge	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
taking	VBG	B-VP	O
the	DT	B-NP	O
gum	NN	I-NP	O
,	,	O	O
used	VBD	B-VP	O
the	DT	B-NP	O
study	NN	I-NP	O
product	NN	I-NP	O
for	IN	B-PP	O
>	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
per	IN	B-PP	O
week	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
(	(	O	O
evaluable	JJ	B-NP	O
population	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
nicotine	NN	I-NP	O
lozenge	NN	I-NP	O
and	CC	O	O
nicotine	NN	B-NP	O
gum	NN	I-NP	O
were	VBD	B-VP	O
equally	RB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
despite	IN	B-PP	O
increased	VBN	B-NP	O
nicotine	NN	I-NP	O
exposure	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
lozenge	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
product	NN	B-NP	O
use	NN	I-NP	O
(	(	O	O
evaluation	NN	B-NP	O
population	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
lozenge	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
gum	NN	I-NP	O
)	)	O	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
during	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
study	NN	I-NP	O
(	(	O	O
safety	NN	B-NP	O
population	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Stratification	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
by	IN	B-PP	O
sex	NN	B-NP	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
extent	NN	B-NP	O
of	IN	B-PP	O
concurrent	JJ	B-NP	O
smoking	NN	I-NP	O
,	,	O	O
extent	NN	B-NP	O
of	IN	B-PP	O
product	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
and	CC	O	O
severity	NN	B-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
clinically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
lozenge	NN	I-NP	O
and	CC	I-NP	O
gum	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
nausea	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
hiccups	NNS	B-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
headache	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
Cl	NN	I-NP	O
,	,	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

Serious	JJ	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
respective	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Fewer	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
either	DT	B-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
considered	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
investigator	NN	I-NP	O
to	TO	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
worsening	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
overall	JJ	I-NP	O
disease	NN	I-NP	O
condition	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
experienced	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
disease	NN	I-NP	O
status	NN	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
nicotine	NN	I-NP	O
lozenge	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
nicotine	NN	I-NP	O
gum	NN	I-NP	O
had	VBD	B-VP	O
comparable	JJ	B-NP	O
safety	NN	I-NP	O
profiles	NNS	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
label	NN	B-NP	O
-	HYPH	O	O
restricted	VBN	B-NP	O
medical	JJ	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
parkinsonian	JJ	B-NP	B
monkeys	NNS	I-NP	O
may	MD	B-VP	O
depend	VB	I-VP	O
upon	IN	B-PP	O
rate	NN	B-NP	O
of	IN	B-PP	O
symptom	NN	B-NP	O
onset	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
(	(	O	O
LIDs	NNS	B-NP	B
)	)	O	O
present	VBP	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
problem	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
patients	NNS	B-NP	O
.	.	O	O

Due	JJ	B-PP	O
to	TO	I-PP	O
the	DT	B-NP	O
interdependence	NN	I-NP	O
of	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
populations	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
difficult	JJ	B-ADJP	O
to	TO	B-VP	O
independently	RB	I-VP	O
examine	VB	I-VP	O
factors	NNS	B-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
influence	VB	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
LIDs	NNS	B-NP	B
.	.	O	O

Using	VBG	B-VP	O
macaque	JJ	B-NP	O
monkeys	NNS	I-NP	O
with	IN	B-PP	O
different	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
MPTP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
parkinsonism	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
degree	NN	I-NP	O
to	TO	B-PP	O
which	WDT	B-NP	O
rate	NN	B-NP	O
of	IN	B-PP	O
symptom	NN	B-NP	O
progression	NN	I-NP	O
,	,	O	O
symptom	NN	B-NP	O
severity	NN	I-NP	O
,	,	O	O
and	CC	O	O
response	NN	B-NP	O
to	TO	B-PP	O
and	CC	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
LIDs	NNS	B-NP	B
.	.	O	O

Monkeys	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	O	O
(	(	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
)	)	O	O
MPTP	NN	B-NP	O
exposure	NN	I-NP	O
,	,	O	O
rapid	JJ	B-NP	O
symptom	NN	I-NP	O
onset	NN	I-NP	O
and	CC	O	O
short	JJ	B-NP	O
symptom	NN	I-NP	O
duration	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
developed	VBD	B-VP	O
dyskinesia	NN	B-NP	B
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
levodopa	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
monkeys	NNS	B-NP	O
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
MPTP	NN	I-NP	O
exposure	NN	I-NP	O
,	,	O	O
slow	JJ	B-NP	O
symptom	NN	I-NP	O
progression	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
long	JJ	B-NP	O
symptom	NN	I-NP	O
duration	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
resistant	JJ	I-ADJP	O
to	TO	B-PP	O
developing	VBG	B-NP	O
LIDs	NNS	I-NP	B
(	(	O	O
e.g.	FW	B-NP	O
,	,	O	O
dyskinesia	NN	B-NP	B
developed	VBD	B-VP	O
no	DT	B-NP	O
sooner	RBR	I-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
levodopa	NN	I-NP	O
administration	NN	I-NP	O
)	)	O	O
.	.	O	O

All	DT	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
similarly	RB	B-ADJP	O
symptomatic	JJ	I-ADJP	O
at	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
similar	JJ	B-NP	O
therapeutic	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
distinct	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
propensity	NN	I-NP	O
to	TO	B-VP	O
develop	VB	I-VP	O
LIDs	NNS	B-NP	B
in	IN	B-PP	O
monkeys	NNS	B-NP	O
with	IN	B-PP	O
different	JJ	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
symptom	NN	B-NP	O
progression	NN	I-NP	O
or	CC	I-NP	O
symptom	NN	I-NP	O
durations	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
levodopa	NN	B-NP	O
and	CC	O	O
demonstrate	VBP	B-VP	O
the	DT	B-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
models	NNS	I-NP	O
for	IN	B-PP	O
further	RB	B-ADVP	O
studying	VBG	B-VP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
LIDs	NNS	B-NP	B
.	.	O	O

Propylthiouracil	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
perinuclear	JJ	I-NP	O
-	HYPH	I-NP	O
staining	NN	I-NP	O
antineutrophil	NN	I-NP	O
cytoplasmic	JJ	I-NP	O
autoantibody	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
vasculitis	NN	I-NP	B
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
pericarditis	NN	B-NP	B
.	.	O	O

To	TO	B-VP	O
describe	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
propylthiouracil	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasculitis	NN	I-NP	B
manifesting	VBG	B-VP	O
with	IN	B-PP	O
pericarditis	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
hyperthyroidism	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
propylthiouracil	NN	B-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
a	DT	B-NP	O
syndrome	NN	I-NP	O
of	IN	B-PP	O
pericarditis	NN	B-NP	B
,	,	O	O
fever	NN	B-NP	B
,	,	O	O
and	CC	O	O
glomerulonephritis	NN	B-NP	B
developed	VBD	B-VP	O
.	.	O	O

Serologic	JJ	B-NP	O
testing	NN	I-NP	O
and	CC	O	O
immunologic	JJ	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
done	VBN	I-VP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
pericardial	JJ	I-NP	O
biopsy	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
Graves	NN	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
had	VBD	B-VP	O
a	DT	B-NP	O
febrile	JJ	I-NP	B
illness	NN	I-NP	I
and	CC	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
pericarditis	NN	B-NP	B
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
biopsy	NN	B-NP	O
.	.	O	O

Serologic	JJ	B-NP	O
evaluation	NN	I-NP	O
revealed	VBD	B-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
perinuclear	JJ	B-NP	O
-	HYPH	I-NP	O
staining	NN	I-NP	O
antineutrophil	NN	I-NP	O
cytoplasmic	JJ	I-NP	O
autoantibodies	NNS	I-NP	O
(	(	O	O
pANCA	NN	B-NP	O
)	)	O	O
against	IN	B-PP	O
myeloperoxidase	NN	B-NP	O
(	(	O	O
MPO	NN	B-NP	O
)	)	O	O
.	.	O	O

Propylthiouracil	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
withdrawn	VBN	I-VP	O
,	,	O	O
and	CC	O	O
she	PRP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
prednisone	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
alleviated	VBD	B-VP	O
her	PRP$	B-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
literature	NN	I-NP	O
review	NN	I-NP	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
prior	JJ	I-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
pericarditis	NN	B-NP	B
in	IN	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
MPO	NN	I-NP	O
pANCA	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
vasculitis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
propylthio	AFX	B-NP	O
-	HYPH	I-NP	O
uracil	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Pericarditis	NN	B-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasculitis	NN	I-NP	B
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
propylthio	AFX	B-NP	O
-	HYPH	I-NP	O
uracil	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
mouse	NN	I-NP	O
lines	NNS	I-NP	O
selected	VBN	B-VP	O
for	IN	B-PP	O
differential	JJ	B-NP	O
sensitivities	NNS	I-NP	O
to	TO	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
carboline	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
are	VBP	B-VP	O
also	RB	B-ADVP	O
differentially	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
various	JJ	B-NP	O
pharmacological	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
GABA	NN	I-NP	O
(	(	I-NP	O
A	NN	I-NP	O
)	)	I-NP	O
receptor	NN	I-NP	O
ligands	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
mouse	NN	I-NP	O
lines	NNS	I-NP	O
were	VBD	B-VP	O
selectively	RB	I-VP	O
bred	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
sensitivity	NN	I-NP	O
(	(	O	O
BS	NN	B-NP	O
line	NN	I-NP	O
)	)	O	O
or	CC	O	O
resistance	NN	B-NP	O
(	(	O	O
BR	NN	B-NP	O
line	NN	I-NP	O
)	)	O	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
i.p.	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
methyl	NN	B-NP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
carboline	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
carboxylate	NN	I-NP	O
(	(	O	O
beta	SYM	O	O
-	HYPH	O	O
CCM	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
inverse	JJ	I-NP	O
agonist	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
GABA	NN	I-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
benzodiazepine	NN	I-NP	O
site	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
aim	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
characterize	VB	I-VP	O
both	DT	B-NP	O
lines	NNS	I-NP	O
s	VBZ	B-VP	O
sensitivities	NNS	B-NP	O
to	TO	B-PP	O
various	JJ	B-NP	O
physiological	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
ligands	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
GABA	NN	I-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
measured	VBD	B-VP	O
diazepam	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
anxiolysis	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
elevated	VBN	I-NP	O
plus	CC	I-NP	O
-	HYPH	I-NP	O
maze	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
diazepam	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
sedation	NN	I-NP	O
by	IN	B-PP	O
recording	VBG	B-VP	O
the	DT	B-NP	O
vigilance	NN	I-NP	O
states	NNS	I-NP	O
,	,	O	O
and	CC	O	O
picrotoxin	NN	B-NP	O
-	HYPH	O	O
and	CC	O	O
pentylenetetrazol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
after	IN	B-PP	O
i.p.	JJ	B-NP	O
injections	NNS	I-NP	O
.	.	O	O

Results	NNS	B-NP	O
presented	VBN	B-VP	O
here	RB	B-ADVP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
differential	JJ	I-NP	O
sensitivities	NNS	I-NP	O
of	IN	B-PP	O
BS	NN	B-NP	O
and	CC	I-NP	O
BR	NN	I-NP	O
lines	NNS	I-NP	O
to	TO	B-PP	O
beta	SYM	O	O
-	HYPH	O	O
CCM	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
extended	VBN	I-VP	O
to	TO	B-PP	O
diazepam	NN	B-NP	O
,	,	O	O
picrotoxin	NN	B-NP	O
,	,	O	O
and	CC	O	O
pentylenetetrazol	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
a	DT	B-NP	O
genetic	JJ	I-NP	O
selection	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
general	JJ	I-NP	O
sensitivity	NN	I-NP	O
and	CC	I-NP	O
resistance	NN	I-NP	O
to	TO	B-PP	O
several	JJ	B-NP	O
ligands	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
GABA	NN	I-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
.	.	O	O

Analgesic	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
ketamine	NN	I-NP	O
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
on	IN	B-PP	O
morphine	NN	B-NP	O
therapy	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
controlled	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
crossover	JJ	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
not	RB	B-ADJP	O
responsive	JJ	I-ADJP	O
to	TO	B-PP	O
morphine	NN	B-NP	O
is	VBZ	B-VP	O
often	RB	B-ADVP	O
problematic	JJ	B-ADJP	O
.	.	O	O

Animal	NN	B-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
antagonists	NNS	B-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
ketamine	NN	B-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
improving	VBG	B-VP	O
opioid	JJ	B-NP	O
analgesia	NN	I-NP	O
in	IN	B-PP	O
difficult	JJ	B-NP	O
pain	NN	I-NP	B
syndromes	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
neuropathic	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
slow	JJ	I-NP	O
bolus	NN	I-NP	O
of	IN	B-PP	O
subhypnotic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
cancer	NN	I-NP	B
patients	NNS	I-NP	O
whose	WP$	B-NP	O
pain	NN	I-NP	B
was	VBD	B-VP	O
unrelieved	JJ	B-ADJP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
crossover	JJ	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
intensity	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
numerical	JJ	I-NP	O
scale	NN	I-NP	O
;	:	O	O
nausea	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
,	,	O	O
drowsiness	NN	B-NP	O
,	,	O	O
confusion	NN	B-NP	B
,	,	O	O
and	CC	O	O
dry	JJ	B-NP	B
mouth	NN	I-NP	I
,	,	O	O
using	VBG	B-VP	O
a	DT	B-NP	O
scale	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
(	(	O	O
not	RB	O	O
at	IN	B-ADVP	O
all	DT	I-ADVP	O
,	,	O	O
slight	JJ	B-ADJP	O
,	,	O	O
a	DT	B-NP	O
lot	NN	I-NP	O
,	,	O	O
awful	JJ	B-ADJP	O
)	)	O	O
;	:	O	O
Mini	NNP	B-NP	O
-	:	O	O
Mental	NNP	B-NP	O
State	NNP	I-NP	O
Examination	NNP	I-NP	O
(	(	O	O
MMSE	NN	B-NP	O
)	)	O	O
;	:	O	O
and	CC	O	O
arterial	JJ	B-NP	O
pressure	NN	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
before	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
(	(	O	O
T0	NN	B-NP	O
)	)	O	O
and	CC	O	O
after	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
(	(	O	O
T30	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
(	(	O	O
T60	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
(	(	O	O
T120	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
(	(	O	O
T180	NN	B-NP	O
)	)	O	O
.	.	O	O

Ketamine	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
saline	NN	B-NP	O
solution	NN	I-NP	O
,	,	O	O
significantly	RB	B-VP	O
reduced	VBD	I-VP	O
the	DT	B-NP	O
pain	NN	I-NP	B
intensity	NN	I-NP	O
in	IN	B-PP	O
almost	RB	B-NP	O
all	PDT	I-NP	O
the	DT	I-NP	O
patients	NNS	I-NP	O
at	IN	B-PP	O
both	DT	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
relevant	JJ	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

Hallucinations	NNS	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
an	DT	B-NP	O
unpleasant	JJ	I-NP	O
sensation	NN	I-NP	O
(	(	O	O
empty	JJ	B-NP	O
head	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
also	RB	I-VP	O
reported	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
episodes	NNS	I-NP	O
reversed	VBD	B-VP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
intravenously	RB	B-ADVP	O
.	.	O	O

Significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
drowsiness	NN	B-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
ketamine	NN	B-NP	O
in	IN	B-PP	O
both	CC	O	O
groups	NNS	B-NP	O
and	CC	O	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
marked	JJ	I-ADJP	O
with	IN	B-PP	O
ketamine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
MMSE	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
T30	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
.	.	O	O

Ketamine	NN	B-NP	O
can	MD	B-VP	O
improve	VB	I-VP	O
morphine	NN	B-NP	O
analgesia	NN	I-NP	O
in	IN	B-PP	O
difficult	JJ	B-NP	O
pain	NN	I-NP	B
syndromes	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
neuropathic	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
taken	VBN	I-VP	O
into	IN	B-PP	O
account	NN	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
when	WRB	B-ADVP	O
using	VBG	B-VP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
observation	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
studies	NNS	B-NP	O
of	IN	B-PP	O
prolonged	VBN	B-NP	O
ketamine	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

Endocrine	JJ	B-NP	O
screening	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
men	NNS	I-NP	O
with	IN	B-PP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
:	:	O	O
clinical	JJ	B-NP	O
significance	NN	I-NP	O
and	CC	I-NP	O
cost	NN	I-NP	O
-	HYPH	B-NP	O
effective	JJ	I-NP	O
strategy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
reviewed	VBD	B-VP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
testosterone	NN	I-NP	O
and	CC	O	O
prolactin	NN	B-NP	O
determination	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
referred	VBD	B-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
compared	VBD	B-VP	O
the	DT	B-NP	O
data	NNS	I-NP	O
with	IN	B-PP	O
history	NN	B-NP	O
,	,	O	O
results	NNS	B-NP	O
of	IN	B-PP	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
,	,	O	O
other	JJ	B-NP	O
etiological	JJ	I-NP	O
investigations	NNS	I-NP	O
and	CC	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
endocrine	JJ	B-NP	O
therapy	NN	I-NP	O
to	TO	B-VP	O
refine	VB	I-VP	O
the	DT	B-NP	O
rules	NNS	I-NP	O
of	IN	B-PP	O
cost	NN	B-NP	O
-	HYPH	B-NP	O
effective	JJ	I-NP	O
endocrine	JJ	I-NP	O
screening	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
pinpoint	VB	I-VP	O
actual	JJ	B-NP	O
responsibility	NN	I-NP	O
for	IN	B-PP	O
hormonal	JJ	B-NP	O
abnormalities	NNS	I-NP	O
.	.	O	O

Testosterone	NN	B-NP	O
and	CC	I-NP	O
prolactin	NN	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
radioimmunoassay	NN	B-NP	O
.	.	O	O

Every	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
screened	VBN	I-VP	O
for	IN	B-PP	O
testosterone	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
screened	VBN	I-VP	O
for	IN	B-PP	O
prolactin	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	B
sexual	JJ	I-NP	I
desire	NN	I-NP	I
,	,	O	O
gynecomastia	NN	B-NP	B
or	CC	O	O
testosterone	NN	B-NP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng.	NN	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
.	.	O	O

Determination	NN	B-NP	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
in	IN	B-PP	O
case	NN	B-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
first	JJ	I-NP	O
results	NNS	I-NP	O
.	.	O	O

Prolactin	NN	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
previous	JJ	I-NP	O
personal	JJ	I-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
systematic	JJ	B-NP	O
prolactin	NN	I-NP	O
determination	NN	I-NP	O
.	.	O	O

Main	NNP	B-NP	O
clinical	JJ	I-NP	O
criteria	NNS	I-NP	O
tested	VBN	B-VP	O
regarding	VBG	B-PP	O
efficiency	NN	B-NP	O
in	IN	B-PP	O
hormone	NN	B-NP	O
determination	NN	I-NP	O
were	VBD	B-VP	O
low	JJ	B-NP	B
sexual	JJ	I-NP	I
desire	NN	I-NP	I
,	,	O	O
small	JJ	B-NP	O
testes	NNS	I-NP	O
and	CC	O	O
gynecomastia	NN	B-NP	B
.	.	O	O

Endocrine	JJ	B-NP	O
therapy	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
testosterone	NN	B-NP	O
heptylate	NN	I-NP	O
or	CC	O	O
human	JJ	B-NP	O
chorionic	JJ	I-NP	O
gonadotropin	NN	I-NP	O
for	IN	B-PP	O
hypogonadism	NN	B-NP	B
and	CC	I-NP	O
bromocriptine	NN	I-NP	O
for	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
.	.	O	O

Testosterone	NN	B-NP	O
was	VBD	B-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng.	NN	I-NP	O
/	SYM	I-NP	O
ml.	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
but	CC	O	O
normal	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
repeat	NN	B-NP	O
determination	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
repeatedly	RB	B-NP	O
low	JJ	I-NP	O
testosterone	NN	I-NP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
age	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
before	IN	B-PP	O
age	NN	B-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
or	CC	O	O
older	JJR	B-ADJP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
pituitary	JJ	I-NP	B
tumors	NNS	I-NP	I
were	VBD	B-VP	O
discovered	VBN	I-VP	O
after	IN	B-PP	O
testosterone	NN	B-NP	O
determination	NN	I-NP	O
.	.	O	O

Most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
low	JJ	I-NP	O
testosterone	NN	I-NP	O
levels	NNS	I-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
nonorganic	JJ	B-NP	O
hypothalamic	JJ	I-NP	B
dysfunction	NN	I-NP	I
because	IN	B-PP	O
of	IN	I-PP	O
normal	JJ	B-NP	O
serum	NN	I-NP	O
luteinizing	VBG	B-VP	O
hormone	NN	B-NP	O
and	CC	I-NP	O
prolactin	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
have	VB	I-VP	O
only	RB	B-NP	O
a	DT	I-NP	O
small	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
(	(	O	O
definite	JJ	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
[	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
]	)	O	O
after	IN	B-PP	O
androgen	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
normal	JJ	B-NP	O
morning	NN	I-NP	O
or	CC	O	O
nocturnal	JJ	B-NP	O
erections	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
definite	JJ	I-NP	O
vasculogenic	JJ	I-NP	O
contributions	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Determining	VBG	B-VP	O
testosterone	NN	B-NP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
low	JJ	B-NP	B
sexual	JJ	I-NP	I
desire	NN	I-NP	I
or	CC	O	O
abnormal	JJ	B-NP	O
physical	JJ	I-NP	O
examination	NN	I-NP	O
would	MD	B-VP	O
have	VB	I-VP	O
missed	VBN	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
testosterone	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
subsequently	RB	B-VP	O
improved	VBN	I-VP	O
by	IN	B-PP	O
androgen	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Prolactin	NN	B-NP	O
exceeded	VBD	B-VP	O
num	CD	B-NP	O
ng.	NN	I-NP	O
/	SYM	B-NP	O
ml.	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
men	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
at	IN	B-PP	O
repeat	NN	B-NP	O
determination	NN	I-NP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
prolactinoma	NN	I-NP	B
was	VBD	B-VP	O
discovered	VBN	I-VP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
are	VBP	B-VP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
we	PRP	B-NP	O
found	VBD	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
decades	NNS	I-NP	O
(	(	O	O
overall	JJ	B-NP	O
prolactin	NN	I-NP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng.	NN	I-NP	O
/	SYM	I-NP	O
ml.	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
prolactinomas	NNS	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Bromocriptine	NN	B-NP	O
was	VBD	B-VP	O
definitely	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
with	IN	B-PP	O
prolactin	NN	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
ng.	NN	I-NP	O
/	SYM	B-NP	O
ml.	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
prolactin	NN	B-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
ng.	NN	I-NP	O
/	SYM	I-NP	O
ml.	NN	I-NP	O
)	)	O	O
.	.	O	O

Testosterone	NN	B-NP	O
was	VBD	B-VP	O
low	JJ	B-ADJP	O
in	IN	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
with	IN	B-PP	O
prolactin	NN	B-NP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng.	NN	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
prevalences	NNS	I-NP	O
and	CC	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
testosterone	NN	I-NP	O
and	CC	O	O
high	JJ	B-NP	O
prolactin	NN	I-NP	O
in	IN	B-PP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
can	MD	B-VP	O
not	RB	I-VP	O
justify	VB	I-VP	O
their	PRP$	B-NP	O
routine	JJ	I-NP	O
determination	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
cost	NN	B-NP	O
-	HYPH	B-NP	O
effective	JJ	I-NP	O
screening	NN	I-NP	O
strategies	NNS	I-NP	O
recommended	VBD	B-VP	O
so	RB	B-ADVP	O
far	RB	I-ADVP	O
missed	VBN	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
improved	VBN	B-VP	O
with	IN	B-PP	O
endocrine	JJ	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
pituitary	JJ	I-NP	B
tumors	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
now	RB	B-ADVP	O
advocate	VBP	B-VP	O
that	IN	B-SBAR	O
before	IN	B-PP	O
age	NN	B-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
testosterone	NN	I-NP	O
be	VB	B-VP	O
determined	VBN	I-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
low	JJ	B-NP	B
sexual	JJ	I-NP	I
desire	NN	I-NP	I
and	CC	O	O
abnormal	JJ	B-NP	O
physical	JJ	I-NP	O
examination	NN	I-NP	O
but	CC	O	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
be	VB	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
men	NNS	I-NP	O
older	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Prolactin	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
determined	VBN	I-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
low	JJ	B-NP	B
sexual	JJ	I-NP	I
desire	NN	I-NP	I
,	,	O	O
gynecomastia	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
testosterone	NN	B-NP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng.	NN	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
.	.	O	O

Thiopentone	NN	B-NP	O
pretreatment	NN	I-NP	O
for	IN	B-PP	O
propofol	NN	B-NP	O
injection	NN	I-NP	O
pain	NN	I-NP	B
in	IN	B-PP	O
ambulatory	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
propofol	NN	B-NP	O
injection	NN	I-NP	O
pain	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
ambulatory	JJ	B-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
were	VBD	B-VP	O
allocated	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
treatments	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anaesthesia	NN	B-NP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
C	NN	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
ml	NN	I-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
,	,	O	O
Group	NNP	B-NP	O
L	NNP	I-NP	O
,	,	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
,	,	O	O
lidocaine	NN	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
Group	NN	I-NP	O
T	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
thiopentone	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Venous	JJ	B-NP	O
discomfort	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
visual	JJ	I-NP	O
analogue	NN	I-NP	O
scale	NN	I-NP	O
(	(	O	O
VAS	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
sec	NN	I-NP	O
after	IN	B-PP	O
commencing	VBG	B-VP	O
propofol	NN	B-NP	O
administration	NN	I-NP	O
using	VBG	B-VP	O
an	DT	B-NP	O
infusion	NN	I-NP	O
pump	NN	I-NP	O
.	.	O	O

Loss	NN	B-NP	B
of	IN	B-PP	I
consciousness	NN	B-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
sec	NN	I-NP	O
.	.	O	O

Visual	JJ	B-NP	O
analogue	NN	I-NP	O
scores	NNS	I-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
)	)	O	O
during	IN	B-PP	O
induction	NN	B-NP	O
were	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
Groups	NNS	B-NP	O
L	NN	I-NP	O
and	CC	O	O
T	NN	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
Group	NN	B-NP	O
C	NN	I-NP	O
;	:	O	O
P	NN	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	O
discomfort	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
Group	NN	B-NP	O
L	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
Group	NN	B-NP	O
C	NN	I-NP	O
but	CC	O	O
not	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
Group	NNP	B-NP	O
T	NNP	I-NP	O
.	VBD	B-VP	O

The	DT	B-NP	O
VAS	NNP	I-NP	O
scores	NNS	I-NP	O
for	IN	B-PP	O
recall	NN	B-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
recovery	NN	I-NP	O
room	NN	I-NP	O
were	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
VAS	NNP	I-NP	O
scores	NNS	I-NP	O
during	IN	B-PP	O
induction	NN	B-NP	O
.	.	O	O

Recovery	NN	B-NP	O
room	NN	I-NP	O
discharge	NN	I-NP	O
times	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
:	:	O	O
C	NN	B-NP	O
;	:	O	O
L	NN	B-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
min	NN	I-NP	O
)	)	O	O
;	:	O	O
T	NN	B-NP	O
.	.	O	O

Assessing	VBG	B-VP	O
their	PRP$	B-NP	O
overall	JJ	I-NP	O
satisfaction	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
would	MD	B-VP	O
choose	VB	I-VP	O
propofol	NN	B-NP	O
anaesthesia	NN	I-NP	O
again	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
lidocaine	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
injection	NN	I-NP	O
pain	NN	I-NP	B
in	IN	B-PP	O
ambulatory	JJ	B-NP	O
patients	NNS	I-NP	O
whereas	IN	B-PP	O
thiopentone	NN	B-NP	O
only	RB	B-ADVP	O
reduces	VBZ	B-VP	O
its	PRP$	B-NP	O
severity	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
i.v.	JJ	B-NP	O
glycopyrrolate	NN	I-NP	O
and	CC	I-NP	O
atropine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
bradycardia	NN	B-NP	B
and	CC	I-NP	O
arrhythmias	NNS	I-NP	B
following	VBG	B-PP	O
repeated	VBN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
glycopyrrolate	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
atropine	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
i.v.	JJ	B-ADJP	O
immediately	RB	B-ADVP	O
before	IN	B-SBAR	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
anaesthesia	NN	B-NP	O
,	,	O	O
to	TO	B-VP	O
prevent	VB	I-VP	O
arrhythmia	NN	B-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
following	VBG	B-PP	O
repeated	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
,	,	O	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
included	VBN	I-VP	O
for	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
dose	NN	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
glycopyrrolate	NN	B-NP	O
and	CC	I-NP	O
atropine	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
bradycardia	NN	B-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
but	CC	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
active	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Bradycardia	NNP	B-NP	B
was	VBD	B-VP	O
prevented	VBN	I-VP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
larger	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
either	CC	B-NP	O
active	JJ	I-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
that	IN	B-SBAR	O
either	CC	O	O
glycopyrrolate	NN	B-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
or	CC	O	O
atropine	NN	B-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
i.v.	NN	I-NP	O
should	MD	B-VP	O
immediately	RB	I-VP	O
precede	VB	I-VP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anaesthesia	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
children	NNS	B-NP	O
,	,	O	O
if	IN	B-SBAR	O
the	DT	B-NP	O
repeated	VBN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
is	VBZ	B-VP	O
anticipated	VBN	I-VP	O
.	.	O	O

Reduction	NN	B-NP	O
in	IN	B-PP	O
caffeine	NN	B-NP	O
toxicity	NN	I-NP	B
by	IN	B-PP	O
acetaminophen	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
allegedly	RB	B-ADVP	O
consumed	VBD	B-VP	O
num	CD	B-NP	O
tablets	NNS	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
over	IN	I-NP	O
-	HYPH	I-NP	O
the	DT	B-NP	O
-	HYPH	I-NP	O
counter	NN	I-NP	O
analgesic	JJ	I-NP	O
containing	VBG	I-NP	O
sodium	NN	I-NP	O
acetylsalicylate	NN	I-NP	O
,	,	O	O
caffeine	NN	B-NP	O
,	,	O	O
and	CC	O	O
acetaminophen	NN	B-NP	O
displayed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
CNS	NN	I-NP	O
stimulation	NN	I-NP	O
despite	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
per	IN	B-PP	O
mL	NN	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
.	.	O	O

Because	IN	B-SBAR	O
salicylates	NNS	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
augment	VB	I-VP	O
the	DT	B-NP	O
stimulatory	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
CNS	NN	I-NP	O
,	,	O	O
attention	NN	B-NP	O
was	VBD	B-VP	O
focused	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
)	)	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
CNS	NN	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
caffeine	NN	B-NP	O
.	.	O	O

Studies	NNS	B-NP	O
in	IN	B-PP	O
DBA	NN	B-NP	O
/	SYM	B-NP	O
2J	NN	I-NP	O
mice	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
:	:	O	O
num	CD	B-NP	O
)	)	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
acetaminophen	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
interval	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
convulsions	NNS	I-NP	B
by	IN	B-PP	O
a	DT	B-NP	O
factor	NN	I-NP	O
of	IN	B-PP	O
about	IN	B-NP	O
num	CD	I-NP	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
acetaminophen	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
audiogenic	JJ	B-NP	O
seizures	NNS	I-NP	B
produced	VBN	B-VP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
caffeine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
sound	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
caffeine	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
acetaminophen	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
,	,	O	O
acetaminophen	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
modify	VB	I-VP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
maximal	JJ	B-NP	O
electroshock	NN	I-NP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
the	DT	B-NP	O
convulsant	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
pentylenetetrezol	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
(	(	O	O
tests	NNS	B-NP	O
performed	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
Anticonvulsant	NNP	I-NP	O
Screening	NNP	I-NP	O
Project	NNP	I-NP	O
of	IN	B-PP	O
NINCDS	NN	B-NP	O
)	)	O	O
.	.	O	O

Acetaminophen	NN	B-NP	O
(	(	O	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
)	)	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
retard	VB	I-VP	O
the	DT	B-NP	O
incorporation	NN	I-NP	O
of	IN	B-PP	O
radioactive	JJ	B-NP	O
adenosine	NN	I-NP	O
into	IN	B-PP	O
ATP	NN	B-NP	O
in	IN	B-PP	O
slices	NNS	B-NP	O
of	IN	B-PP	O
rat	NN	B-NP	O
cerebral	JJ	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
acetaminophen	NN	B-NP	O
antagonizes	VBZ	B-VP	O
the	DT	B-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
CNS	NN	I-NP	O
remains	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

Flestolol	NN	B-NP	O
:	:	O	O
an	DT	B-NP	O
ultra	AFX	I-NP	O
-	HYPH	I-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	B-VP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
blocking	VBG	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Flestolol	NN	B-NP	O
(	(	O	O
ACC	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
nonselective	JJ	I-NP	O
,	,	I-NP	O
competitive	JJ	I-NP	O
,	,	O	O
ultra	AFX	O	O
-	HYPH	O	O
short	JJ	B-ADJP	O
-	HYPH	O	O
acting	VBG	B-VP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
blocking	VBG	I-NP	O
agent	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
any	DT	B-NP	O
intrinsic	JJ	I-NP	O
sympathomimetic	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Flestolol	NN	B-NP	O
is	VBZ	B-VP	O
metabolized	VBN	I-VP	O
by	IN	B-PP	O
plasma	NN	B-NP	O
esterases	NNS	I-NP	O
and	CC	O	O
has	VBZ	B-VP	O
an	DT	B-NP	O
elimination	NN	I-NP	O
half	NN	I-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
of	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
agent	NN	I-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
volunteers	NNS	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
infusion	NN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
flestolol	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
effective	JJ	I-NP	O
beta	SYM	O	O
-	HYPH	O	O
blocking	VBG	B-VP	O
dose	NN	B-NP	O
for	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

Flestolol	NN	B-NP	O
blood	NN	I-NP	O
concentrations	NNS	I-NP	O
increased	VBD	B-VP	O
linearly	RB	B-ADVP	O
with	IN	B-PP	O
increasing	VBG	B-NP	O
dose	NN	I-NP	O
and	CC	I-NP	O
good	JJ	I-NP	O
correlation	NN	I-NP	O
exists	VBZ	B-VP	O
between	IN	B-PP	O
blood	NN	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
flestolol	NN	B-NP	O
and	CC	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
blockade	NN	I-NP	O
.	.	O	O

Flestolol	NN	B-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
attenuation	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
.	.	O	O

Electrophysiologic	JJ	B-NP	O
and	CC	I-NP	O
hemodynamic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
flestolol	NN	B-NP	O
are	VBP	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
beta	NN	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
beta	NN	I-NP	O
blockers	NNS	I-NP	O
,	,	O	O
flestolol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
effects	NNS	I-NP	O
reverse	VBP	B-VP	O
rapidly	RB	B-ADVP	O
(	(	O	O
within	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
)	)	O	O
following	VBG	B-PP	O
discontinuation	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
short	JJ	I-NP	O
half	NN	I-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
.	.	O	O

Flestolol	NN	B-NP	O
effectively	RB	B-ADVP	O
reduced	VBD	B-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
supraventricular	JJ	B-NP	B
tachyarrhythmia	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
unstable	JJ	B-NP	B
angina	NN	I-NP	I
,	,	O	O
flestolol	NN	B-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
safe	JJ	B-ADJP	O
and	CC	I-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
controlling	VBG	B-VP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
flestolol	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
,	,	O	O
well	RB	B-ADVP	O
-	HYPH	B-NP	O
tolerated	VBN	B-VP	O
,	,	O	O
ultra	AFX	B-NP	O
-	HYPH	I-NP	O
short	JJ	B-ADJP	O
-	HYPH	O	O
acting	VBG	B-VP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
blocking	VBG	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
flestolol	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
critical	JJ	I-NP	O
care	NN	I-NP	O
setting	NN	I-NP	O
is	VBZ	B-VP	O
currently	RB	I-VP	O
undergoing	VBG	I-VP	O
investigation	NN	B-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
nitrendipine	NN	I-NP	O
on	IN	B-PP	O
nephrosclerosis	NN	B-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
renovascular	JJ	B-NP	B
hypertension	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
nitrendipine	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
angiotensin	NN	I-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
enalapril	NN	I-NP	O
on	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
albuminuria	NN	B-NP	B
,	,	O	O
renal	JJ	B-NP	O
hemodynamics	NNS	I-NP	O
,	,	O	O
and	CC	O	O
morphology	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nonclipped	JJ	I-NP	O
kidney	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
kidney	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
clip	NN	I-NP	O
renovascular	JJ	I-NP	B
hypertension	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
clipping	VBG	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
renal	JJ	I-NP	O
artery	NN	I-NP	O
,	,	O	O
hypertensive	JJ	B-NP	B
rats	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
untreated	JJ	B-NP	O
hypertensive	JJ	I-NP	B
controls	NNS	I-NP	O
,	,	O	O
enalapril	NN	B-NP	O
-	HYPH	B-VP	O
treated	VBN	I-VP	O
,	,	O	O
or	CC	O	O
nitrendipine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	B-VP	O
.	.	O	O

Sham	NN	B-NP	O
-	HYPH	B-NP	O
operated	VBN	I-NP	O
rats	NNS	I-NP	O
served	VBD	B-VP	O
as	IN	B-PP	O
normotensive	JJ	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
renal	JJ	B-NP	O
hemodynamics	NNS	I-NP	O
(	(	O	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
plasma	NN	I-NP	O
flow	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
anesthetized	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
tissue	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
for	IN	B-PP	O
determination	NN	B-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	O
size	NN	I-NP	O
and	CC	I-NP	O
sclerosis	NN	I-NP	O
.	.	O	O

Enalapril	NNP	B-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
nitrendipine	NN	B-NP	O
reduced	VBD	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
significantly	RB	B-ADVP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
different	JJ	B-ADJP	O
among	IN	B-PP	O
the	DT	B-NP	O
studied	VBN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
plasma	NN	I-NP	O
flow	NN	I-NP	O
increased	VBD	B-VP	O
,	,	O	O
but	CC	O	O
albumin	NN	B-NP	O
excretion	NN	I-NP	O
and	CC	O	O
glomerulosclerosis	NN	B-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
after	IN	B-PP	O
enalapril	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
nitrendipine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
albuminuria	NN	I-NP	B
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
progressively	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
controls	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
glomerulosclerosis	NN	B-NP	B
index	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
nitrendipine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
controls	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
glomerular	JJ	B-NP	O
size	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
nitrendipine	NN	I-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
group	NN	I-NP	O
but	CC	O	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
enalapril	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
controls	NNS	I-NP	O
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
tinnitus	NN	B-NP	B
by	IN	B-PP	O
intratympanic	JJ	B-NP	O
instillation	NN	I-NP	O
of	IN	B-PP	O
lignocaine	NN	B-NP	O
(	(	O	O
lidocaine	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
through	IN	B-PP	O
ventilation	NN	B-NP	O
tubes	NNS	I-NP	O
.	.	O	O

Idiopathic	JJ	B-NP	B
subjective	JJ	I-NP	I
tinnitus	NN	I-NP	I
(	(	O	O
IST	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
obscure	JJ	I-NP	O
otological	JJ	I-NP	O
pathologies	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
paper	NN	I-NP	O
presents	VBZ	B-VP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
treating	VBG	B-VP	O
IST	NN	B-NP	B
by	IN	B-PP	O
intratympanic	JJ	B-NP	O
instillation	NN	I-NP	O
of	IN	B-PP	O
lignocaine	NN	B-NP	O
(	(	O	O
lidocaine	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
through	IN	B-PP	O
a	DT	B-NP	O
grommet	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
weekly	JJ	I-NP	O
courses	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
intractable	JJ	B-NP	O
tinnitus	NN	I-NP	B
entered	VBD	B-VP	O
this	DT	B-NP	O
therapeutic	JJ	I-NP	O
trial	NN	I-NP	O
,	,	O	O
but	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
finished	VBD	B-VP	O
all	DT	B-NP	O
num	CD	I-NP	O
courses	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
tinnitus	NN	I-NP	B
was	VBD	B-VP	O
almost	RB	I-VP	O
completely	RB	I-VP	O
abolished	VBN	I-VP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
the	DT	B-NP	O
decompensated	VBN	I-NP	O
tinnitus	NN	I-NP	B
changed	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
compensated	VBN	I-NP	O
one	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
this	DT	B-NP	O
mode	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
previously	RB	I-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
drugs	NNS	B-NP	O
,	,	O	O
acupuncture	NN	B-NP	O
and	CC	I-NP	O
biofeedback	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
disappointing	JJ	B-NP	O
results	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
warned	VBN	I-VP	O
about	IN	B-PP	O
the	DT	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
vertigo	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
subsides	VBZ	B-VP	O
gradually	RB	B-ADVP	O
with	IN	B-PP	O
every	DT	B-NP	O
new	JJ	I-NP	O
instillation	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
tinnitus	NN	I-NP	B
may	MD	B-VP	O
not	RB	I-VP	O
disappear	VB	I-VP	O
but	CC	O	O
will	MD	B-VP	O
be	VB	I-VP	O
alleviated	VBN	I-VP	O
,	,	O	O
enabling	VBG	B-VP	O
them	PRP	B-NP	O
to	TO	B-VP	O
cope	VB	I-VP	O
more	RBR	B-ADVP	O
easily	RB	I-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
and	CC	O	O
lead	VBP	B-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
normal	JJ	I-NP	O
life	NN	I-NP	O
.	.	O	O

Perhexiline	NN	B-NP	O
maleate	NN	I-NP	O
and	CC	O	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
noted	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
perhexiline	NN	B-NP	O
maleate	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
drug	NN	I-NP	O
widely	RB	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
France	NNP	B-NP	O
(	(	O	O
and	CC	O	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
)	)	O	O
for	IN	B-PP	O
the	DT	B-NP	O
prophylactic	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
angina	NN	B-NP	B
pectoris	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
marked	JJ	I-NP	O
slowing	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
nerve	NN	I-NP	O
conduction	NN	I-NP	O
velocity	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
electromyographic	JJ	I-NP	O
changes	NNS	I-NP	O
imply	VBP	B-VP	O
mainly	RB	B-ADVP	O
a	DT	B-NP	O
demyelinating	VBG	I-NP	B
disorder	NN	I-NP	I
.	.	O	O

Improvement	NN	B-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
with	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
cases	NNS	I-NP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
active	JJ	B-NP	O
denervation	NN	I-NP	O
signified	VBD	B-VP	O
a	DT	B-NP	O
poor	JJ	I-NP	O
prognosis	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
only	RB	B-NP	O
slight	JJ	I-NP	O
improvement	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
underlying	VBG	I-NP	O
mechanism	NN	I-NP	O
causing	VBG	B-VP	O
the	DT	B-NP	O
neuropathy	NN	I-NP	B
is	VBZ	B-VP	O
not	RB	O	O
yet	RB	B-VP	O
fully	RB	I-VP	O
known	VBN	I-VP	O
,	,	O	O
although	IN	B-SBAR	O
some	DT	B-NP	O
evidence	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
lipid	NN	I-NP	O
storage	NN	I-NP	O
process	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
humoral	JJ	B-NP	O
modulators	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
locomotor	NN	B-NP	I
activity	NN	I-NP	I
of	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
humoral	JJ	B-NP	O
modulators	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
morphine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
locomotor	NN	B-NP	I
activity	NN	I-NP	I
of	IN	B-PP	O
mice	NNS	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
subcutaneous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
HC1	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
locomotor	NN	B-NP	I
activity	NN	I-NP	I
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
morphine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
hyperactivity	NN	I-NP	B
was	VBD	B-VP	O
potentiated	VBN	I-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
and	CC	O	O
attenuated	VBN	B-VP	O
by	IN	B-PP	O
physostigmine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
both	CC	O	O
methscopolamine	NN	B-NP	O
and	CC	I-NP	O
neostigmine	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
penetrate	VB	I-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
hyperactivity	NN	I-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	O	O
methyltyrosine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
tyrosine	NN	B-NP	O
hydroxylase	NN	I-NP	O
,	,	O	O
significantly	RB	B-VP	O
decreased	VBD	I-VP	O
the	DT	B-NP	O
activity	NN	I-NP	O
-	HYPH	O	O
increasing	VBG	B-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
p	NN	B-NP	O
-	HYPH	I-NP	O
chlorophenylalamine	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
serotonin	NN	I-NP	O
depletor	NN	I-NP	O
,	,	O	O
caused	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hyperactivity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
activity	NN	I-NP	O
-	HYPH	O	O
increasing	VBG	B-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
are	VBP	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
catecholamines	NNS	B-NP	O
from	IN	B-PP	O
adrenergic	JJ	B-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

And	CC	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
morphine	NN	B-NP	O
acts	VBZ	B-VP	O
by	IN	B-PP	O
retarding	VBG	B-VP	O
the	DT	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
acetylcholine	NN	B-NP	O
at	IN	B-PP	O
some	DT	B-NP	O
central	JJ	I-NP	O
cholinergic	JJ	I-NP	O
synapses	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
also	RB	I-VP	O
suggested	VBN	I-VP	O
from	IN	B-PP	O
collected	VBN	B-NP	O
evidence	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
activity	NN	I-NP	O
-	HYPH	O	O
increasing	VBG	B-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
are	VBP	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
mechanisms	NNS	B-NP	O
different	JJ	B-ADJP	O
from	IN	B-PP	O
those	DT	B-NP	O
which	WDT	B-NP	O
mediate	VBP	B-VP	O
the	DT	B-NP	O
activity	NN	I-NP	O
-	HYPH	O	O
increasing	VBG	B-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Mechanisms	NNS	B-NP	O
of	IN	B-PP	O
FK	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat.	NN	I-NP	O
-	HYPH	O	O
Tacrolimus	NN	B-NP	O
(	(	O	O
FK	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
powerful	JJ	I-NP	O
,	,	O	O
widely	RB	B-VP	O
used	VBN	I-VP	O
immunosuppressant	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
FK	NN	B-NP	O
num	CD	I-NP	O
is	VBZ	B-VP	O
complicated	VBN	I-VP	O
by	IN	B-PP	O
substantial	JJ	B-NP	O
hypertension	NN	I-NP	B
and	CC	I-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
clarify	VB	I-VP	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
FK	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
FK	NN	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
synthesis	NN	I-NP	O
of	IN	B-PP	O
endothelin	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
ET	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
mRNA	NN	B-NP	O
of	IN	B-PP	O
ET	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
endothelin	NN	I-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
ECE	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
endothelial	JJ	I-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
(	(	O	O
eNOS	NN	B-NP	O
)	)	O	O
activity	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
mRNA	NN	B-NP	O
of	IN	B-PP	O
eNOS	NN	B-NP	O
and	CC	I-NP	O
C	NN	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
natriuretic	JJ	I-NP	O
peptide	NN	I-NP	O
(	(	O	O
CNP	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
rat	NN	B-NP	O
blood	NN	I-NP	O
vessels	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
specific	JJ	I-NP	O
endothelin	NN	I-NP	O
type	NN	I-NP	O
A	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
FR	NN	I-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
FK	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

FK	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
mg.	NN	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
d	SYM	B-NP	O
-	:	O	O
num	CD	B-NP	O
given	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
elevated	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
the	DT	B-NP	O
synthesis	NN	I-NP	O
of	IN	B-PP	O
ET	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
ET	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
mRNA	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mesenteric	JJ	I-NP	O
artery	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Little	JJ	B-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
ECE	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
mRNA	NN	I-NP	O
and	CC	I-NP	O
CNP	NN	I-NP	O
mRNA	NN	I-NP	O
.	.	O	O

FK	NN	B-NP	O
num	CD	I-NP	O
decreased	VBD	B-VP	O
eNOS	NN	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
eNOS	NN	B-NP	O
mRNA	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
aorta	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
FR	NN	B-NP	O
num	CD	I-NP	O
prevented	VBD	B-VP	O
FK	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
FK	NN	B-NP	O
num	CD	I-NP	O
may	MD	B-VP	O
increase	VB	I-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
ET	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
production	NN	I-NP	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
by	IN	B-PP	O
decreasing	VBG	B-VP	O
NO	NN	B-NP	O
synthesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
vasculature	NN	I-NP	O
.	.	O	O

Suxamethonium	NN	B-NP	O
induced	VBD	B-VP	O
prolonged	JJ	B-NP	O
apnea	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
electroconvulsive	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Suxamethonium	NN	B-NP	O
causes	VBZ	B-VP	O
prolonged	JJ	B-NP	O
apnea	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
pseudocholinesterase	NN	B-NP	O
enzyme	NN	I-NP	O
gets	VBZ	B-VP	O
deactivated	VBN	I-VP	O
by	IN	B-PP	O
organophosphorus	NN	B-NP	O
(	(	O	O
OP	NN	B-NP	O
)	)	O	O
poisons	NNS	B-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
incident	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
severely	RB	I-NP	O
depressed	JJ	I-NP	B
patient	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
electroconvulsive	JJ	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
ECT	NN	B-NP	O
)	)	O	O
.	.	O	O

Prolonged	JJ	B-NP	O
apnea	NN	I-NP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
case	NN	I-NP	O
ensued	VBD	B-VP	O
because	IN	B-SBAR	O
the	DT	B-NP	O
information	NN	I-NP	O
about	IN	B-PP	O
suicidal	JJ	B-NP	O
attempt	NN	I-NP	O
by	IN	B-PP	O
OP	NN	B-NP	O
compound	NN	I-NP	O
was	VBD	B-VP	O
concealed	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
treating	VBG	I-NP	O
team	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
adjunctive	JJ	I-NP	O
bupropion	NN	I-NP	O
on	IN	B-PP	O
male	JJ	B-NP	O
sexual	JJ	I-NP	B
dysfunction	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
placebo	NN	I-NP	O
-	HYPH	B-VP	O
controlled	VBN	B-NP	O
and	CC	I-NP	O
randomized	VBN	I-NP	O
study	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
adjunctive	JJ	B-NP	O
bupropion	NN	I-NP	O
sustained	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
(	(	O	O
SR	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
male	JJ	B-NP	O
sexual	JJ	I-NP	B
dysfunction	NN	I-NP	I
(	(	O	O
SD	NN	B-NP	B
)	)	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
(	(	O	O
SSRI	NN	B-NP	O
)	)	O	O
,	,	O	O
as	IN	B-SBAR	O
SD	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
SSRIs	NNS	B-NP	O
and	CC	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
effective	JJ	I-NP	O
treatments	NNS	I-NP	O
have	VBP	B-VP	O
yet	RB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
determined	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
randomized	VBN	I-NP	O
sample	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
euthymic	JJ	I-NP	O
men	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
some	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
SSRI	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
men	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
bupropion	NN	B-NP	O
SR	NN	I-NP	O
or	CC	O	O
placebo	NN	B-NP	O
(	(	O	O
twice	RB	B-ADVP	O
daily	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Efficacy	NN	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Clinical	JJ	I-NP	O
Global	NNP	I-NP	O
Impression	NN	I-NP	O
-	HYPH	B-NP	O
Sexual	JJ	I-NP	O
Function	NN	I-NP	O
(	(	O	O
CGI	NN	B-NP	O
-	HYPH	B-NP	O
SF	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
primary	JJ	I-NP	O
outcome	NN	I-NP	O
measure	NN	I-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
International	NNP	I-NP	O
Index	NNP	I-NP	O
of	IN	B-PP	O
Erectile	NNP	B-NP	O
Function	NNP	I-NP	O
(	(	O	O
IIEF	NN	B-NP	O
)	)	O	O
,	,	O	O
Arizona	NNP	B-NP	O
Sexual	NNP	I-NP	O
Experience	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
ASEX	NNP	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
Erectile	JJ	B-NP	B
Dysfunction	NN	I-NP	I
Inventory	NN	I-NP	O
of	IN	B-PP	O
Treatment	NN	B-NP	O
Satisfaction	NN	I-NP	O
(	(	O	O
EDITS	NN	B-NP	O
)	)	O	O
(	(	O	O
secondary	JJ	B-NP	O
outcome	NN	I-NP	O
measures	NNS	I-NP	O
)	)	O	O
.	.	O	O

Participants	NNS	B-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
biweekly	RB	B-ADVP	O
during	IN	B-PP	O
study	NN	B-NP	O
period	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
(	(	O	O
sd	JJ	B-ADJP	O
)	)	O	O
scores	NNS	B-NP	O
for	IN	B-PP	O
CGI	NN	B-NP	O
-	HYPH	B-NP	O
SF	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
,	,	O	O
i.e.	FW	B-ADVP	O
better	RBR	I-ADVP	O
,	,	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
bupropion	NN	B-NP	O
SR	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Men	NN	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
bupropion	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
IIEF	NN	I-NP	O
score	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
different	JJ	I-NP	O
domains	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
IIEF	NN	I-NP	O
.	.	O	O

Total	JJ	B-NP	O
ASEX	NN	I-NP	O
scores	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
,	,	O	O
i.e.	FW	B-ADVP	O
better	RBR	I-ADVP	O
,	,	O	O
among	IN	B-PP	O
men	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
bupropion	NN	B-NP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
at	IN	B-PP	O
num	CD	B-NP	O
vs	IN	I-NP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
EDITS	NNS	I-NP	O
scores	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
bupropion	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ASEX	NN	I-NP	O
score	NN	I-NP	O
and	CC	I-NP	O
CGI	NN	I-NP	O
-	HYPH	B-NP	O
SF	NN	I-NP	O
score	NN	I-NP	O
were	VBD	B-VP	O
correlated	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
linear	JJ	B-NP	O
regression	NN	I-NP	O
analyses	NNS	I-NP	O
the	DT	B-NP	O
CGI	NN	I-NP	O
-	HYPH	B-NP	O
SF	NN	I-NP	O
score	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
significantly	RB	B-ADVP	O
by	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
SD	NN	B-NP	B
,	,	O	O
type	NN	B-NP	O
of	IN	B-PP	O
SSRI	NN	B-NP	O
used	VBN	B-VP	O
and	CC	O	O
age	NN	B-NP	O
.	.	O	O

Bupropion	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
male	JJ	B-NP	O
SD	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
SSRIs	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
empirical	JJ	B-NP	O
support	NN	I-NP	O
for	IN	B-PP	O
conducting	VBG	B-VP	O
a	DT	B-NP	O
further	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
.	.	O	O

Lamivudine	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
reactivation	NN	I-NP	O
in	IN	B-PP	O
hepatitis	NN	B-NP	O
-	HYPH	B-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
HBSAG	NN	B-NP	O
)	)	O	O
seropositive	JJ	B-NP	O
cancer	NN	I-NP	B
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
cytotoxic	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Hepatitis	NN	B-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
(	(	O	O
HBV	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
liver	NN	I-NP	B
disease	NN	I-NP	I
worldwide	RB	B-ADVP	O
.	.	O	O

Cancer	NN	B-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
chronic	JJ	B-NP	O
carriers	NNS	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
hepatic	JJ	I-NP	B
complication	NN	I-NP	I
rate	NN	I-NP	O
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
cytotoxic	JJ	B-NP	O
chemotherapy	NN	I-NP	O
(	(	O	O
CT	NN	B-NP	O
)	)	O	O
and	CC	O	O
this	DT	B-NP	O
has	VBZ	B-VP	O
mainly	RB	I-VP	O
been	VBN	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
HBV	NN	B-NP	O
reactivation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
solid	JJ	B-NP	O
and	CC	I-NP	O
hematological	JJ	I-NP	B
malignancies	NNS	I-NP	I
with	IN	B-PP	O
chronic	JJ	B-NP	O
HBV	NN	I-NP	B
infection	NN	I-NP	I
received	VBD	B-VP	O
the	DT	B-NP	O
antiviral	JJ	I-NP	O
agent	NN	I-NP	O
lamivudine	NN	I-NP	O
prior	RB	B-ADVP	O
and	CC	O	O
during	IN	B-PP	O
CT	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
historical	JJ	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
receive	VB	I-VP	O
lamivudine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
objectives	NNS	I-NP	O
were	VBD	B-VP	O
to	TO	I-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
in	IN	B-PP	O
reducing	VBG	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
reactivation	NN	I-NP	O
,	,	O	O
and	CC	O	O
diminishing	VBG	B-VP	O
morbidity	NN	B-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
during	IN	B-PP	O
CT	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
prophylactic	JJ	I-NP	O
lamivudin	NN	I-NP	O
group	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
prophylactic	JJ	B-NP	O
lamivudine	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
historical	JJ	I-NP	O
controls	NNS	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
CT	NN	B-NP	O
without	IN	B-PP	O
prophylactic	JJ	B-NP	O
lamivudine	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
up	RP	B-PRT	O
during	IN	B-PP	O
and	CC	I-PP	O
for	IN	I-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
CT	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
outcomes	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
for	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
our	PRP$	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
established	VBN	I-VP	O
hepatitis	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
as	IN	B-PP	O
severe	JJ	B-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
prophylactic	JJ	I-NP	O
lamivudine	NN	I-NP	O
group	NN	I-NP	O
severe	JJ	I-NP	O
hepatitis	NN	I-NP	B
were	VBD	B-VP	O
observed	VBN	I-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
ALT	NN	I-NP	O
values	NNS	I-NP	O
revealed	VBD	B-VP	O
significantly	RB	B-NP	O
higher	JJR	I-NP	O
mean	JJ	I-NP	O
alanine	NN	I-NP	O
aminotransferase	NN	I-NP	O
(	(	O	O
ALT	NN	B-NP	O
)	)	O	O
values	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
prophylactic	JJ	I-NP	O
lamivudine	NN	I-NP	O
group	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
:	:	O	O
num	CD	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
prophylactic	JJ	B-NP	O
lamivudine	NN	I-NP	O
significantly	RB	B-ADVP	O
decreases	VBZ	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
reactivation	NN	I-NP	O
and	CC	O	O
overall	JJ	B-NP	O
morbidity	NN	I-NP	O
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
during	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
immunosuppressive	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
appropriate	JJ	I-NP	O
nucleoside	NN	I-NP	O
or	CC	I-NP	O
nucleotide	NN	I-NP	O
analogue	NN	I-NP	O
for	IN	B-PP	O
antiviral	JJ	B-NP	O
prophylaxis	NN	I-NP	O
during	IN	B-PP	O
CT	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
after	IN	B-PP	O
completion	NN	B-NP	O
of	IN	B-PP	O
CT	NN	B-NP	O
.	.	O	O

Ginsenoside	NN	B-NP	O
Rg1	NN	I-NP	O
restores	VBZ	B-VP	O
the	DT	B-NP	O
impairment	NN	I-NP	B
of	IN	B-PP	I
learning	NN	B-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
morphine	NN	I-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Rg1	NN	B-NP	O
,	,	O	O
as	IN	B-PP	O
a	DT	B-NP	O
ginsenoside	NN	I-NP	O
extracted	VBN	B-VP	O
from	IN	B-PP	O
Panax	NN	B-NP	O
ginseng	NN	I-NP	O
,	,	O	O
could	MD	B-VP	O
ameliorate	VB	I-VP	O
spatial	JJ	B-NP	O
learning	NN	I-NP	B
impairment	NN	I-NP	I
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
Rg1	NN	B-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
Rg1	NN	B-NP	O
on	IN	B-PP	O
learning	VBG	B-VP	B
impairment	NN	B-NP	I
by	IN	B-PP	O
chronic	JJ	B-NP	O
morphine	NN	I-NP	O
administration	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
this	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
subcutaneously	RB	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
morphine	NN	B-NP	O
twice	RB	B-NP	O
a	DT	I-NP	O
day	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
hour	NN	I-NP	O
intervals	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
and	CC	O	O
Rg1	NN	B-NP	O
was	VBD	B-VP	O
intraperitoneally	RB	I-VP	O
injected	VBN	I-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
once	RB	O	O
a	DT	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Spatial	JJ	B-NP	O
learning	NN	I-NP	O
capacity	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
Morris	NNP	I-NP	O
water	NN	I-NP	O
maze	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
Morphine	NN	B-NP	O
/	SYM	B-NP	O
Rg1	NN	I-NP	O
decreased	VBD	B-VP	O
escape	NN	B-NP	O
latency	NN	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
the	DT	B-NP	O
time	NN	I-NP	O
spent	VBN	B-VP	O
in	IN	B-PP	O
platform	NN	B-NP	O
quadrant	NN	I-NP	O
and	CC	O	O
entering	VBG	B-VP	O
frequency	NN	B-NP	O
.	.	O	O

By	IN	B-PP	O
implantation	NN	B-NP	O
of	IN	B-PP	O
electrodes	NNS	B-NP	O
and	CC	O	O
electrophysiological	JJ	B-NP	O
recording	NN	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
Rg1	NN	B-NP	O
restored	VBD	B-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
potentiation	NN	I-NP	O
(	(	O	O
LTP	NN	B-NP	O
)	)	O	O
impaired	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
both	CC	O	O
freely	RB	B-VP	O
moving	VBG	I-VP	O
and	CC	O	O
anaesthetised	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
electrophysiological	JJ	I-NP	O
recording	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
Rg1	NN	B-NP	O
restored	VBD	B-VP	O
the	DT	B-NP	O
LTP	NN	I-NP	O
in	IN	B-PP	O
slices	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
morphine	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
changed	VBD	B-VP	O
LTP	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
slices	NNS	I-NP	O
from	IN	B-PP	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
-	HYPH	B-VP	O
or	CC	O	O
morphine	NN	B-NP	O
/	SYM	B-NP	O
Rg1	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
;	:	O	O
this	DT	B-NP	O
restoration	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
antagonist	NN	I-NP	O
MK801	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
Rg1	NN	B-NP	O
may	MD	B-VP	O
significantly	RB	I-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
spatial	JJ	I-NP	O
learning	NN	I-NP	O
capacity	NN	I-NP	O
impaired	VBN	B-VP	O
by	IN	B-PP	O
chonic	JJ	B-NP	O
morphine	NN	I-NP	O
administration	NN	I-NP	O
and	CC	O	O
restore	VB	B-VP	O
the	DT	B-NP	O
morphine	NN	I-NP	O
-	HYPH	B-VP	O
inhibited	VBN	B-NP	O
LTP	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
NMDA	NN	B-NP	O
receptor	NN	I-NP	O
dependent	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
subcutaneous	JJ	B-NP	O
heparin	NN	I-NP	O
injection	NN	I-NP	O
on	IN	B-PP	O
bruising	NN	B-NP	B
and	CC	I-NP	O
pain	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
injection	NN	B-NP	O
duration	NN	I-NP	O
on	IN	B-PP	O
bruising	VBG	B-NP	B
and	CC	I-NP	O
pain	NN	I-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subcutaneous	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
different	JJ	B-NP	O
methods	NNS	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
bruising	NN	B-NP	B
and	CC	I-NP	O
pain	NN	I-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
subcutaneous	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
widely	RB	I-VP	O
studied	VBN	I-VP	O
and	CC	I-VP	O
described	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
injection	NN	B-NP	O
duration	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
bruising	NN	B-NP	B
and	CC	I-NP	O
pain	NN	I-NP	B
is	VBZ	B-VP	O
little	JJ	B-ADJP	O
documented	VBN	B-VP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
as	IN	B-PP	O
within	IN	B-PP	O
-	HYPH	B-NP	O
subject	NN	I-NP	O
,	,	O	O
quasi	AFX	B-NP	O
-	HYPH	I-NP	O
experimental	JJ	B-NP	O
research	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
sample	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
to	TO	B-PP	O
whom	WP	B-NP	O
subcutaneous	JJ	B-NP	O
heparin	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

Heparin	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
seconds	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
abdominal	JJ	I-NP	O
site	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
seconds	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
abdominal	JJ	I-NP	O
site	NN	I-NP	O
.	.	O	O

Injections	NNS	B-NP	O
areas	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
bruising	VBG	B-VP	B
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
each	DT	B-NP	O
injection	NN	I-NP	O
.	.	O	O

Dimensions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bruising	NN	I-NP	B
on	IN	B-PP	O
the	DT	B-NP	O
heparin	NN	I-NP	O
applied	VBD	B-VP	O
areas	NNS	B-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
transparent	JJ	B-NP	O
millimetric	JJ	I-NP	O
measuring	NN	I-NP	O
paper	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
visual	JJ	I-NP	O
analog	NN	I-NP	O
scale	NN	I-NP	O
(	(	O	O
VAS	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
measure	VB	I-VP	O
pain	NN	B-NP	B
intensity	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
stop	NN	I-NP	O
-	HYPH	O	O
watch	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
time	VB	I-VP	O
the	DT	B-NP	O
pain	NN	I-NP	B
period	NN	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
using	VBG	B-VP	O
chi	AFX	B-NP	O
-	HYPH	I-NP	O
square	JJ	I-NP	O
test	NN	I-NP	O
,	,	O	O
Mann	NNP	B-NP	O
-	HYPH	I-NP	O
Whitney	NNP	I-NP	O
U	NNP	I-NP	O
,	,	O	O
Wilcoxon	NNP	B-NP	O
signed	VBD	B-VP	O
ranks	NNS	B-NP	O
tests	NNS	I-NP	O
and	CC	O	O
correlation	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
bruising	VBG	B-VP	B
occurrence	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
seconds	NNS	I-NP	O
duration	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
second	JJ	I-NP	O
injection	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bruising	NN	I-NP	B
was	VBD	B-VP	O
smaller	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
second	JJ	I-NP	O
injection	NN	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
intensity	NN	I-NP	O
and	CC	I-NP	O
pain	NN	I-NP	B
period	NN	I-NP	O
were	VBD	B-VP	O
statistically	RB	B-ADVP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
second	JJ	I-NP	O
injection	NN	I-NP	O
than	IN	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
second	JJ	I-NP	O
injection	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
that	IN	B-SBAR	O
injection	NN	B-NP	O
duration	NN	I-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
bruising	VBG	B-NP	B
and	CC	I-NP	O
pain	NN	I-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
subcutaneous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
repeated	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
larger	JJR	I-NP	O
sample	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
administering	VBG	B-VP	O
subcutaneous	JJ	B-NP	O
heparin	NN	I-NP	O
injections	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
extend	VB	I-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
reserpine	NN	I-NP	O
and	CC	O	O
subchronic	JJ	B-NP	O
haloperidol	NN	I-NP	O
treatments	NNS	I-NP	O
change	VBP	B-VP	O
synaptosomal	JJ	B-NP	O
brain	NN	I-NP	O
glutamate	NN	I-NP	O
uptake	NN	I-NP	O
and	CC	O	O
elicit	VB	B-VP	O
orofacial	JJ	B-NP	B
dyskinesia	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Reserpine	NN	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
orofacial	JJ	I-NP	B
dyskinesia	NN	I-NP	I
are	VBP	B-VP	O
putative	JJ	B-NP	O
animal	NN	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
tardive	NN	B-NP	B
dyskinesia	NN	I-NP	I
(	(	O	O
TD	NN	B-NP	B
)	)	O	O
whose	WP$	B-NP	O
pathophysiology	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
free	JJ	B-NP	O
radical	NN	I-NP	O
generation	NN	I-NP	O
and	CC	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
authors	NNS	I-NP	O
induced	VBD	B-VP	O
orofacial	JJ	B-NP	B
dyskinesia	NN	I-NP	I
by	IN	B-PP	O
acute	JJ	B-NP	O
reserpine	NN	I-NP	O
and	CC	O	O
subchronic	JJ	B-NP	O
haloperidol	NN	I-NP	O
administration	NN	I-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Reserpine	NN	B-NP	O
injection	NN	I-NP	O
every	DT	B-NP	O
other	JJ	I-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
vacuous	JJ	B-NP	O
chewing	NN	I-NP	O
,	,	O	O
tongue	NN	B-NP	O
protrusion	NN	I-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
facial	JJ	B-NP	O
twitching	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
.	.	O	O

Haloperidol	NN	B-NP	O
administration	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
caused	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
vacuous	JJ	B-NP	O
chewing	NN	I-NP	O
,	,	O	O
tongue	NN	B-NP	O
protrusion	NN	I-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
facial	JJ	B-NP	O
twitching	NN	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
weekly	JJ	I-NP	O
evaluations	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
treatments	NNS	I-NP	O
and	CC	O	O
behavioral	JJ	B-NP	O
observation	NN	I-NP	O
,	,	O	O
glutamate	NN	B-NP	O
uptake	NN	I-NP	O
by	IN	B-PP	O
segments	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
was	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
decreased	VBN	I-NP	O
glutamate	NN	I-NP	O
uptake	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
subcortical	JJ	I-NP	O
parts	NNS	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
reserpine	NN	B-NP	O
and	CC	I-NP	O
haloperidol	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
.	.	O	O

Importantly	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
glutamate	NN	B-NP	O
uptake	NN	I-NP	O
correlates	VBZ	B-VP	O
negatively	RB	B-ADVP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
orofacial	JJ	B-NP	B
diskinesia	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
early	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
glutamate	NN	B-NP	O
transport	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
vacuous	JJ	B-NP	O
chewing	NN	I-NP	O
movements	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Acute	JJ	B-NP	B
psychosis	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
phenytoin	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
nonepileptic	JJ	I-NP	O
patient	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
psychosis	NN	B-NP	B
related	VBN	B-VP	O
to	TO	B-PP	O
antiepileptic	JJ	B-NP	O
drug	NN	I-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
usually	RB	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
epileptic	JJ	I-NP	B
brain	NN	I-NP	O
substratum	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
antiepileptic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
nonepileptic	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
psychosis	NN	B-NP	B
following	VBG	B-PP	O
phenytoin	NN	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
trigeminal	JJ	B-NP	B
neuralgia	NN	I-NP	I
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
psychotic	JJ	I-NP	B
symptoms	NNS	I-NP	I
that	WDT	B-NP	O
occur	VBP	B-VP	O
following	VBG	B-PP	O
phenytoin	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
epileptic	JJ	I-NP	B
patients	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
direct	JJ	I-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
medication	NN	B-NP	O
,	,	O	O
unrelated	JJ	B-ADJP	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
gum	NN	B-NP	O
Arabic	JJ	B-ADJP	O
on	IN	B-PP	O
gentamicin	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
:	:	O	O
a	DT	B-NP	O
preliminary	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
work	NN	I-NP	O
we	PRP	B-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
gum	NN	B-NP	O
Arabic	JJ	B-ADJP	O
on	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
gentamicin	NN	B-NP	O
(	(	O	O
GM	NN	B-NP	O
)	)	O	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
vehicle	NN	I-NP	O
,	,	O	O
gum	NN	B-NP	O
Arabic	NNP	I-NP	O
,	,	O	O
or	CC	O	O
gum	NN	B-NP	O
Arabic	NNP	I-NP	O
concomitantly	RB	B-ADVP	O
with	IN	B-PP	O
GM	NNP	B-NP	O
.	.	O	O

Nephrotoxicity	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
measuring	VBG	B-VP	O
the	DT	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
creatinine	NN	B-NP	O
and	CC	I-NP	O
urea	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
glutathione	NN	I-NP	O
(	(	O	O
GSH	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
and	CC	O	O
by	IN	B-PP	O
light	NN	B-NP	O
microscopic	JJ	I-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	O
sections	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
concomitant	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
gum	NN	B-NP	O
Arabic	NNP	I-NP	O
and	CC	I-NP	O
GM	NNP	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
creatinine	NN	B-NP	O
and	CC	I-NP	O
urea	NN	I-NP	O
by	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
(	(	O	O
compared	VBN	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
cellulose	NN	B-NP	O
and	CC	O	O
GM	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
decreased	VBD	B-VP	O
that	IN	B-SBAR	O
of	IN	B-PP	O
cortical	JJ	B-NP	O
GSH	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
compared	VBN	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cellulose	NN	I-NP	O
plus	CC	O	O
GM	NNP	B-NP	O
group	NN	I-NP	O
)	)	O	O
The	DT	B-NP	O
GM	NNP	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
proximal	JJ	I-NP	O
tubular	JJ	I-NP	B
necrosis	NN	I-NP	I
appeared	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
slightly	RB	B-ADJP	O
less	RBR	I-ADJP	O
severe	JJ	I-ADJP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-VP	O
GM	NNP	B-NP	O
together	RB	B-ADVP	O
with	IN	B-PP	O
gum	NN	B-NP	O
Arabic	JJ	B-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
those	DT	B-NP	O
given	VBN	B-PP	O
GM	NNP	B-NP	O
and	CC	O	O
cellulose	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
inferred	VBN	I-VP	O
that	IN	B-SBAR	O
gum	NN	B-NP	O
Arabic	JJ	I-NP	O
treatment	NN	I-NP	O
has	VBZ	B-VP	O
induced	VBN	I-VP	O
a	DT	B-NP	O
modest	JJ	I-NP	O
amelioration	NN	I-NP	O
of	IN	B-PP	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
histological	JJ	I-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
indices	NNS	I-NP	O
of	IN	B-PP	O
GM	NNP	B-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

Further	JJ	B-NP	O
work	NN	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatments	NNS	I-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
functional	JJ	I-NP	O
aspects	NNS	I-NP	O
in	IN	B-PP	O
models	NNS	B-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	B-PP	O
and	CC	I-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
(	(	I-NP	O
s	NNS	I-NP	O
)	)	O	O
involved	VBN	B-VP	O
.	.	O	O

Visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
zonisamide	NN	B-NP	O
.	.	O	O

Zonisamide	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
broad	JJ	I-NP	O
-	HYPH	I-NP	O
spectrum	NN	I-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
various	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

Although	IN	B-SBAR	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
agent	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
complex	JJ	B-NP	O
visual	JJ	I-NP	B
hallucinations	NNS	I-NP	I
and	CC	O	O
altered	VBN	B-NP	O
mental	JJ	I-NP	O
status	NN	I-NP	O
after	IN	B-PP	O
zonisamide	NN	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
begun	VBN	I-VP	O
or	CC	O	O
its	PRP$	B-NP	O
dosage	NN	I-NP	O
increased	VBD	B-VP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
diagnosed	VBN	I-VP	O
earlier	RBR	B-ADVP	O
with	IN	B-PP	O
epilepsy	NN	B-NP	B
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
electroencephalogram	NN	I-NP	O
(	(	O	O
EEG	NN	B-NP	O
)	)	O	O
findings	NNS	B-NP	O
were	VBD	B-VP	O
abnormal	JJ	B-ADJP	O
.	.	O	O

During	IN	B-PP	O
monitoring	NN	B-NP	O
,	,	O	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
did	VBD	B-VP	O
not	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
EEG	NN	B-NP	O
readings	NNS	I-NP	O
,	,	O	O
nor	CC	O	O
did	VBD	O	O
video	NN	B-NP	O
recording	VBG	B-VP	O
capture	NN	B-NP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
described	VBN	I-NP	O
events	NNS	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
experienced	VBN	I-VP	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
before	IN	B-PP	O
this	DT	B-NP	O
event	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
only	JJ	I-NP	O
recent	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
introduction	NN	I-NP	O
or	CC	O	O
increased	VBN	B-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
zonisamide	NN	B-NP	O
.	.	O	O

With	IN	B-PP	O
either	CC	O	O
discontinuation	NN	B-NP	O
or	CC	O	O
decreased	VBN	B-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
disappeared	VBD	B-VP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
recur	VB	I-VP	O
.	.	O	O

Further	JJR	B-NP	O
observations	NNS	I-NP	O
and	CC	I-NP	O
reports	NNS	I-NP	O
will	MD	B-VP	O
help	VB	I-VP	O
clarify	VB	I-VP	O
this	DT	B-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Until	IN	B-PP	O
then	RB	B-NP	O
,	,	O	O
clinicians	NNS	B-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
possible	JJ	I-NP	O
complication	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
zonisamide	NN	B-NP	O
.	.	O	O

GLEPP1	NN	B-NP	O
receptor	NN	I-NP	O
tyrosine	NN	I-NP	O
phosphatase	NN	I-NP	O
(	(	O	O
Ptpro	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
rat	NN	B-NP	O
PAN	NN	I-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
podocyte	NN	I-NP	O
injury	NN	I-NP	O
.	.	O	O

Glomerular	JJ	B-NP	O
epithelial	JJ	I-NP	O
protein	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
GLEPP1	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
podocyte	NN	I-NP	O
receptor	NN	I-NP	O
membrane	NN	I-NP	O
protein	NN	I-NP	O
tyrosine	NN	I-NP	O
phosphatase	NN	I-NP	O
located	JJ	B-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
apical	JJ	I-NP	O
cell	NN	I-NP	O
membrane	NN	I-NP	O
of	IN	B-PP	O
visceral	JJ	B-NP	O
glomerular	JJ	I-NP	O
epithelial	JJ	I-NP	O
cell	NN	I-NP	O
and	CC	I-NP	O
foot	NN	I-NP	O
processes	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
receptor	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
regulating	VBG	B-VP	O
the	DT	B-NP	O
structure	NN	I-NP	O
and	CC	I-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
podocyte	NN	B-NP	O
foot	NN	I-NP	O
process	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
better	RBR	I-VP	O
understand	VB	I-VP	O
the	DT	B-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
GLEPP1	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
amount	NN	I-NP	O
and	CC	I-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
GLEPP1	NN	B-NP	O
protein	NN	I-NP	O
and	CC	O	O
mRNA	NN	B-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
by	IN	B-PP	O
immunohistochemistry	NN	B-NP	O
,	,	O	O
Western	NN	B-NP	O
blot	NN	I-NP	O
and	CC	O	O
RNase	NN	B-NP	O
protection	NN	I-NP	O
assay	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
podocyte	NN	B-NP	O
injury	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
nephrosis	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
single	JJ	B-NP	O
intraperitoneal	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
.	.	O	O

Tissues	NNS	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
PAN	NN	B-NP	O
injection	NN	I-NP	O
so	RB	B-SBAR	O
as	IN	I-SBAR	O
to	TO	B-VP	O
include	VB	I-VP	O
both	CC	O	O
the	DT	B-NP	O
acute	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
foot	NN	B-NP	O
process	NN	I-NP	O
effacement	NN	I-NP	O
(	(	O	O
days	NNS	B-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
glomerulosclerosis	NN	B-NP	B
(	(	O	O
days	NNS	B-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

At	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
GLEPP1	NN	I-NP	O
protein	NN	I-NP	O
and	CC	O	O
mRNA	NN	B-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
range	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
.	.	O	O

This	DT	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
protein	NN	I-NP	O
content	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
podocalyxin	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
significantly	RB	B-ADVP	O
at	IN	B-PP	O
this	DT	B-NP	O
time	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
GLEPP1	NN	I-NP	O
protein	NN	I-NP	O
and	CC	O	O
mRNA	NN	B-NP	O
had	VBD	B-VP	O
begun	VBN	I-VP	O
to	TO	I-VP	O
return	VB	I-VP	O
towards	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

By	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
time	NN	I-NP	O
when	WRB	B-ADVP	O
glomerular	JJ	B-NP	O
scarring	NN	I-NP	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
,	,	O	O
GLEPP1	NN	B-NP	O
was	VBD	B-VP	O
absent	JJ	B-ADJP	O
from	IN	B-PP	O
glomerulosclerotic	JJ	B-NP	O
areas	NNS	I-NP	O
although	IN	B-SBAR	O
the	DT	B-NP	O
total	JJ	I-NP	O
glomerular	JJ	I-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
GLEPP1	NN	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
different	JJ	B-ADJP	O
from	IN	B-PP	O
normal	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
GLEPP1	NN	B-NP	O
expression	NN	I-NP	O
,	,	O	O
unlike	IN	B-PP	O
podocalyxin	NN	B-NP	O
,	,	O	O
reflects	VBZ	B-VP	O
podocyte	NN	B-NP	O
injury	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
PAN	NN	B-NP	O
.	.	O	O

GLEPP1	NN	B-NP	O
expression	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
podocyte	NN	B-NP	O
injury	NN	I-NP	O
.	.	O	O

Ticlopidine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
:	:	O	O
report	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
Chinese	JJ	I-NP	O
patients	NNS	I-NP	O
and	CC	O	O
review	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
Chinese	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
ticlopidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
were	VBD	B-VP	O
reported	VBN	I-VP	O
and	CC	O	O
another	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
English	JJ	I-NP	O
literature	NN	I-NP	O
were	VBD	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
attempted	VBD	B-VP	O
to	TO	I-VP	O
find	VB	I-VP	O
underlying	JJ	B-NP	O
similarities	NNS	I-NP	O
,	,	O	O
evaluate	VBP	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
,	,	O	O
and	CC	O	O
identify	VB	B-VP	O
appropriate	JJ	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
but	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
old	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
who	WP	B-NP	O
died	VBD	B-VP	O
were	VBD	B-VP	O
all	DT	O	O
older	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
old	JJ	B-NP	O
age	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
developing	VBG	B-VP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

Agranulocytosis	NN	B-NP	B
occurred	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
ticlopidine	NN	B-NP	O
,	,	O	O
so	RB	B-NP	O
frequent	JJ	I-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
white	JJ	B-NP	O
cell	NN	I-NP	O
count	NN	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
.	.	O	O

There	EX	B-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
no	DT	B-NP	O
direct	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
or	CC	I-NP	O
duration	NN	I-NP	O
used	VBN	B-VP	O
and	CC	O	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
bone	NN	B-NP	B
marrow	NN	I-NP	I
suppression	NN	I-NP	I
.	.	O	O

Treatment	NN	B-NP	O
for	IN	B-PP	O
ticlopidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
with	IN	B-PP	O
colony	NN	B-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
factors	NNS	B-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
little	JJ	B-NP	O
effect	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
concurrent	JJ	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
died	VBD	B-VP	O
,	,	O	O
should	MD	B-VP	O
alert	VB	I-VP	O
clinicians	NNS	B-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
more	RBR	B-ADJP	O
cautious	JJ	I-ADJP	O
when	WRB	B-ADVP	O
using	VBG	B-VP	O
these	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
simultaneously	RB	B-ADVP	O
.	.	O	O

Facilitation	NN	B-NP	O
of	IN	B-PP	O
memory	NN	B-NP	O
retrieval	NN	I-NP	O
by	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
test	NN	I-NP	O
morphine	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
state	NN	I-NP	O
dependency	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
step	NN	I-NP	O
-	HYPH	B-VP	O
through	IN	B-PP	O
type	NN	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
learning	VBG	B-VP	O
test	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Amnesia	NN	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
and	CC	I-NP	O
cycloheximide	NN	I-NP	O
were	VBD	B-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
given	VBN	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
trial	NN	I-NP	O
(	(	O	O
pre	AFX	O	O
-	HYPH	O	O
test	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
test	NN	I-NP	O
morphine	NN	I-NP	O
also	RB	B-ADVP	O
facilitated	VBD	B-VP	O
the	DT	B-NP	O
memory	NN	I-NP	O
retrieval	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
administered	VBN	B-VP	O
naloxone	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
training	NN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
test	NN	I-NP	O
scopolamine	NN	I-NP	O
partially	RB	B-ADVP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
,	,	O	O
but	CC	O	O
not	RB	O	O
significantly	RB	B-ADVP	O
;	:	O	O
and	CC	O	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
test	NN	I-NP	O
cycloheximide	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
reverse	VB	I-VP	O
the	DT	B-NP	O
cycloheximide	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
facilitation	NN	I-NP	O
of	IN	B-PP	O
memory	NN	B-NP	O
retrieval	NN	I-NP	O
by	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
test	NN	I-NP	O
morphine	NN	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
direct	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
a	DT	B-NP	O
state	NN	I-NP	O
dependent	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Test	NN	B-NP	O
conditions	NNS	I-NP	O
influence	VBP	B-VP	O
the	DT	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
challenge	NN	I-NP	O
in	IN	B-PP	O
rodents	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
conducted	VBN	I-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
differential	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
challenge	NN	I-NP	O
under	IN	B-PP	O
varied	JJ	B-NP	O
experimental	JJ	I-NP	O
test	NN	I-NP	O
conditions	NNS	I-NP	O
routinely	RB	B-VP	O
employed	VBN	I-VP	O
to	TO	B-VP	O
study	VB	I-VP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
behavioral	NN	I-NP	O
and	CC	I-NP	O
neurophysiological	JJ	I-NP	O
responses	NNS	I-NP	O
in	IN	B-PP	O
rodents	NNS	B-NP	O
.	.	O	O

Apomorphine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
nonselective	JJ	I-NP	O
dopamine	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
selected	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
biphasic	JJ	I-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
hypothermia	NN	B-NP	B
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
produce	VB	I-VP	O
distinct	JJ	B-NP	O
changes	NNS	I-NP	O
to	TO	B-PP	O
dopamine	NN	B-NP	O
turnover	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rodent	NN	I-NP	O
brain	NN	I-NP	O
.	.	O	O

From	IN	B-PP	O
such	JJ	B-NP	O
experiments	NNS	I-NP	O
there	EX	B-NP	O
is	VBZ	B-VP	O
evidence	NN	B-NP	O
that	IN	B-SBAR	O
characterization	NN	B-NP	O
and	CC	I-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
rodents	NNS	B-NP	O
critically	RB	B-ADVP	O
depends	VBZ	B-VP	O
upon	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
conditions	NNS	I-NP	O
employed	VBN	B-VP	O
.	.	O	O

In	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
detection	NN	B-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
was	VBD	B-VP	O
facilitated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
acclimatization	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
test	NN	B-NP	O
conditions	NNS	I-NP	O
can	MD	B-VP	O
impact	VB	I-VP	O
upon	IN	B-PP	O
other	JJ	B-NP	O
physiological	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
apomorphine	NN	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypothermia	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
apomorphine	NN	B-NP	O
produced	VBD	B-VP	O
qualitatively	RB	B-NP	O
different	JJ	I-NP	O
responses	NNS	I-NP	O
under	IN	B-PP	O
novel	JJ	B-NP	O
conditions	NNS	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
those	DT	B-NP	O
behaviors	NNS	I-NP	O
elicited	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
home	NN	I-NP	O
test	NN	I-NP	O
cage	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
gross	JJ	I-NP	O
activity	NN	I-NP	O
counts	NNS	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
novel	JJ	I-NP	O
exploratory	NN	I-NP	O
box	NN	I-NP	O
only	RB	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
measures	NNS	B-NP	O
of	IN	B-PP	O
stereotypic	JJ	B-NP	O
behavior	NN	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
.	.	O	O

By	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
apomorphine	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
locomotion	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
prominent	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
novel	JJ	I-NP	O
exploratory	NN	I-NP	O
box	NN	I-NP	O
.	.	O	O

Dopamine	NN	B-NP	O
turnover	NN	I-NP	O
ratios	NNS	I-NP	O
(	(	O	O
DOPAC	NN	B-NP	O
:	:	O	O
DA	NN	B-NP	O
and	CC	I-NP	O
HVA	NN	I-NP	O
:	:	O	O
DA	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
those	DT	B-NP	O
animals	NNS	I-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
exploratory	NN	I-NP	O
box	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
home	NN	I-NP	O
cage	NN	I-NP	O
counterparts	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
reductions	NNS	I-NP	O
in	IN	B-PP	O
striatal	JJ	B-NP	O
dopamine	NN	I-NP	O
turnover	NN	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
both	CC	B-NP	O
novel	JJ	I-NP	O
and	CC	I-NP	O
home	NN	I-NP	O
cage	NN	I-NP	O
environments	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
implications	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
with	IN	B-PP	O
particular	JJ	B-NP	O
emphasis	NN	I-NP	O
upon	IN	B-PP	O
conducting	VBG	B-VP	O
psychopharmacological	JJ	B-NP	O
challenge	NN	I-NP	O
tests	NNS	I-NP	O
in	IN	B-PP	O
rodents	NNS	B-NP	O
.	.	O	O

Tricuspid	JJ	B-NP	B
valve	NN	I-NP	I
regurgitation	NN	I-NP	I
and	CC	O	O
lithium	NN	B-NP	O
carbonate	NN	I-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
newborn	JJ	I-NP	O
infant	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
newborn	NN	I-NP	O
with	IN	B-PP	O
massive	JJ	B-NP	O
tricuspid	JJ	I-NP	B
regurgitation	NN	I-NP	I
,	,	O	O
atrial	JJ	B-NP	B
flutter	NN	I-NP	I
,	,	O	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
high	JJ	I-NP	O
serum	NN	I-NP	O
lithium	NN	I-NP	O
level	NN	I-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
patient	NN	I-NP	O
to	TO	B-VP	O
initially	RB	I-VP	O
manifest	VB	I-VP	O
tricuspid	JJ	B-NP	B
regurgitation	NN	I-NP	I
and	CC	O	O
atrial	JJ	B-NP	B
flutter	NN	I-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
11th	JJ	I-NP	O
described	VBN	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
cardiac	JJ	B-NP	B
disease	NN	I-NP	I
among	IN	B-PP	O
infants	NNS	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
compounds	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
trimester	NN	I-NP	O
of	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
infants	NNS	I-NP	O
had	VBD	B-VP	O
tricuspid	JJ	B-NP	O
valve	NN	I-NP	O
involvement	NN	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
carbonate	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
increasing	VBG	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
congenital	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
when	WRB	B-ADVP	O
taken	VBN	B-VP	O
during	IN	B-PP	O
early	JJ	B-NP	O
pregnancy	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
also	RB	B-ADVP	O
causes	VBZ	B-VP	O
neurologic	JJ	B-NP	B
depression	NN	I-NP	I
,	,	O	O
cyanosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
cardiac	JJ	B-NP	B
arrhythmia	NN	I-NP	I
when	WRB	B-ADVP	O
consumed	VBN	B-VP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
delivery	NN	B-NP	O
.	.	O	O

Phenobarbital	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
dyskinesia	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
neurologically	RB	I-NP	B
-	HYPH	I-NP	I
impaired	JJ	I-NP	I
child	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
child	NN	I-NP	O
with	IN	B-PP	O
known	JJ	B-NP	O
neurologic	JJ	I-NP	B
impairment	NN	I-NP	I
developed	VBD	B-VP	O
a	DT	B-NP	O
dyskinesia	NN	I-NP	B
soon	RB	B-ADVP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
phenobarbital	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

Known	VBN	B-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
movement	NN	B-NP	B
disorders	NNS	I-NP	I
were	VBD	B-VP	O
eliminated	VBN	I-VP	O
after	IN	B-PP	O
evaluation	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
repeat	NN	B-NP	O
challenge	NN	I-NP	O
with	IN	B-PP	O
phenobarbital	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
dyskinesia	NN	I-NP	B
recurred	VBD	B-VP	O
.	.	O	O

Phenobarbital	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
added	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
list	NN	I-NP	O
of	IN	B-PP	O
anticonvulsant	JJ	B-NP	O
drugs	NNS	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
movement	NN	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

Acute	JJ	B-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
ammonia	NN	I-NP	O
may	MD	B-VP	O
predict	VB	I-VP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

Valproic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
VPA	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
epileptic	JJ	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
already	RB	I-VP	O
being	VBG	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
antiepileptic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
standardized	JJ	I-NP	O
loading	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
VPA	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
,	,	O	O
and	CC	O	O
venous	JJ	B-NP	O
blood	NN	I-NP	O
was	VBD	B-VP	O
sampled	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

Ammonia	NN	B-NP	O
(	(	O	O
NH3	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
,	,	O	O
during	IN	B-PP	O
continuous	JJ	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
complained	VBD	B-VP	O
of	IN	B-PP	O
drowsiness	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
than	IN	B-PP	O
in	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
symptom	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
although	IN	B-SBAR	O
VPA	NN	B-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

By	IN	B-PP	O
measuring	VBG	B-VP	O
VPA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
NH3	NN	I-NP	O
content	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
possible	JJ	B-ADJP	O
to	TO	B-VP	O
identify	VB	I-VP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
higher	JJR	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
obtundation	NN	B-NP	O
when	WRB	B-ADVP	O
VPA	NN	B-NP	O
is	VBZ	B-VP	O
given	VBN	I-VP	O
chronically	RB	B-ADVP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
calcitonin	NN	B-NP	O
on	IN	B-PP	O
rat	NN	B-NP	O
extrapyramidal	JJ	I-NP	O
motor	NN	I-NP	O
system	NN	I-NP	O
:	:	O	O
behavioral	JJ	B-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
data	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
i.v.c.	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
and	CC	I-NP	O
salmon	NN	I-NP	O
calcitonin	NN	I-NP	O
on	IN	B-PP	O
biochemical	JJ	B-NP	O
and	CC	I-NP	O
behavioral	JJ	I-NP	O
parameters	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
extrapyramidal	JJ	I-NP	O
motor	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Calcitonin	NN	B-NP	O
injection	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
potentiation	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
and	CC	O	O
a	DT	B-NP	O
partial	JJ	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
.	.	O	O

Moreover	RB	B-NP	O
calcitonin	NN	I-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
nigral	JJ	B-NP	O
GAD	NN	I-NP	O
activity	NN	I-NP	O
but	CC	O	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
striatal	JJ	B-NP	O
DA	NN	I-NP	O
and	CC	I-NP	O
DOPAC	NN	I-NP	O
concentration	NN	I-NP	O
or	CC	O	O
GAD	NN	B-NP	O
activity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
in	IN	B-PP	O
view	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
primary	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
calcitonin	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
striatonigral	JJ	I-NP	O
GABAergic	JJ	I-NP	O
pathway	NN	I-NP	O
mediating	VBG	B-VP	O
the	DT	B-NP	O
DA	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
behavioral	JJ	I-NP	O
messages	NNS	I-NP	O
of	IN	B-PP	O
striatal	JJ	B-NP	O
origin	NN	I-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
hypertrophy	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
hypertrophy	NN	I-NP	I
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
female	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
following	VBG	B-PP	O
daily	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
(	(	O	O
ISO	NN	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
was	VBD	B-VP	O
established	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
tissue	NN	B-NP	O
mass	NN	I-NP	O
,	,	O	O
RNA	NN	B-NP	O
and	CC	I-NP	O
DNA	NN	I-NP	O
content	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
hydroxyproline	NN	B-NP	O
content	NN	I-NP	O
.	.	O	O

Heart	NN	B-NP	O
weight	NN	I-NP	O
increased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
half	JJ	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Ventricular	JJ	B-NP	O
RNA	NN	I-NP	O
content	NN	I-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
and	CC	O	O
reached	VBD	B-VP	O
a	DT	B-NP	O
maximal	JJ	I-NP	O
level	NN	I-NP	O
following	VBG	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
half	JJ	I-NP	O
time	NN	I-NP	O
for	IN	B-PP	O
RNA	NN	B-NP	O
accumulation	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
total	JJ	I-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
hydroxyproline	NN	B-NP	O
remained	VBD	B-VP	O
stable	JJ	B-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
but	CC	O	O
increased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Ventricular	JJ	B-NP	O
DNA	NN	I-NP	O
content	NN	I-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
stage	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
)	)	O	O
of	IN	B-PP	O
hypertrophic	JJ	B-NP	B
growth	NN	I-NP	O
but	CC	O	O
increased	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
steady	JJ	I-NP	O
-	HYPH	I-NP	O
state	NN	I-NP	O
level	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
above	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Intraventricular	JJ	B-NP	O
pressures	NNS	I-NP	O
and	CC	O	O
coronary	JJ	B-NP	O
flow	NN	I-NP	O
measures	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
for	IN	B-PP	O
control	NN	B-NP	O
and	CC	O	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
following	VBG	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
developed	VBN	B-NP	O
hypertrophy	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
dP	NN	B-NP	O
/	SYM	I-NP	O
dt	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ISO	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
hearts	NNS	I-NP	O
was	VBD	B-VP	O
slightly	RB	B-ADVP	O
but	CC	O	O
significantly	RB	B-ADJP	O
elevated	JJ	I-ADJP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
adaptive	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
ISO	NN	B-NP	O
shows	VBZ	B-VP	O
an	DT	B-NP	O
early	JJ	I-NP	O
hypertrophic	JJ	I-NP	B
phase	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
)	)	O	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
substantial	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
RNA	NN	B-NP	O
content	NN	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
mass	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
DNA	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
prolonged	VBN	B-NP	O
stimulation	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
)	)	O	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
represent	VB	I-VP	O
a	DT	B-NP	O
complex	JJ	I-NP	O
integration	NN	I-NP	O
of	IN	B-PP	O
both	CC	B-NP	O
cellular	JJ	I-NP	O
hypertrophy	NN	I-NP	B
and	CC	I-NP	O
hyperplasia	NN	I-NP	B
within	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
.	.	O	O

Co	AFX	B-NP	O
-	HYPH	I-NP	O
carcinogenic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
retinyl	NN	B-NP	O
acetate	NN	I-NP	O
on	IN	B-PP	O
forestomach	NN	B-NP	B
carcinogenesis	NN	I-NP	I
of	IN	B-PP	O
male	JJ	B-NP	O
F344	NN	I-NP	O
rats	NNS	I-NP	O
induced	VBN	B-VP	O
with	IN	B-PP	O
butylated	VBN	B-NP	O
hydroxyanisole	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
potential	JJ	I-NP	O
modifying	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
retinyl	NN	B-NP	O
acetate	NN	I-NP	O
(	(	O	O
RA	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
butylated	VBN	B-NP	O
hydroxyanisole	NN	I-NP	O
(	(	O	O
BHA	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rat	NN	I-NP	O
forestomach	NN	I-NP	B
tumorigenesis	NN	I-NP	I
was	VBD	B-VP	O
examined	VBN	I-VP	O
.	.	O	O

Male	JJ	B-NP	O
F344	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
maintained	VBN	I-VP	O
on	IN	B-PP	O
diet	NN	B-NP	O
containing	VBG	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
BHA	NN	I-NP	O
by	IN	B-PP	O
weight	NN	B-NP	O
and	CC	O	O
simultaneously	RB	B-ADVP	O
on	IN	B-PP	O
drinking	NN	B-NP	O
water	NN	I-NP	O
supplemented	VBN	B-VP	O
with	IN	B-PP	O
RA	NN	B-NP	O
at	IN	B-PP	O
various	JJ	B-NP	O
concentrations	NNS	I-NP	O
(	(	O	O
w	NN	B-NP	O
/	SYM	B-NP	O
v	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
groups	NNS	B-NP	O
given	VBN	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
BHA	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
marked	JJ	B-NP	O
hyperplastic	JJ	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
forestomach	NN	I-NP	O
epithelium	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
co	AFX	O	O
-	HYPH	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
RA	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
forestomach	NN	B-NP	B
tumors	NNS	I-NP	I
(	(	O	O
squamous	JJ	B-NP	B
cell	NN	I-NP	I
papilloma	NN	I-NP	I
and	CC	O	O
carcinoma	NN	B-NP	B
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
carcinoma	NN	B-NP	B
)	)	O	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
rat	NN	I-NP	O
with	IN	B-PP	O
carcinoma	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
given	VBN	B-NP	O
RA	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
water	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
BHA	NN	I-NP	O
,	,	O	O
RA	NN	B-NP	O
co	AFX	O	O
-	HYPH	O	O
administered	VBN	B-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
enhancing	NN	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
BHA	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
epithelial	JJ	I-NP	B
hyperplasia	NN	I-NP	I
.	.	O	O

Tumors	NNS	B-NP	B
,	,	O	O
all	DT	B-NP	O
papillomas	NNS	I-NP	B
,	,	O	O
were	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
RA	NN	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
rat	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
RA	NN	I-NP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	B-NP	O
.	.	O	O

RA	NN	B-NP	O
alone	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
hyperplastic	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
forestomach	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
RA	NN	B-NP	O
acted	VBD	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
carcinogen	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BHA	NN	I-NP	O
forestomach	NN	I-NP	B
carcinogenesis	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Ketanserin	NN	B-NP	O
pretreatment	NN	I-NP	O
reverses	VBZ	B-VP	O
alfentanil	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
.	.	O	O

Systemic	JJ	B-NP	O
pretreatment	NN	I-NP	O
with	IN	B-PP	O
ketanserin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
relatively	RB	I-NP	O
specific	JJ	I-NP	O
type	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
serotonin	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
significantly	RB	B-VP	O
attenuated	VBD	I-VP	O
the	DT	B-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
produced	VBN	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
potent	JJ	I-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	I-NP	O
opiate	NN	I-NP	O
agonist	NN	I-NP	O
alfentanil	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
placement	NN	B-NP	O
of	IN	B-PP	O
subcutaneous	JJ	B-NP	O
electrodes	NNS	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
animal	NN	I-NP	O
s	NN	I-NP	O
left	VBD	B-VP	O
gastrocnemius	NN	B-NP	O
muscle	NN	I-NP	O
,	,	O	O
rigidity	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
analyzing	VBG	B-VP	O
root	NN	B-NP	O
-	HYPH	B-NP	O
mean	JJ	I-NP	O
-	HYPH	I-NP	O
square	NN	I-NP	O
electromyographic	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Intraperitoneal	JJ	B-NP	O
ketanserin	NN	I-NP	O
administration	NN	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
alfentanil	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
electromyographic	JJ	B-NP	O
activity	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
animals	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
.	.	O	O

Chlordiazepoxide	NN	B-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
significantly	RB	I-VP	O
influence	VB	I-VP	O
the	DT	B-NP	O
rigidity	NN	I-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
alfentanil	NN	B-NP	O
.	.	O	O

Despite	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
rigidity	NN	B-NP	B
,	,	O	O
animals	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
ketanserin	NN	B-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
alfentanil	NN	B-NP	O
were	VBD	B-VP	O
motionless	JJ	B-ADJP	O
,	,	O	O
flaccid	NN	B-NP	O
,	,	O	O
and	CC	O	O
less	RBR	B-ADJP	O
responsive	JJ	I-ADJP	O
to	TO	B-PP	O
external	JJ	B-NP	O
stimuli	NNS	I-NP	O
than	IN	B-SBAR	O
were	VBD	B-VP	O
animals	NNS	B-NP	O
receiving	VBG	B-VP	O
alfentanil	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Rats	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
ketanserin	NN	B-NP	O
and	CC	I-NP	O
alfentanil	NN	I-NP	O
exhibited	VBD	B-VP	O
less	RBR	B-NP	O
rearing	JJ	I-NP	O
and	CC	I-NP	O
exploratory	JJ	I-NP	O
behavior	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
recording	NN	I-NP	O
period	NN	I-NP	O
than	IN	B-SBAR	O
did	VBD	O	O
animals	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
ketanserin	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
previous	JJ	B-NP	O
work	NN	I-NP	O
,	,	O	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
muscle	NN	B-NP	B
rigidity	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
clinically	RB	I-NP	O
relevant	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
parenteral	JJ	B-NP	O
narcotic	JJ	I-NP	O
administration	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
partly	RB	I-VP	O
mediated	VBN	I-VP	O
via	IN	B-PP	O
serotonergic	JJ	B-NP	O
pathways	NNS	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
type	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
serotonin	NN	I-NP	O
antagonists	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
clinically	RB	B-ADJP	O
useful	JJ	I-ADJP	O
in	IN	B-PP	O
attenuating	VBG	B-VP	O
opiate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rigidity	NN	I-NP	B
,	,	O	O
although	IN	B-SBAR	O
further	JJ	B-NP	O
studies	NNS	I-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
of	IN	B-PP	O
possibly	RB	B-NP	O
enhanced	VBN	I-NP	O
CNS	NN	I-NP	O
,	,	O	O
cardiovascular	JJ	B-ADJP	B
,	,	O	I
and	CC	O	I
respiratory	JJ	B-NP	I
depression	NN	I-NP	I
.	.	O	O

Glycopyrronium	NN	B-NP	O
requirements	NNS	I-NP	O
for	IN	B-PP	O
antagonism	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
muscarinic	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
edrophonium	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
compared	VBN	I-VP	O
,	,	O	O
in	IN	B-PP	O
num	CD	B-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
glycopyrronium	NN	B-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
given	VBN	B-VP	O
either	CC	O	O
simultaneously	RB	B-ADVP	O
or	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
edrophonium	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
.	.	O	O

Both	DT	B-NP	O
groups	NNS	I-NP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
showed	VBD	B-VP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
beat	NN	I-NP	O
min	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
limits	VBZ	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
beat	IN	B-PP	O
min	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
glycopyrronium	NN	B-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
provided	VBD	B-VP	O
greater	JJR	B-NP	O
cardiovascular	JJ	I-NP	O
stability	NN	I-NP	O
and	CC	O	O
,	,	O	O
given	VBN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
edrophonium	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
minimize	VB	I-VP	O
early	RB	B-ADVP	O
,	,	O	O
edrophonium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
bradycardias	NNS	I-NP	B
.	.	O	O

This	DT	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
glycopyrronium	NN	B-NP	O
provided	VBD	B-VP	O
good	JJ	B-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
oropharyngeal	JJ	B-NP	O
secretions	NNS	I-NP	O
.	.	O	O

Involvement	NN	B-NP	O
of	IN	B-PP	O
locus	NN	B-NP	O
coeruleus	NN	I-NP	O
and	CC	O	O
noradrenergic	JJ	B-NP	O
neurotransmission	NN	I-NP	O
in	IN	B-PP	O
fentanyl	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscular	JJ	I-NP	B
rigidity	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Whereas	IN	B-PP	O
muscular	JJ	B-NP	B
rigidity	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
known	VBN	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
fentanyl	NN	I-NP	O
anesthesia	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
paucity	NN	I-NP	O
of	IN	B-PP	O
information	NN	B-NP	O
exists	VBZ	B-VP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
underlying	VBG	I-NP	O
mechanism	NN	I-NP	O
(	(	I-NP	O
s	NNS	I-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
engagement	NN	I-NP	O
of	IN	B-PP	O
locus	NN	B-NP	O
coeruleus	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pons	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
phenomenon	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
anesthetized	VBN	B-VP	O
with	IN	B-PP	O
ketamine	NN	B-NP	O
.	.	O	O

Under	IN	B-PP	O
proper	JJ	B-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
respiration	NN	B-NP	O
,	,	O	O
body	NN	B-NP	O
temperature	NN	I-NP	O
and	CC	I-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
tidal	JJ	I-NP	O
CO2	NN	I-NP	O
,	,	O	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
consistently	RB	B-VP	O
promoted	VBD	I-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
electromyographic	JJ	B-NP	O
activity	NN	I-NP	O
recorded	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
gastrocnemius	NN	I-NP	O
and	CC	O	O
abdominal	JJ	B-NP	O
rectus	NN	I-NP	O
muscles	NNS	I-NP	O
.	.	O	O

Such	PDT	B-NP	O
an	DT	I-NP	O
induced	VBN	I-NP	O
muscular	JJ	I-NP	B
rigidity	NN	I-NP	I
by	IN	B-PP	O
the	DT	B-NP	O
narcotic	JJ	I-NP	O
agent	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
antagonized	VBN	I-VP	O
or	CC	O	O
even	RB	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
prior	JJ	B-NP	O
electrolytic	JJ	I-NP	O
lesions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
locus	NN	I-NP	O
coeruleus	NN	I-NP	O
or	CC	I-NP	O
pretreatment	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
prazosin	NN	B-NP	O
.	.	O	O

Microinjection	NN	B-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
nl	NN	I-NP	O
)	)	O	O
directly	RB	B-ADVP	O
into	IN	B-PP	O
this	DT	B-NP	O
pontine	JJ	I-NP	O
nucleus	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
elicited	VBD	B-VP	O
discernible	JJ	B-NP	O
electromyographic	JJ	I-NP	O
excitation	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
speculated	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
muscular	JJ	B-NP	B
rigidity	NN	I-NP	I
by	IN	B-PP	O
fentanyl	NN	B-NP	O
may	MD	B-VP	O
involve	VB	I-VP	O
the	DT	B-NP	O
coerulospinal	JJ	I-NP	O
noradrenergic	JJ	I-NP	O
fibers	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
motoneurons	NNS	I-NP	O
.	.	O	O

Cerebral	JJ	B-NP	B
sinus	NN	I-NP	I
thrombosis	NN	I-NP	I
as	IN	B-PP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
hazard	NN	I-NP	O
of	IN	B-PP	O
antifibrinolytic	JJ	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
menorrhagia	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
superior	JJ	B-NP	O
sagittal	JJ	I-NP	B
and	CC	I-NP	I
left	JJ	I-NP	I
transverse	JJ	I-NP	I
sinus	NN	I-NP	I
thrombosis	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
prolonged	VBN	B-NP	O
epsilon	NN	I-NP	O
-	HYPH	B-NP	O
aminocaproic	JJ	I-NP	O
acid	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
menorrhagia	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
antifibrinolytic	JJ	I-NP	O
agent	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
menorrhagia	NN	B-NP	B
to	TO	B-VP	O
promote	VB	I-VP	O
clotting	NN	B-NP	O
and	CC	O	O
reduce	VB	B-VP	O
blood	NN	B-NP	B
loss	NN	I-NP	I
.	.	O	O

Although	IN	B-SBAR	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
thromboembolic	JJ	B-NP	B
disease	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
epsilon	NN	B-NP	O
-	HYPH	B-NP	O
aminocaproic	JJ	I-NP	O
acid	NN	I-NP	O
,	,	O	O
cerebral	JJ	B-NP	B
sinus	NN	I-NP	I
thrombosis	NN	I-NP	I
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
described	VBN	I-VP	O
.	.	O	O

Careful	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
epsilon	NN	B-NP	O
-	HYPH	B-NP	O
aminocaproic	JJ	I-NP	O
acid	NN	I-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
.	.	O	O

Hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
complicating	VBG	B-VP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
serious	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cyclophosphamide	NN	I-NP	O
therapy	NN	I-NP	O
administered	VBN	B-VP	O
before	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
standard	JJ	B-NP	O
practice	NN	I-NP	O
at	IN	B-PP	O
our	PRP$	B-NP	O
institution	NN	I-NP	O
,	,	O	O
patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
scheduled	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
a	DT	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplant	NN	I-NP	O
are	VBP	B-VP	O
treated	VBN	I-VP	O
prophylactically	RB	B-ADVP	O
with	IN	B-PP	O
forced	VBN	B-NP	O
hydration	NN	I-NP	O
and	CC	I-NP	O
bladder	NN	I-NP	O
irrigation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
an	DT	B-NP	O
attempt	NN	I-NP	O
to	TO	B-VP	O
obviate	VB	I-VP	O
the	DT	B-NP	O
inconvenience	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
irrigation	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
feasibility	NN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
uroprophylaxis	NN	B-NP	O
with	IN	B-PP	O
mesna	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
neutralizes	VBZ	B-VP	O
the	DT	B-NP	O
hepatic	JJ	I-NP	O
metabolite	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
that	WDT	B-NP	O
causes	VBZ	B-VP	O
hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
standard	JJ	B-NP	O
prophylaxis	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
symptomatic	JJ	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
mesna	NN	B-NP	O
uroprophylaxis	NN	I-NP	O
before	IN	B-PP	O
allogeneic	JJ	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
had	VBD	B-VP	O
severe	JJ	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
this	DT	B-NP	O
suboptimal	JJ	I-NP	O
result	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
resumed	VBD	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
irrigation	NN	I-NP	O
and	CC	O	O
forced	VBN	B-NP	O
hydration	NN	I-NP	O
to	TO	B-VP	O
minimize	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
.	.	O	O

Reversal	NN	B-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
benzodiazepine	NN	I-NP	O
effects	NNS	I-NP	O
by	IN	B-PP	O
flumazenil	NN	B-NP	O
after	IN	B-PP	O
intravenous	JJ	B-NP	O
conscious	JJ	I-NP	O
sedation	NN	I-NP	O
with	IN	B-PP	O
diazepam	NN	B-NP	O
and	CC	I-NP	O
opioids	NNS	I-NP	O
:	:	O	O
report	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
multicenter	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
Flumazenil	NNP	I-NP	O
in	IN	B-PP	O
Intravenous	JJ	B-NP	O
Conscious	JJ	I-NP	O
Sedation	NN	I-NP	O
with	IN	B-PP	O
Diazepam	NNP	B-NP	O
Multicenter	NNP	I-NP	O
Study	NNP	I-NP	O
Group	NNP	I-NP	O
II	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
benzodiazepine	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
flumazenil	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
multicenter	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Flumazenil	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
(	(	O	O
mean	JJ	B-NP	O
dose	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intravenously	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
given	VBN	I-VP	O
diazepam	NN	B-NP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
opioid	JJ	I-NP	O
(	(	O	O
fentanyl	NN	B-NP	O
,	,	O	O
meperidine	NN	B-NP	O
,	,	O	O
or	CC	O	O
morphine	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
and	CC	I-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
conscious	JJ	I-NP	O
sedation	NN	I-NP	O
for	IN	B-PP	O
diagnostic	JJ	B-NP	O
or	CC	I-NP	O
therapeutic	JJ	I-NP	O
surgical	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
group	NN	I-NP	O
assessable	JJ	B-ADJP	O
for	IN	B-PP	O
efficacy	NN	B-NP	O
comprised	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
flumazenil	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
given	VBN	B-VP	O
placebo	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
flumazenil	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
placebo	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
completely	RB	B-ADVP	O
awake	NN	B-NP	O
and	CC	I-NP	O
alert	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
indicated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
score	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Observer	NNP	I-NP	O
s	VBZ	B-VP	O
Assessment	NNP	B-NP	O
of	IN	B-PP	O
Alertness	NN	B-NP	O
/	SYM	I-NP	O
Sedation	NN	I-NP	O
Scale	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
who	WP	B-NP	O
attained	VBD	B-VP	O
a	DT	B-NP	O
score	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
assessment	NN	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
alertness	NN	B-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
assessment	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Flumazenil	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
also	RB	B-ADVP	O
performed	VBD	B-VP	O
significantly	RB	B-ADJP	O
better	JJR	I-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
Finger	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
Nose	NN	I-NP	O
Test	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
recall	NN	I-NP	O
of	IN	B-PP	O
pictures	NNS	B-NP	O
shown	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
assessment	NN	I-NP	O
.	.	O	O

Flumazenil	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
reported	VBN	B-VP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
flumazenil	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
placebo	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
drug	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
adverse	JJ	I-NP	O
experiences	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
nausea	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
flumazenil	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
nausea	NN	B-NP	B
and	CC	I-NP	O
injection	NN	I-NP	O
-	HYPH	B-NP	O
site	NN	I-NP	O
pain	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Flumazenil	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
promptly	RB	I-VP	O
reverse	VB	I-VP	O
sedation	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
diazepam	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
opioids	NNS	B-NP	O
.	.	O	O

Hepatic	JJ	B-NP	O
adenomas	NNS	I-NP	B
and	CC	O	O
focal	JJ	B-NP	B
nodular	JJ	I-NP	I
hyperplasia	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
in	IN	B-PP	O
young	JJ	B-NP	O
women	NNS	I-NP	O
on	IN	B-PP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
:	:	O	O
case	NN	B-NP	O
reports	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	O
adenoma	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
focal	JJ	B-NP	B
nodular	JJ	I-NP	I
hyperplasia	NN	I-NP	I
presumably	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
,	,	O	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Special	JJ	B-NP	O
reference	NN	I-NP	O
is	VBZ	B-VP	O
made	VBN	I-VP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
clinical	JJ	I-NP	O
presentation	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
totally	RB	B-ADJP	O
asymptomatic	JJ	I-ADJP	O
.	.	O	O

Liver	NN	B-NP	O
-	HYPH	I-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
are	VBP	B-VP	O
of	IN	B-PP	O
little	JJ	B-NP	O
diagnostic	JJ	I-NP	O
value	NN	I-NP	O
,	,	O	O
but	CC	O	O
valuable	JJ	B-NP	O
information	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
both	CC	O	O
liver	NN	B-NP	O
scanning	NN	I-NP	O
and	CC	O	O
hepatic	JJ	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

Histologic	JJ	B-NP	O
differences	NNS	I-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
similarities	NNS	I-NP	O
between	IN	B-PP	O
hepatic	JJ	B-NP	O
adenoma	NN	I-NP	B
and	CC	O	O
focal	JJ	B-NP	B
nodular	JJ	I-NP	I
hyperplasia	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Arterial	JJ	B-NP	O
thromboembolism	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
systemic	JJ	B-NP	O
heparin	NN	I-NP	O
therapy	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
complication	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
.	.	O	O

Arterial	JJ	B-NP	O
thromboembolism	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
recognized	VBN	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	O
heparin	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Characteristic	JJ	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
entity	NN	I-NP	O
is	VBZ	B-VP	O
arterial	JJ	B-NP	B
occlusion	NN	I-NP	I
by	IN	B-PP	O
platelet	NN	B-NP	O
-	HYPH	I-NP	O
fibrin	NN	I-NP	O
thrombi	NN	I-NP	B
with	IN	B-PP	O
distal	JJ	B-NP	O
ischemia	NN	I-NP	B
occurring	VBG	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
preceded	VBN	B-VP	O
by	IN	B-PP	O
profound	JJ	B-NP	O
thrombocytopenia	NN	I-NP	B
with	IN	B-PP	O
platelet	NN	B-NP	O
counts	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
cubic	JJ	B-NP	O
millimeter	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinically	RB	I-NP	O
apparent	JJ	I-NP	O
occlusion	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
gastrointestinal	JJ	B-NP	B
and	CC	I-NP	I
musculoskeletal	JJ	I-NP	I
symptoms	NNS	I-NP	I
that	WDT	B-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
ischemic	JJ	B-ADJP	B
in	IN	B-PP	O
origin	NN	B-NP	O
,	,	O	O
and	CC	O	O
might	MD	B-VP	O
serve	VB	I-VP	O
to	TO	I-VP	O
warn	VB	I-VP	O
the	DT	B-NP	O
clinician	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
complications	NNS	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
phenomena	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
recent	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
common	JJ	I-NP	O
factor	NN	I-NP	O
relating	VBG	B-VP	O
thromboembolism	NN	B-NP	B
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
is	VBZ	B-VP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
platelet	NN	I-NP	B
aggregation	NN	I-NP	I
.	.	O	O

Appropriate	JJ	B-NP	O
treatment	NN	I-NP	O
consists	VBZ	B-VP	O
of	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
,	,	O	O
and	CC	O	O
anticoagulation	NN	B-NP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
warfarin	NN	I-NP	O
if	IN	B-SBAR	O
necessary	JJ	B-ADJP	O
.	.	O	O

Vascular	JJ	B-NP	O
procedures	NNS	I-NP	O
are	VBP	B-VP	O
performed	VBN	I-VP	O
as	IN	B-SBAR	O
indicated	VBN	B-VP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
prognosis	NN	I-NP	O
for	IN	B-PP	O
transplant	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survivors	NNS	I-NP	O
of	IN	B-PP	O
paracetamol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
prognosis	NN	I-NP	O
for	IN	B-PP	O
transplant	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survivors	NNS	I-NP	O
of	IN	B-PP	O
paracetamol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
remains	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

To	TO	B-VP	O
examine	VB	I-VP	O
whether	IN	B-SBAR	O
paracetamol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
increases	VBZ	B-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
mortality	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
followed	VBD	B-VP	O
up	RP	B-PRT	O
all	DT	B-NP	O
transplant	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survivors	NNS	I-NP	O
of	IN	B-PP	O
paracetamol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
injury	NN	I-NP	I
,	,	O	O
hospitalized	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
Danish	JJ	I-NP	O
national	JJ	I-NP	O
referral	JJ	I-NP	O
centre	NN	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
age	NN	B-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
mortality	NN	I-NP	O
rates	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
post	AFX	O	O
-	HYPH	O	O
discharge	NN	B-NP	O
through	IN	B-PP	O
num	CD	B-NP	O
between	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
the	DT	B-NP	O
liver	NN	I-NP	B
injury	NN	I-NP	I
led	VBD	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
and	CC	O	O
those	DT	B-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
it	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	O	O
.	.	O	O

We	PRP	B-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
average	NN	B-NP	O
,	,	O	O
age	NN	B-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
mortality	NN	I-NP	O
rates	NNS	I-NP	O
were	VBD	B-VP	O
slightly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
whose	WP$	B-NP	O
paracetamol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
liver	NN	I-NP	B
injury	NN	I-NP	I
had	VBD	B-VP	O
caused	VBN	I-VP	O
an	DT	B-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
association	NN	I-NP	O
was	VBD	B-VP	O
age	NN	B-NP	O
-	HYPH	B-PP	O
dependent	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
survivors	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
died	VBD	B-VP	O
of	IN	B-PP	O
liver	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
whereas	IN	O	O
suicides	NNS	B-NP	O
were	VBD	B-VP	O
frequent	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
speak	VBP	B-VP	O
against	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

More	RBR	B-ADVP	O
likely	JJ	I-ADVP	O
,	,	O	O
the	DT	B-NP	O
elevated	JJ	I-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
ratio	NN	I-NP	O
resulted	VBD	B-VP	O
from	IN	B-PP	O
incomplete	JJ	B-NP	O
adjustment	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
greater	JJR	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
substance	NN	B-NP	B
abuse	NN	I-NP	I
among	IN	B-PP	O
survivors	NNS	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Paracetamol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
mortality	NN	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
may	MD	B-VP	O
be	VB	I-VP	O
justified	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	B
failure	NN	I-NP	I
,	,	O	O
but	CC	B-PP	O
not	RB	I-PP	O
by	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	B
failure	NN	I-NP	I
itself	PRP	B-NP	O
.	.	O	O

Serotonin	NN	B-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
gene	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
Japanese	JJ	I-NP	O
population	NN	I-NP	O
.	.	O	O

Altered	VBN	B-NP	O
serotonergic	JJ	I-NP	O
neural	JJ	I-NP	O
transmission	NN	I-NP	O
is	VBZ	B-VP	O
hypothesized	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
susceptibility	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
psychotic	JJ	B-NP	B
disorders	NNS	I-NP	I
such	JJ	B-PP	O
as	IN	I-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
serotonin	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT6	NN	I-NP	O
)	)	O	O
receptor	NN	B-NP	O
is	VBZ	B-VP	O
therapeutically	RB	I-VP	O
targeted	VBN	I-VP	O
by	IN	B-PP	O
several	JJ	B-NP	O
second	JJ	I-NP	O
generation	NN	I-NP	O
antipsychotics	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
clozapine	NN	B-NP	O
and	CC	I-NP	O
olanzapine	NN	I-NP	O
,	,	O	O
and	CC	O	O
d	NN	B-NP	O
-	HYPH	B-NP	O
amphetamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperactivity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
is	VBZ	B-VP	O
corrected	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT6	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
disrupted	VBN	I-NP	O
prepulse	NN	I-NP	O
inhibition	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
amphetamine	NN	I-NP	O
or	CC	I-NP	O
phencyclidine	NN	I-NP	O
was	VBD	B-VP	O
restored	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT6	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
animal	NN	I-NP	O
study	NN	I-NP	O
using	VBG	B-VP	O
rats	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
animal	JJ	I-NP	O
models	NNS	I-NP	O
were	VBD	B-VP	O
considered	VBN	I-VP	O
to	TO	B-VP	O
reflect	VB	I-VP	O
the	DT	B-NP	O
positive	JJ	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
above	JJ	I-NP	O
evidence	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
altered	VBN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT6	NN	I-NP	O
receptors	NNS	I-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
psychotic	JJ	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
(	(	O	O
METH	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
are	VBP	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
paranoid	JJ	B-NP	B
type	NN	I-NP	I
schizophrenia	NN	I-NP	I
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
conducted	VBD	B-VP	O
an	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
association	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT6	NN	I-NP	O
gene	NN	I-NP	O
(	(	O	O
HTR6	NN	B-NP	O
)	)	O	O
with	IN	B-PP	O
METH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
.	.	O	O

Using	VBG	B-VP	O
num	CD	B-NP	O
tagging	VBG	I-NP	O
SNPs	NNS	I-NP	O
(	(	O	O
rs6693503	NN	B-NP	O
,	,	O	O
rs1805054	NN	B-NP	O
,	,	O	O
rs4912138	NN	B-NP	O
,	,	O	O
rs3790757	NN	B-NP	O
and	CC	O	O
rs9659997	NN	B-NP	O
)	)	O	O
,	,	O	O
we	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
genetic	JJ	I-NP	O
association	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
case	NN	O	O
-	HYPH	O	O
control	NN	B-NP	O
samples	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
METH	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
Japanese	JJ	I-NP	O
population	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
age	NN	I-NP	O
and	CC	I-NP	O
sex	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
subjects	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
from	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
methamphetamine	NN	I-NP	O
dependence	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

rs6693503	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
METH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
allele	NN	I-NP	O
/	SYM	B-NP	O
genotype	NN	I-NP	O
-	HYPH	B-NP	O
wise	JJ	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
association	NN	I-NP	O
remained	VBD	B-VP	O
significant	JJ	B-ADJP	O
after	IN	B-SBAR	O
Bonferroni	NNP	B-NP	O
correction	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
haplotype	NN	I-NP	O
-	HYPH	B-NP	O
wise	JJ	I-NP	O
analysis	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
detected	VBD	B-VP	O
an	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
markers	NNS	I-NP	O
(	(	O	O
rs6693503	NN	B-NP	O
and	CC	O	O
rs1805054	NN	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
markers	NNS	I-NP	O
(	(	O	O
rs6693503	NN	B-NP	O
,	,	O	O
rs1805054	NN	B-NP	O
and	CC	O	O
rs4912138	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
HTR6	NN	B-NP	O
and	CC	I-NP	O
METH	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

HTR6	NN	B-NP	O
may	MD	B-VP	O
play	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
Japanese	JJ	I-NP	O
population	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
increasing	VBG	B-VP	O
intraperitoneal	JJ	B-NP	O
infusion	NN	I-NP	O
rates	NNS	I-NP	O
on	IN	B-PP	O
bupropion	NN	B-NP	O
hydrochloride	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
if	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
input	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
incidence	NN	B-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
,	,	O	O
since	IN	B-SBAR	O
different	JJ	B-NP	O
controlled	VBN	I-NP	O
release	NN	I-NP	O
formulations	NNS	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
release	NN	I-NP	O
the	DT	B-NP	O
active	JJ	I-NP	O
drug	NN	I-NP	O
at	IN	B-PP	O
different	JJ	B-NP	O
rates	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
varying	VBG	B-VP	O
the	DT	B-NP	O
intraperitoneal	JJ	I-NP	O
infusion	NN	I-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
HCl	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
known	JJ	I-NP	O
convulsive	JJ	I-NP	B
dose	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
CD50	NN	B-NP	O
)	)	O	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
Swiss	JJ	I-NP	O
albino	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mice	NNS	I-NP	O
,	,	O	O
approximately	RB	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
and	CC	O	O
weighing	VBG	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
bupropion	NN	B-NP	O
HCl	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
treatment	NN	I-NP	O
by	IN	B-PP	O
intraperitoneal	JJ	O	O
(	(	O	O
IP	JJ	B-ADJP	O
)	)	O	O
administration	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
animals	NNS	I-NP	O
per	IN	B-PP	O
group	NN	B-NP	O
)	)	O	O
.	.	O	O

Bupropion	NN	B-NP	O
HCl	NN	I-NP	O
was	VBD	B-VP	O
infused	VBN	I-VP	O
through	IN	B-PP	O
a	DT	B-NP	O
surgically	RB	I-NP	O
implanted	VBN	I-NP	O
IP	NN	I-NP	O
dosing	NN	I-NP	O
catheter	NN	I-NP	O
with	IN	B-PP	O
infusions	NNS	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
,	,	O	O
time	NN	B-NP	O
of	IN	B-PP	O
onset	NN	B-NP	O
,	,	O	O
duration	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
convulsions	NNS	I-NP	B
or	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
convulsions	NNS	B-NP	B
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
IP	NN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
HCl	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
by	IN	B-PP	O
bolus	NN	B-NP	O
injection	NN	I-NP	O
induced	VBD	B-VP	O
convulsions	NNS	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
mice	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
convulsing	VBG	B-VP	O
mice	NNS	B-NP	O
)	)	O	O
in	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Logistic	JJ	B-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
infusion	NN	B-NP	O
time	NN	I-NP	O
was	VBD	B-VP	O
significant	JJ	B-ADJP	O
and	CC	O	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
IP	NN	I-NP	O
infusion	NN	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
HCl	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduced	VBD	B-VP	O
odds	NNS	B-NP	O
of	IN	B-PP	O
convulsions	NNS	B-NP	B
at	IN	B-PP	O
infusion	NN	B-NP	O
times	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
bolus	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
infusion	NN	B-NP	O
time	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
further	JJ	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
odds	NNS	I-NP	O
of	IN	B-PP	O
convulsions	NNS	B-NP	B
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
demonstration	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
inverse	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
infusion	NN	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
and	CC	I-NP	O
convulsive	JJ	I-NP	B
dose	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
convulsions	NNS	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
novel	JJ	B-ADJP	O
.	.	O	O

Detailed	JJ	B-NP	O
spectral	JJ	I-NP	O
profile	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
penicillin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
epileptiform	NN	I-NP	B
activity	NN	I-NP	I
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Penicillin	NN	B-NP	O
model	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
epilepsy	NN	B-NP	B
research	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
portray	VB	I-VP	O
a	DT	B-NP	O
detailed	JJ	I-NP	O
spectral	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
penicillin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
epileptiform	NN	I-NP	B
activity	NN	I-NP	I
in	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
basal	JJ	B-NP	O
brain	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
anesthetized	VBN	I-VP	O
with	IN	B-PP	O
i.p.	JJ	B-NP	O
urethane	NN	I-NP	O
and	CC	O	O
connected	VBN	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
electrocorticogram	NN	I-NP	O
setup	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
a	DT	B-NP	O
short	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
basal	JJ	B-NP	O
activity	NN	I-NP	O
recording	NN	I-NP	O
,	,	O	O
epileptic	JJ	B-NP	B
focus	NN	I-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
injecting	VBG	B-VP	O
400IU	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
microl	NN	I-NP	O
penicillin	NN	I-NP	O
-	HYPH	B-NP	O
G	NN	I-NP	O
potassium	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
lateral	JJ	I-NP	O
ventricle	NN	I-NP	O
while	IN	B-SBAR	O
the	DT	B-NP	O
cortical	JJ	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
continuously	RB	I-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Basal	JJ	B-NP	O
activity	NN	I-NP	O
,	,	O	O
latent	JJ	B-NP	O
period	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
penicillin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
epileptiform	NN	I-NP	B
activity	NN	I-NP	I
periods	NNS	I-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
analyzed	VBN	I-VP	O
using	VBG	B-VP	O
both	CC	O	O
conventional	JJ	B-NP	O
methods	NNS	I-NP	O
and	CC	O	O
spectral	JJ	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

Spectral	JJ	B-NP	O
analyses	NNS	I-NP	O
were	VBD	B-VP	O
conducted	VBN	I-VP	O
by	IN	B-PP	O
dividing	VBG	B-VP	O
the	DT	B-NP	O
whole	JJ	I-NP	O
spectrum	NN	I-NP	O
into	IN	B-PP	O
different	JJ	B-NP	O
frequency	NN	I-NP	O
bands	NNS	I-NP	O
including	VBG	B-PP	O
delta	NN	B-NP	O
,	,	O	O
theta	NN	B-NP	O
(	(	O	O
slow	JJ	B-ADJP	O
and	CC	O	O
fast	JJ	B-ADJP	O
)	)	O	O
,	,	O	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
sigma	SYM	B-NP	O
,	,	O	O
beta	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
gamma	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
)	)	O	O
bands	NNS	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
most	RBS	I-NP	O
affected	JJ	I-NP	O
frequency	NN	I-NP	O
bands	NNS	I-NP	O
were	VBD	B-VP	O
delta	SYM	B-ADJP	O
,	,	O	O
theta	SYM	B-NP	O
,	,	O	O
beta	SYM	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
gamma	SYM	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
bands	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
epileptiform	NN	I-NP	B
activity	NN	I-NP	I
and	CC	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
marked	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
spectral	JJ	B-NP	O
densities	NNS	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
investigated	VBN	I-NP	O
episodes	NNS	I-NP	O
(	(	O	O
basal	JJ	B-NP	O
activity	NN	I-NP	O
,	,	O	O
latent	JJ	B-NP	O
period	NN	I-NP	O
and	CC	I-NP	O
epileptiform	NN	I-NP	B
activity	NN	I-NP	I
)	)	O	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
may	MD	B-VP	O
help	VB	I-VP	O
to	TO	I-VP	O
analyze	VB	I-VP	O
novel	JJ	B-NP	O
data	NNS	I-NP	O
obtained	VBN	B-VP	O
using	VBG	B-VP	O
similar	JJ	B-NP	O
experimental	JJ	I-NP	O
models	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
simple	JJ	I-NP	O
analysis	NN	I-NP	O
method	NN	I-NP	O
described	VBN	B-VP	O
here	RB	B-ADVP	O
can	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
similar	JJ	B-NP	O
studies	NNS	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
basic	JJ	I-NP	O
neuronal	JJ	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
or	CC	I-NP	O
other	JJ	I-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
epilepsies	NNS	I-NP	B
.	.	O	O

High	JJ	B-NP	O
dose	NN	I-NP	O
dexmedetomidine	NN	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
sole	JJ	I-NP	O
sedative	NN	I-NP	O
for	IN	B-PP	O
pediatric	JJ	B-NP	O
MRI	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
large	JJ	I-NP	O
-	HYPH	I-NP	O
scale	NN	I-NP	O
retrospective	JJ	I-NP	O
review	NN	I-NP	O
evaluates	VBZ	B-VP	O
the	DT	B-NP	O
sedation	NN	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
dexmedetomidine	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
hemodynamic	JJ	I-NP	O
responses	NNS	I-NP	O
,	,	O	O
efficacy	NN	B-NP	O
and	CC	O	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
dexmedetomidine	NN	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
sole	JJ	I-NP	O
sedative	NN	I-NP	O
for	IN	B-PP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
MRI	NN	B-NP	O
)	)	O	O
studies	NNS	B-NP	O
.	.	O	O

Dexmedetomidine	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
at	IN	B-PP	O
our	PRP$	B-NP	O
institution	NN	I-NP	O
since	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-VP	O
provide	VB	I-VP	O
sedation	NN	B-NP	O
for	IN	B-PP	O
pediatric	JJ	B-NP	O
radiological	JJ	I-NP	O
imaging	NN	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

Over	IN	B-PP	O
time	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
effective	JJ	I-NP	O
protocol	NN	I-NP	O
utilizing	VBG	B-VP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
dexmedetomidine	NN	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
sole	JJ	I-NP	O
sedative	JJ	I-NP	O
agent	NN	I-NP	O
has	VBZ	B-VP	O
evolved	VBN	I-VP	O
.	.	O	O

As	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ongoing	JJ	I-NP	O
Quality	NNP	I-NP	O
Assurance	NNP	I-NP	O
process	NN	I-NP	O
,	,	O	O
data	NNS	B-NP	O
on	IN	B-PP	O
all	DT	B-NP	O
sedations	NNS	I-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
monthly	JJ	B-ADJP	O
and	CC	O	O
protocols	NNS	B-NP	O
modified	VBN	B-VP	O
as	IN	B-PP	O
needed	VBN	B-VP	O
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
from	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
dexmedetomidine	NN	B-NP	O
for	IN	B-PP	O
MRI	NN	B-NP	O
sedation	NN	I-NP	O
from	IN	B-PP	O
April	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
April	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

Since	IN	B-PP	O
num	CD	B-NP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
loading	VBG	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
dexmedetomidine	NN	I-NP	O
protocol	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
microg.kg	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
infusion	NN	I-NP	O
rate	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
microg.kg	NN	I-NP	O
.h	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
sedation	NN	I-NP	O
protocol	NN	I-NP	O
progressively	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
successful	JJ	B-NP	O
sedation	NN	I-NP	O
(	(	O	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
complete	VB	I-VP	O
the	DT	B-NP	O
imaging	NN	I-NP	O
study	NN	I-NP	O
)	)	O	O
when	WRB	B-ADVP	O
using	VBG	B-VP	O
dexmedetomidine	NN	B-NP	O
alone	RB	B-ADVP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
reducing	VBG	B-VP	O
the	DT	B-NP	O
requirement	NN	I-NP	O
for	IN	B-PP	O
adjuvant	JJ	B-NP	O
pentobarbital	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
event	NN	I-NP	O
of	IN	B-PP	O
sedation	NN	B-NP	O
failure	NN	I-NP	O
with	IN	B-PP	O
dexmedetomidine	NN	B-NP	O
alone	RB	B-ADVP	O
and	CC	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
recovery	NN	I-NP	O
time	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
dexmedetomidine	NN	B-NP	O
sedation	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
bradycardia	NN	B-NP	B
,	,	O	O
all	DT	B-NP	O
concomitant	JJ	I-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
blood	NN	I-NP	O
pressures	NNS	I-NP	O
were	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
-	HYPH	B-NP	O
adjusted	VBN	I-NP	O
normal	JJ	I-NP	O
range	NN	I-NP	O
and	CC	I-NP	O
oxygen	NN	I-NP	O
saturations	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
or	CC	O	O
higher	JJR	B-ADVP	O
.	.	O	O

Dexmedetomidine	NN	B-NP	O
in	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
provides	VBZ	B-VP	O
adequate	JJ	B-NP	O
sedation	NN	I-NP	O
for	IN	B-PP	O
pediatric	JJ	B-NP	O
MRI	NN	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
use	NN	B-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
dexmedetomidine	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
outside	IN	B-PP	O
the	DT	B-NP	O
established	JJ	I-NP	O
awake	NN	I-NP	O
norms	NNS	I-NP	O
,	,	O	O
this	DT	B-NP	O
deviation	NN	I-NP	O
is	VBZ	B-VP	O
generally	RB	B-ADVP	O
within	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
norms	NNS	B-NP	O
,	,	O	O
and	CC	O	O
is	VBZ	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
adverse	JJ	B-NP	O
sequelae	NNS	I-NP	O
.	.	O	O

Dexmedetomidine	NN	B-NP	O
is	VBZ	B-VP	O
useful	JJ	B-ADJP	O
as	IN	B-SBAR	O
the	DT	B-NP	O
sole	JJ	I-NP	O
sedative	NN	I-NP	O
for	IN	B-PP	O
pediatric	JJ	B-NP	O
MRI	NN	I-NP	O
.	.	O	O

Methamphetamine	NN	B-NP	O
causes	VBZ	B-VP	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
MAP	NN	I-NP	O
kinase	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
pathways	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brains	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
that	WDT	B-NP	O
display	VBP	B-VP	O
increased	VBN	B-NP	O
aggressiveness	NN	I-NP	B
.	.	O	O

Aggressive	JJ	B-NP	B
behaviors	NNS	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
suffer	VBP	B-VP	O
from	IN	B-PP	O
some	DT	B-NP	O
psychiatric	JJ	I-NP	B
disorders	NNS	I-NP	I
,	,	O	O
and	CC	O	O
are	VBP	B-VP	O
common	JJ	B-ADJP	O
in	IN	B-PP	O
methamphetamine	NN	B-NP	O
(	(	O	O
METH	NN	B-NP	O
)	)	O	O
abusers	NNS	B-NP	O
.	.	O	O

Herein	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
report	VBP	B-VP	O
that	IN	B-SBAR	O
multiple	JJ	B-NP	O
(	(	O	O
but	CC	O	O
not	RB	O	O
single	JJ	B-ADJP	O
)	)	O	O
injections	NNS	B-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
aggressiveness	NN	B-NP	B
in	IN	B-PP	O
male	JJ	B-NP	O
CD	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
aggressiveness	NN	B-NP	B
was	VBD	B-VP	O
not	RB	O	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
METH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
protein	NN	B-NP	O
expression	NN	I-NP	O
using	VBG	B-VP	O
antibody	NN	B-NP	O
microarrays	NNS	I-NP	O
and	CC	O	O
Western	JJ	B-NP	O
blotting	NN	I-NP	O
revealed	VBD	B-VP	O
differential	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
MAP	NN	B-NP	O
kinase	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
pathways	NNS	I-NP	O
after	IN	B-PP	O
multiple	JJ	B-NP	O
and	CC	I-NP	O
single	JJ	I-NP	O
METH	NN	I-NP	O
injections	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
decreases	NNS	I-NP	O
in	IN	B-PP	O
MEK1	NN	B-NP	O
,	,	O	O
Erk2p	NN	B-NP	O
,	,	O	O
GSK3alpha	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
MEK7	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striata	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
after	IN	B-PP	O
multiple	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
.	.	O	O

MEK1	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
also	RB	B-ADVP	O
after	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
,	,	O	O
but	CC	O	O
to	TO	B-PP	O
a	DT	B-NP	O
much	RB	I-NP	O
lesser	JJR	I-NP	O
degree	NN	I-NP	O
than	IN	B-PP	O
after	IN	B-PP	O
multiple	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
frontal	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
GSK3alpha	NN	B-NP	O
after	IN	B-PP	O
multiple	JJ	B-NP	O
(	(	O	O
but	CC	O	O
not	RB	O	O
single	JJ	B-ADJP	O
)	)	O	O
injections	NNS	B-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
MAP	NN	B-NP	O
kinase	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
pathways	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prefronto	AFX	I-NP	O
-	HYPH	I-NP	O
striatal	JJ	I-NP	O
circuitries	NNS	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
aggressive	JJ	B-NP	B
behaviors	NNS	I-NP	I
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Lamotrigine	NN	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
exacerbation	NN	B-NP	O
or	CC	B-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
myoclonus	NN	I-NP	B
in	IN	B-PP	O
idiopathic	JJ	B-NP	B
generalized	VBN	I-NP	I
epilepsies	NNS	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
idiopathic	JJ	B-NP	B
generalized	VBN	I-NP	I
epilepsies	NNS	I-NP	I
(	(	O	O
IGE	NN	B-NP	B
)	)	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
lamotrigine	NN	B-NP	O
(	(	I-NP	O
LTG	NN	I-NP	O
)	)	I-NP	O
experienced	JJ	I-NP	O
exacerbation	NN	I-NP	O
or	CC	I-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
myoclonic	JJ	B-NP	B
jerks	NNS	I-NP	I
(	(	O	O
MJ	NN	B-NP	B
)	)	O	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
LTG	NN	B-NP	O
exacerbated	VBD	B-VP	O
MJ	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
with	IN	B-PP	O
early	JJ	B-NP	O
aggravation	NN	I-NP	O
during	IN	B-PP	O
titration	NN	B-NP	O
.	.	O	O

MJ	NN	B-NP	B
disappeared	VBD	B-VP	O
when	WRB	B-ADVP	O
LTG	NN	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
LTG	NN	B-NP	O
exacerbated	VBD	B-VP	O
MJ	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
delayed	VBN	I-NP	O
but	CC	I-NP	O
more	RBR	I-NP	O
severe	JJ	I-NP	O
manner	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
myoclonic	JJ	B-NP	B
status	NN	I-NP	I
that	WDT	B-NP	O
only	RB	B-ADVP	O
ceased	VBD	B-VP	O
after	IN	B-PP	O
LTG	NN	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

rTMS	NN	B-NP	O
of	IN	B-PP	O
supplementary	JJ	B-NP	O
motor	NN	I-NP	O
area	NN	I-NP	O
modulates	VBZ	B-VP	O
therapy	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
neural	JJ	I-NP	O
mechanisms	NNS	I-NP	O
and	CC	I-NP	O
circuitry	NN	I-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
are	VBP	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

Using	VBG	B-VP	O
repetitive	JJ	B-NP	O
transcranial	JJ	I-NP	O
magnetic	JJ	I-NP	O
stimulation	NN	I-NP	O
(	(	O	O
rTMS	NN	B-NP	O
)	)	O	O
over	IN	B-PP	O
the	DT	B-NP	O
supplementary	JJ	I-NP	O
motor	NN	I-NP	O
area	NN	I-NP	O
(	(	O	O
SMA	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
Parkinson	NNP	I-NP	B
disease	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
authors	NNS	I-NP	O
investigated	VBD	B-VP	O
whether	IN	B-SBAR	O
modulation	NN	B-NP	O
of	IN	B-PP	O
SMA	NN	B-NP	O
excitability	NN	I-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
modification	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
dyskinetic	JJ	I-NP	B
state	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
continuous	JJ	B-NP	O
apomorphine	NN	I-NP	O
infusion.	NN	I-NP	O
rTMS	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
Hz	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
to	TO	B-VP	O
markedly	RB	I-VP	O
reduce	VB	I-VP	O
drug	NN	B-NP	B
-	HYPH	B-NP	I
induced	VBN	I-NP	I
dyskinesias	NNS	I-NP	I
,	,	O	O
whereas	IN	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
Hz	NN	I-NP	O
rTMS	NN	I-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
slight	JJ	I-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
.	.	O	O

Assessment	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
and	CC	I-NP	O
persistence	NN	I-NP	O
of	IN	B-PP	O
amnesia	NN	B-NP	B
during	IN	B-PP	O
procedural	JJ	B-NP	O
sedation	NN	I-NP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
patients	NNS	B-NP	O
s	NNS	I-NP	O
ability	NN	B-NP	O
to	TO	B-VP	O
repeat	VB	I-VP	O
and	CC	I-VP	O
recall	VB	I-VP	O
words	NNS	B-NP	O
presented	VBN	B-VP	O
to	TO	B-PP	O
them	PRP	B-NP	O
while	IN	B-SBAR	O
undergoing	VBG	B-VP	O
procedural	JJ	B-NP	O
sedation	NN	I-NP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
,	,	O	O
and	CC	O	O
correlate	VBP	B-VP	O
their	PRP$	B-NP	O
recall	NN	I-NP	O
with	IN	B-PP	O
their	PRP$	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
awareness	NN	B-NP	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
bispectral	JJ	B-NP	O
index	NN	I-NP	O
(	(	O	O
BIS	NN	B-NP	O
)	)	O	O
monitoring	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
intervention	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
consenting	VBG	B-VP	O
adult	JJ	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
procedural	JJ	B-NP	O
sedation	NN	I-NP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
between	IN	B-PP	O
December	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
October	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
.	.	O	O

BIS	NN	B-NP	O
monitoring	NN	I-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
starting	VBG	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
and	CC	O	O
continuing	VBG	B-VP	O
until	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
regained	VBN	I-VP	O
baseline	NN	B-NP	O
mental	JJ	I-NP	O
status	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
minute	JJ	I-NP	O
intervals	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
procedural	JJ	I-NP	O
sedation	NN	I-NP	O
,	,	O	O
until	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
regained	VBD	B-VP	O
baseline	NN	B-NP	O
mental	JJ	I-NP	O
status	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
word	NN	I-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
standardized	JJ	I-NP	O
list	NN	I-NP	O
was	VBD	B-VP	O
read	VBN	I-VP	O
aloud	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
asked	VBN	I-VP	O
to	TO	B-VP	O
immediately	RB	I-VP	O
repeat	VB	I-VP	O
the	DT	B-NP	O
word	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
investigator	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
the	DT	B-NP	O
word	NN	I-NP	O
was	VBD	B-VP	O
read	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
ability	NN	B-NP	O
to	TO	B-VP	O
repeat	VB	I-VP	O
the	DT	B-NP	O
word	NN	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
asked	VBN	I-VP	O
to	TO	I-VP	O
state	VB	I-VP	O
all	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
words	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
list	NN	I-NP	O
that	IN	B-SBAR	O
he	PRP	B-NP	O
or	CC	I-NP	O
she	PRP	I-NP	O
could	MD	B-VP	O
recall	VB	I-VP	O
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
last	JJ	I-NP	O
word	NN	I-NP	O
recalled	VBN	B-VP	O
from	IN	B-PP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
word	NN	I-NP	O
recalled	VBN	B-VP	O
from	IN	B-PP	O
after	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
was	VBD	B-VP	O
completed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
consenting	NN	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
;	:	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
excluded	VBN	I-VP	O
from	IN	B-PP	O
data	NNS	B-NP	O
analysis	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
protocol	NN	I-NP	O
violation	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
procedural	JJ	I-NP	O
sedations	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
(	(	O	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
standard	JJ	B-NP	O
deviation	NN	I-NP	O
)	)	O	O
time	NN	B-NP	O
of	IN	B-PP	O
data	NNS	B-NP	O
collection	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
initial	JJ	I-NP	O
(	(	O	O
preprocedure	JJ	B-ADJP	O
)	)	O	O
BIS	NN	B-NP	O
score	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
lowest	JJS	I-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
occurring	VBG	B-VP	O
during	IN	B-PP	O
these	DT	B-NP	O
procedural	JJ	I-NP	O
sedations	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
lowest	JJS	I-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
corresponding	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
to	TO	B-VP	O
immediately	RB	I-VP	O
repeat	VB	I-VP	O
words	NNS	B-NP	O
read	VB	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
list	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
highest	JJS	I-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
corresponding	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
inability	NN	I-NP	B
to	TO	B-VP	I
repeat	VB	I-VP	I
words	NNS	B-NP	I
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
corresponding	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
word	NN	I-NP	O
recalled	VBN	B-VP	O
from	IN	B-PP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sedation	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
corresponding	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
word	NN	I-NP	O
recalled	VBN	B-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
was	VBD	B-VP	O
completed	VBN	I-VP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
recalled	VBD	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
word	NN	I-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
read	VBN	I-VP	O
to	TO	B-PP	O
them	PRP	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
protocol	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
lowest	JJS	I-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
for	IN	B-PP	O
any	DT	B-NP	O
recalled	VBN	I-NP	O
word	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
words	NNS	I-NP	O
were	VBD	B-VP	O
recalled	VBN	I-VP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
corresponding	VBG	I-NP	O
BIS	NN	I-NP	O
score	NN	I-NP	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
BIS	NN	B-NP	O
scores	NNS	I-NP	O
during	IN	B-PP	O
which	WDT	B-NP	O
sedated	JJ	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
repeat	VB	I-VP	O
words	NNS	B-NP	O
read	VB	B-VP	O
to	TO	B-PP	O
them	PRP	B-NP	O
but	CC	O	O
are	VBP	B-VP	O
not	RB	O	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
subsequently	RB	I-VP	O
recall	VB	I-VP	O
these	DT	B-NP	O
words	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
recall	NN	I-NP	O
of	IN	B-PP	O
words	NNS	B-NP	O
repeated	VBN	B-VP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
procedural	JJ	B-NP	O
sedation	NN	I-NP	O
in	IN	B-PP	O
BIS	NN	B-NP	O
ranges	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
recall	NN	B-NP	O
after	IN	B-PP	O
procedural	JJ	B-NP	O
sedation	NN	I-NP	O
,	,	O	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
retrograde	JJ	B-NP	B
amnesia	NN	I-NP	I
.	.	O	O

Assessment	NN	B-NP	O
of	IN	B-PP	O
perinatal	JJ	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
and	CC	O	O
rubella	NN	B-NP	B
prevention	NN	I-NP	O
in	IN	B-PP	O
New	NNP	B-NP	O
Hampshire	NNP	I-NP	O
delivery	NN	I-NP	O
hospitals	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
current	JJ	B-NP	O
performance	NN	I-NP	O
on	IN	B-PP	O
recommended	VBN	B-NP	O
perinatal	JJ	I-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
and	CC	O	O
rubella	NN	B-NP	B
prevention	NN	I-NP	O
practices	NNS	I-NP	O
in	IN	B-PP	O
New	NNP	B-NP	O
Hampshire	NNP	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
extracted	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
paired	JJ	I-NP	O
mother	NN	I-NP	O
-	HYPH	O	O
infant	NN	B-NP	O
records	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
year	NN	I-NP	O
num	CD	I-NP	O
birth	NN	I-NP	O
cohort	NN	I-NP	O
in	IN	B-PP	O
New	NNP	B-NP	O
Hampshire	NNP	I-NP	O
s	VBZ	B-VP	O
num	CD	B-NP	O
delivery	NN	I-NP	O
hospitals	NNS	I-NP	O
.	.	O	O

Assessment	NN	B-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
following	NN	I-NP	O
:	:	O	O
prenatal	JJ	B-NP	O
screening	NN	I-NP	O
for	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
and	CC	O	O
rubella	NN	B-NP	B
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
vaccine	NN	I-NP	O
birth	NN	I-NP	O
dose	NN	I-NP	O
to	TO	B-PP	O
all	DT	B-NP	O
infants	NNS	I-NP	O
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
to	TO	B-PP	O
infants	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
born	VBN	I-VP	O
to	TO	B-PP	O
hepatitis	NN	B-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
mothers	NNS	I-NP	O
,	,	O	O
rubella	NN	B-NP	B
immunity	NN	I-NP	O
,	,	O	O
and	CC	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
in	IN	B-PP	O
-	HYPH	B-NP	O
hospital	NN	I-NP	O
postpartum	NN	I-NP	O
rubella	NN	I-NP	B
vaccine	NN	I-NP	O
to	TO	B-VP	O
rubella	VB	I-VP	B
nonimmune	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Prenatal	JJ	B-NP	O
screening	NN	I-NP	O
rates	NNS	I-NP	O
for	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
and	CC	O	O
rubella	NN	B-NP	B
were	VBD	B-VP	O
high	JJ	B-ADJP	O
.	.	O	O

Hepatitis	NN	B-NP	B
B	NN	I-NP	I
vaccine	NN	I-NP	O
birth	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
infants	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
infants	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
born	VBN	I-VP	O
to	TO	B-PP	O
hepatitis	NN	B-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
mothers	NNS	I-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
.	.	O	O

Multivariate	JJ	B-NP	O
logistic	JJ	I-NP	O
regression	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
month	NN	I-NP	O
of	IN	B-PP	O
delivery	NN	B-NP	O
and	CC	I-NP	O
infant	NN	I-NP	O
birth	NN	I-NP	O
weight	NN	I-NP	O
were	VBD	B-VP	O
independent	JJ	B-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
vaccination	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
infants	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
vaccinated	VBN	I-VP	O
in	IN	B-PP	O
January	NNP	B-NP	O
and	CC	I-NP	O
February	NNP	I-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
any	DT	B-NP	O
other	JJ	I-NP	O
months	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
proportion	NN	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
vaccinated	VBN	I-VP	O
in	IN	B-PP	O
December	NNP	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
.	.	O	O

Women	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
born	VBN	I-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
rubella	NN	B-NP	B
nonimmunity	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
-	HYPH	B-NP	O
hospital	NN	I-NP	O
postpartum	NN	I-NP	O
rubella	NN	I-NP	B
vaccine	NN	I-NP	O
administration	NN	I-NP	O
was	VBD	B-VP	O
documented	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
nonimmune	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
documents	VBZ	B-VP	O
good	JJ	B-NP	O
compliance	NN	I-NP	O
in	IN	B-PP	O
New	NNP	B-NP	O
Hampshire	NNP	I-NP	O
s	VBZ	B-VP	O
birthing	NN	B-NP	O
hospitals	NNS	I-NP	O
with	IN	B-PP	O
national	JJ	B-NP	O
guidelines	NNS	I-NP	O
for	IN	B-PP	O
perinatal	JJ	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
and	CC	O	O
rubella	NN	B-NP	B
prevention	NN	I-NP	O
and	CC	O	O
highlights	VBZ	B-VP	O
potential	JJ	B-NP	O
areas	NNS	I-NP	O
for	IN	B-PP	O
improvement	NN	B-NP	O
.	.	O	O

Expression	NN	B-NP	O
of	IN	B-PP	O
p300	NN	B-NP	O
protects	VBZ	B-VP	O
cardiac	JJ	B-NP	O
myocytes	NNS	I-NP	O
from	IN	B-PP	O
apoptosis	NN	B-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
tumor	NN	I-NP	B
agent	NN	I-NP	O
that	WDT	B-NP	O
represses	VBZ	B-VP	O
cardiac	JJ	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
and	CC	O	O
induces	VBZ	B-VP	O
myocardial	JJ	B-NP	O
cell	NN	I-NP	O
apoptosis	NN	I-NP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
depletes	VBZ	B-VP	O
cardiac	JJ	B-NP	O
p300	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
transcriptional	JJ	I-NP	O
coactivator	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
differentiated	VBN	I-NP	O
phenotype	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
myocytes	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
p300	NN	B-NP	O
in	IN	B-PP	O
protection	NN	B-NP	O
against	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
apoptosis	NN	I-NP	O
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

Transgenic	JJ	B-NP	O
mice	NNS	I-NP	O
overexpressing	VBG	B-VP	O
p300	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
and	CC	I-NP	O
wild	JJ	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
doxorubicin	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
transgenic	JJ	B-NP	O
mice	NNS	I-NP	O
exhibited	VBD	B-VP	O
higher	JJR	B-NP	O
survival	NN	I-NP	O
rate	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
more	JJR	B-NP	O
preserved	VBN	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
function	NN	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
sarcomeric	JJ	I-NP	O
actin	NN	I-NP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
induced	VBD	B-VP	O
myocardial	JJ	B-NP	O
cell	NN	I-NP	O
apoptosis	NN	I-NP	O
in	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
mice	NNS	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
transgenic	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Expression	NN	B-NP	O
of	IN	B-PP	O
p300	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
bcl	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
mdm	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
that	DT	B-NP	O
of	IN	B-PP	O
p53	NN	B-NP	O
or	CC	O	O
other	JJ	B-NP	O
members	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bcl	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
family	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
overexpression	NN	B-NP	O
of	IN	B-PP	O
p300	NN	B-NP	O
protects	VBZ	B-VP	O
cardiac	JJ	B-NP	O
myocytes	NNS	I-NP	O
from	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
apoptosis	NN	I-NP	O
and	CC	O	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
adult	JJ	B-NP	O
mice	NNS	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

Mitochondrial	JJ	B-NP	O
DNA	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
respiratory	JJ	I-NP	O
chain	NN	I-NP	O
products	NNS	I-NP	O
are	VBP	B-VP	O
defective	JJ	B-ADJP	O
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

Doxorubicin	NN	B-NP	O
induces	VBZ	B-VP	O
a	DT	B-NP	O
self	NN	I-NP	O
-	HYPH	O	O
perpetuating	VBG	B-VP	O
nephropathy	NN	B-NP	B
characterized	VBN	B-VP	O
by	IN	B-PP	O
early	JJ	B-NP	O
glomerular	JJ	I-NP	B
and	CC	I-NP	I
late	JJ	I-NP	I
-	HYPH	I-NP	I
onset	NN	I-NP	I
tubular	JJ	I-NP	I
lesions	NNS	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
lesions	NNS	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
doxorubicin	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
sacrificed	VBN	I-VP	O
either	CC	O	O
num	CD	B-NP	O
week	NN	I-NP	O
(	(	O	O
'short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
'	''	O	O
)	)	O	O
or	CC	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
(	(	O	O
'long	SYM	O	O
-	HYPH	O	O
term	NN	B-NP	O
'	''	O	O
)	)	O	O
following	VBG	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Additional	JJ	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
either	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
or	CC	O	O
num	CD	B-NP	O
h	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
euthanasia	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
.	.	O	O

Glomerular	JJ	B-NP	B
and	CC	I-NP	I
tubular	JJ	I-NP	I
injury	NN	I-NP	I
was	VBD	B-VP	O
monitored	VBN	I-VP	O
and	CC	O	O
correlated	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
or	CC	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	O
chain	NN	I-NP	O
components	NNS	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
quantified	VBD	B-VP	O
both	CC	O	O
nuclear	JJ	B-NP	O
and	CC	I-NP	O
mitochondrial	JJ	I-NP	O
DNA	NN	I-NP	O
(	(	O	O
mtDNA	NN	B-NP	O
)	)	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
superoxide	NN	B-NP	O
production	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
base	NN	I-NP	O
pair	NN	I-NP	O
common	JJ	I-NP	O
mtDNA	NN	I-NP	O
deletion	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
significant	JJ	B-NP	O
glomerular	JJ	I-NP	B
and	CC	I-NP	I
tubular	JJ	I-NP	I
lesions	NNS	I-NP	I
,	,	O	O
depressed	JJ	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
mtDNA	NN	B-NP	O
-	HYPH	B-NP	O
encoded	VBN	I-NP	O
NADH	NN	I-NP	O
dehydrogenase	NN	I-NP	O
and	CC	I-NP	O
cytochrome	NN	I-NP	O
-	HYPH	O	O
c	NN	B-NP	O
oxidase	NN	I-NP	O
(	(	O	O
COX	NN	B-NP	O
)	)	O	O
and	CC	O	O
increased	VBN	B-NP	O
citrate	NN	I-NP	O
synthase	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
expression	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mtDNA	NN	I-NP	O
-	HYPH	B-VP	O
encoded	VBN	B-NP	O
COX	NN	I-NP	O
subunit	NN	I-NP	O
I	PRP	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
and	CC	O	O
mtDNA	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
fewer	JJR	B-NP	O
tubular	JJ	I-NP	B
lesions	NNS	I-NP	I
,	,	O	O
but	CC	O	O
similar	JJ	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	B
lesions	NNS	I-NP	I
activity	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
all	DT	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
glomerular	JJ	B-NP	B
and	CC	I-NP	I
tubular	JJ	I-NP	I
injury	NN	I-NP	I
were	VBD	B-VP	O
inversely	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
mtDNA	NN	B-NP	O
levels	NNS	I-NP	O
,	,	O	O
mtDNA	NN	B-NP	O
-	HYPH	B-VP	O
encoded	VBN	B-NP	O
respiratory	JJ	I-NP	O
chain	NN	I-NP	O
activities	NNS	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mtDNA	NN	I-NP	O
-	HYPH	B-VP	O
encoded	VBN	B-NP	O
respiratory	JJ	I-NP	O
chain	NN	I-NP	O
subunit	NN	I-NP	O
COX	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
.	.	O	O

Injury	NN	B-NP	O
was	VBD	B-VP	O
positively	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
superoxide	NN	B-NP	O
production	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
nucleus	NN	B-NP	O
-	HYPH	O	O
encoded	VBN	B-VP	O
mitochondrial	JJ	B-NP	O
or	CC	I-NP	O
cytoplasmic	JJ	I-NP	O
enzymes	NNS	I-NP	O
.	.	O	O

Kidneys	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
group	NN	I-NP	O
showed	VBD	B-VP	O
more	JJR	B-NP	O
mtDNA	NN	I-NP	O
deletions	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
animals	NNS	I-NP	O
and	CC	O	O
these	DT	B-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
quantitative	JJ	B-NP	O
and	CC	I-NP	O
qualitative	JJ	I-NP	O
mtDNA	NN	I-NP	O
alterations	NNS	I-NP	O
through	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
mtDNA	NN	B-NP	O
-	HYPH	B-VP	O
encoded	VBN	B-NP	O
respiratory	JJ	I-NP	O
chain	NN	I-NP	O
function	NN	I-NP	O
and	CC	O	O
induction	NN	B-NP	O
of	IN	B-PP	O
superoxide	NN	B-NP	O
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
renal	JJ	I-NP	B
lesions	NNS	I-NP	I
.	.	O	O

Amphotericin	NN	B-NP	O
B	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
AIDS	NN	B-NP	B
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
multiple	JJ	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
activity	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
AIDS	NNP	I-NP	B
patent	NN	I-NP	O
following	VBG	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
African	JJ	I-NP	O
-	HYPH	B-NP	O
American	JJ	I-NP	O
man	NN	I-NP	O
experienced	VBD	B-VP	O
recurrent	JJ	B-NP	O
grand	JJ	I-NP	B
mal	JJ	I-NP	I
seizures	NNS	I-NP	I
during	IN	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
,	,	O	O
then	RB	B-ADVP	O
petit	VBP	B-VP	O
mal	JJ	B-NP	O
seizures	NNS	I-NP	B
as	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
drug	NN	I-NP	O
concentrations	NNS	I-NP	O
decreased	VBD	B-VP	O
with	IN	B-PP	O
time	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
concurrent	JJ	B-NP	O
medications	NNS	I-NP	O
included	VBD	B-VP	O
didanosine	NN	B-NP	O
,	,	O	O
hydroxyzine	NN	B-NP	O
,	,	O	O
promethazine	NN	B-NP	O
,	,	O	O
hydrocortisone	NN	B-NP	O
,	,	O	O
and	CC	O	O
prochlorperazine	NN	B-NP	O
.	.	O	O

Despite	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
and	CC	I-NP	O
lorazepam	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
persisted	VBD	B-VP	O
and	CC	O	O
occurred	VBD	B-VP	O
only	RB	B-ADVP	O
during	IN	B-PP	O
amphotercin	NN	B-NP	O
B	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

AIDS	NN	B-NP	B
and	CC	I-NP	O
cryptococcal	JJ	I-NP	B
meningitis	NN	I-NP	I
,	,	O	O
both	DT	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
,	,	O	O
can	MD	B-VP	O
potentially	RB	I-VP	O
cause	VB	I-VP	O
seizures	NNS	B-NP	B
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	B
abuse	NN	I-NP	I
;	:	O	O
alcohol	NN	B-NP	O
intake	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
withdrawal	NN	B-NP	O
can	MD	B-VP	O
also	RB	I-VP	O
cause	VB	I-VP	O
seizures	NNS	B-NP	B
.	.	O	O

Didanosine	NN	B-NP	O
also	RB	B-ADVP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
inducing	VBG	B-VP	O
seizures	NNS	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
other	JJ	I-NP	O
potential	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
were	VBD	B-VP	O
ruled	VBN	I-VP	O
out	RP	B-PRT	O
.	.	O	O

The	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
AIDS	NNP	I-NP	B
patient	NN	I-NP	O
.	.	O	O

Amphotericin	NN	B-NP	O
B	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
probable	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

To	TO	B-PP	O
date	NN	B-NP	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
but	CC	O	O
healthcare	NN	B-NP	O
providers	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
rare	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Therapeutic	JJ	B-NP	O
drug	NN	I-NP	O
monitoring	NN	I-NP	O
of	IN	B-PP	O
tobramycin	NN	B-NP	O
:	:	O	O
once	RB	B-ADJP	O
-	HYPH	I-ADJP	O
daily	JJ	B-ADJP	O
versus	IN	B-PP	O
twice	RB	B-NP	O
-	HYPH	I-NP	O
daily	JJ	I-NP	O
dosage	NN	I-NP	O
schedules	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
dosage	NN	B-NP	O
regimen	NN	I-NP	O
(	(	O	O
once	RB	B-ADVP	O
-	HYPH	B-ADVP	O
daily	RB	B-ADVP	O
vs.	IN	B-PP	O
twice	RB	B-NP	O
-	HYPH	I-NP	O
daily	RB	B-ADVP	O
)	)	O	O
of	IN	B-PP	O
tobramicyn	NN	B-NP	O
on	IN	B-PP	O
steady	JJ	B-NP	O
-	HYPH	I-NP	O
state	NN	I-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
toxicity	NN	B-NP	B
.	.	O	O

Patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
i.v.	JJ	B-NP	O
tobramycin	NN	I-NP	O
were	VBD	B-VP	O
randomised	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Group	NN	B-NP	O
OD	NN	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
once	RB	I-NP	O
-	HYPH	I-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
tobramycin	NN	B-NP	O
and	CC	I-NP	O
group	NN	I-NP	O
TD	NN	I-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
dose	NN	I-NP	O
divided	VBN	B-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
daily	RB	B-ADVP	O
.	.	O	O

Tobramycin	NN	B-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
(	(	O	O
peak	NN	B-NP	O
and	CC	O	O
trough	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
enzyme	NN	B-NP	O
multiplied	JJ	I-NP	O
immunoassay	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
renal	JJ	I-NP	O
and	CC	I-NP	O
auditory	JJ	I-NP	O
functions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
before	IN	B-ADVP	O
,	,	O	O
during	IN	B-PP	O
and	CC	O	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
sex	NN	B-NP	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
body	NN	B-NP	O
weight	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
or	CC	O	O
cumulative	JJ	B-NP	O
dose	NN	I-NP	O
.	.	O	O

Trough	NN	B-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
<	SYM	B-ADJP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Peak	NN	B-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
>	SYM	B-ADJP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
OD	NN	I-NP	O
group	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
TD	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Mean	JJ	B-NP	O
peak	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
markedly	RB	B-ADJP	O
different	JJ	I-ADJP	O
:	:	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
in	IN	B-PP	O
OD	NN	B-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
in	IN	B-PP	O
TD	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
pharmacokinetics	NNS	I-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
:	:	O	O
Ke	NNP	B-NP	O
,	,	O	O
,	,	O	O
t1	NN	B-NP	O
/	SYM	B-VP	O
num	CD	B-NP	O
,	,	O	O
Vd	NNP	B-NP	O
,	,	O	O
Cl	NNP	B-NP	O
.	.	O	O

Increased	VBN	B-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
OD	NN	B-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
TD	NN	B-NP	O
,	,	O	O
without	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
TD	NN	B-NP	O
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
decreased	VBN	I-VP	B
auditory	JJ	B-NP	I
function	NN	I-NP	I
,	,	O	O
of	IN	B-PP	O
which	WDT	B-NP	O
num	CD	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
auditory	JJ	I-NP	B
loss	NN	I-NP	I
of	IN	B-PP	O
-	SYM	B-NP	O
num	CD	I-NP	O
dB	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
in	IN	B-PP	O
the	DT	B-NP	O
OD	NN	I-NP	O
group	NN	I-NP	O
only	RB	B-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
presented	VBN	B-VP	O
decreased	VBD	B-VP	B
auditory	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
small	JJ	I-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
once	RB	I-NP	O
-	HYPH	I-NP	O
daily	JJ	I-NP	O
dosing	NN	I-NP	O
regimen	NN	I-NP	O
of	IN	B-PP	O
tobramycin	NN	B-NP	O
is	VBZ	B-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
as	RB	B-ADJP	O
effective	JJ	I-ADJP	O
as	IN	B-PP	O
and	CC	O	O
is	VBZ	B-VP	O
no	RB	B-NP	O
more	JJR	I-NP	O
and	CC	I-NP	O
possibly	RB	I-NP	O
less	RBR	I-ADJP	O
toxic	JJ	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
twice	RB	I-NP	O
-	HYPH	I-NP	O
daily	JJ	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
peak	JJ	B-NP	O
concentration	NN	I-NP	O
determination	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
necessary	JJ	B-ADJP	O
,	,	O	O
only	RB	B-NP	O
trough	NN	I-NP	O
samples	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
to	TO	B-VP	O
ensure	VB	I-VP	O
levels	NNS	B-NP	O
below	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
synthetic	JJ	I-NP	O
anthracycline	NN	I-NP	O
derivative	NN	I-NP	O
(	(	O	O
SM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
on	IN	B-PP	O
normal	JJ	B-NP	O
heart	NN	I-NP	O
and	CC	I-NP	O
doxorubicin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
in	IN	B-PP	O
beagle	NN	B-NP	O
dogs	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
cardiotoxic	JJ	I-NP	B
potential	NN	I-NP	O
of	IN	B-PP	O
SM	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
a	DT	B-NP	O
possible	JJ	I-NP	O
deteriorating	VBG	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
SM	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
grade	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
pre	AFX	O	O
-	HYPH	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
doxorubicin	NN	B-NP	O
in	IN	B-PP	O
beagle	NN	B-NP	O
dogs	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
beagle	NN	B-NP	O
dogs	NNS	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
sex	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
intravenously	RB	B-ADVP	O
once	RB	I-ADVP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
either	CC	O	O
a	DT	B-NP	O
sublethal	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
or	CC	I-NP	O
SM	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
experiment	NN	I-NP	O
was	VBD	B-VP	O
terminated	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
ninth	JJ	I-NP	O
dosing	NN	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
which	WDT	B-NP	O
received	VBD	B-VP	O
over	IN	B-NP	O
num	CD	I-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
demonstrated	VBD	B-VP	O
the	DT	B-NP	O
electrocardiogram	NN	I-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
changes	NNS	B-NP	O
,	,	O	O
decrease	NN	B-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
grade	NN	I-NP	O
histopathological	JJ	I-NP	O
cardiomyopathy	NN	I-NP	B
,	,	O	O
while	IN	B-SBAR	O
animals	NNS	B-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
terminally	RB	I-VP	O
sacrificed	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
SM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
administration	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
show	VB	I-VP	O
any	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
ECG	NN	B-NP	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
histopathological	JJ	B-NP	O
examinations	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
examine	VB	I-VP	O
a	DT	B-NP	O
possibly	RB	I-NP	O
deteriorating	VBG	I-NP	O
cardiotoxic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
SM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
grade	NN	I-NP	O
cardiomyopathy	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
dogs	NNS	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
either	CC	O	O
doxorubicin	NN	B-NP	O
or	CC	I-NP	O
SM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
once	RB	B-ADVP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
grade	NN	I-NP	O
cardiotoxic	JJ	I-NP	B
changes	NNS	I-NP	O
were	VBD	B-VP	O
enhanced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
additional	JJ	I-NP	O
doxorubicin	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
contrary	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
SM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
treatment	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
progress	VB	I-VP	O
the	DT	B-NP	O
grade	NN	I-NP	O
of	IN	B-PP	O
cardiomyopathy	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
SM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
any	DT	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
and	CC	O	O
deteriorating	VBG	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

Posteroventral	JJ	B-NP	O
medial	JJ	I-NP	O
pallidotomy	NN	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
Parkinson	NNP	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Posteroventral	JJ	B-NP	O
medial	JJ	I-NP	O
pallidotomy	NN	I-NP	O
sometimes	RB	B-ADVP	O
produces	VBZ	B-VP	O
striking	JJ	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
Parkinson	NNP	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
studies	NNS	I-NP	O
to	TO	B-PP	O
date	NN	B-NP	O
have	VBP	B-VP	O
involved	VBN	I-VP	O
small	JJ	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
underwent	VBD	B-VP	O
serial	JJ	B-NP	O
,	,	I-NP	O
detailed	JJ	I-NP	O
assessments	NNS	I-NP	O
both	CC	B-PP	O
after	IN	B-PP	O
drug	NN	B-NP	O
withdrawal	NN	I-NP	O
(	(	O	O
off	IN	B-PP	O
period	NN	B-NP	O
)	)	O	O
and	CC	O	O
while	IN	B-SBAR	O
taking	VBG	B-VP	O
their	PRP$	B-NP	O
optimal	JJ	I-NP	O
medical	JJ	I-NP	O
regimens	NNS	I-NP	O
(	(	O	O
on	IN	B-PP	O
period	NN	B-NP	O
)	)	O	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
preoperatively	RB	B-ADVP	O
and	CC	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
examined	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
percent	NN	I-NP	O
improvements	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
were	VBD	B-VP	O
as	IN	B-SBAR	O
follows	VBZ	B-VP	O
:	:	O	O
off	RP	B-PRT	O
-	HYPH	B-NP	O
period	NN	I-NP	O
score	NN	I-NP	O
for	IN	B-PP	O
overall	JJ	B-NP	O
motor	NN	I-NP	O
function	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
)	)	O	O
,	,	O	O
with	IN	B-PP	O
most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
contralateral	JJ	I-NP	O
limbs	NNS	I-NP	O
;	:	O	O
off	RB	B-ADVP	O
-	HYPH	B-NP	O
period	NN	I-NP	O
score	NN	I-NP	O
for	IN	B-PP	O
activities	NNS	B-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
living	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
)	)	O	O
;	:	O	O
on	IN	B-PP	O
-	HYPH	B-NP	O
period	NN	I-NP	O
score	NN	I-NP	O
for	IN	B-PP	O
contralateral	JJ	B-NP	O
dyskinesias	NNS	I-NP	B
,	,	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
)	)	O	O
;	:	O	O
and	CC	O	O
on	IN	B-PP	O
-	HYPH	B-NP	O
period	NN	I-NP	O
score	NN	I-NP	O
for	IN	B-PP	O
ipsilateral	JJ	B-NP	O
dyskinesias	NNS	I-NP	B
,	,	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
improvements	NNS	I-NP	O
in	IN	B-PP	O
dyskinesias	NNS	B-NP	B
and	CC	O	O
the	DT	B-NP	O
total	JJ	I-NP	O
scores	NNS	I-NP	O
for	IN	B-PP	O
off	RB	B-NP	O
-	HYPH	I-NP	O
period	NN	I-NP	O
parkinsonism	NN	I-NP	B
,	,	O	O
contralateral	JJ	B-NP	O
bradykinesia	NN	I-NP	B
,	,	O	O
and	CC	O	O
rigidity	NN	B-NP	B
were	VBD	B-VP	O
sustained	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
examined	VBN	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
ipsilateral	JJ	B-NP	O
dyskinesias	NNS	I-NP	B
was	VBD	B-VP	O
lost	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
improvements	NNS	I-NP	O
in	IN	B-PP	O
postural	JJ	B-NP	O
stability	NN	I-NP	O
and	CC	I-NP	O
gait	NN	I-NP	O
lasted	VBD	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Approximately	RB	B-NP	O
half	PDT	I-NP	O
the	DT	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
assistance	NN	B-NP	O
in	IN	B-PP	O
activities	NNS	B-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
living	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
off	JJ	I-NP	O
period	NN	I-NP	O
before	IN	B-SBAR	O
surgery	NN	B-NP	O
became	VBD	B-VP	O
independent	JJ	B-ADJP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
surgery	NN	B-NP	O
were	VBD	B-VP	O
generally	RB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
medication	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
late	JJ	B-NP	O
-	HYPH	I-NP	O
stage	NN	I-NP	O
Parkinson	NN	I-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
,	,	O	O
pallidotomy	NN	B-NP	O
significantly	RB	B-ADVP	O
reduces	VBZ	B-VP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
and	CC	O	O
off	RB	B-ADVP	O
-	HYPH	B-NP	O
period	NN	I-NP	O
disability	NN	I-NP	O
.	.	O	O

Much	JJ	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
benefit	NN	I-NP	O
is	VBZ	B-VP	O
sustained	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
some	DT	B-NP	O
improvements	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
those	DT	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
ipsilateral	JJ	I-NP	O
side	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
axial	JJ	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
wane	VBP	B-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
year	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
on	IN	B-PP	O
-	HYPH	B-NP	O
period	NN	I-NP	O
symptoms	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
resistant	JJ	B-ADJP	O
to	TO	B-PP	O
dopaminergic	JJ	B-NP	O
therapy	NN	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
respond	VB	I-VP	O
to	TO	B-PP	O
pallidotomy	NN	B-NP	O
.	.	O	O

Neuropeptide	NN	B-NP	O
-	HYPH	I-NP	O
Y	NN	I-NP	O
immunoreactivity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
temporal	JJ	B-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
.	.	O	O

Neuropeptide	NN	B-NP	O
-	HYPH	O	O
Y	NN	B-NP	O
(	(	O	O
NPY	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
expressed	VBN	I-VP	O
by	IN	B-PP	O
granule	NN	B-NP	O
cells	NNS	I-NP	O
and	CC	O	O
mossy	JJ	B-NP	O
fibres	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
during	IN	B-PP	O
experimental	JJ	B-NP	O
temporal	JJ	I-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
(	(	O	O
TLE	NN	B-NP	B
)	)	O	O
.	.	O	O

This	DT	B-NP	O
expression	NN	I-NP	O
may	MD	B-VP	O
represent	VB	I-VP	O
an	DT	B-NP	O
endogenous	JJ	I-NP	O
damping	VBG	I-NP	O
mechanism	NN	I-NP	O
since	IN	B-SBAR	O
NPY	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
block	VB	I-VP	O
seizure	NN	B-NP	B
-	HYPH	O	O
like	JJ	B-NP	O
events	NNS	I-NP	O
following	VBG	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
frequency	NN	I-NP	O
stimulation	NN	I-NP	O
in	IN	B-PP	O
hippocampal	JJ	B-NP	O
slices	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
pilocarpine	NN	I-NP	O
(	(	O	O
PILO	NN	B-NP	O
)	)	O	O
model	NN	B-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
followed	VBN	B-VP	O
by	IN	B-PP	O
spontaneous	JJ	B-NP	O
recurrent	JJ	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
related	VBN	B-NP	O
brain	NN	I-NP	B
damage	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
peroxidase	NN	B-NP	O
-	HYPH	B-NP	O
antiperoxidase	NN	I-NP	O
immunostaining	NN	I-NP	O
for	IN	B-PP	O
NPY	NN	B-NP	O
in	IN	B-PP	O
several	JJ	B-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
.	.	O	O

PILO	NN	B-NP	O
-	HYPH	B-NP	O
injected	VBN	I-NP	O
animals	NNS	I-NP	O
exhibited	VBD	B-VP	O
NPY	NN	B-NP	O
immunoreactivity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mossy	NN	I-NP	O
fibre	NN	I-NP	O
terminals	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
inner	JJ	I-NP	O
molecular	JJ	I-NP	O
layer	NN	I-NP	O
and	CC	O	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
within	IN	B-PP	O
presumed	VBN	B-NP	O
granule	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

NPY	NN	B-NP	O
immunoreactivity	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
dramatically	RB	B-ADJP	O
changed	VBN	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
entorhinal	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
amygdala	NN	B-NP	O
and	CC	I-NP	O
sensorimotor	NN	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
PILO	NN	B-NP	O
injected	VBN	I-NP	O
animals	NNS	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
NPY	NN	B-NP	O
-	HYPH	B-NP	O
immunoreactive	JJ	I-NP	O
interneurons	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
changes	NNS	B-NP	O
in	IN	B-PP	O
NPY	NN	B-NP	O
expression	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
expression	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
granule	NN	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
mossy	NN	B-NP	O
fibres	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
vulnerable	JJ	B-NP	O
NPY	NN	I-NP	O
neurons	NNS	I-NP	O
,	,	O	O
are	VBP	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
PILO	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
TLE	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
significance	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
changed	VBN	I-NP	O
synthesis	NN	I-NP	O
of	IN	B-PP	O
NPY	NN	B-NP	O
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
determined	VBN	I-VP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
myopic	JJ	B-NP	O
excimer	NN	I-NP	O
laser	NN	I-NP	O
photorefractive	JJ	I-NP	O
keratectomy	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
electrophysiologic	JJ	I-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
retina	NN	I-NP	O
and	CC	I-NP	O
optic	JJ	I-NP	O
nerve	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
by	IN	B-PP	O
electrophysiologic	JJ	B-NP	O
testing	NN	I-NP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
photorefractive	JJ	B-NP	O
keratectomy	NN	I-NP	O
(	(	O	O
PRK	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
the	DT	B-NP	O
retina	NN	I-NP	O
and	CC	I-NP	O
optic	JJ	I-NP	O
nerve	NN	I-NP	O
.	.	O	O

Eye	NNP	B-NP	O
Clinic	NNP	I-NP	O
,	,	O	O
S	NNP	B-NP	O
.	.	O	O

Salvatore	NNP	B-NP	O
Hospital	NNP	I-NP	O
,	,	O	O
L'Aquila	NNP	B-NP	O
University	NNP	I-NP	O
,	,	O	O
Italy	NNP	B-NP	O
.	.	O	O

Standard	JJ	B-NP	O
pattern	NN	I-NP	O
electroretinograms	NNS	I-NP	O
(	(	O	O
P	NN	B-NP	O
-	HYPH	B-NP	O
ERGs	NNS	I-NP	O
)	)	O	O
and	CC	O	O
standard	JJ	B-NP	O
pattern	NN	I-NP	O
visual	JJ	I-NP	O
evoked	JJ	I-NP	O
potentials	NNS	I-NP	O
(	(	O	O
P	NN	B-NP	O
-	HYPH	B-NP	O
VEPs	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
done	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
eyes	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
myopic	JJ	B-NP	O
PRK	NN	I-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
attempted	VBN	I-NP	O
correction	NN	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
diopters	NNS	I-NP	O
(	(	O	O
D	NN	B-NP	O
)	)	O	O
(	(	O	O
mean	NN	B-NP	O
num	CD	I-NP	O
D	NN	I-NP	O
)	)	O	O
.	.	O	O

Testing	NN	B-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
preoperatively	RB	B-ADVP	O
and	CC	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
postoperatively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
contralateral	JJ	I-NP	O
eyes	NNS	I-NP	O
served	VBD	B-VP	O
as	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
steroid	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
elevated	VBN	I-VP	B
intraocular	JJ	B-NP	I
pressure	NN	I-NP	I
(	(	O	O
IOP	NN	B-NP	O
)	)	O	O
that	WDT	B-NP	O
resolved	VBD	B-VP	O
after	IN	B-PP	O
corticosteroid	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

No	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
between	IN	B-PP	O
treated	VBN	B-NP	O
and	CC	I-NP	O
control	NN	I-NP	O
eyes	NNS	I-NP	O
nor	CC	B-PP	O
between	IN	B-PP	O
treated	VBN	B-NP	O
eyes	NNS	I-NP	O
preoperatively	RB	B-ADVP	O
and	CC	I-ADVP	O
postoperatively	RB	I-ADVP	O
.	.	O	O

Myopic	JJ	B-NP	O
excimer	NN	I-NP	O
laser	NN	I-NP	O
PRK	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
to	TO	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
segment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
transient	JJ	I-NP	O
steroid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
IOP	NN	I-NP	B
rise	NN	I-NP	I
did	VBD	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
functional	JJ	B-NP	O
impairment	NN	I-NP	O
.	.	O	O

Liposomal	JJ	B-NP	O
daunorubicin	NN	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
Kaposi	NNP	I-NP	B
s	NNS	I-NP	I
sarcoma	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
randomized	VBN	I-NP	O
Phase	NN	I-NP	O
num	CD	I-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
liposomal	JJ	B-NP	O
daunorubicin	NN	I-NP	O
(	(	O	O
DaunoXome	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
AIDS	NNP	B-NP	B
related	VBD	B-VP	O
Kaposi	NNP	B-NP	B
s	NNP	I-NP	I
sarcoma	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
homosexual	JJ	I-NP	O
men	NNS	I-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
Kaposi	NNP	I-NP	B
s	NNS	I-NP	I
sarcoma	NN	I-NP	I
were	VBD	B-VP	O
entered	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
trial	NN	I-NP	O
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
size	NN	B-NP	O
,	,	O	O
colour	NN	B-NP	O
and	CC	O	O
associated	VBN	B-NP	O
oedema	NN	I-NP	B
of	IN	B-PP	O
selected	VBN	B-NP	O
target	NN	I-NP	O
lesions	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
.	.	O	O

Clinical	JJ	B-NP	O
,	,	I-NP	O
biochemical	JJ	I-NP	O
and	CC	I-NP	O
haematological	JJ	I-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
assessed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
achieved	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
of	IN	B-PP	O
whom	WP	B-NP	O
num	CD	B-NP	O
subsequently	RB	I-NP	O
relapsed	VBN	I-VP	O
.	.	O	O

Stabilization	NN	B-NP	O
of	IN	B-PP	O
Kaposi	NNP	B-NP	B
s	NNP	I-NP	I
sarcoma	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
,	,	O	O
maintained	VBN	B-VP	O
until	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
trial	NN	I-NP	O
period	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
generally	RB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
few	JJ	B-NP	O
mild	JJ	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
toxicity	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
problem	NN	I-NP	O
encountered	VBN	B-VP	O
was	VBD	B-VP	O
haematological	JJ	B-NP	O
toxicity	NN	I-NP	B
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
experiencing	VBG	B-VP	O
severe	JJ	B-NP	O
neutropenia	NN	I-NP	B
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
small	JJ	I-NP	O
patient	NN	I-NP	O
sample	NN	I-NP	O
,	,	O	O
liposomal	JJ	B-NP	O
daunorubicin	NN	I-NP	O
was	VBD	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
and	CC	I-NP	O
well	RB	I-NP	O
tolerated	VBN	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Kaposi	NNP	B-NP	B
s	NNP	I-NP	I
sarcoma	NN	I-NP	I
.	.	O	O

Failure	NN	B-NP	O
of	IN	B-PP	O
ancrod	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
arterial	JJ	I-NP	O
thrombosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
morbidity	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombosis	NN	I-NP	B
remain	VBP	B-VP	O
high	JJ	B-ADJP	O
despite	IN	B-PP	O
numerous	JJ	B-NP	O
empirical	JJ	I-NP	O
therapies	NNS	I-NP	O
.	.	O	O

Ancrod	NNP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
successfully	RB	B-ADVP	O
for	IN	B-PP	O
prophylaxis	NN	B-NP	O
against	IN	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
thrombosis	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
induced	VBD	B-VP	O
platelet	NN	B-NP	B
aggregation	NN	I-NP	I
who	WP	B-NP	O
require	VBP	B-VP	O
brief	JJ	B-NP	O
reexposure	NN	I-NP	O
to	TO	B-PP	O
heparin	NN	B-NP	O
,	,	O	O
but	CC	O	O
its	PRP$	B-NP	O
success	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
developed	VBN	I-VP	O
the	DT	B-NP	O
thrombosis	NN	I-NP	B
syndrome	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
well	RB	I-VP	O
defined	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
failure	NN	B-NP	O
of	IN	B-PP	O
ancrod	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombosis	NN	I-NP	B
.	.	O	O

Seizure	NN	B-NP	B
after	IN	B-PP	O
flumazenil	NN	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
pediatric	JJ	I-NP	O
patient	NN	I-NP	O
.	.	O	O

Flumazenil	NNP	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
benzodiazepine	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
sedation	NN	B-NP	O
and	CC	O	O
respiratory	JJ	B-NP	B
depression	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
benzodiazepines	NNS	B-NP	O
.	.	O	O

Seizures	NNS	B-NP	B
and	CC	O	O
cardiac	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
have	VBP	B-VP	O
complicated	VBN	I-VP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Overdose	NN	B-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
coingested	VBN	I-VP	O
tricyclic	JJ	B-NP	O
antidepressants	NNS	I-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
complications	NNS	I-NP	O
.	.	O	O

Little	JJ	B-NP	O
information	NN	I-NP	O
exists	VBZ	B-VP	O
concerning	VBG	I-VP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
flumazenil	NN	B-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
generalized	VBN	I-NP	O
tonic	JJ	I-NP	B
-	HYPH	I-NP	I
clonic	JJ	I-NP	I
seizure	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
pediatric	JJ	I-NP	O
patient	NN	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
flumazenil	NN	B-NP	O
.	.	O	O

Remodelling	NN	B-NP	O
of	IN	B-PP	O
nerve	NN	B-NP	O
structure	NN	I-NP	O
in	IN	B-PP	O
experimental	JJ	B-NP	O
isoniazid	NN	I-NP	O
neuropathy	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
neuropathy	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
isoniazid	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
computer	NN	I-NP	O
-	HYPH	O	O
assisted	VBN	B-VP	O
morphometric	JJ	B-NP	O
method	NN	I-NP	O
.	.	O	O

Scatter	NN	B-NP	O
diagrams	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
g	NN	I-NP	O
ratio	NN	I-NP	O
(	(	O	O
quotient	NN	B-NP	O
fibre	NN	I-NP	O
diameter	NN	I-NP	O
/	SYM	B-NP	O
axon	NN	I-NP	O
diameter	NN	I-NP	O
)	)	O	O
define	NN	B-NP	O
regenerating	VBG	B-VP	O
fibres	NNS	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
distinct	JJ	I-NP	O
population	NN	I-NP	O
,	,	O	O
distinguishable	JJ	B-ADJP	O
from	IN	B-PP	O
the	DT	B-NP	O
surviving	VBG	I-NP	O
fibres	NNS	I-NP	O
by	IN	B-PP	O
reduced	VBN	B-NP	O
sheath	NN	I-NP	O
thickness	NN	I-NP	O
and	CC	O	O
reduced	VBD	B-VP	O
axon	NN	B-NP	O
calibre	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
subtle	JJ	I-NP	O
direct	JJ	I-NP	O
toxic	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
fibre	JJ	I-NP	O
population	NN	I-NP	O
,	,	O	O
causing	VBG	B-VP	O
axon	NN	B-NP	O
shrinkage	NN	I-NP	O
masked	VBN	B-VP	O
by	IN	B-PP	O
readjustment	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myelin	NN	I-NP	O
sheath	NN	I-NP	O
.	.	O	O

Selective	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
iopentol	NN	B-NP	O
,	,	I-NP	O
iohexol	NN	I-NP	O
and	CC	I-NP	O
metrizoate	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dog	NN	I-NP	O
.	.	O	O

Induction	NN	B-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
and	CC	I-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
aortic	JJ	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
beagle	NN	I-NP	O
dogs	VBZ	B-VP	O
selective	JJ	B-NP	O
injections	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
with	IN	B-PP	O
iopentol	NN	B-NP	O
,	,	I-NP	O
iohexol	NN	I-NP	O
and	CC	I-NP	O
metrizoate	NN	I-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ml	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
iopentol	NN	I-NP	O
injections	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
iohexol	NN	I-NP	O
injections	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
metrizoate	NN	I-NP	O
injections	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
.	.	O	O

Frequencies	NNS	B-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
after	IN	B-PP	O
iopentol	NN	B-NP	O
and	CC	I-NP	O
iohexol	NN	I-NP	O
than	IN	B-PP	O
after	IN	B-PP	O
metrizoate	NN	B-NP	O
.	.	O	O

Iopentol	NN	B-NP	O
and	CC	I-NP	O
iohexol	NN	I-NP	O
also	RB	B-ADVP	O
produced	VBD	B-VP	O
significantly	RB	B-NP	O
less	JJR	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
aortic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
than	IN	B-PP	O
metrizoate	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
different	JJ	I-NP	O
doses	NNS	I-NP	O
.	.	O	O

Magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	O
venous	JJ	I-NP	B
thrombosis	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
birth	NN	I-NP	O
control	NN	I-NP	O
pills	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
radiographic	JJ	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	O
deep	JJ	I-NP	B
venous	JJ	I-NP	I
thrombosis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
white	JJ	I-NP	O
woman	NN	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
nulliparous	JJ	I-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
relatively	RB	B-NP	O
mild	JJ	I-NP	O
clinical	JJ	I-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
progressing	VBG	B-VP	O
mental	JJ	B-NP	O
status	NN	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
only	JJ	I-NP	O
known	VBN	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
was	VBD	B-VP	O
low	JJ	B-ADJP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
oral	JJ	I-NP	O
contraceptive	JJ	I-NP	O
pills	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
image	NN	I-NP	O
(	(	O	O
MRI	NN	B-NP	O
)	)	O	O
showed	VBD	B-VP	O
increased	VBN	B-NP	O
signal	NN	I-NP	O
intensity	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
internal	JJ	I-NP	O
cerebral	JJ	I-NP	O
veins	NNS	I-NP	O
,	,	O	O
vein	NN	B-NP	O
of	IN	B-PP	O
Galen	NN	B-NP	O
,	,	O	O
and	CC	O	O
straight	JJ	B-NP	O
sinus	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
was	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
arterial	JJ	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

Relation	NN	B-NP	O
of	IN	B-PP	O
perfusion	NN	B-NP	O
defects	NNS	I-NP	O
observed	VBN	B-VP	O
with	IN	B-PP	O
myocardial	JJ	B-NP	O
contrast	NN	I-NP	O
echocardiography	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
stenosis	NN	I-NP	I
:	:	O	O
correlation	NN	B-NP	O
with	IN	B-PP	O
thallium	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
photon	NN	I-NP	O
emission	NN	I-NP	O
tomography	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
myocardial	JJ	B-NP	O
contrast	NN	I-NP	O
echocardiography	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
valuable	JJ	I-NP	O
technique	NN	I-NP	O
for	IN	B-PP	O
delineating	VBG	B-VP	O
regions	NNS	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	O
underperfusion	NN	I-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
coronary	JJ	B-NP	B
occlusion	NN	I-NP	I
and	CC	B-PP	O
to	TO	B-PP	O
critical	JJ	B-NP	O
coronary	JJ	I-NP	B
stenoses	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
hyperemic	JJ	B-NP	B
stimulation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
myocardial	JJ	B-NP	O
contrast	NN	I-NP	O
echocardiography	NN	I-NP	O
performed	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
stable	JJ	I-NP	O
solution	NN	I-NP	O
of	IN	B-PP	O
sonicated	VBN	B-NP	O
albumin	NN	I-NP	O
could	MD	B-VP	O
detect	VB	I-VP	O
regions	NNS	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	O
underperfusion	NN	I-NP	O
resulting	VBG	B-VP	O
from	IN	B-PP	O
various	JJ	B-NP	O
degrees	NNS	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
stenosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
produced	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
open	JJ	I-NP	O
chest	NN	I-NP	O
dogs	NNS	I-NP	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
anatomic	JJ	I-NP	O
area	NN	I-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
measured	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
postmortem	JJ	I-NP	O
dual	JJ	I-NP	O
-	HYPH	I-NP	O
perfusion	NN	I-NP	O
technique	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
thallium	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
photon	NN	I-NP	O
emission	NN	I-NP	O
tomography	NN	I-NP	O
(	(	O	O
SPECT	NN	B-NP	O
)	)	O	O
.	.	O	O

During	IN	B-PP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
s	NNS	I-NP	O
)	)	O	O
coronary	JJ	B-NP	B
occlusion	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
contrast	NN	B-NP	O
echocardiography	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
occlusion	NN	I-NP	O
was	VBD	B-VP	O
produced	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
correlated	VBD	B-VP	O
significantly	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
anatomic	JJ	I-NP	O
area	NN	I-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
dipyridamole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperemia	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
coronary	JJ	I-NP	B
stenosis	NN	I-NP	I
had	VBD	B-VP	O
a	DT	B-NP	O
visible	JJ	I-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
hypoperfusion	NN	B-NP	O
by	IN	B-PP	O
contrast	NN	B-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
without	IN	B-PP	O
a	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
stenosis	NN	I-NP	O
that	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
mild	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
reduction	NN	B-NP	O
in	IN	B-PP	O
dipyridamole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperemia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
during	IN	B-PP	O
stenosis	NN	B-NP	O
correlated	VBD	B-VP	O
significantly	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
anatomic	JJ	I-NP	O
area	NN	I-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
.	.	O	O

Thallium	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
SPECT	NN	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
analyzed	VBN	B-VP	O
during	IN	B-PP	O
dipyridamole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperemia	NN	I-NP	B
;	:	O	O
the	DT	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
anatomic	JJ	I-NP	O
area	NN	I-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
perfusion	NN	I-NP	O
defect	NN	I-NP	O
by	IN	B-PP	O
contrast	NN	B-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
myocardial	JJ	B-NP	O
contrast	NN	I-NP	O
echocardiography	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
visualize	VB	I-VP	O
and	CC	I-VP	O
quantitate	VB	I-VP	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
jeopardized	JJ	B-NP	O
myocardium	NN	I-NP	O
during	IN	B-PP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
degrees	NNS	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
stenosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
obtained	VBN	B-VP	O
show	VBP	B-VP	O
a	DT	B-NP	O
correlation	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
anatomic	JJ	I-NP	O
area	NN	I-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
obtained	VBN	B-VP	O
with	IN	B-PP	O
thallium	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
SPECT	NN	I-NP	O
.	.	O	O

Potential	JJ	B-NP	O
deleterious	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
furosemide	NN	B-NP	O
in	IN	B-PP	O
radiocontrast	NN	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
furosemide	NN	B-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
intravenous	JJ	B-NP	O
fluids	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
radiocontrast	NN	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
referred	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
radiocontrast	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
considered	VBN	B-VP	O
at	IN	B-PP	O
risk	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
preexisting	VBG	B-VP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
,	,	O	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
controlled	VBN	I-NP	O
trial	NN	I-NP	O
,	,	O	O
performed	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
secondary	JJ	I-NP	O
care	NN	I-NP	O
center	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
bed	NN	I-NP	O
private	JJ	I-NP	O
university	NN	I-NP	O
hospital	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
fluids	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
treatment	NN	I-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
furosemide	NN	B-NP	O
intravenously	RB	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
contrast	NN	B-NP	O
material	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
fluids	NNS	B-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	B-NP	O
liters	NNS	I-NP	O
)	)	O	O
.	.	O	O

Radiological	JJ	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
mostly	RB	B-ADVP	O
angiographies	NNS	B-NP	O
performed	VBN	B-VP	O
with	IN	B-PP	O
both	CC	O	O
ionic	JJ	O	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
ionic	JJ	I-NP	O
contrast	NN	I-NP	O
material	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ml	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	B
function	NN	I-NP	I
significantly	RB	B-VP	I
deteriorated	VBN	I-VP	I
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
furosemide	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mumol	NN	I-NP	O
/	SYM	I-NP	O
l	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
no	DT	B-NP	O
change	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	B
failure	NN	I-NP	I
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
weight	NN	B-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
furosemide	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Furosemide	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
deleterious	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
radiocontrast	NN	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
renal	JJ	I-NP	O
pathology	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NN	I-NP	B
insipidus	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NN	I-NP	B
insipidus	NN	I-NP	I
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

At	IN	B-PP	O
necropsy	NN	B-NP	O
microscopy	NN	I-NP	O
shoed	VBD	B-VP	O
unique	JJ	B-NP	O
and	CC	I-NP	O
extensive	JJ	I-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
cells	NNS	B-NP	O
lining	VBG	B-VP	O
the	DT	B-NP	O
distal	JJ	I-NP	O
nephron	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
changes	NNS	I-NP	O
represent	VBP	B-VP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
toxic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
,	,	O	O
reported	VBN	B-VP	O
here	RB	B-ADVP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

Etiologic	JJ	B-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	B
tumors	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
.	.	O	O

Within	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
several	JJ	I-NP	O
years	NNS	I-NP	O
,	,	O	O
previously	RB	B-NP	O
rare	JJ	I-NP	O
liver	NN	I-NP	B
tumors	NNS	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
young	JJ	B-NP	O
women	NNS	I-NP	O
using	VBG	B-VP	O
oral	JJ	B-NP	O
contraceptive	JJ	I-NP	O
steroids	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
Registry	NN	I-NP	O
for	IN	B-PP	O
Liver	NN	B-NP	B
Tumors	NNS	I-NP	I
Associated	VBN	B-VP	O
with	IN	B-PP	O
Oral	JJ	B-NP	O
Contraceptives	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
University	NNP	I-NP	O
of	IN	B-PP	O
California	NNP	B-NP	O
,	,	O	O
Irvine	NNP	B-NP	O
,	,	O	O
has	VBZ	B-VP	O
clearly	RB	I-VP	O
identified	VBN	I-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
recent	JJ	I-NP	O
literature	NN	I-NP	O
contains	VBZ	B-VP	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
.	.	O	O

Common	JJ	B-ADJP	O
to	TO	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
a	DT	B-NP	O
histopathologic	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
focal	JJ	B-NP	B
nodular	JJ	I-NP	I
hyperplasia	NN	I-NP	I
,	,	O	O
adenoma	NN	B-NP	B
,	,	O	O
hamartoma	NN	B-NP	B
,	,	O	O
and	CC	O	O
hepatoma	NN	B-NP	B
.	.	O	O

Significant	JJ	B-NP	O
statistical	JJ	I-NP	O
etiologic	JJ	I-NP	O
factors	NNS	I-NP	O
include	VBP	B-VP	O
prolonged	JJ	B-NP	O
uninterrupted	JJ	I-NP	O
usage	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
contraceptive	JJ	I-NP	O
steroids	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
deaths	NNS	I-NP	O
and	CC	O	O
liver	NN	B-NP	O
rupture	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
attest	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
seriousness	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
new	JJ	I-NP	O
potentially	RB	I-NP	O
lethal	JJ	I-NP	O
adverse	JJ	I-NP	O
phenomenon	NN	I-NP	O
.	.	O	O

Graft	NN	B-NP	B
-	HYPH	B-ADJP	I
versus	IN	B-PP	I
-	HYPH	B-NP	I
host	NN	I-NP	I
disease	NN	I-NP	I
prophylaxis	NN	I-NP	O
with	IN	B-PP	O
everolimus	NN	B-NP	O
and	CC	I-NP	O
tacrolimus	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
sinusoidal	JJ	B-NP	B
obstruction	NN	I-NP	I
syndrome	NN	I-NP	I
and	CC	I-NP	O
microangiopathy	NN	I-NP	B
:	:	O	O
results	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
EVTAC	NN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
calcineurin	NN	I-NP	O
inhibitor	NN	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
methotrexate	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
prophylaxis	NN	I-NP	O
for	IN	B-PP	O
graft	NN	B-NP	B
-	HYPH	B-ADVP	I
versus	IN	B-PP	I
-	HYPH	B-NP	I
host	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
GVHD	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
allogeneic	JJ	B-NP	O
hematopoietic	JJ	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
(	(	O	O
HSCT	NN	B-NP	O
)	)	O	O
.	.	O	O

Everolimus	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
derivative	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
,	,	O	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
mediate	VB	I-VP	O
antileukemia	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
everolimus	NN	B-NP	O
and	CC	I-NP	O
tacrolimus	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
median	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
either	CC	B-NP	O
myelodysplastic	JJ	I-NP	B
syndrome	NN	I-NP	I
or	CC	O	O
acute	JJ	B-NP	B
myeloid	JJ	I-NP	I
leukemia	NN	I-NP	I
undergoing	VBG	B-VP	O
intensive	JJ	B-NP	O
conditioning	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
HSCT	NN	B-NP	O
from	IN	B-PP	O
related	JJ	B-NP	O
or	CC	I-NP	O
unrelated	JJ	I-NP	O
donors	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
engrafted	VBN	B-VP	O
,	,	O	O
and	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
experienced	VBD	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
mucositis	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
GVHD	NN	I-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
chronic	JJ	B-NP	O
extensive	JJ	I-NP	O
GVHD	NN	I-NP	B
.	.	O	O

Transplantation	NN	B-NP	B
-	HYPH	O	I
associated	VBN	B-VP	I
microangiopathy	NN	B-NP	I
(	(	O	O
TMA	NN	B-NP	B
)	)	O	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
terminated	VBN	I-VP	O
prematurely	RB	B-ADVP	O
because	IN	B-SBAR	O
an	DT	B-NP	O
additional	JJ	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
sinusoidal	JJ	B-NP	B
obstruction	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
SOS	NN	B-NP	B
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
fatal	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

With	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
overall	JJ	I-NP	O
survival	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
this	DT	B-NP	O
new	JJ	I-NP	O
combination	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
as	IN	B-PP	O
a	DT	B-NP	O
prophylactic	JJ	I-NP	O
regimen	NN	I-NP	O
for	IN	B-PP	O
acute	JJ	B-NP	O
GVHD	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
TMA	NN	B-NP	B
and	CC	I-NP	O
SOS	NN	I-NP	B
is	VBZ	B-VP	O
considerably	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-SBAR	O
seen	VBN	B-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
regimens	NNS	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
some	DT	B-NP	O
convulsants	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
loreclezole	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
combinations	NNS	I-NP	O
with	IN	B-PP	O
valproate	NN	B-NP	O
or	CC	I-NP	O
clonazepam	NN	I-NP	O
in	IN	B-PP	O
amygdala	NN	B-NP	O
-	HYPH	B-NP	O
kindled	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Loreclezole	NN	B-NP	O
exerted	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
protective	JJ	I-NP	O
action	NN	I-NP	O
in	IN	B-PP	O
amygdala	NN	B-NP	O
-	HYPH	B-NP	O
kindled	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
reducing	VBG	B-VP	O
both	CC	O	O
seizure	NN	B-NP	B
and	CC	O	O
afterdischarge	JJ	B-NP	O
durations	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
combinations	NNS	I-NP	O
of	IN	B-PP	O
loreclezole	NN	B-NP	O
with	IN	B-PP	O
valproate	NN	B-NP	O
,	,	O	O
clonazepam	NN	B-NP	O
,	,	O	O
or	CC	O	O
carbamazepine	NN	B-NP	O
(	(	O	O
applied	VBN	B-VP	O
at	IN	B-PP	O
their	PRP$	B-NP	O
subprotective	JJ	I-NP	O
doses	NNS	I-NP	O
)	)	O	O
also	RB	B-ADVP	O
exhibited	VBD	B-VP	O
antiseizure	JJ	B-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
test	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
first	JJ	I-NP	O
combinations	NNS	I-NP	O
occurred	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
pharmacodynamic	JJ	B-NP	O
nature	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
several	JJ	B-NP	O
chemoconvulsants	NNS	I-NP	O
,	,	O	O
bicuculline	NN	B-NP	O
,	,	O	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
aspartic	JJ	I-NP	O
acid	NN	I-NP	O
and	CC	I-NP	O
BAY	NN	I-NP	O
k	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
(	(	O	O
the	DT	B-NP	O
opener	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
type	NN	I-NP	O
calcium	NN	I-NP	O
channels	NNS	I-NP	O
)	)	O	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
loreclezole	NN	B-NP	O
alone	RB	B-ADVP	O
and	CC	O	O
its	PRP$	B-NP	O
combination	NN	I-NP	O
with	IN	B-PP	O
valproate	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
bicuculline	NN	B-NP	O
,	,	O	O
aminophylline	NN	B-NP	O
and	CC	O	O
BAY	NN	B-NP	O
k	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
anticonvulsive	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
loreclezole	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
clonazepam	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
protective	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
loreclezole	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
combinations	NNS	I-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
antiepileptics	NNS	I-NP	O
may	MD	B-VP	O
involve	VB	I-VP	O
potentiation	NN	B-NP	O
of	IN	B-PP	O
GABAergic	JJ	B-NP	O
neurotransmission	NN	I-NP	O
and	CC	I-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
type	NN	B-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channels	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
with	IN	B-PP	O
concurrent	JJ	B-NP	O
bupropion	NN	I-NP	O
and	CC	I-NP	O
carbimazole	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
liver	NN	I-NP	B
failure	NN	I-NP	I
possibly	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
concurrent	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
and	CC	I-NP	O
carbimazole	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Chinese	JJ	I-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
hyperthyroidism	NN	B-NP	B
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
carbimazole	NN	B-NP	O
and	CC	I-NP	O
propranolol	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
past	JJ	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

He	PRP	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
aid	NN	I-NP	O
for	IN	B-PP	O
smoking	VBG	B-VP	O
cessation	NN	B-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
presentation	NN	B-NP	O
.	.	O	O

He	PRP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
with	IN	B-PP	O
rapid	JJ	B-NP	O
deterioration	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Liver	NN	B-NP	O
biopsy	NN	I-NP	O
showed	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
nonspecific	JJ	B-NP	O
drug	NN	I-NP	B
-	HYPH	O	I
induced	VBN	B-NP	I
acute	JJ	I-NP	I
liver	NN	I-NP	I
injury	NN	I-NP	I
.	.	O	O

His	PRP$	B-NP	O
condition	NN	I-NP	O
was	VBD	B-VP	O
further	RBR	I-VP	O
complicated	VBN	I-VP	O
by	IN	B-PP	O
sepsis	NN	B-NP	B
and	CC	I-NP	O
coagulopathy	NN	I-NP	B
.	.	O	O

Death	NN	B-NP	O
resulted	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
likelihood	NN	I-NP	O
that	IN	B-SBAR	O
bupropion	NN	B-NP	O
induced	VBD	B-VP	O
hepatotoxicity	NN	B-NP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
possible	JJ	B-ADJP	O
,	,	O	O
based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
probability	NN	I-NP	O
scale	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
increasing	VBG	I-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
bupropion	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fatality	NN	B-NP	O
that	WDT	B-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
resulted	VBN	I-VP	O
from	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
bupropion	NN	B-NP	O
while	IN	B-SBAR	O
on	IN	B-PP	O
concomitant	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
carbimazole	NN	B-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
insult	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
bupropion	NN	B-NP	O
given	VBN	B-VP	O
concurrently	RB	B-ADVP	O
with	IN	B-PP	O
other	JJ	B-NP	O
hepatotoxic	JJ	I-NP	B
drugs	NNS	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
term	NN	I-NP	O
hormone	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
perimenopausal	JJ	B-NP	O
and	CC	I-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
.	.	O	O

Hormone	NN	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
HT	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
controlling	VBG	B-VP	O
menopausal	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
has	VBZ	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
and	CC	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
osteoporosis	NN	B-NP	B
and	CC	I-NP	O
dementia	NN	I-NP	B
in	IN	B-PP	O
older	JJR	B-NP	O
women	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
updated	VBN	I-NP	O
version	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
original	JJ	I-NP	O
Cochrane	NN	I-NP	O
review	NN	I-NP	O
first	RB	B-VP	O
published	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
HT	NN	I-NP	O
on	IN	B-PP	O
mortality	NN	B-NP	O
,	,	O	O
cardiovascular	JJ	B-NP	O
outcomes	NNS	I-NP	O
,	,	O	O
cancer	NN	B-NP	B
,	,	O	O
gallbladder	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
cognition	NN	B-NP	O
,	,	O	O
fractures	NNS	B-NP	B
and	CC	O	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
searched	VBD	B-VP	O
the	DT	B-NP	O
following	VBG	I-NP	O
databases	NNS	I-NP	O
to	TO	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
:	:	O	O
Trials	NNS	B-NP	O
Register	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Cochrane	NNP	I-NP	O
Menstrual	NNP	I-NP	B
Disorders	NNP	I-NP	I
and	CC	O	O
Subfertility	NNP	B-NP	O
Group	NNP	I-NP	O
,	,	O	O
Cochrane	NNP	B-NP	O
Central	NNP	I-NP	O
Register	NNP	I-NP	O
of	IN	B-PP	O
Controlled	NNP	B-NP	O
Trials	NNPS	I-NP	O
,	,	O	O
MEDLINE	NNP	B-NP	O
,	,	O	O
EMBASE	NNP	B-NP	O
,	,	O	O
Biological	NNP	B-NP	O
Abstracts	NNPS	I-NP	O
.	.	O	O

Also	RB	B-NP	O
relevant	JJ	I-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
indexed	JJ	I-NP	O
journals	NNS	I-NP	O
and	CC	O	O
conference	NN	B-NP	O
abstracts	NNS	I-NP	O
.	.	O	O

Randomised	VBN	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trials	NNS	I-NP	O
of	IN	B-PP	O
HT	NN	B-NP	O
versus	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
taken	VBN	B-VP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
by	IN	B-PP	O
perimenopausal	JJ	B-NP	O
or	CC	I-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
.	.	O	O

HT	NN	B-NP	O
included	VBD	B-VP	O
oestrogens	NNS	B-NP	O
,	,	O	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
progestogens	NNS	B-NP	O
,	,	O	O
via	IN	B-PP	O
oral	JJ	B-NP	O
,	,	I-NP	O
transdermal	JJ	I-NP	O
,	,	I-NP	O
subcutaneous	JJ	I-NP	O
or	CC	I-NP	O
transnasal	JJ	I-NP	O
routes	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
authors	NNS	I-NP	O
independently	RB	B-ADVP	O
assessed	VBD	B-VP	O
trial	NN	B-NP	O
quality	NN	I-NP	O
and	CC	O	O
extracted	VBN	B-NP	O
data	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
trials	NNS	I-NP	O
involving	VBG	B-VP	O
num	CD	B-NP	O
women	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
relatively	RB	B-NP	O
healthy	JJ	I-NP	O
women	NNS	I-NP	O
,	,	O	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thrombo	AFX	I-NP	I
-	HYPH	I-NP	I
embolism	NN	I-NP	I
or	CC	I-NP	O
coronary	JJ	I-NP	O
event	NN	I-NP	O
(	(	O	O
after	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
s	NNS	I-NP	O
use	NN	I-NP	O
)	)	O	O
,	,	O	O
stroke	NN	B-NP	B
(	(	O	O
after	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
,	,	O	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
and	CC	O	O
gallbladder	NN	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
oestrogen	NN	I-NP	O
-	HYPH	B-VP	O
only	RB	B-NP	O
HT	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thrombo	AFX	I-NP	I
-	HYPH	I-NP	I
embolism	NN	I-NP	I
,	,	I-NP	O
stroke	NN	I-NP	B
and	CC	I-NP	O
gallbladder	NN	I-NP	B
disease	NN	I-NP	I
(	(	O	O
after	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
s	VBZ	B-VP	O
use	NN	B-NP	O
respectively	RB	B-ADVP	O
)	)	O	O
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
only	RB	I-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
benefits	NNS	I-NP	O
of	IN	B-PP	O
HT	NN	B-NP	O
were	VBD	B-VP	O
a	DT	B-NP	O
decreased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
fractures	NNS	B-NP	B
and	CC	O	O
(	(	O	O
for	IN	B-PP	O
combined	VBN	B-NP	O
HT	NN	I-NP	O
)	)	O	O
colon	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
women	NNS	B-NP	O
aged	VBN	B-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
relatively	RB	B-ADJP	O
healthy	JJ	I-ADJP	O
(	(	O	O
i.e.	FW	B-NP	O
generally	RB	B-ADVP	O
fit	VBP	B-VP	O
,	,	O	O
without	IN	B-PP	O
overt	JJ	B-NP	O
disease	NN	I-NP	O
)	)	O	O
and	CC	O	O
taking	VBG	B-VP	O
continuous	JJ	B-NP	O
combined	VBN	I-NP	O
HT	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
dementia	NN	B-NP	B
.	.	O	O

Among	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thrombo	AFX	I-NP	I
-	HYPH	I-NP	I
embolism	NN	I-NP	I
.One	NN	I-NP	O
trial	NN	I-NP	O
analysed	VBD	B-VP	O
subgroups	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
relatively	RB	I-NP	O
healthy	JJ	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
women	NNS	I-NP	O
taking	VBG	B-VP	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
taking	VBG	I-NP	O
oestrogen	NN	I-NP	O
-	HYPH	B-VP	O
only	RB	B-NP	O
HT	NN	I-NP	O
,	,	O	O
versus	IN	B-PP	O
similar	JJ	B-NP	O
-	HYPH	I-NP	O
sized	JJ	I-NP	O
placebo	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
only	RB	I-NP	O
significantly	RB	I-ADVP	O
increased	VBD	B-VP	O
risk	NN	B-NP	O
reported	VBN	B-VP	O
was	VBD	B-VP	O
for	IN	B-PP	O
venous	JJ	B-NP	B
thrombo	AFX	I-NP	I
-	HYPH	I-NP	I
embolism	NN	I-NP	I
in	IN	B-PP	O
women	NNS	B-NP	O
taking	VBG	B-VP	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
:	:	O	O
their	PRP$	B-NP	O
absolute	JJ	I-NP	O
risk	NN	I-NP	O
remained	VBD	B-VP	O
low	JJ	B-ADJP	O
,	,	O	O
at	IN	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
powered	VBN	I-VP	O
to	TO	I-VP	O
detect	VB	I-VP	O
differences	NNS	B-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
of	IN	B-PP	O
younger	JJR	B-NP	O
women	NNS	I-NP	O
.	.	O	O

AUTHORS	NN	B-NP	O
CONCLUSIONS	NNS	I-NP	O
:	:	O	O
HT	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
indicated	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
routine	JJ	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
need	VBP	B-VP	O
more	JJR	B-NP	O
evidence	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
HT	NN	B-NP	O
for	IN	B-PP	O
menopausal	JJ	B-NP	O
symptom	NN	I-NP	O
control	NN	I-NP	O
,	,	O	O
though	IN	B-SBAR	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
relatively	RB	B-ADJP	O
safe	JJ	I-ADJP	O
for	IN	B-PP	O
healthy	JJ	B-NP	O
younger	JJR	I-NP	O
women	NNS	I-NP	O
.	.	O	O

Passage	NN	B-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
around	IN	B-PP	O
gliomas	NNS	B-NP	B
:	:	O	O
a	DT	B-NP	O
potential	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
rebound	NN	B-NP	O
phenomenon	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Widespread	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
brain	NN	B-NP	B
edema	NN	I-NP	I
and	CC	O	O
lower	JJR	B-NP	O
elevated	JJ	I-NP	B
ICP	NN	I-NP	I
in	IN	B-PP	O
brain	NN	B-NP	B
tumor	NN	I-NP	I
patients	NNS	I-NP	O
continues	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
afflicted	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
so	RB	I-NP	O
-	HYPH	I-NP	O
called	VBN	I-NP	O
rebound	NN	I-NP	O
phenomenon	NN	I-NP	O
.	.	O	O

Leakage	NN	B-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
parenchyma	NN	I-NP	O
through	IN	B-PP	O
an	DT	B-NP	O
altered	JJ	I-NP	O
BBB	NN	I-NP	O
and	CC	O	O
secondary	JJ	B-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
osmotic	JJ	B-NP	O
gradient	NN	I-NP	O
is	VBZ	B-VP	O
considered	VBN	I-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
rebound	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
has	VBZ	B-VP	O
only	RB	I-VP	O
been	VBN	I-VP	O
demonstrated	VBN	I-VP	O
experimentally	RB	B-ADVP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
contribution	NN	I-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
issue	NN	I-NP	O
we	PRP	B-NP	O
decided	VBD	B-VP	O
to	TO	I-VP	O
research	VB	I-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
passage	NN	I-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
brain	NN	I-NP	B
tumor	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

Mannitol	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
bolus	NN	I-NP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
(	(	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
malignant	JJ	B-NP	B
glioma	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
brain	NN	I-NP	O
metastases	NNS	I-NP	B
and	CC	O	O
num	CD	B-NP	O
meningioma	NN	I-NP	B
)	)	O	O
about	IN	B-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
before	IN	B-PP	O
craniotomy	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
resection	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
sample	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
surrounding	VBG	I-NP	O
edematous	JJ	I-NP	B
white	JJ	I-NP	O
matter	NN	I-NP	O
was	VBD	B-VP	O
taken	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
ml	NN	I-NP	O
venous	JJ	I-NP	O
blood	NN	I-NP	O
sample	NN	I-NP	O
.	.	O	O

Mannitol	NN	B-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	O	O
white	JJ	B-NP	O
matter	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
modified	VBN	I-NP	O
version	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
enzyme	NN	I-NP	O
assay	NN	I-NP	O
of	IN	B-PP	O
Blonquist	NNP	B-NP	O
et	FW	I-NP	O
al	FW	I-NP	O
.	.	O	O

In	IN	B-PP	O
most	JJS	B-NP	O
glioma	NN	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
mannitol	NN	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
white	JJ	B-NP	O
matter	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
meningioma	NN	B-NP	B
and	CC	O	O
metastases	NNS	B-NP	B
patients	NNS	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
white	JJ	B-NP	O
matter	NN	I-NP	O
concentrations	NNS	I-NP	O
except	IN	B-PP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
infiltration	NN	B-NP	O
by	IN	B-PP	O
neoplastic	JJ	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
even	RB	B-PP	O
after	IN	I-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
bolus	NN	I-NP	O
,	,	O	O
mannitol	NN	B-NP	O
may	MD	B-VP	O
leak	VB	I-VP	O
through	IN	B-PP	O
the	DT	B-NP	O
altered	JJ	I-NP	O
BBB	NN	I-NP	O
near	IN	B-PP	O
gliomas	NNS	B-NP	B
,	,	O	O
reversing	VBG	B-VP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
plasma	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
blood	NN	I-NP	O
osmotic	JJ	I-NP	O
gradient	NN	I-NP	O
,	,	O	O
aggravating	VBG	B-VP	O
peritumoral	JJ	B-NP	O
edema	NN	I-NP	B
and	CC	O	O
promoting	VBG	B-VP	O
rebound	NN	B-NP	O
of	IN	B-PP	O
ICP	NN	B-NP	O
.	.	O	O

Can	MD	O	O
lidocaine	NN	B-NP	O
reduce	VB	B-VP	O
succinylcholine	NN	B-NP	O
induced	JJ	I-NP	O
postoperative	JJ	I-NP	B
myalgia	NN	I-NP	I
?	.	O	O
This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
pretreatment	NN	I-NP	O
on	IN	B-PP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myalgia	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
general	JJ	B-NP	O
anesthesia	NN	I-NP	O
for	IN	B-PP	O
gynecological	JJ	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
manner	NN	I-NP	O
.	.	O	O

Group	NNP	B-NP	O
PS	NNP	I-NP	O
,	,	O	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
received	VBD	B-VP	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
and	CC	I-NP	O
succinylcholine	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
x	SYM	B-NP	O
kg	NN	I-NP	O
;	:	O	O
Group	NN	B-NP	O
LS	NN	I-NP	O
,	,	O	O
lidocaine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
x	SYM	B-NP	O
kg	NN	B-NP	O
and	CC	I-NP	O
succinylcholine	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
x	SYM	B-NP	O
kg	NN	I-NP	O
;	:	O	O
Group	NN	B-NP	O
PR	NN	I-NP	O
,	,	O	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
and	CC	O	O
rocuronium	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
x	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Morphine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
x	SYM	B-NP	O
kg	NN	I-NP	O
iv	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
for	IN	B-PP	O
premedication	NN	B-NP	O
and	CC	O	O
all	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
noninvasive	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
monitor	NN	I-NP	O
,	,	O	O
ECG	NN	B-NP	O
and	CC	O	O
pulse	NN	B-NP	O
oximetry	NN	I-NP	O
.	.	O	O

Anesthesia	NNP	B-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg.kg	NN	I-NP	O
thiopental	NN	I-NP	O
iv.	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
succinylcholine	NN	B-NP	O
(	(	O	O
Group	NN	B-NP	O
PS	NN	I-NP	O
,	,	O	O
LS	NN	B-NP	O
)	)	O	O
or	CC	O	O
rocuronium	NN	B-NP	O
(	(	O	O
Group	NN	B-NP	O
PR	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
tracheal	JJ	B-NP	O
intubation	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
,	,	O	O
and	CC	O	O
degree	NN	B-NP	O
of	IN	B-PP	O
fasciculation	NN	B-NP	B
were	VBD	B-VP	O
assessed	VBN	I-VP	O
visually	RB	B-ADVP	O
on	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
point	NN	I-NP	O
scale	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
investigator	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
blinded	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
administered	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
patient	NN	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
occasions	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
any	DT	B-NP	O
myalgia	NN	I-NP	B
experienced	VBN	B-VP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
structured	JJ	I-NP	O
questionaire	NN	I-NP	O
and	CC	O	O
graded	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
point	NN	I-NP	O
scale	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
investigator	NN	I-NP	O
blinded	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
intraoperative	JJ	I-NP	O
management	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
muscle	NN	B-NP	B
fasciculation	NN	I-NP	I
was	VBD	B-VP	O
not	RB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
Group	NN	B-NP	O
PR	NN	I-NP	O
while	IN	B-SBAR	O
the	DT	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
LS	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	B
fasciculation	NN	I-NP	I
than	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
Group	NNP	B-NP	O
PS	NNP	I-NP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
myalgia	NN	B-NP	B
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
Group	NN	B-NP	O
PS	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
Group	NN	B-NP	O
LS	NN	I-NP	O
and	CC	I-NP	O
PR	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
correlation	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
myalgia	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	B
fasciculation	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
systolic	JJ	B-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
significant	JJ	I-ADJP	O
among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
where	WRB	B-ADVP	O
succinylcholine	NN	B-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
,	,	O	O
lidocaine	NN	B-NP	O
is	VBZ	B-VP	O
proven	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
useful	JJ	I-NP	O
pretreatment	NN	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
myalgia	NN	I-NP	I
.	.	O	O

Open	JJ	B-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
levofloxacin	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
bacterial	JJ	I-NP	O
sinusitis	NN	I-NP	B
in	IN	B-PP	O
adults	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
levofloxacin	NN	B-NP	O
in	IN	B-PP	O
treating	VBG	B-VP	O
adult	JJ	B-NP	O
outpatients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
bacterial	JJ	I-NP	O
sinusitis	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
enrolled	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
centers	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
therapy	NN	I-NP	O
Gram	NN	I-NP	O
s	VBZ	B-VP	O
stain	NN	B-NP	O
and	CC	I-NP	O
culture	NN	I-NP	O
of	IN	B-PP	O
sinus	NN	B-NP	O
exudate	NN	I-NP	O
obtained	VBN	B-VP	O
by	IN	B-PP	O
antral	JJ	B-NP	O
puncture	NN	I-NP	O
or	CC	O	O
nasal	JJ	B-NP	O
endoscopy	NN	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
signs	NNS	B-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
sinus	NN	B-NP	O
radiograph	NN	I-NP	O
or	CC	O	O
computed	VBN	B-NP	O
tomography	NN	I-NP	O
results	NNS	I-NP	O
.	.	O	O

Microbiologic	JJ	B-NP	O
cure	NN	I-NP	O
rates	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
presumed	VBN	B-NP	O
plus	CC	I-NP	O
documented	VBN	I-NP	O
eradication	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
therapy	NN	I-NP	O
pathogen	NN	I-NP	O
(	(	I-NP	O
s	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
pathogens	NNS	I-NP	O
were	VBD	B-VP	O
Haemophilus	NNP	B-NP	O
influenzae	NNP	I-NP	O
,	,	O	O
Streptococcus	NNP	B-NP	O
pneumoniae	NNP	I-NP	O
,	,	O	O
Staphylococcus	NNP	B-NP	O
aureus	NNP	I-NP	O
,	,	O	O
and	CC	O	O
Moraxella	NNP	B-NP	O
catarrhalis	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
clinically	RB	I-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
cured	VBN	I-VP	O
and	CC	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
improved	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
therapy	NN	I-NP	O
evaluation	NN	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
success	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
clinically	RB	B-ADVP	O
failed	VBD	B-VP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
microbiologic	JJ	I-NP	O
eradication	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
presumed	VBN	B-VP	O
plus	CC	I-VP	O
documented	VBN	I-VP	O
)	)	O	O
among	IN	B-PP	O
num	CD	B-NP	O
microbiologically	RB	I-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Microbiologic	JJ	B-NP	O
eradication	NN	I-NP	O
rates	NNS	I-NP	O
(	(	O	O
presumed	VBN	B-VP	O
plus	CC	I-VP	O
documented	VBN	I-VP	O
)	)	O	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
pathogens	NNS	I-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
M.	NN	B-NP	O
catarrhalis	NN	I-NP	O
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
S.	FW	B-NP	O
pneumoniae	FW	I-NP	O
)	)	O	O
at	IN	B-PP	O
the	DT	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
therapy	NN	I-NP	O
visit	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
but	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
cured	VBN	I-VP	O
or	CC	I-VP	O
improved	VBN	I-VP	O
at	IN	B-PP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
therapy	NN	I-NP	O
returned	VBN	B-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
visit	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
remained	VBD	B-VP	O
well	RB	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
therapy	NN	B-NP	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
relapse	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
events	NNS	I-NP	O
considered	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
levofloxacin	NN	B-NP	O
administration	NN	I-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
drug	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
diarrhea	NN	B-NP	B
,	,	O	O
flatulence	NN	B-NP	B
,	,	O	O
and	CC	O	O
nausea	NN	B-NP	B
;	:	O	O
most	RBS	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
mild	JJ	B-ADJP	O
to	TO	B-VP	O
moderate	VB	I-VP	O
in	IN	B-PP	O
severity	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
levofloxacin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
and	CC	I-NP	O
safe	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
acute	JJ	B-NP	O
bacterial	JJ	I-NP	O
sinusitis	NN	I-NP	B
.	.	O	O

Clinical	JJ	B-NP	O
evaluation	NN	I-NP	O
on	IN	B-PP	O
combined	VBN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
prostacyclin	NN	I-NP	O
analogue	NN	I-NP	O
beraprost	NN	I-NP	O
and	CC	O	O
phosphodiesterase	NN	B-NP	O
inhibitor	NN	I-NP	O
cilostazol	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
various	JJ	B-NP	O
oral	JJ	I-NP	O
antiplatelets	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
prostacyclin	NN	I-NP	O
analogue	NN	I-NP	O
beraprost	NN	I-NP	O
(	(	O	O
BPT	NN	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
potent	JJ	I-NP	O
phosphodiesterase	NN	I-NP	O
inhibitor	NN	I-NP	O
cilostazol	NN	I-NP	O
(	(	O	O
CLZ	NN	B-NP	O
)	)	O	O
may	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
untoward	JJ	B-NP	O
clinical	JJ	I-NP	O
effects	NNS	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
possible	JJ	B-NP	O
synergistic	JJ	I-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
intracellular	JJ	B-NP	O
cAMP	NN	I-NP	O
(	(	O	O
cyclic	JJ	B-NP	O
adenosine	NN	I-NP	O
num	CD	I-NP	O
'	SYM	B-NP	O
,	,	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
monophosphate	NN	I-NP	O
)	)	O	O
.	.	O	O

Thereby	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
agents	NNS	I-NP	O
was	VBD	B-VP	O
attempted	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
volunteers	NNS	I-NP	O
were	VBD	B-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
take	VB	I-VP	O
BPT	NN	B-NP	O
/	SYM	B-NP	O
CLZ	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
schedule	NN	I-NP	O
;	:	O	O
BPT	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
t.i.d.	VBN	B-VP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
CLZ	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
t.i.d.	RB	B-ADVP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

At	IN	B-PP	O
various	JJ	B-NP	O
time	NN	I-NP	O
intervals	NNS	I-NP	O
,	,	O	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
and	CC	I-NP	O
blood	NN	I-NP	O
collection	NN	I-NP	O
for	IN	B-PP	O
ex	FW	B-NP	O
vivo	FW	I-NP	O
platelet	NN	I-NP	B
aggregation	NN	I-NP	I
and	CC	I-NP	O
determination	NN	I-NP	O
of	IN	B-PP	O
intraplatelet	JJ	B-NP	O
cAMP	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

Throughout	IN	B-PP	O
the	DT	B-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
significant	JJ	I-NP	O
alteration	NN	I-NP	O
in	IN	B-PP	O
vital	JJ	B-NP	O
signs	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
experienced	VBD	B-VP	O
headache	NN	B-NP	B
of	IN	B-PP	O
a	DT	B-NP	O
short	JJ	I-NP	O
duration	NN	I-NP	O
accompanying	VBG	B-VP	O
facial	JJ	B-NP	B
flush	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
nausea	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
after	IN	B-PP	O
ingestion	NN	B-NP	O
of	IN	B-PP	O
CLZ	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
probably	RB	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
vasodilating	VBG	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
of	IN	B-PP	O
mild	JJ	B-NP	O
degree	NN	I-NP	O
and	CC	O	O
no	DT	B-NP	O
special	JJ	I-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
required	VBN	I-VP	O
.	.	O	O

Intraplatelet	JJ	B-NP	O
cAMP	NN	I-NP	O
content	NN	I-NP	O
was	VBD	B-VP	O
gradually	RB	B-VP	O
but	CC	I-VP	O
significantly	RB	I-VP	O
increased	VBD	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
pmol	NN	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
platelets	NNS	I-NP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
value	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
platelet	NN	I-NP	O
aggregability	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
suppressed	VBN	I-VP	O
at	IN	B-PP	O
various	JJ	B-NP	O
time	NN	I-NP	O
intervals	NNS	I-NP	O
but	CC	O	O
no	DT	B-NP	O
additive	JJ	I-NP	O
or	CC	I-NP	O
synergistic	JJ	I-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
combined	VBN	I-NP	O
administration	NN	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
combined	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
BPT	NN	B-NP	O
/	SYM	B-NP	O
CLZ	NN	I-NP	O
is	VBZ	B-VP	O
safe	JJ	B-ADJP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
though	IN	B-SBAR	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
clinical	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combined	VBN	I-NP	O
administration	NN	I-NP	O
has	VBZ	B-VP	O
yet	RB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
elucidated	VBN	I-VP	O
.	.	O	O

Gastrointestinal	JJ	B-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
etoricoxib	NN	B-NP	O
in	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
patients	NNS	I-NP	O
:	:	O	O
results	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
etoricoxib	NN	I-NP	O
vs	IN	B-PP	O
diclofenac	NN	B-NP	O
sodium	NN	I-NP	O
gastrointestinal	JJ	I-NP	O
tolerability	NN	I-NP	O
and	CC	I-NP	O
effectiveness	NN	I-NP	O
trial	NN	I-NP	O
(	(	O	O
EDGE	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
randomised	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
gastrointestinal	JJ	I-NP	O
(	(	O	O
GI	NN	B-NP	O
)	)	O	O
tolerability	NN	B-NP	O
,	,	O	O
safety	NN	B-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
etoricoxib	NN	B-NP	O
and	CC	I-NP	O
diclofenac	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
(	(	O	O
RA	NN	B-NP	B
)	)	O	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
diagnosed	VBN	B-VP	O
with	IN	B-PP	O
RA	NN	B-NP	B
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
and	CC	O	O
received	VBN	B-VP	O
etoricoxib	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
daily	JJ	I-NP	O
or	CC	I-NP	O
diclofenac	NN	I-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
gastroprotective	JJ	B-NP	O
agents	NNS	I-NP	O
and	CC	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
aspirin	NN	I-NP	O
was	VBD	B-VP	O
allowed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
prespecified	VBN	I-NP	O
primary	JJ	I-NP	O
end	NN	I-NP	O
point	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
cumulative	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
patient	NN	B-NP	O
discontinuations	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
GI	NN	I-NP	O
adverse	JJ	I-NP	O
experiences	NNS	I-NP	O
(	(	O	O
AEs	NNS	B-NP	O
)	)	O	O
.	.	O	O

General	JJ	B-NP	O
safety	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
assessed	VBN	I-VP	O
,	,	O	O
including	VBG	B-PP	O
adjudicated	VBN	B-NP	O
thrombotic	JJ	I-NP	B
cardiovascular	JJ	I-NP	I
event	NN	I-NP	O
data	NNS	I-NP	O
.	.	O	O

Efficacy	NN	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Patient	NN	I-NP	O
Global	NNP	I-NP	O
Assessment	NN	I-NP	O
of	IN	B-PP	O
Disease	NN	B-NP	O
Status	NN	I-NP	O
(	(	O	O
PGADS	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
point	NN	I-NP	O
scale	NN	I-NP	O
)	)	O	O
.	.	O	O

Mean	NN	B-NP	O
(	(	O	O
SD	NN	B-NP	O
;	:	O	O
maximum	NN	B-NP	O
)	)	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
etoricoxib	NN	I-NP	O
and	CC	I-NP	O
diclofenac	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
cumulative	JJ	I-NP	O
discontinuation	NN	I-NP	O
rate	NN	I-NP	O
due	IN	B-PP	O
to	TO	I-PP	O
GI	NN	B-NP	B
AEs	NNS	I-NP	I
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
with	IN	B-PP	O
etoricoxib	NN	B-NP	O
than	IN	B-PP	O
diclofenac	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
vs	IN	I-NP	O
num	CD	I-NP	O
events	NNS	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
;	:	O	O
hazard	NN	B-NP	O
ratio	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
discontinuations	NNS	B-NP	O
for	IN	B-PP	O
hypertension	NN	B-NP	B
-	HYPH	B-NP	O
related	VBN	I-NP	O
and	CC	I-NP	O
oedema	NN	I-NP	B
-	HYPH	B-NP	O
related	VBN	I-NP	O
AEs	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
with	IN	B-PP	O
etoricoxib	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
respectively	RB	B-ADVP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
diclofenac	NN	B-NP	O
.	.	O	O

Etoricoxib	NN	B-NP	O
and	CC	I-NP	O
diclofenac	NN	I-NP	O
treatment	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
similar	JJ	B-NP	O
efficacy	NN	I-NP	O
(	(	O	O
PGADS	NN	B-NP	O
mean	NN	I-NP	O
changes	NNS	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
-	HYPH	B-ADVP	O
num	CD	B-NP	O
vs	NNS	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Etoricoxib	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
lower	JJR	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
discontinuing	VBG	B-VP	O
treatment	NN	B-NP	O
due	IN	B-PP	O
to	TO	B-PP	O
GI	NN	B-NP	B
AEs	NNS	I-NP	I
compared	VBN	B-PP	O
with	IN	B-PP	O
diclofenac	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

Discontinuations	NNS	B-NP	O
from	IN	B-PP	O
renovascular	JJ	B-NP	O
AEs	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
less	RBR	B-ADJP	O
common	JJ	I-ADJP	O
than	IN	B-PP	O
discontinuations	NNS	B-NP	O
from	IN	B-PP	O
GI	NN	B-NP	B
AEs	NNS	I-NP	I
,	,	O	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
with	IN	B-PP	O
etoricoxib	NN	B-NP	O
.	.	O	O

Placebo	AFX	B-NP	O
-	HYPH	I-NP	O
level	NN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
(	(	O	O
EPS	NNS	B-NP	B
)	)	O	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
in	IN	B-PP	O
controlled	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
bipolar	JJ	B-NP	B
mania	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
(	(	O	O
EPS	NNS	B-NP	B
)	)	O	O
,	,	O	O
including	VBG	B-PP	O
akathisia	NN	B-NP	B
,	,	O	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
bipolar	JJ	B-NP	B
mania	NN	I-NP	I
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
similarly	RB	I-NP	O
designed	VBN	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
studies	NNS	I-NP	O
evaluated	VBD	B-VP	O
quetiapine	NN	B-NP	O
monotherapy	NN	I-NP	O
versus	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
lithium	NN	B-NP	O
or	CC	I-NP	O
haloperidol	NN	I-NP	O
monotherapy	NN	I-NP	O
as	IN	B-PP	O
respective	JJ	B-NP	O
active	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
studies	NNS	I-NP	O
evaluated	VBD	B-VP	O
quetiapine	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
mood	NN	I-NP	O
stabilizer	NN	I-NP	O
(	(	O	O
lithium	NN	B-NP	O
or	CC	O	O
divalproex	NN	B-NP	O
,	,	O	O
QTP	NN	B-NP	O
+	SYM	B-NP	O
Li	NN	I-NP	O
/	SYM	I-NP	O
DVP	NN	I-NP	O
)	)	O	O
compared	VBN	B-VP	O
to	TO	B-PP	O
placebo	NN	B-NP	O
and	CC	I-NP	O
mood	NN	I-NP	O
stabilizer	NN	I-NP	O
(	(	O	O
PBO	NN	B-NP	O
+	SYM	B-NP	O
Li	NN	I-NP	O
/	SYM	I-NP	O
DVP	NN	I-NP	O
)	)	O	O
.	.	O	O

Extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Simpson	NNP	I-NP	O
-	HYPH	I-NP	O
Angus	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
SAS	NNP	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
Barnes	NNP	I-NP	O
Akathisia	NNP	I-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
BARS	NNP	B-NP	O
)	)	O	O
,	,	O	O
adverse	JJ	B-NP	O
event	NN	I-NP	O
reports	NNS	I-NP	O
and	CC	O	O
anticholinergic	JJ	B-NP	O
drug	NN	I-NP	O
usage	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
EPS	NN	B-NP	B
-	HYPH	O	O
related	VBN	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
akathisia	NN	B-NP	B
,	,	O	O
was	VBD	B-VP	O
no	DT	B-NP	O
different	JJ	I-NP	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
monotherapy	NN	I-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
EPS	NN	B-NP	B
-	HYPH	O	O
related	VBN	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
with	IN	B-PP	O
QTP	NN	B-NP	O
+	SYM	I-NP	O
Li	NN	I-NP	O
/	SYM	B-NP	O
DVP	NN	I-NP	O
were	VBD	B-VP	O
no	RB	B-ADJP	O
different	JJ	I-ADJP	O
than	IN	B-PP	O
with	IN	B-PP	O
PBO	NN	B-NP	O
+	SYM	B-NP	O
Li	NN	I-NP	O
/	SYM	I-NP	O
DVP	NN	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
events	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
EPS	NNP	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
monotherapy	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
monotherapy	NN	I-NP	O
experienced	VBD	B-VP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
EPS	NNP	B-NP	B
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
akathisia	NN	B-NP	B
was	VBD	B-VP	O
low	JJ	B-ADJP	O
and	CC	I-ADJP	O
similar	JJ	I-ADJP	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
monotherapy	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
with	IN	B-PP	O
QTP	NN	B-NP	O
+	SYM	B-NP	O
Li	NN	I-NP	O
/	SYM	B-NP	O
DVP	NN	I-NP	O
and	CC	I-NP	O
PBO	NN	I-NP	O
+	SYM	B-NP	O
Li	NN	I-NP	O
/	SYM	I-NP	O
DVP	NN	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
tremor	NN	B-NP	B
than	IN	B-PP	O
quetiapine	NN	B-NP	O
;	:	O	O
cerebellar	JJ	B-NP	O
tremor	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
known	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
,	,	O	O
may	MD	B-VP	O
have	VB	I-VP	O
contributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
elevated	VBN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
tremor	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Haloperidol	NN	B-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
akathisia	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
tremor	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
extrapyramidal	JJ	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
than	IN	B-PP	O
quetiapine	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
quetiapine	NN	B-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
on	IN	B-PP	O
SAS	NNP	B-NP	O
and	CC	I-NP	O
BARS	NNP	I-NP	O
scores	NNS	I-NP	O
.	.	O	O

Anticholinergic	JJ	B-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
low	JJ	B-ADJP	O
and	CC	I-ADJP	O
similar	JJ	I-ADJP	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
bipolar	JJ	B-NP	B
mania	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
EPS	NN	B-NP	B
,	,	O	O
including	VBG	B-PP	O
akathisia	NN	B-NP	B
,	,	O	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

Contribution	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sympathetic	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
to	TO	B-PP	O
salt	NN	B-NP	O
-	HYPH	B-NP	O
sensitivity	NN	I-NP	O
in	IN	B-PP	O
lifetime	NN	B-NP	O
captopril	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-NP	O
,	,	O	O
in	IN	B-PP	O
lifetime	NN	B-NP	O
captopril	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
(	(	O	O
SHR	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
sympathetic	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
contributes	VBZ	B-VP	O
importantly	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
dietary	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
supplementation	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
SHR	NN	I-NP	O
(	(	O	O
aged	VBN	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
)	)	O	O
that	WDT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
from	IN	B-PP	O
conception	NN	B-NP	O
onward	RB	B-ADVP	O
with	IN	B-PP	O
either	CC	O	O
captopril	NN	B-NP	O
or	CC	I-NP	O
vehicle	NN	I-NP	O
remained	VBD	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
basal	JJ	I-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
diet	NN	I-NP	O
or	CC	O	O
were	VBD	B-VP	O
fed	VBN	I-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
diet	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
ganglionic	JJ	B-NP	O
blockade	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
an	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
.	.	O	O

Lifetime	NN	B-NP	O
captopril	NN	I-NP	O
treatment	NN	I-NP	O
significantly	RB	B-ADVP	O
lowered	VBD	B-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ganglionic	JJ	I-NP	O
blocker	NN	I-NP	O
hexamethonium	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
MAP	NN	B-NP	O
that	WDT	B-NP	O
eliminated	VBD	B-VP	O
the	DT	B-NP	O
dietary	JJ	I-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increase	NN	I-NP	B
in	IN	B-PP	I
MAP	NN	B-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Infusion	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
alpha2	NN	I-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
clonidine	NN	I-NP	O
also	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
MAP	NN	B-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
SHR	NN	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
fed	VBN	I-VP	O
the	DT	B-NP	O
high	JJ	I-NP	O
(	(	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
)	)	I-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
diet	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
both	CC	O	O
lifetime	NN	B-NP	O
captopril	NN	I-NP	O
-	HYPH	B-VP	O
treated	VBN	I-VP	O
and	CC	O	O
control	NN	B-NP	O
SHR	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
sympathetic	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
pressor	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
diet	NN	I-NP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
beneficial	JJ	I-NP	O
and	CC	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dietary	JJ	B-NP	O
corticosterone	NN	I-NP	O
on	IN	B-PP	O
organophosphorus	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
delayed	VBN	I-NP	O
neuropathy	NN	I-NP	B
in	IN	B-PP	O
chickens	NNS	B-NP	O
.	.	O	O

Tri	AFX	O	O
-	HYPH	B-NP	O
ortho	JJ	I-NP	O
-	HYPH	I-NP	O
tolyl	NN	I-NP	O
phosphate	NN	I-NP	O
(	(	O	O
TOTP	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
,	,	O	O
po	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
diisopropyl	NN	I-NP	O
phosphorofluoridate	NN	I-NP	O
(	(	O	O
DFP	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
sc	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
adult	JJ	B-NP	O
White	NNP	I-NP	O
Leghorn	NNP	I-NP	O
chickens	VBZ	B-VP	O
num	CD	B-NP	O
hr	NN	I-NP	O
after	IN	B-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
placed	VBN	I-VP	O
on	IN	B-PP	O
diets	NNS	B-NP	O
containing	VBG	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
ppm	NN	I-NP	O
corticosterone	NN	I-NP	O
.	.	O	O

Supplemented	VBN	B-NP	O
diets	NNS	I-NP	O
were	VBD	B-VP	O
continued	VBN	I-VP	O
until	IN	B-PP	O
clinical	JJ	B-NP	O
signs	NNS	I-NP	O
and	CC	I-NP	O
lesions	NNS	I-NP	O
of	IN	B-PP	O
delayed	VBN	B-NP	O
neuropathy	NN	I-NP	B
appeared	VBD	B-VP	O
.	.	O	O

Although	IN	B-SBAR	O
low	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
corticosterone	NN	B-NP	O
had	VBD	B-VP	O
beneficial	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
TOTP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neuropathy	NN	I-NP	B
,	,	O	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
ppm	NN	I-NP	O
exacerbated	VBD	B-VP	O
clinical	JJ	B-NP	O
signs	NNS	I-NP	O
in	IN	B-PP	O
chickens	NNS	B-NP	O
given	VBN	B-VP	O
either	CC	O	O
TOTP	NN	B-NP	O
or	CC	I-NP	O
DFP	NN	I-NP	O
.	.	O	O

Neurotoxic	JJ	B-NP	B
esterase	NN	I-NP	O
activities	NNS	I-NP	O
num	CD	B-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
TOTP	NN	B-NP	O
or	CC	I-NP	O
DFP	NN	I-NP	O
were	VBD	B-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
values	NNS	B-NP	O
measured	VBN	B-VP	O
in	IN	B-PP	O
chickens	NNS	B-NP	O
not	RB	B-VP	O
given	VBN	I-VP	O
organophosphorous	JJ	B-NP	O
compounds	NNS	I-NP	O
.	.	O	O

Chickens	NNS	B-NP	O
given	VBN	B-PP	O
num	CD	B-NP	O
ppm	NN	I-NP	O
corticosterone	NN	I-NP	O
without	IN	B-PP	O
TOTP	NN	B-NP	O
or	CC	I-NP	O
DFP	NN	I-NP	O
had	VBD	B-VP	O
significantly	RB	B-NP	O
elevated	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
cholinesterase	NN	I-NP	O
and	CC	O	O
significantly	RB	B-VP	O
inhibited	VBD	I-VP	O
activity	NN	B-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
carboxylesterase	NN	I-NP	O
.	.	O	O

Degenerating	VBG	B-VP	B
myelinated	VBN	B-NP	I
fibers	NNS	I-NP	I
were	VBD	B-VP	O
also	RB	B-ADVP	O
evident	JJ	B-ADJP	O
in	IN	B-PP	O
distal	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nerves	NNS	I-NP	O
of	IN	B-PP	O
chickens	NNS	B-NP	O
given	VBN	B-VP	O
TOTP	NN	B-NP	O
or	CC	I-NP	O
DFP	NN	I-NP	O
.	.	O	O

In	FW	B-NP	O
vivo	FW	I-NP	O
characterization	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
dual	JJ	I-NP	O
adenosine	NN	I-NP	O
A2A	NN	I-NP	O
/	SYM	B-NP	O
A1	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
in	IN	B-PP	O
animal	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
characterization	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
dual	JJ	I-NP	O
adenosine	NN	I-NP	O
A	NN	I-NP	O
(	(	O	O
2A	NN	B-NP	O
)	)	O	O
/	SYM	B-NP	O
A	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
in	IN	B-PP	O
several	JJ	B-NP	O
animal	NN	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

Discovery	NNP	B-NP	O
and	CC	O	O
scale	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
syntheses	NNS	B-NP	O
of	IN	B-PP	O
compound	NN	B-NP	O
num	CD	I-NP	O
are	VBP	B-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
detail	NN	B-NP	O
,	,	O	O
highlighting	VBG	B-VP	O
optimization	NN	B-NP	O
steps	NNS	I-NP	O
that	WDT	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
overall	JJ	I-NP	O
yield	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Compound	NN	B-NP	O
num	CD	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
A	NN	I-NP	O
(	(	O	O
2A	NN	B-NP	O
)	)	O	O
/	SYM	B-NP	O
A	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
(	(	O	O
A	NN	B-NP	O
(	(	O	O
2A	NN	B-NP	O
)	)	O	O
K	NN	B-NP	O
(	(	O	O
i	NN	B-NP	O
)	)	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
nM	NN	I-NP	O
;	:	O	O
A	DT	B-NP	O
K	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
excellent	JJ	B-NP	O
activity	NN	I-NP	O
,	,	O	O
after	IN	B-SBAR	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
,	,	O	O
across	IN	B-PP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
animal	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
including	VBG	B-PP	O
mouse	NN	B-NP	O
and	CC	I-NP	O
rat	NN	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
mouse	NN	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
reserpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
akinesia	NN	I-NP	B
,	,	O	O
rat	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxydopamine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
)	)	O	O
lesion	NN	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rotation	NN	I-NP	O
,	,	O	O
and	CC	O	O
MPTP	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
non	AFX	B-ADJP	O
-	HYPH	B-NP	O
human	JJ	I-NP	O
primate	JJ	I-NP	O
model	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
extremely	RB	I-NP	O
rare	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
delusional	JJ	B-NP	B
parasitosis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
chronic	JJ	I-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
patient	NN	I-NP	O
during	IN	B-PP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
2b	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
patients	NNS	I-NP	O
with	IN	B-PP	O
interferon	NN	B-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
lot	NN	I-NP	O
of	IN	B-PP	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
described	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
develop	VBP	B-VP	O
depression	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
minority	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
evolve	VBP	B-VP	O
to	TO	B-PP	O
psychosis	NN	B-NP	B
.	.	O	O

To	TO	B-PP	O
the	DT	B-NP	O
best	JJS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
psychogenic	JJ	B-NP	B
parasitosis	NN	I-NP	I
occurring	VBG	B-VP	O
during	IN	B-PP	O
interferon	NN	B-NP	O
therapy	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
delusional	JJ	I-NP	B
parasitosis	NN	I-NP	I
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
2b	NN	I-NP	O
weekly	JJ	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
seeing	VBG	B-NP	O
parasites	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
larvae	NNS	I-NP	O
of	IN	B-PP	O
fleas	NNS	B-NP	O
in	IN	B-PP	O
her	PRP$	B-NP	O
stools	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
any	DT	B-NP	O
technical	JJ	I-NP	O
examination	NN	I-NP	O
.	.	O	O

All	PDT	B-NP	O
the	DT	I-NP	O
complaints	NNS	I-NP	O
disappeared	VBD	B-VP	O
after	IN	B-PP	O
stopping	VBG	B-VP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
alpha	SYM	O	O
-	HYPH	O	O
2b	NN	B-NP	O
and	CC	O	O
reappeared	VBD	B-VP	O
after	IN	B-PP	O
restarting	VBG	B-VP	O
it	PRP	B-NP	O
.	.	O	O

She	PRP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
sustained	JJ	I-NP	O
viral	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

Possible	JJ	B-NP	O
neuroleptic	JJ	I-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
concomitant	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
paroxetine	NN	B-NP	O
and	CC	I-NP	O
alprazolam	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
depressive	JJ	B-NP	B
symptoms	NNS	I-NP	I
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
psychiatric	JJ	I-NP	B
hospital	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
insomnia	NN	B-NP	B
,	,	O	O
loss	NN	B-NP	B
of	IN	B-PP	I
appetite	NN	B-NP	I
,	,	O	O
exhaustion	NN	B-NP	O
,	,	O	O
and	CC	O	O
agitation	NN	B-NP	B
.	.	O	O

Medical	JJ	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
paroxetine	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
alprazolam	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
10th	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
paroxetine	NN	B-NP	O
and	CC	I-NP	O
alprazolam	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
exhibited	VBD	B-VP	O
marked	JJ	B-NP	O
psychomotor	NN	I-NP	B
retardation	NN	I-NP	I
,	,	O	O
disorientation	NN	B-NP	O
,	,	O	O
and	CC	O	O
severe	JJ	B-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
with	IN	B-PP	O
tremors	NNS	B-NP	B
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
fever	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
C	NN	I-NP	O
)	)	O	O
,	,	O	O
fluctuating	VBG	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
severe	JJ	B-NP	O
extrapyramidal	JJ	I-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

Laboratory	NN	B-NP	O
tests	NNS	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
creatine	NN	B-NP	O
phosphokinase	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
)	)	O	O
,	,	O	O
aspartate	NN	B-NP	O
aminotransferase	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
)	)	O	O
,	,	O	O
alanine	NN	B-NP	O
aminotransferase	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
BUN	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
received	VBD	B-VP	O
bromocriptine	NN	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
his	PRP$	B-NP	O
symptoms.	NN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
fever	NN	I-NP	B
disappeared	VBD	B-VP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
serum	NN	I-NP	O
CPK	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
normalized	VBN	I-VP	O
(	(	O	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
NMS	NN	B-NP	B
)	)	O	O
,	,	O	O
thus	RB	B-ADVP	O
demonstrating	VBG	B-VP	O
that	IN	B-SBAR	O
NMS	NN	B-NP	B
-	HYPH	B-VP	O
like	JJ	B-NP	O
symptoms	NNS	I-NP	O
can	MD	B-VP	O
occur	VB	I-VP	O
after	IN	B-PP	O
combined	VBN	B-NP	O
paroxetine	NN	I-NP	O
and	CC	I-NP	O
alprazolam	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
score	NN	I-NP	O
obtained	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
algorithm	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
case	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
probable	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
NMS	NN	B-NP	B
-	HYPH	O	O
like	JJ	B-NP	O
adverse	JJ	I-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
combined	JJ	I-NP	O
treatment	NN	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
physiologic	JJ	B-NP	O
and	CC	I-NP	O
environmental	JJ	I-NP	O
aspects	NNS	I-NP	O
specific	JJ	B-ADJP	O
to	TO	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
suspected	VBN	I-VP	O
.	.	O	O

Several	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
NMS	NN	B-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
depressive	JJ	I-NP	B
patients	NNS	I-NP	O
whose	WP$	B-NP	O
symptoms	NNS	I-NP	O
often	RB	B-ADVP	O
include	VBP	B-VP	O
dehydration	NN	B-NP	B
,	,	O	O
agitation	NN	B-NP	B
,	,	O	O
malnutrition	NN	B-NP	B
,	,	O	O
and	CC	O	O
exhaustion	NN	B-NP	O
.	.	O	O

Careful	JJ	B-NP	O
therapeutic	JJ	I-NP	O
intervention	NN	I-NP	O
is	VBZ	B-VP	O
necessary	JJ	B-ADJP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
involving	VBG	B-VP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
suffer	VBP	B-VP	O
from	IN	B-PP	O
depression	NN	B-NP	B
.	.	O	O

Pilocarpine	NN	B-NP	O
seizures	NNS	I-NP	B
cause	VBP	B-VP	O
age	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
impairment	NN	I-NP	B
in	IN	B-PP	I
auditory	JJ	B-NP	I
location	NN	I-NP	I
discrimination	NN	I-NP	I
.	.	O	O

Children	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
have	VBP	B-VP	O
continuous	JJ	B-ADJP	O
or	CC	O	O
rapidly	RB	B-VP	O
repeating	VBG	I-VP	O
seizures	NNS	B-NP	B
that	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
and	CC	O	O
may	MD	B-VP	O
cause	VB	I-VP	O
life	NN	B-NP	O
-	HYPH	B-NP	O
long	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
and	CC	I-NP	O
behavior	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
extent	NN	I-NP	O
to	TO	B-PP	O
which	WDT	B-NP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
causes	VBZ	B-VP	O
deficits	NNS	B-NP	B
in	IN	B-PP	I
auditory	JJ	B-NP	I
discrimination	NN	I-NP	I
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
naturalistic	JJ	I-NP	O
auditory	JJ	I-NP	O
location	NN	I-NP	O
discrimination	NN	I-NP	O
method	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
this	DT	B-NP	O
question	NN	I-NP	O
using	VBG	B-VP	O
an	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

Male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
on	IN	B-PP	O
postnatal	JJ	B-NP	O
day	NN	I-NP	O
(	(	O	O
P	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
or	CC	O	O
a	DT	B-NP	O
convulsant	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
on	IN	B-PP	O
P20	NN	B-NP	O
or	CC	I-NP	O
P45	NN	I-NP	O
.	.	O	O

Pilocarpine	NN	B-NP	O
on	IN	B-PP	O
either	CC	B-NP	O
day	NN	I-NP	O
induced	VBD	B-VP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
;	:	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
at	IN	B-PP	O
P45	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
CA3	NN	B-NP	O
cell	NN	I-NP	O
loss	NN	I-NP	O
and	CC	O	O
spontaneous	JJ	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
whereas	IN	O	O
P20	NN	B-NP	O
rats	NNS	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
cell	NN	I-NP	O
loss	NN	I-NP	O
or	CC	O	O
spontaneous	JJ	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Mature	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
trained	VBN	I-VP	O
with	IN	B-PP	O
sound	JJ	B-NP	O
-	HYPH	I-NP	O
source	NN	I-NP	O
location	NN	I-NP	O
and	CC	I-NP	O
sound	NN	I-NP	O
-	HYPH	B-NP	O
silence	NN	I-NP	O
discriminations	NNS	I-NP	O
.	.	O	O

Control	NN	B-NP	O
(	(	O	O
saline	NN	B-NP	O
P20	NN	I-NP	O
)	)	O	O
rats	NNS	B-NP	O
acquired	VBD	B-VP	O
both	DT	B-NP	O
discriminations	NNS	I-NP	O
immediately	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
(	(	O	O
P20	NN	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
,	,	O	O
acquisition	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sound	JJ	I-NP	O
-	HYPH	I-NP	O
source	NN	I-NP	O
location	NN	I-NP	O
discrimination	NN	I-NP	O
was	VBD	B-VP	O
moderately	RB	B-ADJP	O
impaired	JJ	I-ADJP	O
.	.	O	O

Status	NN	B-NP	B
epilepticus	NN	I-NP	I
(	(	O	O
P45	NN	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
acquire	VB	I-VP	O
either	CC	I-VP	O
sound	VB	I-VP	O
-	HYPH	B-NP	O
source	NN	I-NP	O
location	NN	I-NP	O
or	CC	I-NP	O
sound	NN	I-NP	O
-	HYPH	B-NP	O
silence	NN	I-NP	O
discriminations	NNS	I-NP	O
.	.	O	O

Status	NN	B-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
rat	NN	B-NP	O
causes	VBZ	B-VP	O
an	DT	B-NP	O
age	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
,	,	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
impairment	NN	I-NP	B
in	IN	B-PP	I
auditory	JJ	B-NP	I
discrimination	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
impairment	NN	I-NP	O
may	MD	B-VP	O
explain	VB	I-VP	O
num	CD	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
impaired	JJ	B-NP	B
auditory	NN	I-NP	I
location	NN	I-NP	I
discrimination	NN	I-NP	I
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

Cardiovascular	JJ	B-NP	O
risk	NN	I-NP	O
with	IN	B-PP	O
cyclooxygenase	NN	B-NP	O
inhibitors	NNS	I-NP	O
:	:	O	O
general	JJ	B-NP	O
problem	NN	I-NP	O
with	IN	B-PP	O
substance	NN	B-NP	O
specific	JJ	I-NP	O
differences	NNS	I-NP	O
?	.	O	O
Randomised	VBN	B-VP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
and	CC	O	O
observational	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
,	,	O	O
stroke	NN	B-NP	B
,	,	O	O
hypertension	NN	B-NP	B
and	CC	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
cyclooxygenase	NN	B-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
occurred	VBD	B-VP	O
mainly	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
not	RB	B-ADVP	O
exclusively	RB	I-ADVP	O
,	,	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
concomitant	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Cyclooxygenase	NN	B-NP	O
inhibitors	NNS	I-NP	O
cause	VBP	B-VP	O
complex	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
,	,	I-NP	O
vascular	JJ	I-NP	O
and	CC	I-NP	O
cardiac	JJ	I-NP	O
prostanoid	NN	I-NP	O
profiles	NNS	I-NP	O
thereby	RB	B-VP	O
increasing	VBG	I-VP	O
vascular	JJ	B-NP	O
resistance	NN	I-NP	O
and	CC	I-NP	O
fluid	NN	I-NP	O
retention	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
tends	VBZ	B-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
and	CC	O	O
total	JJ	B-NP	O
exposure	NN	I-NP	O
time	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
individual	JJ	B-NP	O
selective	JJ	I-NP	O
and	CC	I-NP	O
unselective	JJ	I-NP	O
cyclooxygenase	NN	I-NP	O
inhibitors	NNS	I-NP	O
suggests	VBZ	B-VP	O
substance	NN	B-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
differences	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
depend	VB	I-VP	O
on	IN	B-PP	O
differences	NNS	B-NP	O
in	IN	B-PP	O
pharmacokinetic	JJ	B-NP	O
parameters	NNS	I-NP	O
or	CC	O	O
inhibitory	JJ	B-NP	O
potency	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
contributed	VBN	I-VP	O
by	IN	B-PP	O
prostaglandin	NN	B-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Diagnostic	JJ	B-NP	O
markers	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
terminal	JJ	I-NP	O
pro	JJ	I-NP	O
brain	NN	I-NP	O
natriuretic	JJ	I-NP	O
peptide	NN	I-NP	O
(	(	O	O
NT	NN	B-NP	O
-	HYPH	B-NP	O
proBNP	NN	I-NP	O
)	)	O	O
or	CC	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
sensitive	JJ	I-NP	O
C	NN	I-NP	O
-	HYPH	B-NP	O
reactive	JJ	I-NP	O
protein	NN	I-NP	O
might	MD	B-VP	O
help	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
identification	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
,	,	O	O
thus	RB	B-ADVP	O
avoiding	VBG	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
cardiovascular	JJ	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

Predictors	NNS	B-NP	O
of	IN	B-PP	O
decreased	VBN	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
during	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
therapy	NN	I-NP	O
:	:	O	O
results	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
(	(	O	O
SOLVD	NN	B-NP	O
)	)	O	O
BACKGROUND	NN	B-NP	O
:	:	O	O
Although	IN	B-SBAR	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
therapy	NN	I-NP	O
reduces	VBZ	B-VP	O
mortality	NN	B-NP	O
rates	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
CHF	NN	B-NP	B
)	)	O	O
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
cause	VB	I-VP	O
decreased	VBN	I-VP	B
renal	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

Little	JJ	B-NP	O
information	NN	I-NP	O
is	VBZ	B-VP	O
available	JJ	B-ADJP	O
to	TO	B-VP	O
predict	VB	I-VP	O
which	WDT	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
at	IN	B-PP	O
highest	JJS	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
quantify	VB	I-VP	O
specific	JJ	B-NP	O
clinical	JJ	I-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
reduction	NN	B-NP	B
in	IN	B-PP	I
renal	JJ	B-NP	I
function	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
CHF	NN	B-NP	B
who	WP	B-NP	O
are	VBP	B-VP	O
prescribed	VBN	I-VP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
analyzed	VBD	B-VP	O
data	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
Studies	NNS	I-NP	O
of	IN	B-PP	O
Left	NNP	B-NP	B
Ventricular	JJ	I-NP	I
Dysfunction	NN	I-NP	I
(	(	O	O
SOLVD	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
enalapril	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
CHF	NN	B-NP	B
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
randomly	RB	B-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
enalapril	VB	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
randomly	RB	B-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
placebo	VB	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Decreased	VBN	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
>	SYM	O	O
/	SYM	O	O
=0.5	SYM	O	O
mg	NN	O	O
/	SYM	O	O
dL	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
)	)	O	O
from	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
time	NN	B-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
event	NN	I-NP	O
analysis	NN	I-NP	O
to	TO	B-VP	O
identify	VB	I-VP	O
potential	JJ	B-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
decrease	NN	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
including	VBG	B-PP	O
age	NN	B-NP	O
,	,	O	O
baseline	NN	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
,	,	O	O
baseline	NN	B-NP	O
creatinine	NN	I-NP	O
,	,	O	O
low	JJ	B-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
history	NN	B-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
,	,	O	O
diabetes	NN	B-NP	B
,	,	O	O
and	CC	O	O
use	NN	B-NP	O
of	IN	B-PP	O
antiplatelet	JJ	B-NP	O
,	,	I-NP	O
diuretic	JJ	I-NP	O
,	,	O	O
and	CC	O	O
beta	SYM	O	O
-	HYPH	O	O
blocker	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
randomly	RB	B-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
enalapril	VB	I-VP	O
had	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
greater	JJR	I-NP	O
likelihood	NN	I-NP	O
of	IN	B-PP	O
decreased	VBN	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
than	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

By	IN	B-PP	O
multivariate	JJ	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
placebo	NN	I-NP	O
and	CC	I-NP	O
enalapril	NN	I-NP	O
groups	NNS	I-NP	O
older	JJR	B-NP	O
age	NN	I-NP	O
,	,	O	O
diuretic	JJ	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
diabetes	NNS	B-NP	B
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
decreased	VBN	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
,	,	O	O
whereas	IN	O	O
beta	SYM	O	O
-	HYPH	B-NP	O
blocker	NN	I-NP	O
therapy	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
were	VBD	B-VP	O
renoprotective	JJ	B-ADJP	O
.	.	O	O

Older	JJR	B-NP	O
age	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
decreased	VBN	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
but	CC	O	O
significantly	RB	B-ADVP	O
more	RBR	I-ADVP	O
so	RB	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
enalapril	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
enalapril	NN	B-NP	O
:	:	O	O
risk	NN	B-NP	O
ratio	NN	I-NP	O
[	(	O	O
RR	NN	B-NP	O
]	)	O	O
num	CD	B-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
[	(	O	O
CI	NN	B-NP	O
]	)	O	O
num	CD	B-NP	O
-	:	O	O
num	CD	B-NP	O
with	IN	B-PP	O
enalapril	NN	B-NP	O
;	:	O	O
placebo	NN	B-NP	O
:	:	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Diuretic	JJ	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
likewise	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
decreased	VBN	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
enalapril	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Conversely	RB	B-ADVP	O
,	,	O	O
enalapril	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
relative	JJ	I-NP	O
renoprotective	JJ	I-NP	O
effect	NN	I-NP	O
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
diabetes	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
lower	JJR	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
impairment	NN	I-NP	I
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
with	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	O	O
blocker	NN	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
higher	JJR	B-NP	O
baseline	NN	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
(	(	O	O
RR	NN	B-NP	O
num	CD	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
increment	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Enalapril	NNP	B-NP	O
use	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
decreased	VBN	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
CHF	NN	B-NP	B
.	.	O	O

Diuretic	JJ	B-NP	O
use	NN	I-NP	O
and	CC	O	O
advanced	JJ	B-NP	O
age	NN	I-NP	O
increased	VBD	B-VP	O
this	DT	B-NP	O
risk	NN	I-NP	O
.	.	O	O

Diabetes	NNS	B-NP	B
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
impairment	NN	I-NP	I
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
CHF	NN	B-NP	B
,	,	O	O
but	CC	O	O
this	DT	B-NP	O
risk	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
enalapril	NN	I-NP	O
group	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group.	NN	I-NP	O
beta	SYM	B-VP	O
-	HYPH	O	O
Blocker	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
were	VBD	B-VP	O
renoprotective	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Pemoline	NN	B-NP	O
induced	VBD	B-VP	O
acute	JJ	B-NP	O
choreoathetosis	NN	I-NP	B
:	:	O	O
case	NN	B-NP	O
report	NN	I-NP	O
and	CC	O	O
review	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Pemoline	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
oxazolidine	NN	I-NP	O
derivative	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
structurally	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
amphetamines	NNS	B-NP	O
and	CC	O	O
used	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
attention	NN	B-NP	B
deficit	NN	I-NP	I
disorder	NN	I-NP	I
.	.	O	O

Pemoline	NN	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
commonly	RB	I-VP	O
associated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
movement	NN	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
following	VBG	I-NP	O
case	NN	I-NP	O
describes	VBZ	B-VP	O
num	CD	B-NP	O
children	NNS	I-NP	O
acutely	RB	B-VP	O
poisoned	VBN	I-VP	O
with	IN	B-PP	O
pemoline	NN	B-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
profound	JJ	B-NP	O
choreoathetosis	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
,	,	I-NP	O
identical	JJ	I-NP	O
twin	NN	I-NP	O
siblings	NNS	I-NP	O
presented	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
after	IN	B-PP	O
found	VBN	B-NP	O
playing	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
an	DT	I-NP	O
empty	JJ	I-NP	O
bottle	NN	I-NP	O
of	IN	B-PP	O
pemoline	NN	B-NP	O
originally	RB	B-VP	O
containing	VBG	I-VP	O
num	CD	B-NP	O
tablets	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
children	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
medical	JJ	I-NP	O
history	NN	I-NP	O
significant	JJ	B-ADJP	O
for	IN	B-PP	O
attention	NN	B-NP	B
deficit	NN	I-NP	I
disorder	NN	I-NP	I
previously	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
methylphenidate	NN	B-NP	O
without	IN	B-PP	O
success	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
their	PRP$	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
pemoline	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
choreoathetoid	JJ	I-NP	B
movements	NNS	I-NP	O
began	VBD	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
ingestion	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
children	NNS	I-NP	O
gave	VBD	B-VP	O
no	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
prior	JJ	B-NP	O
movement	NN	I-NP	B
disorders	NNS	I-NP	I
and	CC	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
family	NN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
movement	NN	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
children	NNS	I-NP	O
received	VBD	B-VP	O
gastrointestinal	JJ	B-NP	O
decontamination	NN	I-NP	O
and	CC	O	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
benzodiazepines	NNS	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
attempt	NN	I-NP	O
to	TO	B-VP	O
control	VB	I-VP	O
the	DT	B-NP	O
choreoathetoid	JJ	I-NP	B
movements	NNS	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
children	NNS	I-NP	O
continued	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
choreoathetosis	NN	B-NP	B
for	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
children	NNS	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
at	IN	B-PP	O
their	PRP$	B-NP	O
baseline	NN	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
discharged	VBN	I-VP	O
home	NN	B-NP	O
.	.	O	O

Pemoline	NN	B-NP	O
associated	VBN	I-NP	O
movement	NN	I-NP	B
disorder	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
rarely	RB	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
toxicology	NN	I-NP	O
literature	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
choreoathetoid	JJ	B-NP	B
movements	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
presenting	VBG	B-VP	O
after	IN	B-PP	O
pemoline	NN	B-NP	O
overdose	NN	I-NP	B
.	.	O	O

Continuous	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
mesna	NN	B-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
ifosfamide	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
.	.	O	O

Hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
potential	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
administering	VBG	B-VP	O
mesna	NN	B-NP	O
along	IN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
cytotoxic	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Mesna	NNP	B-NP	O
is	VBZ	B-VP	O
generally	RB	I-VP	O
administered	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
route	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
experience	NN	B-NP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
delivery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
has	VBZ	B-VP	O
increased	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
continuous	JJ	I-NP	O
subcutaneous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
mesna	NN	B-NP	O
has	VBZ	B-VP	O
the	DT	B-NP	O
advantage	NN	I-NP	O
of	IN	B-PP	O
not	RB	O	O
requiring	VBG	B-VP	O
intravenous	JJ	B-NP	O
access	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
subcutaneous	JJ	B-NP	O
delivery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neutralizing	VBG	I-NP	O
agent	NN	I-NP	O
will	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
inadequate	JJ	B-NP	O
urinary	JJ	I-NP	O
mesna	NN	I-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
taking	VBG	B-VP	O
oral	JJ	B-NP	O
mesna	NN	I-NP	O
who	WP	B-NP	O
experiences	VBZ	B-VP	O
severe	JJ	B-NP	O
ifosfamide	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
emesis	NN	I-NP	B
and	CC	O	O
is	VBZ	B-VP	O
unable	JJ	B-ADJP	O
to	TO	B-VP	O
absorb	VB	I-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Limited	VBN	B-VP	O
clinical	JJ	B-NP	O
experience	NN	I-NP	O
with	IN	B-PP	O
continuous	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
mesna	NN	I-NP	O
administration	NN	I-NP	O
suggests	VBZ	B-VP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
,	,	I-NP	O
practical	JJ	I-NP	O
,	,	O	O
and	CC	O	O
economic	JJ	B-NP	O
method	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
delivery	NN	I-NP	O
that	WDT	B-NP	O
permits	VBZ	B-VP	O
ifosfamide	NN	B-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
successfully	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
outpatient	NN	I-NP	O
setting	NN	I-NP	O
.	.	O	O

Modification	NN	B-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
action	NN	I-NP	O
by	IN	B-PP	O
hyperammonemia	NN	B-NP	B
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
ammonium	NN	B-NP	O
acetate	NN	I-NP	O
(	(	O	O
NH4Ac	NN	B-NP	O
)	)	O	O
approximately	RB	B-ADVP	O
doubled	VBD	B-VP	O
the	DT	B-NP	O
time	NN	I-NP	O
morphine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
remained	VBD	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
hot	JJ	I-NP	O
surface	NN	I-NP	O
and	CC	O	O
similarly	RB	B-NP	O
increased	VBN	I-NP	O
muscular	JJ	I-NP	O
incoordination	NN	I-NP	B
by	IN	B-PP	O
diazepam	NN	B-NP	O
,	,	O	O
but	CC	O	O
NH4Ac	NN	B-NP	O
treatment	NN	I-NP	O
alone	RB	B-ADVP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
hyperammonemia	NN	B-NP	B
is	VBZ	B-VP	O
capable	JJ	B-ADJP	O
of	IN	B-PP	O
altering	VBG	B-VP	O
drug	NN	B-NP	O
action	NN	I-NP	O
and	CC	O	O
must	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
along	IN	B-ADVP	O
with	IN	B-PP	O
impaired	VBN	B-NP	O
drug	NN	I-NP	O
metabolism	NN	I-NP	O
in	IN	B-PP	O
enhanced	VBN	B-NP	O
drug	NN	I-NP	O
responses	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
liver	NN	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Experiments	NNS	B-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
acetylcholine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catecholamine	NN	I-NP	O
release	NN	I-NP	O
from	IN	B-PP	O
bovine	JJ	B-NP	O
adrenal	JJ	I-NP	O
medulla	NN	I-NP	O
is	VBZ	B-VP	O
depressed	VBN	I-VP	O
as	RB	B-NP	O
much	JJ	I-NP	O
as	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
NH4Ac	NN	I-NP	O
and	CC	I-NP	O
KCl	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
contractions	NNS	I-NP	O
of	IN	B-PP	O
guinea	NN	B-NP	O
-	HYPH	B-NP	O
pig	NN	I-NP	O
ileum	NN	I-NP	O
were	VBD	B-VP	O
inhibited	VBN	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
mM	NN	I-NP	O
NH4Ac	NN	I-NP	O
.	.	O	O

Addition	NN	B-NP	O
of	IN	B-PP	O
excess	JJ	B-NP	O
calcium	NN	I-NP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
depression	NN	I-NP	B
in	IN	B-PP	O
both	DT	B-NP	O
tissues	NNS	I-NP	O
,	,	O	O
but	CC	O	O
calcium	NN	B-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
catecholamine	NN	I-NP	O
release	NN	I-NP	O
by	IN	B-PP	O
acetaldehyde	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
NH4Ac	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
ammonia	NN	B-NP	O
blocks	VBZ	B-VP	O
calcium	NN	B-NP	O
channels	NNS	I-NP	O
.	.	O	O

Parallels	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
NH4Ac	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
verapamil	NN	I-NP	O
support	VBP	B-VP	O
this	DT	B-NP	O
concept	NN	I-NP	O
.	.	O	O

Both	CC	O	O
verapamil	NN	B-NP	O
and	CC	I-NP	O
NH4Ac	NN	I-NP	O
pretreatment	NN	I-NP	O
enhanced	VBD	B-VP	O
morphine	NN	B-NP	O
analgesia	NN	I-NP	B
-	HYPH	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
muscular	JJ	I-NP	O
incoordination	NN	I-NP	B
and	CC	O	O
antagonized	VBD	B-VP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
motor	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
and	CC	O	O
neither	CC	O	O
verapamil	NN	B-NP	O
nor	CC	I-NP	O
NH4Ac	NN	I-NP	O
affected	VBD	B-VP	O
the	DT	B-NP	O
convulsant	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
metrazol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
hyperammonemia	NN	B-NP	B
exerts	VBZ	B-VP	O
a	DT	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blocking	VBG	B-VP	O
action	NN	B-NP	O
which	WDT	B-NP	O
enhances	VBZ	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
depressants	NNS	I-NP	O
and	CC	O	O
certain	JJ	B-NP	O
opioid	JJ	I-NP	O
analgesics	NNS	I-NP	O
.	.	O	O

Risk	NN	B-NP	O
of	IN	B-PP	O
nephropathy	NN	B-NP	B
after	IN	B-PP	O
consumption	NN	B-NP	O
of	IN	B-PP	O
nonionic	JJ	B-NP	O
contrast	NN	I-NP	O
media	NNS	I-NP	O
by	IN	B-PP	O
children	NNS	B-NP	O
undergoing	VBG	B-VP	O
cardiac	JJ	B-NP	O
angiography	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
increasing	VBG	B-VP	O
reports	NNS	B-NP	O
on	IN	B-PP	O
nonionic	JJ	B-NP	O
contrast	NN	I-NP	O
media	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
(	(	O	O
CIN	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
hospitalized	VBN	B-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
during	IN	B-PP	O
cardiac	JJ	B-NP	O
procedures	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
pediatrics	NNS	B-NP	O
are	VBP	B-VP	O
limited	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
even	RB	B-NP	O
less	JJR	I-NP	O
focus	NN	I-NP	O
on	IN	B-PP	O
possible	JJ	B-NP	O
predisposing	VBG	I-NP	O
factors	NNS	I-NP	O
and	CC	O	O
preventive	JJ	B-NP	O
measures	NNS	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
cardiac	JJ	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
determined	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
CIN	NN	B-NP	B
for	IN	B-PP	O
num	CD	B-NP	O
nonionic	JJ	I-NP	O
contrast	NN	I-NP	O
media	NNS	I-NP	O
(	(	O	O
CM	NN	B-NP	O
)	)	O	O
,	,	O	O
iopromide	NN	B-NP	O
and	CC	I-NP	O
iohexol	NN	I-NP	O
,	,	O	O
among	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
younger	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
compared	VBD	B-VP	O
the	DT	B-NP	O
rates	NNS	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
relation	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
type	NN	I-NP	O
and	CC	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
CM	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
cyanosis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
consecutively	RB	B-ADVP	O
received	VBD	B-VP	O
either	CC	O	O
iopromide	NN	B-NP	O
or	CC	I-NP	O
iohexol	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
sodium	NN	I-NP	O
(	(	O	O
Na	NN	B-NP	O
)	)	O	O
,	,	O	O
potassium	NN	B-NP	O
(	(	O	O
K	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
creatinine	NN	B-NP	O
(	(	O	O
Cr	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
before	IN	B-PP	O
angiography	NN	B-NP	O
as	IN	B-PP	O
baseline	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
then	RB	B-VP	O
measured	VBN	I-VP	O
again	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
intervals	NNS	I-NP	O
after	IN	B-PP	O
CM	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Urine	NN	B-NP	O
samples	NNS	I-NP	O
for	IN	B-PP	O
Na	NN	B-NP	O
and	CC	I-NP	O
Cr	NN	I-NP	O
also	RB	B-ADVP	O
were	VBD	B-VP	O
checked	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

Risk	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
,	,	O	O
Injury	NNP	B-NP	B
to	TO	B-PP	I
the	DT	B-NP	I
kidney	NN	I-NP	I
,	,	O	O
Failure	NN	B-NP	B
of	IN	B-PP	I
kidney	NN	B-NP	I
function	NN	I-NP	I
,	,	O	O
Loss	NN	B-NP	B
of	IN	B-PP	I
kidney	NN	B-NP	I
function	NN	I-NP	I
,	,	O	O
and	CC	O	O
End	NN	B-NP	O
-	HYPH	O	O
stage	NN	B-NP	O
renal	JJ	I-NP	B
damage	NN	I-NP	I
(	(	O	O
RIFLE	NN	B-NP	O
criteria	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
define	VB	I-VP	O
CIN	NN	B-NP	B
and	CC	O	O
its	PRP$	B-NP	O
incidence	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
population	NN	I-NP	O
.	.	O	O

Accordingly	RB	B-ADVP	O
,	,	O	O
among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
CIN	NN	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
A	NN	I-NP	O
had	VBD	B-VP	O
increased	VBN	I-VP	O
risk	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
whereas	IN	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
group	NN	B-NP	O
B	NN	I-NP	O
had	VBD	B-VP	O
increased	VBN	I-VP	O
risk	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
.	.	O	O

Whereas	IN	B-SBAR	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
CIN	NN	B-NP	B
were	VBD	B-VP	O
among	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
proper	JJ	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
CM	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
percentage	NN	I-NP	O
increased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
among	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
larger	JJR	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
CIN	NN	B-NP	B
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
different	JJ	I-NP	O
dosages	NNS	I-NP	O
of	IN	B-PP	O
CM	NN	B-NP	O
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
CIN	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
cyanotic	JJ	B-NP	O
congenital	JJ	I-NP	B
heart	NN	I-NP	I
diseases	NNS	I-NP	I
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
from	IN	B-PP	O
that	DT	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
noncyanotic	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
clinically	RB	B-ADJP	O
silent	JJ	I-ADJP	O
,	,	O	O
CIN	NN	B-NP	B
is	VBZ	B-VP	O
not	RB	O	O
rare	JJ	B-ADJP	O
in	IN	B-PP	O
pediatrics	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
depends	VBZ	B-VP	O
on	IN	B-PP	O
dosage	NN	B-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
on	IN	I-PP	O
the	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
consumed	JJ	B-NP	O
nonionic	JJ	I-NP	O
CM	NN	I-NP	O
,	,	B-PP	O
nor	CC	I-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
cyanosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
although	IN	B-SBAR	O
CIN	NN	B-NP	B
usually	RB	B-ADVP	O
is	VBZ	B-VP	O
reversible	JJ	B-NP	O
,	,	I-NP	O
more	JJR	I-NP	O
concern	NN	I-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
such	JJ	B-NP	O
a	DT	I-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
caffeine	NN	B-NP	O
pretreatment	NN	I-NP	O
.	.	O	O

Suboptimal	JJ	B-NP	O
seizure	NN	I-NP	B
duration	NN	I-NP	O
is	VBZ	B-VP	O
commonly	RB	I-VP	O
encountered	VBN	I-VP	O
in	IN	B-PP	O
electroconvulsive	JJ	B-NP	O
therapy	NN	I-NP	O
practice	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
higher	JJR	B-NP	O
seizure	NN	I-NP	B
thresholds	NNS	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
caffeine	NN	I-NP	O
is	VBZ	B-VP	O
commonly	RB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
improve	VB	I-VP	O
seizure	NN	B-NP	B
duration	NN	I-NP	O
and	CC	I-NP	O
quality	NN	I-NP	O
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
generally	RB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
aside	RB	B-ADVP	O
from	IN	B-PP	O
occasional	JJ	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
relatively	RB	B-NP	O
benign	JJ	I-NP	O
ventricular	JJ	I-NP	B
ectopy	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
previous	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
disease	NN	I-NP	I
or	CC	O	O
arrhythmia	NN	B-NP	B
who	WP	B-NP	O
developed	VBD	B-VP	O
sustained	JJ	B-NP	O
bigeminy	JJ	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
brief	JJ	I-NP	O
runs	NNS	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
after	IN	B-PP	O
caffeine	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
intravenous	JJ	B-NP	O
caffeine	NN	I-NP	O
is	VBZ	B-VP	O
generally	RB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
clinician	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
unpredictable	JJ	B-NP	O
and	CC	I-NP	O
serious	JJ	I-NP	O
ventricular	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O

Optical	JJ	B-NP	O
coherence	NN	I-NP	O
tomography	NN	I-NP	O
can	MD	B-VP	O
measure	VB	I-VP	O
axonal	JJ	B-NP	O
loss	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
ethambutol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
map	VB	I-VP	O
and	CC	I-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
pattern	NN	I-NP	O
,	,	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
of	IN	B-PP	O
axonal	JJ	B-NP	B
degeneration	NN	I-NP	I
in	IN	B-PP	O
ethambutol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
using	VBG	B-VP	O
optical	JJ	B-NP	O
coherence	NN	I-NP	O
tomography	NN	I-NP	O
(	(	O	O
OCT	NN	B-NP	O
)	)	O	O
.	.	O	O

Ethambutol	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
antimycobacterial	JJ	I-NP	O
agent	NN	I-NP	O
often	RB	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
tuberculosis	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
serious	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
ethambutol	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
that	WDT	B-NP	O
impairs	VBZ	B-VP	O
visual	JJ	B-NP	O
acuity	NN	I-NP	O
,	,	O	O
contrast	NN	B-NP	O
sensitivity	NN	I-NP	O
,	,	O	O
and	CC	O	O
color	NN	B-NP	O
vision	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
early	RB	B-ADVP	O
on	IN	B-PP	O
,	,	O	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
is	VBZ	B-VP	O
mild	JJ	B-ADJP	O
and	CC	O	O
partly	RB	B-ADJP	O
reversible	JJ	I-ADJP	O
,	,	O	O
the	DT	B-NP	O
funduscopic	JJ	I-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
often	RB	B-ADVP	O
subtle	JJ	B-ADJP	O
and	CC	I-ADJP	O
easy	JJ	I-ADJP	O
to	TO	B-VP	O
miss	VB	I-VP	O
.	.	O	O

num	CD	B-NP	O
subjects	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
ethambutol	NN	B-NP	O
(	(	O	O
EMB	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
of	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
,	,	I-NP	O
intermediate	NN	I-NP	O
-	HYPH	I-NP	O
,	,	O	O
and	CC	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
visual	JJ	I-NP	B
deficits	NNS	I-NP	I
were	VBD	B-VP	O
administered	VBN	I-VP	O
a	DT	B-NP	O
full	JJ	I-NP	O
neuro	AFX	I-NP	O
-	HYPH	I-NP	O
ophthalmologic	JJ	I-NP	O
examination	NN	I-NP	O
including	VBG	B-PP	O
visual	JJ	B-NP	O
acuity	NN	I-NP	O
,	,	O	O
color	NN	B-NP	O
vision	NN	I-NP	O
,	,	O	O
contrast	NN	B-NP	O
sensitivity	NN	I-NP	O
,	,	O	O
and	CC	O	O
fundus	NN	B-NP	O
examination	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
OCT	NN	B-NP	O
(	(	O	O
OCT	NN	B-NP	O
num	CD	I-NP	O
Humphrey	NNP	I-NP	O
-	HYPH	I-NP	O
Zeiss	NNP	I-NP	O
,	,	O	O
Dublin	NNP	B-NP	O
,	,	O	O
CA	NNP	B-NP	O
)	)	O	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
subject	NN	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
retinal	JJ	I-NP	O
nerve	NN	I-NP	O
fiber	NN	I-NP	O
layer	NN	I-NP	O
(	(	O	O
RNFL	NN	B-NP	O
)	)	O	O
analysis	NN	B-NP	O
protocol	NN	I-NP	O
.	.	O	O

OCT	NN	B-NP	O
interpolates	VBZ	B-VP	O
data	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
points	NNS	I-NP	O
around	IN	B-PP	O
the	DT	B-NP	O
optic	JJ	I-NP	O
nerve	NN	I-NP	O
to	TO	B-VP	O
effectively	RB	I-VP	O
map	VB	I-VP	O
out	RP	B-PRT	O
the	DT	B-NP	O
RNFL	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
calculated	VBN	I-NP	O
average	JJ	I-NP	O
RNFL	NNP	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
eyes	NNS	I-NP	O
accumulated	VBN	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
prior	JJ	I-NP	O
studies	NNS	I-NP	O
using	VBG	B-VP	O
OCT	NN	B-NP	O
,	,	O	O
n=661	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
subjects	NNS	I-NP	O
with	IN	B-PP	O
history	NN	B-NP	O
of	IN	B-PP	O
EMB	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
nerve	NN	I-NP	O
fiber	NN	I-NP	O
layer	NN	I-NP	O
thickness	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
quadrant	NN	I-NP	O
(	(	O	O
patient	NN	B-NP	O
A	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
eventual	JJ	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	O
acuity	NN	I-NP	O
and	CC	I-NP	O
fields	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
loss	NN	I-NP	O
;	:	O	O
patient	NN	B-NP	O
B	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
intermediate	JJ	B-NP	O
visual	JJ	I-NP	B
deficits	NNS	I-NP	I
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
loss	NN	I-NP	O
;	:	O	O
patient	NN	B-NP	O
C	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
visual	JJ	I-NP	B
deficits	NNS	I-NP	I
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
loss	NN	I-NP	O
)	)	O	O
,	,	O	O
with	IN	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
mean	JJ	I-NP	O
optic	JJ	I-NP	O
nerve	NN	I-NP	O
thickness	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
microm	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
combined	JJ	I-NP	O
mean	JJ	I-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
fibers	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
superior	JJ	I-NP	O
,	,	I-NP	O
inferior	JJ	I-NP	O
,	,	O	O
and	CC	O	O
nasal	JJ	B-NP	O
quadrants	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
(	(	O	O
num	CD	O	O
)	)	O	O
eyes	NNS	B-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
sets	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
)	)	O	O
of	IN	B-PP	O
eyes	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
with	IN	B-PP	O
persistent	JJ	B-NP	O
visual	JJ	I-NP	B
deficits	NNS	I-NP	I
(	(	O	O
patients	NNS	B-NP	O
B	NN	B-NP	O
and	CC	O	O
C	NN	B-NP	O
)	)	O	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
an	DT	B-NP	O
average	JJ	I-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
nerve	NN	B-NP	O
fiber	NN	I-NP	O
thickness	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
quadrant	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
OCT	NN	I-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
EMB	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
show	VBP	B-VP	O
considerable	JJ	B-NP	O
loss	NN	I-NP	O
especially	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
fibers	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
prior	JJ	B-NP	O
histopathological	JJ	I-NP	O
studies	NNS	I-NP	O
that	WDT	B-NP	O
show	VBP	B-VP	O
predominant	JJ	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
parvo	AFX	B-NP	O
-	HYPH	I-NP	O
cellular	JJ	I-NP	O
axons	NNS	I-NP	O
(	(	O	O
or	CC	O	O
small	JJ	B-NP	O
-	HYPH	I-NP	O
caliber	NN	I-NP	O
axons	NNS	I-NP	O
)	)	O	O
within	IN	B-PP	O
the	DT	B-NP	O
papillo	AFX	I-NP	O
-	HYPH	I-NP	O
macular	JJ	I-NP	O
bundle	NN	I-NP	O
in	IN	B-PP	O
toxic	JJ	B-NP	O
or	CC	I-NP	O
hereditary	JJ	I-NP	O
optic	JJ	I-NP	B
neuropathies	NNS	I-NP	I
.	.	O	O

OCT	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
valuable	JJ	I-NP	O
tool	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
quantitative	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
optic	JJ	B-NP	B
neuropathies	NNS	I-NP	I
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
management	NN	B-NP	O
of	IN	B-PP	O
EMB	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
properly	RB	I-VP	O
manage	VB	I-VP	O
ethambutol	NN	B-NP	O
dosing	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
impairment	NN	I-NP	I
and	CC	O	O
to	TO	B-VP	O
achieve	VB	I-VP	O
proper	JJ	B-NP	O
transition	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
maintenance	NN	I-NP	O
dose	NN	I-NP	O
once	RB	O	O
an	DT	B-NP	O
appropriate	JJ	I-NP	O
loading	NN	I-NP	O
dose	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reached	VBN	I-VP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cyclooxygenase	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
specific	JJ	I-NP	O
inhibitor	NN	I-NP	O
valdecoxib	NN	I-NP	O
versus	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
antiinflammatory	JJ	I-NP	O
agents	NNS	I-NP	O
and	CC	O	O
placebo	NN	B-NP	O
on	IN	B-PP	O
cardiovascular	JJ	B-NP	O
thrombotic	JJ	I-NP	B
events	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
arthritis	NN	B-NP	B
.	.	O	O

There	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
concerns	NNS	B-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	O
thrombotic	JJ	I-NP	B
events	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
higher	JJR	B-ADJP	O
with	IN	B-PP	O
cyclooxygenase	NN	B-NP	O
(	(	O	O
COX	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
inhibitors	NNS	I-NP	O
than	IN	B-PP	O
nonselective	JJ	B-NP	O
nonsteroidal	JJ	I-NP	O
antiinflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
cardiovascular	JJ	B-NP	O
event	NN	I-NP	O
data	NNS	I-NP	O
for	IN	B-PP	O
valdecoxib	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
COX	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
inhibitor	NN	I-NP	O
in	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
osteoarthritis	NN	B-NP	B
and	CC	O	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
randomized	VBN	B-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	O
thrombotic	JJ	I-NP	B
events	NNS	I-NP	O
(	(	O	O
cardiac	JJ	B-NP	O
,	,	I-NP	O
cerebrovascular	JJ	I-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
vascular	JJ	I-NP	O
,	,	O	O
or	CC	O	O
arterial	JJ	B-NP	O
thrombotic	NN	I-NP	B
)	)	O	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
analyzing	VBG	B-VP	O
pooled	VBN	B-NP	O
valdecoxib	NN	I-NP	O
,	,	O	O
nonselective	JJ	B-NP	O
NSAID	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
randomized	VBN	I-NP	O
osteoarthritis	NN	I-NP	B
and	CC	I-NP	O
rheumatoid	JJ	I-NP	B
arthritis	NN	I-NP	I
trials	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
duration	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
aspirin	NN	I-NP	O
and	CC	O	O
nonusers	NNS	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
.	.	O	O

Crude	NN	B-NP	O
and	CC	I-NP	O
exposure	NN	I-NP	O
-	HYPH	B-NP	O
adjusted	VBN	I-NP	O
incidences	NNS	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
events	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
for	IN	B-PP	O
valdecoxib	NN	B-NP	O
,	,	O	O
NSAIDs	NNS	B-NP	O
,	,	O	O
and	CC	O	O
placebo	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
thrombotic	JJ	I-NP	B
events	NNS	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
similar	JJ	B-ADJP	O
for	IN	B-PP	O
each	DT	B-NP	O
valdecoxib	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Thrombotic	JJ	B-NP	B
risk	NN	I-NP	O
was	VBD	B-VP	O
consistently	RB	B-ADJP	O
higher	JJR	I-ADJP	O
for	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
users	NNS	I-NP	O
than	IN	B-PP	O
nonusers	NNS	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
(	(	O	O
placebo	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
valdecoxib	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
NSAIDs	NNS	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
for	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
and	CC	B-PP	O
across	IN	B-PP	O
valdecoxib	NN	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

Short	JJ	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
intermediate	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
therapeutic	JJ	B-NP	O
and	CC	I-NP	O
supratherapeutic	JJ	I-NP	O
valdecoxib	NN	I-NP	O
doses	NNS	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
events	NNS	I-NP	O
relative	JJ	B-ADVP	O
to	TO	B-PP	O
nonselective	JJ	B-NP	O
NSAIDs	NNS	I-NP	O
or	CC	O	O
placebo	NN	B-NP	O
in	IN	B-PP	O
osteoarthritis	NN	B-NP	B
and	CC	O	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
patients	NNS	I-NP	O
in	IN	B-PP	O
controlled	VBN	B-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
crossover	NN	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
for	IN	B-PP	O
SSRI	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
female	JJ	I-NP	O
sexual	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
ephedrine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
and	CC	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
agonist	NN	I-NP	O
previously	RB	B-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
enhance	VB	I-VP	O
genital	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
,	,	O	O
has	VBZ	B-VP	O
beneficial	JJ	B-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
reversing	VBG	B-VP	O
antidepressant	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
sexual	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
sexually	RB	I-NP	B
dysfunctional	JJ	I-NP	I
women	NNS	I-NP	O
receiving	VBG	B-VP	O
either	CC	O	O
fluoxetine	NN	B-NP	O
,	,	O	O
sertraline	NN	B-NP	O
,	,	O	O
or	CC	O	O
paroxetine	NN	B-NP	O
participated	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
over	IN	B-PP	O
study	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ephedrine	NN	B-NP	O
on	IN	B-PP	O
self	AFX	B-NP	O
-	HYPH	I-NP	O
report	NN	I-NP	O
measures	NNS	I-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	O
desire	NN	I-NP	O
,	,	O	O
arousal	NN	B-NP	O
,	,	O	O
orgasm	NN	B-NP	O
,	,	O	O
and	CC	O	O
sexual	JJ	B-NP	O
satisfaction	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
there	EX	B-NP	O
were	VBD	B-VP	O
significant	JJ	B-NP	O
improvements	NNS	I-NP	O
relative	JJ	B-ADJP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
in	IN	B-PP	O
sexual	JJ	B-NP	O
desire	NN	I-NP	O
and	CC	I-NP	O
orgasm	NN	I-NP	O
intensity	NN	I-NP	O
/	SYM	B-NP	O
pleasure	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
ephedrine	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hr	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
sexual	JJ	B-NP	O
activity	NN	I-NP	O
,	,	O	O
significant	JJ	B-NP	O
improvements	NNS	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
measures	NNS	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
sexual	JJ	B-NP	O
arousal	JJ	I-NP	O
and	CC	I-NP	O
orgasmic	JJ	I-NP	O
ability	NN	I-NP	O
also	RB	B-ADVP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
highlight	VBP	B-VP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
conducting	VBG	B-VP	O
placebo	NN	B-NP	O
-	HYPH	B-NP	O
controlled	VBN	I-NP	O
trials	NNS	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
condition	NN	I-NP	O
.	.	O	O

Erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
occurs	VBZ	B-VP	O
following	VBG	B-PP	O
substantia	NN	B-NP	O
nigra	NN	I-NP	O
lesions	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Erectile	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
following	VBG	B-PP	O
uni	AFX	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
bilateral	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxydopamine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
nucleus	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Behavioral	JJ	B-NP	O
apomorphine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
penile	JJ	I-NP	O
erections	NNS	I-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
and	CC	O	O
increased	VBN	B-VP	O
in	IN	B-PP	O
uni	AFX	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
bilateral	JJ	I-NP	O
lesioned	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

Intracavernous	JJ	B-NP	O
pressures	NNS	I-NP	O
,	,	O	O
following	VBG	B-PP	O
electrical	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cavernous	JJ	I-NP	O
nerve	NN	I-NP	O
,	,	O	O
decreased	VBN	B-VP	O
in	IN	B-PP	O
lesioned	VBN	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

Lesions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
were	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
histology	NN	B-NP	O
.	.	O	O

Concentration	NN	B-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
of	IN	B-PP	O
substantia	NN	B-NP	O
nigra	NN	I-NP	O
lesioned	VBD	B-VP	O
rats	NNS	B-NP	O
.	.	O	O

Lesions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
are	VBP	B-VP	O
therefore	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
and	CC	O	O
may	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
erectile	JJ	B-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Potential	JJ	B-NP	O
therapeutic	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
selective	JJ	I-NP	O
dopamine	NN	I-NP	O
D1	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
A	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
:	:	O	O
an	DT	B-NP	O
acute	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
parkinsonian	JJ	B-NP	B
levodopa	NN	I-NP	O
-	HYPH	B-NP	O
primed	VBN	I-NP	O
monkeys	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
D1	NN	B-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
unclear	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
therapeutic	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
selective	JJ	B-NP	O
DA	NN	I-NP	O
D1	NN	I-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
SKF	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloro	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydroxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
allyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
phenyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
tetrahydro	AFX	O	O
-	HYPH	B-NP	O
1H	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
benzaze	NN	I-NP	O
pine	NN	I-NP	O
hydrobromide	NN	I-NP	O
)	)	O	O
and	CC	O	O
A	NN	B-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
(	(	O	O
[	(	O	O
1R	NN	B-NP	O
,	,	O	O
3S	NN	B-NP	O
]	)	O	O
num	CD	B-NP	O
-	:	O	O
[	(	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
admantyl	NN	I-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
aminomethyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydro	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydroxy	NN	I-NP	O
-	HYPH	B-NP	O
1H	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
benzo	NN	I-NP	O
pyran	NN	I-NP	O
hydrochloride	NN	I-NP	O
)	)	O	O
seems	VBZ	B-VP	O
limited	VBN	B-ADJP	O
because	IN	B-PP	O
of	IN	I-PP	O
their	PRP$	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
too	RB	B-ADJP	O
short	JJ	I-ADJP	O
for	IN	B-PP	O
SKF	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
too	RB	B-ADJP	O
long	JJ	I-ADJP	O
for	IN	B-PP	O
A	NN	B-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
conducted	VBD	B-VP	O
the	DT	B-NP	O
present	JJ	I-NP	O
acute	JJ	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
phenyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydropyridine	NN	I-NP	O
(	(	O	O
MPTP	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
exposed	VBN	B-NP	O
cynomolgus	NN	I-NP	O
monkeys	NNS	I-NP	O
primed	VBN	B-VP	O
to	TO	B-VP	O
exhibit	VB	I-VP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
locomotor	NN	I-NP	O
and	CC	O	O
dyskinetic	JJ	B-NP	B
effects	NNS	I-NP	O
on	IN	B-PP	O
challenge	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
A	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
and	CC	I-NP	O
full	JJ	I-NP	O
DA	NN	I-NP	O
D1	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
intermediate	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
.	.	O	O

Levodopa	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
DA	NN	I-NP	O
D2	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
LY	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
[	(	O	O
4aR	NN	B-NP	O
-	HYPH	I-NP	O
trans	NN	I-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
o	AFX	O	O
-	HYPH	O	O
dihydro	AFX	O	O
-	HYPH	B-NP	O
5n	NN	I-NP	O
-	HYPH	B-NP	O
propyl	NN	I-NP	O
-	HYPH	B-NP	O
2H	NN	I-NP	O
-	HYPH	I-NP	O
pyrazo	NN	I-NP	O
lo	AFX	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
quinoline	NN	I-NP	O
hydrochloride	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
also	RB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
comparison	NN	B-NP	O
.	.	O	O

Acute	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
A	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
as	RB	B-ADJP	O
efficacious	JJ	I-ADJP	O
in	IN	B-PP	O
alleviating	VBG	B-VP	O
MPTP	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
parkinsonism	NN	I-NP	B
as	IN	B-PP	O
levodopa	NN	B-NP	O
and	CC	I-NP	O
LY	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
but	CC	O	O
was	VBD	B-VP	O
less	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
reproduce	VB	I-VP	O
the	DT	B-NP	O
levodopa	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
these	DT	B-NP	O
animals	NNS	I-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
either	CC	O	O
LY	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
or	CC	O	O
subsequent	JJ	B-NP	O
challenge	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
.	.	O	O

Selective	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DA	NN	I-NP	O
D1	NN	I-NP	O
receptor	NN	I-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
better	JJR	B-NP	O
integration	NN	I-NP	O
of	IN	B-PP	O
neural	JJ	B-NP	O
inputs	NNS	I-NP	O
transmitted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
internal	JJ	I-NP	O
segment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
globus	NN	I-NP	O
pallidus	NN	I-NP	O
(	(	O	O
referred	VBN	B-VP	O
to	TO	B-PP	O
as	IN	B-PP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
ganglia	NNS	I-NP	O
output	NN	I-NP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
levodopa	NN	B-NP	O
and	CC	O	O
selective	JJ	B-NP	O
DA	NN	I-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
.	.	O	O

Potent	JJ	B-NP	O
DA	NN	I-NP	O
D1	NN	I-NP	O
receptor	NN	I-NP	O
agents	NNS	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
intermediate	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
efficacy	NN	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
A	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
(	(	O	O
approximately	RB	B-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
at	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
tested	VBN	B-VP	O
)	)	O	O
are	VBP	B-VP	O
potential	JJ	B-NP	O
therapeutic	JJ	I-NP	O
tools	NNS	I-NP	O
in	IN	B-PP	O
PD	NN	B-NP	B
and	CC	O	O
merit	NN	B-NP	O
further	JJ	I-NP	O
attention	NN	I-NP	O
.	.	O	O

Deaths	NNS	B-NP	O
from	IN	B-PP	O
local	JJ	B-NP	O
anesthetic	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Median	JJ	B-NP	O
convulsant	NN	I-NP	O
(	(	O	O
CD50	NN	B-NP	O
)	)	O	O
and	CC	O	O
median	JJ	B-NP	O
lethal	JJ	I-NP	O
(	(	O	O
LD50	NN	B-NP	O
)	)	O	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
representative	JJ	I-NP	O
local	JJ	I-NP	O
anesthetics	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
mice	NNS	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
threat	NN	I-NP	O
to	TO	B-PP	O
life	NN	B-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthetic	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
CD50	NN	I-NP	O
and	CC	I-NP	O
LD50	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
bupivacaine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
lidocaine	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
chloroprocaine	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
given	VBN	B-PP	O
intraperitoneally	RB	B-ADVP	O
,	,	O	O
bupivacaine	NN	B-NP	O
thus	RB	B-ADVP	O
was	VBD	B-VP	O
only	RB	B-NP	O
about	RB	I-NP	O
twice	RB	I-NP	O
as	RB	I-NP	O
toxic	JJ	I-ADJP	O
as	IN	B-PP	O
lidocaine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
as	RB	I-NP	O
toxic	JJ	I-ADJP	O
as	IN	B-PP	O
chloroprocaine	NN	B-NP	O
.	.	O	O

Convulsions	NNS	B-NP	B
always	RB	B-ADVP	O
preceded	VBD	B-VP	O
death	NN	B-NP	O
,	,	O	O
except	IN	B-PP	O
after	IN	B-PP	O
precipitous	JJ	B-NP	O
cardiopulmonary	JJ	I-NP	B
arrest	NN	I-NP	I
from	IN	B-PP	O
extreme	JJ	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
CD50	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthetic	JJ	I-NP	O
(	(	O	O
causing	VBG	B-VP	O
convulsions	NNS	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
)	)	O	O
was	VBD	B-VP	O
fatal	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
,	,	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
chloroprocaine	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lidocaine	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
narrow	JJ	I-NP	O
gap	NN	I-NP	O
between	IN	B-PP	O
convulsant	JJ	B-NP	O
and	CC	I-NP	O
lethal	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
untreated	JJ	B-NP	O
convulsions	NNS	I-NP	B
present	VBP	B-VP	O
much	RB	B-NP	O
more	JJR	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
threat	NN	I-NP	O
to	TO	B-PP	O
life	NN	B-NP	O
than	IN	B-PP	O
heretofore	RB	B-NP	O
appreciated	VBN	I-NP	O
.	.	O	O

Myoclonic	JJ	B-NP	B
,	,	I-NP	I
atonic	JJ	I-NP	I
,	,	O	I
and	CC	O	I
absence	NN	B-NP	I
seizures	NNS	I-NP	I
following	VBG	B-PP	O
institution	NN	B-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
children	NNS	I-NP	O
,	,	O	O
aged	VBN	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
carbamazepine	NN	B-NP	O
for	IN	B-PP	O
epilepsy	NN	B-NP	B
,	,	O	O
had	VBD	B-VP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
aberrant	JJ	I-NP	O
reaction	NN	I-NP	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
myoclonic	JJ	B-NP	B
,	,	I-NP	I
atypical	JJ	I-NP	I
absence	NN	I-NP	I
and	CC	O	I
/	SYM	B-NP	I
or	CC	O	I
atonic	JJ	O	I
(	(	O	I
minor	JJ	B-NP	I
motor	NN	I-NP	I
)	)	O	I
seizures	NNS	B-NP	I
within	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
the	DT	B-NP	O
carbamazepine	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
children	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
former	JJ	I-NP	O
state	NN	I-NP	O
very	RB	B-ADVP	O
quickly	RB	I-ADVP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
minor	JJ	I-NP	O
motor	NN	I-NP	O
seizures	NNS	I-NP	B
resolve	VBP	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
persist	VBP	B-VP	O
.	.	O	O

The	DT	B-NP	O
child	NN	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
persisted	VBD	B-VP	O
was	VBD	B-VP	O
later	RB	I-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
ceroid	JJ	B-NP	B
lipofuscinosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
other	JJ	I-NP	O
children	NNS	I-NP	O
are	VBP	B-VP	O
doing	VBG	I-VP	O
well	RB	B-ADVP	O
on	IN	B-PP	O
other	JJ	B-NP	O
anticonvulsants	NNS	I-NP	O
.	.	O	O

Naloxone	NN	B-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-VP	O
captopril	VB	I-VP	O
overdose	RB	B-ADVP	B
.	.	O	O

The	DT	B-NP	O
hemodynamic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
angiotensin	NN	I-NP	O
-	HYPH	B-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitors	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
endogenous	JJ	I-NP	O
opioid	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
opioid	JJ	I-NP	O
antagonist	NN	I-NP	O
naloxone	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
block	VB	I-VP	O
or	CC	I-VP	O
reverse	VB	I-VP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
actions	NNS	I-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
intentional	JJ	I-NP	O
captopril	NN	I-NP	O
overdose	NN	I-NP	B
,	,	O	O
manifested	VBN	B-VP	O
by	IN	B-PP	O
marked	JJ	B-NP	O
hypotension	NN	I-NP	B
,	,	O	O
that	WDT	B-NP	O
resolved	VBD	B-VP	O
promptly	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
naloxone	NN	B-NP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
naloxone	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
experience	NN	I-NP	O
demonstrates	VBZ	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
naloxone	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
resulting	VBG	B-VP	O
from	IN	B-PP	O
captopril	NN	B-NP	O
.	.	O	O

Carbamazepine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Characterization	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
distinct	JJ	I-NP	O
clinical	JJ	I-NP	O
syndromes	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
sinus	NN	B-NP	O
bradycardia	NN	I-NP	B
and	CC	O	O
atrioventricular	JJ	B-NP	B
block	NN	I-NP	I
,	,	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
carbamazepine	NN	B-NP	O
,	,	O	O
prompted	VBD	B-VP	O
an	DT	B-NP	O
extensive	JJ	I-NP	O
literature	NN	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
.	.	O	O

From	IN	B-PP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
distinct	JJ	I-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
emerged	VBD	B-VP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
group	NN	I-NP	O
developed	VBD	B-VP	O
sinus	NN	B-NP	B
tachycardias	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
massive	JJ	I-NP	O
carbamazepine	NN	I-NP	O
overdose	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
group	NN	I-NP	O
consisted	VBD	B-VP	O
almost	RB	B-ADVP	O
exclusively	RB	I-ADVP	O
of	IN	B-PP	O
elderly	JJ	B-NP	O
women	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
potentially	RB	B-NP	O
life	NN	I-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
bradyarrhythmias	NNS	B-NP	B
or	CC	O	O
atrioventricular	JJ	B-NP	B
conduction	NN	I-NP	I
delay	NN	I-NP	I
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
either	CC	O	O
therapeutic	JJ	B-ADJP	O
or	CC	O	O
modestly	RB	B-NP	O
elevated	JJ	I-NP	O
carbamazepine	NN	I-NP	O
serum	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
carbamazepine	NN	B-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
many	JJ	B-NP	O
neurologic	JJ	I-NP	O
and	CC	I-NP	O
psychiatric	JJ	I-NP	B
conditions	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
recognition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
latter	JJ	I-NP	O
syndrome	NN	I-NP	O
has	VBZ	B-VP	O
important	JJ	B-NP	O
implications	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Glutamatergic	JJ	B-NP	O
neurotransmission	NN	I-NP	O
mediated	VBN	B-VP	O
by	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
inferior	JJ	I-NP	O
colliculus	NN	I-NP	O
can	MD	B-VP	O
modulate	VB	I-VP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
inferior	JJ	I-NP	O
colliculus	NN	I-NP	O
(	(	O	O
IC	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
primarily	RB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
processing	NN	I-NP	O
of	IN	B-PP	O
auditory	JJ	B-NP	O
information	NN	I-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
distinguished	VBN	I-VP	O
from	IN	B-PP	O
other	JJ	B-NP	O
auditory	JJ	I-NP	O
nuclei	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
by	IN	B-PP	O
its	PRP$	B-NP	O
connections	NNS	I-NP	O
with	IN	B-PP	O
structures	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
motor	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

Functional	JJ	B-NP	O
evidence	NN	I-NP	O
relating	VBG	B-VP	O
the	DT	B-NP	O
IC	NN	I-NP	O
to	TO	B-PP	O
motor	NN	B-NP	O
behavior	NN	I-NP	O
derives	VBZ	B-VP	O
from	IN	B-PP	O
experiments	NNS	B-NP	O
showing	VBG	B-VP	O
that	IN	B-SBAR	O
activation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
IC	NN	I-NP	O
by	IN	B-PP	O
electrical	JJ	B-NP	O
stimulation	NN	I-NP	O
or	CC	O	O
excitatory	JJ	B-NP	O
amino	JJ	I-NP	O
acid	NN	I-NP	O
microinjection	NN	I-NP	O
causes	VBZ	B-VP	O
freezing	NN	B-NP	O
,	,	O	O
escape	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
behavior	NN	I-NP	O
,	,	O	O
and	CC	O	O
immobility	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
nature	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
immobility	NN	I-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
unclear	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
excitatory	JJ	B-NP	O
amino	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
mechanisms	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
IC	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
dopamine	NN	I-NP	O
receptor	NN	I-NP	O
blocker	NN	I-NP	O
haloperidol	NN	I-NP	O
administered	VBN	B-VP	O
systemically	RB	B-ADVP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
was	VBD	B-VP	O
challenged	VBN	I-VP	O
with	IN	B-PP	O
prior	JJ	B-NP	O
intracollicular	JJ	I-NP	O
microinjections	NNS	I-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
,	,	O	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mmol	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
)	)	O	O
and	CC	O	O
AP7	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
nmol	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
of	IN	B-PP	O
the	DT	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
d	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
nmol	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
intracollicular	JJ	B-NP	O
microinjection	NN	I-NP	O
of	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
AP7	NN	B-NP	O
previous	JJ	B-ADJP	O
to	TO	B-PP	O
systemic	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
significantly	RB	B-ADVP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
as	IN	B-SBAR	O
indicated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
latency	NN	I-NP	O
to	TO	B-VP	O
step	VB	I-VP	O
down	RP	B-PRT	O
from	IN	B-PP	O
a	DT	B-NP	O
horizontal	JJ	I-NP	O
bar	NN	I-NP	O
.	.	O	O

Accordingly	RB	B-ADVP	O
,	,	O	O
intracollicular	JJ	B-NP	O
microinjection	NN	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
latency	NN	I-NP	O
to	TO	B-VP	O
step	VB	I-VP	O
down	RP	B-PRT	O
the	DT	B-NP	O
bar	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
glutamate	NN	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
mechanisms	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
neural	JJ	I-NP	O
circuits	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
IC	NN	I-NP	O
level	NN	I-NP	O
influence	NN	I-NP	O
haloperidol	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
catalepsy	NN	I-NP	B
and	CC	O	O
participate	VB	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Metabotropic	JJ	B-NP	O
glutamate	NN	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
subtype	NN	I-NP	O
modulates	VBZ	B-VP	O
motor	NN	B-NP	O
symptoms	NNS	I-NP	O
in	IN	B-PP	O
rodent	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Metabotropic	JJ	B-NP	O
glutamate	NN	I-NP	O
(	(	O	O
mGlu	NN	B-NP	O
)	)	O	O
receptors	NNS	B-NP	O
modulate	VBP	B-VP	O
synaptic	JJ	B-NP	O
transmission	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
and	CC	O	O
represent	VBP	B-VP	O
promising	JJ	B-NP	O
therapeutic	JJ	I-NP	O
targets	NNS	I-NP	O
for	IN	B-PP	O
symptomatic	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
mGlu	NN	I-NP	O
receptor	NN	I-NP	O
subtypes	NNS	I-NP	O
,	,	O	O
mGlu7	NN	B-NP	O
receptor	NN	I-NP	O
is	VBZ	B-VP	O
prominently	RB	I-VP	O
expressed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
ganglia	NNS	I-NP	O
,	,	O	O
but	CC	O	O
its	PRP$	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
restoring	VBG	B-VP	O
motor	NN	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
animal	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
PD	NN	B-NP	B
is	VBZ	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
,	,	O	O
N	NN	B-NP	O
'	SYM	B-NP	O
-	HYPH	B-NP	O
dibenzhydrylethane	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
diamine	NN	I-NP	O
dihydrochloride	NN	I-NP	O
(	(	O	O
AMN082	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
selective	JJ	I-NP	O
allosteric	JJ	I-NP	O
activator	NN	I-NP	O
of	IN	B-PP	O
mGlu7	NN	B-NP	O
receptors	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
thus	RB	I-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
different	JJ	B-NP	O
rodent	NN	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	B
PD	NN	B-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
oral	JJ	B-NP	O
or	CC	I-NP	O
intrastriatal	JJ	I-NP	O
administration	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
nmol	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
AMN082	NN	B-NP	O
reverses	VBZ	B-VP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

AMN082	NN	B-NP	O
reduces	VBZ	B-VP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rotations	NNS	I-NP	O
in	IN	B-PP	O
unilateral	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxydopamine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
lesioned	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
more	RBR	I-NP	O
complex	JJ	I-NP	O
task	NN	I-NP	O
commonly	RB	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
major	JJ	B-NP	O
akinetic	JJ	I-NP	B
symptoms	NNS	I-NP	O
of	IN	B-PP	O
PD	NN	B-NP	B
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
AMN082	NN	I-NP	O
reverses	VBZ	B-VP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
reaction	NN	I-NP	O
time	NN	I-NP	O
to	TO	B-VP	O
respond	VB	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
cue	NN	I-NP	O
of	IN	B-PP	O
bilateral	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
-	HYPH	B-NP	O
lesioned	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
AMN082	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
mGlu7	NN	I-NP	O
receptor	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
in	IN	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
mGlu7	NN	B-NP	O
receptor	NN	I-NP	O
knockout	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Higher	JJR	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
AMN082	NN	B-NP	O
have	VBP	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
PD	NN	B-NP	B
.	.	O	O

Overall	RB	B-ADVP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
mGlu7	NN	B-NP	O
receptor	NN	I-NP	O
activation	NN	I-NP	O
can	MD	B-VP	O
reverse	VB	I-VP	O
motor	NN	B-NP	O
dysfunction	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
reduced	VBN	B-NP	O
dopamine	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Selective	JJ	B-NP	O
ligands	NNS	I-NP	O
of	IN	B-PP	O
mGlu7	NN	B-NP	O
receptor	NN	I-NP	O
subtypes	NNS	I-NP	O
may	MD	B-VP	O
thus	RB	I-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
promising	JJ	B-NP	O
compounds	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
antiparkinsonian	JJ	B-NP	O
therapeutic	JJ	I-NP	O
strategies	NNS	I-NP	O
.	.	O	O

Nimodipine	NN	B-NP	O
prevents	VBZ	B-VP	O
memory	NN	B-NP	B
impairment	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
nitroglycerin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
adult	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
resultant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
cerebral	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
tested	VBD	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-NP	O
nimodipine	NN	B-NP	O
(	(	O	O
NIMO	NN	B-NP	O
)	)	O	O
administered	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
nitroglycerin	NN	B-NP	O
(	(	O	O
NTG	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
would	MD	B-VP	O
preserve	VB	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
associative	JJ	I-NP	O
memory	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
(	(	O	O
PA	NN	B-NP	O
)	)	O	O
paradigm	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
memory	NN	B-NP	O
retention	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
PA	NN	B-NP	O
training	NN	I-NP	O
,	,	O	O
latencies	NNS	B-NP	O
(	(	O	O
seconds	NNS	B-NP	O
)	)	O	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
for	IN	B-PP	O
entry	NN	B-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
suspended	VBN	I-NP	O
platform	NN	I-NP	O
into	IN	B-PP	O
a	DT	B-NP	O
Plexiglas	NNP	I-NP	O
tube	NN	I-NP	O
where	WRB	B-ADVP	O
a	DT	B-NP	O
shock	NN	I-NP	O
was	VBD	B-VP	O
automatically	RB	I-VP	O
delivered	VBN	I-VP	O
.	.	O	O

Latencies	NNS	B-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
later	RB	B-ADVP	O
for	IN	B-PP	O
a	DT	B-NP	O
testing	NN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
Swiss	JJ	I-NP	O
-	HYPH	I-NP	O
Webster	NN	I-NP	O
mice	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
wk	NN	I-NP	O
)	)	O	O
,	,	O	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
num	CD	B-NP	O
)	)	O	O
saline	NN	B-NP	O
(	(	O	O
control	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
NTG	NN	B-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
learning	VBG	B-VP	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
NTG	NN	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
learning	VBG	B-VP	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
NTG	NN	B-NP	O
and	CC	I-NP	O
NIMO	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
vehicle	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
NIMO	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
and	CC	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
tissue	NN	I-NP	O
oxygenation	NN	I-NP	O
(	(	O	O
PbtO	NN	B-NP	O
)	)	O	O
and	CC	O	O
in	IN	B-PP	O
cerebral	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
separate	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

All	DT	B-NP	O
groups	NNS	I-NP	O
exhibited	VBD	B-VP	O
similar	JJ	B-NP	O
training	NN	I-NP	O
latencies	NNS	I-NP	O
.	.	O	O

Mice	NNS	B-NP	O
subjected	VBN	B-VP	O
to	TO	B-PP	O
hypotensive	JJ	B-NP	B
episodes	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
latency	NN	B-NP	O
time	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
injected	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
,	,	O	O
NTG	NN	B-NP	O
+	SYM	I-NP	O
NIMO	NN	I-NP	O
,	,	O	O
or	CC	O	O
delayed	VBN	B-NP	O
NTG	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
Kruskal	NNP	I-NP	O
-	HYPH	I-NP	O
Wallis	NNP	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
way	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
variance	NN	B-NP	O
indicated	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
separate	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
not	RB	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
behavioral	JJ	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
same	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
NTG	NN	B-NP	O
and	CC	I-NP	O
NTG	NN	I-NP	O
+	SYM	B-NP	O
NIMO	NN	I-NP	O
caused	VBD	B-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
to	TO	B-VP	O
decrease	VB	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
and	CC	B-PP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Mean	JJ	B-NP	O
arterial	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
NIMO	NN	B-NP	O
alone	RB	B-ADVP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
intergroup	NN	I-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

PbtO	NN	B-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
NTG	NN	I-NP	O
group	NN	I-NP	O
and	CC	B-PP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
sem	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
NTG	NN	I-NP	O
+	SYM	B-NP	O
NIMO	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
PA	NN	I-NP	O
retention	NN	I-NP	O
paradigm	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
NTG	NN	B-NP	O
immediately	RB	B-ADVP	O
after	IN	B-SBAR	O
learning	NN	B-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
associative	JJ	I-NP	O
memory	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
whereas	IN	O	O
delayed	VBN	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

NIMO	NN	B-NP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
disruption	NN	I-NP	O
in	IN	B-PP	O
consolidation	NN	B-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
memory	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
NTG	NN	B-NP	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
improve	VB	I-VP	O
latency	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
observed	VBN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
NIMO	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
preservation	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
homeostasis	NN	I-NP	O
during	IN	B-PP	O
hypotension	NN	B-NP	B
,	,	O	O
because	IN	B-SBAR	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PbtO	NN	I-NP	O
indices	NNS	I-NP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
haemopericardium	NN	I-NP	B
and	CC	O	O
gastrointestinal	JJ	B-NP	B
haemorrhage	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
possible	JJ	B-NP	O
interaction	NN	I-NP	O
of	IN	B-PP	O
cranberry	NN	B-NP	O
juice	NN	I-NP	O
with	IN	B-PP	O
warfarin	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
internal	JJ	I-NP	O
haemorrhage	NN	I-NP	B
in	IN	B-PP	O
an	DT	B-NP	O
elderly	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
consumed	VBD	B-VP	O
only	RB	B-NP	O
cranberry	NN	I-NP	O
juice	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
while	IN	B-SBAR	O
maintaining	VBG	B-VP	O
his	PRP$	B-NP	O
usual	JJ	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
propose	VBP	B-VP	O
that	IN	B-SBAR	O
naturally	RB	B-ADVP	O
occurring	VBG	B-VP	O
compounds	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
flavonoids	NNS	B-NP	O
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
fruit	NN	B-NP	O
juices	NNS	I-NP	O
,	,	O	O
may	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
potency	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
by	IN	B-PP	O
competing	VBG	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
enzymes	NNS	I-NP	O
that	WDT	B-NP	O
normally	RB	B-ADVP	O
inactivate	VBP	B-VP	O
warfarin	NN	B-NP	O
.	.	O	O

While	IN	B-SBAR	O
traditionally	RB	B-VP	O
regarded	VBN	I-VP	O
as	IN	B-PP	O
foodstuffs	NNS	B-NP	O
,	,	O	O
consumption	NN	B-NP	O
of	IN	B-PP	O
fruit	NN	B-NP	O
juices	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
when	WRB	B-ADVP	O
patients	NNS	B-NP	O
develop	VBP	B-VP	O
adverse	JJ	B-NP	O
drug	NN	I-NP	O
reactions	NNS	I-NP	O
.	.	O	O

Isoproterenol	NN	B-NP	O
induces	VBZ	B-VP	O
primary	JJ	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
dystrophin	NN	B-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
hearts	NNS	I-NP	O
:	:	O	O
correlation	NN	B-NP	O
with	IN	B-PP	O
myocardial	JJ	B-NP	B
injury	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
damage	NN	I-NP	I
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
a	DT	B-NP	O
mismatch	NN	I-NP	O
of	IN	B-PP	O
oxygen	NN	B-NP	O
supply	NN	I-NP	O
vs.	IN	B-PP	O
demand	NN	B-NP	O
following	VBG	B-PP	O
coronary	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	O	O
myocardial	JJ	B-NP	B
hyperactivity	NN	I-NP	I
is	VBZ	B-VP	O
the	DT	B-NP	O
best	JJS	I-NP	O
explanation	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
complex	JJ	I-NP	O
morphological	JJ	I-NP	O
alterations	NNS	I-NP	O
observed	VBN	B-VP	O
.	.	O	O

Severe	JJ	B-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
structural	JJ	I-NP	O
integrity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sarcolemma	NN	I-NP	O
of	IN	B-PP	O
cardiomyocytes	NNS	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
demonstrated	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
.	.	O	O

Taking	VBG	B-VP	O
into	IN	B-PP	O
account	NN	B-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
sarcolemmal	JJ	I-NP	O
integrity	NN	I-NP	O
is	VBZ	B-VP	O
stabilized	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
dystrophin	NN	I-NP	O
-	HYPH	O	O
glycoprotein	NN	B-NP	O
complex	NN	I-NP	O
(	(	O	O
DGC	NN	B-NP	O
)	)	O	O
that	WDT	B-NP	O
connects	VBZ	B-VP	O
actin	NN	B-NP	O
and	CC	I-NP	O
laminin	NN	I-NP	O
in	IN	B-PP	O
contractile	JJ	B-NP	O
machinery	NN	I-NP	O
and	CC	O	O
extracellular	JJ	B-NP	O
matrix	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
integrins	NNS	B-NP	O
,	,	O	O
this	DT	B-NP	O
study	NN	I-NP	O
tests	VBZ	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
isoproterenol	NN	B-NP	O
affects	VBZ	B-VP	O
sarcolemmal	JJ	B-NP	O
stability	NN	I-NP	O
through	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
DGC	NN	I-NP	O
and	CC	I-NP	O
integrins	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
different	JJ	B-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DGC	NN	I-NP	O
and	CC	I-NP	O
integrin	NN	I-NP	O
to	TO	B-PP	O
isoproterenol	NN	B-NP	O
subcutaneous	JJ	I-NP	O
administration	NN	I-NP	O
.	.	O	O

Immunofluorescent	JJ	B-NP	O
staining	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
dystrophin	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
sensitive	JJ	I-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
structures	NNS	I-NP	O
connecting	VBG	B-VP	O
the	DT	B-NP	O
actin	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cardiomyocyte	NN	I-NP	O
cytoskeleton	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
extracellular	JJ	I-NP	O
matrix	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
sarcomeric	JJ	I-NP	O
actin	NN	I-NP	O
dissolution	NN	I-NP	O
occurred	VBD	B-VP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
reduction	NN	I-NP	O
or	CC	I-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
dystrophin	NN	B-NP	O
.	.	O	O

Subsequently	RB	B-ADVP	O
,	,	O	O
after	IN	B-PP	O
lysis	NN	B-NP	O
of	IN	B-PP	O
myofilaments	NNS	B-NP	O
,	,	O	O
gamma	SYM	O	O
-	HYPH	O	O
sarcoglycan	NN	B-NP	O
,	,	O	O
beta	SYM	O	O
-	HYPH	O	O
dystroglycan	NN	B-NP	O
,	,	O	O
beta1	NN	B-NP	O
-	HYPH	I-NP	O
integrin	NN	I-NP	O
,	,	O	O
and	CC	O	O
laminin	NN	B-NP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
expressions	NNS	I-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
their	PRP$	B-NP	O
breakdown	NN	I-NP	O
,	,	O	O
as	IN	B-PP	O
epiphenomena	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myocytolytic	JJ	I-NP	O
process	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
primary	JJ	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
dystrophin	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
sensitive	JJ	I-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
structural	JJ	I-NP	O
proteins	NNS	I-NP	O
that	WDT	B-NP	O
form	VBP	B-VP	O
the	DT	B-NP	O
DGC	NN	I-NP	O
that	WDT	B-NP	O
connects	VBZ	B-VP	O
the	DT	B-NP	O
extracellular	JJ	I-NP	O
matrix	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
cytoskeleton	NN	I-NP	O
in	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
,	,	O	O
related	VBN	B-VP	O
to	TO	B-PP	O
ischaemic	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
explain	VBP	B-VP	O
the	DT	B-NP	O
severe	JJ	I-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
structural	JJ	I-NP	O
integrity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sarcolemma	NN	I-NP	O
of	IN	B-PP	O
cardiomyocytes	NNS	B-NP	O
and	CC	O	O
hence	RB	B-NP	O
severe	JJ	I-NP	O
and	CC	I-NP	O
irreversible	JJ	I-NP	O
injury	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
.	.	O	O

High	JJ	B-NP	O
fat	NN	I-NP	O
diet	NN	I-NP	O
-	HYPH	O	O
fed	VBN	B-VP	O
obese	JJ	B-NP	B
rats	NNS	I-NP	O
are	VBP	B-VP	O
highly	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Often	RB	B-ADVP	O
,	,	O	O
chemotherapy	NN	B-NP	O
by	IN	B-PP	O
doxorubicin	NN	B-NP	O
(	(	O	O
Adriamycin	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
limited	VBN	I-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
life	NN	B-NP	O
threatening	JJ	I-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
during	IN	B-PP	O
and	CC	O	O
posttherapy	NN	B-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
moderate	JJ	B-NP	O
diet	NN	I-NP	O
restriction	NN	I-NP	O
remarkably	RB	B-ADVP	O
protects	VBZ	B-VP	O
against	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
cardioprotection	NN	I-NP	O
is	VBZ	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
decreased	VBN	B-NP	O
cardiac	JJ	I-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
and	CC	I-NP	O
triglycerides	NNS	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
cardiac	JJ	B-NP	O
fatty	JJ	I-NP	O
-	HYPH	I-NP	O
acid	NN	I-NP	O
oxidation	NN	I-NP	O
,	,	O	O
ATP	NN	B-NP	O
synthesis	NN	I-NP	O
,	,	O	O
and	CC	O	O
upregulated	VBN	B-NP	O
JAK	NN	I-NP	O
/	SYM	I-NP	O
STAT3	NN	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
whether	IN	B-SBAR	O
a	DT	B-NP	O
physiological	JJ	I-NP	O
intervention	NN	I-NP	O
by	IN	B-PP	O
feeding	VBG	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
high	JJ	I-NP	O
fat	NN	I-NP	O
diet	NN	I-NP	O
(	(	O	O
HFD	NN	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
induces	VBZ	B-VP	O
obesity	NN	B-NP	B
in	IN	B-PP	O
male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
)	)	O	O
,	,	O	O
sensitizes	VBZ	B-VP	O
to	TO	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
LD	NN	I-NP	O
dose	NN	I-NP	O
administered	VBN	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
HFD	NN	I-NP	O
feeding	NN	I-NP	O
regimen	NNS	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
higher	JJR	B-NP	O
cardiotoxicity	NN	I-NP	B
,	,	O	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
obese	JJ	I-NP	B
(	(	O	O
OB	NN	B-NP	B
)	)	O	O
rats	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
significant	JJ	I-NP	O
renal	JJ	I-NP	B
or	CC	I-NP	I
hepatic	JJ	I-NP	I
toxicity	NN	I-NP	I
.	.	O	O

Doxorubicin	NN	B-NP	O
toxicokinetics	NNS	I-NP	O
studies	NNS	I-NP	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
accumulation	NN	B-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
and	CC	I-NP	O
doxorubicinol	NN	I-NP	O
(	(	O	O
toxic	JJ	B-NP	O
metabolite	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
diet	NN	I-NP	O
-	HYPH	B-VP	O
fed	VBN	I-VP	O
(	(	O	O
ND	NN	B-NP	O
)	)	O	O
and	CC	O	O
OB	NN	B-NP	B
hearts	NNS	I-NP	O
.	.	O	O

Mechanistic	JJ	B-NP	O
studies	NNS	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
OB	NN	B-NP	B
rats	NNS	I-NP	O
are	VBP	B-VP	O
sensitized	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
:	:	O	O
higher	JJR	B-NP	O
oxyradical	JJ	I-NP	O
stress	NN	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
upregulation	NN	B-NP	O
of	IN	B-PP	O
uncoupling	VBG	B-VP	O
proteins	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
downregulation	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
peroxisome	NN	I-NP	O
proliferators	NNS	I-NP	O
activated	VBD	B-VP	O
receptor	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
,	,	O	O
decreased	VBN	B-NP	O
plasma	NN	I-NP	O
adiponectin	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
cardiac	JJ	B-NP	O
fatty	JJ	I-NP	O
-	HYPH	I-NP	O
acid	NN	I-NP	O
oxidation	NN	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
mitochondrial	JJ	B-NP	O
AMP	NN	I-NP	O
-	HYPH	B-NP	O
alpha2	NN	I-NP	O
protein	NN	I-NP	O
kinase	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
drop	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
ATP	NN	I-NP	O
levels	NNS	I-NP	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
decreased	VBN	B-NP	O
ATP	NN	I-NP	O
/	SYM	B-NP	O
ADP	NN	I-NP	O
ratio	NN	I-NP	O
after	IN	B-PP	O
doxorubicin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Decreased	VBN	B-NP	O
cardiac	JJ	I-NP	O
erythropoietin	NN	I-NP	O
and	CC	O	O
increased	VBN	B-NP	O
SOCS3	NN	I-NP	O
further	RBR	B-ADVP	O
downregulated	VBD	B-VP	O
the	DT	B-NP	O
cardioprotective	JJ	I-NP	O
JAK	NN	I-NP	O
/	SYM	B-VP	O
STAT3	NN	B-NP	O
pathway	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
HFD	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
obese	JJ	I-NP	B
rats	NNS	I-NP	O
are	VBP	B-VP	O
highly	RB	I-VP	O
sensitized	VBN	I-VP	O
to	TO	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
by	IN	B-PP	O
substantially	RB	B-VP	O
downregulating	VBG	I-VP	O
cardiac	JJ	B-NP	O
mitochondrial	JJ	I-NP	O
ATP	NN	I-NP	O
generation	NN	I-NP	O
,	,	O	O
increasing	VBG	B-VP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
downregulating	VBG	B-VP	O
the	DT	B-NP	O
JAK	NN	I-NP	O
/	SYM	B-NP	O
STAT3	NN	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

Complete	JJ	B-NP	O
atrioventricular	JJ	I-NP	B
block	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Sinus	NN	B-NP	B
node	NN	I-NP	I
dysfunction	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
most	RBS	B-ADVP	O
frequently	RB	I-ADVP	O
among	IN	B-PP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
case	NN	I-NP	O
,	,	O	O
complete	JJ	B-NP	O
atrioventricular	JJ	I-NP	B
(	(	O	I
AV	NN	B-NP	I
)	)	O	I
block	VBP	B-VP	I
with	IN	B-PP	O
syncopal	JJ	B-NP	B
attacks	NNS	I-NP	I
developed	VBD	B-VP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
necessitating	VBG	B-VP	O
permanent	JJ	B-NP	O
pacemaker	NN	I-NP	O
implantation	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
lithium	NN	I-NP	O
levels	NNS	I-NP	O
remained	VBD	B-VP	O
under	IN	B-PP	O
or	CC	I-PP	O
within	IN	I-PP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
range	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
syncopal	JJ	I-NP	B
attacks	NNS	I-NP	I
.	.	O	O

Lithium	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
extreme	JJ	B-NP	O
caution	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mild	JJ	B-NP	O
disturbance	NN	I-NP	O
of	IN	B-PP	O
AV	NN	B-NP	O
conduction	NN	I-NP	O
.	.	O	O

Neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
ziprasidone	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
NMS	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
the	DT	B-NP	O
rarest	NN	I-NP	O
and	CC	O	O
most	RBS	B-ADJP	O
serious	JJ	I-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
neuroleptic	JJ	I-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
movement	NN	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
NMS	NN	B-NP	B
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
ziprasidone	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
conventional	JJ	B-NP	O
neuroleptics	NNS	I-NP	O
are	VBP	B-VP	O
more	RBR	I-VP	O
frequently	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
NMS	NN	B-NP	B
,	,	O	O
atypical	JJ	B-NP	O
antipsychotic	JJ	I-NP	O
drugs	NNS	I-NP	O
like	IN	B-PP	O
ziprasidone	NN	B-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
cause	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
who	WP	B-NP	O
developed	VBD	B-VP	O
signs	NNS	B-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
NMS	NN	B-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
orally	RB	B-NP	O
administrated	VBN	I-NP	O
ziprasidone	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
earliest	JJS	I-NP	O
(	(	O	O
second	JJ	B-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
)	)	O	O
NMS	NN	B-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
ziprasidone	NN	B-NP	O
reported	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Role	NN	B-NP	O
of	IN	B-PP	O
mangiferin	NN	B-NP	O
on	IN	B-PP	O
biochemical	JJ	B-NP	O
alterations	NNS	I-NP	O
and	CC	O	O
antioxidant	JJ	B-NP	O
status	NN	I-NP	O
in	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
dealt	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
mangiferin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
polyphenol	NN	I-NP	O
from	IN	B-PP	O
Mangifera	NNP	B-NP	O
indica	NNP	I-NP	O
Linn.	NNP	I-NP	O
(	(	O	O
Anacardiaceae	NNP	B-NP	O
)	)	O	O
,	,	O	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
(	(	O	O
ISPH	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
(	(	O	O
MI	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
through	IN	B-PP	O
its	PRP$	B-NP	O
antioxidative	JJ	I-NP	O
mechanism	NN	I-NP	O
.	.	O	O

Subcutaneous	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
ISPH	NN	B-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
caused	VBD	B-VP	O
myocardial	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
rat	NN	B-NP	O
heart	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
lactate	NN	I-NP	O
dehydrogenase	NN	I-NP	O
(	(	O	O
LDH	NN	B-NP	O
)	)	O	O
and	CC	O	O
creatine	NN	B-NP	O
phosphokinase	NN	I-NP	O
isoenzymes	NNS	I-NP	O
(	(	O	O
CK	NN	B-NP	O
-	HYPH	O	O
MB	NN	B-NP	O
)	)	O	O
,	,	O	O
increased	VBN	B-NP	O
uric	JJ	I-NP	O
acid	NN	I-NP	O
level	NN	I-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
plasma	NN	I-NP	O
iron	NN	I-NP	O
binding	NN	I-NP	O
capacity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
mangiferin	NN	B-NP	O
was	VBD	B-VP	O
analyzed	VBN	I-VP	O
by	IN	B-PP	O
triphenyl	NN	B-NP	O
tetrazolium	NN	I-NP	O
chloride	NN	I-NP	O
(	(	O	O
TTC	NN	B-NP	O
)	)	O	O
test	NN	B-NP	O
used	VBN	B-VP	O
for	IN	B-PP	O
macroscopic	JJ	B-NP	O
enzyme	NN	I-NP	O
mapping	NN	I-NP	O
assay	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ischemic	JJ	I-NP	B
myocardium	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
heart	NN	I-NP	O
tissue	NN	I-NP	O
antioxidant	JJ	I-NP	O
enzymes	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
superoxide	NN	B-NP	O
dismutase	NN	I-NP	O
,	,	O	O
catalase	NN	B-NP	O
,	,	O	O
glutathione	NN	B-NP	O
peroxidase	NN	I-NP	O
,	,	O	O
glutathione	NN	B-NP	O
transferase	NN	I-NP	O
and	CC	O	O
glutathione	NN	B-NP	O
reductase	NN	I-NP	O
activities	NNS	I-NP	O
,	,	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
enzymic	JJ	B-NP	O
antioxidants	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
cerruloplasmin	NN	B-NP	O
,	,	O	O
Vitamin	NNP	B-NP	O
C	NNP	I-NP	O
,	,	O	O
Vitamin	NN	B-NP	O
E	NN	I-NP	O
and	CC	I-NP	O
glutathione	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
altered	VBN	I-VP	O
in	IN	B-PP	O
MI	NN	B-NP	B
rats	NNS	I-NP	O
.	.	O	O

Upon	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
mangiferin	NN	B-NP	O
given	VBN	B-VP	O
intraperitoneally	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
to	TO	B-PP	O
MI	NN	B-NP	B
rats	NNS	I-NP	O
protected	VBD	B-VP	O
the	DT	B-NP	O
above	RB	I-NP	O
-	HYPH	I-NP	O
mentioned	VBN	I-NP	O
parameters	NNS	I-NP	O
to	TO	B-VP	O
fall	VB	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Activities	NNS	B-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
tissue	NN	I-NP	O
enzymic	JJ	I-NP	O
antioxidants	NNS	I-NP	O
and	CC	I-NP	O
serum	NN	I-NP	O
non	AFX	O	O
-	HYPH	B-NP	O
enzymic	JJ	I-NP	O
antioxidants	NNS	I-NP	O
levels	NNS	I-NP	O
rose	VBD	B-VP	O
significantly	RB	B-ADVP	O
upon	IN	B-PP	O
mangiferin	NN	B-NP	O
administration	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
to	TO	B-PP	O
ISPH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
MI	NN	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

From	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
mangiferin	NN	B-NP	O
exerts	VBZ	B-VP	O
a	DT	B-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
against	IN	B-PP	O
ISPH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
MI	NN	I-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
antioxidant	JJ	I-NP	O
potential	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
regulated	VBD	B-VP	O
the	DT	B-NP	O
tissues	NNS	I-NP	O
defense	NN	I-NP	O
system	NN	I-NP	O
against	IN	B-PP	O
cardiac	JJ	B-NP	B
damage	NN	I-NP	I
.	.	O	O

Remifentanil	NN	B-NP	O
pretreatment	NN	I-NP	O
reduces	VBZ	B-VP	O
myoclonus	NN	B-NP	B
after	IN	B-PP	O
etomidate	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
remifentanil	NN	B-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
gender	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
myoclonus	NN	B-NP	B
after	IN	B-PP	O
anesthesia	NN	B-NP	O
induction	NN	I-NP	O
with	IN	B-PP	O
etomidate	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
university	NN	I-NP	O
hospital	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
pretreated	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blinded	JJ	I-NP	O
fashion	NN	I-NP	O
with	IN	B-PP	O
remifentanil	NN	B-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
remifentanil	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
injection	NN	I-NP	O
,	,	O	O
etomidate	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
.	.	O	O

Myoclonus	NN	B-NP	B
was	VBD	B-VP	O
recorded	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
scale	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
grade	NN	I-NP	O
of	IN	B-PP	O
sedation	NN	B-NP	O
(	(	O	O
none	NN	B-NP	O
,	,	O	O
mild	JJ	B-NP	O
,	,	I-NP	O
moderate	JJ	I-NP	O
,	,	I-NP	O
severe	JJ	I-NP	O
)	)	O	O
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
pruritus	NN	B-NP	B
,	,	O	O
and	CC	O	O
apnea	NN	B-NP	B
were	VBD	B-VP	O
recorded	VBN	I-VP	O
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
myoclonus	NN	B-NP	B
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
remifentanil	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
sedation	NN	B-NP	O
,	,	O	O
apnea	NN	B-NP	B
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
or	CC	O	O
pruritus	NN	B-NP	B
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
male	JJ	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significantly	RB	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
myoclonus	NN	B-NP	B
after	IN	B-PP	O
etomidate	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
remifentanil	NN	B-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
reduced	VBD	B-VP	O
myoclonus	NN	B-NP	B
after	IN	B-PP	O
etomidate	NN	B-NP	O
induction	NN	I-NP	O
without	IN	B-PP	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
sedation	NN	B-NP	O
,	,	O	O
apnea	NN	B-NP	B
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
or	CC	O	O
pruritus	NN	B-NP	B
.	.	O	O

Men	NN	B-NP	O
experience	NN	I-NP	O
increased	VBD	B-VP	O
incidence	NN	B-NP	O
of	IN	B-PP	O
myoclonus	NN	B-NP	B
than	IN	B-PP	O
women	NNS	B-NP	O
after	IN	B-PP	O
etomidate	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Daidzein	NN	B-NP	O
activates	VBZ	B-VP	O
choline	NN	B-NP	O
acetyltransferase	NN	I-NP	O
from	IN	B-PP	O
MC	NN	B-NP	O
-	HYPH	I-NP	O
IXC	NN	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
improves	VBZ	B-VP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
choline	NN	I-NP	O
acetyltransferase	NN	I-NP	O
(	(	O	O
ChAT	NN	B-NP	O
)	)	O	O
activator	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
enhances	VBZ	B-VP	O
cholinergic	JJ	B-NP	O
transmission	NN	I-NP	O
via	IN	B-PP	O
an	DT	B-NP	O
augmentation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
enzymatic	JJ	I-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
acetylcholine	NN	B-NP	O
(	(	O	O
ACh	NN	B-NP	O
)	)	O	O
,	,	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
AD	NN	B-NP	B
)	)	O	O
.	.	O	O

Methanolic	JJ	B-NP	O
extracts	NNS	I-NP	O
from	IN	B-PP	O
Pueraria	NNP	B-NP	O
thunbergiana	NNP	I-NP	O
exhibited	VBD	B-VP	O
an	DT	B-NP	O
activation	NN	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
ChAT	NN	B-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

Via	IN	B-PP	O
the	DT	B-NP	O
sequential	JJ	I-NP	O
isolation	NN	I-NP	O
of	IN	B-PP	O
Pueraria	NNP	B-NP	O
thunbergiana	NNP	I-NP	O
,	,	O	O
the	DT	B-NP	O
active	JJ	I-NP	O
component	NN	I-NP	O
was	VBD	B-VP	O
ultimately	RB	I-VP	O
identified	VBN	I-VP	O
as	IN	B-PP	O
daidzein	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
'	SYM	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dihydroxy	NN	I-NP	O
-	HYPH	I-NP	O
isoflavone	NN	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
daidzein	NN	B-NP	O
from	IN	B-PP	O
Pueraria	NNP	B-NP	O
thunbergiana	NN	I-NP	O
on	IN	B-PP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
impairments	NNS	I-NP	B
of	IN	B-PP	I
learning	NN	B-NP	I
and	CC	I-NP	I
memory	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
in	FW	B-NP	O
vivo	FW	I-NP	O
tests	NNS	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
daidzein	NN	B-NP	O
to	TO	B-PP	O
mice	NNS	B-NP	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
significantly	RB	B-ADVP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
,	,	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
Y	NN	I-NP	O
-	HYPH	B-NP	O
maze	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Injections	NNS	B-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
into	IN	B-PP	O
mice	NNS	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
impaired	JJ	B-NP	O
performance	NN	I-NP	O
on	IN	B-PP	O
Y	NN	B-NP	O
-	HYPH	B-NP	O
maze	NN	I-NP	O
tests	NNS	I-NP	O
(	(	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
decreases	VBZ	B-VP	O
in	IN	B-PP	O
alternation	NN	B-NP	O
behavior	NN	I-NP	O
)	)	O	O
.	.	O	O

By	IN	B-PP	O
way	NN	B-NP	O
of	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
mice	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
daidzein	NN	B-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
scopolamine	NN	I-NP	O
injections	NNS	I-NP	O
were	VBD	B-VP	O
noticeably	RB	I-VP	O
protected	VBN	I-VP	O
from	IN	B-PP	O
this	DT	B-NP	O
performance	NN	I-NP	O
impairment	NN	I-NP	O
(	(	O	O
an	DT	B-NP	O
approximately	RB	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
%	NN	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
alternation	NN	B-NP	O
behavior	NN	I-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
daidzein	NN	B-NP	O
might	MD	B-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
acetylcholine	NN	B-NP	O
biosynthesis	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
ChAT	NN	I-NP	O
activator	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
also	RB	B-ADVP	O
ameliorates	VBZ	B-VP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

Possible	JJ	B-NP	O
azithromycin	NN	I-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
hiccups	NNS	I-NP	B
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
hiccups	NNS	I-NP	B
associated	VBN	B-VP	O
by	IN	B-PP	O
azithromycin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
presented	VBN	B-VP	O
with	IN	B-PP	O
persistent	JJ	B-NP	O
hiccups	NNS	I-NP	B
after	IN	B-PP	O
beginning	VBG	B-VP	O
azithromycin	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
pharyngitis	NN	B-NP	B
.	.	O	O

Hiccups	NNS	B-NP	B
were	VBD	B-VP	O
persistent	JJ	B-ADJP	O
and	CC	I-ADJP	O
exhausting	JJ	I-ADJP	O
.	.	O	O

Discontinuation	NN	B-NP	O
of	IN	B-PP	O
azithromycin	NN	B-NP	O
and	CC	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
baclofen	NN	B-NP	O
finally	RB	B-NP	O
resolved	VBN	I-NP	O
hiccups	NNS	I-NP	B
.	.	O	O

No	DT	B-NP	O
organic	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
hiccups	NNS	B-NP	B
was	VBD	B-VP	O
identified	VBN	I-VP	O
despite	IN	B-PP	O
extensive	JJ	B-NP	O
investigation	NN	I-NP	O
.	.	O	O

Pharmacotherapeutic	JJ	B-NP	O
agents	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
uncommonly	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hiccups	NNS	B-NP	B
.	.	O	O

Corticosteroids	NNS	B-NP	O
(	(	O	O
dexamethasone	NN	B-NP	O
and	CC	O	O
methylprednisolone	NN	B-NP	O
)	)	O	O
,	,	O	O
benzodiazepines	NNS	B-NP	O
(	(	O	O
midazolam	NN	B-NP	O
)	)	O	O
and	CC	O	O
general	JJ	B-NP	O
anaesthesia	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
the	DT	B-NP	O
specific	JJ	I-NP	O
agents	NNS	I-NP	O
mentioned	VBD	B-VP	O
most	RBS	B-ADVP	O
frequently	RB	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
as	IN	B-PP	O
being	VBG	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hiccups	NNS	B-NP	B
.	.	O	O

Few	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hiccups	NNS	I-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
related	VBN	B-ADJP	O
to	TO	B-PP	O
macrolide	NN	B-NP	O
antimicrobials	NNS	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
reaction	NN	I-NP	O
probability	NN	I-NP	O
scale	NN	I-NP	O
this	DT	B-NP	O
event	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
classified	VBN	I-VP	O
as	IN	B-PP	O
possible	JJ	B-ADJP	O
(	(	O	O
score	NN	B-NP	O
num	CD	B-NP	O
points	NNS	I-NP	O
)	)	O	O
,	,	O	O
mostly	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
close	JJ	I-NP	O
temporal	JJ	I-NP	O
sequence	NN	I-NP	O
,	,	O	O
previous	JJ	B-NP	O
reports	NNS	I-NP	O
on	IN	B-PP	O
this	DT	B-NP	O
reaction	NN	I-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
macrolides	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
alternative	JJ	I-NP	O
explanation	NN	I-NP	O
for	IN	B-PP	O
hiccups	NNS	B-NP	B
.	.	O	O

Our	PRP$	B-NP	O
hypothesis	NN	I-NP	O
is	VBZ	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
vagal	JJ	I-NP	O
mechanism	NN	I-NP	O
mediated	VBN	B-VP	O
by	IN	B-PP	O
azithromycin	NN	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
hiccups	NNS	B-NP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
.	.	O	O

Diagnosis	NN	B-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hiccups	NNS	I-NP	B
is	VBZ	B-VP	O
difficult	JJ	B-ADJP	O
and	CC	O	O
often	RB	B-VP	O
achieved	VBN	I-VP	O
only	RB	B-ADVP	O
by	IN	B-PP	O
a	DT	B-NP	O
process	NN	I-NP	O
of	IN	B-PP	O
elimination	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
macrolide	NN	B-NP	O
antimicrobials	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hiccups	NNS	B-NP	B
and	CC	O	O
vagal	JJ	B-NP	O
mechanism	NN	I-NP	O
could	MD	B-VP	O
explain	VB	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
.	.	O	O

Time	NN	B-NP	O
trends	NNS	I-NP	O
in	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
hemorrhage	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
annual	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-ADJP	O
bleeding	VBG	B-VP	B
at	IN	B-PP	O
Brigham	NNP	B-NP	O
and	CC	I-NP	O
Women	NNP	I-NP	O
s	NNP	I-NP	O
Hospital	NNP	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
admissions	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
period	NN	I-NP	O
(	(	O	O
January	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
October	NNP	B-NP	O
num	CD	I-NP	O
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
admissions	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
time	NN	I-NP	O
period	NN	I-NP	O
(	(	O	O
November	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
August	NNP	B-NP	O
num	CD	I-NP	O
)	)	O	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
major	JJ	B-NP	O
and	CC	I-NP	O
intracranial	JJ	I-NP	B
bleeding	NN	I-NP	I
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
second	NN	I-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
haemorrhagic	JJ	I-NP	B
myocarditis	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
cyclophosphamide	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Haemorrhagic	JJ	B-NP	B
myocarditis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
but	CC	I-NP	O
important	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Echocardiographic	JJ	B-NP	O
identification	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
disorder	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
made	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
believe	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
ultrasound	JJ	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
disorder	NN	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
induces	VBZ	B-VP	O
attacks	NNS	B-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
without	IN	B-PP	I
aura	NN	B-NP	I
in	IN	B-PP	O
sufferers	NNS	B-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
with	IN	B-PP	I
aura	NN	B-NP	I
.	.	O	O

Migraine	NN	B-NP	B
with	IN	B-PP	I
aura	NN	B-NP	I
and	CC	I-NP	O
migraine	NN	I-NP	B
without	IN	B-PP	I
aura	NN	B-NP	I
have	VBP	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
pain	NN	I-NP	B
phase	NN	I-NP	O
,	,	O	O
thus	RB	B-ADVP	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
migraine	NN	B-NP	B
with	IN	B-PP	I
aura	NN	B-NP	I
and	CC	I-NP	O
migraine	NN	I-NP	B
without	IN	B-PP	I
aura	NN	B-NP	I
share	VBP	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
pathway	NN	I-NP	O
of	IN	B-PP	O
nociception	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
recent	JJ	B-NP	O
years	NNS	I-NP	O
,	,	O	O
increasing	VBG	B-VP	O
evidence	NN	B-NP	O
has	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
messenger	NN	I-NP	O
molecule	NN	I-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
pain	NN	B-NP	B
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
without	IN	B-PP	I
aura	NN	B-NP	I
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
clarify	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
same	JJ	I-NP	O
is	VBZ	B-VP	O
true	JJ	B-ADJP	O
for	IN	B-PP	O
migraine	NN	B-NP	B
with	IN	B-PP	I
aura	NN	B-NP	I
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
headache	NN	I-NP	B
response	NN	I-NP	O
to	TO	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
(	(	O	O
GTN	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
sufferers	NNS	I-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
with	IN	B-PP	I
aura	NN	B-NP	I
.	.	O	O

The	DT	B-NP	O
specific	JJ	I-NP	O
aim	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
elucidate	VB	I-VP	O
whether	IN	B-SBAR	O
an	DT	B-NP	O
aura	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
an	DT	B-NP	O
attack	NN	I-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
without	IN	B-PP	I
aura	NN	B-NP	I
could	MD	B-VP	O
be	VB	I-VP	O
induced	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
served	VBD	B-VP	O
as	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Aura	NNP	B-NP	O
symptoms	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
elicited	VBN	I-VP	O
in	IN	B-PP	O
any	DT	B-NP	O
subject	NN	I-NP	O
.	.	O	O

Headache	PRP	B-NP	B
was	VBD	B-VP	O
more	RBR	B-ADJP	O
severe	JJ	I-ADJP	O
in	IN	B-PP	O
migraineurs	NNS	B-NP	B
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
during	IN	B-PP	O
and	CC	O	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
GTN	NN	B-NP	O
infusion	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
during	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
GTN	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
headache	NN	I-NP	B
gradually	RB	B-ADVP	O
disappeared	VBD	B-VP	O
,	,	O	O
whereas	IN	O	O
in	IN	B-PP	O
migraineurs	NNS	B-NP	B
peak	VBP	B-VP	O
headache	NN	B-NP	B
intensity	NN	I-NP	O
occurred	VBD	B-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
infusion	NN	B-NP	O
.	.	O	O

At	IN	B-PP	O
this	DT	B-NP	O
time	NN	I-NP	O
the	DT	B-NP	O
induced	VBN	I-NP	O
headache	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
migraineurs	NNS	I-NP	B
fulfilled	VBD	B-VP	O
the	DT	B-NP	O
diagnostic	JJ	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
migraine	NN	B-NP	B
without	IN	B-PP	I
aura	NN	B-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
International	NNP	I-NP	O
Headache	NNP	I-NP	B
Society	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
therefore	RB	B-ADVP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
NO	NN	B-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pain	NN	I-NP	B
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
with	IN	B-PP	I
aura	NN	B-NP	I
.	.	O	O

Since	IN	B-SBAR	O
cortical	JJ	B-NP	O
spreading	VBG	I-NP	O
depression	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
liberate	VB	I-VP	O
NO	NN	B-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
,	,	O	O
this	DT	B-NP	O
finding	NN	I-NP	O
may	MD	B-VP	O
help	VB	I-VP	O
our	PRP$	B-NP	O
understanding	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
coupling	NN	I-NP	O
between	IN	B-PP	O
cortical	JJ	B-NP	O
spreading	VBG	I-NP	O
depression	NN	I-NP	B
and	CC	I-NP	O
headache	NN	I-NP	B
in	IN	B-PP	O
migraine	NN	B-NP	B
with	IN	B-PP	I
aura	NN	B-NP	I
.	.	O	O

Stroke	NN	B-NP	B
and	CC	I-NP	O
cocaine	NN	I-NP	O
or	CC	I-NP	O
amphetamine	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
amphetamine	NN	I-NP	O
use	NN	I-NP	O
with	IN	B-PP	O
hemorrhagic	JJ	B-NP	O
and	CC	I-NP	O
ischemic	JJ	I-NP	B
stroke	NN	I-NP	B
is	VBZ	B-VP	O
based	VBN	I-VP	O
almost	RB	B-ADVP	O
solely	RB	I-ADVP	O
on	IN	B-PP	O
data	NNS	B-NP	O
from	IN	B-PP	O
case	NN	B-NP	O
series	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
limited	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
epidemiologic	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
stroke	NN	B-NP	B
and	CC	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
amphetamine	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
done	VBN	I-VP	O
in	IN	B-PP	O
settings	NNS	B-NP	O
that	WDT	B-NP	O
serve	VBP	B-VP	O
mostly	RB	B-ADVP	O
the	DT	B-NP	O
poor	JJ	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
minorities	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
defined	VBN	I-NP	O
population	NN	I-NP	O
comprising	VBG	B-VP	O
members	NNS	B-NP	O
of	IN	B-PP	O
Kaiser	NNP	B-NP	O
Permanente	NNP	I-NP	O
of	IN	B-PP	O
Northern	NNP	B-NP	O
and	CC	O	O
Southern	NNP	B-NP	O
California	NNP	I-NP	O
.	.	O	O

We	PRP	B-NP	O
attempted	VBD	B-VP	O
to	TO	I-VP	O
identify	VB	I-VP	O
all	DT	B-NP	O
incident	JJ	I-NP	O
strokes	NNS	I-NP	B
in	IN	B-PP	O
women	NNS	B-NP	O
ages	NNS	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
using	VBG	B-VP	O
hospital	NN	B-NP	O
admission	NN	I-NP	O
and	CC	I-NP	O
discharge	NN	I-NP	O
records	NNS	I-NP	O
,	,	O	O
emergency	NN	B-NP	O
department	NN	I-NP	O
logs	NNS	I-NP	O
,	,	O	O
and	CC	O	O
payment	NN	B-NP	O
requests	NNS	I-NP	O
for	IN	B-PP	O
out	RB	B-NP	O
-	HYPH	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
plan	NN	I-NP	O
hospitalizations	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
selected	VBD	B-VP	O
controls	NNS	B-NP	O
,	,	O	O
matched	VBN	B-VP	O
on	IN	B-PP	O
age	NN	B-NP	O
and	CC	I-NP	O
facility	NN	I-NP	O
of	IN	B-PP	O
usual	JJ	B-NP	O
care	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
random	NN	B-NP	O
from	IN	B-PP	O
healthy	JJ	B-NP	O
members	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
health	NN	I-NP	O
plan	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
obtained	VBD	B-VP	O
information	NN	B-NP	O
in	IN	B-PP	O
face	NN	B-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
face	NN	I-NP	O
interviews	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
confirmed	VBN	I-NP	O
stroke	NN	I-NP	B
cases	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
univariate	JJ	I-NP	O
matched	NN	I-NP	O
odds	VBZ	B-VP	O
ratio	NN	B-NP	O
for	IN	B-PP	O
stroke	NN	B-NP	B
in	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
admitted	VBD	B-VP	O
to	TO	B-PP	O
using	VBG	B-VP	O
cocaine	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
amphetamine	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

After	IN	B-PP	O
further	JJR	B-NP	O
adjustment	NN	I-NP	O
for	IN	B-PP	O
potential	JJ	B-NP	O
confounders	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
reported	VBD	B-VP	O
using	VBG	I-VP	O
cocaine	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
amphetamine	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
amphetamine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
stroke	NN	B-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
socioeconomically	RB	I-NP	O
heterogeneous	JJ	I-NP	O
,	,	I-NP	O
insured	JJ	I-NP	O
urban	JJ	I-NP	O
population	NN	I-NP	O
.	.	O	O

Prevention	NN	B-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
with	IN	B-PP	O
tamoxifen	NN	B-NP	O
:	:	O	O
preliminary	JJ	B-NP	O
findings	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
Italian	JJ	I-NP	O
randomised	VBN	I-NP	O
trial	NN	I-NP	O
among	IN	B-PP	O
hysterectomised	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Italian	JJ	B-NP	O
Tamoxifen	NNP	I-NP	O
Prevention	NNP	I-NP	O
Study	NNP	I-NP	O
.	.	O	O

Tamoxifen	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
candidate	NN	I-NP	O
chemopreventive	JJ	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
drug	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

Therefore	RB	B-ADVP	O
we	PRP	B-NP	O
did	VBD	B-VP	O
a	DT	B-NP	O
trial	NN	I-NP	O
in	IN	B-PP	O
hysterectomised	VBN	B-NP	O
women	NNS	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
chemopreventive	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
October	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
we	PRP	B-NP	O
started	VBD	B-VP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
placebo	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-VP	O
,	,	O	O
randomised	VBN	B-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
(	(	O	O
mainly	RB	B-ADVP	O
in	IN	B-PP	O
Italy	NNP	B-NP	O
)	)	O	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
and	CC	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
had	VBN	I-VP	O
a	DT	B-NP	O
hysterectomy	NN	I-NP	O
.	.	O	O

Women	NNS	B-NP	O
were	VBD	B-VP	O
randomised	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
tamoxifen	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
or	CC	O	O
placebo	NN	B-NP	O
,	,	O	O
both	CC	B-PP	O
orally	RB	I-PP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
original	JJ	I-NP	O
plan	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
follow	VB	I-VP	O
the	DT	B-NP	O
intervention	NN	I-NP	O
phase	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
s	VBZ	B-VP	O
follow	VB	I-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
.	.	O	O

In	IN	B-PP	O
June	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
the	DT	B-NP	O
trialists	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
data	NNS	I-NP	O
-	HYPH	O	O
monitoring	VBG	B-VP	O
committee	NN	B-NP	O
decided	VBD	B-VP	O
to	TO	I-VP	O
end	VB	I-VP	O
recruitment	NN	B-NP	O
primarily	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
dropping	VBG	B-VP	O
out	IN	B-PP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Recruitment	NN	B-NP	O
ended	VBD	B-VP	O
on	IN	B-PP	O
July	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
study	NN	I-NP	O
will	MD	B-VP	O
continue	VB	I-VP	O
as	IN	B-SBAR	O
planned	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
endpoints	NNS	I-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
and	CC	O	O
deaths	NNS	B-NP	O
from	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
preliminary	JJ	I-NP	O
interim	JJ	I-NP	O
analysis	NN	I-NP	O
is	VBZ	B-VP	O
based	VBN	I-VP	O
on	IN	B-PP	O
intention	NN	B-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
treat	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
women	NNS	I-NP	O
were	VBD	B-VP	O
randomised	VBN	I-VP	O
;	:	O	O
participating	VBG	B-NP	O
women	NNS	I-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
median	JJ	I-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
for	IN	B-PP	O
major	JJ	B-NP	O
endpoints.	NN	I-NP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
occurred	VBD	B-VP	O
so	RB	B-ADVP	O
far	RB	I-ADVP	O
;	:	O	O
there	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
no	DT	B-NP	O
deaths	NNS	I-NP	O
from	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
breast	NN	B-NP	B
-	HYPH	B-NP	I
cancer	NN	I-NP	I
frequency	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
)	)	O	O
and	CC	O	O
tamoxifen	NN	B-NP	O
arms	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
among	IN	B-PP	O
women	NNS	B-NP	O
receiving	VBG	B-VP	O
tamoxifen	NN	B-NP	O
who	WP	B-NP	O
also	RB	B-ADVP	O
used	VBD	B-VP	O
hormone	NN	B-NP	O
-	HYPH	B-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
trial	NN	I-NP	O
:	:	O	O
among	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
on	IN	B-PP	O
such	JJ	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
allocated	VBN	B-VP	O
to	TO	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
compared	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
case	NN	I-NP	O
among	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
allocated	VBN	B-VP	O
to	TO	B-PP	O
tamoxifen	NN	B-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
vascular	JJ	B-NP	B
events	NNS	I-NP	I
and	CC	O	O
hypertriglyceridaemia	NN	B-NP	B
among	IN	B-PP	O
women	NNS	B-NP	O
on	IN	B-PP	O
tamoxifen	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
this	DT	B-NP	O
preliminary	JJ	I-NP	O
analysis	NN	I-NP	O
has	VBZ	B-VP	O
low	JJ	B-NP	O
power	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
this	DT	B-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
at	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
normal	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
postulated	VBN	I-NP	O
protective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
are	VBP	B-VP	O
not	RB	O	O
yet	RB	B-ADJP	O
apparent	JJ	I-ADJP	O
.	.	O	O

Women	NNS	B-NP	O
using	VBG	B-VP	O
hormone	NN	B-NP	O
-	HYPH	I-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
benefited	VBN	I-VP	O
from	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
deaths	NNS	I-NP	O
from	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
recorded	VBN	B-VP	O
in	IN	B-PP	O
women	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
essential	JJ	B-ADJP	O
to	TO	B-VP	O
continue	VB	I-VP	O
follow	VB	I-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
to	TO	B-VP	O
quantify	VB	I-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
risks	NNS	I-NP	O
and	CC	I-NP	O
benefits	NNS	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
pupillary	JJ	B-NP	B
oscillation	NN	I-NP	I
as	IN	B-PP	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
paranoia	NN	I-NP	B
.	.	O	O

Cocaine	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
paranoia	NN	I-NP	B
(	(	O	O
CIP	NN	B-NP	B
)	)	O	O
remains	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
idiopathic	JJ	B-NP	O
paranoia	NN	I-NP	B
for	IN	B-PP	O
which	WDT	B-NP	O
no	DT	B-NP	O
psychophysiologic	JJ	I-NP	O
marker	NN	I-NP	O
has	VBZ	B-VP	O
yet	RB	I-VP	O
emerged	VBN	I-VP	O
.	.	O	O

Measures	NNS	B-NP	O
of	IN	B-PP	O
pupillary	JJ	B-NP	B
oscillation	NN	I-NP	I
were	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
significantly	RB	I-VP	O
distinguish	VB	I-VP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
abstinent	JJ	B-NP	O
crack	NN	I-NP	O
cocaine	NN	I-NP	O
abusers	NNS	I-NP	O
endorsing	VBG	B-VP	O
past	JJ	B-NP	O
CIP	NN	I-NP	B
from	IN	B-PP	O
another	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
crack	NN	B-NP	O
addicts	NNS	I-NP	O
who	WP	B-NP	O
denied	VBD	B-VP	O
past	JJ	B-NP	O
CIP	NN	I-NP	B
.	.	O	O

Seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
combined	VBN	B-NP	O
levomepromazine	NN	I-NP	O
-	HYPH	B-NP	O
fluvoxamine	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
combined	VBN	B-NP	O
levomepromazine	NN	I-NP	O
-	HYPH	O	O
fluvoxamine	NN	B-NP	O
treatment	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

It	PRP	B-NP	O
seems	VBZ	B-VP	O
that	IN	B-SBAR	O
combined	VBN	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
fluvoxamine	NN	B-NP	O
with	IN	B-PP	O
phenothiazines	NNS	B-NP	O
may	MD	B-VP	O
possess	VB	I-VP	O
proconvulsive	JJ	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Why	WRB	B-ADVP	O
may	MD	O	O
epsilon	NN	B-NP	O
-	HYPH	O	O
aminocaproic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
EACA	NN	B-NP	O
)	)	O	O
induce	VBP	B-VP	O
myopathy	NN	B-NP	B
in	IN	B-PP	O
man	NN	B-NP	O
?	.	O	O
Report	NNP	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
and	CC	I-NP	O
literature	NN	I-NP	O
review	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
necrotizing	VBG	B-VP	B
myopathy	NN	B-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
short	JJ	I-NP	O
epsilon	NN	I-NP	O
-	HYPH	B-NP	O
aminocaproic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
EACA	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
subarachnoid	JJ	B-NP	B
haemorrhage	NN	I-NP	I
(	(	O	O
SAH	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

Pathogenetic	JJ	B-NP	O
hypotheses	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
ranitidine	NN	B-NP	O
and	CC	I-NP	O
cimetidine	NN	I-NP	O
in	IN	B-PP	O
inhibiting	VBG	B-VP	O
acid	NN	B-NP	O
secretion	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
gastric	JJ	B-NP	O
hypersecretory	NN	I-NP	O
states	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
H2	NN	I-NP	O
-	HYPH	I-NP	O
histamine	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
ranitidine	NN	I-NP	O
and	CC	I-NP	O
cimetidine	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
abilities	NNS	I-NP	O
to	TO	B-VP	O
control	VB	I-VP	O
gastric	JJ	B-NP	O
acid	NN	I-NP	O
hypersecretion	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
basis	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
gastric	JJ	B-NP	O
acid	NN	I-NP	O
hypersecretory	JJ	I-NP	O
states	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
Zollinger	NN	B-NP	B
-	HYPH	I-NP	I
Ellison	NN	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
systemic	JJ	B-NP	B
mastocytosis	NN	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
idiopathic	JJ	B-NP	O
hypersecretion	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
and	CC	I-NP	O
ranitidine	NN	I-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
.	.	O	O

The	DT	B-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
anticholinergic	JJ	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
and	CC	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
close	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
daily	JJ	I-NP	O
maintenance	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
drug	NN	I-NP	O
needed	VBN	B-VP	O
to	TO	B-VP	O
control	VB	I-VP	O
acid	NN	B-NP	O
secretion	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
ranitidine	NN	B-NP	O
was	VBD	B-VP	O
threefold	RB	B-ADJP	O
more	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
cimetidine	NN	B-NP	O
both	CC	B-PP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
inhibition	NN	I-NP	O
studies	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
median	JJ	I-NP	O
maintenance	NN	I-NP	O
dose	NN	I-NP	O
needed	VBN	B-VP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
for	IN	B-PP	O
ranitidine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
for	IN	B-PP	O
cimetidine	NN	B-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
males	NNS	I-NP	O
developed	VBD	B-VP	O
breast	NN	B-NP	O
changes	NNS	I-NP	O
or	CC	O	O
impotence	NN	B-NP	B
while	IN	B-SBAR	O
taking	VBG	B-VP	O
cimetidine	NN	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
all	DT	B-NP	O
cases	NNS	I-NP	O
these	DT	B-NP	O
changes	NNS	I-NP	O
disappeared	VBD	B-VP	O
when	WRB	B-ADVP	O
cimetidine	NN	B-NP	O
was	VBD	B-VP	O
replaced	VBN	I-VP	O
by	IN	B-PP	O
ranitidine	NN	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
;	:	O	O
median	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
or	CC	O	O
ranitidine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
;	:	O	O
median	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
was	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hepatic	JJ	B-NP	B
or	CC	I-NP	I
hematologic	JJ	I-NP	I
toxicity	NN	I-NP	I
or	CC	I-NP	O
alterations	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
gastrin	NN	I-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
but	CC	O	O
ranitidine	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
lower	JJR	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
level	NN	I-NP	O
than	IN	B-SBAR	O
seen	VBN	B-VP	O
with	IN	B-PP	O
cimetidine	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
can	MD	B-VP	O
adequately	RB	I-VP	O
inhibit	VB	I-VP	O
acid	NN	B-NP	O
secretion	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
gastric	JJ	B-NP	O
hypersecretory	NN	I-NP	O
states	NNS	I-NP	O
.	.	O	O

Both	DT	B-NP	O
are	VBP	B-VP	O
safe	JJ	B-ADJP	O
at	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
but	CC	O	O
ranitidine	NN	B-NP	O
is	VBZ	B-VP	O
threefold	RB	B-ADJP	O
more	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
and	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
the	DT	B-NP	O
antiandrogen	NN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
frequently	RB	B-VP	O
seen	VBN	I-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
catch	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Reye	NNP	I-NP	B
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
Reye	NN	B-NP	B
syndrome	NN	I-NP	I
from	IN	B-PP	O
The	DT	B-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Hospital	NNP	B-NP	O
,	,	O	O
Camperdown	NNP	B-NP	O
,	,	O	O
Australia	NNP	B-NP	O
,	,	O	O
occurring	VBG	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

Of	IN	B-PP	O
these	DT	B-NP	O
,	,	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
met	VBD	B-VP	O
the	DT	B-NP	O
US	NNP	I-NP	O
Public	NNP	I-NP	O
Health	NNP	I-NP	O
Service	NNP	I-NP	O
Centers	NNP	I-NP	O
for	IN	B-PP	O
Disease	NNP	B-NP	O
Control	NNP	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
Reye	NN	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Aspirin	NN	B-NP	O
or	CC	I-NP	O
salicylate	NN	I-NP	O
ingestion	NN	I-NP	O
had	VBD	B-VP	O
occurred	VBN	I-VP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
and	CC	O	O
paracetamol	NN	B-NP	O
(	(	O	O
acetaminophen	NN	B-NP	O
)	)	O	O
had	VBD	B-VP	O
been	VBN	I-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Pathologic	JJ	B-NP	O
confirmation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
Reye	NN	B-NP	B
syndrome	NN	I-NP	I
was	VBD	B-VP	O
accomplished	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
Reye	NN	B-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
New	NNP	B-NP	O
South	NNP	I-NP	O
Wales	NNP	I-NP	O
,	,	O	O
Australia	NNP	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
estimated	VBN	I-VP	O
from	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
recent	JJ	B-NP	O
US	NNP	I-NP	O
data	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
in	IN	B-PP	O
Great	NNP	B-NP	O
Britain	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
mortality	NN	I-NP	O
for	IN	B-PP	O
these	DT	B-NP	O
Reye	NNP	I-NP	B
syndrome	NN	I-NP	I
cases	NNS	I-NP	O
in	IN	B-PP	O
Australia	NNP	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
fatality	NN	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
.	.	O	O

In	IN	B-PP	O
Australia	NNP	B-NP	O
,	,	O	O
the	DT	B-NP	O
pediatric	JJ	I-NP	O
usage	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
extremely	RB	B-ADJP	O
low	JJ	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
past	JJ	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
paracetamol	NN	B-NP	O
(	(	O	O
acetaminophen	NN	B-NP	O
)	)	O	O
dominating	VBG	B-VP	O
the	DT	B-NP	O
pediatric	JJ	I-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
antipyretic	JJ	I-NP	O
market	NN	I-NP	O
.	.	O	O

Reye	NN	B-NP	B
syndrome	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
disappearing	VBG	I-VP	O
from	IN	B-PP	O
Australia	NNP	B-NP	O
despite	IN	B-PP	O
a	DT	B-NP	O
total	JJ	I-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
salicylates	NNS	B-NP	O
or	CC	O	O
aspirin	NN	B-NP	O
ingestion	NN	I-NP	O
,	,	O	O
since	IN	B-SBAR	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
cases	NNS	I-NP	O
found	VBN	B-VP	O
at	IN	B-PP	O
The	DT	B-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Hospital	NNP	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
.	.	O	O

St	NNP	B-NP	B
Anthony	NNP	I-NP	I
s	VBZ	B-VP	I
fire	NN	B-NP	I
,	,	O	O
then	RB	B-ADVP	O
and	CC	O	O
now	RB	B-ADVP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
and	CC	O	O
historical	JJ	B-NP	O
review	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
rare	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
morbid	NN	B-NP	O
vasospasm	NN	I-NP	B
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
striking	JJ	B-NP	O
angiographic	JJ	I-NP	O
findings	NNS	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
ingestion	NN	I-NP	O
of	IN	B-PP	O
methysergide	NN	B-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
brief	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
on	IN	B-PP	O
similar	JJ	B-NP	O
cases	NNS	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
discussion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
ergot	NN	B-NP	O
includes	VBZ	B-VP	O
its	PRP$	B-NP	O
original	JJ	I-NP	O
discovery	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
epidemics	NNS	I-NP	O
of	IN	B-PP	O
gangrene	NN	B-NP	B
that	IN	B-NP	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
caused	VBN	I-VP	O
through	IN	B-PP	O
the	DT	B-NP	O
ages	NNS	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
past	JJ	I-NP	O
and	CC	I-NP	O
present	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
migraine	NN	B-NP	B
headache	NN	I-NP	I
.	.	O	O

Despite	IN	B-PP	O
the	DT	B-NP	O
advent	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
and	CC	O	O
beta	SYM	B-NP	O
-	HYPH	O	O
adrenergic	JJ	B-NP	O
antagonists	NNS	I-NP	O
,	,	O	O
ergot	NN	B-NP	O
preparations	NNS	I-NP	O
continue	VBP	B-VP	O
to	TO	I-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
migraine	NN	B-NP	B
therapy	NN	I-NP	O
,	,	O	O
so	IN	B-SBAR	O
that	IN	I-SBAR	O
the	DT	B-NP	O
danger	NN	I-NP	O
of	IN	B-PP	O
St	NNP	B-NP	B
Anthony	NNP	I-NP	I
s	VBZ	B-VP	I
fire	NN	B-NP	I
persists	VBZ	B-VP	O
.	.	O	O

Beta	SYM	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
hypokalemia	NN	I-NP	B
and	CC	O	O
its	PRP$	B-NP	O
abolishment	NN	I-NP	O
by	IN	B-PP	O
oxprenolol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
and	CC	I-NP	O
concentration	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
relationship	NN	I-NP	O
of	IN	B-PP	O
terbutaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypokalemia	NN	I-NP	B
was	VBD	B-VP	O
studied	VBN	I-VP	O
,	,	O	O
using	VBG	B-VP	O
computer	NN	B-NP	O
-	HYPH	O	O
aided	VBN	B-VP	O
pharmacokinetic	JJ	B-NP	O
-	HYPH	I-NP	O
dynamic	JJ	I-NP	O
modeling	NN	I-NP	O
.	.	O	O

Subsequently	RB	B-ADVP	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
oxprenolol	NN	B-NP	O
in	IN	B-PP	O
antagonizing	VBG	B-VP	O
such	JJ	B-NP	O
hypokalemia	NN	I-NP	B
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
pharmacokinetic	JJ	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
subcutaneous	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
terbutaline	NN	B-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
occasions	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
hour	NN	I-NP	O
after	IN	B-SBAR	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
hour	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
oxprenolol	NN	I-NP	O
orally	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
period	NN	I-NP	O
after	IN	B-PP	O
terbutaline	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
taken	VBN	I-VP	O
for	IN	B-PP	O
determination	NN	B-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
potassium	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
drug	NN	B-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
sigmoid	JJ	I-NP	O
Emax	NN	I-NP	O
model	NN	I-NP	O
offered	VBD	B-VP	O
a	DT	B-NP	O
good	JJ	I-NP	O
description	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
relation	NN	I-NP	O
between	IN	B-PP	O
terbutaline	NN	B-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
potassium	NN	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Oxprenolol	NN	B-NP	O
caused	VBD	B-VP	O
decreases	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
terbutaline	NN	B-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
distribution	NN	B-NP	O
and	CC	I-NP	O
clearance	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
AUC	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
spite	NN	B-NP	O
of	IN	B-PP	O
higher	JJR	B-NP	O
terbutaline	NN	I-NP	O
concentrations	NNS	I-NP	O
after	IN	B-PP	O
oxprenolol	NN	B-NP	O
pretreatment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
hypokalemia	NN	I-NP	B
was	VBD	B-VP	O
almost	RB	I-VP	O
completely	RB	I-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
blocking	VBG	I-NP	O
action	NN	I-NP	O
.	.	O	O

Midline	NN	B-NP	O
B3	NN	I-NP	O
serotonin	NN	I-NP	O
nerves	VBZ	B-VP	O
in	IN	B-PP	O
rat	NN	B-NP	O
medulla	NN	I-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
hypotensive	JJ	B-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
methyldopa	NN	B-NP	O
.	.	O	O

Previous	JJ	B-NP	O
experiments	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
laboratory	NN	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
microinjection	NN	B-NP	O
of	IN	B-PP	O
methyldopa	NN	B-NP	O
onto	IN	B-PP	O
the	DT	B-NP	O
ventrolateral	JJ	I-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
B3	NN	I-NP	O
serotonin	NN	I-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
medulla	NN	I-NP	O
elicits	VBZ	B-VP	O
a	DT	B-NP	O
hypotensive	JJ	I-NP	B
response	NN	I-NP	O
mediated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
projection	NN	I-NP	O
descending	VBG	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
experiments	NNS	I-NP	O
were	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
midline	NN	I-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
B3	NN	I-NP	O
serotonin	NN	I-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
medulla	NN	I-NP	O
,	,	O	O
coinciding	VBG	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
raphe	NN	I-NP	O
magnus	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
,	,	I-NP	O
stroke	NN	I-NP	B
-	HYPH	I-NP	O
prone	JJ	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
microinjection	NN	B-NP	O
of	IN	B-PP	O
methyldopa	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
midline	NN	I-NP	O
B3	NN	I-NP	O
serotonin	NN	I-NP	O
cell	NN	I-NP	O
group	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
medulla	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
hypotension	NN	I-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
maximal	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
abolished	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
serotonin	NN	I-NP	O
neurotoxin	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydroxytryptamine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DHT	NN	I-NP	O
)	)	O	O
injected	VBN	B-VP	O
intracerebroventricularly	RB	B-ADVP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
intraspinal	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DHT	NN	I-NP	O
to	TO	B-VP	O
produce	VB	I-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
selective	JJ	I-NP	O
lesion	NN	I-NP	O
of	IN	B-PP	O
only	RB	B-VP	O
descending	VBG	I-VP	O
serotonin	NN	B-NP	O
projections	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
this	DT	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Further	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DHT	NN	I-NP	O
lesion	NN	I-NP	O
of	IN	B-PP	O
serotonin	NN	B-NP	O
nerves	VBZ	B-VP	O
travelling	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
median	JJ	I-NP	O
forebrain	NN	I-NP	O
bundle	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
main	JJ	I-NP	O
ascending	JJ	I-NP	O
pathways	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
B3	NN	I-NP	O
serotonin	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
midline	NN	I-NP	O
B3	NN	I-NP	O
serotonin	NN	I-NP	O
methyldopa	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
therefore	RB	B-ADVP	O
that	IN	B-SBAR	O
,	,	O	O
unlike	IN	B-PP	O
the	DT	B-NP	O
ventrolateral	JJ	I-NP	O
B3	NN	I-NP	O
cells	NNS	I-NP	O
which	WDT	B-NP	O
mediate	VBP	B-VP	O
a	DT	B-NP	O
methyldopa	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
via	IN	B-PP	O
descending	VBG	B-VP	O
projections	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
midline	NN	I-NP	O
serotonin	NN	I-NP	O
B3	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
medulla	NN	I-NP	O
contribute	VBP	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
action	NN	I-NP	O
of	IN	B-PP	O
methyldopa	NN	B-NP	O
,	,	O	O
either	CC	O	O
by	IN	B-PP	O
way	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
ascending	VBG	I-NP	O
projection	NN	I-NP	O
which	WDT	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
pass	VB	I-VP	O
through	IN	B-PP	O
the	DT	B-NP	O
median	JJ	I-NP	O
forebrain	NN	I-NP	O
bundle	NN	I-NP	O
,	,	O	O
or	CC	O	O
through	IN	B-PP	O
a	DT	B-NP	O
projection	NN	I-NP	O
restricted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
caudal	JJ	I-NP	O
brainstem	NN	I-NP	O
.	.	O	O

Yohimbine	NN	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	B
side	NN	I-NP	I
effects	NNS	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
serotonin	NN	B-NP	O
reuptake	NN	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

Preclinical	JJ	B-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
yohimbine	PRP	B-NP	O
facilitates	VBZ	B-VP	O
sexual	JJ	B-NP	O
behavior	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
helpful	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
male	JJ	B-NP	B
impotence	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
yohimbine	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
the	DT	B-NP	O
sexual	JJ	I-NP	B
side	NN	I-NP	I
effects	NNS	I-NP	I
of	IN	B-PP	O
clomipramine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
evaluated	VBD	B-VP	O
yohimbine	PRP	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
sexual	JJ	I-NP	B
side	NN	I-NP	I
effects	NNS	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
serotonin	NN	B-NP	O
reuptake	NN	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
either	CC	B-NP	O
obsessive	JJ	I-NP	B
compulsive	JJ	I-NP	I
disorder	NN	I-NP	I
,	,	O	O
trichotillomania	NN	B-NP	B
,	,	O	O
anxiety	NN	B-NP	B
,	,	O	O
or	CC	O	O
affective	JJ	B-NP	B
disorders	NNS	I-NP	I
who	WP	B-NP	O
suffered	VBD	B-VP	O
sexual	JJ	B-NP	B
side	NN	I-NP	I
effects	NNS	I-NP	I
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
serotonin	NN	B-NP	O
reuptake	NN	I-NP	O
blockers	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
yohimbine	NN	B-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
p.r.n.	JJ	I-NP	O
basis	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
open	JJ	I-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
.	.	O	O

Various	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
yohimbine	NN	B-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
ideal	JJ	I-NP	O
dose	NN	I-NP	O
for	IN	B-PP	O
each	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
improved	VBN	I-VP	O
sexual	JJ	B-NP	O
functioning	VBG	I-NP	O
after	IN	B-PP	O
taking	VBG	B-VP	O
yohimbine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
comply	VB	I-VP	O
with	IN	B-PP	O
yohimbine	NN	B-NP	O
treatment	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
therapeutic	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Side	NN	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
yohimbine	NN	B-NP	O
included	VBD	B-VP	O
excessive	JJ	B-NP	O
sweating	NN	I-NP	O
,	,	O	O
increased	VBN	B-NP	O
anxiety	NN	I-NP	B
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
wound	VB	I-NP	O
-	HYPH	O	O
up	RP	B-PRT	O
feeling	NN	B-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
yohimbine	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
sexual	JJ	I-NP	B
side	NN	I-NP	I
effects	NNS	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
serotonin	NN	B-NP	O
reuptake	NN	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

Future	JJ	B-NP	O
controlled	JJ	I-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
further	RB	I-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effectiveness	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
yohimbine	NN	B-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
indication	NN	I-NP	O
.	.	O	O

Hypersensitivity	NN	B-NP	B
immune	JJ	I-NP	O
reaction	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
mechanism	NN	I-NP	O
for	IN	B-PP	O
dilevalol	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
lymphocyte	NN	B-NP	O
reactivity	NN	I-NP	O
to	TO	B-PP	O
dilevalol	NN	B-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
serum	NN	B-NP	O
containing	VBG	B-VP	O
putative	JJ	B-NP	O
ex	FW	I-NP	O
vivo	FW	I-NP	O
dilevalol	NN	I-NP	O
antigens	NNS	I-NP	O
or	CC	I-NP	O
metabolites	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
dilevalol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
dilevalol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Peripheral	JJ	B-NP	O
blood	NN	I-NP	O
mononuclear	JJ	I-NP	O
cells	NNS	I-NP	O
collected	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
were	VBD	B-VP	O
cultured	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
solution	NN	I-NP	O
of	IN	B-PP	O
dilevalol	NN	B-NP	O
and	CC	O	O
also	RB	B-ADVP	O
with	IN	B-PP	O
sera	NNS	B-NP	O
collected	VBN	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
volunteer	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
dilevalol	NN	B-NP	O
intake	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
similar	JJ	I-NP	O
protocol	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
lymphocytes	NNS	B-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
healthy	JJ	I-NP	O
subject	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
lymphocyte	NN	I-NP	O
proliferation	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
either	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
healthy	JJ	I-NP	O
volunteer	NN	I-NP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
dilevalol	NN	B-NP	O
solutions	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
proliferative	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
serum	NN	B-NP	O
collected	VBN	B-VP	O
after	IN	B-PP	O
dilevalol	NN	B-NP	O
intake	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
proliferative	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
collected	VBN	B-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
intake	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
reactivity	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
when	WRB	B-ADVP	O
lymphocytes	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
healthy	JJ	I-NP	O
subject	NN	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
under	IN	B-PP	O
similar	JJ	B-NP	O
conditions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
methodology	NN	I-NP	O
used	VBN	B-VP	O
allowed	VBD	B-VP	O
the	DT	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
lymphocyte	NN	B-NP	O
sensitization	NN	I-NP	O
to	TO	B-PP	O
sera	NNS	B-NP	O
containing	VBG	B-VP	O
ex	FW	B-ADVP	O
vivo	FW	B-ADVP	O
-	HYPH	I-ADVP	O
prepared	VBN	B-NP	O
dilevalol	NN	I-NP	O
antigens	NNS	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
immunologic	JJ	I-NP	O
mechanism	NN	I-NP	O
in	IN	B-PP	O
dilevalol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Reversible	JJ	B-NP	O
myocardial	JJ	I-NP	B
hypertrophy	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
tacrolimus	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
pediatric	JJ	I-NP	O
heart	NN	I-NP	O
transplant	NN	I-NP	O
recipient	NN	I-NP	O
:	:	O	O
case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

Tacrolimus	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
immunosuppressant	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
frequently	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
organ	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
include	VBP	B-VP	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
.	.	O	O

Herein	RB	B-ADVP	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
transient	JJ	B-NP	O
myocardial	JJ	I-NP	B
hypertrophy	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
tacrolimus	NN	B-NP	O
after	IN	B-PP	O
heart	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hypertrophy	NN	I-NP	B
caused	VBD	B-VP	O
no	DT	B-NP	O
clinical	JJ	I-NP	O
symptoms	NNS	I-NP	O
but	CC	O	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
elevation	NN	B-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
brain	NN	I-NP	O
natriuretic	JJ	I-NP	O
peptide	NN	I-NP	O
concentration	NN	I-NP	O
and	CC	O	O
confirmed	VBN	B-VP	O
at	IN	B-PP	O
echocardiography	NN	B-NP	O
.	.	O	O

Initially	RB	B-ADVP	O
,	,	O	O
allograft	NN	B-NP	O
rejection	NN	I-NP	O
was	VBD	B-VP	O
feared	VBN	I-VP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
myocardial	JJ	B-NP	O
biopsy	NN	I-NP	O
samples	NNS	I-NP	O
revealed	VBD	B-VP	O
only	RB	B-NP	O
interstitial	JJ	I-NP	O
edema	NN	I-NP	B
and	CC	O	O
mild	JJ	B-NP	O
myocardial	JJ	I-NP	B
hypertrophy	NN	I-NP	I
;	:	O	O
neither	CC	O	O
cellular	JJ	B-NP	O
nor	CC	I-NP	O
humoral	JJ	I-NP	O
rejection	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
blood	NN	I-NP	O
tacrolimus	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
usual	JJ	B-ADJP	O
at	IN	B-PP	O
that	DT	B-NP	O
time	NN	I-NP	O
;	:	O	O
thus	RB	B-ADVP	O
,	,	O	O
tacrolimus	NN	B-NP	O
dosage	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
.	.	O	O

Myocardial	JJ	B-NP	B
hypertrophy	NN	I-NP	I
completely	RB	B-VP	O
resolved	VBN	I-VP	O
upon	IN	B-PP	O
reducing	VBG	B-VP	O
the	DT	B-NP	O
target	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
recur	VB	I-VP	O
,	,	O	O
as	IN	B-SBAR	O
confirmed	VBN	B-VP	O
at	IN	B-PP	O
echocardiography	NN	B-NP	O
and	CC	O	O
myocardial	JJ	B-NP	O
biopsy	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
tacrolimus	NN	B-NP	O
induces	VBZ	B-VP	O
reversible	JJ	B-NP	O
myocardial	JJ	I-NP	B
hypertrophy	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
tacrolimus	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
blood	NN	B-NP	O
concentration	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
carefully	RB	B-ADJP	O
controlled	JJ	B-NP	O
and	CC	I-NP	O
extreme	JJ	I-NP	O
attention	NN	I-NP	O
paid	VBN	B-VP	O
to	TO	B-PP	O
cardiac	JJ	B-NP	O
involvement	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
unilateral	JJ	B-NP	O
pallidotomy	NN	I-NP	O
and	CC	I-NP	O
subthalamotomy	NN	I-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
idiopathic	JJ	I-NP	B
Parkinson	NNP	I-NP	I
s	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
stereotactic	JJ	B-NP	O
unilateral	JJ	I-NP	O
pallidotomy	NN	I-NP	O
and	CC	I-NP	O
subthalamotomy	NN	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
idiopathic	JJ	I-NP	B
Parkinson	NNP	I-NP	I
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
refractory	JJ	B-ADJP	O
to	TO	B-PP	O
medical	JJ	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
similar	JJ	B-NP	O
characteristics	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
disease	NN	B-NP	O
,	,	O	O
disabling	VBG	B-VP	O
motor	NN	B-NP	O
fluctuations	NNS	I-NP	O
(	(	O	O
Hoehn	NNP	B-NP	O
_	NNP	I-NP	O
Yahr	NNP	I-NP	O
stage	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
off	JJ	B-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
phases	NNS	I-NP	O
)	)	O	O
and	CC	O	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
were	VBD	B-VP	O
selected	VBN	I-VP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
bilateral	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
their	PRP$	B-NP	O
levodopa	NN	I-NP	O
equivalent	JJ	I-NP	O
dosing	NN	I-NP	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
operated	VBN	I-VP	O
on	RP	B-PRT	O
in	IN	B-PP	O
the	DT	B-NP	O
globus	NN	I-NP	O
pallidus	NN	I-NP	O
interna	NN	I-NP	O
(	(	O	O
GPi	NN	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
subthalamic	JJ	I-NP	O
nucleus	NN	I-NP	O
(	(	O	O
STN	NN	B-NP	O
)	)	O	O
.	.	O	O

Clinical	JJ	B-NP	O
evaluation	NN	I-NP	O
included	VBD	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Unified	NNP	I-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
UPDRS	NNP	B-NP	O
)	)	O	O
,	,	O	O
Hoehn_Yahr	NN	B-NP	O
score	NN	I-NP	O
and	CC	O	O
Schwab	NNP	B-NP	O
England	NNP	I-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
living	NN	I-NP	O
(	(	O	O
ADL	NN	B-NP	O
)	)	O	O
score	NN	B-NP	O
in	IN	B-PP	O
on	IN	B-PP	O
'	SYM	B-NP	O
-	HYPH	B-PP	O
and	CC	I-PP	O
off	IN	B-PP	O
'	SYM	B-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
conditions	NNS	I-NP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
contralateral	JJ	I-NP	O
major	JJ	I-NP	O
parkinsonian	JJ	I-NP	B
motor	NN	I-NP	O
signs	NNS	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
followed	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Levodopa	NN	B-NP	O
equivalent	JJ	I-NP	O
daily	JJ	I-NP	O
intake	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
STN	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
UPDRS	NNP	B-NP	O
,	,	O	O
Hoehn	NNP	B-NP	O
_	NNP	I-NP	O
Yahr	NNP	I-NP	O
and	CC	O	O
Schwab	NNP	B-NP	O
England	NNP	I-NP	O
ADL	NNP	I-NP	O
scores	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Cognitive	JJ	B-NP	O
functions	NNS	I-NP	O
were	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Complications	NNS	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
left	JJ	I-NP	O
homonymous	JJ	I-NP	B
hemianopsia	NN	I-NP	I
after	IN	B-PP	O
pallidotomy	NN	B-NP	O
and	CC	O	O
another	DT	B-NP	O
num	CD	I-NP	O
developed	VBN	B-VP	O
left	VBD	B-VP	O
hemiballistic	JJ	B-NP	O
movements	NNS	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
subthalamotomy	NN	B-NP	O
which	WDT	B-NP	O
partly	RB	B-ADVP	O
improved	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
with	IN	B-PP	O
Valproate	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
lesions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
unilateral	JJ	I-NP	O
STN	NN	I-NP	O
and	CC	I-NP	O
GPi	NN	I-NP	O
are	VBP	B-VP	O
equally	RB	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	JJ	B-NP	O
PD	NN	I-NP	B
refractory	JJ	B-ADJP	O
to	TO	B-PP	O
medical	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Protective	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
antithrombin	NN	B-NP	O
on	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
nephrosis	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
antithrombin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
plasma	NN	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
coagulation	NN	B-NP	O
factors	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrosis	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Antithrombin	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
once	IN	B-SBAR	O
a	DT	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
antithrombin	NN	B-NP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hematological	JJ	I-NP	B
abnormalities	NNS	I-NP	I
.	.	O	O

Puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
dysfunction	NN	I-NP	I
and	CC	I-NP	O
hyperlipidemia	NN	I-NP	B
were	VBD	B-VP	O
also	RB	I-VP	O
suppressed	VBN	I-VP	O
.	.	O	O

Histopathological	JJ	B-NP	O
examination	NN	I-NP	O
revealed	VBD	B-VP	O
severe	JJ	B-NP	O
renal	JJ	I-NP	B
damage	NN	I-NP	I
such	JJ	B-PP	O
as	IN	I-PP	O
proteinaceous	JJ	B-NP	O
casts	NNS	I-NP	O
in	IN	B-PP	O
tubuli	NNS	B-NP	O
and	CC	O	O
tubular	JJ	B-NP	O
expansion	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
an	DT	B-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
damage	NN	I-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
antithrombin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
antithrombin	NN	B-NP	O
treatment	NN	I-NP	O
markedly	RB	B-ADVP	O
suppressed	VBD	B-VP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
apoptosis	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
tubular	JJ	I-NP	O
epithelial	JJ	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
cytokine	NN	I-NP	O
content	NN	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
decreased	VBN	I-VP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
thrombin	NN	B-NP	O
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
antithrombin	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
clinically	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Reverse	JJ	B-ADJP	O
or	CC	O	O
inverted	VBN	B-VP	O
left	VBD	B-VP	B
ventricular	JJ	B-NP	I
apical	JJ	I-NP	I
ballooning	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
reverse	JJ	B-NP	O
Takotsubo	NNP	I-NP	B
cardiomyopathy	NN	I-NP	I
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
young	JJ	I-NP	O
woman	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Transient	JJ	B-NP	O
left	JJ	I-NP	B
ventricular	JJ	I-NP	I
apical	JJ	I-NP	I
ballooning	NN	I-NP	I
syndrome	NN	I-NP	I
was	VBD	B-VP	O
first	RB	I-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
Japan	NNP	B-NP	O
as	IN	B-PP	O
Takotsubo	NNP	B-NP	B
cardiomyopathy	NN	I-NP	I
.	.	O	O
This	DT	B-NP	O
syndrome	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
many	JJ	B-NP	O
other	JJ	I-NP	O
countries	NNS	I-NP	O
.	.	O	O

Many	JJ	B-NP	O
variations	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
recently	RB	I-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rarest	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
reverse	JJ	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
hyperdynamic	JJ	B-NP	O
apex	NN	I-NP	O
and	CC	O	O
complete	JJ	B-NP	O
akinesia	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
base	NN	I-NP	O
(	(	O	O
as	IN	B-SBAR	O
opposed	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
classic	JJ	I-NP	O
apical	JJ	I-NP	B
ballooning	NN	I-NP	I
)	)	O	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
article	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
report	VBP	B-VP	O
an	DT	B-NP	O
interesting	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
young	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
rare	JJ	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
reverse	JJ	B-NP	O
apical	JJ	I-NP	B
ballooning	NN	I-NP	I
syndrome	NN	I-NP	I
occurring	VBG	B-VP	O
after	IN	B-PP	O
amphetamine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
is	VBZ	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
review	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Attenuated	VBN	B-NP	O
disruption	NN	I-NP	O
of	IN	B-PP	O
prepulse	NN	B-NP	O
inhibition	NN	I-NP	O
by	IN	B-PP	O
dopaminergic	JJ	B-NP	O
stimulation	NN	I-NP	O
after	IN	B-PP	O
maternal	JJ	B-NP	O
deprivation	NN	I-NP	O
and	CC	O	O
adolescent	JJ	B-NP	O
corticosterone	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
may	MD	B-VP	O
include	VB	I-VP	O
an	DT	B-NP	O
early	JJ	I-NP	O
neurodevelopmental	JJ	I-NP	O
stress	NN	I-NP	O
component	NN	I-NP	O
which	WDT	B-NP	O
increases	VBZ	B-VP	O
vulnerability	NN	B-NP	O
to	TO	B-PP	O
later	JJ	B-NP	O
stressful	JJ	I-NP	O
life	NN	I-NP	O
events	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
overt	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
early	JJ	I-NP	O
stress	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
maternal	JJ	B-NP	O
deprivation	NN	I-NP	O
,	,	O	O
combined	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
later	JJ	I-NP	O
stress	NN	I-NP	O
,	,	O	O
simulated	VBN	B-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
periadolescent	JJ	I-NP	O
corticosterone	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
behaviour	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Acute	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
apomorphine	NN	B-NP	O
caused	VBD	B-VP	O
disruption	NN	B-NP	O
of	IN	B-PP	O
prepulse	NN	B-NP	O
inhibition	NN	I-NP	O
(	(	O	O
PPI	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
controls	NNS	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
either	CC	O	O
maternal	JJ	B-NP	O
deprivation	NN	I-NP	O
or	CC	O	O
corticosterone	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
surprisingly	RB	B-ADJP	O
absent	JJ	I-ADJP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
early	JJ	I-NP	O
and	CC	I-NP	O
late	JJ	I-NP	O
stress	NN	I-NP	O
.	.	O	O

Amphetamine	NN	B-NP	O
treatment	NN	I-NP	O
significantly	RB	B-ADVP	O
disrupted	VBD	B-VP	O
PPI	NN	B-NP	O
in	IN	B-PP	O
both	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
deprived	VBN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
absent	JJ	B-ADJP	O
in	IN	B-PP	O
both	CC	B-NP	O
maternally	RB	I-NP	O
deprived	VBN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
serotonin	NN	I-NP	O
-	HYPH	I-NP	O
1A	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OH	NN	I-NP	O
-	HYPH	I-NP	O
DPAT	NN	I-NP	O
,	,	O	O
induced	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
disruption	NN	I-NP	O
of	IN	B-PP	O
PPI	NN	B-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	B
hyperactivity	NN	I-NP	I
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
an	DT	B-NP	O
inhibitory	JJ	I-NP	O
interaction	NN	I-NP	O
of	IN	B-PP	O
early	JJ	B-NP	O
stress	NN	I-NP	O
,	,	O	O
caused	VBN	B-VP	O
by	IN	B-PP	O
maternal	JJ	B-NP	O
deprivation	NN	I-NP	O
,	,	O	O
combined	VBN	B-VP	O
with	IN	B-PP	O
adolescent	JJ	B-NP	O
stress	NN	I-NP	O
,	,	O	O
simulated	VBN	B-VP	O
by	IN	B-PP	O
corticosterone	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
dopaminergic	JJ	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
PPI	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
altered	VBN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
and	CC	I-NP	O
amphetamine	NN	I-NP	O
could	MD	B-VP	O
indicate	VB	I-VP	O
differential	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
dopamine	NN	B-NP	O
receptor	NN	I-NP	O
signalling	NN	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
functional	JJ	B-NP	O
desensitisation	NN	I-NP	O
,	,	O	O
or	CC	O	O
altered	VBN	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
sensory	JJ	B-NP	O
gating	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
nucleus	NN	I-NP	O
accumbens	VBZ	B-VP	O
by	IN	B-PP	O
limbic	JJ	B-NP	O
structures	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
.	.	O	O

Peripheral	JJ	B-NP	O
iron	NN	I-NP	O
dextran	NN	I-NP	O
induced	VBD	B-VP	O
degeneration	NN	B-NP	B
of	IN	B-PP	I
dopaminergic	JJ	B-NP	I
neurons	NNS	I-NP	I
in	IN	B-PP	O
rat	NN	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
.	.	O	O

Iron	NN	B-NP	O
accumulation	NN	I-NP	O
is	VBZ	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
demonstrate	VB	I-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
peripheral	JJ	B-NP	O
iron	NN	I-NP	O
overload	NN	I-NP	O
and	CC	O	O
dopaminergic	JJ	B-NP	O
neuron	NN	I-NP	O
loss	NN	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
(	(	O	O
SN	NN	B-NP	O
)	)	O	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
used	VBD	B-VP	O
fast	JJ	B-NP	O
cyclic	JJ	I-NP	O
voltammetry	NN	I-NP	O
,	,	O	O
tyrosine	NN	B-NP	O
hydroxylase	NN	I-NP	O
(	(	O	O
TH	NN	B-NP	O
)	)	O	O
immunohistochemistry	NN	B-NP	O
,	,	O	O
Perls	NNP	B-NP	O
s	VBZ	B-VP	O
iron	NN	B-NP	O
staining	NN	I-NP	O
,	,	O	O
and	CC	O	O
high	JJ	B-NP	O
performance	NN	I-NP	O
liquid	NN	I-NP	O
chromatography	NN	I-NP	O
-	HYPH	B-NP	O
electrochemical	JJ	I-NP	O
detection	NN	I-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
degeneration	NN	I-NP	B
of	IN	B-PP	I
dopaminergic	JJ	B-NP	I
neurons	NNS	I-NP	I
and	CC	O	O
increased	VBN	B-NP	O
iron	NN	I-NP	O
content	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SN	NN	I-NP	O
of	IN	B-PP	O
iron	NN	B-NP	O
dextran	NN	I-NP	O
overloaded	VBD	B-VP	O
animals	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
peripheral	JJ	B-NP	O
iron	NN	I-NP	O
dextran	NN	I-NP	O
overload	NN	I-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
iron	NN	I-NP	O
staining	VBG	B-VP	O
positive	JJ	B-NP	O
cells	NNS	I-NP	O
and	CC	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
TH	NN	B-NP	O
-	HYPH	B-NP	O
immunoreactive	JJ	I-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SN	NN	I-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
,	,	O	O
dopamine	NN	B-NP	O
release	NN	I-NP	O
and	CC	I-NP	O
content	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
contents	NNS	I-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
caudate	JJ	B-NP	O
putamen	NNS	I-NP	O
.	.	O	O

Even	RB	B-NP	O
more	RBR	I-NP	O
dramatic	JJ	I-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
overload	JJ	I-NP	O
group	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
peripheral	JJ	B-NP	O
iron	NN	I-NP	O
dextran	NN	I-NP	O
can	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
iron	NN	I-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SN	NN	I-NP	O
,	,	O	O
where	WRB	B-ADVP	O
excessive	JJ	B-NP	O
iron	NN	I-NP	O
causes	VBZ	B-VP	O
the	DT	B-NP	O
degeneration	NN	I-NP	B
of	IN	B-PP	I
dopaminergic	JJ	B-NP	I
neurons	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
chronic	JJ	I-NP	O
iron	NN	I-NP	O
overload	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
more	RBR	B-ADJP	O
destructive	JJ	I-ADJP	O
to	TO	B-PP	O
dopaminergic	JJ	B-NP	O
neurons	NNS	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
iron	NN	I-NP	O
overload	NN	I-NP	O
.	.	O	O

Warfarin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
leukocytoclastic	JJ	I-NP	B
vasculitis	NN	I-NP	I
.	.	O	O

Skin	NN	B-NP	O
reactions	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
coumarin	NN	I-NP	O
-	HYPH	B-NP	O
derived	VBN	I-NP	O
anticoagulants	NNS	I-NP	O
are	VBP	B-VP	O
an	DT	B-NP	O
uncommon	JJ	I-NP	O
occurrence	NN	I-NP	O
.	.	O	O

Leukocytoclastic	JJ	B-NP	B
vasculitis	NN	I-NP	I
(	(	O	O
LV	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
primarily	RB	B-ADVP	O
a	DT	B-NP	O
cutaneous	JJ	I-NP	B
small	JJ	I-NP	I
vessel	NN	I-NP	I
vasculitis	NN	I-NP	I
,	,	O	O
though	IN	B-SBAR	O
systemic	JJ	B-NP	O
involvement	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
encountered	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
late	JJ	B-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
LV	NN	I-NP	B
probably	RB	B-ADVP	O
due	IN	B-PP	O
to	TO	B-PP	O
warfarin	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
skin	NN	B-NP	B
eruptions	NNS	I-NP	I
that	WDT	B-NP	O
developed	VBD	B-VP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
warfarin	NN	B-NP	O
for	IN	B-PP	O
several	JJ	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
skin	NN	B-NP	B
lesion	NN	I-NP	I
biopsies	NNS	I-NP	O
were	VBD	B-VP	O
available	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
confirming	VBG	B-VP	O
LV	NN	B-NP	B
Cutaneous	JJ	I-NP	I
lesions	NNS	I-NP	I
resolved	VBN	B-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
after	IN	B-SBAR	O
warfarin	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
rechallenge	VBP	B-VP	O
with	IN	B-PP	O
warfarin	NN	B-NP	O
led	VBD	B-VP	O
to	TO	I-VP	O
recurrence	VB	I-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
lesions	NNS	I-NP	O
.	.	O	O

LV	NN	B-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
late	JJ	I-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
adverse	JJ	I-NP	O
reaction	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
warfarin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
aspartate	NN	I-NP	O
receptors	NNS	I-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
degeneration	NN	B-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	O
motor	NN	I-NP	O
neurons	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
neuraxial	JJ	B-NP	O
morphine	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
noninjurious	JJ	I-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	B
cord	NN	I-NP	I
ischemia	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
degeneration	NN	I-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	O
motor	NN	I-NP	O
neurons	NNS	I-NP	O
and	CC	O	O
activation	NN	B-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
d	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
receptors	NNS	B-NP	O
after	IN	B-PP	O
neuraxial	JJ	B-NP	O
morphine	NN	I-NP	O
following	VBG	B-PP	O
a	DT	B-NP	O
noninjurious	JJ	I-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
aortic	JJ	B-NP	B
occlusion	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Spinal	JJ	B-NP	B
cord	NN	I-NP	I
ischemia	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
aortic	JJ	B-NP	B
occlusion	NN	I-NP	I
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
balloon	NN	I-NP	O
catheter	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
microdialysis	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
muL	NN	I-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
mug	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
intrathecally	RB	B-ADVP	O
(	(	O	O
IT	RB	B-ADVP	O
)	)	O	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
reflow	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mug	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
muL	NN	I-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
IT	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
sham	NN	B-NP	O
operation	NN	I-NP	O
.	.	O	O

Microdialysis	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
preischemia	NN	B-NP	O
,	,	O	O
before	IN	B-PP	O
IT	NN	B-NP	O
injection	NN	I-NP	O
,	,	O	O
and	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
h	NN	I-NP	O
of	IN	B-PP	O
reperfusion	NN	B-NP	O
(	(	O	O
after	IN	B-PP	O
IT	NN	B-NP	O
injection	NN	I-NP	O
)	)	O	O
.	.	O	O

Second	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
IT	NN	B-NP	O
MK	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
histopathologic	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
after	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
spastic	JJ	I-NP	B
paraparesis	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
IT	PRP	B-NP	O
morphine	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
cerebrospinal	JJ	I-NP	O
fluid	NN	I-NP	O
(	(	O	O
CSF	NN	B-NP	O
)	)	O	O
glutamate	NN	B-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
group	NN	B-NP	O
M	NN	I-NP	O
relative	JJ	B-ADJP	O
to	TO	B-PP	O
both	CC	O	O
baseline	NN	B-NP	O
and	CC	I-NP	O
group	NN	I-NP	O
C	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
increase	NN	I-NP	O
persisted	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
hrs	NNS	I-NP	O
.	.	O	O

IT	NN	B-NP	O
MK	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
dark	NN	B-NP	O
-	HYPH	O	O
stained	VBN	B-VP	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
motoneurons	NNS	B-NP	O
after	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
spastic	JJ	I-NP	B
paraparesis	NN	I-NP	I
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
saline	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
IT	NN	B-NP	O
morphine	NN	I-NP	O
induces	VBZ	B-VP	O
spastic	JJ	B-NP	B
paraparesis	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
concomitant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
CSF	NN	B-NP	O
glutamate	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
NMDA	NN	B-NP	O
receptor	NN	I-NP	O
activation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
opioids	NNS	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
neurotoxic	JJ	B-ADJP	B
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	B
cord	NN	I-NP	I
ischemia	NN	I-NP	I
via	IN	B-PP	O
NMDA	NN	B-NP	O
receptor	NN	I-NP	O
activation	NN	I-NP	O
.	.	O	O

Reduced	VBN	B-NP	O
sodium	NN	I-NP	O
channel	NN	I-NP	O
density	NN	I-NP	O
,	,	O	O
altered	VBD	B-VP	O
voltage	NN	B-NP	O
dependence	NN	I-NP	O
of	IN	B-PP	O
inactivation	NN	B-NP	O
,	,	O	O
and	CC	O	O
increased	VBD	B-VP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
lacking	VBG	B-VP	O
sodium	NN	B-NP	O
channel	NN	I-NP	O
beta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
subunits	NNS	I-NP	O
.	.	O	O

Sodium	NN	B-NP	O
channel	NN	I-NP	O
beta	SYM	O	O
-	HYPH	O	O
subunits	NNS	B-NP	O
modulate	VBP	B-VP	O
channel	NN	B-NP	O
gating	NN	I-NP	O
,	,	O	O
assembly	NN	B-NP	O
,	,	O	O
and	CC	O	O
cell	NN	B-NP	O
surface	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
heterologous	JJ	B-NP	O
cell	NN	I-NP	O
systems	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
generated	VBD	B-VP	O
beta2	NN	B-NP	O
mice	NNS	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
beta2	NN	B-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
channel	NN	I-NP	O
density	NN	I-NP	O
,	,	O	O
localization	NN	B-NP	O
,	,	O	O
and	CC	O	O
function	NN	B-NP	O
in	IN	B-PP	O
neurons	NNS	B-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

Measurements	NNS	B-NP	O
of	IN	B-PP	O
[	(	O	O
H	NN	B-NP	O
]	)	O	O
saxitoxin	NN	B-NP	O
(	(	O	O
STX	NN	B-NP	O
)	)	O	O
binding	NN	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
membrane	NN	I-NP	O
sodium	NN	I-NP	O
channels	NNS	I-NP	O
in	IN	B-PP	O
beta2	NN	B-NP	O
neurons	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
beta2	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
negative	JJ	B-NP	O
shifts	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
voltage	NN	I-NP	O
dependence	NN	I-NP	O
of	IN	B-PP	O
inactivation	NN	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
significant	JJ	B-NP	O
decreases	NNS	I-NP	O
in	IN	B-PP	O
sodium	NN	B-NP	O
current	NN	I-NP	O
density	NN	I-NP	O
in	IN	B-PP	O
acutely	RB	B-NP	O
dissociated	VBN	I-NP	O
hippocampal	JJ	I-NP	O
neurons	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
integral	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
compound	NN	I-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
in	IN	B-PP	O
optic	JJ	B-NP	O
nerve	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
action	NN	B-NP	O
potential	NN	I-NP	O
generation	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
functional	JJ	B-NP	O
plasma	NN	I-NP	O
membrane	NN	I-NP	O
sodium	NN	I-NP	O
channels	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
conduction	NN	I-NP	O
velocity	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
number	NN	I-NP	O
and	CC	I-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
axons	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
optic	JJ	I-NP	O
nerve	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
specific	JJ	I-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
(	(	O	O
v	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
channels	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
nodes	NNS	I-NP	O
of	IN	B-PP	O
Ranvier	NN	B-NP	O
were	VBD	B-VP	O
unchanged.	JJ	B-NP	O
beta2	NN	I-NP	O
mice	NNS	I-NP	O
displayed	VBD	B-VP	O
increased	VBN	B-NP	O
susceptibility	NN	I-NP	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
as	IN	B-SBAR	O
indicated	VBN	B-VP	O
by	IN	B-PP	O
reduced	VBN	B-NP	O
latency	NN	I-NP	O
and	CC	I-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
,	,	O	O
but	CC	O	O
seemed	VBD	B-VP	O
normal	JJ	B-ADJP	O
in	IN	B-PP	O
other	JJ	B-NP	O
neurological	JJ	I-NP	O
tests	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
observations	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
beta2	NN	B-NP	O
-	HYPH	B-NP	O
subunits	NNS	I-NP	O
play	VBP	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
channel	NN	I-NP	O
density	NN	I-NP	O
and	CC	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
neurons	NNS	B-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
and	CC	O	O
are	VBP	B-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
normal	JJ	B-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
generation	NN	I-NP	O
and	CC	O	O
control	NN	B-NP	O
of	IN	B-PP	O
excitability	NN	B-NP	O
.	.	O	O

Screening	NN	B-NP	O
for	IN	B-PP	O
stimulant	JJ	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
seizure	NN	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
positive	JJ	B-NP	O
plasma	NN	I-NP	O
drug	NN	I-NP	O
screening	NN	I-NP	O
for	IN	B-PP	O
cocaine	NN	B-NP	O
or	CC	I-NP	O
amphetamine	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
seizure	NN	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
evaluated	VBD	B-VP	O
consecutive	JJ	B-NP	O
eligible	JJ	I-NP	O
seizure	NN	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
plasma	NN	I-NP	O
sample	NN	I-NP	O
collected	VBN	B-VP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
clinical	JJ	I-NP	O
evaluation	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
amphetamine	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
cocaine	NN	I-NP	O
metabolite	NN	I-NP	O
benzoylecgonine	NN	I-NP	O
using	VBG	B-VP	O
enzyme	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
immunoassay	NN	I-NP	O
methodology	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
samples	NNS	I-NP	O
with	IN	B-PP	O
benzoylecgonine	NN	B-NP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mL	NN	I-NP	O
or	CC	O	O
an	DT	B-NP	O
amphetamine	NN	I-NP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mL	NN	I-NP	O
were	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
positive	JJ	B-ADJP	O
.	.	O	O

Patient	NN	B-NP	O
demographics	NNS	I-NP	O
,	,	O	O
history	NN	B-NP	O
of	IN	B-PP	O
underlying	VBG	B-VP	O
drug	NN	B-NP	O
or	CC	I-NP	O
alcohol	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
seizure	NN	I-NP	B
disorder	NN	I-NP	O
,	,	O	O
estimated	VBN	B-VP	O
time	NN	B-NP	O
from	IN	B-PP	O
seizure	NN	B-NP	B
to	TO	B-PP	O
sample	NN	B-NP	O
collection	NN	I-NP	O
,	,	O	O
history	NN	B-NP	O
or	CC	I-NP	O
suspicion	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	B
or	CC	I-NP	I
amphetamine	NN	I-NP	I
abuse	NN	I-NP	I
,	,	O	O
results	NNS	B-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
urine	NN	I-NP	O
testing	NN	I-NP	O
for	IN	B-PP	O
drugs	NNS	B-NP	O
of	IN	B-PP	O
abuse	NN	B-NP	O
,	,	O	O
and	CC	O	O
assay	NN	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
without	IN	B-PP	O
patient	NN	B-NP	O
identifiers	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
plasma	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
by	IN	B-PP	O
immunoassay	NN	B-NP	O
testing	NN	I-NP	O
for	IN	B-PP	O
benzoylecgonine	NN	B-NP	O
and	CC	O	O
no	DT	B-NP	O
samples	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
for	IN	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

Positive	JJ	B-NP	O
test	NN	I-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
in	IN	B-PP	O
patient	NN	B-NP	O
visits	NNS	I-NP	O
where	WRB	B-ADVP	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
history	NN	I-NP	O
or	CC	I-NP	O
suspicion	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	B
or	CC	I-NP	I
amphetamine	NN	I-NP	I
abuse	NN	I-NP	I
.	.	O	O

During	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
routine	JJ	B-NP	O
plasma	NN	I-NP	O
screening	NN	I-NP	O
for	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
amphetamines	NNS	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
seizure	NN	I-NP	B
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
low	JJ	I-NP	O
yield	NN	I-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
,	,	O	O
routine	JJ	B-NP	O
plasma	NN	I-NP	O
screening	NN	I-NP	O
would	MD	B-VP	O
yield	VB	I-VP	O
few	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
stimulant	JJ	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
neither	CC	O	O
a	DT	B-NP	O
history	NN	I-NP	O
nor	CC	I-NP	O
suspicion	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	B
abuse	NN	I-NP	I
in	IN	B-PP	O
this	DT	B-NP	O
population	NN	I-NP	O
.	.	O	O

Evidence	NN	B-NP	O
of	IN	B-PP	O
functional	JJ	B-NP	O
somatotopy	NN	I-NP	O
in	IN	B-PP	O
GPi	NNP	B-NP	O
from	IN	B-PP	O
results	NNS	B-NP	O
of	IN	B-PP	O
pallidotomy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
functional	JJ	I-NP	O
anatomy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
globus	NN	I-NP	O
pallidus	NN	I-NP	O
internus	NN	I-NP	O
(	(	O	O
GPi	NN	B-NP	O
)	)	O	O
by	IN	B-PP	O
studying	VBG	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
unilateral	JJ	B-NP	O
pallidotomy	NN	I-NP	O
on	IN	B-PP	O
parkinsonian	JJ	B-ADJP	B
off	IN	B-PP	O
signs	NNS	B-NP	O
and	CC	I-NP	O
levodopa	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
(	(	O	O
LID	NN	B-NP	B
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
significant	JJ	B-NP	O
positive	JJ	I-NP	O
correlations	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
preoperative	JJ	I-NP	O
levodopa	NN	I-NP	O
responsiveness	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
signs	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
levodopa	NN	I-NP	O
responsiveness	NN	I-NP	O
of	IN	B-PP	O
scores	NNS	B-NP	O
in	IN	B-PP	O
timed	VBN	B-NP	O
tests	NNS	I-NP	O
(	(	O	O
Core	NNP	B-NP	O
Assessment	NNP	I-NP	O
Program	NNP	I-NP	O
for	IN	B-PP	O
Intracerebral	NNP	B-NP	O
Transplantations	NNP	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
contralateral	JJ	I-NP	O
limbs	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
scores	NNS	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
correlation	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
LID	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
found	VBD	B-VP	O
a	DT	B-NP	O
highly	RB	I-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
lesion	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
GPi	NNP	I-NP	O
and	CC	O	O
the	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
LID	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
contralateral	JJ	I-NP	O
limbs	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
volume	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
parkinsonian	JJ	B-NP	B
off	IN	B-PP	O
signs	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
volumes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
lesion	NN	I-NP	O
cylinder	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
dorsal	JJ	I-NP	O
lesion	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
outcome	NN	I-NP	O
of	IN	B-PP	O
either	CC	O	O
dyskinesias	NNS	B-NP	B
or	CC	O	O
parkinsonian	JJ	B-ADJP	B
off	IN	B-PP	O
signs	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
differential	JJ	I-NP	O
predictive	JJ	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
responsiveness	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
outcome	NN	I-NP	O
of	IN	B-PP	O
parkinsonian	JJ	B-NP	B
off	IN	B-PP	O
signs	NNS	B-NP	O
and	CC	O	O
LID	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
different	JJ	I-NP	O
correlations	NNS	I-NP	O
of	IN	B-PP	O
ventral	JJ	B-NP	O
lesion	NN	I-NP	O
volume	NN	I-NP	O
with	IN	B-PP	O
dyskinesias	NNS	B-NP	B
and	CC	O	O
parkinsonian	JJ	B-ADJP	B
off	RP	B-PRT	O
signs	NNS	B-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
different	JJ	B-NP	O
anatomical	JJ	I-NP	O
or	CC	I-NP	O
pathophysiological	JJ	I-NP	O
substrates	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
generation	NN	I-NP	O
of	IN	B-PP	O
parkinsonian	JJ	B-NP	B
off	IN	B-PP	O
signs	NNS	B-NP	O
and	CC	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

Whereas	IN	B-PP	O
cells	NNS	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
wider	JJR	I-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
GPi	NNP	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
parkinsonism	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
GPi	NNP	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
crucial	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
LID	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
our	PRP$	B-NP	O
observations	NNS	I-NP	O
are	VBP	B-VP	O
additional	JJ	B-NP	O
proof	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
functional	JJ	I-NP	O
somatotopy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
systems	NNS	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
GPi	NNP	I-NP	O
that	WDT	B-NP	O
mediate	VBP	B-VP	O
parkinsonism	NN	B-NP	B
and	CC	I-NP	O
dyskinesias	NNS	I-NP	B
,	,	O	O
especially	RB	B-ADVP	O
along	IN	B-PP	O
the	DT	B-NP	O
dorsoventral	JJ	I-NP	O
trajectory	NN	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
pallidotomy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
outcome	NN	I-NP	O
of	IN	B-PP	O
pallidotomy	NN	B-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
lesion	NN	I-NP	O
involves	VBZ	B-VP	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
and	CC	I-NP	O
dorsal	JJ	I-NP	O
GPi	NNP	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
net	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
alteration	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
pathways	NNS	B-NP	O
which	WDT	B-NP	O
mediate	VBP	B-VP	O
different	JJ	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
and	CC	O	O
hence	RB	B-VP	O
could	MD	I-VP	O
be	VB	I-VP	O
variable	JJ	B-ADJP	O
.	.	O	O

Pain	NN	B-NP	B
responses	NNS	I-NP	O
in	IN	B-PP	O
methadone	NN	B-NP	O
-	HYPH	O	O
maintained	VBN	B-NP	O
opioid	JJ	I-NP	O
abusers	NNS	I-NP	O
.	.	O	O

Providing	VBG	B-VP	O
pain	NN	B-NP	B
management	NN	I-NP	O
for	IN	B-PP	O
known	JJ	B-NP	O
opioid	JJ	I-NP	O
abusers	NNS	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
challenging	JJ	I-NP	O
clinical	JJ	I-NP	O
task	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
part	NN	B-NP	O
because	IN	B-SBAR	O
little	JJ	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
about	IN	B-PP	O
their	PRP$	B-NP	O
pain	NN	I-NP	B
experience	NN	I-NP	O
and	CC	O	O
analgesic	JJ	B-NP	O
requirements	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
describe	VB	I-VP	O
pain	NN	B-NP	B
tolerance	NN	I-NP	O
and	CC	O	O
analgesic	JJ	B-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
sample	NN	I-NP	O
of	IN	B-PP	O
opioid	JJ	B-NP	B
addicts	NNS	I-NP	I
stabilized	VBN	B-VP	O
in	IN	B-PP	O
methadone	NN	B-NP	O
-	HYPH	B-NP	O
maintenance	NN	I-NP	O
(	(	O	O
MM	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
matched	VBN	B-NP	O
nondependent	JJ	I-NP	O
control	NN	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

By	IN	B-PP	O
using	VBG	B-VP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-VP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
way	NN	I-NP	O
factorial	JJ	I-NP	O
design	NN	I-NP	O
,	,	O	O
tolerance	NN	B-NP	O
to	TO	B-PP	O
cold	JJ	B-NP	O
-	HYPH	I-NP	O
pressor	NN	I-NP	O
(	(	O	O
CP	NN	B-NP	O
)	)	O	O
pain	NN	B-NP	B
was	VBD	B-VP	O
examined	VBN	I-VP	O
,	,	O	O
both	CC	O	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
therapeutic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
common	JJ	B-NP	O
opioid	JJ	I-NP	O
and	CC	I-NP	O
nonsteroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
analgesic	JJ	I-NP	O
agents	NNS	I-NP	O
.	.	O	O

Results	NNS	B-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
MM	NN	B-NP	O
individuals	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	RBR	I-ADJP	O
tolerant	JJ	I-ADJP	O
of	IN	B-PP	O
CP	NN	B-NP	O
pain	NN	I-NP	B
than	IN	B-PP	O
control	JJ	B-NP	O
subjects	NNS	I-NP	O
,	,	O	O
replicating	VBG	B-VP	O
previous	JJ	B-NP	O
work	NN	I-NP	O
.	.	O	O

Analgesic	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
significant	JJ	B-ADJP	O
neither	CC	B-PP	O
for	IN	B-PP	O
medication	NN	B-NP	O
nor	CC	I-NP	O
group	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
MM	NN	B-NP	O
opioid	JJ	I-NP	O
abusers	NNS	I-NP	O
represent	VBP	B-VP	O
a	DT	B-NP	O
pain	NN	I-NP	B
-	HYPH	B-NP	I
intolerant	JJ	I-NP	I
subset	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Their	PRP$	B-NP	O
complaints	NNS	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
evaluated	VBN	I-VP	O
seriously	RB	B-ADVP	O
and	CC	O	O
managed	VBD	B-VP	O
aggressively	RB	B-ADVP	O
.	.	O	O

Urine	NN	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
glucosaminidase	NN	I-NP	O
-	HYPH	B-NP	O
-	:	O	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
damage	NN	I-NP	O
?	.	O	O
BACKGROUND	NN	B-NP	O
:	:	O	O
Although	IN	B-SBAR	O
an	DT	B-NP	O
indicator	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
tubular	JJ	I-NP	I
dysfunction	NN	I-NP	I
,	,	O	O
an	DT	B-NP	O
increased	VBN	I-NP	O
urinary	JJ	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
glucosaminidase	NN	B-NP	O
(	(	O	O
NAG	NN	B-NP	O
)	)	O	O
activity	NN	B-NP	O
might	MD	B-VP	O
reflect	VB	I-VP	O
increased	VBN	B-NP	O
lysosomal	JJ	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
tubular	JJ	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

Puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
Sprague	NNP	B-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
proteinuria	NN	B-NP	B
.	.	O	O

Total	JJ	B-NP	O
protein	NN	I-NP	O
,	,	O	O
albumin	NN	B-NP	O
,	,	O	O
NAG	NN	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
protein	NN	B-NP	O
electrophoretic	JJ	I-NP	O
pattern	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
daily	JJ	B-NP	O
urine	NN	I-NP	O
samples	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
morphological	JJ	I-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
and	CC	O	O
the	DT	B-NP	O
NAG	NN	I-NP	O
isoenzyme	NN	I-NP	O
patterns	NNS	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
intravenous	JJ	B-NP	O
PAN	NN	I-NP	O
urine	NN	I-NP	O
volume	NN	I-NP	O
and	CC	O	O
urine	NN	B-NP	O
NAG	NN	I-NP	O
activity	NN	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
but	CC	O	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

After	IN	B-SBAR	O
day	NN	B-NP	O
num	CD	I-NP	O
all	DT	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
urine	NN	B-NP	O
albumin	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
protein	NN	I-NP	O
excretion	NN	I-NP	O
and	CC	O	O
NAG	NN	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Electrophoresis	NN	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
generalised	VBN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
middle	JJ	B-NP	O
and	CC	I-NP	O
high	JJ	I-NP	O
molecular	JJ	I-NP	O
weight	NN	I-NP	O
urine	NN	I-NP	O
proteins	NNS	I-NP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	B-NP	O
onwards	NNS	I-NP	O
.	.	O	O

Protein	NN	B-NP	O
droplets	NNS	I-NP	O
first	RB	B-ADVP	O
appeared	VBD	B-VP	O
prominent	JJ	B-ADJP	O
in	IN	B-PP	O
tubular	JJ	B-NP	O
cells	NNS	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Peak	JJ	B-NP	O
urine	NN	I-NP	O
NAG	NN	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
NAG	NN	B-NP	O
isoenzyme	NN	I-NP	O
pattern	NN	I-NP	O
coincided	VBD	B-VP	O
with	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
peak	JJ	I-NP	O
proteinuria	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
intracellular	JJ	B-NP	O
protein	NN	I-NP	O
and	CC	I-NP	O
NAG	NN	I-NP	O
droplets	NNS	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	B-NP	O
onwards	NNS	I-NP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
lysosomal	JJ	B-NP	O
turnover	NN	I-NP	O
and	CC	O	O
hence	RB	B-ADVP	O
urine	NN	B-NP	O
NAG	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
occurs	VBZ	B-VP	O
when	WRB	B-ADVP	O
increased	VBN	B-NP	O
protein	NN	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
tubular	JJ	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

Urine	NN	B-NP	O
NAG	NN	I-NP	O
activity	NN	I-NP	O
is	VBZ	B-VP	O
thus	RB	B-ADVP	O
a	DT	B-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
altered	VBN	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
tubules	NNS	I-NP	O
and	CC	O	O
not	RB	O	O
simply	RB	B-ADVP	O
an	DT	B-NP	O
indicator	NN	I-NP	O
of	IN	B-PP	O
damage	NN	B-NP	O
.	.	O	O

Over	IN	B-PP	O
expression	NN	B-NP	O
of	IN	B-PP	O
vascular	JJ	B-NP	O
endothelial	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
receptor	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rat	NN	I-NP	O
pituitary	JJ	I-NP	B
tumors	NNS	I-NP	I
may	MD	B-VP	O
mediate	VB	I-VP	O
estrogen	NN	B-NP	O
-	HYPH	O	O
initiated	VBN	B-NP	O
tumor	NN	I-NP	B
angiogenesis	NN	I-NP	O
.	.	O	O

Estrogens	NNS	B-NP	O
,	,	O	O
which	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
several	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
and	CC	I-NP	O
animal	JJ	I-NP	O
cancers	NNS	I-NP	B
,	,	O	O
can	MD	B-VP	O
induce	VB	I-VP	O
tumor	NN	B-NP	B
angiogenesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pituitary	NN	I-NP	O
of	IN	B-PP	O
Fischer	NNP	B-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanistic	JJ	I-NP	O
details	NNS	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
angiogenesis	NN	I-NP	O
induction	NN	I-NP	O
,	,	O	O
during	IN	B-PP	O
estrogen	NN	B-NP	O
carcinogenesis	NN	I-NP	B
,	,	O	O
are	VBP	B-VP	O
still	RB	B-ADVP	O
unknown	JJ	B-ADJP	O
.	.	O	O

To	TO	B-VP	O
elucidate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
angiogenesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pituitary	NN	I-NP	O
of	IN	B-PP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessels	NNS	I-NP	O
was	VBD	B-VP	O
analysed	VBN	I-VP	O
using	VBG	B-VP	O
factor	NN	B-NP	O
num	CD	I-NP	O
related	JJ	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
FVIIIRAg	NN	B-NP	O
)	)	O	O
immunohistochemistry	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
vascular	JJ	B-NP	O
endothelial	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
/	SYM	B-NP	O
vascular	JJ	I-NP	O
permeability	NN	I-NP	O
factor	NN	I-NP	O
(	(	O	O
VEGF	NN	B-NP	O
/	SYM	B-NP	O
VPF	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
by	IN	B-PP	O
Western	JJ	B-NP	O
blot	NN	I-NP	O
and	CC	O	O
immunohistochemical	JJ	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
VEGF	NN	B-NP	O
receptor	NN	I-NP	O
(	(	O	O
VEGFR	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
Flk	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
KDR	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
also	RB	I-VP	O
examined	VBN	I-VP	O
by	IN	B-PP	O
immunohistochemistry	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
17beta	NN	B-NP	O
-	HYPH	O	O
estradiol	NN	B-NP	O
(	(	O	O
E2	NN	B-NP	O
)	)	O	O
induces	VBZ	B-VP	O
neovascularization	NN	B-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
growth	NN	I-NP	O
and	CC	I-NP	O
enlargement	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessels	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
exposure	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
high	JJ	I-NP	O
tumor	NN	I-NP	B
angiogenic	JJ	I-NP	O
potential	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
elevated	VBN	I-NP	O
VEGF	NN	I-NP	O
/	SYM	I-NP	O
VPF	NN	I-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
E2	NN	I-NP	O
exposed	VBN	B-VP	O
pituitary	NN	B-NP	O
of	IN	B-PP	O
ovariectomized	VBN	O	O
(	(	O	O
OVEX	NN	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
.	.	O	O

VEGF	NN	B-NP	O
/	SYM	I-NP	O
VPF	NN	I-NP	O
and	CC	I-NP	O
FVIIIRAg	NN	I-NP	O
immunohistochemistry	NN	I-NP	O
and	CC	O	O
endothelial	JJ	B-NP	O
specific	JJ	I-NP	O
lectin	NN	I-NP	O
(	(	O	O
UEA1	NN	B-NP	O
)	)	O	O
binding	NN	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
VEGF	NN	B-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
initially	RB	B-ADVP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
blood	NN	I-NP	O
vessels	NNS	I-NP	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
E2	NN	B-NP	O
exposure	NN	I-NP	O
,	,	O	O
VEGF	NN	B-NP	O
/	SYM	B-VP	O
VPF	NN	B-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
endothelial	JJ	I-NP	O
cell	NN	I-NP	O
population	NN	I-NP	O
,	,	O	O
sharply	RB	B-VP	O
declined	VBD	I-VP	O
and	CC	I-VP	O
was	VBD	I-VP	O
restricted	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
vessels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
endothelial	JJ	I-NP	O
-	HYPH	I-NP	O
derived	VBN	I-NP	O
VEGF	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
clear	JJ	B-ADJP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
immunohistochemical	JJ	B-NP	O
studies	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
VEGFR	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
flk	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
KDR	NN	I-NP	O
)	)	O	O
,	,	O	O
expression	NN	B-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
microblood	NN	B-NP	O
vessels	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
E2	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
over	IN	B-PP	O
expression	NN	B-NP	O
of	IN	B-PP	O
VEGF	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
receptor	NN	I-NP	O
(	(	O	O
VEGFR	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
may	MD	B-VP	O
play	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
step	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
induced	VBD	B-VP	O
tumor	NN	B-NP	B
angiogenesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
pituitary	NN	I-NP	O
.	.	O	O

Pravastatin	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
myopathy	NN	I-NP	B
.	.	O	O

Report	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
inflammatory	JJ	I-NP	B
myopathy	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
pravastatin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
hydrophilic	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
methylglutaril	NN	I-NP	O
coenzyme	NN	I-NP	O
A	NN	I-NP	O
reductase	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
was	VBD	B-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
non	AFX	B-NP	B
-	HYPH	I-NP	I
insulin	NN	I-NP	I
-	HYPH	I-NP	I
dependent	JJ	I-NP	I
diabetes	NNS	I-NP	I
mellitus	NN	I-NP	I
and	CC	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

He	PRP	B-NP	O
assumed	VBD	B-VP	O
pravastatin	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
hypercholesterolemia	NN	B-NP	B
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
myopathy	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
limbs	NNS	I-NP	O
which	WDT	B-NP	O
resolved	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
pravastatin	NN	B-NP	O
discontinuation	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
previously	RB	I-NP	O
unknown	JJ	I-NP	O
hypothyroidism	NN	I-NP	B
,	,	O	O
probably	RB	B-ADVP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
chronic	JJ	B-NP	O
autoimmune	JJ	I-NP	B
thyroiditis	NN	I-NP	I
,	,	O	O
was	VBD	B-VP	O
evidenced	VBN	I-VP	O
.	.	O	O

Muscle	NN	B-NP	O
biopsy	NN	I-NP	O
(	(	O	O
left	JJ	B-NP	O
gastrocnemius	NN	I-NP	O
)	)	O	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
perimysial	JJ	I-NP	O
and	CC	I-NP	O
endomysial	JJ	I-NP	O
inflammatory	JJ	I-NP	O
infiltrate	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
CD4	NN	B-NP	O
+	SYM	B-VP	O
lymphocytes	NNS	B-NP	O
.	.	O	O

While	IN	B-SBAR	O
lovastatin	NN	B-NP	O
and	CC	I-NP	O
simvastatin	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
toxic	JJ	B-NP	O
myopathy	NN	I-NP	B
,	,	O	O
pravastatin	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
myopathy	NN	I-NP	B
could	MD	B-VP	O
represent	VB	I-VP	O
a	DT	B-NP	O
distinct	JJ	I-NP	O
,	,	I-NP	O
inflammatory	JJ	I-NP	O
entity	NN	I-NP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	I-NP	O
effect	NN	I-NP	O
and	CC	I-NP	O
structure	NN	I-NP	O
-	HYPH	B-NP	O
function	NN	I-NP	O
relationships	NNS	I-NP	O
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
cardiomyopathy	NN	I-NP	B
(	(	O	O
CM	NN	B-NP	B
)	)	O	O
produced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
anticancer	JJ	I-NP	O
drug	NN	I-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
DXR	NN	B-NP	O
)	)	O	O
(	(	O	O
Adriamycin	NN	B-NP	O
)	)	O	O
provides	VBZ	B-VP	O
a	DT	B-NP	O
unique	JJ	I-NP	O
opportunity	NN	I-NP	O
to	TO	B-VP	O
analyze	VB	I-VP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
and	CC	I-NP	O
structure	NN	I-NP	O
-	HYPH	B-NP	O
function	NN	I-NP	O
relationships	NNS	I-NP	O
during	IN	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
measured	VBD	B-VP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
morphologic	JJ	B-NP	O
damage	NN	I-NP	O
by	IN	B-PP	O
ultrastructural	JJ	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
endomyocardial	JJ	B-NP	O
biopsy	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
performance	NN	B-NP	O
abnormally	RB	B-ADVP	O
by	IN	B-PP	O
right	JJ	B-NP	O
heart	NN	I-NP	O
catheterization	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
DXR	NN	B-NP	O
.	.	O	O

Morphologic	JJ	B-NP	O
damage	NN	I-NP	O
was	VBD	B-VP	O
variable	JJ	B-ADJP	O
but	CC	O	O
was	VBD	B-VP	O
proportional	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
cumulative	JJ	I-NP	O
DXR	NN	I-NP	O
dose	NN	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
.	.	O	O

Performance	NN	B-NP	O
abnormalities	NNS	I-NP	O
correlated	VBD	B-VP	O
weakly	RB	B-ADVP	O
with	IN	B-PP	O
dose	NN	B-NP	O
,	,	O	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
curvilinear	JJ	I-NP	O
relationship	NN	I-NP	O
,	,	O	O
and	CC	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
expression	NN	B-NP	O
.	.	O	O

Catheterization	NN	B-NP	O
abnormalities	NNS	I-NP	O
correlated	VBD	B-VP	O
well	RB	B-ADVP	O
with	IN	B-PP	O
morphologic	JJ	B-NP	O
damage	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
subgroup	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
exercise	NN	B-NP	O
hemodynamics	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
,	,	O	O
and	CC	O	O
this	DT	B-NP	O
relationship	NN	I-NP	O
also	RB	B-ADVP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
curvilinear	NN	I-NP	O
,	,	O	O
threshold	DT	B-NP	O
configuration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
DXR	NN	B-NP	O
-	HYPH	B-NP	O
CM	NN	I-NP	B
myocardial	JJ	I-NP	B
damage	NN	I-NP	I
is	VBZ	B-VP	O
proportional	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
cytotoxic	JJ	B-NP	O
insult	NN	I-NP	O
(	(	O	O
DXR	NN	B-NP	O
dose	NN	I-NP	O
)	)	O	O
while	IN	B-SBAR	O
myocardial	JJ	B-NP	O
function	NN	I-NP	O
is	VBZ	B-VP	O
preserved	VBN	I-VP	O
until	IN	B-SBAR	O
a	DT	B-NP	O
critical	JJ	I-NP	O
dose	NN	I-NP	O
or	CC	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
damage	NN	B-NP	O
is	VBZ	B-VP	O
reached	VBN	I-VP	O
,	,	O	O
after	IN	B-PP	O
which	WDT	B-NP	O
myocardial	JJ	B-NP	O
performance	NN	I-NP	O
deteriorates	VBZ	B-VP	O
rapidly	RB	B-ADVP	O
.	.	O	O

Fatal	JJ	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
following	VBG	B-PP	O
topical	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ophthalmic	JJ	B-NP	O
chloramphenicol	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
died	VBD	B-VP	O
of	IN	B-PP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
undergoing	VBG	B-VP	O
cataract	NN	B-NP	B
extraction	NN	I-NP	O
and	CC	O	O
beginning	VBG	B-VP	O
topical	JJ	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
chloramphenicol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
pancytopenia	NN	B-NP	B
began	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
idiosyncratic	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
chloramphenicol	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
second	JJ	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
after	IN	B-PP	O
topical	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
chloramphenicol	NN	B-NP	O
for	IN	B-PP	O
ocular	JJ	B-NP	O
conditions	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
reversible	JJ	B-NP	O
bone	NN	I-NP	B
marrow	NN	I-NP	I
hypoplasia	NN	I-NP	I
have	VBP	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Any	DT	B-NP	O
other	JJ	I-NP	O
suspected	VBN	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
ocular	JJ	B-NP	B
toxicity	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
topically	RB	B-NP	O
applied	VBN	I-NP	O
chloramphenicol	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
reported	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
National	NNP	I-NP	O
Registry	NNP	I-NP	O
of	IN	B-PP	O
Drug	NNP	B-NP	O
-	HYPH	B-NP	O
Induced	NNP	I-NP	O
Ocular	NNP	I-NP	O
Side	NNP	I-NP	O
Effects	NNS	I-NP	O
,	,	O	O
Oregon	NNP	B-NP	O
Health	NNP	I-NP	O
Sciences	NNP	I-NP	O
University	NNP	I-NP	O
,	,	O	O
Portland	NNP	B-NP	O
,	,	O	O
OR	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

Bradycardia	NNP	B-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
trihexyphenidyl	NN	B-NP	O
hydrochloride	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
chronic	JJ	I-NP	O
schizophrenic	JJ	I-NP	B
patient	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
anticholinergic	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
trihexyphenidyl	NN	B-NP	O
hydrochloride	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
,	,	O	O
paradoxically	RB	B-ADVP	O
,	,	O	O
sinus	NN	B-NP	O
bradycardia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
reaction	NN	I-NP	O
was	VBD	B-VP	O
specific	JJ	B-ADJP	O
to	TO	B-PP	O
trihexyphenidyl	NN	B-NP	O
and	CC	O	O
not	RB	O	O
to	TO	B-PP	O
other	JJ	B-NP	O
anticholinergic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
antidyskinetic	JJ	I-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
psychiatric	JJ	I-NP	B
practice	NN	I-NP	O
and	CC	I-NP	O
physicians	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Experimental	JJ	B-NP	O
cyclosporine	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
:	:	O	O
risk	NN	B-NP	O
of	IN	B-PP	O
concomitant	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
(	(	O	O
CSA	NN	B-NP	O
)	)	O	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
various	JJ	B-NP	O
chemotherapeutics	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
CSA	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
caused	VBD	B-VP	O
renal	JJ	B-NP	O
functional	JJ	I-NP	O
and	CC	I-NP	O
structural	JJ	I-NP	O
changes	NNS	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
reported	VBN	B-VP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
combined	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
CSA	NN	B-NP	O
and	CC	O	O
various	JJ	B-NP	O
chemotherapeutic	JJ	I-NP	O
drugs	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
nephrotoxic	JJ	I-NP	B
potential	NN	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
gentamicin	NN	B-NP	O
(	(	O	O
at	IN	B-PP	O
therapeutic	JJ	B-NP	O
doses	NNS	I-NP	O
)	)	O	O
,	,	O	O
amphothericin	NN	B-NP	O
B	NN	I-NP	O
and	CC	O	O
ketoconazole	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
frequently	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
immunosuppressed	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
aggravate	VB	I-VP	O
the	DT	B-NP	O
CSA	NN	I-NP	O
induced	VBD	B-VP	O
toxicity	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

Gentamicin	NN	B-NP	O
at	IN	B-PP	O
toxic	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
increased	VBN	B-NP	O
CSA	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
nephrotoxicity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
CSA	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
different	JJ	I-NP	O
pathogenetic	JJ	I-NP	O
mechanism	NN	I-NP	O
.	.	O	O

Receptor	NN	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	B
hyperactivity	NN	I-NP	I
in	IN	B-PP	O
chronic	JJ	B-NP	O
nicotine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
pretreated	VBN	I-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
or	CC	I-NP	O
nicotine	NN	I-NP	O
by	IN	B-PP	O
subcutaneously	RB	B-VP	O
implanting	VBG	I-VP	O
each	DT	B-NP	O
animal	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
Alzet	NNP	I-NP	O
osmotic	JJ	I-NP	O
mini	AFX	I-NP	O
-	HYPH	I-NP	O
pump	NN	I-NP	O
which	WDT	B-NP	O
continuously	RB	B-ADVP	O
released	VBD	B-VP	O
saline	NN	B-NP	O
or	CC	I-NP	O
nicotine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
pretreatment	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
animals	NNS	B-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
(	(	O	O
i	NN	B-NP	O
)	)	O	O
determining	VBG	B-VP	O
their	PRP$	B-NP	O
locomotor	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
acutely	RB	B-NP	O
injected	VBN	I-NP	O
nicotine	NN	I-NP	O
and	CC	O	O
(	(	B-LST	O
ii	LS	I-LST	O
)	)	O	O
measuring	VBG	B-VP	O
the	DT	B-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
[	(	I-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
nicotine	NN	I-NP	O
and	CC	O	O
[	(	B-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
spiperone	NN	I-NP	O
binding	NN	I-NP	O
sites	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
no	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
response	NN	I-NP	O
,	,	O	O
striatal	JJ	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
[	(	I-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
nicotine	NN	I-NP	O
and	CC	O	O
[	(	B-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
spiperone	NN	I-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
nicotine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
day	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
rats	NNS	B-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
pretreated	VBN	I-VP	O
with	IN	B-PP	O
nicotine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
nicotine	NN	I-NP	O
-	HYPH	B-VP	O
stimulated	VBN	B-NP	O
locomotor	NN	I-NP	O
response	NN	I-NP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
[	(	I-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
nicotine	NN	I-NP	O
binding	NN	I-NP	O
sites	NNS	I-NP	O
and	CC	O	O
also	RB	B-ADVP	O
with	IN	B-PP	O
an	DT	B-NP	O
elevated	VBN	I-NP	O
dopamine	NN	I-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
level	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
striatal	JJ	B-NP	O
[	(	I-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
spiperone	NN	I-NP	O
binding	NN	I-NP	O
sites	NNS	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
animals	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
nicotine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
nicotine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
response	NN	I-NP	O
remained	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
potentiated	VBN	I-VP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
elevated	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
striatal	JJ	B-NP	O
[	(	I-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
spiperone	NN	I-NP	O
binding	NN	I-NP	O
sites	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
striatal	JJ	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
[	(	I-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
nicotine	NN	I-NP	O
binding	NN	I-NP	O
sites	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
striatal	JJ	I-NP	O
DA	NN	I-NP	O
level	NN	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
chronic	JJ	B-NP	O
nicotine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
develop	VBP	B-VP	O
locomotor	NN	B-NP	B
hyperactivity	NN	I-NP	I
in	IN	B-PP	O
response	NN	I-PP	O
to	TO	I-PP	O
nicotine	NN	B-NP	O
initially	RB	B-ADJP	O
due	JJ	I-ADJP	O
to	TO	B-PP	O
increases	NNS	B-NP	O
of	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
density	NN	I-NP	O
of	IN	B-PP	O
nicotinic	JJ	B-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
DA	NN	B-NP	O
concentration	NN	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
inducing	VBG	B-VP	O
DA	NN	B-NP	O
receptor	NN	I-NP	O
supersensitivity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
.	.	O	O

Hydrocortisone	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
humans	NNS	B-NP	O
:	:	O	O
pressor	NN	B-NP	O
responsiveness	NN	I-NP	O
and	CC	O	O
sympathetic	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Oral	JJ	B-NP	O
hydrocortisone	NN	I-NP	O
increases	VBZ	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
enhances	VBZ	B-VP	O
pressor	NN	B-NP	O
responsiveness	NN	I-NP	O
in	IN	B-PP	O
normal	JJ	B-NP	O
human	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
hydrocortisone	NN	I-NP	O
on	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
peripheral	JJ	I-NP	O
resistance	NN	I-NP	O
,	,	O	O
forearm	NN	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
,	,	O	O
and	CC	O	O
norepinephrine	NN	B-NP	O
spillover	NN	I-NP	O
to	TO	B-PP	O
plasma	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
male	JJ	I-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
diastolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-NP	O
,	,	I-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	B
cardiac	JJ	I-NP	I
output	NN	I-NP	I
.	.	O	O

Total	JJ	B-NP	O
peripheral	JJ	I-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
fell	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
.	.	O	O

Resting	VBG	B-VP	O
forearm	NN	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
reflex	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
cold	JJ	I-NP	O
pressor	NN	I-NP	O
test	NN	I-NP	O
was	VBD	B-VP	O
accentuated	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
resistance	NN	B-NP	O
increasing	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
/	SYM	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
/	SYM	B-NP	O
min	NN	B-NP	O
(	(	O	O
R	NN	B-NP	O
units	NNS	I-NP	O
)	)	O	O
before	IN	B-PP	O
treatment	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
R	NN	I-NP	O
units	NNS	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
forearm	NN	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
accompanying	VBG	B-VP	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	B-NP	O
norepinephrine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
after	IN	B-PP	O
hydrocortisone	NN	B-NP	O
,	,	O	O
increasing	VBG	B-VP	O
from	IN	B-PP	O
an	DT	B-NP	O
average	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
R	NN	I-NP	O
units	NNS	I-NP	O
before	IN	B-PP	O
treatment	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
R	NN	I-NP	O
units	NNS	I-NP	O
after	IN	B-PP	O
hydrocortisone	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
shift	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
left	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
relation	NN	I-NP	O
and	CC	I-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
threshold	NN	B-NP	O
suggested	VBD	B-VP	O
increased	VBN	B-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
norepinephrine	NN	B-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Measurement	NN	B-NP	O
of	IN	B-PP	O
resting	VBG	B-NP	O
norepinephrine	NN	I-NP	O
spillover	NN	I-NP	O
rate	NN	I-NP	O
to	TO	B-PP	O
plasma	NN	B-NP	O
and	CC	I-NP	O
norepinephrine	NN	I-NP	O
uptake	NN	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
overall	RB	B-ADVP	O
resting	VBG	B-VP	O
sympathetic	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
increased	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
rise	NN	I-NP	B
in	IN	B-PP	I
resting	VBG	B-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
with	IN	B-PP	O
hydrocortisone	NN	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	B
cardiac	JJ	I-NP	I
output	NN	I-NP	I
(	(	O	O
presumably	RB	B-ADVP	O
due	IN	B-PP	O
to	TO	B-PP	O
increased	VBN	B-NP	O
blood	NN	I-NP	O
volume	NN	I-NP	O
)	)	O	O
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
suprofen	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
perfused	VBN	I-NP	O
rat	NN	I-NP	O
kidney	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
suprofen	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
damage	NN	B-NP	O
remains	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
direct	JJ	I-NP	O
nephrotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
suprofen	NN	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
recirculating	VBG	I-NP	O
isolated	VBN	I-NP	O
rat	NN	I-NP	O
kidney	NN	I-NP	O
perfused	VBN	B-VP	O
with	IN	B-PP	O
cell	NN	B-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
buffer	NN	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
of	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
sodium	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
oxygen	NN	B-NP	O
consumption	NN	I-NP	O
,	,	O	O
or	CC	O	O
urinary	JJ	B-NP	O
flow	NN	I-NP	O
rates	NNS	I-NP	O
in	IN	B-PP	O
kidneys	NNS	B-NP	O
perfused	VBN	B-VP	O
with	IN	B-PP	O
suprofen	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
suprofen	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
perfused	VBN	B-VP	O
with	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
;	:	O	O
no	DT	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
with	IN	B-PP	O
suprofen	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
baseline	NN	I-NP	O
excretion	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-PP	O
suprofen	NN	B-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
fractional	JJ	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
summary	NN	B-NP	O
,	,	O	O
suprofen	NN	B-NP	O
causes	VBZ	B-VP	O
acute	JJ	B-NP	B
declines	NNS	I-NP	I
in	IN	B-PP	I
renal	JJ	B-NP	I
function	NN	I-NP	I
,	,	O	O
most	RBS	B-ADVP	O
likely	RB	I-ADVP	O
by	IN	B-PP	O
directly	RB	B-ADVP	O
altering	VBG	B-VP	O
the	DT	B-NP	O
intrarenal	JJ	I-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
brainstem	NN	I-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
behavior	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
sensory	NN	I-NP	O
/	SYM	B-VP	O
motor	NN	B-NP	O
behaviors	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
electrical	JJ	B-NP	O
discharges	NNS	I-NP	O
recorded	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
bilateral	JJ	I-NP	O
brainstem	NN	I-NP	O
were	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
WKY	NN	I-NP	O
rats	NNS	I-NP	O
by	IN	B-PP	O
mechanical	JJ	B-NP	O
(	(	O	O
electrode	NN	B-NP	O
implants	NNS	I-NP	O
)	)	O	O
and	CC	O	O
DC	NN	B-NP	O
electrical	JJ	I-NP	O
current	JJ	I-NP	O
stimulations	NNS	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
acute	JJ	B-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
electrode	NN	I-NP	O
implant	NN	I-NP	O
implicated	VBD	B-VP	O
num	CD	B-NP	O
side	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
reticular	JJ	I-NP	O
system	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
but	CC	O	O
subjects	NNS	B-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
incapacitated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
stimulations	NNS	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
subcutaneously	RB	B-ADVP	O
for	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
experiment	NN	I-NP	O
and	CC	I-NP	O
subsequent	JJ	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	B-NP	O
doses	NNS	I-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
chronic	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
generated	VBD	B-VP	O
more	RBR	B-NP	O
abnormal	JJ	I-NP	O
behaviors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
perturbation	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
the	DT	B-NP	O
electrically	RB	I-NP	O
perturbated	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
abnormal	JJ	I-NP	O
behaviors	NNS	I-NP	O
were	VBD	B-VP	O
yawning	VBG	I-VP	O
,	,	O	O
retrocollis	NN	B-NP	O
,	,	O	O
hyperactivity	NN	B-NP	B
,	,	O	O
hypersensitivity	NN	B-NP	B
,	,	O	O
beating	VBG	B-VP	O
drum	NN	B-NP	O
behavior	NN	I-NP	O
,	,	O	O
squealing	NN	B-NP	O
,	,	O	O
head	NN	B-NP	O
bobbing	NN	I-NP	O
,	,	O	O
circling	NN	B-NP	O
,	,	O	O
sniffing	NN	B-NP	O
,	,	O	O
abnormal	JJ	B-NP	O
posturing	NN	I-NP	O
,	,	O	O
and	CC	O	O
facial	JJ	B-NP	O
twitching	NN	I-NP	O
.	.	O	O

Shifts	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
power	NN	I-NP	O
frequency	NN	I-NP	O
spectra	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
discharge	NN	I-NP	O
patterns	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
between	IN	B-PP	O
quiet	JJ	B-ADJP	O
and	CC	O	O
pacing	VBG	B-VP	O
behavioral	JJ	B-NP	O
states	NNS	I-NP	O
.	.	O	O

Hypersensitivity	NN	B-NP	B
to	TO	B-PP	O
various	JJ	B-NP	O
auditory	NN	I-NP	O
,	,	O	O
tactile	NN	B-NP	O
,	,	O	O
and	CC	O	O
visual	JJ	B-NP	O
stimulation	NN	I-NP	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
and	CC	O	O
shifts	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
ambient	NN	I-NP	O
power	NN	I-NP	O
spectral	JJ	I-NP	O
frequency	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
tactile	JJ	B-NP	O
stimulation	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
generates	VBZ	B-VP	O
and	CC	I-VP	O
propagates	VBZ	I-VP	O
pathological	JJ	B-NP	O
discharges	NNS	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
elicited	VBN	I-VP	O
by	IN	B-PP	O
mechanical	JJ	B-NP	O
and	CC	I-NP	O
DC	NN	I-NP	O
electrical	JJ	I-NP	O
perturbation	NN	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
activate	VB	I-VP	O
the	DT	B-NP	O
discharge	NN	I-NP	O
system	NN	I-NP	O
and	CC	O	O
thus	RB	B-VP	O
induce	VBP	I-VP	O
abnormal	JJ	B-NP	O
behaviors	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
generated	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
discharge	NN	I-NP	O
site	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
distant	JJ	B-NP	O
sites	NNS	I-NP	O
to	TO	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
discharge	NN	I-NP	O
propagates	NNS	I-NP	O
.	.	O	O

Cognitive	JJ	B-NP	O
functions	NNS	I-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
since	IN	B-PP	O
dopaminergic	JJ	B-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
cellular	JJ	I-NP	O
elements	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
level	NN	I-NP	O
are	VBP	B-VP	O
also	RB	I-VP	O
implicated	VBN	I-VP	O
.	.	O	O

Increased	VBN	B-NP	O
sulfation	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
7alpha	NN	B-NP	O
-	HYPH	B-NP	O
hydroxylation	NN	I-NP	O
of	IN	B-PP	O
deoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cholestasis	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Deoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
conjugation	NN	I-NP	O
,	,	O	O
transport	NN	B-NP	O
capacity	NN	I-NP	O
,	,	O	O
and	CC	O	O
metabolism	NN	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
control	NN	B-NP	O
and	CC	O	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Control	NN	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
capacity	NN	I-NP	O
to	TO	B-VP	O
transport	VB	I-VP	O
deoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
than	IN	B-PP	O
taurodeoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
and	CC	O	O
both	DT	B-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
by	IN	B-PP	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
[	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
14C	NN	I-NP	O
]	)	I-NP	O
sodium	NN	I-NP	O
deoxycholate	NN	I-NP	O
infusion	NN	I-NP	O
,	,	O	O
[	(	B-NP	O
14C	NN	I-NP	O
]	)	I-NP	O
biliary	JJ	I-NP	O
bile	NN	I-NP	O
acid	NN	I-NP	O
secretion	NN	I-NP	O
increased	VBD	B-VP	O
,	,	O	O
but	CC	O	O
bile	NN	B-NP	O
flow	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
either	CC	O	O
control	NN	B-NP	O
or	CC	O	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
excreted	VBD	B-VP	O
significantly	RB	B-NP	O
less	JJR	I-NP	O
14C	NN	I-NP	O
as	IN	B-PP	O
taurocholic	JJ	B-NP	O
acid	NN	I-NP	O
than	IN	B-SBAR	O
did	VBD	O	O
control	NN	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
7alpha	NN	B-NP	O
-	HYPH	B-NP	O
hydroxylation	NN	I-NP	O
of	IN	B-PP	O
taurodeoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

Ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
treatment	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
impair	VB	I-VP	O
conjugation	NN	B-NP	O
of	IN	B-PP	O
deoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
sulfation	NN	B-NP	O
of	IN	B-PP	O
taurodeoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
to	TO	B-PP	O
nearly	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
rat	NN	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
poorer	JJR	I-NP	O
tolerance	NN	I-NP	O
for	IN	B-PP	O
deoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
than	IN	B-SBAR	O
do	VBP	B-VP	O
certain	JJ	B-NP	O
other	JJ	I-NP	O
species	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
rat	NN	I-NP	O
converts	VBZ	B-VP	O
deoxycholic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
poor	JJ	I-NP	O
choleretic	JJ	I-NP	O
,	,	O	O
to	TO	B-PP	O
taurocholic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
good	JJ	I-NP	O
choleretic	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
this	DT	B-NP	O
conversion	NN	I-NP	O
is	VBZ	B-VP	O
impaired	VBN	I-VP	O
with	IN	B-PP	O
ethinyl	NN	B-NP	O
estradiol	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
sulfation	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
alternate	JJ	I-NP	O
pathway	NN	I-NP	O
for	IN	B-PP	O
excretion	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
potentially	RB	I-NP	O
harmful	JJ	I-NP	O
bile	NN	I-NP	O
acid	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
ouabain	NN	B-NP	O
on	IN	B-PP	O
myocardial	JJ	B-NP	O
oxygen	NN	I-NP	O
supply	NN	I-NP	O
and	CC	O	O
demand	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
hemodynamic	JJ	I-NP	O
,	,	I-NP	O
volumetric	JJ	I-NP	O
,	,	O	O
and	CC	O	O
metabolic	JJ	B-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
digitalis	NN	B-NP	O
glycosides	NNS	I-NP	O
on	IN	B-PP	O
myocardial	JJ	B-NP	O
oxygen	NN	I-NP	O
supply	NN	I-NP	O
and	CC	O	O
demand	NN	B-NP	O
are	VBP	B-VP	O
of	IN	B-PP	O
particular	JJ	B-NP	O
interest	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
obstructive	JJ	B-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
but	CC	O	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
measured	VBN	I-VP	O
previously	RB	B-ADVP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ouabain	NN	B-NP	O
on	IN	B-PP	O
hemodynamic	JJ	B-NP	O
,	,	I-NP	O
volumetric	JJ	I-NP	O
,	,	O	O
and	CC	O	O
metabolic	JJ	B-NP	O
parameters	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
chronic	JJ	I-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
without	IN	B-PP	O
clinical	JJ	B-NP	O
congestive	JJ	I-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Because	IN	B-SBAR	O
the	DT	B-NP	O
protocol	NN	I-NP	O
was	VBD	B-VP	O
long	JJ	B-NP	O
and	CC	I-NP	O
involved	VBN	I-NP	O
interventions	NNS	I-NP	O
which	WDT	B-NP	O
might	MD	B-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
determinations	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
also	RB	B-ADVP	O
studied	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
using	VBG	B-VP	O
an	DT	B-NP	O
identical	JJ	I-NP	O
protocol	NN	I-NP	O
except	IN	B-PP	O
that	IN	B-SBAR	O
ouabain	NN	B-NP	O
administration	NN	I-NP	O
was	VBD	B-VP	O
omitted	VBN	I-VP	O
.	.	O	O

Left	VBN	B-NP	O
ventricular	JJ	I-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
volume	NN	I-NP	O
fell	VBD	B-VP	O
in	IN	B-PP	O
each	DT	B-NP	O
patient	NN	I-NP	O
given	VBN	B-PP	O
ouabain	NN	B-NP	O
,	,	O	O
even	RB	B-SBAR	O
though	IN	I-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
initially	RB	I-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Left	VBN	B-NP	O
ventricular	JJ	I-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
fell	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
SE	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
and	CC	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
volume	NN	I-NP	O
fell	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
ml	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
ouabain	NN	B-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
completed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
maximum	JJ	I-NP	O
velocity	NN	I-NP	O
of	IN	B-PP	O
contractile	JJ	B-NP	O
element	NN	I-NP	O
shortening	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-VP	O
/	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
ml	NN	I-NP	O
/	SYM	I-NP	O
s	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
muscle	NN	I-NP	O
-	HYPH	B-NP	O
lengths	NN	I-NP	O
/	SYM	I-NP	O
s	NN	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
contractility	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
parameters	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
myocardial	JJ	B-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
occurred	VBD	B-VP	O
after	IN	B-SBAR	O
ouabain	NN	B-NP	O
administration	NN	I-NP	O
but	CC	O	O
this	DT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ouabain	NN	I-NP	O
patients	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
who	WP	B-NP	O
are	VBP	B-VP	O
not	RB	O	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
congestive	JJ	I-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
left	VBD	B-VP	B
ventricular	JJ	B-NP	I
end	NN	I-NP	I
-	HYPH	B-NP	I
diastolic	JJ	I-NP	I
volume	NN	I-NP	I
falls	VBZ	B-VP	I
after	IN	B-PP	O
ouabain	NN	B-NP	O
administration	NN	I-NP	O
even	RB	B-ADVP	O
when	WRB	B-ADVP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
initially	RB	B-ADJP	O
normal	JJ	I-ADJP	O
.	.	O	O

Though	IN	B-SBAR	O
this	DT	B-NP	O
fall	NN	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
wall	NN	B-NP	O
tension	NN	I-NP	O
,	,	O	O
and	CC	O	O
,	,	O	O
therefore	RB	B-ADVP	O
,	,	O	O
of	IN	B-PP	O
myocardial	JJ	B-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
sufficient	JJ	B-NP	O
magnitude	NN	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
a	DT	B-NP	O
net	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
myocardial	JJ	B-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
.	.	O	O

Nevertheless	RB	B-ADVP	O
,	,	O	O
compensatory	JJ	B-NP	O
mechanisms	NNS	I-NP	O
prevent	VBP	B-VP	O
a	DT	B-NP	O
deterioration	NN	I-NP	O
of	IN	B-PP	O
resting	VBG	B-NP	O
myocardial	JJ	I-NP	O
metabolism	NN	I-NP	O
.	.	O	O

Prolongation	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
QT	NN	I-NP	I
interval	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
cisapride	NN	B-NP	O
-	HYPH	I-NP	O
diltiazem	NN	I-NP	O
interaction	NN	I-NP	O
.	.	O	O

Cisapride	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
cytochrome	NN	I-NP	O
P450	NN	I-NP	O
3A4	NN	I-NP	O
(	(	O	O
CYP3A4	NN	B-NP	O
)	)	O	O
substrate	NN	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
prescribed	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
gastrointestinal	JJ	B-NP	B
motility	NN	I-NP	I
disorders	NNS	I-NP	I
.	.	O	O

Prolongation	NN	B-NP	B
of	IN	B-PP	I
QT	NN	B-NP	I
interval	NN	I-NP	I
,	,	O	O
torsades	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
,	,	O	O
and	CC	O	O
sudden	JJ	B-NP	B
cardiac	JJ	I-NP	I
death	NN	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
after	IN	B-PP	O
concomitant	JJ	B-NP	O
administration	NN	I-NP	O
with	IN	B-PP	O
erythromycin	NN	B-NP	O
or	CC	I-NP	O
azole	NN	I-NP	O
antifungal	JJ	I-NP	O
agents	NNS	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	B-PP	O
with	IN	I-PP	O
other	JJ	B-NP	O
CYP3A4	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
possible	JJ	I-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
taking	VBG	I-VP	O
cisapride	NN	B-NP	O
for	IN	B-PP	O
gastroesophageal	JJ	B-NP	B
reflux	NN	I-NP	I
disorder	NN	I-NP	I
and	CC	I-NP	O
diltiazem	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
agent	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
inhibitory	JJ	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
CYP3A4	NN	B-NP	O
,	,	O	O
for	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
in	IN	B-PP	O
near	JJ	B-NP	O
syncope	NN	I-NP	B
and	CC	O	O
had	VBD	B-VP	O
QT	NN	B-NP	B
-	HYPH	B-NP	I
interval	NN	I-NP	I
prolongation	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
discontinuing	VBG	B-VP	O
cisapride	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
QT	NN	I-NP	O
interval	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
and	CC	O	O
symptoms	NNS	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
recur	VB	I-VP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
caution	NN	B-NP	O
be	VB	B-VP	O
taken	VBN	I-VP	O
when	WRB	B-ADVP	O
cisapride	NN	B-NP	O
is	VBZ	B-VP	O
prescribed	VBN	I-VP	O
with	IN	B-PP	O
any	DT	B-NP	O
potent	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
CYP3A4	NN	B-NP	O
,	,	O	O
including	VBG	B-PP	O
diltiazem	NN	B-NP	O
.	.	O	O

Paclitaxel	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
carboplatin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
advanced	VBN	B-NP	O
ovarian	JJ	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
maximum	NN	I-NP	O
tolerated	VBN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
(	(	O	O
Taxol	NN	B-NP	O
;	:	O	O
Bristol	NNP	B-NP	O
-	:	O	O
Myers	NNP	B-NP	O
Squibb	NNP	I-NP	O
Company	NNP	I-NP	O
,	,	O	O
Princeton	NNP	B-NP	O
,	,	O	O
NJ	NNP	B-NP	O
)	)	O	O
given	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
carboplatin	NN	B-NP	O
administered	VBN	B-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
to	TO	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
ovarian	JJ	I-NP	B
cancer	NN	I-NP	I
,	,	O	O
paclitaxel	NN	B-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
escalated	VBN	I-VP	O
as	IN	B-SBAR	O
follows	VBZ	B-VP	O
:	:	O	O
level	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
;	:	O	O
level	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
;	:	O	O
level	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
;	:	O	O
and	CC	O	O
level	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
fixed	VBN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
at	IN	B-PP	O
levels	NNS	B-NP	O
num	CD	B-NP	O
through	IN	B-PP	O
num	CD	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	I-VP	O
achieve	VB	I-VP	O
an	DT	B-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
concentration	NN	I-NP	O
-	HYPH	O	O
time	NN	B-NP	O
curve	NN	I-NP	O
(	(	O	O
AUC	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Calvert	NNP	I-NP	O
formula	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
levels	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
carboplatin	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
targeted	VBN	I-VP	O
at	IN	B-PP	O
AUCs	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
combined	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
paclitaxel	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
.	.	O	O

To	TO	B-PP	O
date	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
previously	RB	I-NP	O
untreated	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
all	DT	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
good	JJ	I-NP	O
performance	NN	I-NP	O
status	NN	I-NP	O
(	(	O	O
Eastern	NNP	B-NP	O
Cooperative	NNP	I-NP	O
Oncology	NNP	I-NP	O
Group	NNP	I-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
entered	VBN	I-VP	O
into	IN	B-PP	O
this	DT	B-NP	O
ongoing	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
toxicity	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
was	VBD	B-VP	O
myelosuppression	NN	B-NP	B
(	(	O	O
leukopenia	NN	B-NP	B
,	,	O	O
granulocytopenia	NN	B-NP	B
,	,	O	O
and	CC	O	O
thrombocytopenia	NN	B-NP	B
)	)	O	O
.	.	O	O

Neurotoxicity	NN	B-NP	B
was	VBD	B-VP	O
largely	RB	B-ADJP	O
moderate	JJ	I-ADJP	O
.	.	O	O

So	RB	B-ADVP	O
far	RB	I-ADVP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
;	:	O	O
of	IN	B-PP	O
these	DT	B-NP	O
,	,	O	O
num	CD	B-NP	O
showed	VBD	B-VP	O
objective	JJ	B-NP	O
(	(	O	O
complete	JJ	B-ADJP	O
or	CC	I-ADJP	O
partial	JJ	I-ADJP	O
)	)	O	O
response	NN	B-NP	O
and	CC	I-NP	O
disease	NN	I-NP	O
stabilized	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
disease	NN	B-NP	O
progression	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
administered	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
followed	VBD	B-VP	O
immediately	RB	B-ADVP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
at	IN	B-PP	O
an	DT	B-NP	O
AUC	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
safely	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
schedule	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
outpatient	NN	I-NP	O
setting	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
recommended	VBN	I-NP	O
dose	NN	I-NP	O
for	IN	B-PP	O
phase	NN	B-NP	O
num	CD	B-NP	O
studies	NNS	I-NP	O
is	VBZ	B-VP	O
paclitaxel	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
and	CC	I-NP	O
carboplatin	NN	I-NP	O
AUC	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
by	IN	B-PP	O
conversion	NN	B-NP	O
to	TO	B-PP	O
cyclosporine	NN	B-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
tacrolimus	NN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
persist	VBP	B-VP	O
despite	IN	B-PP	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
,	,	O	O
conversion	NN	B-NP	O
to	TO	B-PP	O
cyclosporine	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-VP	O
immunosuppression	NN	B-NP	O
(	(	O	O
CyA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
necessary	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
characterized	VBD	B-VP	O
tacrolimus	NN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
that	WDT	B-NP	O
warranted	VBD	B-VP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
,	,	O	O
and	CC	O	O
outcomes	VBZ	B-VP	O
after	IN	B-PP	O
conversion	NN	B-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
liver	NN	I-NP	O
recipients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
tacrolimus	NN	B-NP	O
as	IN	B-PP	O
primary	JJ	B-NP	O
immunosuppression	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
required	VBD	B-VP	O
conversion	NN	B-NP	O
to	TO	B-PP	O
CyA	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
recorded	VBD	B-VP	O
indication	NN	B-NP	O
for	IN	B-PP	O
conversion	NN	B-NP	O
,	,	O	O
whether	IN	B-SBAR	O
conversion	NN	B-NP	O
was	VBD	B-VP	O
early	JJ	B-ADJP	O
or	CC	I-ADJP	O
late	JJ	I-ADJP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
,	,	O	O
tacrolimus	NN	B-NP	O
dose	NN	I-NP	O
and	CC	I-NP	O
trough	NN	I-NP	O
blood	NN	I-NP	O
level	NN	I-NP	O
at	IN	B-PP	O
conversion	NN	B-NP	O
,	,	O	O
and	CC	O	O
incidence	NN	B-NP	O
of	IN	B-PP	O
rejection	NN	B-NP	O
after	IN	B-PP	O
conversion	NN	B-NP	O
.	.	O	O

Conversion	NN	B-NP	O
was	VBD	B-VP	O
early	JJ	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
late	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Indications	NNS	B-NP	O
for	IN	B-PP	O
early	JJ	B-NP	O
conversion	NN	I-NP	O
were	VBD	B-VP	O
neurotoxicity	NN	B-NP	B
,	,	O	O
(	(	O	B
insulin	NN	B-NP	I
-	HYPH	O	I
dependent	JJ	O	I
)	)	O	I
diabetes	NN	B-NP	I
mellitus	NN	I-NP	I
(	(	O	O
IDDM	NN	B-NP	B
)	)	O	O
,	,	O	O
nephrotoxicity	NN	B-NP	B
,	,	O	O
gastrointestinal	JJ	B-ADJP	B
(	(	O	I
GI	NN	B-NP	I
)	)	O	I
toxicity	NN	B-NP	I
,	,	O	O
and	CC	O	O
cardiomyopathy	NN	B-NP	B
,	,	O	O
and	CC	O	O
for	IN	B-PP	O
late	JJ	B-NP	O
conversion	NN	I-NP	O
were	VBD	B-VP	O
neurotoxicity	NN	B-NP	B
,	,	O	O
IDDM	NN	B-NP	B
,	,	O	O
nephrotoxicity	NN	B-NP	B
,	,	O	O
GI	NN	B-NP	B
toxicity	NN	I-NP	I
,	,	O	O
hepatotoxicity	NN	B-NP	B
,	,	O	O
post	AFX	B-NP	B
-	HYPH	I-NP	I
transplant	NN	I-NP	I
lmphoproliferate	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PTLD	NN	B-NP	B
)	)	O	O
,	,	O	O
cardiomyopathy	NN	B-NP	B
,	,	O	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
,	,	O	O
and	CC	O	O
pruritus	NN	B-NP	B
.	.	O	O

All	DT	B-NP	O
early	JJ	I-NP	O
-	HYPH	I-NP	O
conversion	NN	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
improvement	NN	B-NP	O
/	SYM	I-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
.	.	O	O

Among	IN	B-PP	O
late	JJ	B-NP	O
-	HYPH	I-NP	O
conversion	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
improvement	NN	B-NP	O
/	SYM	B-NP	O
resolution	NN	I-NP	O
;	:	O	O
in	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
persisted	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
rejection	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
alive	JJ	B-ADJP	O
with	IN	B-PP	O
functioning	VBG	B-VP	O
grafts	NNS	B-NP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
)	)	O	O
after	IN	B-PP	O
conversion	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
tacrolimus	NN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
unresponsive	JJ	B-ADJP	O
to	TO	B-PP	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
,	,	O	O
conversion	NN	B-NP	O
to	TO	B-PP	O
CyA	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
accomplished	VBN	I-VP	O
safely	RB	B-ADVP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
rejection	NN	B-NP	O
and	CC	O	O
excellent	JJ	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
outcome	NN	I-NP	O
.	.	O	O

Relative	JJ	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
netilmicin	NN	B-NP	O
and	CC	I-NP	O
tobramycin	NN	I-NP	O
in	IN	B-PP	O
oncology	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
prospectively	RB	B-ADVP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
netilmicin	NN	B-NP	O
sulfate	NN	I-NP	O
or	CC	O	O
tobramycin	NN	B-NP	O
sulfate	NN	I-NP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
piperacillin	NN	B-NP	O
sodium	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
immunocompromised	VBN	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
presumed	VBN	B-NP	O
severe	JJ	I-NP	O
infections	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
regimens	NNS	I-NP	O
were	VBD	B-VP	O
equally	RB	B-ADJP	O
efficacious	JJ	I-ADJP	O
.	.	O	O

Nephrotoxicity	NN	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
proportion	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
netilmicin	NN	B-NP	O
and	CC	I-NP	O
tobramycin	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
vs	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Ototoxicity	NN	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
netilmicin	NN	I-NP	O
and	CC	I-NP	O
piperacillin	NN	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
tobramycin	NN	I-NP	O
and	CC	I-NP	O
piperacillin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
those	DT	B-NP	O
evaluated	VBN	B-VP	O
with	IN	B-PP	O
posttherapy	NN	B-NP	O
audiograms	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
netilmicin	NN	I-NP	O
and	CC	I-NP	O
piperacillin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
auditory	JJ	B-NP	O
thresholds	NNS	I-NP	O
return	VBP	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
tobramycin	NN	I-NP	O
and	CC	I-NP	O
piperacillin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
greater	JJR	B-NP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dB	NN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
auditory	JJ	B-NP	O
threshold	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
total	NN	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dB	NN	I-NP	O
changes	NNS	I-NP	O
(	(	O	O
increases	NNS	B-NP	O
and	CC	I-NP	O
decreases	NNS	I-NP	O
)	)	O	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
netilmicin	NN	B-NP	O
and	CC	I-NP	O
piperacillin	NN	I-NP	O
-	HYPH	O	O
vs	CC	O	O
tobramycin	NN	B-NP	O
and	CC	I-NP	O
piperacillin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
vs	IN	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
aminoglycoside	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
ototoxicity	NN	I-NP	B
was	VBD	B-VP	O
less	RBR	B-ADJP	O
severe	JJ	I-ADJP	O
and	CC	O	O
more	RBR	B-ADVP	O
often	RB	I-ADVP	O
reversible	JJ	B-ADVP	O
with	IN	B-PP	O
netilmicin	NN	B-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
tobramycin	NN	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
synthetase	NN	I-NP	O
inhibitors	NNS	I-NP	O
on	IN	B-PP	O
experimentally	RB	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
of	IN	B-PP	O
prostaglandins	NNS	B-NP	O
(	(	O	O
PGs	NNS	B-NP	O
)	)	O	O
to	TO	B-VP	O
seizure	VB	I-VP	B
induction	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
PG	NN	I-NP	O
synthetase	NN	I-NP	O
inhibitors	NNS	I-NP	O
on	IN	B-PP	O
convulsions	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
flurothyl	NN	B-NP	O
,	,	O	O
picrotoxin	NN	B-NP	O
,	,	O	O
pentetrazol	NN	B-NP	O
(	(	O	O
PTZ	NN	B-NP	O
)	)	O	O
,	,	O	O
electroshock	NN	B-NP	O
or	CC	I-NP	O
bicuculline	NN	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Ibuprofen	NN	B-NP	O
,	,	O	O
sulindac	NN	B-NP	O
,	,	O	O
mefenamic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
and	CC	O	O
low	JJ	B-NP	O
dose	NN	I-NP	O
meclofenamic	JJ	I-NP	O
acid	NN	I-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
latency	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
onset	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
flurothyl	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
PTZ	NN	B-NP	O
models	NNS	I-NP	O
;	:	O	O
the	DT	B-NP	O
electroshock	NN	I-NP	O
,	,	I-NP	O
picrotoxin	NN	I-NP	O
and	CC	I-NP	O
bicuculline	NN	I-NP	O
models	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pretreatment	NN	I-NP	O
agents	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
PGs	NNS	B-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
(	(	I-NP	O
s	NNS	I-NP	O
)	)	O	O
underlying	VBG	B-VP	O
fluorthyl	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
PTZ	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
convulsions	NNS	I-NP	B
,	,	O	O
but	CC	O	O
not	RB	O	O
picrotoxin	NN	B-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
electroshock	NN	B-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
or	CC	O	O
bicuculline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

Angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
inhibitor	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
angioedema	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
stomach	NN	I-NP	O
and	CC	O	O
small	JJ	B-NP	O
intestine	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
African	JJ	I-NP	O
-	HYPH	I-NP	O
American	JJ	I-NP	O
female	NN	I-NP	O
with	IN	B-PP	O
newly	RB	B-NP	O
diagnosed	VBN	I-NP	O
hypertension	NN	I-NP	B
,	,	O	O
who	WP	B-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
pill	NN	I-NP	O
of	IN	B-PP	O
amlodipine	NN	B-NP	O
/	SYM	O	O
benazapril	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
very	RB	I-NP	O
next	JJ	I-NP	O
day	NN	I-NP	O
,	,	O	O
she	PRP	B-NP	O
presented	VBD	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
room	NN	I-NP	O
(	(	O	O
ER	NN	B-NP	O
)	)	O	O
with	IN	B-PP	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
,	,	I-NP	O
nausea	NN	I-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
.	.	O	O

Physical	JJ	B-NP	O
exam	NN	I-NP	O
,	,	O	O
complete	JJ	B-NP	O
metabolic	JJ	I-NP	O
panel	NN	I-NP	O
,	,	O	O
and	CC	O	O
hemogram	NN	B-NP	O
were	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
range	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
discharged	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
ER	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
fluid	NN	B-NP	O
and	CC	I-NP	O
analgesics	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
she	PRP	B-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
ER	NN	I-NP	O
the	DT	B-NP	O
next	JJ	I-NP	O
day	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
complaints	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
time	NN	I-NP	O
the	DT	B-NP	O
physical	JJ	I-NP	O
exam	NN	I-NP	O
was	VBD	B-VP	O
significant	JJ	B-ADJP	O
for	IN	B-PP	O
a	DT	B-NP	O
distended	JJ	I-NP	O
abdomen	NN	I-NP	O
with	IN	B-PP	O
dullness	NN	B-NP	O
to	TO	B-PP	O
percussion	NN	B-NP	O
.	.	O	O

CT	NN	B-NP	O
scan	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
abdomen	NN	I-NP	O
revealed	VBD	B-VP	O
markedly	RB	B-NP	O
thickened	VBN	I-NP	O
antrum	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
stomach	NN	I-NP	O
,	,	I-NP	O
duodenum	NN	I-NP	O
and	CC	I-NP	O
jejunum	NN	I-NP	O
,	,	O	O
along	IN	B-PP	O
with	IN	B-PP	O
fluid	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
abdominal	JJ	I-NP	O
and	CC	I-NP	O
pelvic	JJ	I-NP	O
cavity	NN	I-NP	O
.	.	O	O

Angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
(	(	O	O
ACEI	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
angioedema	NN	I-NP	B
was	VBD	B-VP	O
suspected	VBN	I-VP	O
,	,	O	O
and	CC	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
hypertensive	JJ	I-NP	B
medications	NNS	I-NP	O
were	VBD	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

Her	PRP$	B-NP	O
symptoms	NNS	I-NP	O
improved	VBN	B-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
,	,	O	O
and	CC	O	O
repeat	NN	B-NP	O
CT	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
revealed	VBD	B-VP	O
marked	JJ	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
stomach	NN	B-NP	O
and	CC	O	O
small	JJ	B-NP	O
bowel	NN	I-NP	O
thickening	NN	I-NP	O
and	CC	I-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
ascites	NNS	B-NP	B
.	.	O	O

The	DT	B-NP	O
recognition	NN	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
and	CC	O	O
angiotensin	NN	B-NP	O
receptor	NN	I-NP	O
blocker	NN	I-NP	O
(	(	O	O
ARB	NN	B-NP	O
)	)	O	O
intestinal	JJ	B-NP	B
angioedema	NN	I-NP	I
constitutes	VBZ	B-VP	O
a	DT	B-NP	O
challenge	NN	I-NP	O
to	TO	B-PP	O
primary	JJ	B-NP	O
care	NN	I-NP	O
physicians	NNS	I-NP	O
,	,	O	O
internists	NNS	B-NP	O
,	,	O	O
emergency	NN	B-NP	O
room	NN	I-NP	O
personal	JJ	B-ADJP	O
and	CC	O	O
surgeons	NNS	B-NP	O
.	.	O	O

Valproic	JJ	B-NP	O
acid	NN	I-NP	O
num	CD	I-NP	O
:	:	O	O
time	NN	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
biomarkers	NNS	I-NP	O
,	,	O	O
liver	NN	B-NP	B
toxicity	NN	I-NP	I
,	,	O	O
and	CC	O	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
metabolite	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
VPA	NN	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
recently	RB	B-ADVP	O
demonstrated	VBN	B-VP	O
by	IN	B-PP	O
elevated	VBN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
F	NN	I-NP	O
(	(	O	O
2t	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
isoprostane	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
F	NN	I-NP	O
(	(	O	O
2t	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IsoP	NN	I-NP	O
)	)	O	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
temporal	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
VPA	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
and	CC	I-NP	O
hepatotoxicity	NN	I-NP	B
,	,	O	O
adult	JJ	B-NP	O
male	JJ	I-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
ip	RB	B-ADVP	O
with	IN	B-PP	O
VPA	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
saline	NN	I-NP	O
(	(	O	O
vehicle	NN	B-NP	O
)	)	O	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Oxidative	JJ	B-NP	O
stress	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
determining	VBG	B-VP	O
plasma	NN	B-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
F	NN	I-NP	O
(	(	O	O
2t	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IsoP	NN	I-NP	O
,	,	O	O
lipid	NN	B-NP	O
hydroperoxides	NNS	I-NP	O
(	(	O	O
LPO	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
thiobarbituric	JJ	B-NP	O
acid	NN	I-NP	O
reactive	JJ	I-NP	O
substances	NNS	I-NP	O
(	(	O	O
TBARs	NNS	B-NP	O
)	)	O	O
.	.	O	O

Plasma	NN	B-NP	O
and	CC	O	O
liver	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
F	NN	I-NP	O
(	(	O	O
2t	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IsoP	NN	I-NP	O
were	VBD	B-VP	O
elevated	VBN	I-VP	O
and	CC	O	O
reached	VBD	B-VP	O
a	DT	B-NP	O
plateau	NN	I-NP	O
after	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
VPA	NN	B-NP	O
treatment	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
control	NN	B-NP	O
.	.	O	O

Liver	NN	B-NP	O
LPO	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
elevated	VBN	I-VP	O
until	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Liver	NN	B-NP	O
and	CC	I-NP	O
plasma	NN	I-NP	O
TBARs	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
increased	VBN	I-VP	O
until	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Liver	NN	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
based	VBN	B-PP	O
on	IN	B-PP	O
serum	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	O	O
glutathione	NN	B-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
transferase	NN	I-NP	O
(	(	O	O
alpha	SYM	O	O
-	HYPH	O	O
GST	NN	B-NP	O
)	)	O	O
and	CC	O	O
by	IN	B-PP	O
histology	NN	B-NP	O
.	.	O	O

Serum	NN	B-NP	O
alpha	SYM	O	O
-	HYPH	O	O
GST	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
elevated	VBN	I-VP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
which	WDT	B-NP	O
corresponded	VBD	B-VP	O
to	TO	B-PP	O
hepatotoxicity	NN	B-NP	B
as	IN	B-SBAR	O
shown	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
increasing	VBG	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
inflammation	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
capsule	NN	I-NP	O
,	,	O	O
necrosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
steatosis	NN	B-NP	B
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
liver	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
oxidation	NN	I-NP	O
metabolites	NNS	I-NP	O
of	IN	B-PP	O
VPA	NN	B-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
while	IN	B-SBAR	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
ene	NN	I-NP	O
-	HYPH	I-NP	O
VPA	NN	I-NP	O
and	CC	O	O
(	(	O	O
E	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
diene	NN	I-NP	O
-	HYPH	I-NP	O
VPA	NN	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
elevated	JJ	B-ADJP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
VPA	NN	B-NP	O
treatment	NN	I-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
F	NN	I-NP	O
(	(	O	O
2t	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IsoP	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
precedes	VBZ	B-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
necrosis	NN	B-NP	B
,	,	O	O
steatosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
elevated	VBN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
GST	NN	B-NP	O
.	.	O	O

Pheochromocytoma	NN	B-NP	B
unmasked	JJ	B-ADJP	O
by	IN	B-PP	O
amisulpride	NN	B-NP	O
and	CC	I-NP	O
tiapride	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
describe	VB	I-VP	O
the	DT	B-NP	O
unmasking	NN	I-NP	O
of	IN	B-PP	O
pheochromocytoma	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
amisulpride	NN	B-NP	O
and	CC	I-NP	O
tiapride	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
white	JJ	I-NP	O
man	NN	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
hypertension	NN	I-NP	B
with	IN	B-PP	O
severe	JJ	B-NP	O
headache	NN	I-NP	B
and	CC	O	O
vomiting	VBG	B-VP	B
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
amisulpride	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
and	CC	I-NP	O
tiapride	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
immediately	RB	I-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
after	IN	B-PP	O
subsequent	JJ	B-NP	O
nicardipine	NN	I-NP	O
and	CC	O	O
verapamil	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Abdominal	JJ	B-NP	O
ultrasound	NN	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
adrenal	JJ	I-NP	O
mass	NN	I-NP	O
,	,	O	O
and	CC	O	O
postoperative	JJ	B-NP	O
histologic	JJ	I-NP	O
examination	NN	I-NP	O
confirmed	VBD	B-VP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
pheochromocytoma	NN	B-NP	B
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
pheochromocytoma	NN	B-NP	B
are	VBP	B-VP	O
often	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
substituted	VBN	B-NP	O
benzamide	NN	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
underlying	JJ	I-NP	O
mechanism	NN	I-NP	O
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
case	NN	I-NP	O
,	,	O	O
use	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
probability	NN	I-NP	O
scale	NN	I-NP	O
indicated	VBD	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
crisis	NN	I-NP	O
and	CC	I-NP	O
amisulpride	NN	I-NP	O
and	CC	I-NP	O
tiapride	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

As	IN	B-PP	O
of	IN	B-PP	O
March	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
amisulpride	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
tiapride	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypertensive	JJ	I-NP	B
crisis	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
pheochromocytoma	NN	B-NP	B
.	.	O	O

Physicians	NNS	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
healthcare	NN	I-NP	O
professionals	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
potential	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
tiapride	NN	B-NP	O
and	CC	I-NP	O
amisulpride	NN	I-NP	O
.	.	O	O

Quantitative	JJ	B-NP	O
drug	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
stimulant	JJ	B-NP	O
psychosis	NN	I-NP	B
:	:	O	O
relationship	NN	B-NP	O
to	TO	B-PP	O
symptom	NN	B-NP	O
severity	NN	I-NP	O
,	,	O	O
catecholamines	NNS	B-NP	O
and	CC	O	O
hyperkinesia	NN	B-NP	B
.	.	O	O

To	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
quantitative	JJ	B-NP	O
stimulant	JJ	I-NP	O
drug	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
catecholamines	NNS	B-NP	O
,	,	O	O
and	CC	O	O
psychotic	JJ	B-NP	B
symptoms	NNS	I-NP	I
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
psychiatric	JJ	I-NP	B
emergency	NN	I-NP	O
service	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
or	CC	I-NP	O
cocaine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
psychosis	NN	I-NP	B
were	VBD	B-VP	O
interviewed	VBN	I-VP	O
,	,	O	O
and	CC	O	O
plasma	NN	B-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
for	IN	B-PP	O
quantitative	JJ	B-NP	O
assays	NNS	I-NP	O
of	IN	B-PP	O
stimulant	NN	B-NP	O
drug	NN	I-NP	O
and	CC	O	O
catecholamine	NN	B-NP	O
metabolite	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Methamphetamine	NN	B-NP	O
or	CC	I-NP	O
amphetamine	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
several	JJ	B-NP	O
psychopathology	NN	I-NP	O
scores	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
global	JJ	I-NP	O
hyperkinesia	NN	I-NP	B
rating	NN	I-NP	O
.	.	O	O

HVA	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
global	JJ	B-NP	O
hyperkinesia	NN	I-NP	B
but	CC	B-PP	O
not	RB	B-PP	O
to	TO	I-PP	O
psychopathology	NN	B-NP	O
ratings	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
many	JJ	B-NP	O
other	JJ	I-NP	O
factors	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
sensitization	NN	B-NP	O
may	MD	B-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
,	,	O	O
intensity	NN	B-NP	O
of	IN	B-PP	O
stimulant	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
psychotic	JJ	I-NP	B
symptoms	NNS	I-NP	I
and	CC	I-NP	O
stereotypies	NNS	I-NP	B
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
in	IN	B-PP	O
part	NN	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-ADJP	O
related	VBN	I-ADJP	O
.	.	O	O

Delayed	VBN	B-NP	O
asystolic	JJ	I-NP	B
cardiac	JJ	I-NP	B
arrest	NN	I-NP	I
after	IN	B-PP	O
diltiazem	NN	B-NP	O
overdose	NN	I-NP	B
;	:	O	O
resuscitation	NN	B-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
calcium	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
took	VBD	B-VP	O
a	DT	B-NP	O
mixed	VBN	I-NP	O
overdose	NN	I-NP	B
including	VBG	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
of	IN	B-PP	O
diltiazem	NN	B-NP	O
,	,	O	O
paracetamol	NN	B-NP	O
,	,	O	O
aspirin	NN	B-NP	O
,	,	O	O
isosorbide	NN	B-NP	O
nitrate	NN	I-NP	O
,	,	O	O
and	CC	O	O
alcohol	NN	B-NP	O
.	.	O	O

He	PRP	B-NP	O
initially	RB	B-ADVP	O
presented	VBD	B-VP	O
to	TO	B-PP	O
hospital	NN	B-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
with	IN	B-PP	O
mild	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
activated	VBN	B-NP	O
charcoal	NN	I-NP	O
and	CC	O	O
intravenous	JJ	B-NP	O
fluids	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
overdose	NN	I-NP	B
he	PRP	B-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
generalised	VBN	I-NP	O
tonic	JJ	I-NP	B
-	HYPH	I-NP	I
clonic	JJ	I-NP	I
seizures	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
remained	VBD	B-VP	O
unresponsive	JJ	B-ADJP	O
with	IN	B-PP	O
junctional	JJ	B-NP	O
bradycardia	NN	I-NP	B
,	,	O	O
unrecordable	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
then	RB	O	O
became	VBD	B-VP	O
asystolic	JJ	B-ADJP	B
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
resuscitated	VBN	I-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
)	)	O	O
intravenous	JJ	B-NP	O
calcium	NN	I-NP	O
and	CC	O	O
adrenaline	NN	B-NP	O
(	(	O	O
epinephrine	NN	B-NP	O
)	)	O	O
.	.	O	O

He	PRP	B-NP	O
required	VBD	B-VP	O
inotropic	JJ	B-NP	O
support	NN	I-NP	O
and	CC	O	O
temporary	JJ	B-NP	O
pacing	NN	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
suggests	VBZ	B-VP	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
aggressive	JJ	B-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
calcium	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
diltiazem	NN	I-NP	O
overdose	NN	I-NP	B
,	,	O	O
particularly	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
asystole	NN	B-NP	B
.	.	O	O

It	PRP	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
early	RB	B-ADVP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
after	IN	B-PP	O
diltiazem	NN	B-NP	O
overdose	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
also	RB	B-ADVP	O
highlights	VBZ	B-VP	O
the	DT	B-NP	O
problems	NNS	I-NP	O
with	IN	B-PP	O
delayed	VBN	B-NP	O
toxicity	NN	I-NP	B
when	WRB	B-ADVP	O
whole	JJ	B-NP	O
bowel	NN	I-NP	O
irrigation	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
administered	VBN	I-VP	O
.	.	O	O

Renal	JJ	B-NP	B
papillary	JJ	I-NP	I
necrosis	NN	I-NP	I
due	IN	B-PP	O
to	TO	B-PP	O
naproxen	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
,	,	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
sulindac	NN	B-NP	O
,	,	O	O
fenoprofen	NN	B-NP	O
calcium	NN	I-NP	O
,	,	O	O
high	JJ	B-NP	O
dose	NN	I-NP	O
salicylates	NNS	I-NP	O
and	CC	O	O
gold	NN	B-NP	O
salts	NNS	I-NP	O
,	,	O	O
developed	VBD	B-VP	O
renal	JJ	B-NP	B
papillary	JJ	I-NP	I
necrosis	NN	I-NP	I
(	(	O	O
RPN	NN	B-NP	B
)	)	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
institution	NN	B-NP	O
of	IN	B-PP	O
naproxen	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
other	JJ	I-NP	O
factor	NN	I-NP	O
predisposing	VBG	B-VP	O
to	TO	B-PP	O
RPN	NN	B-NP	B
could	MD	B-VP	O
be	VB	I-VP	O
discovered	VBN	I-VP	O
.	.	O	O

Sulindac	NN	B-NP	O
was	VBD	B-VP	O
substituted	VBN	I-VP	O
for	IN	B-PP	O
naproxen	NN	B-NP	O
and	CC	O	O
no	DT	B-NP	O
further	JJ	I-NP	O
adverse	JJ	I-NP	O
renal	JJ	I-NP	O
effects	NNS	I-NP	O
occurred	VBD	B-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
review	VBP	B-VP	O
previous	JJ	B-NP	O
reports	NNS	I-NP	O
linking	VBG	B-VP	O
RPN	NN	B-NP	B
to	TO	B-PP	O
antiinflammatory	JJ	B-NP	O
drug	NN	I-NP	O
use	NN	I-NP	O
and	CC	O	O
discuss	VBP	B-VP	O
possible	JJ	B-NP	O
advantages	NNS	I-NP	O
of	IN	B-PP	O
sulindac	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
experienced	VBN	I-VP	O
renal	JJ	B-NP	B
toxicity	NN	I-NP	I
from	IN	B-PP	O
other	JJ	B-NP	O
antiinflammatory	JJ	I-NP	O
agents	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-PP	O
adrenergic	JJ	B-NP	O
blocking	VBG	I-NP	O
drugs	NNS	I-NP	O
and	CC	I-NP	O
verapamil	NN	I-NP	O
-	HYPH	O	O
-	HYPH	O	O
report	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
ischaemic	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
developed	VBD	B-VP	O
profound	JJ	B-NP	O
cardiac	JJ	I-NP	B
failure	NN	I-NP	I
,	,	O	O
hypotension	NN	B-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
during	IN	B-PP	O
combined	VBN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
verapamil	NN	B-NP	O
and	CC	O	O
beta	SYM	B-NP	O
-	HYPH	O	O
adrenergic	JJ	B-NP	O
blocking	VBG	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
clinical	JJ	I-NP	O
picture	NN	I-NP	O
resolved	VBN	B-VP	O
completely	RB	B-ADVP	O
with	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Baseline	NNP	B-NP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
cardiac	JJ	B-NP	O
catheterisation	NN	I-NP	O
or	CC	O	O
nuclear	JJ	B-NP	O
angiography	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
only	RB	B-VP	O
mildly	RB	I-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
.	.	O	O

Simultaneously	RB	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	O	O
adrenergic	JJ	B-NP	O
blocking	VBG	I-NP	O
drugs	NNS	I-NP	O
and	CC	I-NP	O
verapamil	NN	I-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
profound	JJ	B-NP	O
adverse	JJ	I-NP	O
interactions	NNS	I-NP	O
and	CC	O	O
should	MD	B-VP	O
only	RB	I-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
with	IN	B-PP	O
great	JJ	B-NP	O
caution	NN	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
bendrofluazide	NN	B-NP	O
and	CC	I-NP	O
propranolol	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
mild	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Report	NNP	B-NP	O
of	IN	B-PP	O
Medical	NNP	B-NP	O
Research	NNP	I-NP	O
Council	NNP	I-NP	O
Working	NNP	I-NP	O
Party	NNP	I-NP	O
on	IN	B-PP	O
Mild	NNP	B-NP	O
to	TO	B-VP	O
Moderate	VB	I-VP	O
Hypertension	NN	B-NP	B
.	.	O	O

Participants	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Medical	NNP	I-NP	O
Research	NNP	I-NP	O
Council	NNP	I-NP	O
treatment	NN	I-NP	O
trial	NN	I-NP	O
for	IN	B-PP	O
mild	JJ	B-NP	O
hypertension	NN	I-NP	B
are	VBP	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
:	:	O	O
bendrofluazide	NN	B-NP	O
,	,	O	O
propranolol	NN	B-NP	O
,	,	O	O
or	CC	O	O
a	DT	B-NP	O
placebo	NN	I-NP	O
for	IN	B-PP	O
either	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
trial	NN	I-NP	O
is	VBZ	B-VP	O
single	JJ	B-ADJP	O
-	HYPH	B-NP	O
blind.	SYM	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
observation	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
completed	VBN	I-VP	O
so	RB	B-ADVP	O
far	RB	I-ADVP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
active	JJ	B-NP	O
drugs	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
placebos	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
an	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
bendrofluazide	NN	B-NP	O
treatment	NN	I-NP	O
and	CC	I-NP	O
impotence	NN	I-NP	B
,	,	O	O
and	CC	O	O
impotence	NN	B-NP	B
also	RB	B-ADVP	O
occurred	VBD	B-VP	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
propranolol	NN	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
those	DT	B-NP	O
taking	VBG	I-NP	O
placebos	NNS	I-NP	O
.	.	O	O

Other	JJ	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
significantly	RB	B-VP	O
linked	VBN	I-VP	O
with	IN	B-PP	O
active	JJ	B-NP	O
drugs	NNS	I-NP	O
include	VBP	B-VP	O
impaired	JJ	B-NP	B
glucose	NN	I-NP	I
tolerance	NN	I-NP	I
in	IN	B-PP	O
men	NNS	B-NP	O
and	CC	I-NP	O
women	NNS	I-NP	O
and	CC	O	O
gout	NN	B-NP	B
in	IN	B-PP	O
men	NNS	B-NP	O
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
bendrofluazide	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
and	CC	O	O
Raynaud	NNP	B-NP	B
s	NNS	I-NP	I
phenomenon	NN	I-NP	I
and	CC	I-NP	O
dyspnoea	NN	I-NP	B
in	IN	B-PP	O
men	NNS	B-NP	O
and	CC	I-NP	O
women	NNS	I-NP	O
taking	VBG	B-VP	O
propranolol	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
corneal	JJ	I-NP	B
disease	NN	I-NP	I
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
occurred	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
propranolol	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Mean	JJ	B-NP	O
serum	NN	I-NP	O
potassium	NN	I-NP	O
level	NN	I-NP	O
fell	VBD	B-VP	O
,	,	O	O
and	CC	O	O
urea	NN	B-NP	O
and	CC	O	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
levels	NNS	I-NP	O
rose	VBD	B-VP	O
,	,	O	O
in	IN	B-PP	O
men	NNS	B-NP	O
and	CC	I-NP	O
women	NNS	I-NP	O
taking	VBG	B-VP	O
bendrofluazide	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
propranolol	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
serum	NN	B-NP	O
potassium	NN	I-NP	O
and	CC	O	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
levels	NNS	I-NP	O
rose	VBD	B-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
sexes	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
urea	NN	I-NP	O
level	NN	I-NP	O
rose	VBD	B-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
women	NNS	B-NP	O
only	RB	B-ADVP	O
.	.	O	O

Dexmedetomidine	NN	B-NP	O
and	CC	I-NP	O
cardiac	JJ	I-NP	O
protection	NN	I-NP	O
for	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
cardiac	JJ	I-NP	O
surgery	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
meta	JJ	I-NP	O
-	HYPH	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
randomised	VBN	B-NP	O
controlled	VBN	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
systematic	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dexmedetomidine	NN	B-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
outcomes	NNS	I-NP	O
following	VBG	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
cardiac	JJ	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
included	VBD	B-VP	O
prospective	JJ	B-ADJP	O
,	,	O	O
randomised	VBD	B-VP	O
peri	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
dexmedetomidine	NN	B-NP	O
that	WDT	B-NP	O
reported	VBD	B-VP	O
mortality	NN	B-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
morbidity	NN	I-NP	O
or	CC	O	O
adverse	JJ	B-NP	O
drug	NN	I-NP	O
events	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
PubMed	NNP	I-NP	O
Central	NNP	I-NP	O
and	CC	I-NP	O
EMBASE	NNP	I-NP	O
search	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
up	RP	B-PRT	O
to	TO	B-PP	O
July	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
reference	NN	I-NP	O
lists	NNS	I-NP	O
of	IN	B-PP	O
identified	VBN	B-NP	O
papers	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
further	JJ	B-NP	O
trials	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
studies	NNS	I-NP	O
identified	VBN	B-VP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
meta	JJ	I-NP	O
-	HYPH	I-NP	O
analysis	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
.	.	O	O

Dexmedetomidine	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
trend	NN	I-NP	O
towards	IN	B-PP	O
improved	VBN	B-NP	O
cardiac	JJ	I-NP	O
outcomes	NNS	I-NP	O
;	:	O	O
all	RB	B-NP	O
-	HYPH	I-NP	O
cause	NN	I-NP	O
mortality	NN	I-NP	O
,	,	O	O
non	AFX	O	O
-	HYPH	B-NP	O
fatal	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
,	,	O	O
and	CC	O	O
myocardial	JJ	B-NP	B
ischaemia	NN	I-NP	I
.	.	O	O

Peri	NNP	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
were	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
.	.	O	O

An	DT	B-NP	O
anticholinergic	JJ	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reduce	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
bradycardia	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
randomised	VBN	I-NP	O
placebo	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
dexmedetomidine	NN	B-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Differential	JJ	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
serum	NN	I-NP	O
creatine	NN	I-NP	O
kinase	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
systemic	JJ	B-NP	B
lupus	NN	I-NP	I
erythematosus	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
bioptic	JJ	I-NP	O
findings	NNS	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
chloroquine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myopathy	NN	I-NP	B
.	.	O	O

Since	IN	B-PP	O
num	CD	B-NP	O
she	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
suffering	VBG	I-VP	O
from	IN	B-PP	O
systemic	JJ	B-NP	B
lupus	NN	I-NP	I
erythematosus	NN	I-NP	I
(	(	O	O
SLE	NN	B-NP	B
)	)	O	O
with	IN	B-PP	O
renal	JJ	B-NP	B
involvement	NN	I-NP	I
and	CC	I-NP	O
undergone	NN	I-NP	O
periods	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
azathioprine	NN	B-NP	O
and	CC	I-NP	O
cyclophosphamide	NN	I-NP	O
.	.	O	O

Additional	JJ	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
chloroquine	NN	B-NP	O
(	(	O	O
CQ	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
started	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
arthralgia	NN	B-NP	B
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
,	,	O	O
slightly	RB	B-VP	O
increased	VBD	I-VP	O
creatine	NN	B-NP	O
kinase	NN	I-NP	O
(	(	O	O
CK	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

Myositis	NN	B-NP	B
was	VBD	B-VP	O
suspected	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
steroids	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
CK	NN	I-NP	O
increase	NN	I-NP	O
persisted	VBD	B-VP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
she	PRP	B-NP	O
developed	VBD	B-VP	O
progressive	JJ	B-NP	O
muscular	JJ	I-NP	B
weakness	NN	I-NP	I
and	CC	O	O
muscular	JJ	B-NP	B
atrophy	NN	I-NP	I
.	.	O	O

Routine	NN	B-NP	O
controls	NNS	I-NP	O
revealed	VBD	B-VP	O
markedly	RB	B-NP	O
elevated	JJ	I-NP	O
CK	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
neurological	JJ	I-NP	O
and	CC	I-NP	O
electrophysiological	JJ	I-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
typical	JJ	B-ADJP	O
of	IN	B-PP	O
myositis	NN	B-NP	B
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
muscle	NN	B-NP	O
biopsy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
deltoid	JJ	I-NP	O
muscle	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
exclude	VB	I-VP	O
polymyositis	NN	B-NP	B
or	CC	O	O
toxic	JJ	B-NP	O
myopathy	NN	I-NP	B
.	.	O	O

As	IN	B-SBAR	O
it	PRP	B-NP	O
revealed	VBD	B-VP	O
chloroquine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myopathy	NN	I-NP	B
,	,	O	O
medication	NN	B-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

Discriminating	VBG	B-VP	O
between	IN	B-PP	O
primary	JJ	B-NP	O
SLE	NN	I-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
affection	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
musculoskeletal	JJ	I-NP	I
system	NN	I-NP	I
and	CC	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
for	IN	B-PP	O
appropriate	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
SLE	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
immunocompromised	JJ	B-NP	O
children	NNS	I-NP	O
.	.	O	O

Adenovirus	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
morbidity	NN	B-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
immunocompromised	JJ	I-NP	O
host	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
pediatrics	NNS	B-NP	O
is	VBZ	B-VP	O
increasing	VBG	I-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
growing	VBG	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
immunocompromised	JJ	B-NP	O
children	NNS	I-NP	O
,	,	O	O
where	WRB	B-ADVP	O
case	NN	B-NP	O
fatality	NN	I-NP	O
rates	NNS	I-NP	O
as	RB	B-ADJP	O
high	JJ	I-ADJP	O
as	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
no	DT	B-NP	O
approved	VBN	I-NP	O
antiviral	JJ	I-NP	O
agents	NNS	I-NP	O
with	IN	B-PP	O
proven	JJ	B-NP	O
efficacy	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
,	,	O	O
nor	CC	O	O
are	VBP	B-VP	O
there	RB	B-ADVP	O
any	DT	B-NP	O
prospective	JJ	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
controlled	VBN	I-NP	O
trials	NNS	I-NP	O
of	IN	B-PP	O
potentially	RB	B-NP	O
useful	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
adenovirus	NN	I-NP	O
therapies	NNS	I-NP	O
.	.	O	O

Apparent	JJ	B-NP	O
clinical	JJ	I-NP	O
success	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
is	VBZ	B-VP	O
limited	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
and	CC	O	O
small	JJ	B-NP	O
series	NN	I-NP	O
.	.	O	O

Experience	NN	B-NP	O
is	VBZ	B-VP	O
greatest	JJS	B-ADJP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
and	CC	I-NP	O
cidofovir	NN	I-NP	O
.	.	O	O

Ribavirin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
guanosine	NN	I-NP	O
analogue	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
broad	JJ	B-NP	O
antiviral	JJ	I-NP	O
activity	NN	I-NP	O
against	IN	B-PP	O
both	CC	O	O
RNA	NN	B-NP	O
and	CC	I-NP	O
DNA	NN	I-NP	O
viruses	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
documented	VBN	B-NP	O
activity	NN	I-NP	O
against	IN	B-PP	O
adenovirus	NN	B-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

Ribavirin	NN	B-NP	O
is	VBZ	B-VP	O
licensed	VBN	I-VP	O
in	IN	B-PP	O
aerosol	NN	B-NP	O
form	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	B
syncytial	JJ	I-NP	I
virus	NN	I-NP	I
infection	NN	I-NP	I
,	,	O	O
and	CC	O	O
orally	RB	B-ADVP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
interferon	NN	B-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
hepatitis	NN	B-NP	B
C	NN	I-NP	I
.	.	O	O

Intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
for	IN	B-PP	O
infection	NN	B-NP	B
with	IN	B-PP	I
hemorrhagic	JJ	B-NP	I
fever	NN	I-NP	I
viruses	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
is	VBZ	B-VP	O
reversible	JJ	B-NP	O
mild	JJ	I-NP	O
anemia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cidofovir	NN	B-NP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
infection	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
limited	VBN	I-VP	O
by	IN	B-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
significant	JJ	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
our	PRP$	B-NP	O
experience	NN	I-NP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
immunocompromised	JJ	B-NP	O
children	NNS	I-NP	O
and	CC	O	O
review	VB	B-VP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
retrospectively	RB	B-ADVP	O
reviewed	VBD	B-VP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
for	IN	B-PP	O
documented	VBN	B-NP	O
severe	JJ	I-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
adenovirus	NN	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
after	IN	B-PP	O
cardiac	JJ	B-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplants	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplant	NN	I-NP	O
patient	NN	I-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
intravenous	JJ	B-NP	O
cidofovir	NN	I-NP	O
for	IN	B-PP	O
progressive	JJ	B-NP	O
disseminated	VBN	I-NP	O
disease	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
additional	JJ	I-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
developed	VBD	B-VP	O
adenovirus	NN	B-NP	B
pneumonia	NN	I-NP	I
;	:	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
neonates	NNS	B-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
had	VBD	B-VP	O
partial	JJ	B-NP	O
DiGeorge	NNP	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
remaining	VBG	I-NP	O
infant	NN	I-NP	O
had	VBD	B-VP	O
recently	RB	I-VP	O
undergone	VBN	I-VP	O
a	DT	B-NP	O
cardiac	JJ	I-NP	O
transplant	NN	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
compassionate	JJ	I-NP	O
-	HYPH	I-NP	O
use	NN	I-NP	O
protocol	NN	I-NP	O
.	.	O	O

Complete	JJ	B-NP	O
clinical	JJ	I-NP	O
recovery	NN	I-NP	O
followed	VBD	B-VP	O
later	RB	B-ADVP	O
by	IN	B-PP	O
viral	JJ	B-NP	O
clearance	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
:	:	O	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
transplant	NN	I-NP	O
recipient	NN	I-NP	O
with	IN	B-PP	O
adenovirus	NN	B-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
immunocompetent	JJ	I-NP	O
neonate	NN	I-NP	O
with	IN	B-PP	O
adenovirus	NN	B-NP	B
pneumonia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
died	VBD	B-VP	O
of	IN	B-PP	O
adenovirus	NN	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
cidofovir	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
child	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
progressive	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
and	CC	I-NP	O
neutropenia	NN	I-NP	B
.	.	O	O

Our	PRP$	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
is	VBZ	B-VP	O
representative	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
spectrum	NN	I-NP	O
of	IN	B-PP	O
immunocompromised	JJ	B-NP	O
children	NNS	I-NP	O
at	IN	B-PP	O
greatest	JJS	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
,	,	O	O
namely	RB	B-NP	O
solid	JJ	I-NP	O
-	HYPH	I-NP	O
organ	NN	I-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
,	,	O	O
neonates	NNS	B-NP	O
,	,	O	O
and	CC	O	O
children	NNS	B-NP	O
with	IN	B-PP	O
immunodeficiency	NN	B-NP	B
.	.	O	O

Although	IN	B-SBAR	O
intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
effective	JJ	B-ADJP	O
for	IN	B-PP	O
all	DT	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
this	DT	B-NP	O
series	NN	I-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
therapy	NN	B-NP	O
is	VBZ	B-VP	O
unlikely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
benefit	NN	B-NP	O
if	IN	B-SBAR	O
begun	VBN	B-VP	O
late	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
infection	NN	I-NP	B
.	.	O	O

Early	RB	B-NP	O
identification	NN	I-NP	O
,	,	O	O
eg	NN	B-NP	O
by	IN	B-PP	O
polymerase	NN	B-NP	O
chain	NN	I-NP	O
reaction	NN	I-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
patients	NNS	I-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
of	IN	B-PP	O
disseminated	VBN	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
may	MD	B-VP	O
permit	VB	I-VP	O
earlier	JJR	B-NP	O
antiviral	JJ	I-NP	O
treatment	NN	I-NP	O
and	CC	O	O
better	JJR	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
therapeutic	JJ	B-NP	O
response	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
adenovirus	NN	I-NP	B
disease	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
recovered	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
availability	NN	I-NP	O
of	IN	B-PP	O
newer	JJR	B-NP	O
rapid	JJ	I-NP	O
diagnostic	NN	I-NP	O
techniques	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
polymerase	NN	B-NP	O
chain	NN	I-NP	O
reaction	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
make	VB	I-VP	O
earlier	RBR	B-ADVP	O
,	,	O	O
more	RBR	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
adenovirus	NN	B-NP	B
infection	NN	I-NP	I
possible	JJ	B-ADJP	O
.	.	O	O

Given	VBN	B-PP	O
the	DT	B-NP	O
seriousness	NN	I-NP	O
and	CC	O	O
increasing	VBG	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
adenovirus	NN	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
certain	JJ	B-NP	O
hosts	NNS	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
children	NNS	B-NP	O
,	,	O	O
a	DT	B-NP	O
large	JJ	I-NP	O
,	,	I-NP	O
multicenter	JJ	I-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
potentially	RB	B-NP	O
useful	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
adenoviral	JJ	I-NP	O
therapies	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
intravenous	JJ	B-NP	O
ribavirin	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
clearly	RB	I-VP	O
required	VBN	I-VP	O
to	TO	I-VP	O
demonstrate	VB	I-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
effective	JJ	I-NP	O
and	CC	I-NP	O
least	JJS	I-NP	O
toxic	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Hepatotoxicity	NN	B-NP	B
of	IN	B-PP	O
amiodarone	NN	B-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
has	VBZ	B-VP	O
proved	VBN	I-VP	O
very	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
otherwise	RB	B-NP	O
resistant	JJ	I-NP	O
cardiac	JJ	I-NP	O
tachyarrhythmias	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
has	VBZ	B-VP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
been	VBN	B-VP	O
limited	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
serious	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
cholestatic	JJ	B-NP	B
hepatitis	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
amiodarone	NN	B-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
below	IN	B-PP	O
and	CC	O	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hepatotoxicity	NN	I-NP	B
of	IN	B-PP	O
amiodarone	NN	B-NP	O
is	VBZ	B-VP	O
given	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
solid	JJ	B-NP	O
evidence	NN	I-NP	O
exists	VBZ	B-VP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	B
injury	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
amiodarone	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
steatosis	NN	B-NP	B
,	,	O	O
alterations	NNS	B-NP	O
resembling	VBG	B-VP	O
alcoholic	JJ	B-NP	B
hepatitis	NN	I-NP	I
,	,	O	O
cholestatic	JJ	B-NP	B
hepatitis	NN	I-NP	I
and	CC	O	O
micronodular	JJ	B-NP	O
cirrhosis	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
receiving	VBG	B-VP	O
amiodarone	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
regularly	RB	I-VP	O
screened	VBN	I-VP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
hepatic	JJ	B-NP	O
enzyme	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Therapy	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
discontinued	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
suspicion	NN	I-NP	O
of	IN	B-PP	O
cholestatic	JJ	B-NP	B
injury	NN	I-NP	I
or	CC	I-NP	O
hepatomegaly	NN	I-NP	B
.	.	O	O

Catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
combinations	NNS	B-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
morphine	NN	I-NP	O
:	:	O	O
potentiation	NN	B-NP	O
,	,	O	O
antagonism	NN	B-NP	O
,	,	O	O
tolerance	NN	B-NP	O
and	CC	O	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
tolerance	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
both	CC	O	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
morphine	NN	I-NP	O
induced	VBD	B-VP	O
analgesia	NN	B-NP	B
and	CC	I-NP	O
catalepsy	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
ketamine	NN	B-NP	O
produced	VBD	B-VP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
tolerance	NN	I-NP	O
to	TO	B-PP	O
morphine	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
morphine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
tolerance	NN	B-NP	O
to	TO	B-PP	O
ketamine	NN	B-NP	O
but	CC	O	O
rather	RB	B-VP	O
augmented	VBD	I-VP	O
the	DT	B-NP	O
cataleptic	JJ	I-NP	B
response	NN	I-NP	O
;	:	O	O
this	DT	B-NP	O
augmentation	NN	I-NP	O
was	VBD	B-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
residual	JJ	B-NP	O
morphine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
studies	NNS	I-NP	O
explored	VBD	B-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
righting	VBG	B-VP	O
reflex	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
effective	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
morphine	NN	I-NP	O
,	,	O	O
administered	VBN	B-VP	O
simultaneously	RB	B-ADVP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
mutual	JJ	B-NP	O
potentiation	NN	I-NP	O
between	IN	B-PP	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
effective	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
morphine	NN	I-NP	O
,	,	O	O
but	CC	O	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
effective	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
partly	RB	B-VP	O
antagonized	VBD	I-VP	O
fully	RB	B-ADJP	O
-	HYPH	I-ADJP	O
effective	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

Latency	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
righting	VBG	B-VP	O
reflex	NN	B-NP	O
,	,	I-NP	O
rigidity	NN	I-NP	B
and	CC	I-NP	O
behavior	NN	I-NP	O
on	IN	B-PP	O
recovery	NN	B-NP	O
,	,	O	O
reflected	VBD	B-VP	O
the	DT	B-NP	O
relative	JJ	I-NP	O
predominance	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
or	CC	I-NP	O
morphine	NN	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
combination	NN	I-NP	O
.	.	O	O

Naloxone	NN	B-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
induced	VBN	I-NP	O
cataleptic	JJ	I-NP	B
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
degree	NN	I-NP	O
and	CC	I-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
tolerance	NN	B-NP	O
to	TO	B-PP	O
daily	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
effective	JJ	I-NP	O
dose	NN	I-NP	O
combinations	NNS	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
morphine	NN	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
.	.	O	O

Rats	NNS	B-NP	O
,	,	O	O
tolerant	JJ	B-ADJP	O
to	TO	B-PP	O
ketamine	NN	B-NP	O
-	HYPH	B-NP	O
dominant	JJ	I-NP	O
combinations	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
cross	AFX	B-ADJP	O
-	HYPH	I-ADJP	O
tolerant	JJ	B-ADJP	O
to	TO	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
those	DT	B-NP	O
tolerant	JJ	B-ADJP	O
to	TO	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
dominant	JJ	I-NP	O
combinations	NNS	I-NP	O
were	VBD	B-VP	O
cross	AFX	B-ADJP	O
-	HYPH	I-ADJP	O
tolerant	JJ	B-ADJP	O
to	TO	B-PP	O
morphine	NN	B-NP	O
but	CC	O	O
showed	VBD	B-VP	O
either	CC	O	O
no	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
tolerance	NN	I-NP	O
or	CC	O	O
an	DT	B-NP	O
augmented	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
ketamine	NN	B-NP	O
.	.	O	O

While	IN	B-SBAR	O
the	DT	B-NP	O
mutual	JJ	I-NP	O
potentiation	NN	I-NP	O
,	,	O	O
antagonism	NN	B-NP	O
and	CC	O	O
tolerance	NN	B-NP	O
suggest	VBP	B-VP	O
common	JJ	B-NP	O
mechanisms	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
differences	NNS	B-NP	O
in	IN	B-PP	O
latency	NN	B-NP	O
,	,	I-NP	O
rigidity	NN	I-NP	B
and	CC	I-NP	O
behavior	NN	I-NP	O
,	,	O	O
asymmetry	NN	B-NP	O
of	IN	B-PP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
tolerance	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
widely	RB	I-NP	O
-	HYPH	I-NP	O
different	JJ	I-NP	O
ID50	NN	I-NP	O
for	IN	B-PP	O
naloxone	NN	B-NP	O
would	MD	B-VP	O
argue	VB	I-VP	O
against	IN	B-PP	O
an	DT	B-NP	O
action	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
opioid	JJ	I-NP	O
site	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
AIDS	NN	B-NP	B
on	IN	B-PP	O
tenofovir	NN	B-NP	O
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
prolonged	VBN	B-NP	O
vancomycin	NN	I-NP	O
course	NN	I-NP	O
for	IN	B-PP	O
osteomyelitis	NN	B-NP	B
.	.	O	O

Renal	JJ	B-NP	B
failure	NN	I-NP	I
developed	VBD	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
prolonged	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
vancomycin	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
tenofovir	NN	B-NP	O
disoproxil	NN	I-NP	O
fumarate	NN	I-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
antiretroviral	JJ	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

Tenofovir	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
Fanconi	NNP	B-NP	B
syndrome	NN	I-NP	I
and	CC	O	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
proximal	JJ	I-NP	O
renal	JJ	I-NP	O
tubule	NN	I-NP	O
.	.	O	O

Vancomycin	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
infrequent	JJ	B-ADJP	O
but	CC	O	O
may	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
coadministration	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
nephrotoxic	JJ	I-NP	B
agent	NN	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
that	DT	B-NP	O
tenofovir	NN	I-NP	O
may	MD	B-VP	O
raise	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
during	IN	B-PP	O
prolonged	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
vancomycin	NN	B-NP	O
.	.	O	O

Delayed	VBN	B-NP	O
leukoencephalopathy	NN	I-NP	B
with	IN	B-PP	O
stroke	NN	B-NP	B
-	HYPH	O	O
like	JJ	B-NP	O
presentation	NN	I-NP	O
in	IN	B-PP	O
chemotherapy	NN	B-NP	O
recipients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
transient	JJ	I-NP	O
leukoencephalopathy	NN	I-NP	B
mimicking	VBG	B-VP	O
cerebrovascular	JJ	B-NP	B
accident	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
,	,	O	O
most	RBS	B-ADVP	O
commonly	RB	I-ADVP	O
in	IN	B-PP	O
recipients	NNS	B-NP	O
of	IN	B-PP	O
intrathecal	JJ	B-NP	O
methotrexate	NN	I-NP	O
for	IN	B-PP	O
childhood	NN	B-NP	O
leukaemia	NN	I-NP	B
.	.	O	O

Recently	RB	B-NP	O
published	VBN	I-NP	O
neuroimaging	NN	I-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
pathophysiology	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
agents	NNS	I-NP	O
and	CC	O	O
modes	NNS	B-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
reviewed	VBD	B-VP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
literature	NN	I-NP	O
for	IN	B-PP	O
single	JJ	B-NP	O
reports	NNS	I-NP	O
and	CC	O	O
case	NN	O	O
series	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
presenting	VBG	B-VP	O
with	IN	B-PP	O
stroke	NN	B-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
episodes	NNS	I-NP	O
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
systemic	JJ	B-NP	O
or	CC	I-NP	O
intrathecal	JJ	I-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
only	RB	B-ADVP	O
included	VBD	B-VP	O
studies	NNS	B-NP	O
providing	VBG	B-VP	O
detailed	JJ	B-NP	O
neuroimaging	NN	I-NP	O
data	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
cerebrovascular	JJ	B-NP	B
accidents	NNS	I-NP	I
were	VBD	B-VP	O
excluded	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
identified	VBD	B-VP	O
num	CD	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
toxic	JJ	B-NP	O
leukoencephalopathy	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
methotrexate	NN	B-NP	O
(	(	O	O
intrathecal	JJ	B-ADJP	O
,	,	O	O
systemic	JJ	B-ADVP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
derivative	JJ	I-NP	O
carmofur	NN	I-NP	O
,	,	O	O
and	CC	O	O
capecitabine	NN	B-NP	O
.	.	O	O

Diffusion	NN	B-NP	O
weighted	VBD	B-VP	O
imaging	NN	B-NP	O
(	(	O	O
DWI	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
revealed	VBD	B-VP	O
well	RB	B-NP	O
demarcated	VBN	I-NP	O
hyperintense	JJ	I-NP	O
lesions	NNS	I-NP	B
within	IN	B-PP	I
the	DT	B-NP	I
subcortical	JJ	I-NP	I
white	JJ	I-NP	I
matter	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
cerebral	JJ	I-NP	O
hemispheres	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
corpus	NN	I-NP	O
callosum	NN	I-NP	O
,	,	O	O
corresponding	VBG	B-VP	O
to	TO	B-PP	O
areas	NNS	B-NP	O
of	IN	B-PP	O
decreased	VBN	B-NP	O
proton	NN	I-NP	O
diffusion	NN	I-NP	O
on	IN	B-PP	O
apparent	JJ	B-NP	O
diffusion	NN	I-NP	O
coefficient	NN	I-NP	O
(	(	O	O
ADC	NN	B-NP	O
)	)	O	O
maps	NNS	B-NP	O
(	(	O	O
available	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
)	)	O	O
.	.	O	O

Lesions	NNS	B-NP	O
exceeded	VBD	B-VP	O
the	DT	B-NP	O
confines	NNS	I-NP	O
of	IN	B-PP	O
adjacent	JJ	B-NP	O
vascular	JJ	I-NP	O
territories	NNS	I-NP	O
.	.	O	O

Complete	JJ	B-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
normalisation	NN	B-NP	O
of	IN	B-PP	O
ADC	NN	B-NP	O
abnormalities	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
fluid	NN	B-NP	O
attenuated	VBD	B-VP	O
inversion	NN	B-NP	O
recovery	NN	I-NP	O
(	(	O	O
FLAIR	NN	B-NP	O
)	)	O	O
sequences	NNS	B-NP	O
frequently	RB	B-ADVP	O
revealed	VBD	B-VP	O
persistent	JJ	B-NP	O
white	JJ	I-NP	B
matter	NN	I-NP	I
abnormalities	NNS	I-NP	I
.	.	O	O

Several	JJ	B-NP	O
pathophysiological	JJ	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
delayed	VBN	B-NP	O
leukoencephalopathy	NN	I-NP	B
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
intrathecal	JJ	B-NP	O
or	CC	I-NP	O
systemic	JJ	I-NP	O
chemotherapy	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
.	.	O	O

DWI	NN	B-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
cohort	NN	I-NP	O
are	VBP	B-VP	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
cytotoxic	JJ	B-NP	B
oedema	NN	I-NP	I
within	IN	B-PP	I
cerebral	JJ	B-NP	I
white	JJ	I-NP	I
matter	NN	I-NP	I
and	CC	O	O
lend	NN	B-NP	O
support	NN	I-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
at	IN	I-NP	O
least	JJS	I-NP	O
partially	RB	I-NP	O
reversible	JJ	I-NP	O
metabolic	JJ	I-NP	O
derangement	NN	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
.	.	O	O

Down	RB	B-ADVP	O
-	HYPH	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
transporter	NN	I-NP	O
function	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
linking	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
alteration	NN	I-NP	O
of	IN	B-PP	O
sensitivity	NN	B-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
-	HYPH	I-NP	O
anesthetics	NNS	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
and	CC	O	O
the	DT	B-NP	O
counteraction	NN	I-NP	O
by	IN	B-PP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
with	IN	B-PP	O
local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
.	.	O	O

Alterations	NNS	B-NP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
transporter	NN	I-NP	O
(	(	O	O
NET	NN	B-NP	O
)	)	O	O
function	NN	B-NP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
NET	NN	B-NP	O
in	IN	B-PP	O
relation	NN	B-NP	O
to	TO	B-PP	O
sensitization	NN	B-NP	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
induce	VBP	B-VP	O
by	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	O	O
local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Daily	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
NET	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
decreased	VBD	B-VP	O
[	(	O	O
H	NN	B-NP	O
]	)	I-NP	O
norepinephrine	NN	I-NP	O
uptake	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
P2	NN	I-NP	O
fractions	NNS	I-NP	O
of	IN	B-PP	O
hippocampus	NN	B-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
cortex	NN	B-NP	O
,	,	O	O
striatum	NN	B-NP	O
or	CC	I-NP	O
amygdalae	NN	I-NP	O
.	.	O	O

Co	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	B-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
,	,	O	O
bupivacaine	NN	B-NP	O
or	CC	O	O
tricaine	NN	B-NP	O
with	IN	B-PP	O
desipramine	NN	B-NP	O
reversed	VBD	B-VP	O
this	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

Daily	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
increased	VBD	B-VP	O
[	(	O	O
H	NN	B-NP	O
]	)	I-NP	O
norepinephrine	NN	I-NP	O
uptake	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
.	.	O	O

Daily	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
appearance	NN	B-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
and	CC	O	O
decreased	VBD	B-VP	O
that	DT	B-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

Co	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	B-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
with	IN	B-PP	O
desipramine	NN	B-NP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
convulsive	JJ	B-NP	B
activity	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
and	CC	I-NP	O
cocaine	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
repeated	VBN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-ADVP	O
down	RB	I-ADVP	O
-	HYPH	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
hippocampal	JJ	B-NP	O
NET	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
desipramine	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
relevant	JJ	B-ADJP	O
to	TO	B-PP	O
desipramine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
sensitization	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

Inhibition	NN	B-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
channels	NNS	I-NP	O
by	IN	B-PP	O
local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
may	MD	B-VP	O
regulate	VB	I-VP	O
desipramine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
down	RB	B-ADVP	O
-	HYPH	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
NET	NN	B-NP	O
function	NN	I-NP	O
.	.	O	O

Repeated	VBN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
induces	VBZ	B-VP	O
up	RB	B-ADVP	O
-	HYPH	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
hippocampal	JJ	B-NP	O
NET	NN	I-NP	O
function	NN	I-NP	O
.	.	O	O

Desipramine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
sensitization	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
seizures	NNS	I-NP	B
may	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
mechanism	NN	I-NP	O
distinct	JJ	B-ADJP	O
from	IN	B-PP	O
kindling	VBG	B-VP	O
resulting	VBG	B-VP	O
from	IN	B-PP	O
repeated	VBN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Definition	NN	B-NP	O
and	CC	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
anemia	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
infected	VBN	B-VP	B
with	IN	B-PP	I
hepatitis	NN	B-NP	I
C	NN	I-NP	I
virus	NN	I-NP	I
.	.	O	O

Chronic	JJ	B-NP	B
infection	NN	I-NP	I
with	IN	B-PP	I
hepatitis	NN	B-NP	I
C	NN	I-NP	I
virus	NN	I-NP	I
(	(	O	O
HCV	NN	B-NP	O
)	)	O	O
can	MD	B-VP	O
progress	VB	I-VP	O
to	TO	B-PP	O
cirrhosis	NN	B-NP	B
,	,	O	O
hepatocellular	JJ	B-NP	B
carcinoma	NN	I-NP	I
,	,	O	O
and	CC	O	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
liver	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
best	JJS	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
HCV	NN	B-NP	B
infection	NN	I-NP	I
is	VBZ	B-VP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
this	DT	B-NP	O
regimen	NN	I-NP	O
produces	VBZ	B-VP	O
sustained	JJ	B-NP	O
virologic	JJ	I-NP	O
responses	NNS	I-NP	O
(	(	O	O
SVRs	NNS	B-NP	O
)	)	O	O
in	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
it	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
.	.	O	O

Hemoglobin	NN	B-NP	O
concentrations	NNS	I-NP	O
decrease	VBP	B-VP	O
mainly	RB	B-ADVP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolysis	NN	I-NP	B
,	,	O	O
and	CC	O	O
this	DT	B-NP	O
anemia	NN	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
problematic	JJ	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
HCV	NN	B-NP	B
infection	NN	I-NP	I
,	,	O	O
especially	RB	B-ADVP	O
those	DT	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
comorbid	VBN	I-VP	O
renal	JJ	B-NP	B
or	CC	I-NP	I
cardiovascular	JJ	I-NP	I
disorders	NNS	I-NP	I
.	.	O	O

In	IN	B-PP	O
general	JJ	B-ADJP	O
,	,	O	O
anemia	NN	B-NP	B
can	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
morbidity	NN	B-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
have	VB	I-VP	O
negative	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
cerebral	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
quality	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
ribavirin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
anemia	NN	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
or	CC	I-NP	O
discontinuation	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
approach	NN	I-NP	O
compromises	VBZ	B-VP	O
outcomes	NNS	B-NP	O
by	IN	B-PP	O
significantly	RB	B-VP	O
decreasing	VBG	I-VP	O
SVR	NN	B-NP	O
rates	NNS	I-NP	O
.	.	O	O

Recombinant	JJ	B-NP	O
human	JJ	I-NP	O
erythropoietin	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
to	TO	I-VP	O
manage	VB	I-VP	O
ribavirin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
anemia	NN	I-NP	B
but	CC	O	O
has	VBZ	B-VP	O
other	JJ	B-NP	O
potential	JJ	I-NP	O
disadvantages	NNS	I-NP	O
.	.	O	O

Viramidine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
liver	NN	I-NP	O
-	HYPH	O	O
targeting	VBG	B-VP	O
prodrug	NN	B-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
,	,	O	O
has	VBZ	B-VP	O
the	DT	B-NP	O
potential	NN	I-NP	O
to	TO	B-VP	O
maintain	VB	I-VP	O
the	DT	B-NP	O
virologic	JJ	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
while	IN	B-SBAR	O
decreasing	VBG	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
.	.	O	O

Calcium	NN	B-NP	O
carbonate	NN	I-NP	O
toxicity	NN	I-NP	B
:	:	O	O
the	DT	B-NP	O
updated	VBN	I-NP	O
milk	NN	I-NP	B
-	HYPH	I-NP	I
alkali	JJ	I-NP	I
syndrome	NN	I-NP	I
;	:	O	O
report	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
describe	VB	I-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
calcium	NN	B-NP	O
carbonate	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypercalcemia	NN	I-NP	B
and	CC	I-NP	O
gain	NN	I-NP	O
insights	NNS	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
cause	NN	I-NP	O
and	CC	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
milk	NN	I-NP	B
-	HYPH	B-NP	I
alkali	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
data	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
hypercalcemia	NN	I-NP	B
and	CC	O	O
review	VB	B-VP	O
the	DT	B-NP	O
pertinent	JJ	I-NP	O
literature	NN	I-NP	O
on	IN	B-PP	O
milk	NN	B-NP	B
-	HYPH	B-NP	I
alkali	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
,	,	O	O
relative	JJ	B-NP	O
metabolic	JJ	I-NP	B
alkalosis	NN	I-NP	I
,	,	O	O
and	CC	O	O
low	JJ	B-NP	O
parathyroid	NN	I-NP	O
hormone	NN	I-NP	O
(	(	O	O
PTH	NN	B-NP	O
)	)	O	O
,	,	O	O
PTH	NN	B-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
peptide	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dihydroxyvitamin	NN	I-NP	O
D	NN	I-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
malignant	JJ	I-NP	O
lesion	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Treatment	NN	B-NP	O
included	VBD	B-VP	O
aggressive	JJ	B-NP	O
hydration	NN	I-NP	O
and	CC	O	O
varied	VBD	B-VP	O
amounts	NNS	B-NP	O
of	IN	B-PP	O
furosemide	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
serum	NN	I-NP	O
calcium	NN	I-NP	O
concentrations	NNS	I-NP	O
received	VBD	B-VP	O
pamidronate	NN	B-NP	O
intravenously	RB	B-ADVP	O
,	,	O	O
which	WDT	B-NP	O
caused	VBD	B-VP	O
severe	JJ	B-NP	O
hypocalcemia	NN	I-NP	B
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
ingesting	VBG	I-VP	O
acceptable	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
elemental	JJ	B-NP	O
calcium	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
daily	RB	B-ADVP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
carbonate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
highlighted	JJ	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
review	VBP	B-VP	O
the	DT	B-NP	O
history	NN	I-NP	O
,	,	O	O
classification	NN	B-NP	O
,	,	O	O
pathophysiologic	JJ	B-NP	O
features	NNS	I-NP	O
,	,	O	O
and	CC	O	O
treatment	NN	B-NP	O
of	IN	B-PP	O
milk	NN	B-NP	B
-	HYPH	B-NP	I
alkali	NN	I-NP	I
syndrome	NN	I-NP	I
and	CC	O	O
summarize	VB	B-VP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
reported	VBN	B-VP	O
from	IN	B-PP	O
early	RB	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

Milk	NN	B-NP	B
-	HYPH	I-NP	I
alkali	JJ	I-NP	I
syndrome	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
unexplained	JJ	B-NP	O
hypercalcemia	NN	I-NP	B
and	CC	O	O
can	MD	B-VP	O
be	VB	I-VP	O
precipitated	VBN	I-VP	O
by	IN	B-PP	O
small	JJ	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
orally	RB	B-NP	O
ingested	VBN	I-NP	O
calcium	NN	I-NP	O
carbonate	NN	I-NP	O
in	IN	B-PP	O
susceptible	JJ	B-NP	O
persons	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
hydration	NN	B-NP	O
,	,	O	O
furosemide	NN	B-NP	O
,	,	O	O
and	CC	O	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
calcium	NN	I-NP	O
and	CC	I-NP	O
vitamin	NN	I-NP	O
D	NN	I-NP	O
source	NN	I-NP	O
is	VBZ	B-VP	O
adequate	JJ	B-ADJP	O
.	.	O	O

Pamidronate	NN	B-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
considerable	JJ	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
hypocalcemia	NN	B-NP	B
,	,	O	O
even	RB	B-ADVP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
initially	RB	B-NP	O
severe	JJ	I-NP	O
hypercalcemia	NN	I-NP	B
.	.	O	O

Management	NN	B-NP	O
strategies	NNS	I-NP	O
for	IN	B-PP	O
ribavirin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
C	NN	I-NP	I
:	:	O	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
economic	JJ	I-NP	O
implications	NNS	I-NP	O
.	.	O	O

Recently	RB	B-NP	O
published	VBN	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
increased	VBN	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
cost	NN	I-NP	O
-	HYPH	O	O
effectiveness	NN	B-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
interferon	NN	B-NP	O
and	CC	O	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
2b	NN	I-NP	O
/	SYM	I-NP	O
ribavirin	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
interferon	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	O	O
monotherapy	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
(	(	O	O
CHC	NN	B-NP	B
)	)	O	O
.	.	O	O

Combination	NN	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
clinically	RB	I-NP	O
important	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
:	:	O	O
ribavirin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
(	(	O	O
RIHA	NN	B-NP	B
)	)	O	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
direct	JJ	I-NP	O
health	NN	I-NP	O
-	HYPH	I-NP	O
care	NN	I-NP	O
costs	NNS	I-NP	O
and	CC	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
RIHA	NN	B-NP	B
during	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
CHC	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
setting	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
systematic	JJ	I-NP	O
literature	NN	I-NP	O
review	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
to	TO	I-VP	O
synthesize	VB	I-VP	O
information	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
RIHA	NN	B-NP	B
.	.	O	O

Decision	NN	B-NP	O
-	HYPH	I-NP	O
analytic	JJ	I-NP	O
techniques	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
cost	NN	I-NP	O
of	IN	B-PP	O
treating	VBG	B-VP	O
RIHA	NN	B-NP	B
.	.	O	O

Uncertainty	NN	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
using	VBG	B-VP	O
sensitivity	NN	B-NP	O
analyses	NNS	I-NP	O
.	.	O	O

RIHA	NN	B-NP	B
,	,	O	O
defined	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
hemoglobin	NN	B-NP	O
to	TO	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
,	,	O	O
occurs	VBZ	B-VP	O
in	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
standard	NN	I-NP	O
of	IN	B-PP	O
care	NN	B-NP	O
for	IN	B-PP	O
management	NN	B-NP	O
of	IN	B-PP	O
RIHA	NN	B-NP	B
is	VBZ	B-VP	O
reduction	NN	B-NP	O
or	CC	I-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ribavirin	NN	I-NP	O
dosage	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
estimated	VBD	B-VP	O
the	DT	B-NP	O
direct	JJ	I-NP	O
cost	NN	I-NP	O
of	IN	B-PP	O
treating	VBG	B-VP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
RIHA	NN	I-NP	B
to	TO	B-VP	O
be	VB	I-VP	O
num	CD	B-NP	O
per	IN	B-PP	O
patient	NN	B-NP	O
receiving	VBG	B-VP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
per	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	B-NP	O
week	NN	I-NP	O
treatment	NN	I-NP	O
course	NN	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
way	NN	I-NP	O
sensitivity	NN	I-NP	O
analyses	NNS	I-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

In	IN	B-PP	O
comparison	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
cost	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
direct	JJ	I-NP	O
cost	NN	I-NP	O
of	IN	B-PP	O
treating	VBG	B-VP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
RIHA	NN	I-NP	B
is	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
costs	NNS	I-NP	O
.	.	O	O

Questions	NNS	B-NP	O
remain	VBP	B-VP	O
about	IN	B-PP	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
RIHA	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
real	JJ	I-NP	O
-	HYPH	I-NP	O
world	NN	I-NP	O
population	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
these	DT	B-NP	O
uncertainties	NNS	I-NP	O
,	,	O	O
this	DT	B-NP	O
initial	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
direct	JJ	I-NP	O
cost	NN	I-NP	O
of	IN	B-PP	O
treating	VBG	B-VP	O
RIHA	NNP	B-NP	B
provides	VBZ	B-VP	O
an	DT	B-NP	O
estimate	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cost	NN	I-NP	O
and	CC	I-NP	O
management	NN	I-NP	O
implications	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
clinically	RB	I-NP	O
important	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
amine	NN	B-NP	O
pretreatment	NN	I-NP	O
on	IN	B-PP	O
ketamine	NN	B-NP	O
catatonia	NN	I-NP	B
in	IN	B-PP	O
pinealectomized	VBN	B-NP	O
or	CC	I-NP	O
hypophysectomized	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
clarify	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
catecholamines	NNS	B-NP	O
and	CC	O	O
pineal	JJ	B-NP	O
idolamines	NNS	I-NP	O
on	IN	B-PP	O
ketamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catatonia	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
intact	JJ	I-NP	O
,	,	I-NP	O
pinealectomized	VBN	I-NP	O
or	CC	I-NP	O
hypophysectomized	VBN	I-NP	O
chick	NN	I-NP	O
and	CC	I-NP	O
rat	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
pinealectomized	VBN	I-NP	O
chick	NN	I-NP	O
,	,	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
dopamine	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
catatonia	NN	B-NP	B
(	(	O	O
DOC	NN	B-NP	O
)	)	O	O
after	IN	B-PP	O
ketamine	NN	B-NP	O
,	,	O	O
but	CC	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
norepinephrine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	O	O
.	.	O	O

The	DT	B-NP	O
pineal	JJ	I-NP	O
indolamines	NNS	I-NP	O
exhibited	VBD	B-VP	O
mixed	JJ	B-NP	O
actions	NNS	I-NP	O
.	.	O	O

Serotonin	NN	B-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
serotonin	NN	I-NP	O
which	WDT	B-NP	O
augmented	VBD	B-VP	O
ketamine	NN	B-NP	O
DOC	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
do	VB	I-VP	O
so	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pineal	JJ	I-NP	O
gland	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
melatonin	NN	B-NP	O
potentiated	VBD	B-VP	O
the	DT	B-NP	O
ketamine	NN	I-NP	O
DOC	NN	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
intact	JJ	I-NP	O
and	CC	I-NP	O
pinealectomized	VBN	I-NP	O
chick	NN	I-NP	O
.	.	O	O

Ketamine	NN	B-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
potent	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
hypophysectomized	VBN	I-NP	O
chick	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
circadian	JJ	I-NP	O
rhythm	NN	I-NP	O
noted	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
intact	JJ	I-NP	O
chick	NN	I-NP	O
was	VBD	B-VP	O
absent	JJ	B-ADJP	O
;	:	O	O
furthermore	RB	B-ADVP	O
,	,	O	O
melatonin	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
augment	VB	I-VP	O
the	DT	B-NP	O
ketamine	NN	I-NP	O
DOC	NN	I-NP	O
whereas	IN	B-PP	O
dopamine	NN	B-NP	O
continued	VBD	B-VP	O
to	TO	I-VP	O
do	VB	I-VP	O
so	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
demonstrate	VB	I-VP	O
a	DT	B-NP	O
species	NN	I-NP	O
difference	NN	I-NP	O
regarding	VBG	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
amines	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
pineal	NN	I-NP	O
in	IN	B-PP	O
spite	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
immature	JJ	I-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
young	JJ	I-NP	O
chick	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
intact	JJ	I-NP	O
barrier	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
these	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pituitary	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
augmentation	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
DOC	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
melatonin	NN	B-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
dopamine	NN	B-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
act	VB	I-VP	O
on	IN	B-PP	O
systems	NNS	B-NP	O
more	RBR	B-VP	O
closely	RB	I-VP	O
involved	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
catatonia	NN	I-NP	B
rather	RB	B-PP	O
than	IN	I-PP	O
directly	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
pituitary	NN	I-NP	O
.	.	O	O

Multicenter	JJ	B-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
multiple	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
,	,	O	O
parallel	JJ	B-NP	O
-	HYPH	I-NP	O
groups	NNS	I-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
azelastine	NN	B-NP	O
,	,	O	O
chlorpheniramine	NN	B-NP	O
,	,	O	O
and	CC	O	O
placebo	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
spring	NN	B-NP	B
allergic	JJ	I-NP	I
rhinitis	NN	I-NP	I
.	.	O	O

Azelastine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
novel	JJ	I-NP	O
antiallergic	JJ	I-NP	O
medication	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
chlorpheniramine	NN	B-NP	O
maleate	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
for	IN	B-PP	O
efficacy	NN	B-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
spring	NN	B-NP	B
allergic	JJ	I-NP	I
rhinitis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
multicenter	JJ	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
multiple	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
,	,	O	O
parallel	JJ	B-NP	O
-	HYPH	I-NP	O
groups	NNS	I-NP	O
study	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
participated	VBD	B-VP	O
.	.	O	O

Subjects	NNS	B-NP	O
ranged	VBD	B-VP	O
in	IN	B-PP	O
age	NN	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
and	CC	O	O
had	VBD	B-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
spring	NN	B-NP	B
allergic	JJ	I-NP	I
rhinitis	NN	I-NP	I
,	,	O	O
confirmed	VBN	B-VP	O
by	IN	B-PP	O
positive	JJ	B-NP	O
skin	NN	I-NP	O
test	NN	I-NP	O
to	TO	B-PP	O
spring	NN	B-NP	O
aeroallergens	NNS	I-NP	O
.	.	O	O

Medications	NNS	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
daily	RB	I-NP	O
;	:	O	O
the	DT	B-NP	O
azelastine	NN	I-NP	O
groups	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
morning	NN	I-NP	O
and	CC	I-NP	O
evening	NN	I-NP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
and	CC	I-NP	O
late	JJ	I-NP	O
afternoon	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
chlorpheniramine	NN	I-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
daily	RB	I-NP	O
.	.	O	O

Daily	JJ	B-NP	O
subject	NN	I-NP	O
symptom	NN	I-NP	O
cards	NNS	I-NP	O
were	VBD	B-VP	O
completed	VBN	I-VP	O
during	IN	B-PP	O
a	DT	B-NP	O
screening	NN	I-NP	O
period	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
pretreatment	NN	B-NP	O
symptoms	NNS	I-NP	O
and	CC	B-PP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
treatment	NN	I-NP	O
period	NN	I-NP	O
while	IN	B-SBAR	O
subjects	NNS	B-NP	O
received	VBD	B-VP	O
study	NN	B-NP	O
medications	NNS	I-NP	O
.	.	O	O

Individual	JJ	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
total	JJ	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
and	CC	O	O
major	JJ	B-NP	O
symptoms	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
efficacy	NN	B-NP	O
of	IN	B-PP	O
medication	NN	B-NP	O
.	.	O	O

Elicited	VBN	B-VP	O
,	,	O	O
volunteered	VBN	B-VP	O
,	,	O	O
and	CC	O	O
observed	VBD	B-VP	O
adverse	JJ	B-NP	O
experiences	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
for	IN	B-PP	O
each	DT	B-NP	O
subject	NN	I-NP	O
and	CC	O	O
compared	VBN	B-VP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

Vital	JJ	B-NP	O
signs	NNS	I-NP	O
,	,	O	O
body	NN	B-NP	O
weights	NNS	I-NP	O
,	,	O	O
serum	NN	B-NP	O
chemistry	NN	I-NP	O
values	NNS	I-NP	O
,	,	O	O
complete	JJ	B-NP	O
blood	NN	I-NP	O
cell	NN	I-NP	O
counts	NNS	I-NP	O
,	,	O	O
urine	NN	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
and	CC	O	O
electrocardiograms	NNS	B-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
for	IN	B-PP	O
each	DT	B-NP	O
subject	NN	I-NP	O
and	CC	O	O
compared	VBN	B-VP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

Symptoms	NNS	B-NP	O
relief	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
receiving	VBG	B-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
azelastine	NN	B-NP	O
was	VBD	B-VP	O
statistically	RB	B-ADJP	O
greater	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
during	IN	B-PP	O
all	DT	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Lower	JJR	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
azelastine	NN	B-NP	O
were	VBD	B-VP	O
statistically	RB	B-ADJP	O
more	RBR	I-ADJP	O
effective	JJ	I-ADJP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
only	RB	B-ADVP	O
during	IN	B-PP	O
portions	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
chlorpheniramine	NN	I-NP	O
group	NN	I-NP	O
did	VBD	B-VP	O
have	VB	I-VP	O
fewer	JJR	B-NP	O
symptoms	NNS	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
difference	NN	I-NP	O
never	RB	B-ADVP	O
reached	VBD	B-VP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
during	IN	B-PP	O
any	DT	B-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
serious	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Drowsiness	NN	B-NP	B
and	CC	I-NP	O
altered	JJ	I-NP	B
taste	NN	I-NP	I
perception	NN	I-NP	I
were	VBD	B-VP	O
increased	VBN	I-VP	O
significantly	RB	B-ADVP	O
over	IN	B-PP	O
placebo	NN	B-NP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
azelastine	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Azelastine	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
,	,	I-NP	O
efficacious	JJ	I-NP	O
medication	NN	I-NP	O
for	IN	B-PP	O
seasonal	JJ	B-NP	B
allergic	JJ	I-NP	I
rhinitis	NN	I-NP	I
.	.	O	O

Obsolete	JJ	B-NP	O
but	CC	I-NP	O
dangerous	JJ	I-NP	O
antacid	NN	I-NP	O
preparations	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
hypercalcaemia	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
recurrent	JJ	B-NP	O
nephrolithiasis	NN	I-NP	B
are	VBP	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
regularly	RB	I-VP	O
consumed	VBN	I-VP	O
large	JJ	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
carbon	NN	I-NP	O
-	HYPH	B-NP	O
ate	NN	I-NP	O
-	HYPH	B-NP	O
sodium	NN	I-NP	O
bicarbonate	NN	I-NP	O
powders	NNS	I-NP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
powders	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
pharmacists	NNS	B-NP	O
unknown	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
s	VBZ	B-VP	O
medical	JJ	B-NP	O
practitioners	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
preparations	NNS	I-NP	O
were	VBD	B-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
problems	NNS	B-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
such	JJ	B-NP	O
powders	NNS	I-NP	O
should	MD	B-VP	O
no	RB	I-VP	O
longer	RB	I-VP	O
be	VB	I-VP	O
freely	RB	B-ADJP	O
obtainable	JJ	I-ADJP	O
.	.	O	O

Prolonged	JJ	B-NP	O
paralysis	NN	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
nondepolarizing	VBG	B-VP	O
neuromuscular	JJ	B-NP	O
blocking	VBG	I-NP	O
agents	NNS	I-NP	O
and	CC	I-NP	O
corticosteroids	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
nondepolarizing	VBG	B-VP	O
neuromuscular	JJ	B-NP	O
blocking	VBG	I-NP	O
agents	NNS	I-NP	O
(	(	O	O
ND	NN	B-NP	O
-	HYPH	B-NP	O
NMBA	NN	I-NP	O
)	)	O	O
has	VBZ	B-VP	O
recently	RB	I-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
prolonged	VBN	B-NP	O
muscle	NN	I-NP	B
weakness	NN	I-NP	I
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lesion	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
predisposing	VBG	I-NP	O
factors	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
age	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
acute	JJ	B-NP	O
respiratory	JJ	I-NP	B
insufficiency	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
prolonged	VBN	I-VP	O
weakness	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
ND	NN	B-NP	O
-	HYPH	B-NP	O
NMBAs	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
intravenous	JJ	B-NP	O
corticosteroids	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-NP	O
but	CC	I-NP	O
hepatic	JJ	I-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
impaired	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
all	DT	B-NP	O
had	VBD	B-VP	O
acidosis	NN	B-NP	B
.	.	O	O

Electrophysiologic	JJ	B-NP	O
studies	NNS	I-NP	O
revealed	VBD	B-VP	O
low	JJ	B-NP	O
amplitude	NN	I-NP	O
compound	NN	I-NP	O
motor	NN	I-NP	O
action	NN	I-NP	O
potentials	NNS	I-NP	O
,	,	O	O
normal	JJ	B-NP	O
sensory	JJ	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
and	CC	O	O
fibrillations	NNS	B-NP	O
.	.	O	O

Repetitive	JJ	B-NP	O
stimulation	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
Hz	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
decremental	JJ	I-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
vecuronium	NN	I-NP	O
level	NN	I-NP	O
measured	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
discontinued	VBN	I-VP	O
was	VBD	B-VP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
muscle	NN	I-NP	O
biopsy	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
showed	VBD	B-VP	O
loss	NN	B-NP	B
of	IN	B-PP	I
thick	JJ	B-NP	I
,	,	I-NP	I
myosin	NN	I-NP	I
filaments	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
weakness	NN	I-NP	B
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
is	VBZ	B-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
pathology	NN	B-NP	B
at	IN	B-PP	I
both	CC	O	I
the	DT	B-NP	I
neuromuscular	JJ	I-NP	I
junction	NN	I-NP	I
(	(	O	O
most	RBS	B-ADVP	O
likely	RB	I-ADVP	O
due	IN	B-PP	O
to	TO	B-PP	O
ND	NN	B-NP	O
-	HYPH	I-NP	O
NMBA	NN	I-NP	O
)	)	O	O
and	CC	O	O
muscle	NN	B-NP	O
(	(	O	O
most	RBS	B-ADVP	O
likely	RB	I-ADVP	O
due	IN	B-PP	O
to	TO	B-PP	O
corticosteroids	NNS	B-NP	O
)	)	O	O
.	.	O	O

Hepatic	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	I-NP	O
acidosis	NN	I-NP	B
are	VBP	B-VP	O
contributing	VBG	I-VP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
.	.	O	O

Prostaglandin	NN	B-NP	O
E2	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
bladder	NN	I-NP	B
hyperactivity	NN	I-NP	I
in	IN	B-PP	O
normal	JJ	B-NP	O
,	,	I-NP	O
conscious	JJ	I-NP	O
rats	NNS	I-NP	O
:	:	O	O
involvement	NN	B-NP	O
of	IN	B-PP	O
tachykinins	NNS	B-NP	O
?	.	O	O
In	IN	B-PP	O
normal	JJ	B-NP	O
conscious	JJ	I-NP	O
rats	NNS	I-NP	O
investigated	VBN	B-VP	O
by	IN	B-PP	O
continuous	JJ	B-NP	O
cystometry	NN	I-NP	O
,	,	O	O
intravesically	RB	B-VP	O
instilled	VBN	I-VP	O
prostaglandin	NN	B-NP	O
(	(	O	O
PG	NN	B-NP	O
)	)	O	O
E2	NN	B-NP	O
facilitated	VBD	B-VP	O
micturition	NN	B-NP	O
and	CC	O	O
increased	VBD	B-VP	O
basal	JJ	B-NP	O
intravesical	JJ	I-NP	O
pressure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
attenuated	VBN	I-VP	O
by	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
NK1	NN	I-NP	O
receptor	NN	I-NP	O
selective	JJ	I-NP	O
antagonist	NN	I-NP	O
RP	NN	I-NP	O
num	CD	I-NP	O
and	CC	O	O
the	DT	B-NP	O
NK2	NN	I-NP	O
receptor	NN	I-NP	O
selective	JJ	I-NP	O
antagonist	NN	I-NP	O
SR	NN	I-NP	O
num	CD	I-NP	O
given	VBN	B-VP	O
intra	AFX	O	O
-	HYPH	O	O
arterially	RB	B-ADVP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
was	VBD	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
stimulation	NN	B-NP	O
of	IN	B-PP	O
both	CC	O	O
NK1	NN	B-NP	O
and	CC	I-NP	O
NK2	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Intra	AFX	B-NP	O
-	HYPH	B-VP	O
arterially	RB	B-NP	O
given	VBN	I-NP	O
PGE2	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
distinct	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
bladder	NN	B-NP	O
pressure	NN	I-NP	O
before	IN	B-PP	O
initiating	VBG	B-VP	O
a	DT	B-NP	O
micturition	NN	I-NP	O
reflex	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
PG	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
contractant	NN	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
detrusor	NN	I-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	I-NP	O
PGE2	NN	I-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	I-NP	O
RP	NN	I-NP	O
num	CD	I-NP	O
or	CC	O	O
SR	NN	B-NP	O
num	CD	I-NP	O
which	WDT	B-NP	O
opens	VBZ	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
micturition	NN	I-NP	O
reflex	NN	I-NP	O
elicited	VBN	B-VP	O
by	IN	B-PP	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	I-NP	O
PGE2	NN	I-NP	O
was	VBD	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
pathways	NNS	B-NP	O
other	JJ	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
reflex	NN	I-NP	O
initiated	VBN	B-VP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
PG	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
intravesically	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
results	NNS	I-NP	O
thus	RB	B-ADVP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	I-NP	O
PGE2	NN	I-NP	O
,	,	O	O
given	VBN	B-PP	O
near	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
initiate	VB	I-VP	O
micturition	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
rat	NN	I-NP	O
chiefly	RB	B-ADVP	O
by	IN	B-PP	O
directly	RB	B-VP	O
contracting	VBG	I-VP	O
the	DT	B-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
detrusor	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
intravesically	RB	B-ADVP	O
,	,	O	O
PGE2	NN	B-NP	O
may	MD	B-VP	O
stimulate	VB	I-VP	O
micturition	NN	B-NP	O
by	IN	B-PP	O
releasing	VBG	B-VP	O
tachykinins	NNS	B-NP	O
from	IN	B-PP	O
nerves	NNS	B-NP	O
in	IN	B-PP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
immediately	RB	B-ADVP	O
below	IN	B-PP	O
the	DT	B-NP	O
urothelium	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
tachykinins	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
turn	NN	B-NP	O
,	,	O	O
initiate	VB	B-VP	O
a	DT	B-NP	O
micturition	NN	I-NP	O
reflex	NN	I-NP	O
by	IN	B-PP	O
stimulating	VBG	B-VP	O
NK1	NN	B-NP	O
and	CC	I-NP	O
NK2	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Prostanoids	NNS	B-NP	O
may	MD	B-VP	O
,	,	O	O
via	IN	B-PP	O
release	NN	B-NP	O
of	IN	B-PP	O
tachykinins	NNS	B-NP	O
,	,	O	O
contribute	VBP	B-VP	O
to	TO	B-PP	O
both	CC	O	O
urge	NN	B-NP	O
and	CC	I-NP	O
bladder	NN	I-NP	B
hyperactivity	NN	I-NP	I
seen	VBN	B-VP	O
in	IN	B-PP	O
inflammatory	JJ	B-NP	O
conditions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
urinary	JJ	I-NP	O
tract	NN	I-NP	O
.	.	O	O

Thiazide	NN	B-NP	O
diuretics	NNS	I-NP	O
,	,	O	O
hypokalemia	NN	B-NP	B
and	CC	O	O
cardiac	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O

Thiazide	NN	B-NP	O
diuretics	NNS	I-NP	O
are	VBP	B-VP	O
widely	RB	I-VP	O
accepted	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
cornerstone	NN	I-NP	O
of	IN	B-PP	O
antihypertensive	JJ	B-NP	O
treatment	NN	I-NP	O
programs	NNS	I-NP	O
.	.	O	O

Hypokalemia	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
commonly	RB	I-NP	O
encountered	VBN	I-NP	O
metabolic	JJ	I-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
thiazide	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
treated	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
low	JJ	I-NP	O
renin	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
normal	JJ	I-NP	O
renin	NN	I-NP	O
)	)	O	O
with	IN	B-PP	O
moderate	JJ	B-NP	O
diastolic	JJ	I-NP	B
hypertension	NN	I-NP	I
with	IN	B-PP	O
hydrochlorothiazide	NN	B-NP	O
(	(	O	O
HCTC	NN	B-NP	O
)	)	O	O
administered	VBN	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
twice	RB	I-NP	O
daily	JJ	I-NP	O
schedule	NN	I-NP	O
.	.	O	O

Initial	JJ	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
at	IN	B-PP	O
monthly	JJ	B-NP	O
intervals	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
daily	RB	B-ADVP	O
until	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
normalized	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
K	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
period	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mEq	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
an	DT	O	O
on	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
HCTZ	NN	I-NP	O
daily	RB	B-ADVP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mEq	NN	I-NP	O
/	SYM	O	O
l	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Corresponding	VBG	B-VP	O
figures	NNS	B-NP	O
for	IN	B-PP	O
whole	JJ	B-NP	O
body	NN	I-NP	O
K	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-ADJP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mEq	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
we	PRP	B-NP	O
observed	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
HCTZ	NN	B-NP	O
therapy	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
PVC	NN	B-NP	O
s	NNS	I-NP	O
during	IN	B-PP	O
rest	NN	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
during	IN	B-PP	O
static	JJ	B-NP	O
and	CC	I-NP	O
dynamic	JJ	I-NP	O
exercise	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
rest	NN	B-NP	O
we	PRP	B-NP	O
observed	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
PVC	NN	I-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
SEM	NN	B-NP	O
and	CC	B-PP	O
during	IN	B-PP	O
static	JJ	B-NP	O
and	CC	I-NP	O
dynamic	JJ	I-NP	O
exercise	NN	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Corresponding	VBG	B-VP	O
figures	NNS	B-NP	O
during	IN	B-PP	O
HCTZ	NN	B-NP	O
therapy	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
daily	RB	B-ADVP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
PVC	NN	B-NP	O
s	NNS	I-NP	O
correlated	VBD	B-VP	O
significantly	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
K	NN	I-NP	O
+	SYM	B-VP	O
observed	VBN	B-NP	O
r	NN	I-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
,	,	O	O
p	NN	B-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
we	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
thiazide	NN	B-NP	O
diuretics	NNS	I-NP	O
cause	VBP	B-VP	O
hypokalemia	NN	B-NP	B
and	CC	I-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
potassium	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
more	RBR	I-NP	O
profound	JJ	I-NP	O
hypokalemia	NN	I-NP	B
,	,	O	O
the	DT	O	O
greater	JJR	O	O
the	DT	B-NP	O
propensity	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
PVC	NN	B-NP	O
s	NNS	I-NP	O
.	.	O	O

Diuretics	NNS	B-NP	O
,	,	O	O
potassium	NN	B-NP	O
and	CC	I-NP	O
arrhythmias	NNS	I-NP	B
in	IN	B-PP	O
hypertensive	JJ	B-NP	B
coronary	JJ	I-NP	B
disease	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
that	IN	B-SBAR	O
modest	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
potassium	NN	I-NP	O
can	MD	B-VP	O
alter	VB	I-VP	O
the	DT	B-NP	O
tendency	NN	I-NP	O
towards	IN	B-PP	O
cardiac	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O

If	IN	B-SBAR	O
this	DT	B-NP	O
were	VBD	B-VP	O
so	RB	B-ADVP	O
,	,	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
might	MD	B-VP	O
be	VB	I-VP	O
especially	RB	B-ADJP	O
susceptible	JJ	I-ADJP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
myocardial	JJ	B-NP	O
electrical	JJ	I-NP	O
excitability	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mild	JJ	B-NP	O
essential	JJ	I-NP	O
hypertension	NN	I-NP	B
and	CC	O	O
known	VBN	B-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
potassium	NN	I-NP	O
-	HYPH	O	O
conserving	VBG	B-VP	O
diuretic	JJ	B-ADJP	O
(	(	O	O
amiloride	NN	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
similar	JJ	I-NP	O
period	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
potassium	NN	I-NP	O
-	HYPH	B-VP	O
losing	VBG	I-VP	O
diuretic	JJ	B-NP	O
(	(	O	O
chlorthalidone	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
randomised	VBN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
potassium	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
on	IN	B-PP	O
average	JJ	B-NP	O
num	CD	I-NP	O
mmol	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
lower	JJR	B-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
chlorthalidone	NN	I-NP	O
phase	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
amiloride	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
volume	NN	I-NP	O
states	NNS	I-NP	O
as	IN	B-SBAR	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
bodyweight	NN	B-NP	O
,	,	O	O
plasma	NN	B-NP	O
renin	NN	I-NP	O
and	CC	O	O
noradrenaline	NN	B-NP	O
(	(	O	O
norepinephrine	NN	B-NP	O
)	)	O	O
concentrations	NNS	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
regimens	NNS	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
to	TO	B-PP	O
amiloride	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
chlorthalidone	NN	I-NP	O
phase	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
ectopic	JJ	I-NP	I
beats	NNS	I-NP	I
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
Holter	NN	I-NP	O
monitoring	NN	I-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
higher	JJR	I-NP	O
Lown	JJ	I-NP	O
grading	NN	I-NP	O
,	,	O	O
increased	VBN	B-NP	O
upslope	NN	I-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
monophasic	JJ	I-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
,	,	O	O
prolonged	VBD	B-VP	O
ventricular	JJ	B-NP	O
effective	JJ	I-NP	O
refractory	JJ	I-NP	O
period	NN	I-NP	O
,	,	O	O
and	CC	O	O
increased	VBN	B-NP	O
electrical	JJ	I-NP	O
instability	NN	I-NP	O
during	IN	B-PP	O
programmed	VBN	B-NP	O
ventricular	JJ	I-NP	O
stimulation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
above	JJ	I-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
because	IN	B-SBAR	O
potassium	NN	B-NP	O
-	HYPH	B-VP	O
losing	VBG	I-VP	O
diuretic	JJ	B-NP	O
therapy	NN	I-NP	O
can	MD	B-VP	O
increase	VB	I-VP	O
myocardial	JJ	B-NP	O
electrical	JJ	I-NP	O
excitability	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
ischaemic	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
even	RB	B-NP	O
minor	JJ	I-NP	O
falls	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
potassium	NN	I-NP	O
concentrations	NNS	I-NP	O
are	VBP	B-VP	O
probably	RB	B-ADVP	O
best	RBS	B-VP	O
avoided	VBN	I-VP	O
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

GABA	NN	B-NP	O
involvement	NN	I-NP	O
in	IN	B-PP	O
naloxone	NN	B-NP	O
induced	VBD	B-VP	O
reversal	NN	B-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	B
paralysis	NN	I-NP	I
produced	VBN	B-VP	O
by	IN	B-PP	O
thiopental	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
agent	NN	I-NP	O
is	VBZ	B-VP	O
yet	RB	B-ADJP	O
available	JJ	I-ADJP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
respiratory	JJ	B-NP	B
paralysis	NN	I-NP	I
produced	VBN	B-VP	O
by	IN	B-PP	O
CNS	NN	B-NP	O
depressants	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
general	JJ	B-NP	O
anesthetics	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
naloxone	NN	I-NP	O
reversed	VBD	B-VP	O
respiratory	JJ	B-NP	B
paralysis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
thiopental	NN	B-NP	O
in	IN	B-PP	O
rats.	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
i.v.	JJ	B-NP	O
thiopental	NN	I-NP	O
produced	VBD	B-VP	O
anesthesia	NN	B-NP	O
without	IN	B-PP	O
altering	VBG	B-VP	O
respiratory	JJ	B-NP	O
rate	NN	I-NP	O
,	,	O	O
increased	VBN	B-NP	O
GABA	NN	I-NP	O
,	,	O	O
decreased	VBN	B-NP	O
glutamate	NN	I-NP	O
,	,	O	O
and	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
aspartate	NN	B-NP	O
or	CC	I-NP	O
glycine	NN	I-NP	O
levels	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
cortex	NN	I-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
stem	NN	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
thiosemicarbazide	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
abolished	VBD	B-VP	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
action	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
respiratory	JJ	I-NP	O
depressant	NN	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
thiopental.	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
i.v.	JJ	B-NP	O
thiopental	NN	I-NP	O
produced	VBD	B-VP	O
respiratory	JJ	B-NP	B
arrest	NN	I-NP	I
with	IN	B-PP	O
further	JJ	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
GABA	NN	B-NP	O
and	CC	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
glutamate	NN	B-NP	O
again	RB	B-ADVP	O
in	IN	B-PP	O
cortex	NN	B-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
stem	NN	I-NP	O
without	IN	B-PP	O
affecting	VBG	B-VP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
amino	JJ	I-NP	O
acids	NNS	I-NP	O
studied	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
regions	NNS	I-NP	O
of	IN	B-PP	O
rat	NN	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Naloxone	NN	B-NP	O
reversed	VBD	B-VP	O
respiratory	JJ	B-NP	B
paralysis	NN	I-NP	I
,	,	O	O
glutamate	NN	B-NP	O
and	CC	I-NP	O
GABA	NN	I-NP	O
levels	NNS	I-NP	O
to	TO	B-VP	O
control	VB	I-VP	O
values	NNS	B-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
stem	NN	I-NP	O
and	CC	O	O
cortex	NN	B-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
caudate	NN	B-NP	O
or	CC	I-NP	O
cerebellum	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
naloxone	NN	B-NP	O
reverses	VBZ	B-VP	O
respiratory	JJ	B-NP	B
paralysis	NN	I-NP	I
produced	VBN	B-VP	O
by	IN	B-PP	O
thiopental	NN	B-NP	O
and	CC	O	O
involves	VBZ	B-VP	O
GABA	NN	B-NP	O
in	IN	B-PP	O
its	PRP$	B-NP	O
action	NN	I-NP	O
.	.	O	O

National	JJ	B-NP	O
project	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
mother	NN	B-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
infant	NN	I-NP	O
infection	NN	I-NP	B
by	IN	B-PP	I
hepatitis	NN	B-NP	I
B	NN	I-NP	I
virus	NN	I-NP	I
in	IN	B-PP	O
Japan	NNP	B-NP	O
.	.	O	O

In	IN	B-PP	O
Japan	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
nationwide	JJ	I-NP	O
prevention	NN	I-NP	O
program	NN	I-NP	O
against	IN	B-PP	O
mother	NN	B-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
infant	NN	I-NP	O
infection	NN	I-NP	B
by	IN	B-PP	I
hepatitis	NN	B-NP	I
B	NN	I-NP	I
virus	NN	I-NP	I
(	(	O	O
HBV	NN	B-NP	O
)	)	O	O
started	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

This	DT	B-NP	O
program	NN	I-NP	O
consists	VBZ	B-VP	O
of	IN	B-PP	O
double	JJ	B-NP	O
screenings	NNS	I-NP	O
of	IN	B-PP	O
pregnant	JJ	B-NP	O
women	NNS	I-NP	O
and	CC	O	O
prophylactic	JJ	B-NP	O
treatment	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
infants	NNS	I-NP	O
born	VBN	B-VP	O
to	TO	B-PP	O
both	CC	O	O
hepatitis	NN	B-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
HBsAg	NN	B-NP	O
)	)	O	O
and	CC	O	O
hepatitis	NN	B-NP	O
B	NN	I-NP	O
e	NN	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
HBeAg	NN	B-NP	O
)	)	O	O
positive	JJ	B-NP	O
mothers	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
infants	NNS	I-NP	O
are	VBP	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
(	(	O	O
HBIG	NN	B-NP	O
)	)	O	O
and	CC	O	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
derived	VBN	I-NP	O
hepatitis	NN	I-NP	O
B	NN	I-NP	O
vaccine	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
sent	VBD	B-VP	O
questionnaires	NNS	B-NP	O
about	IN	B-PP	O
the	DT	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
procedure	NN	I-NP	O
or	CC	I-NP	O
examination	NN	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
investigation	NN	B-NP	O
period	NN	I-NP	O
to	TO	B-PP	O
each	DT	B-NP	O
local	JJ	I-NP	O
government	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
pregnant	JJ	I-NP	O
women	NNS	I-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
chance	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
HBsAg	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
positive	JJ	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
HBeAg	NN	I-NP	O
positive	JJ	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
HBsAg	NN	B-NP	O
positive	JJ	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
HBsAg	NN	I-NP	O
positive	JJ	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
neonates	NNS	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
infants	NNS	B-NP	O
before	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

Some	DT	B-NP	O
problems	NNS	I-NP	O
may	MD	B-VP	O
arise	VB	I-VP	O
,	,	O	O
because	IN	B-SBAR	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
infants	NNS	B-NP	O
need	VBP	B-VP	O
the	DT	B-NP	O
fourth	JJ	I-NP	O
vaccination	NN	I-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
restricted	JJ	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

Nociceptive	JJ	B-NP	O
effects	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
intrathecal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
D2	NN	I-NP	O
,	,	O	O
E2	NN	B-NP	O
,	,	O	O
or	CC	O	O
F2	NN	B-NP	O
alpha	NN	I-NP	O
to	TO	B-PP	O
conscious	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
intrathecal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
prostaglandins	NNS	B-NP	O
on	IN	B-PP	O
pain	NN	B-NP	B
responses	NNS	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
using	VBG	B-VP	O
hot	JJ	B-NP	O
plate	NN	I-NP	O
and	CC	O	O
acetic	JJ	B-NP	O
acid	NN	I-NP	O
writhing	NN	I-NP	O
tests	NNS	I-NP	O
.	.	O	O

Prostaglandin	NN	B-NP	O
D2	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mouse	NN	I-NP	O
)	)	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
hyperalgesic	JJ	I-NP	B
action	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
hot	JJ	I-NP	O
plate	NN	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
period	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
.	.	O	O

Prostaglandin	NN	B-NP	O
E2	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
hyperalgesic	JJ	I-NP	B
effect	NN	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
pg	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mouse	NN	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
lasted	VBD	B-VP	O
shorter	JJR	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
)	)	O	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
D2	NN	I-NP	O
.	.	O	O

Similar	JJ	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
by	IN	B-PP	O
acetic	JJ	B-NP	O
acid	NN	I-NP	O
writhing	NN	I-NP	O
tests	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
hyperalgesic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
D2	NN	I-NP	O
was	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
simultaneous	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
substance	NN	I-NP	O
P	NN	I-NP	O
antagonist	NN	I-NP	O
(	(	O	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
)	)	O	O
but	CC	B-PP	O
not	RB	B-NP	O
by	IN	B-PP	O
AH6809	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
prostanoid	NN	I-NP	O
EP1	NN	I-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

Conversely	RB	B-ADVP	O
,	,	O	O
prostaglandin	NN	B-NP	O
E2	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperalgesia	NN	I-NP	B
was	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
AH6809	NN	B-NP	O
(	(	O	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
)	)	O	O
but	CC	B-PP	O
not	RB	B-PP	O
by	IN	I-PP	O
the	DT	B-NP	O
substance	NN	I-NP	O
P	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

Prostaglandin	NN	B-NP	O
F2	NN	I-NP	O
alpha	NN	I-NP	O
had	VBD	B-VP	O
little	JJ	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
pain	NN	B-NP	B
responses	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
both	CC	O	O
prostaglandin	NN	B-NP	O
D2	NN	I-NP	O
and	CC	O	O
prostaglandin	NN	B-NP	O
E2	NN	I-NP	O
exert	VBP	B-VP	O
hyperalgesia	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
different	JJ	B-NP	O
ways	NNS	I-NP	O
.	.	O	O

Swallowing	VBG	B-VP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
atrial	JJ	I-NP	B
tachyarrhythmia	NN	I-NP	I
triggered	VBN	B-VP	O
by	IN	B-PP	O
salbutamol	NN	B-NP	O
:	:	O	O
case	NN	B-NP	O
report	NN	I-NP	O
and	CC	O	O
review	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
experienced	VBD	B-VP	O
chest	NN	B-NP	O
discomfort	NN	I-NP	O
while	IN	B-SBAR	O
swallowing	VBG	B-VP	O
.	.	O	O

On	IN	B-PP	O
electrocardiogram	NN	B-NP	O
,	,	O	O
episodes	NNS	B-NP	O
of	IN	B-PP	O
atrial	JJ	B-NP	B
tachyarrhythmia	NN	I-NP	I
were	VBD	B-VP	O
recorded	VBN	I-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
swallowing	VBG	B-VP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
Holter	NNP	I-NP	O
monitoring	NN	I-NP	O
recorded	VBD	B-VP	O
several	JJ	B-NP	O
events	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
arrhythmia	NN	I-NP	B
resolved	VBN	B-VP	O
after	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
atenolol	NN	B-NP	O
,	,	O	O
but	CC	O	O
recurred	VBD	B-VP	O
a	DT	B-NP	O
year	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
noticed	VBD	B-VP	O
that	IN	B-SBAR	O
before	IN	B-SBAR	O
these	DT	B-NP	O
episodes	NNS	I-NP	O
he	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
using	VBG	I-VP	O
an	DT	B-NP	O
inhalator	NN	I-NP	O
of	IN	B-PP	O
salbutamol	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
stopping	VBG	B-VP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
and	CC	O	O
after	IN	B-PP	O
a	DT	B-NP	O
week	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
atenolol	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
disappeared	VBD	B-VP	O
.	.	O	O

Swallowing	VBG	B-VP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
atrial	JJ	I-NP	B
tachyarrhythmia	NN	I-NP	I
(	(	O	O
SIAT	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
phenomenon	NN	I-NP	O
.	.	O	O

Fewer	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
SIAT	NN	B-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
article	NN	I-NP	O
summarizes	VBZ	B-VP	O
all	PDT	B-NP	O
the	DT	I-NP	O
cases	NNS	I-NP	O
published	VBN	B-VP	O
,	,	O	O
creating	VBG	B-VP	O
a	DT	B-NP	O
comprehensive	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
knowledge	NN	I-NP	O
and	CC	I-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
SIAT	NN	B-NP	B
.	.	O	O

It	PRP	B-NP	O
discusses	VBZ	B-VP	O
demographics	NNS	B-NP	O
,	,	O	O
clinical	JJ	B-NP	O
characteristics	NNS	I-NP	O
and	CC	I-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
arrhythmia	NN	B-NP	B
,	,	O	O
postulated	VBN	B-VP	O
mechanisms	NNS	B-NP	O
of	IN	B-PP	O
SIAT	NN	B-NP	B
,	,	O	O
and	CC	O	O
different	JJ	B-NP	O
treatment	NN	I-NP	O
possibilities	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
medications	NNS	B-NP	O
,	,	O	O
surgery	NN	B-NP	O
,	,	O	O
and	CC	O	O
radiofrequency	NN	B-NP	O
catheter	NN	I-NP	O
ablation	NN	I-NP	O
(	(	O	O
RFCA	NN	B-NP	O
)	)	O	O
.	.	O	O

Salbutamol	NN	B-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
here	RB	B-ADVP	O
as	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
trigger	NN	I-NP	O
for	IN	B-PP	O
SIAT	NN	B-NP	B
.	.	O	O

Although	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
difficult	JJ	B-ADJP	O
to	TO	B-VP	O
define	VB	I-VP	O
causality	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
logical	JJ	B-ADJP	O
to	TO	B-VP	O
think	VB	I-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
agonist	NN	I-NP	O
like	JJ	I-NP	O
salbutamol	NN	I-NP	O
(	(	O	O
known	VBN	B-VP	O
to	TO	B-VP	O
induce	VB	I-VP	O
tachycardia	NN	B-NP	B
)	)	O	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
trigger	NN	I-NP	O
of	IN	B-PP	O
adrenergic	JJ	B-NP	O
reflexes	NNS	I-NP	O
originating	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
esophagus	NN	I-NP	O
while	IN	B-SBAR	O
swallowing	VBG	B-VP	O
and	CC	O	O
that	IN	B-SBAR	O
a	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocker	NN	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
atenolol	NN	B-NP	O
(	(	O	O
that	WDT	B-NP	O
blocks	VBZ	B-VP	O
the	DT	B-NP	O
adrenergic	JJ	I-NP	O
activity	NN	I-NP	O
)	)	O	O
may	MD	B-VP	O
relieve	VB	I-VP	O
it	PRP	B-NP	O
.	.	O	O

Coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
treatment	NN	I-NP	O
ameliorates	VBZ	B-VP	O
acute	JJ	B-NP	O
cisplatin	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
nephroprotective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
injury	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
i.p.	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
.	.	O	O

Coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
applied	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
,	,	O	O
starting	VBG	B-VP	O
num	CD	B-NP	O
day	NN	I-NP	O
before	IN	B-PP	O
cisplatin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
blood	NN	B-NP	O
urea	NN	I-NP	O
nitrogen	NN	I-NP	O
and	CC	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
cisplatin	NN	B-NP	O
.	.	O	O

Coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
significantly	RB	B-ADVP	O
compensated	VBD	B-VP	O
deficits	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
antioxidant	JJ	I-NP	O
defense	NN	I-NP	O
mechanisms	NNS	I-NP	O
(	(	O	O
reduced	VBN	B-NP	O
glutathione	NN	I-NP	O
level	NN	I-NP	O
and	CC	I-NP	O
superoxide	NN	I-NP	O
dismutase	NN	I-NP	O
activity	NN	I-NP	O
)	)	O	O
,	,	O	O
suppressed	VBD	B-VP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
elevations	NNS	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
necrosis	NN	I-NP	B
factor	NN	I-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
,	,	O	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
and	CC	I-NP	O
platinum	NN	I-NP	O
ion	NN	I-NP	O
concentration	NN	I-NP	O
,	,	O	O
and	CC	O	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
reductions	NNS	I-NP	O
of	IN	B-PP	O
selenium	NN	B-NP	O
and	CC	I-NP	O
zinc	NN	I-NP	O
ions	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
tissue	NN	I-NP	O
resulted	VBD	B-VP	O
from	IN	B-PP	O
cisplatin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
histopathological	JJ	B-NP	O
renal	JJ	I-NP	B
tissue	NN	I-NP	I
damage	NN	I-NP	I
mediated	VBN	B-VP	O
by	IN	B-PP	O
cisplatin	NN	B-NP	O
was	VBD	B-VP	O
ameliorated	VBN	I-VP	O
by	IN	B-PP	O
coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Immunohistochemical	JJ	B-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
cisplatin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
overexpression	NN	I-NP	O
of	IN	B-PP	O
inducible	JJ	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
,	,	O	O
nuclear	JJ	B-NP	O
factor	NN	I-NP	O
-	HYPH	B-NP	O
kappaB	NN	I-NP	O
,	,	O	O
caspase	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
p53	NN	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
tissue	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
coenzyme	NN	B-NP	O
Q10	NN	I-NP	O
represents	VBZ	B-VP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
therapeutic	JJ	I-NP	O
option	NN	I-NP	O
to	TO	B-VP	O
protect	VB	I-VP	O
against	IN	B-PP	O
acute	JJ	B-NP	O
cisplatin	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
commonly	RB	B-VP	O
encountered	VBN	I-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
practice	NN	I-NP	O
.	.	O	O

Metformin	NN	B-NP	O
prevents	VBZ	B-VP	O
experimental	JJ	B-NP	O
gentamicin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
by	IN	B-PP	O
a	DT	B-NP	O
mitochondria	NNS	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
antidiabetic	JJ	I-NP	O
drug	NN	I-NP	O
metformin	NN	I-NP	O
can	MD	B-VP	O
diminish	VB	I-VP	O
apoptosis	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
endothelial	JJ	B-NP	O
cells	NNS	I-NP	O
and	CC	O	O
prevent	VB	B-VP	O
vascular	JJ	B-NP	B
dysfunction	NN	I-NP	I
even	RB	B-ADVP	O
in	IN	B-PP	O
nondiabetic	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
tested	VBD	B-VP	O
whether	IN	B-SBAR	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
gentamicin	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Mitochondrial	JJ	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
respiration	NN	B-NP	O
intensity	NN	I-NP	O
,	,	O	O
levels	NNS	B-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
,	,	O	O
permeability	NN	B-NP	O
transition	NN	I-NP	O
,	,	O	O
and	CC	O	O
cytochrome	NN	B-NP	O
c	NN	I-NP	O
release	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
gentamicin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Metformin	NN	B-NP	O
treatment	NN	I-NP	O
fully	RB	B-VP	O
blocked	VBD	I-VP	O
gentamicin	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
glucosaminidase	NN	B-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
and	CC	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
antioxidant	JJ	B-NP	O
systems	NNS	I-NP	O
.	.	O	O

Metformin	NN	B-NP	O
also	RB	B-ADVP	O
protected	VBD	B-VP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
from	IN	B-PP	O
histological	JJ	B-NP	O
damage	NN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
gentamicin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
markers	NNS	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
their	PRP$	B-NP	O
correction	NN	I-NP	O
by	IN	B-PP	O
metformin	NN	B-NP	O
were	VBD	B-VP	O
complemented	VBN	I-VP	O
by	IN	B-PP	O
in	FW	B-NP	O
vitro	FW	I-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
gentamicin	NN	B-NP	O
treatment	NN	I-NP	O
depleted	VBD	B-VP	O
respiratory	JJ	B-NP	O
components	NNS	I-NP	O
(	(	O	O
cytochrome	NN	B-NP	O
c	NN	I-NP	O
,	,	O	O
NADH	NN	B-NP	O
)	)	O	O
,	,	O	O
probably	RB	B-ADVP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
opening	NN	I-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	O
transition	NN	I-NP	O
pores	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
injuries	NNS	I-NP	O
,	,	O	O
partly	RB	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
electron	NN	I-NP	O
transfer	NN	I-NP	O
chain	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
by	IN	B-PP	O
metformin	NN	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
our	PRP$	B-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
pleiotropic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
can	MD	B-VP	O
lessen	VB	I-VP	O
gentamicin	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
and	CC	O	O
improve	VB	B-VP	O
mitochondrial	JJ	B-NP	O
homeostasis	NN	I-NP	O
.	.	O	O

Sedation	NN	B-NP	O
depth	NN	I-NP	O
during	IN	B-PP	O
spinal	JJ	B-NP	O
anesthesia	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
hip	NN	B-NP	B
fracture	NN	I-NP	I
repair	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
limiting	VBG	B-VP	O
intraoperative	JJ	B-NP	O
sedation	NN	I-NP	O
depth	NN	I-NP	O
during	IN	B-PP	O
spinal	JJ	B-NP	O
anesthesia	NN	I-NP	O
for	IN	B-PP	O
hip	NN	B-NP	B
fracture	NN	I-NP	I
repair	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
can	MD	B-VP	O
decrease	VB	I-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	O	O
randomized	VBN	B-VP	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
at	IN	B-PP	O
an	DT	B-NP	O
academic	JJ	I-NP	O
medical	JJ	I-NP	O
center	NN	I-NP	O
of	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
preoperative	JJ	B-NP	O
delirium	NN	I-NP	B
or	CC	O	O
severe	JJ	B-NP	O
dementia	NN	I-NP	B
who	WP	B-NP	O
underwent	VBD	B-VP	O
hip	NN	B-NP	B
fracture	NN	I-NP	I
repair	NN	I-NP	O
under	IN	B-PP	O
spinal	JJ	B-NP	O
anesthesia	NN	I-NP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
sedation	NN	I-NP	O
.	.	O	O

Sedation	NN	B-NP	O
depth	NN	I-NP	O
was	VBD	B-VP	O
titrated	VBN	I-VP	O
using	VBG	B-VP	O
processed	VBN	B-NP	O
electroencephalography	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
bispectral	JJ	I-NP	O
index	NN	I-NP	O
(	(	O	O
BIS	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-VP	O
receive	VB	I-VP	O
either	CC	I-VP	O
deep	VB	I-VP	O
(	(	O	O
BIS	NN	B-NP	O
,	,	O	O
approximately	RB	B-NP	O
num	CD	I-NP	O
)	)	O	O
or	CC	O	O
light	NN	B-NP	O
sedation	NN	I-NP	O
.	.	O	O

Postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
was	VBD	B-VP	O
assessed	VBN	I-VP	O
as	IN	B-SBAR	O
defined	VBN	B-VP	O
by	IN	B-PP	O
Diagnostic	NNP	B-NP	O
and	CC	I-NP	O
Statistical	NNP	I-NP	O
Manual	NNP	I-NP	O
of	IN	B-PP	O
Mental	NNP	B-NP	B
Disorders	NNP	I-NP	I
(	(	O	O
Third	NNP	B-NP	O
Edition	NNP	I-NP	O
Revised	NNP	I-NP	O
)	)	O	O
criteria	NNS	B-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Confusion	NNP	I-NP	O
Assessment	NNP	I-NP	O
Method	NNP	I-NP	O
beginning	VBG	B-VP	O
at	IN	B-PP	O
any	DT	B-NP	O
time	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
.	.	O	O

From	IN	B-PP	O
April	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
through	IN	B-PP	O
October	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
light	JJ	I-NP	O
sedation	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
incident	NN	I-NP	O
of	IN	B-PP	O
delirium	NN	B-NP	B
will	MD	B-VP	O
be	VB	I-VP	O
prevented	VBN	I-VP	O
for	IN	B-PP	O
every	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
light	JJ	B-NP	O
sedation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	NN	I-NP	O
+	SYM	B-VP	O
/	SYM	B-NP	O
-	HYPH	I-NP	O
SD	NN	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
days	NNS	B-NP	O
of	IN	B-PP	O
delirium	NN	B-NP	B
during	IN	B-PP	O
hospitalization	NN	B-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
light	JJ	I-NP	O
sedation	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
deep	JJ	I-NP	O
sedation	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
light	JJ	B-NP	O
propofol	NN	I-NP	O
sedation	NN	I-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
deep	JJ	B-NP	O
sedation	NN	I-NP	O
.	.	O	O

Limiting	VBG	B-VP	O
depth	NN	B-NP	O
of	IN	B-PP	O
sedation	NN	B-NP	O
during	IN	B-PP	O
spinal	JJ	B-NP	O
anesthesia	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
simple	JJ	I-NP	O
,	,	I-NP	O
safe	JJ	I-NP	O
,	,	I-NP	O
and	CC	I-NP	O
cost	NN	I-NP	O
-	HYPH	I-NP	O
effective	JJ	I-NP	O
intervention	NN	I-NP	O
for	IN	B-PP	O
preventing	VBG	B-VP	O
postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
that	WDT	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
widely	RB	B-ADVP	O
and	CC	I-ADVP	O
readily	RB	I-ADVP	O
adopted	VBN	B-VP	O
.	.	O	O

Sorafenib	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
spasm	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
renal	JJ	I-NP	B
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
was	VBD	B-VP	O
admitted	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
continuing	VBG	B-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
at	IN	B-PP	O
rest	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
before	IN	B-PP	O
his	PRP$	B-NP	O
admission	NN	I-NP	O
,	,	O	O
sorafenib	NN	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
started	VBN	I-VP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
ST	NN	I-NP	O
-	HYPH	I-NP	O
elevation	NN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
by	IN	B-PP	O
laboratory	NN	B-NP	O
data	NNS	I-NP	O
and	CC	O	O
electrocardiogram	NN	B-NP	O
.	.	O	O

Enhanced	VBN	B-NP	O
heart	NN	I-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
subendocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
stenosis	NN	I-NP	O
in	IN	B-PP	O
coronary	JJ	B-NP	O
arteries	NNS	I-NP	O
on	IN	B-PP	O
angiography	NN	B-NP	O
.	.	O	O

Coronary	JJ	B-NP	B
artery	NN	I-NP	I
spasm	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
provocative	JJ	I-NP	O
test	NN	I-NP	O
.	.	O	O

Cessation	NN	B-NP	O
of	IN	B-PP	O
sorafenib	NN	B-NP	O
and	CC	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
Ca	NN	B-NP	O
-	HYPH	B-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
and	CC	I-NP	O
nitrates	NNS	I-NP	O
ameliorated	VBD	B-VP	O
his	PRP$	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
but	CC	O	O
relapse	NN	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
resumption	NN	B-NP	O
of	IN	B-PP	O
sorafenib	NN	B-NP	O
.	.	O	O

Addition	NN	B-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
nicorandil	NN	I-NP	O
reduced	VBD	B-VP	O
his	PRP$	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
maintained	VBN	B-VP	O
stable	JJ	B-NP	B
angina	NN	I-NP	I
status	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
sorafenib	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
spasm	NN	I-NP	I
.	.	O	O

Sorafenib	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
multikinase	JJ	I-NP	O
inhibitor	NN	I-NP	O
that	WDT	B-NP	O
targets	VBZ	B-VP	O
signaling	NN	B-NP	O
pathways	NNS	I-NP	O
necessary	JJ	B-ADJP	O
for	IN	B-PP	O
cellular	JJ	B-NP	O
proliferation	NN	I-NP	O
and	CC	I-NP	O
survival	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
Rho	NN	I-NP	O
/	SYM	B-NP	O
ROCK	NN	I-NP	O
pathway	NN	I-NP	O
has	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
spasm	NN	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
report	NN	I-NP	O
may	MD	B-VP	O
show	VB	I-VP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Rho	NN	I-NP	O
/	SYM	B-NP	O
ROCK	NN	I-NP	O
pathway	NN	I-NP	O
by	IN	B-PP	O
sorafenib	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Anxiogenic	JJ	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
and	CC	I-NP	O
norfloxacin	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
anxiogenic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
fluoroquinolones	NNS	B-NP	O
,	,	O	O
namely	RB	B-NP	O
ciprofloxacin	NN	I-NP	O
and	CC	I-NP	O
norfloxacin	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
Charles	NNP	I-NP	O
Foster	NNP	I-NP	O
albino	NNP	I-NP	O
rats	NNS	I-NP	O
of	IN	B-PP	O
either	DT	B-NP	O
sex	NN	I-NP	O
,	,	O	O
weighing	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
orally	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
experiments	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
fifth	JJ	I-NP	O
day	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
tests	NNS	I-NP	O
included	VBD	B-VP	O
open	JJ	B-NP	O
-	HYPH	I-NP	O
field	NN	I-NP	O
exploratory	NN	I-NP	O
behaviour	NN	I-NP	O
,	,	O	O
elevated	VBD	B-VP	O
plus	CC	O	O
maze	NN	B-NP	O
and	CC	O	O
elevated	VBD	B-VP	O
num	CD	B-NP	O
maze	NN	I-NP	O
,	,	O	O
social	JJ	B-NP	O
interaction	NN	I-NP	O
and	CC	I-NP	O
novelty	NN	I-NP	O
-	HYPH	O	O
suppressed	VBN	B-NP	O
feeding	NN	I-NP	O
latency	NN	I-NP	O
behaviour	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
ciprofloxacin	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
norfloxacin	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
showed	VBD	B-VP	O
anxious	JJ	B-NP	B
behaviour	NN	I-NP	I
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
parameters	NNS	I-NP	O
studied	VBN	B-VP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
ciprofloxacin	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
norfloxacin	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
from	IN	B-PP	O
each	DT	B-NP	O
other	JJ	I-NP	O
in	IN	B-PP	O
various	JJ	B-NP	O
behavioural	JJ	I-NP	O
parameters	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
experimental	JJ	I-NP	O
findings	NNS	I-NP	O
substantiate	VBP	B-VP	O
the	DT	B-NP	O
clinically	RB	I-NP	O
observed	VBN	I-NP	O
anxiogenic	JJ	I-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
and	CC	I-NP	O
norfloxacin	NN	I-NP	O
.	.	O	O

Myocardial	JJ	B-NP	O
Fas	NN	I-NP	O
ligand	NN	I-NP	O
expression	NN	I-NP	O
increases	VBZ	B-VP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
AZT	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

Dilated	VBN	B-NP	B
cardiomyopathy	NN	I-NP	I
(	(	O	O
DCM	NN	B-NP	B
)	)	O	O
and	CC	O	O
myocarditis	NN	B-NP	B
occur	VBP	B-VP	O
in	IN	B-PP	O
many	JJ	B-NP	O
HIV	NN	I-NP	B
-	HYPH	I-NP	I
infected	VBN	I-NP	I
individuals	NNS	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
symptomatic	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Highly	RB	B-NP	O
active	JJ	I-NP	O
antiretroviral	JJ	I-NP	O
therapy	NN	I-NP	O
(	(	O	O
HAART	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
morbidity	NN	B-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
of	IN	B-PP	O
acquired	VBN	B-NP	B
immunodeficiency	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
AIDS	NN	B-NP	B
)	)	O	O
,	,	O	O
but	CC	O	O
has	VBZ	B-VP	O
resulted	VBN	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	B
and	CC	I-NP	I
skeletal	JJ	I-NP	I
myopathies	NNS	I-NP	I
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
HAART	NN	I-NP	O
component	NN	I-NP	O
zidovudine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
azido	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
'	SYM	I-NP	O
,	,	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
deoxythymidine	NN	I-NP	O
;	:	O	O
AZT	NN	B-NP	O
)	)	O	O
triggers	VBZ	B-VP	O
the	DT	B-NP	O
Fas	NN	I-NP	O
-	HYPH	O	O
dependent	JJ	B-NP	O
cell	NN	I-NP	O
-	HYPH	B-NP	O
death	NN	I-NP	O
pathway	NN	I-NP	O
and	CC	O	O
cause	VBP	B-VP	O
cytoskeletal	JJ	B-NP	O
disruption	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
murine	JJ	I-NP	B
model	NN	I-NP	O
of	IN	B-PP	O
DCM	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
transgenic	JJ	I-NP	O
(	(	O	O
expressing	VBG	B-VP	O
Fas	NN	B-NP	O
ligand	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
myocardium	NN	I-NP	O
:	:	O	O
FasL	NN	B-NP	O
Tg	NN	I-NP	O
)	)	O	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
transgenic	JJ	O	O
(	(	O	O
NTg	NN	B-NP	O
)	)	O	O
mice	NNS	B-NP	O
received	VBD	B-VP	O
water	NN	B-NP	O
ad	NN	I-NP	O
libitum	NN	I-NP	O
containing	VBG	B-VP	O
different	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
AZT	NNP	B-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
echocardiography	NN	B-NP	O
and	CC	I-NP	O
morphology	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
histopathologic	JJ	B-NP	O
and	CC	I-NP	O
immunohistochemical	JJ	I-NP	O
methods	NNS	I-NP	O
.	.	O	O

NTg	NN	B-NP	O
and	CC	I-NP	O
untreated	JJ	I-NP	O
FasL	NN	I-NP	O
Tg	NN	I-NP	O
mice	NNS	I-NP	O
showed	VBD	B-VP	O
little	JJ	B-NP	O
or	CC	I-NP	O
no	DT	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
structure	NN	I-NP	O
or	CC	I-NP	O
function	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
AZT	NN	B-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
FasL	NN	I-NP	O
Tg	NN	I-NP	O
mice	NNS	I-NP	O
developed	VBD	B-VP	O
cardiac	JJ	B-NP	B
dilation	NN	I-NP	I
and	CC	O	O
depressed	VBD	B-VP	O
cardiac	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
concomitant	JJ	B-NP	O
inflammatory	JJ	I-NP	O
infiltration	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
ventricles	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
sarcolemmal	JJ	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
Fas	NN	B-NP	O
and	CC	I-NP	O
FasL	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
increased	VBN	B-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
caspase	NN	B-NP	O
num	CD	I-NP	O
translocation	NN	I-NP	O
of	IN	B-PP	O
calpain	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
sarcolemma	NN	I-NP	O
and	CC	I-NP	O
sarcomere	NN	I-NP	O
,	,	O	O
and	CC	O	O
increased	VBN	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
cells	NNS	B-NP	O
undergoing	VBG	B-VP	O
apoptosis	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
dystrophin	NN	B-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
troponin	NN	I-NP	O
num	CD	I-NP	O
localization	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
loss	NN	B-NP	O
of	IN	B-PP	O
sarcolemmal	JJ	B-NP	O
integrity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
Fas	NN	B-NP	O
ligand	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
myocardium	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
identified	VBN	B-VP	O
in	IN	B-PP	O
HIV	NN	B-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
might	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
susceptibility	NN	I-NP	O
to	TO	B-PP	O
HAART	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
due	IN	B-PP	O
to	TO	I-PP	O
activation	NN	B-NP	O
of	IN	B-PP	O
apoptotic	JJ	B-NP	O
pathways	NNS	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	B
dilation	NN	I-NP	I
and	CC	I-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

Valproate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
chorea	NN	I-NP	B
and	CC	I-NP	O
encephalopathy	NN	I-NP	B
in	IN	B-PP	O
atypical	JJ	B-NP	O
nonketotic	JJ	I-NP	B
hyperglycinemia	NN	I-NP	I
.	.	O	O

Nonketotic	JJ	B-NP	B
hyperglycinemia	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
disorder	NN	I-NP	B
of	IN	B-PP	I
amino	JJ	B-NP	I
acid	NN	I-NP	I
metabolism	NN	I-NP	I
in	IN	B-PP	O
which	WDT	B-NP	O
a	DT	B-NP	O
defect	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
glycine	NN	I-NP	O
cleavage	NN	I-NP	O
system	NN	I-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
glycine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
and	CC	O	O
other	JJ	B-NP	O
body	NN	I-NP	O
compartments	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
classical	JJ	I-NP	O
form	NN	I-NP	O
it	PRP	B-NP	O
presents	VBZ	B-VP	O
as	IN	B-PP	O
neonatal	JJ	B-NP	O
apnea	NN	I-NP	B
,	,	O	O
intractable	JJ	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
and	CC	O	O
hypotonia	NN	B-NP	B
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
significant	JJ	B-NP	O
psychomotor	NN	I-NP	B
retardation	NN	I-NP	I
.	.	O	O

An	DT	B-NP	O
important	JJ	I-NP	O
subset	NN	I-NP	O
of	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
nonketotic	JJ	B-NP	B
hyperglycinemia	NN	I-NP	I
are	VBP	B-VP	O
atypical	JJ	B-NP	O
variants	NNS	I-NP	O
who	WP	B-NP	O
present	VBP	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
heterogeneous	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
mild	JJ	B-NP	O
language	NN	I-NP	B
delay	NN	I-NP	I
and	CC	O	O
mental	JJ	B-NP	B
retardation	NN	I-NP	I
,	,	O	O
who	WP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
nonketotic	JJ	B-NP	B
hyperglycinemia	NN	I-NP	I
following	VBG	B-PP	O
her	PRP$	B-NP	O
presentation	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
encephalopathy	NN	I-NP	B
and	CC	I-NP	O
chorea	NN	I-NP	B
shortly	RB	B-ADVP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
valproate	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Microinjection	NN	B-NP	O
of	IN	B-PP	O
ritanserin	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
CA1	NN	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
hippocampus	NN	B-NP	O
improves	VBZ	B-VP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
in	IN	B-PP	O
adult	JJ	B-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ritanserin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT2	NN	I-NP	O
antagonist	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
scopolamine	NN	B-NP	O
(	(	O	O
muscarinic	JJ	B-NP	O
cholinergic	JJ	I-NP	O
antagonist	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
in	IN	B-PP	O
Morris	NNP	B-NP	O
water	NN	I-NP	O
maze	NN	I-NP	O
(	(	O	O
MWM	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
and	CC	O	O
bilaterally	RB	B-VP	O
cannulated	VBN	I-VP	O
into	IN	B-PP	O
CA1	NN	B-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
week	NN	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
they	PRP	B-NP	O
received	VBD	B-VP	O
repeatedly	RB	B-ADVP	O
vehicles	NNS	B-NP	O
(	(	O	O
saline	NN	B-NP	O
,	,	O	O
DMSO	NN	B-NP	O
,	,	O	O
saline+DMSO	NN	B-NP	O
)	)	O	O
,	,	O	O
scopolamine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
saline	NN	I-NP	O
/	SYM	B-NP	O
side	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
training	NN	B-NP	O
)	)	O	O
,	,	O	O
ritanserin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
DMSO	NN	I-NP	O
/	SYM	B-NP	O
side	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
training	NN	B-NP	O
)	)	O	O
and	CC	O	O
scopolamine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
ritanserin	NN	B-NP	O
injection	NN	I-NP	O
)	)	O	O
+ritanserin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
DMSO	NN	I-NP	O
)	)	O	O
through	IN	B-PP	O
cannulae	NNS	B-NP	O
each	DT	B-NP	O
day	NN	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
trial	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
MWM	NN	B-NP	O
during	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
position	NN	I-NP	O
of	IN	B-PP	O
hidden	JJ	B-NP	O
platform	NN	I-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
fifth	JJ	I-NP	O
day	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
platform	NN	I-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
above	IN	B-PP	O
the	DT	B-NP	O
water	NN	I-NP	O
surface	NN	I-NP	O
in	IN	B-PP	O
another	DT	B-NP	O
position	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
,	,	O	O
motivational	JJ	B-NP	O
and	CC	I-NP	O
visual	JJ	I-NP	O
systems	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
escape	NN	B-NP	O
latencies	NNS	I-NP	O
and	CC	O	O
traveled	VBN	B-NP	O
distances	NNS	I-NP	O
to	TO	B-VP	O
find	VB	I-VP	O
platform	NN	B-NP	O
in	IN	B-PP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
to	TO	B-PP	O
saline	NN	B-NP	O
group	NN	I-NP	O
.	.	O	O

Ritanserin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
/	SYM	B-NP	O
side	NN	I-NP	O
)	)	O	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mentioned	VBN	I-NP	O
parameters	NNS	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
DMSO	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
scopolamine	NN	B-NP	O
and	CC	I-NP	O
ritanserin	NN	I-NP	O
co	AFX	O	O
-	HYPH	B-NP	O
administration	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
escape	NN	B-NP	O
latencies	NNS	I-NP	O
and	CC	O	O
traveled	VBN	B-VP	O
distances	NNS	B-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
microinjection	NN	B-NP	O
of	IN	B-PP	O
ritanserin	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
CA1	NN	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
improves	VBZ	B-VP	O
the	DT	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

Hypoxia	NN	B-NP	B
in	IN	B-PP	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
with	IN	B-PP	O
proteinuria	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
glomerular	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Despite	IN	B-PP	O
the	DT	B-NP	O
increasing	VBG	I-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
identify	VB	I-VP	O
and	CC	I-VP	O
quantify	VB	I-VP	O
tissue	NN	B-NP	O
oxygenation	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
cellular	JJ	I-NP	O
level	NN	I-NP	O
,	,	O	O
relatively	RB	B-NP	O
few	JJ	I-NP	O
methods	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
available	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
hypoxia	NN	I-NP	B
-	HYPH	B-NP	O
responsive	JJ	I-NP	O
reporter	NN	I-NP	O
vector	NN	I-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
hypoxia	NN	I-NP	B
-	HYPH	B-NP	O
responsive	JJ	I-NP	O
element	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
vascular	JJ	I-NP	O
endothelial	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
untranslated	JJ	I-NP	O
region	NN	I-NP	O
and	CC	O	O
generated	VBD	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
hypoxia	NN	I-NP	B
-	HYPH	O	O
sensing	VBG	B-VP	O
transgenic	JJ	B-NP	O
rat	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
then	RB	B-ADVP	O
applied	VBD	B-VP	O
this	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
tubulointerstitial	JJ	B-NP	O
hypoxia	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
diseased	JJ	I-NP	B
kidney	NN	I-NP	I
.	.	O	O

With	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
were	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
identify	VB	I-VP	O
diffuse	JJ	B-NP	O
cortical	JJ	I-NP	O
hypoxia	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
and	CC	O	O
focal	JJ	B-NP	O
and	CC	I-NP	O
segmental	JJ	I-NP	O
hypoxia	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
remnant	NN	I-NP	O
kidney	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

Expression	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypoxia	NN	I-NP	B
-	HYPH	B-NP	O
responsive	JJ	I-NP	O
transgene	NN	I-NP	O
increased	VBD	B-VP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
reaching	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
fold	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
model	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
remnant	NN	I-NP	O
kidney	NN	I-NP	O
model	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
that	DT	B-NP	O
of	IN	B-PP	O
vascular	JJ	B-NP	O
endothelial	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
mild	JJ	I-NP	O
decrease	NN	I-NP	O
,	,	O	O
reflecting	VBG	B-VP	O
distinct	JJ	B-NP	O
behaviors	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
genes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
hypoxia	NN	B-NP	B
showed	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
correlation	NN	I-NP	O
with	IN	B-PP	O
microscopic	JJ	B-NP	O
tubulointerstitial	JJ	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
models	NNS	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
identified	VBD	B-VP	O
the	DT	B-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
proliferating	VBG	B-VP	O
cell	NN	B-NP	O
nuclear	JJ	I-NP	O
antigen	NN	I-NP	O
-	HYPH	B-VP	O
positive	JJ	B-ADJP	O
,	,	O	O
ED	VBN	B-VP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
positive	JJ	I-NP	O
,	,	O	O
and	CC	O	O
terminal	JJ	B-NP	O
dUTP	NN	I-NP	O
nick	NN	I-NP	O
-	HYPH	B-NP	O
end	NN	I-NP	O
labeled	VBN	B-VP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hypoxic	JJ	I-NP	B
cortical	JJ	I-NP	O
area	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
remnant	NN	I-NP	O
kidney	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
propose	VBP	B-VP	O
here	RB	B-ADVP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
pathological	JJ	I-NP	O
tie	NN	I-NP	O
between	IN	B-PP	O
chronic	JJ	B-NP	O
tubulointerstitial	JJ	I-NP	O
hypoxia	NN	I-NP	B
and	CC	O	O
progressive	JJ	B-NP	O
glomerular	JJ	I-NP	B
diseases	NNS	I-NP	I
.	.	O	O

Consensus	NNP	B-NP	O
statement	NN	I-NP	O
concerning	VBG	B-VP	O
cardiotoxicity	NN	B-NP	B
occurring	VBG	B-VP	O
during	IN	B-PP	O
haematopoietic	JJ	B-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
autoimmune	JJ	B-NP	B
diseases	NNS	I-NP	I
,	,	O	O
with	IN	B-PP	O
special	JJ	B-NP	O
reference	NN	I-NP	O
to	TO	B-PP	O
systemic	JJ	B-NP	B
sclerosis	NN	I-NP	I
and	CC	O	O
multiple	JJ	B-NP	B
sclerosis	NN	I-NP	I
.	.	O	O

Autologous	JJ	B-NP	O
haematopoietic	JJ	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
is	VBZ	B-VP	O
now	RB	B-ADVP	O
a	DT	B-NP	O
feasible	JJ	I-NP	O
and	CC	I-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
selected	VBN	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
autoimmune	JJ	I-NP	B
diseases	NNS	I-NP	I
.	.	O	O

Worldwide	RB	B-ADVP	O
,	,	O	O
over	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
transplanted	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
context	NN	I-NP	O
of	IN	B-PP	O
phase	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
encouraging	VBG	I-VP	O
enough	RB	B-ADVP	O
to	TO	B-VP	O
begin	VB	I-VP	O
randomised	VBN	I-VP	O
phase	NN	B-NP	O
num	CD	B-NP	O
trials	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
as	IN	B-SBAR	O
predicted	VBN	B-VP	O
,	,	O	O
significant	JJ	B-NP	O
transplant	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
morbidity	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
primarily	RB	B-ADJP	O
due	JJ	I-ADJP	O
to	TO	B-PP	O
complications	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
either	CC	O	O
the	DT	B-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
at	IN	B-PP	O
transplant	NN	B-NP	O
or	CC	O	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
infections	NNS	B-NP	B
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
deaths	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
is	VBZ	B-VP	O
low	JJ	B-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
caution	NN	B-NP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
when	WRB	B-ADVP	O
cyclophosphamide	NN	B-NP	O
or	CC	O	O
anthracyclines	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
mitoxantrone	NN	B-NP	O
are	VBP	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
underlying	VBG	I-NP	O
heart	NN	I-NP	B
damage	NN	I-NP	I
,	,	O	O
for	IN	B-PP	O
example	NN	B-NP	O
,	,	O	O
systemic	JJ	B-NP	B
sclerosis	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
meeting	NN	I-NP	O
was	VBD	B-VP	O
held	VBN	I-VP	O
in	IN	B-PP	O
Florence	NN	B-NP	O
,	,	O	O
bringing	VBG	B-VP	O
together	RB	B-ADVP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
experts	NNS	B-NP	O
in	IN	B-PP	O
various	JJ	B-NP	O
fields	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
rheumatology	NN	B-NP	O
,	,	O	O
cardiology	NN	B-NP	O
,	,	O	O
neurology	NN	B-NP	O
,	,	O	O
pharmacology	NN	B-NP	O
and	CC	O	O
transplantation	NN	B-NP	O
medicine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
object	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
meeting	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
analyse	VB	I-VP	O
existing	VBG	B-NP	O
data	NNS	I-NP	O
,	,	O	O
both	CC	O	O
published	VBN	B-VP	O
or	CC	O	O
available	JJ	B-ADJP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
European	NNP	I-NP	O
Group	NNP	I-NP	O
for	IN	B-PP	O
Blood	NNP	B-NP	O
and	CC	I-NP	O
Marrow	NNP	I-NP	O
Transplantation	NNP	I-NP	O
autoimmune	JJ	I-NP	B
disease	NN	I-NP	I
database	NN	I-NP	O
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
propose	VB	I-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
full	JJ	I-NP	O
cardiological	JJ	I-NP	O
assessment	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
during	IN	I-PP	O
the	DT	B-NP	O
transplant	NN	I-NP	O
emerged	VBD	B-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
recommendation	NN	I-NP	O
.	.	O	O

Immunohistochemical	JJ	B-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
inducible	JJ	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
iNOS	NN	B-NP	O
)	)	O	O
,	,	O	O
basic	JJ	B-NP	O
fibroblast	NN	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
(	(	O	O
bFGF	NN	B-NP	O
)	)	O	O
and	CC	O	O
tumor	NN	B-NP	B
growth	NN	I-NP	O
factor	NN	I-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
(	(	O	O
TGF	NN	B-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
arteritis	NN	B-NP	B
induced	VBN	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
fenoldopam	NN	B-NP	O
and	CC	I-NP	O
theophylline	NN	I-NP	O
,	,	O	O
vasodilators	NNS	B-NP	O
.	.	O	O

Arteritis	NN	B-NP	B
induced	VBN	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
vasodilators	NNS	B-NP	O
,	,	O	O
fenoldopam	NN	B-NP	O
and	CC	I-NP	O
theophylline	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
immunohistochemically	RB	B-ADVP	O
for	IN	B-PP	O
expressions	NNS	B-NP	O
of	IN	B-PP	O
inducible	JJ	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
(	(	O	O
iNOS	NN	B-NP	O
)	)	O	O
,	,	O	O
basic	JJ	B-NP	O
fibroblast	NN	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
(	(	O	O
bFGF	NN	B-NP	O
)	)	O	O
and	CC	O	O
tumor	NN	B-NP	B
growth	NN	I-NP	O
factor	NN	I-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
(	(	O	O
TGF	NN	B-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
)	)	O	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
fenoldopam	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
by	IN	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
following	VBG	B-VP	O
repeated	VBN	B-NP	O
daily	JJ	I-NP	O
oral	JJ	I-NP	O
administrations	NNS	I-NP	O
of	IN	B-PP	O
theophylline	NN	B-NP	O
.	.	O	O

Irrespective	JJ	B-NP	O
of	IN	B-PP	O
theophylline	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
iNOS	NN	B-NP	O
antigens	NNS	I-NP	O
were	VBD	B-VP	O
remarkably	RB	B-ADJP	O
abundant	JJ	I-ADJP	O
in	IN	B-PP	O
ED	VBN	B-VP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
post	AFX	O	O
-	HYPH	O	O
fenoldopam	NN	O	O
-	HYPH	O	O
infusion	NN	B-NP	O
(	(	O	O
DPI	NN	B-NP	O
)	)	O	O
;	:	O	O
bFGF	NN	B-NP	O
antigens	NNS	I-NP	O
were	VBD	B-VP	O
remarkably	RB	B-ADJP	O
abundant	JJ	I-ADJP	O
in	IN	B-PP	O
ED	VBN	B-VP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
DPI	NN	I-NP	O
;	:	O	O
TGF	NN	B-NP	O
-	HYPH	I-NP	O
beta1	NN	I-NP	O
antigens	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
ED	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
on	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
num	CD	B-NP	O
DPI	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
peak	JJ	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
iNOS	NN	B-NP	O
antigen	NN	I-NP	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
bFGF	NN	B-NP	O
antigen	NN	I-NP	O
,	,	O	O
and	CC	O	O
bFGF	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
suppressive	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
iNOS	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
rat	NN	I-NP	O
arteritis	NN	I-NP	B
models	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
TGF	NN	B-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
suppressive	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
iNOS	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
models	NNS	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
-	HYPH	I-NP	O
molecular	JJ	I-NP	O
-	HYPH	I-NP	O
weight	NN	I-NP	O
heparin	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mechanical	JJ	B-NP	O
heart	NN	I-NP	O
valves	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
interruption	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
anticoagulant	NN	I-NP	O
(	(	O	O
OAC	NN	B-NP	O
)	)	O	O
administration	NN	B-NP	O
is	VBZ	B-VP	O
sometimes	RB	I-VP	O
indicated	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mechanical	JJ	B-NP	O
heart	NN	I-NP	O
valves	NNS	I-NP	O
,	,	O	O
mainly	RB	B-ADVP	O
before	IN	B-PP	O
noncardiac	JJ	B-NP	O
surgery	NN	I-NP	O
,	,	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
surgical	JJ	B-NP	O
interventions	NNS	I-NP	O
,	,	O	O
and	CC	O	O
pregnancy	NN	B-NP	O
.	.	O	O

Unfractionated	JJ	B-NP	O
heparin	NN	I-NP	O
(	(	O	O
UH	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
currently	RB	B-ADVP	O
the	DT	B-NP	O
substitute	NN	I-NP	O
for	IN	B-PP	O
selected	VBN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
-	HYPH	I-NP	O
molecular	JJ	I-NP	O
-	HYPH	I-NP	O
weight	NN	I-NP	O
heparin	NN	I-NP	O
(	(	O	O
LMWH	NN	B-NP	O
)	)	O	O
offers	VBZ	B-VP	O
theoretical	JJ	B-NP	O
advantages	NNS	I-NP	O
over	IN	B-PP	O
UH	NN	B-NP	O
,	,	O	O
but	CC	O	O
is	VBZ	B-VP	O
not	RB	I-VP	O
currently	RB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
guidelines	NNS	I-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
alternative	NN	I-NP	O
to	TO	B-PP	O
UH	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
prosthetic	JJ	B-NP	O
valves	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
review	VB	I-VP	O
the	DT	B-NP	O
data	NNS	I-NP	O
accumulated	VBN	B-VP	O
so	RB	B-ADVP	O
far	RB	I-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
LMWH	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
population	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
discuss	VB	I-VP	O
its	PRP$	B-NP	O
applicability	NN	I-NP	O
in	IN	B-PP	O
common	JJ	B-NP	O
practice	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
this	DT	B-NP	O
paper	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
current	JJ	I-NP	O
medical	JJ	I-NP	O
literature	NN	I-NP	O
on	IN	B-PP	O
LMWH	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mechanical	JJ	B-NP	O
heart	NN	I-NP	O
valves	NNS	I-NP	O
was	VBD	B-VP	O
extensively	RB	I-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
series	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
studies	NNS	I-NP	O
was	VBD	B-VP	O
randomized	VBN	I-VP	O
,	,	O	O
and	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
prospective	JJ	B-ADJP	O
.	.	O	O

Data	NNS	B-NP	O
to	TO	B-VP	O
establish	VB	I-VP	O
the	DT	B-NP	O
thromboembolic	JJ	I-NP	B
risk	NN	I-NP	O
were	VBD	B-VP	O
incomplete	JJ	B-ADJP	O
.	.	O	O

After	IN	B-PP	O
excluding	VBG	B-VP	O
case	NN	B-NP	O
reports	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
following	VBG	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
constructed	VBN	I-VP	O
:	:	O	O
(	(	B-LST	O
a	LS	I-LST	O
)	)	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
administration	NN	I-NP	O
,	,	O	O
after	IN	B-PP	O
valve	NN	B-NP	O
insertion	NN	I-NP	O
;	:	O	O
(	(	B-LST	O
b	LS	I-LST	O
)	)	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
,	,	O	O
perioperative	JJ	O	O
(	(	O	O
noncardiac	JJ	B-ADJP	O
)	)	O	O
/	SYM	B-NP	O
periprocedural	JJ	B-ADJP	O
;	:	O	O
(	(	B-LST	O
c	LS	I-LST	O
)	)	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
,	,	O	O
due	IN	B-PP	O
to	TO	I-PP	O
intolerance	NN	B-NP	O
to	TO	B-PP	O
OAC	NN	B-NP	O
;	:	O	O
(	(	B-LST	O
d	LS	I-LST	O
)	)	O	O
long	JJ	O	O
-	HYPH	O	O
term	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
thromboembolism	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
studies	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
groups	NNS	B-NP	O
a	NN	I-NP	O
,	,	O	O
b	NN	B-NP	O
,	,	O	O
c	NN	B-NP	O
,	,	O	O
and	CC	O	O
d	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
;	:	O	O
for	IN	B-PP	O
hemorrhage	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
overall	JJ	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
respective	JJ	I-NP	O
groups	NNS	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mechanical	JJ	B-NP	O
heart	NN	I-NP	O
valves	NNS	I-NP	O
,	,	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
LMWH	NN	I-NP	O
therapy	NN	I-NP	O
compares	VBZ	B-VP	O
favorably	RB	B-ADVP	O
with	IN	B-PP	O
UH	NN	B-NP	O
.	.	O	O

Data	NNS	B-NP	O
on	IN	B-PP	O
mid	NN	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
LMWH	NN	I-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
sparse	JJ	B-ADJP	O
.	.	O	O

Further	RB	B-NP	O
randomized	VBN	I-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
confirm	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
precise	JJ	I-NP	O
indications	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
LMWH	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
mechanical	JJ	B-NP	O
heart	NN	I-NP	O
valves	NNS	I-NP	O
.	.	O	O

Topiramate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrolithiasis	NN	I-NP	B
.	.	O	O

Topiramate	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
recently	RB	I-NP	O
developed	VBN	I-NP	O
antiepileptic	JJ	I-NP	O
medication	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
becoming	VBG	I-VP	O
more	RBR	B-VP	O
widely	RB	I-VP	O
prescribed	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
efficacy	NN	I-NP	O
in	IN	B-PP	O
treating	VBG	B-VP	O
refractory	JJ	B-NP	B
seizures	NNS	I-NP	I
.	.	O	O

Urologists	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
medication	NN	I-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
metabolic	JJ	B-NP	B
acidosis	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
carbonic	JJ	B-NP	O
anhydrase	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
distal	JJ	I-NP	O
tubular	JJ	I-NP	O
acidification	NN	I-NP	O
defect	NN	I-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
,	,	O	O
thus	RB	B-ADVP	O
impairing	VBG	B-VP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
compensatory	JJ	I-NP	O
drop	NN	I-NP	O
in	IN	B-PP	O
urine	NN	B-NP	O
pH	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
factors	NNS	I-NP	O
can	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
phosphate	NN	I-NP	O
nephrolithiasis	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
topiramate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrolithiasis	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
urologic	JJ	I-NP	O
literature	NN	I-NP	O
.	.	O	O

Spironolactone	NN	B-NP	O
:	:	O	O
is	VBZ	B-VP	O
it	PRP	B-NP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
hypokalemia	NN	I-NP	B
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
?	.	O	O
OBJECTIVE	NN	B-NP	O
:	:	O	O
Nephrotoxicity	NN	B-NP	B
is	VBZ	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
(	(	O	O
AmB	NN	B-NP	O
)	)	O	O
,	,	O	O
often	RB	B-ADVP	O
limiting	VBG	B-VP	O
administration	NN	B-NP	O
of	IN	B-PP	O
full	JJ	B-NP	O
dosage	NN	I-NP	O
.	.	O	O

Selective	JJ	B-NP	O
distal	JJ	I-NP	O
tubular	JJ	I-NP	O
epithelial	JJ	I-NP	O
toxicity	NN	I-NP	B
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
profound	JJ	I-NP	O
potassium	NN	I-NP	O
wasting	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
clinical	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
AmB	NN	B-NP	O
.	.	O	O

Potassium	NN	B-NP	O
depletion	NN	I-NP	O
also	RB	B-ADVP	O
potentiates	VBZ	B-VP	O
the	DT	B-NP	O
tubular	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
AmB	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
spironolactone	NN	B-NP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
potassium	NN	B-NP	O
requirements	NNS	I-NP	O
and	CC	O	O
to	TO	B-VP	O
prevent	VB	I-VP	O
hypokalemia	NN	B-NP	B
in	IN	B-PP	O
neutropenic	JJ	B-NP	B
patients	NNS	I-NP	O
on	IN	B-PP	O
AmB	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
various	JJ	B-NP	O
hematological	JJ	I-NP	B
disorders	NNS	I-NP	I
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-VP	O
receive	VB	I-VP	O
either	CC	B-NP	O
intravenous	JJ	I-NP	O
AmB	NN	I-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
AmB	NN	B-NP	O
and	CC	O	O
oral	JJ	B-NP	O
spironolactone	NN	I-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
when	WRB	B-ADVP	O
developing	VBG	B-VP	O
a	DT	B-NP	O
proven	VBN	I-NP	O
or	CC	I-NP	O
suspected	VBN	I-NP	O
fungal	JJ	I-NP	B
infection	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
receiving	VBG	B-VP	O
concomitant	JJ	B-NP	O
AmB	NN	I-NP	O
and	CC	I-NP	O
spironolactone	NN	I-NP	O
had	VBD	B-VP	O
significantly	RB	B-NP	O
higher	JJR	I-NP	O
plasma	NN	I-NP	O
potassium	NN	I-NP	O
levels	NNS	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
receiving	VBG	B-VP	O
AmB	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Those	DT	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
AmB	NN	B-NP	O
and	CC	I-NP	O
spironolactone	NN	I-NP	O
required	VBD	B-VP	O
significantly	RB	B-NP	O
less	JJR	I-NP	O
potassium	NN	I-NP	O
supplementation	NN	I-NP	O
to	TO	B-VP	O
maintain	VB	I-VP	O
their	PRP$	B-NP	O
plasma	NN	I-NP	O
potassium	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
range	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
urinary	JJ	B-NP	O
potassium	NN	I-NP	O
losses	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
AmB	NN	B-NP	O
and	CC	I-NP	O
spironolactone	NN	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
receiving	VBG	I-NP	O
AmB	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
spironolactone	NN	B-NP	O
can	MD	B-VP	O
reduce	VB	I-VP	O
potassium	NN	B-NP	O
requirements	NNS	I-NP	O
and	CC	O	O
prevent	VB	B-VP	O
hypokalemia	NN	B-NP	B
by	IN	B-PP	O
reducing	VBG	B-VP	O
urinary	JJ	B-NP	O
potassium	NN	I-NP	O
loss	NN	I-NP	O
in	IN	B-PP	O
neutropenic	JJ	B-NP	B
patients	NNS	I-NP	O
on	IN	B-PP	O
AmB	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Dopamine	NN	B-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
signaling	NN	I-NP	O
controls	VBZ	B-VP	O
neuronal	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
muscarinic	JJ	B-NP	O
and	CC	I-NP	O
glutamatergic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Dopamine	NN	B-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
,	,	O	O
through	IN	B-PP	O
D1	NN	B-NP	O
/	SYM	O	O
D2	NN	B-NP	O
receptor	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
signaling	NN	I-NP	O
,	,	O	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
epileptic	JJ	B-NP	B
seizures	NNS	I-NP	I
arising	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
limbic	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Excitotoxicity	NN	B-NP	B
leading	VBG	B-VP	O
to	TO	B-PP	O
neuronal	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
affected	VBN	I-NP	O
areas	NNS	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
cellular	JJ	I-NP	O
level	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
respect	NN	I-NP	O
,	,	O	O
little	JJ	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
about	IN	B-PP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
DA	NN	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neuronal	JJ	I-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
analyze	VBP	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
and	CC	O	O
neurotoxicity	NN	B-NP	B
in	IN	B-PP	O
D2R	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
cholinergic	JJ	I-NP	O
agonist	NN	I-NP	O
pilocarpine	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
these	DT	B-NP	O
results	NNS	I-NP	O
with	IN	B-PP	O
those	DT	B-NP	O
previously	RB	B-VP	O
obtained	VBN	I-VP	O
with	IN	B-PP	O
kainic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
KA	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
potent	JJ	I-NP	O
glutamate	NN	I-NP	O
agonist	NN	I-NP	O
.	.	O	O

Importantly	RB	B-ADVP	O
,	,	O	O
D2R	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
develop	VBP	B-VP	O
seizures	NNS	B-NP	B
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
not	RB	O	O
epileptogenic	JJ	B-ADJP	O
for	IN	B-PP	O
WT	JJ	B-NP	O
littermates	NNS	I-NP	O
and	CC	O	O
show	VB	B-VP	O
greater	JJR	B-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
result	VBP	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
more	RBR	I-NP	O
widespread	JJ	I-NP	O
neuronal	JJ	I-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
both	CC	O	O
WT	NN	B-NP	O
and	CC	I-NP	O
D2R	NN	I-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
brains	NNS	B-NP	O
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
KA	NN	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
D2R	NN	B-NP	O
lowers	VBZ	B-VP	O
the	DT	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
both	CC	O	O
glutamate	NN	B-NP	O
and	CC	I-NP	O
acetylcholine	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurodegeneration	NN	I-NP	B
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
distinct	JJ	B-NP	O
interactions	NNS	I-NP	O
of	IN	B-PP	O
D2R	NN	B-NP	O
signaling	NN	I-NP	O
with	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
neurotransmitters	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
with	IN	B-PP	O
a	DT	B-NP	O
dopamine	NN	I-NP	O
agonist	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

Risperidone	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
potent	JJ	I-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
both	CC	O	O
serotonergic	JJ	O	O
(	(	O	O
5HT2A	NN	B-NP	O
)	)	O	O
and	CC	O	O
dopaminergic	JJ	B-NP	O
D2	NN	I-NP	O
receptors	NNS	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
in	IN	B-PP	O
adults	NNS	B-NP	O
and	CC	I-NP	O
children	NNS	I-NP	O
.	.	O	O

Chronically	RB	B-NP	O
elevated	JJ	I-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
prolactinomas	NNS	B-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
arrested	VBN	B-NP	O
growth	NN	I-NP	O
and	CC	I-NP	O
development	NN	I-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
either	CC	O	O
delayed	VBN	B-VP	B
puberty	NN	B-NP	I
or	CC	O	O
short	JJ	B-NP	O
stature	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
possibilities	NNS	I-NP	O
stress	VBP	B-VP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
and	CC	I-NP	O
effective	JJ	I-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
in	IN	B-PP	O
youth	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
successful	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
with	IN	B-PP	O
cabergoline	NN	B-NP	O
in	IN	B-PP	O
youth	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
undertook	VBD	B-VP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
case	NN	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
cabergoline	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
males	NNS	I-NP	O
(	(	O	O
age	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
Diagnostic	NNP	B-NP	O
and	CC	I-NP	O
Statistical	NNP	I-NP	O
Manual	NNP	I-NP	O
of	IN	B-PP	O
Mental	NNP	B-NP	B
Disorders	NNP	I-NP	I
(	(	O	O
fourth	JJ	B-NP	O
edition	NN	I-NP	O
)	)	I-NP	O
bipolar	JJ	I-NP	B
disorder	NN	I-NP	I
or	CC	I-NP	O
psychoses	NNS	I-NP	B
,	,	O	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
elevations	NNS	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mL	NN	I-NP	O
,	,	O	O
normal	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
mL	NN	I-NP	O
)	)	O	O
,	,	O	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
cabergoline	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
serum	NN	B-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
normalized	VBN	B-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
cabergoline	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
week	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
cabergoline	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Cabergoline	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
without	IN	B-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Cabergoline	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
in	IN	B-PP	O
youth	NN	B-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
further	JJ	B-NP	O
research	NN	I-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
.	.	O	O

Cholestatic	JJ	B-NP	B
jaundice	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
cholestatic	JJ	B-NP	B
jaundice	NN	I-NP	I
shortly	RB	B-ADVP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
metformin	NN	B-NP	O
hydrochloride	NN	I-NP	O
.	.	O	O

Ultrasound	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
and	CC	O	O
abdominal	JJ	B-NP	O
CT	NN	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

An	DT	B-NP	O
ERCP	NN	I-NP	O
showed	VBD	B-VP	O
normal	JJ	B-NP	O
biliary	JJ	I-NP	O
anatomy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
percutaneous	JJ	I-NP	O
liver	NN	I-NP	O
biopsy	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
showing	VBG	B-VP	O
marked	JJ	B-NP	O
cholestasis	NN	I-NP	B
,	,	O	O
with	IN	B-PP	O
portal	JJ	B-NP	O
edema	NN	I-NP	B
,	,	O	O
ductular	JJ	B-NP	O
proliferation	NN	I-NP	O
,	,	O	O
and	CC	O	O
acute	JJ	B-NP	O
inflammation	NN	I-NP	B
.	.	O	O

Metformin	NN	B-NP	O
hydrochloride	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
jaundice	NN	B-NP	B
resolved	VBN	B-VP	O
slowly	RB	B-ADVP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Given	VBN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
his	PRP$	B-NP	O
jaundice	NN	I-NP	B
num	CD	I-NP	O
wk	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
believe	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
case	NN	I-NP	O
represents	VBZ	B-VP	O
an	DT	B-NP	O
example	NN	I-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
such	JJ	I-NP	O
case	NN	I-NP	O
reported	VBD	B-VP	O
.	.	O	O

Electro	AFX	B-NP	O
-	HYPH	I-NP	O
oculography	NN	B-NP	O
,	,	O	O
electroretinography	NN	B-NP	O
,	,	O	O
visual	JJ	B-NP	O
evoked	JJ	I-NP	O
potentials	NNS	I-NP	O
,	,	O	O
and	CC	O	O
multifocal	JJ	B-NP	O
electroretinography	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
vigabatrin	NN	B-NP	O
-	HYPH	O	O
attributed	VBN	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
constriction	NN	I-NP	I
.	.	O	O

Symptomatic	JJ	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
constriction	NN	I-NP	I
thought	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
vigabatrin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
visual	JJ	I-NP	O
fields	NNS	I-NP	O
and	CC	O	O
visual	JJ	B-NP	O
electrophysiology	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
known	VBN	B-NP	O
vigabatrin	NN	I-NP	O
-	HYPH	B-VP	O
attributed	VBN	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
loss	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
previously	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
no	RB	B-ADVP	O
longer	RBR	I-ADVP	O
receiving	VBG	B-VP	O
vigabatrin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
central	JJ	I-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
fields	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
Humphrey	NNP	I-NP	O
Visual	NNP	I-NP	O
Field	NNP	I-NP	O
Analyzer	NNP	I-NP	O
.	.	O	O

Full	JJ	B-NP	O
visual	JJ	I-NP	O
electrophysiology	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
flash	NN	B-NP	O
electroretinography	NN	I-NP	O
(	(	O	O
ERG	NN	B-NP	O
)	)	O	O
,	,	O	O
pattern	NN	B-NP	O
electroretinography	NN	I-NP	O
,	,	O	O
multifocal	JJ	B-NP	O
ERG	NN	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
VERIS	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
electro	AFX	O	O
-	HYPH	O	O
oculography	NN	B-NP	O
,	,	O	O
and	CC	O	O
flash	NN	B-NP	O
and	CC	I-NP	O
pattern	NN	I-NP	O
visual	JJ	I-NP	O
evoked	JJ	I-NP	O
potentials	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
marked	JJ	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
constriction	NN	I-NP	I
with	IN	B-PP	O
some	DT	B-NP	O
sparing	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
visual	JJ	I-NP	O
field	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
eighth	NN	I-NP	O
exhibited	VBD	B-VP	O
concentric	JJ	B-NP	O
constriction	NN	I-NP	O
.	.	O	O

Most	JJS	B-NP	O
electrophysiological	JJ	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
usually	RB	B-ADVP	O
just	RB	B-ADVP	O
within	IN	B-PP	O
normal	JJ	B-NP	O
limits	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
subnormal	JJ	B-NP	O
Arden	NNP	I-NP	O
electro	AFX	O	O
-	HYPH	O	O
oculography	NN	B-NP	O
indices	NNS	I-NP	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
abnormally	RB	I-NP	O
delayed	VBN	I-NP	O
photopic	JJ	I-NP	O
b	NN	I-NP	O
wave	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
delayed	VBN	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
Hz	NN	I-NP	O
flicker	NN	I-NP	O
b	NN	I-NP	O
waves	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
delayed	VBN	I-VP	O
oscillatory	JJ	B-NP	O
potentials	NNS	I-NP	O
.	.	O	O

Multifocal	JJ	B-NP	O
ERG	NN	I-NP	O
showed	VBD	B-VP	O
abnormalities	NNS	B-NP	O
that	WDT	B-NP	O
sometimes	RB	B-ADVP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
visual	JJ	I-NP	O
field	NN	I-NP	O
appearance	NN	I-NP	O
and	CC	O	O
confirmed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
deficit	NN	I-NP	O
occurs	VBZ	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
retinal	JJ	I-NP	O
level	NN	I-NP	O
.	.	O	O

Marked	VBN	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
constriction	NN	I-NP	I
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
vigabatrin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
field	NN	I-NP	O
defects	NNS	I-NP	O
and	CC	O	O
some	DT	B-NP	O
electrophysiological	JJ	I-NP	O
abnormalities	NNS	I-NP	O
persist	VBP	B-VP	O
when	WRB	B-ADVP	O
vigabatrin	NN	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
withdrawn	VBN	I-VP	O
.	.	O	O

Conversion	NN	B-NP	O
to	TO	B-PP	O
rapamycin	NN	B-NP	O
immunosuppression	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
:	:	O	O
report	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
initial	JJ	I-NP	O
experience	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
RAPA	NN	B-NP	O
conversion	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
cyclosporine	NN	B-NP	O
(	(	O	O
CsA	NN	B-NP	O
)	)	O	O
or	CC	O	O
tacrolimus	NN	B-NP	O
(	(	O	O
Tac	NN	B-NP	O
)	)	O	O
toxicity	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
renal	JJ	I-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
were	VBD	B-VP	O
switched	VBN	I-VP	O
to	TO	B-PP	O
fixed	VBN	B-NP	O
dose	NN	I-NP	O
rapamycin	NN	I-NP	O
(	(	O	O
RAPA	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
posttransplant	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
monitoring	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
initially	RB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
adjust	VB	I-VP	O
doses	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
indications	NNS	I-NP	O
for	IN	B-PP	O
switch	NN	B-NP	O
were	VBD	B-VP	O
chronic	JJ	B-NP	O
CsA	NN	I-NP	O
or	CC	I-NP	O
Tac	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
,	,	O	O
acute	JJ	B-NP	O
CsA	NN	I-NP	O
or	CC	I-NP	O
Tac	NN	I-NP	O
toxicity	NN	I-NP	B
,	,	O	O
severe	JJ	B-NP	O
facial	JJ	I-NP	B
dysmorphism	NN	I-NP	I
,	,	O	O
posttransplant	JJ	B-NP	B
lymphoproliferative	JJ	I-NP	I
disorder	NN	I-NP	I
(	(	O	O
PTLD	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
remission	NN	B-NP	O
,	,	O	O
and	CC	O	O
hepatotoxicity	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
is	VBZ	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
switched	VBD	B-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
chronic	JJ	B-NP	O
nephrotoxicity	NN	I-NP	B
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
[	(	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
micromol	NN	I-NP	O
/	SYM	I-NP	O
liter	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
]	)	O	O
.	.	O	O

Facial	JJ	B-NP	B
dysmorphism	NN	I-NP	I
improved	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
relapse	NN	I-NP	O
of	IN	B-PP	O
PTLD	NN	B-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
pneumonia	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
Pneumocystis	NN	I-NP	B
carinii	NN	I-NP	I
pneumonia	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
infectious	JJ	I-NP	B
mononucleosis	NN	I-NP	I
with	IN	B-PP	O
polyclonal	JJ	B-NP	O
PTLD	NN	I-NP	B
lung	NN	I-NP	O
infiltrate	NN	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
bronchiolitis	NN	B-NP	B
obliterans	NNS	I-NP	I
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
deaths	NNS	I-NP	O
.	.	O	O

RAPA	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
because	IN	B-PP	O
of	IN	I-PP	O
pneumonia	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
PTLD	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
oral	JJ	B-NP	O
aphtous	JJ	I-NP	B
ulcers	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

RAPA	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
high	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

RAPA	NN	B-NP	O
conversion	NN	I-NP	O
provides	VBZ	B-VP	O
adequate	JJ	B-NP	O
immunosuppression	NN	I-NP	O
to	TO	B-VP	O
enable	VB	I-VP	O
CsA	NN	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
converting	VBG	B-VP	O
patients	NNS	B-NP	O
to	TO	B-PP	O
RAPA	NN	B-NP	O
drug	NN	I-NP	O
levels	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
to	TO	I-VP	O
avoid	VB	I-VP	O
over	AFX	B-NP	O
-	HYPH	I-NP	O
immunosuppression	NN	I-NP	O
and	CC	I-NP	O
adequate	JJ	I-NP	O
antiviral	JJ	I-NP	O
and	CC	I-NP	O
Pneumocystis	NN	I-NP	B
carinii	NN	I-NP	I
pneumonia	NN	I-NP	I
prophylaxis	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
.	.	O	O

Worsening	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
by	IN	B-PP	O
motor	NN	B-NP	O
and	CC	O	O
mental	JJ	B-NP	O
tasks	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
with	IN	B-PP	O
disabling	VBG	B-NP	O
dyskinesia	NN	I-NP	B
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
mental	JJ	O	O
(	(	O	O
mental	JJ	B-NP	O
calculation	NN	I-NP	O
)	)	O	O
and	CC	O	O
motor	NN	B-NP	O
(	(	O	O
flexion	NN	B-NP	O
/	SYM	B-NP	O
extension	NN	I-NP	O
of	IN	B-PP	O
right	JJ	B-NP	O
fingers	NNS	I-NP	O
,	,	O	O
flexion	NN	B-NP	O
/	SYM	I-NP	O
extension	NN	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
fingers	NNS	I-NP	O
,	,	O	O
flexion	NN	B-NP	O
/	SYM	I-NP	O
extension	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neck	NN	I-NP	O
,	,	O	O
speaking	VBG	B-VP	O
aloud	RB	B-ADVP	O
)	)	O	O
tasks	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
worsening	NN	I-NP	O
of	IN	B-PP	O
peak	NN	B-NP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
dyskinesia	NN	I-NP	B
following	VBG	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
score	NN	I-NP	O
at	IN	B-PP	O
rest	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
aggravation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dyskinesia	NN	I-NP	B
score	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
during	IN	B-PP	O
speaking	VBG	B-VP	O
aloud	RB	B-ADVP	O
,	,	O	O
movements	NNS	B-NP	O
of	IN	B-PP	O
right	JJ	B-NP	O
and	CC	I-NP	O
left	JJ	I-NP	O
fingers	NNS	I-NP	O
,	,	O	O
movements	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neck	NN	I-NP	O
,	,	O	O
and	CC	O	O
mental	JJ	B-NP	O
calculation	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
activation	NN	B-NP	O
tasks	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
speaking	VBG	B-VP	O
aloud	RB	B-ADVP	O
could	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
objective	JJ	B-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
dyskinesia	NN	B-NP	B
severity	NN	I-NP	O
.	.	O	O

Structural	JJ	B-NP	B
and	CC	I-NP	I
functional	JJ	I-NP	I
impairment	NN	I-NP	I
of	IN	B-PP	I
mitochondria	NNS	B-NP	I
in	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
:	:	O	O
suppression	NN	B-NP	O
of	IN	B-PP	O
cytochrome	NN	B-NP	O
c	NN	I-NP	O
oxidase	NN	I-NP	O
num	CD	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
(	(	O	O
ADR	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
cancer	NN	B-NP	B
chemotherapy	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
limited	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
cumulative	JJ	I-NP	O
cardiovascular	JJ	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

Earlier	JJR	B-NP	O
observations	NNS	I-NP	O
that	IN	B-SBAR	O
ADR	NN	B-NP	O
interacts	VBZ	B-VP	O
with	IN	B-PP	O
mitochondrial	JJ	B-NP	O
cytochrome	NN	I-NP	O
c	NN	I-NP	O
oxidase	NN	I-NP	O
(	(	O	O
COX	NN	B-NP	O
)	)	O	O
and	CC	O	O
suppresses	VBZ	B-VP	O
its	PRP$	B-NP	O
enzyme	NN	I-NP	O
activity	NN	I-NP	O
led	VBD	B-VP	O
us	PRP	B-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
ADR	NN	B-NP	O
s	VBZ	B-VP	O
action	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
functions	NNS	I-NP	O
and	CC	O	O
heart	NN	B-NP	O
mitochondrial	JJ	I-NP	O
morphology	NN	I-NP	O
in	IN	B-PP	O
Balb	NN	B-NP	O
-	HYPH	B-NP	O
c	NN	I-NP	O
mice	NNS	I-NP	O
i.p.	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
ADR	NN	B-NP	O
for	IN	B-PP	O
several	JJ	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
various	JJ	B-NP	O
times	NNS	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
for	IN	B-PP	O
cardiovascular	JJ	B-NP	O
functions	NNS	I-NP	O
by	IN	B-PP	O
electrocardiography	NN	B-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
heart	NN	B-NP	O
tissue	NN	I-NP	O
damage	NN	I-NP	O
by	IN	B-PP	O
electron	NN	B-NP	O
microscopy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
parallel	JJ	B-NP	O
,	,	I-NP	O
total	JJ	I-NP	O
RNA	NN	I-NP	O
was	VBD	B-VP	O
extracted	VBN	I-VP	O
from	IN	B-PP	O
samples	NNS	B-NP	O
of	IN	B-PP	O
dissected	VBN	B-NP	O
heart	NN	I-NP	O
and	CC	O	O
analyzed	VBN	B-VP	O
by	IN	B-PP	O
Northern	NN	B-NP	O
blot	NN	I-NP	O
hybridization	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
steady	JJ	I-NP	O
-	HYPH	I-NP	O
state	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
RNA	NN	I-NP	O
transcripts	NNS	I-NP	O
encoded	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
COXII	NN	I-NP	O
,	,	O	O
COXIII	NN	B-NP	O
,	,	O	O
and	CC	O	O
COXIV	NN	B-NP	O
genes	NNS	I-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
samples	NNS	B-NP	O
obtained	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
for	IN	B-PP	O
comparative	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
ADR	NN	B-NP	O
caused	VBD	B-VP	O
cardiovascular	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
characterized	VBN	B-VP	O
by	IN	B-PP	O
bradycardia	NN	B-NP	B
,	,	O	O
extension	NN	B-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	O
depolarization	NN	I-NP	O
time	NN	I-NP	O
(	(	O	O
tQRS	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
failure	NN	B-NP	O
of	IN	B-PP	O
QRS	NN	B-NP	O
at	IN	B-PP	O
high	JJ	B-NP	O
concentrations	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
)	)	O	O
the	DT	B-NP	O
heart	NN	I-NP	O
mitochondria	NNS	I-NP	O
underwent	VBD	B-VP	O
swelling	NN	B-NP	B
,	,	O	O
fusion	NN	B-NP	O
,	,	O	O
dissolution	NN	B-NP	O
,	,	O	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
disruption	NN	B-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	O
cristae	NNS	I-NP	O
after	IN	B-PP	O
several	JJ	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Such	JJ	B-NP	O
abnormalities	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mitochondria	NNS	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
tissue	NN	I-NP	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
genes	NNS	I-NP	O
of	IN	B-PP	O
COX	NN	B-NP	O
enzyme	NN	I-NP	O
examined	VBN	B-VP	O
,	,	O	O
only	RB	B-NP	O
COXII	NN	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
was	VBD	B-VP	O
suppressed	VBN	I-VP	O
by	IN	B-PP	O
ADR	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
mainly	RB	B-ADVP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
both	CC	O	O
heart	NN	B-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
.	.	O	O

Knowing	VBG	B-VP	O
that	IN	B-SBAR	O
heart	NN	B-NP	O
mitochondria	NNS	I-NP	O
represent	VBP	B-VP	O
almost	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
muscle	NN	I-NP	O
by	IN	B-PP	O
weight	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
deteriorating	VBG	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ADR	NN	B-NP	O
on	IN	B-PP	O
cardiovascular	JJ	B-NP	O
function	NN	I-NP	O
involve	VBP	B-VP	O
mitochondrial	JJ	B-NP	B
structural	JJ	I-NP	I
and	CC	I-NP	I
functional	JJ	I-NP	I
impairment	NN	I-NP	I
.	.	O	O

Enhanced	VBN	B-NP	O
bradycardia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenoceptor	NN	I-NP	O
antagonists	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
isoniazid	NN	B-NP	O
.	.	O	O

High	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
isoniazid	NN	B-NP	O
increase	NN	I-NP	O
hypotension	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
vasodilators	NNS	B-NP	O
and	CC	O	O
change	VB	B-VP	O
the	DT	B-NP	O
accompanying	VBG	I-NP	O
reflex	NN	I-NP	O
tachycardia	NN	I-NP	B
to	TO	B-PP	O
bradycardia	NN	B-NP	B
,	,	O	O
an	DT	B-NP	O
interaction	NN	I-NP	O
attributed	VBN	B-VP	O
to	TO	B-PP	O
decreased	VBN	B-NP	O
synthesis	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
gamma	SYM	B-NP	O
-	HYPH	B-VP	O
aminobutyric	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
GABA	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
possible	JJ	I-NP	O
enhancement	NN	I-NP	O
by	IN	B-PP	O
isoniazid	NN	B-NP	O
of	IN	B-PP	O
bradycardia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenoceptor	NN	I-NP	O
antagonists	NNS	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
anaesthetised	VBN	B-VP	O
with	IN	B-PP	O
chloralose	NN	B-NP	O
-	HYPH	I-NP	O
urethane	NN	I-NP	O
.	.	O	O

Isoniazid	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
bradycardia	NN	B-NP	B
after	IN	B-PP	O
propranolol	NN	B-NP	O
,	,	O	O
pindolol	NN	B-NP	O
,	,	O	O
labetalol	NN	B-NP	O
and	CC	I-NP	O
atenolol	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
after	IN	B-PP	O
clonidine	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	B-PP	O
after	IN	I-PP	O
hexamethonium	NN	B-NP	O
or	CC	I-NP	O
carbachol	NN	I-NP	O
.	.	O	O

Enhancement	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
methylatropine	NN	B-NP	O
or	CC	O	O
previously	RB	B-VP	O
vagotomised	VBN	I-VP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
compatible	JJ	B-ADJP	O
with	IN	B-PP	O
interference	NN	B-NP	O
by	IN	B-PP	O
isoniazid	NN	B-NP	O
with	IN	B-PP	O
GABAergic	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
parasympathetic	JJ	I-NP	O
tone	NN	I-NP	O
.	.	O	O

Such	JJ	B-NP	O
interference	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
exerted	VBN	I-VP	O
centrally	RB	B-ADVP	O
,	,	O	O
possibly	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
nucleus	NN	I-NP	O
ambiguus	NN	I-NP	O
,	,	O	O
or	CC	O	O
peripherally	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
sinus	NN	I-NP	O
node	NN	I-NP	O
.	.	O	O

Epileptogenic	JJ	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
after	IN	B-SBAR	O
drug	NN	B-NP	O
induces	VBZ	B-VP	O
SLE	NN	B-NP	B
(	(	O	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
and	CC	O	O
epilepsy	NN	B-NP	B
)	)	O	O
OBJECTIVE	NN	B-NP	O
:	:	O	O
To	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
multivitamin	NN	B-NP	O
supplementation	NN	I-NP	O
in	IN	B-PP	O
epileptic	JJ	B-NP	B
women	NNS	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
during	IN	I-PP	O
pregnancy	NN	B-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
structural	JJ	B-NP	O
birth	NN	I-NP	B
defects	NNS	I-NP	I
and	CC	I-NP	O
epilepsy	NN	I-NP	B
-	HYPH	O	O
related	VBN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

First	RB	B-ADVP	O
a	DT	B-NP	O
randomised	VBN	I-NP	O
trial	NN	I-NP	O
,	,	O	O
later	JJ	B-NP	O
periconception	NN	I-NP	O
care	NN	I-NP	O
including	VBG	B-PP	O
in	IN	B-PP	O
total	JJ	B-NP	O
num	CD	I-NP	O
females	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
epileptic	JJ	I-NP	B
women	NNS	I-NP	O
with	IN	B-PP	O
periconceptional	JJ	B-NP	O
folic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
multivitamin	NN	B-NP	O
supplementation	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
one	NN	I-NP	O
developed	VBD	B-VP	O
epilepsy	NN	B-NP	B
-	HYPH	B-PP	O
related	VBN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
periconception	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
epileptic	JJ	I-NP	B
woman	NN	I-NP	O
delivered	VBD	B-VP	O
a	DT	B-NP	O
newborn	NN	I-NP	O
with	IN	B-PP	O
cleft	NN	B-NP	B
lip	NN	I-NP	I
and	CC	I-NP	I
palate	NN	I-NP	I
.	.	O	O

Another	DT	B-NP	O
patient	NN	I-NP	O
exhibited	VBD	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
cluster	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
periconception	NN	I-NP	O
period	NN	I-NP	O
using	VBG	B-VP	O
another	DT	B-NP	O
multivitamin	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
epileptic	JJ	I-NP	B
woman	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
continuously	RB	B-ADVP	O
by	IN	B-PP	O
carbamazepine	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	O
folic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
multivitamin	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
20th	JJ	I-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
.	.	O	O

She	PRP	B-NP	O
developed	VBD	B-VP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
and	CC	O	O
later	JJ	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	B
lupus	NN	I-NP	I
erythematodes	NNS	I-NP	I
.	.	O	O

Her	PRP$	B-NP	O
pregnancy	NN	I-NP	O
ended	VBD	B-VP	O
with	IN	B-PP	O
stillbirth	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
epileptic	JJ	I-NP	B
pregnant	JJ	I-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
autoimmune	JJ	B-NP	B
disease	NN	I-NP	I
(	(	O	O
probably	RB	B-ADVP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lupus	NN	I-NP	B
)	)	O	O
could	MD	B-VP	O
damage	VB	I-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
,	,	O	O
therefore	RB	B-ADVP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
triggered	VBD	B-VP	O
a	DT	B-NP	O
cluster	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

Physiological	JJ	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
both	CC	B-PP	O
in	IN	B-PP	O
healthy	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
epileptic	JJ	I-NP	B
women	NNS	I-NP	O
,	,	O	O
all	DT	B-NP	O
without	IN	B-PP	O
any	DT	B-NP	O
autoimmune	JJ	I-NP	B
disease	NN	I-NP	I
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
epileptic	JJ	B-NP	B
seizures	NNS	I-NP	I
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
cisapride	NN	B-NP	O
on	IN	B-PP	O
symptoms	NNS	B-NP	O
and	CC	O	O
postcibal	JJ	B-NP	O
small	JJ	I-NP	O
-	HYPH	I-NP	O
bowel	NN	I-NP	O
motor	NN	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
irritable	JJ	B-NP	B
bowel	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Irritable	JJ	B-NP	B
bowel	NN	I-NP	I
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
and	CC	I-NP	O
discomfort	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
disordered	VBN	B-NP	B
gastrointestinal	JJ	I-NP	I
motility	NN	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
aim	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
prokinetic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
cisapride	NN	B-NP	O
,	,	O	O
on	IN	B-PP	O
postprandial	JJ	B-NP	O
jejunal	JJ	I-NP	O
motility	NN	I-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
irritable	JJ	I-NP	B
bowel	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
IBS	NN	B-NP	B
)	)	O	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
IBS	NNP	B-NP	B
underwent	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
ambulatory	JJ	I-NP	O
jejunal	JJ	I-NP	O
manometry	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
s	NN	I-NP	O
treatment	NN	I-NP	O
[	(	O	O
cisapride	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
daily	JJ	I-NP	O
or	CC	O	O
placebo	NN	B-NP	O
]	)	O	O
.	.	O	O

In	IN	B-PP	O
diarrhoea	NN	B-NP	B
-	HYPH	O	O
predominant	JJ	B-NP	O
patients	NNS	I-NP	O
significant	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
contraction	NN	B-NP	O
characteristics	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
cisapride	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
cisapride	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
diarrhoea	NN	I-NP	B
-	HYPH	O	O
predominant	JJ	B-NP	O
patients	NNS	I-NP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
contraction	NN	I-NP	O
amplitude	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
contraction	NN	I-NP	O
duration	NN	I-NP	O
longer	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
contraction	NN	I-NP	O
frequency	NN	I-NP	O
lower	JJR	B-ADVP	O
(	(	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
versus	IN	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
cont.	NN	I-NP	O
/	SYM	O	O
min	NN	B-NP	O
,	,	O	O
cisapride	NN	B-NP	O
versus	IN	B-PP	O
placebo	NN	B-NP	O
;	:	O	O
pretreatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
cont.	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
]	)	O	O
than	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
jejunal	JJ	B-NP	O
motility	NN	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
constipation	NN	I-NP	B
-	HYPH	B-NP	O
predominant	JJ	I-NP	O
IBS	NNP	I-NP	B
group	NN	I-NP	O
.	.	O	O

Symptoms	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
using	VBG	B-VP	O
a	DT	B-NP	O
visual	JJ	I-NP	O
analogue	NN	I-NP	O
scale	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
treatment	NN	B-NP	O
.	.	O	O

Symptom	NN	B-NP	O
scores	NNS	I-NP	O
relating	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
constipation	NN	B-NP	B
were	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
cisapride	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
constipation	NN	I-NP	B
-	HYPH	B-NP	O
predominant	JJ	I-NP	O
IBS	NN	I-NP	B
patients	NNS	I-NP	O
[	(	O	O
score	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
versus	IN	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mm	NN	I-NP	O
,	,	O	O
cisapride	NN	B-NP	O
versus	IN	B-PP	O
placebo	NN	B-NP	O
;	:	O	O
pretreatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mm	NN	I-NP	O
]	)	O	O
.	.	O	O

Diarrhoea	NN	B-NP	B
-	HYPH	I-NP	O
predominant	JJ	I-NP	O
IBS	NN	I-NP	B
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
pain	NN	I-NP	B
score	NN	I-NP	O
after	IN	B-PP	O
cisapride	NN	B-NP	O
therapy	NN	I-NP	O
[	(	O	O
score	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
versus	IN	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mm	NN	I-NP	O
,	,	O	O
cisapride	NN	B-NP	O
versus	IN	B-PP	O
placebo	NN	B-NP	O
;	:	O	O
pretreatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mm	NN	I-NP	O
]	)	O	O
.	.	O	O

Cisapride	NN	B-NP	O
affects	VBZ	B-VP	O
jejunal	JJ	B-NP	O
contraction	NN	I-NP	O
characteristics	NNS	I-NP	O
and	CC	O	O
some	DT	B-NP	O
symptoms	NNS	I-NP	O
in	IN	B-PP	O
IBS	NNP	B-NP	B
.	.	O	O

Clarithromycin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

Clarithromycin	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
relatively	RB	I-NP	O
new	JJ	I-NP	O
macrolide	NN	I-NP	O
antibiotic	NN	I-NP	O
that	WDT	B-NP	O
offers	VBZ	B-VP	O
twice	RB	B-NP	O
-	HYPH	I-NP	O
daily	JJ	I-NP	O
dosing	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
differs	VBZ	B-VP	O
from	IN	B-PP	O
erythromycin	NN	B-NP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
methylation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hydroxyl	NN	I-NP	O
group	NN	I-NP	O
at	IN	B-PP	O
position	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
erythromycin	NN	B-NP	O
is	VBZ	B-VP	O
established	VBN	I-VP	O
,	,	O	O
including	VBG	B-PP	O
gastroenteritis	NN	B-NP	B
and	CC	I-NP	O
interactions	NNS	I-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
subject	JJ	B-ADJP	O
to	TO	B-PP	O
hepatic	JJ	B-NP	O
mixed	VBN	I-NP	O
-	HYPH	I-NP	O
function	NN	I-NP	O
oxidase	NN	I-NP	O
metabolism	NN	I-NP	O
,	,	O	O
experience	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
newer	JJR	I-NP	O
macrolides	NNS	I-NP	O
is	VBZ	B-VP	O
still	RB	I-VP	O
being	VBG	I-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Cardiotoxicity	NN	B-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
demonstrated	VBN	I-VP	O
after	IN	B-PP	O
both	CC	B-NP	O
intravenous	JJ	I-NP	O
and	CC	I-NP	O
oral	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
erythromycin	NN	B-NP	O
but	CC	O	O
has	VBZ	B-VP	O
never	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
newer	JJR	I-NP	O
macrolides	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
dysrhythmias	NNS	I-NP	I
that	WDT	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-SBAR	O
num	CD	B-NP	O
therapeutic	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
clarithromycin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
dysrhythmias	NNS	I-NP	B
resolved	VBN	B-VP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Persistent	JJ	B-NP	O
nephrogenic	JJ	I-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
following	VBG	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
severe	JJ	B-NP	O
hypernatraemic	JJ	I-NP	O
dehydration	NN	I-NP	B
following	VBG	B-PP	O
a	DT	B-NP	O
head	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
years	NNS	I-NP	O
previously	RB	B-ADVP	O
he	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
diagnosed	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
lithium	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrogenic	JJ	I-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
,	,	O	O
and	CC	O	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

He	PRP	B-NP	O
remained	VBD	B-VP	O
thirsty	JJ	B-ADJP	O
and	CC	I-ADJP	O
polyuric	JJ	I-ADJP	B
despite	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
and	CC	I-NP	O
investigations	NNS	I-NP	O
on	IN	B-PP	O
admission	NN	B-NP	O
showed	VBD	B-VP	O
him	PRP	B-NP	O
to	TO	B-VP	O
have	VB	I-VP	O
normal	JJ	B-NP	O
osmoregulated	JJ	I-NP	O
thirst	NN	I-NP	O
and	CC	I-NP	O
vasopressin	NN	I-NP	O
secretion	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
clear	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
nephrogenic	JJ	B-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
.	.	O	O

Lithium	NN	B-NP	O
induced	VBD	B-VP	O
nephrogenic	JJ	B-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
is	VBZ	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
reversible	JJ	B-ADJP	O
on	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
but	CC	O	O
polyuria	NN	B-NP	B
persisted	VBD	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-SBAR	O
lithium	NN	B-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
discuss	VBP	B-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
renal	JJ	I-NP	O
mechanisms	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
implications	NNS	I-NP	O
for	IN	B-PP	O
management	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrogenic	JJ	I-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
.	.	O	O

Late	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
after	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
malignant	JJ	I-NP	O
bone	NN	I-NP	B
tumor	NN	I-NP	I
.	.	O	O

Cardiac	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
survivors	NNS	I-NP	O
of	IN	B-PP	O
malignant	JJ	B-NP	O
bone	NN	I-NP	B
tumors	NNS	I-NP	I
who	WP	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
Rosen	NNP	B-NP	O
s	NNS	I-NP	O
T5	NN	I-NP	O
or	CC	I-NP	O
T10	NN	I-NP	O
protocol	NN	I-NP	O
,	,	O	O
both	DT	B-NP	O
including	VBG	I-NP	O
doxorubicin	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
age	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
(	(	O	O
median	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
(	(	O	O
median	NN	B-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
following	VBG	B-PP	O
completion	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Cumulative	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
(	(	O	O
median	JJ	B-NP	O
dose	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
evaluation	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
,	,	O	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
,	,	O	O
electrocardiogram	NN	B-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
,	,	O	O
signal	NN	B-NP	O
averaged	VBD	B-VP	O
ECG	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
ambulatory	JJ	I-NP	O
ECG	NN	I-NP	O
,	,	O	O
echocardiography	NN	B-NP	O
and	CC	O	O
radionuclide	NN	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
,	,	O	O
defined	VBN	B-VP	O
as	IN	B-PP	O
having	VBG	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
abnormalities	NNS	I-NP	O
:	:	O	O
late	JJ	B-NP	O
potentials	NNS	I-NP	O
,	,	O	O
complex	JJ	B-NP	O
ventricular	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
,	,	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	B
dilation	NN	I-NP	I
,	,	O	O
decreased	VBD	B-VP	O
shortening	NN	B-NP	O
fraction	NN	I-NP	O
,	,	O	O
or	CC	O	O
decreased	VBN	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
abnormalities	NNS	I-NP	I
increased	VBD	B-VP	O
with	IN	B-PP	O
length	NN	B-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

No	DT	B-NP	O
correlation	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
demonstrated	VBN	I-VP	O
between	IN	B-PP	O
cumulative	JJ	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
status	NN	I-NP	O
,	,	O	O
except	IN	B-PP	O
for	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
variability	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
adjusted	VBN	B-VP	O
to	TO	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
posterior	JJ	I-NP	O
wall	NN	I-NP	O
thickness	NN	I-NP	O
(	(	O	O
LVPW	NN	B-NP	O
index	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
high	JJ	B-ADJP	O
and	CC	O	O
increases	VBZ	B-VP	O
with	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
,	,	O	O
irrespective	JJ	B-ADJP	O
of	IN	B-PP	O
cumulative	JJ	B-NP	O
dose	NN	I-NP	O
.	.	O	O

Life	NN	B-NP	O
-	HYPH	B-NP	O
long	JJ	I-NP	O
cardiac	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
heart	NN	B-NP	O
rate	NN	I-NP	O
variability	NN	I-NP	O
and	CC	O	O
LVPW	NN	B-NP	O
index	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
sensitive	JJ	B-NP	O
indicators	NNS	I-NP	O
for	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
.	.	O	O

Venous	JJ	B-NP	B
complications	NNS	I-NP	I
of	IN	B-PP	O
midazolam	NN	B-NP	O
versus	IN	B-PP	O
diazepam	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
some	DT	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
suggested	VBN	I-VP	O
fewer	JJR	B-NP	O
venous	JJ	I-NP	B
complications	NNS	I-NP	I
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
midazolam	NN	B-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
diazepam	NN	B-NP	O
for	IN	B-PP	O
endoscopic	JJ	B-NP	O
procedures	NNS	I-NP	O
,	,	O	O
this	DT	B-NP	O
variable	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
well	RB	B-ADJP	O
documented	VBN	I-ADJP	O
.	.	O	O

We	PRP	B-NP	O
prospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
complications	NNS	I-NP	I
after	IN	B-PP	O
intravenous	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
or	CC	I-NP	O
midazolam	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
colonoscopy	NN	B-NP	O
and	CC	I-NP	O
esophagogastroduodenoscopy	NN	I-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
venous	JJ	B-NP	B
complications	NNS	I-NP	I
were	VBD	B-VP	O
more	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
with	IN	B-PP	O
diazepam	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
than	IN	B-PP	O
with	IN	B-PP	O
midazolam	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
palpable	JJ	I-NP	O
venous	JJ	I-NP	O
cord	NN	I-NP	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
diazepam	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
midazolam	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
site	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
diazepam	NN	I-NP	O
group	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
midazolam	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Swelling	NN	B-NP	B
and	CC	I-NP	O
warmth	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
site	NN	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
significantly	RB	I-ADJP	O
different	JJ	I-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Smoking	NN	B-NP	O
,	,	O	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drug	NN	I-NP	O
use	NN	I-NP	O
,	,	O	O
intravenous	JJ	B-NP	O
catheter	NN	I-NP	O
site	NN	I-NP	O
,	,	O	O
dwell	NN	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
needle	NN	I-NP	O
,	,	O	O
alcohol	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
and	CC	O	O
pain	NN	B-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
complications	NNS	I-NP	I
.	.	O	O

Tetany	NN	B-NP	B
and	CC	I-NP	O
rhabdomyolysis	NN	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
surreptitious	JJ	B-NP	O
furosemide	NN	I-NP	O
-	HYPH	O	O
-	HYPH	O	O
importance	NN	B-NP	O
of	IN	B-PP	O
magnesium	NN	B-NP	O
supplementation	NN	I-NP	O
.	.	O	O

Diuretics	NNS	B-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
hypokalemia	NN	B-NP	B
,	,	I-NP	O
hypocalcemia	NN	I-NP	B
and	CC	I-NP	O
hypomagnesemia	NN	I-NP	B
.	.	O	O

While	IN	B-SBAR	O
severe	JJ	B-NP	O
hypokalemia	NN	I-NP	B
may	MD	B-VP	O
cause	VB	I-VP	O
muscle	NN	B-NP	B
weakness	NN	I-NP	I
,	,	O	O
severe	JJ	B-NP	O
hypomagnesemia	NN	I-NP	B
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
muscle	NN	B-NP	B
spasms	NNS	I-NP	I
and	CC	O	O
tetany	NN	B-NP	B
which	WDT	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
corrected	VBN	I-VP	O
by	IN	B-PP	O
potassium	NN	B-NP	O
and	CC	I-NP	O
calcium	NN	I-NP	O
supplementation	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Surreptitious	JJ	B-NP	O
diuretic	JJ	I-NP	O
ingestion	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
,	,	O	O
mainly	RB	B-ADVP	O
in	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
concerned	VBN	I-VP	O
that	IN	B-SBAR	O
they	PRP	B-NP	O
are	VBP	B-VP	O
obese	JJ	B-ADJP	B
or	CC	I-ADJP	O
edematous	JJ	I-ADJP	B
.	.	O	O

Symptomatic	JJ	B-NP	O
hypokalemia	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
case	NN	I-NP	O
hypocalcemia	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
magnesium	NN	B-NP	O
depletion	NN	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Loss	NN	B-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
decarboxylase	NN	I-NP	O
mRNA	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
neurons	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
following	VBG	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

In	FW	B-NP	O
situ	FW	I-NP	O
hybridization	NN	I-NP	O
methods	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
glutamic	JJ	B-NP	O
acid	NN	I-NP	O
decarboxylase	NN	I-NP	O
(	(	O	O
GAD	NN	B-NP	O
)	)	O	O
mRNA	NN	B-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
neurons	NNS	B-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
hilus	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
are	VBP	B-VP	O
vulnerable	JJ	B-ADJP	O
to	TO	B-PP	O
seizure	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
damage	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
intraperitoneally	RB	B-ADVP	O
with	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
formation	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
histologically	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
week	NN	I-NP	O
intervals	NNS	I-NP	O
after	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

In	FW	B-NP	O
situ	FW	I-NP	O
hybridization	NN	I-NP	O
histochemistry	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
a	DT	B-NP	O
digoxigenin	NN	I-NP	O
-	HYPH	O	O
labeled	VBN	B-NP	O
GAD	NN	I-NP	O
cRNA	NN	I-NP	O
probe	NN	I-NP	O
,	,	O	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
substantial	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
GAD	NN	B-NP	O
mRNA	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
neurons	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hilus	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
at	IN	B-PP	O
all	DT	B-NP	O
time	NN	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

Additional	JJ	B-NP	O
neuronanatomical	JJ	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
cresyl	NN	B-NP	O
violet	NN	I-NP	O
staining	NN	I-NP	O
,	,	O	O
neuronal	JJ	B-NP	B
degeneration	NN	I-NP	I
methods	NNS	I-NP	O
,	,	O	O
and	CC	O	O
histochemical	JJ	B-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
glial	JJ	B-NP	O
fibrillary	JJ	I-NP	O
acidic	JJ	I-NP	O
protein	NN	I-NP	O
,	,	O	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
GAD	NN	B-NP	O
mRNA	NN	I-NP	O
-	HYPH	B-VP	O
containing	VBG	B-NP	O
neurons	NNS	I-NP	O
was	VBD	B-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
neuronal	JJ	B-NP	B
loss	NN	I-NP	I
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
to	TO	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
GAD	NN	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
GAD	NN	B-NP	O
mRNA	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
neurons	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hilus	NN	I-NP	O
contrasted	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
relative	JJ	I-NP	O
preservation	NN	I-NP	O
of	IN	B-PP	O
labeled	VBN	B-NP	O
putative	JJ	I-NP	O
basket	NN	I-NP	O
cells	NNS	I-NP	O
along	IN	B-PP	O
the	DT	B-NP	O
inner	JJ	I-NP	O
margin	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
layer	NN	I-NP	O
.	.	O	O

Quantitative	JJ	B-NP	O
analyses	NNS	I-NP	O
of	IN	B-PP	O
labeled	VBN	B-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
regions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
week	NN	I-NP	O
groups	NNS	I-NP	O
showed	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
decreases	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
GAD	NN	B-NP	O
mRNA	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
neurons	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hilus	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
layer	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
layer	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
included	VBD	B-VP	O
labeled	VBN	B-NP	O
neurons	NNS	I-NP	O
along	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
margin	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
layer	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
subpopulation	NN	I-NP	O
of	IN	B-PP	O
GAD	NN	B-NP	O
mRNA	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
neurons	NNS	B-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
is	VBZ	B-VP	O
selectively	RB	B-ADJP	O
vulnerable	JJ	I-ADJP	O
to	TO	B-PP	O
seizure	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
damage	NN	I-NP	O
.	.	O	O

Such	JJ	B-NP	O
differential	JJ	I-NP	O
vulnerability	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
another	DT	B-NP	O
indication	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
heterogeneity	NN	I-NP	O
of	IN	B-PP	O
GABA	NN	B-NP	O
neurons	NNS	I-NP	O
.	.	O	O

Protective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
on	IN	B-PP	O
indomethacin	NN	B-NP	O
induced	VBD	B-VP	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
protective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
hospitalized	VBN	B-NP	O
elderly	JJ	I-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
indomethacin	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hospitalized	VBD	B-VP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
required	VBD	B-VP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
antiinflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAID	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
either	CC	O	O
indomethacin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
Group	NN	B-NP	O
A	NN	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
indomethacin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
plus	CC	O	O
misoprostol	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
(	(	O	O
Group	NN	B-NP	O
B	NN	I-NP	O
)	)	O	O
.	.	O	O

Laboratory	NN	B-NP	O
variables	NNS	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
[	(	O	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
,	,	O	O
blood	NN	B-NP	O
urea	NN	I-NP	O
nitrogen	NN	I-NP	O
(	(	O	O
BUN	NN	B-NP	O
)	)	O	O
and	CC	O	O
electrolytes	NNS	B-NP	O
]	)	O	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
before	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
and	CC	O	O
every	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
,	,	O	O
until	IN	B-PP	O
termination	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
(	(	O	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
)	)	O	O
.	.	O	O

Response	NN	B-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
visual	JJ	I-NP	O
analog	NN	I-NP	O
scale	NN	I-NP	O
for	IN	B-PP	O
severity	NN	B-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
completed	VBD	B-VP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
A	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
B	NN	I-NP	O
.	.	O	O

BUN	NN	B-NP	O
and	CC	I-NP	O
creatinine	NN	I-NP	O
increased	VBD	B-VP	O
by	IN	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
baseline	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
Group	NN	B-NP	O
A	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
compared	VBN	B-PP	O
to	TO	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
Group	NN	B-NP	O
B	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Potassium	NN	B-NP	O
(	(	O	O
K	NN	B-NP	O
)	)	O	O
increment	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mEq	NN	I-NP	O
/	SYM	B-NP	O
l	NN	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
Group	NN	B-NP	O
A	NN	I-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
Group	NN	B-NP	O
B	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
increments	NNS	I-NP	O
in	IN	B-PP	O
BUN	NN	B-NP	O
,	,	O	O
creatinine	NN	B-NP	O
,	,	O	O
and	CC	O	O
K	NN	B-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
Group	NN	B-NP	O
B	NN	I-NP	O
patients	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
Group	NN	B-NP	O
A	NN	I-NP	O
.	.	O	O

Response	NN	B-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Hospitalized	VBN	B-NP	O
elderly	JJ	I-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
at	IN	B-PP	O
risk	NN	B-NP	O
for	IN	B-PP	O
developing	VBG	B-VP	O
indomethacin	NN	B-NP	O
related	JJ	I-NP	O
renal	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Addition	NN	B-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
can	MD	B-VP	O
minimize	VB	I-VP	O
this	DT	B-NP	O
renal	JJ	I-NP	B
impairment	NN	I-NP	I
without	IN	B-PP	O
affecting	VBG	B-VP	O
pain	NN	B-NP	B
control	NN	I-NP	O
.	.	O	O

Nephrotoxic	JJ	B-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
aminoglycoside	NN	B-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
protein	NN	I-NP	O
reabsorption	NN	I-NP	O
and	CC	I-NP	O
accumulation	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
quantify	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
gentamicin	NN	B-NP	O
,	,	O	O
kanamycin	NN	B-NP	O
and	CC	I-NP	O
netilmicin	NN	I-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
protein	NN	I-NP	O
reabsorption	NN	I-NP	O
and	CC	I-NP	O
accumulation	NN	I-NP	O
,	,	O	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
intraperitoneally	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

Scanning	NN	B-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomerular	JJ	I-NP	O
endothelia	NN	I-NP	O
,	,	O	O
urinary	JJ	B-NP	O
measurements	NNS	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
,	,	O	O
potassium	NN	B-NP	O
,	,	O	O
endogenous	JJ	B-NP	O
lysozyme	NN	I-NP	O
,	,	O	O
N	NN	B-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
glucosaminidase	NN	B-NP	O
(	(	O	O
NAG	NN	B-NP	O
)	)	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
clearance	NN	B-NP	O
and	CC	I-NP	O
accumulation	NN	I-NP	O
experiments	NNS	I-NP	O
after	IN	B-PP	O
i.v.	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
egg	NN	B-NP	O
-	HYPH	B-NP	O
white	JJ	I-NP	O
lysozyme	NN	I-NP	O
and	CC	I-NP	O
measurements	NNS	I-NP	O
of	IN	B-PP	O
inulin	NN	B-NP	O
clearance	NN	I-NP	O
(	(	O	O
GFR	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
done	VBN	I-VP	O
in	IN	B-PP	O
each	DT	B-NP	O
treatment	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Gentamicin	NN	B-NP	O
administration	NN	I-NP	O
decreased	VBD	B-VP	O
diameter	NN	B-NP	O
,	,	I-NP	O
density	NN	I-NP	O
and	CC	I-NP	O
shape	NN	I-NP	O
of	IN	B-PP	O
endothelial	JJ	B-NP	O
fenestrae	NNS	I-NP	O
.	.	O	O

Kanamycin	NN	B-NP	O
and	CC	I-NP	O
netilmicin	NN	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
used	VBN	B-VP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
aminoglycosides	NNS	I-NP	O
decreased	VBD	B-VP	O
GFR	NN	B-NP	O
and	CC	O	O
increased	VBD	B-VP	O
urinary	JJ	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
and	CC	I-NP	O
potassium	NN	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
gentamicin	NN	B-NP	O
and	CC	I-NP	O
kanamycin	NN	I-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
percentage	NN	I-NP	O
reabsorption	NN	I-NP	O
and	CC	I-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
lysozyme	NN	B-NP	O
after	IN	B-SBAR	O
i.v.	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
egg	NN	B-NP	O
-	HYPH	B-NP	O
white	JJ	I-NP	O
lysozyme	NN	I-NP	O
netilmicin	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

Daily	JJ	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
protein	NN	I-NP	O
,	,	O	O
endogenous	JJ	B-NP	O
lysozyme	NN	I-NP	O
and	CC	I-NP	O
NAG	NN	I-NP	O
increased	VBD	B-VP	O
only	RB	B-ADVP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
kanamycin	NN	B-NP	O
and	CC	I-NP	O
gentamicin	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
aminoglycosides	NNS	B-NP	O
may	MD	B-VP	O
act	VB	I-VP	O
as	IN	B-PP	O
nephrotoxicants	NNS	B-NP	O
at	IN	B-PP	O
glomerular	JJ	B-ADJP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
tubular	JJ	B-NP	O
level	NN	I-NP	O
inducing	VBG	B-VP	O
impairment	NN	B-NP	B
of	IN	B-PP	I
renal	JJ	B-NP	I
reabsorption	NN	I-NP	I
and	CC	I-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
proteins	NNS	B-NP	O
.	.	O	O

Pharmacology	NN	B-NP	O
of	IN	B-PP	O
GYKI	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
num	CD	I-NP	O
(	(	O	O
chlorpropanol	NN	B-NP	O
,	,	O	O
Tobanum	NNP	B-NP	O
)	)	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
potent	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
compound	NN	I-NP	O
GYKI	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
as	IN	B-PP	O
a	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
more	RBR	B-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
propranolol	NN	B-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

Its	PRP$	B-NP	O
antiarrhythmic	JJ	I-NP	O
effectiveness	NN	I-NP	O
surpasses	VBZ	B-VP	O
that	DT	B-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	I-NP	O
pindolol	NN	I-NP	O
inhibiting	VBG	B-VP	O
the	DT	B-NP	O
ouabain	NN	I-NP	O
arrhythmia	NN	I-NP	B
in	IN	B-PP	O
dogs	NNS	B-NP	O
and	CC	I-NP	O
cats	NNS	I-NP	O
.	.	O	O

GYKI	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
num	CD	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
negligible	JJ	I-NP	O
cardiodepressant	NN	I-NP	O
activity	NN	I-NP	O
;	:	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
cardioselective	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
compound	NN	I-NP	O
shows	VBZ	B-VP	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
and	CC	I-NP	O
long	JJ	I-NP	O
lasting	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
prolonged	VBN	I-NP	O
elimination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
radioactivity	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
14C	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
and	CC	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
half	JJ	I-NP	O
life	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
unlabeled	JJ	I-NP	O
substance	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
was	VBD	B-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

Chorea	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
contraception	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
chorea	NN	B-NP	B
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
were	VBD	B-VP	O
young	JJ	B-NP	O
patients	NNS	I-NP	O
whose	WP$	B-NP	O
chorea	NN	I-NP	B
developed	VBD	B-VP	O
long	RB	B-ADVP	O
after	IN	B-SBAR	O
treatment	NN	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
started	VBN	I-VP	O
and	CC	O	O
disappeared	VBD	B-VP	O
soon	RB	B-ADVP	O
after	IN	B-SBAR	O
it	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
third	JJ	I-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
acute	JJ	B-NP	O
amphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
chorea	NN	I-NP	B
after	IN	B-PP	O
prolonged	JJ	B-NP	O
oral	JJ	I-NP	O
contraception	NN	I-NP	O
.	.	O	O

Prolonged	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
female	JJ	B-NP	O
sex	NN	I-NP	O
hormones	NNS	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
chorea	NN	B-NP	B
in	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
previously	RB	I-VP	O
had	VBD	I-VP	O
chorea	NN	B-NP	B
or	CC	O	O
rheumatic	JJ	B-NP	B
fever	NN	I-NP	I
.	.	O	O

Reversal	NN	B-NP	O
of	IN	B-PP	O
ammonia	NN	B-NP	O
coma	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
peripheral	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Ammonia	NNP	B-NP	O
coma	NN	I-NP	B
was	VBD	B-VP	O
produced	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
intraperitonealinjection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mmol	NN	I-NP	O
NH4CL	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
coma	NN	I-NP	B
was	VBD	B-VP	O
prevented	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mmol	NN	I-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
given	VBN	B-VP	O
by	IN	B-PP	O
gastric	JJ	B-NP	O
intubation	NN	I-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
ammonium	NN	I-NP	O
salt	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
dopa	NN	B-NP	O
was	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
ammonia	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
dopamine	NN	I-NP	O
,	,	O	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
ammonia	NN	B-NP	O
and	CC	I-NP	O
urea	NN	I-NP	O
.	.	O	O

Intraventricular	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
raise	VB	I-VP	O
the	DT	B-NP	O
brain	NN	I-NP	O
dopamine	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
extent	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
ammonia	NN	I-NP	O
coma	NN	I-NP	B
nor	CC	O	O
affect	VB	B-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
ammonia	NN	I-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
nephrectomy	NN	I-NP	O
eliminated	VBD	B-VP	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
dopa	NN	B-NP	O
on	IN	B-PP	O
blood	NN	B-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
ammonia	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
ammonia	NN	I-NP	O
coma	NN	I-NP	B
was	VBD	B-VP	O
not	RB	I-VP	O
prevented	VBN	I-VP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
ammonia	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
ammonia	NN	B-NP	O
coma	NN	I-NP	B
after	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
,	,	O	O
can	MD	B-VP	O
be	VB	I-VP	O
accounted	VBN	I-VP	O
for	IN	B-PP	O
by	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
its	PRP$	B-NP	O
central	JJ	I-NP	O
action	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
a	DT	B-NP	O
reasonable	JJ	I-NP	O
explanation	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
encephalopathic	JJ	I-NP	B
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
L	NN	B-NP	O
-	HYPH	B-VP	O
dopa	NN	B-NP	O
.	.	O	O

Heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Unfractionated	JJ	B-NP	O
heparin	NN	I-NP	O
sodium	NN	I-NP	O
(	(	O	O
UFH	NN	B-NP	O
)	)	O	O
or	CC	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
molecular	JJ	I-NP	O
weight	NN	I-NP	O
heparin	NN	I-NP	O
(	(	O	O
LMWH	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
anticoagulant	JJ	B-NP	O
protocols	NNS	I-NP	O
at	IN	B-PP	O
several	JJ	B-NP	O
institutions	NNS	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
thrombosis	NN	B-NP	B
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Heparin	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
thrombocytopenia	NN	I-NP	B
(	(	O	O
HIT	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
immune	JJ	I-NP	O
-	HYPH	I-NP	O
mediated	VBN	I-NP	O
reaction	NN	I-NP	O
to	TO	B-PP	O
heparin	NN	B-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
platelet	NN	B-NP	O
count	NN	I-NP	O
decreases	VBZ	B-VP	O
of	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
frequencies	NNS	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
and	CC	O	O
platelet	NN	B-NP	O
factor	NN	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
heparin	NN	I-NP	O
-	HYPH	B-NP	O
reactive	JJ	I-NP	O
antibody	NN	I-NP	O
(	(	O	O
HIT	NN	B-NP	B
antibody	NN	I-NP	O
)	)	O	O
positivity	NN	B-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
are	VBP	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
underwent	VBD	B-VP	O
living	VBG	I-VP	O
donor	NN	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
started	VBD	B-VP	O
LMWH	NN	B-NP	O
on	IN	B-PP	O
postoperative	JJ	B-NP	O
day	NN	I-NP	O
(	(	O	O
POD	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
switching	NN	I-NP	O
to	TO	B-PP	O
UFH	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
UFH	NN	B-NP	O
was	VBD	B-VP	O
changed	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
activated	VBN	I-NP	O
clotting	NN	I-NP	O
time	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

HIT	NN	B-NP	B
antibody	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
the	DT	B-NP	O
day	NN	I-NP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Platelet	NN	B-NP	O
count	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
platelet	NN	I-NP	O
counts	NNS	I-NP	O
preoperatively	RB	B-ADVP	O
,	,	B-PP	O
and	CC	I-PP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
hepatic	JJ	B-NP	O
artery	NN	I-NP	O
thrombosis	NN	I-NP	B
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
,	,	O	O
although	IN	B-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
HIT	NN	B-NP	B
antibody	NN	I-NP	O
-	HYPH	B-VP	O
negative	JJ	B-ADJP	O
and	CC	O	O
their	PRP$	B-NP	O
platelet	NN	I-NP	O
counts	NNS	I-NP	O
were	VBD	B-VP	O
stable	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
other	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
platelet	NN	I-NP	O
count	NN	I-NP	O
decreased	VBD	B-VP	O
suddenly	RB	B-ADVP	O
from	IN	B-PP	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
and	CC	B-PP	O
from	IN	B-PP	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
heparin	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
platelet	NN	I-NP	B
aggregation	NN	I-NP	I
test	NN	I-NP	O
was	VBD	B-VP	O
negative	JJ	B-ADJP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
antibody	NN	I-NP	O
-	HYPH	O	O
positive	JJ	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
preoperatively	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
on	IN	B-PP	O
POD	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
/	SYM	B-NP	O
patients	NNS	B-NP	O
developed	VBD	B-VP	O
UFH	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
HIT	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
series	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
was	VBD	B-VP	O
uncommon	JJ	B-ADJP	O
.	.	O	O

PTU	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
vasculitis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
girl	NN	I-NP	O
with	IN	B-PP	O
Turner	NN	B-NP	B
Syndrome	NN	I-NP	I
and	CC	I-NP	O
Graves	NN	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Palpable	JJ	B-NP	O
purpura	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
concerning	VBG	I-NP	O
clinical	JJ	I-NP	O
finding	NN	I-NP	O
in	IN	B-PP	O
pediatric	JJ	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
can	MD	B-VP	O
have	VB	I-VP	O
many	JJ	B-NP	O
causes	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
infectious	JJ	B-NP	O
and	CC	I-NP	O
autoimmune	JJ	I-NP	O
processes	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
rare	JJ	I-NP	O
cause	NN	I-NP	O
,	,	O	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasculitis	NN	I-NP	B
,	,	O	O
may	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
antineutrophil	NN	B-NP	O
cytoplasmic	JJ	I-NP	O
antibodies	NNS	I-NP	O
(	(	O	O
ANCAs	NNS	B-NP	O
)	)	O	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
medication	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
girl	NN	I-NP	O
with	IN	B-PP	O
Turner	NN	B-NP	B
syndrome	NN	I-NP	I
and	CC	I-NP	O
Graves	NN	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
who	WP	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
palpable	JJ	B-NP	O
purpuric	JJ	I-NP	B
lesions	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
propylthiouracil	NN	B-NP	O
(	(	O	O
PTU	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
associated	VBN	B-NP	O
vasculitis	NN	I-NP	B
was	VBD	B-VP	O
made	VBN	I-VP	O
by	IN	B-PP	O
observation	NN	B-NP	O
of	IN	B-PP	O
consistent	JJ	B-NP	O
clinical	JJ	I-NP	O
features	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
elevated	JJ	B-NP	O
ANA	NN	I-NP	O
and	CC	I-NP	O
ANCA	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
observed	VBN	I-NP	O
clinical	JJ	I-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
following	VBG	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
PTU	NN	B-NP	O
.	.	O	O

Subsequent	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
hyperthyroidism	NN	I-NP	B
with	IN	B-PP	O
radioablation	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
exacerbation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
vasculitis	NN	I-NP	B
,	,	O	O
a	DT	B-NP	O
complication	NN	I-NP	O
described	VBN	B-VP	O
in	IN	B-PP	O
prior	JJ	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
.	.	O	O

Succinylcholine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
masseter	NN	I-NP	B
muscle	NN	I-NP	I
rigidity	NN	I-NP	I
during	IN	B-PP	O
bronchoscopic	JJ	B-NP	O
removal	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
tracheal	JJ	I-NP	O
foreign	JJ	I-NP	O
body	NN	I-NP	O
.	.	O	O

Masseter	NN	B-NP	B
muscle	NN	I-NP	I
rigidity	NN	I-NP	I
during	IN	B-PP	O
general	JJ	B-NP	O
anesthesia	NN	I-NP	O
is	VBZ	B-VP	O
considered	VBN	I-VP	O
an	DT	B-NP	O
early	JJ	I-NP	O
warning	NN	I-NP	O
sign	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
malignant	JJ	B-NP	B
hyperthermia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
decision	NN	I-NP	O
whether	IN	B-SBAR	O
to	TO	B-VP	O
continue	VB	I-VP	O
or	CC	I-VP	O
discontinue	VB	I-VP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
depends	VBZ	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
urgency	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
surgery	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
masseter	NN	B-NP	B
muscle	NN	I-NP	I
rigidity	NN	I-NP	I
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
masseter	NN	I-NP	B
muscle	NN	I-NP	I
rigidity	NN	I-NP	I
(	(	O	O
jaw	NN	B-NP	B
of	IN	B-PP	I
steel	NN	B-NP	I
)	)	O	O
after	IN	B-PP	O
succinylcholine	NN	B-NP	O
(	(	O	O
Sch	NN	B-NP	O
)	)	O	O
administration	NN	B-NP	O
during	IN	B-PP	O
general	JJ	B-NP	O
anesthetic	JJ	I-NP	O
management	NN	I-NP	O
for	IN	B-PP	O
rigid	JJ	B-NP	O
bronchoscopic	JJ	I-NP	O
removal	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
tracheal	JJ	I-NP	O
foreign	JJ	I-NP	O
body	NN	I-NP	O
.	.	O	O

Anesthesia	NNP	B-NP	O
was	VBD	B-VP	O
continued	VBN	I-VP	O
uneventfully	RB	B-ADVP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
infusion	NN	I-NP	O
while	IN	B-SBAR	O
all	DT	B-NP	O
facilities	NNS	I-NP	O
were	VBD	B-VP	O
available	JJ	B-ADJP	O
to	TO	B-VP	O
detect	VB	I-VP	O
and	CC	I-VP	O
treat	VB	I-VP	O
malignant	JJ	B-NP	B
hyperthermia	NN	I-NP	I
.	.	O	O

Minor	JJ	B-NP	O
neurological	JJ	I-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
cognitive	JJ	B-NP	O
development	NN	I-NP	O
,	,	O	O
and	CC	O	O
somatic	JJ	B-NP	O
development	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
dexamethasone	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
very	RB	B-NP	O
-	HYPH	I-NP	O
low	JJ	I-NP	O
birth	NN	I-NP	O
-	HYPH	I-NP	O
weight	NN	B-NP	O
infants	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
minor	JJ	B-NP	O
neurological	JJ	I-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
cognitive	JJ	B-NP	O
development	NN	I-NP	O
,	,	O	O
and	CC	O	O
somatic	JJ	B-NP	O
development	NN	I-NP	O
after	IN	B-PP	O
dexamethasone	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
very	RB	B-NP	O
-	HYPH	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
birthweight	NN	I-NP	O
infants	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
after	IN	B-PP	O
dexamethasone	NN	B-NP	O
treatment	NN	I-NP	O
were	VBD	B-VP	O
matched	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
without	IN	B-PP	O
dexamethasone	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
7th	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
28th	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

Exclusion	NN	B-NP	O
criteria	NNS	I-NP	O
were	VBD	B-VP	O
asphyxia	NN	B-NP	B
,	,	O	O
malformations	NNS	B-NP	B
,	,	O	O
major	JJ	B-NP	O
surgical	JJ	I-NP	O
interventions	NNS	I-NP	O
,	,	O	O
small	JJ	B-ADJP	O
for	IN	B-PP	O
gestational	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
intraventricular	JJ	B-NP	O
haemorrhage	NN	I-NP	B
grades	NNS	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
,	,	O	O
periventricular	JJ	B-NP	B
leukomalacia	NN	I-NP	I
,	,	O	O
and	CC	O	O
severe	JJ	B-NP	O
psychomotor	NN	I-NP	B
retardation	NN	I-NP	I
.	.	O	O

Each	DT	B-NP	O
child	NN	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
neuropediatrician	NN	I-NP	O
for	IN	B-PP	O
minor	JJ	B-NP	O
neurological	JJ	I-NP	B
dysfunctions	NNS	I-NP	I
and	CC	O	O
tested	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
psychologist	NN	I-NP	O
for	IN	B-PP	O
cognitive	JJ	B-NP	O
development	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
Kaufman	NNP	I-NP	O
Assessment	NNP	I-NP	O
Battery	NNP	I-NP	O
for	IN	B-PP	O
Children	NNP	B-NP	O
and	CC	O	O
a	DT	B-NP	O
Draw	NN	I-NP	O
-	HYPH	O	O
a	SYM	B-NP	O
-	:	O	O
Man	NNP	B-NP	O
Test	NNP	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
demographic	JJ	B-NP	O
data	NNS	I-NP	O
,	,	O	O
growth	NN	B-NP	O
,	,	O	O
and	CC	O	O
socio	AFX	O	O
-	HYPH	O	O
economic	JJ	B-NP	O
status	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Fine	JJ	B-NP	O
motor	NN	I-NP	O
skills	NNS	I-NP	O
and	CC	O	O
gross	JJ	B-NP	O
motor	NN	I-NP	O
function	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
better	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
Draw	NNP	I-NP	O
-	:	O	O
a	DT	B-NP	O
-	:	O	O
Man	NNP	B-NP	O
Test	NNP	I-NP	O
,	,	O	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
showed	VBD	B-VP	O
better	JJR	B-NP	O
results	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
speech	NN	B-NP	O
,	,	O	O
social	JJ	B-NP	O
development	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
Kaufman	NNP	I-NP	O
Assessment	NNP	I-NP	O
Battery	NNP	I-NP	O
for	IN	B-PP	O
Children	NNP	B-NP	O
.	.	O	O

After	IN	B-PP	O
dexamethasone	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
children	NNS	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
minor	JJ	B-NP	O
neurological	JJ	I-NP	B
dysfunctions	NNS	I-NP	I
.	.	O	O

Neurological	JJ	B-NP	O
development	NN	I-NP	O
was	VBD	B-VP	O
affected	VBN	I-VP	O
even	RB	B-ADVP	O
without	IN	B-PP	O
neurological	JJ	B-NP	O
diagnosis	NN	I-NP	O
.	.	O	O

Further	RB	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
studies	NNS	B-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
fully	RB	I-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
on	IN	B-PP	O
neurological	JJ	B-NP	O
and	CC	I-NP	O
cognitive	JJ	I-NP	O
development	NN	I-NP	O
.	.	O	O

Force	NN	B-NP	O
overflow	NN	I-NP	O
and	CC	I-NP	O
levodopa	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
assessed	VBD	B-VP	O
force	NN	B-NP	O
coordination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hand	NN	I-NP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
relationship	NN	I-NP	O
to	TO	B-PP	O
motor	NN	B-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
to	TO	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
(	(	O	O
LID	NN	B-NP	B
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
with	IN	B-PP	O
and	CC	I-PP	O
without	IN	I-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
,	,	O	O
and	CC	O	O
age	NN	B-NP	O
-	HYPH	B-VP	O
matched	VBN	B-NP	O
healthy	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
motor	NN	I-NP	O
score	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Unified	NNP	I-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
,	,	O	O
a	DT	B-NP	O
dyskinesia	NN	I-NP	B
score	NN	I-NP	O
and	CC	I-NP	O
force	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
grip	NN	I-NP	O
-	HYPH	I-NP	O
lift	NN	I-NP	O
paradigm	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
ON	NN	B-NP	O
and	CC	I-NP	O
OFF	NN	I-NP	O
levodopa	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
pathological	JJ	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
forces	NNS	B-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
ON	NN	B-NP	O
-	HYPH	I-NP	O
state	NN	I-NP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
+	SYM	I-NP	O
LID	NN	I-NP	B
only	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
+	SYM	I-NP	O
LID	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
force	NN	I-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
pressing	VBG	B-VP	O
down	RP	B-PRT	O
the	DT	B-NP	O
object	NN	I-NP	O
before	IN	B-PP	O
lifting	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
levodopa	NN	B-NP	O
.	.	O	O

An	DT	B-NP	O
overshooting	NN	I-NP	O
of	IN	B-PP	O
peak	NN	B-NP	O
grip	NN	I-NP	O
force	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
static	JJ	B-NP	O
grip	NN	I-NP	O
force	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
ON	NN	I-NP	O
-	HYPH	B-ADJP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
OFF	NN	I-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
condition	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
no	DT	B-NP	O
excessive	JJ	I-NP	O
force	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
-	HYPH	I-NP	O
LID	NN	I-NP	B
.	.	O	O

Peak	JJ	B-NP	O
grip	NN	I-NP	O
force	NN	I-NP	O
in	IN	B-PP	O
ON	NN	B-NP	O
-	HYPH	B-NP	O
state	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
+	SYM	I-NP	O
LID	NN	I-NP	B
than	IN	B-PP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
-	HYPH	I-NP	O
LID	NN	I-NP	B
,	,	O	O
while	IN	B-SBAR	O
static	JJ	B-NP	O
grip	NN	I-NP	O
force	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

Severity	NN	B-NP	O
of	IN	B-PP	O
peak	NN	B-NP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
dyskinesias	NNS	I-NP	B
was	VBD	B-VP	O
strongly	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
grip	NN	B-NP	O
force	NN	I-NP	O
in	IN	B-PP	O
ON	NN	B-NP	O
-	HYPH	B-NP	O
state	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
correlation	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
forces	NNS	B-NP	O
and	CC	O	O
the	DT	B-NP	O
motor	NN	I-NP	O
score	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
with	IN	B-PP	O
the	DT	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
dopaminergic	JJ	B-NP	O
medication	NN	I-NP	O
.	.	O	O

Force	NN	B-NP	O
excess	NN	I-NP	O
was	VBD	B-VP	O
only	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
LID	NN	B-NP	B
and	CC	I-NP	O
motor	NN	I-NP	O
fluctuations	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
close	JJ	I-NP	O
relationship	NN	I-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
overshooting	NN	I-NP	O
of	IN	B-PP	O
forces	NNS	B-NP	O
and	CC	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
ON	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
condition	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
postulate	VBP	B-VP	O
that	IN	B-SBAR	O
both	CC	O	O
LID	NN	B-NP	B
and	CC	I-NP	O
grip	NN	I-NP	O
force	NN	I-NP	O
excess	JJ	I-NP	O
share	NN	I-NP	O
common	JJ	I-NP	O
pathophysiological	JJ	I-NP	O
mechanisms	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
motor	NN	B-NP	O
fluctuations	NNS	I-NP	O
.	.	O	O

Postinfarction	NN	B-NP	O
ventricular	JJ	I-NP	B
septal	JJ	I-NP	I
defect	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
steroid	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
postinfarction	NN	B-NP	O
ventricular	JJ	I-NP	B
septal	JJ	I-NP	I
rupture	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
steroid	NN	I-NP	O
therapy	NN	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
favourable	JJ	I-NP	O
outcome	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
cases	NNS	I-NP	O
described	VBN	B-VP	O
.	.	O	O

A	DT	B-NP	O
possible	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
steroid	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
subsequent	JJ	B-NP	O
postinfarction	NN	I-NP	O
septal	JJ	I-NP	B
rupture	NN	I-NP	I
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Angioedema	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
droperidol	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Angioedema	NNP	B-NP	B
,	,	O	O
also	RB	B-VP	O
known	VBN	I-VP	O
as	IN	B-PP	O
angioneurotic	JJ	B-NP	B
edema	NN	I-NP	I
or	CC	O	O
Quincke	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
demarcated	VBN	B-VP	O
,	,	O	O
localized	VBN	B-NP	O
edema	NN	I-NP	B
involving	VBG	B-VP	O
the	DT	B-NP	O
subcutaneous	JJ	I-NP	O
tissues	NNS	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
upper	JJ	B-NP	B
-	HYPH	I-NP	I
airway	NN	I-NP	I
obstruction	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
previously	RB	I-NP	O
healthy	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
known	VBN	I-NP	O
drug	NN	I-NP	B
allergies	NNS	I-NP	I
in	IN	B-PP	O
whom	WP	B-NP	O
angioedema	NN	B-NP	B
with	IN	B-PP	O
significant	JJ	B-NP	O
tongue	NN	I-NP	B
swelling	NN	I-NP	I
and	CC	I-NP	O
protrusion	NN	I-NP	O
developed	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
droperidol	NN	B-NP	O
.	.	O	O

Clarithromycin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
on	IN	B-PP	O
continuous	JJ	B-NP	O
ambulatory	JJ	I-NP	O
peritoneal	JJ	I-NP	O
dialysis	NN	I-NP	O
.	.	O	O

Visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
are	VBP	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
event	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
and	CC	O	O
not	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-PP	O
uremia	FW	B-NP	B
per	FW	I-NP	O
se	FW	I-NP	O
.	.	O	O

Unreported	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
is	VBZ	B-VP	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
occurring	VBG	B-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
new	JJ	I-NP	O
macrolide	NN	I-NP	O
antibiotic	NN	I-NP	O
,	,	O	O
clarithromycin	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
such	PDT	B-NP	O
a	DT	I-NP	O
case	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
(	(	O	O
ESRD	NN	B-NP	B
)	)	O	O
maintained	VBN	B-VP	O
on	IN	B-PP	O
continuous	JJ	B-NP	O
ambulatory	JJ	I-NP	O
peritoneal	JJ	I-NP	O
dialysis	NN	I-NP	O
(	(	O	O
CAPD	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
relatively	RB	I-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
clarithromycin	NN	B-NP	O
in	IN	B-PP	O
face	NN	B-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
functionally	RB	I-NP	O
anephric	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
underlying	VBG	B-VP	O
aluminum	NN	B-NP	O
intoxication	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
have	VB	I-VP	O
facilitated	VBN	I-VP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
neurotoxic	JJ	I-NP	B
side	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
understand	VB	I-VP	O
the	DT	B-NP	O
pharmacokinetics	NNS	I-NP	O
of	IN	B-PP	O
medications	NNS	B-NP	O
in	IN	B-PP	O
face	NN	B-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
interactions	NNS	I-NP	O
,	,	O	O
and	CC	O	O
how	WRB	B-ADVP	O
these	DT	B-NP	O
factors	NNS	I-NP	O
should	MD	B-VP	O
help	VB	I-VP	O
guide	VB	I-VP	O
medication	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ESRD	NNP	I-NP	B
patient	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
renal	JJ	I-NP	B
toxicity	NN	I-NP	I
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
(	(	O	O
adriamycin	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
loaded	VBN	B-NP	O
cyanoacrylate	NN	I-NP	O
nanoparticles	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
doxorubicin	NN	I-NP	O
-	HYPH	O	O
loaded	VBN	B-VP	O
nanoparticle	NN	B-NP	O
(	(	O	O
DXNP	NN	B-NP	O
)	)	O	O
renal	JJ	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
explored	VBN	I-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
normal	JJ	I-NP	O
rats	NNS	I-NP	O
and	CC	I-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
experimental	JJ	B-NP	O
glomerulonephritis	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
normal	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
given	VBN	B-VP	O
free	JJ	B-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
DX	NN	B-NP	O
)	)	O	O
died	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
all	DT	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
and	CC	O	O
all	DT	B-NP	O
rats	NNS	I-NP	O
having	VBG	B-VP	O
received	VBN	I-VP	O
free	JJ	B-NP	O
NP	NN	I-NP	O
or	CC	I-NP	O
DXNP	NN	I-NP	O
survived	VBD	B-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
higher	JJR	I-NP	O
proteinuria	NN	I-NP	B
appeared	VBD	B-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
DXNP	NN	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
those	DT	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
DX	NN	B-NP	O
.	.	O	O

Free	JJ	B-NP	O
NP	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
provoke	VB	I-VP	O
any	DT	B-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
hr	NN	I-NP	O
post	AFX	O	O
-	HYPH	O	O
injection	NN	B-NP	O
,	,	O	O
DXNP	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-ADJP	O
times	NNS	I-ADJP	O
more	JJR	I-ADJP	O
concentrated	VBD	B-VP	O
in	IN	B-PP	O
kidneys	NNS	B-NP	O
than	IN	B-PP	O
free	JJ	B-NP	O
DX	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
immune	JJ	B-NP	O
experimental	JJ	I-NP	O
glomerulonephritis	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
given	VBN	B-VP	O
DX	NN	B-NP	O
died	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
by	IN	B-PP	O
DXNP	NN	B-NP	O
,	,	O	O
NP	NN	B-NP	O
,	,	O	O
or	CC	O	O
untreated	JJ	B-ADJP	O
,	,	O	O
which	WDT	B-NP	O
all	DT	O	O
survived	VBD	B-VP	O
.	.	O	O

Proteinuria	NNP	B-NP	B
appeared	VBD	B-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
series	NN	I-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
more	RBR	I-NP	O
intense	JJ	I-NP	O
and	CC	I-NP	O
prolonged	JJ	I-NP	O
after	IN	B-PP	O
doxorubicin	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
significant	JJ	B-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
DXNP	NN	B-NP	O
and	CC	I-NP	O
DX	NN	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
treated	VBN	B-VP	O
by	IN	B-PP	O
unloaded	JJ	B-NP	O
NP	NN	I-NP	O
behaved	VBD	B-VP	O
as	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
in	IN	B-PP	O
these	DT	B-NP	O
experimental	JJ	I-NP	O
conditions	NNS	I-NP	O
,	,	O	O
DXNP	NN	B-NP	O
killed	VBD	B-VP	O
less	JJR	B-NP	O
animals	NNS	I-NP	O
than	IN	B-PP	O
free	JJ	B-NP	O
DX	NN	I-NP	O
,	,	O	O
despite	IN	B-PP	O
of	IN	B-PP	O
an	DT	B-NP	O
enhanced	VBN	I-NP	O
renal	JJ	I-NP	B
toxicity	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
former	JJ	I-NP	O
.	.	O	O

Both	DT	B-NP	O
effects	NNS	I-NP	O
(	(	O	O
better	JJR	B-NP	O
survival	NN	I-NP	O
and	CC	I-NP	O
nephrosis	NN	I-NP	B
)	)	O	O
are	VBP	B-VP	O
most	RBS	I-VP	O
probably	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
enhanced	VBN	I-NP	O
capture	NN	I-NP	O
of	IN	B-PP	O
DXNP	NN	B-NP	O
by	IN	B-PP	O
cells	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mononuclear	JJ	I-NP	O
phagocyte	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
mesangial	JJ	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

Etoposide	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
is	VBZ	B-VP	O
reported	VBN	I-VP	O
after	IN	B-PP	O
chemotherapy	NN	B-NP	O
containing	VBG	B-VP	O
etoposide	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
coronary	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Possible	JJ	B-NP	O
causal	JJ	I-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Subjective	JJ	B-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	B
dysfunction	NN	I-NP	I
of	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
digoxin	NN	B-NP	O
.	.	O	O

Various	JJ	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
male	JJ	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
received	VBN	I-VP	O
digoxin	NN	B-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
longterm	JJ	I-NP	O
basis	NN	I-NP	O
have	VBP	B-VP	O
increased	VBN	I-VP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
estrogen	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
testosterone	NN	I-NP	O
and	CC	O	O
luteinizing	VBG	B-VP	O
hormone	NN	B-NP	O
(	(	O	O
LH	NN	B-NP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
links	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
digoxin	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
sexual	JJ	B-NP	O
behavior	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
digoxin	NN	B-NP	O
on	IN	B-PP	O
plasma	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
estradiol	NN	B-NP	O
,	,	O	O
testosterone	NN	B-NP	O
,	,	O	O
and	CC	O	O
LH	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
and	CC	I-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
without	IN	B-PP	O
digoxin	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
of	IN	B-PP	O
similar	JJ	B-NP	O
cardiac	JJ	I-NP	O
functional	JJ	I-NP	O
capacity	NN	I-NP	O
and	CC	O	O
age	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
and	CC	O	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
selected	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
rheumatic	JJ	I-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
patients	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
subjective	JJ	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	O
behavior	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
and	CC	I-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
,	,	O	O
using	VBG	B-VP	O
parameters	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
sexual	JJ	B-NP	O
desire	NN	I-NP	O
,	,	O	O
sexual	JJ	B-NP	O
excitement	NN	I-NP	O
,	,	O	O
and	CC	O	O
frequency	NN	B-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	O
relations	NNS	I-NP	O
.	.	O	O

Personal	JJ	B-NP	O
interviews	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
questionnaire	NN	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	O
behavior	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
reports	NNS	I-NP	O
concerning	VBG	B-VP	O
digoxin	NN	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
plasma	NN	B-NP	O
estradiol	NN	I-NP	O
,	,	O	O
testosterone	NN	B-NP	O
,	,	O	O
and	CC	O	O
LH	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
means	NNS	I-NP	O
were	VBD	B-VP	O
significant	JJ	B-ADJP	O
.	.	O	O

Tests	NNS	B-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
sexual	JJ	B-NP	O
behavior	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	B
in	IN	B-PP	I
sexual	JJ	B-NP	I
desire	NN	I-NP	I
,	,	O	O
sexual	JJ	B-NP	O
excitement	NN	I-NP	O
phase	NN	I-NP	O
(	(	O	O
erection	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
frequency	NN	B-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	O
relations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
indomethacin	NN	B-NP	O
-	HYPH	I-NP	O
-	HYPH	I-NP	O
lymphocyte	NN	I-NP	O
transformation	NN	I-NP	O
tests	NNS	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

Although	IN	B-SBAR	O
indomethacin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
clinical	JJ	I-NP	O
observations	NNS	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
role	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
definitely	RB	I-VP	O
established	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
is	VBZ	B-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
which	WDT	B-NP	O
no	DT	B-NP	O
drugs	NNS	I-NP	O
other	JJ	B-ADJP	O
than	IN	B-PP	O
allopurinol	NN	B-NP	O
and	CC	I-NP	O
indomethacin	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
.	.	O	O

Indomethacin	NN	B-NP	O
was	VBD	B-VP	O
first	RB	I-VP	O
given	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
positive	JJ	I-NP	O
lymphocyte	NN	I-NP	O
transformation	NN	I-NP	O
test	NN	I-NP	O
with	IN	B-PP	O
indomethacin	NN	B-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
further	RBR	B-ADVP	O
substantiates	VBZ	B-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
causing	VBG	B-VP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
susceptible	JJ	I-NP	O
patient	NN	I-NP	O
.	.	O	O

Fortunately	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
very	RB	I-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
and	CC	I-NP	O
urinary	JJ	I-NP	O
lipids	NNS	I-NP	O
and	CC	I-NP	O
lipoproteins	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
by	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	I-VP	O
ascertain	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
alterations	NNS	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
lipoproteins	NNS	I-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
were	VBD	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
per	FW	B-ADVP	O
se	FW	I-ADVP	O
,	,	O	O
or	CC	O	O
,	,	O	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
in	IN	B-PP	O
part	NN	B-NP	O
,	,	O	O
to	TO	B-PP	O
the	DT	B-NP	O
aminonucleoside	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	O	O
urinary	JJ	B-NP	O
lipoproteins	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
subsequent	JJ	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Since	IN	B-SBAR	O
massive	JJ	B-NP	O
albuminuria	NN	I-NP	B
occurred	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
course	NN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
stages	NNS	I-NP	O
:	:	O	O
pre	AFX	O	O
-	HYPH	O	O
nephrotic	JJ	B-NP	B
stage	NN	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
nephrotic	JJ	B-NP	B
stage	NN	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	B-NP	O
nephrotic	JJ	I-NP	B
stage	NN	I-NP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
fatty	JJ	B-NP	O
acids	NNS	I-NP	O
,	,	O	O
triacylglycerol	NN	B-NP	O
and	CC	I-NP	O
VLDL	NN	I-NP	O
decreased	VBD	B-VP	O
while	IN	B-SBAR	O
that	DT	B-NP	O
of	IN	B-PP	O
phospholipid	NN	B-NP	O
,	,	O	O
cholesteryl	NN	B-NP	O
esters	NNS	I-NP	O
and	CC	O	O
HDL	NN	B-NP	O
remained	VBD	B-VP	O
constant	JJ	B-ADJP	O
.	.	O	O

Plasma	NN	B-NP	O
apolipoprotein	NN	I-NP	O
A	NN	I-NP	O
-	HYPH	O	O
I	PRP	B-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
increase	NN	I-NP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
beginning	NN	I-NP	O
of	IN	B-PP	O
nephrotic	JJ	B-NP	B
stage	NN	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
the	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
albumin	NN	I-NP	O
dropped	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
very	RB	I-NP	O
low	JJ	I-NP	O
level	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
that	DT	B-NP	O
of	IN	B-PP	O
apolipoprotein	NN	B-NP	O
A	NN	I-NP	O
-	HYPH	O	O
I	PRP	B-NP	O
increased	VBD	B-VP	O
abruptly	RB	B-ADVP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
increase	NN	I-NP	O
)	)	O	O
and	CC	O	O
continued	VBD	B-VP	O
to	TO	I-VP	O
rise	VB	I-VP	O
,	,	O	O
although	IN	B-SBAR	O
less	RBR	B-ADVP	O
steeply	RB	I-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
HDL	NN	B-NP	O
followed	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
pattern	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
VLDL	NN	I-NP	O
and	CC	I-NP	O
LDL	NN	I-NP	O
increased	VBD	B-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
later	JJ	I-NP	O
stage	NN	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Plasma	NN	B-NP	O
apolipoprotein	NN	I-NP	O
A	NN	I-NP	O
-	HYPH	O	O
I	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
in	IN	B-PP	O
HDL	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
in	IN	B-PP	O
the	DT	B-NP	O
LDL	NN	I-NP	O
density	NN	I-NP	O
class	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
nephrotic	JJ	I-NP	B
stage	NN	I-NP	O
lipoproteinuria	NN	I-NP	O
was	VBD	B-VP	O
negligible	JJ	B-ADJP	O
,	,	O	O
while	IN	B-SBAR	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
nephrotic	JJ	I-NP	B
stage	NN	I-NP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
lipoproteins	NNS	I-NP	O
consisted	VBD	B-VP	O
mainly	RB	B-ADVP	O
of	IN	B-PP	O
HDL	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
alters	VBZ	B-VP	O
plasma	NN	B-NP	O
lipoproteins	NNS	I-NP	O
by	IN	B-PP	O
lowering	VBG	B-VP	O
VLDL	NN	B-NP	O
and	CC	O	O
increasing	VBG	B-NP	O
HDL	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
early	JJ	I-NP	O
and	CC	I-NP	O
striking	JJ	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
HDL	NN	I-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
nephrotic	JJ	B-NP	B
rats	NNS	I-NP	O
is	VBZ	B-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
on	IN	B-PP	O
HDL	NN	B-NP	O
metabolism	NN	I-NP	O
.	.	O	O

Circulating	VBG	B-VP	O
lysosomal	JJ	B-NP	O
enzymes	NNS	I-NP	O
and	CC	O	O
acute	JJ	B-NP	B
hepatic	JJ	I-NP	I
necrosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lysosomal	JJ	I-NP	O
enzymes	NNS	I-NP	O
acid	NN	I-NP	O
and	CC	O	O
neutral	JJ	B-NP	O
protease	NN	I-NP	O
,	,	O	O
N	NN	B-NP	O
-	HYPH	B-NP	O
acetylglucosaminidase	NN	I-NP	O
,	,	O	O
and	CC	O	O
acid	NN	B-NP	O
phosphatase	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Acid	NN	B-NP	O
protease	NN	I-NP	O
(	(	O	O
cathepsin	NN	B-NP	O
D	NN	I-NP	O
)	)	O	O
activity	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
about	RB	B-ADJP	O
tenfold	RB	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
died	VBD	B-VP	O
and	CC	O	O
nearly	RB	B-ADVP	O
fourfold	RB	I-ADVP	O
in	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
survived	VBD	B-VP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
after	IN	B-PP	O
paracetamol	NN	B-NP	O
overdose	NN	I-NP	B
,	,	O	O
whereas	IN	O	O
activities	NNS	B-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
equally	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
viral	JJ	B-NP	B
hepatitis	NN	I-NP	I
whether	IN	B-SBAR	O
or	CC	O	O
not	RB	O	O
they	PRP	B-NP	O
survived	VBD	B-VP	O
.	.	O	O

A	DT	B-NP	O
correlation	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
serum	NN	B-NP	O
acid	NN	I-NP	O
protease	NN	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
prothrombin	NN	B-NP	O
time	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
cathepsin	NN	B-NP	O
D	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
sustained	JJ	B-ADJP	O
over	IN	B-PP	O
several	JJ	B-NP	O
days	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
aspartate	NN	B-NP	O
aminotransferase	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
sharp	JJ	I-NP	O
early	JJ	I-NP	O
peak	NN	I-NP	O
and	CC	B-NP	O
then	RB	I-NP	O
a	DT	B-NP	O
fall	NN	I-NP	O
.	.	O	O

Circulating	VBG	B-VP	O
lysosomal	JJ	B-NP	O
proteases	NNS	I-NP	O
can	MD	B-VP	O
damage	VB	I-VP	O
other	JJ	B-NP	O
organs	NNS	I-NP	O
,	,	O	O
and	CC	O	O
measurement	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
activity	NN	I-NP	O
may	MD	B-VP	O
therefore	RB	I-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
added	VBN	B-NP	O
value	NN	I-NP	O
in	IN	B-PP	O
assessing	VBG	B-VP	O
prognosis	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
condition	NN	I-NP	O
.	.	O	O

Transketolase	NN	B-NP	O
abnormality	NN	I-NP	O
in	IN	B-PP	O
tolazamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
Wernicke	NN	I-NP	B
s	NNS	I-NP	I
encephalopathy	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
a	DT	B-NP	O
thiamine	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
enzyme	NN	I-NP	O
,	,	O	O
transketolase	NN	B-NP	O
,	,	O	O
from	IN	B-PP	O
fibroblasts	NNS	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
diabetic	JJ	I-NP	B
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
Wernicke	NNP	B-NP	B
s	NN	I-NP	I
encephalopathy	NN	I-NP	I
when	WRB	B-ADVP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
tolazamide	NN	B-NP	O
,	,	O	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
delineate	VB	I-VP	O
if	IN	B-SBAR	O
this	DT	B-NP	O
patient	NN	I-NP	O
also	RB	B-ADVP	O
had	VBD	B-VP	O
transketolase	NN	B-NP	O
abnormality	NN	I-NP	O
[	(	O	O
high	JJ	B-NP	O
Km	NN	I-NP	O
for	IN	B-PP	O
thiamine	NN	B-NP	O
pyrophosphate	NN	I-NP	O
(	(	O	O
TPP	NN	B-NP	O
)	)	O	O
]	)	O	O
,	,	O	O
as	RB	O	O
previously	RB	B-ADVP	O
reported	VBN	B-VP	O
in	IN	B-PP	O
postalcoholic	JJ	B-NP	O
Wernicke	NNP	I-NP	B
-	HYPH	I-NP	I
Korsakoff	NNP	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
also	RB	B-ADVP	O
studied	VBD	B-VP	O
this	DT	B-NP	O
enzyme	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
diabetic	JJ	I-NP	B
kindreds	NNS	I-NP	O
without	IN	B-PP	O
any	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
Wernicke	NNP	B-NP	B
s	NNS	I-NP	I
encephalopathy	NN	I-NP	I
and	CC	B-PP	O
from	IN	B-PP	O
num	CD	B-NP	O
normal	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
above	RB	I-NP	O
-	HYPH	I-NP	O
mentioned	VBN	I-NP	O
patient	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diabetic	JJ	I-NP	B
kindreds	NNS	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
Wernicke	NNP	B-NP	B
s	NN	I-NP	I
encephalopathy	NN	I-NP	I
had	VBD	B-VP	O
abnormal	JJ	B-NP	O
transketolase	NN	I-NP	O
as	IN	B-SBAR	O
determined	VBN	B-VP	O
by	IN	B-PP	O
its	PRP$	B-NP	O
Km	NN	I-NP	O
for	IN	B-PP	O
TPP	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
similarity	NN	I-NP	O
between	IN	B-PP	O
postalcoholic	JJ	B-NP	O
Wernicke	NNP	I-NP	B
-	HYPH	I-NP	I
Korsakoff	NNP	I-NP	I
syndrome	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
tolazamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
Wernicke	NN	I-NP	B
s	VBZ	B-VP	I
encephalopathy	NN	B-NP	I
from	IN	B-PP	O
the	DT	B-NP	O
standpoint	NN	I-NP	O
of	IN	B-PP	O
transketolase	NN	B-NP	O
abnormality	NN	I-NP	O
.	.	O	O

Mechanisms	NNS	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
epinephrine	NN	B-NP	O
:	:	O	O
comparison	NN	B-NP	O
with	IN	B-PP	O
exercise	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ischemia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
in	IN	B-PP	O
eliciting	VBG	B-VP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Objective	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
ischemia	NN	B-NP	B
and	CC	I-NP	O
factors	NNS	I-NP	O
increasing	VBG	B-VP	O
myocardial	JJ	B-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
during	IN	B-PP	O
epinephrine	NN	B-NP	O
infusion	NN	I-NP	O
and	CC	O	O
supine	NN	B-NP	O
bicycle	NN	I-NP	O
exercise	NN	I-NP	O
.	.	O	O

Both	CC	O	O
epinephrine	NN	B-NP	O
and	CC	I-NP	O
exercise	NN	I-NP	O
produced	VBD	B-VP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
as	IN	B-SBAR	O
evidenced	VBN	B-VP	O
by	IN	B-PP	O
ST	JJ	B-NP	O
segment	NN	I-NP	O
depression	NN	I-NP	B
and	CC	I-NP	O
angina	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
epinephrine	NN	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
exercise	NN	B-NP	O
.	.	O	O

Exercise	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
was	VBD	B-VP	O
marked	VBN	I-VP	O
predominantly	RB	B-ADVP	O
by	IN	B-PP	O
increased	VBN	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
rate	NN	I-NP	O
-	HYPH	B-NP	O
pressure	NN	I-NP	O
product	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
minor	JJ	I-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
end	NN	B-NP	O
-	HYPH	I-NP	O
diastolic	JJ	I-NP	O
volume	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ischemia	NN	I-NP	B
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
contractility	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	O
less	RBR	I-NP	O
pronounced	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
rate	NN	I-NP	O
-	HYPH	B-NP	O
pressure	NN	I-NP	O
product	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
ischemia	NN	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
epinephrine	NN	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
may	MD	B-VP	O
occur	VB	I-VP	O
during	IN	B-PP	O
states	NNS	B-NP	O
of	IN	B-PP	O
emotional	JJ	B-NP	O
distress	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
a	DT	B-NP	O
mechanism	NN	I-NP	O
distinct	JJ	B-ADJP	O
from	IN	B-PP	O
that	DT	B-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
physical	JJ	B-NP	O
exertion	NN	I-NP	O
.	.	O	O

Transient	JJ	B-NP	O
contralateral	JJ	I-NP	B
rotation	NN	I-NP	I
following	VBG	B-PP	O
unilateral	JJ	B-NP	O
substantia	NN	I-NP	B
nigra	NN	I-NP	I
lesion	NN	I-NP	I
reflects	VBZ	B-VP	O
susceptibility	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nigrostriatal	JJ	I-NP	O
system	NN	I-NP	O
to	TO	B-PP	O
exhaustion	NN	B-NP	O
by	IN	B-PP	O
amphetamine	NN	B-NP	O
.	.	O	O

Following	VBG	B-PP	O
unilateral	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
induced	VBN	I-NP	O
SN	NN	I-NP	B
lesion	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
transient	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
contralateral	JJ	B-NP	B
rotation	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
precede	VB	I-VP	O
the	DT	B-NP	O
predominant	JJ	I-NP	O
ipsilateral	JJ	I-NP	B
circling	NN	I-NP	I
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
clarify	VB	I-VP	O
the	DT	B-NP	O
nature	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
initial	JJ	I-NP	O
contralateral	JJ	I-NP	B
rotation	NN	I-NP	I
we	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
recovery	NN	B-NP	O
period	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
lesion	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rotational	JJ	I-NP	B
behavior	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
post	IN	B-PP	O
lesion	NN	B-NP	O
,	,	O	O
most	JJS	B-NP	O
rats	NNS	I-NP	O
circled	VBD	B-VP	O
predominantly	RB	B-ADJP	O
contralaterally	RB	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
lesion	NN	I-NP	O
.	.	O	O

Such	JJ	B-NP	O
contralateral	JJ	I-NP	B
rotation	NN	I-NP	I
may	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
either	CC	O	O
degeneration	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
breakdown	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DA	NN	I-NP	O
pool	NN	I-NP	O
,	,	O	O
or	CC	O	O
lesion	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
DA	NN	B-NP	O
turnover	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
spared	JJ	I-NP	O
neurons	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
substantial	JJ	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
contralateral	JJ	B-NP	O
preference	NN	I-NP	O
was	VBD	B-VP	O
still	RB	B-ADVP	O
evident	JJ	B-ADJP	O
when	WRB	B-ADVP	O
amphetamine	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
lesioning	VBG	B-VP	O
,	,	O	O
indicating	VBG	B-VP	O
involvement	NN	B-NP	O
of	IN	B-PP	O
spared	VBN	B-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
contralateral	JJ	I-NP	B
rotation	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
recovery	NN	B-NP	O
(	(	O	O
and	CC	O	O
irrespective	JJ	B-ADJP	O
of	IN	B-PP	O
either	CC	O	O
lesion	NN	B-NP	O
volume	NN	I-NP	O
,	,	O	O
amphetamine	NN	B-NP	O
dose	NN	I-NP	O
,	,	O	O
or	CC	O	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
lesion	NN	I-NP	O
motor	NN	I-NP	O
exercise	NN	I-NP	O
)	)	O	O
,	,	O	O
amphetamine	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
rotation	NN	I-NP	B
tended	VBD	B-VP	O
to	TO	I-VP	O
become	VB	I-VP	O
gradually	RB	B-ADJP	O
more	RBR	I-ADJP	O
ipsilateral	JJ	I-ADJP	O
as	IN	B-PP	O
the	DT	B-NP	O
observation	NN	I-NP	O
session	NN	I-NP	O
progressed	VBD	B-VP	O
,	,	O	O
and	CC	O	O
all	DT	B-NP	O
rats	NNS	I-NP	O
circled	VBD	B-VP	O
ipsilaterally	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
lesion	NN	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
further	JJ	B-NP	O
amphetamine	NN	I-NP	O
injections	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
amphetamine	NN	B-NP	O
has	VBZ	B-VP	O
an	DT	B-NP	O
irreversible	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
lesion	NN	I-NP	O
DA	NN	I-NP	O
pool	NN	I-NP	O
contributing	VBG	B-VP	O
to	TO	B-PP	O
contralateral	JJ	B-NP	B
rotation	NN	I-NP	I
.	.	O	O

Thyroid	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
-	HYPH	O	O
concentrating	VBG	B-VP	O
ability	NN	B-NP	O
during	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
adenylate	NN	B-NP	O
cyclase	NN	I-NP	O
inhibition	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
important	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
both	CC	B-NP	O
nephrogenic	JJ	I-NP	B
diabetes	NNS	I-NP	I
insipidus	NN	I-NP	I
and	CC	I-NP	O
hypothyroidism	NN	I-NP	B
during	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
measured	VBD	B-VP	O
serum	NN	B-NP	O
thyroxine	NN	I-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
-	HYPH	O	O
concentrating	VBG	B-VP	O
ability	NN	B-NP	O
(	(	O	O
Umax	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
response	NN	I-PP	O
to	TO	I-PP	O
desmopressin	NN	B-NP	O
(	(	O	O
DDAVP	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
lithium	NN	B-NP	O
.	.	O	O

Hypothyroidism	NN	B-NP	B
developed	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
while	IN	B-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
taking	VBG	I-VP	O
lithium	NN	B-NP	O
.	.	O	O

Impaired	JJ	B-NP	O
Umax	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
both	CC	B-NP	O
euthyroid	JJ	I-NP	O
and	CC	I-NP	O
hypothyroid	JJ	I-NP	B
patients	NNS	I-NP	O
while	IN	B-SBAR	O
some	DT	B-NP	O
hypothyroid	JJ	I-NP	B
patients	NNS	I-NP	O
concentrated	VBD	B-VP	O
their	PRP$	B-NP	O
urine	NN	I-NP	O
well	RB	B-ADVP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
dominant	JJ	I-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
lithium	NN	B-NP	O
exerts	VBZ	B-VP	O
these	DT	B-NP	O
num	CD	I-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
different	JJ	B-ADJP	O
.	.	O	O

Sensitivity	NN	B-NP	O
of	IN	B-PP	O
erythroid	JJ	B-NP	O
progenitor	NN	I-NP	O
colonies	NNS	I-NP	O
to	TO	B-PP	O
erythropoietin	NN	B-NP	O
in	IN	B-PP	O
azidothymidine	NN	B-NP	O
treated	VBN	B-VP	O
immunodeficient	JJ	B-NP	B
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
anaemia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
azido	AFX	O	O
-	HYPH	O	O
3'dideoxythymidine	NN	B-NP	O
(	(	O	O
AZT	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
poorly	RB	I-VP	O
understood	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
used	VBN	I-VP	O
a	DT	B-NP	O
murine	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
AIDS	NN	B-NP	B
,	,	O	O
infection	NN	B-NP	B
of	IN	B-PP	O
female	JJ	B-NP	O
C57BL	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
LP	NN	B-NP	O
-	HYPH	B-NP	O
BM5	NN	I-NP	O
murine	JJ	I-NP	O
leukaemia	NN	I-NP	B
(	(	O	O
MuLV	NN	B-NP	O
)	)	O	O
virus	NN	B-NP	O
,	,	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
AZT	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anaemia	NN	I-NP	B
is	VBZ	B-VP	O
due	JJ	B-ADJP	O
,	,	O	O
in	IN	B-PP	O
part	NN	B-NP	O
,	,	O	O
to	TO	B-PP	O
decreased	VBN	B-NP	O
responsiveness	NN	I-NP	O
of	IN	B-PP	O
erythropoietic	JJ	B-NP	O
precursors	NNS	I-NP	O
(	(	O	O
BFU	NN	B-NP	O
-	HYPH	O	O
e	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
erythropoietin	NN	B-NP	O
(	(	O	O
EPO	NN	B-NP	O
)	)	O	O
.	.	O	O

Mice	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
LP	NN	B-NP	O
-	HYPH	B-NP	O
BM5	NN	I-NP	O
MuLV	NN	I-NP	O
disease	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
AZT	NNP	B-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
drinking	NN	I-NP	O
water	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
.	.	O	O

AZT	NN	B-NP	O
produced	VBD	B-VP	O
anaemia	NN	B-NP	B
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
fashion	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
the	DT	B-NP	O
anaemia	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
splenic	JJ	B-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
BFU	NN	I-NP	O
-	HYPH	B-NP	O
e	NN	I-NP	O
in	IN	B-PP	O
AZT	NNP	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
increased	VBD	B-VP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
over	IN	B-PP	O
levels	NNS	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
infected	JJ	B-NP	O
untreated	JJ	I-NP	O
animals	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Colony	NN	B-NP	O
formation	NN	I-NP	O
by	IN	B-PP	O
splenic	JJ	B-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
BFUe	NN	I-NP	O
was	VBD	B-VP	O
stimulated	VBN	I-VP	O
at	IN	B-PP	O
lower	JJR	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
EPO	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
receiving	VBG	B-VP	O
AZT	NNP	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
than	IN	B-PP	O
for	IN	B-PP	O
infected	JJ	B-NP	O
,	,	I-NP	O
untreated	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

By	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
both	CC	B-NP	O
splenic	JJ	I-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
BFU	NN	I-NP	O
-	HYPH	B-NP	O
e	NN	I-NP	O
of	IN	B-PP	O
treated	VBN	B-NP	O
animals	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
that	DT	B-NP	O
observed	VBN	B-VP	O
from	IN	B-PP	O
cells	NNS	B-NP	O
of	IN	B-PP	O
infected	JJ	B-NP	O
untreated	JJ	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
EPO	NN	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
AZT	NNP	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
appropriate	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
anaemia	NN	B-NP	B
observed	VBN	B-VP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
phenylhydrazine	NN	B-NP	O
(	(	O	O
PHZ	NN	B-NP	O
)	)	O	O
treated	VBN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
BFU	NN	B-NP	O
-	HYPH	B-NP	O
e	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
erythroblasts	NNS	I-NP	O
observed	VBN	B-VP	O
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
in	IN	B-PP	O
AZT	NN	B-NP	O
and	CC	O	O
PHZ	NN	B-NP	O
treated	VBN	B-VP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
similar	JJ	B-NP	O
degrees	NNS	I-NP	O
of	IN	B-PP	O
anaemia	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
reticulocytosis	NN	B-NP	B
was	VBD	B-VP	O
inappropriate	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
anaemia	NN	B-NP	B
observed	VBN	B-VP	O
in	IN	B-PP	O
AZT	NNP	B-NP	O
treated	VBN	B-VP	O
infected	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

AZT	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
peripheral	JJ	I-NP	O
anaemia	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
face	NN	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
BFU	NN	B-NP	O
-	HYPH	B-NP	O
e	NN	I-NP	O
and	CC	O	O
increased	VBN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
EPO	NN	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
lesion	NN	I-NP	O
in	IN	B-PP	O
terminal	JJ	B-NP	O
differentiation	NN	I-NP	O
.	.	O	O

Detection	NN	B-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
cardiac	JJ	I-NP	O
adrenergic	JJ	I-NP	O
neuron	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
with	IN	B-PP	O
iodine	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
metaiodobenzylguanidine	NN	I-NP	O
.	.	O	O

Radiolabeled	VBN	B-NP	O
metaiodobenzylguanidine	NN	I-NP	O
(	(	O	O
MIBG	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
analog	NN	I-NP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
(	(	O	O
NE	NN	B-NP	O
)	)	O	O
,	,	O	O
serves	VBZ	B-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
index	NN	I-NP	O
of	IN	B-PP	O
adrenergic	JJ	B-NP	O
neuron	NN	I-NP	O
integrity	NN	I-NP	O
and	CC	I-NP	O
function	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
,	,	O	O
we	PRP	B-NP	O
tested	VBD	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
abnormal	JJ	B-NP	O
cardiac	JJ	I-NP	O
adrenergic	JJ	I-NP	O
neuron	NN	I-NP	O
activity	NN	I-NP	O
may	MD	B-VP	O
appear	VB	I-VP	O
and	CC	O	O
be	VB	B-VP	O
exacerbated	VBN	I-VP	O
dose	NN	B-NP	O
-	HYPH	B-ADVP	O
dependently	RB	B-ADVP	O
in	IN	B-PP	O
adriamycin	NN	B-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
vacuolar	JJ	B-NP	B
degeneration	NN	I-NP	I
of	IN	B-PP	I
myocardial	JJ	B-NP	I
cells	NNS	I-NP	I
was	VBD	B-VP	O
analyzed	VBN	I-VP	O
in	IN	B-PP	O
relation	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
abnormalities	NNS	I-NP	O
or	CC	O	O
only	RB	B-NP	O
isolated	VBN	I-NP	O
degeneration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
isolated	VBN	B-VP	O
or	CC	O	O
scattered	VBN	B-VP	O
degeneration	NN	B-NP	O
in	IN	B-PP	O
half	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
frequent	JJ	B-NP	O
scattered	VBN	I-NP	O
degeneration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
scattered	JJ	B-NP	O
or	CC	I-NP	O
focal	JJ	I-NP	O
degeneration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
and	CC	O	O
extensive	JJ	B-NP	O
degeneration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Myocardial	JJ	B-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
[	(	O	O
125I	NN	B-NP	O
]	)	O	O
MIBG	NN	B-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
intravenous	JJ	B-NP	O
injection	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
groups	NNS	I-NP	O
treated	VBN	B-VP	O
num	CD	B-NP	O
wk	NN	I-NP	O
or	CC	I-NP	O
less	JJR	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
slightly	RB	I-NP	O
lower	JJR	I-NP	O
accumulation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
ventricular	JJ	I-NP	O
wall	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
)	)	O	O
and	CC	O	O
significantly	RB	B-NP	O
lower	JJR	I-NP	O
accumulation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
wall	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
MIBG	NN	B-NP	O
accumulation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
and	CC	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
wall	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
MIBG	NN	B-NP	O
accumulation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
and	CC	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
wall	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
MIBG	NN	B-NP	O
accumulation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
myocardium	NN	I-NP	O
decreased	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
adriamycin	NN	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
impaired	JJ	B-NP	O
cardiac	JJ	I-NP	O
adrenergic	JJ	I-NP	O
neuron	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
slight	JJ	B-NP	O
myocardial	JJ	I-NP	B
impairment	NN	I-NP	I
(	(	O	O
scattered	VBN	B-VP	O
or	CC	O	O
focal	JJ	B-NP	O
vacuolar	JJ	I-NP	B
degeneration	NN	I-NP	I
)	)	O	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
MIBG	NN	B-NP	O
scintigraphy	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

Amnestic	JJ	B-NP	B
syndrome	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
propranolol	NN	B-NP	O
toxicity	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
elderly	JJ	I-NP	O
woman	NN	I-NP	O
developed	VBD	B-VP	O
an	DT	B-NP	O
Alzheimer	NNP	I-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
subacute	JJ	I-NP	O
dementia	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
manifestations	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
severe	JJ	B-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
memory	NN	B-NP	O
accounted	VBD	B-VP	O
for	IN	B-PP	O
virtually	RB	B-NP	O
all	DT	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
abnormalities	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
evidence	NN	B-NP	O
that	IN	B-SBAR	O
cerebral	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
drug	NN	B-NP	O
toxicity	NN	I-NP	B
can	MD	B-VP	O
exhibit	VB	I-VP	O
patterns	NNS	B-NP	O
that	WDT	B-NP	O
suggest	VBP	B-VP	O
highly	RB	B-NP	O
selective	JJ	I-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
functional	JJ	B-NP	O
subdivisions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Biphasic	JJ	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
SA	NN	I-NP	O
node	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dog	NN	I-NP	O
heart	NN	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
to	TO	B-PP	O
selective	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
SA	NN	I-NP	O
node	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dog	NN	I-NP	O
heart	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
using	VBG	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
perfusion	NN	I-NP	O
technique	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
SA	NN	I-NP	O
node	NN	I-NP	O
artery	NN	I-NP	O
.	.	O	O

Injections	NNS	B-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
microgram	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
artery	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
depression	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
SA	NN	I-NP	O
nodal	JJ	I-NP	O
activity	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
action	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
depression	NN	I-NP	B
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
sudden	JJ	I-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
stimulatory	JJ	I-NP	O
phase	NN	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
vagotomy	NN	I-NP	O
and	CC	I-NP	O
sympathectomy	NN	I-NP	O
or	CC	O	O
prior	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
ganglion	NN	I-NP	O
blocker	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
inhibit	VB	I-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ketamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
,	,	O	O
while	IN	B-SBAR	O
it	PRP	B-NP	O
was	VBD	B-VP	O
completely	RB	I-VP	O
abolished	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
reserpinized	VBN	I-NP	O
dogs	NNS	I-NP	O
or	CC	B-PP	O
by	IN	B-PP	O
a	DT	B-NP	O
prior	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocking	VBG	B-VP	O
agent	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
SA	NN	I-NP	O
node	NN	I-NP	O
artery	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
may	MD	B-VP	O
indicate	VB	I-VP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
adrenergic	JJ	I-NP	O
mechanism	NN	I-NP	O
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
excitatory	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
injected	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
SA	NN	I-NP	O
node	NN	I-NP	O
artery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
cholinesterase	NN	I-NP	O
in	IN	B-PP	O
succinylcholine	NN	B-NP	O
apnoea	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
demonstrating	VBG	B-VP	O
unexpected	JJ	B-NP	O
prolonged	VBN	I-NP	O
apnoea	NN	I-NP	B
lasting	VBG	B-VP	O
several	JJ	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
succinylcholine	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
preparation	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
serum	NN	I-NP	O
cholinesterase	NN	I-NP	O
.	.	O	O

Adequate	JJ	B-NP	O
spontaneous	JJ	I-NP	O
respiration	NN	I-NP	O
was	VBD	B-VP	O
re	AFX	B-ADJP	O
-	HYPH	B-NP	O
established	VBN	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
biochemical	JJ	B-NP	O
genetic	JJ	I-NP	O
examinations	NNS	I-NP	O
confirmed	VBD	B-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
atypical	JJ	I-NP	O
serum	NN	I-NP	O
cholinesterase	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
none	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
usual	JJ	I-NP	O
variants	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
therefore	RB	I-VP	O
supposed	VBN	I-VP	O
that	IN	B-SBAR	O
other	JJ	B-NP	O
unknown	JJ	I-NP	O
variants	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
cholinesterase	NN	I-NP	O
exist	NN	I-NP	O
which	WDT	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
hydrolyze	VB	I-VP	O
succinylcholine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
cholinesterase	NN	I-NP	O
in	IN	B-PP	O
succinylcholine	NN	B-NP	O
apnoea	NN	I-NP	B
provided	VBD	B-VP	O
considerable	JJ	B-NP	O
relief	NN	I-NP	O
to	TO	B-PP	O
both	CC	O	O
patient	NN	B-NP	O
and	CC	I-NP	O
anaesthetist	NN	I-NP	O
.	.	O	O

Orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
occurs	VBZ	B-VP	O
following	VBG	B-PP	O
alpha	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
blockade	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
-	HYPH	O	O
pretreated	VBN	B-VP	O
conscious	JJ	B-NP	O
spontaneously	RB	I-NP	O
hypertensive	JJ	I-NP	B
rats.	NNS	I-NP	O
num	CD	B-NP	O
.	.	O	O

Studies	NNS	B-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
whether	IN	B-SBAR	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
treatment	NN	I-NP	O
alters	VBZ	B-VP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
function	NN	I-NP	O
for	IN	B-PP	O
orthostatic	JJ	B-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
arterial	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
spontaneously	RB	I-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
(	(	O	O
SHR	NN	B-NP	O
)	)	O	O
.	.	O	O
num	CD	B-NP	O
.	.	O	O

Conscious	JJ	B-NP	O
SHR	NN	I-NP	O
(	(	O	O
male	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
head	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
tilts	NNS	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
s	NN	I-NP	O
following	VBG	B-PP	O
acute	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
prazosin	NN	B-NP	O
or	CC	I-NP	O
rauwolscine	NN	I-NP	O
.	.	O	O

Orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
average	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
femoral	JJ	B-ADJP	O
)	)	O	O
over	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
s	NN	I-NP	O
tilt	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
basal	JJ	I-NP	O
MAP	NN	I-NP	O
of	IN	B-PP	O
conscious	JJ	B-NP	O
SHR	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
extent	NN	I-NP	O
by	IN	B-PP	O
prazosin	NN	B-NP	O
(	(	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
MAP	NN	I-NP	O
)	)	O	O
and	CC	O	O
rauwolscine	NN	B-NP	O
(	(	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
MAP	NN	I-NP	O
)	)	O	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
head	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
tilt	NN	B-NP	O
induced	VBD	B-VP	O
orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
SHR	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
prazosin	NN	B-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
SHR	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
rauwolscine	NN	B-NP	O
.	.	O	O
num	CD	B-NP	O
.	.	O	O

Conscious	JJ	B-NP	O
SHR	NN	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
with	IN	B-PP	O
prazosin	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
kg	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
day	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
i.p.	RB	B-ADVP	O
for	IN	B-PP	O
chronic	JJ	B-NP	O
alpha	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
blockade	NN	I-NP	O
.	.	O	O

MAP	NN	B-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
SHR	NN	I-NP	O
after	IN	B-PP	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
untreated	JJ	I-NP	O
SHR	NN	I-NP	O
.	.	O	O

Head	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
tilts	NNS	B-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
rats	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
orthostatic	JJ	B-NP	B
hypotension	NN	I-NP	I
when	WRB	B-ADVP	O
performed	VBN	B-VP	O
either	CC	O	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
or	CC	B-PP	O
after	IN	I-PP	O
acute	JJ	B-NP	O
dosing	NN	I-NP	O
of	IN	B-PP	O
prazosin	NN	B-NP	O
.	.	O	O

Conversely	RB	B-ADVP	O
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
rauwolscine	NN	B-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
treated	VBN	B-NP	O
SHR	NN	I-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
MAP	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
subsequent	JJ	B-NP	O
tilts	NNS	I-NP	O
induced	VBD	B-VP	O
further	JJ	B-NP	O
drops	NNS	I-NP	O
of	IN	B-PP	O
MAP	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
rats.	NNS	I-NP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
pressor	NN	I-NP	O
responses	NNS	I-NP	O
and	CC	O	O
bradycardia	NN	B-NP	B
to	TO	B-PP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
agonist	NN	I-NP	O
cirazoline	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
agonist	NN	I-NP	O
Abbott	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
noradrenaline	NN	B-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
SHR	NN	I-NP	O
with	IN	B-PP	O
and	CC	O	O
without	IN	B-PP	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
pretreatment	NN	I-NP	O
.	.	O	O

Both	CC	O	O
the	DT	B-NP	O
pressor	NN	I-NP	O
and	CC	I-NP	O
bradycardia	NN	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
cirazoline	NN	B-NP	O
were	VBD	B-VP	O
abolished	VBN	I-VP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
treated	VBN	B-VP	O
SHR	NN	B-NP	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
untreated	JJ	I-NP	O
SHR	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
pressor	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Abbott	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
SHR	NN	B-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
accompanying	VBG	I-NP	O
bradycardia	NN	I-NP	B
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
SHR	NN	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
treatment	NN	I-NP	O
than	IN	B-PP	O
without	IN	B-PP	O
such	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
bradycardia	NN	I-NP	B
that	WDT	B-NP	O
accompanied	VBD	B-VP	O
the	DT	B-NP	O
noradrenaline	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
SHR	NN	B-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
with	IN	B-PP	O
and	CC	O	O
without	IN	B-PP	O
chronic	JJ	B-NP	O
prazosin	NN	I-NP	O
treatment	NN	I-NP	O
despite	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
alpha	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
blocked	VBD	B-VP	O
SHR.	NNP	B-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Coexistence	NN	B-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	B
venous	JJ	I-NP	I
sinus	NN	I-NP	I
and	CC	O	I
internal	JJ	B-NP	I
carotid	JJ	I-NP	I
artery	NN	I-NP	I
thrombosis	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
exogenous	JJ	B-NP	O
sex	NN	I-NP	O
hormones	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
forty	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
premenopausal	JJ	I-NP	O
woman	NN	I-NP	O
developed	VBD	B-VP	O
headache	NN	B-NP	B
,	,	I-NP	O
nausea	NN	I-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
,	,	O	O
left	VBD	B-VP	O
hemiparesis	NN	B-NP	B
and	CC	I-NP	O
seizure	NN	I-NP	B
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
parenteral	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
progesterone	NN	B-NP	O
and	CC	I-NP	O
estradiol	NN	I-NP	O
.	.	O	O

Diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
(	(	O	O
DM	NN	B-NP	B
)	)	O	O
was	VBD	B-VP	O
found	VBN	I-VP	O
during	IN	B-PP	O
admission	NN	B-NP	O
.	.	O	O

Computed	VBN	B-NP	O
tomography	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
hemorrhagic	JJ	I-NP	B
infarct	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
frontal	JJ	I-NP	O
lobe	NN	I-NP	O
and	CC	O	O
increased	VBN	B-NP	O
density	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
superior	JJ	I-NP	O
sagittal	JJ	I-NP	O
sinus	NN	I-NP	O
(	(	O	O
SSS	NN	B-NP	O
)	)	O	O
.	.	O	O

Left	VBN	B-NP	O
carotid	NN	I-NP	O
angiography	NN	I-NP	O
found	VBD	B-VP	O
occlusion	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
left	JJ	I-NP	I
internal	JJ	I-NP	I
carotid	NN	I-NP	I
artery	NN	I-NP	I
(	(	O	O
ICA	NN	B-NP	O
)	)	O	O
.	.	O	O

Right	RB	B-ADVP	O
carotid	NN	B-NP	O
angiograms	NNS	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
show	VB	I-VP	O
the	DT	B-NP	O
SSS	NN	I-NP	O
and	CC	O	O
inferior	JJ	B-NP	O
sagittal	JJ	I-NP	O
sinus	NN	I-NP	O
,	,	O	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
sinus	NN	I-NP	I
thrombosis	NN	I-NP	I
.	.	O	O

Coexistence	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cerebral	JJ	I-NP	B
artery	NN	I-NP	I
and	CC	O	I
the	DT	B-NP	I
venous	JJ	I-NP	I
sinus	NN	I-NP	I
occlusion	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
infrequently	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
authors	NNS	I-NP	O
postulate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
estradiol	NN	B-NP	O
and	CC	I-NP	O
progesterone	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
DM	NN	I-NP	B
increased	VBD	B-VP	O
vascular	JJ	B-NP	O
thrombogenicity	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
provided	VBD	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
denominator	NN	I-NP	O
for	IN	B-PP	O
thrombosis	NN	B-NP	B
of	IN	B-PP	I
both	CC	O	I
the	DT	B-NP	I
ICA	NN	I-NP	I
and	CC	O	I
the	DT	B-NP	I
venous	JJ	I-NP	I
sinus	NN	I-NP	I
.	.	O	O

Chloroquine	NN	B-NP	O
related	JJ	I-NP	O
complete	JJ	I-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
with	IN	B-PP	O
blindness	NN	B-NP	B
:	:	O	O
case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
African	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
history	NN	B-NP	O
of	IN	B-PP	O
regular	JJ	B-NP	O
chloroquine	NN	I-NP	O
ingestion	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
progressive	JJ	B-NP	O
deterioration	NN	I-NP	B
of	IN	B-PP	I
vision	NN	B-NP	I
,	,	O	O
easy	JJ	B-NP	O
fatiguability	NN	I-NP	B
,	,	O	O
dyspnoea	NN	B-NP	B
,	,	O	O
dizziness	NN	B-NP	B
progressing	VBG	B-VP	O
to	TO	B-PP	O
syncopal	JJ	B-NP	B
attacks	NNS	I-NP	I
.	.	O	O

Ophthalmological	JJ	B-NP	O
assessment	NN	I-NP	O
revealed	VBD	B-VP	O
features	NNS	B-NP	O
of	IN	B-PP	O
chloroquine	NN	B-NP	O
retinopathy	NN	I-NP	B
,	,	O	O
cardiac	JJ	B-NP	O
assessment	NN	I-NP	O
revealed	VBD	B-VP	O
features	NNS	B-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
complete	JJ	I-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
with	IN	B-PP	O
right	JJ	B-NP	B
bundle	NN	I-NP	I
branch	NN	I-NP	I
block	NN	I-NP	I
pattern	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
was	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
pacemaker	NN	B-NP	O
insertion	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
resolved	VBD	B-VP	O
spontaneously	RB	I-VP	O
following	VBG	I-VP	O
chloroquine	NN	B-NP	O
discontinuation	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
however	RB	B-ADVP	O
remains	VBZ	B-VP	O
blind	JJ	B-ADJP	B
.	.	O	O

Systemic	JJ	B-NP	O
toxicity	NN	I-NP	B
and	CC	I-NP	O
resuscitation	NN	I-NP	O
in	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
,	,	O	O
levobupivacaine	NN	B-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
or	CC	O	O
ropivacaine	NN	B-NP	O
-	HYPH	O	O
infused	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
systemic	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
,	,	O	O
levobupivacaine	NN	B-NP	O
,	,	O	O
and	CC	O	O
ropivacaine	NN	B-NP	O
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
resuscitate	VB	I-VP	O
rats	NNS	B-NP	O
after	IN	B-PP	O
lethal	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
local	JJ	I-NP	O
anesthetics	NNS	I-NP	O
.	.	O	O

Bupivacaine	NN	B-NP	O
,	,	O	O
levobupivacaine	NN	B-NP	O
,	,	O	O
or	CC	O	O
ropivacaine	NN	B-NP	O
was	VBD	B-VP	O
infused	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
kg	NN	I-NP	O
.	.	I-NP	O
min	NN	I-NP	O
while	IN	B-SBAR	O
electrocardiogram	NN	B-NP	O
,	,	O	O
electroencephalogram	NN	B-NP	O
,	,	O	O
and	CC	O	O
arterial	JJ	B-NP	O
pressure	NN	I-NP	O
were	VBD	B-VP	O
continuously	RB	I-VP	O
monitored	VBN	I-VP	O
.	.	O	O

When	WRB	B-ADVP	O
asystole	NN	B-NP	B
was	VBD	B-VP	O
recorded	VBN	I-VP	O
,	,	O	O
drug	NN	B-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
and	CC	O	O
a	DT	B-NP	O
resuscitation	NN	I-NP	O
sequence	NN	I-NP	O
was	VBD	B-VP	O
begun	VBN	I-VP	O
.	.	O	O

Epinephrine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
intervals	NNS	I-NP	O
while	IN	B-SBAR	O
external	JJ	B-NP	O
cardiac	JJ	I-NP	O
compressions	NNS	I-NP	O
were	VBD	B-VP	O
applied	VBN	I-VP	O
.	.	O	O

Resuscitation	NN	B-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
successful	JJ	B-ADJP	O
when	WRB	B-ADVP	O
a	DT	B-NP	O
systolic	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
was	VBD	B-VP	O
achieved	VBN	I-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cumulative	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
and	CC	I-NP	O
ropivacaine	NN	I-NP	O
that	WDT	B-NP	O
produced	VBD	B-VP	O
seizures	NNS	B-NP	B
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
and	CC	O	O
were	VBD	B-VP	O
larger	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
cumulative	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
that	WDT	B-NP	O
produced	VBD	B-VP	O
dysrhythmias	NNS	B-NP	B
and	CC	I-NP	O
asystole	NN	I-NP	B
were	VBD	B-VP	O
smaller	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
corresponding	VBG	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ropivacaine	NN	B-NP	O
,	,	O	O
but	CC	O	O
they	PRP	B-NP	O
were	VBD	B-VP	O
larger	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
successful	JJ	B-NP	O
resuscitations	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
smaller	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
was	VBD	B-VP	O
required	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
Ropivacaine	NNP	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
systemic	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
is	VBZ	B-VP	O
intermediate	JJ	B-ADJP	O
between	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
ropivacaine	NN	B-NP	O
and	CC	I-NP	O
bupivacaine	NN	I-NP	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
ropivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
arrest	NN	I-NP	I
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
more	RBR	B-ADJP	O
susceptible	JJ	I-ADJP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
than	IN	B-PP	O
that	DT	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
bupivacaine	NN	B-NP	O
or	CC	I-NP	O
levobupivacaine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
oxacalcitriol	NN	I-NP	O
suppresses	VBZ	B-VP	O
secondary	JJ	B-NP	B
hyperparathyroidism	NN	I-NP	I
without	IN	B-PP	O
inducing	VBG	B-VP	O
low	JJ	B-NP	B
bone	NN	I-NP	I
turnover	NN	I-NP	I
in	IN	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Calcitriol	NN	B-NP	O
therapy	NN	I-NP	O
suppresses	VBZ	B-VP	O
serum	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
parathyroid	NN	B-NP	O
hormone	NN	I-NP	O
(	(	O	O
PTH	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
but	CC	O	O
has	VBZ	B-VP	O
several	JJ	B-NP	O
drawbacks	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
hypercalcemia	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
marked	JJ	B-NP	O
suppression	NN	I-NP	B
of	IN	B-PP	I
bone	NN	B-NP	I
turnover	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
adynamic	JJ	B-NP	B
bone	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
new	JJ	I-NP	O
vitamin	NN	I-NP	O
D	NN	I-NP	O
analogue	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
oxacalcitriol	NN	I-NP	O
(	(	O	O
OCT	NN	B-NP	O
)	)	O	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
promising	JJ	B-NP	O
characteristics	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
OCT	NN	B-NP	O
on	IN	B-PP	O
serum	NN	B-NP	O
PTH	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
bone	NN	B-NP	O
turnover	NN	I-NP	O
in	IN	B-PP	O
states	NNS	B-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
or	CC	I-NP	O
impaired	JJ	I-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
dogs	NNS	I-NP	O
were	VBD	B-VP	O
either	RB	I-VP	O
nephrectomized	VBN	I-VP	O
or	CC	O	O
sham	NN	B-NP	O
-	HYPH	B-NP	O
operated	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
animals	NNS	I-NP	O
received	VBD	B-VP	O
supplemental	JJ	B-NP	O
phosphate	NN	I-NP	O
to	TO	B-VP	O
enhance	VB	I-VP	O
PTH	NN	B-NP	O
secretion	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
phosphate	NN	B-NP	O
supplementation	NN	I-NP	O
,	,	O	O
half	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Nx	NNP	I-NP	O
and	CC	I-NP	O
Sham	NNP	I-NP	O
dogs	NNS	I-NP	O
received	VBD	B-VP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
OCT	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
per	IN	B-PP	O
week	NN	B-NP	O
)	)	O	O
;	:	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
half	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
vehicle	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Thereafter	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
treatment	NN	I-NP	O
modalities	NNS	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
subset	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
were	VBD	B-VP	O
crossed	VBN	I-VP	O
over	RP	B-PRT	O
for	IN	B-PP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Biochemical	JJ	B-NP	O
and	CC	I-NP	O
hormonal	JJ	I-NP	O
indices	NNS	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
metabolism	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
and	CC	O	O
bone	NN	B-NP	O
biopsies	NNS	I-NP	O
were	VBD	B-VP	O
done	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
OCT	NN	B-NP	O
or	CC	O	O
vehicle	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
and	CC	O	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
crossover	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
Nx	NN	B-NP	O
dogs	NNS	I-NP	O
,	,	O	O
OCT	NN	B-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	O
serum	NN	B-NP	O
PTH	NN	I-NP	O
levels	NNS	I-NP	O
soon	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
long	RB	B-ADVP	O
-	HYPH	O	O
standing	VBG	B-VP	O
secondary	JJ	B-NP	B
hyperparathyroidism	NN	I-NP	I
,	,	O	O
OCT	NN	B-NP	O
stabilized	VBD	B-VP	O
serum	NN	B-NP	O
PTH	NN	I-NP	O
levels	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
PTH	NN	I-NP	O
levels	NNS	I-NP	O
rose	VBD	B-VP	O
thereafter	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
rise	NN	I-NP	O
was	VBD	B-VP	O
less	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
baseline	NN	B-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
rise	NN	I-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
Nx	NN	B-NP	O
control	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
episodes	NNS	B-NP	O
of	IN	B-PP	O
hypercalcemia	NN	B-NP	B
and	CC	I-NP	O
hyperphosphatemia	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
animals	NNS	B-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
,	,	O	O
OCT	NN	B-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
PTH	NN	I-NP	O
levels	NNS	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
sustained	VBN	I-VP	O
with	IN	B-PP	O
lowering	VBG	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
Nx	NN	B-NP	O
dogs	NNS	I-NP	O
,	,	O	O
OCT	NN	B-NP	O
reversed	VBD	B-VP	O
abnormal	JJ	B-NP	O
bone	NN	I-NP	O
formation	NN	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
woven	JJ	B-NP	B
osteoid	JJ	I-NP	I
and	CC	I-NP	O
fibrosis	NN	I-NP	B
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
alter	VB	I-VP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
bone	NN	B-NP	O
turnover	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
OCT	NN	B-NP	O
improved	VBD	B-VP	O
mineralization	NN	B-NP	O
lag	NN	I-NP	O
time	NN	I-NP	O
,	,	O	O
(	(	O	O
that	DT	B-NP	O
is	VBZ	B-VP	O
,	,	O	O
the	DT	B-NP	O
rate	NN	I-NP	O
at	IN	B-PP	O
which	WDT	B-NP	O
osteoid	JJ	B-NP	O
mineralizes	NNS	I-NP	O
)	)	O	O
in	IN	B-PP	O
both	CC	O	O
Nx	NN	B-NP	O
and	CC	I-NP	O
Sham	NN	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
even	RB	B-SBAR	O
though	IN	I-SBAR	O
OCT	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
completely	RB	I-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
hypercalcemia	NN	B-NP	B
in	IN	B-PP	O
experimental	JJ	B-NP	O
dogs	NNS	I-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
use	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
secondary	JJ	B-NP	B
hyperparathyroidism	NN	I-NP	I
because	IN	B-SBAR	O
it	PRP	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
low	JJ	B-NP	B
bone	NN	I-NP	I
turnover	NN	I-NP	I
and	CC	O	O
,	,	O	O
therefore	RB	B-ADVP	O
,	,	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
adynamic	JJ	B-NP	B
bone	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Chemotherapy	NN	B-NP	O
of	IN	B-PP	O
advanced	VBN	B-NP	O
inoperable	JJ	I-NP	O
non	AFX	I-NP	B
-	HYPH	I-NP	I
small	JJ	B-NP	I
cell	NN	I-NP	I
lung	NN	I-NP	I
cancer	NN	I-NP	I
with	IN	B-PP	O
paclitaxel	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
.	.	O	O

Paclitaxel	NN	B-NP	O
(	(	O	O
Taxol	NN	B-NP	O
;	:	O	O
Bristol	NNP	B-NP	O
-	:	O	O
Myers	NNP	B-NP	O
Squibb	NNP	I-NP	O
Company	NNP	I-NP	O
,	,	O	O
Princeton	NNP	B-NP	O
,	,	O	O
NJ	NNP	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
demonstrated	VBN	I-VP	O
significant	JJ	B-NP	O
antineoplastic	JJ	I-NP	O
activity	NN	I-NP	O
against	IN	B-PP	O
different	JJ	B-NP	O
tumor	NN	I-NP	B
types	NNS	I-NP	O
,	,	O	O
notably	RB	B-NP	O
ovarian	JJ	I-NP	B
and	CC	I-NP	I
breast	NN	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
phase	NN	I-NP	O
num	CD	B-NP	O
trials	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
paclitaxel	NN	I-NP	O
infusions	NNS	I-NP	O
in	IN	B-PP	O
chemotherapy	NN	B-NP	O
-	HYPH	O	O
naive	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
stage	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
non	AFX	O	B
-	HYPH	O	I
small	JJ	B-NP	I
cell	NN	I-NP	I
lung	NN	I-NP	I
cancer	NN	I-NP	I
(	(	O	O
NSCLC	NN	B-NP	B
)	)	O	O
reported	VBD	B-VP	O
response	NN	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

Leukopenia	NNP	B-NP	B
was	VBD	B-VP	O
dose	NN	B-NP	O
limiting	NN	I-NP	O
:	:	O	O
as	RB	B-NP	O
many	JJ	I-NP	O
as	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
experienced	VBD	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
leukopenia	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
paclitaxel	NN	I-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
inoperable	JJ	B-NP	O
stage	NN	I-NP	O
IIIB	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
NSCLC	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
(	(	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
)	)	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
median	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
(	(	O	O
age	NN	B-NP	O
range	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
performance	NN	I-NP	O
status	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
through	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Most	JJS	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
stage	NN	B-NP	O
num	CD	I-NP	O
NSCLC	NN	I-NP	B
.	.	O	O

Paclitaxel	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
was	VBD	B-VP	O
infused	VBN	I-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
with	IN	B-PP	O
standard	JJ	B-NP	O
prophylactic	JJ	I-NP	O
premedication	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
partial	JJ	B-NP	O
remission	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
disease	NN	B-NP	O
progression	NN	I-NP	O
.	.	O	O

Hematologic	JJ	B-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
mild	JJ	B-ADJP	O
:	:	O	O
only	RB	B-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
,	,	O	O
while	IN	B-SBAR	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Grade	NNP	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
polyneuropathy	NN	I-NP	B
affected	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
while	IN	B-SBAR	O
only	RB	B-NP	O
num	CD	I-NP	O
experienced	JJ	I-NP	O
severe	JJ	I-NP	O
polyneuropathy	NN	I-NP	B
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
myalgia	NN	I-NP	B
/	SYM	B-NP	O
arthralgia	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
but	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
experienced	JJ	I-NP	O
grade	NN	I-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Nausea	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
were	VBD	B-VP	O
infrequent	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
experiencing	VBG	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
and	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
experiencing	VBG	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Paclitaxel	NN	B-NP	O
is	VBZ	B-VP	O
thus	RB	B-ADVP	O
an	DT	B-NP	O
active	JJ	I-NP	O
single	JJ	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
population	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
proving	VBG	B-VP	O
comparably	RB	B-ADJP	O
effective	JJ	I-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
and	CC	I-NP	O
superior	NN	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
hematologic	JJ	B-NP	O
and	CC	I-NP	O
nonhematologic	JJ	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Further	JJ	B-NP	O
phase	NN	I-NP	O
num	CD	B-NP	O
studies	NNS	I-NP	O
with	IN	B-PP	O
paclitaxel	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
active	JJ	B-ADJP	O
against	IN	B-PP	O
NSCLC	NN	B-NP	B
are	VBP	B-VP	O
indicated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
phase	NN	B-NP	O
num	CD	B-NP	O
studies	NNS	I-NP	O
comparing	VBG	B-VP	O
paclitaxel	NN	B-NP	O
with	IN	B-PP	O
standard	JJ	B-NP	O
chemotherapy	NN	I-NP	O
remain	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
completed	VBN	I-VP	O
.	.	O	O

Cerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
phenylpropanolamine	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
caffeine	NN	B-NP	O
.	.	O	O

Phenylpropanolamine	NN	B-NP	O
(	(	O	O
PPA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
drug	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
serious	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
including	VBG	B-PP	O
stroke	NN	B-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
often	RB	I-VP	O
combined	VBN	I-VP	O
with	IN	B-PP	O
caffeine	NN	B-NP	O
in	IN	B-PP	O
diet	NN	B-NP	O
preparations	NNS	I-NP	O
and	CC	O	O
look	NN	B-NP	O
-	HYPH	B-ADJP	O
alike	JJ	B-NP	O
pills	NNS	I-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
PPA	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
can	MD	B-VP	O
lead	VB	I-VP	O
to	TO	I-VP	O
stroke	VB	I-VP	B
in	IN	B-PP	O
normotensive	JJ	B-ADJP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
hypertensive	JJ	B-NP	B
rats	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
administered	VBD	B-VP	O
the	DT	B-NP	O
combination	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
allowed	VBN	I-NP	O
human	JJ	I-NP	O
dose	NN	I-NP	O
calculated	VBN	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
per	IN	B-PP	O
weight	NN	B-NP	O
basis	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Subarachnoid	JJ	B-NP	B
and	CC	I-NP	I
cerebral	JJ	I-NP	I
hemorrhage	NN	I-NP	I
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
PPA	NN	I-NP	O
/	SYM	B-VP	O
caffeine	NN	B-NP	O
administration	NN	I-NP	O
(	(	O	O
same	JJ	B-NP	O
dose	NN	I-NP	O
)	)	O	O
lead	VBP	B-VP	O
to	TO	B-PP	O
acute	JJ	B-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
normotensive	JJ	I-NP	O
and	CC	I-NP	O
hypertensive	JJ	I-NP	B
animals	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
PPA	NN	B-NP	O
/	SYM	B-NP	O
caffeine	NN	I-NP	O
can	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
cerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
in	IN	B-PP	O
previously	RB	B-NP	O
hypertensive	JJ	I-NP	B
animals	NNS	I-NP	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
in	IN	B-PP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
allowed	VBN	I-NP	O
dosage	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
acute	JJ	I-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
contributing	VBG	I-NP	O
factor	NN	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
amiodarone	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
or	CC	O	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
.	.	O	O

Amiodarone	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
sustained	VBN	I-VP	O
,	,	O	O
symptomatic	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
(	(	O	O
VT	NN	B-NP	B
)	)	O	O
or	CC	O	O
a	DT	B-NP	O
cardiac	JJ	I-NP	B
arrest	NN	I-NP	I
and	CC	O	O
who	WP	B-NP	O
were	VBD	B-VP	O
refractory	JJ	B-ADJP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
antiarrhythmic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
loading	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
maintenance	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
continued	VBD	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
amiodarone	NN	B-NP	O
and	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
symptomatic	JJ	B-NP	O
VT	NN	I-NP	B
or	CC	O	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
(	(	O	O
VF	NN	B-NP	B
)	)	O	O
over	IN	B-PP	O
a	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	I-NP	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
nonfatal	JJ	I-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
VT	NN	B-NP	B
and	CC	O	O
were	VBD	B-VP	O
successfully	RB	I-VP	O
managed	VBN	I-VP	O
by	IN	B-PP	O
continuing	VBG	B-NP	O
amiodarone	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
dose	NN	I-NP	O
or	CC	B-PP	O
by	IN	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
conventional	JJ	I-NP	O
antiarrhythmic	JJ	I-NP	O
drug	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reactions	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
forced	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
symptomatic	JJ	I-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
were	VBD	B-VP	O
tremor	NN	B-NP	B
or	CC	I-NP	O
ataxia	NN	I-NP	B
,	,	I-NP	O
nausea	NN	I-NP	B
and	CC	I-NP	O
anorexia	NN	I-NP	B
,	,	O	O
visual	JJ	B-NP	B
halos	NNS	I-NP	I
or	CC	O	I
blurring	VBG	B-VP	I
,	,	O	O
thyroid	JJ	B-NP	B
function	NN	I-NP	I
abnormalities	NNS	I-NP	I
and	CC	O	O
pulmonary	JJ	B-NP	B
interstitial	JJ	I-NP	I
infiltrates	NNS	I-NP	I
.	.	O	O

Although	IN	B-SBAR	O
large	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
amiodarone	NN	I-NP	O
is	VBZ	B-VP	O
highly	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
VT	NN	B-NP	B
or	CC	I-NP	O
VF	NN	I-NP	B
refractory	JJ	B-ADJP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
antiarrhythmic	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
causes	VBZ	B-VP	O
significant	JJ	B-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
dose	NN	I-NP	O
is	VBZ	B-VP	O
adjusted	VBN	I-VP	O
based	VBN	B-PP	O
on	IN	B-PP	O
clinical	JJ	B-NP	O
response	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
VT	NN	B-NP	B
or	CC	I-NP	O
VF	NN	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
successfully	RB	I-VP	O
managed	VBN	I-VP	O
with	IN	B-PP	O
amiodarone	NN	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
therapy	NN	I-NP	O
on	IN	B-PP	O
desipramine	NN	B-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
contributor	NN	I-NP	O
to	TO	B-PP	O
mortality	NN	B-NP	O
in	IN	B-PP	O
tricyclic	JJ	B-NP	O
antidepressant	NN	I-NP	O
overdose	NN	I-NP	B
.	.	O	O

Recent	JJ	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
tricyclic	JJ	B-NP	O
antidepressants	NNS	I-NP	O
inhibit	VBP	B-VP	O
calcium	NN	B-NP	O
influx	NN	I-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
tissues	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
addressed	VBD	B-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockade	NN	I-NP	O
in	IN	B-PP	O
tricyclic	JJ	B-NP	O
antidepressant	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
interventions	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
previously	RB	B-ADVP	O
to	TO	B-VP	O
improve	VB	I-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
with	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
overdose	NN	I-NP	B
.	.	O	O

CaCl2	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
.	.	O	O

Anesthetized	VBN	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
tricyclic	JJ	I-NP	O
antidepressant	NN	I-NP	O
desipramine	NN	I-NP	O
IP	NN	I-NP	O
to	TO	B-VP	O
produce	VB	I-VP	O
hypotension	NN	B-NP	B
,	,	O	O
QRS	NN	B-NP	O
prolongation	NN	I-NP	O
,	,	O	O
and	CC	O	O
bradycardia	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
min	NN	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
animals	NNS	B-NP	O
received	VBD	B-VP	O
CaCl2	NN	B-NP	O
,	,	O	O
NaHCO3	NN	B-NP	O
,	,	O	O
or	CC	O	O
saline	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
second	JJ	I-NP	O
experiment	NN	I-NP	O
,	,	O	O
rats	NNS	B-NP	O
received	VBD	B-VP	O
tricyclic	JJ	B-NP	O
antidepressant	NN	I-NP	O
desipramine	NN	I-NP	O
IP	NN	I-NP	O
followed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
.	.	O	O

NaHCO3	NN	B-NP	O
briefly	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
min	NN	I-NP	O
)	)	O	O
reversed	VBD	B-VP	O
hypotension	NN	B-NP	B
and	CC	I-NP	O
QRS	NN	I-NP	O
prolongation	NN	I-NP	O
.	.	O	O

CaCl2	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
improve	VB	I-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
and	CC	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
CaCl2	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
CaCl2	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reverse	VB	I-VP	O
tricyclic	JJ	B-NP	O
antidepressant	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

CaCl2	NN	B-NP	O
therapy	NN	I-NP	O
may	MD	B-VP	O
possibly	RB	I-VP	O
worsen	VB	I-VP	O
both	CC	O	O
cardiovascular	JJ	B-NP	B
and	CC	I-NP	I
central	JJ	I-NP	I
nervous	JJ	I-NP	I
system	NN	I-NP	I
toxicity	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
support	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
inhibition	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
tricyclic	JJ	B-NP	O
antidepressant	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Phase	NN	B-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
cis	NN	I-NP	O
-	HYPH	B-NP	O
retinoic	JJ	I-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
neuroblastoma	NN	B-NP	B
following	VBG	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
neuroblastoma	NN	B-NP	B
cell	NN	I-NP	O
lines	NNS	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
cis	NN	I-NP	O
-	HYPH	O	O
retinoic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
cis	NN	B-NP	O
-	HYPH	O	O
RA	NN	B-NP	O
)	)	O	O
can	MD	B-VP	O
cause	VB	I-VP	O
sustained	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
proliferation	NN	B-NP	O
.	.	O	O

Since	IN	B-SBAR	O
cis	NN	B-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
has	VBZ	B-VP	O
demonstrated	VBN	I-VP	O
clinical	JJ	B-NP	O
responses	NNS	I-NP	O
in	IN	B-PP	O
neuroblastoma	NN	B-NP	B
patients	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
relapse	NN	B-NP	O
after	IN	B-PP	O
cytotoxic	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
maximal	JJ	I-NP	O
-	HYPH	I-NP	O
tolerated	VBN	I-NP	O
dosage	NN	I-NP	O
(	(	O	O
MTD	NN	B-NP	O
)	)	O	O
,	,	O	O
toxicities	NNS	B-NP	B
,	,	O	O
and	CC	O	O
pharmacokinetics	NNS	B-NP	O
of	IN	B-PP	O
cis	NN	B-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
administered	VBN	B-VP	O
on	IN	B-PP	O
an	DT	B-NP	O
intermittent	JJ	I-NP	O
schedule	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
neuroblastoma	NN	B-NP	B
following	VBG	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
(	(	O	O
BMT	NN	B-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
assessable	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
cis	NN	I-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
administered	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
equally	RB	I-NP	O
divided	VBN	I-NP	O
doses	NNS	I-NP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
rest	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
courses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
escalated	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
until	IN	B-PP	O
dose	NN	B-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
toxicity	NN	B-NP	B
(	(	O	O
DLT	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
intrapatient	JJ	I-NP	O
dose	NN	I-NP	O
escalation	NN	I-NP	O
was	VBD	B-VP	O
permitted	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
MTD	NN	I-NP	O
of	IN	B-PP	O
cis	NN	B-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	I-NP	O
d	NN	I-NP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
toxicities	NNS	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
included	VBD	B-VP	O
hypercalcemia	NN	B-NP	B
,	,	O	O
rash	NN	B-NP	B
,	,	O	O
and	CC	O	O
anemia	NN	B-NP	B
/	SYM	I-NP	O
thrombocytopenia	NN	I-NP	B
/	SYM	B-NP	O
emesis	NN	I-NP	B
/	SYM	I-NP	O
rash	NN	I-NP	B
.	.	O	O

All	DT	B-NP	O
toxicities	NNS	I-NP	B
resolved	VBN	B-VP	O
after	IN	B-PP	O
cis	NN	B-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
complete	JJ	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
marrow	NN	B-NP	O
metastases	NNS	I-NP	B
.	.	O	O

Serum	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mumol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	B-NP	O
(	(	O	O
peak	NN	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mumol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	B-NP	O
(	(	O	O
trough	NN	B-NP	O
)	)	O	O
at	IN	B-PP	O
the	DT	B-NP	O
MTD	NN	I-NP	O
were	VBD	B-VP	O
maintained	VBN	I-VP	O
during	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
DLT	NN	I-NP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
serum	NN	B-NP	O
levels	NNS	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
mumol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
MTD	NN	I-NP	O
of	IN	B-PP	O
cis	NN	B-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
given	VBN	B-PP	O
on	IN	B-PP	O
this	DT	B-NP	O
intermittent	JJ	I-NP	O
schedule	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	I-NP	O
d	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
levels	NNS	I-NP	O
known	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
against	IN	B-PP	O
neuroblastoma	NN	B-NP	B
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
were	VBD	B-VP	O
achieved	VBN	I-VP	O
at	IN	B-PP	O
this	DT	B-NP	O
dose	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
DLT	NN	I-NP	O
included	VBD	B-VP	O
hypercalcemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
predicted	VBN	I-VP	O
by	IN	B-PP	O
serum	NN	B-NP	O
cis	NN	I-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Monitoring	NN	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
and	CC	I-NP	O
cis	NN	I-NP	O
-	HYPH	B-NP	O
RA	NN	I-NP	O
levels	NNS	I-NP	O
is	VBZ	B-VP	O
indicated	VBN	I-VP	O
in	IN	B-PP	O
future	JJ	B-NP	O
trials	NNS	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
on	IN	B-PP	O
gross	JJ	B-NP	O
behavioural	JJ	I-NP	O
changes	NNS	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
carbachol	NN	B-NP	O
and	CC	I-NP	O
eserine	NN	I-NP	O
in	IN	B-PP	O
cats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
injected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
cerebral	JJ	I-NP	O
ventricles	NNS	I-NP	O
of	IN	B-PP	O
group	NN	B-NP	O
-	HYPH	O	O
housed	VBN	B-NP	O
unanaesthetized	JJ	I-NP	O
cats	NNS	I-NP	O
upon	IN	B-PP	O
vocalization	NN	B-NP	O
(	(	O	O
rage	NN	B-NP	O
,	,	O	O
hissing	NN	B-NP	O
and	CC	O	O
snarling	NN	B-NP	O
)	)	O	O
,	,	O	O
fighting	NN	B-NP	O
(	(	O	O
attack	NN	B-NP	O
with	IN	B-PP	O
paws	NNS	B-NP	O
and	CC	I-NP	O
claws	NNS	I-NP	O
,	,	O	O
defense	NN	B-NP	O
with	IN	B-PP	O
paws	NNS	B-NP	O
and	CC	I-NP	O
claws	NNS	I-NP	O
and	CC	O	O
biting	VBG	B-VP	O
)	)	O	O
,	,	O	O
mydriasis	NN	B-NP	B
,	,	O	O
tremor	NN	B-NP	B
and	CC	O	O
clonic	JJ	B-NP	B
-	HYPH	I-NP	I
tonic	JJ	I-NP	I
convulsions	NNS	I-NP	I
produced	VBN	B-VP	O
by	IN	B-PP	O
carbachol	NN	B-NP	O
and	CC	I-NP	O
eserine	NN	I-NP	O
injected	VBN	B-VP	O
similarly	RB	B-ADVP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Calcium	NN	B-NP	O
chloride	NN	I-NP	O
depressed	VBD	B-VP	O
or	CC	O	O
almost	RB	B-ADVP	O
completely	RB	I-ADVP	O
abolished	VBD	B-VP	O
the	DT	B-NP	O
vocalization	NN	I-NP	O
and	CC	I-NP	O
fighting	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
carbachol	NN	B-NP	O
and	CC	I-NP	O
eserine	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
mydriasis	NN	B-NP	B
,	,	O	O
tremor	NN	B-NP	B
and	CC	O	O
clonic	JJ	B-NP	B
-	HYPH	I-NP	I
tonic	JJ	I-NP	I
convulsions	NNS	I-NP	I
evoked	VBN	B-VP	O
by	IN	B-PP	O
carbachol	NN	B-NP	O
and	CC	I-NP	O
eserine	NN	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
changed	VBN	I-VP	O
by	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
apparent	JJ	B-ADJP	O
that	IN	B-SBAR	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
can	MD	B-VP	O
dissociate	VB	I-VP	O
vocalization	NN	B-NP	O
and	CC	I-NP	O
fighting	NN	I-NP	O
from	IN	B-PP	O
autonomic	JJ	B-NP	O
and	CC	I-NP	O
motor	NN	I-NP	O
phenomena	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
mydriasis	NN	B-NP	B
,	,	O	O
tremor	NN	B-NP	B
and	CC	O	O
clonic	JJ	B-NP	B
-	HYPH	I-NP	I
tonic	JJ	I-NP	I
convulsions	NNS	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
carbachol	NN	B-NP	O
and	CC	I-NP	O
eserine	NN	I-NP	O
.	.	O	O

Calcium	NN	B-NP	O
chloride	NN	I-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
vocalization	NN	I-NP	O
and	CC	I-NP	O
fighting	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
carbachol	NN	B-NP	O
and	CC	I-NP	O
eserine	NN	I-NP	O
most	RBS	B-ADVP	O
probably	RB	I-ADVP	O
by	IN	B-PP	O
a	DT	B-NP	O
nonspecific	JJ	I-NP	O
stabilizing	VBG	I-NP	O
action	NN	I-NP	O
on	IN	B-PP	O
central	JJ	B-NP	O
muscarinic	JJ	I-NP	O
cholinoceptive	JJ	I-NP	O
sites	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
further	RBR	B-ADVP	O
support	VBP	B-VP	O
the	DT	B-NP	O
view	NN	I-NP	O
that	IN	B-SBAR	O
calcium	NN	B-NP	O
ions	NNS	I-NP	O
in	IN	B-PP	O
excess	NN	B-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
atropine	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
action	NN	I-NP	O
also	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Multiple	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
penicillamine	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
.	.	O	O

Skin	NN	B-NP	B
rashes	NNS	I-NP	I
,	,	O	O
proteinuria	NN	B-NP	B
,	,	O	O
systemic	JJ	B-NP	B
lupus	NN	I-NP	I
erythematosus	NN	I-NP	I
,	,	O	O
polymyositis	NN	B-NP	B
and	CC	O	O
myasthenia	NN	B-NP	B
gravis	NN	I-NP	I
have	VBP	B-VP	O
all	DT	O	O
been	VBN	B-VP	O
recorded	VBN	I-VP	O
as	IN	B-PP	O
complications	NNS	B-NP	O
of	IN	B-PP	O
penicillamine	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
developed	VBN	I-VP	O
all	DT	B-NP	O
num	CD	I-NP	O
is	VBZ	B-VP	O
now	RB	I-VP	O
described	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
skin	NN	I-NP	B
lesion	NN	I-NP	I
resembled	VBD	B-VP	O
elastosis	NN	B-NP	B
perforans	NNS	I-NP	I
serpiginosa	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Wilson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
penicillamine	NN	B-NP	O
.	.	O	O

Electrocardiographic	JJ	B-NP	O
changes	NNS	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
psychotropic	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
cardiac	JJ	B-NP	O
manifestations	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
while	IN	B-SBAR	O
taking	VBG	B-VP	O
psychotropic	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
either	CC	O	O
phenothiazines	NNS	B-NP	O
or	CC	O	O
tricyclic	JJ	B-NP	O
antidepressants	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
several	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
Mellaril	NNP	B-NP	O
(	(	O	O
thioridazine	NN	B-NP	O
)	)	O	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
fatal	JJ	B-ADJP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
.	.	O	O

Supraventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
developed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
Thorazine	NN	B-NP	O
(	(	O	O
chlorpromazine	NN	B-NP	O
)	)	O	O
.	.	O	O

Aventyl	NN	B-NP	O
(	(	O	O
nortriptyline	NN	B-NP	O
)	)	O	O
and	CC	O	O
Elavil	NN	B-NP	O
(	(	O	O
amitriptyline	NN	B-NP	O
)	)	O	O
each	DT	B-NP	O
produced	VBD	B-VP	O
left	JJ	B-NP	B
bundle	NN	I-NP	I
branch	NN	I-NP	I
block	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
.	.	O	O

Electrocardiographic	JJ	B-NP	O
T	NN	I-NP	O
and	CC	I-NP	O
U	NN	I-NP	O
wave	NN	I-NP	O
abnormalities	NNS	I-NP	O
were	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
ventricular	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
responded	VBD	B-VP	O
to	TO	B-PP	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
and	CC	O	O
to	TO	B-VP	O
direct	VB	I-VP	O
current	JJ	B-NP	O
electric	JJ	I-NP	O
shock	NN	I-NP	O
;	:	O	O
ventricular	JJ	B-NP	O
pacing	NN	I-NP	O
was	VBD	B-VP	O
required	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
instances	NNS	I-NP	O
and	CC	O	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
ventricular	JJ	B-NP	O
pacing	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
tachyarrhythmias	NNS	I-NP	B
generally	RB	B-ADVP	O
subsided	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
or	CC	O	O
younger	JJR	B-ADJP	O
;	:	O	O
only	RB	B-NP	O
num	CD	I-NP	O
clearly	RB	B-ADVP	O
had	VBD	B-VP	O
antecedent	JJ	B-NP	O
heart	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

Major	JJ	B-NP	O
cardiac	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
are	VBP	B-VP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
hazard	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
heart	NN	B-NP	B
disease	NN	I-NP	I
who	WP	B-NP	O
are	VBP	B-VP	O
receiving	VBG	I-VP	O
customary	JJ	B-NP	O
therapeutic	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
psychotropic	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
to	TO	I-VP	O
quantify	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
complications	NNS	I-NP	I
to	TO	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
phenothiazines	NNS	B-NP	O
or	CC	O	O
tricyclic	JJ	B-NP	O
antidepressant	NN	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Serotonergic	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
benzodiazepines	NNS	B-NP	O
and	CC	O	O
baclofen	NN	B-NP	O
block	VBP	B-VP	O
muscimol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myoclonic	JJ	I-NP	B
jerks	NNS	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
strain	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
male	JJ	B-NP	O
Swiss	JJ	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
muscimol	NN	B-NP	O
produced	VBD	B-VP	O
myoclonic	JJ	B-NP	B
jerks	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
(	(	B-LST	O
i.p.	LS	I-LST	O
)	)	O	O
dose	NN	B-NP	O
induced	VBD	B-VP	O
this	DT	B-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mice	NNS	I-NP	O
tested	VBN	B-VP	O
and	CC	O	O
the	DT	B-NP	O
peak	JJ	I-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
jerks	NNS	I-NP	O
per	IN	B-PP	O
min	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
.	.	O	O

Increasing	VBG	B-VP	O
the	DT	B-NP	O
brain	NN	I-NP	O
serotonin	NN	I-NP	O
levels	NNS	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytryptophan	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
peripheral	JJ	I-NP	O
decarboxylase	NN	I-NP	O
inhibitor	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
muscimol	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
experiment	NN	I-NP	O
l	NN	I-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
was	VBD	B-VP	O
without	IN	B-PP	O
effect	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
serotonin	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
MK	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
muscimol	NN	B-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
benzodiazepines	NNS	I-NP	O
,	,	O	O
clonazepam	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
several	JJ	B-ADJP	O
fold	RB	B-ADJP	O
more	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
diazepam	NN	B-NP	O
in	IN	B-PP	O
blocking	VBG	B-VP	O
the	DT	B-NP	O
myoclonic	JJ	I-NP	B
jerks	NNS	I-NP	I
.	.	O	O

While	IN	B-SBAR	O
-	HYPH	B-NP	O
baclofen	NN	I-NP	O
proved	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
muscimol	NN	B-NP	O
,	,	O	O
its	PRP$	B-NP	O
-	HYPH	I-NP	O
isomer	NN	I-NP	O
lacked	VBD	B-VP	O
this	DT	B-NP	O
property	NN	I-NP	O
.	.	O	O

Considering	VBG	B-VP	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HTP	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
benzodiazepines	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
beneficial	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
myoclonus	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
muscimol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myoclonus	NN	I-NP	B
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
satisfactory	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
prove	VB	I-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
drug	NN	I-NP	O
treatments	NNS	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
condition	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
indicated	VBD	B-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
-	HYPH	B-NP	O
baclofen	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
myoclonus	NN	I-NP	B
.	.	O	O

Hyperglycemic	JJ	B-NP	B
acidotic	JJ	I-NP	I
coma	NN	I-NP	I
and	CC	I-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
Kearns	NNP	B-NP	B
-	HYPH	B-NP	I
Sayre	NNP	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
paper	NN	I-NP	O
presents	VBZ	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
metabolic	JJ	I-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
young	JJ	I-NP	O
boys	NNS	I-NP	O
with	IN	B-PP	O
long	RB	B-NP	O
-	HYPH	I-NP	O
standing	VBG	B-VP	O
Kearns	NNP	B-NP	B
-	HYPH	I-NP	I
Sayre	NNP	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Following	VBG	B-PP	O
short	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
oral	JJ	B-NP	O
prednisone	NN	I-NP	O
,	,	O	O
both	DT	B-NP	O
boys	NNS	I-NP	O
developed	VBD	B-VP	O
lethargy	NN	B-NP	B
,	,	O	O
increasing	VBG	B-VP	O
somnolence	NN	B-NP	B
,	,	O	O
polydipsia	NN	B-NP	B
,	,	O	O
polyphagia	NN	B-NP	B
,	,	O	O
and	CC	O	O
polyuria	NN	B-NP	B
.	.	O	O

Both	DT	B-NP	O
presented	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
room	NN	I-NP	O
with	IN	B-PP	O
profound	JJ	B-NP	O
coma	NN	I-NP	B
,	,	O	O
hypotension	NN	B-NP	B
,	,	O	O
severe	JJ	B-NP	O
hyperglycemia	NN	I-NP	B
,	,	O	O
and	CC	O	O
acidosis	NN	B-NP	B
.	.	O	O

Nonketotic	JJ	B-NP	O
lactic	JJ	I-NP	B
acidosis	NN	I-NP	I
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
ketosis	NN	B-NP	B
without	IN	B-PP	O
a	DT	B-NP	O
known	VBN	I-NP	O
serum	NN	I-NP	O
lactate	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
.	.	O	O

Respiratory	JJ	B-NP	B
failure	NN	I-NP	I
rapidly	RB	B-ADVP	O
ensued	VBD	B-VP	O
and	CC	O	O
both	DT	B-NP	O
patients	NNS	I-NP	O
expired	VBD	B-VP	O
in	IN	B-PP	O
spite	NN	B-NP	O
of	IN	B-PP	O
efforts	NNS	B-NP	O
at	IN	B-PP	O
resuscitation	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
believe	VBP	B-VP	O
these	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
represent	VBP	B-VP	O
a	DT	B-NP	O
newly	RB	I-NP	O
described	VBN	I-NP	O
and	CC	I-NP	O
catastrophic	JJ	I-NP	O
metabolic	JJ	I-NP	B
-	HYPH	I-NP	I
endocrine	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
Kearns	NNP	I-NP	B
-	HYPH	I-NP	I
Sayre	NNP	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
active	JJ	B-NP	O
constituents	NNS	I-NP	O
of	IN	B-PP	O
Crocus	NNP	B-NP	O
sativus	NNP	I-NP	O
L.	NNP	I-NP	O
,	,	O	O
crocin	NN	B-NP	O
on	IN	B-PP	O
streptozocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
sporadic	JJ	B-NP	O
Alzheimer	NNP	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
water	NN	B-NP	O
-	HYPH	B-NP	O
soluble	JJ	I-NP	O
carotenoids	NNS	I-NP	O
,	,	O	O
crocins	NNS	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
the	DT	B-NP	O
main	JJ	I-NP	O
and	CC	I-NP	O
active	JJ	I-NP	O
components	NNS	I-NP	O
of	IN	B-PP	O
Crocus	NNP	B-NP	O
sativus	NNP	I-NP	O
L.	NNP	I-NP	O
extract	NN	I-NP	O
in	IN	B-PP	O
learning	NN	B-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
processes	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
crocins	NNS	B-NP	O
on	IN	B-PP	O
sporadic	JJ	B-NP	O
Alzheimer	NNP	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
intracerebroventricular	JJ	B-NP	O
(	(	O	O
icv	NN	B-NP	O
)	)	O	O
streptozocin	NN	B-NP	O
(	(	O	O
STZ	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Male	JJ	B-NP	O
adult	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
control	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
crocins	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
STZ	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
STZ	NN	I-NP	O
+	SYM	I-NP	O
crocins	NNS	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
groups	NNS	I-NP	O
,	,	O	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
icv	NN	I-NP	O
bilaterally	RB	B-ADVP	O
in	IN	B-PP	O
first	JJ	B-NP	O
day	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
similar	JJ	I-NP	O
STZ	NN	I-NP	O
-	HYPH	I-NP	O
icv	NN	I-NP	O
application	NN	I-NP	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
STZ	NN	B-NP	O
+	CC	B-NP	O
crocin	NN	I-NP	O
animal	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
crocin	NN	B-NP	O
was	VBD	B-VP	O
applied	VBN	I-VP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
i.p.	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
day	NN	I-NP	O
pre	AFX	O	O
-	HYPH	B-NP	O
surgery	NN	I-NP	O
and	CC	O	O
continued	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Prescription	NN	B-NP	O
of	IN	B-PP	O
crocin	NN	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
once	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
learning	NN	I-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
performance	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
paradigm	NN	I-NP	O
,	,	O	O
and	CC	O	O
for	IN	B-PP	O
spatial	JJ	B-NP	O
cognition	NN	I-NP	O
evaluation	NN	I-NP	O
,	,	O	O
Y	NN	B-NP	O
-	HYPH	B-NP	O
maze	NN	I-NP	O
task	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
out	RP	B-PRT	O
that	IN	B-SBAR	O
crocin	NN	B-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
STZ	NN	I-NP	O
-	HYPH	O	O
injected	VBN	B-NP	O
rats	NNS	I-NP	O
show	VBP	B-VP	O
higher	JJR	B-NP	O
correct	JJ	I-NP	O
choices	NNS	I-NP	O
and	CC	O	O
lower	JJR	B-NP	O
errors	NNS	I-NP	O
in	IN	B-PP	O
Y	NN	B-NP	O
-	HYPH	B-NP	O
maze	NN	I-NP	O
than	IN	B-PP	O
vehicle	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
STZ	NN	I-NP	O
-	HYPH	B-NP	O
injected	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
crocin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mentioned	VBN	I-NP	O
dose	NN	I-NP	O
could	MD	B-VP	O
significantly	RB	I-VP	O
attenuated	VBD	I-VP	O
learning	NN	B-NP	B
and	CC	I-NP	I
memory	NN	I-NP	I
impairment	NN	I-NP	I
in	IN	B-PP	O
treated	VBN	B-NP	O
STZ	NN	I-NP	O
-	HYPH	B-VP	O
injected	VBN	B-NP	O
group	NN	I-NP	O
in	IN	B-PP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
the	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
crocin	NN	B-NP	O
in	IN	B-PP	O
antagonizing	VBG	B-VP	O
the	DT	B-NP	O
cognitive	JJ	I-NP	B
deficits	NNS	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
icv	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
potential	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
neurodegenerative	JJ	B-NP	B
diseases	NNS	I-NP	I
such	JJ	B-PP	O
as	IN	I-PP	O
Alzheimer	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Rosaceiform	NN	B-NP	O
dermatitis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
topical	JJ	B-NP	O
tacrolimus	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
herein	RB	B-ADVP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
rosacea	NN	B-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
dermatitis	NN	I-NP	B
eruptions	NNS	I-NP	B
while	IN	B-SBAR	O
using	VBG	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
tacrolimus	NN	I-NP	O
ointment	NN	I-NP	O
for	IN	B-PP	O
facial	JJ	B-NP	B
dermatitis	NN	I-NP	I
.	.	O	O

Skin	NN	B-NP	O
biopsy	NN	I-NP	O
specimens	NNS	I-NP	O
showed	VBD	B-VP	O
telangiectasia	NN	B-NP	B
and	CC	O	O
noncaseating	JJ	B-NP	O
epithelioid	JJ	I-NP	O
granulomatous	JJ	I-NP	O
tissue	NN	I-NP	O
formation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
papillary	JJ	I-NP	O
to	TO	B-PP	O
mid	JJ	B-NP	O
dermis	NN	I-NP	O
.	.	O	O

Continuous	JJ	B-NP	O
topical	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
immunomodulators	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
tacrolimus	NN	B-NP	O
or	CC	I-NP	O
pimecrolimus	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
regarded	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
rosaceiform	NN	B-NP	O
dermatitis	NN	I-NP	B
,	,	O	O
although	IN	B-SBAR	O
many	JJ	B-NP	O
cases	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
novel	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
delivery	NN	I-NP	O
system	NN	I-NP	O
to	TO	B-VP	O
promote	VB	I-VP	O
the	DT	B-NP	O
passage	NN	I-NP	O
through	IN	B-PP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
investigation	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
potentiality	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
delivery	NN	I-NP	O
system	NN	I-NP	O
to	TO	B-VP	O
promote	VB	I-VP	O
the	DT	B-NP	O
passage	NN	I-NP	O
through	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
(	(	O	O
BBB	NN	B-NP	O
)	)	O	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
to	TO	B-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
brain	NN	I-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
bioactive	JJ	I-NP	O
compound	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
coated	VBN	B-NP	O
poly	NN	I-NP	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	O	O
lactid	JJ	B-NP	O
acid	NN	I-NP	O
nanoparticles	NNS	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
colloidal	JJ	B-NP	O
drug	NN	I-NP	O
delivery	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
trespass	VB	I-VP	O
the	DT	B-NP	O
BBB	NNP	I-NP	O
.	.	O	O

Tacrine	NN	B-NP	O
,	,	O	O
administered	VBN	B-VP	O
in	IN	B-PP	O
LiCl	NN	B-NP	O
pre	AFX	O	O
-	HYPH	O	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
induces	VBZ	B-VP	O
electrocorticographic	JJ	B-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
delayed	VBN	B-VP	O
hippocampal	JJ	B-NP	B
damage	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
tacrine	NN	B-NP	O
-	HYPH	O	O
loaded	VBN	B-NP	O
poly	NN	I-NP	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	O	O
lactid	JJ	B-NP	O
acid	NN	I-NP	O
nanoparticles	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
saline	NN	I-NP	O
solution	NN	I-NP	O
of	IN	B-PP	O
tacrine	NN	B-NP	O
and	CC	O	O
an	DT	B-NP	O
empty	JJ	I-NP	O
colloidal	JJ	I-NP	O
nanoparticle	NN	I-NP	O
suspension	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
following	VBG	B-PP	O
i.p.	JJ	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
LiCl	NN	B-NP	O
-	HYPH	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

All	PDT	B-NP	O
the	DT	I-NP	O
animals	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
tacrine	NN	B-NP	O
-	HYPH	B-NP	O
loaded	VBN	I-NP	O
nanoparticles	NNS	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
earlier	JJR	I-NP	O
outcome	NN	I-NP	O
of	IN	B-PP	O
CNS	NN	B-NP	O
adverse	JJ	I-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
i.e.	FW	B-NP	O
epileptic	JJ	I-NP	B
onset	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
those	DT	B-NP	O
animals	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
free	JJ	I-NP	O
compound	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
min	NN	I-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
tacrine	NN	B-NP	O
-	HYPH	B-NP	O
loaded	VBN	I-NP	O
nanoparticles	NNS	I-NP	O
administration	NN	I-NP	O
induced	VBD	B-VP	O
damage	NN	B-NP	B
of	IN	B-PP	I
neuronal	JJ	B-NP	I
cells	NNS	I-NP	I
in	IN	B-PP	O
CA1	NN	B-NP	O
field	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
saline	NN	I-NP	O
solution	NN	I-NP	O
of	IN	B-PP	O
tacrine	NN	B-NP	O
only	RB	B-PP	O
in	IN	I-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

Empty	JJ	B-NP	O
nanoparticles	NNS	I-NP	O
provided	VBD	B-VP	O
similar	JJ	B-NP	O
results	NNS	I-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
(	(	O	O
saline	NN	B-NP	O
-	HYPH	B-VP	O
treated	VBN	I-VP	O
)	)	O	O
group	NN	B-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
time	NN	B-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
and	CC	O	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
neurodegenerative	JJ	B-NP	O
processes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
tacrine	NN	I-NP	O
-	HYPH	B-NP	O
lithium	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
,	,	O	O
could	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
preliminarily	RB	B-ADVP	O
the	DT	B-NP	O
capability	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
delivery	NN	I-NP	O
system	NN	I-NP	O
to	TO	B-VP	O
trespass	VB	I-VP	O
(	(	O	O
or	CC	O	O
not	RB	O	O
)	)	O	O
the	DT	B-NP	O
BBB	NN	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

The	DT	B-NP	O
antiarrhythmic	JJ	I-NP	O
effect	NN	I-NP	O
and	CC	O	O
possible	JJ	B-NP	O
ionic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
on	IN	B-PP	O
animal	NN	B-NP	O
models	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
and	CC	O	O
explore	VB	B-VP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
ionic	JJ	I-NP	O
mechanism	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
both	CC	O	O
aconitine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rat	NN	I-NP	O
and	CC	I-NP	O
ouabain	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
guinea	NN	I-NP	O
pig	NN	I-NP	O
arrhythmia	NN	I-NP	B
models	NNS	I-NP	O
.	.	O	O

Confocal	JJ	B-NP	O
microscopy	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
measure	VB	I-VP	O
intracellular	JJ	B-NP	O
free	JJ	I-NP	O
-	HYPH	I-NP	O
calcium	NN	I-NP	O
concentrations	NNS	I-NP	O
(	(	O	O
[	(	O	O
Ca	NN	O	O
]	)	O	O
(	(	B-LST	O
i	LS	I-LST	O
)	)	O	O
)	)	O	O
in	IN	B-PP	O
isolated	VBN	B-NP	O
myocytes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
data	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
pilocarpine	NN	B-NP	O
significantly	RB	B-ADVP	O
delayed	VBD	B-VP	O
onset	NN	B-NP	O
of	IN	B-PP	O
arrhythmias	NNS	B-NP	B
,	,	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
and	CC	I-NP	I
fibrillation	NN	I-NP	I
,	,	O	O
reduced	VBD	B-VP	O
arrhythmia	NN	B-NP	B
score	NN	I-NP	O
,	,	O	O
and	CC	O	O
increased	VBD	B-VP	O
the	DT	B-NP	O
survival	NN	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
arrhythmic	JJ	B-NP	B
rats	NNS	I-NP	O
and	CC	O	O
guinea	NN	B-NP	O
pigs.	NN	I-NP	O
[	(	O	O
Ca	NN	B-NP	O
]	)	O	O
(	(	B-LST	O
i	LS	I-LST	O
)	)	O	O
overload	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
aconitine	NN	B-NP	O
or	CC	I-NP	O
ouabain	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
isolated	VBN	B-NP	O
myocytes	NNS	I-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
pilocarpine	NN	B-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
M	NN	B-NP	O
-	HYPH	B-NP	O
muscarinic	JJ	I-NP	O
acetylcholine	NN	I-NP	O
receptor	NN	I-NP	O
(	(	O	O
mAChR	NN	B-NP	O
)	)	O	O
antagonist	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
DAMP	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
diphenylacetoxy	NN	I-NP	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methylpiperidine	NN	I-NP	O
-	HYPH	I-NP	O
methiodide	NN	I-NP	O
)	)	O	O
partially	RB	B-ADVP	O
abolished	VBD	B-VP	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
pilocarpine	NN	B-NP	O
produced	VBD	B-VP	O
antiarrhythmic	JJ	B-NP	O
actions	NNS	I-NP	O
on	IN	B-PP	O
arrhythmic	JJ	B-NP	B
rat	NN	I-NP	O
and	CC	I-NP	O
guinea	NN	I-NP	O
pig	NN	I-NP	O
models	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
aconitine	NN	B-NP	O
or	CC	I-NP	O
ouabain	NN	I-NP	O
via	IN	B-PP	O
stimulating	VBG	B-VP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
M	NN	I-NP	O
-	HYPH	B-NP	O
mAChR	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
Ca	NN	B-NP	O
handling	NN	I-NP	O
.	.	O	O

Disulfiram	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
transient	JJ	I-NP	O
optic	JJ	I-NP	B
and	CC	I-NP	I
peripheral	JJ	I-NP	I
neuropathy	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
optic	JJ	B-NP	B
and	CC	I-NP	I
peripheral	JJ	I-NP	I
neuropathy	NN	I-NP	I
after	IN	B-PP	O
chronic	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
disulfiram	NN	B-NP	O
for	IN	B-PP	O
alcohol	NN	B-NP	B
dependence	NN	I-NP	I
management	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
presented	VBN	B-VP	O
with	IN	B-PP	O
gradual	JJ	B-NP	O
loss	NN	I-NP	B
of	IN	B-PP	I
vision	NN	B-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
with	IN	B-PP	O
intermittent	JJ	B-NP	O
headaches	NNS	I-NP	B
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

He	PRP	B-NP	O
also	RB	B-ADVP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
paraesthesia	NN	B-NP	B
with	IN	B-PP	O
numbness	NN	B-NP	B
in	IN	B-PP	O
both	DT	B-NP	O
feet	NNS	I-NP	O
.	.	O	O

His	PRP$	B-NP	O
vision	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
and	CC	I-NP	O
left	JJ	I-NP	O
eyes	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Fundoscopy	NNP	B-NP	O
revealed	VBD	B-VP	O
bilaterally	RB	I-VP	O
swollen	VBN	I-VP	O
optic	JJ	B-NP	O
nerve	NN	I-NP	O
heads	NNS	I-NP	O
.	.	O	O

Visual	JJ	B-NP	O
field	NN	I-NP	O
testing	NN	I-NP	O
confirmed	VBD	B-VP	O
bilateral	JJ	B-NP	O
central	JJ	I-NP	O
-	HYPH	I-NP	O
caecal	JJ	I-NP	O
scotomata	NNS	I-NP	B
.	.	O	O

He	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taking	VBG	I-VP	O
disulfiram	NN	B-NP	O
for	IN	B-PP	O
alcohol	NN	B-NP	B
dependence	NN	I-NP	I
for	IN	B-PP	O
the	DT	B-NP	O
preceding	VBG	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Disulfiram	NN	B-NP	O
discontinuation	NN	I-NP	O
lead	VBP	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
immediate	JJ	I-NP	O
symptomatic	JJ	I-NP	O
improvement	NN	I-NP	O
.	.	O	O

Physicians	NNS	B-NP	O
initiating	VBG	B-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
disulfiram	NN	I-NP	O
therapy	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
these	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

They	PRP	B-NP	O
should	MD	B-VP	O
recommend	VB	I-VP	O
annual	JJ	B-NP	O
ophthalmic	JJ	I-NP	O
reviews	NNS	I-NP	O
with	IN	B-PP	O
visual	JJ	B-NP	O
field	NN	I-NP	O
testing	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
reassured	VBN	I-VP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
reversibility	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Sustained	VBN	B-NP	O
clinical	JJ	I-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
decompensated	VBN	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
cirrhosis	NN	I-NP	B
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
lamivudine	NN	B-NP	O
monotherapy	NN	I-NP	O
.	.	O	O

Hepatitis	NN	B-NP	B
B	NN	I-NP	I
virus	NN	I-NP	I
(	(	O	I
HBV	NN	B-NP	I
)	)	O	I
infection	NN	B-NP	I
,	,	O	O
which	WDT	B-NP	O
causes	VBZ	B-VP	O
liver	NN	B-NP	B
cirrhosis	NN	I-NP	I
and	CC	O	O
hepatocellular	JJ	B-NP	B
carcinoma	NN	I-NP	I
,	,	O	O
remains	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
health	NN	I-NP	O
problem	NN	I-NP	O
in	IN	B-PP	O
Asian	JJ	B-NP	O
countries	NNS	I-NP	O
.	.	O	O

Recent	JJ	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
vaccine	NN	B-NP	O
for	IN	B-PP	O
prevention	NN	B-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
successful	JJ	B-ADJP	O
in	IN	B-PP	O
reducing	VBG	B-VP	O
the	DT	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
chronically	RB	B-NP	O
infected	JJ	I-NP	O
carriers	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
standard	JJ	I-NP	O
medical	JJ	I-NP	O
therapies	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
established	VBN	I-VP	O
up	RP	B-PRT	O
to	TO	B-PP	O
now	RB	B-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
encountered	VBD	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
decompensated	VBN	B-NP	O
HBV	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
cirrhosis	NN	I-NP	B
who	WP	B-NP	O
exhibited	VBD	B-VP	O
the	DT	B-NP	O
dramatic	JJ	I-NP	O
improvements	NNS	I-NP	O
after	IN	B-PP	O
antiviral	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
conventional	JJ	I-NP	O
medical	JJ	I-NP	O
treatments	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
effective	JJ	B-ADJP	O
for	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
thus	RB	B-ADVP	O
this	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
referred	VBN	I-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
hospital	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
reverse	JJ	I-NP	O
transcriptase	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
dramatically	RB	B-ADVP	O
improved	VBD	B-VP	O
her	PRP$	B-NP	O
liver	NN	I-NP	O
severity	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
this	DT	B-NP	O
period	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
drug	NN	I-NP	O
resistant	JJ	I-NP	O
mutant	JJ	I-NP	O
HBV	NN	I-NP	O
emerged	VBD	B-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
serum	NN	I-NP	O
HBV	NN	I-NP	O
-	HYPH	I-NP	O
DNA	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
continuously	RB	I-VP	O
suppressed	VBN	I-VP	O
.	.	O	O

These	DT	B-NP	O
virological	JJ	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
maintained	VBN	I-VP	O
even	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
antiviral	JJ	I-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
both	CC	O	O
hepatitis	NN	B-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
and	CC	O	O
e	NN	B-NP	O
antigen	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
disappeared	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
HBV	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
cirrhosis	NN	I-NP	B
,	,	O	O
like	IN	B-PP	O
our	PRP$	B-NP	O
present	JJ	I-NP	O
case	NN	I-NP	O
,	,	O	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
initial	JJ	I-NP	O
medical	JJ	I-NP	O
therapeutic	JJ	I-NP	O
option	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
countries	NNS	B-NP	O
where	WRB	B-ADVP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
reliably	RB	B-ADJP	O
available	JJ	I-ADJP	O
.	.	O	O

Dual	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
melatonin	NN	B-NP	O
on	IN	B-PP	O
barbiturate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
narcosis	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Melatonin	NN	B-NP	O
affects	VBZ	B-VP	O
the	DT	B-NP	O
circadian	JJ	I-NP	O
sleep	NN	I-NP	O
/	SYM	B-NP	O
wake	NN	I-NP	O
cycle	NN	I-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
clear	JJ	B-ADJP	O
whether	IN	B-SBAR	O
it	PRP	B-NP	O
may	MD	B-VP	O
influence	VB	I-VP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
narcosis	NN	I-NP	B
.	.	O	O

Sodium	NN	B-NP	O
thiopenthal	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intraperitoneally	RB	B-ADVP	O
into	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
pre	AFX	O	O
-	HYPH	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
melatonin	NN	B-NP	O
.	.	O	O

Melatonin	NN	B-NP	O
pre	AFX	O	O
-	HYPH	O	O
treatment	NN	B-NP	O
affected	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
dual	JJ	I-NP	O
manner	NN	I-NP	O
barbiturate	NN	I-NP	O
narcosis	NN	I-NP	B
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
correlation	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
particular	JJ	B-NP	O
,	,	I-NP	O
low	JJ	I-NP	O
doses	NNS	I-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
latency	NN	I-NP	O
to	TO	B-PP	O
and	CC	O	O
prolonged	VBD	B-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
barbiturate	NN	B-NP	O
narcosis	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
highest	JJS	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
melatonin	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
paradoxical	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
latency	NN	I-NP	O
and	CC	O	O
produced	VBD	B-VP	O
a	DT	B-NP	O
sustained	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
narcosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
mortality	NN	B-NP	O
rate	NN	I-NP	O
.	.	O	O

Melatonin	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
influenced	VBD	B-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
the	DT	B-NP	O
latency	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
-	HYPH	B-NP	O
or	CC	I-NP	O
diazepam	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
narcosis	NN	I-NP	B
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
dual	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
melatonin	NN	B-NP	O
on	IN	B-PP	O
pharmacological	JJ	B-NP	O
narcosis	NN	I-NP	B
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
specific	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
barbiturate	NN	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
NIK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
cholinesterase	NN	B-NP	O
and	CC	I-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
NIK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
cholinesterase	NN	B-NP	O
,	,	O	O
scopolamine	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
amnesia	NN	I-NP	B
and	CC	O	O
spontaneous	JJ	B-NP	O
movement	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
and	CC	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
known	VBN	I-NP	O
cholinesterase	NN	I-NP	O
inhibitors	NNS	I-NP	O
tacrine	NN	I-NP	O
and	CC	I-NP	O
E	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

NIK	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
tacrine	NN	I-NP	O
and	CC	I-NP	O
E	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
all	DT	B-ADVP	O
strongly	RB	I-ADVP	O
inhibited	VBD	B-VP	O
acetylcholinesterase	NN	B-NP	O
(	(	O	O
AChE	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
human	JJ	B-NP	O
red	JJ	I-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
NIK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
tacrine	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
E	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
strongly	RB	B-ADVP	O
inhibited	VBD	B-VP	O
butyrylcholinestrase	NN	B-NP	O
(	(	O	O
BuChE	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
human	JJ	B-NP	O
serum	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
produced	VBD	B-VP	O
mixed	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
AChE	NN	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
NIK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
AChE	NN	B-NP	O
was	VBD	B-VP	O
reversible	JJ	B-ADJP	O
.	.	O	O

All	DT	B-NP	O
compounds	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
p.o.	NN	I-NP	O
significantly	RB	B-ADVP	O
improved	VBD	B-VP	O
the	DT	B-NP	O
amnesia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
performing	VBG	B-VP	O
a	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
compounds	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
p.o.	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
decrease	VB	I-VP	O
spontaneous	JJ	B-NP	O
movement	NN	I-NP	O
by	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
NIK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
improves	VBZ	B-VP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
but	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
spontaneous	JJ	B-NP	O
movement	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
NIK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Alzheimer	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Nightmares	NNS	B-NP	O
and	CC	I-NP	O
hallucinations	NNS	I-NP	B
after	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
intake	NN	I-NP	O
of	IN	B-PP	O
tramadol	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
antidepressants	NNS	B-NP	O
.	.	O	O

Tramadol	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
weak	JJ	I-NP	O
opioid	NN	I-NP	O
with	IN	B-PP	O
effects	NNS	B-NP	O
on	IN	B-PP	O
adrenergic	JJ	B-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
neurotransmission	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
cancer	NN	B-NP	B
pain	NN	I-NP	B
and	CC	O	O
chronic	JJ	B-NP	O
non	JJ	I-NP	O
malignant	JJ	I-NP	O
pain	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
paroxetine	NN	B-NP	O
and	CC	I-NP	O
dosulepine	NN	I-NP	O
hydrochloride	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
tetraparetic	JJ	I-NP	B
patient	NN	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
hallucinations	NNS	B-NP	B
that	WDT	B-NP	O
only	RB	B-ADVP	O
stopped	VBD	B-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
psycho	AFX	B-NP	O
-	HYPH	B-NP	O
active	JJ	I-NP	O
drugs	NNS	I-NP	O
and	CC	I-NP	O
tramadol	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
questions	NNS	I-NP	O
the	DT	B-NP	O
long	JJ	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
killers	NNS	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
psycho	AFX	B-NP	O
-	HYPH	I-NP	O
active	JJ	I-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
non	JJ	I-NP	O
malignant	JJ	I-NP	O
pain	NN	I-NP	B
,	,	O	O
especially	RB	B-ADVP	O
if	IN	B-SBAR	O
pain	NN	B-NP	B
is	VBZ	B-VP	O
under	IN	B-PP	O
control	NN	B-NP	O
.	.	O	O

Apparent	JJ	B-NP	O
cure	NN	I-NP	O
of	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
by	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
sustained	JJ	B-NP	O
remissions	NNS	I-NP	O
and	CC	O	O
possible	JJ	B-NP	O
cure	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
erosive	JJ	I-NP	O
rheumatoid	JJ	I-NP	B
arthritis	NN	I-NP	I
(	(	O	O
RA	NN	B-NP	B
)	)	O	O
by	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
(	(	O	O
BMT	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

BMT	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
severe	JJ	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
which	WDT	B-NP	O
was	VBD	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
gold	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
case	NN	I-NP	O
and	CC	I-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
since	IN	B-SBAR	O
the	DT	B-NP	O
transplants	NNS	I-NP	O
(	(	O	O
representing	VBG	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
since	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
immunosuppressive	JJ	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
RA	NN	I-NP	B
in	IN	B-PP	O
each	DT	B-NP	O
case	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
completely	RB	B-ADJP	O
quiescent	JJ	I-ADJP	O
.	.	O	O

Although	IN	B-SBAR	O
short	JJ	B-NP	O
term	NN	I-NP	O
remission	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
RA	NN	I-NP	B
following	VBG	B-PP	O
BMT	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
,	,	O	O
these	DT	B-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
cases	NNS	I-NP	O
for	IN	B-PP	O
which	WDT	B-NP	O
prolonged	JJ	B-NP	O
followup	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
available	JJ	B-ADJP	O
.	.	O	O

This	DT	B-NP	O
experience	NN	I-NP	O
raises	VBZ	B-VP	O
the	DT	B-NP	O
question	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
BMT	NN	B-NP	O
itself	PRP	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
therapeutic	JJ	I-NP	O
option	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
uncontrolled	JJ	B-NP	O
destructive	JJ	I-NP	O
synovitis	NN	I-NP	B
.	.	O	O

Urinary	JJ	B-NP	O
enzymes	NNS	I-NP	O
and	CC	O	O
protein	NN	B-NP	O
patterns	NNS	I-NP	O
as	IN	B-PP	O
indicators	NNS	B-NP	O
of	IN	B-PP	O
injury	NN	B-NP	B
to	TO	B-PP	I
different	JJ	B-NP	I
regions	NNS	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
kidney	NN	I-NP	I
.	.	O	O

Acute	JJ	B-NP	B
experimental	JJ	I-NP	I
models	NNS	I-NP	I
of	IN	B-PP	I
renal	JJ	B-NP	I
damage	NN	I-NP	I
to	TO	B-PP	O
the	DT	B-NP	O
proximal	JJ	I-NP	O
tubular	JJ	I-NP	O
,	,	I-NP	O
glomerular	JJ	I-NP	O
,	,	O	O
and	CC	O	O
papillary	JJ	B-NP	O
regions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
were	VBD	B-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
hexachloro	AFX	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
:	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
butadiene	NN	I-NP	O
(	(	O	O
HCBD	NN	B-NP	O
)	)	O	O
,	,	O	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
bromoethylamine	NN	I-NP	O
(	(	O	O
BEA	NN	B-NP	O
)	)	O	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Several	JJ	B-NP	O
routine	JJ	I-NP	O
indicators	NNS	I-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
enzymes	NNS	I-NP	O
alkaline	NN	I-NP	O
phosphatase	NN	I-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	O	O
-	HYPH	O	O
glucosaminidase	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
weight	NN	I-NP	O
of	IN	B-PP	O
protein	NN	B-NP	B
excretion	NN	I-NP	I
were	VBD	B-VP	O
determined	VBN	I-VP	O
on	IN	B-PP	O
urine	NN	B-NP	O
samples	NNS	I-NP	O
.	.	O	O

Tubular	JJ	B-NP	O
damage	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
HCBD	NN	B-NP	O
or	CC	I-NP	O
BEA	NN	I-NP	O
was	VBD	B-VP	O
discriminated	VBN	I-VP	O
both	CC	O	O
quantitatively	RB	B-ADVP	O
and	CC	I-ADVP	O
qualitatively	RB	I-ADVP	O
from	IN	B-PP	O
glomerular	JJ	B-NP	B
damage	NN	I-NP	I
produced	VBN	B-VP	O
by	IN	B-PP	O
PAN	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
latter	JJ	I-NP	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
pronounced	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
protein	NN	B-NP	B
excretion	NN	I-NP	I
,	,	O	O
especially	RB	B-ADVP	O
proteins	NNS	B-NP	O
with	IN	B-PP	O
molecular	JJ	B-NP	O
weight	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
Da	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
protein	NN	B-NP	B
excretion	NN	I-NP	I
in	IN	B-PP	O
tubular	JJ	B-NP	O
damage	NN	I-NP	O
was	VBD	B-VP	O
raised	VBN	I-VP	O
only	RB	B-ADVP	O
slightly	RB	I-ADVP	O
and	CC	O	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
excretion	NN	B-NP	B
of	IN	B-PP	I
proteins	NNS	B-NP	I
of	IN	B-PP	O
a	DT	B-NP	O
wide	JJ	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
molecular	JJ	B-NP	O
weights	NNS	I-NP	O
.	.	O	O

Proximal	JJ	B-NP	O
tubular	JJ	I-NP	O
damage	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
HCBD	NN	B-NP	O
and	CC	O	O
papillary	JJ	B-NP	O
damage	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
BEA	NN	B-NP	O
were	VBD	B-VP	O
distinguished	VBN	I-VP	O
both	CC	O	O
by	IN	B-PP	O
conventional	JJ	B-NP	O
urinalysis	NN	I-NP	O
(	(	O	O
volume	NN	B-NP	O
and	CC	O	O
specific	JJ	B-NP	O
gravity	NN	I-NP	O
)	)	O	O
and	CC	O	O
by	IN	B-PP	O
measurement	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
urinary	JJ	I-NP	O
enzymes	NNS	I-NP	O
.	.	O	O

Alkaline	NN	B-NP	O
phosphatase	NN	I-NP	O
and	CC	I-NP	O
glucose	NN	I-NP	O
were	VBD	B-VP	O
markedly	RB	B-ADVP	O
and	CC	O	O
transiently	RB	B-ADJP	O
elevated	JJ	I-ADJP	O
in	IN	B-PP	O
proximal	JJ	B-NP	O
tubular	JJ	I-NP	O
damage	NN	I-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	O	O
-	HYPH	O	O
glucosaminidase	NN	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
sustained	JJ	I-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
papillary	JJ	B-NP	O
damage	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
both	CC	O	O
selective	JJ	B-NP	O
urinary	JJ	I-NP	O
enzymes	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
weight	NN	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	O
proteins	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
provide	VB	I-VP	O
diagnostic	JJ	B-NP	O
information	NN	I-NP	O
about	IN	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
.	.	O	O

Neuromuscular	JJ	B-NP	B
blockade	NN	I-NP	I
with	IN	B-PP	O
magnesium	NN	B-NP	O
sulfate	NN	I-NP	O
and	CC	I-NP	O
nifedipine	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
tocolysis	NN	B-NP	O
with	IN	B-PP	O
nifedipine	NN	B-NP	O
developed	VBD	B-VP	O
neuromuscular	JJ	B-NP	B
blockade	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
magnesium	NN	B-NP	O
sulfate	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
reaction	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
nifedipine	NN	B-NP	O
can	MD	B-VP	O
seriously	RB	I-VP	O
potentiate	VB	I-VP	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
magnesium	NN	B-NP	O
.	.	O	O

Caution	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
exercised	VBN	I-VP	O
when	WRB	B-ADVP	O
these	DT	B-NP	O
num	CD	I-NP	O
tocolytics	NNS	I-NP	O
are	VBP	B-VP	O
combined	VBN	I-VP	O
.	.	O	O

Ifosfamide	NN	B-NP	O
continuous	JJ	I-NP	O
infusion	NN	I-NP	O
without	IN	B-PP	O
mesna	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
cycle	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
administered	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
continuous	JJ	I-NP	O
infusion	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
without	IN	B-PP	O
Mesna	NNP	B-NP	O
.	.	O	O

The	DT	B-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
deliver	VB	I-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
total	JJ	B-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
that	WDT	B-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
standard	JJ	B-NP	O
bolus	NN	I-NP	O
or	CC	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
infusions	NNS	I-NP	O
administered	VBN	B-VP	O
with	IN	B-PP	O
Mesna	NNP	B-NP	O
.	.	O	O

Dose	NN	B-NP	O
escalations	NNS	I-NP	O
proceeded	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	I-NP	O
d	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
transient	JJ	B-NP	O
microscopic	JJ	I-NP	O
hematuria	NN	I-NP	B
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	I-NP	O
d	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
instances	NNS	I-NP	O
of	IN	B-PP	O
macroscopic	JJ	B-NP	O
hematuria	NN	I-NP	B
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	I-NP	O
d	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
nonurologic	JJ	B-NP	O
toxicity	NN	I-NP	B
;	:	O	O
confusion	NN	B-NP	B
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
and	CC	O	O
Grade	NN	B-NP	O
num	CD	I-NP	O
leukopenia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
recommended	VBN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
delivers	VBZ	B-VP	O
a	DT	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
per	IN	B-PP	O
cycle	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
delivered	VBN	B-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
practice	NN	I-NP	O
for	IN	B-PP	O
bolus	NN	B-NP	O
or	CC	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
few	JJ	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
multiple	JJ	B-NP	O
courses	NNS	I-NP	O
over	IN	B-PP	O
time	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
cumulative	JJ	I-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
indeterminate	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
trial	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
predictability	NN	I-NP	O
of	IN	B-PP	O
hematuria	NN	B-NP	B
are	VBP	B-VP	O
not	RB	O	O
precise	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
at	IN	B-NP	O
least	JJS	I-NP	O
daily	JJ	I-NP	O
monitoring	NN	I-NP	O
by	IN	B-PP	O
urine	NN	B-NP	O
Hematest	NN	I-NP	O
is	VBZ	B-VP	O
essential	JJ	B-ADJP	O
,	,	O	O
adding	VBG	B-VP	O
Mesna	NNP	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
infusate	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
persistent	JJ	B-NP	O
hematuria	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
protracted	JJ	I-NP	O
infusion	NN	I-NP	O
schedule	NN	I-NP	O
for	IN	B-PP	O
ifosfamide	NN	B-NP	O
permits	VBZ	B-VP	O
convenient	JJ	B-NP	O
outpatient	NN	I-NP	O
administration	NN	I-NP	O
without	IN	B-PP	O
Mesna	NNP	B-NP	O
and	CC	O	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
cost	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
usage	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
agent	NN	I-NP	O
by	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
per	IN	B-PP	O
cycle	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
but	CC	O	O
a	DT	B-NP	O
comparative	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
standard	JJ	B-NP	O
bolus	NN	I-NP	O
schedules	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
protracted	JJ	I-NP	O
infusion	NN	I-NP	O
schedule	NN	I-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
maintained	VBN	I-VP	O
.	.	O	O

Myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
pregnancy	NN	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
clomiphene	NN	B-NP	O
citrate	NN	I-NP	O
for	IN	B-PP	O
ovulation	NN	B-NP	O
induction	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Clomiphene	NN	B-NP	O
citrate	NN	I-NP	O
(	(	O	O
CC	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
commonly	RB	I-VP	O
prescribed	VBN	I-VP	O
for	IN	B-PP	O
ovulation	NN	B-NP	O
induction	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
considered	VBN	I-VP	O
safe	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
minimal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Thromboembolism	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
but	CC	I-NP	O
life	NN	I-NP	O
-	HYPH	B-NP	O
threatening	VBG	B-VP	O
complication	NN	B-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
after	IN	B-PP	O
ovulation	NN	B-NP	O
induction	NN	I-NP	O
with	IN	B-PP	O
CC	NN	B-NP	O
.	.	O	O

Spontaneous	JJ	B-NP	O
coronary	JJ	I-NP	B
thrombosis	NN	I-NP	I
or	CC	I-NP	O
thromboembolism	NN	I-NP	B
with	IN	B-PP	O
subsequent	JJ	B-NP	O
clot	NN	I-NP	O
lysis	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
as	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
(	(	O	O
MI	NN	B-NP	B
)	)	O	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
subsequently	RB	I-NP	O
normal	JJ	I-NP	O
coronary	JJ	I-NP	O
angiogram	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
gestation	NN	I-NP	O
had	VBD	B-VP	O
recently	RB	I-VP	O
received	VBN	I-VP	O
CC	NN	B-NP	O
for	IN	B-PP	O
ovulation	NN	B-NP	O
induction	NN	I-NP	O
and	CC	O	O
presented	VBD	B-VP	O
with	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
.	.	O	O

An	DT	B-NP	O
electrocardiogram	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
lateral	JJ	I-NP	O
and	CC	I-NP	O
anterior	JJ	I-NP	O
wall	NN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

Cardiac	JJ	B-NP	O
enzymes	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
peak	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
troponin	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
initial	JJ	I-NP	O
exercise	NN	I-NP	O
stress	NN	I-NP	O
test	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
at	IN	B-PP	O
high	JJ	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
radiation	NN	B-NP	B
injury	NN	I-NP	I
to	TO	B-PP	O
the	DT	B-NP	O
fetus	NN	I-NP	O
,	,	O	O
so	RB	O	O
a	DT	B-NP	O
coronary	JJ	I-NP	O
angiogram	NN	I-NP	O
was	VBD	B-VP	O
postponed	VBN	I-VP	O
until	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
trimester	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
showed	VBD	B-VP	O
normal	JJ	B-NP	O
coronary	JJ	I-NP	O
vessels	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
documenting	VBG	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
CC	NN	B-NP	O
and	CC	O	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

Thrombosis	NN	B-NP	B
might	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
but	CC	I-NP	O
hazardous	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
CC	NN	B-NP	O
.	.	O	O

Given	VBN	B-PP	O
this	DT	B-NP	O
life	NN	I-NP	O
-	HYPH	B-VP	O
threatening	VBG	I-VP	O
complication	NN	B-NP	O
,	,	O	O
appropriate	JJ	B-NP	O
prophylactic	JJ	I-NP	O
measures	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
woman	NN	I-NP	O
undergoing	VBG	B-VP	O
ovarian	JJ	B-NP	O
stimulation	NN	I-NP	O
.	.	O	O

Hepatonecrosis	NN	B-NP	B
and	CC	I-NP	O
cholangitis	NN	I-NP	B
related	VBN	B-VP	O
to	TO	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
phenobarbital	NN	I-NP	O
therapy	NN	I-NP	O
:	:	O	O
an	DT	B-NP	O
autopsy	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Phenobarbital	NN	B-NP	O
(	(	O	O
PB	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
a	DT	B-NP	O
reputation	NN	I-NP	O
for	IN	B-PP	O
safety	NN	B-NP	O
,	,	O	O
and	CC	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
commonly	RB	I-VP	O
believed	VBN	I-VP	O
that	IN	B-SBAR	O
PB	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
aminotransferase	NN	I-NP	O
levels	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
indicate	VB	I-VP	O
or	CC	I-VP	O
predict	VB	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
significant	JJ	B-NP	O
chronic	JJ	I-NP	O
liver	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
report	VBP	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
PB	NN	B-NP	O
who	WP	B-NP	O
died	VBD	B-VP	O
suddenly	RB	B-ADVP	O
:	:	O	O
num	CD	B-NP	O
as	IN	B-PP	O
consequence	NN	B-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
other	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
bronchopneumonia	NN	I-NP	B
.	.	O	O

At	IN	B-PP	O
autopsy	NN	B-NP	O
,	,	O	O
analysis	NN	B-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
parenchyma	NN	I-NP	O
revealed	VBD	B-VP	O
rich	JJ	B-NP	O
portal	JJ	I-NP	O
inflammatory	JJ	I-NP	O
infiltrate	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
mixed	VBN	B-NP	O
eosinophil	NN	I-NP	O
and	CC	I-NP	O
monocyte	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
several	JJ	B-NP	O
foci	NNS	I-NP	O
of	IN	B-PP	O
necrosis	NN	B-NP	B
surrounded	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
hard	JJ	I-NP	O
ring	NN	I-NP	O
of	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
granulomatous	JJ	I-NP	O
tissue	NN	I-NP	O
.	.	O	O

Inflammatory	JJ	B-NP	O
reactions	NNS	I-NP	O
of	IN	B-PP	O
internal	JJ	B-NP	O
and	CC	I-NP	O
external	JJ	I-NP	O
hepatic	JJ	I-NP	O
biliary	JJ	I-NP	O
ducts	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
seen	VBN	I-VP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
illustrate	VBP	B-VP	O
that	IN	B-SBAR	O
PB	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
liver	NN	I-NP	B
damage	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
more	RBR	B-NP	O
serious	JJ	I-NP	O
and	CC	I-NP	O
deleterious	JJ	I-NP	O
consequences	NNS	I-NP	O
.	.	O	O

For	IN	B-PP	O
this	DT	B-NP	O
reason	NN	I-NP	O
,	,	O	O
each	DT	B-NP	O
clinician	NN	I-NP	O
should	MD	B-VP	O
recognize	VB	I-VP	O
this	DT	B-NP	O
entity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
differential	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
PB	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-VP	O
asymptomatic	JJ	B-NP	O
chronic	JJ	I-NP	B
hepatic	JJ	I-NP	I
enzyme	NN	I-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

Ethambutol	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
optic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Ethambutol	NN	B-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
tuberculosis	NN	B-NP	B
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
prevalent	JJ	B-ADJP	O
in	IN	B-PP	O
Southeast	NNP	B-NP	O
Asia	NNP	I-NP	O
,	,	O	O
and	CC	O	O
can	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
permanent	JJ	B-NP	O
visual	JJ	I-NP	B
loss	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
which	WDT	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
bitemporal	JJ	B-NP	B
hemianopia	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
ethambutol	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
toxic	JJ	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
are	VBP	B-VP	O
described	VBN	I-VP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
loss	NN	B-NP	B
of	IN	B-PP	I
central	JJ	B-NP	I
visual	JJ	I-NP	I
acuity	NN	I-NP	I
,	,	O	I
colour	NN	B-NP	I
vision	NN	I-NP	I
(	(	O	I
Ishihara	NN	B-NP	I
)	)	O	I
and	CC	O	I
visual	JJ	B-NP	I
field	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
loss	NN	I-NP	I
had	VBD	B-VP	O
a	DT	B-NP	O
bitemporal	JJ	I-NP	O
flavour	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
involvement	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
optic	JJ	I-NP	O
chiasm	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
stopping	VBG	B-VP	O
ethambutol	NN	B-NP	O
on	IN	B-PP	O
diagnosis	NN	B-NP	O
,	,	O	O
visual	JJ	B-NP	O
function	NN	I-NP	O
continued	VBD	B-VP	O
to	TO	I-VP	O
deteriorate	VB	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Subsequent	JJ	B-NP	O
improvement	NN	I-NP	O
was	VBD	B-VP	O
mild	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
case	NN	I-NP	O
,	,	O	O
visual	JJ	B-NP	O
acuity	NN	I-NP	O
and	CC	I-NP	O
colour	NN	I-NP	O
vision	NN	I-NP	O
normalised	VBD	B-VP	O
but	CC	O	O
the	DT	B-NP	O
optic	JJ	I-NP	O
discs	NNS	I-NP	O
were	VBD	B-VP	O
pale	JJ	B-ADJP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
some	DT	B-NP	O
permanent	JJ	I-NP	O
loss	NN	I-NP	B
of	IN	B-PP	I
visual	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

Ethambutol	NN	B-NP	O
usage	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
permanent	JJ	B-NP	O
visual	JJ	I-NP	B
loss	NN	I-NP	I
and	CC	O	O
should	MD	B-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
if	IN	B-SBAR	O
possible	JJ	B-ADJP	O
or	CC	O	O
used	VBN	B-VP	O
with	IN	B-PP	O
caution	NN	B-NP	O
and	CC	O	O
proper	JJ	B-NP	O
ophthalmological	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
.	.	O	O

The	DT	B-NP	O
author	NN	I-NP	O
postulates	VBZ	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
ethambutol	NN	B-NP	O
associated	JJ	I-NP	O
chiasmopathy	NN	I-NP	O
,	,	O	O
ethambutol	NN	B-NP	O
may	MD	B-VP	O
initially	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
optic	JJ	I-NP	O
nerves	NNS	I-NP	O
and	CC	O	O
subsequently	RB	B-ADVP	O
progress	NN	B-NP	O
to	TO	B-VP	O
involve	VB	I-VP	O
the	DT	B-NP	O
optic	JJ	I-NP	O
chiasm	NN	I-NP	O
.	.	O	O

Tolerability	NN	B-NP	O
of	IN	B-PP	O
nimesulide	NN	B-NP	O
and	CC	I-NP	O
paracetamol	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
NSAID	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
urticaria	NN	I-NP	B
/	SYM	B-NP	O
angioedema	NN	I-NP	B
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
tolerance	NN	I-NP	O
of	IN	B-PP	O
nimesulide	NN	B-NP	O
and	CC	I-NP	O
paracetamol	NN	I-NP	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
with	IN	B-PP	O
cutaneous	JJ	B-NP	O
,	,	I-NP	O
respiratory	JJ	I-NP	O
and	CC	I-NP	O
anaphylactoid	JJ	I-NP	O
reactions	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
tolerability	NN	B-NP	O
and	CC	I-NP	O
reliability	NN	I-NP	O
of	IN	B-PP	O
nimesulide	NN	B-NP	O
and	CC	I-NP	O
paracetamol	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
very	RB	I-NP	O
large	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
exclusive	JJ	I-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
documented	VBN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
NSAID	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
urticaria	NN	I-NP	B
/	SYM	B-NP	O
angioedema	NN	I-NP	B
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
evaluated	VBD	B-VP	O
whether	IN	B-SBAR	O
some	DT	B-NP	O
factors	NNS	I-NP	O
have	VBP	B-VP	O
the	DT	B-NP	O
potential	NN	I-NP	O
to	TO	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
reaction	NN	B-NP	O
to	TO	B-PP	O
paracetamol	NN	B-NP	O
and	CC	I-NP	O
nimesulide	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
placebo	NN	I-NP	O
-	HYPH	B-VP	O
controlled	VBN	B-NP	O
oral	JJ	I-NP	O
challenge	NN	I-NP	O
procedure	NN	I-NP	O
with	IN	B-PP	O
nimesulide	NN	B-NP	O
or	CC	I-NP	O
paracetamol	NN	I-NP	O
was	VBD	B-VP	O
applied	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
NSAID	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
urticaria	NN	I-NP	B
/	SYM	B-NP	O
angioedema	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
reactions	NNS	B-NP	O
to	TO	B-PP	O
nimesulide	NN	B-NP	O
or	CC	I-NP	O
paracetamol	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
tested	VBN	B-VP	O
with	IN	B-PP	O
nimesulide	NN	B-NP	O
num	CD	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
test	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
of	IN	B-PP	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
submitted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
challenge	NN	I-NP	O
with	IN	B-PP	O
paracetamol	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
tolerate	VB	I-VP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
urticaria	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
subjects	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
NSAID	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
urticaria	NN	I-NP	B
/	SYM	B-NP	O
angioedema	NN	B-NP	B
or	CC	I-NP	O
angioedema	NN	I-NP	B
alone	RB	B-ADVP	O
(	(	O	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
chronic	JJ	B-NP	O
urticaria	NN	I-NP	B
)	)	O	O
resulted	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
intolerant	JJ	B-ADJP	O
to	TO	B-PP	O
alternative	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Taken	VBN	B-VP	O
together	RB	B-ADVP	O
,	,	O	O
our	PRP$	B-NP	O
results	NNS	I-NP	O
confirm	VBP	B-VP	O
the	DT	B-NP	O
good	JJ	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
nimesulide	NN	B-NP	O
and	CC	I-NP	O
paracetamol	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
urticaria	NN	B-NP	B
/	SYM	B-NP	O
angioedema	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
NSAIDs	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
reaction	NN	B-NP	O
to	TO	B-PP	O
these	DT	B-NP	O
alternative	JJ	I-NP	O
study	NN	I-NP	O
drugs	NNS	I-NP	O
is	VBZ	B-VP	O
statistically	RB	I-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
urticaria	NN	I-NP	B
and	CC	O	O
,	,	O	O
above	IN	B-PP	O
all	DT	B-NP	O
,	,	O	O
by	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
NSAID	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
angioedema	NN	I-NP	B
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
on	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
electrophysiological	JJ	I-NP	O
determinants	NNS	I-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

Atrial	JJ	B-NP	B
tachycardia	NN	I-NP	I
-	HYPH	B-NP	O
induced	VBN	I-NP	O
remodeling	NN	I-NP	O
promotes	VBZ	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
and	CC	I-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
(	(	O	O
AF	NN	B-NP	B
)	)	O	O
and	CC	O	O
decreases	VBZ	B-VP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
Ca	NN	I-NP	O
current	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
also	RB	B-ADVP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
suggestion	NN	I-NP	O
that	IN	B-NP	O
acute	JJ	B-NP	O
L	NN	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
Ca	NN	I-NP	O
channel	NN	I-NP	O
blockade	NN	I-NP	O
can	MD	B-VP	O
promote	VB	I-VP	O
AF	NN	B-NP	B
,	,	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
AF	NN	I-NP	B
promoting	VBG	B-VP	O
effect	NN	B-NP	O
of	IN	B-PP	O
Ca	NN	B-NP	O
channel	NN	I-NP	O
inhibition	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
AF	NN	B-NP	B
promotion	NN	I-NP	O
by	IN	B-PP	O
Ca	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
administered	VBD	B-VP	O
verapamil	NN	B-NP	O
to	TO	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
chloralose	NN	I-NP	O
anesthetized	VBN	B-NP	O
dogs	NNS	I-NP	O
.	.	O	O

Diltiazem	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
comparison	NN	I-NP	O
drug	NN	I-NP	O
and	CC	O	O
autonomic	JJ	B-NP	O
blockade	NN	I-NP	O
with	IN	B-PP	O
atropine	NN	B-NP	O
and	CC	I-NP	O
nadolol	NN	I-NP	O
was	VBD	B-VP	O
applied	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
experiments	NNS	I-NP	O
.	.	O	O

Epicardial	NNP	B-NP	O
mapping	VBG	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
epicardial	JJ	I-NP	O
electrodes	NNS	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
activation	NN	B-NP	O
during	IN	B-PP	O
AF	NN	B-NP	B
.	.	O	O

Verapamil	NN	B-NP	O
caused	VBD	B-VP	O
AF	NN	B-NP	B
promotion	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
,	,	O	O
increasing	VBG	B-VP	O
mean	JJ	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
AF	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
burst	NN	B-NP	O
pacing	NN	I-NP	O
,	,	O	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
S.E.	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
loading	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	I-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Underlying	VBG	B-VP	O
electrophysiological	JJ	B-NP	O
mechanisms	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
detail	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
additional	JJ	I-NP	O
dogs	NNS	I-NP	O
under	IN	B-PP	O
control	NN	B-NP	O
conditions	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
experiments	NNS	I-NP	O
,	,	O	O
verapamil	NN	B-NP	O
shortened	VBD	B-VP	O
mean	JJ	B-NP	O
effective	JJ	I-NP	O
refractory	JJ	I-NP	O
period	NN	I-NP	O
(	(	O	O
ERP	NN	B-NP	O
)	)	O	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
ms	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
cycle	NN	I-NP	O
length	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ms	NN	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
ERP	NN	B-NP	O
heterogeneity	NN	I-NP	O
,	,	O	O
heterogeneously	RB	B-ADVP	O
accelerated	VBD	B-VP	O
atrial	JJ	B-NP	O
conduction	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
cycle	NN	I-NP	O
length	NN	I-NP	O
of	IN	B-PP	O
AF	NN	B-NP	B
.	.	O	O

Diltiazem	NNP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
ERP	NN	B-NP	O
,	,	O	O
AF	NN	B-NP	B
cycle	NN	I-NP	O
length	NN	I-NP	O
or	CC	O	O
AF	NN	B-NP	B
duration	NN	I-NP	O
,	,	O	O
but	CC	O	O
produced	VBD	B-VP	O
conduction	NN	B-NP	O
acceleration	NN	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
verapamil	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
autonomic	JJ	B-NP	O
blockade	NN	I-NP	O
,	,	O	O
verapamil	NN	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
promote	VB	I-VP	O
AF	NN	B-NP	B
and	CC	O	O
increased	VBD	B-VP	O
,	,	O	O
rather	RB	B-PP	O
than	IN	I-PP	O
decreasing	VBG	B-VP	O
,	,	O	O
refractoriness	NN	B-NP	O
.	.	O	O

Neither	CC	O	O
verapamil	NN	B-NP	O
nor	CC	I-NP	O
diltiazem	NN	I-NP	O
affected	VBD	B-VP	O
atrial	JJ	B-NP	O
conduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
autonomic	JJ	B-NP	O
blockade	NN	I-NP	O
.	.	O	O

Epicardial	JJ	B-NP	O
mapping	NN	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
verapamil	NN	B-NP	O
promoted	VBD	B-VP	O
AF	NN	B-NP	B
by	IN	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
simultaneous	JJ	B-NP	O
wavefronts	NNS	I-NP	O
reflected	VBN	B-VP	O
by	IN	B-PP	O
separate	JJ	B-NP	O
zones	NNS	I-NP	O
of	IN	B-PP	O
reactivation	NN	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
cycle	NN	I-NP	O
.	.	O	O

Verapamil	NN	B-NP	O
promotes	VBZ	B-VP	O
AF	NN	B-NP	B
in	IN	B-PP	O
normal	JJ	B-NP	O
dogs	NNS	I-NP	O
by	IN	B-PP	O
promoting	VBG	B-VP	O
multiple	JJ	B-NP	O
circuit	NN	I-NP	O
reentry	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
effect	NN	I-NP	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
intact	JJ	B-NP	O
autonomic	JJ	I-NP	O
tone	NN	I-NP	O
and	CC	O	O
not	RB	B-VP	O
shared	VBN	I-VP	O
by	IN	B-PP	O
diltiazem	NN	B-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
,	,	O	O
bradycardia	NN	B-NP	B
,	,	O	O
and	CC	O	O
asystole	NN	B-NP	B
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
methylprednisolone	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
monitored	VBN	I-NP	O
patient	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
,	,	O	O
bradycardia	NN	B-NP	B
,	,	O	O
and	CC	O	O
asystole	NN	B-NP	B
after	IN	B-SBAR	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methylprednisolone	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
electrocardiographic	JJ	B-ADJP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
monitoring	NN	B-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
episode	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	B
cardiac	JJ	I-NP	B
disease	NN	I-NP	I
num	CD	B-NP	O
years	NNS	I-NP	O
earlier	RBR	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
pulmonary	JJ	I-NP	B
-	HYPH	I-NP	I
renal	JJ	I-NP	I
syndrome	NN	I-NP	I
with	IN	B-PP	O
hemoptysis	NN	B-NP	B
,	,	O	O
rapidly	RB	B-NP	O
progressive	JJ	I-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
,	,	O	O
and	CC	O	O
hypoxemia	NN	B-NP	B
that	WDT	B-NP	O
required	VBD	B-VP	O
mechanical	JJ	B-NP	O
ventilation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
receiving	VBG	B-VP	O
advanced	JJ	B-NP	O
cardiopulmonary	JJ	I-NP	O
resuscitation	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
cardiac	JJ	B-NP	O
rhythm	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ECG	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
junctional	JJ	I-NP	O
rhythm	NN	I-NP	O
without	IN	B-PP	O
ventricular	JJ	B-NP	B
arrhythmia	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
reviews	VBZ	B-VP	O
the	DT	B-NP	O
current	JJ	I-NP	O
proposed	VBN	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
sudden	JJ	B-NP	B
death	NN	I-NP	I
after	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
methylprednisolone	NN	I-NP	O
(	(	O	O
IVMP	NN	B-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
well	RB	I-VP	O
understood	VBN	I-VP	O
because	IN	B-SBAR	O
,	,	O	O
in	IN	B-PP	O
most	JJS	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
monitored	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
moment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
event	NN	I-NP	O
.	.	O	O

Rapid	JJ	B-NP	O
infusion	NN	I-NP	O
and	CC	O	O
underlying	VBG	B-VP	O
cardiac	JJ	B-NP	B
disease	NN	I-NP	I
were	VBD	B-VP	O
important	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
case	NN	I-NP	O
reported	VBN	B-VP	O
here	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
authors	NNS	I-NP	O
discount	VBP	B-VP	O
ventricular	JJ	B-NP	B
arrhythmia	NN	I-NP	I
as	IN	B-PP	O
the	DT	B-NP	O
main	JJ	I-NP	O
mechanism	NN	I-NP	O
.	.	O	O

Lifetime	NN	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
azidothymidine	NN	B-NP	O
(	(	O	O
AZT	NN	B-NP	O
)	)	O	O
produces	VBZ	B-VP	O
myelodysplasia	NN	B-NP	B
.	.	O	O

AZT	NNP	B-NP	O
has	VBZ	B-VP	O
induced	VBN	I-VP	O
a	DT	B-NP	O
macrocytic	JJ	I-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
AIDS	NN	B-NP	B
patients	NNS	I-NP	O
on	IN	B-PP	O
long	JJ	B-NP	O
term	NN	I-NP	O
AZT	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
generally	RB	I-VP	O
assumed	VBN	I-VP	O
that	IN	B-SBAR	O
DNA	NN	B-NP	O
elongation	NN	I-NP	O
is	VBZ	B-VP	O
stopped	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
insertion	NN	I-NP	O
of	IN	B-PP	O
AZT	NNP	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
chain	NN	I-NP	O
in	IN	B-PP	O
place	NN	B-NP	O
of	IN	B-PP	O
thymidine	NN	B-NP	O
thus	RB	B-ADVP	O
preventing	VBG	B-VP	O
the	DT	B-NP	O
phosphate	NN	I-NP	O
hydroxyl	NN	I-NP	O
linkages	NNS	I-NP	O
and	CC	O	O
therefore	RB	B-VP	O
suppresses	VBZ	I-VP	O
hemopoietic	JJ	B-NP	O
progenitor	NN	I-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
early	JJ	I-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
differentiation	NN	B-NP	O
.	.	O	O

CBA	NN	B-NP	O
/	SYM	I-NP	O
Ca	NN	I-NP	O
male	JJ	I-NP	O
mice	NNS	I-NP	O
started	VBN	B-VP	O
on	IN	B-PP	O
AZT	NNP	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
H2O	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
and	CC	O	O
kept	VBD	B-VP	O
on	IN	B-PP	O
it	PRP	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
when	WRB	B-ADVP	O
dosage	NN	B-NP	O
reduced	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
H2O	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
,	,	O	O
another	DT	B-NP	O
group	NN	I-NP	O
removed	VBN	B-VP	O
from	IN	B-PP	O
AZT	NNP	B-NP	O
to	TO	B-VP	O
see	VB	I-VP	O
recovery	NN	B-NP	O
,	,	O	O
and	CC	O	O
third	JJ	B-NP	O
group	NN	I-NP	O
remained	VBD	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
mice	NNS	I-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
had	VBD	B-VP	O
average	JJ	B-NP	O
platelet	NN	I-NP	O
counts	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
.	.	O	O

Histological	JJ	B-NP	O
examination	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
such	JJ	B-NP	O
thrombocytopenia	NN	I-NP	B
showed	VBD	B-VP	O
changes	NNS	B-NP	O
compatible	JJ	B-ADJP	O
with	IN	B-PP	O
myelodysplastic	JJ	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
MDS	NN	B-NP	B
)	)	O	O
.	.	O	O

A	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
histological	JJ	B-NP	O
patterns	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hypocellular	JJ	B-NP	O
myelodysplasia	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hypersegmented	JJ	B-NP	O
myelodysplastic	JJ	I-NP	B
granulocytosis	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hypercellular	JJ	B-NP	O
marrow	NN	I-NP	O
with	IN	B-PP	O
abnormal	JJ	B-NP	O
megakaryocytes	NNS	I-NP	O
with	IN	B-PP	O
bizarre	JJ	B-NP	O
nuclei	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
megakaryocytic	JJ	B-NP	O
myelosis	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
hyperplastic	JJ	I-NP	B
marrow	NN	I-NP	I
,	,	O	O
dysmyelopoiesis	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
hypocellular	JJ	I-NP	B
marrow	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
myelodysplasia	NN	B-NP	B
with	IN	B-PP	O
dyserythropoiesis	NN	B-NP	B
,	,	O	O
hemosiderosis	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
hypocellular	JJ	I-NP	B
marrow	NN	I-NP	I
.	.	O	O

Above	IN	B-PP	O
mentioned	VBN	B-NP	O
AZT	NNP	I-NP	O
incorporation	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
induced	VBN	I-VP	O
an	DT	B-NP	O
ineffective	JJ	I-NP	O
hemopoiesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
primitive	JJ	I-NP	O
hemopoietic	JJ	I-NP	O
progenitor	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
seen	VBN	I-VP	O
commonly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
myelodysplastic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Influence	NN	B-NP	O
of	IN	B-PP	O
diet	NN	B-NP	O
free	JJ	B-ADJP	O
of	IN	B-PP	O
NAD	NN	B-NP	O
-	HYPH	O	O
precursors	NNS	B-NP	O
on	IN	B-PP	O
acetaminophen	NN	B-NP	O
hepatotoxicity	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
demonstrated	VBD	B-VP	O
the	DT	B-NP	O
hepatoprotective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
nicotinic	JJ	B-NP	O
acid	NN	I-NP	O
amide	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
poly	NN	B-NP	O
(	(	O	O
ADP	NN	B-NP	O
-	HYPH	B-NP	O
ribose	NN	I-NP	O
)	)	O	O
polymerase	NN	B-NP	O
(	(	O	O
PARP	NN	B-NP	O
;	:	O	O
EC	NNP	B-NP	O
num	CD	I-NP	O
)	)	O	O
on	IN	B-PP	O
mice	NNS	B-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
acetaminophen	NN	B-NP	O
(	(	O	O
AAP	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
hepatitis	NN	I-NP	B
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
AAP	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
injury	NN	I-NP	I
involves	VBZ	B-VP	O
a	DT	B-NP	O
step	NN	I-NP	O
which	WDT	B-NP	O
depends	VBZ	B-VP	O
on	IN	B-PP	O
adenoribosylation	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
investigates	VBZ	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
diet	NN	I-NP	O
free	JJ	B-ADJP	O
of	IN	B-PP	O
precursors	NNS	B-NP	O
of	IN	B-PP	O
NAD	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
substrate	NN	I-NP	O
on	IN	B-PP	O
which	WDT	B-NP	O
PARP	NN	B-NP	O
acts	VBZ	B-VP	O
,	,	O	O
in	IN	B-PP	O
female	JJ	B-NP	O
NMRI	NN	I-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
AAP	NN	B-NP	O
hepatitis	NN	I-NP	B
and	CC	O	O
evaluates	VBZ	B-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
simultaneous	JJ	B-NP	O
ethanol	NN	I-NP	O
consumption	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

Liver	NN	B-NP	B
injuries	NNS	I-NP	I
were	VBD	B-VP	O
quantified	VBN	I-VP	O
as	IN	B-PP	O
serum	NN	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
-	HYPH	O	O
oxaloacetate	NN	B-NP	O
transaminase	NN	I-NP	O
(	(	O	O
GOT	NN	B-NP	O
)	)	O	O
and	CC	O	O
glutamate	NN	B-NP	O
-	HYPH	O	O
pyruvate	NN	B-NP	O
transaminase	NN	I-NP	O
(	(	O	O
GPT	NN	B-NP	O
)	)	O	O
.	.	O	O

While	IN	B-SBAR	O
AAP	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
transaminase	NN	I-NP	O
activities	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
kept	VBN	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
standard	JJ	I-NP	O
laboratory	NN	I-NP	O
diet	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
exacerbated	VBN	I-VP	O
by	IN	B-PP	O
ethanol	NN	B-NP	O
and	CC	O	O
inhibited	VBN	B-VP	O
by	IN	B-PP	O
nicotinic	JJ	B-NP	O
acid	NN	I-NP	O
amide	NN	I-NP	O
(	(	O	O
NAA	NN	B-NP	O
)	)	O	O
,	,	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
fed	VBN	B-VP	O
a	DT	B-NP	O
diet	NN	I-NP	O
free	JJ	B-ADJP	O
of	IN	B-PP	O
precursors	NNS	B-NP	O
of	IN	B-PP	O
NAD	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
only	RB	B-NP	O
minor	JJ	I-NP	O
increases	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
transaminase	NN	I-NP	O
activities	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
AAP	NN	B-NP	O
,	,	O	O
and	CC	O	O
unlike	IN	B-PP	O
the	DT	B-NP	O
exacerbation	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
ethanol	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
standard	JJ	I-NP	O
diet	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
liver	NN	I-NP	B
damage	NN	I-NP	I
was	VBD	B-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
ethanol	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
further	JJ	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
,	,	O	O
when	WRB	B-ADVP	O
NAA	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
ethanol	NN	B-NP	O
/	SYM	B-NP	O
AAP	NN	I-NP	O
-	HYPH	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
evidence	NN	B-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
AAP	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
hepatitis	NN	I-NP	B
and	CC	O	O
its	PRP$	B-NP	O
exacerbation	NN	I-NP	O
by	IN	B-PP	O
ethanol	NN	B-NP	O
can	MD	B-VP	O
either	CC	O	O
be	VB	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
end	NN	B-NP	O
-	HYPH	I-NP	O
product	NN	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
PARP	NN	B-NP	O
by	IN	B-PP	O
NAA	NN	B-NP	O
or	CC	B-PP	O
by	IN	B-PP	O
dietary	JJ	B-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
enzyme	NN	I-NP	O
s	NN	I-NP	O
substrate	NN	I-NP	O
NAD	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
see	VBP	B-VP	O
the	DT	B-NP	O
main	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
NAA	NN	B-NP	O
as	IN	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
combinational	JJ	I-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
pharmaceutical	JJ	B-NP	O
preparations	NNS	I-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
avoid	VB	I-VP	O
hepatic	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
analgesic	JJ	B-ADJP	O
.	.	O	O

Antiarrhythmic	JJ	B-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
cibenzoline	NN	B-NP	O
on	IN	B-PP	O
canine	JJ	B-NP	O
ventricular	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O

Using	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
stage	NN	I-NP	O
coronary	JJ	I-NP	O
ligation	NN	I-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
digitalis	NN	B-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
and	CC	O	O
adrenaline	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
canine	JJ	I-NP	O
ventricular	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
,	,	O	O
antiarrhythmic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cibenzoline	NN	B-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
minimum	JJ	I-NP	O
effective	JJ	I-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
for	IN	B-PP	O
each	DT	B-NP	O
arrhythmia	NN	I-NP	B
model	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

Cibenzoline	NN	B-NP	O
suppressed	VBD	B-VP	O
all	PDT	B-NP	O
the	DT	I-NP	O
arrhythmias	NNS	I-NP	B
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
minimum	JJ	I-NP	O
effective	JJ	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
for	IN	B-PP	O
arrhythmias	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
coronary	JJ	I-NP	O
ligation	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
coronary	JJ	I-NP	O
ligation	NN	I-NP	O
,	,	O	O
digitalis	NN	B-NP	O
,	,	O	O
and	CC	O	O
adrenaline	NN	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
concentration	NN	I-NP	O
for	IN	B-PP	O
adrenaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
arrhythmia	NN	I-NP	B
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
arrhythmias	NNS	B-NP	B
.	.	O	O

This	DT	B-NP	O
pharmacological	JJ	I-NP	O
profile	NN	I-NP	O
is	VBZ	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
mexiletine	NN	B-NP	O
and	CC	I-NP	O
tocainide	NN	I-NP	O
,	,	O	O
and	CC	O	O
all	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
have	VBP	B-VP	O
central	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
stimulant	JJ	B-NP	O
action	NN	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
cibenzoline	NN	B-NP	O
had	VBD	B-VP	O
only	RB	B-NP	O
weak	JJ	I-NP	O
hypotensive	JJ	I-NP	B
and	CC	I-NP	O
sinus	NN	I-NP	O
node	NN	I-NP	O
depressive	JJ	I-NP	B
effects	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
orally	RB	B-ADJP	O
active	JJ	I-ADJP	O
when	WRB	B-ADVP	O
given	VBN	B-PP	O
to	TO	B-PP	O
coronary	JJ	B-NP	O
ligation	NN	I-NP	O
arrhythmia	NN	I-NP	B
dogs	NNS	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
clinical	JJ	I-NP	O
usefulness	NN	I-NP	O
is	VBZ	B-VP	O
expected	VBN	I-VP	O
.	.	O	O

Immunopathology	NN	B-NP	O
of	IN	B-PP	O
penicillamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
glomerular	JJ	I-NP	B
disease	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
developed	VBD	B-VP	O
heavy	JJ	B-NP	O
proteinuria	NN	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
.	.	O	O

Light	NN	B-NP	O
microscopy	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
biopsy	NN	I-NP	O
samples	NNS	I-NP	O
showed	VBD	B-VP	O
minimal	JJ	B-NP	O
glomerular	JJ	I-NP	O
capillary	JJ	I-NP	O
wall	NN	I-NP	O
thickening	VBG	B-VP	O
and	CC	O	O
mesangial	JJ	B-NP	O
matrix	NN	I-NP	O
increase	NN	I-NP	O
,	,	O	O
or	CC	O	O
no	DT	B-NP	O
departure	NN	I-NP	O
from	IN	B-PP	O
normal	JJ	B-ADJP	O
.	.	O	O

Electron	NN	B-NP	O
microscopy	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
revealed	VBD	B-VP	O
subepithelial	JJ	B-NP	O
electron	NN	I-NP	O
-	HYPH	B-NP	O
dense	JJ	I-NP	O
deposits	NNS	I-NP	O
,	,	O	O
fusion	NN	B-NP	O
of	IN	B-PP	O
epithelial	JJ	B-NP	O
cell	NN	I-NP	O
foot	NN	I-NP	O
processes	NNS	I-NP	O
,	,	O	O
and	CC	O	O
evidence	NN	B-NP	O
of	IN	B-PP	O
mesangial	JJ	B-NP	O
cell	NN	I-NP	O
hyperactivity	NN	I-NP	O
.	.	O	O

Immunofluorescence	NN	B-NP	O
microscopy	NN	I-NP	O
demonstrated	VBD	B-VP	O
granular	JJ	B-NP	O
capillary	JJ	I-NP	O
wall	NN	I-NP	O
deposits	NNS	I-NP	O
of	IN	B-PP	O
IgG	NN	B-NP	O
and	CC	I-NP	O
C3	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
early	JJ	B-NP	O
membranous	JJ	I-NP	B
glomerulonephritis	NN	I-NP	I
,	,	O	O
differences	NNS	B-NP	O
being	VBG	B-VP	O
observed	VBN	I-VP	O
however	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
staining	VBG	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	I-NP	O
complement	NN	I-NP	O
components	NNS	I-NP	O
C1q	NN	I-NP	O
and	CC	I-NP	O
C4	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
tentatively	RB	I-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
complement	NN	B-NP	O
was	VBD	B-VP	O
activated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
classical	JJ	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

Ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
from	IN	B-PP	O
diatrizoate	NN	B-NP	O
with	IN	B-PP	O
and	CC	B-PP	O
without	IN	B-PP	O
chelating	VBG	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
Renografin	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
Hypaque	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
by	IN	B-PP	O
selective	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
of	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

Renografin	NN	B-NP	O
contains	VBZ	B-VP	O
the	DT	B-NP	O
chelating	VBG	I-NP	O
agents	NNS	I-NP	O
sodium	NN	I-NP	O
citrate	NN	I-NP	O
and	CC	O	O
disodium	NN	B-NP	O
edetate	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
Hypaque	NN	B-NP	O
contains	VBZ	B-VP	O
calcium	NN	B-NP	O
disodium	NN	I-NP	O
edetate	NN	I-NP	O
and	CC	O	O
no	DT	B-NP	O
sodium	NN	I-NP	O
citrate	NN	I-NP	O
.	.	O	O

Ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
occurred	VBD	B-VP	O
significantly	RB	B-ADVP	O
more	RBR	I-ADVP	O
often	RB	I-ADVP	O
with	IN	B-PP	O
Renografin	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
chelating	VBG	B-NP	O
agents	NNS	I-NP	O
contribute	VBP	B-VP	O
to	TO	B-PP	O
toxicity	NN	B-NP	B
in	IN	B-PP	O
coronary	JJ	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

Rapid	JJ	B-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
anticoagulation	NN	B-NP	O
reduces	VBZ	B-VP	O
hemorrhage	NN	B-NP	B
volume	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
mouse	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
.	.	O	O

Warfarin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
(	(	O	O
W	NN	B-NP	O
-	HYPH	B-NP	O
ICH	NN	I-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
stroke	NN	B-NP	B
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
consensus	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
W	NN	B-NP	O
-	HYPH	I-NP	O
ICH	NN	I-NP	B
.	.	O	O

Using	VBG	B-VP	O
a	DT	B-NP	O
mouse	NN	I-NP	O
model	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
tested	VBD	B-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
rapid	JJ	I-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
anticoagulation	NN	B-NP	O
using	VBG	B-VP	O
human	JJ	B-NP	O
prothrombin	NN	I-NP	O
complex	NN	I-NP	O
concentrate	NN	I-NP	O
(	(	O	O
PCC	NN	B-NP	O
)	)	O	O
can	MD	B-VP	O
reduce	VB	I-VP	O
hemorrhagic	JJ	B-NP	O
blood	NN	I-NP	O
volume	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
CD	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
warfarin	NN	B-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
a	DT	O	O
mean	JJ	O	O
(	(	O	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
s.d.	NN	B-NP	O
)	)	O	O
International	NNP	B-NP	O
Normalized	NNP	I-NP	O
Ratio	NNP	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
.	.	O	O

First	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
intravenous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
PCC	NN	I-NP	O
rapidly	RB	B-ADVP	O
reversed	VBD	B-VP	O
anticoagulation	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Second	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
stereotactic	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
collagenase	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	I-VP	O
induce	VB	I-VP	O
hemorrhage	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
striatum	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
PCC	NN	B-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
i.v.	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
hemorrhage	NN	B-NP	B
induction	NN	I-NP	O
,	,	O	O
hemorrhagic	JJ	B-NP	O
blood	NN	I-NP	O
volume	NN	I-NP	O
was	VBD	B-VP	O
quantified	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
photometric	JJ	I-NP	O
hemoglobin	NN	I-NP	O
assay	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
hemorrhagic	JJ	I-NP	O
blood	NN	I-NP	O
volume	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
PCC	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
saline	NN	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
saline	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mice	NNS	I-NP	O
developed	VBD	B-VP	O
large	JJ	B-NP	O
hematomas	NNS	I-NP	B
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
such	JJ	B-NP	O
extensive	JJ	I-NP	O
lesions	NNS	I-NP	O
were	VBD	B-VP	O
never	RB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
PCC	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
provide	VBP	B-VP	O
experimental	JJ	B-NP	O
data	NNS	I-NP	O
suggesting	VBG	B-VP	O
PCC	NN	B-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
acute	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
W	NN	B-NP	O
-	HYPH	B-NP	O
ICH	NN	I-NP	B
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
reducing	VBG	B-VP	O
hemorrhagic	JJ	B-NP	O
blood	NN	I-NP	O
volume	NN	I-NP	O
.	.	O	O

Future	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
potential	NN	I-NP	O
emerging	VBG	B-VP	O
from	IN	B-PP	O
our	PRP$	B-NP	O
finding	NN	I-NP	O
for	IN	B-PP	O
human	JJ	B-NP	O
W	NN	I-NP	O
-	HYPH	B-NP	O
ICH	NN	I-NP	B
.	.	O	O

Impact	NN	B-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
exposure	NN	I-NP	O
after	IN	B-PP	O
pregnancy	NN	B-NP	O
recognition	NN	I-NP	O
on	IN	B-PP	O
ultrasonographic	JJ	B-NP	O
fetal	JJ	I-NP	O
growth	NN	I-NP	O
measures	NNS	I-NP	O
.	.	O	O

More	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
decades	NNS	I-NP	O
after	IN	B-PP	O
Jones	NNP	B-NP	O
and	CC	I-NP	O
Smith	NNP	I-NP	O
reported	VBD	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
devastation	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
alcohol	NN	B-NP	O
exposure	NN	I-NP	O
on	IN	B-PP	O
fetal	JJ	B-NP	O
development	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
heavy	JJ	B-NP	O
drinking	NN	I-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
remain	VBP	B-VP	O
relatively	RB	B-ADJP	O
unchanged	JJ	I-ADJP	O
.	.	O	O

Early	RB	B-NP	O
identification	NN	I-NP	O
of	IN	B-PP	O
fetal	JJ	B-NP	O
alcohol	NN	I-NP	O
exposure	NN	I-NP	O
and	CC	O	O
maternal	JJ	B-NP	O
abstinence	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
better	JJR	B-NP	O
infant	NN	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
biometry	NN	B-NP	O
for	IN	B-PP	O
detecting	VBG	B-VP	O
alcohol	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
fetal	JJ	I-NP	O
growth	NN	I-NP	B
impairment	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
obtained	VBD	B-VP	O
fetal	JJ	B-NP	O
ultrasound	JJ	I-NP	O
measures	NNS	I-NP	O
from	IN	B-PP	O
routine	JJ	B-NP	O
ultrasound	JJ	I-NP	O
examinations	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
pregnant	JJ	I-NP	O
hazardous	JJ	I-NP	O
drinkers	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
brief	JJ	I-NP	O
alcohol	NN	I-NP	O
intervention	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
fetal	JJ	I-NP	O
measures	NNS	I-NP	O
for	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
quit	VBP	B-VP	O
after	IN	B-PP	O
learning	VBG	B-VP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
pregnancies	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
measures	NNS	B-NP	O
for	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
continued	VBD	B-VP	O
some	DT	B-NP	O
drinking	NN	I-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
pregnancies	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
intensity	NN	B-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
consumption	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
poorer	JJR	B-NP	O
fetal	JJ	I-NP	O
outcomes	NNS	I-NP	O
,	,	O	O
separate	JJ	B-NP	O
analyses	NNS	I-NP	O
were	VBD	B-VP	O
conducted	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
heavy	JJ	I-NP	O
alcohol	NN	I-NP	O
consumers	NNS	I-NP	O
.	.	O	O

Fetal	JJ	B-NP	O
measures	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
heavy	NN	I-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
fetuses	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
measures	NNS	B-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
nondrinking	JJ	I-NP	O
group	NN	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
representative	JJ	B-ADJP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
,	,	I-NP	O
uncomplicated	JJ	I-NP	O
pregnancies	NNS	I-NP	O
from	IN	B-PP	O
our	PRP$	B-NP	O
clinics	NNS	I-NP	O
.	.	O	O

Analyses	NNS	B-NP	O
of	IN	B-PP	O
covariance	NN	B-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
there	EX	B-NP	O
were	VBD	B-VP	O
differences	NNS	B-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
after	IN	B-PP	O
controlling	VBG	B-VP	O
for	IN	B-PP	O
influences	NNS	B-NP	O
of	IN	B-PP	O
gestational	JJ	B-NP	O
age	NN	I-NP	O
and	CC	I-NP	O
drug	NN	I-NP	B
abuse	NN	I-NP	I
.	.	O	O

Nearly	RB	B-NP	O
half	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pregnant	JJ	I-NP	O
drinkers	NNS	I-NP	O
abstained	VBN	B-VP	O
after	IN	B-PP	O
learning	VBG	B-VP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
pregnancies	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
women	NNS	B-NP	O
reportedly	RB	B-ADVP	O
quit	VBP	B-VP	O
drinking	VBG	I-VP	O
early	RB	B-ADVP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
pregnancies	NNS	I-NP	O
,	,	O	O
fetal	JJ	B-NP	O
growth	NN	I-NP	O
measures	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
significantly	RB	I-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
alcohol	NN	I-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
group	NN	I-NP	O
,	,	O	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
prior	JJ	B-NP	O
drinking	NN	I-NP	O
patterns	NNS	I-NP	O
.	.	O	O

Any	DT	B-NP	O
alcohol	NN	I-NP	O
consumption	NN	I-NP	O
postpregnancy	NN	I-NP	O
recognition	NN	I-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
heavy	JJ	I-NP	O
drinkers	NNS	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
reduced	VBN	B-NP	B
cerebellar	JJ	I-NP	I
growth	NN	I-NP	I
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
decreased	VBN	B-NP	B
cranial	NN	I-NP	I
to	TO	B-PP	I
body	NN	B-NP	I
growth	NN	I-NP	I
in	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
either	CC	O	O
quit	NN	B-NP	O
drinking	NN	I-NP	O
or	CC	O	O
who	WP	B-NP	O
were	VBD	B-VP	O
nondrinkers	NNS	B-NP	O
.	.	O	O

Amphetamine	NN	B-NP	O
abuse	NN	I-NP	O
was	VBD	B-VP	O
predictive	JJ	B-ADJP	O
of	IN	B-PP	O
larger	JJR	B-NP	O
cranial	NN	I-NP	O
to	TO	B-PP	O
body	NN	B-NP	O
growth	NN	I-NP	O
ratios	NNS	I-NP	O
.	.	O	O

Alterations	NNS	B-NP	O
in	IN	B-PP	O
fetal	JJ	B-NP	O
biometric	JJ	I-NP	O
measurements	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
among	IN	B-PP	O
the	DT	B-NP	O
heavy	JJ	I-NP	O
drinkers	NNS	I-NP	O
only	RB	B-ADVP	O
when	WRB	B-ADVP	O
they	PRP	B-NP	O
continued	VBD	B-VP	O
drinking	VBG	I-VP	O
after	IN	B-PP	O
becoming	VBG	B-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
pregnancies	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
reliance	NN	I-NP	O
on	IN	B-PP	O
self	NN	B-NP	O
-	HYPH	O	O
reported	VBN	B-NP	O
drinking	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
limitation	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
these	DT	B-NP	O
findings	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
benefits	NNS	I-NP	O
of	IN	B-PP	O
early	JJ	B-NP	O
abstinence	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
ultrasound	JJ	B-NP	O
examinations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
fetal	JJ	B-NP	O
alcohol	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
Thai	JJ	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
overactive	JJ	B-NP	B
bladder	NN	I-NP	I
after	IN	B-PP	O
tolterodine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
Thai	JJ	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
overactive	JJ	B-NP	B
bladder	NN	I-NP	I
(	(	O	O
OAB	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
tolterodine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
women	NNS	I-NP	O
(	(	O	O
aged	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
diagnosed	VBN	B-VP	O
as	IN	B-PP	O
having	VBG	B-VP	O
OAB	NN	B-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
Gynecology	NNP	I-NP	O
Clinic	NNP	I-NP	O
,	,	O	O
King	NNP	B-NP	O
Chulalongkorn	NNP	I-NP	O
Memorial	NNP	I-NP	O
Hospital	NNP	I-NP	O
from	IN	B-PP	O
January	NNP	B-NP	O
to	TO	B-PP	O
April	NNP	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Tolterodine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
,	,	O	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
changes	NNS	B-NP	O
in	IN	B-PP	O
micturition	NN	B-NP	O
diary	JJ	I-NP	O
variables	NNS	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

Short	JJ	B-NP	O
form	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
SF36	NN	B-NP	O
)	)	O	O
questionaires	VBZ	B-VP	O
(	(	O	O
Thai	JJ	B-NP	O
version	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
given	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
all	DT	B-NP	O
micturition	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
nocturia	NN	B-NP	B
episodes	NNS	I-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
per	IN	B-PP	O
night	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
dry	JJ	B-NP	B
month	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
reporting	VBG	B-VP	O
a	DT	B-NP	O
moderate	JJ	I-NP	O
degree	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
case	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
degree	NN	I-NP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
case	NN	I-NP	O
withdrew	VBD	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
dry	JJ	I-NP	B
mouth	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
SF	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
scores	NNS	I-NP	O
changed	VBD	B-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
domains	NNS	I-NP	O
of	IN	B-PP	O
physical	JJ	B-NP	O
functioning	NN	I-NP	O
,	,	O	O
role	NN	B-NP	O
function	NN	I-NP	O
emotional	JJ	B-NP	O
,	,	I-NP	O
social	JJ	I-NP	O
function	NN	I-NP	O
and	CC	O	O
mental	JJ	B-NP	O
heath	NN	I-NP	O
.	.	O	O

Tolterodine	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
its	PRP$	B-NP	O
effects	NNS	I-NP	O
improved	VBD	B-VP	O
the	DT	B-NP	O
quality	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
in	IN	B-PP	O
Thai	JJ	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
.	.	O	O

Absence	NN	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
cerebral	JJ	I-NP	O
vasoconstriction	NN	I-NP	O
after	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
subarachnoid	JJ	B-NP	B
hemorrhage	NN	I-NP	I
.	.	O	O

Cocaine	NN	B-NP	O
use	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
neurovascular	JJ	B-NP	B
complications	NNS	I-NP	I
,	,	O	O
including	VBG	B-PP	O
arterial	JJ	B-NP	O
vasoconstriction	NN	I-NP	O
and	CC	I-NP	O
vasculitis	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
are	VBP	B-VP	O
few	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
angiographic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
on	IN	B-PP	O
human	JJ	B-NP	O
cerebral	JJ	I-NP	O
arteries	NNS	I-NP	O
.	.	O	O

Information	NN	B-NP	O
on	IN	B-PP	O
these	DT	B-NP	O
effects	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
angiograms	NNS	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
subarachnoid	NN	I-NP	B
hemorrhage	NN	I-NP	I
(	(	O	O
SAH	NN	B-NP	B
)	)	O	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
angiography	NN	B-NP	O
shortly	RB	B-ADVP	O
after	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
screened	VBD	B-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
SAH	NN	B-NP	B
retrospectively	RB	B-ADVP	O
and	CC	O	O
identified	VBD	B-VP	O
those	DT	B-NP	O
with	IN	B-PP	O
positive	JJ	B-NP	O
urine	NN	I-NP	O
toxicology	NN	I-NP	O
for	IN	B-PP	O
cocaine	NN	B-NP	O
or	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
.	.	O	O

Quantitative	JJ	B-NP	O
arterial	JJ	I-NP	O
diameter	NN	I-NP	O
measurements	NNS	I-NP	O
from	IN	B-PP	O
angiograms	NNS	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
measurements	NNS	B-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
SAH	NN	B-NP	B
who	WP	B-NP	O
were	VBD	B-VP	O
matched	VBN	I-VP	O
for	IN	B-PP	O
factors	NNS	B-NP	O
known	VBN	B-VP	O
to	TO	I-VP	O
influence	VB	I-VP	O
arterial	JJ	B-NP	O
diameter	NN	I-NP	O
.	.	O	O

Qualitative	JJ	B-NP	O
comparisons	NNS	I-NP	O
of	IN	B-PP	O
small	JJ	B-NP	O
artery	NN	I-NP	O
changes	NNS	I-NP	O
also	RB	B-ADVP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
positive	JJ	B-NP	O
cocaine	NN	I-NP	O
toxicology	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
diameters	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
intradural	JJ	I-NP	O
internal	JJ	I-NP	O
carotid	NN	I-NP	O
,	,	O	O
sphenoidal	JJ	B-NP	O
segment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
middle	JJ	I-NP	O
cerebral	NN	I-NP	O
,	,	O	O
precommunicating	VBG	B-VP	O
segment	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
cerebral	NN	I-NP	O
,	,	O	O
or	CC	O	O
basilar	JJ	B-NP	O
arteries	NNS	I-NP	O
(	(	O	O
p	NN	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
for	IN	B-PP	O
all	DT	B-NP	O
comparisons	NNS	I-NP	O
,	,	O	O
unpaired	JJ	B-NP	O
t	NN	I-NP	O
-	HYPH	B-NP	O
tests	NNS	I-NP	O
)	)	O	O
.	.	O	O

There	EX	B-NP	O
also	RB	B-ADVP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
when	WRB	B-ADVP	O
expressing	VBG	B-VP	O
diameters	NNS	B-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
sum	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
precommunicating	VBG	I-NP	O
segment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
cerebral	JJ	I-NP	O
+	JJ	I-NP	O
sphenoidal	JJ	I-NP	O
segment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
middle	JJ	I-NP	O
cerebral	JJ	I-NP	O
+	SYM	I-NP	O
supraclinoid	JJ	I-NP	O
internal	JJ	I-NP	O
carotid	NN	I-NP	O
artery	NN	I-NP	O
+	CC	O	O
basilar	JJ	B-NP	O
artery	NN	I-NP	O
divided	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
diameter	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
petrous	JJ	I-NP	O
internal	JJ	I-NP	O
carotid	NN	I-NP	O
artery	NN	I-NP	O
(	(	O	O
p	NN	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
,	,	O	O
unpaired	JJ	B-NP	O
t	NN	I-NP	O
-	HYPH	B-NP	O
tests	NNS	I-NP	O
)	)	O	O
.	.	O	O

Qualitative	JJ	B-NP	O
assessments	NNS	I-NP	O
showed	VBD	B-VP	O
num	CD	B-NP	O
arterial	JJ	I-NP	O
irregularities	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
distal	JJ	I-NP	O
vasculature	NN	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
quantitative	JJ	I-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
narrowing	NN	B-NP	O
of	IN	B-PP	O
large	JJ	B-NP	O
cerebral	JJ	I-NP	O
arteries	NNS	I-NP	O
or	CC	O	O
qualitative	JJ	B-NP	O
angiographic	JJ	I-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
distal	JJ	B-NP	O
narrowing	NN	I-NP	O
or	CC	I-NP	O
vasculitis	NN	I-NP	B
could	MD	B-VP	O
be	VB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
angiography	NN	B-NP	O
after	IN	B-PP	O
aneurysmal	JJ	B-NP	B
SAH	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
following	VBG	B-PP	O
chemotherapy	NN	B-NP	O
for	IN	B-PP	O
stage	NN	B-NP	O
num	CD	I-NP	O
diffuse	JJ	I-NP	O
large	JJ	I-NP	O
B	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
gastric	JJ	I-NP	B
lymphoma	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
myotonic	JJ	B-NP	B
dystrophy	NN	I-NP	I
(	(	O	O
Steinert	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
)	)	O	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
unusual	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
diffuse	JJ	B-NP	O
B	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
gastric	JJ	I-NP	B
lymphoma	NN	I-NP	I
and	CC	O	O
myotonic	JJ	B-NP	B
dystrophy	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
adult	JJ	B-NP	O
muscular	JJ	I-NP	B
dystrophy	NN	I-NP	I
,	,	O	O
and	CC	O	O
sudden	JJ	B-NP	O
atrial	JJ	I-NP	B
fibrillation	NN	I-NP	I
following	VBG	B-PP	O
num	CD	B-NP	O
cycle	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
chemotherapy	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
patient	NN	I-NP	O
.	.	O	O

Atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
or	CC	O	O
other	JJ	B-NP	O
cardiac	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
are	VBP	B-VP	O
unusual	JJ	B-NP	O
complications	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
cardiac	JJ	I-NP	B
toxicity	NN	I-NP	I
intrinsically	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
aggressive	JJ	I-NP	O
chemotherapy	NN	I-NP	O
employed	VBN	B-VP	O
could	MD	B-VP	O
function	VB	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
triggering	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
predisposed	VBN	I-NP	O
myocardium	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
metastatic	JJ	I-NP	O
renal	JJ	I-NP	B
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
and	CC	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
metastatic	JJ	I-NP	O
renal	JJ	I-NP	B
cell	NN	I-NP	I
cancer	NN	I-NP	I
and	CC	O	O
to	TO	B-VP	O
measure	VB	I-VP	O
changes	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
angiogenic	JJ	I-NP	O
factor	NN	I-NP	O
,	,	O	O
vascular	JJ	B-NP	O
endothelial	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
(	(	O	O
VEGF	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
with	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
using	VBG	B-VP	O
an	DT	B-NP	O
intra	AFX	I-NP	O
-	HYPH	I-NP	O
patient	NN	I-NP	O
dose	NN	I-NP	O
escalation	NN	I-NP	O
schedule	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
began	VBD	B-VP	O
thalidomide	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
and	CC	O	O
escalated	VBN	B-VP	O
as	IN	B-SBAR	O
tolerated	VBN	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
d	NN	B-NP	O
by	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
had	VBN	I-VP	O
previous	JJ	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
IL	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
performance	NN	B-NP	O
status	NN	I-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
plasma	NN	I-NP	O
VEGF165	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
dual	JJ	B-NP	O
monoclonal	JJ	I-NP	O
ELISA	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
hepatic	JJ	B-NP	O
and	CC	I-NP	O
pulmonary	JJ	I-NP	O
metastases	NNS	I-NP	B
,	,	O	O
num	CD	B-NP	O
minor	JJ	I-NP	O
response	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
stable	JJ	B-ADJP	O
for	IN	B-PP	O
over	IN	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Somnolence	NN	B-NP	B
and	CC	I-NP	O
constipation	NN	I-NP	B
were	VBD	B-VP	O
prominent	JJ	B-NP	O
toxicities	NNS	I-NP	B
and	CC	O	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
tolerate	VB	I-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
day	NN	I-NP	O
dose	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
plasma	NN	I-NP	O
VEGF165	NN	I-NP	O
levels	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
with	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	B
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
doses	NNS	B-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
was	VBD	B-VP	O
difficult	JJ	B-ADJP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
population	NN	I-NP	O
,	,	O	O
however	RB	B-NP	O
lower	JJR	I-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
practical	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	I-NP	O
response	NN	I-NP	O
relationship	NN	I-NP	O
,	,	O	O
if	IN	B-SBAR	O
any	DT	B-NP	O
,	,	O	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
for	IN	B-PP	O
renal	JJ	B-NP	B
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
striatum	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
target	NN	I-NP	O
for	IN	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
rigor	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
mGluR1	NN	B-NP	O
,	,	O	O
but	CC	B-CONJP	O
not	RB	I-CONJP	O
an	DT	B-NP	O
agonist	NN	I-NP	O
of	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
metabotropic	JJ	I-NP	O
glutamate	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
find	VB	I-VP	O
out	RP	B-PRT	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
metabotropic	JJ	I-NP	O
receptor	NN	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
group	NN	I-NP	O
num	CD	B-NP	O
mGluRs	NNS	I-NP	O
,	,	O	O
localized	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
antiparkinsonian	JJ	B-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Haloperidol	NN	B-NP	O
induced	VBD	B-VP	O
parkinsonian	NN	B-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
,	,	O	O
measured	VBN	B-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
resistance	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
s	VBZ	B-VP	O
hind	NN	B-NP	O
foot	NN	I-NP	O
to	TO	B-PP	O
passive	JJ	B-NP	O
flexion	NN	I-NP	O
and	CC	I-NP	O
extension	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
ankle	NN	I-NP	O
joint.	NN	I-NP	O
(	(	O	O
RS	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
aminoindan	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dicarboxylic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
AIDA	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
potent	JJ	I-NP	O
and	CC	I-NP	O
selective	JJ	I-NP	O
mGluR1	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
or	CC	O	O
(	(	O	O
2R	NN	B-NP	O
,	,	O	O
4R	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
aminopyrrolidine	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dicarboxylate	NN	I-NP	O
(	(	O	O
2R	NN	B-NP	O
,	,	O	O
4R	NN	B-NP	O
-	HYPH	B-NP	O
APDC	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
group	NN	I-NP	O
num	CD	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
bilaterally	RB	B-ADVP	O
into	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

AIDA	NN	B-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
microl	NN	I-NP	O
diminished	VBD	B-VP	O
the	DT	B-NP	O
haloperidol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
2R	NN	B-NP	O
,	,	O	O
4R	NN	B-NP	O
-	HYPH	B-NP	O
APDC	NN	I-NP	O
injections	NNS	I-NP	O
were	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
results	NNS	I-NP	O
may	MD	B-VP	O
suggest	VB	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
striatal	JJ	B-NP	O
mGluR1	NN	I-NP	O
,	,	O	O
but	CC	B-CONJP	O
not	RB	I-CONJP	O
the	DT	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
mGluRs	NNS	I-NP	O
,	,	O	O
may	MD	B-VP	O
ameliorate	VB	I-VP	O
parkinsonian	JJ	B-NP	B
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
.	.	O	O

Acute	JJ	B-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
isoflurane	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
following	VBG	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
inhalational	JJ	I-NP	O
anesthetic	JJ	I-NP	O
isoflurane	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
healthy	JJ	I-NP	O
woman	NN	I-NP	O
from	IN	B-PP	O
Iraq	NNP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
num	CD	B-NP	O
weeks	NNS	I-NP	O
following	VBG	B-PP	O
repair	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
rotator	NN	I-NP	O
cuff	NN	I-NP	O
under	IN	B-PP	O
general	JJ	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
viral	JJ	B-NP	O
,	,	I-NP	O
autoimmune	JJ	I-NP	O
,	,	I-NP	O
or	CC	I-NP	O
metabolic	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
.	.	O	O

No	DT	B-NP	O
other	JJ	I-NP	O
medications	NNS	I-NP	O
were	VBD	B-VP	O
involved	VBN	I-VP	O
except	IN	B-PP	O
for	IN	B-PP	O
dipyrone	NN	B-NP	O
for	IN	B-PP	O
analgesia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
alanine	NN	I-NP	O
aminotransferase	NN	I-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
peak	JJ	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
serum	NN	I-NP	O
bilirubin	NN	I-NP	O
reached	VBD	B-VP	O
a	DT	B-NP	O
peak	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
slow	JJ	B-NP	O
improvement	NN	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Accidental	JJ	B-NP	O
reexposure	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
to	TO	B-PP	O
dipyrone	NN	B-NP	O
was	VBD	B-VP	O
uneventful	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
histologic	JJ	I-NP	O
picture	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
resembles	VBZ	B-VP	O
halothane	NN	B-NP	B
hepatitis	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Isoflurane	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
common	JJ	I-NP	O
anesthetic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
can	MD	B-VP	O
cause	VB	I-VP	O
severe	JJ	B-NP	O
cholestatic	JJ	I-NP	B
hepatitis	NN	I-NP	I
.	.	O	O

Calcitonin	NN	B-NP	O
gene	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
peptide	NN	I-NP	O
levels	NNS	I-NP	O
during	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
headache	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
tension	NN	I-NP	B
-	HYPH	I-NP	I
type	NN	I-NP	I
headache	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
that	IN	B-SBAR	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
induced	VBD	B-VP	O
headache	NN	B-NP	B
in	IN	B-PP	O
primary	JJ	B-NP	B
headaches	NNS	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
release	NN	B-NP	O
of	IN	B-PP	O
calcitonin	NN	B-NP	O
gene	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
peptide	NN	I-NP	O
(	(	O	O
CGRP	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
plasma	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
CGRP	NN	B-NP	O
during	IN	B-PP	O
headache	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
NO	NN	I-NP	O
donor	NN	I-NP	O
glyceryl	NN	I-NP	O
trinitrate	NN	I-NP	O
(	(	O	O
GTN	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
tension	NN	I-NP	B
-	HYPH	I-NP	I
type	NN	I-NP	I
headache	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	O	O
min	NN	B-NP	O
GTN	NN	I-NP	O
or	CC	O	O
placebo	NN	B-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
headache	NN	I-NP	B
-	HYPH	O	O
free	JJ	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
start	NN	B-NP	O
of	IN	B-PP	O
infusion	NN	B-NP	O
.	.	O	O

Both	DT	B-NP	O
patients	NNS	I-NP	O
and	CC	I-NP	O
controls	NNS	I-NP	O
developed	VBD	B-VP	O
significantly	RB	B-NP	O
stronger	JJR	I-NP	O
immediate	JJ	I-NP	O
headache	NN	I-NP	B
on	IN	B-PP	O
the	DT	B-NP	O
GTN	NN	I-NP	O
day	NN	I-NP	O
than	IN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
day	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
headache	NN	I-NP	B
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
more	RBR	I-ADJP	O
pronounced	JJ	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
CGRP	NN	I-NP	O
curve	NN	I-NP	O
(	(	O	O
AUCCGRP	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
GTN	NN	B-NP	O
vs.	CC	I-NP	O
placebo	NN	I-NP	O
day	NN	I-NP	O
in	IN	B-PP	O
either	CC	O	O
patients	NNS	B-NP	O
or	CC	O	O
controls	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
AUCCGRP	NN	I-NP	O
recorded	VBN	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
GTN	NN	I-NP	O
day	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
between	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

Both	DT	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	I-NP	O
controls	NNS	I-NP	O
,	,	O	O
CGRP	NN	B-NP	O
levels	NNS	I-NP	O
changed	VBD	B-VP	O
significantly	RB	B-ADVP	O
over	IN	B-PP	O
time	NN	B-NP	O
,	,	O	O
on	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
GTN	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
NO	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
immediate	JJ	I-NP	O
headache	NN	I-NP	B
is	VBZ	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
release	NN	B-NP	O
of	IN	B-PP	O
CGRP	NN	B-NP	O
.	.	O	O

Myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
spasm	NN	I-NP	I
during	IN	B-PP	O
dobutamine	NN	B-NP	O
stress	NN	I-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

Dobutamine	NN	B-NP	O
stress	NN	I-NP	O
echocardiography	NN	I-NP	O
(	(	O	O
DSE	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
and	CC	I-NP	O
safe	JJ	I-NP	O
provocation	NN	I-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
.	.	O	O

Until	IN	B-PP	O
now	RB	B-NP	O
,	,	O	O
the	DT	B-NP	O
test	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
focused	VBN	I-VP	O
only	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
organic	JJ	I-NP	O
lesion	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
,	,	O	O
and	CC	O	O
positive	JJ	B-NP	O
DSE	NN	I-NP	O
has	VBZ	B-VP	O
indicated	VBN	I-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
significant	JJ	B-NP	O
fixed	VBN	I-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
stenosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
whether	IN	B-SBAR	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
coronary	JJ	B-NP	B
spasm	NN	I-NP	I
is	VBZ	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
dobutamine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
DSE	NN	B-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
spastic	JJ	I-NP	I
angina	NN	I-NP	I
but	CC	B-PP	O
without	IN	B-PP	O
significant	JJ	B-NP	O
fixed	VBN	I-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
stenosis	NN	I-NP	I
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
anginal	JJ	B-NP	B
attacks	NNS	I-NP	O
at	IN	B-PP	O
rest	NN	B-NP	O
with	IN	B-PP	O
ST	JJ	B-NP	O
elevation	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
electrocardiogram	NN	I-NP	O
(	(	O	O
variant	JJ	B-NP	B
angina	NN	I-NP	I
)	)	O	O
.	.	O	O

Coronary	JJ	B-NP	O
spasm	NN	I-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
intracoronary	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
acetylcholine	NN	B-NP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
fixed	VBN	I-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
stenosis	NN	I-NP	I
was	VBD	B-VP	O
documented	VBN	I-VP	O
on	IN	B-PP	O
angiograms	NNS	B-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

DSE	NN	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
dobutamine	NN	I-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
incremental	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
asynergy	NN	B-NP	O
with	IN	B-PP	O
ST	JJ	B-NP	O
elevation	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
during	IN	B-PP	O
asynergy	NN	B-NP	O
,	,	O	O
and	CC	O	O
both	DT	B-NP	O
chest	JJS	I-NP	B
pain	NN	I-NP	I
and	CC	I-NP	O
electrocardiographic	JJ	I-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
asynergy	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
dobutamine	NN	B-NP	O
can	MD	B-VP	O
provoke	VB	I-VP	O
coronary	JJ	B-NP	B
spasm	NN	I-NP	I
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
spastic	JJ	I-NP	I
angina	NN	I-NP	I
.	.	O	O

When	WRB	B-ADVP	O
DSE	NN	B-NP	O
is	VBZ	B-VP	O
performed	VBN	I-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
fixed	VBN	B-NP	O
coronary	JJ	I-NP	B
stenosis	NN	I-NP	I
,	,	O	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
coronary	JJ	B-NP	B
spasm	NN	I-NP	I
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
genesis	NN	I-NP	O
of	IN	B-PP	O
asynergy	NN	B-NP	O
.	.	O	O

Nitric	JJ	B-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
lead	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
recently	RB	B-ADVP	O
showed	VBD	B-VP	O
elevated	JJ	B-NP	O
reactive	JJ	I-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
(	(	O	O
ROS	NN	B-NP	O
)	)	O	O
,	,	O	O
reduced	VBD	B-VP	O
urinary	JJ	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
metabolites	NNS	I-NP	O
(	(	O	O
NOx	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
increased	VBD	B-VP	O
NO	NN	B-NP	O
sequestration	NN	I-NP	O
as	IN	B-PP	O
nitrotyrosine	NN	B-NP	O
in	IN	B-PP	O
various	JJ	B-NP	O
tissues	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
lead	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
discern	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
NOx	NN	I-NP	O
in	IN	B-PP	O
lead	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
is	VBZ	B-VP	O
,	,	O	O
in	IN	B-PP	O
part	NN	B-NP	O
,	,	O	O
due	JJ	B-PP	O
to	TO	B-PP	O
depressed	JJ	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
(	(	O	O
NOS	NN	B-NP	O
)	)	O	O
expression	NN	B-NP	O
.	.	O	O

Male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
lead	NN	I-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
group	NN	I-NP	O
(	(	O	O
given	VBN	B-NP	O
lead	NN	I-NP	O
acetate	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
ppm	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
drinking	NN	B-NP	O
water	NN	I-NP	O
and	CC	O	O
regular	JJ	B-NP	O
rat	NN	I-NP	O
chow	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
group	NN	I-NP	O
given	VBN	B-PP	O
lead	NN	B-NP	O
and	CC	O	O
vitamin	NN	B-NP	O
E	NN	I-NP	O
-	HYPH	B-VP	O
fortified	VBN	B-NP	O
chow	NN	I-NP	O
,	,	O	O
or	CC	O	O
a	DT	B-NP	O
normal	JJ	I-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
given	VBN	B-VP	O
either	CC	B-NP	O
regular	JJ	I-NP	O
food	NN	I-NP	O
and	CC	I-NP	O
water	NN	I-NP	O
or	CC	I-NP	O
vitamin	NN	I-NP	O
E	NN	I-NP	O
-	HYPH	B-VP	O
fortified	VBN	B-NP	O
food	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Tail	NN	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
urinary	JJ	B-NP	O
NOx	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
malondialdehyde	NN	I-NP	O
(	(	O	O
MDA	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
endothelial	JJ	B-NP	O
and	CC	I-NP	O
inducible	JJ	I-NP	O
NOS	NN	I-NP	O
(	(	O	O
eNOS	NN	B-NP	O
and	CC	O	O
iNOS	NN	B-NP	O
)	)	O	O
isotypes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
aorta	NN	I-NP	O
and	CC	I-NP	O
kidney	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
lead	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
plasma	NN	B-NP	O
MDA	NN	I-NP	O
concentration	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
NOx	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
paradoxical	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
vascular	JJ	B-NP	O
and	CC	I-NP	O
renal	JJ	I-NP	O
tissue	NN	I-NP	O
eNOS	NN	I-NP	O
and	CC	O	O
iNOS	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

Vitamin	NN	B-NP	O
E	NN	I-NP	O
supplementation	NN	I-NP	O
ameliorated	VBD	B-VP	O
hypertension	NN	B-NP	B
,	,	O	O
lowered	VBD	B-VP	O
plasma	NN	B-NP	O
MDA	NN	I-NP	O
concentration	NN	I-NP	O
,	,	O	O
and	CC	O	O
raised	VBD	B-VP	O
urinary	JJ	B-NP	O
NOx	NN	I-NP	O
excretion	NN	I-NP	O
while	IN	B-SBAR	O
significantly	RB	B-VP	O
lowering	VBG	I-VP	O
vascular	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
not	RB	B-ADJP	O
renal	JJ	I-ADJP	O
,	,	O	O
tissue	NN	B-NP	O
eNOS	NN	I-NP	O
and	CC	O	O
iNOS	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

Vitamin	NN	B-NP	O
E	NN	I-NP	O
supplementation	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
either	CC	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
MDA	NN	I-NP	O
,	,	O	O
or	CC	O	O
NOS	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
also	RB	B-ADVP	O
revealed	VBD	B-VP	O
significant	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
NOS	NN	B-NP	O
enzymatic	JJ	I-NP	O
activity	NN	I-NP	O
by	IN	B-PP	O
lead	NN	B-NP	O
in	IN	B-PP	O
cell	NN	B-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
preparations	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
lead	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
compensatory	JJ	I-NP	O
upregulation	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
and	CC	I-NP	O
vascular	JJ	I-NP	O
eNOS	NN	I-NP	O
and	CC	I-NP	O
iNOS	NN	I-NP	O
expression	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
,	,	O	O
in	IN	B-PP	O
part	NN	B-NP	O
,	,	O	O
due	IN	B-PP	O
to	TO	I-PP	O
ROS	NN	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
NO	NN	I-NP	O
inactivation	NN	I-NP	O
,	,	O	O
lead	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
NOS	NN	B-NP	O
activity	NN	I-NP	O
,	,	O	O
and	CC	O	O
perhaps	RB	B-NP	O
stimulatory	JJ	I-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
shear	NN	I-NP	O
stress	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

Risk	NN	B-NP	O
for	IN	B-PP	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
among	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
fenfluramine	NN	B-NP	O
and	CC	I-NP	O
dexfenfluramine	NN	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
echocardiography	NN	B-NP	O
before	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
medication	NN	B-NP	O
.	.	O	O

Because	IN	B-SBAR	O
uncontrolled	JJ	B-NP	O
echocardiographic	JJ	I-NP	O
surveys	NNS	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
fenfluramine	NN	B-NP	O
and	CC	I-NP	O
dexfenfluramine	NN	I-NP	O
had	VBD	B-VP	O
valvular	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
withdrawn	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
market	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
new	JJ	B-ADJP	O
or	CC	O	O
worsening	VBG	B-VP	O
valvular	JJ	B-NP	B
abnormalities	NNS	I-NP	I
among	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
fenfluramine	NN	B-NP	O
or	CC	I-NP	O
dexfenfluramine	NN	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
echocardiography	NN	B-NP	O
before	IN	B-SBAR	O
they	PRP	B-NP	O
began	VBD	B-VP	O
to	TO	I-VP	O
take	VB	I-VP	O
these	DT	B-NP	O
medications	NNS	I-NP	O
.	.	O	O

Cohort	JJ	B-NP	O
study	NN	I-NP	O
.	.	O	O

Academic	JJ	B-NP	O
primary	JJ	I-NP	O
care	NN	I-NP	O
practices	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
fenfluramine	NN	B-NP	O
or	CC	I-NP	O
dexfenfluramine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
echocardiograms	NNS	B-NP	O
obtained	VBN	B-VP	O
before	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
echocardiography	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
outcome	NN	I-NP	O
was	VBD	B-VP	O
new	JJ	B-ADJP	O
or	CC	O	O
worsening	VBG	B-VP	O
valvulopathy	NN	B-NP	B
,	,	O	O
defined	VBN	B-VP	O
as	IN	B-PP	O
progression	NN	B-NP	O
of	IN	B-PP	O
either	CC	B-NP	O
aortic	JJ	I-NP	B
or	CC	I-NP	I
mitral	JJ	I-NP	I
regurgitation	NN	I-NP	I
by	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
severity	NN	B-NP	O
and	CC	I-NP	O
disease	NN	I-NP	O
that	WDT	B-NP	O
met	VBD	B-VP	O
U.S	NNP	B-NP	O
.	.	O	O

Food	NNP	B-NP	O
and	CC	I-NP	O
Drug	NNP	I-NP	O
Administration	NNP	I-NP	O
criteria	NNS	I-NP	O
(	(	O	O
at	IN	B-NP	O
least	JJS	I-NP	O
mild	JJ	I-NP	O
aortic	JJ	I-NP	B
regurgitation	NN	I-NP	I
or	CC	O	O
moderate	JJ	B-NP	O
mitral	JJ	I-NP	B
regurgitation	NN	I-NP	I
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
[	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
]	)	O	O
)	)	O	O
receiving	VBG	B-VP	O
fenfluramine	NN	B-NP	O
-	HYPH	O	O
phentermine	NN	B-NP	O
developed	VBD	B-VP	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
had	VBD	B-VP	O
baseline	NN	B-NP	O
bicuspid	JJ	I-NP	B
aortic	JJ	I-NP	I
valve	NN	I-NP	I
and	CC	O	O
mild	JJ	B-NP	O
aortic	JJ	I-NP	B
regurgitation	NN	I-NP	I
that	WDT	B-NP	O
progressed	VBD	B-VP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
regurgitation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
new	JJ	B-NP	O
moderate	JJ	I-NP	O
aortic	JJ	I-NP	B
insufficiency	NN	I-NP	I
.	.	O	O

Users	NNS	B-NP	O
of	IN	B-PP	O
diet	NN	B-NP	O
medications	NNS	I-NP	O
are	VBP	B-VP	O
at	IN	B-PP	O
risk	NN	B-NP	O
for	IN	B-PP	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
reported	VBN	B-VP	O
previously	RB	B-ADVP	O
.	.	O	O

Carboplatin	NN	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
striking	JJ	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
s	NN	I-NP	O
advantages	NNS	I-NP	O
(	(	O	O
CBDCA	NN	B-NP	O
)	)	O	O
over	IN	B-PP	O
cisplatin	NN	B-NP	O
(	(	O	O
CDDP	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
its	PRP$	B-NP	O
markedly	RB	I-NP	O
reduced	VBN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
neurotoxic	JJ	B-NP	B
effects	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
CBDCA	NN	B-NP	O
higher	JJR	B-NP	O
-	HYPH	I-NP	O
intensity	NN	I-NP	O
schedules	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
neurotoxic	JJ	I-NP	B
drugs	NNS	I-NP	O
in	IN	B-PP	O
polychemotherapy	NN	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
some	DT	B-NP	O
concern	NN	I-NP	O
about	IN	B-PP	O
its	PRP$	B-NP	O
safety	NN	I-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
peripheral	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
damage	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
different	JJ	I-NP	O
schedules	NNS	I-NP	O
of	IN	B-PP	O
CBDCA	NN	B-NP	O
administration	NN	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
Wistar	NNP	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Neurotoxicity	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
for	IN	B-PP	O
behavioral	NN	B-NP	O
(	(	O	O
tail	NN	B-NP	O
-	HYPH	B-NP	O
flick	NN	I-NP	O
test	NN	I-NP	O
)	)	O	O
,	,	O	O
neurophysiological	JJ	B-ADJP	O
(	(	O	O
nerve	NN	B-NP	O
conduction	NN	I-NP	O
velocity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
tail	NN	I-NP	O
nerve	NN	I-NP	O
)	)	O	O
,	,	O	O
morphological	JJ	B-NP	O
,	,	I-NP	O
morphometrical	JJ	I-NP	O
and	CC	I-NP	O
analytical	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

CBDCA	NN	B-NP	O
administration	NN	I-NP	O
induced	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
peripheral	JJ	I-NP	B
neurotoxicity	NN	I-NP	I
.	.	O	O

Pain	NN	B-NP	B
perception	NN	I-NP	O
and	CC	O	O
nerve	NN	B-NP	O
conduction	NN	I-NP	O
velocity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
tail	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
impaired	JJ	I-ADJP	O
,	,	O	O
particularly	RB	B-ADVP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
dorsal	JJ	I-NP	O
root	NN	I-NP	O
ganglia	NNS	I-NP	O
sensory	VBP	B-VP	O
neurons	NNS	B-NP	O
and	CC	O	O
,	,	O	O
to	TO	B-PP	O
a	DT	B-NP	O
lesser	JJR	I-NP	O
extent	NN	I-NP	O
,	,	O	O
satellite	NN	B-NP	O
cells	NNS	I-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
changes	NNS	I-NP	O
as	IN	B-PP	O
those	DT	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
CDDP	NN	B-NP	O
,	,	O	O
mainly	RB	B-ADVP	O
affecting	VBG	B-VP	O
the	DT	B-NP	O
nucleus	NN	I-NP	O
and	CC	I-NP	O
nucleolus	NN	I-NP	O
of	IN	B-PP	O
ganglionic	JJ	B-NP	O
sensory	JJ	I-NP	O
neurons	NNS	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
significant	JJ	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
platinum	NN	B-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
dorsal	JJ	I-NP	O
root	NN	I-NP	O
ganglia	NNS	I-NP	O
and	CC	O	O
kidney	NN	B-NP	O
after	IN	B-PP	O
CBDCA	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

CBDCA	NN	B-NP	O
is	VBZ	B-VP	O
neurotoxic	JJ	B-ADJP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
model	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
pathological	JJ	B-NP	O
changes	NNS	I-NP	O
it	PRP	B-NP	O
induces	VBZ	B-VP	O
are	VBP	B-VP	O
so	RB	B-ADJP	O
closely	RB	I-ADJP	O
similar	JJ	I-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
CDDP	NN	B-NP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
probable	JJ	B-ADJP	O
that	IN	B-SBAR	O
neurotoxicity	NN	B-NP	B
is	VBZ	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
mechanism	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
model	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
CBDCA	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Iatrogenic	JJ	B-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
carcinoma	NN	I-NP	I
after	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
large	JJ	I-NP	O
French	JJ	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

F	NN	B-NP	O
d	NN	I-NP	O
ration	NN	I-NP	O
Nationale	NNP	I-NP	O
des	NNP	I-NP	O
Centres	NNP	I-NP	O
de	IN	I-NP	O
Lutte	NNP	I-NP	O
Contre	NNP	I-NP	O
le	NNP	I-NP	O
Cancer	NNP	I-NP	O
(	(	O	O
FNCLCC	NN	B-NP	O
)	)	O	O
.	.	O	O

Since	IN	B-SBAR	O
tamoxifen	NN	B-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
treatment	NN	I-NP	O
and	CC	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
its	PRP$	B-NP	O
endometrial	JJ	I-NP	O
iatrogenic	JJ	I-NP	O
effects	NNS	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
carefully	RB	I-VP	O
examined	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
investigated	VBN	I-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
and	CC	I-NP	O
tamoxifen	NN	I-NP	O
use	NN	I-NP	O
or	CC	O	O
other	JJ	B-NP	O
treatments	NNS	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Cases	NNS	B-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
diagnosed	VBN	B-VP	O
after	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
matched	VBN	B-VP	O
for	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
year	NN	B-NP	O
of	IN	B-PP	O
diagnosis	NN	B-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
and	CC	O	O
hospital	NN	B-NP	O
and	CC	O	O
survival	NN	B-NP	O
time	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
intact	JJ	I-NP	O
uterus	NN	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
.	.	O	O

Women	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
tamoxifen	NN	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
more	RBR	I-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
diagnosed	VBN	B-VP	O
than	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
not	RB	O	O
.	.	O	O

Univariate	JJ	B-NP	O
and	CC	I-NP	O
adjusted	VBN	I-NP	O
analyses	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
length	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
or	CC	O	O
the	DT	B-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
received	VBD	B-VP	O
,	,	O	O
irrespective	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Women	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
pelvic	JJ	B-NP	O
radiotherapy	NN	I-NP	O
also	RB	B-ADVP	O
had	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
risk	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
adjusting	VBG	B-VP	O
for	IN	B-PP	O
confounding	VBG	B-VP	O
factors	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
for	IN	B-PP	O
tamoxifen	NN	B-NP	O
users	NNS	I-NP	O
,	,	O	O
treatment	NN	B-NP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
and	CC	O	O
pelvic	JJ	B-NP	O
radiotherapy	NN	I-NP	O
.	.	O	O

Women	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
and	CC	O	O
had	VBD	B-VP	O
received	VBN	I-VP	O
tamoxifen	NN	B-NP	O
had	VBD	B-VP	O
more	RBR	B-NP	O
advanced	JJ	I-NP	B
disease	NN	I-NP	I
and	CC	O	O
poorer	JJR	B-NP	O
prognosis	NN	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
who	WP	B-NP	O
had	VBD	B-VP	O
not	RB	I-VP	O
received	VBN	I-VP	O
this	DT	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
causal	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
in	IN	B-PP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
particularly	RB	B-ADVP	O
when	WRB	B-ADVP	O
used	VBN	B-VP	O
as	IN	B-PP	O
currently	RB	B-ADVP	O
proposed	VBN	B-VP	O
for	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
prevention	NN	I-NP	O
.	.	O	O

Pelvic	JJ	B-NP	O
radiotherapy	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
iatrogenic	JJ	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

Endometrial	JJ	B-NP	B
cancers	NNS	I-NP	I
diagnosed	VBN	B-VP	O
in	IN	B-PP	O
women	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
tamoxifen	NN	B-NP	O
have	VBP	B-VP	O
poorer	JJR	B-NP	O
prognosis	NN	I-NP	O
.	.	O	O

Women	NNS	B-NP	O
who	WP	B-NP	O
receive	VBP	B-VP	O
tamoxifen	NN	B-NP	O
for	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
should	MD	B-VP	O
be	VB	I-VP	O
offered	VBN	I-VP	O
gynaecological	JJ	B-NP	O
surveillance	NN	I-NP	O
during	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
treatment	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
-	HYPH	I-NP	O
benefit	NN	I-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
preventive	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
is	VBZ	B-VP	O
clearly	RB	I-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Granulosa	NN	B-NP	B
cell	NN	I-NP	I
tumor	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
ovary	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
antecedent	JJ	B-NP	O
tamoxifen	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
attention	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
focused	VBN	I-VP	O
recently	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
estrogenic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
.	.	O	O

Review	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
reveals	VBZ	B-VP	O
an	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
tamoxifen	NN	B-NP	O
use	NN	I-NP	O
and	CC	O	O
gynecologic	JJ	B-NP	O
tumors	NNS	I-NP	B
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
postmenopausal	JJ	I-NP	O
woman	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
tamoxifen	NN	B-NP	O
for	IN	B-PP	O
stage	NN	B-NP	O
num	CD	I-NP	O
estrogen	NN	I-NP	O
receptor	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
breast	NN	I-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

Her	PRP$	B-NP	O
aspartate	NN	I-NP	O
transaminase	NN	I-NP	O
and	CC	I-NP	O
alanine	NN	I-NP	O
transaminase	NN	I-NP	O
levels	NNS	I-NP	O
increase	VBP	B-VP	O
markedly	RB	B-ADVP	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
tamoxifen	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
elevated	JJ	B-NP	O
serum	NN	I-NP	O
transaminases	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
stage	NN	I-NP	O
Ic	NN	I-NP	O
granulosa	NN	I-NP	B
cell	NN	I-NP	I
tumor	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
ovary	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
tamoxifen	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
dysfunction	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
at	IN	B-PP	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
granulosa	NN	B-NP	B
cell	NN	I-NP	I
tumors	NNS	I-NP	I
because	IN	B-PP	O
of	IN	I-PP	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
tamoxifen	NN	B-NP	O
metabolism	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
murine	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
adenomyosis	NN	B-NP	B
:	:	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
fluoxetine	NN	B-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
adenomyosis	NN	B-NP	B
induction	NN	I-NP	O
in	IN	B-PP	O
Wistar	NNP	B-NP	O
albino	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
fluoxetine	NN	B-NP	O
given	VBN	B-VP	O
to	TO	B-PP	O
castrated	VBN	B-NP	O
and	CC	I-NP	O
noncastrated	JJ	I-NP	O
rats	NNS	I-NP	O
caused	VBD	B-VP	O
hyperprolactinemia	NN	B-NP	B
and	CC	O	O
its	PRP$	B-NP	O
effects	NNS	I-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
adenomyosis	NN	B-NP	B
.	.	O	O

Fluoxetine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
Wistar	NNP	B-NP	O
Albino	NNP	I-NP	O
rats	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
to	TO	B-VP	O
produce	VB	I-VP	O
hyperprolactinemia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
consisting	VBG	B-VP	O
of	IN	B-PP	O
castrated	VBN	B-NP	O
and	CC	I-NP	O
noncastrated	JJ	I-NP	O
rats	NNS	I-NP	O
and	CC	O	O
compared	VBN	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
castrated	VBN	B-NP	O
and	CC	I-NP	O
noncastrated	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

Prolactin	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
uteri	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
removed	VBN	I-VP	O
for	IN	B-PP	O
histopathological	JJ	B-NP	O
analysis	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Marmara	NNP	B-NP	O
University	NNP	I-NP	O
School	NNP	I-NP	O
of	IN	B-PP	O
Medicine	NNP	B-NP	O
,	,	O	O
Department	NNP	B-NP	O
of	IN	B-PP	O
Histology	NNP	B-NP	O
and	CC	I-NP	O
Embryology	NNP	I-NP	O
,	,	O	O
Zeynep	NNP	B-NP	O
Kamil	NNP	I-NP	O
Women	NNP	I-NP	O
and	CC	I-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Hospital	NNP	B-NP	O
.	.	O	O

Serum	NN	B-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
uterine	JJ	B-NP	O
histopathology	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
castrated	VBN	B-NP	O
and	CC	I-NP	O
noncastrated	JJ	I-NP	O
groups	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
fluoxetine	NN	B-NP	O
were	VBD	B-VP	O
statistically	RB	B-ADVP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
respective	JJ	I-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Histological	JJ	B-NP	O
studies	NNS	I-NP	O
revealed	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
adenomyosis	NN	B-NP	B
,	,	O	O
all	DT	B-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
noncastrated	JJ	I-NP	O
group	NN	I-NP	O
receiving	VBG	B-VP	O
fluoxetine	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
high	JJ	B-NP	O
serum	NN	I-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
cause	VBP	B-VP	O
degeneration	NN	B-NP	O
of	IN	B-PP	O
myometrial	JJ	B-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
ovarian	JJ	B-NP	O
steroids	NNS	I-NP	O
that	WDT	B-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
myometrial	JJ	I-NP	O
invasion	NN	I-NP	O
by	IN	B-PP	O
endometrial	JJ	B-NP	O
stroma	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
invasion	NN	I-NP	O
eventually	RB	B-ADVP	O
progresses	VBZ	B-VP	O
to	TO	B-PP	O
adenomyosis	NN	B-NP	B
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
deliberate	JJ	B-NP	O
hypotension	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
labetalol	NN	B-NP	O
with	IN	B-PP	O
isoflurane	NN	B-NP	O
on	IN	B-PP	O
neuropsychological	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
deliberate	JJ	B-NP	O
hypotension	NN	I-NP	B
on	IN	B-PP	O
brain	NN	B-NP	O
function	NN	I-NP	O
measured	VBN	B-VP	O
by	IN	B-PP	O
neuropsychological	JJ	B-NP	O
tests	NNS	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
anaesthetized	VBN	I-VP	O
for	IN	B-PP	O
middle	JJ	B-NP	O
-	HYPH	I-NP	O
ear	NN	I-NP	O
surgery	NN	I-NP	O
with	IN	B-PP	O
deliberate	JJ	B-NP	O
hypotension	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
labetalol	NN	B-NP	O
with	IN	B-PP	O
isoflurane	NN	B-NP	O
(	(	O	O
hypotensive	JJ	B-NP	B
group	NN	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
hypotension	NN	B-NP	B
served	VBD	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
before	IN	B-PP	O
hypotension	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
during	IN	B-PP	O
hypotension	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
group	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
during	IN	B-PP	O
anaesthesia	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
following	VBG	I-NP	O
psychological	JJ	I-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
subtests	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Wechsler	NNP	I-NP	O
Adult	NNP	I-NP	O
Intelligence	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
similarities	NNS	B-NP	O
,	,	O	O
digit	NN	B-NP	O
span	NN	I-NP	O
,	,	O	O
vocabulary	NN	B-NP	O
and	CC	I-NP	O
digit	NN	I-NP	O
symbol	NN	I-NP	O
)	)	O	O
,	,	O	O
Trail	NN	B-NP	O
-	HYPH	O	O
Making	VBG	B-VP	O
tests	NNS	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
B	NN	I-NP	O
,	,	O	O
Zung	NN	B-NP	O
tests	NNS	I-NP	O
(	(	O	O
self	NN	B-NP	O
-	HYPH	O	O
rating	VBG	B-VP	O
anxiety	NN	B-NP	B
scale	NN	I-NP	O
and	CC	I-NP	O
self	NN	I-NP	O
-	HYPH	O	O
rating	VBG	B-VP	O
depression	NN	B-NP	B
scale	NN	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
part	NN	I-NP	O
memory	NN	I-NP	O
test	NN	I-NP	O
battery	NN	I-NP	O
with	IN	B-PP	O
immediate	JJ	B-NP	O
and	CC	I-NP	O
delayed	VBN	I-NP	O
recall	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
preoperatively	RB	B-ADVP	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
postoperatively	RB	B-ADVP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
in	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tests	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
from	IN	B-PP	O
preoperative	JJ	B-NP	O
value	NN	I-NP	O
to	TO	B-PP	O
postoperative	JJ	B-NP	O
value	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
hypotension	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
labetalol	NN	B-NP	O
with	IN	B-PP	O
isoflurane	NN	B-NP	O
has	VBZ	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
harmful	JJ	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
mental	JJ	B-NP	O
functions	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
normotensive	JJ	B-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

Auditory	JJ	B-NP	O
disturbance	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
interscalene	NN	B-NP	O
brachial	JJ	I-NP	O
plexus	NN	I-NP	O
block	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
an	DT	B-NP	O
audiometric	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
surgery	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
shoulder	NN	I-NP	O
region	NN	I-NP	O
under	IN	B-PP	O
an	DT	B-NP	O
interscalene	NN	I-NP	O
brachial	JJ	I-NP	O
plexus	NN	I-NP	O
block	NN	I-NP	O
(	(	O	O
IBPB	NN	B-NP	O
)	)	O	O
.	.	O	O

Bupivacaine	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
adrenaline	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hr	NN	I-NP	O
continuous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
bupivacaine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
audiometric	JJ	I-NP	O
threshold	NN	I-NP	O
measurements	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
kHz	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
made	VBN	I-VP	O
:	:	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
before	IN	B-PP	O
IBPB	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
second	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
third	JJ	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
operation	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
hearing	VBG	B-VP	B
impairment	NN	B-NP	I
on	IN	B-PP	O
the	DT	B-NP	O
side	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
block	NN	I-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
after	IN	B-PP	O
operation	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
num	CD	B-NP	O
measurements	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
day	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
frequencies	NNS	I-NP	O
at	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
impairment	NN	I-NP	O
occurred	VBD	B-VP	O
varied	JJ	B-ADJP	O
between	IN	B-PP	O
patients	NNS	B-NP	O
;	:	O	O
in	IN	B-PP	O
num	CD	B-NP	O
only	RB	I-NP	O
low	JJ	I-NP	O
frequencies	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
kHz	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
involved	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
maximum	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
threshold	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
dB	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
kHz	NN	I-NP	O
measured	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
continuous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
hearing	VBG	I-VP	O
threshold	NN	B-NP	O
changes	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
dB	NN	I-NP	O
)	)	O	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
kHz	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
opposite	JJ	I-NP	O
side	NN	I-NP	O
also	RB	B-ADVP	O
.	.	O	O

IBPB	NN	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
transient	JJ	B-NP	O
auditory	JJ	I-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
ipsilateral	JJ	I-NP	O
ear	NN	I-NP	O
,	,	O	O
possibly	RB	B-ADVP	O
via	IN	B-PP	O
an	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
sympathetic	JJ	B-NP	O
innervation	NN	I-NP	O
.	.	O	O

Midazolam	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
thiopentone	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
induction	NN	I-NP	O
agent	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
premedicated	VBN	B-VP	O
with	IN	B-PP	O
scopolamine	NN	B-NP	O
+	SYM	I-NP	O
morphine	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
sleep	NN	I-NP	O
-	HYPH	O	O
inducing	VBG	B-VP	O
effect	NN	B-NP	O
of	IN	B-PP	O
midazolam	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
i.v.	NN	I-NP	O
was	VBD	B-VP	O
clearly	RB	B-ADJP	O
slower	JJR	I-ADJP	O
in	IN	B-PP	O
onset	NN	B-NP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
thiopentone	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
i.v.	RB	B-NP	O
Somewhat	RB	I-NP	O
fewer	JJR	I-NP	O
cardiovascular	JJ	I-NP	O
and	CC	I-NP	O
local	JJ	I-NP	O
sequelae	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
midazolam	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
but	CC	O	O
,	,	O	O
although	IN	B-SBAR	O
apnoea	NN	B-NP	B
occurred	VBD	B-VP	O
less	RBR	B-ADVP	O
often	RB	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
midazolam	NN	I-NP	O
group	NN	I-NP	O
it	PRP	B-NP	O
lasted	VBD	B-VP	O
longer	RBR	B-ADVP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
whole	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
midazolam	NN	B-NP	O
and	CC	I-NP	O
thiopentone	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
apparent	JJ	I-NP	O
clinical	JJ	I-NP	O
consequences	NNS	I-NP	O
.	.	O	O

Midazolam	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
alternative	JJ	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
induction	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

Cardiotoxic	JJ	B-NP	B
and	CC	I-NP	O
possible	JJ	I-NP	O
leukemogenic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
in	IN	B-PP	O
nonhuman	JJ	B-NP	O
primates.	NN	I-NP	O
num	CD	B-NP	O
monkeys	NNS	I-NP	O
(	(	O	O
macaques	NNS	B-NP	O
)	)	O	O
received	VBD	B-VP	O
adriamycin	NN	B-NP	O
by	IN	B-PP	O
monthly	JJ	B-NP	O
intravenous	JJ	I-NP	O
injections	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
.	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
monkeys	NNS	I-NP	O
developed	VBD	B-VP	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
at	IN	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
cumulative	JJ	I-NP	O
adriamycin	NN	I-NP	O
dose	NN	I-NP	O
well	RB	B-ADVP	O
below	IN	B-PP	O
that	DT	B-NP	O
considered	VBN	B-VP	O
the	DT	B-NP	O
safe	JJ	I-NP	O
upper	JJ	I-NP	O
limit	NN	I-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

Histologically	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
myocardial	JJ	I-NP	B
lesions	NNS	I-NP	I
resembled	VBD	B-VP	O
those	DT	B-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
human	JJ	B-NP	O
anthracycline	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
monkeys	NNS	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
myeloblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
after	IN	B-PP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
;	:	O	O
the	DT	B-NP	O
10th	JJ	I-NP	O
monkey	NN	I-NP	O
is	VBZ	B-VP	O
alive	JJ	B-ADJP	O
and	CC	O	O
well	RB	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
adriamycin	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
potent	JJ	I-NP	O
cardiotoxin	NN	I-NP	O
in	IN	B-PP	O
monkeys	NNS	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
man	NN	B-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
leukemia	NN	B-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
prolonged	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
cardiomyopathy	NN	I-NP	B
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
left	JJ	B-NP	O
-	HYPH	I-NP	O
sided	JJ	I-NP	O
Wilms	NNP	I-NP	B
tumor	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
Wilms	NNP	B-NP	B
tumor	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
kidney	NN	I-NP	O
experienced	VBD	B-VP	O
severe	JJ	B-NP	O
anthracycline	NN	I-NP	O
cardiomyopathy	NN	I-NP	B
after	IN	B-PP	O
irradiation	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
tumor	NN	I-NP	B
bed	NN	I-NP	O
and	CC	O	O
conventional	JJ	B-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
cardiomyopathy	NN	I-NP	B
is	VBZ	B-VP	O
attributed	VBN	I-VP	O
num	CD	B-NP	O
)	)	O	O
to	TO	B-PP	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
radiation	NN	B-NP	O
fields	NNS	I-NP	O
for	IN	B-PP	O
left	JJ	B-NP	O
Wilms	NNP	I-NP	B
tumor	NN	I-NP	I
include	VBP	B-VP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
portion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
to	TO	B-PP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
and	CC	I-NP	O
irradiation	NN	I-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
muscle	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
that	IN	B-SBAR	O
doxorubicin	NN	B-NP	O
dosage	NN	I-NP	O
be	VB	B-VP	O
sharply	RB	I-VP	O
restricted	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
Wilms	NNP	B-NP	B
tumor	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
kidney	NN	I-NP	O
who	WP	B-NP	O
receive	VBP	B-VP	O
postoperative	JJ	B-NP	O
irradiation	NN	I-NP	O
.	.	O	O

Promotional	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
testosterone	NN	B-NP	O
and	CC	O	O
dietary	JJ	B-NP	O
fat	NN	I-NP	O
on	IN	B-PP	O
prostate	NN	B-NP	O
carcinogenesis	NN	I-NP	B
in	IN	B-PP	O
genetically	RB	B-NP	O
susceptible	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Germfree	JJ	O	O
(	(	O	O
GF	NN	B-NP	O
)	)	O	O
Lobund	NN	B-NP	O
strain	NN	I-NP	O
Wistar	NNP	I-NP	O
(	(	O	O
LW	NNP	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
,	,	O	O
fed	VBN	B-VP	O
vegetable	JJ	B-NP	O
diet	NN	I-NP	O
L	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
have	VBP	B-VP	O
developed	VBN	I-VP	O
prostate	NN	B-NP	B
adenocarcinomas	NNS	I-NP	I
spontaneously	RB	B-ADVP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
incidence	NN	I-NP	O
)	)	O	O
at	IN	B-PP	O
average	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Conventional	JJ	B-NP	O
LW	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
implanted	VBN	B-VP	O
with	IN	B-PP	O
testosterone	NN	B-NP	O
at	IN	B-PP	O
age	NN	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
developed	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
after	IN	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
developed	VBN	I-VP	O
gross	JJ	B-NP	O
tumors	NNS	I-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
when	WRB	B-ADVP	O
it	PRP	B-NP	O
included	VBD	B-VP	O
microscopic	JJ	B-NP	O
tumors	NNS	I-NP	B
.	.	O	O

Preliminary	JJ	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
testosterone	NN	B-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
LW	NN	I-NP	O
rats	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
fed	VBN	I-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
diet	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
supplemented	VBN	I-VP	O
with	IN	B-PP	O
corn	NN	B-NP	O
oil	NN	I-NP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
fat	NN	I-NP	O
,	,	O	O
developed	VBD	B-VP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
after	IN	B-PP	O
intervals	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Aged	NNP	B-NP	O
GF	NNP	I-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
(	(	O	O
SD	NNP	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
developed	VBN	I-VP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
spontaneously	RB	B-ADVP	O
.	.	O	O

Conventional	JJ	B-NP	O
SD	NN	I-NP	O
rats	NNS	I-NP	O
fed	VBN	B-VP	O
diet	NN	B-NP	O
L	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
and	CC	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
testosterone	NN	B-NP	O
developed	VBD	B-VP	O
only	RB	B-NP	O
prostatitis	NN	I-NP	B
.	.	O	O

Experimental	JJ	B-NP	O
designs	NNS	I-NP	O
should	MD	B-VP	O
consider	VB	I-VP	O
genetic	JJ	B-NP	O
susceptibility	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
basic	JJ	I-NP	O
prerequisite	NN	I-NP	O
for	IN	B-PP	O
studies	NNS	B-NP	O
on	IN	B-PP	O
experimental	JJ	B-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Mitomycin	NN	B-NP	O
C	NN	I-NP	O
associated	VBN	B-VP	O
hemolytic	JJ	B-NP	B
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Mitomycin	NN	B-NP	O
C	NN	I-NP	O
associated	VBN	B-VP	O
Hemolytic	JJ	B-NP	B
Uremic	JJ	I-NP	I
Syndrome	NN	I-NP	I
(	(	O	O
HUS	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
fatal	JJ	I-NP	O
but	CC	I-NP	O
uncommon	JJ	I-NP	O
condition	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
yet	RB	I-VP	O
widely	RB	I-VP	O
recognised	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
consists	VBZ	B-VP	O
of	IN	B-PP	O
microangiopathic	JJ	B-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
,	,	O	O
thrombocytopenia	NN	B-NP	B
and	CC	O	O
progressive	JJ	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
mitomycin	NN	B-NP	O
C	NN	I-NP	O
treatment	NN	I-NP	O
and	CC	O	O
affects	VBZ	B-VP	O
about	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
agent	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
usually	RB	B-ADVP	O
develops	VBZ	B-VP	O
about	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mth	NN	I-NP	O
after	IN	B-PP	O
start	NN	B-NP	O
of	IN	B-PP	O
mitomycin	NN	B-NP	O
C	NN	I-NP	O
treatment	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
mortality	NN	I-NP	O
is	VBZ	B-VP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
from	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
or	CC	O	O
pulmonary	JJ	B-NP	B
edema	NN	I-NP	I
.	.	O	O

Renal	JJ	B-NP	B
lesions	NNS	I-NP	I
are	VBP	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
idiopathic	JJ	B-NP	O
HUS	NNS	I-NP	B
and	CC	O	O
include	VBP	B-VP	O
arteriolar	JJ	B-NP	O
fibrin	NN	I-NP	O
thrombi	NN	I-NP	B
,	,	O	O
expanded	VBD	B-VP	O
subendothelial	JJ	B-NP	O
zones	NNS	I-NP	O
in	IN	B-PP	O
glomerular	JJ	B-NP	O
capillary	JJ	I-NP	O
walls	NNS	I-NP	O
,	,	O	O
ischemic	JJ	B-NP	B
wrinkling	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	O
basement	NN	I-NP	O
membranes	NNS	I-NP	O
and	CC	I-NP	O
mesangiolysis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
is	VBZ	B-VP	O
postulated	VBN	I-VP	O
as	IN	B-PP	O
mitomycin	NN	B-NP	O
C	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
endothelial	JJ	I-NP	O
cell	NN	I-NP	O
damage	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
course	NN	I-NP	O
and	CC	O	O
pathological	JJ	B-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
yr	NN	I-NP	O
-	HYPH	I-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
gastric	JJ	B-NP	B
adenocarcinoma	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
while	IN	B-SBAR	O
on	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
mitomycin	NN	B-NP	O
C	NN	I-NP	O
and	CC	O	O
died	VBD	B-VP	O
in	IN	B-PP	O
pulmonary	JJ	B-NP	B
edema	NN	I-NP	I
.	.	O	O

Continuous	JJ	B-NP	O
ambulatory	JJ	I-NP	O
ECG	NN	I-NP	O
monitoring	VBG	B-VP	O
during	IN	B-PP	O
fluorouracil	NN	B-NP	O
therapy	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
there	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
anecdotal	JJ	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
fluorouracil	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
therapy	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
phenomenon	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
systematic	JJ	I-NP	O
fashion	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
prospectively	RB	B-ADVP	O
performed	VBD	B-VP	O
continuous	JJ	B-NP	O
ambulatory	JJ	I-NP	O
ECG	NN	I-NP	O
monitoring	VBG	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
solid	JJ	B-NP	O
tumors	NNS	I-NP	B
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	B
ST	NN	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
before	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

Anginal	JJ	B-NP	B
episodes	NNS	I-NP	O
were	VBD	B-VP	O
rare	JJ	B-ADJP	O
:	:	O	O
only	RB	B-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
angina	NN	B-NP	B
(	(	O	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
)	)	O	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
asymptomatic	JJ	B-NP	O
ST	NN	I-NP	O
changes	NNS	I-NP	O
(	(	O	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
ST	NN	I-NP	O
deviation	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
common	JJ	B-ADJP	O
:	:	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
ST	NN	B-NP	O
changes	NNS	I-NP	O
before	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
v	IN	B-PP	O
num	CD	B-NP	O
during	IN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	B
episodes	NNS	I-NP	O
per	IN	B-PP	O
patient	NN	B-NP	O
per	IN	B-PP	O
hour	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
v	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
ECG	NN	B-NP	O
changes	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
per	IN	B-PP	O
patient	NN	B-NP	O
per	IN	B-PP	O
hour	NN	B-NP	O
before	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
v	SYM	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
per	IN	B-PP	O
patient	NN	B-NP	O
per	IN	B-PP	O
hour	NN	B-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
.	.	O	O

ECG	NN	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
among	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
known	JJ	B-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
sudden	JJ	B-NP	B
death	NN	I-NP	I
,	,	O	O
both	DT	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
occurred	VBD	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
chemotherapy	NN	I-NP	O
course	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
infusion	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
silent	JJ	B-NP	O
ST	NN	I-NP	O
segment	NN	I-NP	O
deviation	NN	I-NP	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
ischemia	NN	B-NP	B
,	,	O	O
particularly	RB	B-ADVP	O
among	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
significance	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
ECG	NN	I-NP	O
changes	NNS	I-NP	O
remain	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
determined	VBN	I-VP	O
.	.	O	O

Lethal	JJ	B-NP	O
anuria	NN	I-NP	B
complicating	VBG	B-VP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
ifosfamide	NN	I-NP	O
chemotherapy	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
patient	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
impaired	JJ	I-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
sixty	JJ	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
,	,	O	O
previously	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
cisplatin	NN	B-NP	O
,	,	O	O
developed	VBD	B-VP	O
an	DT	B-NP	O
irreversible	JJ	I-NP	O
lethal	JJ	I-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
with	IN	B-PP	O
anuria	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
bolus	NN	I-NP	O
ifosfamide	NN	I-NP	O
.	.	O	O

Postrenal	JJ	B-NP	B
failure	NN	I-NP	I
was	VBD	B-VP	O
excluded	VBN	I-VP	O
by	IN	B-PP	O
echography	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
prerenal	JJ	I-NP	O
component	NN	I-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
contributed	VBN	I-VP	O
to	TO	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
because	IN	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
hypotension	NN	I-NP	B
,	,	O	O
due	IN	B-PP	O
to	TO	B-PP	O
an	DT	B-NP	O
increasing	VBG	I-NP	O
ascitis	NN	I-NP	O
,	,	O	O
occurring	VBG	B-VP	O
just	RB	B-ADVP	O
before	IN	B-PP	O
anuria	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
correction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hemodynamic	JJ	I-NP	O
parameters	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
improve	VB	I-VP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Ifosfamide	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
known	JJ	I-NP	O
nephrotoxic	JJ	I-NP	B
drug	NN	I-NP	O
with	IN	B-PP	O
demonstrated	VBN	B-NP	O
tubulopathies	NNS	I-NP	B
.	.	O	O

We	PRP	B-NP	O
strongly	RB	B-ADVP	O
suspect	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
lethal	JJ	I-NP	O
anuria	NN	I-NP	B
was	VBD	B-VP	O
mainly	RB	B-ADJP	O
due	JJ	I-ADJP	O
to	TO	B-PP	O
ifosfamide	NN	B-NP	O
,	,	O	O
occurring	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
having	VBG	B-VP	O
received	VBN	I-VP	O
previous	JJ	B-NP	O
cisplatin	NN	I-NP	O
chemotherapy	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
poor	JJ	B-NP	O
kidney	NN	I-NP	O
perfusion	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
transient	JJ	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
recommend	VBP	B-VP	O
careful	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
nephrotoxic	JJ	B-NP	B
chemotherapy	NN	I-NP	O
and	CC	O	O
inadequate	JJ	B-NP	O
renal	JJ	I-NP	O
perfusion	NN	I-NP	O
.	.	O	O

Central	JJ	B-NP	O
vein	NN	I-NP	B
thrombosis	NN	I-NP	I
and	CC	O	O
topical	JJ	B-NP	O
dipivalyl	NN	I-NP	O
epinephrine	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
report	NN	I-NP	O
is	VBZ	B-VP	O
given	VBN	I-VP	O
on	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
female	NN	I-NP	O
who	WP	B-NP	O
acquired	VBD	B-VP	O
central	JJ	B-NP	O
vein	NN	I-NP	B
thrombosis	NN	I-NP	I
in	IN	B-PP	O
her	PRP$	B-NP	O
seeing	VBG	I-NP	O
eye	NN	I-NP	O
num	CD	I-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
having	VBG	B-VP	O
started	VBN	I-VP	O
topical	JJ	B-NP	O
medication	NN	I-NP	O
with	IN	B-PP	O
dipivalyl	NN	B-NP	O
epinephrine	NN	I-NP	O
for	IN	B-PP	O
advanced	VBN	B-NP	O
glaucoma	NN	I-NP	B
discovered	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
eye	NN	I-NP	O
.	.	O	O

From	IN	B-PP	O
present	JJ	B-NP	O
knowledge	NN	I-NP	O
about	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
adrenergic	JJ	B-NP	O
eye	NN	I-NP	O
drops	VBZ	B-VP	O
on	IN	B-PP	O
ocular	JJ	B-NP	O
blood	NN	I-NP	O
circulation	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
difficult	JJ	B-ADJP	O
to	TO	B-VP	O
suggest	VB	I-VP	O
an	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
events	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
coincidental	JJ	B-ADJP	O
only	RB	B-ADVP	O
.	.	O	O

Amelioration	NN	B-NP	O
of	IN	B-PP	O
bendrofluazide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypokalemia	NN	I-NP	B
by	IN	B-PP	O
timolol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
beta	NN	I-NP	O
adrenergic	JJ	I-NP	O
blocking	VBG	I-NP	O
drug	NN	I-NP	O
,	,	O	O
timolol	NN	B-NP	O
,	,	O	O
tended	VBD	B-VP	O
to	TO	I-VP	O
correct	VB	I-VP	O
the	DT	B-NP	O
hypokalemia	NN	I-NP	B
of	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
bendrofluazide	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
male	JJ	I-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
small	JJ	B-ADJP	O
it	PRP	B-NP	O
was	VBD	B-VP	O
significant	JJ	B-ADJP	O
.	.	O	O

Timolol	NN	B-NP	O
also	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
aldosterone	NN	I-NP	O
and	CC	O	O
urine	NN	B-NP	O
potassium	NN	I-NP	O
excretion	NN	I-NP	O
following	VBG	B-PP	O
bendrofluazide	NN	B-NP	O
and	CC	O	O
increased	VBD	B-VP	O
the	DT	B-NP	O
urine	NN	I-NP	O
sodium	NN	I-NP	O
/	SYM	B-NP	O
potassium	NN	I-NP	O
ratio	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
shift	NN	I-NP	O
of	IN	B-PP	O
potassium	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
intracellular	JJ	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
extracellular	JJ	I-NP	O
space	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
and	CC	I-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
on	IN	B-PP	O
bone	NN	B-NP	O
mineral	NN	I-NP	O
density	NN	I-NP	O
in	IN	B-PP	O
boys	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
on	IN	B-PP	O
trabecular	JJ	B-NP	O
bone	NN	I-NP	O
mineral	NN	I-NP	O
density	NN	I-NP	O
(	(	O	O
BMD	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
children	NNS	B-NP	O
and	CC	I-NP	O
adolescents	NNS	I-NP	O
.	.	O	O

Medically	RB	B-NP	O
healthy	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
males	NNS	I-NP	O
chronically	RB	B-VP	O
treated	VBN	I-VP	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
naturalistic	JJ	I-NP	O
setting	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
were	VBD	B-VP	O
recruited	VBN	I-VP	O
for	IN	B-PP	O
this	DT	B-NP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
study	NN	I-NP	O
through	IN	B-PP	O
child	NN	B-NP	O
psychiatry	NN	I-NP	O
outpatient	NN	I-NP	O
clinics	NNS	I-NP	O
between	IN	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
June	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

Anthropometric	JJ	B-NP	O
measurements	NNS	I-NP	O
and	CC	O	O
laboratory	NN	B-NP	O
testing	NN	I-NP	O
were	VBD	B-VP	O
conducted	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
diagnoses	NNS	I-NP	O
were	VBD	B-VP	O
based	VBN	I-VP	O
on	IN	B-PP	O
chart	NN	B-NP	O
review	NN	I-NP	O
,	,	O	O
and	CC	O	O
developmental	JJ	B-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
history	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
record	NN	I-NP	O
.	.	O	O

Volumetric	JJ	B-NP	O
BMD	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ultradistal	JJ	I-NP	O
radius	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
peripheral	JJ	B-NP	O
quantitative	JJ	I-NP	O
computed	VBN	I-NP	O
tomography	NN	I-NP	O
,	,	O	O
and	CC	O	O
areal	VBP	B-VP	O
BMD	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lumbar	NN	I-NP	O
spine	NN	I-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
using	VBG	B-VP	O
dual	JJ	B-NP	O
-	HYPH	I-NP	O
energy	NN	I-NP	O
x	SYM	O	O
-	HYPH	O	O
ray	NN	B-NP	O
absorptiometry	NN	I-NP	O
.	.	O	O

Hyperprolactinemia	NN	B-NP	B
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
boys	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
mean	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
testosterone	NN	I-NP	O
concentration	NN	I-NP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
pubertal	JJ	B-NP	O
status	NN	I-NP	O
but	CC	O	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
.	.	O	O

As	IN	B-SBAR	O
expected	VBN	B-VP	O
,	,	O	O
bone	NN	B-NP	O
mineral	NN	I-NP	O
content	NN	I-NP	O
and	CC	I-NP	O
BMD	NN	I-NP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
sexual	JJ	B-NP	O
maturity	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
adjusting	VBG	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
sexual	JJ	B-NP	O
development	NN	I-NP	O
and	CC	O	O
height	NN	B-NP	O
and	CC	I-NP	O
BMI	NN	I-NP	O
z	NN	I-NP	O
scores	NNS	I-NP	O
,	,	O	O
serum	NN	B-NP	O
prolactin	NN	I-NP	O
was	VBD	B-VP	O
negatively	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
trabecular	JJ	B-NP	O
volumetric	JJ	I-NP	O
BMD	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
ultradistal	JJ	I-NP	O
radius	NN	I-NP	O
.	.	O	O

Controlling	VBG	B-VP	O
for	IN	B-PP	O
relevant	JJ	B-NP	O
covariates	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
also	RB	B-ADVP	O
found	VBD	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
selective	JJ	B-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
(	(	O	O
SSRIs	NNS	B-NP	O
)	)	O	O
to	TO	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
lower	JJR	B-NP	O
trabecular	JJ	I-NP	O
BMD	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
radius	NN	I-NP	O
and	CC	I-NP	O
BMD	NN	I-NP	O
z	NN	I-NP	O
score	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
lumbar	NN	I-NP	O
spine	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
became	VBD	B-VP	O
more	RBR	B-ADJP	O
marked	VBN	I-ADJP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
was	VBD	B-VP	O
restricted	JJ	B-ADJP	O
to	TO	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
Hispanic	JJ	I-NP	O
white	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
documented	VBN	I-NP	O
fractures	NNS	I-NP	B
,	,	O	O
num	CD	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
risperidone	NN	B-NP	O
and	CC	I-NP	O
SSRIs	NNS	I-NP	O
were	VBD	B-VP	O
started	VBN	I-VP	O
,	,	O	O
and	CC	O	O
none	NN	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
link	VB	I-VP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
and	CC	I-NP	O
SSRI	NN	I-NP	O
treatment	NN	I-NP	O
to	TO	B-PP	O
lower	JJR	B-NP	O
BMD	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
and	CC	I-NP	O
adolescents	NNS	I-NP	O
.	.	O	O

Future	JJ	B-NP	O
research	NN	I-NP	O
should	MD	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
longitudinal	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
its	PRP$	B-NP	O
temporal	JJ	I-NP	O
stability	NN	I-NP	O
and	CC	O	O
whether	IN	B-SBAR	O
a	DT	B-NP	O
higher	JJR	I-NP	O
fracture	NN	I-NP	O
rate	NN	I-NP	O
ensues	NNS	I-NP	O
.	.	O	O

Seizures	NNS	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
levofloxacin	NN	B-NP	O
:	:	O	O
case	NN	B-NP	O
presentation	NN	I-NP	O
and	CC	O	O
literature	NN	B-NP	O
review	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
seizures	NNS	B-NP	B
shortly	RB	B-ADVP	O
after	IN	B-PP	O
initiating	VBG	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
levofloxacin	NN	B-NP	O
and	CC	O	O
to	TO	B-VP	O
discuss	VB	I-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
cytochrome	NN	B-NP	O
P450	NN	I-NP	O
(	(	O	O
CYP	NN	B-NP	O
)	)	O	O
1A2	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
in	IN	B-PP	O
other	JJ	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
of	IN	B-PP	O
levofloxacin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Several	JJ	B-NP	O
biomedical	JJ	I-NP	O
databases	NNS	I-NP	O
were	VBD	B-VP	O
searched	VBN	I-VP	O
including	VBG	B-PP	O
MEDLINE	NNP	B-NP	O
,	,	I-NP	O
Cochrane	NNP	I-NP	O
and	CC	I-NP	O
Ovid	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
search	NN	I-NP	O
terms	NNS	I-NP	O
utilized	VBN	B-VP	O
were	VBD	B-VP	O
case	NN	B-NP	O
report	NN	I-NP	O
and	CC	I-NP	O
levofloxacin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
search	NN	I-NP	O
was	VBD	B-VP	O
limited	VBN	I-VP	O
to	TO	B-PP	O
studies	NNS	B-NP	O
published	VBN	B-VP	O
in	IN	B-PP	O
English	NNP	B-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
levofloxacin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
CYP1A2	NN	B-NP	O
by	IN	B-PP	O
levofloxacin	NN	B-NP	O
are	VBP	B-VP	O
likely	RB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
outcome	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
are	VBP	B-VP	O
exhorted	VBN	I-VP	O
to	TO	I-VP	O
pay	VB	I-VP	O
close	JJ	B-NP	O
attention	NN	I-NP	O
when	WRB	B-ADVP	O
initiating	VBG	B-VP	O
levofloxacin	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
medications	NNS	B-NP	O
with	IN	B-PP	O
epileptogenic	JJ	B-NP	O
properties	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
CYP1A2	NN	B-NP	O
substrates	NNS	I-NP	O
.	.	O	O

Mice	NNS	B-NP	O
lacking	VBG	B-VP	O
mPGES	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
are	VBP	B-VP	O
resistant	JJ	B-ADJP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polyuria	NN	I-NP	B
.	.	O	O

Cyclooxygenase	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
activity	NN	I-NP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polyuria	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
,	,	I-NP	O
terminal	JJ	I-NP	O
prostaglandin	NN	I-NP	O
(	(	O	O
PG	NN	B-NP	O
)	)	O	O
isomerase	NN	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	I-VP	O
assess	VB	I-VP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polyuria	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
deficient	JJ	B-ADJP	O
in	IN	B-PP	O
microsomal	JJ	B-NP	O
prostaglandin	NN	I-NP	O
E	NN	I-NP	O
synthase	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
mPGES	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
wk	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
LiCl	NN	B-NP	O
in	IN	B-PP	O
mPGES	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
+	SYM	O	O
mice	NNS	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
polyuria	NN	I-NP	B
with	IN	B-PP	O
hyposmotic	JJ	B-NP	O
urine	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
elevated	JJ	B-NP	O
renal	JJ	I-NP	O
mPGES	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
urine	NN	B-NP	O
PGE	NN	I-NP	O
excretion	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
mPGES	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
largely	RB	B-ADJP	O
resistant	JJ	I-ADJP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
polyuria	NN	I-NP	B
and	CC	O	O
a	DT	B-NP	O
urine	NN	I-NP	O
concentrating	VBG	I-NP	O
defect	NN	I-NP	O
,	,	O	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
nearly	RB	B-NP	O
complete	JJ	I-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
urine	NN	I-NP	O
PGE	NN	I-NP	O
and	CC	O	O
cAMP	NN	B-NP	O
output	NN	I-NP	O
.	.	O	O

Immunoblotting	NN	B-NP	O
,	,	O	O
immunohistochemistry	NN	B-NP	O
,	,	O	O
and	CC	O	O
quantitative	JJ	B-ADJP	O
(	(	O	O
q	NN	B-NP	O
)	)	O	O
RT	NN	B-NP	O
-	HYPH	O	O
PCR	NN	B-NP	O
consistently	RB	B-ADVP	O
detected	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
aquaporin	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
AQP2	NN	B-NP	O
)	)	O	O
protein	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
renal	JJ	I-NP	O
cortex	NN	I-NP	O
and	CC	I-NP	O
medulla	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
+	SYM	B-VP	O
mice	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
decrease	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
attenuated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
-	HYPH	I-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
mice.	SYM	B-NP	O
qRT	NN	I-NP	O
-	HYPH	O	O
PCR	NN	B-NP	O
detected	VBD	B-VP	O
similar	JJ	B-NP	O
patterns	NNS	I-NP	O
of	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
AQP2	NN	B-NP	O
mRNA	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
medulla	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
total	JJ	I-NP	O
protein	NN	I-NP	O
abundance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Na	NN	I-NP	O
-	HYPH	B-NP	O
K	NN	I-NP	O
-	HYPH	O	O
2Cl	NN	B-NP	O
cotransporter	NN	I-NP	O
(	(	O	O
NKCC2	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
medulla	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
+	SYM	I-NP	O
/	SYM	I-NP	O
+	SYM	I-NP	O
mice	NNS	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
dowregulation	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
medullary	JJ	I-NP	O
NKCC2	NN	I-NP	O
expression	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
attenuated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
-	HYPH	I-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
mice	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
mPGES	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
derived	VBN	I-NP	O
PGE	NN	I-NP	O
mediates	VBZ	B-VP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polyuria	NN	I-NP	B
likely	RB	B-ADJP	O
via	IN	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
AQP2	NN	B-NP	O
and	CC	I-NP	O
NKCC2	NN	I-NP	O
expression	NN	I-NP	O
.	.	O	O

Identification	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
simple	JJ	I-NP	O
and	CC	I-NP	O
sensitive	JJ	I-NP	O
microplate	NN	I-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
oversulfated	JJ	B-NP	O
chondroitin	NN	I-NP	O
sulfate	NN	I-NP	O
in	IN	B-PP	O
heparin	NN	B-NP	O
products	NNS	I-NP	O
.	.	O	O

Heparin	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
commonly	RB	I-NP	O
implemented	VBN	I-NP	O
anticoagulant	NN	I-NP	O
used	VBN	B-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
critically	RB	B-NP	O
ill	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
commercial	JJ	B-NP	O
lots	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
products	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
contaminated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
oversulfated	JJ	I-NP	O
chondroitin	NN	I-NP	O
sulfate	NN	I-NP	O
(	(	O	O
OSCS	NN	B-NP	O
)	)	O	O
derivative	NN	B-NP	O
that	WDT	B-NP	O
could	MD	B-VP	O
elicit	VB	I-VP	O
a	DT	B-NP	O
hypotensive	JJ	I-NP	B
response	NN	I-NP	O
in	IN	B-PP	O
pigs	NNS	B-NP	O
following	VBG	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
both	CC	O	O
contaminated	VBN	B-NP	O
heparin	NN	I-NP	O
products	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
synthetically	RB	I-NP	O
produced	VBN	I-NP	O
derivative	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
OSCS	NN	I-NP	O
produces	VBZ	B-VP	O
dose	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
pigs	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
no	DT	I-NP	O
observed	VBN	I-NP	O
effect	NN	I-NP	O
level	NN	I-NP	O
(	(	O	O
NOEL	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
this	DT	B-NP	O
contaminant	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
approximately	RB	B-NP	O
1mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
corresponding	VBG	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
contamination	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
OSCS	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
heparin	NN	B-NP	O
products	NNS	I-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
simple	JJ	I-NP	O
,	,	I-NP	O
inexpensive	JJ	I-NP	O
,	,	I-NP	O
commercially	RB	I-NP	O
available	JJ	I-NP	O
heparin	NN	I-NP	O
enzyme	NN	I-NP	O
immunoassay	NN	I-NP	O
(	(	O	O
EIA	NN	B-NP	O
)	)	O	O
kit	NN	B-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
limit	NN	I-NP	O
of	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
well	RB	B-ADVP	O
below	IN	B-PP	O
the	DT	B-NP	O
NOEL	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
kit	NN	I-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
method	NN	I-NP	O
to	TO	B-VP	O
test	VB	I-VP	O
heparin	NN	B-NP	O
products	NNS	I-NP	O
for	IN	B-PP	O
contamination	NN	B-NP	O
with	IN	B-PP	O
oversulfated	JJ	B-NP	O
GAG	NN	I-NP	O
derivatives	NNS	I-NP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
cardiomyopathy	NN	I-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
inflammation	NN	I-NP	B
and	CC	I-NP	O
apoptosis	NN	I-NP	O
are	VBP	B-VP	O
attenuated	VBN	I-VP	O
by	IN	B-PP	O
gene	NN	B-NP	O
deletion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kinin	NN	I-NP	O
B1	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anthracycline	NN	I-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
limited	VBN	I-VP	O
by	IN	B-PP	O
its	PRP$	B-NP	O
cardiotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
apoptosis	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
elucidate	VB	I-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kinin	NN	I-NP	O
B1	NN	I-NP	O
receptor	NN	I-NP	O
(	(	O	O
B1R	NN	B-NP	O
)	)	O	O
during	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
cardiomyopathy	NN	I-NP	B
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
B1R	NN	B-NP	O
knockout	NN	I-NP	O
mice	NNS	I-NP	O
(	(	O	O
B1R	NN	B-NP	O
)	)	O	O
by	IN	B-PP	O
investigating	VBG	B-VP	O
cardiac	JJ	B-NP	O
inflammation	NN	I-NP	B
and	CC	I-NP	O
apoptosis	NN	I-NP	O
after	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

DOX	NN	B-NP	O
control	NN	I-NP	O
mice	NNS	I-NP	O
showed	VBD	B-VP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
measured	VBN	B-VP	O
by	IN	B-PP	O
pressure	NN	B-NP	O
-	HYPH	O	O
volume	NN	B-NP	O
loops	VBZ	B-VP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
activation	NN	I-NP	O
state	NN	I-NP	O
of	IN	B-PP	O
AKT	NN	B-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
bax	NN	I-NP	O
/	SYM	O	O
bcl2	NN	B-NP	O
ratio	NN	I-NP	O
in	IN	B-PP	O
Western	JJ	B-NP	O
blots	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
cardiac	JJ	B-NP	B
apoptosis	NN	I-NP	I
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
mRNA	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
proinflammatory	JJ	I-NP	O
cytokine	NN	I-NP	O
interleukin	NN	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
tissue	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
DOX	NN	B-NP	O
B1R	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
was	VBD	B-VP	O
improved	VBN	I-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
DOX	NN	B-NP	O
control	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
normalization	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bax	NN	I-NP	O
/	SYM	B-NP	O
bcl	NN	I-NP	O
-	SYM	O	O
num	CD	B-NP	O
ratio	NN	I-NP	O
and	CC	O	O
interleukin	NN	B-NP	O
num	CD	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
AKT	NN	B-NP	O
activation	NN	I-NP	O
state	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
B1R	NN	B-NP	O
is	VBZ	B-VP	O
detrimental	JJ	B-ADJP	O
in	IN	B-PP	O
DOX	NN	B-NP	O
cardiomyopathy	NN	I-NP	B
in	IN	B-PP	O
that	IN	B-NP	O
it	PRP	B-NP	O
mediates	VBZ	B-VP	O
the	DT	B-NP	O
inflammatory	JJ	I-NP	O
response	NN	I-NP	O
and	CC	I-NP	O
apoptosis	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
insights	NNS	I-NP	O
might	MD	B-VP	O
have	VB	I-VP	O
useful	JJ	B-NP	O
implications	NNS	I-NP	O
for	IN	B-PP	O
future	JJ	B-NP	O
studies	NNS	I-NP	O
utilizing	VBG	B-VP	O
B1R	NN	B-NP	O
antagonists	NNS	I-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
DOX	NN	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

Hepatotoxicity	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
sulfasalazine	NN	B-NP	O
in	IN	B-PP	O
inflammatory	JJ	B-NP	O
arthritis	NN	I-NP	B
:	:	O	O
A	DT	B-NP	O
case	NN	I-NP	O
series	NN	I-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
local	JJ	I-NP	O
surveillance	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
.	.	O	O

Spontaneous	JJ	B-NP	O
reporting	NN	I-NP	O
systems	NNS	I-NP	O
for	IN	B-PP	O
adverse	JJ	B-NP	O
drug	NN	I-NP	O
reactions	NNS	I-NP	O
(	(	O	O
ADRs	NNS	B-NP	O
)	)	O	O
are	VBP	B-VP	O
handicapped	VBN	I-VP	O
by	IN	B-PP	O
under	IN	B-PP	O
-	HYPH	B-NP	O
reporting	VBG	I-NP	O
and	CC	I-NP	O
limited	JJ	I-NP	O
detail	NN	I-NP	O
on	IN	B-PP	O
individual	JJ	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
an	DT	B-NP	O
investigation	NN	I-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
local	JJ	I-NP	O
surveillance	NN	I-NP	O
for	IN	B-PP	O
serious	JJ	B-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reactions	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
disease	NN	B-NP	O
modifying	VBG	B-VP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
rheumatic	JJ	I-NP	O
drugs	NNS	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
triggered	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Serious	JJ	B-NP	O
ADR	NN	I-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
solicited	VBN	I-VP	O
from	IN	B-PP	O
local	JJ	B-NP	O
clinicians	NNS	I-NP	O
by	IN	B-PP	O
regular	JJ	B-NP	O
postcards	NNS	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
past	JJ	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
'	POS	B-NP	O
,	,	O	O
who	WP	B-NP	O
had	VBD	B-VP	B
hepatotoxicity	NN	B-NP	O
on	IN	B-PP	O
sulfasalazine	NN	B-NP	O
and	CC	O	O
met	VBD	B-VP	O
a	DT	B-NP	O
definition	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
serious	JJ	I-NP	O
ADR	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
clinicians	NNS	I-NP	O
reviewed	VBD	B-VP	O
structured	VBN	I-VP	O
case	NN	B-NP	O
reports	NNS	I-NP	O
and	CC	O	O
assessed	VBN	B-NP	O
causality	NN	I-NP	O
by	IN	B-PP	O
consensus	NN	B-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
using	VBG	B-VP	O
a	DT	B-NP	O
causality	NN	I-NP	O
assessment	NN	I-NP	O
instrument	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
likely	JJ	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
with	IN	B-PP	O
sulfasalazine	NN	B-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
by	IN	B-PP	O
making	VBG	B-VP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
conservative	JJ	B-NP	O
assumptions	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
occurred	VBD	B-VP	O
during	IN	B-PP	O
surveillance	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
hospitalised	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
in	IN	B-PP	O
hepatic	JJ	B-NP	B
failure	NN	I-NP	I
-	HYPH	B-NP	O
num	CD	I-NP	O
died	VBD	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
liver	NN	I-NP	O
transplant	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
but	IN	I-NP	O
num	CD	I-NP	O
event	NN	I-NP	O
occurred	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
skin	NN	I-NP	B
rash	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
eosinophilia	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
of	IN	B-PP	O
Black	JJ	B-NP	O
British	NNP	I-NP	O
of	IN	B-PP	O
African	JJ	B-NP	O
or	CC	I-NP	O
Caribbean	JJ	I-NP	O
descent	NN	I-NP	O
.	.	O	O

Liver	NN	B-NP	O
enzymes	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
hepatocellular	JJ	I-NP	O
pattern	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
mixed	VBN	I-NP	O
pattern	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	I-NP	O
related	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
was	VBD	B-VP	O
judged	VBN	I-VP	O
probable	JJ	B-ADJP	O
or	CC	O	O
highly	RB	B-ADJP	O
probable	JJ	I-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
likely	JJ	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
hepatotoxicity	NN	I-NP	B
with	IN	B-PP	O
sulfasalazine	NN	B-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
treated	VBN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Serious	JJ	B-NP	O
hepatotoxicity	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
sulfasalazine	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
under	IN	B-PP	O
-	HYPH	B-NP	O
appreciated	VBN	I-NP	O
and	CC	I-NP	O
intensive	JJ	I-NP	O
monitoring	NN	I-NP	O
and	CC	I-NP	O
vigilance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
is	VBZ	B-VP	O
especially	RB	B-ADJP	O
important	JJ	I-ADJP	O
.	.	O	O

An	DT	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
amikacin	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
hematology	NN	I-NP	O
/	SYM	B-NP	O
oncology	NN	I-NP	O
population	NN	I-NP	O
.	.	O	O

Amikacin	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
aminoglycoside	NN	I-NP	O
commonly	RB	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
provide	VB	I-VP	O
empirical	JJ	B-NP	O
double	JJ	I-NP	O
gram	NN	I-NP	O
-	HYPH	B-NP	O
negative	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
febrile	JJ	B-NP	B
neutropenia	NN	I-NP	I
and	CC	O	O
other	JJ	B-NP	O
suspected	VBN	I-NP	O
infections	NNS	I-NP	B
.	.	O	O

Strategies	NNS	B-NP	O
of	IN	B-PP	O
extended	VBN	B-NP	O
-	HYPH	I-NP	O
interval	JJ	I-NP	O
and	CC	I-NP	O
conventional	JJ	I-NP	O
dosing	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
utilized	VBN	I-VP	O
extensively	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
general	JJ	I-NP	O
medical	JJ	I-NP	O
population	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
data	NNS	B-NP	O
are	VBP	B-VP	O
lacking	VBG	I-VP	O
to	TO	I-VP	O
support	VB	I-VP	O
a	DT	B-NP	O
dosing	NN	I-NP	O
strategy	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hematology	NN	I-NP	O
/	SYM	B-NP	O
oncology	NN	I-NP	O
population	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
amikacin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
an	DT	B-NP	O
adult	JJ	I-NP	O
hematology	NN	I-NP	O
/	SYM	B-NP	O
oncology	NN	I-NP	O
population	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
trial	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
university	NN	I-NP	O
-	HYPH	O	O
affiliated	VBN	B-VP	O
medical	JJ	B-NP	O
center	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
diagnosis	NN	I-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
a	DT	B-NP	O
hematologic	JJ	I-NP	B
/	SYM	I-NP	I
oncologic	JJ	I-NP	I
disorder	NN	I-NP	I
that	WDT	B-NP	O
required	VBD	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
aminoglycoside	NN	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-PP	O
either	CC	O	O
conventional	JJ	B-NP	O
or	CC	I-NP	O
extended	JJ	I-NP	O
-	HYPH	I-NP	O
interval	NN	I-NP	O
amikacin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
and	CC	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
efficacy	NN	B-NP	O
via	IN	B-PP	O
amikacin	NN	B-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
with	IN	B-PP	O
respective	JJ	B-NP	O
pathogens	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
and	CC	I-NP	O
extended	JJ	I-NP	O
-	HYPH	I-NP	O
interval	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
at	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
culture	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
none	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
extended	VBN	I-NP	O
-	HYPH	I-NP	O
interval	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
dosing	NN	I-NP	O
regimens	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
was	VBD	B-VP	O
variable	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Efficacy	NN	B-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
assessed	VBN	I-VP	O
.	.	O	O

Memory	NN	B-NP	O
function	NN	I-NP	O
and	CC	O	O
serotonin	NN	B-NP	O
transporter	NN	I-NP	O
promoter	NN	I-NP	O
gene	NN	I-NP	O
polymorphism	NN	I-NP	O
in	IN	B-PP	O
ecstasy	NN	B-NP	O
(	(	O	O
MDMA	NN	B-NP	O
)	)	O	O
users	NNS	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methylenedioxymethamphetamine	NN	I-NP	O
(	(	O	O
MDMA	NN	B-NP	O
or	CC	O	O
ecstasy	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
damage	VB	I-VP	O
brain	NN	B-NP	O
serotonin	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
)	)	O	O
neurons	NNS	B-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
and	CC	O	O
possibly	RB	B-NP	O
humans	NNS	I-NP	O
,	,	O	O
little	JJ	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
about	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
consequences	NNS	I-NP	O
of	IN	B-PP	O
MDMA	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
neurotoxic	JJ	I-NP	B
lesions	NNS	I-NP	I
on	IN	B-PP	O
functions	NNS	B-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
transporters	NNS	I-NP	O
play	VBP	B-VP	O
a	DT	B-NP	O
key	JJ	I-NP	O
element	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
synaptic	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
transmission	NN	I-NP	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
control	VB	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
covariance	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
polymorphism	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
transporter	NN	I-NP	O
promoter	NN	I-NP	O
gene	NN	I-NP	O
region	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HTTLPR	NN	I-NP	O
)	)	O	O
when	WRB	B-ADVP	O
studying	VBG	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
MDMA	NN	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
cognitive	JJ	B-NP	O
functioning	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
moderate	JJ	B-NP	O
and	CC	I-NP	O
heavy	JJ	I-NP	O
MDMA	NN	I-NP	O
use	NN	I-NP	O
on	IN	B-PP	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
abstention	NN	I-NP	O
from	IN	B-PP	O
MDMA	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
genotyped	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HTTLPR	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
second	JJ	I-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
these	DT	B-NP	O
effects	NNS	I-NP	O
differ	VBP	B-VP	O
for	IN	B-PP	O
females	NNS	B-NP	O
and	CC	I-NP	O
males	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
moderate	JJ	I-NP	O
MDMA	NN	I-NP	O
users	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
heavy	JJ	I-NP	O
MDMA	NN	I-NP	O
+	SYM	B-NP	O
users	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
ex	NN	I-NP	O
-	HYPH	I-NP	O
MDMA	NN	I-NP	O
+	SYM	B-NP	O
users	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
battery	NN	I-NP	O
of	IN	B-PP	O
neuropsychological	JJ	B-NP	O
tests	NNS	I-NP	O
.	.	O	O

DNA	NN	B-NP	O
from	IN	B-PP	O
peripheral	JJ	B-NP	O
nuclear	JJ	I-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
genotyped	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HTTLPR	NN	I-NP	O
using	VBG	B-VP	O
standard	JJ	B-NP	O
polymerase	NN	I-NP	O
chain	NN	I-NP	O
reaction	NN	I-NP	O
methods.A	NN	I-NP	O
significant	JJ	I-NP	O
group	NN	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
only	RB	B-ADVP	O
on	IN	B-PP	O
memory	NN	B-NP	O
function	NN	I-NP	O
tasks	NNS	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
on	IN	I-PP	O
reaction	NN	B-NP	O
times	NNS	I-NP	O
or	CC	I-NP	O
attention	NN	I-NP	O
/	SYM	B-NP	O
executive	NN	B-NP	O
functioning	NN	I-NP	O
.	.	O	O

Heavy	NN	B-NP	O
and	CC	I-NP	O
ex	NN	I-NP	O
-	HYPH	B-NP	O
MDMA	NN	I-NP	O
+	SYM	I-NP	O
users	NNS	I-NP	O
performed	VBD	B-VP	O
significantly	RB	B-ADJP	O
poorer	JJR	I-ADJP	O
on	IN	B-PP	O
memory	NN	B-NP	O
tasks	NNS	I-NP	O
than	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
memory	NN	B-NP	B
impairment	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
moderate	JJ	B-NP	O
MDMA	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HTTLPR	NN	I-NP	O
or	CC	I-NP	O
gender	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

While	IN	B-SBAR	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
MDMA	NN	B-NP	O
in	IN	B-PP	O
quantities	NNS	B-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
moderate	JJ	B-ADJP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
impaired	JJ	B-NP	B
memory	NN	I-NP	I
functioning	VBG	B-VP	I
,	,	O	O
heavy	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
MDMA	NN	B-NP	O
use	NN	I-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
long	JJ	B-NP	O
lasting	JJ	I-NP	O
memory	NN	I-NP	B
impairments	NNS	I-NP	I
.	.	O	O

No	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HTTLPR	NN	I-NP	O
or	CC	I-NP	O
gender	NN	I-NP	O
on	IN	B-PP	O
memory	NN	B-NP	O
function	NN	I-NP	O
or	CC	O	O
MDMA	NN	B-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Aging	VBG	B-VP	O
process	NN	B-NP	O
of	IN	B-PP	O
epithelial	JJ	B-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
prostate	NN	I-NP	O
lateral	JJ	I-NP	O
lobe	NN	I-NP	O
in	IN	B-PP	O
experimental	JJ	B-NP	O
hyperprolactinemia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
,	,	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
(	(	O	O
HAL	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
age	NN	B-NP	O
related	VBN	I-NP	O
morphology	NN	I-NP	O
and	CC	I-NP	O
function	NN	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
epithelial	JJ	B-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
prostate	NN	I-NP	O
lateral	JJ	I-NP	O
lobe	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
sexually	RB	B-NP	O
mature	JJ	I-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
prolactin	NN	B-NP	O
(	(	O	O
PRL	NN	B-NP	O
)	)	O	O
and	CC	O	O
testosterone	NN	B-NP	O
(	(	O	O
T	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
.	.	O	O

Tissue	NN	B-NP	O
sections	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
with	IN	B-PP	O
light	NN	B-NP	O
and	CC	I-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
.	.	O	O

Immunohistochemical	JJ	B-NP	O
reactions	NNS	I-NP	O
for	IN	B-PP	O
Anti	AFX	B-NP	O
-	HYPH	I-NP	O
Proliferating	VBG	B-VP	O
Cell	NN	B-NP	O
Nuclear	JJ	I-NP	O
Antigen	NN	I-NP	O
(	(	O	O
PCNA	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
rats	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
:	:	O	O
PRL	NN	B-NP	O
was	VBD	B-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
twice	RB	I-NP	O
higher	JJR	I-NP	O
,	,	O	O
whereas	IN	O	O
T	NN	B-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
almost	RB	B-ADJP	O
twice	RB	I-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Light	NN	B-NP	O
microscopy	NN	I-NP	O
visualized	VBD	B-VP	O
the	DT	B-NP	O
following	NN	I-NP	O
:	:	O	O
hypertrophy	NN	B-NP	B
and	CC	I-NP	O
epithelium	NN	I-NP	O
hyperplasia	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
glandular	JJ	I-NP	O
ducts	NNS	I-NP	O
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
PCNA	NN	I-NP	O
expression	NN	I-NP	O
.	.	O	O

Electron	NN	B-NP	O
microscopy	NN	I-NP	O
revealed	VBD	B-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
columnar	JJ	B-NP	O
epithelial	JJ	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
concerning	VBG	B-VP	O
organelles	NNS	B-NP	O
,	,	O	O
engaged	VBN	B-VP	O
in	IN	B-PP	O
protein	NN	B-NP	O
synthesis	NN	I-NP	O
and	CC	I-NP	O
secretion	NN	I-NP	O
.	.	O	O

Does	VBZ	O	O
supplemental	JJ	B-NP	O
vitamin	NN	I-NP	O
C	NN	I-NP	O
increase	VBP	B-VP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
risk	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
diabetes	NN	B-NP	B
?	.	O	O
BACKGROUND	NN	B-NP	O
:	:	O	O
Vitamin	NN	B-NP	O
C	NN	I-NP	O
acts	VBZ	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
antioxidant	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
can	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
prooxidant	NN	I-NP	O
and	CC	I-NP	O
glycate	NN	I-NP	O
protein	NN	I-NP	O
under	IN	B-PP	O
certain	JJ	B-NP	O
circumstances	NNS	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
led	VBD	B-VP	O
us	PRP	B-NP	O
to	TO	B-VP	O
hypothesize	VB	I-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
high	JJ	I-NP	O
intake	NN	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
C	NN	I-NP	O
in	IN	B-PP	O
diabetic	JJ	B-NP	B
persons	NNS	I-NP	O
might	MD	B-VP	O
promote	VB	I-VP	O
atherosclerosis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
relation	NN	I-NP	O
between	IN	B-PP	O
vitamin	NN	B-NP	O
C	NN	I-NP	O
intake	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
from	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
relation	NN	I-NP	O
between	IN	B-PP	O
vitamin	NN	B-NP	O
C	NN	I-NP	O
intake	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
from	IN	B-PP	O
total	JJ	B-NP	O
cardiovascular	JJ	I-NP	B
disease	NN	I-NP	I
,	,	O	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
stroke	VBD	B-VP	B
in	IN	B-PP	O
num	CD	B-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
who	WP	B-NP	O
reported	VBD	B-VP	O
being	VBG	I-VP	O
diabetic	JJ	B-ADJP	B
at	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

Diet	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
food	NN	I-NP	O
-	HYPH	I-NP	O
frequency	NN	I-NP	O
questionnaire	NN	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
and	CC	O	O
subjects	NNS	B-NP	O
initially	RB	B-ADJP	O
free	JJ	I-ADJP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
were	VBD	B-VP	O
prospectively	RB	I-VP	O
followed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
y	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
adjustment	NN	B-NP	O
for	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
risk	NN	I-NP	O
factors	NNS	I-NP	O
,	,	O	O
type	NN	B-NP	O
of	IN	B-PP	O
diabetes	NN	B-NP	B
medication	NN	I-NP	O
used	VBN	B-VP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
diabetes	NN	B-NP	B
,	,	O	O
and	CC	O	O
intakes	NNS	B-NP	O
of	IN	B-PP	O
folate	NN	B-NP	O
,	,	O	O
vitamin	NN	B-NP	O
E	NN	I-NP	O
,	,	O	O
and	CC	O	O
beta	SYM	O	O
-	HYPH	O	O
carotene	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
adjusted	VBN	I-NP	O
relative	JJ	I-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
cardiovascular	JJ	I-NP	B
disease	NN	I-NP	I
mortality	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
across	IN	B-PP	O
quintiles	NNS	B-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
vitamin	NN	I-NP	O
C	NN	I-NP	O
intake	NN	I-NP	O
from	IN	B-PP	O
food	NN	B-NP	O
and	CC	I-NP	O
supplements	NNS	I-NP	O
.	.	O	O

Adjusted	VBN	B-NP	O
relative	JJ	I-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
were	VBD	B-VP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
and	CC	O	O
of	IN	B-PP	O
stroke	NN	B-NP	B
were	VBD	B-VP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
dietary	JJ	B-NP	O
and	CC	I-NP	O
supplemental	JJ	I-NP	O
vitamin	NN	I-NP	O
C	NN	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
separately	RB	B-ADVP	O
,	,	O	O
only	RB	B-NP	O
supplemental	JJ	I-NP	O
vitamin	NN	I-NP	O
C	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
mortality	NN	B-NP	O
endpoints	NNS	I-NP	O
.	.	O	O

Vitamin	NN	B-NP	O
C	NN	I-NP	O
intake	NN	I-NP	O
was	VBD	B-VP	O
unrelated	JJ	B-ADJP	O
to	TO	B-PP	O
mortality	NN	B-NP	O
from	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
nondiabetic	JJ	I-NP	O
subjects	NNS	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
high	JJ	I-NP	O
vitamin	NN	I-NP	O
C	NN	I-NP	O
intake	NN	I-NP	O
from	IN	B-PP	O
supplements	NNS	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
mortality	NN	I-NP	O
in	IN	B-PP	O
postmenopausal	JJ	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
diabetes	NN	B-NP	B
.	.	O	O

Absolute	JJ	B-NP	O
and	CC	I-NP	O
attributable	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
in	IN	B-PP	O
women	NNS	B-NP	O
on	IN	B-PP	O
combined	VBN	B-NP	O
cyproterone	NN	I-NP	O
acetate	NN	I-NP	O
and	CC	I-NP	O
ethinylestradiol	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
achieve	VB	I-VP	O
absolute	JJ	B-NP	O
risk	NN	I-NP	O
estimates	NNS	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
(	(	O	O
VTE	NN	B-NP	B
)	)	O	O
among	IN	B-PP	O
women	NNS	B-NP	O
on	IN	B-PP	O
cyproterone	NN	B-NP	O
acetate	NN	I-NP	O
plus	CC	O	O
ethinylestradiol	NN	B-NP	O
(	(	O	O
CPA	NN	B-NP	O
/	SYM	O	O
EE	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
among	IN	B-PP	O
women	NNS	B-NP	O
on	IN	B-PP	O
combined	JJ	B-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
(	(	O	O
COCs	NNS	B-NP	O
)	)	O	O
.	.	O	O

From	IN	B-PP	O
the	DT	B-NP	O
Danish	NNP	I-NP	O
National	NNP	I-NP	O
Register	NNP	I-NP	O
of	IN	B-PP	O
Patients	NNP	B-NP	O
(	(	O	O
NRP	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
the	DT	B-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
Danish	JJ	I-NP	O
women	NNS	I-NP	O
,	,	O	O
ages	NNS	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
searched	VBN	I-VP	O
for	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
.	.	O	O

COC	NN	B-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
ascertained	VBN	I-VP	O
through	IN	B-PP	O
mailed	JJ	B-NP	O
questionnaires	NNS	I-NP	O
.	.	O	O

Sales	NNS	B-NP	O
statistics	NNS	I-NP	O
of	IN	B-PP	O
COCs	NNS	B-NP	O
and	CC	O	O
CPA	NN	B-NP	O
/	SYM	I-NP	O
EE	NN	I-NP	O
were	VBD	B-VP	O
provided	VBN	I-VP	O
through	IN	B-PP	O
Danish	NNP	B-NP	O
Drug	NNP	I-NP	O
Statistics	NNPS	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
frame	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
had	VBN	I-VP	O
VTE	NNP	B-NP	B
while	IN	B-SBAR	O
on	IN	B-PP	O
COCs	NNS	B-NP	O
.	.	O	O

Of	IN	B-PP	O
these	DT	B-NP	O
women	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
on	IN	B-PP	O
levonorgestrel	NN	B-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
COCs	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
were	VBD	B-VP	O
on	IN	B-PP	O
CPA	NN	B-NP	O
/	SYM	B-NP	O
EE	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
corresponding	VBG	I-NP	O
absolute	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
per	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
women	NNS	I-NP	O
years	NNS	I-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
women	NNS	I-NP	O
on	IN	B-PP	O
COCs	NNS	B-NP	O
,	,	O	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
per	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
women	NNS	I-NP	O
years	NNS	I-NP	O
among	IN	B-PP	O
women	NNS	B-NP	O
on	IN	B-PP	O
levonorgestrel	NN	B-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
COCs	NNS	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
per	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
women	NNS	I-NP	O
years	NNS	I-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
women	NNS	I-NP	O
on	IN	B-PP	O
CPA	NN	B-NP	O
/	SYM	I-NP	O
EE	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
the	DT	B-NP	O
absolute	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
among	IN	B-PP	O
Danish	JJ	B-NP	O
women	NNS	I-NP	O
on	IN	B-PP	O
COCs	NNS	B-NP	O
is	VBZ	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
among	IN	B-PP	O
women	NNS	B-NP	O
taking	VBG	B-VP	O
CPA	NN	B-NP	O
/	SYM	I-NP	O
EE	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
on	IN	B-PP	O
hepatic	JJ	B-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
cytochrome	NN	I-NP	O
P450s	NNS	I-NP	O
and	CC	I-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
P450	NN	B-NP	O
modulation	NN	I-NP	O
in	IN	B-PP	O
lindane	NN	B-NP	O
induced	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
produce	VB	I-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
P450	NN	B-NP	O
dependent	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
ethoxyresorufin	NN	I-NP	O
-	HYPH	B-NP	O
O	NN	I-NP	O
-	HYPH	O	O
deethylase	NN	B-NP	O
(	(	O	O
EROD	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
pentoxyresorufin	NN	I-NP	O
-	HYPH	B-NP	O
O	NN	I-NP	O
-	HYPH	O	O
dealkylase	NN	B-NP	O
(	(	O	O
PROD	NN	B-NP	O
)	)	O	O
and	CC	O	O
N	NN	B-NP	O
-	HYPH	O	O
nitrosodimethylamine	NN	B-NP	O
demethylase	NN	I-NP	O
(	(	O	O
NDMA	NN	B-NP	O
-	HYPH	B-NP	O
d	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
rat	NN	B-NP	O
brain	NN	I-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hepatic	JJ	I-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
P450	NN	I-NP	O
monooxygenases	NNS	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
exposure	NN	B-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
observed	VBN	B-VP	O
with	IN	B-PP	O
different	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
induction	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
P450	NN	B-NP	O
monooxygenases	NNS	I-NP	O
was	VBD	B-VP	O
several	JJ	B-ADJP	O
fold	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
liver	NN	B-NP	O
microsomes	NNS	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Western	NN	B-NP	O
blotting	NN	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
indicated	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
P450	NN	I-NP	O
enzymes	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
P450	NN	B-NP	O
1A1	NN	I-NP	O
/	SYM	B-NP	O
1A2	NN	I-NP	O
,	,	O	O
2B1	NN	B-NP	O
/	SYM	B-NP	O
2B2	NN	I-NP	O
and	CC	I-NP	O
2E1	NN	I-NP	O
isoenzymes	NNS	I-NP	O
.	.	O	O

In	FW	B-NP	O
vitro	FW	I-NP	O
studies	NNS	I-NP	O
using	VBG	B-VP	O
organic	JJ	B-NP	O
inhibitors	NNS	I-NP	O
specific	JJ	B-ADJP	O
for	IN	B-PP	O
individual	JJ	B-NP	O
P450	NN	I-NP	O
isoenzymes	NNS	I-NP	O
and	CC	O	O
antibody	NN	B-NP	O
inhibition	NN	I-NP	O
experiments	NNS	I-NP	O
have	VBP	B-VP	O
further	RBR	I-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
PROD	NN	B-NP	O
,	,	I-NP	O
EROD	NN	I-NP	O
and	CC	I-NP	O
NDMA	NN	I-NP	O
-	HYPH	B-NP	O
d	NN	I-NP	O
are	VBP	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
P450	NN	B-NP	O
2B1	NN	I-NP	O
/	SYM	B-NP	O
2B2	NN	I-NP	O
,	,	O	O
1A1	NN	B-NP	O
/	SYM	B-NP	O
1A2	NN	I-NP	O
and	CC	I-NP	O
2E1	NN	I-NP	O
isoenzymes	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Induction	NN	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
further	RBR	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
while	IN	B-SBAR	O
pretreatment	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methylcholanthrene	NN	I-NP	O
(	(	O	O
MC	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
inducer	NN	I-NP	O
of	IN	B-PP	O
P4501A1	NN	B-NP	O
/	SYM	O	O
1A2	NN	B-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
any	DT	B-NP	O
significant	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
,	,	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
phenobarbital	NN	B-NP	O
(	(	O	O
PB	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
inducer	NN	I-NP	O
of	IN	B-PP	O
P450	NN	B-NP	O
2B1	NN	I-NP	O
/	SYM	B-VP	O
2B2	NN	B-NP	O
or	CC	I-NP	O
ethanol	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
inducer	NN	I-NP	O
of	IN	B-PP	O
P450	NN	B-NP	O
2E1	NN	I-NP	O
catalysed	VBD	B-VP	O
reactions	NNS	B-NP	O
,	,	O	O
significantly	RB	B-VP	O
increased	VBD	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
P450	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
metabolism	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
was	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
cobalt	NN	B-NP	O
chloride	NN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
convulsions	NNS	B-NP	B
was	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
lindane	NN	B-NP	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
lindane	NN	B-NP	O
per	FW	B-ADVP	O
se	FW	I-ADVP	O
or	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
formed	VBN	B-VP	O
by	IN	B-PP	O
PB	NN	B-NP	O
or	CC	I-NP	O
ethanol	NN	I-NP	O
inducible	JJ	I-NP	O
P450	NN	I-NP	O
isoenzymes	NNS	I-NP	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
its	PRP$	B-NP	O
neurobehavioral	JJ	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Seizure	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
sleep	NN	B-NP	B
deprivation	NN	I-NP	I
and	CC	O	O
sustained	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
bupropion	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
a	DT	B-NP	O
generalized	VBN	I-NP	O
seizure	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
sustained	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
bupropion	NN	I-NP	O
use	NN	I-NP	O
and	CC	O	O
sleep	NN	B-NP	B
deprivation	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
subject	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	JJ	I-NP	O
smoker	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
participating	VBG	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
evaluating	VBG	B-VP	O
an	DT	B-NP	O
investigational	JJ	I-NP	O
medication	NN	I-NP	O
for	IN	B-PP	O
smoking	NN	B-NP	O
cessation	NN	I-NP	O
that	WDT	B-NP	O
used	VBD	B-VP	O
sustained	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
bupropion	NN	I-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
active	JJ	I-NP	O
control	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
subject	NN	I-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
generalized	VBN	I-NP	O
tonic	JJ	I-NP	O
clonic	JJ	I-NP	O
seizure	NN	I-NP	B
after	IN	B-PP	O
staying	VBG	B-VP	O
up	RP	B-PRT	O
nearly	RB	B-NP	O
all	DT	I-NP	O
night	NN	I-NP	O
packing	NN	I-NP	O
and	CC	O	O
moving	VBG	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
residence	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
other	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
sleep	NN	B-NP	B
deprivation	NN	I-NP	I
may	MD	B-VP	O
add	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bupropion	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Nephrotoxic	JJ	B-NP	B
effects	NNS	I-NP	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
angiography	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
iodinated	VBN	B-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
can	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
nephropathy	NN	B-NP	B
.	.	O	O

Whether	IN	B-SBAR	O
iso	AFX	B-NP	O
-	HYPH	I-NP	O
osmolar	JJ	I-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
is	VBZ	B-VP	O
less	RBR	B-ADJP	O
nephrotoxic	JJ	I-ADJP	B
than	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
osmolar	JJ	I-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	B-NP	O
patients	NNS	I-NP	O
is	VBZ	B-VP	O
uncertain	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
multicenter	JJ	I-NP	O
study	NN	I-NP	O
comparing	VBG	B-VP	O
the	DT	B-NP	O
nephrotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
iso	AFX	I-NP	O
-	HYPH	I-NP	O
osmolar	JJ	I-NP	O
,	,	I-NP	O
dimeric	JJ	I-NP	O
,	,	I-NP	O
nonionic	JJ	I-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
,	,	O	O
iodixanol	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
osmolar	JJ	I-NP	O
,	,	I-NP	O
nonionic	JJ	I-NP	O
,	,	I-NP	O
monomeric	JJ	I-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
,	,	O	O
iohexol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
involved	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
diabetes	NN	B-NP	B
with	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
coronary	JJ	B-NP	O
or	CC	I-NP	O
aortofemoral	JJ	I-NP	O
angiography	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
end	NN	I-NP	O
point	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
peak	JJ	I-NP	O
increase	NN	I-NP	O
from	IN	B-PP	O
base	NN	B-NP	O
line	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
angiography	NN	B-NP	O
.	.	O	O

Other	JJ	B-NP	O
end	NN	I-NP	O
points	NNS	I-NP	O
were	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
or	CC	O	O
more	JJR	B-NP	O
,	,	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
or	CC	O	O
more	JJR	B-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
iodixanol	NN	B-NP	O
.	.	O	O

From	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
peak	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
creatinine	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
iodixanol	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
iohexol	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
iodixanol	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
)	)	O	O
had	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
or	CC	O	O
more	JJR	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
iohexol	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
)	)	O	O
.	.	O	O

No	DT	B-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
iodixanol	NN	B-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
or	CC	O	O
more	JJR	B-NP	O
,	,	O	O
but	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
iohexol	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
percent	NN	I-NP	O
)	)	O	O
did	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
iodixanol	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
deciliter	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
iohexol	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Nephropathy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
contrast	NN	B-NP	O
medium	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
less	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
develop	VB	I-VP	O
in	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	B-NP	O
patients	NNS	I-NP	O
when	WRB	B-ADVP	O
iodixanol	NN	B-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
a	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
osmolar	JJ	I-NP	O
,	,	I-NP	O
nonionic	JJ	I-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
.	.	O	O

Experimental	JJ	B-NP	O
cranial	JJ	I-NP	O
pain	NN	I-NP	B
elicited	VBN	B-VP	O
by	IN	B-PP	O
capsaicin	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
PET	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
a	DT	B-NP	O
positron	NN	I-NP	O
emission	NN	I-NP	O
tomography	NN	I-NP	O
(	(	O	O
PET	NN	B-NP	O
)	)	O	O
study	NN	B-NP	O
it	PRP	B-NP	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
recently	RB	B-ADVP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
migraine	NN	B-NP	B
without	IN	B-PP	O
aura	NN	B-NP	O
certain	JJ	I-NP	O
areas	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
stem	NN	I-NP	O
were	VBD	B-VP	O
activated	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
headache	NN	I-NP	B
state	NN	I-NP	O
,	,	O	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
headache	NN	I-NP	B
free	JJ	I-NP	O
interval	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
brain	NN	I-NP	O
stem	NN	I-NP	O
activation	NN	I-NP	O
is	VBZ	B-VP	O
inherent	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
migraine	NN	I-NP	B
attack	NN	I-NP	O
itself	PRP	B-NP	O
and	CC	O	O
represents	VBZ	B-VP	O
the	DT	B-NP	O
so	RB	I-NP	O
called	VBN	I-NP	O
migraine	NN	I-NP	B
generator	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
test	VB	I-VP	O
this	DT	B-NP	O
hypothesis	NN	I-NP	O
we	PRP	B-NP	O
performed	VBD	B-VP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
pain	NN	I-NP	B
study	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
volunteers	NNS	I-NP	O
,	,	O	O
using	VBG	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
positioning	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PET	NN	I-NP	O
scanner	NN	I-NP	O
as	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
migraine	NN	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
small	JJ	I-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
subcutaneously	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
forehead	NN	I-NP	O
to	TO	B-VP	O
evoke	VB	I-VP	O
a	DT	B-NP	O
burning	VBG	I-NP	O
painful	JJ	I-NP	B
sensation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
division	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
trigeminal	JJ	I-NP	O
nerve	NN	I-NP	O
.	.	O	O

Increases	NNS	B-NP	O
of	IN	B-PP	O
regional	JJ	B-NP	O
cerebral	JJ	I-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
(	(	O	O
rCBF	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
found	VBN	I-VP	O
bilaterally	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
insula	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
cingulate	NN	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
cavernous	JJ	I-NP	O
sinus	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
cerebellum	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
stereotactic	JJ	I-NP	O
space	NN	I-NP	O
limits	NNS	I-NP	O
as	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
above	RB	I-NP	O
mentioned	VBN	I-NP	O
migraine	NN	I-NP	B
study	NN	I-NP	O
no	DT	B-NP	O
brain	NN	I-NP	O
stem	NN	I-NP	O
activation	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
pain	NN	I-NP	B
state	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
pain	NN	I-NP	B
free	JJ	I-NP	O
state	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
activation	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cavernous	JJ	I-NP	O
sinus	NN	I-NP	O
however	RB	B-ADVP	O
,	,	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
structure	NN	I-NP	O
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
trigeminal	JJ	B-NP	O
transmitted	VBN	I-NP	O
pain	NN	I-NP	B
as	IN	B-PP	O
such	JJ	B-NP	O
,	,	O	O
rather	RB	B-PP	O
than	IN	I-PP	O
in	IN	B-PP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
headache	NN	B-NP	B
as	IN	B-SBAR	O
was	VBD	B-VP	O
suggested	VBN	I-VP	O
for	IN	B-PP	O
cluster	NN	B-NP	B
headache	NN	I-NP	I
.	.	O	O

Neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
with	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

Neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
blockade	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
ganglia	NNS	I-NP	O
.	.	O	O

Risperidone	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
benzisoxazole	NN	I-NP	O
derivative	NN	I-NP	O
antipsychotic	JJ	B-ADJP	O
,	,	O	O
has	VBZ	B-VP	O
high	JJ	B-NP	O
serotonin	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT2	NN	I-NP	O
receptor	NN	I-NP	O
blockade	NN	I-NP	O
and	CC	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
blockade	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
high	JJ	I-NP	O
ratio	NN	I-NP	O
is	VBZ	B-VP	O
believed	VBN	I-VP	O
to	TO	I-VP	O
impart	VB	I-VP	O
the	DT	B-NP	O
low	JJ	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
with	IN	B-PP	O
risperidone	NN	B-NP	O
at	IN	B-PP	O
low	JJ	B-NP	O
dosages	NNS	I-NP	O
.	.	O	O

With	IN	B-PP	O
this	DT	B-NP	O
low	JJ	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
extrapyramidal	JJ	B-NP	B
symptoms	NNS	I-NP	I
,	,	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
thought	VBN	I-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
might	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
lowered	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
developed	VBD	B-VP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
after	IN	B-PP	O
monotherapy	NN	B-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
syndrome	NN	I-NP	O
reversed	VBD	B-VP	O
after	IN	B-PP	O
discontinuing	VBG	B-VP	O
risperidone	NN	B-NP	O
and	CC	O	O
starting	VBG	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
dantrolene	NN	B-NP	O
and	CC	I-NP	O
bromocriptine	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
appears	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
protection	NN	I-NP	O
from	IN	B-PP	O
extrapyramidal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
observed	VBN	B-VP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
ensure	VB	I-VP	O
protection	NN	B-NP	O
from	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Hepatic	JJ	B-NP	O
and	CC	I-NP	O
extrahepatic	JJ	I-NP	O
angiotensinogen	NN	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Plasma	NN	B-NP	O
concentration	NN	I-NP	O
and	CC	O	O
urine	NN	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
proteins	NNS	I-NP	O
are	VBP	B-VP	O
altered	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
NS	NN	B-NP	B
)	)	O	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
work	NN	I-NP	O
the	DT	B-NP	O
messenger	NN	I-NP	O
ribonucleic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
mRNA	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
of	IN	B-PP	O
angiotensinogen	NN	B-NP	O
(	(	O	O
Ao	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
slot	NN	I-NP	O
-	HYPH	B-NP	O
blot	NN	I-NP	O
hybridization	NN	I-NP	O
technique	NN	I-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
extrahepatic	JJ	I-NP	O
tissues	NNS	I-NP	O
:	:	O	O
kidney	NN	B-NP	O
,	,	O	O
heart	NN	B-NP	O
,	,	O	O
brain	NN	B-NP	O
,	,	O	O
and	CC	O	O
adrenal	JJ	B-NP	O
gland	NN	I-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
,	,	O	O
nephrotic	JJ	B-ADJP	B
,	,	O	O
and	CC	O	O
pair	NN	B-NP	O
-	HYPH	O	O
fed	VBN	B-VP	O
(	(	O	O
PF	NN	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
.	.	O	O

NS	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
amino	JJ	O	O
-	HYPH	O	O
nucleoside	NN	B-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
.	.	O	O

Although	IN	B-SBAR	O
a	DT	B-NP	O
great	JJ	I-NP	O
urinary	JJ	I-NP	O
excretion	NN	I-NP	O
and	CC	I-NP	O
half	NN	I-NP	O
-	HYPH	I-NP	O
normal	JJ	I-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
Ao	NNP	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
PAN	NN	B-NP	O
injection	NN	I-NP	O
,	,	O	O
when	WRB	B-ADVP	O
NS	NN	B-NP	B
was	VBD	B-VP	O
clearly	RB	I-VP	O
established	VBN	I-VP	O
,	,	O	O
hepatic	JJ	B-NP	O
Ao	NN	I-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
Ao	NNP	I-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
in	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
extrahepatic	JJ	I-NP	O
tissues	NNS	I-NP	O
studied	VBN	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
nor	CC	O	O
did	VBD	O	O
its	PRP$	B-NP	O
hepatic	JJ	I-NP	O
levels	NNS	I-NP	O
at	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
after	IN	B-SBAR	O
PAN	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
hepatic	JJ	I-NP	O
and	CC	I-NP	O
extrahepatic	JJ	I-NP	O
Ao	NN	I-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
are	VBP	B-VP	O
unaltered	JJ	B-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
NS	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
PAN	NN	B-NP	O
.	.	O	O

Cyclophosphamide	NN	B-NP	O
associated	VBN	I-NP	O
bladder	NN	I-NP	B
cancer	NN	I-NP	I
-	HYPH	B-VP	O
-	:	O	O
a	DT	B-NP	O
highly	RB	I-NP	O
aggressive	JJ	I-NP	O
disease	NN	I-NP	O
:	:	O	O
analysis	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
gained	VBD	B-VP	O
knowledge	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
etiology	NN	I-NP	O
,	,	I-NP	O
treatment	NN	I-NP	O
and	CC	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
associated	JJ	I-NP	O
urothelial	JJ	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
medical	JJ	I-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
(	(	O	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
associated	VBN	I-NP	O
bladder	NN	I-NP	B
cancer	NN	I-NP	I
were	VBD	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

All	DT	B-NP	O
tumors	NNS	I-NP	B
were	VBD	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
transitional	JJ	I-NP	O
cell	NN	I-NP	O
carcinoma	NN	I-NP	B
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
initially	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
endoscopic	JJ	B-NP	O
resection	NN	I-NP	O
alone	RB	B-ADVP	O
only	RB	B-NP	O
num	CD	I-NP	O
is	VBZ	B-VP	O
alive	JJ	B-ADJP	O
without	IN	B-PP	O
disease	NN	B-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
early	JJ	B-NP	O
cystectomy	NN	I-NP	O
num	CD	B-NP	O
were	VBD	B-VP	O
alive	JJ	B-ADJP	O
at	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
remaining	VBG	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
extensive	JJ	B-NP	O
cancer	NN	I-NP	B
underwent	VBD	B-VP	O
partial	JJ	B-NP	O
cystectomy	NN	I-NP	O
for	IN	B-PP	O
palliation	NN	B-NP	O
and	CC	O	O
died	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Cyclophosphamide	NN	B-NP	O
associated	VBN	I-NP	O
bladder	NN	I-NP	B
tumor	NN	I-NP	I
is	VBZ	B-VP	O
an	DT	B-NP	O
aggressive	JJ	I-NP	O
disease	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
survival	NN	I-NP	O
is	VBZ	B-VP	O
possible	JJ	B-ADJP	O
when	WRB	B-ADVP	O
radical	JJ	B-NP	O
cystectomy	NN	I-NP	O
is	VBZ	B-VP	O
performed	VBN	I-VP	O
for	IN	B-PP	O
bladder	NN	B-NP	B
tumors	NNS	I-NP	I
with	IN	B-PP	O
any	DT	B-NP	O
sign	NN	I-NP	O
of	IN	B-PP	O
invasion	NN	B-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
recurrent	JJ	B-NP	O
high	JJ	I-NP	O
grade	NN	I-NP	O
disease	NN	I-NP	O
,	,	O	O
even	RB	B-ADVP	O
when	WRB	I-ADVP	O
noninvasive	JJ	B-ADVP	O
.	.	O	O

Leg	NNP	B-NP	B
and	CC	O	I
back	JJ	B-NP	I
pain	NN	I-NP	I
after	IN	B-PP	O
spinal	JJ	B-NP	O
anaesthesia	NN	I-NP	O
involving	VBG	B-VP	O
hyperbaric	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lignocaine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
aged	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
who	WP	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
lignocaine	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
glucose	NN	I-NP	O
solution	NN	I-NP	O
for	IN	B-PP	O
spinal	JJ	B-NP	O
anaesthesia	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
pain	NN	B-NP	B
in	IN	B-PP	I
the	DT	B-NP	I
legs	NNS	I-NP	I
and	CC	O	I
/	SYM	B-NP	I
or	CC	O	I
back	RB	B-ADVP	I
after	IN	B-PP	O
recovery	NN	B-NP	O
from	IN	B-PP	O
anaesthesia	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
affected	VBN	B-VP	O
were	VBD	B-VP	O
younger	JJR	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dural	JJ	I-NP	O
puncture	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
individuals	NNS	I-NP	O
without	IN	B-PP	O
pain	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
pain	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
pain	NN	B-NP	B
admitted	VBN	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
alcohol	NN	I-NP	O
intake	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
contributing	VBG	I-NP	O
factor	NN	I-NP	O
.	.	O	O

Leg	NN	B-NP	B
and	CC	O	I
/	SYM	B-NP	I
or	CC	O	I
back	RB	B-ADVP	I
pain	NN	B-NP	I
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
intrathecal	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
hyperbaric	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lignocaine	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
elevations	NNS	I-NP	O
with	IN	B-PP	O
caffeine	NN	B-NP	O
in	IN	B-PP	O
men	NNS	B-NP	O
with	IN	B-PP	O
borderline	JJ	B-NP	O
systemic	JJ	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Whether	IN	B-PP	O
the	DT	B-NP	O
vasoconstrictive	JJ	I-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
are	VBP	B-VP	O
enhanced	VBN	I-VP	O
in	IN	B-PP	O
hypertensive	JJ	B-NP	B
persons	NNS	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
demonstrated	VBN	I-VP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
caffeine	NN	B-NP	O
versus	IN	B-PP	O
placebo	NN	B-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
men	NNS	I-NP	O
(	(	O	O
aged	VBN	B-ADJP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
selected	VBN	B-VP	O
after	IN	B-PP	O
screening	VBG	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
occasions	NNS	I-NP	O
.	.	O	O

Borderline	NN	B-NP	O
hypertensive	JJ	I-NP	B
men	NNS	I-NP	O
were	VBD	B-VP	O
selected	VBN	I-VP	O
with	IN	B-PP	O
screening	VBG	B-VP	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
diastolic	JJ	B-NP	O
BP	NN	I-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
controls	NNS	I-NP	O
reported	VBD	B-VP	O
no	DT	B-NP	O
parental	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
and	CC	O	O
had	VBD	B-VP	O
screening	NN	B-NP	O
BP	NN	I-NP	O
<	SYM	B-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
.	.	O	O

Participants	NNS	B-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
tested	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
occasions	NNS	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
abstinence	NN	I-NP	O
from	IN	B-PP	O
caffeine	NN	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
protocols	NNS	I-NP	O
;	:	O	O
this	DT	B-NP	O
required	VBD	B-VP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
laboratory	NN	I-NP	O
visits	NNS	I-NP	O
.	.	O	O

Caffeine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
diastolic	JJ	B-NP	O
BP	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
larger	JJR	I-NP	O
in	IN	B-PP	O
borderline	JJ	B-NP	O
subjects	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
larger	JJR	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
impedance	NN	B-NP	O
-	HYPH	B-NP	O
derived	VBN	I-NP	O
measures	NNS	I-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
consistent	JJ	B-ADJP	O
and	CC	O	O
reached	VBN	B-VP	O
significance	NN	B-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
protocols	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
borderline	JJ	B-NP	O
subjects	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
diastolic	JJ	B-NP	O
BP	NN	I-NP	O
changes	NNS	I-NP	O
exceeded	VBD	B-VP	O
the	DT	B-NP	O
median	JJ	I-NP	O
control	NN	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Consequently	RB	B-ADVP	O
,	,	O	O
whereas	IN	O	O
all	DT	B-NP	O
participants	NNS	I-NP	O
exhibited	VBD	B-VP	O
normotensive	JJ	B-NP	O
levels	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
resting	VBG	I-NP	O
predrug	NN	I-NP	O
baseline	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
borderline	JJ	B-NP	O
subjects	NNS	I-NP	O
achieved	VBD	B-VP	O
hypertensive	JJ	B-NP	B
BP	NN	I-NP	O
levels	NNS	I-NP	O
after	IN	B-PP	O
caffeine	NN	B-NP	O
ingestion	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
borderline	JJ	B-NP	O
hypertensive	JJ	I-NP	B
men	NNS	I-NP	O
,	,	O	O
exaggerated	VBD	B-VP	O
responses	NNS	B-NP	O
to	TO	B-PP	O
caffeine	NN	B-NP	O
were	VBD	B-VP	O
:	:	O	O
selective	JJ	B-ADJP	O
for	IN	B-PP	O
diastolic	JJ	B-NP	O
BP	NN	I-NP	O
,	,	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
greater	JJR	B-NP	O
vasoconstriction	NN	I-NP	O
,	,	O	O
replicated	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
protocols	NNS	I-NP	O
,	,	O	O
and	CC	O	O
representative	NN	B-NP	O
of	IN	B-PP	O
nearly	RB	B-NP	O
all	DT	I-NP	O
borderline	JJ	I-NP	O
hypertensives	NNS	I-NP	B
.	.	O	O

We	PRP	B-NP	O
suspect	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
caffeine	NN	B-NP	O
to	TO	B-VP	O
stabilize	VB	I-VP	O
high	JJ	B-NP	O
resistance	NN	I-NP	O
states	NNS	I-NP	O
in	IN	B-PP	O
susceptible	JJ	B-NP	O
persons	NNS	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
its	PRP$	B-NP	O
use	NN	I-NP	O
may	MD	B-VP	O
facilitate	VB	I-VP	O
their	PRP$	B-NP	O
disease	NN	I-NP	O
progression	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
hinder	JJR	B-NP	O
accurate	JJ	I-NP	O
diagnosis	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Hallucinations	NNS	B-NP	B
and	CC	I-NP	O
ifosfamide	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Hallucinations	NNS	B-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
symptom	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
are	VBP	B-VP	O
a	DT	B-NP	O
known	JJ	I-NP	O
but	CC	O	O
poorly	RB	B-NP	O
described	VBN	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
.	.	O	O

Most	JJS	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hallucinations	NNS	I-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
mental	JJ	I-NP	O
status	NN	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
interviewed	VBD	B-VP	O
num	CD	B-NP	O
persons	NNS	I-NP	O
with	IN	B-PP	O
ifosfamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hallucinations	NNS	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
clear	JJ	I-NP	O
sensorium	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
ifosfamide	NN	I-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplant	NN	I-NP	O
procedure	NN	I-NP	O
.	.	O	O

Hallucinations	NNS	B-NP	B
occurred	VBD	B-VP	O
only	RB	B-ADVP	O
when	WRB	I-ADVP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
eyes	NNS	I-NP	O
were	VBD	B-VP	O
closed	VBN	B-ADJP	O
and	CC	O	O
,	,	O	O
in	IN	B-PP	O
all	DT	B-NP	O
but	IN	B-PP	O
num	CD	B-NP	O
case	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
disturbing	JJ	B-NP	O
or	CC	I-NP	O
frightening	NN	I-NP	O
.	.	O	O

Underreporting	VBG	B-VP	O
of	IN	B-PP	O
these	DT	B-NP	O
hallucinations	NNS	I-NP	B
by	IN	B-PP	O
patients	NNS	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
.	.	O	O

Hallucinations	NNS	B-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
sole	JJ	I-NP	O
or	CC	I-NP	O
first	JJ	I-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
neurotoxicity	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
dose	NN	B-NP	O
and	CC	I-NP	O
infusion	NN	I-NP	O
-	HYPH	B-NP	O
time	NN	I-NP	O
related	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
clinician	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
alerted	VBN	I-VP	O
for	IN	B-PP	O
possible	JJ	B-NP	O
ifosfamide	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hallucinations	NNS	I-NP	B
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
occur	VB	I-VP	O
without	IN	B-PP	O
other	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
neurotoxicity	NN	B-NP	B
.	.	B-NP	O
Eyes	NNPS	I-NP	O
-	HYPH	O	O
closed	VBN	B-VP	O
hallucinatory	JJ	B-NP	B
experiences	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
feature	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
presentation	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
anxious	JJ	B-ADJP	O
about	IN	B-PP	O
this	DT	B-NP	O
experience	NN	I-NP	O
respond	VBP	B-VP	O
well	RB	B-ADVP	O
to	TO	B-PP	O
support	NN	B-NP	O
and	CC	I-NP	O
education	NN	I-NP	O
about	IN	B-PP	O
this	DT	B-NP	O
occurrence	NN	I-NP	O
.	.	O	O

Optimal	JJ	B-NP	O
pharmacologic	JJ	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
disturbed	JJ	B-NP	O
patients	NNS	I-NP	O
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

If	IN	B-SBAR	O
agitation	NN	B-NP	B
becomes	VBZ	B-VP	O
marked	JJ	B-NP	O
,	,	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
potency	NN	I-NP	O
neuroleptics	NNS	I-NP	O
(	(	O	O
i.e.	FW	B-NP	O
,	,	I-NP	O
haloperidol	NN	I-NP	O
)	)	O	O
may	MD	B-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
.	.	O	O

Chlorpropamide	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
adult	NN	B-NP	B
-	HYPH	B-NP	I
onset	NN	I-NP	I
diabetes	NNS	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
chlorpropamide	NN	B-NP	O
(	(	O	O
Diabenese	NN	B-NP	O
)	)	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
toxic	JJ	I-NP	B
optic	JJ	I-NP	I
neuropathy	NN	I-NP	I
that	WDT	B-NP	O
resolved	VBD	B-VP	O
with	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
chlorpropamide	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Visual	JJ	B-NP	B
loss	NN	I-NP	I
occurs	VBZ	B-VP	O
in	IN	B-PP	O
diabetics	NNS	B-NP	B
for	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
reasons	NNS	B-NP	O
,	,	O	O
and	CC	O	O
accurate	JJ	B-NP	O
diagnosis	NN	I-NP	O
is	VBZ	B-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
institute	VB	I-VP	O
appropriate	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
differential	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
diabetics	NNS	B-NP	B
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
and	CC	I-NP	O
thalamotomy	NN	I-NP	O
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
limbs	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
Parkinsonism	NNP	B-NP	B
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
choreic	JJ	B-ADJP	O
,	,	O	O
ballistic	JJ	B-ADJP	O
or	CC	I-ADJP	O
dystonic	JJ	I-ADJP	B
in	IN	B-PP	O
type	NN	B-NP	O
,	,	O	O
was	VBD	B-VP	O
alleviated	VBN	I-VP	O
almost	RB	B-ADVP	O
completely	RB	I-ADVP	O
by	IN	B-PP	O
stereotaxic	JJ	B-NP	O
surgery	NN	I-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
microelectrode	NN	I-NP	O
technique	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
ventralis	NN	I-NP	O
oralis	VBZ	B-VP	O
anterior	JJ	B-NP	O
and	CC	I-NP	O
posterior	JJ	I-NP	O
nuclei	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
thalamus	NN	I-NP	O
,	,	O	O
but	CC	O	O
much	RB	B-ADJP	O
less	JJR	I-ADJP	O
by	IN	B-PP	O
the	DT	B-NP	O
ventralis	NN	I-NP	O
intermedius	NN	I-NP	O
nucleus	NN	I-NP	O
.	.	O	O

Control	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
by	IN	B-PP	O
thalamic	JJ	B-NP	B
lesions	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
routine	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Parkinsonism	NN	B-NP	B
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Factors	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
and	CC	O	O
clinical	JJ	B-NP	O
outcome	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
amikacin	NN	B-NP	O
.	.	O	O

Data	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
amikacin	NN	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
for	IN	B-PP	O
factors	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
data	NNS	B-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
factors	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
outcome	NN	I-NP	O
.	.	O	O

Variables	NNS	B-NP	O
evaluated	VBN	B-VP	O
included	VBD	B-VP	O
patient	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
level	NN	I-NP	O
,	,	O	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
total	JJ	B-NP	O
dose	NN	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
,	,	O	O
organism	NN	B-NP	O
minimum	JJ	I-NP	O
inhibitory	JJ	I-NP	O
concentration	NN	I-NP	O
(	(	O	O
MIC	NN	B-NP	O
)	)	O	O
,	,	O	O
mean	JJ	B-NP	O
peak	JJ	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
trough	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
concentration	NN	I-NP	O
-	HYPH	O	O
time	NN	B-NP	O
curve	NN	I-NP	O
(	(	O	O
AUC	NN	B-NP	O
)	)	O	O
,	,	O	O
total	JJ	B-NP	O
AUC	NN	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
AUC	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
MIC	NN	B-NP	O
,	,	O	O
total	JJ	B-NP	O
AUC	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
MIC	NN	B-NP	O
,	,	O	O
mean	JJ	B-NP	O
Schumacher	NNP	I-NP	O
s	NN	I-NP	O
intensity	NN	I-NP	O
factor	NN	I-NP	O
(	(	O	O
IF	NN	B-NP	O
)	)	O	O
,	,	O	O
total	JJ	B-NP	O
IF	NN	I-NP	O
,	,	O	O
In	IN	B-PP	O
(	(	O	O
mean	JJ	B-NP	O
maximum	JJ	I-NP	O
concentration	NN	I-NP	O
[	(	O	O
Cmax	NN	B-NP	O
]	)	O	O
/	SYM	B-NP	O
MIC	NN	I-NP	O
)	)	O	O
.	.	O	O

Model	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
pharmacokinetic	JJ	I-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
calculated	VBN	I-VP	O
by	IN	B-PP	O
computer	NN	B-NP	O
based	VBN	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
compartment	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
the	DT	B-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
individually	RB	B-ADVP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
and	CC	O	O
total	JJ	B-NP	O
AUC	NN	I-NP	O
correlated	VBD	B-VP	O
significantly	RB	B-ADVP	O
with	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
stepwise	JJ	I-NP	O
discriminant	JJ	I-NP	O
function	NN	I-NP	O
analysis	NN	I-NP	O
identified	VBD	B-VP	O
only	RB	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
important	JJ	I-NP	O
factor	NN	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
Bayes	NNS	B-NP	O
s	VBZ	B-VP	O
theorem	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
predictive	JJ	I-NP	O
accuracy	NN	I-NP	O
of	IN	B-PP	O
identifying	VBG	B-VP	O
nephrotoxic	JJ	B-NP	B
patients	NNS	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
examined	VBN	B-VP	O
individually	RB	B-ADVP	O
,	,	O	O
mean	JJ	B-NP	O
IF	NNP	I-NP	O
,	,	O	O
MIC	NNP	B-NP	O
,	,	O	O
total	JJ	B-NP	O
dose	NN	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
,	,	O	O
and	CC	O	O
ln	NN	B-NP	O
(	(	O	O
mean	JJ	B-NP	O
Cmax	NN	I-NP	O
/	SYM	B-NP	O
MIC	NN	I-NP	O
)	)	O	O
correlated	VBD	B-VP	O
significantly	RB	B-ADVP	O
with	IN	B-PP	O
cure	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
simultaneous	JJ	I-NP	O
multivariable	JJ	I-NP	O
analysis	NN	I-NP	O
identified	VBD	B-VP	O
IF	NN	B-NP	O
,	,	O	O
MIC	NN	B-NP	O
,	,	O	O
and	CC	O	O
total	JJ	B-NP	O
dose	NN	I-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
num	CD	B-NP	O
model	NN	I-NP	O
and	CC	O	O
ln	NN	B-NP	O
(	(	O	O
mean	JJ	B-NP	O
Cmax	NN	I-NP	O
/	SYM	B-NP	O
MIC	NN	I-NP	O
)	)	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
second	JJ	I-NP	O
statistical	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
parameters	NNS	B-NP	O
selected	VBN	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
the	DT	B-NP	O
greatest	JJS	I-NP	O
prospective	JJ	I-NP	O
value	NN	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
Bayes	NNS	B-NP	O
s	NNS	I-NP	O
theorem	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
model	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
predictive	JJ	I-NP	O
accuracy	NN	I-NP	O
of	IN	B-PP	O
identifying	VBG	B-VP	O
patients	NNS	B-NP	O
not	RB	B-VP	O
cured	VBN	I-VP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

For	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
model	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
predictive	JJ	I-NP	O
accuracy	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
transplantation	NN	I-NP	O
:	:	O	O
improved	VBN	B-NP	O
quality	NN	I-NP	O
of	IN	B-PP	O
survival	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
modified	VBN	I-NP	O
immunosuppressive	JJ	I-NP	O
protocol	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
protocols	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
retrospectively	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
subsequent	JJ	I-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
group	NN	B-NP	O
I	NN	I-NP	O
,	,	O	O
cyclosporine	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
loading	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
and	CC	O	O
then	RB	B-ADVP	O
continued	VBN	B-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
to	TO	B-VP	O
keep	VB	I-VP	O
a	DT	B-NP	O
whole	JJ	I-NP	O
blood	NN	I-NP	O
level	NN	I-NP	O
about	RB	B-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
cyclosporine	NN	B-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
only	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
dosage	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
complemented	VBN	I-VP	O
by	IN	B-PP	O
azathioprine	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
postoperative	JJ	I-NP	O
week	NN	I-NP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
better	RBR	I-NP	O
perioperative	JJ	I-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
as	IN	B-SBAR	O
determined	VBN	B-VP	O
by	IN	B-PP	O
serum	NN	B-NP	O
blood	NN	I-NP	O
urea	NN	I-NP	O
nitrogen	NN	I-NP	O
and	CC	I-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
nephrotoxicity	NN	I-NP	B
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
cyclosporine	NN	B-NP	O
.	.	O	O

Despite	IN	B-PP	O
this	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
late	JJ	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
,	,	O	O
group	NN	B-NP	O
num	CD	I-NP	O
still	RB	B-ADVP	O
shows	VBZ	B-VP	O
a	DT	B-NP	O
slow	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
think	VBP	B-VP	O
that	IN	B-SBAR	O
even	RB	B-NP	O
these	DT	I-NP	O
lower	JJR	I-NP	O
dosages	NNS	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
chronic	JJ	B-NP	O
nephrotoxicity	NN	I-NP	B
and	CC	O	O
that	IN	B-SBAR	O
further	JJ	B-NP	O
modification	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
immunosuppressive	JJ	I-NP	O
regimen	NN	I-NP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
to	TO	B-VP	O
completely	RB	I-VP	O
abolish	VB	I-VP	O
this	DT	B-NP	O
toxic	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Reversible	JJ	B-NP	O
cholestasis	NN	I-NP	B
with	IN	B-PP	O
bile	NN	B-NP	B
duct	NN	I-NP	I
injury	NN	I-NP	I
following	VBG	B-PP	O
azathioprine	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
primary	JJ	B-NP	O
polymyositis	NN	I-NP	B
and	CC	O	O
without	IN	B-PP	O
previous	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
developed	VBD	B-VP	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
cholestasis	NN	I-NP	B
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
azathioprine	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Liver	NN	B-NP	O
biopsy	NN	I-NP	O
showed	VBD	B-VP	O
cholestasis	NN	B-NP	B
with	IN	B-PP	O
both	CC	B-NP	O
cytological	JJ	I-NP	O
and	CC	I-NP	O
architectural	JJ	I-NP	O
alterations	NNS	I-NP	O
of	IN	B-PP	O
interlobular	JJ	B-NP	O
bile	NN	I-NP	O
ducts	NNS	I-NP	O
.	.	O	O

Azathioprine	NN	B-NP	O
withdrawal	NN	I-NP	O
resulted	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
abnormalities	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
believed	VBN	I-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
reversible	JJ	B-NP	O
azathioprine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cholestasis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
histological	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
bile	NN	B-NP	B
duct	NN	I-NP	I
injury	NN	I-NP	I
.	.	O	O

Renal	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
hemodynamics	NNS	I-NP	O
during	IN	B-PP	O
prolonged	VBN	B-NP	O
isoflurane	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
isoflurane	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
on	IN	B-PP	O
glomerular	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
human	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
GFR	NN	B-NP	O
)	)	O	O
and	CC	O	O
effective	JJ	B-NP	O
renal	JJ	I-NP	O
plasma	NN	I-NP	O
flow	NN	I-NP	O
(	(	O	O
ERPF	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
inulin	NN	B-NP	O
and	CC	O	O
para	AFX	O	O
-	HYPH	O	O
aminohippurate	NN	B-NP	O
(	(	O	O
PAH	NN	B-NP	O
)	)	O	O
clearance	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Anesthesia	NNP	B-NP	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
with	IN	B-PP	O
fentanyl	NN	B-NP	O
,	,	O	O
nitrous	JJ	B-NP	O
oxide	NN	I-NP	O
,	,	O	O
oxygen	NN	B-NP	O
,	,	O	O
and	CC	O	O
isoflurane	NN	B-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
min	NN	I-NP	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
isoflurane	NN	I-NP	O
inspired	VBD	B-VP	O
concentration	NN	B-NP	O
to	TO	B-VP	O
maintain	VB	I-VP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
.	.	O	O

GFR	NN	B-NP	O
and	CC	I-NP	O
ERPF	NN	I-NP	O
decreased	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
but	CC	O	O
not	RB	O	O
significantly	RB	B-ADJP	O
more	JJR	I-ADJP	O
during	IN	B-PP	O
hypotension	NN	B-NP	B
.	.	O	O

Postoperatively	RB	B-ADVP	O
,	,	O	O
ERPF	NN	B-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
preoperative	JJ	B-NP	O
values	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
GFR	NN	B-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
preoperative	JJ	B-NP	O
values	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
increased	VBD	B-VP	O
during	IN	B-PP	O
anesthesia	NN	B-NP	O
but	CC	O	O
decreased	VBD	B-VP	O
when	WRB	B-ADVP	O
hypotension	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
,	,	O	O
allowing	VBG	B-VP	O
the	DT	B-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
renal	JJ	B-NP	O
compensatory	JJ	I-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
preserved	VBN	I-VP	O
during	IN	B-PP	O
isoflurane	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
and	CC	O	O
that	IN	B-SBAR	O
renal	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
hemodynamics	NNS	I-NP	O
quickly	RB	B-ADVP	O
return	VB	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
when	WRB	B-ADVP	O
normotension	NN	B-NP	O
is	VBZ	B-VP	O
resumed	VBN	I-VP	O
.	.	O	O

Debrisoquine	NN	B-NP	O
phenotype	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
pharmacokinetics	NNS	I-NP	O
and	CC	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
pharmacodynamics	NNS	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
enantiomers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
metabolism	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cardioselective	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocker	NN	I-NP	O
metoprolol	NN	I-NP	O
is	VBZ	B-VP	O
under	IN	B-PP	O
genetic	JJ	B-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
debrisoquine	NN	I-NP	O
/	SYM	B-NP	O
sparteine	NN	I-NP	O
type	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
metabolic	JJ	I-NP	O
phenotypes	NNS	I-NP	O
,	,	O	O
extensive	JJ	B-ADJP	O
(	(	O	O
EM	NN	B-NP	O
)	)	O	O
and	CC	O	O
poor	JJ	B-NP	O
metabolizers	NNS	I-NP	O
(	(	O	O
PM	NN	B-NP	O
)	)	O	O
,	,	O	O
show	VBP	B-VP	O
different	JJ	B-NP	O
stereoselective	JJ	I-NP	O
metabolism	NN	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
apparently	RB	B-ADVP	O
higher	JJR	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adrenoceptor	NN	I-NP	O
antagonistic	JJ	I-NP	O
potency	NN	I-NP	O
of	IN	B-PP	O
racemic	JJ	B-NP	O
metoprolol	NN	I-NP	O
in	IN	B-PP	O
EMs	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
latter	JJ	I-NP	O
also	RB	B-ADVP	O
applies	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adrenoceptor	NN	I-NP	O
antagonism	NN	I-NP	O
by	IN	B-PP	O
metoprolol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
effect	NN	I-NP	O
studied	VBN	B-VP	O
was	VBD	B-VP	O
the	DT	B-NP	O
antagonism	NN	I-NP	O
by	IN	B-PP	O
metoprolol	NN	B-NP	O
of	IN	B-PP	O
terbutaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypokalemia	NN	I-NP	B
.	.	O	O

By	IN	B-PP	O
using	VBG	B-VP	O
pharmacokinetic	JJ	B-NP	O
pharmacodynamic	JJ	I-NP	O
modeling	NN	I-NP	O
the	DT	B-NP	O
pharmacodynamics	NNS	I-NP	O
of	IN	B-PP	O
racemic	JJ	B-NP	O
metoprolol	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
active	JJ	I-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
isomer	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
quantitated	VBN	I-VP	O
in	IN	B-PP	O
EMs	NNS	B-NP	O
and	CC	I-NP	O
PMs	NNS	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
IC50	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
representing	VBG	B-VP	O
metoprolol	NN	B-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
half	JJ	B-NP	O
-	HYPH	I-NP	O
maximum	NN	I-NP	O
receptor	NN	I-NP	O
occupancy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
EMs	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
terbutaline	NN	B-NP	O
s.c.	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
occasions	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
)	)	O	O
num	CD	B-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
num	CD	B-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
p.o	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
PMs	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
protocol	NN	I-NP	O
,	,	O	O
except	IN	B-PP	O
for	IN	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
terbutaline	NN	I-NP	O
dose	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
samples	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
potassium	NN	I-NP	O
,	,	O	O
terbutaline	NN	B-NP	O
,	,	O	O
metoprolol	NN	B-NP	O
(	(	O	O
racemic	JJ	B-ADJP	O
,	,	O	O
R	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
S	NN	I-NP	O
-	HYPH	I-NP	O
isomer	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
hydroxymetoprolol	NN	B-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
taken	VBN	I-VP	O
at	IN	B-PP	O
regular	JJ	B-NP	O
time	NN	I-NP	O
intervals	NNS	I-NP	O
,	,	O	O
during	IN	B-PP	O
num	CD	B-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
metoprolol	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
PMs	NNS	B-NP	O
,	,	O	O
metoprolol	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
terbutaline	NN	I-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
vs.	IN	B-PP	O
time	NN	B-NP	O
curve	NN	I-NP	O
.	.	O	O

Higher	JJR	B-NP	O
metoprolol	NN	I-NP	O
/	SYM	O	O
alpha	SYM	O	O
-	HYPH	O	O
hydroxymetoprolol	NN	B-NP	O
ratios	NNS	I-NP	O
in	IN	B-PP	O
PMs	NNS	B-NP	O
were	VBD	B-VP	O
predictive	JJ	B-ADJP	O
for	IN	B-PP	O
higher	JJR	B-NP	O
R	NN	I-NP	O
-	HYPH	O	O
/	SYM	B-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
isomer	NN	I-NP	O
ratios	NNS	I-NP	O
of	IN	B-PP	O
unchanged	JJ	B-NP	O
drug	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
metoprolol	NN	B-NP	O
potency	NN	I-NP	O
with	IN	B-PP	O
higher	JJR	B-NP	O
racemic	JJ	I-NP	O
metoprolol	NN	I-NP	O
IC50	NN	I-NP	O
values	NNS	I-NP	O
in	IN	B-PP	O
PMs	NNS	B-NP	O
than	IN	B-PP	O
EMs	NNS	B-NP	O
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Cefotetan	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
immune	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
.	.	O	O

Immune	JJ	B-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
adsorption	NN	I-NP	O
mechanism	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
primarily	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
penicillins	NNS	B-NP	O
and	CC	O	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
cephalosporins	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
anemia	NN	B-NP	B
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
intravenous	JJ	B-NP	O
cefotetan	NN	I-NP	O
.	.	O	O

Cefotetan	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
antibodies	NNS	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NNS	I-NP	O
serum	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
an	DT	B-NP	O
eluate	NN	I-NP	O
prepared	VBN	B-VP	O
from	IN	B-PP	O
his	PRP$	B-NP	O
red	JJ	I-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
eluate	NN	I-NP	O
also	RB	B-ADVP	O
reacted	VBD	B-VP	O
weakly	RB	B-ADVP	O
with	IN	B-PP	O
red	JJ	B-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
cefotetan	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
concomitant	JJ	I-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
warm	NN	B-NP	O
-	HYPH	B-NP	O
reactive	JJ	I-NP	O
autoantibodies	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
observations	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
extravascular	JJ	B-NP	O
hemolysis	NN	I-NP	B
,	,	O	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
,	,	O	O
possibly	RB	B-VP	O
involving	VBG	I-VP	O
both	CC	O	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
adsorption	NN	I-NP	O
and	CC	I-NP	O
autoantibody	NN	I-NP	O
formation	NN	I-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
emphasizes	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
increased	VBN	B-NP	O
awareness	NN	I-NP	O
of	IN	B-PP	O
hemolytic	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
all	DT	B-NP	O
cephalosporins	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
subsequent	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
rifampicin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
study	NN	B-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
reported	VBN	B-VP	O
earlier	RBR	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
clinical	JJ	I-NP	O
presentation	NN	I-NP	O
is	VBZ	B-VP	O
made	VBN	I-VP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
that	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
earlier	RBR	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
developed	VBN	I-VP	O
transient	JJ	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
after	IN	B-PP	O
the	DT	B-NP	O
intermittent	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
rifampicin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
olig	NN	B-NP	O
-	HYPH	B-NP	O
anuria	NN	I-NP	B
lasted	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
hemodialysis	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
unrelated	JJ	B-NP	O
causes	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
period	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
re	AFX	O	O
-	HYPH	O	O
examined	VBN	B-VP	O
were	VBD	B-VP	O
clinically	RB	I-VP	O
cured	VBN	I-VP	O
.	.	O	O

Pathologic	JJ	B-NP	O
findings	NNS	I-NP	O
by	IN	B-PP	O
light	NN	B-NP	O
microscopy	NN	I-NP	O
and	CC	O	O
immunofluorescence	NN	B-NP	O
at	IN	B-PP	O
biopsy	NN	B-NP	O
were	VBD	B-VP	O
scarce	JJ	B-ADJP	O
.	.	O	O

Nothing	NN	B-NP	O
abnormal	JJ	I-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
by	IN	B-PP	O
electron	NN	B-NP	O
microscopy	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
studied	VBN	B-VP	O
.	.	O	O

Renal	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
the	DT	B-NP	O
excretion	NN	I-NP	O
at	IN	B-PP	O
131I	NN	B-NP	O
-	HYPH	B-NP	O
hippuran	NN	I-NP	O
renography	NN	I-NP	O
was	VBD	B-VP	O
slightly	RB	I-VP	O
slowed	VBN	I-VP	O
.	.	O	O

Although	IN	B-SBAR	O
in	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
stage	NN	I-NP	O
the	DT	B-NP	O
renal	JJ	I-NP	B
lesions	NNS	I-NP	I
histologically	RB	B-ADVP	O
appeared	VBD	B-VP	O
toxic	JJ	B-NP	O
,	,	I-NP	O
evidence	NN	I-NP	O
suggestive	JJ	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
immunological	JJ	I-NP	O
mechanism	NN	I-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
excluded	VBN	I-VP	O
.	.	O	O

Type	NN	B-NP	B
B	NN	I-NP	I
hepatitis	NN	I-NP	I
after	IN	B-PP	O
needle	NN	B-NP	O
-	HYPH	B-NP	O
stick	NN	I-NP	O
exposure	NN	I-NP	O
:	:	O	O
prevention	NN	B-NP	O
with	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
.	.	O	O

Final	JJ	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Veterans	NNP	I-NP	O
Administration	NNP	I-NP	O
Cooperative	NNP	I-NP	O
Study	NNP	I-NP	O
.	.	O	O

Hepatitis	NN	B-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
(	(	O	O
HBIG	NN	B-NP	O
)	)	O	O
and	CC	O	O
immune	JJ	B-NP	O
serum	NN	I-NP	O
globulin	NN	I-NP	O
(	(	O	O
ISG	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
their	PRP$	B-NP	O
relative	JJ	I-NP	O
efficacies	NNS	I-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
type	NN	B-NP	B
B	NN	I-NP	I
hepatitis	NN	I-NP	I
after	IN	B-PP	O
needle	NN	B-NP	O
-	HYPH	B-NP	O
stick	NN	I-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
hepatitis	NN	B-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
HBsAG	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
donors	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
hepatitis	NN	I-NP	B
developed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
HBIG	NN	B-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
ISG	NN	B-NP	O
recipients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
seroconversion	NN	B-NP	O
(	(	O	O
anti	AFX	O	O
-	HYPH	B-NP	O
HBs	NNS	I-NP	O
)	)	O	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

Mild	JJ	B-NP	O
and	CC	I-NP	O
transient	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-VP	O
effects	NNS	B-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
ISG	NN	B-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
HBIG	NN	B-NP	O
recipients	NNS	I-NP	O
.	.	O	O

Available	JJ	B-NP	O
donor	NN	I-NP	O
sera	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
DNA	NN	B-NP	O
polymerase	NN	I-NP	O
(	(	O	O
DNAP	NN	B-NP	O
)	)	O	O
and	CC	O	O
e	NN	B-NP	O
antigen	NN	I-NP	O
and	CC	O	O
antibody	NN	B-NP	O
(	(	O	O
HBeAg	NN	B-NP	O
;	:	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
HBE	NN	I-NP	O
)	)	O	O
.	.	O	O

Both	CC	O	O
DNAP	NN	B-NP	O
and	CC	I-NP	O
HBeAg	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
highly	RB	I-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
infectivity	NN	I-NP	O
of	IN	B-PP	O
HBsAg	NN	B-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
donors	NNS	I-NP	O
.	.	O	O

Hepatitis	NN	B-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
remained	VBD	B-VP	O
significantly	RB	B-ADJP	O
superior	JJ	I-ADJP	O
to	TO	B-PP	O
ISG	NN	B-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
type	NN	B-NP	B
B	NN	I-NP	I
hepatitis	NN	I-NP	I
even	RB	B-ADVP	O
when	WRB	I-ADVP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
was	VBD	B-VP	O
confined	VBN	I-VP	O
to	TO	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
subgroups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
ISG	NN	B-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
type	NN	B-NP	B
B	NN	I-NP	I
hepatitis	NN	I-NP	I
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
ascertained	VBN	I-VP	O
because	IN	B-SBAR	O
a	DT	B-NP	O
true	JJ	I-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
included	VBN	I-VP	O
.	.	O	O

Serotonin	NN	B-NP	B
syndrome	NN	I-NP	I
from	IN	B-PP	O
venlafaxine	NN	B-NP	O
-	HYPH	B-NP	O
tranylcypromine	NN	I-NP	O
interaction	NN	I-NP	O
.	.	O	O

Excessive	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
serotonin	NN	B-NP	O
5HT1A	NN	I-NP	O
receptors	NNS	I-NP	O
causes	VBZ	B-VP	O
a	DT	B-NP	O
syndrome	NN	I-NP	O
of	IN	B-PP	O
serotonin	NN	B-NP	O
excess	NN	I-NP	O
that	WDT	B-NP	O
consists	VBZ	B-VP	O
of	IN	B-PP	O
shivering	NN	B-NP	O
,	,	O	O
muscle	NN	B-NP	B
rigidity	NN	I-NP	I
,	,	O	O
salivation	NN	B-NP	B
,	,	O	O
confusion	NN	B-NP	B
,	,	O	O
agitation	NN	B-NP	B
and	CC	I-NP	O
hyperthermia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
a	DT	B-NP	O
monoamine	NN	I-NP	O
oxidase	NN	I-NP	O
inhibitor	NN	I-NP	O
(	(	O	O
MAOI	NN	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
specific	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
.	.	O	O

Venlafaxine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
antidepressant	NN	I-NP	O
agent	NN	I-NP	O
that	WDT	B-NP	O
inhibits	VBZ	B-VP	O
the	DT	B-NP	O
reuptake	NN	I-NP	O
of	IN	B-PP	O
serotonin	NN	B-NP	O
and	CC	I-NP	O
norepinephrine	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
venlafaxine	NN	I-NP	O
-	HYPH	I-NP	O
MAOI	NN	I-NP	O
interaction	NN	I-NP	O
that	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
serotonin	NN	I-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
y	NN	I-NP	O
-	HYPH	I-NP	O
old	JJ	I-NP	O
male	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
taking	VBG	I-VP	O
tranylcypromine	NN	B-NP	O
for	IN	B-PP	O
depression	NN	B-NP	B
.	.	O	O

He	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
well	RB	B-ADVP	O
until	IN	B-SBAR	O
the	DT	B-NP	O
morning	NN	I-NP	O
of	IN	B-PP	O
presentation	NN	B-NP	O
when	WRB	B-ADVP	O
he	PRP	B-NP	O
took	VBD	B-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
tab	NN	I-NP	O
of	IN	B-PP	O
venlafaxine	NN	B-NP	O
.	.	O	O

Within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
he	PRP	B-NP	O
became	VBD	B-VP	O
confused	VBN	B-ADJP	O
with	IN	B-PP	O
jerking	VBG	B-VP	O
movements	NNS	B-NP	O
of	IN	B-PP	O
his	PRP$	B-NP	O
extremities	NNS	I-NP	O
,	,	I-NP	O
tremors	NNS	I-NP	B
and	CC	I-NP	O
rigidity	NN	I-NP	B
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
brought	VBN	I-VP	O
directly	RB	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
hospital	NN	I-NP	O
where	WRB	B-ADVP	O
he	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
agitated	VBN	I-VP	O
and	CC	I-VP	O
confused	VBN	I-VP	O
with	IN	B-PP	O
shivering	VBG	B-VP	O
,	,	O	O
myoclonic	JJ	B-NP	B
jerks	NNS	I-NP	I
,	,	O	O
rigidity	NN	B-NP	B
,	,	O	O
salivation	NN	B-NP	B
and	CC	I-NP	O
diaphoresis	NN	I-NP	O
.	.	O	O

His	PRP$	B-NP	O
pupils	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
mm	NN	I-NP	O
and	CC	O	O
sluggishly	RB	B-ADJP	O
reactive	JJ	I-ADJP	O
to	TO	B-PP	O
light	NN	B-NP	O
.	.	O	O

Vital	JJ	B-NP	O
signs	NNS	I-NP	O
were	VBD	B-VP	O
:	:	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
,	,	O	O
respiratory	JJ	B-NP	O
rate	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
,	,	O	O
and	CC	O	O
temperature	NN	B-NP	O
num	CD	I-NP	O
F	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
i.v.	RB	B-ADVP	O
he	PRP	B-NP	O
remained	VBD	B-VP	O
tremulous	JJ	B-ADJP	O
with	IN	B-PP	O
muscle	NN	B-NP	B
rigidity	NN	I-NP	I
and	CC	O	O
clenched	JJ	B-NP	O
jaws	NNS	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
intubated	VBN	I-VP	O
for	IN	B-PP	O
airway	NN	B-NP	O
protection	NN	I-NP	O
and	CC	O	O
because	RB	B-PP	O
of	IN	I-PP	O
hypoventilation	NN	B-NP	B
,	,	O	O
and	CC	O	O
was	VBD	B-VP	O
paralyzed	VBN	I-VP	B
to	TO	I-VP	O
control	VB	I-VP	O
muscle	NN	B-NP	B
rigidity	NN	I-NP	I
.	.	O	O

His	PRP$	B-NP	O
subsequent	JJ	I-NP	O
course	NN	I-NP	O
was	VBD	B-VP	O
remarkable	JJ	B-ADJP	O
for	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
immune	JJ	I-NP	O
thrombocytopenia	NN	I-NP	B
which	WDT	B-NP	O
resolved	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
maximal	JJ	B-NP	O
temperature	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
F	NN	I-NP	O
and	CC	O	O
his	PRP$	B-NP	O
CPK	NN	I-NP	O
remained	VBD	B-VP	O
<	SYM	B-ADJP	O
num	CD	B-NP	O
units	NNS	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
other	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
.	.	O	O

His	PRP$	B-NP	O
mental	JJ	I-NP	O
status	NN	I-NP	O
normalized	VBN	B-VP	O
and	CC	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
transferred	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
psychiatry	NN	I-NP	O
ward	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
patient	NN	I-NP	O
survived	VBD	B-VP	O
without	IN	B-PP	O
sequelae	NNS	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
aggressive	JJ	I-NP	O
sedation	NN	I-NP	O
and	CC	O	O
neuromuscular	JJ	B-NP	O
paralysis	NN	I-NP	B
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
nondopaminergic	JJ	B-NP	O
drugs	NNS	I-NP	O
on	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
MPTP	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
monkeys	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
monkeys	NNS	I-NP	O
was	VBD	B-VP	O
rendered	VBN	I-VP	O
parkinsonian	JJ	B-ADJP	B
with	IN	B-PP	O
the	DT	B-NP	O
toxin	NN	I-NP	O
MPTP	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
treated	VBN	I-VP	O
chronically	RB	B-ADVP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
DOPA	NN	I-NP	O
/	SYM	B-VP	O
benserazide	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
given	VBN	B-VP	O
orally	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
dose	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
striking	JJ	I-NP	O
antiparkinsonian	JJ	I-NP	O
effect	NN	I-NP	O
,	,	O	O
but	CC	O	O
all	DT	B-NP	O
animals	NNS	I-NP	O
manifested	VBD	B-VP	O
dyskinesia	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
agents	NNS	B-NP	O
acting	VBG	B-VP	O
primarily	RB	B-ADVP	O
on	IN	B-PP	O
neurotransmitters	NNS	B-NP	O
other	JJ	B-ADJP	O
than	IN	B-PP	O
dopamine	NN	B-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
DOPA	NN	B-NP	O
to	TO	B-VP	O
see	VB	I-VP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
dyskinetic	JJ	I-NP	B
movements	NNS	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
modified	VBN	I-VP	O
.	.	O	O

Several	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
clonidine	NN	B-NP	O
,	,	O	O
physostigmine	NN	B-NP	O
,	,	O	O
methysergide	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
MDOT	NN	I-NP	O
,	,	O	O
propranolol	NN	B-NP	O
,	,	O	O
and	CC	O	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
markedly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
dyskinetic	JJ	I-NP	B
movements	NNS	I-NP	O
but	CC	B-PP	O
at	IN	B-PP	O
the	DT	B-NP	O
cost	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
return	NN	I-NP	O
of	IN	B-PP	O
parkinsonian	JJ	B-NP	B
symptomatology	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
yohimbine	NN	B-NP	O
and	CC	I-NP	O
meperidine	NN	I-NP	O
reduced	VBD	B-VP	O
predominantly	RB	B-ADVP	O
the	DT	B-NP	O
dyskinetic	JJ	I-NP	B
movements	NNS	I-NP	O
.	.	O	O

Baclofen	NN	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
monkey	NN	I-NP	O
against	IN	B-PP	O
a	DT	B-NP	O
more	RBR	I-NP	O
dystonic	JJ	I-NP	B
form	NN	I-NP	O
of	IN	B-PP	O
dyskinesia	NN	B-NP	B
.	.	O	O

Atropine	NN	B-NP	O
converted	VBD	B-VP	O
the	DT	B-NP	O
dystonic	JJ	I-NP	B
movements	NNS	I-NP	O
into	IN	B-PP	O
chorea	NN	B-NP	B
.	.	O	O

CCNU	NN	B-NP	O
(	(	O	O
lomustine	NN	B-NP	O
)	)	O	O
toxicity	NN	B-NP	B
in	IN	B-PP	O
dogs	NNS	B-NP	O
:	:	O	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
describe	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
haematological	JJ	B-NP	B
,	,	I-NP	I
renal	JJ	I-NP	I
,	,	I-NP	I
hepatic	JJ	I-NP	I
and	CC	I-NP	I
gastrointestinal	JJ	I-NP	I
toxicities	NNS	I-NP	I
in	IN	B-PP	O
tumour	NN	B-NP	O
-	HYPH	O	O
bearing	VBG	B-VP	O
dogs	NNS	B-NP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroethyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
cyclohexyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
nitrosourea	NN	I-NP	O
(	(	O	O
CCNU	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
medical	JJ	I-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
CCNU	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
Melbourne	NNP	I-NP	O
Veterinary	NNP	I-NP	O
Specialist	NNP	I-NP	O
Centre	NNP	I-NP	O
between	IN	B-PP	O
February	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
December	NNP	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
retrospectively	RB	I-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
CCNU	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
met	VBD	B-VP	O
the	DT	B-NP	O
inclusion	NN	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
toxicity	NN	B-NP	B
.	.	O	O

CCNU	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
most	RBS	B-ADVP	O
commonly	RB	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
lymphoma	NN	B-NP	B
,	,	O	O
mast	NN	B-NP	B
cell	NN	I-NP	I
tumour	NN	I-NP	I
,	,	O	O
brain	NN	B-NP	B
tumour	NN	I-NP	I
,	,	O	O
histiocytic	JJ	B-NP	B
tumours	NNS	I-NP	I
and	CC	O	O
epitheliotropic	JJ	B-NP	B
lymphoma	NN	I-NP	I
.	.	O	O

Throughout	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
dogs	NNS	B-NP	O
experienced	VBD	B-VP	O
neutropenia	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
experienced	JJ	I-NP	O
anaemia	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
experienced	JJ	I-NP	O
thrombocytopenia	NN	I-NP	B
.	.	O	O

Gastrointestinal	JJ	B-NP	B
toxicosis	NN	I-NP	I
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
dogs	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
sign	NN	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
vomiting	VBG	I-VP	B
.	.	O	O

Potential	JJ	B-NP	O
renal	JJ	I-NP	O
toxicity	NN	I-NP	B
and	CC	O	O
elevated	JJ	B-NP	O
alanine	NN	I-NP	O
transaminase	NN	I-NP	O
(	(	O	O
ALT	NN	B-NP	O
)	)	O	O
concentration	NN	B-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
dogs	NNS	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	B
failure	NN	I-NP	I
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

CCNU	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
dogs	NNS	B-NP	O
is	VBZ	B-VP	O
common	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
is	VBZ	B-VP	O
usually	RB	B-ADVP	O
not	RB	O	O
life	NN	B-NP	O
threatening	NN	I-NP	O
.	.	O	O

Neuroactive	JJ	B-NP	O
steroids	NNS	I-NP	O
protect	VBP	B-VP	O
against	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	O	O
and	CC	O	O
kainic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
limbic	JJ	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Several	JJ	B-NP	O
structurally	RB	I-NP	O
related	VBN	I-NP	O
metabolites	NNS	I-NP	O
of	IN	B-PP	O
progesterone	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
alpha	SYM	O	O
-	HYPH	O	O
hydroxy	NN	B-NP	O
pregnane	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
ones	NNS	I-NP	O
)	)	O	O
and	CC	O	O
deoxycorticosterone	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
alpha	SYM	O	O
-	HYPH	O	O
hydroxy	NN	B-NP	O
pregnane	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
diol	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
ones	NNS	I-NP	O
)	)	O	O
and	CC	O	O
their	PRP$	B-NP	O
num	CD	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
epimers	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
for	IN	B-PP	O
protective	JJ	B-NP	O
activity	NN	I-NP	O
against	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	O	O
,	,	O	O
kainic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
and	CC	O	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Steroids	NNS	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
group	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
position	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
H	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
or	CC	O	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
configurations	NNS	B-NP	O
were	VBD	B-VP	O
highly	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
protecting	VBG	B-VP	O
against	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
limbic	JJ	I-NP	O
motor	NN	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
corresponding	VBG	I-NP	O
epimers	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
group	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
position	NN	I-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
effective	JJ	B-ADJP	O
but	CC	O	O
less	RBR	B-ADJP	O
potent	JJ	I-ADJP	O
(	(	O	O
ED50	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	O	O
i.p.	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
neuroactive	JJ	I-NP	O
steroids	NNS	I-NP	O
were	VBD	B-VP	O
considerably	RB	B-ADJP	O
less	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
benzodiazepine	NN	I-NP	O
clonazepam	NN	I-NP	O
in	IN	B-PP	O
protecting	VBG	B-VP	O
against	IN	B-PP	O
pilocarpine	NN	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
steroids	NNS	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
alpha	SYM	O	O
,	,	O	O
num	CD	B-NP	O
alpha	SYM	O	O
-	HYPH	O	O
configuration	NN	B-NP	O
had	VBD	B-VP	O
comparable	JJ	B-NP	O
or	CC	I-NP	O
higher	JJR	I-NP	O
protective	JJ	I-NP	O
index	NN	I-NP	O
values	NNS	I-NP	O
(	(	O	O
TD50	NN	B-NP	O
for	IN	B-PP	O
motor	NN	B-NP	O
impairment	NN	I-NP	O
divided	VBN	B-VP	O
by	IN	B-PP	O
ED50	NN	B-NP	O
for	IN	B-PP	O
seizure	NN	B-NP	B
protection	NN	I-NP	O
)	)	O	O
than	IN	B-PP	O
clonazepam	NN	B-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
some	DT	B-NP	O
neuroactive	JJ	I-NP	O
steroids	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
lower	JJR	B-NP	O
relative	JJ	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Steroids	NNS	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
alpha	SYM	O	O
,	,	O	O
num	CD	B-NP	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
or	CC	O	O
num	CD	B-NP	O
beta	SYM	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
alpha	SYM	O	O
-	HYPH	O	O
configurations	NNS	B-NP	O
also	RB	B-ADVP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
delay	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
limbic	JJ	B-NP	O
seizures	NNS	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
kainic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
completely	RB	I-VP	O
protect	VB	I-VP	O
against	IN	B-PP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
a	DT	B-NP	O
second	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
steroid	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
num	CD	B-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
dose	NN	I-NP	O
,	,	O	O
complete	JJ	B-NP	O
protection	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
kainic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
limbic	JJ	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
was	VBD	B-VP	O
obtained	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
steroids	NNS	I-NP	O
also	RB	B-ADVP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
delay	NN	I-NP	O
in	IN	B-PP	O
NMDA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lethality	NN	I-NP	O
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
completely	RB	I-VP	O
protect	VB	I-VP	O
against	IN	B-PP	O
NMDA	NN	B-NP	O
seizures	NNS	I-NP	B
or	CC	O	O
lethality	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
neuroactive	JJ	B-NP	O
steroids	NNS	I-NP	O
are	VBP	B-VP	O
highly	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
protecting	VBG	B-VP	O
against	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	O	O
and	CC	O	O
kainic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
utility	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
some	DT	B-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
butyl	NN	I-NP	O
-	HYPH	B-NP	O
deoxynojirimycin	NN	I-NP	O
(	(	O	O
SC	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
and	CC	O	O
zidovudine	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	B
-	HYPH	O	I
num	CD	B-NP	I
infection	NN	I-NP	I
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
CD4	NN	I-NP	O
cells	NNS	I-NP	O
/	SYM	B-VP	O
mm3	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	O	O
randomized	VBD	B-VP	O
phase	NN	B-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
butyl	NN	I-NP	O
-	HYPH	B-NP	O
deoxynojirimycin	NN	I-NP	O
(	(	O	O
SC	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
(	(	O	O
an	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
glucosidase	NN	I-NP	O
num	CD	I-NP	O
inhibitor	NN	I-NP	O
)	)	O	O
and	CC	O	O
zidovudine	NN	B-NP	O
versus	IN	B-PP	O
zidovudine	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
CD4	NN	I-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
mm3	NN	B-NP	O
who	WP	B-NP	O
tolerated	VBD	B-VP	O
<	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
prior	JJ	B-NP	O
zidovudine	NN	I-NP	O
therapy	NN	I-NP	O
received	VBD	B-VP	O
SC	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
zidovudine	NN	B-NP	O
or	CC	I-NP	O
zidovudine	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
zidovudine	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
and	CC	I-NP	O
zidovudine	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
discontinued	VBN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
SC	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
steady	JJ	I-NP	O
-	HYPH	I-NP	O
state	NN	I-NP	O
trough	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
below	IN	B-PP	O
the	DT	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
inhibitory	JJ	I-NP	O
concentration	NN	I-NP	O
for	IN	B-PP	O
human	JJ	B-NP	O
immunodeficiency	NN	I-NP	B
virus	NN	I-NP	O
(	(	O	O
HIV	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
CD4	NN	B-NP	O
cells	NNS	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	B-NP	O
mm3	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
mm3	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
and	CC	I-NP	O
zidovudine	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

For	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
prior	JJ	B-NP	O
zidovudine	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
CD4	NN	B-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
and	CC	I-NP	O
zidovudine	NN	I-NP	O
groups	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	B-NP	O
mm3	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
mm3	NN	B-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
cells	NNS	I-NP	O
/	SYM	B-NP	O
mm3	NN	B-NP	O
and	CC	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
mm3	NN	B-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
suppression	NN	B-NP	O
of	IN	B-PP	O
HIV	NN	B-NP	O
p24	NN	I-NP	O
antigenemia	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
and	CC	I-NP	O
zidovudine	NN	I-NP	O
groups	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Diarrhea	NN	B-NP	B
,	,	O	O
flatulence	NN	B-NP	B
,	,	O	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
,	,	O	O
and	CC	O	O
weight	NN	B-NP	B
loss	NN	I-NP	I
were	VBD	B-VP	O
common	JJ	B-ADJP	O
for	IN	B-PP	O
combination	NN	B-NP	O
recipients.	NN	I-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Recent	JJ	B-NP	O
preclinical	JJ	I-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
thymidylate	NN	I-NP	O
synthase	NN	I-NP	O
inhibitor	NN	I-NP	O
N10	NN	I-NP	O
-	HYPH	B-NP	O
propargyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dideazafolic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
CB	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

CB	NN	B-NP	O
num	CD	I-NP	O
N10	NN	I-NP	O
-	HYPH	B-NP	O
propargyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dideazafolic	JJ	I-NP	O
acid	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
tight	JJ	I-NP	O
-	HYPH	I-NP	O
binding	VBG	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
thymidylate	NN	B-NP	O
synthase	NN	I-NP	O
(	(	O	O
TS	NN	B-NP	O
)	)	O	O
whose	WP$	B-NP	O
cytotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
mediated	VBN	I-VP	O
solely	RB	B-ADVP	O
through	IN	B-PP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
enzyme	NN	I-NP	O
.	.	O	O

Recent	JJ	B-NP	O
preclinical	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
focused	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
intracellular	JJ	I-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
CB	NN	B-NP	O
num	CD	B-NP	O
polyglutamates	NNS	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
exposure	NN	I-NP	O
of	IN	B-PP	O
L1210	NN	B-NP	O
cells	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
microM	NN	I-NP	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
CB	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
extractable	JJ	I-NP	O
radioactivity	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
accounted	VBN	I-VP	O
for	IN	B-PP	O
as	IN	B-PP	O
CB	NN	B-NP	O
num	CD	I-NP	O
tetra	AFX	O	O
-	HYPH	O	O
and	CC	O	O
pentaglutamate	NN	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
determined	VBN	B-VP	O
by	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
pressure	NN	I-NP	O
liquid	NN	I-NP	O
chromatography	NN	I-NP	O
(	(	O	O
HPLC	NN	B-NP	O
)	)	O	O
analyses	NNS	B-NP	O
.	.	O	O

As	IN	B-SBAR	O
inhibitors	NNS	B-NP	O
of	IN	B-PP	O
isolated	VBN	B-NP	O
L1210	NN	I-NP	O
TS	NN	I-NP	O
,	,	O	O
CB	NN	B-NP	O
num	CD	I-NP	O
di	NN	I-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
tri	AFX	O	O
-	HYPH	O	O
,	,	O	O
tetra	AFX	O	O
-	HYPH	O	O
and	CC	O	O
pentaglutamate	NN	B-NP	O
are	VBP	B-VP	O
num	CD	B-NP	O
-	HYPH	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
fold	RB	B-ADJP	O
more	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
CB	NN	B-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
formation	NN	I-NP	O
may	MD	B-VP	O
,	,	O	O
therefore	RB	B-ADVP	O
,	,	O	O
be	VB	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
determinant	NN	I-NP	O
of	IN	B-PP	O
CB	NN	B-NP	O
num	CD	I-NP	O
cytotoxicity	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
early	JJ	B-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
with	IN	B-PP	O
CB	NN	B-NP	O
num	CD	I-NP	O
activity	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
ovarian	JJ	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
hepatoma	NN	B-NP	B
,	,	O	O
and	CC	O	O
mesothelioma	NN	B-NP	B
.	.	O	O

Toxicities	NNS	B-NP	B
included	VBD	B-VP	O
hepatotoxicity	NN	B-NP	B
,	,	O	O
malaise	NN	B-NP	B
,	,	O	O
and	CC	O	O
dose	NN	B-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
latter	JJ	I-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
drug	NN	B-NP	O
precipitation	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
tubule	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
poor	JJ	I-NP	O
solubility	NN	I-NP	O
of	IN	B-PP	O
CB	NN	B-NP	O
num	CD	I-NP	O
under	IN	B-PP	O
acidic	JJ	B-NP	O
conditions	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
an	DT	B-NP	O
attempt	NN	I-NP	O
to	TO	B-VP	O
overcome	VB	I-VP	O
this	DT	B-NP	O
problem	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
CB	NN	B-NP	O
num	CD	I-NP	O
administered	VBN	B-VP	O
with	IN	B-PP	O
alkaline	NN	B-NP	O
diuresis	NN	I-NP	O
is	VBZ	B-VP	O
under	IN	B-PP	O
way	NN	B-NP	O
.	.	O	O

Preliminary	JJ	B-NP	O
results	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
achieved	VBN	I-VP	O
with	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
instance	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
toxicity	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Hepatotoxicity	NN	B-NP	B
and	CC	I-NP	O
malaise	NN	I-NP	B
are	VBP	B-VP	O
again	RB	B-ADVP	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequent	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Evidence	NN	B-NP	O
of	IN	B-PP	O
antitumor	JJ	B-NP	O
activity	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Pharmacokinetic	JJ	B-NP	O
investigations	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
alkaline	NN	B-NP	O
diuresis	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
CB	NN	B-NP	O
num	CD	I-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
or	CC	O	O
urinary	JJ	B-NP	O
excretion	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
satisfactory	JJ	B-NP	O
urinary	JJ	I-NP	O
alkalinization	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
readily	RB	I-VP	O
achieved	VBN	I-VP	O
.	.	O	O

Ethopropazine	NN	B-NP	O
and	CC	I-NP	O
benztropine	NN	I-NP	O
in	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
parkinsonism	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
controlled	VBN	I-NP	O
study	NN	I-NP	O
ethopropazine	NN	I-NP	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
benztropine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
parkinsonism	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
fluphenazine	NN	B-NP	O
enanthate	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
schizophrenic	JJ	I-NP	B
outpatients	NNS	I-NP	O
.	.	O	O

Ethopropazine	NN	B-NP	O
and	CC	I-NP	O
benztropine	NN	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
equally	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
controlling	VBG	B-VP	O
parkinsonian	JJ	B-NP	B
symptoms	NNS	I-NP	I
and	CC	O	O
were	VBD	B-VP	O
as	RB	B-ADJP	O
efficacious	JJ	I-ADJP	O
as	IN	B-PP	O
procyclidine	NN	B-NP	O
,	,	O	O
their	PRP$	B-NP	O
previous	JJ	I-NP	O
antiparkinsonian	JJ	I-NP	O
drug	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
benztropine	NN	B-NP	O
treated	VBN	B-VP	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
tardive	JJ	B-NP	B
dyskinesia	NN	I-NP	I
compared	VBN	B-VP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
condition	NN	I-NP	O
during	IN	B-PP	O
procyclindine	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
and	CC	O	O
significantly	RB	B-NP	O
more	JJR	I-NP	O
anxiety	NN	I-NP	B
and	CC	I-NP	O
depression	NN	I-NP	B
than	IN	B-PP	O
ethopropazine	NN	B-NP	O
treated	VBN	B-VP	O
patients	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
benztropine	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
the	DT	B-NP	O
anticholinergic	JJ	I-NP	O
drug	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
parkinsonian	JJ	I-NP	B
symptoms	NNS	I-NP	I
,	,	O	O
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
more	RBR	I-NP	O
toxic	JJ	I-NP	O
central	JJ	I-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
atropinic	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
tocopherol	NN	I-NP	O
and	CC	I-NP	O
deferoxamine	NN	I-NP	O
on	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Methamphetamine	NN	B-NP	O
(	(	O	O
MA	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
dopaminergic	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
believed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
free	JJ	B-NP	O
radicals	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	O	O
-	HYPH	O	O
tocopherol	NN	B-NP	O
(	(	O	O
alpha	SYM	O	O
-	HYPH	O	O
TC	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
scavenger	NN	I-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
,	,	O	O
and	CC	O	O
deferoxamine	NN	B-NP	O
(	(	O	O
DFO	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
iron	NN	I-NP	O
chelator	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
MA	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Male	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
MA	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
rat	NN	I-NP	O
received	VBD	B-VP	O
either	CC	O	O
alpha	SYM	O	O
-	HYPH	O	O
TC	NN	B-NP	O
intraperitoneally	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
MA	JJ	B-NP	O
administration	NN	I-NP	O
or	CC	I-NP	O
DFO	NN	I-NP	O
subcutaneously	RB	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
MA	JJ	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
,	,	O	O
serotonin	NN	B-NP	O
and	CC	O	O
their	PRP$	B-NP	O
metabolites	NNS	I-NP	O
decreased	VBD	B-VP	O
significantly	RB	B-ADVP	O
after	IN	B-SBAR	O
MA	JJ	B-NP	O
administration	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
TC	NN	I-NP	O
and	CC	I-NP	O
DFO	NN	I-NP	O
pretreatment.	NN	I-NP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
TC	NN	I-NP	O
and	CC	I-NP	O
DFO	NN	I-NP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
MA	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperthermia	NN	I-NP	B
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
reduced	VBN	I-NP	O
glutathione	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
MA	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
attenuated	VBN	I-VP	O
by	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
TC	NN	I-NP	O
and	CC	I-NP	O
DFO	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
TC	NN	I-NP	O
and	CC	I-NP	O
DFO	NN	I-NP	O
ameliorate	VBP	B-VP	O
the	DT	B-NP	O
MA	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
neuronal	JJ	I-NP	B
damage	NN	I-NP	I
by	IN	B-PP	O
decreasing	VBG	B-VP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
with	IN	B-PP	O
mesna	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	I
.	.	O	O

Hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
(	(	O	O
HC	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
limiting	VBG	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
with	IN	B-PP	O
ifosfamide	NN	B-NP	O
(	(	O	O
IFS	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
presented	VBN	B-VP	O
here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
mesna	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
IFS	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
HC	NN	I-NP	B
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
rats	NNS	I-NP	O
per	IN	B-PP	O
group	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
or	CC	I-NP	O
mesna	NN	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
(	(	O	O
i.p.	RB	B-ADVP	O
)	)	O	O
before	IN	B-PP	O
and	CC	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
(	(	B-LST	O
v.o.	LS	I-LST	O
)	)	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
IFS	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
mesna	NNS	B-NP	O
were	VBD	B-VP	O
replaced	VBN	I-VP	O
with	IN	B-PP	O
dexamethasone	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
with	IN	B-PP	O
dexamethasone	NN	B-NP	O
plus	CC	I-NP	O
mesna	NN	I-NP	O
.	.	O	O

Cystitis	NN	B-NP	B
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
its	PRP$	B-NP	O
induction	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
bladder	NN	B-NP	O
wet	JJ	I-NP	O
weight	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
macroscopic	JJ	B-NP	O
and	CC	I-NP	O
microscopic	JJ	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
replacement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
dose	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
mesna	NN	B-NP	O
with	IN	B-PP	O
dexamethasone	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
bladder	NN	B-NP	O
wet	JJ	I-NP	O
weight	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
IFS	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
it	PRP	B-NP	O
almost	RB	B-ADVP	O
abolished	VBD	B-VP	O
the	DT	B-NP	O
macroscopic	JJ	I-NP	O
and	CC	I-NP	O
microscopic	JJ	I-NP	O
alterations	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
IFS	NN	B-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
mesna	NN	B-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
efficient	JJ	I-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
mesna	NN	B-NP	O
alone	RB	B-ADVP	O
when	WRB	B-ADVP	O
evaluated	VBN	B-VP	O
microscopically	RB	B-ADVP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
mesna	NN	B-NP	O
was	VBD	B-VP	O
efficient	JJ	B-ADJP	O
in	IN	B-PP	O
blocking	VBG	B-VP	O
IFS	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
HC	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
replacement	NN	I-NP	O
of	IN	B-PP	O
last	JJ	B-NP	O
num	CD	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
mesna	NN	B-NP	O
with	IN	B-PP	O
saline	NN	B-NP	O
or	CC	O	O
all	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mesna	NN	I-NP	O
doses	VBZ	B-VP	O
with	IN	B-PP	O
dexamethasone	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
HC	NN	B-NP	B
.	.	O	O

Behavioral	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
reserpine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dizocilpine	NN	B-NP	O
(	(	O	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
noncompetitive	JJ	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
antagonist	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
on	IN	B-PP	O
dopamine	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
behaviors	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
reserpine	NN	B-NP	O
treatments	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
focuses	VBZ	B-VP	O
on	IN	B-PP	O
behavioral	JJ	B-NP	O
syndromes	NNS	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
models	NNS	B-NP	O
for	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
or	CC	O	O
tardive	JJ	B-NP	B
dyskinesia	NN	I-NP	I
,	,	O	O
and	CC	O	O
its	PRP$	B-NP	O
response	NN	I-NP	O
after	IN	B-PP	O
glutamatergic	JJ	B-NP	O
blockage	NN	I-NP	O
.	.	O	O

Reserpine	NN	B-NP	O
,	,	O	O
administered	VBN	B-VP	O
once	RB	B-ADVP	O
every	DT	B-NP	O
other	JJ	I-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
produced	VBD	B-VP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
orofacial	JJ	B-NP	B
dyskinesia	NN	I-NP	I
,	,	O	O
tongue	NN	B-NP	O
protrusion	NN	I-NP	O
and	CC	O	O
vacuous	JJ	B-NP	O
chewing	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
signs	NNS	B-NP	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
tardive	JJ	B-NP	B
dyskinesia	NN	I-NP	I
.	.	O	O

Reserpine	NN	B-NP	O
also	RB	B-ADVP	O
produced	VBD	B-VP	O
tremor	NN	B-NP	B
and	CC	I-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
signs	NNS	B-NP	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

MK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
,	,	O	O
administered	VBN	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
observation	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
vacuous	JJ	I-NP	O
chewing	NN	I-NP	O
movements	NNS	I-NP	O
,	,	O	O
tongue	NN	B-NP	O
protrusions	NNS	I-NP	O
and	CC	O	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
reserpine	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
injection	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
tremor	NN	B-NP	B
in	IN	B-PP	O
reserpine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Reserpine	NN	B-NP	O
,	,	O	O
administered	VBN	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
and	CC	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
apomophine	NN	B-NP	O
injection	NN	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
oral	JJ	B-NP	B
dyskinesia	NN	I-NP	I
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
reserpine	NN	B-NP	O
induced	VBD	B-VP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
tremor	NN	B-NP	B
and	CC	I-NP	O
catalepsy	NN	I-NP	B
compared	VBN	B-VP	O
to	TO	B-PP	O
control	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
administration	NN	I-NP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
and	CC	I-NP	O
tremor	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
reserpine	NN	B-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
reserpine	NN	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
observation	NN	I-NP	O
test	NN	I-NP	O
produced	VBD	B-VP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
vacuous	JJ	B-NP	O
chewing	NN	I-NP	O
movements	NNS	I-NP	O
and	CC	O	O
tongue	NN	B-NP	O
protrusion	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
tremor	NN	B-NP	B
and	CC	I-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
whereas	IN	O	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
injection	NN	I-NP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
reserpine	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
reserpine	NN	B-NP	O
produces	VBZ	B-VP	O
different	JJ	B-NP	O
and	CC	I-NP	O
abnormal	JJ	I-NP	B
movements	NNS	I-NP	I
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
dose	NN	B-NP	O
and	CC	I-NP	O
schedule	NN	I-NP	O
employed	VBN	B-VP	O
and	CC	O	O
can	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
parkinsonian	JJ	B-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
and	CC	I-NP	O
tardive	JJ	I-NP	B
dsykinesia	NN	I-NP	I
signs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
glutamatergic	JJ	I-NP	O
blockage	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
NMDA	NN	B-NP	O
can	MD	B-VP	O
restore	VB	I-VP	O
these	DT	B-NP	O
signs	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
vacuous	JJ	B-NP	O
chewing	NN	I-NP	O
movements	NNS	I-NP	O
,	,	O	O
tongue	NN	B-NP	O
protrusions	NNS	I-NP	O
,	,	O	O
catalepsy	NN	B-NP	B
and	CC	I-NP	O
tremor	NN	I-NP	B
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
employed	VBN	I-NP	O
model	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
sphincter	NN	I-NP	B
of	IN	B-PP	I
Oddi	NNP	B-NP	I
spasm	NN	I-NP	I
evoked	VBN	B-VP	O
by	IN	B-PP	O
prostigmine	NN	B-NP	O
-	HYPH	B-NP	O
morphine	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
prostigmine	NN	I-NP	O
-	HYPH	B-NP	O
morphine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
sphincter	NN	I-NP	B
of	IN	B-PP	I
Oddi	NNP	B-NP	I
spasm	NN	I-NP	I
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
female	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
sphincter	NN	B-NP	B
of	IN	B-PP	I
Oddi	NNP	B-NP	I
dyskinesia	NN	I-NP	I
.	.	O	O

Sphincter	NNP	B-NP	B
of	IN	B-PP	I
Oddi	NNP	B-NP	I
spasm	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
prostigmine	NN	B-NP	O
-	HYPH	B-NP	O
morphine	NN	I-NP	O
administration	NN	I-NP	O
and	CC	O	O
visualized	VBN	B-VP	O
by	IN	B-PP	O
quantitative	JJ	B-NP	O
hepatobiliary	JJ	I-NP	O
scintigraphy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
entire	JJ	I-NP	O
procedure	NN	I-NP	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
during	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

Prostigmine	NN	B-NP	O
-	HYPH	I-NP	O
morphine	NN	I-NP	O
provocation	NN	I-NP	O
caused	VBD	B-VP	O
significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
peak	JJ	B-NP	O
activity	NN	I-NP	O
(	(	O	O
Tmax	NN	B-NP	O
)	)	O	O
over	IN	B-PP	O
the	DT	B-NP	O
hepatic	JJ	I-NP	O
hilum	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
common	JJ	I-NP	O
bile	NN	I-NP	O
duct	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
half	JJ	I-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
excretion	NN	B-NP	O
(	(	O	O
T1	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
)	)	O	O
over	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
parenchyma	NN	I-NP	O
,	,	I-NP	O
HH	NN	I-NP	O
and	CC	I-NP	O
CBD	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
spasm	NN	I-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sphincter	NN	I-NP	O
of	IN	B-PP	O
Oddi	NNP	B-NP	O
.	.	O	O

Glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
infusion	NN	I-NP	O
completely	RB	B-ADVP	O
normalized	VBD	B-VP	O
the	DT	B-NP	O
prostigmine	NN	I-NP	O
-	HYPH	B-NP	O
morphine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
quantitative	JJ	I-NP	O
parameters	NNS	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
sphincter	NN	I-NP	O
-	HYPH	O	O
relaxing	VBG	B-VP	O
effect	NN	B-NP	O
of	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
morphine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
sphincter	NN	I-NP	B
of	IN	B-PP	I
Oddi	NNP	B-NP	I
spasm	NN	I-NP	I
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

Since	IN	B-SBAR	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
is	VBZ	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
overcome	VB	I-VP	O
even	RB	B-NP	O
the	DT	I-NP	O
drastic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
,	,	O	O
it	PRP	B-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
relevance	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
sphincter	NN	B-NP	B
of	IN	B-PP	I
Oddi	NNP	B-NP	I
dyskinesia	NN	I-NP	I
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
steroid	NN	I-NP	O
administration	NN	I-NP	O
on	IN	B-PP	O
ventilatory	JJ	B-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
muscles	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Occasional	JJ	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
acute	JJ	B-NP	O
myopathy	NN	I-NP	B
may	MD	B-VP	O
occur	VB	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
massive	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
corticosteroids	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
myopathy	NN	I-NP	B
is	VBZ	B-VP	O
poorly	RB	I-VP	O
understood	VBN	I-VP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
daily	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
(	(	O	O
C	NN	B-NP	O
)	)	O	O
,	,	O	O
methylprednisolone	NN	B-NP	O
(	(	O	O
M	NN	B-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
triamcinolone	NN	B-NP	O
(	(	O	O
T	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
.	.	O	O

Nutritional	JJ	B-NP	O
intake	NN	I-NP	O
,	,	O	O
measured	VBN	B-VP	O
daily	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	B
of	IN	B-PP	I
food	NN	B-NP	I
intake	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
steroid	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
(	(	O	O
-	SYM	B-NP	O
num	CD	I-NP	O
and	CC	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
M	NN	B-NP	O
and	CC	O	O
T	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
loss	NN	I-NP	B
in	IN	B-PP	I
body	NN	B-NP	I
weight	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
remaining	VBG	I-NP	O
animals	NNS	I-NP	O
,	,	O	O
diaphragm	NN	B-NP	O
contractility	NN	I-NP	O
and	CC	O	O
histopathologic	JJ	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
muscles	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

Weights	NNS	B-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
muscles	NNS	I-NP	O
were	VBD	B-VP	O
similarly	RB	I-VP	O
decreased	VBN	I-VP	O
after	IN	B-PP	O
steroid	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Maximal	JJ	B-NP	O
twitches	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diaphragm	NN	I-NP	O
were	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
C	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
M	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
T	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Half	NN	B-NP	O
-	HYPH	I-NP	O
relaxation	NN	I-NP	O
time	NN	I-NP	O
was	VBD	B-VP	O
prolonged	VBN	I-VP	O
in	IN	B-PP	O
both	CC	O	O
steroid	NN	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
and	CC	O	O
time	NN	B-NP	O
to	TO	B-PP	O
peak	JJ	B-NP	O
tension	NN	I-NP	O
was	VBD	B-VP	O
longer	RBR	B-ADVP	O
with	IN	B-PP	O
M	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
tetanic	JJ	B-NP	B
tensions	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
.	.	O	O

Steroid	NN	B-NP	O
treatment	NN	I-NP	O
also	RB	B-ADVP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
leftward	JJ	I-NP	O
shift	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
force	NN	I-NP	O
-	HYPH	B-NP	O
frequency	NN	I-NP	O
curve	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
Hz	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
saline	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

ATPase	NN	B-NP	O
staining	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diaphragm	NN	I-NP	O
,	,	O	O
scalenus	NN	B-NP	O
medius	NN	I-NP	O
,	,	O	O
and	CC	O	O
gastrocnemius	NN	B-NP	O
showed	VBD	B-VP	O
type	NN	B-NP	O
IIb	NN	I-NP	O
fiber	NN	I-NP	O
atrophy	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
steroid	NN	I-NP	O
groups	NNS	I-NP	O
and	CC	O	O
also	RB	B-ADVP	O
diaphragmatic	JJ	B-NP	O
type	NN	I-NP	O
IIa	NN	I-NP	O
atrophy	NN	I-NP	B
with	IN	B-PP	O
T	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
histologic	JJ	B-NP	O
examinations	NNS	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
muscular	JJ	I-NP	O
pattern	NN	I-NP	O
with	IN	B-PP	O
absence	NN	B-NP	O
of	IN	B-PP	O
necrosis	NN	B-NP	B
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
pair	NN	I-NP	O
-	HYPH	B-VP	O
fed	VBN	I-VP	O
(	(	O	O
PF	NN	B-NP	O
)	)	O	O
study	NN	B-NP	O
,	,	O	O
performed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
(	(	O	O
C	NN	B-NP	O
,	,	O	O
T	NN	B-NP	O
,	,	O	O
and	CC	O	O
PF	NN	B-NP	O
)	)	O	O
,	,	O	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
muscle	NN	B-NP	B
atrophy	NN	I-NP	I
was	VBD	B-VP	O
considerably	RB	B-ADJP	O
less	RBR	I-ADJP	O
pronounced	JJ	I-ADJP	O
in	IN	B-PP	O
PF	NN	B-NP	O
animals	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
T	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
massive	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
steroids	NNS	B-NP	O
induced	VBD	B-VP	O
severe	JJ	B-NP	O
respiratory	NN	I-NP	O
and	CC	I-NP	O
limb	NN	I-NP	O
muscle	NN	I-NP	O
wasting	NN	I-NP	O
;	:	O	O
both	DT	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
steroids	NNS	B-NP	O
induced	VBD	B-VP	O
predominantly	RB	B-NP	O
type	NN	I-NP	O
IIb	NN	I-NP	O
atrophy	NN	I-NP	B
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
expected	JJ	I-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
diaphragm	NN	B-NP	O
contractile	JJ	I-NP	O
properties	NNS	I-NP	O
;	:	O	O
neither	DT	B-NP	O
steroid	NN	I-NP	O
caused	VBD	B-VP	O
muscle	NN	B-NP	O
necrosis	NN	I-NP	B
;	:	O	O
type	NN	B-NP	O
IIb	NN	I-NP	O
atrophy	NN	I-NP	B
was	VBD	B-VP	O
not	RB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
acute	JJ	B-NP	O
nutritional	JJ	I-NP	O
deprivation	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Refractory	JJ	B-NP	O
cardiogenic	JJ	I-NP	B
shock	NN	I-NP	I
and	CC	O	O
complete	JJ	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
after	IN	B-PP	O
verapamil	NN	B-NP	O
SR	NN	I-NP	O
and	CC	O	O
metoprolol	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
complete	JJ	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
and	CC	O	O
refractory	JJ	B-NP	O
hypotension	NN	I-NP	B
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
therapeutic	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
sustained	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
verapamil	NN	I-NP	O
with	IN	B-PP	O
concomitant	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
continued	VBD	B-VP	O
to	TO	I-VP	O
remain	VB	I-VP	O
hypotensive	JJ	B-ADJP	B
with	IN	B-PP	O
complete	JJ	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
,	,	O	O
even	RB	B-ADVP	O
with	IN	B-PP	O
multiple	JJ	B-NP	O
uses	NNS	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
atropine	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
pressor	NN	B-NP	O
agents	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
dopamine	NN	B-NP	O
and	CC	I-NP	O
dobutamine	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
shortly	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
calcium	NN	I-NP	O
chloride	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
refractory	JJ	I-NP	O
hypotension	NN	I-NP	B
and	CC	O	O
complete	JJ	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
resolved	VBN	B-VP	O
.	.	O	O

A	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
clinical	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antipurine	JJ	I-NP	O
antifolate	JJ	I-NP	O
lometrexol	NN	I-NP	O
(	(	O	O
DDATHF	NN	B-NP	O
)	)	O	O
given	VBN	B-PP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
folic	JJ	I-NP	O
acid	NN	I-NP	O
.	.	O	O

Lometrexol	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
antifolate	NN	I-NP	O
which	WDT	B-NP	O
inhibits	VBZ	B-VP	O
glycinamide	NN	B-NP	O
ribonucleotide	NN	I-NP	O
formyltransferase	NN	I-NP	O
(	(	O	O
GARFT	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
enzyme	NN	I-NP	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
de	FW	B-NP	O
novo	FW	I-NP	O
purine	NN	I-NP	O
synthesis	NN	I-NP	O
.	.	O	O

Extensive	JJ	B-NP	O
experimental	JJ	I-NP	O
and	CC	I-NP	O
limited	JJ	I-NP	O
clinical	JJ	I-NP	O
data	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
lometrexol	NN	B-NP	O
has	VBZ	B-VP	O
activity	NN	B-NP	O
against	IN	B-PP	O
tumours	NNS	B-NP	B
which	WDT	B-NP	O
are	VBP	B-VP	O
refractory	JJ	B-ADJP	O
to	TO	B-PP	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
notably	RB	B-NP	O
methotrexate	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
initial	JJ	I-NP	O
clinical	JJ	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
lometrexol	NN	B-NP	O
was	VBD	B-VP	O
curtailed	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
severe	JJ	B-NP	O
and	CC	I-NP	O
cumulative	JJ	I-NP	O
antiproliferative	JJ	I-NP	O
toxicities	NNS	I-NP	B
.	.	O	O

Preclinical	JJ	B-NP	O
murine	JJ	I-NP	O
studies	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
lometrexol	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
low	JJ	B-NP	O
dose	NN	I-NP	O
folic	JJ	I-NP	O
acid	NN	I-NP	O
administration	NN	I-NP	O
,	,	O	O
i.e.	FW	B-PP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
following	VBG	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
bolus	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
observation	NN	I-NP	O
prompted	VBD	B-VP	O
a	DT	B-NP	O
Phase	NN	I-NP	O
num	CD	I-NP	O
clinical	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
lometrexol	NN	B-NP	O
given	VBN	B-VP	O
with	IN	B-PP	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
supplementation	NN	I-NP	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
confirmed	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
lometrexol	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
markedly	RB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
supplementation	NN	I-NP	O
.	.	O	O

Thrombocytopenia	NN	B-NP	B
and	CC	I-NP	O
mucositis	NN	I-NP	B
were	VBD	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
toxicities	NNS	I-NP	B
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
clear	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
clinical	JJ	B-NP	O
toxicity	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
folate	NN	I-NP	O
elevation	NN	I-NP	O
.	.	O	O

Associated	VBN	B-NP	O
studies	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
lometrexol	NN	B-NP	O
plasma	NN	I-NP	O
pharmacokinetics	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
altered	VBN	I-VP	O
by	IN	B-PP	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
administration	NN	I-NP	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
supplementation	NN	B-NP	O
is	VBZ	B-VP	O
unlikely	JJ	B-ADJP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
toxicity	NN	B-NP	B
by	IN	B-PP	O
enhancing	VBG	B-VP	O
lometrexol	NN	B-NP	O
plasma	NN	I-NP	O
clearance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
work	NN	I-NP	O
described	VBN	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
has	VBZ	B-VP	O
identified	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
a	DT	B-NP	O
clinically	RB	I-NP	O
acceptable	JJ	I-NP	O
schedule	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
GARFT	NN	I-NP	O
inhibitor	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
information	NN	I-NP	O
will	MD	B-VP	O
facilitate	VB	I-VP	O
the	DT	B-NP	O
future	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
compounds	NNS	B-NP	O
in	IN	B-PP	O
cancer	NN	B-NP	B
therapy	NN	I-NP	O
.	.	O	O

Involvement	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mu	SYM	I-NP	O
-	HYPH	I-NP	O
opiate	NN	I-NP	O
receptor	NN	I-NP	O
in	IN	B-PP	O
peripheral	JJ	B-NP	O
analgesia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
intradermal	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
mu	NN	B-NP	O
(	(	O	O
morphine	NN	B-NP	O
,	,	O	O
Tyr	NN	B-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
Ala	NN	I-NP	O
-	HYPH	B-NP	O
Gly	NN	I-NP	O
-	HYPH	B-NP	O
NMe	NN	I-NP	O
-	HYPH	B-NP	O
Phe	NN	I-NP	O
-	HYPH	B-NP	O
Gly	NN	I-NP	O
-	HYPH	B-NP	O
ol	NN	I-NP	O
and	CC	O	O
morphiceptin	NN	B-NP	O
)	)	O	O
,	,	O	O
kappa	NN	B-NP	O
(	(	O	O
trans	AFX	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
dichloro	AFX	O	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	I-NP	O
N	NN	I-NP	O
[	(	O	O
num	CD	O	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
pyrrolidinyl	NN	I-NP	O
)	)	O	O
cyclohexyl	NN	B-NP	O
]	)	O	O
benzeneactemide	NN	B-NP	O
)	)	O	O
and	CC	O	O
delta	NN	B-NP	O
(	(	O	O
[	(	O	O
D	NN	B-NP	O
-	HYPH	I-NP	O
Pen2.5	NN	I-NP	O
]	)	O	O
-	HYPH	B-NP	O
enkephalin	NN	I-NP	O
and	CC	O	O
[	(	B-NP	O
D	NN	I-NP	O
-	HYPH	I-NP	O
Ser2	NN	I-NP	O
]	)	O	O
-	HYPH	B-NP	O
[	(	I-NP	O
Leu	NN	I-NP	O
]	)	I-NP	O
enkephalin	NN	I-NP	O
-	HYPH	B-NP	O
Thr	NN	I-NP	O
)	)	O	O
selective	JJ	B-NP	O
opioid	JJ	I-NP	O
-	HYPH	I-NP	O
agonists	NNS	I-NP	O
,	,	O	O
by	IN	B-PP	O
themselves	PRP	B-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
mechanical	JJ	I-NP	O
nociceptive	JJ	I-NP	O
threshold	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hindpaw	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Intradermal	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
mu	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
delta	SYM	B-NP	O
or	CC	O	O
kappa	SYM	B-NP	O
opioid	JJ	I-NP	O
-	HYPH	I-NP	O
agonists	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
produced	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
E2	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperalgesia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
analgesic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mu	SYM	I-NP	O
-	HYPH	I-NP	O
agonist	NN	I-NP	O
morphine	NN	I-NP	O
was	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	O	O
dependently	RB	B-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
naloxone	NN	B-NP	O
and	CC	O	O
prevented	VBN	B-VP	O
by	IN	B-PP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
pertussis	NN	B-NP	O
toxin	NN	I-NP	O
.	.	O	O

Morphine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	O	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
alter	VB	B-VP	O
the	DT	B-NP	O
hyperalgesia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
bromo	NN	I-NP	O
cyclic	JJ	I-NP	O
adenosine	NN	I-NP	O
monophosphate	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
analgesic	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
opioids	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
terminals	NNS	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	O
afferents	NNS	I-NP	O
is	VBZ	B-VP	O
via	IN	B-PP	O
a	DT	B-NP	O
binding	VBG	I-NP	O
site	NN	I-NP	O
with	IN	B-PP	O
characteristics	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mu	SYM	I-NP	O
-	HYPH	I-NP	O
opioid	JJ	I-NP	O
receptor	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
this	DT	B-NP	O
action	NN	I-NP	O
is	VBZ	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cyclic	JJ	I-NP	O
adenosine	NN	I-NP	O
monophosphate	NN	I-NP	O
second	JJ	I-NP	O
messenger	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

Adequate	JJ	B-NP	O
timing	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hemolysis	NN	B-NP	B
during	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
interferon	NN	B-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
.	.	O	O

Hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
is	VBZ	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
interferon	NN	B-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
ribavirin	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
,	,	O	O
dose	NN	B-NP	O
reduction	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
event	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
clinical	JJ	I-NP	O
retrospective	JJ	I-NP	O
cohort	JJ	I-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
have	VBP	B-VP	O
examined	VBN	I-VP	O
the	DT	B-NP	O
suitable	JJ	I-NP	O
timing	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hemolysis	NN	B-NP	B
during	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
HCV	NN	B-NP	O
-	HYPH	B-NP	O
genotype	NN	I-NP	O
1b	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
high	JJ	B-NP	O
virus	NN	I-NP	O
load	NN	I-NP	O
,	,	O	O
and	CC	O	O
received	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
developed	VBD	B-VP	O
anemia	NN	B-NP	B
with	IN	B-PP	O
hemoglobin	NN	B-NP	O
level	NN	I-NP	O
<	SYM	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	B-NP	O
or	CC	I-NP	O
anemia	NN	I-NP	B
-	HYPH	B-NP	O
related	VBN	I-NP	O
signs	NNS	I-NP	O
during	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
that	DT	B-NP	O
,	,	O	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
num	CD	B-NP	O
tablet	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
could	MD	B-VP	O
continue	VB	I-VP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
(	(	O	O
group	NN	B-NP	O
A	NN	I-NP	O
)	)	O	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
continue	VB	I-VP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
because	IN	B-SBAR	O
their	PRP$	B-NP	O
<	SYM	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
hemoglobin	NN	I-NP	O
values	NNS	I-NP	O
decreased	VBD	B-VP	O
to	TO	B-PP	O
or	CC	O	O
anemia	NN	B-NP	B
-	HYPH	O	O
related	VBN	B-NP	O
severe	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
occurred	VBD	B-VP	O
(	(	O	O
group	NN	B-NP	O
B	NN	I-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
final	JJ	I-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
after	IN	B-PP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
in	IN	B-PP	O
groups	NNS	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
B	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
sustained	JJ	I-NP	O
virological	JJ	I-NP	O
response	NN	I-NP	O
(	(	O	O
SVR	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
A	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
B	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
SVR	NN	B-NP	O
+	CC	O	O
biological	JJ	B-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
A	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
B	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
slight	JJ	B-NP	O
significance	NN	I-NP	O
.	.	O	O

With	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
hemoglobin	NN	B-NP	O
level	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
reduction	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
continuation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
>	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
hemoglobin	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
<	SYM	B-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
.	.	O	O

Reduction	NN	B-NP	O
of	IN	B-PP	O
ribavirin	NN	B-NP	O
at	IN	B-PP	O
hemoglobin	NN	B-NP	O
level	NN	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	I-NP	O
is	VBZ	B-VP	O
suitable	JJ	B-ADJP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
efficacy	NN	B-NP	O
and	CC	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
expression	NN	I-NP	O
and	CC	O	O
apical	JJ	B-NP	O
targeting	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
ENaC	NN	I-NP	O
subunits	NNS	I-NP	O
in	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
often	RB	I-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
sodium	NN	B-NP	O
retention	NN	I-NP	O
and	CC	O	O
generalized	VBN	B-NP	O
edema	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
basis	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
decreased	VBN	I-NP	O
renal	JJ	I-NP	O
sodium	NN	I-NP	O
excretion	NN	I-NP	O
remains	VBZ	B-VP	O
undefined	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
epithelial	JJ	B-NP	O
Na	NN	I-NP	O
channel	NN	I-NP	O
(	(	O	O
ENaC	NN	B-NP	O
)	)	O	O
subunit	NN	B-NP	O
dysregulation	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
sodium	NN	I-NP	O
retention	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
experimental	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
only	RB	B-NP	O
vehicle	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
PAN	NN	B-NP	O
treatment	NN	I-NP	O
induced	VBD	B-VP	O
significant	JJ	B-NP	O
proteinuria	NN	I-NP	B
,	,	O	O
hypoalbuminemia	NN	B-NP	B
,	,	O	O
decreased	VBD	B-VP	O
urinary	JJ	B-NP	O
sodium	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
and	CC	O	O
extensive	JJ	B-NP	O
ascites	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
protein	NN	I-NP	O
abundance	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	O	O
-	HYPH	O	O
ENaC	NN	B-NP	O
and	CC	O	O
beta	SYM	O	O
-	HYPH	O	O
ENaC	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
inner	JJ	I-NP	O
stripe	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
outer	JJ	I-NP	O
medulla	NN	I-NP	O
(	(	O	O
ISOM	NN	B-NP	O
)	)	O	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
inner	JJ	I-NP	O
medulla	NN	I-NP	O
(	(	O	O
IM	NN	B-NP	O
)	)	O	O
but	CC	O	O
was	VBD	B-VP	O
not	RB	I-VP	O
altered	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cortex.	NN	I-NP	O
gamma	SYM	B-VP	O
-	HYPH	B-NP	O
ENaC	NN	I-NP	O
abundance	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
,	,	O	O
ISOM	NN	B-NP	O
,	,	O	O
and	CC	O	O
IM	NN	B-NP	O
.	.	O	O

Immunoperoxidase	NN	B-NP	O
brightfield	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
laser	NN	I-NP	O
-	HYPH	O	O
scanning	VBG	B-VP	O
confocal	JJ	B-NP	O
fluorescence	NN	I-NP	O
microscopy	NN	I-NP	O
demonstrated	VBD	B-VP	O
increased	VBN	I-VP	O
targeting	VBG	B-NP	O
of	IN	B-PP	O
alpha	SYM	O	O
-	HYPH	O	O
ENaC	NN	B-NP	O
,	,	O	O
beta	SYM	O	O
-	HYPH	O	O
ENaC	NN	B-NP	O
,	,	O	O
and	CC	O	O
gamma	SYM	O	O
-	HYPH	O	O
ENaC	NN	B-NP	O
subunits	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
apical	JJ	I-NP	O
plasma	NN	I-NP	O
membrane	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
distal	JJ	I-NP	O
convoluted	JJ	I-NP	O
tubule	NN	I-NP	O
(	(	O	O
DCT2	NN	B-NP	O
)	)	O	O
,	,	O	O
connecting	VBG	B-VP	O
tubule	NN	B-NP	O
,	,	O	O
and	CC	O	O
cortical	JJ	B-NP	O
and	CC	I-NP	O
medullary	JJ	I-NP	O
collecting	VBG	I-NP	O
duct	NN	I-NP	O
segments	NNS	I-NP	O
.	.	O	O

Immunoelectron	NN	B-NP	O
microscopy	NN	I-NP	O
further	RBR	B-ADVP	O
revealed	VBD	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
labeling	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-VP	O
ENaC	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
apical	JJ	I-NP	O
plasma	NN	I-NP	O
membrane	NN	I-NP	O
of	IN	B-PP	O
cortical	JJ	B-NP	O
collecting	VBG	I-NP	O
duct	NN	I-NP	O
principal	JJ	I-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
PAN	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
enhanced	VBN	B-NP	O
apical	JJ	I-NP	O
targeting	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
ENaC	NN	I-NP	O
subunits	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
protein	NN	I-NP	O
abundances	NNS	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
/	SYM	B-NP	O
H	NN	I-NP	O
exchanger	NN	I-NP	O
type	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
NHE3	NN	B-NP	O
)	)	O	O
,	,	O	O
Na	NN	B-NP	O
-	HYPH	B-NP	O
K	NN	I-NP	O
-	HYPH	O	O
2Cl	NN	B-NP	O
cotransporter	NN	I-NP	O
(	(	O	O
BSC	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
thiazide	NN	B-NP	O
-	HYPH	O	O
sensitive	JJ	B-NP	O
Na	NN	I-NP	O
-	HYPH	B-NP	O
Cl	NN	I-NP	O
cotransporter	NN	I-NP	O
(	(	O	O
TSC	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
abundance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
subunit	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Na	NN	I-NP	O
-	HYPH	B-NP	O
K	NN	I-NP	O
-	HYPH	O	O
ATPase	NN	B-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
and	CC	I-NP	O
ISOM	NN	I-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
IM	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
increased	VBN	I-NP	O
or	CC	I-NP	O
sustained	VBN	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
ENaC	NN	B-NP	O
subunits	NNS	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
apical	JJ	I-NP	O
targeting	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
DCT2	NN	I-NP	O
,	,	O	O
connecting	VBG	B-VP	O
tubule	NN	B-NP	O
,	,	O	O
and	CC	O	O
collecting	VBG	B-VP	O
duct	NN	B-NP	O
are	VBP	B-VP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
sodium	NN	I-NP	O
retention	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
PAN	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotic	JJ	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
decreased	VBN	I-NP	O
abundance	NN	I-NP	O
of	IN	B-PP	O
NHE3	NN	B-NP	O
,	,	O	O
BSC	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
TSC	NN	I-NP	O
,	,	O	O
and	CC	O	O
Na	NN	B-NP	O
-	HYPH	B-NP	O
K	NN	I-NP	O
-	HYPH	I-NP	O
ATPase	NN	I-NP	O
may	MD	B-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
compensatory	JJ	I-NP	O
role	NN	I-NP	O
to	TO	B-VP	O
promote	VB	I-VP	O
sodium	NN	B-NP	O
excretion	NN	I-NP	O
.	.	O	O

Does	VBZ	O	O
hormone	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
have	VBP	B-VP	O
a	DT	B-NP	O
detrimental	JJ	I-NP	B
effect	NN	I-NP	I
on	IN	B-PP	I
memory	NN	B-NP	I
and	CC	I-NP	I
cognition	NN	I-NP	I
?	.	O	O
A	DT	B-NP	O
pilot	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
examines	VBZ	B-VP	O
whether	IN	B-SBAR	O
hormone	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
affects	VBZ	B-VP	O
cognition	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
participating	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
randomised	VBN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
anastrozole	NN	B-NP	O
,	,	O	O
tamoxifen	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
combined	VBN	B-VP	O
(	(	O	O
ATAC	NN	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
without	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
completed	VBD	B-VP	O
a	DT	B-NP	O
battery	NN	I-NP	O
of	IN	B-PP	O
neuropsychological	JJ	B-NP	O
measures	NNS	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
impaired	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
processing	NN	I-NP	O
speed	NN	I-NP	O
task	NN	I-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
a	DT	B-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
immediate	JJ	B-NP	O
verbal	JJ	I-NP	O
memory	NN	I-NP	O
after	IN	B-PP	O
controlling	VBG	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
hormone	NN	B-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Patient	NN	B-NP	O
group	NN	I-NP	O
performance	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
significantly	RB	B-ADJP	O
related	VBN	I-ADJP	O
to	TO	B-PP	O
length	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
or	CC	I-NP	O
measures	NNS	I-NP	O
of	IN	B-PP	O
psychological	JJ	B-NP	O
morbidity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
specific	JJ	B-NP	O
impairments	NNS	I-NP	O
in	IN	B-PP	O
processing	VBG	B-VP	O
speed	NN	B-NP	O
and	CC	O	O
verbal	JJ	B-NP	O
memory	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
receiving	VBG	B-VP	O
hormonal	JJ	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

Verbal	JJ	B-NP	O
memory	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
especially	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
oestrogen	NN	B-NP	O
levels	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
finding	NN	I-NP	O
commonly	RB	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
studies	NNS	B-NP	O
of	IN	B-PP	O
hormone	NN	B-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
view	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
hormone	NN	B-NP	O
therapies	NNS	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
adjuvant	JJ	I-NP	O
and	CC	I-NP	O
preventative	JJ	I-NP	O
setting	VBG	I-NP	O
their	PRP$	B-NP	O
impact	NN	I-NP	O
on	IN	B-PP	O
cognitive	JJ	B-NP	O
functioning	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
investigated	VBN	I-VP	O
more	RBR	B-ADVP	O
thoroughly	RB	I-ADVP	O
.	.	O	O

Association	NN	B-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
production	NN	I-NP	O
and	CC	I-NP	O
apoptosis	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
recent	JJ	B-NP	O
studies	NNS	I-NP	O
increased	VBD	B-VP	O
amounts	NNS	B-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
and	CC	O	O
apoptosis	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
various	JJ	B-NP	O
pathological	JJ	I-NP	O
conditions	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
studied	VBN	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
apoptosis	NN	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
(	(	O	O
ADR	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
alteration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
NO	NN	I-NP	O
pathway	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
measuring	VBG	B-VP	O
nitrite	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
/	SYM	B-NP	O
urine	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
evaluating	VBG	B-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
vascular	JJ	B-NP	O
reactivity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
perfused	VBN	I-NP	O
rat	NN	I-NP	O
kidney	NN	I-NP	O
(	(	O	O
IPRK	NN	B-NP	O
)	)	O	O
system	NN	B-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
stratified	VBN	I-VP	O
into	IN	B-PP	O
control	NN	B-NP	O
groups	NNS	I-NP	O
and	CC	I-NP	O
ADR	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
:	:	O	O
group	NN	B-NP	O
num	CD	B-NP	O
animals	NNS	I-NP	O
receiving	VBG	B-VP	O
saline	NN	B-NP	O
;	:	O	O
and	CC	O	O
group	NN	B-NP	O
num	CD	B-NP	O
animals	NNS	I-NP	O
receiving	VBG	B-VP	O
aminoguanidine	NN	B-NP	O
(	(	O	O
AG	NN	B-NP	O
)	)	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
inducible	JJ	B-NP	O
-	HYPH	I-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
day	NN	B-NP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
sacrificed	VBN	I-VP	O
after	IN	B-PP	O
obtaining	VBG	B-VP	O
material	NN	B-NP	O
for	IN	B-PP	O
biochemical	JJ	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

Histopathological	JJ	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
ADR	NN	B-NP	O
revealed	VBD	B-VP	O
focal	JJ	B-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
mesangial	JJ	B-NP	B
proliferation	NN	I-NP	I
and	CC	O	O
mild	JJ	B-NP	O
tubulointerstitial	JJ	I-NP	B
inflammation	NN	I-NP	I
.	.	O	O

They	PRP	B-NP	O
also	RB	B-ADVP	O
had	VBD	B-VP	O
significantly	RB	B-NP	O
higher	JJR	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Urine	NN	B-NP	O
nitrite	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
ADR	NN	I-NP	O
-	HYPH	I-NP	O
nephropathy	NN	I-NP	B
group	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
IPRK	NN	I-NP	O
phenylephrine	NN	I-NP	O
and	CC	I-NP	O
acetylcholine	NN	I-NP	O
related	VBN	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
impaired	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
ADR	NN	I-NP	O
-	HYPH	I-NP	O
nephropathy	NN	I-NP	B
group	NN	I-NP	O
.	.	O	O

Apoptosis	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
ADR	NN	I-NP	O
-	HYPH	I-NP	O
nephropathy	NN	I-NP	B
group	NN	I-NP	O
,	,	O	O
numerous	JJ	B-NP	O
apoptotic	JJ	I-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
tubulointerstitial	JJ	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

Double	JJ	B-NP	O
staining	NN	I-NP	O
revealed	VBD	B-VP	O
numerous	JJ	B-NP	O
interstitial	JJ	I-NP	O
apoptotic	JJ	I-NP	O
cells	NNS	I-NP	O
to	TO	B-VP	O
stain	VB	I-VP	O
for	IN	B-PP	O
ED1	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
marker	NN	I-NP	O
for	IN	B-PP	O
monocytes	NNS	B-NP	O
/	SYM	B-VP	O
macrophages	NNS	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
AG	NN	B-NP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
vascular	JJ	I-NP	O
bed	NN	I-NP	O
responses	NNS	I-NP	O
and	CC	O	O
reduced	VBD	B-VP	O
both	CC	O	O
urine	NN	B-NP	O
nitrite	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
apoptosis	NN	B-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
interactions	NNS	B-NP	O
between	IN	B-PP	O
NO	NN	B-NP	O
and	CC	I-NP	O
apoptosis	NN	I-NP	O
are	VBP	B-VP	O
important	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ADR	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
attenuating	VBG	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
carteolol	NN	B-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
that	IN	B-SBAR	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
adrenoceptor	NN	B-NP	O
antagonists	NNS	I-NP	O
are	VBP	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
akathisia	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
extrapyramidal	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
that	WDT	B-NP	O
occur	VBP	B-VP	O
during	IN	B-PP	O
neuroleptic	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
extrapyramidal	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
suitable	JJ	B-ADJP	O
as	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
predicting	VBG	B-VP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
in	IN	B-PP	O
humans	NNS	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
was	VBD	B-VP	O
not	RB	I-VP	O
considered	VBN	I-VP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
akathisia	NN	I-NP	B
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
carteolol	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
behaviorally	RB	I-VP	O
studied	VBN	I-VP	O
and	CC	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	I-NP	O
biperiden	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
muscarinic	JJ	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

Carteolol	NN	B-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
propranolol	NN	B-NP	O
and	CC	I-NP	O
biperiden	NN	I-NP	O
,	,	O	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
haloperidol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
carteolol	NN	B-NP	O
was	VBD	B-VP	O
almost	RB	B-ADJP	O
comparable	JJ	I-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
weaker	JJR	B-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
biperiden	NN	B-NP	O
.	.	O	O

Carteolol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
evoke	VB	I-VP	O
postsynaptic	JJ	B-NP	O
dopamine	NN	I-NP	O
receptor	NN	I-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
behavioral	JJ	B-NP	O
signs	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
stereotypy	NN	B-NP	O
and	CC	I-NP	O
hyperlocomotion	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Carteolol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
antagonize	VB	I-VP	O
the	DT	B-NP	O
inhibitory	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
on	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
stereotypy	NN	I-NP	O
and	CC	I-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
carteolol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
evoke	VB	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT1A	NN	I-NP	O
receptor	NN	I-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
behavioral	JJ	B-NP	O
signs	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
flat	JJ	B-NP	O
body	NN	I-NP	O
posture	NN	I-NP	O
and	CC	O	O
forepaw	NN	B-NP	O
treading	NN	I-NP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
inhibit	VB	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytryptophan	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
head	NN	I-NP	O
twitch	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
carteolol	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
inhibit	VB	I-VP	O
physostigmine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lethality	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
strongly	RB	B-VP	O
suggest	VBP	I-VP	O
that	IN	B-SBAR	O
carteolol	NN	B-NP	O
improves	VBZ	B-VP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
via	IN	B-PP	O
its	PRP$	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
antagonistic	JJ	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
is	VBZ	B-VP	O
expected	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
akathisia	NN	B-NP	B
without	IN	B-PP	O
attenuating	VBG	B-VP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
antipsychotic	JJ	I-NP	O
effects	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
postsynaptic	JJ	I-NP	O
dopamine	NN	I-NP	O
receptor	NN	I-NP	O
antagonistic	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Penicillamine	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
rapidly	RB	I-NP	O
progressive	JJ	I-NP	O
glomerulonephritis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
presented	VBD	B-VP	O
rapidly	RB	B-NP	O
progressive	JJ	I-NP	O
glomerulonephritis	NN	I-NP	B
(	(	O	O
RPGN	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Light	NN	B-NP	O
microscopy	NN	I-NP	O
study	NN	I-NP	O
showed	VBD	B-VP	O
severe	JJ	B-NP	O
glomerulonephritis	NN	I-NP	B
with	IN	B-PP	O
crescent	JJ	B-NP	O
formation	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomeruli	NN	I-NP	O
and	CC	I-NP	O
infiltration	NN	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
wall	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
arteriole	NN	I-NP	O
.	.	O	O

Immunofluorescence	NN	B-NP	O
revealed	VBD	B-VP	O
scanty	JJ	B-NP	O
granular	JJ	I-NP	O
IgG	NN	I-NP	O
,	,	O	O
IgA	NN	B-NP	O
and	CC	I-NP	O
C3	NN	I-NP	O
deposits	NNS	I-NP	O
along	IN	B-PP	O
the	DT	B-NP	O
capillary	JJ	I-NP	O
walls	NNS	I-NP	O
and	CC	I-NP	O
mesangium	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
steroid	NN	B-NP	O
pulse	NN	I-NP	O
,	,	O	O
plasmapheresis	NN	B-NP	O
,	,	O	O
cyclophosphamide	NN	B-NP	O
and	CC	O	O
antiplatelet	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
complete	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
achieved	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
new	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
RPGN	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
treatment	NN	I-NP	O
emphasizes	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
frequent	JJ	B-NP	O
monitoring	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	O
sediment	NN	I-NP	O
and	CC	I-NP	O
proteinuria	NN	I-NP	B
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
prompt	JJ	I-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
and	CC	O	O
vigorous	JJ	B-NP	O
treatment	NN	I-NP	O
measures	NNS	I-NP	O
could	MD	B-VP	O
allow	VB	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
good	JJ	I-NP	O
prognosis	NN	I-NP	O
as	IN	B-PP	O
in	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
.	.	O	O

Nature	NN	B-NP	O
,	,	O	O
time	NN	B-NP	O
course	NN	I-NP	O
and	CC	O	O
dose	NN	B-NP	O
dependence	NN	I-NP	O
of	IN	B-PP	O
zidovudine	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
:	:	O	O
results	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
Multicenter	NNP	I-NP	O
Canadian	NNP	I-NP	O
Azidothymidine	NNP	I-NP	O
Trial	NNP	I-NP	O
.	.	O	O

To	TO	B-VP	O
characterize	VB	I-VP	O
the	DT	B-NP	O
nature	NN	I-NP	O
,	,	O	O
time	NN	B-NP	O
course	NN	I-NP	O
and	CC	O	O
dose	NN	B-NP	O
dependency	NN	I-NP	O
of	IN	B-PP	O
zidovudine	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
undertook	VBD	B-VP	O
a	DT	B-NP	O
multicenter	JJ	I-NP	O
,	,	I-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
dose	NN	I-NP	O
-	HYPH	I-NP	O
range	NN	I-NP	O
finding	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
study	NN	I-NP	O
group	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
HIV	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
homosexual	JJ	I-NP	O
men	NNS	I-NP	O
belonging	VBG	B-VP	O
to	TO	B-PP	O
groups	NNS	B-NP	O
num	CD	B-NP	O
B	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
C2	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
Centers	NNPS	I-NP	O
for	IN	B-PP	O
Disease	NN	B-NP	O
Control	NN	I-NP	O
(	(	O	O
CDC	NN	B-NP	O
)	)	O	O
classification	NN	B-NP	O
of	IN	B-PP	O
HIV	NN	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Following	VBG	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
volunteers	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
zidovudine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
washout	NN	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
which	WDT	B-NP	O
they	PRP	B-NP	O
were	VBD	B-VP	O
re	AFX	B-ADJP	O
-	HYPH	I-ADJP	O
started	VBN	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
highest	JJS	I-NP	O
tolerated	VBN	I-NP	O
dose	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hourly	JJ	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	O	O
hourly	RB	B-ADVP	O
or	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hourly	JJ	I-NP	O
regimens	NNS	I-NP	O
within	IN	B-PP	O
CDC	NN	B-NP	O
groups	NNS	I-NP	O
while	IN	B-SBAR	O
taking	VBG	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
and	CC	I-NP	O
laboratory	NN	I-NP	O
evaluations	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

Symptomatic	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
subjects	NNS	B-NP	O
,	,	O	O
most	RBS	B-ADVP	O
commonly	RB	I-ADVP	O
nausea	NN	B-NP	B
,	,	I-NP	O
fatigue	NN	I-NP	B
and	CC	I-NP	O
headache	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
were	VBD	B-VP	O
generally	RB	B-ADVP	O
self	AFX	O	O
-	HYPH	O	O
limited	VBN	B-VP	O
,	,	O	O
reappearing	VBG	B-VP	O
briefly	RB	B-ADVP	O
at	IN	B-PP	O
each	DT	B-NP	O
dose	NN	I-NP	O
increment	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
hemoglobin	NN	B-NP	O
occurred	VBD	B-VP	O
shortly	RB	B-ADVP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
dose	NN	B-ADJP	O
dependent	JJ	I-ADJP	O
and	CC	O	O
reversed	VBN	B-VP	O
rapidly	RB	B-ADVP	O
upon	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
red	JJ	I-NP	O
blood	NN	I-NP	O
cell	NN	I-NP	O
count	NN	I-NP	O
decrease	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
mean	JJ	I-NP	O
cell	NN	I-NP	O
volume	NN	I-NP	O
increase	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
granulocyte	NN	I-NP	O
count	NN	I-NP	O
decrease	NN	I-NP	O
developed	VBD	B-VP	O
early	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
fashion	NN	I-NP	O
,	,	O	O
reverting	VBG	B-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
partially	RB	B-ADVP	O
during	IN	B-PP	O
the	DT	B-NP	O
washout	NN	I-NP	O
phase	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
reticulocyte	NN	B-NP	O
count	NN	I-NP	O
was	VBD	B-VP	O
dose	NN	B-ADJP	O
related	JJ	I-ADJP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
further	JJ	I-NP	O
change	NN	I-NP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
escalated	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

Bone	NN	B-NP	O
marrow	NN	I-NP	O
changes	NNS	I-NP	O
occurred	VBD	B-VP	O
rapidly	RB	B-VP	O
as	RB	I-VP	O
demonstrated	VBN	I-VP	O
by	IN	B-PP	O
megaloblastosis	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
specimens	NNS	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	B
optic	JJ	I-NP	I
neuropathy	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
combined	VBN	B-NP	O
ethambutol	NN	I-NP	O
and	CC	I-NP	O
isoniazid	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
an	DT	B-NP	O
unsuccessful	JJ	I-NP	O
cadaver	NN	I-NP	O
kidney	NN	I-NP	O
transplantation	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
ethambutol	NN	B-NP	O
and	CC	I-NP	O
isoniazid	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
bilateral	JJ	I-NP	B
retrobulbar	NN	I-NP	I
neuropathy	NN	I-NP	I
with	IN	B-PP	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
central	JJ	I-NP	O
bitemporal	JJ	I-NP	O
hemianopic	JJ	I-NP	O
scotoma	NN	I-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Ethambutol	NN	B-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
and	CC	O	O
only	RB	B-NP	O
small	JJ	I-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
visual	JJ	I-NP	O
acuity	NN	I-NP	O
followed	VBD	B-VP	O
.	.	O	O

Isoniazid	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
later	RB	B-ADVP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
dramatic	JJ	I-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
visual	JJ	I-NP	O
acuity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hazards	NNS	I-NP	O
of	IN	B-PP	O
optic	JJ	B-NP	O
nerve	NN	I-NP	O
toxicity	NN	I-NP	B
due	IN	B-PP	O
to	TO	I-PP	O
ethambutol	NN	B-NP	O
are	VBP	B-VP	O
known	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
emphasize	VBP	B-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
danger	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
ethambutol	NN	B-NP	O
and	CC	I-NP	O
isoniazid	NN	I-NP	O
.	.	O	O

Progestational	JJ	B-NP	O
agents	NNS	I-NP	O
and	CC	O	O
blood	NN	B-NP	B
coagulation	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
.	.	O	O

Thromboembolic	JJ	B-NP	B
and	CC	I-NP	O
other	JJ	I-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
contraceptive	JJ	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
relationship	NN	B-NP	O
to	TO	B-PP	O
pretreatment	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	B
coagulation	NN	I-NP	I
factors	NNS	I-NP	O
:	:	O	O
summary	JJ	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
months	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
studies	NNS	I-NP	O
relating	VBG	B-VP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
to	TO	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
hematologic	JJ	B-NP	O
parameters	NNS	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
certain	JJ	B-NP	O
factors	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	B
coagulation	NN	I-NP	I
and	CC	I-NP	O
fibrinolysin	NN	I-NP	O
systems	NNS	I-NP	O
(	(	O	O
factors	NNS	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
X	NN	B-NP	O
and	CC	I-NP	O
plasminogen	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
complications	NNS	I-NP	O
developed	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
abnormal	JJ	I-NP	O
blood	NN	I-NP	B
coagulation	NN	I-NP	I
profile	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
hypercoagulability	NN	B-NP	B
before	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Some	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
represented	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
extreme	JJ	I-NP	O
abnormalities	NNS	I-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
;	:	O	O
some	DT	B-NP	O
increased	VBN	B-VP	O
further	RBR	B-ADVP	O
during	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
before	IN	B-PP	O
receiving	VBG	B-VP	O
any	DT	B-NP	O
medication	NN	I-NP	O
,	,	O	O
shortly	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
base	NN	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
retinopathy	NN	B-NP	B
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
she	PRP	B-NP	O
began	VBD	B-VP	O
therapy	NN	B-NP	O
,	,	O	O
and	CC	O	O
another	DT	B-NP	O
developed	VBN	I-NP	O
thrombophlebitis	NN	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
fourth	JJ	I-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
thrombophlebitis	NN	B-NP	B
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
contraceptive	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
A	NN	I-NP	O
or	CC	I-NP	O
AB	NN	I-NP	O
blood	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
suggested	VBD	B-VP	O
the	DT	B-NP	O
possiblility	NN	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
propensity	NN	I-NP	O
for	IN	B-PP	O
thromboembolic	JJ	B-NP	B
episodes	NNS	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
possessing	VBG	B-VP	O
the	DT	B-NP	O
A	NN	I-NP	O
antigen	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
appears	VBZ	B-VP	O
from	IN	B-PP	O
these	DT	B-NP	O
data	NNS	I-NP	O
that	IN	B-NP	O
hematologic	JJ	B-NP	O
work	NN	I-NP	O
-	HYPH	O	O
ups	NNS	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
about	IN	O	O
to	TO	B-VP	O
start	VB	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
oral	JJ	I-NP	O
contraceptive	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
child	NN	I-NP	O
with	IN	B-PP	O
cerebral	JJ	B-NP	B
palsy	JJ	I-NP	I
undergoing	VBG	I-NP	O
sevoflurane	NN	I-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
after	IN	B-PP	O
preoperative	JJ	B-NP	O
clonidine	NN	I-NP	O
.	.	O	O

Clonidine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
frequently	RB	I-NP	O
administered	VBN	I-NP	O
alpha2	NN	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
agonist	NN	I-NP	O
which	WDT	B-NP	O
can	MD	B-VP	O
decrease	VB	I-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
child	NN	I-NP	O
with	IN	B-PP	O
cerebral	JJ	B-NP	B
palsy	NN	I-NP	I
and	CC	I-NP	O
seizure	NN	I-NP	B
disorder	NN	I-NP	I
,	,	O	O
receiving	VBG	B-VP	O
clonidine	NN	B-NP	O
for	IN	B-PP	O
restlessness	NN	B-NP	B
,	,	O	O
who	WP	B-NP	O
presented	VBD	B-VP	O
for	IN	B-PP	O
placement	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
baclofen	NN	I-NP	O
pump	NN	I-NP	O
.	.	O	O

Without	IN	B-PP	O
the	DT	B-NP	O
knowledge	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
personnel	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
mother	NN	B-NP	O
administered	VBN	B-VP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
evening	NN	I-NP	O
before	IN	B-PP	O
and	CC	O	O
morning	NN	B-NP	O
of	IN	B-PP	O
surgery	NN	B-NP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
anxiety	NN	B-NP	B
.	.	O	O

During	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
bradycardia	NN	B-NP	B
and	CC	I-NP	O
hypotension	NN	I-NP	B
requiring	VBG	B-VP	O
cardiac	JJ	B-NP	O
resuscitation	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
no	DT	B-NP	O
previous	JJ	I-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
child	NN	I-NP	O
undergoing	VBG	B-VP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
UMB24	NN	B-NP	O
and	CC	O	O
-	HYPH	B-NP	O
SM	NN	I-NP	O
num	CD	I-NP	O
putative	JJ	I-NP	O
sigma2	NN	I-NP	O
-	HYPH	O	O
preferring	VBG	B-VP	O
antagonists	NNS	B-NP	O
,	,	O	O
on	IN	B-PP	O
behavioral	JJ	B-NP	O
toxic	JJ	I-NP	O
and	CC	I-NP	O
stimulant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Earlier	JJR	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
antagonism	NN	B-NP	O
of	IN	B-PP	O
sigma1	NN	B-NP	O
receptors	NNS	I-NP	O
attenuates	VBZ	B-VP	O
the	DT	B-NP	O
convulsive	JJ	I-NP	B
,	,	I-NP	O
lethal	JJ	I-NP	O
,	,	I-NP	O
locomotor	JJ	I-NP	O
stimulatory	JJ	I-NP	O
and	CC	I-NP	O
rewarding	JJ	I-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
sigma2	NN	B-NP	O
receptors	NNS	I-NP	O
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
because	IN	B-SBAR	O
experimental	JJ	B-NP	O
tools	NNS	I-NP	O
to	TO	B-VP	O
selectively	RB	I-VP	O
target	VB	I-VP	O
this	DT	B-NP	O
subtype	NN	I-NP	O
are	VBP	B-VP	O
unavailable	JJ	B-ADJP	O
.	.	O	O

To	TO	B-VP	O
begin	VB	I-VP	O
addressing	VBG	I-VP	O
this	DT	B-NP	O
need	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
characterized	VBD	B-VP	O
UMB24	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
phenethyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
pyridyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
piperazine	NN	I-NP	O
)	)	O	O
and	CC	O	O
-	HYPH	B-NP	O
SM	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
3alpha	NN	B-NP	O
-	HYPH	B-NP	O
tropanyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chorophenoxy	NN	I-NP	O
)	)	O	O
butyrate	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
receptor	NN	B-NP	O
binding	NN	I-NP	O
and	CC	O	O
behavioral	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Receptor	NN	B-NP	O
binding	NN	I-NP	O
studies	NNS	I-NP	O
confirmed	VBD	B-VP	O
that	IN	B-SBAR	O
UMB24	NN	B-NP	O
and	CC	O	O
-	HYPH	B-NP	O
SM	NN	I-NP	O
num	CD	I-NP	O
display	NN	I-NP	O
preferential	JJ	I-NP	O
affinity	NN	I-NP	O
for	IN	B-PP	O
sigma2	NN	B-NP	O
over	IN	B-PP	O
sigma1	NN	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
behavioral	JJ	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
pretreatment	NN	B-NP	O
of	IN	B-PP	O
Swiss	JJ	B-NP	O
Webster	NNP	I-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
UMB24	NN	B-NP	O
or	CC	O	O
-	HYPH	B-NP	O
SM	NN	I-NP	O
num	CD	I-NP	O
significantly	RB	B-ADVP	O
attenuated	VBD	B-VP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
and	CC	O	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
lethality	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
administered	VBN	B-VP	O
alone	RB	B-ADVP	O
,	,	O	O
-	HYPH	B-NP	O
SM	NN	I-NP	O
num	CD	I-NP	O
produced	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
effects	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-VP	O
control	VB	I-VP	O
injections	NNS	B-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
,	,	O	O
but	CC	O	O
UMB24	NN	B-NP	O
had	VBD	B-VP	O
locomotor	JJ	B-NP	O
depressant	JJ	I-NP	O
actions	NNS	I-NP	O
.	.	O	O

Together	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
sigma2	NN	B-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
have	VBP	B-VP	O
the	DT	B-NP	O
potential	NN	I-NP	O
to	TO	B-VP	O
attenuate	VB	I-VP	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
and	CC	O	O
further	JJ	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
more	RBR	B-NP	O
selective	JJ	I-NP	O
,	,	I-NP	O
high	JJ	I-NP	O
affinity	NN	I-NP	O
ligands	NNS	I-NP	O
are	VBP	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Methimazole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cholestatic	JJ	I-NP	B
jaundice	NN	I-NP	I
.	.	O	O

Methimazole	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
and	CC	O	O
generally	RB	B-ADVP	O
well	RB	I-ADVP	O
-	HYPH	B-NP	O
tolerated	VBN	I-NP	O
antithyroid	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
had	VBD	B-VP	O
severe	JJ	B-NP	O
jaundice	NN	I-NP	B
and	CC	O	O
itching	VBG	B-VP	B
num	CD	B-NP	O
month	NN	I-NP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
methimazole	NN	B-NP	O
and	CC	I-NP	O
propranolol	NN	I-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
hyperthyroidism	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
continued	VBD	B-VP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
another	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
jaundice	NN	B-NP	B
until	IN	B-SBAR	O
she	PRP	B-NP	O
finished	VBD	B-VP	O
both	DT	B-NP	O
medications	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
seen	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
she	PRP	B-NP	O
still	RB	B-ADVP	O
had	VBD	B-VP	O
severe	JJ	B-NP	O
icterus	NN	I-NP	B
,	,	O	O
pruritus	NN	B-NP	B
,	,	O	O
and	CC	O	O
hyperbilirubinemia	NN	B-NP	B
,	,	O	O
formed	VBN	B-VP	O
mainly	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
conjugated	VBN	I-NP	O
fraction	NN	I-NP	O
.	.	O	O

Methimazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cholestasis	NN	I-NP	B
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
,	,	O	O
and	CC	O	O
propranolol	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
resumed	VBN	I-VP	O
.	.	O	O

Over	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
improved	VBD	B-VP	O
and	CC	O	O
plasma	NN	B-NP	O
bilirubin	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
without	IN	B-PP	O
methimazole	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
rare	JJ	B-NP	O
cases	NNS	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
few	JJ	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
drug	NN	I-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
severe	JJ	B-NP	O
and	CC	I-NP	O
reversible	JJ	I-NP	O
cholestatic	JJ	I-NP	B
jaundice	NN	I-NP	I
.	.	O	O

Physicians	NNS	B-NP	O
and	CC	I-NP	O
patients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
so	RB	B-SBAR	O
that	IN	I-SBAR	O
,	,	O	O
upon	IN	B-PP	O
occurrence	NN	B-NP	O
,	,	O	O
they	PRP	B-NP	O
can	MD	B-VP	O
discontinue	VB	I-VP	O
methimazole	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
avoid	VB	B-VP	O
unnecessary	JJ	B-NP	O
invasive	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

Ciprofloxacin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
and	CC	O	O
autoimmune	JJ	B-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
.	.	O	O

Ciprofloxacin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
several	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
including	VBG	B-PP	O
interstitial	JJ	B-NP	B
nephritis	NN	I-NP	I
and	CC	O	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
side	JJ	I-NP	O
effects	NNS	I-NP	O
is	VBZ	B-VP	O
extremely	RB	B-ADJP	O
rare	JJ	I-ADJP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
and	CC	O	O
autoimmune	JJ	B-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
.	.	O	O

Hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
improved	VBD	B-VP	O
after	IN	B-PP	O
stopping	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
and	CC	I-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
steroid	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Unfortunately	RB	B-ADVP	O
,	,	O	O
acute	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
was	VBD	B-VP	O
irreversible	JJ	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Contribution	NN	B-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
valproate	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
syndrome	NN	I-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
secretion	NN	I-NP	I
of	IN	B-PP	I
antidiuretic	JJ	B-NP	I
hormone	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
sodium	NN	B-NP	O
valproate	NN	I-NP	O
(	(	O	O
VPA	NN	B-NP	O
)	)	O	O
and	CC	O	O
who	WP	B-NP	O
subsequently	RB	B-ADVP	O
developed	VBD	B-VP	O
the	DT	B-NP	O
syndrome	NN	I-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
secretion	NN	I-NP	I
of	IN	B-PP	I
antidiuretic	JJ	B-NP	I
hormone	NN	I-NP	I
(	(	O	O
SIADH	NN	B-NP	B
)	)	O	O
.	.	O	O

He	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taking	VBG	I-VP	O
VPA	NN	B-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
idiopathic	JJ	B-NP	O
generalized	VBN	I-NP	O
tonic	JJ	I-NP	B
-	HYPH	I-NP	I
clonic	JJ	I-NP	I
convulsions	NNS	I-NP	I
since	IN	B-SBAR	O
he	PRP	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
old	JJ	B-ADJP	O
.	.	O	O

After	IN	B-PP	O
substituting	VBG	B-VP	O
VPA	NN	B-NP	O
with	IN	B-PP	O
zonisamide	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
serum	NN	I-NP	O
sodium	NN	I-NP	O
level	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
.	.	O	O

We	PRP	B-NP	O
consider	VBP	B-VP	O
this	DT	B-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
SIADH	NN	B-NP	B
to	TO	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
factors	NNS	B-NP	O
including	VBG	B-PP	O
a	DT	B-NP	O
weakness	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
central	JJ	I-NP	I
nervous	JJ	I-NP	I
system	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
VPA	NN	B-NP	O
.	.	O	O

Vasopressin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
milrinone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
severe	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
phosphodiesterase	NN	B-NP	O
inhibitors	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
milrinone	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
is	VBZ	B-VP	O
frequently	RB	B-ADJP	O
restricted	JJ	I-ADJP	O
because	IN	B-SBAR	O
they	PRP	B-NP	O
cause	VBP	B-VP	O
vasodilation	NN	B-NP	O
and	CC	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
decompensated	VBN	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
with	IN	B-PP	O
hypotension	NN	B-NP	B
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
milrinone	NN	B-NP	O
,	,	O	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
vasopressin	NN	B-NP	O
restored	VBD	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
without	IN	B-PP	O
inhibiting	VBG	B-VP	O
the	DT	B-NP	O
inotropic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
milrinone	NN	B-NP	O
.	.	O	O

Halogenated	VBN	B-NP	O
anesthetics	NNS	I-NP	O
form	VBP	B-VP	O
liver	NN	B-NP	O
adducts	NNS	I-NP	O
and	CC	I-NP	O
antigens	NNS	I-NP	O
that	IN	B-NP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
react	NN	I-NP	O
with	IN	B-PP	O
halothane	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
antibodies	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
halogenated	VBN	I-NP	O
anesthetics	NNS	I-NP	O
,	,	I-NP	O
enflurane	NN	I-NP	O
and	CC	I-NP	O
isoflurane	NN	I-NP	O
,	,	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
allergic	JJ	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
hepatic	JJ	I-NP	B
injury	NN	I-NP	I
both	CC	O	O
alone	RB	B-ADVP	O
and	CC	O	O
following	VBG	B-PP	O
previous	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
halothane	NN	B-NP	O
.	.	O	O

Halothane	NN	B-NP	O
hepatitis	NN	I-NP	B
appears	VBZ	B-VP	O
to	TO	I-VP	O
involve	VB	I-VP	O
an	DT	B-NP	O
aberrant	JJ	I-NP	O
immune	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
antibody	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
protein	NN	I-NP	O
-	HYPH	O	O
bound	VBN	B-NP	O
biotransformation	NN	I-NP	O
product	NN	I-NP	O
(	(	O	O
trifluoroacetyl	NN	B-NP	O
adduct	NN	I-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
detected	VBN	I-VP	O
on	IN	B-PP	O
halothane	NN	B-NP	O
hepatitis	NN	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
reactivity	NN	I-NP	O
between	IN	B-PP	O
enflurane	NN	B-NP	O
and	CC	I-NP	O
isoflurane	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypersensitivity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
halothane	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
subcellular	JJ	I-NP	O
and	CC	I-NP	O
lobular	JJ	I-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	O
neoantigens	NNS	I-NP	O
recognized	VBN	B-VP	O
by	IN	B-PP	O
halothane	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
antibodies	NNS	I-NP	O
following	VBG	B-PP	O
enflurane	NN	B-NP	O
and	CC	I-NP	O
isoflurane	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
biochemical	JJ	I-NP	O
nature	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
neoantigens	NNS	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
animal	NN	I-NP	O
models	NNS	I-NP	O
.	.	O	O

Enflurane	NN	B-NP	O
administration	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
neoantigens	NNS	B-NP	O
detected	VBN	B-VP	O
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
microsomal	JJ	I-NP	O
and	CC	I-NP	O
cytosolic	JJ	I-NP	O
fraction	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
homogenates	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
centrilobular	JJ	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
liver	NN	I-NP	O
,	,	O	O
biochemical	JJ	B-NP	O
analysis	NN	I-NP	O
detected	VBD	B-VP	O
fluorinated	VBN	I-VP	O
liver	NN	B-NP	O
adducts	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
up	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
fold	RB	I-ADJP	O
greater	JJR	I-ADJP	O
in	IN	B-PP	O
guinea	NN	B-NP	O
pigs	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
supports	VBZ	B-VP	O
and	CC	I-VP	O
extends	VBZ	I-VP	O
previous	JJ	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
mechanism	NN	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
enflurane	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
isoflurane	NN	B-NP	O
could	MD	B-VP	O
produce	VB	I-VP	O
a	DT	B-NP	O
hypersensitivity	NN	I-NP	B
condition	NN	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
halothane	NN	B-NP	O
hepatitis	NN	I-NP	B
either	CC	O	O
alone	RB	B-ADVP	O
or	CC	O	O
subsequent	JJ	B-ADJP	O
to	TO	B-PP	O
halothane	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
guinea	NN	I-NP	O
pig	NN	I-NP	O
would	MD	B-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
further	JJ	B-NP	O
investigations	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
immunological	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
these	DT	B-NP	O
antigens	NNS	I-NP	O
.	.	O	O

Induction	NN	B-NP	O
by	IN	B-PP	O
paracetamol	NN	B-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
and	CC	I-NP	I
liver	NN	I-NP	I
tumours	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
on	IN	B-PP	O
hepatocyte	NN	B-NP	O
fine	NN	I-NP	O
structure	NN	I-NP	O
.	.	O	O

Groups	NNS	B-NP	O
of	IN	B-PP	O
male	JJ	B-NP	O
and	CC	I-NP	O
female	JJ	I-NP	O
inbred	JJ	I-NP	O
Leeds	NNS	I-NP	O
strain	NN	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
fed	VBN	I-VP	O
diets	NNS	B-NP	O
containing	VBG	B-VP	O
either	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
paracetamol	NN	I-NP	O
by	IN	B-PP	O
weight	NN	B-NP	O
for	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
dosage	NN	I-NP	O
level	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
sexes	NNS	I-NP	O
developed	VBD	B-VP	O
neoplastic	JJ	B-NP	O
nodules	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
incidence	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
rats	NNS	I-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
gross	JJ	B-NP	O
enlargement	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
livers	NNS	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
foci	NNS	B-NP	O
of	IN	B-PP	O
cellular	JJ	B-NP	O
alteration	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
latter	JJ	I-NP	O
also	RB	B-VP	O
being	VBG	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
dosage	NN	I-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Papillomas	NNS	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
transitional	JJ	I-NP	O
epithelium	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
developed	VBN	B-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
paracetamol	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
rats	NNS	I-NP	O
bore	VBD	B-VP	O
bladder	NN	B-NP	B
carcinomas	NNS	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
significant	JJ	B-NP	O
yields	NNS	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
tumours	NNS	I-NP	I
were	VBD	B-VP	O
only	RB	I-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
low	JJ	B-NP	O
dosage	NN	I-NP	O
females	NNS	I-NP	O
and	CC	O	O
high	JJ	B-NP	O
dosage	NN	I-NP	O
males	NNS	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
paracetamol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
developed	VBD	B-VP	O
hyperplasia	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
epithelium	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
coincident	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
calculi	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
low	JJ	I-NP	O
yield	NN	I-NP	O
of	IN	B-PP	O
tumours	NNS	B-NP	B
at	IN	B-PP	O
various	JJ	B-NP	O
other	JJ	I-NP	O
sites	NNS	I-NP	O
also	RB	B-ADVP	O
arose	VBP	B-VP	O
following	VBG	B-PP	O
paracetamol	NN	B-NP	O
feeding	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
electron	NN	I-NP	O
microscope	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
livers	NNS	I-NP	O
of	IN	B-PP	O
paracetamol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
revealed	VBD	B-VP	O
ultrastructural	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hepatocytes	NNS	I-NP	O
that	WDT	B-NP	O
resemble	VBP	B-VP	O
those	DT	B-NP	O
that	WDT	B-NP	O
result	VBP	B-VP	O
from	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
known	JJ	B-NP	O
hepatocarcinogens	NNS	I-NP	B
.	.	O	O

Rat	NN	B-NP	O
extraocular	JJ	I-NP	O
muscle	NN	I-NP	O
regeneration	NN	I-NP	O
.	.	O	O

Repair	NN	B-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthetic	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
damage	NN	I-NP	O
.	.	O	O

Local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
commonly	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
ophthalmic	JJ	B-NP	O
surgery	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
bupivacaine	NN	I-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
mepivacaine	NN	I-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
lidocaine	NN	I-NP	O
hydrochloride	NN	I-NP	O
plus	CC	O	O
num	CD	B-NP	O
:	SYM	I-NP	O
num	CD	I-NP	O
epinephrine	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
retrobulbar	JJ	I-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
rat	NN	B-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Controls	NNS	B-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
physiological	JJ	B-NP	O
saline	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
anesthetics	NNS	I-NP	O
produced	VBD	B-VP	O
massive	JJ	B-NP	O
degeneration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
extraocular	JJ	I-NP	O
muscles	NNS	I-NP	O
.	.	O	O

Muscle	NN	B-NP	B
degeneration	NN	I-NP	I
is	VBZ	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
regeneration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
damaged	VBN	I-NP	O
muscle	NN	I-NP	O
fibers	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
muscle	NN	B-NP	B
damage	NN	I-NP	I
,	,	O	O
severe	JJ	B-NP	O
damage	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
harderian	JJ	B-NP	O
glands	NNS	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
after	IN	B-SBAR	O
exposure	NN	B-NP	O
to	TO	B-PP	O
mepivacaine	NN	B-NP	O
and	CC	I-NP	O
lidocaine	NN	I-NP	O
plus	CC	I-NP	O
epinephrine	NN	I-NP	O
.	.	O	O

With	IN	B-PP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
hypothesized	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
temporary	JJ	I-NP	O
diplopia	NN	I-NP	B
sometimes	RB	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
after	IN	B-PP	O
ophthalmic	JJ	B-NP	O
surgery	NN	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
anesthetic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
extraocular	JJ	I-NP	O
muscles	NNS	I-NP	O
.	.	O	O

Reversal	NN	B-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
by	IN	B-PP	O
novel	JJ	B-NP	O
aryl	NN	I-NP	O
-	HYPH	B-NP	O
piperazine	NN	I-NP	O
anxiolytic	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
novel	JJ	I-NP	O
anxiolytic	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
buspirone	NN	B-NP	O
,	,	O	O
reverses	VBZ	B-VP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
aryl	NN	B-NP	O
-	HYPH	I-NP	O
piperazine	NN	I-NP	O
analogues	NNS	I-NP	O
of	IN	B-PP	O
buspirone	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxytryptaminergic	JJ	I-NP	O
agonists	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
haloperidol	NN	B-NP	O
induced	JJ	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

Those	DT	B-NP	O
drugs	NNS	I-NP	O
with	IN	B-PP	O
strong	JJ	B-NP	O
affinity	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytryptamine1a	NN	I-NP	O
receptors	NNS	I-NP	O
were	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
catalepsy	NN	B-NP	B
.	.	O	O

Drugs	NNS	B-NP	O
with	IN	B-PP	O
affinity	NN	B-NP	O
for	IN	B-PP	O
other	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
receptors	NNS	I-NP	O
or	CC	O	O
weak	JJ	B-NP	O
affinity	NN	I-NP	O
were	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
postsynaptic	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
receptors	NNS	I-NP	O
neither	CC	O	O
inhibited	VBD	B-VP	O
nor	CC	I-VP	O
potentiated	VBD	I-VP	O
reversal	NN	B-NP	O
of	IN	B-PP	O
catalepsy	NN	B-NP	B
and	CC	O	O
leaves	VBZ	B-VP	O
open	RP	B-PRT	O
the	DT	B-NP	O
question	NN	I-NP	O
as	IN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
site	NN	I-NP	O
or	CC	I-NP	O
mechanism	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

Diazepam	NN	B-NP	O
facilitates	VBZ	B-VP	O
reflex	NN	B-NP	O
bradycardia	NN	I-NP	B
in	IN	B-PP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
on	IN	B-PP	O
cardiovascular	JJ	B-NP	O
function	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
reflex	NN	B-NP	O
bradycardia	NN	I-NP	B
was	VBD	B-VP	O
produced	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
adrenaline	NN	B-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
pretreatment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
diazepam	NN	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
causing	VBG	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
adrenaline	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
enhance	VB	I-VP	O
the	DT	B-NP	O
adrenaline	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
reflex	NN	I-NP	O
bradycardia	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
diazepam	NN	I-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
adrenaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
reflex	NN	I-NP	O
bradycardia	NN	I-NP	B
was	VBD	B-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
pretreatment	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
intravenous	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
picrotoxin	NN	B-NP	O
(	(	O	O
an	DT	B-NP	O
agent	NN	I-NP	O
blocks	VBZ	B-VP	O
chloride	NN	B-NP	O
channels	NNS	I-NP	O
by	IN	B-PP	O
binding	VBG	B-VP	O
to	TO	B-PP	O
sites	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
benzodiazepine	NN	I-NP	O
-	HYPH	B-NP	O
GABA	NN	I-NP	O
-	HYPH	I-NP	O
chloride	NN	I-NP	O
channel	NN	I-NP	O
macromolecular	JJ	I-NP	O
complex	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
diazepam	NN	B-NP	O
acts	VBZ	B-VP	O
through	IN	B-PP	O
the	DT	B-NP	O
benzodiazepine	NN	I-NP	O
-	HYPH	B-NP	O
GABA	NN	I-NP	O
-	HYPH	I-NP	O
chloride	NN	I-NP	O
channel	NN	I-NP	O
macromolecular	JJ	I-NP	O
complex	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
to	TO	B-VP	O
facilitate	VB	I-VP	O
reflex	NN	B-NP	O
bradycardia	NN	I-NP	B
mediated	VBN	B-VP	O
through	IN	B-PP	O
baroreceptor	NN	B-NP	O
reflexes	NNS	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
arterial	JJ	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
carbamazepine	NN	I-NP	O
inhibits	VBZ	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthetic	JJ	I-NP	O
seizures	NNS	I-NP	B
kindled	VBN	B-VP	O
by	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
lidocaine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
(	(	O	O
CBZ	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
on	IN	B-PP	O
local	JJ	B-NP	O
anesthetic	JJ	I-NP	O
-	HYPH	I-NP	O
kindled	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
lethality	NN	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
different	JJ	B-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kindling	NN	I-NP	O
process	NN	I-NP	O
and	CC	B-PP	O
under	IN	B-PP	O
different	JJ	B-NP	O
methods	NNS	I-NP	O
of	IN	B-PP	O
CBZ	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
oral	JJ	I-NP	O
CBZ	NN	I-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
both	CC	O	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
cocaine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
but	CC	O	O
had	VBD	B-VP	O
little	JJ	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
fully	RB	I-NP	O
developed	VBN	I-NP	O
local	JJ	I-NP	O
anesthetic	JJ	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Chronic	JJ	B-NP	O
CBZ	NN	I-NP	O
also	RB	B-ADVP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
-	HYPH	O	O
related	VBN	B-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
injected	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
CBZ	NN	I-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
doses	NNS	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
completed	VBN	B-NP	O
lidocaine	NN	I-NP	O
-	HYPH	B-VP	O
kindled	VBN	I-VP	O
or	CC	O	O
acute	JJ	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Repeated	VBN	B-NP	O
i.p.	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
CBZ	NN	B-NP	O
also	RB	B-ADVP	O
was	VBD	B-VP	O
without	IN	B-PP	O
effect	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
or	CC	I-NP	O
cocaine	NN	I-NP	O
-	HYPH	O	O
kindled	VBN	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
differential	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
CBZ	NN	B-NP	O
depending	VBG	B-VP	O
upon	IN	B-PP	O
stage	NN	B-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
development	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
distinct	JJ	B-NP	O
mechanisms	NNS	I-NP	O
underlie	VBP	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
versus	IN	B-PP	O
maintenance	NN	B-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthetic	NN	I-NP	O
-	HYPH	B-NP	O
kindled	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
repeated	VBN	I-NP	O
,	,	O	O
intermittent	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
CBZ	NN	B-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
different	JJ	B-NP	O
biochemical	JJ	I-NP	O
consequences	NNS	I-NP	O
result	VBP	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
different	JJ	I-NP	O
treatment	NN	I-NP	O
regimens	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
CBZ	NN	I-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
toxic	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
human	JJ	B-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
by	IN	B-PP	O
these	DT	B-NP	O
data	NNS	I-NP	O
,	,	O	O
but	CC	O	O
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
directly	RB	I-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

D	NN	B-NP	O
-	HYPH	I-NP	O
penicillamine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
localized	VBN	B-NP	B
scleroderma	NN	I-NP	I
.	.	O	O

Localized	VBN	B-NP	B
scleroderma	NN	I-NP	I
has	VBZ	B-VP	O
no	DT	B-NP	O
recognized	VBN	I-NP	O
internal	JJ	I-NP	O
organ	NN	I-NP	O
involvement	NN	I-NP	O
but	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
disfiguring	VBG	I-VP	O
and	CC	I-VP	O
disabling	VBG	I-VP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
cutaneous	JJ	I-NP	O
lesions	NNS	I-NP	O
are	VBP	B-VP	O
extensive	JJ	B-NP	O
or	CC	I-NP	O
affect	NN	I-NP	O
children	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
accepted	VBN	I-NP	O
or	CC	I-NP	O
proven	VBN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
localized	VBN	B-NP	B
scleroderma	NN	I-NP	I
.	.	O	O

Case	NN	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
,	,	I-NP	O
extensive	JJ	I-NP	O
localized	JJ	I-NP	B
scleroderma	NN	I-NP	I
who	WP	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	I-NP	O
penicillamine	NN	I-NP	O
are	VBP	B-VP	O
summarized	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
article	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
judged	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
favorable	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
course	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Improvement	NN	B-NP	O
began	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
and	CC	O	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
active	JJ	B-NP	O
cutaneous	JJ	I-NP	O
lesions	NNS	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
skin	NN	B-NP	O
softening	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
more	JJR	I-NP	O
normal	JJ	I-NP	O
growth	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
affected	VBN	I-NP	O
limb	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
.	.	O	O

Joint	NN	B-NP	O
stiffness	NN	I-NP	O
and	CC	I-NP	O
contractures	NNS	I-NP	B
also	RB	B-ADVP	O
improved	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
favorable	JJ	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
as	RB	B-ADJP	O
low	JJ	I-ADJP	O
as	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
given	VBN	B-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

D	NN	B-NP	O
-	HYPH	I-NP	O
Penicillamine	NN	I-NP	O
caused	VBD	B-VP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
and	CC	O	O
milder	JJR	B-NP	O
reversible	JJ	I-NP	O
proteinuria	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
other	JJ	I-NP	O
patients	NNS	I-NP	O
;	:	O	O
none	NN	B-NP	O
developed	VBD	B-VP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
localized	VBN	B-NP	B
scleroderma	NN	I-NP	I
.	.	O	O

Preservation	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
during	IN	B-PP	O
hypotension	NN	B-NP	B
induced	VBN	B-VP	O
with	IN	B-PP	O
fenoldopam	NN	B-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
could	MD	B-VP	O
induce	VB	I-VP	O
hypotension	NN	B-NP	B
with	IN	B-PP	O
different	JJ	B-NP	O
pharmacological	JJ	I-NP	O
actions	NNS	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
advantageous	JJ	B-ADJP	O
because	IN	B-SBAR	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
unique	JJ	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
drug	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
minimized	VBN	I-VP	O
by	IN	B-PP	O
selecting	VBG	B-VP	O
appropriate	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Specific	JJ	B-NP	O
dopamine	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
DA1	NN	B-NP	O
)	)	O	O
and	CC	O	O
dopamine	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
DA2	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
agonists	NNS	I-NP	O
are	VBP	B-VP	O
now	RB	B-ADVP	O
under	IN	B-PP	O
clinical	JJ	B-NP	O
investigation	NN	I-NP	O
.	.	O	O

Fenoldopam	NN	B-NP	O
mesylate	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
DA1	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
that	WDT	B-NP	O
lowers	VBZ	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
by	IN	B-PP	O
vasodilatation	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
fenoldopam	NN	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
induce	VB	I-VP	O
hypotension	NN	B-NP	B
and	CC	O	O
preserve	VB	B-VP	O
blood	NN	B-NP	O
flow	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
.	.	O	O

Systemic	JJ	B-NP	O
aortic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
continuously	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
carotid	JJ	I-NP	O
arterial	JJ	I-NP	O
catheter	NN	I-NP	O
and	CC	O	O
an	DT	B-NP	O
electromagnetic	JJ	I-NP	O
flow	NN	I-NP	O
probe	NN	I-NP	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
and	CC	I-NP	O
renal	JJ	I-NP	O
vascular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
fenoldopam	NN	B-NP	O
and	CC	I-NP	O
sodium	NN	I-NP	O
nitroprusside	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
under	IN	B-PP	O
halothane	NN	B-NP	O
general	JJ	I-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

Mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
with	IN	B-PP	O
infusion	NN	B-NP	O
of	IN	B-PP	O
fenoldopam	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
with	IN	B-PP	O
infusion	NN	B-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
(	(	O	O
NS	NN	B-NP	O
)	)	O	O
.	.	O	O

Renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
(	(	O	O
RBF	NN	B-NP	O
)	)	O	O
increased	VBD	B-VP	O
during	IN	B-PP	O
fenoldopam	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
during	IN	B-PP	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
arteriolar	JJ	I-NP	O
and	CC	I-NP	O
venous	JJ	I-NP	O
vasodilator	NN	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
produce	VB	I-VP	O
redistribution	NN	B-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
flow	NN	I-NP	O
away	RB	B-ADVP	O
from	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
during	IN	B-PP	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Fenoldopam	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
dopamine	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
DA1	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
agonist	NN	I-NP	O
that	WDT	B-NP	O
causes	VBZ	B-VP	O
vasodilatation	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
and	CC	O	O
other	JJ	B-NP	O
organs	NNS	I-NP	O
with	IN	B-PP	O
DA1	NN	B-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
preserves	VBZ	B-VP	O
blood	NN	B-NP	O
flow	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
during	IN	B-PP	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Antiarrhythmic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
optical	JJ	B-NP	O
isomers	NNS	I-NP	O
of	IN	B-PP	O
cibenzoline	NN	B-NP	O
on	IN	B-PP	O
canine	JJ	B-NP	O
ventricular	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O

Antiarrhythmic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
cibenzoline	NN	I-NP	O
and	CC	O	O
-	HYPH	B-NP	O
cibenzoline	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
using	VBG	B-VP	O
num	CD	B-NP	O
canine	JJ	I-NP	O
ventricular	JJ	I-NP	B
arrhythmia	NN	I-NP	I
models	NNS	I-NP	O
.	.	O	O

Digitalis	NNP	B-NP	O
arrhythmia	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
suppressed	VBN	I-VP	O
by	IN	B-PP	O
Na	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
intermittent	JJ	B-NP	O
intravenous	JJ	I-NP	O
(	(	O	O
i.v.	JJ	B-ADJP	O
)	)	O	O
injection	NN	B-NP	O
of	IN	B-PP	O
ouabain	NN	B-NP	O
in	IN	B-PP	O
pentobarbital	NN	B-NP	O
-	HYPH	B-NP	O
anesthetized	VBN	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

Adrenaline	NN	B-NP	B
arrhythmia	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
suppressed	VBN	I-VP	O
by	IN	B-PP	O
Ca	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
adrenaline	NN	B-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
halothane	NN	B-NP	O
-	HYPH	B-NP	O
anesthetized	VBN	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
i.v.	JJ	I-NP	O
-	HYPH	I-NP	O
cibenzoline	NN	I-NP	O
suppressed	VBD	B-VP	O
digitalis	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
adrenaline	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
arrhythmias	NNS	I-NP	B
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
minimum	JJ	I-NP	O
effective	JJ	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
cibenzoline	NN	I-NP	O
for	IN	B-PP	O
digitalis	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	O	O
adrenaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
arrhythmias	NNS	I-NP	B
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
lower	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
i.v.	NN	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
cibenzoline	NN	I-NP	O
suppressed	VBD	B-VP	O
the	DT	B-NP	O
digitalis	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
arrhythmia	NN	I-NP	B
,	,	O	O
whereas	IN	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
i.v.	NN	I-NP	O
was	VBD	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
suppress	VB	I-VP	O
adrenaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
arrhythmias	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
minimum	JJ	I-NP	O
effective	JJ	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
cibenzoline	NN	I-NP	O
for	IN	B-PP	O
digitalis	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
adrenaline	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
arrhythmia	NN	I-NP	B
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
stronger	JJR	I-NP	O
antiarrhythmic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
cibenzoline	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
-	HYPH	B-NP	O
isomer	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
an	DT	B-NP	O
effect	NN	I-NP	O
nearly	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
stronger	JJR	I-NP	O
in	IN	B-PP	O
suppressing	VBG	B-VP	O
Na	NN	B-NP	O
channels	NNS	I-NP	O
,	,	O	O
but	CC	O	O
effects	NNS	B-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
on	IN	B-PP	O
Ca	NN	B-NP	O
channels	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
almost	RB	B-ADJP	O
equipotent	JJ	I-ADJP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
Hibiscus	NNP	B-NP	O
rosa	NNP	I-NP	O
sinensis	NN	I-NP	O
on	IN	B-PP	O
reserpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurobehavioral	JJ	I-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
methanolic	JJ	B-NP	O
extract	NN	I-NP	O
of	IN	B-PP	O
Hibiscus	NNP	B-NP	O
rosa	NN	I-NP	O
sinensis	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
on	IN	B-PP	O
reserpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
orofacial	JJ	I-NP	O
dyskinesia	NN	I-NP	B
and	CC	O	O
neurochemical	JJ	B-NP	O
alterations	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intraperitoneal	JJ	B-NP	O
reserpine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
every	DT	B-NP	O
other	JJ	I-NP	O
day	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
vacuous	JJ	I-NP	O
chewing	NN	I-NP	O
movements	NNS	I-NP	O
and	CC	O	O
tongue	NN	B-NP	O
protrusions	NNS	I-NP	O
were	VBD	B-VP	O
counted	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

Reserpine	NN	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
significantly	RB	B-ADVP	O
developed	VBD	B-VP	O
vacuous	JJ	B-NP	O
chewing	NN	I-NP	O
movements	NNS	I-NP	O
and	CC	O	O
tongue	NN	B-NP	O
protrusions	NNS	I-NP	O
however	RB	B-ADVP	O
,	,	O	O
coadministration	NN	B-NP	O
of	IN	B-PP	O
Hibiscus	NNP	B-NP	O
rosa	NNP	I-NP	O
sinensis	NN	I-NP	O
roots	NNS	I-NP	O
extract	NN	I-NP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Biochemical	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
reserpine	NN	I-NP	O
treatment	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
superoxide	NN	B-NP	O
dismutase	NN	I-NP	O
(	(	O	O
SOD	NN	B-NP	O
)	)	O	O
,	,	O	O
catalase	NN	B-NP	O
(	(	O	O
CAT	NN	B-NP	O
)	)	O	O
and	CC	O	O
glutathione	NN	B-NP	O
reductase	NN	I-NP	O
(	(	O	O
GSH	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
index	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
process	NN	I-NP	O
.	.	O	O

Coadministration	NN	B-NP	O
of	IN	B-PP	O
extract	NN	B-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
lipid	NN	I-NP	O
peroxidation	NN	I-NP	O
and	CC	O	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
SOD	NN	I-NP	O
,	,	O	O
CAT	NN	B-NP	O
and	CC	I-NP	O
GSH	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
Hibiscus	NNP	B-NP	O
rosa	NNP	I-NP	O
sinensis	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
against	IN	B-PP	O
reserpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
orofacial	JJ	I-NP	O
dyskinesia	NN	I-NP	B
and	CC	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
aqueous	JJ	B-NP	O
and	CC	I-NP	O
gellan	JJ	I-NP	O
ophthalmic	JJ	I-NP	O
timolol	NN	I-NP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
glaucoma	NN	B-NP	B
.	.	O	O

Topical	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocker	NN	I-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
routine	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
glaucoma	NN	B-NP	B
.	.	O	O

Therapy	NN	B-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
systemic	JJ	B-NP	O
absorption	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
resting	VBG	B-NP	O
and	CC	I-NP	O
peak	JJ	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
quantified	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
trial	NN	I-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
aqueous	JJ	I-NP	O
timolol	NN	I-NP	O
(	(	O	O
timolol	NN	B-NP	O
solution	NN	I-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
timolol	NN	I-NP	O
suspension	NN	I-NP	O
that	WDT	B-NP	O
forms	VBZ	B-VP	O
a	DT	B-NP	O
gel	NN	I-NP	O
on	IN	B-PP	O
application	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
conjunctiva	NN	I-NP	O
(	(	O	O
timolol	NN	B-NP	O
gellan	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
currently	RB	B-VP	O
being	VBG	I-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
glaucoma	NN	B-NP	B
to	TO	B-VP	O
quantify	VB	I-VP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
Caucasian	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	O
open	JJ	I-NP	B
-	HYPH	I-NP	I
angle	NN	I-NP	I
glaucoma	NN	I-NP	I
or	CC	O	O
ocular	JJ	B-NP	B
hypertension	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
(	(	O	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
)	)	O	O
age	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
and	CC	O	O
crossed	VBN	B-VP	O
over	RP	B-PRT	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
masked	VBN	I-NP	O
manner	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
(	(	O	O
morning	NN	B-NP	O
and	CC	O	O
evening	NN	B-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
)	)	O	O
,	,	O	O
timolol	NN	B-NP	O
solution	NN	I-NP	O
(	(	O	O
morning	NN	B-NP	O
and	CC	O	O
evening	NN	B-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
timolol	NN	B-NP	O
gellan	NN	I-NP	O
(	(	O	O
morning	NN	B-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
evening	NN	I-NP	O
)	)	O	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
13th	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
period	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
recorded	VBN	I-VP	O
continuously	RB	B-ADVP	O
during	IN	B-PP	O
a	DT	B-NP	O
typical	JJ	I-NP	O
,	,	I-NP	O
ambulant	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Both	CC	O	O
timolol	NN	B-NP	O
solution	NN	I-NP	O
and	CC	O	O
timolol	NN	B-NP	O
gellan	NN	I-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
and	CC	O	O
this	DT	B-NP	O
reduction	NN	I-NP	O
was	VBD	B-VP	O
most	RBS	B-ADJP	O
pronounced	JJ	I-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
daytime	NN	I-NP	O
(	(	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
)	)	O	O
.	.	O	O

Timolol	NN	B-NP	O
gellan	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
numerically	RB	I-NP	O
but	CC	B-PP	O
not	RB	B-NP	O
significantly	RB	I-NP	O
smaller	JJR	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
timolol	NN	B-NP	O
solution	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
night	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
on	IN	B-PP	O
placebo	NN	B-NP	O
and	CC	I-NP	O
timolol	NN	I-NP	O
gellan	NN	I-NP	O
were	VBD	B-VP	O
both	DT	O	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
than	IN	B-PP	O
on	IN	B-PP	O
timolol	NN	B-NP	O
solution	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
solution	NN	B-NP	O
and	CC	I-NP	O
gellan	NN	I-NP	O
treatments	NNS	I-NP	O
was	VBD	B-VP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

Both	CC	O	O
timolol	NN	B-NP	O
solution	NN	I-NP	O
and	CC	O	O
timolol	NN	B-NP	O
gellan	NN	I-NP	O
decrease	VBP	B-VP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
most	RBS	B-ADJP	O
pronounced	JJ	I-ADJP	O
during	IN	B-PP	O
the	DT	B-NP	O
active	JJ	I-NP	O
daytime	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
quantify	VBP	B-VP	O
the	DT	B-NP	O
modest	JJ	I-NP	O
bradycardia	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
ophthalmic	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocker	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
typical	JJ	I-NP	O
patient	NN	I-NP	O
population	NN	I-NP	O
on	IN	B-PP	O
therapy	NN	B-NP	O
for	IN	B-PP	O
glaucoma	NN	B-NP	B
.	.	O	O

Although	IN	B-SBAR	O
exercise	NN	B-NP	O
performance	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
trial	NN	I-NP	O
,	,	O	O
reductions	NNS	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
magnitude	NN	I-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
substantial	JJ	B-NP	O
clinical	JJ	I-NP	O
consequences	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
flourouracil	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
apical	JJ	I-NP	B
ballooning	NN	I-NP	I
syndrome	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
apical	JJ	I-NP	B
ballooning	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
ABS	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
recently	RB	I-NP	O
described	VBN	I-NP	O
stress	NN	I-NP	O
-	HYPH	O	O
mediated	VBN	B-VP	O
acute	JJ	B-NP	B
cardiac	JJ	I-NP	I
syndrome	NN	I-NP	I
characterized	VBN	B-VP	O
by	IN	B-PP	O
transient	JJ	B-NP	O
wall	NN	I-NP	O
-	HYPH	B-NP	O
motion	NN	I-NP	O
abnormalities	NNS	I-NP	O
involving	VBG	B-VP	O
the	DT	B-NP	O
apex	NN	I-NP	O
and	CC	I-NP	O
midventricle	NN	I-NP	O
with	IN	B-PP	O
hyperkinesis	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
(	(	O	O
LV	NN	B-NP	O
)	)	O	O
segments	NNS	B-NP	O
without	IN	B-PP	O
obstructive	JJ	B-NP	O
epicardial	JJ	I-NP	B
coronary	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Cardiotoxicity	NN	B-NP	B
is	VBZ	B-VP	O
not	RB	O	O
an	DT	B-NP	O
uncommon	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
chemotherapeutic	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
are	VBP	B-VP	O
no	DT	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
ABS	NNP	B-NP	B
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
chemotherapeutic	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
the	DT	B-NP	O
syndrome	NN	I-NP	O
after	IN	B-PP	O
chemotherapy	NN	B-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
cancer	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
typical	JJ	B-NP	O
ischemic	JJ	I-NP	B
chest	NN	I-NP	B
pain	NN	I-NP	I
,	,	O	O
elevated	VBD	B-VP	O
cardiac	JJ	B-NP	O
enzymes	NNS	I-NP	O
with	IN	B-PP	O
significant	JJ	B-NP	O
ST	NN	I-NP	O
-	HYPH	I-NP	O
segment	NN	I-NP	O
abnormalities	NNS	I-NP	O
on	IN	B-PP	O
her	PRP$	B-NP	O
electrocardiogram	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
underwent	VBD	B-VP	O
recent	JJ	B-NP	O
chemotherapy	NN	I-NP	O
with	IN	B-PP	O
fluorouracil	NN	B-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
colorectal	JJ	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Echocardiography	NN	B-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
wall	NN	I-NP	O
-	HYPH	B-NP	O
motion	NN	I-NP	O
abnormality	NN	I-NP	O
involving	VBG	B-VP	O
the	DT	B-NP	O
apical	JJ	I-NP	O
and	CC	I-NP	O
periapical	JJ	I-NP	O
segments	NNS	I-NP	O
which	WDT	B-NP	O
appeared	VBD	B-VP	O
akinetic	JJ	B-ADJP	B
.	.	O	O

Coronary	JJ	B-NP	O
angiography	NN	I-NP	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
obstructive	JJ	I-NP	O
coronary	JJ	I-NP	O
lesions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
stabilized	VBN	I-VP	O
with	IN	B-PP	O
medical	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
later	RB	B-ADVP	O
she	PRP	B-NP	O
remained	VBD	B-VP	O
completely	RB	B-ADJP	O
asymptomatic	JJ	I-ADJP	O
.	.	O	O

Echocardiogram	NN	B-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
apical	JJ	I-NP	O
akinesis	NN	I-NP	B
.	.	O	O

Pathogenetic	JJ	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
complications	NNS	I-NP	I
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
chemotherapy	NN	B-NP	O
include	VBP	B-VP	O
coronary	JJ	B-NP	B
vasospasm	NN	I-NP	I
,	,	O	O
endothelial	JJ	B-NP	O
damage	NN	I-NP	O
and	CC	O	O
consequent	JJ	B-NP	O
thrombus	NN	I-NP	B
formation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
,	,	O	O
both	DT	B-NP	O
supraphysiologic	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
catecholamines	NNS	I-NP	O
and	CC	O	O
stress	NN	B-NP	O
related	VBN	I-NP	O
neuropeptides	NNS	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
cancer	NN	B-NP	B
diagnosis	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
chemotherapy	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
contributed	VBN	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
ABS	NNP	B-NP	B
.	.	O	O

Reduction	NN	B-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
during	IN	B-PP	O
induction	NN	B-NP	O
with	IN	B-PP	O
target	NN	B-NP	O
-	HYPH	B-NP	O
controlled	VBN	I-NP	O
propofol	NN	I-NP	O
and	CC	I-NP	O
remifentanil	NN	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
on	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
is	VBZ	B-VP	O
unpleasant	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
propofol	NN	B-NP	O
infusion	NN	I-NP	O
pain	NN	I-NP	B
might	MD	B-VP	O
be	VB	I-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
infusing	VBG	B-VP	O
remifentanil	NN	B-NP	O
before	IN	B-PP	O
starting	VBG	B-VP	O
the	DT	B-NP	O
propofol	NN	I-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
setting	NN	I-NP	O
where	WRB	B-ADVP	O
target	NN	B-NP	O
-	HYPH	B-NP	O
controlled	VBN	I-NP	O
infusions	NNS	I-NP	O
(	(	O	O
TCI	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
-	HYPH	O	O
site	NN	B-NP	O
concentration	NN	I-NP	O
(	(	O	O
Ce	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
remifentanil	NN	B-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
pain	NN	I-NP	B
without	IN	B-PP	O
producing	VBG	B-VP	O
complications	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
general	JJ	B-NP	O
surgery	NN	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
(	(	O	O
control	NN	B-NP	O
)	)	O	O
or	CC	O	O
remifentanil	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
target	NN	I-NP	O
Ce	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
ml	NN	I-NP	O
(	(	O	O
R2	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
ng	NN	I-NP	O
ml	NN	I-NP	O
(	(	O	O
R4	NN	B-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
ng	NN	I-NP	O
ml	NN	I-NP	O
(	(	O	O
R6	NN	B-NP	O
)	)	O	O
administered	VBN	B-VP	O
via	IN	B-PP	O
TCI	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
target	NN	I-NP	O
Ce	NN	I-NP	O
was	VBD	B-VP	O
achieved	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
.	.	O	O

Remifentanil	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
complications	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
remifentanil	NN	I-NP	O
infusion	NN	I-NP	O
,	,	O	O
and	CC	O	O
pain	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
propofol	NN	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
using	VBG	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
point	NN	I-NP	O
scale	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
propofol	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
Groups	NNS	B-NP	O
R4	NN	I-NP	O
and	CC	I-NP	O
R6	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
and	CC	I-NP	O
R2	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
was	VBD	B-VP	O
less	RBR	B-ADJP	O
severe	JJ	I-ADJP	O
in	IN	B-PP	O
Groups	NNS	B-NP	O
R4	NN	I-NP	O
and	CC	I-NP	O
R6	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
and	CC	I-NP	O
R2	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
both	CC	O	O
incidence	NN	B-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
were	VBD	B-VP	O
not	RB	B-ADJP	O
different	JJ	I-ADJP	O
between	IN	B-PP	O
Groups	NNS	B-NP	O
R4	NN	I-NP	O
and	CC	I-NP	O
R6	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
complications	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anaesthesia	NN	B-NP	O
with	IN	B-PP	O
TCI	NN	B-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
and	CC	I-NP	O
remifentanil	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
propofol	NN	B-NP	O
infusion	NN	I-NP	O
pain	NN	I-NP	B
was	VBD	B-VP	O
achieved	VBN	I-VP	O
without	IN	B-PP	O
significant	JJ	B-NP	O
complications	NNS	I-NP	O
by	IN	B-PP	O
prior	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
remifentanil	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
target	NN	I-NP	O
Ce	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
ml	NN	I-NP	O
.	.	O	O

Prenatal	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
fluoxetine	NN	B-NP	O
induces	VBZ	B-VP	O
fetal	JJ	B-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Fluoxetine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
antidepressant	NN	I-NP	O
widely	RB	B-VP	O
used	VBN	I-VP	O
by	IN	B-PP	O
pregnant	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Epidemiological	JJ	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
fluoxetine	NN	B-NP	O
exposure	NN	I-NP	O
prenatally	RB	B-ADVP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
pulmonary	JJ	I-NP	B
hypertension	NN	I-NP	I
syndrome	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
newborn	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
this	DT	B-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
and	CC	I-ADJP	O
paradoxical	JJ	I-ADJP	O
,	,	O	O
considering	VBG	B-VP	O
the	DT	B-NP	O
current	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
pulmonary	JJ	I-NP	B
hypertension	NN	I-NP	I
protective	JJ	I-NP	O
fluoxetine	NN	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
rodents	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
fluoxetine	NN	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
fetal	JJ	B-NP	O
rat	NN	I-NP	O
pulmonary	JJ	I-NP	O
vascular	JJ	I-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
mechanical	JJ	I-NP	O
properties	NNS	I-NP	O
and	CC	O	O
cell	NN	B-NP	O
proliferation	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
fluoxetine	NN	B-NP	O
from	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
through	IN	B-PP	O
Day	NNP	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
.	.	O	O

Fetuses	NNS	B-NP	O
were	VBD	B-VP	O
delivered	VBN	I-VP	O
by	IN	B-PP	O
cesarean	JJ	B-NP	O
section	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
fluoxetine	NN	B-NP	O
exposure	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
fetal	JJ	B-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
as	IN	B-SBAR	O
evidenced	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
weight	NN	I-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
ventricle	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
ventricle	NN	I-NP	O
plus	CC	I-NP	O
septum	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
pulmonary	JJ	B-NP	O
arterial	JJ	I-NP	O
medial	JJ	I-NP	O
thickness	NN	I-NP	O
.	.	O	O

Postnatal	JJ	B-NP	O
mortality	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
among	IN	B-PP	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
and	CC	O	O
arterial	JJ	B-NP	O
oxygen	NN	I-NP	O
saturation	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
and	CC	O	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
fluoxetine	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
pups	NNS	I-NP	O
.	.	O	O

In	FW	B-ADVP	O
vitro	FW	I-ADVP	O
,	,	O	O
fluoxetine	NN	B-NP	O
induced	VBD	B-VP	O
pulmonary	JJ	B-NP	O
arterial	JJ	I-NP	O
muscle	NN	I-NP	O
contraction	NN	I-NP	O
in	IN	B-PP	O
fetal	JJ	B-NP	O
,	,	I-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
adult	JJ	I-NP	O
,	,	O	O
animals	NNS	B-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
serotonin	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
contraction	NN	I-NP	O
at	IN	B-PP	O
both	DT	B-NP	O
ages	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
in	IN	B-PP	O
utero	NN	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
fluoxetine	NN	I-NP	O
concentration	NN	I-NP	O
the	DT	B-NP	O
pulmonary	JJ	I-NP	O
arterial	JJ	I-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
fetal	JJ	B-NP	O
,	,	I-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
adult	JJ	I-NP	O
,	,	O	O
cells	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
adult	NN	I-NP	O
,	,	O	O
fluoxetine	NN	B-NP	O
exposure	NN	I-NP	O
in	IN	B-PP	O
utero	NN	B-NP	O
induces	VBZ	B-VP	O
pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
fetal	JJ	I-NP	O
rat	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
developmentally	RB	I-NP	O
regulated	VBN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
pulmonary	JJ	B-NP	O
vascular	JJ	I-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
proliferation	NN	I-NP	O
.	.	O	O

Syncope	NN	B-NP	B
and	CC	I-NP	O
QT	NN	I-NP	B
prolongation	NN	I-NP	I
among	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
methadone	NN	B-NP	O
for	IN	B-PP	O
heroin	NN	B-NP	O
dependence	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
city	NN	I-NP	O
of	IN	B-PP	O
Copenhagen	NN	B-NP	O
.	.	O	O

Methadone	NN	B-NP	O
is	VBZ	B-VP	O
prescribed	VBN	I-VP	O
to	TO	I-VP	O
heroin	VB	I-VP	O
addicts	NNS	B-NP	O
to	TO	B-VP	O
decrease	VB	I-VP	O
illicit	JJ	B-NP	O
opioid	JJ	I-NP	O
use	NN	I-NP	O
.	.	O	O

Prolongation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
QT	NN	I-NP	O
interval	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ECG	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
(	(	O	O
TdP	NN	B-NP	B
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
methadone	NN	B-NP	O
users	NNS	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
heroin	NN	B-NP	O
addicts	NNS	I-NP	O
sometimes	RB	B-ADVP	O
faint	VBP	B-VP	O
while	IN	B-SBAR	O
using	VBG	B-VP	O
illicit	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
doctors	NNS	B-NP	O
might	MD	B-VP	O
attribute	VB	I-VP	O
too	RB	B-NP	O
many	JJ	I-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
syncope	NN	B-NP	B
to	TO	B-VP	O
illicit	VB	I-VP	O
drug	NN	B-NP	O
use	NN	I-NP	O
and	CC	O	O
thereby	RB	B-VP	O
underestimate	VBP	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
TdP	NN	B-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
special	JJ	I-NP	O
population	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
high	JJ	I-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
population	NN	I-NP	O
may	MD	B-VP	O
,	,	O	O
in	IN	B-PP	O
part	NN	B-NP	O
,	,	O	O
be	VB	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
proarrhythmic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
methadone	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
cross	AFX	O	O
-	HYPH	B-NP	O
sectional	JJ	I-NP	O
study	NN	I-NP	O
interview	NN	I-NP	O
,	,	O	O
ECGs	NNS	B-NP	O
and	CC	O	O
blood	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
of	IN	B-PP	O
adult	JJ	B-NP	O
heroin	NN	I-NP	O
addicts	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
methadone	NN	B-NP	O
or	CC	I-NP	O
buprenorphine	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
daily	JJ	I-NP	O
basis	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
Drug	NNP	I-NP	O
Addiction	NNP	I-NP	O
Service	NNP	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
municipal	NN	I-NP	O
of	IN	B-PP	O
Copenhagen	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
(	(	O	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
QT	NN	I-NP	O
interval	NN	I-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
lead	JJ	I-NP	O
ECGs	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
participants	NNS	I-NP	O
were	VBD	B-VP	O
interviewed	VBN	I-VP	O
about	IN	B-PP	O
any	DT	B-NP	O
experience	NN	I-NP	O
of	IN	B-PP	O
syncope	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
opioid	JJ	B-NP	O
dose	NN	I-NP	O
and	CC	I-NP	O
QT	NN	I-NP	O
,	,	O	O
and	CC	O	O
methadone	NN	B-NP	O
dose	NN	I-NP	O
and	CC	O	O
reporting	NN	B-NP	O
of	IN	B-PP	O
syncope	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
multivariate	JJ	B-NP	O
linear	JJ	I-NP	O
regression	NN	I-NP	O
and	CC	O	O
logistic	JJ	B-NP	O
regression	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Methadone	NN	B-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
longer	JJR	B-NP	O
QT	NN	I-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ms	NN	I-NP	O
/	SYM	B-NP	O
mg	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
buprenorphine	NN	B-NP	O
and	CC	I-NP	O
QTc	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
methadone	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
women	NNS	I-NP	O
had	VBD	B-VP	O
prolonged	VBN	I-VP	B
QTc	NN	B-NP	I
interval	NN	I-NP	I
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
buprenorphine	NN	B-NP	O
had	VBD	B-VP	O
QTc	NN	B-NP	O
interval	NN	I-NP	O
>	SYM	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
higher	JJR	I-NP	O
methadone	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
)	)	O	O
times	NNS	B-NP	O
higher	JJR	B-NP	O
odds	NNS	I-NP	O
for	IN	B-PP	O
syncope	NN	B-NP	B
.	.	O	O

Methadone	NN	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
and	CC	O	O
higher	JJR	B-NP	O
reporting	NN	I-NP	O
of	IN	B-PP	O
syncope	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
of	IN	B-PP	O
heroin	NN	B-NP	O
addicts	NNS	I-NP	O
.	.	O	O

Peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cytosine	NN	I-NP	O
arabinoside	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
myeloid	JJ	I-NP	I
leukemia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cytosine	NN	I-NP	O
arabinoside	NN	I-NP	O
is	VBZ	B-VP	O
well	RB	I-VP	O
recognized	VBN	I-VP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
cytosine	NN	B-NP	O
arabinoside	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
infrequently	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Japanese	JJ	I-NP	O
man	NN	I-NP	O
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
myeloid	JJ	I-NP	I
leukemia	NN	I-NP	I
.	.	O	O

After	IN	B-SBAR	O
he	PRP	B-NP	O
achieved	VBD	B-VP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
,	,	O	O
he	PRP	B-NP	O
received	VBD	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cytosine	NN	I-NP	O
arabinoside	NN	I-NP	O
treatment	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
twice	RB	B-NP	O
a	DT	I-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
;	:	O	O
total	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
)	)	O	O
as	IN	B-PP	O
consolidation	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cytosine	NN	I-NP	O
arabinoside	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
no	DT	B-NP	O
unusual	JJ	I-NP	O
symptoms	NNS	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
numbness	NN	B-NP	B
in	IN	B-PP	O
his	PRP$	B-NP	O
right	JJ	I-NP	O
foot	NN	I-NP	O
.	.	O	O

Electromyogram	NN	B-NP	O
and	CC	I-NP	O
nerve	NN	I-NP	O
-	HYPH	B-NP	O
conduction	NN	I-NP	O
studies	NNS	I-NP	O
showed	VBD	B-VP	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
in	IN	B-PP	O
both	CC	B-NP	O
peroneal	JJ	I-NP	O
nerves	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
neuropathy	NN	I-NP	B
was	VBD	B-VP	O
gradually	RB	I-VP	O
resolving	VBG	I-VP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
after	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
received	VBD	B-VP	O
allogeneic	JJ	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
worsened	VBD	B-VP	O
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
graft	NN	B-NP	B
-	HYPH	B-ADVP	I
versus	IN	B-PP	I
-	HYPH	B-NP	I
host	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
subsequently	RB	B-ADVP	O
responded	VBD	B-VP	O
to	TO	B-PP	O
methylprednisolone	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
are	VBP	B-VP	O
still	RB	B-ADVP	O
unclear	JJ	B-NP	O
,	,	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cytosine	NN	I-NP	O
arabinoside	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
therapy	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
potentially	RB	B-ADJP	O
toxic	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
,	,	O	O
and	CC	O	O
auto	NN	B-NP	O
/	SYM	B-NP	O
alloimmunity	NN	I-NP	O
may	MD	B-VP	O
play	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

Atorvastatin	NN	B-NP	O
prevented	VBD	B-VP	O
and	CC	O	O
reversed	VBD	B-VP	O
dexamethasone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
antioxidant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
atorvastatin	NN	B-NP	O
(	(	O	O
atorva	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
dexamethasone	NN	B-NP	O
(	(	O	O
dex	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
male	JJ	I-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
atorva	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
or	CC	O	O
tap	NN	B-NP	O
water	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Dex	NN	B-NP	O
increased	VBD	B-VP	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADVP	O
/	SYM	B-NP	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
and	CC	O	O
plasma	NN	B-NP	O
superoxide	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
prevention	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
SBP	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
atorva	NN	I-NP	O
+	SYM	B-NP	O
dex	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADVP	O
/	SYM	B-NP	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
,	,	O	O
but	CC	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
dex	NN	I-NP	O
-	HYPH	B-VP	O
only	RB	B-NP	O
group	NN	I-NP	O
.	.	O	O

Atorva	NNP	B-NP	O
reversed	VBD	B-VP	O
dex	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
and	CC	O	O
decreased	VBN	B-NP	O
plasma	NN	I-NP	O
superoxide	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
nitrate	NN	I-NP	O
/	SYM	O	O
nitrite	NN	B-NP	O
(	(	O	O
NOx	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
dex	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
saline	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Atorva	NNP	B-NP	O
affected	VBD	B-VP	O
neither	CC	O	O
plasma	NN	B-NP	O
NOx	NN	I-NP	O
nor	CC	O	O
thymus	NN	B-NP	O
weight	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
atorvastatin	NN	B-NP	O
prevented	VBD	B-VP	O
and	CC	O	O
reversed	VBD	B-VP	O
dexamethasone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
prodrugs	NNS	I-NP	O
of	IN	B-PP	O
potent	JJ	B-NP	O
and	CC	I-NP	O
selective	JJ	I-NP	O
GluR5	NN	I-NP	O
kainate	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
actives	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
animal	NN	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
.	.	O	O

Amino	NN	B-NP	O
acids	NNS	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
potent	JJ	I-NP	O
and	CC	I-NP	O
selective	JJ	I-NP	O
competitive	JJ	I-NP	O
GluR5	NN	I-NP	O
KA	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
,	,	O	O
exhibited	VBD	B-VP	O
high	JJ	B-NP	O
GluR5	NN	I-NP	O
receptor	NN	I-NP	O
affinity	NN	I-NP	O
over	IN	B-PP	O
other	JJ	B-NP	O
glutamate	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Their	PRP$	B-NP	O
ester	NN	I-NP	O
prodrugs	NNS	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
orally	RB	B-ADJP	O
active	JJ	I-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
:	:	O	O
reversal	NN	B-NP	O
of	IN	B-PP	O
formalin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
paw	NN	I-NP	O
licking	NN	I-NP	O
,	,	O	O
carrageenan	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
thermal	JJ	I-NP	B
hyperalgesia	NN	I-NP	I
,	,	O	O
and	CC	O	O
capsaicin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
mechanical	JJ	I-NP	B
hyperalgesia	NN	I-NP	I
.	.	O	O

Sirolimus	NN	B-NP	O
and	CC	I-NP	O
mycophenolate	NN	I-NP	O
mofetil	NN	I-NP	O
for	IN	B-PP	O
calcineurin	NN	B-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
immunosuppression	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
.	.	O	O

Calcineurin	NN	B-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
cyclosporine	NN	B-NP	O
and	CC	I-NP	O
tacrolimus	NN	I-NP	O
,	,	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
almost	RB	B-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
are	VBP	B-VP	O
highly	RB	B-ADJP	O
effective	JJ	I-ADJP	O
and	CC	O	O
represent	VBP	B-VP	O
the	DT	B-NP	O
mainstay	NN	I-NP	O
of	IN	B-PP	O
transplant	NN	B-NP	O
immunosuppression	NN	I-NP	O
,	,	O	O
they	PRP	B-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

Acute	JJ	B-NP	O
nephrotoxicity	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
occurs	VBZ	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
period	NN	I-NP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
,	,	O	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
dialysis	NN	B-NP	O
,	,	O	O
and	CC	O	O
chronic	JJ	B-NP	O
nephrotoxicity	NN	I-NP	B
may	MD	B-VP	O
eventually	RB	I-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
graft	NN	B-NP	O
loss	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
nephrotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
becoming	VBG	I-VP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
as	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
marginal	JJ	B-NP	O
kidneys	NNS	I-NP	O
for	IN	B-PP	O
transplantation	NN	B-NP	O
increases	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
recently	RB	I-NP	O
available	JJ	I-NP	O
immunosuppressive	JJ	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
mycophenolate	NN	B-NP	O
mofetil	NN	I-NP	O
and	CC	O	O
sirolimus	NN	B-NP	O
(	(	O	O
rapamycin	NN	B-NP	O
)	)	O	O
,	,	O	O
have	VBP	B-VP	O
no	DT	B-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
agents	NNS	I-NP	O
has	VBZ	B-VP	O
led	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
paradigms	NNS	I-NP	O
of	IN	B-PP	O
immunosuppressive	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
paper	NN	I-NP	O
reviews	VBZ	B-VP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
investigated	VBN	I-VP	O
these	DT	B-NP	O
new	JJ	I-NP	O
approaches	NNS	I-NP	O
to	TO	B-PP	O
immunosuppression	NN	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
.	.	O	O

Erythropoietin	NN	B-NP	O
restores	VBZ	B-VP	O
the	DT	B-NP	O
anemia	NN	I-NP	B
-	HYPH	B-VP	O
induced	VBN	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
cytotoxicity	NN	I-NP	B
in	IN	B-PP	O
rat	NN	B-NP	O
tumors	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
anemia	NN	B-NP	B
prevention	NN	I-NP	O
by	IN	B-PP	O
recombinant	JJ	B-NP	O
human	JJ	I-NP	O
erythropoietin	NN	I-NP	O
(	(	O	O
rHuEPO	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
cytotoxicity	NN	I-NP	B
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
in	IN	B-PP	O
solid	JJ	B-NP	O
experimental	JJ	I-NP	O
tumors	NNS	I-NP	B
.	.	O	O

Anemia	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
using	VBG	I-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
lasting	VBG	B-VP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hemoglobin	NN	I-NP	O
concentration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
second	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
anemia	NN	B-NP	B
was	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
rHuEPO	NN	B-NP	O
administered	VBN	B-VP	O
s.c.	JJ	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
/	SYM	I-NP	O
week	NN	I-NP	O
starting	VBG	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
before	IN	B-PP	O
carboplatin	NN	B-NP	O
application	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
carboplatin	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
tumors	NNS	B-NP	B
(	(	O	O
DS	NN	B-NP	O
-	HYPH	O	O
sarcoma	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
implanted	VBN	I-VP	O
s.c.	JJ	B-ADJP	O
onto	IN	B-PP	O
the	DT	B-NP	O
hind	NN	I-NP	O
food	NN	I-NP	O
dorsum	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
carboplatin	NN	B-NP	O
nor	CC	O	O
rHuEPO	NN	B-NP	O
treatment	NN	I-NP	O
influenced	VBD	B-VP	O
tumor	NN	B-NP	B
growth	NN	I-NP	O
rate	NN	I-NP	O
per	FW	B-ADVP	O
se	FW	I-ADVP	O
.	.	O	O

When	WRB	B-ADVP	O
tumors	NNS	B-NP	B
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
implantation	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
growth	NN	I-NP	O
delay	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
subsequent	JJ	I-NP	O
regrowth	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tumors	NNS	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
anemia	NN	I-NP	B
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
growth	NN	I-NP	O
delay	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
shorter	JJR	I-ADJP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
nonanemic	JJ	B-NP	O
controls	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
where	WRB	B-ADVP	O
anemia	NN	B-NP	B
was	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
rHuEPO	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
growth	NN	B-NP	O
delay	NN	I-NP	O
was	VBD	B-VP	O
comparable	JJ	B-ADJP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
nonanemic	JJ	B-NP	O
controls	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
chemotherapy	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
reduces	VBZ	B-VP	O
cytotoxicity	NN	B-NP	B
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
in	IN	B-PP	O
tumors	NNS	B-NP	B
,	,	O	O
whereas	IN	O	O
correction	NN	B-NP	O
of	IN	B-PP	O
anemia	NN	B-NP	B
by	IN	B-PP	O
rHuEPO	NN	B-NP	O
treatment	NN	I-NP	O
(	(	O	O
epoetin	NN	B-NP	O
alpha	NN	I-NP	O
)	)	O	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
sensitivity	NN	I-NP	O
,	,	O	O
probably	RB	B-ADVP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
improved	VBN	I-NP	O
oxygen	NN	I-NP	O
supply	NN	I-NP	O
to	TO	B-PP	O
tumor	NN	B-NP	B
tissue	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
nitrergic	JJ	B-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsion	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
mouse	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
nitro	NN	I-NP	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
ester	NN	I-NP	O
(	(	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
NAME	NN	I-NP	O
)	)	O	O
a	DT	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
synthase	NN	B-NP	O
inhibitor	NN	I-NP	O
and	CC	I-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
NO	NN	I-NP	O
precursor	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
on	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
experiment	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
received	VBD	B-VP	O
physiological	JJ	B-NP	O
saline	NN	I-NP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	O	O
arginine	NN	B-NP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
NAME	NN	I-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
these	DT	B-NP	O
injections	NNS	I-NP	O
,	,	O	O
all	DT	B-NP	O
mice	NNS	I-NP	O
received	VBD	B-VP	O
lidocaine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
experiment	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
received	VBD	B-VP	O
similar	JJ	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
experiment	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
these	DT	B-NP	O
injections	NNS	I-NP	O
,	,	O	O
all	DT	B-NP	O
mice	NNS	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
.	.	O	O

L	NN	B-NP	O
-	HYPH	I-NP	O
NAME	NN	I-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
treatment	NN	I-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
significantly	RB	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
may	MD	B-VP	O
suggest	VB	I-VP	O
that	IN	B-SBAR	O
NO	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
proconvulsant	JJ	I-NP	O
mediator	NN	I-NP	O
in	IN	B-PP	O
lidocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
metoprolol	NN	I-NP	O
or	CC	O	O
intravenous	JJ	B-NP	O
metoprolol	NN	I-NP	O
plus	CC	O	O
glucagon	NN	B-NP	O
on	IN	B-PP	O
dobutamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
on	IN	B-PP	O
dobutamine	NN	B-NP	O
stress	NN	I-NP	O
testing	NN	I-NP	O
with	IN	B-PP	O
technetium	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
sestamibi	NNS	I-NP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
photon	NN	I-NP	O
emission	NN	I-NP	O
computed	VBD	B-VP	O
tomography	NN	B-NP	O
imaging	NN	I-NP	O
and	CC	I-NP	O
ST	NN	I-NP	O
-	HYPH	I-NP	O
segment	NN	I-NP	O
monitoring	NN	I-NP	O
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
glucagon	NN	I-NP	O
on	IN	B-PP	O
metoprolol	NN	B-NP	O
s	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Randomized	VBN	B-VP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
.	.	O	O

Community	NN	B-NP	O
hospital	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
known	JJ	B-NP	O
reversible	JJ	I-NP	O
perfusion	NN	I-NP	O
defects	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
underwent	VBD	B-VP	O
dobutamine	NN	B-NP	O
stress	NN	I-NP	O
tests	NNS	I-NP	O
per	IN	B-PP	O
standard	JJ	B-NP	O
protocol	NN	I-NP	O
.	.	O	O

Before	IN	B-SBAR	O
dobutamine	NN	B-NP	O
was	VBD	B-VP	O
begun	VBN	I-VP	O
,	,	O	O
no	DT	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
visit	NN	I-NP	O
,	,	O	O
and	CC	O	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
on	IN	B-PP	O
subsequent	JJ	B-NP	O
visits	NNS	I-NP	O
to	TO	B-VP	O
receive	VB	I-VP	O
metoprolol	NN	B-NP	O
or	CC	I-NP	O
metoprolol	NN	I-NP	O
plus	CC	O	O
glucagon	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

Metoprolol	NN	B-NP	O
was	VBD	B-VP	O
dosed	VBN	I-VP	O
to	TO	I-VP	O
achieve	VB	I-VP	O
a	DT	B-NP	O
resting	JJ	I-NP	O
predobutamine	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
below	IN	B-PP	O
num	CD	B-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
minute	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
total	JJ	I-NP	O
intravenous	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
.	.	O	O

Metoprolol	NN	B-NP	O
reduced	VBD	B-VP	O
maximum	JJ	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
summed	JJ	B-NP	O
stress	NN	I-NP	O
scores	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
summed	VBN	B-NP	O
difference	NN	I-NP	O
scores	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
control	NN	B-NP	O
.	.	O	O

Metoprolol	NN	B-NP	O
plus	CC	I-NP	O
glucagon	NN	I-NP	O
also	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
maximum	JJ	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
control	NN	B-NP	O
.	.	O	O

Summed	VBN	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
summed	VBD	B-VP	O
difference	NN	B-NP	O
scores	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
significantly	RB	B-VP	O
reduced	VBN	I-VP	O
,	,	O	O
although	IN	B-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lower	JJR	B-ADJP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
than	IN	B-PP	O
control	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
any	DT	B-NP	O
parameter	NN	I-NP	O
between	IN	B-PP	O
metoprolol	NN	B-NP	O
and	CC	I-NP	O
metoprolol	NN	I-NP	O
-	HYPH	B-NP	O
glucagon	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
dobutamine	NN	B-NP	O
stress	NN	I-NP	O
testing	NN	I-NP	O
,	,	O	O
metoprolol	NN	B-NP	O
attenuates	VBZ	B-VP	O
or	CC	I-VP	O
eliminates	VBZ	I-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
.	.	O	O

Glucagon	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
somewhat	RB	B-ADJP	O
effective	JJ	I-ADJP	O
,	,	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
correct	VB	I-VP	O
this	DT	B-NP	O
effect	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
extent	NN	I-NP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
clinically	RB	B-ADVP	O
.	.	O	O

Prednisolone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
dysfunction	NN	I-NP	I
is	VBZ	B-VP	O
caused	VBN	I-VP	O
more	JJR	B-NP	O
by	IN	B-PP	O
atrophy	NN	B-NP	B
than	IN	B-PP	O
by	IN	B-PP	O
altered	JJ	B-NP	O
acetylcholine	NN	I-NP	O
receptor	NN	I-NP	O
expression	NN	I-NP	O
.	.	O	O

Large	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
glucocorticoids	NNS	B-NP	O
can	MD	B-VP	O
alter	VB	I-VP	O
muscle	NN	B-NP	O
physiology	NN	I-NP	O
and	CC	O	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
neuromuscular	JJ	B-NP	O
blocking	VBG	I-NP	O
drugs	NNS	I-NP	O
by	IN	B-PP	O
mechanisms	NNS	B-NP	O
not	RB	O	O
clearly	RB	B-VP	O
understood	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
moderate	JJ	B-NP	O
and	CC	I-NP	O
large	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
prednisolone	NN	B-NP	O
on	IN	B-PP	O
muscle	NN	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
pharmacology	NN	I-NP	O
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
relationship	NN	I-NP	O
to	TO	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
muscle	NN	B-NP	O
size	NN	I-NP	O
and	CC	I-NP	O
acetylcholine	NN	I-NP	O
receptor	NN	I-NP	O
(	(	O	O
AChR	NN	B-NP	O
)	)	O	O
expression	NN	B-NP	O
.	.	O	O

With	IN	B-PP	O
institutional	JJ	B-NP	O
approval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
daily	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
prednisolone	NN	I-NP	O
(	(	O	O
P10	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
prednisolone	NN	I-NP	O
(	(	O	O
P100	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
an	DT	B-NP	O
equal	JJ	I-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
(	(	O	O
S	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
fourth	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
was	VBD	B-VP	O
pair	NN	I-VP	O
fed	VBN	I-VP	O
(	(	O	O
food	NN	B-NP	O
restricted	VBN	B-VP	O
)	)	O	O
with	IN	B-PP	O
the	DT	B-NP	O
P100	NN	I-NP	O
rats	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
(	(	O	O
FR	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
.	.	O	O

On	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
nerve	NN	I-NP	O
-	HYPH	O	O
evoked	VBN	B-VP	O
peak	JJ	B-NP	O
twitch	NN	I-NP	O
tensions	NNS	I-NP	O
,	,	O	O
tetanic	JJ	B-NP	B
tensions	NNS	I-NP	O
,	,	O	O
and	CC	O	O
fatigability	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
curves	NNS	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
tubocurarine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
tibialis	NN	I-NP	O
cranialis	NN	I-NP	O
muscle	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
and	CC	O	O
related	VBN	B-VP	O
to	TO	B-PP	O
muscle	NN	B-NP	O
mass	NN	I-NP	O
or	CC	O	O
expression	NN	B-NP	O
of	IN	B-PP	O
AChRs	NNS	B-NP	O
.	.	O	O

Rate	NN	B-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
gain	NN	I-NP	O
was	VBD	B-VP	O
depressed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
P100	NN	I-NP	O
,	,	O	O
FR	NN	B-NP	O
,	,	O	O
and	CC	O	O
P10	NN	B-NP	O
groups	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
S	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Tibialis	NN	B-NP	O
muscle	NN	I-NP	O
mass	NN	I-NP	O
was	VBD	B-VP	O
smaller	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
P100	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
P10	NN	I-NP	O
or	CC	I-NP	O
S	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
evoked	VBN	I-NP	O
peak	JJ	I-NP	O
twitch	NN	I-NP	O
and	CC	O	O
tetanic	JJ	B-NP	B
tensions	NNS	I-NP	O
were	VBD	B-VP	O
less	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
P100	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
P10	NN	I-NP	O
or	CC	I-NP	O
S	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
tension	NN	B-NP	O
per	IN	B-PP	O
milligram	NN	B-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	O
mass	NN	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
P100	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
S	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
effective	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	O	O
tubocurarine	NN	B-NP	O
(	(	O	O
microg	NN	B-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
tibialis	NN	I-NP	O
muscle	NN	I-NP	O
was	VBD	B-VP	O
smaller	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
P10	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
S	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
P100	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

AChR	NN	B-NP	O
expression	NN	I-NP	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
P10	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
S	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
evoked	VBN	I-NP	O
tensions	NNS	I-NP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
muscle	NN	B-NP	O
mass	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	B-PP	O
not	RB	I-PP	O
with	IN	B-PP	O
expression	NN	B-NP	O
of	IN	B-PP	O
AChR	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
effective	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	O	O
tubocurarine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
muscle	NN	B-NP	O
mass	NN	I-NP	O
or	CC	O	O
AChR	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
neuromuscular	JJ	I-NP	B
dysfunction	NN	I-NP	I
after	IN	B-SBAR	O
prednisolone	NN	B-NP	O
is	VBZ	B-VP	O
dose	NN	B-NP	O
-	HYPH	O	O
dependent	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
derives	VBZ	B-VP	O
primarily	RB	B-ADVP	O
from	IN	B-PP	O
muscle	NN	B-NP	B
atrophy	NN	I-NP	I
and	CC	O	O
derives	VBZ	B-VP	O
less	RBR	B-ADVP	O
so	RB	I-ADVP	O
from	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
AChR	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
chronic	JJ	B-NP	O
glucocorticoid	NN	I-NP	O
therapy	NN	I-NP	O
alters	VBZ	B-VP	O
neuromuscular	JJ	B-NP	O
physiology	NN	I-NP	O
and	CC	I-NP	O
pharmacology	NN	I-NP	O
are	VBP	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
observed	VBN	I-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-ADJP	O
dependent	JJ	I-ADJP	O
and	CC	O	O
derive	VBP	B-VP	O
primarily	RB	B-ADVP	O
from	IN	B-PP	O
muscle	NN	B-NP	B
atrophy	NN	I-NP	I
and	CC	O	O
derive	VBP	B-VP	O
less	JJR	B-ADJP	O
from	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
acetylcholine	NN	B-NP	O
receptor	NN	I-NP	O
expression	NN	I-NP	O
.	.	O	O

Rapid	JJ	B-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
diltiazem	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
tetany	NN	I-NP	B
with	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
tetany	NN	B-NP	B
with	IN	B-PP	O
sudden	JJ	B-NP	O
respiratory	JJ	I-NP	B
arrest	NN	I-NP	I
after	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
diltiazem	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
rapidly	RB	B-ADVP	O
resolved	VBD	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
tetany	NN	B-NP	B
with	IN	B-PP	O
prompt	JJ	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
averting	VBG	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
more	RBR	B-NP	O
aggressive	JJ	I-NP	O
airway	NN	I-NP	O
management	NN	I-NP	O
and	CC	O	O
ventilatory	JJ	B-NP	O
support	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
emergency	NN	I-NP	O
physician	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
that	IN	B-SBAR	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
tetany	NN	B-NP	B
may	MD	B-VP	O
accompany	VB	I-VP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
diltiazem	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
calcium	NN	B-NP	O
chloride	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
and	CC	I-NP	O
effective	JJ	I-NP	O
remedy	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
on	IN	B-PP	O
hemostasis	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
aneurysmal	JJ	B-NP	B
subarachnoid	JJ	I-NP	I
hemorrhage	NN	I-NP	I
.	.	O	O

Platelet	NN	B-NP	O
function	NN	I-NP	O
is	VBZ	B-VP	O
impaired	VBN	I-VP	O
by	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
with	IN	B-PP	O
prominent	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

Their	PRP$	B-NP	O
safety	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
intracranial	JJ	B-NP	O
surgery	NN	I-NP	O
is	VBZ	B-VP	O
under	IN	B-PP	O
debate	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
aneurysmal	JJ	B-NP	B
subarachnoid	JJ	I-NP	I
hemorrhage	NN	I-NP	I
(	(	O	O
SAH	NN	B-NP	B
)	)	O	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-VP	O
receive	VB	I-VP	O
either	CC	O	O
ketoprofen	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
a	DT	B-NP	O
day	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
weak	JJ	I-NP	O
NSAID	NN	I-NP	O
,	,	O	O
acetaminophen	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
g	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
a	DT	B-NP	O
day	NN	I-NP	O
starting	VBG	B-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
aneurysmal	JJ	B-NP	B
SAH	NN	I-NP	B
.	.	O	O

Treatment	NN	B-NP	O
was	VBD	B-VP	O
continued	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
postoperatively	RB	B-ADVP	O
.	.	O	O

Test	JJS	B-NP	O
blood	NN	I-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
taken	VBN	I-VP	O
before	IN	B-PP	O
treatment	NN	B-NP	O
and	CC	I-NP	O
surgery	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
on	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
,	,	I-NP	O
third	JJ	I-NP	O
,	,	O	O
and	CC	O	O
fifth	JJ	B-NP	O
postoperative	JJ	I-NP	O
mornings	NNS	I-NP	O
.	.	O	O

Maximal	JJ	B-NP	O
platelet	NN	I-NP	B
aggregation	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
microM	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
diphosphate	NN	I-NP	O
decreased	VBD	B-VP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
ketoprofen	NN	B-NP	O
.	.	O	O

Aggregation	NN	B-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
ketoprofen	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
acetaminophen	NN	I-NP	O
group	NN	I-NP	O
just	RB	B-ADVP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
postoperative	JJ	I-NP	O
day	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
maximal	JJ	B-NP	O
platelet	NN	I-NP	B
aggregation	NN	I-NP	I
increased	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
acetaminophen	NN	I-NP	O
group	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
postoperative	JJ	I-NP	O
day	NN	I-NP	O
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
pretreatment	NN	I-NP	O
platelet	NN	I-NP	B
aggregation	NN	I-NP	I
results	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ketoprofen	NN	I-NP	O
group	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
postoperative	JJ	I-NP	O
intracranial	JJ	I-NP	O
hematoma	NN	I-NP	B
.	.	O	O

Coagulation	NN	B-NP	O
(	(	O	O
prothrombin	NN	B-NP	O
time	NN	I-NP	O
[	(	O	O
PT	NN	B-NP	O
]	)	O	O
,	,	O	O
activated	VBN	B-VP	O
partial	JJ	B-NP	O
thromboplastin	NN	I-NP	O
time	NN	I-NP	O
[	(	O	O
APPT	NN	B-NP	O
]	)	O	O
,	,	O	O
fibrinogen	NN	B-NP	O
concentration	NN	I-NP	O
,	,	O	O
and	CC	O	O
antithrombin	NN	B-NP	O
num	CD	I-NP	O
[	(	O	O
AT	NN	B-NP	O
num	CD	I-NP	O
]	)	O	O
)	)	O	O
was	VBD	B-VP	O
comparable	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Ketoprofen	NN	B-NP	O
but	CC	O	O
not	RB	O	O
acetaminophen	VB	B-VP	O
impaired	JJ	B-NP	O
platelet	NN	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
SAH	NN	B-NP	B
.	.	O	O

If	IN	B-SBAR	O
ketoprofen	NN	B-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
on	IN	B-PP	O
cerebral	JJ	B-NP	O
artery	NN	I-NP	B
aneurysms	NNS	I-NP	I
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
pose	VB	I-VP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
hemorrhage	NN	B-NP	B
.	.	O	O

Value	NN	B-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
in	IN	B-PP	O
prevention	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arthralgia	NN	I-NP	B
-	HYPH	B-NP	O
myalgia	NN	I-NP	B
syndrome	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
iron	NN	B-NP	O
dextran	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
randomized	VBN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
dose	NN	I-NP	O
infusion	NN	I-NP	O
(	(	O	O
TDI	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
iron	NN	B-NP	O
dextran	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
well	RB	I-VP	O
documented	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
treated	VBN	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
arthralgia	NN	I-NP	B
-	HYPH	I-NP	O
myalgia	NN	I-NP	B
syndrome	NN	I-NP	O
develops	VBZ	B-VP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
intravenous	JJ	O	O
(	(	O	O
i.v.	JJ	B-ADJP	O
)	)	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
(	(	O	O
MP	NN	B-NP	O
)	)	O	O
prevents	VBZ	B-VP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
,	,	O	O
ages	NNS	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
received	JJ	B-NP	O
either	CC	I-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
TDI	NN	B-NP	O
(	(	O	O
group	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
i.v.	JJ	I-NP	O
MP	NN	I-NP	O
before	IN	B-PP	O
and	CC	O	O
saline	NN	B-NP	O
after	IN	B-PP	O
TDI	NN	B-NP	O
(	(	O	O
group	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
i.v.	JJ	I-NP	O
MP	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
TDI	NN	B-NP	O
(	(	O	O
group	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
and	CC	I-NP	O
reactions	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
and	CC	I-VP	O
graded	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
severity	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
group	NN	B-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
reactions	NNS	B-NP	O
to	TO	B-PP	O
TDI	NNP	B-NP	O
.	.	O	O

The	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
reactions	NNS	B-NP	O
(	(	O	O
minimal	JJ	B-NP	O
,	,	I-NP	O
mild	JJ	I-NP	O
,	,	I-NP	O
and	CC	I-NP	O
moderate	JJ	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
was	VBD	B-VP	O
as	IN	B-SBAR	O
follows	VBZ	B-VP	O
:	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
;	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
;	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
sided	JJ	I-NP	O
Fisher	NNP	I-NP	O
s	VBZ	B-VP	O
exact	JJ	B-NP	O
test	NN	I-NP	O
using	VBG	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
intervals	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
approximation	NN	I-NP	O
of	IN	B-PP	O
Woolf	NNP	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
administration	NN	B-NP	O
of	IN	B-PP	O
MP	NN	B-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
TDI	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arthralgia	NN	I-NP	B
-	HYPH	B-NP	O
myalgia	NN	I-NP	B
syndrome	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
mg	NN	I-NP	O
i.v.	JJ	I-NP	O
MP	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
routinely	RB	B-ADVP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
TDI	NN	B-NP	O
of	IN	B-PP	O
iron	NN	B-NP	O
dextran	NN	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Non	NNP	B-NP	B
-	HYPH	I-NP	I
Hodgkin	NNP	I-NP	I
s	VBZ	B-VP	I
Lymphoma	NNP	B-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
vincristine	NN	B-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
term	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
interviewed	VBN	I-VP	O
with	IN	B-PP	O
emphasis	NN	B-NP	O
on	IN	B-PP	O
neuropathic	JJ	B-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

Physical	JJ	B-NP	O
and	CC	I-NP	O
quantitative	JJ	I-NP	O
sensory	JJ	I-NP	O
examination	NN	I-NP	O
with	IN	B-PP	O
determination	NN	B-NP	O
of	IN	B-PP	O
vibratory	JJ	B-NP	O
perception	NN	I-NP	O
and	CC	O	O
thermal	JJ	B-NP	O
discrimination	NN	I-NP	O
thresholds	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
(	(	O	O
median	NN	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
)	)	O	O
after	IN	B-PP	O
vincristine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
reported	VBD	B-VP	O
neuropathic	JJ	B-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
symptoms	NNS	I-NP	O
were	VBD	B-VP	O
still	RB	B-ADVP	O
present	JJ	B-ADJP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
examination	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
sensory	VBP	B-VP	O
signs	NNS	B-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
predominated	VBD	B-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
symptoms	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
past	NN	I-NP	O
.	.	O	O

Symptoms	NNS	B-NP	O
persisted	VBD	B-VP	O
maximally	RB	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
since	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
age	NN	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
and	CC	B-PP	O
without	IN	B-PP	O
complaints	NNS	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
examination	NN	B-NP	O
.	.	O	O

Normal	JJ	B-NP	O
reflexes	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
third	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Neuropathic	JJ	B-NP	O
complaints	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
very	RB	B-ADJP	O
troublesome	JJ	I-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
term	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
with	IN	B-PP	O
the	DT	B-NP	O
above	RB	I-NP	O
mentioned	VBN	I-NP	O
vincristine	NN	I-NP	O
dose	NN	I-NP	O
schedule	NN	I-NP	O
signs	NNS	I-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
neuropathy	NN	I-NP	B
are	VBP	B-VP	O
reversible	JJ	B-ADJP	O
for	IN	B-PP	O
a	DT	B-NP	O
great	JJ	I-NP	O
deal	NN	I-NP	O
and	CC	I-NP	O
prognosis	NN	I-NP	O
is	VBZ	B-VP	O
fairly	RB	B-ADJP	O
good	JJ	I-ADJP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
polymyositis	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	B
biliary	JJ	I-NP	I
cirrhosis	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	I-NP	O
penicillamine	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
many	JJ	B-NP	O
rheumatologic	JJ	I-NP	B
diseases	NNS	I-NP	I
,	,	O	O
toxicity	NN	B-NP	B
limits	VBZ	B-VP	O
its	PRP$	B-NP	O
usefulness	NN	I-NP	O
in	IN	B-PP	O
many	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Polymyositis	NN	B-NP	B
/	SYM	I-NP	O
dermatomyositis	NN	I-NP	B
can	MD	B-VP	O
develop	VB	I-VP	O
as	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
autoimmune	JJ	I-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
but	CC	O	O
its	PRP$	B-NP	O
exact	JJ	I-NP	O
pathogenesis	NN	I-NP	O
remains	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	B
biliary	JJ	I-NP	I
cirrhosis	NN	I-NP	I
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
polymyositis	NN	B-NP	B
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
described	VBD	B-VP	O
the	DT	B-NP	O
special	JJ	I-NP	O
clinical	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
receiving	VBG	B-VP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
penicillamine	NN	I-NP	O
therapy	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
followed	VBN	I-VP	O
carefully	RB	B-ADVP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
autoimmune	JJ	B-NP	O
complications	NNS	I-NP	O
like	IN	B-PP	O
polymyositis	NN	B-NP	B
/	SYM	B-VP	O
dermatomyositis	NN	B-NP	B
.	.	O	O

Photodistributed	VBN	B-NP	O
nifedipine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
facial	JJ	I-NP	O
telangiectasia	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
nifedipine	NN	B-NP	O
(	(	O	O
Adalat	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
photodistributed	VBN	I-VP	O
facial	JJ	B-NP	O
telangiectasia	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
became	VBD	B-VP	O
more	RBR	B-ADJP	O
noticeable	JJ	I-ADJP	O
with	IN	B-PP	O
time	NN	B-NP	O
.	.	O	O

Neither	DT	B-NP	O
patient	NN	I-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
photosensitivity	NN	B-NP	O
or	CC	I-NP	O
flushing	NN	I-NP	B
.	.	O	O

Both	DT	B-NP	O
patients	NNS	I-NP	O
reported	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
cosmetic	JJ	I-NP	O
improvement	NN	I-NP	O
after	IN	B-PP	O
discontinuing	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
commenced	VBD	B-VP	O
the	DT	B-NP	O
closely	RB	I-NP	O
related	JJ	I-NP	O
drug	NN	I-NP	O
amlodipine	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
with	IN	B-PP	O
recurrence	NN	B-NP	O
of	IN	B-PP	O
telangiectasia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
photodistribution	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
telangiectasia	NN	I-NP	B
suggests	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
drug	NN	I-NP	O
/	SYM	B-NP	O
light	NN	I-NP	O
interaction	NN	I-NP	O
.	.	O	O

Nephrotoxicity	NN	B-NP	B
of	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
FK506	NN	I-NP	O
:	:	O	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
calcineurin	NN	B-NP	O
phosphatase	NN	I-NP	O
.	.	O	O

Cyclosporin	NN	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
Fujimycine	NN	I-NP	O
,	,	O	O
but	CC	B-CONJP	O
not	RB	I-CONJP	O
the	DT	B-NP	O
related	VBN	I-NP	O
macrolide	NN	I-NP	O
immunosuppressant	NN	I-NP	O
rapamycin	NN	I-NP	O
,	,	O	O
caused	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
degenerative	JJ	B-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
proximal	JJ	B-NP	O
tubular	JJ	I-NP	O
epithelium	NN	I-NP	O
,	,	O	O
and	CC	O	O
hypertrophy	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
juxtaglomerular	JJ	I-NP	O
apparatus	NN	I-NP	O
in	IN	B-PP	O
male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
molecular	JJ	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
CsA	NN	B-NP	O
and	CC	I-NP	O
FK506	NN	I-NP	O
toxicity	NN	I-NP	B
were	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Cyclophilin	NN	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
FK506	NN	I-NP	O
-	HYPH	O	O
binding	VBG	B-NP	O
protein	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
main	JJ	I-NP	O
intracytoplasmic	JJ	I-NP	O
receptors	NNS	I-NP	O
for	IN	B-PP	O
CsA	NN	B-NP	O
and	CC	I-NP	O
FK506	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
were	VBD	B-VP	O
each	DT	B-NP	O
detected	VBN	B-VP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
tissue	NN	I-NP	O
extract	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
,	,	O	O
high	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
immunoreactive	JJ	B-NP	O
and	CC	I-NP	O
enzymatically	RB	I-NP	O
active	JJ	I-NP	O
calcineurin	NN	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
immunosuppressants	NNS	I-NP	O
CsA	NN	I-NP	O
and	CC	I-NP	O
FK506	NN	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	B-PP	O
by	IN	I-PP	O
rapamycin	NN	B-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
specific	JJ	B-NP	O
immunophilin	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
calcineurin	NN	I-NP	O
complexes	NNS	I-NP	O
formed	VBD	B-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
CsA	NN	B-NP	O
and	CC	I-NP	O
FK506	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
rapamycin	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
nephrotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
CsA	NN	B-NP	O
and	CC	I-NP	O
FK506	NN	I-NP	O
is	VBZ	B-VP	O
likely	RB	I-VP	O
mediated	VBN	I-VP	O
through	IN	B-PP	O
binding	NN	B-NP	O
to	TO	B-PP	O
renal	JJ	B-NP	O
immunophilin	NN	I-NP	O
and	CC	O	O
inhibiting	VBG	B-VP	O
calcineurin	NN	B-NP	O
phosphatase	NN	I-NP	O
.	.	O	O

Massive	JJ	B-NP	O
cerebral	JJ	I-NP	B
edema	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
fulminant	JJ	B-NP	O
hepatic	JJ	I-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
acetaminophen	NN	B-NP	O
overdose	NN	I-NP	B
:	:	O	O
possible	JJ	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
cranial	JJ	B-NP	O
decompression	NN	I-NP	O
.	.	O	O

Cerebral	JJ	B-NP	B
edema	NN	I-NP	I
may	MD	B-VP	O
complicate	VB	I-VP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Response	NN	B-NP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
therapy	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
disappointing	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
fatal	JJ	B-NP	O
acetaminophen	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
fulminant	JJ	I-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
signs	NNS	B-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	B
edema	NN	I-NP	I
,	,	O	O
unresponsive	JJ	B-ADJP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
medical	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Cranial	JJ	B-NP	O
decompression	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
.	.	O	O

A	DT	B-NP	O
justification	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
further	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
cranial	JJ	B-NP	O
decompression	NN	I-NP	O
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

Gentamicin	NN	B-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
neonate	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
autopsy	NN	I-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
premature	JJ	I-NP	O
baby	NN	I-NP	O
who	WP	B-NP	O
died	VBD	B-VP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
after	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
gentamicin	NN	B-NP	O
and	CC	I-NP	O
penicillin	NN	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
gentamicin	NN	I-NP	O
concentration	NN	I-NP	O
had	VBD	B-VP	O
reached	VBN	I-VP	O
toxic	JJ	B-NP	O
levels	NNS	I-NP	O
when	WRB	B-ADVP	O
anuria	NN	B-NP	B
developed	VBD	B-VP	O
.	.	O	O

Numerous	JJ	B-NP	O
periodic	JJ	I-NP	O
acid	NN	I-NP	O
Schiff	NNP	I-NP	O
(	(	O	O
PAS	NNP	B-NP	O
)	)	O	O
positive	JJ	B-NP	O
,	,	I-NP	O
diastase	NN	I-NP	O
resistant	JJ	I-NP	O
cytoplasmic	JJ	I-NP	O
inclusion	NN	I-NP	O
bodies	NNS	I-NP	O
which	WDT	B-NP	O
appeared	VBD	B-VP	O
as	IN	B-SBAR	O
myelin	JJ	B-NP	O
figures	NNS	I-NP	O
in	IN	B-PP	O
cytosegresomes	NNS	B-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
electron	NN	I-NP	O
microscope	NN	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
proximal	JJ	I-NP	O
convoluted	JJ	I-NP	O
tubules	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
pathological	JJ	I-NP	O
changes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
gentamicin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
neonatal	JJ	I-NP	O
kidneys	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Anti	AFX	B-NP	O
-	HYPH	I-NP	O
carcinogenic	JJ	B-NP	B
action	NN	I-NP	O
of	IN	B-PP	O
phenobarbital	NN	B-NP	O
given	VBN	B-VP	O
simultaneously	RB	B-ADVP	O
with	IN	B-PP	O
diethylnitrosamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
work	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
planned	VBN	I-VP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
elucidate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
phenobarbital	NN	B-NP	O
on	IN	B-PP	O
carcinogenesis	NN	B-NP	B
when	WRB	B-ADVP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
administered	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
with	IN	B-PP	O
diethylnitrosamine	NN	B-NP	O
.	.	O	O

Wistar	NNP	B-NP	O
rats	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
DEN	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
by	IN	B-PP	O
DEN	NN	B-NP	O
+	SYM	B-NP	O
PB	NN	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
schedule	NN	I-NP	O
for	IN	B-PP	O
hepatocarcinogenesis	NN	B-NP	B
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
number	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
induced	VBN	B-NP	O
PAS	NN	I-NP	O
positive	JJ	I-NP	O
preneoplastic	JJ	I-NP	B
foci	NNS	I-NP	I
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
when	WRB	B-ADVP	O
PB	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
with	IN	B-PP	O
DEN	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mitotic	JJ	I-NP	O
inhibition	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
micronuclei	NNS	B-NP	O
normally	RB	B-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
partial	JJ	B-NP	O
hepatectomy	NN	I-NP	O
in	IN	B-PP	O
DEN	NN	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
significantly	RB	B-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
DEN	NN	B-NP	O
+	SYM	B-NP	O
PB	NN	I-NP	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
last	RB	B-NP	O
only	RB	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
PB	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
significantly	RB	B-ADVP	O
the	DT	B-NP	O
last	JJ	I-NP	O
parameters	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
DEN	NN	B-NP	O
+	SYM	B-NP	O
PB	NN	I-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
survival	NN	I-NP	O
was	VBD	B-VP	O
prolonged	JJ	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
tumor	NN	I-NP	B
incidence	NN	I-NP	O
decreased	VBD	B-VP	O
as	RB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
obtained	VBN	B-VP	O
by	IN	B-PP	O
DEN	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
PB	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
promotes	VBZ	B-VP	O
carcinogenesis	NN	B-NP	B
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
DEN	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
carcinogen	NN	I-NP	O
effect	NN	I-NP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
simultaneously	RB	B-ADVP	O
with	IN	B-PP	O
DEN	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
carcinogen	NN	I-NP	O
effect	NN	I-NP	O
acts	VBZ	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
on	IN	B-PP	O
the	DT	B-NP	O
promotion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
precancerous	JJ	I-NP	B
lesions	NNS	I-NP	I
.	.	O	O

Biochemical	JJ	B-NP	O
investigations	NNS	I-NP	O
are	VBP	B-VP	O
in	IN	B-PP	O
progress	NN	B-NP	O
to	TO	B-VP	O
obtain	VB	I-VP	O
more	JJR	B-NP	O
information	NN	I-NP	O
about	IN	B-PP	O
this	DT	B-NP	O
paradoxical	JJ	I-NP	O
PB	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Post	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
rigidity	NN	I-NP	B
after	IN	B-PP	O
fentanyl	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
thoraco	AFX	B-NP	O
-	HYPH	I-NP	O
abdominal	JJ	I-NP	O
rigidity	NN	I-NP	B
leading	VBG	B-VP	O
to	TO	B-PP	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
is	VBZ	B-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
period	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
elderly	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
moderate	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
successfully	RB	I-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
naloxone	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
mechanisms	NNS	I-NP	O
possibly	RB	B-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
accident	NN	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Postpartum	NNP	B-NP	O
psychosis	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
bromocriptine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
multigravida	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
prior	JJ	I-NP	O
psychiatric	JJ	I-NP	B
history	NN	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
with	IN	B-PP	O
postpartum	NN	B-NP	O
psychosis	NN	I-NP	B
,	,	O	O
having	VBG	B-VP	O
received	VBN	I-VP	O
bromocriptine	NN	B-NP	O
for	IN	B-PP	O
inhibition	NN	B-NP	B
of	IN	B-PP	I
lactation	NN	B-NP	I
.	.	O	O

Bromocriptine	NN	B-NP	O
given	VBN	B-PP	O
in	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
psychosis	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
cases	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
bromocriptine	NN	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
psychosis	NN	B-NP	B
even	RB	B-ADVP	O
when	WRB	I-ADVP	O
given	VBN	B-PP	O
in	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
dependency	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
mitomycin	NN	B-NP	O
C	NN	I-NP	O
.	.	O	O

Since	IN	B-SBAR	O
num	CD	B-NP	O
mitomycin	NN	I-NP	O
C	NN	I-NP	O
(	(	O	O
MMC	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
cardiotoxic	JJ	B-ADJP	B
,	,	O	O
especially	RB	B-ADVP	O
when	WRB	B-ADVP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
or	CC	O	O
given	VBN	B-PP	O
following	VBG	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

Data	NNS	B-NP	O
on	IN	B-PP	O
dose	NN	B-NP	O
dependency	NN	I-NP	O
or	CC	I-NP	O
incidence	NN	I-NP	O
concerning	VBG	B-VP	O
this	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
initiated	VBN	I-VP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
obtain	VB	I-VP	O
some	DT	B-NP	O
more	JJR	I-NP	O
data	NNS	I-NP	O
on	IN	B-PP	O
these	DT	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
MMC	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
by	IN	B-PP	O
repeated	VBN	B-NP	O
physical	JJ	I-NP	O
examinations	NNS	I-NP	O
,	,	O	O
chest	NN	B-NP	O
X	SYM	B-NP	O
-	HYPH	B-NP	O
rays	NNS	I-NP	O
,	,	O	O
electro	AFX	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
echocardiography	NN	I-NP	O
and	CC	I-NP	O
radionuclide	NN	I-NP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
(	(	O	O
EF	NN	B-NP	O
)	)	O	O
determinations	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
per	IN	B-PP	O
cumulative	JJ	B-NP	O
dose	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
cardiac	JJ	B-NP	B
failure	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
m	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
MMC	NN	I-NP	O
and	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
m	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
doxorubicin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cardiac	JJ	I-NP	B
failure	NN	I-NP	I
was	VBD	B-VP	O
predicted	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
drop	NN	I-NP	O
in	IN	B-PP	O
EF	NN	B-NP	O
determined	VBN	B-VP	O
during	IN	B-PP	O
a	DT	B-NP	O
cold	JJ	I-NP	O
pressor	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
clinical	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
,	,	O	O
nor	CC	O	O
did	VBD	O	O
the	DT	B-NP	O
studied	VBN	I-NP	O
parameters	NNS	I-NP	O
change	VBP	B-VP	O
.	.	O	O

The	DT	B-NP	O
literature	NN	I-NP	O
on	IN	B-PP	O
this	DT	B-NP	O
subject	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
combined	VBN	I-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
MMC	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
dose	NN	B-NP	O
dependent	JJ	I-NP	O
,	,	O	O
occurring	VBG	B-VP	O
at	IN	B-PP	O
cumulative	JJ	B-NP	O
dose	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
m	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
,	,	O	O
mainly	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
also	RB	B-ADVP	O
(	(	O	O
previously	RB	B-ADVP	O
or	CC	I-ADVP	O
simultaneously	RB	I-ADVP	O
)	)	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
even	RB	B-ADVP	O
for	IN	B-PP	O
this	DT	B-NP	O
risk	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Phlorizin	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
glycosuria	NN	I-NP	B
does	VBZ	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
gentamicin	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Because	IN	B-SBAR	O
rats	NNS	B-NP	O
with	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NN	I-NP	B
mellitus	NN	I-NP	I
(	(	O	O
DM	NN	B-NP	B
)	)	O	O
have	VBP	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
solute	JJ	I-NP	O
diuresis	NN	I-NP	O
(	(	O	O
glycosuria	NN	B-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
)	)	O	O
,	,	O	O
we	PRP	B-NP	O
have	VBP	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
may	NN	I-NP	O
in	IN	B-PP	O
part	NN	B-NP	O
be	VB	B-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
resistance	NN	I-NP	O
to	TO	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
(	(	O	O
ARF	NN	B-NP	B
)	)	O	O
.	.	O	O

The	DT	B-NP	O
protection	NN	I-NP	O
from	IN	B-PP	O
gentamicin	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
diabetic	JJ	B-NP	B
rats	NNS	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
solute	JJ	I-NP	O
diuresis	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
blockage	NN	B-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
glucose	NN	I-NP	O
reabsorption	NN	I-NP	O
with	IN	B-PP	O
phlorizin	NN	B-NP	O
(	(	O	O
P	NN	B-NP	O
)	)	O	O
.	.	O	O

DM	NN	B-NP	B
rats	NNS	I-NP	O
with	IN	B-PP	O
mild	JJ	B-NP	O
glycosuria	NN	I-NP	B
(	(	O	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
degree	NN	B-NP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
P	NN	I-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
also	RB	I-VP	O
studied	VBN	I-VP	O
.	.	O	O

Unanesthetized	JJ	B-NP	O
adult	JJ	I-NP	O
female	NN	I-NP	O
,	,	O	O
Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
and	CC	O	O
studied	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
P	NN	B-NP	O
alone	RB	B-ADVP	O
)	)	O	O
received	VBD	B-VP	O
P	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
;	:	O	O
Group	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
P	NN	B-NP	O
+	SYM	O	O
gentamicin	NN	B-NP	O
)	)	O	O
;	:	O	O
Group	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
gentamicin	NN	B-NP	O
alone	RB	B-ADVP	O
)	)	O	O
and	CC	O	O
Group	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
mild	JJ	B-NP	O
DM	NN	I-NP	B
+	SYM	B-NP	O
gentamicin	NN	I-NP	O
)	)	O	O
.	.	O	O

Nephrotoxic	JJ	B-NP	B
doses	NNS	I-NP	O
of	IN	B-PP	O
gentamicin	NN	B-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
study	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
of	IN	B-PP	O
groups	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

In	IN	B-PP	O
Group	NN	B-NP	O
I	NN	I-NP	O
,	,	O	O
P	NN	B-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
moderate	JJ	I-NP	O
and	CC	I-NP	O
stable	JJ	I-NP	O
glycosuria	NN	I-NP	B
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
functional	JJ	I-NP	O
or	CC	I-NP	O
morphologic	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
or	CC	O	O
damage	NN	B-NP	O
(	(	O	O
tubular	JJ	B-NP	B
necrosis	NN	I-NP	I
score	NN	I-NP	O
[	(	O	O
maximum	NN	B-NP	O
num	CD	I-NP	O
]	)	O	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
P	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
ARF	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
:	:	O	O
maximal	JJ	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
CCr	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
lysozymuria	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
;	:	O	O
tubular	JJ	B-NP	B
necrosis	NN	I-NP	I
score	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Tiapride	NN	B-NP	O
in	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
involuntary	JJ	I-NP	B
movements	NNS	I-NP	I
.	.	O	O

Tiapride	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
substituted	VBN	I-NP	O
benzamide	NN	I-NP	O
derivative	NN	I-NP	O
closely	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-PP	O
metoclopramide	NN	B-NP	O
,	,	O	O
reduced	VBD	B-VP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
peak	NN	I-NP	O
dose	NN	I-NP	O
involuntary	JJ	I-NP	B
movements	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
idiopathic	JJ	B-NP	B
Parkinson	NNP	I-NP	I
s	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
an	DT	B-NP	O
unacceptable	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
disability	NN	B-NP	O
from	IN	B-PP	O
Parkinsonism	NN	B-NP	B
with	IN	B-PP	O
aggravation	NN	B-NP	O
of	IN	B-PP	O
end	NN	B-NP	O
-	HYPH	B-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
akinesia	NN	I-NP	B
led	VBD	B-VP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
cessation	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Tiapride	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
early	JJ	B-NP	O
morning	NN	I-NP	O
of	IN	B-PP	O
off	NN	B-NP	O
-	HYPH	B-NP	O
period	NN	I-NP	O
segmental	JJ	I-NP	O
dystonia	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
fail	VBP	B-VP	O
to	TO	I-VP	O
support	VB	I-VP	O
the	DT	B-NP	O
notion	NN	I-NP	O
that	IN	B-SBAR	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
are	VBP	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
overstimulation	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
separate	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
deep	JJ	I-NP	O
brain	NN	I-NP	O
stimulation	NN	I-NP	O
on	IN	B-PP	O
cortical	JJ	B-NP	O
epileptic	JJ	I-NP	B
discharges	NNS	I-NP	O
in	IN	B-PP	O
penicillin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
epilepsy	NN	I-NP	B
model	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Experimental	JJ	B-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
revealed	VBN	I-VP	O
that	IN	B-SBAR	O
hippocampal	JJ	B-NP	O
DBS	NNP	I-NP	O
can	MD	B-VP	O
control	VB	I-VP	O
epileptic	JJ	B-NP	B
activity	NN	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
is	VBZ	B-VP	O
obscure	JJ	B-NP	O
and	CC	I-NP	O
optimal	JJ	I-NP	O
stimulation	NN	I-NP	O
parameters	NNS	I-NP	O
are	VBP	B-VP	O
not	RB	O	O
clearly	RB	B-VP	O
defined	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
frequency	NN	I-NP	O
hippocampal	JJ	I-NP	O
stimulation	NN	I-NP	O
on	IN	B-PP	O
cortical	JJ	B-NP	O
epileptic	JJ	I-NP	B
activity	NN	I-NP	O
in	IN	B-PP	O
penicillin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
epilepsy	NN	I-NP	B
model	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
implanted	VBN	I-VP	O
DBS	NNP	B-NP	O
electrodes	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
group	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
hippocampal	JJ	I-NP	O
DBS	NN	I-NP	O
was	VBD	B-VP	O
off	RB	B-ADVP	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
hippocampal	JJ	I-NP	O
DBS	NNP	I-NP	O
was	VBD	B-VP	O
on	IN	B-PP	O
(	(	O	O
num	CD	B-NP	O
Hz	NN	I-NP	O
,	,	O	O
0.5V	NN	B-NP	O
,	,	O	O
1V	NN	B-NP	O
,	,	O	O
2V	NN	B-NP	O
,	,	O	O
and	CC	O	O
5V	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
sec	NN	I-NP	O
)	)	O	O
following	VBG	B-PP	O
penicillin	NN	B-NP	O
G	NN	I-NP	O
injection	NN	I-NP	O
intracortically	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
hippocampal	JJ	I-NP	O
DBS	NN	I-NP	O
was	VBD	B-VP	O
on	IN	B-PP	O
following	VBG	B-VP	O
num	CD	B-NP	O
l	NN	I-NP	O
saline	NN	I-NP	O
injection	NN	I-NP	O
intracortically	RB	B-ADVP	O
.	.	O	O

EEG	NN	B-NP	O
recordings	NNS	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
before	IN	B-PP	O
and	CC	O	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
following	VBG	B-PP	O
penicillin	NN	B-NP	O
-	HYPH	B-NP	O
G	NN	I-NP	O
injection	NN	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
at	IN	B-PP	O
10th	JJ	B-NP	O
minutes	NNS	I-NP	O
following	VBG	B-PP	O
each	DT	B-NP	O
stimulus	NN	I-NP	O
for	IN	B-PP	O
analysis	NN	B-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
frequency	NN	B-NP	O
,	,	O	O
amplitude	NN	B-NP	O
,	,	O	O
and	CC	O	O
power	NN	B-NP	O
spectrum	NN	I-NP	O
.	.	O	O

High	JJ	B-NP	O
frequency	NN	I-NP	O
hippocampal	JJ	I-NP	O
DBS	NNP	I-NP	O
suppressed	VBD	B-VP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
penicillin	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cortical	JJ	I-NP	O
epileptic	JJ	I-NP	B
activity	NN	I-NP	O
independent	JJ	B-ADJP	O
from	IN	B-PP	O
stimulus	NN	B-NP	O
intensity	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
hippocampal	JJ	B-NP	O
stimulation	NN	I-NP	O
alone	RB	B-ADVP	O
lead	VBP	B-VP	O
only	RB	B-ADVP	O
to	TO	B-VP	O
diffuse	VB	I-VP	O
slowing	NN	B-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	O
bioelectrical	JJ	I-NP	O
activity	NN	I-NP	O
at	IN	B-PP	O
5V	NN	B-NP	O
stimulation	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
continuous	JJ	B-NP	O
high	JJ	I-NP	O
frequency	NN	I-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
suppressed	VBD	B-VP	O
acute	JJ	B-NP	O
cortical	JJ	I-NP	O
epileptic	JJ	I-NP	B
activity	NN	I-NP	O
effectively	RB	B-ADVP	O
without	IN	B-PP	O
causing	VBG	B-VP	O
secondary	JJ	B-NP	O
epileptic	JJ	I-NP	B
discharges	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
important	JJ	B-ADJP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
defining	VBG	B-VP	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
parameters	NNS	I-NP	O
of	IN	B-PP	O
hippocampal	JJ	B-NP	O
DBS	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
epilepsy	NN	B-NP	B
.	.	O	O

Neural	JJ	B-NP	O
correlates	NNS	I-NP	O
of	IN	B-PP	O
S	NN	B-NP	O
-	HYPH	B-NP	O
ketamine	NN	I-NP	O
induced	VBD	B-VP	O
psychosis	NN	B-NP	B
during	IN	B-PP	O
overt	JJ	B-NP	O
continuous	JJ	I-NP	O
verbal	JJ	I-NP	O
fluency	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
glutamatergic	JJ	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

Administered	VBN	B-VP	O
to	TO	B-PP	O
healthy	JJ	B-NP	O
volunteers	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
subanesthetic	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
competitive	JJ	I-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
ketamine	NN	I-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
psychopathological	JJ	B-NP	O
symptoms	NNS	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
,	,	O	O
ketamine	NN	B-NP	O
exacerbates	VBZ	B-VP	O
the	DT	B-NP	O
core	NN	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
illness	NN	B-NP	O
,	,	O	O
supporting	VBG	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
glutamatergic	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
counterbalanced	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
design	NN	I-NP	O
,	,	O	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
a	DT	B-NP	O
continuous	JJ	I-NP	O
subanesthetic	JJ	I-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
ketamine	NN	I-NP	O
infusion	NN	I-NP	O
while	IN	B-SBAR	O
differences	NNS	B-NP	O
in	IN	B-PP	O
BOLD	NN	B-NP	O
responses	NNS	I-NP	O
measured	VBN	B-VP	O
with	IN	B-PP	O
fMRI	NN	B-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
scanning	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
subjects	NNS	B-NP	O
performed	VBD	B-VP	O
continuous	JJ	B-NP	O
overt	JJ	I-NP	O
verbal	JJ	I-NP	O
fluency	NN	I-NP	O
tasks	NNS	I-NP	O
(	(	O	O
phonological	JJ	B-NP	O
,	,	I-NP	O
lexical	JJ	I-NP	O
and	CC	I-NP	O
semantic	JJ	I-NP	O
)	)	O	O
.	.	O	O

Ketamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
psychopathological	JJ	I-NP	O
symptoms	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
Positive	JJ	I-NP	O
and	CC	I-NP	O
Negative	JJ	I-NP	O
Syndrome	NN	I-NP	O
Scale	NN	I-NP	O
(	(	O	O
PANSS	NN	B-NP	O
)	)	O	O
.	.	O	O

Ketamine	NN	B-NP	O
elicited	VBD	B-VP	O
psychosis	NN	B-NP	B
like	IN	B-PP	O
psychopathology	NN	B-NP	O
.	.	O	O

Post	AFX	B-NP	O
-	HYPH	I-NP	O
hoc	NN	I-NP	O
t	NN	I-NP	O
-	HYPH	I-NP	O
tests	NNS	I-NP	O
revealed	VBD	B-VP	O
significant	JJ	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
placebo	NN	B-NP	O
and	CC	I-NP	O
ketamine	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
words	NNS	B-NP	O
generated	VBN	B-VP	O
during	IN	B-PP	O
lexical	JJ	B-NP	O
and	CC	I-NP	O
semantic	JJ	I-NP	O
verbal	JJ	I-NP	O
fluency	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
phonological	JJ	I-NP	O
domain	NN	I-NP	O
remained	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
.	.	O	O

Ketamine	NN	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
enhanced	VBN	B-NP	O
cortical	JJ	I-NP	O
activations	NNS	I-NP	O
in	IN	B-PP	O
supramarginal	JJ	B-NP	O
and	CC	I-NP	O
frontal	JJ	I-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
for	IN	B-PP	O
phonological	JJ	B-NP	O
and	CC	I-NP	O
lexical	JJ	I-NP	O
verbal	JJ	I-NP	O
fluency	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	B-PP	O
for	IN	I-PP	O
semantic	JJ	B-NP	O
verbal	JJ	I-NP	O
fluency	NN	I-NP	O
.	.	O	O

Ketamine	NN	B-NP	O
induces	VBZ	B-VP	O
activation	NN	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
frontal	JJ	B-NP	O
and	CC	I-NP	O
temporal	JJ	I-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
further	JJ	B-NP	O
support	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
dysfunction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

Dopamine	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
believed	VBN	I-VP	O
that	IN	B-SBAR	O
dopamine	NN	B-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
mediates	VBZ	B-VP	O
methamphetamine	NN	B-NP	O
(	(	O	O
METH	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
toxicity	NN	I-NP	B
to	TO	B-VP	O
brain	VB	I-VP	O
dopaminergic	JJ	B-NP	O
neurons	NNS	I-NP	O
,	,	O	O
because	IN	B-SBAR	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
interfere	VBP	B-VP	O
with	IN	B-PP	O
DA	NN	B-NP	O
neurotransmission	NN	I-NP	O
decrease	NN	I-NP	O
toxicity	NN	I-NP	B
,	,	O	O
whereas	IN	O	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
increase	VBP	B-VP	O
DA	NN	B-NP	O
neurotransmission	NN	I-NP	O
enhance	VBP	B-VP	O
toxicity	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
temperature	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
to	TO	I-VP	O
manipulate	VB	I-VP	O
brain	NN	B-NP	O
DA	NN	I-NP	O
neurotransmission	NN	I-NP	O
confound	VBD	B-VP	O
interpretation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
data	NNS	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
recently	RB	I-NP	O
reported	VBN	I-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
dihydroxyphenylalanine	NN	B-NP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
methyl	NN	I-NP	O
-	HYPH	O	O
para	AFX	O	O
-	HYPH	O	O
tyrosine	NN	B-NP	O
on	IN	B-PP	O
METH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
DA	NN	I-NP	O
neurotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
also	RB	I-VP	O
confounded	VBN	I-VP	O
by	IN	B-PP	O
drug	NN	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
body	NN	B-NP	O
temperature	NN	I-NP	O
.	.	O	O

Further	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
mice	NNS	B-NP	O
genetically	RB	B-VP	O
engineered	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
deficient	JJ	B-ADJP	O
in	IN	B-PP	O
brain	NN	B-NP	O
DA	NN	I-NP	O
develop	VBP	B-VP	O
METH	NN	B-NP	O
neurotoxicity	NN	I-NP	B
,	,	O	O
as	RB	B-ADVP	O
long	RB	I-ADVP	O
as	IN	B-SBAR	O
the	DT	B-NP	O
thermic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
are	VBP	B-VP	O
preserved	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
mice	NNS	B-NP	O
genetically	RB	B-VP	O
engineered	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
unilateral	JJ	B-NP	O
brain	NN	I-NP	O
DA	NN	I-NP	O
deficits	NNS	I-NP	O
develop	VBP	B-VP	O
METH	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
dopaminergic	JJ	I-NP	B
deficits	NNS	I-NP	I
that	WDT	B-NP	O
are	VBP	B-VP	O
of	IN	B-PP	O
comparable	JJ	B-NP	O
magnitude	NN	I-NP	O
on	IN	B-PP	O
both	DT	B-NP	O
sides	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Taken	VBN	B-VP	O
together	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
findings	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
DA	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dopaminergic	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
and	CC	O	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
mechanisms	NNS	B-NP	O
independent	JJ	B-ADJP	O
of	IN	B-PP	O
DA	NN	B-NP	O
warrant	NN	I-NP	O
more	RBR	B-NP	O
intense	JJ	I-NP	O
investigation	NN	I-NP	O
.	.	O	O

Brainstem	NN	B-NP	B
dysgenesis	NN	I-NP	I
in	IN	B-PP	O
an	DT	B-NP	O
infant	NN	I-NP	O
prenatally	RB	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Many	JJ	B-NP	O
authors	NNS	I-NP	O
described	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
fetus	NN	I-NP	O
of	IN	B-PP	O
maternal	JJ	B-NP	O
cocaine	NN	I-NP	B
abuse	NN	I-NP	I
during	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

Vasoconstriction	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
common	JJ	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
wide	JJ	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
fetal	JJ	B-NP	B
anomalies	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
an	DT	B-NP	O
infant	NN	I-NP	O
with	IN	B-PP	O
multiple	JJ	B-NP	B
cranial	JJ	I-NP	I
-	HYPH	I-NP	I
nerve	NN	I-NP	I
involvement	NN	I-NP	I
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
brainstem	NN	B-NP	B
dysgenesis	NN	I-NP	I
,	,	O	O
born	VBN	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
cocaine	NN	I-NP	B
-	HYPH	O	I
addicted	VBN	B-NP	I
mother	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
in	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

Diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
is	VBZ	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
(	(	O	O
ROS	NNS	B-NP	O
)	)	O	O
.	.	O	O

Nrf2	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
transcription	NN	I-NP	O
factor	NN	I-NP	O
that	WDT	B-NP	O
controls	VBZ	B-VP	O
the	DT	B-NP	O
antioxidant	JJ	I-NP	O
response	NN	I-NP	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
maintaining	VBG	B-VP	O
cellular	JJ	B-NP	O
redox	NN	I-NP	O
homeostasis	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
report	VBP	B-VP	O
our	PRP$	B-NP	O
findings	NNS	I-NP	O
demonstrating	VBG	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
against	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
explore	VBP	B-VP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
against	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
using	VBG	B-VP	O
human	JJ	B-NP	O
kidney	NN	I-NP	O
biopsy	NN	I-NP	O
tissues	NNS	I-NP	O
from	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
patients	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
streptozotocin	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
model	NN	I-NP	O
in	IN	B-PP	O
Nrf2	NN	B-NP	O
mice	NNS	I-NP	O
,	,	O	O
and	CC	O	O
cultured	VBN	B-VP	O
human	JJ	B-NP	O
mesangial	JJ	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
glomeruli	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
patients	NNS	I-NP	O
were	VBD	B-VP	O
under	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
elevated	VBN	I-VP	O
Nrf2	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
animal	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
Nrf2	NN	B-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
crucial	JJ	B-ADJP	O
in	IN	B-PP	O
ameliorating	VBG	B-VP	O
streptozotocin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
damage	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
evident	JJ	B-ADJP	O
by	IN	B-PP	O
Nrf2	NN	B-NP	O
mice	NNS	I-NP	O
having	VBG	B-VP	O
higher	JJR	B-NP	O
ROS	NN	I-NP	O
production	NN	I-NP	O
and	CC	O	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
greater	JJR	B-NP	O
oxidative	JJ	I-NP	O
DNA	NN	I-NP	O
damage	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
compared	VBN	B-PP	O
with	IN	B-PP	O
Nrf2	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Mechanistic	JJ	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
both	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
and	CC	O	O
in	FW	B-NP	O
vitro	FW	I-NP	O
systems	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
Nrf2	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
protection	NN	I-NP	O
against	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
is	VBZ	B-VP	O
,	,	O	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
,	,	O	O
partially	RB	B-ADVP	O
through	IN	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
transforming	VBG	B-VP	O
growth	NN	B-NP	O
factor	NN	I-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
(	(	O	O
TGF	NN	B-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
)	)	O	O
and	CC	O	O
reduction	NN	B-NP	O
of	IN	B-PP	O
extracellular	JJ	B-NP	O
matrix	NN	I-NP	O
production	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
human	JJ	B-NP	O
renal	JJ	I-NP	O
mesangial	JJ	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
high	JJ	B-NP	O
glucose	NN	I-NP	O
induced	VBD	B-VP	O
ROS	NN	B-NP	O
production	NN	I-NP	O
and	CC	O	O
activated	VBN	B-VP	O
expression	NN	B-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
downstream	JJ	I-NP	O
genes	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
activation	NN	B-NP	O
or	CC	O	O
overexpression	NN	B-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
promoter	NN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
TGF	NN	B-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
knockdown	NN	B-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
by	IN	B-PP	O
siRNA	NN	B-NP	O
enhanced	VBD	B-VP	O
TGF	NN	B-NP	O
-	HYPH	B-NP	O
beta1	NN	I-NP	O
transcription	NN	I-NP	O
and	CC	O	O
fibronectin	NN	B-NP	O
production	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
work	NN	I-NP	O
clearly	RB	B-ADVP	O
indicates	VBZ	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
in	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
dietary	JJ	B-NP	O
or	CC	I-NP	O
therapeutic	JJ	I-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
Nrf2	NN	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
strategy	NN	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
or	CC	I-VP	O
slow	VB	I-VP	O
down	RP	B-PRT	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
tranexamic	JJ	I-NP	O
Acid	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
nonischemic	JJ	B-NP	O
clinical	JJ	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
cardiac	JJ	B-NP	O
surgical	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
centers	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
observed	VBD	B-VP	O
a	DT	B-NP	O
notable	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
convulsive	JJ	I-NP	B
seizures	NNS	I-NP	B
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
having	VBG	B-VP	O
undergone	VBN	I-VP	O
major	JJ	B-NP	O
cardiac	JJ	I-NP	O
surgical	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
temporally	RB	B-ADJP	O
coincident	JJ	I-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
tranexamic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
TXA	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
after	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
aprotinin	NN	B-NP	O
from	IN	B-PP	O
general	JJ	B-NP	O
clinical	JJ	I-NP	O
usage	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
review	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
perform	VB	I-VP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
analysis	NN	I-NP	O
to	TO	B-VP	O
examine	VB	I-VP	O
whether	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
relation	NN	I-NP	O
between	IN	B-PP	O
TXA	NN	B-NP	O
usage	NN	I-NP	O
and	CC	O	O
seizures	NNS	B-NP	B
after	IN	B-PP	O
cardiac	JJ	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
in	IN	B-PP	O
-	HYPH	B-NP	O
depth	NN	I-NP	O
chart	NN	I-NP	O
review	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
perioperative	JJ	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Electroencephalographic	JJ	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
recorded	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
all	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
formal	JJ	I-NP	O
neurological	JJ	I-NP	O
evaluation	NN	I-NP	O
and	CC	I-NP	O
brain	NN	I-NP	O
imaging	NN	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
cerebral	JJ	I-NP	B
ischemic	JJ	I-NP	I
injury	NN	I-NP	I
,	,	O	O
but	CC	O	O
seizures	NNS	B-NP	B
were	VBD	B-VP	O
likely	RB	B-ADJP	O
due	JJ	I-ADJP	O
to	TO	B-PP	O
ischemic	JJ	B-NP	B
brain	NN	I-NP	I
injury	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
seizures	NNS	B-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
permanent	JJ	B-NP	O
neurological	JJ	I-NP	B
abnormalities	NNS	I-NP	I
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
seizures	NNS	B-NP	B
received	VBD	B-VP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
TXA	NN	B-NP	O
intraoperatively	RB	B-VP	O
ranging	VBG	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
open	JJ	B-NP	O
chamber	NN	I-NP	O
rather	RB	B-PP	O
than	IN	I-PP	O
coronary	JJ	B-NP	O
bypass	NN	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
but	IN	I-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
were	VBD	B-VP	O
managed	VBN	I-VP	O
using	VBG	B-VP	O
cardiopulmonary	JJ	B-NP	O
bypass	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	B
ischemic	JJ	I-NP	I
,	,	I-NP	O
metabolic	JJ	I-NP	O
,	,	I-NP	O
or	CC	I-NP	O
hyperthermia	NN	I-NP	B
-	HYPH	O	O
induced	VBN	B-NP	O
causes	NNS	I-NP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
seizures	NNS	I-NP	B
was	VBD	B-VP	O
apparent	JJ	B-ADJP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
use	NN	B-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
TXA	NN	I-NP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
cardiopulmonary	JJ	B-NP	O
bypass	NN	I-NP	O
and	CC	O	O
open	JJ	B-NP	O
-	HYPH	I-NP	O
chamber	NN	I-NP	O
cardiac	JJ	I-NP	O
surgery	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
susceptible	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Recurrent	JJ	B-NP	O
dysosmia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
pyrazinamide	NN	B-NP	O
.	.	O	O

Pyrazinamide	NN	B-NP	O
can	MD	B-VP	O
have	VB	I-VP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
hepatic	JJ	B-NP	B
toxicity	NN	I-NP	I
,	,	O	O
hyperuricemia	NN	B-NP	B
or	CC	O	O
digestive	JJ	B-NP	O
disorders	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
rare	JJ	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
taste	NN	B-NP	O
and	CC	I-NP	O
smell	NN	I-NP	O
function	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
for	IN	B-PP	O
pyrazinamide	NN	B-NP	O
when	WRB	B-ADVP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
reversible	JJ	B-NP	O
olfactory	JJ	I-NP	B
disorder	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
pyrazinamide	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
rechallenge	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
every	DT	B-NP	O
day	NN	I-NP	O
a	DT	B-NP	O
sensation	NN	I-NP	O
of	IN	B-PP	O
smelling	VBG	B-VP	O
something	NN	B-NP	O
burning	VBG	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
intake	NN	I-NP	O
.	.	O	O

Dysosmia	NN	B-NP	B
disappeared	VBD	B-VP	O
completely	RB	B-ADVP	O
after	IN	B-PP	O
pyrazinamide	NN	B-NP	O
withdrawal	NN	I-NP	O
and	CC	O	O
recurred	VBD	B-VP	O
after	IN	B-PP	O
its	PRP$	B-NP	O
rechallenge	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
was	VBD	B-VP	O
reported	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
Tunisian	NNP	I-NP	O
Centre	NNP	I-NP	O
of	IN	B-PP	O
Pharmacovigilance	NNP	B-NP	O
.	.	O	O

Longitudinal	JJ	B-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
air	NN	B-NP	O
conduction	NN	I-NP	O
audiograms	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
difluoromethylornithine	NN	B-NP	O
and	CC	I-NP	O
sulindac	NN	I-NP	O
for	IN	B-PP	O
prevention	NN	B-NP	O
of	IN	B-PP	O
sporadic	JJ	B-NP	O
colorectal	JJ	I-NP	B
adenomas	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
adenomatous	JJ	B-NP	B
polyps	NNS	I-NP	I
after	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
with	IN	B-PP	O
difluoromethylornithine	NN	B-NP	O
(	(	O	O
DFMO	NN	B-NP	O
)	)	O	O
plus	CC	O	O
sulindac	NN	B-NP	O
or	CC	O	O
matched	VBN	B-NP	O
placebos	NNS	I-NP	O
.	.	O	O

Temporary	JJ	B-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
known	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
DFMO	NN	B-NP	O
,	,	O	O
thus	RB	B-ADVP	O
a	DT	B-NP	O
comprehensive	JJ	I-NP	O
approach	NN	I-NP	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
to	TO	I-VP	O
analyze	VB	I-VP	O
serial	JJ	B-NP	O
air	NN	I-NP	O
conduction	NN	I-NP	O
audiograms	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
generalized	VBN	I-NP	O
estimating	NN	I-NP	O
equation	NN	I-NP	O
method	NN	I-NP	O
estimated	VBD	B-VP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
treatment	NN	B-NP	O
arms	NNS	I-NP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-VP	O
change	VB	I-VP	O
in	IN	B-PP	O
air	NN	B-NP	O
conduction	NN	I-NP	O
pure	JJ	I-NP	O
tone	NN	I-NP	O
thresholds	NNS	I-NP	O
while	IN	B-SBAR	O
accounting	VBG	B-VP	O
for	IN	B-PP	O
within	IN	B-PP	O
-	HYPH	B-NP	O
subject	NN	I-NP	O
correlation	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
repeated	VBN	B-NP	O
measurements	NNS	I-NP	O
at	IN	B-PP	O
frequencies	NNS	B-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
an	DT	B-NP	O
average	JJ	I-NP	O
difference	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
dB	NN	I-NP	O
between	IN	B-PP	O
subjects	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
DFMO	NN	B-NP	O
plus	CC	I-NP	O
sulindac	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
adjusted	VBN	B-VP	O
for	IN	B-PP	O
baseline	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
and	CC	O	O
frequencies	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
speech	NN	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
Hz	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
estimated	VBN	I-NP	O
difference	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
dB	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
.	.	O	O

Dose	NN	B-NP	O
intensity	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
add	VB	I-VP	O
information	NN	B-NP	O
to	TO	B-PP	O
models	NNS	B-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
DFMO	NN	I-NP	O
plus	CC	I-NP	O
sulindac	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
dB	NN	I-NP	O
hearing	NN	I-NP	O
reduction	NN	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
consecutive	JJ	I-NP	O
frequencies	NNS	I-NP	O
across	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
range	NN	I-NP	O
tested	VBN	B-VP	O
.	.	O	O

Follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
air	NN	B-NP	O
conduction	NN	I-NP	O
done	VBN	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
end	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
adjusted	VBN	I-NP	O
mean	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
hearing	VBG	B-VP	O
thresholds	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
dB	NN	I-NP	O
between	IN	B-PP	O
treatment	NN	B-NP	O
arms	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
subjects	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
DFMO	NN	I-NP	O
plus	CC	I-NP	O
sulindac	NN	I-NP	O
group	NN	I-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
compared	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
estimated	VBN	I-NP	O
attributable	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
ototoxicity	NN	B-NP	B
from	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
<	SYM	I-NP	O
num	CD	I-NP	O
dB	NN	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
DFMO	NN	B-NP	O
plus	CC	I-NP	O
sulindac	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

Increased	VBN	B-NP	O
mental	JJ	I-NP	B
slowing	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
APOE	NN	I-NP	O
epsilon4	NN	I-NP	O
allele	NN	I-NP	O
after	IN	B-PP	O
trihexyphenidyl	NN	B-NP	O
oral	JJ	I-NP	O
anticholinergic	JJ	I-NP	O
challenge	NN	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
elderly	JJ	I-NP	O
.	.	O	O

The	DT	B-NP	O
objectives	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
to	TO	I-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
APOE	NN	B-NP	O
epsilon4	NN	I-NP	O
and	CC	O	O
subjective	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
trihexyphenidyl	NN	B-NP	O
on	IN	B-PP	O
measures	NNS	B-NP	O
reflecting	VBG	B-VP	O
sedation	NN	B-NP	O
and	CC	I-NP	O
confusion	NN	I-NP	B
and	CC	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
trihexyphenidyl	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
subjective	JJ	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
objective	JJ	B-NP	O
memory	NN	I-NP	O
performance	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
comprised	VBD	B-VP	O
num	CD	B-NP	O
cognitively	RB	I-NP	O
intact	JJ	I-NP	O
,	,	I-NP	O
health	NN	I-NP	O
elderly	JJ	I-NP	O
adults	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
APOE	NN	I-NP	O
epsilon4	NN	I-NP	O
carriers	NNS	I-NP	O
)	)	O	O
at	IN	B-PP	O
an	DT	B-NP	O
outpatient	NN	I-NP	O
geriatric	JJ	I-NP	O
psychiatry	NN	I-NP	O
research	NN	I-NP	O
clinic	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
way	NN	I-NP	O
,	,	O	O
crossover	VB	B-VP	O
experimental	JJ	B-NP	O
design	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
participants	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
trihexyphenidyl	NN	I-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
administered	VBN	B-VP	O
in	IN	B-PP	O
counterbalanced	JJ	B-NP	O
sequences	NNS	I-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Bond	NNP	B-NP	O
and	CC	I-NP	O
Lader	NNP	I-NP	O
s	VBZ	B-VP	O
visual	JJ	B-NP	O
analog	NN	I-NP	O
scales	NNS	I-NP	O
and	CC	O	O
alternate	JJ	B-NP	O
versions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Buschke	NNP	I-NP	O
Selective	NNP	I-NP	O
Reminding	NNP	I-NP	O
Test	NNP	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
repeated	VBN	I-NP	O
measures	VBZ	B-VP	O
design	NN	B-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
hours	NNS	I-NP	O
postdrug	JJ	I-NP	O
administration	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
oral	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
trihexyphenidyl	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
increased	VBN	B-NP	O
subjective	JJ	I-NP	O
ratings	NNS	I-NP	O
of	IN	B-PP	O
mental	JJ	B-NP	B
slowness	NN	I-NP	I
in	IN	B-PP	O
carriers	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
APOE	NN	I-NP	O
epsilon4	NN	I-NP	O
allele	NN	I-NP	O
only	RB	B-ADVP	O
.	.	O	O

Drug	NN	B-NP	O
effects	NNS	I-NP	O
as	IN	B-SBAR	O
determined	VBN	B-VP	O
by	IN	B-PP	O
difference	NN	B-NP	O
scores	NNS	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
trihexyphenidyl	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
on	IN	B-PP	O
ratings	NNS	B-NP	O
of	IN	B-PP	O
mental	JJ	B-NP	B
slowness	NN	I-NP	I
significantly	RB	B-VP	O
correlated	VBD	I-VP	O
with	IN	B-PP	O
total	JJ	B-NP	O
and	CC	I-NP	O
delayed	VBN	I-NP	O
recall	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Buschke	NNP	I-NP	O
Selective	NNP	I-NP	O
Reminding	NNP	I-NP	O
Test	NNP	I-NP	O
in	IN	B-PP	O
carriers	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
APOE	NN	I-NP	O
epsilon4	NN	I-NP	O
allele	NN	I-NP	O
only	RB	B-ADVP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
significant	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
with	IN	B-PP	O
other	JJ	B-NP	O
visual	JJ	I-NP	O
analog	NN	I-NP	O
scales	NNS	I-NP	O
reflecting	VBG	B-VP	O
subjective	JJ	B-NP	O
sedation	NN	I-NP	O
and	CC	O	O
clear	JJ	B-NP	O
-	HYPH	I-NP	O
headedness	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
epsilon4	NN	I-NP	O
allele	NN	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
elderly	JJ	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
subjective	JJ	I-NP	O
mental	JJ	I-NP	B
slowing	NN	I-NP	I
after	IN	B-PP	O
trihexyphenidyl	NN	B-NP	O
anticholinergic	JJ	I-NP	O
challenge	NN	I-NP	O
.	.	O	O

Behavioral	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
pubertal	JJ	B-NP	O
anabolic	JJ	I-NP	O
androgenic	JJ	I-NP	O
steroid	NN	I-NP	O
exposure	NN	I-NP	O
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
serotonin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
interactive	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
anabolic	JJ	I-NP	O
androgenic	JJ	I-NP	O
steroid	NN	I-NP	O
(	(	O	O
AAS	NN	B-NP	O
)	)	O	O
exposure	NN	B-NP	O
and	CC	O	O
brain	NN	B-NP	O
serotonin	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytryptamine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
)	)	O	O
depletion	NN	B-NP	O
on	IN	B-PP	O
behavior	NN	B-NP	O
of	IN	B-PP	O
pubertal	JJ	B-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Serotonin	NN	B-NP	O
was	VBD	B-VP	O
depleted	VBN	I-VP	O
beginning	VBG	B-PP	O
on	IN	B-PP	O
postnatal	JJ	B-NP	O
day	NN	I-NP	O
num	CD	I-NP	O
with	IN	B-PP	O
parachlorophenylalanine	NN	B-NP	O
;	:	O	O
controls	NNS	B-NP	O
received	VBD	B-VP	O
saline	NN	B-NP	O
.	.	O	O

At	IN	B-PP	O
puberty	NN	B-NP	O
(	(	O	O
P40	NN	B-NP	O
)	)	O	O
,	,	O	O
half	PDT	B-NP	O
the	DT	I-NP	O
PCPA	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
and	CC	O	O
half	PDT	B-NP	O
the	DT	I-NP	O
saline	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
began	VBD	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
testosterone	NN	B-NP	O
.	.	O	O

Behavioral	JJ	B-NP	O
measures	NNS	I-NP	O
included	VBD	B-VP	O
locomotion	NN	B-NP	O
,	,	O	O
irritability	NN	B-NP	B
,	,	O	O
copulation	NN	B-NP	O
,	,	O	O
partner	NN	B-NP	O
preference	NN	I-NP	O
,	,	O	O
and	CC	O	O
aggression	NN	B-NP	B
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
aggression	NN	B-NP	B
in	IN	B-PP	O
their	PRP$	B-NP	O
home	NN	I-NP	O
cage	NN	I-NP	O
,	,	O	O
both	CC	B-PP	O
with	IN	I-PP	O
and	CC	O	O
without	IN	B-PP	O
physical	JJ	B-NP	O
provocation	NN	I-NP	O
(	(	O	O
mild	JJ	B-NP	O
tail	NN	I-NP	O
pinch	NN	I-NP	O
)	)	O	O
.	.	O	O

Brain	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
metabolite	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxyindoleacetic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HIAA	NN	I-NP	O
)	)	O	O
,	,	O	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
using	VBG	B-VP	O
HPLC	NN	B-NP	O
.	.	O	O

PCPA	NN	B-NP	O
significantly	RB	B-VP	O
and	CC	I-VP	O
substantially	RB	I-VP	O
depleted	VBD	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HIAA	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
examined	VBN	B-VP	O
.	.	O	O

Chronic	JJ	B-NP	O
T	NN	I-NP	O
treatment	NN	I-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HIAA	NN	I-NP	O
in	IN	B-PP	O
certain	JJ	B-NP	O
brain	NN	I-NP	O
areas	NNS	I-NP	O
,	,	O	O
but	CC	O	O
to	TO	B-PP	O
a	DT	B-NP	O
much	RB	I-NP	O
lesser	JJR	I-NP	O
extent	NN	I-NP	O
than	IN	B-PP	O
PCPA	NN	B-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
PCPA	NN	B-NP	O
alone	RB	B-ADVP	O
significantly	RB	B-VP	O
decreased	VBD	I-VP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
irritability	NN	B-NP	B
but	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
sexual	JJ	B-NP	O
behavior	NN	I-NP	O
,	,	O	O
partner	NN	B-NP	O
preference	NN	I-NP	O
,	,	O	O
or	CC	O	O
aggression	NN	B-NP	B
.	.	O	O

T	NN	B-NP	O
alone	RB	B-ADVP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
locomotion	NN	B-NP	O
,	,	O	O
irritability	NN	B-NP	B
,	,	O	O
or	CC	O	O
sexual	JJ	B-NP	O
behavior	NN	I-NP	O
but	CC	O	O
increased	VBD	B-VP	O
partner	NN	B-NP	O
preference	NN	I-NP	O
and	CC	I-NP	O
aggression	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
striking	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
combining	VBG	B-VP	O
T+PCPA	NN	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
attack	NN	B-NP	O
frequency	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
latency	NN	I-NP	O
to	TO	B-VP	O
attack	VB	I-VP	O
,	,	O	O
particularly	RB	B-ADVP	O
following	VBG	B-PP	O
physical	JJ	B-NP	O
provocation	NN	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
these	DT	B-NP	O
data	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
speculated	VBN	I-VP	O
that	IN	B-SBAR	O
pubertal	JJ	B-NP	O
AAS	NN	I-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
central	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
especially	RB	B-ADJP	O
prone	JJ	I-ADJP	O
to	TO	B-VP	O
exhibit	VB	I-VP	O
aggressive	JJ	B-NP	B
behavior	NN	I-NP	I
.	.	O	O

Intracavitary	JJ	B-NP	O
chemotherapy	NN	I-NP	O
(	(	O	O
paclitaxel	NN	B-NP	O
/	SYM	O	O
carboplatin	NN	B-NP	O
liquid	JJ	I-NP	O
crystalline	NN	I-NP	O
cubic	JJ	I-NP	O
phases	NNS	I-NP	O
)	)	O	O
for	IN	B-PP	O
recurrent	JJ	B-NP	O
glioblastoma	NN	I-NP	B
-	HYPH	O	O
-	HYPH	O	O
clinical	JJ	B-NP	O
observations	NNS	I-NP	O
.	.	O	O

Human	JJ	B-NP	O
malignant	JJ	I-NP	O
brain	NN	I-NP	B
tumors	NNS	I-NP	I
have	VBP	B-VP	O
a	DT	B-NP	O
poor	JJ	I-NP	O
prognosis	NN	I-NP	O
in	IN	B-PP	O
spite	NN	B-NP	O
of	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	I-NP	O
radiation	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Cubic	JJ	B-NP	O
phases	NNS	I-NP	O
consist	VBP	B-VP	O
of	IN	B-PP	O
curved	VBN	B-NP	O
biocontinuous	JJ	I-NP	O
lipid	NN	I-NP	O
bilayers	NNS	I-NP	O
,	,	O	O
separating	VBG	B-VP	O
num	CD	B-NP	O
congruent	JJ	I-NP	O
networks	NNS	I-NP	O
of	IN	B-PP	O
water	NN	B-NP	O
channels	NNS	I-NP	O
.	.	O	O

Used	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
host	NN	I-NP	O
for	IN	B-PP	O
cytotoxic	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
gel	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
matrix	NN	I-NP	O
can	MD	B-VP	O
easily	RB	I-VP	O
be	VB	I-VP	O
applied	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
walls	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
surgical	JJ	I-NP	O
resection	NN	I-NP	O
cavity	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
human	JJ	B-NP	O
glioblastoma	NN	I-NP	B
recurrences	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
feasibility	NN	I-NP	O
,	,	O	O
safety	NN	B-NP	O
,	,	O	O
and	CC	O	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
surgical	JJ	I-NP	O
intracavitary	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
and	CC	I-NP	O
carboplatin	NN	I-NP	O
encapsulated	VBN	B-VP	O
by	IN	B-PP	O
liquid	JJ	B-NP	O
crystalline	NN	I-NP	O
cubic	JJ	I-NP	O
phases	NNS	I-NP	O
are	VBP	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
glioblastoma	NN	I-NP	B
multiforme	NN	I-NP	O
underwent	VBD	B-VP	O
re	AFX	B-NP	O
-	HYPH	I-NP	O
resection	NN	I-NP	O
and	CC	O	O
received	VBD	B-VP	O
an	DT	B-NP	O
intracavitary	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
and	CC	O	O
carboplatin	NN	B-NP	O
cubic	JJ	I-NP	O
phases	NNS	I-NP	O
in	IN	B-PP	O
different	JJ	B-NP	O
dosages	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
paclitaxel	NN	I-NP	O
and	CC	O	O
suffered	VBD	B-VP	O
from	IN	B-PP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
brain	NN	I-NP	B
edema	NN	I-NP	I
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
remaining	VBG	I-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
only	RB	B-NP	O
a	DT	I-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
paclitaxel	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
latter	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
brain	NN	B-NP	B
edema	NN	I-NP	I
was	VBD	B-VP	O
markedly	RB	I-VP	O
reduced	VBN	I-VP	O
and	CC	O	O
dealt	VBN	B-VP	O
medically	RB	B-ADVP	O
.	.	O	O

Intracavitary	JJ	B-NP	O
chemotherapy	NN	I-NP	O
in	IN	B-PP	O
recurrent	JJ	B-NP	O
glioblastoma	NN	I-NP	B
using	VBG	B-VP	O
cubic	JJ	B-NP	O
phases	NNS	I-NP	O
is	VBZ	B-VP	O
feasible	JJ	B-ADJP	O
and	CC	I-ADJP	O
safe	JJ	I-ADJP	O
,	,	O	O
yet	RB	B-ADVP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
benefit	NN	I-NP	O
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
.	.	O	O

Methylphenidate	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
obsessive	JJ	I-NP	B
-	HYPH	I-NP	I
compulsive	JJ	I-NP	I
symptoms	NNS	I-NP	I
in	IN	B-PP	O
an	DT	B-NP	O
elderly	JJ	I-NP	O
man	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
treatment	NN	B-NP	B
-	HYPH	B-NP	I
resistant	JJ	I-NP	I
depression	NN	I-NP	I
and	CC	O	O
early	JJ	B-NP	O
Alzheimer	NNP	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
was	VBD	B-VP	O
started	VBN	I-VP	O
on	IN	B-PP	O
methylphenidate	NN	B-NP	O
.	.	O	O

Significant	JJ	B-NP	O
obsessive	JJ	I-NP	B
-	HYPH	I-NP	I
compulsive	JJ	I-NP	I
behavior	NN	I-NP	I
ensued	VBD	B-VP	O
but	CC	I-VP	O
diminished	VBD	I-VP	O
over	IN	B-PP	O
several	JJ	B-NP	O
weeks	NNS	I-NP	O
when	WRB	B-ADVP	O
methylphenidate	NN	B-NP	O
was	VBD	B-VP	O
replaced	VBN	I-VP	O
by	IN	B-PP	O
fluvoxamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
prior	JJ	I-NP	O
psychiatric	JJ	I-NP	B
history	NN	I-NP	O
,	,	O	O
but	CC	O	O
he	PRP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
sister	NN	I-NP	O
with	IN	B-PP	O
obsessive	JJ	B-NP	B
-	HYPH	I-NP	I
compulsive	JJ	I-NP	I
disorder	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
appears	VBZ	B-VP	O
that	IN	B-SBAR	O
methylphenidate	NN	B-NP	O
precipitated	VBD	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
pathological	JJ	B-NP	O
behavior	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
after	IN	B-PP	O
intravenous	JJ	B-NP	O
metoclopramide	NN	I-NP	O
-	HYPH	O	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
repeated	VBN	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
metoclopramide	NN	B-NP	O
causing	VBG	B-VP	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
where	WRB	B-ADVP	O
intravenous	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
metoclopramide	NN	B-NP	O
was	VBD	B-VP	O
immediately	RB	I-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
asystole	NN	B-NP	B
repeatedly	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
received	VBD	B-VP	O
metoclopramide	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
i.v.	JJ	I-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
interviewing	VBG	B-VP	O
the	DT	B-NP	O
attending	VBG	I-NP	O
nurses	NNS	I-NP	O
and	CC	O	O
reviewing	VBG	B-VP	O
the	DT	B-NP	O
written	VBN	I-NP	O
documentation	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
clear	JJ	B-ADJP	O
that	IN	B-SBAR	O
every	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
metoclopramide	NN	B-NP	O
was	VBD	B-VP	O
immediately	RB	B-ADVP	O
(	(	O	O
within	IN	B-PP	O
s	NNS	B-NP	O
)	)	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
asystole	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
asystole	NN	I-NP	B
lasted	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
occasions	NNS	I-NP	O
,	,	O	O
on	IN	B-PP	O
num	CD	B-NP	O
occasion	NN	I-NP	O
it	PRP	B-NP	O
lasted	VBD	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
received	VBD	B-VP	O
atropine	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
and	CC	I-NP	O
chest	NN	I-NP	O
compressions	NNS	I-NP	O
,	,	O	O
before	IN	B-PP	O
sinus	NN	B-NP	O
rhythm	NN	I-NP	O
again	RB	B-ADVP	O
took	VBD	B-VP	O
over	RP	B-PRT	O
.	.	O	O

We	PRP	B-NP	O
interpret	VBP	B-VP	O
this	DT	B-NP	O
as	IN	B-PP	O
episodes	NNS	B-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
metoclopramide	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
rapid	JJ	I-NP	O
injection	NN	I-NP	O
via	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
venous	JJ	I-NP	O
route	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
concomitant	JJ	I-NP	O
tapering	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
infusion	NN	I-NP	O
might	MD	B-VP	O
have	VB	I-VP	O
contributed	VBN	I-VP	O
in	IN	B-PP	O
precipitating	VBG	B-VP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
immune	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
prophylactic	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cefotetan	NN	B-NP	O
in	IN	B-PP	O
obstetric	JJ	B-NP	O
and	CC	I-NP	O
gynecologic	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

Second	JJ	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
third	JJ	I-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
cephalosporins	NNS	I-NP	O
,	,	O	O
especially	RB	B-NP	O
cefotetan	NN	I-NP	O
,	,	O	O
are	VBP	B-VP	O
increasingly	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
,	,	I-NP	O
sometimes	RB	I-NP	O
fatal	JJ	I-NP	O
immune	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
noticed	VBD	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
cefotetan	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hemolytic	JJ	I-NP	B
anemias	NNS	I-NP	I
were	VBD	B-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
cefotetan	NN	B-NP	O
prophylactically	RB	B-ADVP	O
for	IN	B-PP	O
obstetric	JJ	B-NP	O
and	CC	I-NP	O
gynecologic	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
immune	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
are	VBP	B-VP	O
described	VBN	I-VP	O
.	.	O	O

Cauda	NNP	B-NP	B
equina	NNP	I-NP	I
syndrome	NN	I-NP	I
after	IN	B-PP	O
spinal	JJ	B-NP	O
anaesthesia	NN	I-NP	O
with	IN	B-PP	O
hyperbaric	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lignocaine	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
cauda	NN	B-NP	B
equina	NN	I-NP	I
syndrome	NN	I-NP	I
reported	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
Swedish	NNP	I-NP	O
Pharmaceutical	NNP	I-NP	O
Insurance	NNP	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
cauda	NN	B-NP	B
equina	NN	I-NP	I
syndrome	NN	I-NP	I
with	IN	B-PP	O
varying	VBG	B-NP	O
severity	NN	I-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
Swedish	NNP	I-NP	O
Pharmaceutical	NNP	I-NP	O
Insurance	NNP	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
period	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
.	.	O	O

All	DT	B-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
spinal	JJ	B-NP	O
anaesthesia	NN	I-NP	O
using	VBG	B-VP	O
hyperbaric	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lignocaine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
had	VBD	B-VP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
shot	NN	I-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
repeat	NN	I-NP	O
spinal	JJ	I-NP	O
anaesthetic	NN	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
inadequate	JJ	B-NP	O
block	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
hyperbaric	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lignocaine	NN	I-NP	O
administered	VBN	B-VP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
most	RBS	I-VP	O
likely	RB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
direct	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
of	IN	B-PP	O
hyperbaric	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lignocaine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
direct	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
was	VBD	B-VP	O
also	RB	B-ADVP	O
probable	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
unfortunately	RB	B-NP	O
radiological	JJ	I-NP	O
investigations	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
done	VBN	I-VP	O
to	TO	B-VP	O
definitely	RB	I-VP	O
exclude	VB	I-VP	O
a	DT	B-NP	O
compressive	JJ	I-NP	O
aetiology	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
cases	NNS	I-NP	O
sustained	VBD	B-VP	O
permanent	JJ	B-NP	O
neurological	JJ	I-NP	B
deficits	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
recommend	VBP	B-VP	O
that	IN	B-SBAR	O
hyperbaric	JJ	B-NP	O
lignocaine	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
concentrations	NNS	B-NP	O
not	RB	B-ADJP	O
greater	JJR	I-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
a	DT	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
preferably	RB	B-VP	O
not	RB	I-VP	O
exceeding	VBG	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
.	.	O	O

Cortical	JJ	B-NP	O
motor	NN	I-NP	O
overactivation	NN	I-NP	O
in	IN	B-PP	O
parkinsonian	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
peak	NN	I-NP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
dyskinesia	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
studied	VBN	I-VP	O
the	DT	B-NP	O
regional	JJ	I-NP	O
cerebral	JJ	I-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
(	(	O	O
rCBF	NN	B-NP	O
)	)	O	O
changes	NNS	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
execution	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
finger	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
thumb	NN	I-NP	O
opposition	NN	I-NP	O
motor	NN	I-NP	O
task	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
supplementary	JJ	I-NP	O
and	CC	I-NP	O
primary	JJ	I-NP	O
motor	NN	I-NP	O
cortex	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
parkinsonian	JJ	B-NP	B
patients	NNS	I-NP	O
on	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
medication	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
one	NN	I-NP	O
without	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
dopa	NN	I-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
with	IN	B-PP	O
moderate	JJ	B-NP	O
peak	NN	I-NP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
dyskinesia	NN	I-NP	B
,	,	O	O
and	CC	O	O
of	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
normal	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Single	JJ	B-NP	O
photon	NN	I-NP	O
emission	NN	I-NP	O
tomography	NN	I-NP	O
with	IN	B-PP	O
i.v.	JJ	B-NP	O
133Xe	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
measure	VB	I-VP	O
the	DT	B-NP	O
rCBF	NN	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
dyskinetic	JJ	I-NP	B
parkinsonian	JJ	I-NP	B
patients	NNS	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
markedly	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
dyskinetic	JJ	I-NP	B
parkinsonian	JJ	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
overactivation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
supplementary	JJ	I-NP	O
motor	NN	I-NP	O
area	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
ipsi	AFX	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
contralateral	JJ	I-NP	O
primary	JJ	I-NP	O
motor	NN	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
compatible	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
hyperkinetic	JJ	I-NP	B
abnormal	JJ	I-NP	B
involuntary	JJ	I-NP	I
movement	NN	I-NP	I
,	,	O	O
like	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
peak	NN	I-NP	O
dose	NN	I-NP	O
dyskinesia	NN	I-NP	B
,	,	O	O
is	VBZ	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
disinhibition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
and	CC	I-NP	O
associated	VBN	I-NP	O
motor	NN	I-NP	O
cortex	NN	I-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
an	DT	B-NP	O
excessive	JJ	I-NP	O
outflow	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pallidothalamocortical	JJ	I-NP	O
motor	NN	I-NP	O
loop	NN	I-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ocular	JJ	I-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
perfusion	NN	B-NP	O
-	HYPH	O	O
cultured	VBN	B-NP	O
human	JJ	I-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Glucocorticoid	NN	B-NP	O
administration	NN	I-NP	O
can	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
ocular	JJ	B-NP	B
hypertension	NN	I-NP	I
and	CC	I-NP	O
corticosteroid	NN	I-NP	B
glaucoma	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
subset	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
population	NN	I-NP	O
through	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
aqueous	JJ	I-NP	O
humor	NN	I-NP	O
outflow	NN	I-NP	O
facility	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
glucocorticoid	NN	B-NP	O
treatment	NN	I-NP	O
can	MD	B-VP	O
directly	RB	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
outflow	NN	I-NP	O
facility	NN	I-NP	O
of	IN	B-PP	O
isolated	VBN	B-NP	O
,	,	I-NP	O
perfusion	NN	I-NP	O
-	HYPH	I-NP	O
cultured	VBN	B-NP	O
human	JJ	I-NP	O
eyes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
anterior	JJ	I-NP	O
segments	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
donor	NN	I-NP	O
eyes	NNS	I-NP	O
from	IN	B-PP	O
regional	JJ	B-NP	O
eye	NN	I-NP	O
banks	NNS	I-NP	O
were	VBD	B-VP	O
placed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
constant	JJ	I-NP	O
flow	NN	I-NP	O
,	,	O	O
variable	JJ	B-NP	O
pressure	NN	I-NP	O
perfusion	NN	I-NP	O
culture	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

Paired	VBN	B-NP	O
eyes	NNS	I-NP	O
were	VBD	B-VP	O
perfused	VBN	I-VP	O
in	IN	B-PP	O
serum	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
media	NNS	I-NP	O
with	IN	B-PP	O
or	CC	B-NP	O
without	IN	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
dexamethasone	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Intraocular	JJ	B-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
monitored	VBN	I-VP	O
daily	RB	B-ADVP	O
.	.	O	O

After	IN	B-PP	O
incubation	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
eyes	NNS	I-NP	O
were	VBD	B-VP	O
morphologically	RB	I-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
light	NN	B-NP	O
microscopy	NN	I-NP	O
,	,	O	O
transmission	NN	B-NP	O
and	CC	O	O
scanning	NN	B-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
,	,	O	O
and	CC	O	O
scanning	NN	B-NP	O
laser	NN	I-NP	O
confocal	JJ	I-NP	O
microscopy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
intraocular	JJ	B-NP	O
pressure	NN	I-NP	O
developed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
pairs	NNS	I-NP	O
of	IN	B-PP	O
eyes	NNS	B-NP	O
perfused	VBN	B-VP	O
with	IN	B-PP	O
dexamethasone	NN	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
pressure	NN	I-NP	O
rise	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
contralateral	JJ	I-NP	O
control	NN	I-NP	O
eyes	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
receive	VB	I-VP	O
dexamethasone	NN	B-NP	O
,	,	O	O
maintained	VBD	B-VP	O
a	DT	B-NP	O
stable	JJ	I-NP	O
intraocular	JJ	I-NP	O
pressure	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
outflow	NN	I-NP	O
pathway	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
untreated	JJ	I-NP	O
eyes	NNS	I-NP	O
appeared	VBD	B-VP	O
morphologically	RB	B-ADJP	O
normal	JJ	I-ADJP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
dexamethasone	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
hypertensive	JJ	B-NP	B
eyes	NNS	I-NP	I
had	VBD	B-VP	O
thickened	VBN	I-VP	O
trabecular	JJ	B-NP	O
beams	NNS	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
intertrabecular	JJ	B-NP	O
spaces	NNS	I-NP	O
,	,	O	O
thickened	VBD	B-VP	O
juxtacanalicular	JJ	B-NP	O
tissue	NN	I-NP	O
,	,	O	O
activated	VBN	B-NP	O
trabecular	JJ	I-NP	O
meshwork	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
and	CC	O	O
increased	VBN	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
amorphogranular	JJ	B-NP	O
extracellular	JJ	I-NP	O
material	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
juxtacanalicular	JJ	I-NP	O
tissue	NN	I-NP	O
and	CC	B-PP	O
beneath	IN	B-PP	O
the	DT	B-NP	O
endothelial	JJ	I-NP	O
lining	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
canal	NN	I-NP	O
of	IN	B-PP	O
Schlemm	NNP	B-NP	O
.	.	O	O

The	DT	B-NP	O
dexamethasone	NN	I-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
nonresponder	JJ	I-NP	O
eyes	NNS	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
morphologically	RB	B-ADJP	O
similar	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
untreated	JJ	I-NP	O
eyes	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
several	JJ	B-NP	O
subtle	JJ	I-NP	O
dexamethasone	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
morphologic	JJ	I-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
evident	JJ	B-ADJP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
isolated	VBN	B-NP	O
,	,	I-NP	O
perfusion	NN	I-NP	O
-	HYPH	I-NP	O
cultured	VBN	B-NP	O
human	JJ	I-NP	O
eyes	NNS	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
generation	NN	I-NP	O
of	IN	B-PP	O
ocular	JJ	B-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dexamethasone	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Steroid	NN	B-NP	O
treatment	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
morphologic	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
trabecular	JJ	I-NP	O
meshwork	NN	I-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
reported	VBN	B-VP	O
for	IN	B-PP	O
corticosteroid	NN	B-NP	B
glaucoma	NN	I-NP	I
and	CC	O	O
open	JJ	B-NP	B
angle	NN	I-NP	I
glaucoma	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
system	NN	I-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
model	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
pathogenic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
steroid	NN	B-NP	B
glaucoma	NN	I-NP	I
and	CC	O	O
primary	JJ	B-NP	B
open	JJ	I-NP	I
angle	NN	I-NP	I
glaucoma	NN	I-NP	I
.	.	O	O

Cognitive	JJ	B-NP	B
deterioration	NN	I-NP	I
from	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
abuse	NN	I-NP	O
of	IN	B-PP	O
dextromethorphan	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Dextromethorphan	NN	B-NP	O
(	(	O	O
DM	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
dextrorotatory	JJ	I-NP	O
isomer	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	I-NP	O
methylmorphinan	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
the	DT	B-NP	O
main	JJ	I-NP	O
ingredient	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
widely	RB	B-ADJP	O
available	JJ	I-ADJP	O
,	,	O	O
over	IN	B-PP	O
-	HYPH	B-NP	O
the	DT	B-NP	O
-	HYPH	I-NP	O
counter	NN	I-NP	O
antitussives	NNS	I-NP	O
.	.	O	O

Initial	JJ	B-NP	O
studies	NNS	I-NP	O
(	(	O	O
Bornstein	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
possessed	VBD	B-VP	O
no	DT	B-NP	O
respiratory	JJ	I-NP	O
suppressant	JJ	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
no	DT	B-NP	O
addiction	NN	I-NP	O
liability	NN	I-NP	O
.	.	O	O

Subsequently	RB	B-ADVP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
several	JJ	B-NP	O
articles	NNS	I-NP	O
reporting	VBG	B-VP	O
abuse	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
have	VBP	B-VP	O
appeared	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
nausea	NN	B-NP	B
,	,	O	O
restlessness	NN	B-NP	B
,	,	O	O
insomnia	NN	B-NP	B
,	,	O	O
ataxia	NN	B-NP	B
,	,	O	O
slurred	VBD	B-VP	O
speech	NN	B-NP	O
and	CC	I-NP	O
nystagmus	NN	I-NP	B
to	TO	B-PP	O
mood	NN	B-NP	O
changes	NNS	I-NP	O
,	,	O	O
perceptual	JJ	B-NP	O
alterations	NNS	I-NP	O
,	,	O	O
inattention	NN	B-NP	O
,	,	O	O
disorientation	NN	B-NP	O
and	CC	O	O
aggressive	JJ	B-NP	B
behavior	NN	I-NP	I
(	(	O	O
Rammer	NN	B-NP	O
et	FW	B-NP	O
al	FW	I-NP	O
num	CD	I-NP	O
;	:	O	O
Katona	NNP	B-NP	O
and	CC	I-NP	O
Watson	NNP	I-NP	O
num	CD	I-NP	O
;	:	O	O
Isbell	NNP	B-NP	O
and	CC	I-NP	O
Fraser	NNP	I-NP	O
num	CD	I-NP	O
;	:	O	O
Devlin	NNP	B-NP	O
et	FW	I-NP	O
al	FW	I-NP	O
num	CD	I-NP	O
;	:	O	O
McCarthy	NNP	B-NP	O
num	CD	I-NP	O
;	:	O	O
Dodds	NNP	B-NP	O
and	CC	I-NP	O
Revai	NNP	I-NP	O
num	CD	I-NP	O
;	:	O	O
Degkwitz	NNP	B-NP	O
num	CD	I-NP	O
;	:	O	O
Hildebrand	NNP	B-NP	O
et	FW	I-NP	O
al	FW	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

There	EX	B-NP	O
have	VBP	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
num	CD	B-NP	O
reported	VBN	I-NP	O
fatalities	NNS	I-NP	O
from	IN	B-PP	O
DM	NN	B-NP	O
overdoses	VBZ	B-VP	O
(	(	O	O
Fleming	VBG	B-VP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
are	VBP	B-VP	O
no	DT	B-NP	O
reports	NNS	I-NP	O
describing	VBG	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
abuse	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	B
deterioration	NN	I-NP	I
resulting	VBG	B-VP	O
from	IN	B-PP	O
prolonged	VBN	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
DM	NN	B-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
lithium	NN	I-NP	O
treatment	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
kidney	NN	I-NP	O
.	.	O	O

Interim	JJ	B-NP	O
report	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
report	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
lithium	NN	I-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
.	.	O	O

Creatinine	NN	B-NP	O
clearance	NN	I-NP	O
,	,	O	O
maximum	JJ	B-NP	O
urinary	JJ	I-NP	O
osmolality	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
hour	NN	I-NP	O
urine	NN	I-NP	O
volume	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
affectively	RB	I-NP	O
ill	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
on	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
lithium	NN	I-NP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
norms	NNS	B-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
values	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
tests	NNS	I-NP	O
from	IN	B-PP	O
screening	VBG	B-VP	O
prior	JJ	B-ADVP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
,	,	O	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
most	JJS	B-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
evidence	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
for	IN	B-PP	O
any	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
during	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
clearance	NN	I-NP	O
values	NNS	I-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
several	JJ	B-NP	O
patients	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
accounted	VBN	I-VP	O
for	IN	B-PP	O
by	IN	B-PP	O
their	PRP$	B-NP	O
age	NN	I-NP	O
and	CC	O	O
their	PRP$	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
lithium	NN	I-NP	O
values	NNS	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
concentration	NN	I-NP	O
defect	NN	I-NP	O
appeared	VBD	B-VP	O
frequent	JJ	B-ADJP	O
but	CC	O	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
impairment	NN	I-NP	O
is	VBZ	B-VP	O
difficult	JJ	B-ADJP	O
to	TO	B-VP	O
assess	VB	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
uncertainty	NN	I-NP	O
about	IN	B-PP	O
the	DT	B-NP	O
norms	NNS	I-NP	O
applicable	JJ	B-ADJP	O
to	TO	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
concentration	NN	I-NP	O
defect	NN	I-NP	O
appeared	VBD	B-VP	O
reversible	JJ	B-ADJP	O
,	,	O	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
in	IN	B-PP	O
part	NN	B-NP	O
.	.	O	O

Polyuria	NN	B-NP	B
above	IN	B-PP	O
num	CD	B-NP	O
litres	NNS	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

An	DT	B-NP	O
attempt	NN	I-NP	O
is	VBZ	B-VP	O
made	VBN	I-VP	O
to	TO	I-VP	O
draw	VB	I-VP	O
practical	JJ	B-NP	O
conclusions	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
preliminary	JJ	I-NP	O
findings	NNS	I-NP	O
.	.	O	O

Complete	JJ	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
following	VBG	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
trazodone	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
starting	VBG	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
trazodone	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
complete	JJ	B-NP	O
heart	NN	I-NP	B
block	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
illustrates	VBZ	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
despite	IN	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
earlier	JJR	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
trazodone	NN	B-NP	O
s	VBZ	B-VP	O
effect	NN	B-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
conduction	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
severe	JJ	B-ADJP	O
in	IN	B-PP	O
individuals	NNS	B-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
for	IN	B-PP	O
conduction	NN	B-NP	O
delay	NN	I-NP	O
.	.	O	O

Quinidine	NN	B-NP	O
phenylethylbarbiturate	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
fulminant	JJ	I-NP	O
hepatitis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
pregnant	JJ	I-NP	O
woman	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Laotian	JJ	I-NP	O
patient	NN	I-NP	O
affected	VBN	B-VP	O
by	IN	B-PP	O
fulminant	JJ	B-NP	O
hepatitis	NN	I-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
trimester	NN	I-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
pregnancy	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
quinidine	NN	B-NP	O
phenylethylbarbiturate	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
delivery	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
underwent	VBD	B-VP	O
orthotopic	JJ	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
in	IN	B-PP	O
good	JJ	B-NP	O
condition	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Quinidine	NN	B-NP	O
itself	PRP	B-NP	O
or	CC	O	O
phenylethylbarbiturate	VB	B-VP	O
may	MD	B-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
fulminant	JJ	B-NP	O
hepatitis	NN	I-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
epidemiology	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
flank	NN	I-NP	B
pain	NN	I-NP	I
syndrome	NN	I-NP	O
from	IN	B-PP	O
suprofen	NN	B-NP	O
.	.	O	O

Suprofen	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
nonsteroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
marketed	VBN	I-VP	O
in	IN	B-PP	O
early	JJ	B-NP	O
num	CD	I-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
analgesic	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Until	IN	B-SBAR	O
physicians	NNS	B-NP	O
began	VBD	B-VP	O
reporting	VBG	I-VP	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
acute	JJ	I-NP	O
flank	NN	I-NP	B
pain	NN	I-NP	I
syndrome	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
spontaneous	JJ	I-NP	O
reporting	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
persons	NNS	I-NP	O
used	VBD	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
.	.	O	O

Through	IN	B-PP	O
August	NNP	B-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

To	TO	B-VP	O
elucidate	VB	I-VP	O
the	DT	B-NP	O
epidemiology	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
syndrome	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
,	,	O	O
comparing	VBG	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
case	NN	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
spontaneous	JJ	I-NP	O
reporting	VBG	I-NP	O
system	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
suprofen	NN	I-NP	O
-	HYPH	O	O
exposed	VBN	B-NP	O
control	NN	I-NP	O
subjects	NNS	I-NP	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
the	DT	B-NP	O
syndrome	NN	I-NP	O
.	.	O	O

Case	NN	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
men	NNS	B-NP	O
(	(	O	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
suffer	VBP	B-VP	O
from	IN	B-PP	O
hay	NN	B-NP	B
fever	NN	I-NP	I
and	CC	O	O
asthma	NN	B-NP	B
(	(	O	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
;	:	O	O
to	TO	B-VP	O
participate	VB	I-VP	O
in	IN	B-PP	O
regular	JJ	B-NP	O
exercise	NN	I-NP	O
(	(	O	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
Nautilus	NN	B-NP	O
equipment	NN	I-NP	O
;	:	O	O
and	CC	O	O
to	TO	B-VP	O
use	VB	I-VP	O
alcohol	NN	B-NP	O
(	(	O	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Possible	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
included	VBD	B-VP	O
young	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
concurrent	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
analgesic	JJ	I-NP	O
agents	NNS	I-NP	O
(	(	O	O
especially	RB	B-NP	O
ibuprofen	NN	I-NP	O
)	)	O	O
,	,	O	O
preexisting	VBG	B-VP	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	B
stones	NNS	I-NP	I
,	,	O	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
gout	NN	B-NP	B
,	,	O	O
a	DT	B-NP	O
recent	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
activity	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
recent	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
sun	NN	B-NP	O
exposure	NN	I-NP	O
,	,	O	O
and	CC	O	O
residence	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Sunbelt	NNP	I-NP	O
.	.	O	O

These	DT	B-NP	O
were	VBD	B-VP	O
findings	NNS	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
suggestive	JJ	B-ADJP	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
reach	VB	I-VP	O
conventional	JJ	B-NP	O
statistical	JJ	I-NP	O
significance	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
postulated	VBN	I-NP	O
mechanism	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
unusual	JJ	I-NP	O
syndrome	NN	I-NP	O
:	:	O	O
acute	JJ	B-NP	O
diffuse	JJ	I-NP	O
crystallization	NN	I-NP	O
of	IN	B-PP	O
uric	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
tubules	NNS	I-NP	O
.	.	O	O

Hemolytic	JJ	B-NP	B
-	HYPH	I-NP	I
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
ingestion	NN	B-NP	O
of	IN	B-PP	O
quinine	NN	B-NP	O
.	.	O	O

Hemolytic	JJ	B-NP	B
-	HYPH	I-NP	I
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
following	VBG	B-PP	O
quinine	NN	B-NP	O
ingestion	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
newly	RB	I-NP	O
described	VBN	I-NP	O
phenomenon	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
just	RB	B-NP	O
num	CD	I-NP	O
previous	JJ	I-NP	O
descriptions	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
5th	JJ	I-NP	O
case	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
reaction	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
antibodies	NNS	B-NP	O
reactive	JJ	B-ADJP	O
against	IN	B-PP	O
platelets	NNS	B-NP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
quinine	NN	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
has	VBZ	B-VP	O
included	VBN	I-VP	O
use	NN	B-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
exchange	NN	I-NP	O
,	,	O	O
prednisone	NN	B-NP	O
,	,	O	O
aspirin	NN	B-NP	O
,	,	O	O
and	CC	O	O
dipyridamole	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
have	VBP	B-VP	O
all	DT	O	O
regained	VBD	B-VP	O
some	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
whether	IN	B-SBAR	O
pharmacological	JJ	B-NP	O
treatment	NN	I-NP	O
or	CC	O	O
spontaneous	JJ	B-NP	O
resolution	NN	I-NP	O
is	VBZ	B-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
improvement	NN	I-NP	O
.	.	O	O

Quinine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
hemolytic	JJ	I-NP	B
-	HYPH	I-NP	I
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
probably	RB	B-ADVP	O
occurs	VBZ	B-VP	O
more	RBR	B-ADVP	O
often	RB	I-ADVP	O
than	IN	B-SBAR	O
is	VBZ	B-VP	O
recognized	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
recognize	VB	I-VP	O
this	DT	B-NP	O
reaction	NN	I-NP	O
when	WRB	B-ADVP	O
it	PRP	B-NP	O
occurs	VBZ	B-VP	O
and	CC	O	O
to	TO	B-VP	O
avoid	VB	I-VP	O
further	JJ	B-NP	O
quinine	NN	I-NP	O
exposure	NN	I-NP	O
,	,	O	O
since	IN	B-SBAR	O
the	DT	B-NP	O
reaction	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
recurrent	JJ	B-ADJP	O
.	.	O	O

Pyeloureteral	JJ	B-NP	O
filling	NN	I-NP	O
defects	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
systemic	JJ	B-NP	O
anticoagulation	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
etiology	NN	I-NP	O
of	IN	B-PP	O
pyeloureteritis	NN	B-NP	B
cystica	NN	I-NP	I
has	VBZ	B-VP	O
long	RB	I-VP	O
been	VBN	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
chronic	JJ	B-NP	O
infection	NN	I-NP	B
and	CC	I-NP	O
inflammation	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
unique	JJ	B-ADJP	O
in	IN	B-PP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
acute	JJ	I-NP	O
onset	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
rapid	JJ	I-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
pyeloureteral	JJ	B-NP	O
filling	NN	I-NP	O
defects	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
were	VBD	B-VP	O
documented	VBN	I-VP	O
by	IN	B-PP	O
radiography	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
antecedent	JJ	B-NP	O
or	CC	I-NP	O
concurrent	JJ	I-NP	O
infection	NN	I-NP	B
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
disease	NN	I-NP	O
occurred	VBD	B-VP	O
subsequent	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
suspected	VBN	B-NP	O
pelvic	JJ	I-NP	O
thrombophlebitis	NN	I-NP	B
and	CC	O	O
cleared	VBD	B-VP	O
rapidly	RB	B-ADJP	O
subsequent	JJ	I-ADJP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
discontinuation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
resolution	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
radiographic	JJ	I-NP	O
findings	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
helpful	JJ	B-ADJP	O
in	IN	B-PP	O
distinguishing	VBG	B-VP	O
between	IN	B-PP	O
true	JJ	B-NP	O
pyeloureteritis	NN	I-NP	B
cystica	NN	I-NP	I
and	CC	O	O
submucosal	JJ	B-NP	B
hemorrhage	NN	I-NP	I
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
peroxisomes	NNS	B-NP	O
in	IN	B-PP	O
preneoplastic	JJ	B-NP	O
liver	NN	I-NP	O
and	CC	I-NP	O
hepatoma	NN	I-NP	B
of	IN	B-PP	O
mice	NNS	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
benzene	NN	I-NP	O
hexachloride	NN	I-NP	O
.	.	O	O

Peroxisomes	NNS	B-NP	O
in	IN	B-PP	O
hepatomas	NNS	B-NP	B
and	CC	O	O
hyperplastic	JJ	B-NP	O
preneoplastic	JJ	I-NP	O
liver	NN	I-NP	B
lesions	NNS	I-NP	I
induced	VBN	B-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
ppm	NN	I-NP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
benzene	NN	I-NP	O
hexachloride	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
histochemically	RB	B-ADVP	O
and	CC	O	O
electron	NN	B-NP	O
microscopically	RB	B-ADVP	O
.	.	O	O

Although	IN	B-SBAR	O
most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hepatomas	NNS	I-NP	B
were	VBD	B-VP	O
well	RB	B-ADVP	O
-	HYPH	B-NP	O
differentiated	VBN	I-NP	O
tumors	NNS	I-NP	B
and	CC	O	O
contained	VBD	B-VP	O
a	DT	B-NP	O
considerable	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
peroxisomes	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
tumor	NN	I-NP	B
cells	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
respond	VB	I-VP	O
to	TO	B-PP	O
ethyl	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
p	NN	I-NP	O
-	HYPH	O	O
chlorophenoxyisobutyrate	NN	B-NP	O
with	IN	B-PP	O
proliferation	NN	B-NP	O
of	IN	B-PP	O
peroxisomes	NNS	B-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
16th	JJ	I-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
carcinogen	NN	B-NP	O
feeding	NN	I-NP	O
,	,	O	O
hyperplastic	JJ	B-NP	O
nodules	NNS	I-NP	O
appeared	VBD	B-VP	O
and	CC	O	O
advanced	VBD	B-VP	O
to	TO	B-PP	O
further	JJ	B-NP	O
stages	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nodules	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
considerable	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
peroxisomes	NNS	B-NP	O
and	CC	O	O
the	DT	B-NP	O
inductive	JJ	I-NP	O
proliferation	NN	I-NP	O
of	IN	B-PP	O
peroxisomes	NNS	B-NP	O
.	.	O	O

Within	IN	B-PP	O
the	DT	B-NP	O
nodules	NNS	I-NP	O
,	,	O	O
foci	NNS	B-NP	O
of	IN	B-PP	O
proliferation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cells	NNS	I-NP	O
that	WDT	B-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
inducibility	NN	I-NP	O
of	IN	B-PP	O
proliferation	NN	B-NP	O
of	IN	B-PP	O
peroxisomes	NNS	B-NP	O
appeared	VBD	B-VP	O
.	.	O	O

These	DT	B-NP	O
cells	NNS	I-NP	O
proliferated	VBD	B-VP	O
further	RBR	B-ADVP	O
,	,	O	O
replacing	VBG	B-VP	O
the	DT	B-NP	O
most	JJS	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nodules	NNS	I-NP	O
,	,	O	O
and	CC	O	O
with	IN	B-PP	O
this	DT	B-NP	O
process	NN	I-NP	O
hepatomas	NNS	I-NP	B
appeared	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
formed	VBN	I-VP	O
.	.	O	O

No	DT	B-NP	O
abnormal	JJ	I-NP	O
matrical	JJ	I-NP	O
inclusions	NNS	I-NP	O
of	IN	B-PP	O
peroxisomes	NNS	B-NP	O
were	VBD	B-VP	O
formed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
hyperplastic	JJ	B-NP	O
nodules	NNS	I-NP	O
by	IN	B-PP	O
ethyl	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
p	NN	I-NP	O
-	HYPH	I-NP	O
chlorophenoxyisobutyrate	NN	I-NP	O
unlike	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Quinidine	NN	B-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
quinidine	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
persistent	JJ	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
SGOT	NN	B-NP	O
,	,	O	O
lactic	JJ	B-NP	O
acid	NN	I-NP	O
dehydrogenase	NN	I-NP	O
,	,	O	O
and	CC	O	O
alkaline	NN	B-NP	O
phosphatase	NN	I-NP	O
.	.	O	O

Liver	NN	B-NP	O
biopsy	NN	I-NP	O
showed	VBD	B-VP	O
active	JJ	B-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

Discontinuance	NN	B-NP	O
of	IN	B-PP	O
quinidine	NN	B-NP	O
therapy	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
normalization	NN	B-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
challenge	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
quinidine	NN	B-NP	O
caused	VBD	B-VP	O
clinical	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
abrupt	JJ	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
SGOT	NN	B-NP	O
,	,	O	O
alkaline	NN	B-NP	O
phosphatase	NN	I-NP	O
,	,	O	O
and	CC	O	O
lactic	JJ	B-NP	O
acid	NN	I-NP	O
dehydrogenase	NN	I-NP	O
values	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
concluded	VBD	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
quinidine	NN	B-NP	O
hepatotoxicity	NN	I-NP	B
and	CC	O	O
believe	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
reported	VBN	B-VP	O
with	IN	B-PP	O
liver	NN	B-NP	O
biopsy	NN	I-NP	O
documentation	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
also	RB	B-ADVP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
even	RB	B-PP	O
after	IN	I-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
administration	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
hepatic	JJ	I-NP	B
toxicity	NN	I-NP	I
is	VBZ	B-VP	O
reversible	JJ	B-ADJP	O
.	.	O	O

Cholesteryl	NN	B-NP	O
hemisuccinate	NN	I-NP	O
treatment	NN	I-NP	O
protects	VBZ	B-VP	O
rodents	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
,	,	O	O
adriamycin	NN	B-NP	O
,	,	O	O
carbon	NN	B-NP	O
tetrachloride	NN	I-NP	O
,	,	O	O
chloroform	NN	B-NP	O
and	CC	I-NP	O
galactosamine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
stabilizer	NN	I-NP	O
/	SYM	B-NP	O
rigidifier	NN	I-NP	O
of	IN	B-PP	O
membranes	NNS	B-NP	O
,	,	O	O
cholesteryl	NN	B-NP	O
hemisuccinate	NN	I-NP	O
,	,	O	O
tris	NN	B-NP	O
salt	NN	I-NP	O
(	(	O	O
CS	NN	B-NP	O
)	)	O	O
administration	NN	B-NP	O
has	VBZ	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
protect	VB	I-VP	O
rats	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
hepatotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
carbon	NN	B-NP	O
tetrachloride	NN	I-NP	O
(	(	O	O
CCl4	NN	B-NP	O
)	)	O	O
.	.	O	O

To	TO	B-VP	O
further	VB	I-VP	O
our	PRP$	B-NP	O
understanding	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
CS	NN	B-NP	O
cytoprotection	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
examined	VBD	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
and	CC	I-NP	O
mice	NNS	I-NP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
abilities	NNS	I-NP	O
of	IN	B-PP	O
CS	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
hydrolyzable	JJ	I-NP	O
ether	NN	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
CS	NN	B-NP	O
,	,	O	O
gamma	SYM	B-NP	O
-	HYPH	B-VP	O
cholesteryloxybutyric	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
tris	NN	B-NP	O
salt	NN	I-NP	O
(	(	O	O
CSE	NN	B-NP	O
)	)	O	O
against	IN	B-PP	O
acetaminophen	NN	B-NP	O
-	HYPH	O	O
,	,	O	O
adriamycin	NN	B-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
carbon	NN	B-NP	O
tetrachloride	NN	I-NP	O
-	HYPH	B-ADJP	O
,	,	O	O
chloroform	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
galactosamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
CS	NN	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
protection	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
selective	JJ	B-ADJP	O
for	IN	B-PP	O
a	DT	B-NP	O
particular	JJ	I-NP	O
species	NNS	I-NP	O
,	,	O	O
organ	NN	B-NP	O
system	NN	I-NP	O
or	CC	O	O
toxic	JJ	B-NP	O
chemical	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
pretreatment	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
rats	NNS	I-NP	O
and	CC	I-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
CS	NNP	B-NP	O
,	,	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
significant	JJ	B-NP	O
protection	NN	I-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
hepatotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
CCl4	NN	B-NP	O
,	,	I-NP	O
CHCl3	NN	I-NP	O
,	,	I-NP	O
acetaminophen	NN	I-NP	O
and	CC	I-NP	O
galactosamine	NN	I-NP	O
and	CC	O	O
against	IN	B-PP	O
the	DT	B-NP	O
lethal	JJ	I-NP	O
(	(	O	O
and	CC	O	O
presumably	RB	B-ADJP	O
cardiotoxic	JJ	I-ADJP	B
)	)	O	O
effect	NN	B-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Maximal	JJ	B-NP	O
CS	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
protection	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
pretreated	VBD	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
insult	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
CS	JJ	B-NP	O
intervenes	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
critical	JJ	I-NP	O
cellular	JJ	I-NP	O
event	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
common	JJ	I-NP	O
pathway	NN	I-NP	O
to	TO	B-PP	O
toxic	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
CS	NN	B-NP	O
protection	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
chemical	JJ	B-NP	O
bioactivation	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
toxic	JJ	I-NP	O
reactive	JJ	I-NP	O
intermediate	NN	I-NP	O
(	(	O	O
in	IN	B-PP	O
light	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
protection	NN	I-NP	O
observed	VBN	B-VP	O
against	IN	B-PP	O
galactosamine	NN	B-NP	O
hepatotoxicity	NN	I-NP	B
)	)	O	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
data	NNS	I-NP	O
presented	VBN	B-VP	O
,	,	O	O
we	PRP	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
exclude	VB	I-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
CS	JJ	B-NP	O
administration	NN	I-NP	O
inhibits	VBZ	B-VP	O
chemical	JJ	B-NP	O
bioactivation	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
do	VBP	B-VP	O
suggest	VB	I-VP	O
that	IN	B-SBAR	O
CS	NN	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
protection	NN	I-NP	O
is	VBZ	B-VP	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
intact	JJ	I-NP	O
anionic	JJ	I-NP	O
CS	NN	I-NP	O
molecule	NN	I-NP	O
(	(	O	O
non	AFX	O	O
-	HYPH	O	O
hydrolyzable	JJ	B-NP	O
CSE	NN	I-NP	O
was	VBD	B-VP	O
as	RB	B-ADJP	O
protective	JJ	I-ADJP	O
as	IN	B-PP	O
CS	NN	B-NP	O
)	)	O	O
,	,	O	O
whose	WP$	B-NP	O
mechanism	NN	I-NP	O
has	VBZ	B-VP	O
yet	RB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
defined	VBN	I-VP	O
.	.	O	O

DSMM	NN	B-NP	O
XI	NN	I-NP	O
study	NN	I-NP	O
:	:	O	O
dose	NN	B-NP	O
definition	NN	I-NP	O
for	IN	B-PP	O
intravenous	JJ	B-NP	O
cyclophosphamide	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
bortezomib	NN	B-NP	O
/	SYM	I-NP	O
dexamethasone	NN	I-NP	O
for	IN	B-PP	O
remission	NN	B-NP	O
induction	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
newly	RB	B-NP	O
diagnosed	VBN	I-NP	O
myeloma	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
recommended	VBN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
bortezomib	NN	B-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
as	IN	B-PP	O
induction	NN	B-NP	O
treatment	NN	I-NP	O
before	IN	B-PP	O
stem	NN	B-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
for	IN	B-PP	O
younger	JJR	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
newly	RB	B-NP	O
diagnosed	VBN	I-NP	O
multiple	JJ	I-NP	B
myeloma	NN	I-NP	I
(	(	O	O
MM	NN	B-NP	B
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
bortezomib	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
plus	CC	O	O
dexamethasone	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
bortezomib	NN	B-NP	O
injection	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
day	NN	I-NP	O
after	IN	B-SBAR	O
plus	CC	O	O
cyclophosphamide	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
maximum	NN	I-NP	O
tolerated	VBN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
this	DT	B-NP	O
dose	NN	I-NP	O
level	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
achieved	VBN	B-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
[	(	O	O
complete	JJ	B-NP	O
response	NN	I-NP	O
(	(	O	O
CR	NN	B-NP	O
)	)	O	O
plus	CC	O	O
partial	JJ	B-NP	O
response	NN	I-NP	O
(	(	O	O
PR	NN	B-NP	O
)	)	O	O
]	)	O	O
across	IN	B-PP	O
all	DT	B-NP	O
dose	NN	I-NP	O
levels	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CR	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
patient	NN	I-NP	O
experienced	VBD	B-VP	O
progressive	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
frequent	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
hematological	JJ	B-NP	B
and	CC	I-NP	I
gastrointestinal	JJ	I-NP	I
toxicities	NNS	I-NP	I
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
neuropathy	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
bortezomib	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
induction	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
newly	RB	B-NP	O
diagnosed	VBN	I-NP	O
MM	NN	I-NP	B
that	WDT	B-NP	O
warrants	VBZ	B-VP	O
further	JJ	B-NP	O
investigation	NN	I-NP	O
.	.	O	O

Results	NNS	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
comparative	JJ	I-NP	O
,	,	I-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
multicenter	JJ	B-NP	O
,	,	I-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
telmisartan	NN	B-NP	O
and	CC	I-NP	O
amlodipine	NN	I-NP	O
versus	CC	I-NP	O
amlodipine	NN	I-NP	O
monotherapy	NN	I-NP	O
in	IN	B-PP	O
Indian	JJ	B-NP	O
adults	NNS	I-NP	O
with	IN	B-PP	O
stage	NN	B-NP	O
num	CD	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
fixed	VBN	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
combination	NN	I-NP	O
(	(	O	O
FDC	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
telmisartan	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
+	SYM	B-NP	O
amlodipine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
(	(	O	O
T+A	NN	B-NP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
amlodipine	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
monotherapy	NN	I-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
adult	JJ	B-NP	O
Indian	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
stage	NN	B-NP	O
num	CD	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
comparative	JJ	I-NP	O
,	,	I-NP	O
Phase	NN	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
multicenter	JJ	B-NP	O
,	,	I-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
Indian	JJ	B-NP	O
patients	NNS	I-NP	O
aged	VBN	B-ADJP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
with	IN	B-PP	O
established	VBN	B-NP	O
stage	NN	I-NP	O
num	CD	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
FDC	NN	I-NP	O
of	IN	B-PP	O
T+A	NN	B-NP	O
or	CC	I-NP	O
A	NN	I-NP	O
QD	NN	I-NP	O
before	IN	B-PP	O
breakfast	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
;	:	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
and	CC	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
sitting	VBG	I-NP	O
position	NN	I-NP	O
.	.	O	O

Primary	JJ	B-NP	O
efficacy	NN	I-NP	O
end	NN	I-NP	O
points	NNS	I-NP	O
were	VBD	B-VP	O
reduction	NN	B-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
systolic	JJ	I-NP	O
BP	NN	I-NP	O
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
/	SYM	B-NP	O
diastolic	JJ	I-NP	O
BP	NN	I-NP	O
(	(	O	O
DBP	NN	B-NP	O
)	)	O	O
from	IN	B-PP	O
baseline	NN	B-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
end	NN	B-NP	O
and	CC	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
responders	NNS	B-NP	O
at	IN	B-PP	O
end	NN	B-NP	O
of	IN	B-PP	O
study	NN	B-NP	O
.	.	O	O

Tolerability	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
treatment	NN	B-NP	O
-	HYPH	O	O
emergent	JJ	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
,	,	O	O
identified	VBN	B-VP	O
using	VBG	B-VP	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
,	,	O	O
laboratory	NN	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
and	CC	O	O
electrocardiography	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
)	)	O	O
completed	VBD	B-VP	O
the	DT	B-NP	O
study	NN	I-NP	O
while	IN	B-SBAR	O
num	CD	B-NP	O
were	VBD	B-VP	O
lost	VBN	I-VP	O
to	TO	I-VP	O
follow	VB	I-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
and	CC	O	O
considered	VBN	B-VP	O
with	IN	B-PP	O
-	HYPH	B-NP	O
drawn	VBN	B-VP	O
.	.	O	O

At	IN	B-PP	O
study	NN	B-NP	O
end	NN	I-NP	O
,	,	O	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
percentage	NN	I-NP	O
reductions	NNS	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
within	IN	B-PP	O
groups	NNS	B-NP	O
and	CC	B-PP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
SBP	NN	B-NP	O
and	CC	I-NP	O
DBP	NN	I-NP	O
.	.	O	O

Response	NN	B-NP	O
rates	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
T+A	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
A	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
prevalences	NNS	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
significantly	RB	I-ADJP	O
different	JJ	I-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Peripheral	JJ	B-NP	O
edema	NN	I-NP	B
was	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
T+A	NN	I-NP	O
group	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
A	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
and	CC	O	O
cough	NN	B-NP	B
was	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
T+A	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
A	NN	I-NP	O
group	NN	I-NP	O
;	:	O	O
these	DT	B-NP	O
differences	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reach	VB	I-VP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidences	NNS	I-NP	O
of	IN	B-PP	O
headache	NN	B-NP	B
,	,	O	O
dizziness	NN	B-NP	B
,	,	O	O
and	CC	O	O
diarrhea	NN	B-NP	B
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
these	DT	B-NP	O
Indian	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
stage	NN	B-NP	O
num	CD	I-NP	O
hypertension	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
FDC	NN	I-NP	O
of	IN	B-PP	O
T+A	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
significantly	RB	B-ADJP	O
more	RBR	I-ADJP	O
effective	JJ	I-ADJP	O
,	,	O	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
BP	NN	B-NP	O
reductions	NNS	I-NP	O
,	,	O	O
than	IN	B-PP	O
A	NN	B-NP	O
,	,	O	O
and	CC	O	O
both	DT	B-NP	O
treatments	NNS	I-NP	O
were	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
.	.	O	O

Cutaneous	JJ	B-NP	B
leucocytoclastic	JJ	I-NP	I
vasculitis	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
oxacillin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
oxacillin	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
Staphylococcus	FW	B-NP	B
aureus	FW	I-NP	I
bacteremia	NN	I-NP	I
,	,	O	O
developed	VBD	B-VP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
and	CC	O	O
diffuse	JJ	B-NP	O
,	,	I-NP	O
symmetric	JJ	I-NP	O
,	,	I-NP	O
palpable	JJ	I-NP	O
purpuric	JJ	I-NP	B
lesions	NNS	I-NP	I
on	IN	B-PP	O
his	PRP$	B-NP	O
feet	NNS	I-NP	O
.	.	O	O

Necrotic	JJ	B-NP	B
blisters	NNS	I-NP	I
were	VBD	B-VP	O
noted	VBN	I-VP	O
on	IN	B-PP	O
his	PRP$	B-NP	O
fingers	NNS	I-NP	O
.	.	O	O

Skin	NN	B-NP	O
biopsies	NNS	I-NP	O
showed	VBD	B-VP	O
findings	NNS	B-NP	O
diagnostic	JJ	B-ADJP	O
of	IN	B-PP	O
leucocytoclastic	JJ	B-NP	B
vasculitis	NN	I-NP	I
.	.	O	O

Oxacillin	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
patient	NN	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
corticosteroids	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
rash	NN	I-NP	B
disappeared	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
function	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
.	.	O	O

Leucocytoclastic	JJ	B-NP	B
vasculitis	NN	I-NP	I
presents	VBZ	B-VP	O
as	IN	B-PP	O
palpable	JJ	B-NP	O
purpura	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
extremities	NNS	I-NP	O
often	RB	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
,	,	O	O
arthralgia	NN	B-NP	B
,	,	O	O
and	CC	O	O
renal	JJ	B-NP	B
involvement	NN	I-NP	I
.	.	O	O

Etiologic	JJ	B-NP	O
factors	NNS	I-NP	O
or	CC	O	O
associated	VBN	B-NP	O
disorders	NNS	I-NP	O
include	VBP	B-VP	O
infections	NNS	B-NP	B
,	,	O	O
medications	NNS	B-NP	O
,	,	O	O
collagen	NN	B-NP	B
vascular	JJ	I-NP	I
disease	NN	I-NP	I
and	CC	O	O
neoplasia	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
half	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
no	DT	B-NP	O
etiologic	JJ	I-NP	O
factor	NN	I-NP	O
is	VBZ	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

Usually	RB	B-ADVP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
self	NN	I-NP	O
-	HYPH	O	O
limited	VBN	B-NP	O
disorder	NN	I-NP	O
,	,	O	O
but	CC	O	O
corticosteroid	NN	B-NP	O
therapy	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
needed	VBN	I-VP	O
in	IN	B-PP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
cases	NNS	B-NP	O
since	IN	B-PP	O
early	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
corticosteroids	NNS	B-NP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
cases	NNS	I-NP	O
can	MD	B-VP	O
prevent	VB	I-VP	O
complications	NNS	B-NP	O
.	.	O	O

Oxacillin	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
included	VBN	I-VP	O
among	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
leucocytoclastic	JJ	B-NP	B
vasculitis	NN	I-NP	I
.	.	O	O

Naloxazone	NN	B-NP	O
pretreatment	NN	I-NP	O
modifies	VBZ	B-VP	O
cardiorespiratory	JJ	B-ADJP	O
,	,	O	O
temperature	NN	B-NP	O
,	,	O	O
and	CC	O	O
behavioral	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

Behavioral	JJ	B-NP	O
and	CC	I-NP	O
cardiorespiratory	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
lethal	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
or	CC	I-NP	O
naloxazone	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
affinity	NN	I-NP	O
mu	SYM	B-NP	O
num	CD	B-NP	O
opioid	JJ	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
naloxazone	NN	B-NP	O
significantly	RB	B-ADVP	O
blocked	VBD	B-VP	O
morphine	NN	B-NP	O
analgesia	NN	I-NP	B
,	,	O	O
catalepsy	NN	B-NP	B
and	CC	I-NP	O
hypothermia	NN	I-NP	B
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
which	WDT	B-NP	O
completely	RB	B-ADVP	O
eliminated	VBD	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
affinity	NN	I-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
membranes	NNS	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
naloxazone	NN	B-NP	O
significantly	RB	B-ADVP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
morphine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
respiratory	JJ	I-NP	B
depression	NN	I-NP	I
,	,	O	O
whereas	IN	O	O
morphine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
bradycardia	NN	I-NP	B
was	VBD	B-VP	O
less	RBR	I-VP	O
affected	VBN	I-VP	O
.	.	O	O

Results	NNS	B-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
subpopulations	NNS	B-NP	O
of	IN	B-PP	O
mu	SYM	B-NP	O
receptors	NNS	I-NP	O
may	MD	B-VP	O
mediate	VB	I-VP	O
selective	JJ	B-NP	O
behavioral	JJ	I-NP	O
and	CC	I-NP	O
cardiorespiratory	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

Dexrazoxane	NN	B-NP	O
protects	VBZ	B-VP	O
against	IN	B-PP	O
myelosuppression	NN	B-NP	B
from	IN	B-PP	O
the	DT	B-NP	O
DNA	NN	I-NP	O
cleavage	NN	I-NP	O
-	HYPH	O	O
enhancing	VBG	B-VP	O
drugs	NNS	B-NP	O
etoposide	NN	I-NP	O
and	CC	I-NP	O
daunorubicin	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
doxorubicin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
anthracyclines	NNS	I-NP	O
daunorubicin	NN	I-NP	O
and	CC	I-NP	O
doxorubicin	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
epipodophyllotoxin	NN	I-NP	O
etoposide	NN	I-NP	O
are	VBP	B-VP	O
potent	JJ	B-NP	O
DNA	NN	I-NP	O
cleavage	NN	I-NP	O
-	HYPH	O	O
enhancing	VBG	B-VP	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
oncology	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
myelosuppression	NN	B-NP	B
and	CC	O	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
limit	VBP	B-VP	O
their	PRP$	B-NP	O
use	NN	I-NP	O
.	.	O	O

Dexrazoxane	NN	B-NP	O
(	(	O	O
ICRF	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
for	IN	B-PP	O
protection	NN	B-NP	O
against	IN	B-PP	O
anthracycline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
their	PRP$	B-NP	O
widespread	JJ	I-NP	O
use	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
hematologic	JJ	I-NP	B
toxicity	NN	I-NP	I
following	VBG	B-PP	O
coadministration	NN	B-NP	O
of	IN	B-PP	O
dexrazoxane	NN	B-NP	O
and	CC	O	O
these	DT	B-NP	O
num	CD	I-NP	O
structurally	RB	I-NP	O
different	JJ	I-NP	O
DNA	NN	I-NP	O
cleavage	NN	I-NP	O
enhancers	NNS	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
:	:	O	O
Sensitivity	NN	B-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
and	CC	I-NP	O
murine	JJ	I-NP	O
blood	NN	I-NP	O
progenitor	NN	I-NP	O
cells	NNS	I-NP	O
to	TO	B-PP	O
etoposide	NN	B-NP	O
,	,	O	O
daunorubicin	NN	B-NP	O
,	,	O	O
and	CC	O	O
doxorubicin	NN	B-NP	O
+	SYM	B-NP	O
/	SYM	O	O
-	HYPH	O	O
dexrazoxane	NN	B-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
granulocyte	NN	B-NP	O
-	HYPH	I-NP	O
macrophage	NN	I-NP	O
colony	NN	I-NP	O
forming	VBG	B-VP	O
assays	NNS	B-NP	O
.	.	O	O

Likewise	RB	B-ADVP	O
,	,	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
B6D2F1	NN	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
etoposide	NN	B-NP	O
,	,	O	O
daunorubicin	NN	B-NP	O
,	,	O	O
and	CC	O	O
doxorubicin	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
dexrazoxane	NN	B-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
wide	JJ	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
doses	NNS	B-NP	O
:	:	O	O
posttreatment	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
full	JJ	I-NP	O
hematologic	JJ	I-NP	O
evaluation	NN	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
.	.	O	O

Nontoxic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
dexrazoxane	NN	B-NP	O
reduced	VBD	B-VP	O
myelosuppression	NN	B-NP	B
and	CC	I-NP	O
weight	NN	I-NP	B
loss	NN	I-NP	I
from	IN	B-PP	O
daunorubicin	NN	B-NP	O
and	CC	I-NP	O
etoposide	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
and	CC	O	O
antagonized	VBD	B-VP	O
their	PRP$	B-NP	O
antiproliferative	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
colony	NN	I-NP	O
assay	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
dexrazoxane	NN	B-NP	O
neither	CC	O	O
reduced	VBD	B-VP	O
myelosuppression	NN	B-NP	B
,	,	O	O
weight	NN	B-NP	B
loss	NN	I-NP	I
,	,	O	O
nor	CC	O	O
the	DT	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
cytotoxicity	NN	I-NP	B
from	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
our	PRP$	B-NP	O
findings	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
observation	NN	I-NP	O
that	IN	B-SBAR	O
dexrazoxane	NN	B-NP	O
reduces	VBZ	B-VP	O
neither	CC	O	O
hematologic	JJ	B-NP	O
activity	NN	I-NP	O
nor	CC	O	O
antitumor	JJ	B-NP	O
activity	NN	I-NP	O
from	IN	B-PP	O
doxorubicin	NN	B-NP	O
clinically	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
potent	JJ	I-NP	O
antagonism	NN	I-NP	O
of	IN	B-PP	O
daunorubicin	NN	B-NP	O
activity	NN	I-NP	O
raises	VBZ	B-VP	O
concern	NN	B-NP	O
;	:	O	O
a	DT	B-NP	O
possible	JJ	I-NP	O
interference	NN	I-NP	O
with	IN	B-PP	O
anticancer	JJ	B-NP	O
efficacy	NN	I-NP	O
certainly	RB	B-ADVP	O
would	MD	B-VP	O
call	VB	I-VP	O
for	IN	B-PP	O
renewed	VBN	B-NP	O
attention	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
also	RB	B-ADVP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
significant	JJ	B-NP	O
etoposide	NN	I-NP	O
dose	NN	I-NP	O
escalation	NN	I-NP	O
is	VBZ	B-VP	O
perhaps	RB	B-ADVP	O
possible	JJ	B-ADJP	O
by	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
dexrazoxane	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
trials	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
brain	NN	B-NP	O
metastases	NNS	I-NP	B
combining	VBG	B-VP	O
dexrazoxane	NN	B-NP	O
and	CC	O	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
etoposide	NN	B-NP	O
is	VBZ	B-VP	O
ongoing	VBG	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
improving	VBG	B-VP	O
efficacy	NN	B-NP	O
without	IN	B-PP	O
aggravating	VBG	B-VP	O
hematologic	JJ	B-NP	B
toxicity	NN	I-NP	I
.	.	O	O

If	IN	B-SBAR	O
successful	JJ	B-ADJP	O
,	,	O	O
this	DT	B-NP	O
represents	VBZ	B-VP	O
an	DT	B-NP	O
exciting	JJ	I-NP	O
mechanism	NN	I-NP	O
for	IN	B-PP	O
pharmacologic	JJ	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
from	IN	B-PP	O
cytotoxic	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
novel	JJ	I-NP	O
compound	NN	I-NP	O
aniracetam	NN	I-NP	O
(	(	O	O
Ro	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
upon	IN	B-PP	O
impaired	JJ	B-NP	B
learning	NN	I-NP	I
and	CC	I-NP	I
memory	NN	I-NP	I
in	IN	B-PP	O
rodents	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
improvements	NNS	I-NP	O
or	CC	I-NP	O
normalizations	NNS	I-NP	O
of	IN	B-PP	O
impaired	JJ	B-NP	B
cognitive	JJ	I-NP	I
functions	NNS	I-NP	I
were	VBD	B-VP	O
seen	VBN	I-VP	O
at	IN	B-PP	O
oral	JJ	B-NP	O
aniracetam	NN	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
.	.	O	O

Generally	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
curves	NNS	I-NP	O
were	VBD	B-VP	O
bell	NN	B-NP	O
-	HYPH	O	O
shaped	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
mechanisms	NNS	I-NP	O
underlying	VBG	B-VP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
aniracetam	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
therapeutic	JJ	I-NP	O
window	NN	I-NP	O
are	VBP	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

Piracetam	NNP	B-NP	O
,	,	O	O
another	DT	B-NP	O
pyrrolidinone	NN	I-NP	O
derivative	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
comparison	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
active	JJ	B-ADJP	O
only	RB	B-PP	O
in	IN	I-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
tests	NNS	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
about	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tenth	NN	I-NP	O
the	DT	B-NP	O
potency	NN	I-NP	O
of	IN	B-PP	O
aniracetam	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
aniracetam	NN	B-NP	O
improves	VBZ	B-VP	O
cognitive	JJ	B-NP	O
functions	NNS	I-NP	O
which	WDT	B-NP	O
are	VBP	B-VP	O
impaired	VBN	I-VP	O
by	IN	B-PP	O
different	JJ	B-NP	O
procedure	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
different	JJ	B-NP	O
phases	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
learning	NN	I-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
process	NN	I-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
potentiation	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
effects	NNS	B-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
on	IN	B-PP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Morphine	NN	B-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
nicotine	NN	B-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
was	VBD	B-VP	O
potentiated	VBN	I-VP	O
by	IN	B-PP	O
nicotine	NN	B-NP	O
.	.	O	O

Intraperitoneal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
atropine	NN	B-NP	O
,	,	O	O
naloxone	NN	B-NP	O
,	,	O	O
mecamylamine	NN	B-NP	O
,	,	O	O
and	CC	O	O
hexamethonium	NN	B-NP	O
to	TO	B-PP	O
mice	NNS	B-NP	O
reduced	VBD	B-VP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
with	IN	B-PP	O
nicotine	NN	B-NP	O
.	.	O	O

Intracerebroventricular	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
atropine	NN	B-NP	O
,	,	O	O
hexamethonium	NN	B-NP	O
,	,	O	O
and	CC	O	O
naloxone	NN	B-NP	O
also	RB	B-ADVP	O
decreased	VBD	B-VP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
plus	CC	I-NP	O
nicotine	NN	I-NP	O
.	.	O	O

Intraperitoneal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
atropine	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
intraperitoneal	JJ	B-NP	O
or	CC	I-NP	O
intracerebroventricular	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
hexamethonium	NN	B-NP	O
,	,	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
morphine	NN	B-NP	O
catalepsy	NN	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
elicited	VBN	I-VP	O
by	IN	B-PP	O
opioid	JJ	B-NP	O
and	CC	I-NP	O
cholinergic	JJ	I-NP	O
receptors	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
potentiation	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
nicotine	NN	B-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
mediated	VBN	I-VP	O
through	IN	B-PP	O
cholinergic	JJ	B-NP	O
receptor	NN	I-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

Reduced	VBN	B-NP	O
cardiotoxicity	NN	I-NP	B
and	CC	O	O
preserved	VBN	B-VP	O
antitumor	JJ	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
liposome	NN	B-NP	O
-	HYPH	B-NP	O
encapsulated	VBN	I-NP	O
doxorubicin	NN	I-NP	O
and	CC	I-NP	O
cyclophosphamide	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
conventional	JJ	B-NP	O
doxorubicin	NN	I-NP	O
and	CC	I-NP	O
cyclophosphamide	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
multicenter	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
Myocet	NN	B-NP	O
(	(	O	O
liposome	NN	B-NP	O
-	HYPH	O	O
encapsulated	VBN	B-NP	O
doxorubicin	NN	I-NP	O
;	:	O	O
The	DT	B-NP	O
Liposome	NNP	I-NP	O
Company	NNP	I-NP	O
,	,	O	O
Elan	NNP	B-NP	O
Corporation	NNP	I-NP	O
,	,	O	O
Princeton	NNP	B-NP	O
,	,	O	O
NJ	NNP	B-NP	O
)	)	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
significantly	RB	B-ADVP	O
reduces	VBZ	B-VP	O
doxorubicin	NN	B-NP	O
cardiotoxicity	NN	I-NP	B
while	IN	B-SBAR	O
providing	VBG	B-VP	O
comparable	JJ	B-NP	O
antitumor	JJ	I-NP	O
efficacy	NN	I-NP	O
in	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
(	(	O	O
MBC	NN	B-NP	B
)	)	O	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
MBC	NN	B-NP	B
and	CC	O	O
no	DT	B-NP	O
prior	JJ	I-NP	O
chemotherapy	NN	I-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
disease	NN	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-VP	O
receive	VB	I-VP	O
either	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m	NN	I-NP	O
of	IN	B-PP	O
Myocet	NN	B-NP	O
(	(	O	O
M	NN	B-NP	O
)	)	O	O
or	CC	O	O
conventional	JJ	B-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
,	,	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
C	NN	B-NP	O
)	)	O	O
,	,	O	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
until	IN	B-SBAR	O
disease	NN	B-NP	O
progression	NN	I-NP	O
or	CC	O	O
unacceptable	JJ	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Cardiotoxicity	NN	B-NP	B
was	VBD	B-VP	O
defined	VBN	I-VP	O
by	IN	B-PP	O
reductions	NNS	B-NP	O
in	IN	B-PP	O
left	JJ	B-NP	O
-	HYPH	I-NP	O
ventricular	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
,	,	O	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
serial	JJ	B-NP	O
multigated	JJ	I-NP	O
radionuclide	NN	I-NP	O
angiography	NN	I-NP	O
scans	NNS	I-NP	O
,	,	O	O
or	CC	O	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
CHF	NN	B-NP	B
)	)	O	O
.	.	O	O

Antitumor	JJ	B-NP	O
efficacy	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
objective	JJ	B-NP	O
tumor	NN	I-NP	B
response	NN	I-NP	O
rates	NNS	I-NP	O
(	(	O	O
World	NNP	B-NP	O
Health	NNP	I-NP	O
Organization	NNP	I-NP	O
criteria	NNS	I-NP	O
)	)	O	O
,	,	O	O
time	NN	B-NP	O
to	TO	B-PP	O
progression	NN	B-NP	O
,	,	O	O
and	CC	O	O
survival	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
MC	NN	B-NP	O
patients	NNS	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
CHF	NN	B-NP	B
)	)	O	O
of	IN	B-PP	O
AC	NN	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
cardiotoxicity	NN	B-NP	B
.	.	O	O

Median	JJ	B-NP	O
cumulative	JJ	I-NP	O
doxorubicin	NN	I-NP	O
dose	NN	I-NP	O
at	IN	B-PP	O
onset	NN	B-NP	O
was	VBD	B-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m	NN	I-NP	O
for	IN	B-PP	O
MC	NN	B-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
for	IN	B-PP	O
AC	NN	B-NP	O
.	.	O	O

MC	NN	B-NP	O
patients	NNS	I-NP	O
also	RB	B-ADVP	O
experienced	VBD	B-VP	O
less	JJR	B-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
.	.	O	O

Antitumor	JJ	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
MC	NN	B-NP	O
versus	IN	B-PP	O
AC	NN	B-NP	O
was	VBD	B-VP	O
comparable	JJ	B-ADJP	O
:	:	O	O
objective	JJ	B-NP	O
response	NN	I-NP	O
rates	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
median	JJ	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
progression	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
;	:	O	O
median	JJ	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
failure	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
;	:	O	O
and	CC	O	O
median	JJ	B-NP	O
survival	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
versus	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Myocet	NN	B-NP	O
improves	VBZ	B-VP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
index	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
by	IN	B-PP	O
significantly	RB	B-VP	O
reducing	VBG	I-VP	O
cardiotoxicity	NN	B-NP	B
and	CC	O	O
grade	NN	B-NP	O
num	CD	B-NP	O
neutropenia	NN	I-NP	B
and	CC	O	O
provides	VBZ	B-VP	O
comparable	JJ	B-NP	O
antitumor	JJ	I-NP	O
efficacy	NN	I-NP	O
,	,	O	O
when	WRB	B-ADVP	O
used	VBN	B-VP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
as	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
MBC	NN	B-NP	B
.	.	O	O

Protective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
platelet	NN	I-NP	O
-	HYPH	O	O
activating	VBG	B-VP	O
factor	NN	B-NP	O
antagonist	NN	I-NP	O
,	,	O	O
BN	NN	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiovascular	JJ	I-NP	B
impairments	NNS	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
local	JJ	I-NP	O
anaesthetic	JJ	I-NP	O
bupivacaine	NN	I-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
elicited	VBD	B-VP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
decrease	NN	I-NP	B
of	IN	B-PP	I
mean	JJ	B-NP	I
arterial	JJ	I-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
(	(	O	I
MBP	NN	B-NP	I
)	)	O	I
and	CC	O	I
heart	NN	B-NP	I
rate	NN	I-NP	I
(	(	O	I
HR	NN	B-NP	I
)	)	O	I
leading	VBG	B-VP	O
to	TO	B-PP	O
death	NN	B-NP	O
(	(	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Intravenous	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
specific	JJ	I-NP	O
platelet	NN	I-NP	O
-	HYPH	O	O
activating	VBG	B-VP	O
factor	NN	B-NP	O
(	(	O	O
PAF	NN	B-NP	O
)	)	O	O
antagonist	NN	B-NP	O
BN	NN	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
bupivacaine	NN	B-NP	O
administration	NN	I-NP	O
suppressed	VBD	B-VP	O
both	CC	O	O
the	DT	B-NP	O
decrease	NN	I-NP	B
of	IN	B-PP	I
MBP	NN	B-NP	I
and	CC	I-NP	I
HR	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
BN	NN	I-NP	O
num	CD	I-NP	O
given	VBN	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
or	CC	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
administered	VBN	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
i.v.	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
were	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

When	WRB	B-ADVP	O
BN	NN	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
bupivacaine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
partial	JJ	I-NP	O
reversion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
decrease	NN	I-NP	B
of	IN	B-PP	I
MBP	NN	B-NP	I
and	CC	I-NP	I
HR	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
was	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
partial	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ECG	NN	I-NP	O
alterations	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
pretreatment	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
BN	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Since	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
BN	NN	B-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
all	DT	B-NP	O
doses	NNS	I-NP	O
studied	VBN	B-VP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
MBP	NN	B-NP	O
and	CC	I-NP	O
HR	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
used	VBN	B-VP	O
,	,	O	O
the	DT	B-NP	O
bulk	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
results	NNS	I-NP	O
clearly	RB	B-ADVP	O
demonstrate	VBP	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
BN	NN	B-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
antagonist	NN	I-NP	O
of	IN	B-PP	O
PAF	NN	B-NP	O
,	,	O	O
against	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiovascular	JJ	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
its	PRP$	B-NP	O
direct	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
heart	NN	B-NP	O
,	,	O	O
PAF	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiovascular	JJ	I-NP	B
alterations	NNS	I-NP	I
.	.	O	O

Benzylacyclouridine	NN	B-NP	O
reverses	VBZ	B-VP	O
azidothymidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
marrow	NN	I-NP	B
suppression	NN	I-NP	I
without	IN	B-PP	O
impairment	NN	B-NP	O
of	IN	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
human	JJ	B-NP	O
immunodeficiency	NN	I-NP	B
virus	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
extracellular	JJ	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
uridine	NN	B-NP	O
(	(	O	O
Urd	NN	B-NP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
reduce	VB	I-VP	O
,	,	O	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
,	,	O	O
azidothymidine	NN	B-NP	O
(	(	O	O
AZT	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
granulocyte	NN	I-NP	O
-	HYPH	I-NP	O
macrophage	NN	I-NP	O
progenitor	NN	I-NP	O
cells	NNS	I-NP	O
without	IN	B-PP	O
impairment	NN	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
antihuman	JJ	I-NP	O
immunodeficiency	NN	I-NP	B
virus	NN	I-NP	O
(	(	O	O
HIV	NN	B-NP	O
)	)	O	O
activity	NN	B-NP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
toxicities	NNS	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
Urd	NNP	I-NP	O
administration	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
benzylacyclouridine	NN	B-NP	O
(	(	O	O
BAU	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
effect	NN	B-NP	O
,	,	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
AZT	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
and	CC	I-NP	O
leukopenia	NN	I-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
agent	NN	I-NP	O
inhibits	VBZ	B-VP	O
Urd	NNP	B-NP	O
catabolism	NN	I-NP	O
and	CC	O	O
,	,	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
Urd	NNP	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
Urd	NNP	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
mice	NNS	B-NP	O
rendered	VBD	B-VP	O
anemic	JJ	B-NP	B
and	CC	I-NP	O
leukopenic	JJ	I-NP	B
by	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
AZT	NNP	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
drinking	NN	B-NP	O
water	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
continued	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
AZT	NNP	B-NP	O
plus	CC	O	O
daily	JJ	B-NP	O
BAU	NN	I-NP	O
partially	RB	B-ADVP	O
reversed	VBD	B-VP	O
AZT	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
and	CC	I-NP	O
leukopenia	NN	I-NP	B
,	,	O	O
increased	VBN	B-NP	O
peripheral	JJ	I-NP	O
reticulocytes	NNS	I-NP	O
,	,	O	O
increased	VBN	B-NP	O
cellularity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
marrow	NN	I-NP	O
,	,	O	O
and	CC	O	O
improved	VBN	B-NP	O
megaloblastosis	NN	I-NP	B
.	.	O	O

When	WRB	B-ADVP	O
coadministered	VBN	B-VP	O
with	IN	B-PP	O
AZT	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
BAU	NN	B-NP	O
reduced	VBD	B-VP	O
AZT	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
marrow	NN	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

In	FW	B-ADVP	O
vitro	FW	I-ADVP	O
,	,	O	O
at	IN	B-PP	O
a	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mumol	NN	I-NP	O
/	SYM	O	O
L	NN	B-NP	O
,	,	O	O
BAU	NN	B-NP	O
possesses	VBZ	B-VP	O
minimal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
HIV	NN	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
has	VBZ	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
AZT	NNP	B-NP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
the	DT	B-NP	O
HIV	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cytopathic	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
MT4	NN	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
implications	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Cyclophosphamide	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
cystitis	NN	I-NP	B
in	IN	B-PP	O
freely	RB	B-NP	O
-	HYPH	I-NP	O
moving	VBG	B-VP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
:	:	O	O
behavioral	JJ	B-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
visceral	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
develop	VB	I-VP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
visceral	JJ	B-NP	B
pain	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
behavioral	JJ	I-NP	O
approach	NN	I-NP	O
.	.	O	O

Cyclophosphamide	NN	B-NP	O
(	(	O	O
CP	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
antitumoral	JJ	I-NP	O
agent	NN	I-NP	O
known	VBN	B-VP	O
to	TO	B-VP	O
produce	VB	I-VP	O
toxic	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
wall	NN	I-NP	O
through	IN	B-PP	O
its	PRP$	B-NP	O
main	JJ	I-NP	O
toxic	JJ	I-NP	O
metabolite	NN	I-NP	O
acrolein	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
induce	VB	I-VP	O
cystitis	NN	B-NP	B
.	.	O	O

CP	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg.	NN	I-NP	O
/	SYM	I-NP	O
kg.	NN	I-NP	O
i.p.	RB	B-ADVP	O
to	TO	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
behavior	NN	I-NP	O
observed	VBN	B-VP	O
and	CC	I-VP	O
scored	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
on	IN	B-PP	O
CP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
behavioral	NN	I-NP	O
modifications	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
administered	VBN	I-VP	O
alone	RB	B-ADVP	O
and	CC	O	O
after	IN	B-PP	O
naloxone	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
CP	NN	B-NP	O
injection	NN	I-NP	O
,	,	O	O
that	DT	B-NP	O
is	VBZ	B-VP	O
,	,	O	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
bladder	NN	I-NP	O
was	VBD	B-VP	O
removed	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
rats	NNS	I-NP	O
for	IN	B-PP	O
histological	JJ	B-NP	O
examination	NN	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
to	TO	B-VP	O
show	VB	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
bladder	NN	I-NP	O
is	VBZ	B-VP	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
CP	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
behavioral	JJ	I-NP	O
modifications	NNS	I-NP	O
,	,	O	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
CP	NN	B-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
/	SYM	B-NP	O
kg.	NN	I-NP	O
i.p.	RB	B-ADVP	O
and	CC	O	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
intravesical	JJ	I-NP	O
route	NN	I-NP	O
,	,	O	O
and	CC	O	O
acrolein	NN	B-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
intravesical	JJ	I-NP	O
route	NN	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
/	SYM	B-NP	O
kg.	NN	I-NP	O
i.v.	JJ	I-NP	O
RESULTS	NNS	I-NP	O
:	:	O	O
CP	NN	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-VP	O
relatedly	RB	I-VP	O
induced	VBN	I-VP	O
marked	JJ	B-NP	O
behavioral	JJ	I-NP	O
modifications	NNS	I-NP	O
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
:	:	O	O
breathing	NN	B-NP	O
rate	NN	I-NP	O
decrease	NN	I-NP	O
,	,	O	O
closing	VBG	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
eyes	NNS	I-NP	O
and	CC	I-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
specific	JJ	B-NP	O
postures	NNS	I-NP	O
.	.	O	O

Morphine	NN	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependently	RB	B-ADVP	O
reversed	VBD	B-VP	O
these	DT	B-NP	O
behavioral	JJ	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
/	SYM	B-NP	O
kg.	NN	I-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
almost	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
score	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
CP	NN	B-NP	O
num	CD	I-NP	O
mg.	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
completely	RB	I-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
naloxone	NN	B-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
,	,	O	O
histological	JJ	B-NP	O
modifications	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
wall	NN	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
chorionic	JJ	B-NP	O
and	CC	I-NP	O
muscle	NN	I-NP	O
layer	NN	I-NP	O
edema	NN	I-NP	B
,	,	O	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
CP	NN	B-NP	O
num	CD	I-NP	O
mg.	NN	I-NP	O
/	SYM	O	O
kg.	NN	B-NP	O
i.p.	RB	B-ADVP	O
produced	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
marked	JJ	I-NP	O
behavioral	JJ	I-NP	O
modifications	NNS	I-NP	O
as	IN	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Administered	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
intravesically	RB	B-ADVP	O
,	,	O	O
CP	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
any	DT	B-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
acrolein	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg.	NN	I-NP	O
intravesically	RB	B-ADVP	O
induced	VBD	B-VP	O
behavioral	JJ	B-NP	O
modifications	NNS	I-NP	O
identical	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
under	IN	B-PP	O
CP	NN	B-NP	O
num	CD	I-NP	O
mg.	NN	I-NP	O
/	SYM	B-NP	O
kg.	NN	I-NP	O
i.p.	RB	B-ADVP	O
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
maximal	JJ	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Conversely	RB	B-ADVP	O
,	,	O	O
acrolein	NN	B-NP	O
num	CD	I-NP	O
mg.	NN	I-NP	O
/	SYM	O	O
kg.	NN	B-NP	O
i.v.	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
any	DT	B-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
at	IN	B-ADVP	O
all	DT	I-ADVP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
CP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
interesting	JJ	I-NP	O
new	JJ	I-NP	O
behavioral	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
visceral	JJ	I-NP	B
pain	NN	I-NP	I
,	,	O	O
allowing	VBG	B-VP	O
a	DT	B-NP	O
better	JJR	I-NP	O
understanding	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
painful	JJ	I-NP	B
syndromes	NNS	I-NP	I
and	CC	O	O
thus	RB	B-ADVP	O
a	DT	B-NP	O
better	JJR	I-NP	O
therapeutic	JJ	I-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
them	PRP	B-NP	O
.	.	O	O

Hyperalgesia	NN	B-NP	B
and	CC	I-NP	O
myoclonus	NN	I-NP	B
in	IN	B-PP	O
terminal	JJ	B-NP	O
cancer	NN	I-NP	B
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
continuous	JJ	B-NP	O
intravenous	JJ	I-NP	O
morphine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cancer	NN	I-NP	B
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
terminal	JJ	I-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
morphine	NN	I-NP	O
developed	VBD	B-VP	O
hyperalgesia	NN	B-NP	B
.	.	O	O

All	DT	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
retrospectively	RB	I-VP	O
sampled	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
hospitals	NNS	I-NP	O
in	IN	B-PP	O
Copenhagen	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
universal	JJ	B-NP	O
hyperalgesia	NN	I-NP	B
and	CC	I-NP	O
hyperesthesia	NN	I-NP	B
which	WDT	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
myoclonus	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
a	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
existing	VBG	I-NP	O
neuralgia	NN	I-NP	B
increased	VBD	B-VP	O
to	TO	B-PP	O
excruciating	VBG	B-VP	O
intensity	NN	B-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
myoclonus	NN	I-NP	B
occurred	VBD	B-VP	O
simultaneously	RB	B-ADVP	O
.	.	O	O

Although	IN	B-SBAR	O
only	JJ	B-NP	O
few	JJ	I-NP	O
clinical	JJ	I-NP	O
descriptions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
hyperalgesia	NN	B-NP	B
/	SYM	B-NP	O
myoclonus	NN	I-NP	B
and	CC	O	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
are	VBP	B-VP	O
available	JJ	B-ADJP	O
,	,	O	O
experimental	JJ	B-NP	O
support	NN	I-NP	O
from	IN	B-PP	O
animal	NN	B-NP	O
studies	NNS	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
morphine	NN	B-NP	O
,	,	O	O
or	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
,	,	O	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
causative	JJ	I-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
observed	VBN	I-NP	O
behavioural	JJ	I-NP	O
syndrome	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
and	CC	O	O
treatment	NN	B-NP	O
proposals	NNS	I-NP	O
given	VBN	B-PP	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
more	JJR	B-NP	O
efficacious	JJ	I-NP	O
opioids	NNS	I-NP	O
with	IN	B-PP	O
less	RBR	B-NP	O
excitatory	JJ	I-NP	O
potency	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
situations	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
vancomycin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
vancomycin	NN	B-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Vancomycin	NN	B-NP	O
was	VBD	B-VP	O
curative	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
proven	JJ	B-NP	O
infection	NN	I-NP	B
.	.	O	O

Drugs	NNS	B-NP	O
were	VBD	B-VP	O
ceased	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
;	:	O	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
vancomycin	NN	I-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
the	DT	B-NP	O
likely	JJ	I-NP	O
cause	NN	I-NP	O
.	.	O	O

Reactions	NNS	B-NP	O
included	VBD	B-VP	O
thrombophlebitis	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
rash	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
nephrotoxicity	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
proteinuria	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
and	CC	O	O
ototoxicity	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
tested	VBN	B-VP	O
by	IN	B-PP	O
audiometry	NN	B-NP	O
)	)	O	O
.	.	O	O

Thrombophlebitis	NN	B-NP	B
occurred	VBD	B-VP	O
only	RB	B-ADVP	O
with	IN	B-PP	O
infusion	NN	B-NP	O
through	IN	B-PP	O
peripheral	JJ	B-NP	O
cannulae	NNS	I-NP	O
;	:	O	O
nephrotoxicity	NN	B-NP	B
and	CC	I-NP	O
ototoxicity	NN	I-NP	B
were	VBD	B-VP	O
confined	VBN	I-VP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
an	DT	B-NP	O
aminoglycoside	NN	I-NP	O
plus	CC	I-NP	O
vancomycin	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
vancomycin	NN	B-NP	O
,	,	O	O
administered	VBN	B-VP	O
appropriately	RB	B-ADVP	O
,	,	O	O
constitutes	VBZ	B-VP	O
safe	JJ	B-NP	O
,	,	I-NP	O
effective	JJ	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
infections	NNS	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
susceptible	JJ	B-NP	O
bacteria	NNS	I-NP	O
.	.	O	O

Blockade	NN	B-NP	O
of	IN	B-PP	O
both	CC	O	O
D	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
D	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
dopamine	NN	I-NP	O
receptors	NNS	I-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
catalepsy	NN	B-NP	B
in	IN	B-PP	O
mice.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
catalepsy	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
dopamine	NN	B-NP	O
antagonists	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
tested	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
possible	JJ	I-NP	O
dopamine	NN	I-NP	O
subtypes	NNS	I-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
catalepsy	NN	B-NP	B
was	VBD	B-VP	O
determined.	VBN	I-VP	O
num	CD	B-NP	O
.	.	O	O

Dopamine	NN	B-NP	O
antagonist	NN	I-NP	O
fluphenazine	NN	I-NP	O
,	,	O	O
D	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
antagonist	NN	I-NP	O
SCH	NN	I-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
antagonist	NN	I-NP	O
sulpiride	NN	I-NP	O
induced	VBD	B-VP	O
catalepsy	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
fluphenazine	NN	B-NP	O
and	CC	I-NP	O
sulpiride	NN	I-NP	O
was	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-ADJP	O
dependent	JJ	I-ADJP	O
.	.	O	O

Combination	NN	B-NP	O
of	IN	B-PP	O
SCH	NN	B-NP	O
num	CD	I-NP	O
with	IN	B-PP	O
sulpiride	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
catalepsy	NN	B-NP	B
potentiation.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

D	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
agonist	NN	I-NP	O
SKF	NN	I-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
agonist	NN	I-NP	O
quinpirole	NN	I-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
fluphenazine	NN	B-NP	O
,	,	O	O
SCH	NN	B-NP	O
num	CD	I-NP	O
or	CC	O	O
sulpiride.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Combination	NN	B-NP	O
of	IN	B-PP	O
SKF	NN	B-NP	O
num	CD	I-NP	O
with	IN	B-PP	O
quinpirole	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
potentiated	JJ	B-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
dopamine	NN	B-NP	O
antagonists.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
may	MD	B-VP	O
indicate	VB	I-VP	O
that	IN	B-SBAR	O
although	IN	B-SBAR	O
D	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
blockade	NN	I-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
catalepsy	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
receptor	NN	I-NP	O
may	MD	B-VP	O
plan	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
.	.	O	O

Dextran	NN	B-NP	O
-	HYPH	I-NP	O
etodolac	NN	I-NP	O
conjugates	NNS	I-NP	O
:	:	O	O
synthesis	NN	B-NP	O
,	,	O	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-NP	O
vivo	FW	I-NP	O
evaluation	NN	I-NP	O
.	.	O	O

Etodolac	NN	B-NP	O
(	(	O	O
E	NN	B-NP	O
)	)	O	O
,	,	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
narcotic	JJ	I-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
antiinflammatory	JJ	I-NP	O
drug	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
biodegradable	JJ	I-NP	O
polymer	NN	I-NP	O
dextran	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
utilized	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
carrier	NN	I-NP	O
for	IN	B-PP	O
synthesis	NN	B-NP	O
of	IN	B-PP	O
etodolac	NN	B-NP	O
-	HYPH	B-NP	O
dextran	NN	I-NP	O
conjugates	NNS	I-NP	O
(	(	O	O
ED	VBN	B-VP	O
)	)	O	O
to	TO	B-VP	O
improve	VB	I-VP	O
its	PRP$	B-NP	O
aqueous	JJ	I-NP	O
solubility	NN	I-NP	O
and	CC	O	O
reduce	VB	B-VP	O
gastrointestinal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
activated	VBN	I-NP	O
moiety	NN	I-NP	O
,	,	O	O
i.e.	FW	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
acylimidazole	NN	I-NP	O
derivative	NN	I-NP	O
of	IN	B-PP	O
etodolac	NN	B-NP	O
(	(	O	O
EAI	NN	B-NP	O
)	)	O	O
,	,	O	O
was	VBD	B-VP	O
condensed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
polysaccharide	NN	I-NP	O
polymer	NN	I-NP	O
dextran	NN	I-NP	O
of	IN	B-PP	O
different	JJ	B-NP	O
molecular	JJ	I-NP	O
weights	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

IR	NN	B-NP	O
spectral	JJ	I-NP	O
data	NNS	I-NP	O
confirmed	VBD	B-VP	O
formation	NN	B-NP	O
of	IN	B-PP	O
ester	NN	B-NP	O
bonding	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
conjugates	NNS	I-NP	O
.	.	O	O

Etodolac	NN	B-NP	O
contents	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
UV	NN	B-NP	O
-	HYPH	B-NP	O
spectrophotometric	JJ	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
molecular	JJ	I-NP	O
weights	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
measuring	VBG	B-VP	O
viscosity	NN	B-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Mark	NNP	I-NP	O
-	HYPH	I-NP	O
Howink	NNP	I-NP	O
-	HYPH	I-NP	O
Sakurada	NNP	I-NP	O
equation	NN	I-NP	O
.	.	O	O

In	FW	B-NP	O
vitro	FW	I-NP	O
hydrolysis	NN	I-NP	O
of	IN	B-PP	O
ED	NN	B-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
in	IN	B-PP	O
aqueous	JJ	B-NP	O
buffers	NNS	I-NP	O
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
v	NN	B-NP	O
/	SYM	B-NP	O
v	NN	I-NP	O
)	)	I-NP	O
human	JJ	I-NP	O
plasma	NN	I-NP	O
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

At	IN	B-PP	O
pH	NN	B-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
etodolac	NN	B-NP	O
release	NN	I-NP	O
from	IN	B-PP	O
ED	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
aqueous	JJ	B-NP	O
buffer	NN	I-NP	O
of	IN	B-PP	O
pH	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
human	JJ	I-NP	O
plasma	NN	I-NP	O
(	(	O	O
pH	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
following	VBG	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
order	NN	I-NP	O
kinetics	NNS	I-NP	O
.	.	O	O

In	FW	B-NP	O
vivo	FW	I-NP	O
investigations	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

Acute	JJ	B-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
antiinflammatory	JJ	I-NP	O
activities	NNS	I-NP	O
were	VBD	B-VP	O
ascertained	VBN	I-VP	O
using	VBG	B-VP	O
acetic	JJ	B-NP	O
acid	NN	I-NP	O
induced	VBD	B-VP	O
writhing	VBG	I-VP	B
model	NN	B-NP	O
(	(	O	O
mice	NNS	B-NP	O
)	)	O	O
and	CC	O	O
carrageenan	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rat	NN	I-NP	O
paw	NN	I-NP	O
edema	NN	I-NP	B
model	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
,	,	I-NP	O
E	NN	I-NP	O
and	CC	I-NP	O
ED1	NN	I-NP	O
-	HYPH	B-NP	O
ED4	NN	I-NP	O
showed	VBD	B-VP	O
highly	RB	B-NP	O
significant	JJ	I-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
antiinflammatory	JJ	I-NP	O
activities	NNS	I-NP	O
.	.	O	O

Biological	JJ	B-NP	O
evaluation	NN	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
conjugates	NNS	B-NP	O
(	(	O	O
ED1	NN	B-NP	O
-	HYPH	B-NP	O
ED4	NN	I-NP	O
)	)	O	O
retained	VBD	B-VP	O
comparable	JJ	B-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
antiinflammatory	JJ	I-NP	O
activities	NNS	I-NP	O
with	IN	B-PP	O
remarkably	RB	B-NP	O
reduced	VBN	I-NP	O
ulcerogenicity	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
parent	NN	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
-	SYM	I-NP	O
etodolac	NN	B-NP	O
.	.	O	O

Hypersensitivity	NN	B-NP	B
myocarditis	NN	I-NP	B
complicating	VBG	B-VP	O
hypertrophic	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
heart	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
eosinophilic	JJ	B-NP	B
myocarditis	NN	I-NP	I
complicating	VBG	B-VP	O
hypertrophic	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
known	VBN	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
hypertrophic	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
,	,	O	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
with	IN	B-PP	O
biventricular	JJ	B-NP	B
failure	NN	I-NP	I
and	CC	O	O
managed	VBD	B-VP	O
aggressively	RB	B-ADVP	O
with	IN	B-PP	O
dobutamine	NN	B-NP	O
infusion	NN	I-NP	O
and	CC	O	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
while	IN	B-SBAR	O
being	VBG	B-VP	O
assessed	VBN	I-VP	O
for	IN	B-PP	O
heart	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
transthoracic	JJ	B-NP	O
echocardiogram	NN	I-NP	O
,	,	O	O
she	PRP	B-NP	O
had	VBD	B-VP	O
moderate	JJ	B-NP	O
left	JJ	I-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
with	IN	B-PP	O
regional	JJ	B-NP	O
variability	NN	I-NP	O
and	CC	O	O
moderate	JJ	B-NP	O
mitral	JJ	I-NP	B
regurgitation	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
recipient	JJ	I-NP	O
s	NN	I-NP	O
heart	NN	I-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
apical	JJ	B-NP	O
hypertrophic	JJ	I-NP	B
cardiomyopathy	NN	I-NP	I
and	CC	I-NP	O
myocarditis	NN	I-NP	B
with	IN	B-PP	O
abundant	JJ	B-NP	O
eosinophils	NNS	I-NP	O
.	.	O	O

Myocarditis	NN	B-NP	B
is	VBZ	B-VP	O
rare	JJ	B-NP	O
and	CC	I-NP	O
eosinophilic	JJ	I-NP	B
myocarditis	NN	I-NP	I
is	VBZ	B-VP	O
rarer	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
hypersensitivity	NN	I-NP	B
(	(	O	O
eosinophilic	JJ	O	B
)	)	O	O
myocarditis	NN	B-NP	B
was	VBD	B-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
dobutamine	NN	B-NP	O
infusion	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Eosinophilic	JJ	B-NP	B
myocarditis	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
explanted	VBN	B-NP	O
hearts	NNS	I-NP	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
multidrug	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
-	HYPH	I-NP	O
trans	AFX	I-NP	O
-	HYPH	I-NP	O
retinoic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
erythema	NN	I-NP	B
nodosum	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
promyelocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
.	.	O	O

Erythema	NN	B-NP	B
nodosum	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
all	DT	B-NP	O
-	HYPH	I-NP	O
trans	AFX	I-NP	O
-	HYPH	I-NP	O
retinoic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
ATRA	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
acute	JJ	B-NP	B
promyelocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
(	(	O	O
APL	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
very	RB	B-ADJP	O
rare	JJ	I-ADJP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
classic	JJ	B-NP	O
APL	NN	I-NP	B
who	WP	B-NP	O
developed	VBD	B-VP	O
erythema	NN	B-NP	B
nodosum	NN	I-NP	I
during	IN	B-PP	O
ATRA	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Fever	RB	B-ADVP	B
and	CC	O	O
subsequent	JJ	B-NP	O
multiple	JJ	I-NP	O
painful	JJ	I-NP	B
erythematous	JJ	I-NP	B
nodules	NNS	I-NP	I
over	IN	B-PP	O
extremities	NNS	B-NP	O
developed	VBN	B-VP	O
on	IN	B-PP	O
D11	NN	B-NP	O
,	,	O	O
D16	NN	B-NP	O
,	,	O	O
D17	NN	B-NP	O
,	,	O	O
and	CC	O	O
D19	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
after	IN	B-PP	O
ATRA	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
skin	NN	I-NP	O
biopsy	NN	I-NP	O
taken	VBN	B-VP	O
from	IN	B-PP	O
each	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
erythema	NN	B-NP	B
nodosum	NN	I-NP	I
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
short	JJ	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
steroids	NNS	B-NP	O
.	.	O	O

Fever	NNP	B-NP	B
subsided	VBD	B-VP	O
rapidly	RB	B-ADVP	O
and	CC	O	O
the	DT	B-NP	O
skin	NN	I-NP	O
lesions	NNS	I-NP	O
regressed	VBD	B-VP	O
completely	RB	B-ADVP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
achieved	VBD	B-VP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
without	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
ATRA	NN	B-NP	O
.	.	O	O

ATRA	NN	B-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
possible	JJ	I-NP	O
etiology	NN	I-NP	O
of	IN	B-PP	O
erythema	NN	B-NP	B
nodosum	NN	I-NP	I
in	IN	B-PP	O
our	PRP$	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
steroid	NN	B-NP	O
is	VBZ	B-VP	O
very	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
ATRA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
erythema	NN	I-NP	B
nodosum	NN	I-NP	I
.	.	O	O

Delayed	VBN	B-VP	O
-	HYPH	B-NP	O
onset	NN	I-NP	O
heparin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
.	.	O	O

Heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
presents	VBZ	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
heparin	NN	B-NP	O
exposure	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
arterial	JJ	B-NP	B
or	CC	I-NP	I
venous	JJ	I-NP	I
thromboemboli	NNS	I-NP	I
.	.	O	O

Delayed	VBN	B-NP	O
recognition	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
contribute	VBP	B-VP	O
to	TO	B-PP	O
poor	JJ	B-NP	O
patient	NN	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
describe	VB	I-VP	O
and	CC	I-VP	O
increase	VB	I-VP	O
awareness	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
scenario	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
onset	NN	I-NP	O
or	CC	I-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
are	VBP	B-VP	O
delayed	VBN	I-VP	O
.	.	O	O

Retrospective	JJ	B-NP	O
case	NN	I-NP	O
series	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
large	JJ	I-NP	O
urban	JJ	I-NP	O
hospitals	NNS	I-NP	O
(	(	O	O
with	IN	B-PP	O
active	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
surgery	NN	I-NP	O
programs	NNS	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
seen	VBN	B-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
heparin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
became	VBD	B-VP	O
apparent	JJ	B-ADJP	O
on	IN	B-PP	O
delayed	VBN	B-NP	O
presentation	NN	I-NP	O
with	IN	B-PP	O
thromboembolic	JJ	B-NP	B
complications	NNS	I-NP	O
.	.	O	O

Platelet	NN	B-NP	O
counts	NNS	I-NP	O
,	,	O	O
onset	NN	B-NP	O
of	IN	B-PP	O
objectively	RB	B-NP	O
determined	VBN	I-NP	O
thromboembolism	NN	I-NP	B
,	,	O	O
results	NNS	B-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
platelet	NN	I-NP	O
factor	NN	I-NP	O
num	CD	I-NP	O
antibody	NN	I-NP	O
tests	NNS	I-NP	O
,	,	O	O
and	CC	O	O
outcomes	NNS	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
went	VBD	B-VP	O
home	RB	B-ADVP	O
after	IN	B-PP	O
hospitalizations	NNS	B-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
included	VBN	I-VP	O
heparin	NN	B-NP	O
exposure	NN	I-NP	O
-	HYPH	B-VP	O
-	SYM	B-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
thrombocytopenia	NN	I-NP	B
recognized	VBN	B-VP	O
-	HYPH	B-ADJP	O
-	HYPH	B-CONJP	O
only	RB	B-ADVP	O
to	TO	B-VP	O
return	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
(	(	O	O
median	NN	B-NP	O
,	,	O	O
day	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
with	IN	B-PP	O
thromboembolic	JJ	B-NP	B
complications	NNS	I-NP	O
.	.	O	O

Thromboemboli	NNP	B-NP	B
were	VBD	B-VP	O
venous	JJ	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
pulmonary	JJ	B-NP	B
emboli	NNS	I-NP	I
)	)	O	O
or	CC	O	O
arterial	JJ	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
or	CC	O	O
both	DT	B-NP	O
.	.	O	O

Platelet	NN	B-NP	O
counts	NNS	I-NP	O
were	VBD	B-VP	O
mildly	RB	I-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
but	CC	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
on	IN	B-PP	O
second	JJ	B-NP	O
presentation	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
readmission	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
therapeutic	JJ	B-NP	O
heparin	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
worsened	VBD	B-VP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
s	VBZ	B-VP	O
clinical	JJ	B-NP	O
condition	NN	I-NP	O
and	CC	O	O
,	,	O	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
platelet	NN	I-NP	O
count	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
at	IN	B-PP	O
readmission	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
L	NN	B-NP	O
;	:	O	O
mean	JJ	B-NP	O
nadir	NN	I-NP	O
after	IN	B-PP	O
heparin	NN	B-NP	O
re	AFX	O	O
-	HYPH	O	O
exposure	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
L	NN	B-NP	O
)	)	O	O
.	.	O	O

Results	NNS	B-NP	O
of	IN	B-PP	O
serologic	JJ	B-NP	O
tests	NNS	I-NP	O
for	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
antibodies	NNS	I-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Subsequent	JJ	B-NP	O
treatments	NNS	I-NP	O
included	VBD	B-VP	O
alternative	JJ	B-NP	O
anticoagulants	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
thrombolytic	JJ	B-NP	O
drugs	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
inferior	JJ	B-NP	O
vena	NN	I-NP	O
cava	NN	I-NP	O
filters	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
and	CC	O	O
,	,	O	O
eventually	RB	B-ADVP	O
,	,	O	O
warfarin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
.	.	O	O

Delayed	VBN	B-VP	O
-	HYPH	B-NP	O
onset	NN	I-NP	O
heparin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
is	VBZ	B-VP	O
increasingly	RB	I-VP	O
being	VBG	I-VP	O
recognized	VBN	I-VP	O
.	.	O	O

To	TO	B-VP	O
avoid	VB	I-VP	O
disastrous	JJ	B-NP	O
outcomes	NNS	I-NP	O
,	,	O	O
physicians	NNS	B-NP	O
must	MD	B-VP	O
consider	VB	I-VP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
whenever	WRB	B-ADVP	O
a	DT	B-NP	O
recently	RB	I-NP	O
hospitalized	VBN	I-NP	O
patient	NN	I-NP	O
returns	NNS	I-NP	O
with	IN	B-PP	O
thromboembolism	NN	B-NP	B
;	:	O	O
therapy	NN	B-NP	O
with	IN	B-PP	O
alternative	JJ	B-NP	O
anticoagulants	NNS	I-NP	O
,	,	B-NP	O
not	RB	I-NP	O
heparin	NN	I-NP	O
,	,	O	O
should	MD	B-VP	O
be	VB	I-VP	O
initiated	VBN	I-VP	O
.	.	O	O

Valsartan	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
angiotensin	NN	I-NP	O
num	CD	I-NP	O
antagonist	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
essential	JJ	B-NP	O
hypertension	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
comparative	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
against	IN	B-PP	O
amlodipine	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
antihypertensive	JJ	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
angiotensin	NN	I-NP	O
num	CD	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
valsartan	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
reference	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
amlodipine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
adult	JJ	I-NP	O
outpatients	NNS	I-NP	O
with	IN	B-PP	O
mild	JJ	B-ADJP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
hypertension	NN	I-NP	B
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
in	IN	B-PP	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
fashion	NN	I-NP	O
and	CC	I-NP	O
equal	JJ	I-NP	O
number	NN	I-NP	O
to	TO	B-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
valsartan	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
amlodipine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
whose	WP$	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
remained	VBD	B-VP	O
uncontrolled	JJ	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
amlodipine	NN	I-NP	O
was	VBD	B-VP	O
added	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
efficacy	NN	I-NP	O
variable	NN	I-NP	O
was	VBD	B-VP	O
change	NN	B-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
sitting	VBG	I-NP	O
diastolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Secondary	JJ	B-NP	O
variables	NNS	I-NP	O
included	VBD	B-VP	O
change	NN	B-NP	O
in	IN	B-PP	O
sitting	VBG	B-VP	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
responder	NN	I-NP	O
rates	NNS	I-NP	O
.	.	O	O

Both	CC	O	O
valsartan	NN	B-NP	O
and	CC	I-NP	O
amlodipine	NN	I-NP	O
were	VBD	B-VP	O
effective	JJ	B-ADJP	O
at	IN	B-PP	O
lowering	VBG	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Similar	JJ	B-NP	O
decreases	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
for	IN	B-PP	O
any	DT	B-NP	O
variable	JJ	I-NP	O
analyzed	VBN	I-NP	O
.	.	O	O

For	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
variable	JJ	I-NP	O
the	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
in	IN	B-PP	O
favor	NN	B-NP	O
of	IN	B-PP	O
valsartan	NN	B-NP	O
.	.	O	O

Responder	NN	B-NP	O
rates	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
valsartan	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
for	IN	B-PP	O
amlodipine	NN	B-NP	O
.	.	O	O

Both	DT	B-NP	O
treatments	NNS	I-NP	O
were	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
dependent	JJ	I-NP	O
edema	NN	I-NP	B
was	VBD	B-VP	O
somewhat	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
amlodipine	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
valsartan	NN	B-NP	O
is	VBZ	B-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
as	RB	B-ADJP	O
effective	JJ	I-ADJP	O
as	IN	B-PP	O
amlodipine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
mild	JJ	B-NP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
also	RB	B-ADVP	O
show	VBP	B-VP	O
valsartan	NN	B-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
characteristic	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
comparator	NN	I-NP	O
class	NN	I-NP	O
,	,	O	O
dihydropyridine	NN	B-NP	O
calcium	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

KF17837	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
novel	JJ	I-NP	O
selective	JJ	I-NP	O
adenosine	NN	I-NP	O
A2A	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
with	IN	B-PP	O
anticataleptic	JJ	B-NP	O
activity	NN	I-NP	O
.	.	O	O

KF17837	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
selective	JJ	I-NP	O
adenosine	NN	I-NP	O
A2A	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

Oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
KF17837	NN	B-NP	O
significantly	RB	B-ADVP	O
ameliorated	VBD	B-VP	O
the	DT	B-NP	O
cataleptic	JJ	I-NP	B
responses	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
intracerebroventricular	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
adenosine	NN	I-NP	O
A2A	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
CGS	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
)	)	O	O
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

KF17837	NN	B-NP	O
also	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
reserpine	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
anticataleptic	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
exhibited	VBN	I-VP	O
dose	NN	B-NP	O
dependently	RB	B-ADVP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
p.o.	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
KF17837	NN	B-NP	O
potentiated	VBD	B-VP	O
the	DT	B-NP	O
anticataleptic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
subthreshold	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydroxyphenylalanine	NN	I-NP	O
plus	CC	I-NP	O
benserazide	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
KF17837	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
centrally	RB	I-NP	O
active	JJ	I-NP	O
adenosine	NN	I-NP	O
A2A	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nigrostriatal	JJ	I-NP	O
pathway	NN	I-NP	O
is	VBZ	B-VP	O
potentiated	VBN	I-VP	O
by	IN	B-PP	O
adenosine	NN	B-NP	O
A2A	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
KF17837	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
parkinsonism	NN	B-NP	B
.	.	O	O

Some	DT	B-NP	O
central	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
repeated	VBN	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
fluvoxamine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
repeated	VBN	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
fluvoxamine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
uptake	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
behavioral	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dopaminomimetics	NNS	B-NP	O
and	CC	O	O
methoxamine	NN	B-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
animal	NN	I-NP	O
behavior	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
despair	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
repeated	VBN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
fluvoxamine	NN	B-NP	O
(	(	O	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
potentiated	VBD	B-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
(	(	O	O
weaker	JJR	B-ADJP	O
)	)	O	O
the	DT	B-NP	O
amphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
hyperactivity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
nomifensine	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
remained	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
by	IN	B-PP	O
fluvoxamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
by	IN	B-PP	O
intracerebroventricularly	RB	B-NP	O
administered	VBN	I-NP	O
methoxamine	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
repeated	VBN	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
fluvoxamine	NN	B-NP	O
.	.	O	O

Given	VBN	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
fluvoxamine	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
immobilization	NN	I-NP	O
time	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
despair	NN	I-NP	O
test	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
fluvoxamine	NN	B-NP	O
given	VBN	B-VP	O
repeatedly	RB	B-ADVP	O
acts	VBZ	B-VP	O
differently	RB	B-ADVP	O
than	IN	B-PP	O
citalopram	NN	B-NP	O
,	,	O	O
another	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
uptake	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
and	CC	O	O
differs	VBZ	B-VP	O
also	RB	B-ADVP	O
from	IN	B-PP	O
other	JJ	B-NP	O
antidepressant	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
congestive	JJ	I-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
patient	NN	I-NP	O
on	IN	B-PP	O
amiodarone	NN	B-NP	O
presenting	VBG	B-VP	O
with	IN	B-PP	O
myxedemic	JJ	B-NP	B
coma	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
myxedema	NN	B-NP	B
coma	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypothyroidism	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
congestive	JJ	I-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
CHF	NN	B-NP	B
)	)	O	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
and	CC	B-PP	O
after	IN	B-PP	O
reviewing	VBG	B-VP	O
the	DT	B-NP	O
literature	NN	I-NP	O
there	EX	B-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
myxedema	NN	B-NP	B
coma	NN	I-NP	I
during	IN	B-PP	O
long	JJ	B-NP	O
term	NN	I-NP	O
amiodarone	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Myxedema	NN	B-NP	B
coma	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
life	NN	I-NP	O
threatening	NN	I-NP	O
condition	NN	I-NP	O
that	WDT	B-NP	O
carries	VBZ	B-VP	O
a	DT	B-NP	O
mortality	NN	I-NP	O
reaching	VBG	B-VP	O
as	RB	B-ADVP	O
high	JJ	I-ADVP	O
as	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
condition	NN	I-NP	O
is	VBZ	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
thyroxine	NN	I-NP	O
(	(	O	O
T4	NN	B-NP	O
)	)	O	O
or	CC	O	O
intravenous	JJ	B-ADJP	O
tri	AFX	O	O
-	HYPH	O	O
iodo	AFX	O	O
-	HYPH	O	O
thyronine	NN	B-NP	O
(	(	O	O
T3	NN	B-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
CHF	NN	B-NP	B
on	IN	B-PP	O
amiodarone	NN	B-NP	O
may	MD	B-VP	O
suffer	VB	I-VP	O
serious	JJ	B-NP	O
morbidity	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
from	IN	B-PP	O
hypothyroidism	NN	B-NP	B
,	,	O	O
and	CC	O	O
thus	RB	B-VP	O
may	MD	I-VP	O
deserve	VB	I-VP	O
closer	RBR	B-VP	O
follow	VB	I-VP	O
up	RP	B-PRT	O
for	IN	B-PP	O
thyroid	NN	B-NP	O
stimulating	VBG	B-VP	O
hormone	NN	B-NP	O
(	(	O	O
TSH	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
carries	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
clinical	JJ	I-NP	O
application	NN	I-NP	O
given	VBN	B-PP	O
the	DT	B-NP	O
frequent	JJ	I-NP	O
usage	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
among	IN	B-PP	O
CHF	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
myriad	JJ	I-NP	O
clinical	JJ	I-NP	O
presentation	NN	I-NP	O
of	IN	B-PP	O
myxedema	NN	B-NP	B
coma	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
serious	JJ	I-NP	O
morbidity	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
stresses	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
suspect	VB	I-VP	O
this	DT	B-NP	O
clinical	JJ	I-NP	O
syndrome	NN	I-NP	O
among	IN	B-PP	O
CHF	NN	B-NP	B
patients	NNS	I-NP	O
presenting	VBG	B-VP	O
with	IN	B-PP	O
hypotension	NN	B-NP	B
,	,	O	O
weakness	NN	B-NP	B
or	CC	O	O
other	JJ	B-NP	O
unexplained	JJ	I-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

Fear	NN	B-NP	O
-	HYPH	B-PP	O
potentiated	VBN	B-NP	O
startle	NN	I-NP	B
,	,	B-PP	O
but	CC	I-PP	O
not	RB	O	O
light	NN	B-NP	O
-	HYPH	O	O
enhanced	VBN	B-VP	O
startle	NN	B-NP	B
,	,	O	O
is	VBZ	B-VP	O
enhanced	VBN	I-VP	O
by	IN	B-PP	O
anxiogenic	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
light	NN	I-NP	O
-	HYPH	B-VP	O
enhanced	VBN	B-NP	O
startle	NN	I-NP	B
paradigm	NN	I-NP	O
(	(	O	O
LES	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
to	TO	B-PP	O
model	NN	B-NP	O
anxiety	NN	I-NP	B
,	,	O	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
cue	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
fear	NN	I-NP	O
-	HYPH	O	O
potentiated	VBN	B-VP	O
startle	NN	B-NP	B
(	(	O	O
FPS	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
to	TO	I-VP	O
model	VB	I-VP	O
conditioned	JJ	B-NP	O
fear	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
pharmacological	JJ	I-NP	O
profiles	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
paradigms	NNS	I-NP	O
are	VBP	B-VP	O
very	RB	B-ADJP	O
similar	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
putative	JJ	B-NP	O
anxiogenic	JJ	I-NP	O
drugs	NNS	I-NP	O
on	IN	B-PP	O
LES	NN	B-NP	O
and	CC	I-NP	O
FPS	NN	I-NP	O
and	CC	O	O
aimed	VBN	B-VP	O
at	IN	B-PP	O
determining	VBG	B-VP	O
the	DT	B-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
LES	NN	B-NP	O
for	IN	B-PP	O
anxiogenic	JJ	B-NP	O
drugs	NNS	I-NP	O
and	CC	O	O
to	TO	B-VP	O
potentially	RB	I-VP	O
showing	VBG	I-VP	O
a	DT	B-NP	O
pharmacological	JJ	I-NP	O
differentiation	NN	I-NP	O
between	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
paradigms	NNS	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
each	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
antagonist	NN	I-NP	O
yohimbine	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
(	(	O	O
2C	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
agonist	NN	I-NP	O
m	NN	I-NP	O
-	HYPH	B-NP	O
chlorophenylpiperazine	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
GABA	NN	I-NP	O
(	(	I-NP	O
A	NN	I-NP	O
)	)	I-NP	O
inverse	JJ	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
pentylenetetrazole	NN	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
subsequently	RB	I-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
either	CC	O	O
LES	NN	B-NP	O
or	CC	I-NP	O
FPS	NN	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
enhanced	VBD	B-VP	O
LES	NNS	B-NP	O
,	,	O	O
whereas	IN	O	O
mCPP	NN	B-NP	O
increased	VBD	B-VP	O
percentage	NN	B-NP	O
FPS	NNS	I-NP	O
and	CC	O	O
yohimbine	NN	B-NP	O
increased	VBD	B-VP	O
absolute	JJ	B-NP	O
FPS	NN	I-NP	O
values	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
yohimbine	NN	B-NP	O
increased	VBD	B-VP	O
baseline	NN	B-NP	O
startle	NN	I-NP	B
amplitude	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
LES	NNP	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
mCPP	NN	B-NP	O
suppressed	VBD	B-VP	O
baseline	NN	B-NP	O
startle	NN	I-NP	B
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
LES	NN	I-NP	O
and	CC	I-NP	O
FPS	NN	I-NP	O
and	CC	I-NP	O
PTZ	NN	I-NP	O
suppressed	VBD	B-VP	O
baseline	NN	B-NP	O
startle	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
FPS	NNP	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
findings	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
FPS	NNP	I-NP	O
paradigm	NN	I-NP	O
,	,	O	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
exacerbate	VB	I-VP	O
the	DT	B-NP	O
LES	NN	I-NP	O
response	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
clear	JJ	I-NP	O
pharmacological	JJ	I-NP	O
differentiation	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
LES	NNS	B-NP	O
and	CC	I-NP	O
FPS	NNS	I-NP	O
.	.	O	O

Proteinase	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
antineutrophil	NN	I-NP	O
cytoplasmic	JJ	I-NP	O
antibody	NN	I-NP	O
-	HYPH	O	O
(	(	O	O
PR3	NN	B-NP	O
-	HYPH	I-NP	O
ANCA	NN	I-NP	O
)	)	I-NP	O
positive	JJ	I-NP	O
necrotizing	VBG	I-NP	O
glomerulonephritis	NN	I-NP	B
after	IN	B-PP	O
restarting	VBG	B-VP	O
sulphasalazine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
ulcerative	JJ	B-NP	B
colitis	NN	I-NP	I
developed	VBD	B-VP	O
red	JJ	B-NP	B
eyes	NNS	I-NP	I
,	,	O	O
pleural	JJ	B-NP	B
effusion	NN	I-NP	I
,	,	O	O
eosinophilia	NN	B-NP	B
and	CC	O	O
urinary	JJ	B-NP	B
abnormalities	NNS	I-NP	I
after	IN	B-PP	O
restarting	VBG	B-VP	O
of	IN	B-PP	O
sulphasalazine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Light	NN	B-NP	O
microscopy	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
kidney	NN	I-NP	O
biopsy	NN	I-NP	O
revealed	VBD	B-VP	O
segmental	JJ	B-NP	B
necrotizing	VBG	I-NP	I
glomerulonephritis	NN	I-NP	I
without	IN	B-PP	O
deposition	NN	B-NP	O
of	IN	B-PP	O
immunoglobulin	NN	B-NP	O
or	CC	I-NP	O
complement	NN	I-NP	O
.	.	O	O

Proteinase	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
antineutrophil	NN	I-NP	O
cytoplasmic	JJ	I-NP	O
antibody	NN	I-NP	O
(	(	O	O
PR3	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
)	)	O	O
titer	NN	B-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
ELISA	NN	I-NP	O
units	NNS	I-NP	O
(	(	O	O
EU	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
sera	NNS	B-NP	O
,	,	O	O
myeloperoxidase	NN	B-NP	O
-	HYPH	O	O
ANCA	NN	B-NP	O
was	VBD	B-VP	O
negative	JJ	B-ADJP	O
.	.	O	O

PR3	NN	B-NP	O
-	HYPH	I-NP	O
ANCA	NN	I-NP	O
titer	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
EU	NN	I-NP	O
in	IN	B-PP	O
pleural	JJ	B-NP	B
effusions	NNS	I-NP	I
on	IN	B-PP	O
right	JJ	B-NP	O
and	CC	I-NP	O
left	JJ	I-NP	O
side	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Although	IN	B-SBAR	O
cessation	NN	B-NP	O
of	IN	B-PP	O
sulphasalazine	NN	B-NP	O
treatment	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
improvements	NNS	B-NP	O
in	IN	B-PP	O
fever	NN	B-NP	B
,	,	O	O
red	JJ	B-NP	B
eyes	NNS	I-NP	I
,	,	O	O
chest	NN	B-NP	B
pain	NN	I-NP	I
,	,	O	O
titer	NN	B-NP	O
of	IN	B-PP	O
C	NN	B-NP	O
-	HYPH	B-NP	O
reactive	JJ	I-NP	O
protein	NN	I-NP	O
and	CC	I-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pleural	JJ	I-NP	B
effusions	NNS	I-NP	I
,	,	O	O
we	PRP	B-NP	O
initiated	VBD	B-VP	O
steroid	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
because	IN	B-SBAR	O
PR3	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
titer	NN	I-NP	O
rose	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
EU	NN	I-NP	O
,	,	O	O
eosinophil	NN	B-NP	O
count	NN	I-NP	O
increased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
microl	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
pleural	JJ	I-NP	B
effusion	NN	I-NP	I
remained	VBD	B-VP	O
.	.	O	O

num	CD	B-NP	O
month	NN	I-NP	O
after	IN	B-PP	O
steroid	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
pleural	JJ	I-NP	B
effusion	NN	I-NP	I
disappeared	VBD	B-VP	O
,	,	O	O
and	CC	O	O
PR3	NN	B-NP	O
-	HYPH	I-NP	O
ANCA	NN	I-NP	O
titer	NN	I-NP	O
normalized	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
sulphasalazine	NN	B-NP	O
can	MD	B-VP	O
induce	VB	I-VP	O
PR3	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
necrotizing	VBG	I-NP	O
glomerulonephritis	NN	I-NP	B
.	.	O	O

Is	VBZ	O	O
phenytoin	NN	B-NP	O
administration	NN	I-NP	O
safe	JJ	B-ADJP	O
in	IN	B-PP	O
a	DT	B-NP	O
hypothermic	JJ	I-NP	B
child	NN	I-NP	O
?	.	O	O
A	DT	B-NP	O
male	JJ	I-NP	O
neonate	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
Chiari	NNP	I-NP	B
malformation	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
leaking	VBG	I-NP	O
myelomeningocoele	NN	I-NP	O
underwent	VBD	B-VP	O
ventriculoperitoneal	JJ	B-NP	O
shunt	NN	I-NP	O
insertion	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
repair	NN	B-NP	O
of	IN	B-PP	O
myelomeningocoele	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
anaesthesia	NN	B-NP	O
and	CC	I-NP	O
surgery	NN	I-NP	O
,	,	O	O
he	PRP	B-NP	O
inadvertently	RB	B-ADVP	O
became	VBD	B-VP	O
moderately	RB	B-ADJP	O
hypothermic	JJ	I-ADJP	B
.	.	O	O

Intravenous	JJ	B-NP	O
phenytoin	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
later	JJ	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
surgery	NN	I-NP	O
for	IN	B-PP	O
seizure	NN	B-NP	B
prophylaxis	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
phenytoin	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
severe	JJ	I-NP	O
bradycardia	NN	I-NP	B
,	,	O	O
refractory	JJ	B-ADJP	O
to	TO	B-PP	O
atropine	NN	B-NP	O
and	CC	I-NP	O
adrenaline	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cardiac	JJ	I-NP	O
depressant	JJ	I-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
and	CC	I-NP	O
hypothermia	NN	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
additive	JJ	B-ADJP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
hypothermia	NN	B-NP	B
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
cardiac	JJ	I-NP	O
event	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

As	IN	B-SBAR	O
phenytoin	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
drug	NN	I-NP	O
,	,	O	O
clinicians	NNS	B-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
interaction	NN	I-NP	O
.	.	O	O

Amisulpride	NN	B-NP	O
related	VBN	B-VP	O
tic	JJ	B-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
symptoms	NNS	I-NP	I
in	IN	B-PP	O
an	DT	B-NP	O
adolescent	JJ	I-NP	O
schizophrenic	NN	I-NP	B
.	.	O	O

Tic	JJ	B-NP	B
disorders	NNS	I-NP	I
can	MD	B-VP	O
be	VB	I-VP	O
effectively	RB	I-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
atypical	JJ	B-NP	O
antipsychotics	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
risperidone	NN	B-NP	O
,	,	I-NP	O
olanzapine	NN	I-NP	O
and	CC	I-NP	O
ziprasidone	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
are	VBP	B-VP	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
that	WDT	B-NP	O
show	VBP	B-VP	O
tic	JJ	B-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
symptoms	NNS	I-NP	I
,	,	O	O
including	VBG	B-PP	O
motor	NN	B-NP	O
and	CC	O	O
phonic	JJ	B-NP	O
variants	NNS	I-NP	O
,	,	O	O
occurring	VBG	B-VP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
or	CC	I-NP	O
clozapine	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
girl	NN	I-NP	O
schizophrenic	NN	I-NP	B
who	WP	B-NP	O
developed	VBD	B-VP	O
frequent	JJ	B-NP	O
involuntary	JJ	I-NP	B
eye	NN	I-NP	I
-	HYPH	O	I
blinking	VBG	B-VP	I
movements	NNS	B-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
amisulpride	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
tic	JJ	I-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
symptoms	NNS	I-NP	I
resolved	VBN	B-VP	O
completely	RB	B-ADVP	O
after	IN	B-SBAR	O
we	PRP	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
amisulpride	NN	B-NP	O
down	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
her	PRP$	B-NP	O
psychosis	NN	I-NP	B
recurred	VBD	B-VP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
dose	NN	I-NP	O
reduction	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
then	RB	B-ADVP	O
placed	VBD	B-VP	O
her	PRP	B-NP	O
on	IN	B-PP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
of	IN	B-PP	O
quetiapine	NN	B-NP	O
.	.	O	O

She	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
in	IN	B-PP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
combined	VBN	I-NP	O
medications	NNS	I-NP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
and	CC	O	O
maintains	VBZ	B-VP	O
a	DT	B-NP	O
fair	JJ	I-NP	O
role	NN	I-NP	O
function	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
more	RBR	I-NP	O
tic	JJ	I-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
symptoms	NNS	I-NP	I
or	CC	O	O
other	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Together	RB	B-ADVP	O
with	IN	B-PP	O
previously	RB	B-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
tic	JJ	B-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
symptoms	NNS	I-NP	I
might	MD	B-VP	O
occur	VB	I-VP	O
in	IN	B-PP	O
certain	JJ	B-NP	O
vulnerable	JJ	I-NP	O
individuals	NNS	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
atypical	JJ	B-NP	O
antipsychotics	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
quetiapine	NN	B-NP	O
,	,	O	O
clozapine	NN	B-NP	O
,	,	O	O
or	CC	O	O
amisulpride	NN	B-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
developmental	JJ	B-NP	O
toxicology	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
(	(	O	O
acetylsalicylic	JJ	B-NP	O
acid	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
using	VBG	B-VP	O
selected	VBN	B-NP	O
dosing	NN	I-NP	O
paradigms	NNS	I-NP	O
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
for	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
low	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
developmental	JJ	B-NP	B
anomalies	NNS	I-NP	I
occurs	VBZ	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-VP	O
NSAIDs	NNS	B-NP	O
on	IN	B-PP	O
specific	JJ	B-NP	O
days	NNS	I-NP	O
during	IN	B-PP	O
organogenesis	NN	B-NP	O
.	.	O	O

Aspirin	NN	B-NP	O
(	(	O	O
acetylsalicylic	JJ	B-NP	O
acid	NN	I-NP	O
[	(	O	O
ASA	NN	B-NP	O
]	)	O	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
irreversible	JJ	I-NP	O
cyclooxygenase	NN	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
induces	VBZ	B-VP	O
developmental	JJ	B-NP	B
anomalies	NNS	I-NP	I
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
to	TO	B-PP	O
Wistar	NNP	B-NP	O
rats	NNS	I-NP	O
on	IN	B-PP	O
gestational	JJ	B-NP	O
day	NN	I-NP	O
(	(	O	O
GD	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
(	(	O	O
Kimmel	NNP	B-NP	O
CA	NNP	I-NP	O
,	,	O	O
Wilson	NNP	B-NP	O
JG	NNP	I-NP	O
,	,	O	O
Schumacher	NNP	B-NP	O
HJ	NNP	I-NP	O
.	.	O	O

Teratology	NN	B-NP	O
num	CD	I-NP	O
:	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
no	DT	B-NP	O
published	VBN	I-NP	O
ASA	NN	I-NP	O
studies	NNS	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
multiple	JJ	I-NP	O
dosing	NN	I-NP	O
paradigm	NN	I-NP	O
of	IN	B-PP	O
GDs	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

Objectives	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
to	TO	I-VP	O
compare	VB	I-VP	O
results	NNS	B-NP	O
between	IN	B-PP	O
Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
(	(	O	O
SD	NNP	B-NP	O
)	)	O	O
and	CC	O	O
Wistar	NNP	B-NP	O
strains	NNS	I-NP	O
when	WRB	B-ADVP	O
ASA	NN	B-NP	O
is	VBZ	B-VP	O
administered	VBN	I-VP	O
on	IN	B-PP	O
GD	NN	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
;	:	O	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
malformation	NN	I-NP	O
patterns	NNS	I-NP	O
following	VBG	B-PP	O
single	JJ	B-NP	O
and	CC	I-NP	O
multiple	JJ	I-NP	O
dosings	NNS	I-NP	O
during	IN	B-PP	O
organogenesis	NN	B-NP	O
in	IN	B-PP	O
SD	NNP	B-NP	O
rats	NNS	I-NP	O
;	:	O	O
and	CC	O	O
to	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
maternal	JJ	B-NP	O
gastrointestinal	JJ	I-NP	B
toxicity	NN	I-NP	I
confounds	VBZ	B-VP	O
the	DT	B-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
incidence	NN	I-NP	O
malformations	NNS	I-NP	B
with	IN	B-PP	O
ASA	NN	B-NP	O
when	WRB	B-ADVP	O
a	DT	B-NP	O
multiple	JJ	I-NP	O
dosing	NN	I-NP	O
paradigm	NN	I-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
.	.	O	O

ASA	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
on	IN	B-PP	O
GD	NN	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
and	CC	B-PP	O
from	IN	B-PP	O
GD	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
GD	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
multiple	JJ	I-NP	O
dose	NN	I-NP	O
study	NN	I-NP	O
to	TO	B-PP	O
SD	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
on	IN	B-PP	O
GD	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
fetuses	NNS	B-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
viscerally	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
literature	NN	I-NP	O
evaluation	NN	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
NSAIDs	NNS	B-NP	O
induce	VBP	B-VP	O
ventricular	JJ	B-NP	B
septal	JJ	I-NP	I
defects	NNS	I-NP	I
(	(	O	O
VSDs	NNS	B-NP	B
)	)	O	O
and	CC	O	O
midline	NN	B-NP	B
defects	NNS	I-NP	I
(	(	O	O
MDs	NNS	B-NP	B
)	)	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
and	CC	O	O
diaphragmatic	JJ	B-NP	B
hernia	NN	I-NP	I
(	(	O	O
DH	NN	B-NP	B
)	)	O	O
,	,	O	O
MDs	NNS	B-NP	B
,	,	O	O
and	CC	O	O
VSDs	NNS	B-NP	B
in	IN	B-PP	O
rabbits	NNS	B-NP	O
(	(	O	O
Cook	NNP	B-NP	O
JC	NNP	I-NP	O
et	FW	I-NP	O
al.	FW	I-NP	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
;	:	O	O
hence	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
focused	VBD	B-VP	O
on	IN	B-PP	O
these	DT	B-NP	O
malformations	NNS	I-NP	B
,	,	O	O
even	RB	B-SBAR	O
though	IN	I-SBAR	O
ASA	NN	B-NP	O
induces	VBZ	B-VP	O
several	JJ	B-NP	O
other	JJ	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
incidence	NN	I-NP	O
malformations	NNS	I-NP	B
.	.	O	O

In	IN	B-PP	O
single	JJ	B-NP	O
dose	NN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
DH	NN	B-NP	B
,	,	O	O
MD	NN	B-NP	B
,	,	O	O
and	CC	O	O
VSD	NN	B-NP	B
were	VBD	B-VP	O
induced	VBN	I-VP	O
on	IN	B-PP	O
GDs	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

VSD	NN	B-NP	B
also	RB	B-ADVP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
following	VBG	B-PP	O
treatment	NN	B-NP	O
on	IN	B-PP	O
GD	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
DH	NN	B-NP	B
and	CC	I-NP	O
MD	NN	I-NP	B
were	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
multiple	JJ	I-NP	O
dose	NN	I-NP	O
study	NN	I-NP	O
design	NN	I-NP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
and	CC	O	O
VSD	NN	B-NP	B
was	VBD	B-VP	O
noted	VBN	I-VP	O
across	IN	B-PP	O
all	DT	B-NP	O
dose	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

High	JJ	B-NP	O
concordance	NN	I-NP	O
in	IN	B-PP	O
major	JJ	B-NP	O
developmental	JJ	I-NP	B
anomalies	NNS	I-NP	I
between	IN	B-PP	O
Wistar	NNP	B-NP	O
and	CC	I-NP	O
SD	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
exception	NN	I-NP	O
of	IN	B-PP	O
VSD	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
SD	NNP	I-NP	O
rats	NNS	I-NP	O
and	CC	I-NP	O
hydrocephalus	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Variations	NNS	B-NP	O
and	CC	I-NP	O
malformations	NNS	I-NP	B
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
when	WRB	B-ADVP	O
ASA	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
or	CC	B-PP	O
during	IN	B-PP	O
the	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
organogenesis	NN	B-NP	O
(	(	O	O
GDs	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
evident	JJ	B-ADJP	O
that	IN	B-SBAR	O
,	,	O	O
by	IN	B-PP	O
titrating	VBG	B-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
a	DT	B-NP	O
maximum	NN	I-NP	O
tolerated	VBD	B-VP	O
dose	NN	B-NP	O
,	,	O	O
malformations	NNS	B-NP	B
that	WDT	B-NP	O
normally	RB	B-ADVP	O
occur	VBP	B-VP	O
at	IN	B-PP	O
low	JJ	B-NP	O
incidence	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
reported	VBN	B-VP	O
from	IN	B-PP	O
previous	JJ	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
could	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
induced	VBN	I-VP	O
with	IN	B-PP	O
ASA	NN	B-NP	O
given	VBN	B-VP	O
at	IN	B-PP	O
multiple	JJ	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

Torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
metoclopramide	NN	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
elderly	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
preexisting	VBG	B-VP	O
complete	JJ	B-NP	O
left	JJ	I-NP	B
bundle	NN	I-NP	I
branch	NN	I-NP	I
block	NN	I-NP	I
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
growing	VBG	I-NP	O
list	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
implicated	VBN	B-VP	O
in	IN	B-PP	O
acquired	VBN	B-NP	O
long	JJ	I-NP	B
QT	NN	I-NP	I
syndrome	NN	I-NP	I
and	CC	O	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
torsadogenic	JJ	I-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
metoclopramide	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
antiemetic	JJ	I-NP	O
and	CC	I-NP	O
prokinetic	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
despite	IN	B-PP	O
its	PRP$	B-NP	O
chemical	JJ	I-NP	O
similarity	NN	I-NP	O
to	TO	B-PP	O
procainamide	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
preexisting	VBG	B-VP	O
complete	JJ	B-NP	O
left	JJ	I-NP	B
bundle	NN	I-NP	I
branch	NN	I-NP	I
block	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
after	IN	B-PP	O
intravenous	JJ	B-NP	O
and	CC	I-NP	O
oral	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
metoclopramide	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
patient	NN	I-NP	O
also	RB	B-ADVP	O
developed	VBD	B-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
when	WRB	B-ADVP	O
cisapride	NN	B-NP	O
and	CC	I-NP	O
erythromycin	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
num	CD	I-NP	O
episodes	NNS	I-NP	O
were	VBD	B-VP	O
suppressed	VBN	I-VP	O
successfully	RB	B-ADVP	O
after	IN	B-PP	O
discontinuing	VBG	B-VP	O
the	DT	B-NP	O
offending	VBG	I-NP	O
drugs	NNS	I-NP	O
and	CC	O	O
administering	VBG	B-VP	O
class	NN	B-NP	O
IB	NN	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
documentation	NN	I-NP	O
that	IN	B-NP	O
metoclopramide	NN	B-NP	O
provokes	NNS	I-NP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
clinically	RB	B-ADVP	O
.	.	O	O

Metoclopramide	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
cautiously	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
.	.	O	O

Apomorphine	NN	B-NP	O
:	:	O	O
an	DT	B-NP	O
underutilized	JJ	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Apomorphine	NN	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
dopaminergic	JJ	I-NP	O
drug	NN	I-NP	O
ever	RB	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

While	IN	B-SBAR	O
powerful	JJ	B-NP	O
antiparkinsonian	JJ	I-NP	O
effects	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
as	RB	B-ADVP	O
early	RB	I-ADVP	O
as	IN	B-PP	O
num	CD	B-NP	O
the	DT	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
treating	VBG	B-VP	O
fluctuating	VBG	I-VP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
by	IN	B-PP	O
subcutaneous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
has	VBZ	B-VP	O
only	RB	I-VP	O
recently	RB	I-VP	O
become	VB	I-VP	O
the	DT	B-NP	O
subject	NN	I-NP	O
of	IN	B-PP	O
systematic	JJ	B-NP	O
study	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
small	JJ	B-NP	O
scale	NN	I-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
have	VBP	B-VP	O
unequivocally	RB	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
intermittent	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
apomorphine	NN	I-NP	O
injections	NNS	I-NP	O
produce	VBP	B-VP	O
antiparkinsonian	JJ	B-NP	O
benefit	NN	I-NP	O
close	NN	I-NP	O
if	IN	B-CONJP	O
not	RB	I-CONJP	O
identical	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
seen	VBN	B-VP	O
with	IN	B-PP	O
levodopa	NN	B-NP	O
and	CC	O	O
that	IN	B-SBAR	O
apomorphine	NN	B-NP	O
rescue	NN	I-NP	O
injections	NNS	I-NP	O
can	MD	B-VP	O
reliably	RB	I-VP	O
revert	VB	I-VP	O
off	RP	B-PRT	O
-	HYPH	B-NP	O
periods	NNS	I-NP	O
even	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
complex	NN	B-NP	O
on	IN	B-PP	O
-	HYPH	B-NP	O
off	RP	I-NP	O
motor	NN	B-NP	O
swings	NNS	I-NP	O
.	.	O	O

Continuous	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
apomorphine	NN	I-NP	O
infusions	NNS	I-NP	O
can	MD	B-VP	O
reduce	VB	I-VP	O
daily	RB	B-ADVP	O
off	RB	B-ADVP	O
-	HYPH	O	O
time	NN	B-NP	O
by	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
which	WDT	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
stronger	JJR	I-NP	O
effect	NN	I-NP	O
than	IN	B-PP	O
that	DT	B-NP	O
generally	RB	B-VP	O
seen	VBN	I-VP	O
with	IN	B-PP	O
add	NN	B-NP	O
-	HYPH	B-ADVP	O
on	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
dopamine	NN	I-NP	O
agonists	NNS	I-NP	O
or	CC	O	O
COMT	NN	B-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Extended	VBN	B-VP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
studies	NNS	B-NP	O
of	IN	B-PP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
persistence	NN	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
efficacy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
convincing	VBG	I-VP	O
clinical	JJ	B-NP	O
evidence	NN	I-NP	O
that	IN	B-SBAR	O
monotherapy	NN	B-NP	O
with	IN	B-PP	O
continuous	JJ	B-NP	O
subcutaneous	JJ	I-NP	O
apomorphine	NN	I-NP	O
infusions	NNS	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
marked	JJ	B-NP	O
reductions	NNS	I-NP	O
of	IN	B-PP	O
preexisting	VBG	B-VP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
subcutaneous	JJ	B-NP	O
apomorphine	NN	I-NP	O
treatment	NN	I-NP	O
are	VBP	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
cutaneous	JJ	B-NP	O
tolerability	NN	I-NP	O
problems	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
sedation	NN	B-NP	O
and	CC	O	O
psychiatric	JJ	B-NP	B
complications	NNS	I-NP	O
play	VBP	B-VP	O
a	DT	B-NP	O
lesser	JJR	I-NP	O
role	NN	I-NP	O
.	.	O	O

Given	VBN	B-PP	O
the	DT	B-NP	O
marked	JJ	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
efficacy	NN	B-NP	O
of	IN	B-PP	O
subcutaneous	JJ	B-NP	O
apomorphine	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
fluctuating	VBG	B-VP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
,	,	O	O
this	DT	B-NP	O
approach	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
deserve	VB	I-VP	O
more	RBR	B-NP	O
widespread	JJ	I-NP	O
clinical	JJ	I-NP	O
use	NN	I-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
excited	JJ	I-NP	O
delirium	NN	I-NP	B
following	VBG	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
:	:	O	O
epidemiologic	JJ	B-NP	O
findings	NNS	I-NP	O
provide	VBP	B-VP	O
new	JJ	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
mechanisms	NNS	B-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
an	DT	B-NP	O
outbreak	NN	I-NP	O
of	IN	B-PP	O
deaths	NNS	B-NP	O
from	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
excited	VBN	I-NP	O
delirium	NN	I-NP	B
(	(	O	O
EDDs	NNS	B-NP	B
)	)	O	O
in	IN	B-PP	O
Dade	NNP	B-NP	O
County	NNP	I-NP	O
,	,	O	O
Florida	NNP	B-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

From	IN	B-PP	O
a	DT	B-NP	O
registry	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
deaths	NNS	I-NP	O
in	IN	B-PP	O
Dade	NNP	B-NP	O
County	NNP	I-NP	O
,	,	O	O
Florida	NNP	B-NP	O
,	,	O	O
from	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
EDDs	NNS	I-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
victims	NNS	I-NP	O
of	IN	B-PP	O
accidental	JJ	B-NP	O
cocaine	NN	I-NP	O
overdose	NN	I-NP	B
without	IN	B-PP	O
excited	JJ	B-NP	O
delirium	NN	I-NP	B
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
EDDs	NNS	B-NP	B
were	VBD	B-VP	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
black	JJ	B-NP	O
,	,	I-NP	O
male	JJ	I-NP	O
,	,	I-NP	O
and	CC	I-NP	O
younger	JJR	I-NP	O
.	.	O	O

They	PRP	B-NP	O
were	VBD	B-VP	O
less	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
low	JJ	I-NP	O
body	NN	I-NP	O
mass	NN	I-NP	O
index	NN	I-NP	O
,	,	O	O
and	CC	O	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
died	VBN	I-VP	O
in	IN	B-PP	O
police	NN	B-NP	O
custody	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
have	VB	I-VP	O
received	VBN	I-VP	O
medical	JJ	B-NP	O
treatment	NN	I-NP	O
immediately	RB	B-ADVP	O
before	IN	B-PP	O
death	NN	B-NP	O
,	,	O	O
to	TO	B-VP	O
have	VB	I-VP	O
survived	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
longer	JJR	I-NP	O
period	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
have	VB	I-VP	O
developed	VBN	I-VP	O
hyperthermia	NN	B-NP	B
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
have	VB	I-VP	O
died	VBN	I-VP	O
in	IN	B-PP	O
summer	NN	B-NP	O
months	NNS	I-NP	O
.	.	O	O

EDDs	NNS	B-NP	B
had	VBD	B-VP	O
concentrations	NNS	B-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
benzoylecgonine	NN	I-NP	O
in	IN	B-PP	O
autopsy	NN	B-NP	O
blood	NN	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
for	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
epidemiologic	JJ	I-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
most	RBS	B-ADJP	O
consistent	JJ	I-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
chronic	JJ	B-NP	O
cocaine	NN	I-NP	O
use	NN	I-NP	O
disrupts	VBZ	B-VP	O
dopaminergic	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
,	,	O	O
when	WRB	B-ADVP	O
coupled	VBN	B-VP	O
with	IN	B-PP	O
recent	JJ	B-NP	O
cocaine	NN	I-NP	O
use	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
precipitate	VB	I-VP	O
agitation	NN	B-NP	B
,	,	O	O
delirium	NN	B-NP	B
,	,	O	O
aberrant	JJ	B-NP	O
thermoregulation	NN	I-NP	O
,	,	O	O
rhabdomyolysis	NN	B-NP	B
,	,	O	O
and	CC	O	O
sudden	JJ	B-NP	B
death	NN	I-NP	I
.	.	O	O

Heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
,	,	O	O
thrombosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
hemorrhage	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
heparin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Clinical	JJ	B-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
disorder	NN	I-NP	O
include	VBP	B-VP	O
hemorrhage	NN	B-NP	B
or	CC	O	O
,	,	O	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
,	,	O	O
thromboembolic	JJ	B-NP	B
events	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
heparin	NN	B-NP	O
.	.	O	O

Laboratory	NN	B-NP	O
testing	NN	I-NP	O
has	VBZ	B-VP	O
revealed	VBN	I-VP	O
a	DT	B-NP	B
falling	VBG	I-NP	I
platelet	NN	I-NP	I
count	NN	I-NP	I
,	,	O	O
increased	VBD	B-VP	O
resistance	NN	B-NP	O
to	TO	B-PP	O
heparin	NN	B-NP	O
,	,	O	O
and	CC	O	O
aggregation	NN	B-NP	O
of	IN	B-PP	O
platelets	NNS	B-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
plasma	NN	B-NP	O
when	WRB	B-ADVP	O
heparin	NN	B-NP	O
is	VBZ	B-VP	O
added	VBN	I-VP	O
.	.	O	O

Immunologic	JJ	B-NP	O
testing	NN	I-NP	O
has	VBZ	B-VP	O
demonstrated	VBN	I-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
heparin	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
platelet	NN	I-NP	O
membrane	NN	I-NP	O
antibody	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
deaths	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
hemorrhagic	JJ	I-NP	B
and	CC	I-NP	I
thromboembolic	JJ	I-NP	I
complications	NNS	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
surgical	JJ	I-NP	O
procedures	NNS	I-NP	O
to	TO	B-VP	O
manage	VB	I-VP	O
the	DT	B-NP	O
complications	NNS	I-NP	O
confirm	VBP	B-VP	O
the	DT	B-NP	O
seriousness	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
disorder	NN	I-NP	O
.	.	O	O

Specific	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
identified	VBN	I-VP	O
;	:	O	O
therefore	RB	B-ADVP	O
,	,	O	O
all	DT	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
heparin	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
.	.	O	O

If	IN	B-SBAR	O
the	DT	B-NP	O
platelet	NN	I-NP	O
count	NN	I-NP	O
falls	VBZ	B-VP	O
to	TO	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
mm3	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
is	VBZ	B-VP	O
receiving	VBG	I-VP	O
heparin	NN	B-NP	O
,	,	O	O
platelet	NN	B-NP	B
aggregation	NN	I-NP	I
testing	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
plasma	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
indicated	VBN	I-VP	O
.	.	O	O

Management	NN	B-NP	O
consists	VBZ	B-VP	O
of	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
,	,	O	O
platelet	NN	B-NP	O
anti	AFX	O	O
-	HYPH	O	O
aggregating	VBG	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
and	CC	O	O
alternate	JJ	B-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
anticoagulation	NN	B-NP	O
when	WRB	B-ADVP	O
indicated	VBN	B-VP	O
.	.	O	O

Cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
.	.	O	O

Report	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
angina	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
colon	NN	B-NP	B
carcinoma	NN	I-NP	I
and	CC	O	O
liver	NN	B-NP	O
metastasis	NN	I-NP	B
who	WP	B-NP	O
presented	VBD	B-VP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
administration	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
electrocardiographic	JJ	I-NP	O
evolution	NN	I-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
Prinzmetal	JJ	B-NP	B
s	NNS	I-NP	I
angina	NN	I-NP	I
,	,	O	O
and	CC	O	O
chest	JJS	B-NP	B
pain	NN	I-NP	I
promptly	RB	B-VP	O
resolved	VBN	I-VP	O
with	IN	B-PP	O
nifedipine	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
coronary	JJ	B-NP	B
spasm	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
calcium	NN	B-NP	O
antagonists	NNS	I-NP	O
may	MD	B-VP	O
probably	RB	I-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
or	CC	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Toxicity	NN	B-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
remission	NN	B-NP	O
inducing	VBG	I-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
.	.	O	O

Association	NN	B-NP	O
with	IN	B-PP	O
HLA	NN	B-NP	O
-	HYPH	B-NP	O
B35	NN	I-NP	O
and	CC	I-NP	O
Cw4	NN	I-NP	O
antigens	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
(	(	O	O
RA	NN	B-NP	B
)	)	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
toxicity	NN	B-NP	B
while	IN	B-SBAR	O
taking	VBG	B-VP	O
remission	NN	B-NP	O
inducing	VBG	I-NP	O
drugs	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
without	IN	B-PP	O
toxicity	NN	B-NP	B
were	VBD	B-VP	O
studied	VBN	I-VP	O
for	IN	B-PP	O
possible	JJ	B-NP	O
associations	NNS	I-NP	O
with	IN	B-PP	O
class	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
HLA	NN	I-NP	O
antigens	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
strong	JJ	I-NP	O
association	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
nephritis	NN	B-NP	B
and	CC	I-NP	O
dermatitis	NN	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
Tiopronin	NN	B-NP	O
(	(	O	O
a	DT	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
Penicillamine	NN	I-NP	O
like	JJ	I-NP	O
compound	NN	I-NP	O
)	)	O	O
and	CC	O	O
class	NN	B-NP	O
num	CD	I-NP	O
antigens	NNS	I-NP	O
B35	NN	I-NP	O
-	HYPH	B-NP	O
Cw4	NN	I-NP	O
,	,	O	O
and	CC	O	O
between	IN	B-PP	O
dermatitis	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
gold	NN	B-NP	O
thiosulphate	NN	I-NP	O
and	CC	I-NP	O
B35	NN	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
to	TO	B-PP	O
healthy	JJ	B-NP	O
controls	NNS	I-NP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
DR5	NN	I-NP	O
frequency	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
RA	NN	B-NP	B
except	IN	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
Tiopronin	NN	I-NP	O
related	JJ	I-NP	O
nephritis	NN	I-NP	B
group	NN	I-NP	O
.	.	O	O

Transient	JJ	B-NP	O
hemiparesis	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
rare	JJ	I-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
diphenylhydantoin	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Report	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
diphenylhydantoin	NN	B-NP	O
(	(	O	O
DPH	NN	B-NP	O
)	)	O	O
overdose	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequently	RB	I-NP	O
encountered	VBN	I-NP	O
neurological	JJ	I-NP	O
signs	NNS	I-NP	O
are	VBP	B-VP	O
those	DT	B-NP	O
of	IN	B-PP	O
cerebellar	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Very	RB	B-ADVP	O
rarely	RB	I-ADVP	O
,	,	O	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
neurological	JJ	I-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
are	VBP	B-VP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	O
origin	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
who	WP	B-NP	O
suffered	VBD	B-VP	O
progressive	JJ	B-NP	O
hemiparesis	NN	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
DPH	NN	B-NP	O
overdose	NN	I-NP	B
.	.	O	O

Both	DT	B-NP	O
had	VBD	B-VP	O
brain	NN	B-NP	O
surgery	NN	I-NP	O
before	IN	B-PP	O
DPH	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
assumed	VBN	I-VP	O
that	IN	B-SBAR	O
patients	NNS	B-NP	O
with	IN	B-PP	O
some	DT	B-NP	O
cerebral	JJ	I-NP	B
damage	NN	I-NP	I
are	VBP	B-VP	O
liable	JJ	B-ADJP	O
to	TO	B-VP	O
manifest	VB	I-VP	O
DPH	NN	B-NP	O
toxicity	NN	I-NP	B
as	IN	B-PP	O
focal	JJ	B-NP	O
neurological	JJ	I-NP	O
signs	NNS	I-NP	O
.	.	O	O

Nerve	NN	B-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
and	CC	O	O
prostaglandins	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
urine	NN	I-NP	O
of	IN	B-PP	O
female	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
overactive	JJ	B-NP	B
bladder	NN	I-NP	I
.	.	O	O

NGF	NN	B-NP	O
and	CC	I-NP	O
PGs	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
pathological	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
and	CC	O	O
these	DT	B-NP	O
changes	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
urine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
NGF	NN	I-NP	O
and	CC	I-NP	O
PGs	NNS	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
groups	NNS	I-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
without	IN	B-PP	O
bladder	NN	B-NP	O
symptoms	NNS	I-NP	O
who	WP	B-NP	O
served	VBD	B-VP	O
as	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Evaluation	NN	B-NP	O
included	VBD	B-VP	O
patient	NN	B-NP	O
history	NN	I-NP	O
,	,	O	O
urinalysis	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
voiding	NN	I-NP	O
diary	NN	I-NP	O
and	CC	O	O
urodynamic	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Urine	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
.	.	O	O

NGF	NN	B-NP	O
,	,	I-NP	O
PGE2	NN	I-NP	O
,	,	I-NP	O
PGF2alpha	NN	I-NP	O
and	CC	I-NP	O
PGI2	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
enzyme	NN	B-NP	O
-	HYPH	O	O
linked	VBN	B-VP	O
immunosorbent	JJ	B-NP	O
assay	NN	I-NP	O
and	CC	O	O
compared	VBN	B-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
correlations	NNS	B-NP	O
between	IN	B-PP	O
urinary	JJ	B-NP	O
NGF	NN	I-NP	O
and	CC	I-NP	O
PG	NN	I-NP	O
,	,	O	O
and	CC	O	O
urodynamic	JJ	B-NP	O
parameters	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
were	VBD	B-VP	O
examined	VBN	I-VP	O
.	.	O	O

Urinary	JJ	B-NP	O
NGF	NN	I-NP	O
,	,	I-NP	O
PGE2	NN	I-NP	O
and	CC	I-NP	O
PGF2alpha	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
urinary	JJ	B-NP	O
PGI2	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
different	JJ	B-ADJP	O
between	IN	B-PP	O
controls	NNS	B-NP	O
and	CC	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
urinary	JJ	I-NP	O
PGE2	NN	I-NP	O
positively	RB	B-ADVP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
volume	NN	B-NP	O
at	IN	B-PP	O
first	JJ	B-NP	O
desire	NN	I-NP	O
to	TO	B-PP	O
void	NN	B-NP	O
and	CC	O	O
maximum	JJ	B-NP	O
cystometric	JJ	I-NP	O
capacity	NN	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
NGF	NN	I-NP	O
,	,	I-NP	O
PGF2alpha	NN	I-NP	O
and	CC	I-NP	O
PGI2	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
urodynamic	JJ	B-NP	O
parameters	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
OAB	NN	B-NP	B
.	.	O	O

NGF	NN	B-NP	O
and	CC	I-NP	O
PGs	NNS	I-NP	O
have	VBP	B-VP	O
important	JJ	B-NP	O
roles	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
OAB	NN	B-NP	B
symptoms	NNS	I-NP	O
in	IN	B-PP	O
female	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
factors	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
as	IN	B-SBAR	O
markers	NNS	B-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
OAB	NN	B-NP	B
symptoms	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
low	JJ	I-NP	B
back	JJ	I-NP	I
pain	NN	I-NP	I
during	IN	B-PP	O
intravenous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
represents	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
antiarrhythmic	JJ	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
cardioversion	NN	B-NP	O
of	IN	B-PP	O
recent	JJ	B-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
atrial	JJ	I-NP	B
fibrillation	NN	I-NP	I
(	(	O	O
AF	NN	B-NP	B
)	)	O	O
and	CC	O	O
maintenance	NN	B-NP	O
of	IN	B-PP	O
sinus	NN	B-NP	O
rhythm	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
briefly	RB	B-ADVP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
recent	JJ	B-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
atrial	JJ	I-NP	B
fibrillation	NN	I-NP	I
,	,	O	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
devastating	VBG	I-NP	O
low	JJ	I-NP	B
back	NN	I-NP	I
pain	VBP	B-VP	I
a	DT	B-NP	O
few	JJ	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
amiodarone	NN	I-NP	O
loading	NN	I-NP	O
.	.	O	O

Notably	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
ever	RB	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
literature	NN	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
reaction	NN	I-NP	O
since	IN	B-PP	O
prompt	JJ	B-NP	O
termination	NN	I-NP	O
of	IN	B-PP	O
parenteral	JJ	B-NP	O
administration	NN	I-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
complete	JJ	B-NP	O
resolution	NN	I-NP	O
.	.	O	O

Postoperative	JJ	B-NP	B
myalgia	NN	I-NP	I
after	IN	B-PP	O
succinylcholine	NN	B-NP	O
:	:	O	O
no	DT	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
inflammatory	JJ	I-NP	O
origin	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
succinylcholine	NN	B-NP	O
is	VBZ	B-VP	O
postoperative	JJ	B-NP	B
myalgia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
myalgia	NN	I-NP	B
is	VBZ	B-VP	O
still	RB	B-ADVP	O
unclear	JJ	B-ADJP	O
;	:	O	O
inflammation	NN	B-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
but	CC	O	O
without	IN	B-PP	O
convincing	VBG	B-VP	O
evidence	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
designed	VBD	B-VP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
an	DT	B-NP	O
inflammatory	JJ	I-NP	O
reaction	NN	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
myalgia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
myalgia	NN	I-NP	B
was	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
or	CC	I-NP	O
dexamethasone	NN	I-NP	O
before	IN	B-PP	O
succinylcholine	NN	B-NP	O
.	.	O	O

Incidence	NN	B-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
myalgia	NN	B-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dexamethasone	NN	I-NP	O
group	NN	I-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
myalgia	NN	B-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
saline	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
and	CC	O	O
severe	JJ	B-NP	O
myalgia	NN	I-NP	B
was	VBD	B-VP	O
reported	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
(	(	O	O
not	RB	O	O
significant	JJ	B-ADJP	O
)	)	O	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
still	RB	B-VP	O
suffered	VBN	I-VP	O
from	IN	B-PP	O
myalgia	NN	B-NP	B
(	(	O	O
not	RB	O	O
significant	JJ	B-ADJP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
interleukin	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
IL	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
as	IN	B-PP	O
an	DT	B-NP	O
early	JJ	I-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
inflammation	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
subgroup	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
IL	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
for	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
only	RB	B-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
reported	VBD	B-VP	O
myalgia	NN	B-NP	B
;	:	O	O
no	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
myalgia	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
IL	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
inflammatory	JJ	I-NP	O
origin	NN	I-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
myalgia	NN	I-NP	B
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
before	IN	B-PP	O
succinylcholine	NN	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
decreasing	VBG	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
postoperative	JJ	I-NP	B
myalgia	NN	I-NP	I
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
postoperative	JJ	B-NP	B
myalgia	NN	I-NP	I
and	CC	I-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
interleukin	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
inflammation	NN	B-NP	B
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
dexamethasone	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
justified	JJ	B-ADJP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
postoperative	JJ	B-NP	B
myalgia	NN	I-NP	I
after	IN	B-PP	O
succinylcholine	NN	B-NP	O
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
oromandibular	JJ	I-NP	O
dystonia	NN	I-NP	B
in	IN	B-PP	O
progressive	JJ	B-NP	B
supranuclear	JJ	I-NP	I
palsy	NN	I-NP	I
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
and	CC	O	O
multiple	JJ	B-NP	B
system	NN	I-NP	I
atrophy	NN	I-NP	I
.	.	O	O

Cranial	JJ	B-NP	O
dystonias	NNS	I-NP	B
are	VBP	B-VP	O
rare	JJ	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
progressive	JJ	B-NP	B
supranuclear	JJ	I-NP	I
palsy	NN	I-NP	I
(	(	O	O
PSP	NN	B-NP	B
)	)	O	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
reversible	JJ	B-NP	O
levodopa	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
Oromandibular	JJ	I-NP	B
dystonia	NN	I-NP	I
(	(	O	O
OMD	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
PSP	NN	I-NP	B
patient	NN	I-NP	O
to	TO	B-VP	O
highlight	VB	I-VP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
recognizing	VBG	B-VP	O
this	DT	B-NP	O
drug	NN	I-NP	O
related	JJ	I-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
PSP	NN	B-NP	B
,	,	O	O
and	CC	O	O
discuss	VBP	B-VP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
underlying	VBG	I-NP	O
pathophysiology	NN	I-NP	O
.	.	O	O

Protective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
edaravone	NN	B-NP	O
against	IN	B-PP	O
streptomycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vestibulotoxicity	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
guinea	NN	I-NP	O
pig	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
alleviation	NN	B-NP	O
of	IN	B-PP	O
streptomycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vestibulotoxicity	NN	I-NP	B
by	IN	B-PP	O
edaravone	NN	B-NP	O
in	IN	B-PP	O
guinea	NN	B-NP	O
pigs	NNS	I-NP	O
.	.	O	O

Edaravone	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
free	JJ	I-NP	O
radical	NN	I-NP	O
scavenger	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
potent	JJ	B-NP	O
free	JJ	I-NP	O
radical	NN	I-NP	O
quenching	VBG	B-VP	O
action	NN	B-NP	O
and	CC	O	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
practice	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
cerebral	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

Streptomycin	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
inner	JJ	I-NP	O
ear	NN	I-NP	O
by	IN	B-PP	O
osmotic	JJ	B-NP	O
pump	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
and	CC	O	O
edaravone	NN	B-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
was	VBD	B-VP	O
intraperitoneally	RB	I-VP	O
injected	VBN	I-VP	O
once	RB	B-ADVP	O
a	DT	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
horizontal	JJ	B-ADJP	O
vestibulo	AFX	B-NP	O
-	HYPH	I-NP	O
ocular	JJ	I-NP	O
reflex	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
vestibular	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
injected	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
showed	VBD	B-VP	O
statistically	RB	B-NP	O
smaller	JJR	I-NP	O
gains	NNS	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
injected	VBN	B-VP	O
with	IN	B-PP	O
edaravone	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
edaravone	NN	B-NP	O
suppresses	VBZ	B-VP	O
streptomycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vestibulotoxicity	NN	I-NP	B
.	.	O	O

Ketamine	NN	B-NP	O
in	IN	B-PP	O
war	NN	B-NP	O
/	SYM	B-NP	O
tropical	JJ	I-NP	O
surgery	NN	I-NP	O
(	(	O	O
a	DT	B-NP	O
final	JJ	I-NP	O
tribute	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
racemic	JJ	I-NP	O
mixture	NN	I-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
technique	NN	I-NP	O
of	IN	B-PP	O
continuous	JJ	B-NP	O
intravenous	JJ	I-NP	O
anaesthesia	NN	I-NP	O
with	IN	B-PP	O
ketamine	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
successfully	RB	B-ADVP	O
during	IN	B-PP	O
the	DT	B-NP	O
Somalia	NNP	I-NP	O
civil	JJ	I-NP	O
war	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
in	IN	B-PP	O
north	JJ	B-NP	O
Uganda	NNP	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
operations	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
aged	VBN	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
undergoing	VBG	B-VP	O
limb	NN	B-NP	O
and	CC	O	O
abdominal	JJ	B-NP	O
surgery	NN	I-NP	O
including	VBG	B-PP	O
caesarian	JJ	B-NP	O
sections	NNS	I-NP	O
and	CC	I-NP	O
interventions	NNS	I-NP	O
in	IN	B-PP	O
neonates	NNS	B-NP	O
.	.	O	O

Operations	NNS	B-NP	O
lasting	VBG	B-VP	O
up	RB	B-ADVP	O
to	TO	B-PP	O
2h	NN	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
sophisticated	JJ	B-NP	O
equipment	NN	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
pulse	NN	B-NP	O
oximeters	NNS	I-NP	O
or	CC	O	O
ventilators	NNS	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
spontaneous	JJ	B-NP	O
ventilation	NN	I-NP	O
breathing	NN	I-NP	O
air	NN	I-NP	O
/	SYM	B-NP	O
oxygen	NN	I-NP	O
only	RB	B-ADVP	O
.	.	O	O

After	IN	B-PP	O
premedication	NN	B-NP	O
with	IN	B-PP	O
diazepam	NN	B-NP	O
,	,	I-NP	O
glycopyrrolate	NN	I-NP	O
and	CC	I-NP	O
local	JJ	I-NP	O
anaesthesia	NN	I-NP	O
,	,	O	O
and	CC	O	O
induction	NN	B-NP	O
with	IN	B-PP	O
standard	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
maintenance	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
ketamine	NN	B-NP	O
proved	VBD	B-VP	O
safe	JJ	B-ADJP	O
and	CC	I-ADJP	O
effective	JJ	I-ADJP	O
.	.	O	O

Emphasis	NN	B-NP	O
was	VBD	B-VP	O
placed	VBN	I-VP	O
on	IN	B-PP	O
bedside	NN	B-NP	O
clinical	JJ	I-NP	O
monitoring	NN	I-NP	O
,	,	O	O
relying	VBG	B-VP	O
heavily	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Diazepam	NN	B-NP	O
,	,	O	O
unless	IN	B-SBAR	O
contraindicated	VBN	B-NP	O
or	CC	I-NP	O
risky	JJ	I-NP	O
,	,	O	O
remains	VBZ	B-VP	O
the	DT	B-NP	O
only	RB	I-NP	O
necessary	JJ	I-NP	O
complementary	JJ	I-NP	O
drug	NN	I-NP	O
to	TO	B-PP	O
ketamine	NN	B-NP	O
as	IN	B-SBAR	O
it	PRP	B-NP	O
buffers	VBZ	B-VP	O
its	PRP$	B-NP	O
cardiovascular	JJ	I-NP	O
response	NN	I-NP	O
and	CC	O	O
decreases	VBZ	B-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
and	CC	I-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
operative	JJ	B-NP	O
and	CC	I-NP	O
postoperative	JJ	I-NP	O
hallucinations	NNS	I-NP	B
.	.	O	O

Local	JJ	B-NP	O
anaesthetic	JJ	I-NP	O
blocks	NNS	I-NP	O
were	VBD	B-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
decreasing	VBG	B-VP	O
the	DT	B-NP	O
requirement	NN	I-NP	O
for	IN	B-PP	O
postoperative	JJ	B-NP	O
analgesia	NN	I-NP	B
.	.	O	O

An	DT	B-NP	O
antisialogue	NN	I-NP	O
was	VBD	B-VP	O
usually	RB	B-ADJP	O
unnecessary	JJ	I-ADJP	O
in	IN	B-PP	O
operations	NNS	B-NP	O
lasting	VBG	B-VP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
,	,	O	O
glycopyrrolate	NN	B-NP	O
being	VBG	B-VP	O
the	DT	B-NP	O
best	JJS	I-NP	O
choice	NN	I-NP	O
for	IN	B-PP	O
its	PRP$	B-NP	O
lowest	JJS	I-NP	O
psychotropic	JJ	I-NP	O
and	CC	I-NP	O
chronotropic	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
hot	JJ	I-NP	O
climate	NN	I-NP	O
.	.	O	O

Experience	NN	B-NP	O
in	IN	B-PP	O
war	NN	B-NP	O
/	SYM	B-NP	O
tropical	JJ	I-NP	O
settings	NNS	I-NP	O
suggests	VBZ	B-VP	O
this	DT	B-NP	O
technique	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
civilian	JJ	B-NP	O
contexts	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
outdoor	JJ	B-NP	O
life	NN	I-NP	O
-	HYPH	O	O
saving	VBG	B-VP	O
emergency	NN	B-NP	O
surgery	NN	I-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
mass	NN	B-NP	O
casualties	NNS	I-NP	O
where	WRB	B-ADVP	O
,	,	O	O
e.g.	FW	B-NP	O
amputation	NN	I-NP	O
and	CC	O	O
rapid	JJ	B-NP	O
extrication	NN	I-NP	O
were	VBD	B-VP	O
required	VBN	I-VP	O
.	.	O	O

Steroid	NN	B-NP	O
structure	NN	I-NP	O
and	CC	O	O
pharmacological	JJ	B-NP	O
properties	NNS	I-NP	O
determine	VBP	B-VP	O
the	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
amnesic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
pregnenolone	NN	B-NP	O
sulphate	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Pregnenolone	NN	B-NP	O
sulphate	NN	I-NP	O
(	(	O	O
PREGS	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
generated	VBN	I-VP	O
interest	NN	B-NP	O
as	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
potent	JJ	I-NP	O
memory	NN	I-NP	O
-	HYPH	O	O
enhancing	VBG	B-VP	O
neurosteroids	NNS	B-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
rodent	NN	B-NP	O
learning	NN	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
particular	JJ	B-NP	O
importance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ageing	VBG	I-NP	O
process	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
this	DT	B-NP	O
endogenous	JJ	I-NP	O
steroid	NN	I-NP	O
enhances	VBZ	B-VP	O
memory	NN	B-NP	O
formation	NN	I-NP	O
is	VBZ	B-VP	O
hypothesized	VBN	I-VP	O
to	TO	I-VP	O
involve	VB	I-VP	O
actions	NNS	B-NP	O
on	IN	B-PP	O
glutamatergic	JJ	B-NP	O
and	CC	I-NP	O
GABAergic	JJ	I-NP	O
systems	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
hypothesis	NN	I-NP	O
stems	VBZ	B-VP	O
from	IN	B-PP	O
findings	NNS	B-NP	O
that	IN	B-SBAR	O
PREGS	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
potent	JJ	I-NP	O
positive	JJ	I-NP	O
modulator	NN	I-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
d	NN	I-NP	O
-	HYPH	B-NP	O
aspartate	NN	I-NP	O
receptors	NNS	I-NP	O
(	(	O	O
NMDARs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
negative	JJ	I-NP	O
modulator	NN	I-NP	O
of	IN	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	O	O
aminobutyric	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
receptors	NNS	B-NP	O
(	(	O	O
GABA	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
Rs	NNS	B-NP	O
)	)	O	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
PREGS	NN	B-NP	O
is	VBZ	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
the	DT	B-NP	O
amnesic	JJ	I-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
NMDAR	NN	B-NP	O
and	CC	I-NP	O
GABA	NN	I-NP	O
(	(	I-NP	O
A	NN	I-NP	O
)	)	I-NP	O
R	NN	I-NP	O
ligands	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
investigate	VB	I-VP	O
this	DT	B-NP	O
hypothesis	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
examined	VBN	B-VP	O
the	DT	B-NP	O
memory	NN	I-NP	O
-	HYPH	O	O
altering	VBG	B-VP	O
abilities	NNS	B-NP	O
of	IN	B-PP	O
structural	JJ	B-NP	O
analogs	NNS	I-NP	O
of	IN	B-PP	O
PREGS	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
differ	VBP	B-VP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
NMDAR	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
GABA	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
R	NN	B-NP	O
function	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
analogs	NNS	I-NP	O
tested	VBN	B-VP	O
were	VBD	B-VP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
ketopregnenolone	NN	I-NP	O
sulphate	NN	I-NP	O
(	(	O	O
an	DT	B-NP	O
agent	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
inactive	JJ	B-ADJP	O
at	IN	B-PP	O
GABA	NN	B-NP	O
(	(	I-NP	O
A	NN	I-NP	O
)	)	I-NP	O
Rs	NNS	I-NP	O
and	CC	I-NP	O
NMDARs	NNS	I-NP	O
)	)	O	O
,	,	O	O
epipregnanolone	NN	B-NP	O
(	(	O	O
[	(	O	O
3beta	NN	B-NP	O
-	HYPH	B-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
5beta	NN	I-NP	O
-	HYPH	B-NP	O
pregnan	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
]	)	I-NP	O
sulphate	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
both	CC	O	O
GABA	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
Rs	NNS	B-NP	O
and	CC	I-NP	O
NMDARs	NNS	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
newly	RB	I-NP	O
synthesized	VBN	I-NP	O
PREGS	NN	I-NP	O
enantiomer	NN	I-NP	O
(	(	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
identical	JJ	B-ADJP	O
to	TO	B-PP	O
PREGS	NN	B-NP	O
in	IN	B-PP	O
effects	NNS	B-NP	O
on	IN	B-PP	O
GABA	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
Rs	NNS	B-NP	O
and	CC	I-NP	O
NMDARs	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
memory	NN	I-NP	O
-	HYPH	O	O
enhancing	VBG	B-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
PREGS	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
analogs	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

Both	CC	O	O
PREGS	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
enantiomer	NN	I-NP	O
blocked	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
unlike	IN	B-PP	O
PREGS	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
ketopregnenolone	NN	I-NP	O
sulphate	NN	I-NP	O
and	CC	O	O
epipregnanolone	NN	B-NP	O
sulphate	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
block	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
altering	VBG	B-VP	O
the	DT	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
diminishes	VBZ	B-VP	O
the	DT	B-NP	O
memory	NN	I-NP	O
-	HYPH	O	O
enhancing	VBG	B-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
PREGS	NN	B-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
enantioselectivity	NN	B-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
natural	JJ	B-NP	O
PREGS	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
order	NN	I-NP	O
of	IN	B-PP	O
magnitude	NN	B-NP	O
more	RBR	B-ADJP	O
effective	JJ	I-ADJP	O
than	IN	B-PP	O
its	PRP$	B-NP	O
synthetic	JJ	I-NP	O
enantiomer	NN	I-NP	O
in	IN	B-PP	O
reversing	VBG	B-VP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
identify	VBP	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
neuropharmacological	JJ	I-NP	O
site	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
memory	NN	B-NP	O
processes	NNS	I-NP	O
by	IN	B-PP	O
neuroactive	JJ	B-NP	O
steroids	NNS	I-NP	O
.	.	O	O

Preliminary	JJ	B-NP	O
efficacy	NN	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
intrathecal	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
American	JJ	I-NP	O
formulation	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

Preclinical	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
intrathecal	JJ	B-NP	O
adenosine	NN	I-NP	O
suggest	VBP	B-VP	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
and	CC	I-NP	I
chronic	JJ	I-NP	I
pain	NN	I-NP	I
in	IN	B-PP	O
humans	NNS	B-NP	O
,	,	O	O
and	CC	O	O
preliminary	JJ	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
volunteers	NNS	B-NP	O
and	CC	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
Swedish	JJ	I-NP	O
formulation	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
suggests	VBZ	B-VP	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
hypersensitivity	NN	B-NP	B
states	NNS	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
with	IN	I-PP	O
acute	JJ	B-NP	O
noxious	JJ	I-NP	O
stimulation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
screen	VB	I-VP	O
for	IN	B-PP	O
efficacy	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
different	JJ	I-NP	O
formulation	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
marketed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
US	NNP	I-NP	O
,	,	O	O
using	VBG	B-VP	O
both	CC	O	O
acute	JJ	B-NP	O
noxious	JJ	I-NP	O
stimulation	NN	I-NP	O
and	CC	I-NP	O
capsaicin	NN	I-NP	O
-	HYPH	O	O
evoked	VBN	B-VP	O
mechanical	JJ	B-NP	O
hypersensitivity	NN	I-NP	B
.	.	O	O

Following	VBG	B-PP	O
Food	NNP	B-NP	O
and	CC	I-NP	O
Drug	NNP	I-NP	O
Administration	NNP	I-NP	O
and	CC	O	O
institutional	JJ	B-NP	O
review	NN	I-NP	O
board	NN	I-NP	O
approval	NN	I-NP	O
and	CC	O	O
written	VBN	B-VP	O
informed	VBN	B-NP	O
consent	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
volunteers	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
trials	NNS	I-NP	O
:	:	O	O
an	DT	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
,	,	O	O
dose	NN	B-NP	O
-	HYPH	O	O
escalating	VBG	B-VP	O
trial	NN	B-NP	O
with	IN	B-PP	O
intrathecal	JJ	B-NP	O
adenosine	NN	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
.	.	O	O

Cerebrospinal	JJ	B-NP	O
fluid	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
for	IN	B-PP	O
pharmacokinetic	JJ	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
and	CC	O	O
pain	NN	B-NP	B
ratings	NNS	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
acute	JJ	B-NP	O
heat	NN	I-NP	O
stimuli	NNS	I-NP	O
and	CC	I-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
mechanical	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
and	CC	I-NP	O
allodynia	NN	I-NP	B
after	IN	B-PP	O
intradermal	JJ	B-NP	O
capsaicin	NN	I-NP	O
injection	NN	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

Adenosine	NN	B-NP	O
produced	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
pain	NN	B-NP	B
report	NN	I-NP	O
to	TO	B-PP	O
acute	JJ	B-NP	O
noxious	JJ	I-NP	O
thermal	JJ	I-NP	O
or	CC	I-NP	O
chemical	JJ	I-NP	O
stimulation	NN	I-NP	O
but	CC	O	O
reduced	VBD	B-VP	O
mechanical	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
and	CC	I-NP	O
allodynia	NN	I-NP	B
from	IN	B-PP	O
intradermal	JJ	B-NP	O
capsaicin	NN	I-NP	O
injection	NN	I-NP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
residence	NN	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
in	IN	B-PP	O
cerebrospinal	JJ	B-NP	O
fluid	NN	I-NP	O
was	VBD	B-VP	O
short	JJ	B-ADJP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
show	VBP	B-VP	O
selective	JJ	B-NP	O
inhibition	NN	I-NP	O
by	IN	B-PP	O
intrathecal	JJ	B-NP	O
adenosine	NN	I-NP	O
of	IN	B-PP	O
hypersensitivity	NN	B-NP	B
,	,	O	O
presumed	VBN	B-VP	O
to	TO	I-VP	O
reflect	VB	I-VP	O
central	JJ	B-NP	O
sensitization	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
after	IN	B-PP	O
peripheral	JJ	B-NP	O
capsaicin	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
lasting	JJ	I-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
that	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
preliminary	JJ	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
neuropathic	JJ	I-NP	B
pain	NN	I-NP	I
and	CC	O	O
is	VBZ	B-VP	O
not	RB	O	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
prolonged	VBN	B-NP	O
residence	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
in	IN	B-PP	O
cerebrospinal	JJ	B-NP	O
fluid	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
maintenance	NN	I-NP	O
therapy	NN	I-NP	O
on	IN	B-PP	O
thyroid	NN	B-NP	O
and	CC	O	O
parathyroid	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
changes	NNS	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
lithium	NN	B-NP	O
maintenance	NN	I-NP	O
therapy	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
thyroid	NN	B-NP	O
,	,	I-NP	O
parathyroid	NN	I-NP	O
and	CC	I-NP	O
ion	NN	I-NP	O
alterations	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
and	CC	O	O
family	NN	B-NP	O
history	NN	I-NP	O
(	(	O	O
whether	IN	B-SBAR	O
or	CC	O	O
not	RB	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
first	JJ	I-NP	O
-	HYPH	I-NP	O
degree	NN	I-NP	O
relative	JJ	B-ADJP	O
with	IN	B-PP	O
thyroid	JJ	B-NP	B
disease	NN	I-NP	I
)	)	O	O
.	.	O	O

Prospective	JJ	B-NP	O
study	NN	I-NP	O
.	.	O	O

Affective	JJ	B-NP	O
Disorders	NNP	I-NP	O
Clinic	NNP	I-NP	O
at	IN	B-PP	O
St	NNP	B-NP	O
.	.	O	O

Mary	NNP	B-NP	O
s	VBZ	B-VP	O
Hospital	NNP	B-NP	O
,	,	O	O
Montreal	NNP	B-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
receiving	VBG	B-VP	O
lithium	NN	B-NP	O
maintenance	NN	I-NP	O
therapy	NN	I-NP	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
s	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
s	VBZ	B-VP	O
duration	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
psychiatric	JJ	I-NP	B
or	CC	I-NP	O
endocrinological	JJ	I-NP	O
diagnoses	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
s	VBZ	B-VP	O
out	RP	B-PRT	O
-	HYPH	B-NP	O
patient	NN	I-NP	O
clinics	NNS	I-NP	O
.	.	O	O

Laboratory	NN	B-NP	O
analyses	NNS	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
,	,	I-NP	O
magnesium	NN	I-NP	O
and	CC	I-NP	O
thyroid	NN	I-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
hormone	NN	B-NP	O
levels	NNS	I-NP	O
performed	VBN	B-VP	O
before	IN	B-PP	O
beginning	VBG	B-VP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
biannual	JJ	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
.	.	O	O

Hypothyroidism	NN	B-NP	B
developed	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
excluding	VBG	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
hypothyroid	NN	B-NP	B
at	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
having	VBG	B-VP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
degree	NN	I-NP	O
relatives	NNS	I-NP	O
affected	VBN	B-VP	O
by	IN	B-PP	O
thyroid	JJ	B-NP	B
illness	NN	I-NP	I
had	VBD	B-VP	O
accelerated	VBN	I-VP	O
onset	NN	B-NP	O
of	IN	B-PP	O
hypothyroidism	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
a	DT	B-NP	O
family	NN	I-NP	O
history	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
)	)	O	O
.	.	O	O

Women	NNS	B-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
were	VBD	B-VP	O
more	RBR	I-VP	O
often	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
hypothyroidism	NN	B-NP	B
than	IN	B-PP	O
women	NNS	B-NP	O
under	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Magnesium	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
were	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
calcium	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
either	DT	B-NP	O
baseline	NN	I-NP	O
levels	NNS	I-NP	O
or	CC	O	O
control	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
lithium	NN	B-NP	O
treatment	NN	I-NP	O
counteracted	VBD	B-VP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
calcium	NN	I-NP	O
levels	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
aging	NN	B-NP	O
.	.	O	O

Familial	JJ	B-NP	O
thyroid	NN	I-NP	B
illness	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
hypothyroidism	NN	B-NP	B
and	CC	I-NP	O
hypercalcemia	NN	I-NP	B
during	IN	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
toxicity	NN	I-NP	B
following	VBG	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
(	(	O	O
formerly	RB	B-ADVP	O
rapamycin	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
psoriasis	NN	B-NP	B
:	:	O	O
association	NN	B-NP	O
of	IN	B-PP	O
capillary	JJ	B-NP	B
leak	NN	I-NP	I
syndrome	NN	I-NP	I
with	IN	B-PP	O
apoptosis	NN	B-NP	O
of	IN	B-PP	O
lesional	JJ	B-NP	O
lymphocytes	NNS	I-NP	O
.	.	O	O

Sirolimus	NN	B-NP	O
(	(	O	O
formerly	RB	B-NP	O
rapamycin	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
immunosuppressive	JJ	I-NP	O
agent	NN	I-NP	O
that	WDT	B-NP	O
interferes	VBZ	B-VP	O
with	IN	B-PP	O
T	NN	B-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
activation	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
individuals	NNS	I-NP	O
with	IN	B-PP	O
psoriasis	NN	B-NP	B
developed	VBD	B-VP	O
a	DT	B-NP	O
capillary	JJ	I-NP	B
leak	NN	I-NP	I
syndrome	NN	I-NP	I
following	VBG	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
sirolimus	NN	I-NP	O
lesional	JJ	I-NP	O
skin	NN	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
activated	VBN	B-NP	O
peripheral	JJ	I-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
for	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
apoptosis	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
keratome	NN	I-NP	O
skin	NN	I-NP	O
specimen	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
sirolimus	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
capillary	JJ	I-NP	B
leak	NN	I-NP	I
syndrome	NN	I-NP	I
had	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
percentage	NN	B-NP	O
of	IN	B-PP	O
apoptotic	JJ	B-NP	O
cells	NNS	I-NP	O
(	(	O	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
an	DT	B-NP	O
unaffected	JJ	I-NP	O
sirolimus	NN	I-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
psoriasis	NN	B-NP	B
.	.	O	O

Activated	VBN	B-NP	O
peripheral	JJ	I-NP	O
blood	NN	I-NP	O
T	NN	I-NP	O
cells	NNS	I-NP	O
from	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
psoriasis	NN	B-NP	B
tended	VBD	B-VP	O
to	TO	I-VP	O
exhibit	VB	I-VP	O
greater	JJR	B-NP	O
spontaneous	JJ	I-NP	O
or	CC	I-NP	O
dexamethasone	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
apoptosis	NN	I-NP	O
than	IN	B-SBAR	O
did	VBD	O	O
normal	JJ	B-NP	O
T	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	I-PP	O
presence	NN	I-PP	O
of	IN	I-PP	O
sirolimus	NN	B-NP	O
.	.	O	O

Severe	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
include	VBP	B-VP	O
fever	NN	B-NP	B
,	,	O	O
anemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
capillary	JJ	B-NP	B
leak	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
symptoms	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
apoptosis	NN	I-NP	O
of	IN	B-PP	O
lesional	JJ	B-NP	O
leukocytes	NNS	I-NP	O
,	,	O	O
especially	RB	B-NP	O
activated	VBN	I-NP	O
T	NN	I-NP	O
lymphocytes	NNS	I-NP	O
,	,	O	O
and	CC	O	O
possibly	RB	B-ADVP	O
release	NN	B-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
mediators	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
patients	NNS	B-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
psoriasis	NN	I-NP	B
may	MD	B-VP	O
develop	VB	I-VP	O
capillary	JJ	B-NP	B
leak	NN	I-NP	I
from	IN	B-PP	O
various	JJ	B-NP	O
systemic	JJ	I-NP	O
therapies	NNS	I-NP	O
,	,	O	O
clinical	JJ	B-NP	O
monitoring	NN	I-NP	O
is	VBZ	B-VP	O
advisable	JJ	B-ADJP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
inflammatory	JJ	B-NP	B
diseases	NNS	I-NP	I
who	WP	B-NP	O
are	VBP	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
immune	JJ	B-NP	O
modulators	NNS	I-NP	O
.	.	O	O

Contribution	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glycine	NN	I-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
rostral	JJ	B-NP	O
and	CC	I-NP	O
intermediate	JJ	I-NP	O
-	HYPH	I-NP	O
caudal	JJ	I-NP	O
parts	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	O
tone	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glycine	NN	I-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	O
tone	NN	I-NP	O
.	.	O	O

Muscle	NN	B-NP	O
tone	NN	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
combined	JJ	I-NP	O
mechanoand	NN	I-NP	O
electromyographic	JJ	I-NP	O
method	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
measured	VBD	B-VP	O
simultaneously	RB	B-ADVP	O
the	DT	B-NP	O
muscle	NN	I-NP	O
resistance	NN	I-NP	O
(	(	O	O
MMG	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
s	VBZ	B-VP	O
hind	NN	B-NP	O
foot	NN	I-NP	O
to	TO	B-PP	O
passive	JJ	B-NP	O
extension	NN	I-NP	O
and	CC	I-NP	O
flexion	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ankle	NN	I-NP	O
joint	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
electromyographic	JJ	I-NP	O
activity	NN	I-NP	O
(	(	O	O
EMG	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
the	DT	B-NP	O
antagonistic	JJ	I-NP	O
muscles	NNS	I-NP	O
of	IN	B-PP	O
that	DT	B-NP	O
joint	NN	I-NP	O
:	:	O	O
gastrocnemius	NN	B-NP	O
and	CC	I-NP	O
tibialis	NN	I-NP	O
anterior	RB	B-ADVP	O
.	.	O	O

Muscle	NN	B-NP	B
rigidity	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dichlorokynurenic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DCKA	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
glycine	NN	I-NP	O
site	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
injected	VBN	B-VP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
microl	NN	I-NP	O
bilaterally	RB	B-ADVP	O
,	,	O	O
into	IN	B-PP	O
the	DT	B-NP	O
rostral	JJ	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
both	CC	O	O
the	DT	B-NP	O
haloperidol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
(	(	O	O
MMG	NN	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
enhanced	VBN	I-NP	O
electromyographic	JJ	I-NP	O
activity	NN	I-NP	O
(	(	O	O
EMG	NN	B-NP	O
)	)	O	O
.	.	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
DCKA	NN	I-NP	O
injected	VBN	B-VP	O
bilaterally	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
microl	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
intermediate	JJ	I-NP	O
-	HYPH	I-NP	O
caudal	JJ	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
not	RB	B-VP	O
pretreated	VBN	I-VP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
muscle	NN	I-NP	O
tone	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
blockade	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glycine	NN	I-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rostral	JJ	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
mainly	RB	B-ADJP	O
responsible	JJ	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
antiparkinsonian	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Efficacy	NN	B-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
lovastatin	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
moderate	JJ	B-NP	O
hypercholesterolemia	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
lovastatin	NN	B-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
moderate	JJ	B-NP	O
hypercholesterolemia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
Expanded	NNP	I-NP	O
Clinical	NNP	I-NP	O
Evaluation	NNP	I-NP	O
of	IN	B-PP	O
Lovastatin	NN	B-NP	O
(	(	O	O
EXCEL	NN	B-NP	O
)	)	O	O
Study	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
multicenter	JJ	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
diet	NN	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
which	WDT	B-NP	O
participants	NNS	B-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
placebo	NN	B-NP	O
or	CC	I-NP	O
lovastatin	NN	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Ambulatory	JJ	B-NP	O
patients	NNS	I-NP	O
recruited	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
participating	VBG	I-NP	O
centers	NNS	I-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
.	.	O	O

Women	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
total	NN	I-NP	O
,	,	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
density	NN	I-NP	O
lipoprotein	NN	I-NP	O
(	(	O	O
LDL	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
density	NN	I-NP	O
lipoprotein	NN	I-NP	O
(	(	O	O
HDL	NN	B-NP	O
)	)	O	O
cholesterol	NN	B-NP	O
,	,	O	O
and	CC	O	O
triglycerides	NNS	B-NP	O
;	:	O	O
and	CC	O	O
laboratory	NN	B-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
monitored	VBN	B-VP	O
periodically	RB	B-ADVP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
women	NNS	B-NP	O
,	,	O	O
lovastatin	NN	B-NP	O
produced	VBD	B-VP	O
sustained	JJ	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
)	)	O	O
,	,	O	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
changes	NNS	I-NP	O
:	:	O	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
LDL	NN	B-NP	O
cholesterol	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
and	CC	O	O
triglycerides	NNS	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
increases	NNS	B-NP	O
in	IN	B-PP	O
HDL	NN	B-NP	O
cholesterol	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Depending	VBG	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
,	,	O	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
lovastatin	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
women	NNS	I-NP	O
achieved	VBD	B-VP	O
the	DT	B-NP	O
National	NNP	I-NP	O
Cholesterol	NNP	I-NP	O
Education	NNP	I-NP	O
Program	NNP	I-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
LDL	NN	B-NP	O
cholesterol	NN	I-NP	O
levels	NNS	I-NP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mmol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
achieved	VBD	B-VP	O
the	DT	B-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mmol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
.	.	O	O

Successive	JJ	B-NP	O
transaminase	NN	I-NP	O
elevations	NNS	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
limit	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
and	CC	O	O
were	VBD	B-VP	O
dose	NN	B-NP	O
dependent	JJ	B-ADJP	O
above	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Myopathy	NN	B-NP	B
,	,	O	O
defined	VBN	B-VP	O
as	IN	B-PP	O
muscle	NN	B-NP	O
symptoms	NNS	I-NP	O
with	IN	B-PP	O
creatine	NN	B-NP	O
kinase	NN	I-NP	O
elevations	NNS	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
limit	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
,	,	O	O
was	VBD	B-VP	O
rare	JJ	B-ADJP	O
and	CC	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
recommended	VBN	I-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
lovastatin	NN	B-NP	O
.	.	O	O

Estrogen	NN	B-NP	O
-	HYPH	I-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
either	CC	O	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
or	CC	I-NP	O
safety	NN	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
lovastatin	NN	B-NP	O
.	.	O	O

Lovastatin	NN	B-NP	O
is	VBZ	B-VP	O
highly	RB	B-ADJP	O
effective	JJ	I-ADJP	O
and	CC	O	O
generally	RB	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
as	IN	B-PP	O
therapy	NN	B-NP	O
for	IN	B-PP	O
primary	JJ	B-NP	O
hypercholesterolemia	NN	I-NP	B
in	IN	B-PP	O
women	NNS	B-NP	O
.	.	O	O

REM	NN	B-NP	B
sleep	NN	I-NP	I
deprivation	NN	I-NP	I
changes	VBZ	B-VP	O
behavioral	JJ	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
catecholaminergic	JJ	B-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
receptor	NN	I-NP	O
activation	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
REM	NN	B-NP	B
sleep	NN	I-NP	I
deprivation	NN	I-NP	I
(	(	O	O
REMD	NN	B-NP	B
)	)	O	O
on	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aggressiveness	NN	I-NP	B
and	CC	I-NP	O
quipazine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
head	NN	I-NP	B
twitches	NNS	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
of	IN	B-PP	O
REMD	NN	B-NP	B
increased	VBD	B-VP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aggressiveness	NN	I-NP	B
,	,	O	O
and	CC	O	O
reduced	VBN	B-VP	O
(	(	O	O
immediately	RB	B-PP	O
after	IN	I-PP	O
completing	VBG	B-VP	O
of	IN	B-PP	O
REMD	NN	B-NP	B
)	)	O	O
or	CC	O	O
increased	VBN	B-VP	O
(	(	O	O
num	CD	B-NP	O
hr	NN	I-NP	O
after	IN	B-PP	O
completing	VBG	B-VP	O
of	IN	B-PP	O
REMD	NN	B-NP	B
)	)	O	O
quipazine	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
head	NN	I-NP	B
twitches	NNS	I-NP	I
.	.	O	O

Results	NNS	B-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
similarity	NN	B-NP	O
to	TO	B-PP	O
pharmacological	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
antidepressive	JJ	I-NP	O
treatments	NNS	I-NP	O
.	.	O	O

Extrapyramidal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
oral	JJ	B-NP	O
haloperidol	NN	I-NP	O
:	:	O	O
an	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
explanatory	JJ	B-NP	O
patient	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
characteristics	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
extrapyramidal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
(	(	O	O
EPS	NNS	B-NP	O
)	)	O	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
parkinsonism	NN	B-NP	B
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
at	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
and	CC	O	O
in	IN	B-PP	O
younger	JJR	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Prophylactic	JJ	B-NP	O
antiparkinsonian	JJ	I-NP	O
medication	NN	I-NP	O
was	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
younger	JJR	B-ADJP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
medications	NNS	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
both	CC	B-NP	O
young	JJ	I-NP	O
and	CC	I-NP	O
old	JJ	I-NP	O
patients	NNS	I-NP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
after	IN	B-PP	O
parkinsonism	NN	B-NP	B
developed	VBD	B-VP	O
.	.	O	O

Akathisia	NN	B-NP	B
was	VBD	B-VP	O
controlled	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
benzodiazepine	NN	I-NP	O
lorazepam	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
prophylactic	JJ	B-NP	O
antiparkinsonians	NNS	I-NP	O
were	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
points	VBZ	B-VP	O
to	TO	B-PP	O
patient	NN	B-NP	O
characteristics	NNS	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
significance	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
EPS	NN	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O

Hepatic	JJ	B-NP	B
veno	AFX	I-NP	I
-	HYPH	I-NP	I
occlusive	JJ	I-NP	I
disease	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
thioguanine	NN	I-NP	O
.	.	O	O

Clinically	RB	B-ADJP	O
reversible	JJ	I-ADJP	O
veno	AFX	B-NP	B
-	HYPH	I-NP	I
occlusive	JJ	I-NP	I
disease	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
liver	NN	I-NP	I
developed	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
lymphocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
maintenance	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
thioguanine	NN	I-NP	O
.	.	O	O

Serial	JJ	B-NP	O
liver	NN	I-NP	O
biopsies	NNS	I-NP	O
showed	VBD	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
and	CC	I-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
intense	JJ	B-NP	O
sinusoidal	JJ	I-NP	O
engorgement	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
this	DT	B-NP	O
disease	NN	I-NP	O
was	VBD	B-VP	O
clinically	RB	B-ADJP	O
reversible	JJ	I-ADJP	O
,	,	O	O
some	DT	B-NP	O
subintimal	JJ	I-NP	O
fibrosis	NN	I-NP	B
about	IN	B-PP	O
the	DT	B-NP	O
terminal	JJ	I-NP	O
hepatic	JJ	I-NP	O
veins	NNS	I-NP	O
persisted	VBD	B-VP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
presented	VBD	B-VP	O
a	DT	B-NP	O
unique	JJ	I-NP	O
opportunity	NN	I-NP	O
to	TO	B-VP	O
observe	VB	I-VP	O
the	DT	B-NP	O
histologic	JJ	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
clinically	RB	B-NP	O
reversible	JJ	I-NP	O
hepatic	JJ	I-NP	B
veno	AFX	I-NP	I
-	HYPH	I-NP	I
occlusive	JJ	I-NP	I
disease	NN	I-NP	I
over	IN	B-PP	O
time	NN	B-NP	O
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
veno	AFX	B-NP	O
-	HYPH	I-NP	O
occlusive	JJ	I-NP	O
related	VBN	B-VP	O
solely	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
thioguanine	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
urothelial	JJ	I-NP	B
toxicity	NN	I-NP	I
by	IN	B-PP	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mercaptoethane	NN	I-NP	O
sulphonate	NN	I-NP	O
(	(	O	O
MESNA	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
inoperable	JJ	B-NP	O
lung	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
thiol	NN	I-NP	O
compound	NN	I-NP	O
sodium	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mercaptoethane	NN	I-NP	O
sulphonate	NN	I-NP	O
(	(	O	O
MESNA	NN	B-NP	O
)	)	O	O
against	IN	B-PP	O
urothelial	JJ	B-NP	B
toxicity	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
ifosfamide	NN	B-NP	O
(	(	O	O
IF	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
inoperable	JJ	B-NP	O
lung	NN	I-NP	B
cancer	NN	I-NP	I
under	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
IF	NN	B-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
polychemotherapy	NN	I-NP	O
regimen	NN	I-NP	O
repeated	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
cycle	NN	I-NP	O
.	.	O	O

MESNA	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
orally	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
IF	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
,	,	O	O
each	DT	B-NP	O
administered	VBN	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
hr	NN	I-NP	O
(	(	O	O
=	SYM	B-VP	O
injection	NN	B-NP	O
of	IN	B-PP	O
IF	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
hr	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
hr	NN	I-NP	O
p.i	NN	I-NP	O
.	.	O	O

Out	IN	B-PP	O
of	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
treatment	NN	I-NP	O
we	PRP	B-NP	O
observed	VBD	B-VP	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
asymptomatic	JJ	B-NP	O
microscopic	JJ	I-NP	O
haematuria	NN	I-NP	B
and	CC	O	O
no	DT	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
gross	JJ	B-NP	O
haematuria	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
under	IN	B-PP	O
protection	NN	B-NP	O
with	IN	B-PP	O
MESNA	NN	B-NP	O
there	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
complete	JJ	I-NP	O
remissions	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
partial	JJ	I-NP	O
remissions	NNS	I-NP	O
(	(	O	O
total	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
further	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
under	IN	B-PP	O
polychemotherapy	NN	B-NP	O
with	IN	B-PP	O
IF	NN	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
conventional	JJ	B-NP	O
prophylactic	JJ	I-NP	O
measures	NNS	I-NP	O
(	(	O	O
raised	VBN	B-NP	O
fluid	NN	I-NP	O
intake	NN	I-NP	O
and	CC	O	O
forced	VBN	B-NP	O
diuresis	NN	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
there	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
complete	JJ	I-NP	O
and	CC	O	O
num	CD	B-NP	O
partial	JJ	I-NP	O
remissions	NNS	I-NP	O
(	(	O	O
total	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
but	CC	O	O
nearly	RB	B-NP	O
all	DT	I-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
either	CC	O	O
gross	JJ	B-NP	O
haematuria	NN	I-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
irritation	NN	I-NP	I
(	(	O	O
cystitis	NN	B-NP	B
and	CC	O	O
pollakisuria	NN	B-NP	B
)	)	O	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
appreciable	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
MESNA	NN	I-NP	O
series	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
prophylaxis	NN	I-NP	O
series	NN	I-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
either	CC	O	O
haematological	JJ	B-NP	O
or	CC	I-NP	O
systemic	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
cytostatic	JJ	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
view	NN	I-NP	O
that	IN	B-SBAR	O
MESNA	NN	B-NP	O
,	,	O	O
given	VBN	B-VP	O
orally	RB	B-ADVP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
combined	JJ	B-NP	O
cytostatic	JJ	I-NP	O
regimens	NNS	I-NP	O
which	WDT	B-NP	O
include	VBP	B-VP	O
IF	NN	B-NP	O
,	,	O	O
simplifies	VBZ	B-VP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
provides	VBZ	B-VP	O
optimum	JJ	B-NP	O
protection	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
epithelium	NN	I-NP	O
.	.	O	O

Protection	NN	B-NP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
MESNA	NN	I-NP	O
is	VBZ	B-VP	O
particularly	RB	B-ADJP	O
suitable	JJ	I-ADJP	O
for	IN	B-PP	O
outpatients	NNS	B-NP	O
.	.	O	O

Time	NN	B-NP	O
course	NN	I-NP	O
alterations	NNS	I-NP	O
of	IN	B-PP	O
QTC	NN	B-NP	O
interval	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-VP	O
hypaque	VB	I-VP	O
num	CD	B-NP	O
.	.	O	O

Sequential	JJ	B-NP	O
measurement	NN	I-NP	O
of	IN	B-PP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
during	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
angiography	NN	I-NP	O
was	VBD	B-VP	O
made	VBN	I-VP	O
num	CD	B-NP	O
seconds	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
hypaque	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
found	VBN	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
normal	JJ	B-NP	O
left	JJ	I-NP	O
ventricles	NNS	I-NP	O
and	CC	O	O
coronary	JJ	B-NP	O
arteries	NNS	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
QTC	NN	I-NP	B
prolongation	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
seconds	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
minute	NN	I-NP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
marked	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
.	.	O	O

Production	NN	B-NP	O
of	IN	B-PP	O
autochthonous	JJ	B-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
in	IN	B-PP	O
Lobund	NNP	B-NP	O
-	HYPH	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
by	IN	B-PP	O
treatments	NNS	B-NP	O
with	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
nitroso	NN	I-NP	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methylurea	NN	I-NP	O
and	CC	I-NP	O
testosterone	NN	I-NP	O
.	.	O	O

More	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
Lobund	NNP	B-NP	O
-	HYPH	O	O
Wistar	NNP	B-NP	O
(	(	O	O
L	NN	B-NP	O
-	HYPH	O	O
W	NN	B-NP	O
)	)	O	O
strain	NN	B-NP	O
rats	NNS	I-NP	O
developed	VBD	B-VP	O
large	JJ	B-NP	O
,	,	I-NP	O
palpable	JJ	I-NP	O
prostate	NN	I-NP	B
adenocarcinomas	NNS	I-NP	I
(	(	O	O
PAs	NNS	B-NP	B
)	)	O	O
following	VBG	B-PP	O
treatments	NNS	B-NP	O
with	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
nitroso	NN	I-NP	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	O	O
methylurea	NN	B-NP	O
(	(	O	O
CAS	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
testosterone	NN	B-NP	O
propionate	NN	I-NP	O
[	(	O	O
(	(	O	O
TP	NN	B-NP	O
)	)	O	O
CAS	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
]	)	O	O
,	,	O	O
and	CC	O	O
most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tumor	NN	I-NP	B
-	HYPH	B-VP	O
bearing	VBG	B-NP	O
rats	NNS	I-NP	O
manifested	VBD	B-VP	O
metastatic	JJ	B-NP	O
lesions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incubation	NN	I-NP	O
periods	NNS	I-NP	O
averaged	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Within	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
timeframe	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
W	NN	I-NP	O
rat	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
palpable	JJ	I-NP	O
PA	NN	I-NP	B
when	WRB	B-ADVP	O
treated	VBN	B-VP	O
only	RB	B-ADVP	O
with	IN	B-PP	O
TP	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
W	NN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
TP	NN	B-NP	O
acted	VBD	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
tumor	NN	I-NP	B
enhancement	NN	I-NP	O
agent	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
primary	JJ	B-NP	O
emphasis	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
dystonia	NN	I-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
syndrome	NN	I-NP	O
after	IN	B-PP	O
neuropeptide	NN	B-NP	O
(	(	O	O
MSH	NN	B-NP	O
/	SYM	O	O
ACTH	NN	O	O
)	)	O	O
stimulation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
locus	NN	I-NP	O
ceruleus	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
movement	NN	I-NP	B
disorder	NN	I-NP	I
investigated	VBN	B-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
has	VBZ	B-VP	O
some	DT	B-NP	O
features	NNS	I-NP	O
in	IN	B-PP	O
common	JJ	B-ADJP	O
with	IN	B-PP	O
human	JJ	B-NP	O
idiopathic	JJ	I-NP	O
dystonia	NN	I-NP	B
,	,	O	O
and	CC	O	O
information	NN	B-NP	O
obtained	VBN	B-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
potential	JJ	B-NP	O
clinical	JJ	I-NP	O
benefit	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
experimental	JJ	I-NP	O
results	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
peptidergic	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
LC	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
NE	NN	I-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
cerebellar	JJ	B-NP	O
Purkinje	NN	I-NP	O
cells	NNS	I-NP	O
located	VBN	B-VP	O
at	IN	B-PP	O
terminals	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ceruleo	AFX	I-NP	O
-	HYPH	I-NP	O
cerebellar	JJ	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	B-ADJP	O
certain	JJ	I-ADJP	O
as	IN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
following	NN	I-NP	O
:	:	O	O
(	(	B-LST	O
a	LS	I-LST	O
)	)	O	O
what	WP	B-NP	O
receptors	NNS	I-NP	O
were	VBD	B-VP	O
stimulated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
ACTH	NN	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
terminal	JJ	I-NP	O
fragments	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
LC	NN	I-NP	O
that	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
disorder	NN	I-NP	O
;	:	O	O
(	(	B-LST	O
b	LS	I-LST	O
)	)	O	O
whether	IN	B-SBAR	O
NE	NN	B-NP	O
,	,	O	O
released	VBN	B-VP	O
onto	IN	B-PP	O
Purkinje	NN	B-NP	O
cell	NN	I-NP	O
synapses	NNS	I-NP	O
located	VBN	B-VP	O
at	IN	B-PP	O
terminals	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ceruleo	AFX	I-NP	O
-	HYPH	I-NP	O
cerebellar	JJ	I-NP	O
pathway	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
indeed	RB	I-VP	O
cause	VB	I-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
depression	NN	I-NP	B
at	IN	B-PP	O
Purkinje	NNP	B-NP	O
cell	NN	I-NP	O
synapses	NNS	I-NP	O
(	(	O	O
previously	RB	B-VP	O
described	VBN	I-VP	O
by	IN	B-PP	O
others	NNS	B-NP	O
)	)	O	O
that	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
movement	NN	I-NP	B
disorder	NN	I-NP	I
;	:	O	O
(	(	B-LST	O
c	LS	I-LST	O
)	)	O	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
inhibitory	JJ	B-NP	O
Purkinje	NN	I-NP	O
cells	NNS	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
disinhibition	NN	B-NP	O
or	CC	O	O
increased	VBN	B-NP	O
excitability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
unilateral	JJ	I-NP	O
cerebellar	JJ	I-NP	O
fastigial	JJ	I-NP	O
or	CC	I-NP	O
interpositus	NN	I-NP	O
nuclei	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
output	NN	I-NP	O
targets	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Purkinje	NNP	I-NP	O
cell	NN	I-NP	O
axons	NNS	I-NP	O
,	,	O	O
that	WDT	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
contributing	VBG	I-NP	O
factor	NN	I-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
disorder	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
questions	NNS	I-NP	O
are	VBP	B-VP	O
currently	RB	I-VP	O
being	VBG	I-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Dexmedetomidine	NN	B-NP	O
,	,	O	O
acting	VBG	B-VP	O
through	IN	B-PP	O
central	JJ	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adrenoceptors	NNS	I-NP	O
,	,	O	O
prevents	VBZ	B-VP	O
opiate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
highly	RB	I-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adrenergic	JJ	I-NP	O
agonist	NN	I-NP	O
dexmedetomidine	NN	I-NP	O
(	(	O	O
D	NN	B-NP	O
-	HYPH	B-VP	O
MED	VBN	I-VP	O
)	)	O	O
is	VBZ	B-VP	O
capable	JJ	B-ADJP	O
of	IN	B-PP	O
inducing	VBG	B-VP	O
muscle	NN	B-NP	B
flaccidity	NN	I-NP	I
and	CC	O	O
anesthesia	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
and	CC	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

Intense	JJ	B-NP	O
generalized	VBN	I-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
is	VBZ	B-VP	O
an	DT	B-NP	O
undesirable	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
potent	JJ	B-NP	O
opiate	JJ	I-NP	O
agonists	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
neurochemistry	NN	I-NP	O
of	IN	B-PP	O
opiate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rigidity	NN	I-NP	B
has	VBZ	B-VP	O
yet	RB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
fully	RB	I-VP	O
elucidated	VBN	I-VP	O
,	,	O	O
recent	JJ	B-NP	O
work	NN	I-NP	O
suggests	VBZ	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
central	JJ	I-NP	O
adrenergic	JJ	I-NP	O
mechanism	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
authors	NNS	I-NP	O
determined	VBD	B-VP	O
if	IN	B-SBAR	O
treatment	NN	B-NP	O
with	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-VP	O
MED	VBN	I-VP	O
prevents	VBZ	B-VP	O
the	DT	B-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
alfentanil	NN	I-NP	O
anesthesia	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
intraperitoneally	RB	B-ADVP	O
with	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
num	CD	I-NP	O
regimens	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
)	)	O	O
L	NN	B-NP	O
-	HYPH	O	O
MED	VBN	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
MED	VBN	B-VP	O
,	,	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
)	)	O	O
D	NN	B-NP	O
-	HYPH	O	O
MED	VBN	B-VP	O
,	,	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
)	)	O	O
D	NN	B-NP	O
-	HYPH	O	O
MED	VBN	B-VP	O
[	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
]	)	O	O
and	CC	O	O
the	DT	B-NP	O
central	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	B-VP	O
alpha	SYM	B-NP	O
-	SYM	O	O
num	CD	B-NP	O
antagonist	NN	I-NP	O
,	,	O	O
idazoxan	NN	B-NP	O
[	(	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
]	)	O	O
;	:	O	O
num	CD	B-NP	O
)	)	O	O
D	NN	B-NP	O
-	HYPH	O	O
MED	VBN	B-VP	O
[	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
]	)	O	O
and	CC	O	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
-	HYPH	I-NP	O
acting	VBG	B-VP	O
alpha	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
antagonist	NN	I-NP	O
DG	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
[	(	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
]	)	O	O
,	,	O	O
or	CC	O	O
;	:	O	O
num	CD	B-NP	O
)	)	O	O
saline	NN	B-NP	O
.	.	O	O

Baseline	NN	B-NP	O
electromyographic	JJ	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
recorded	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
gastrocnemius	NN	I-NP	O
muscle	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Each	DT	B-NP	O
rat	NN	I-NP	O
was	VBD	B-VP	O
then	RB	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
alfentanil	NN	B-NP	O
.	.	O	O

ALF	NN	B-NP	O
injection	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
hindlimb	NN	B-NP	O
EMG	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
L	NN	I-NP	O
-	HYPH	B-VP	O
MED	VBN	B-NP	O
treatment	NN	I-NP	O
group	NN	I-NP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
indistinguishable	JJ	B-ADJP	O
from	IN	B-PP	O
that	DT	B-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
D	NN	B-NP	O
-	HYPH	B-VP	O
MED	VBN	I-VP	O
prevented	VBD	B-VP	O
alfentanil	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
rigidity	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
fashion	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
small	JJ	I-NP	O
EMG	NN	I-NP	O
values	NNS	I-NP	O
obtained	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
MED	VBN	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
with	IN	B-PP	O
those	DT	B-NP	O
recorded	VBN	B-VP	O
in	IN	B-PP	O
earlier	JJR	B-NP	O
studies	NNS	I-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
animals	NNS	I-NP	O
not	RB	B-VP	O
given	VBN	I-VP	O
any	DT	B-NP	O
opiate	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
MED	VBN	I-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
flaccid	JJ	B-ADJP	O
,	,	O	O
akinetic	JJ	B-ADJP	B
,	,	O	O
and	CC	O	O
lacked	VBD	B-VP	O
a	DT	B-NP	O
startle	JJ	I-NP	B
response	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
experimental	JJ	I-NP	O
period.	NN	I-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Seizure	NN	B-NP	B
activity	NN	I-NP	O
with	IN	B-PP	O
imipenem	NN	B-NP	O
therapy	NN	I-NP	O
:	:	O	O
incidence	NN	B-NP	O
and	CC	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
elderly	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
either	CC	B-NP	O
cerebral	JJ	I-NP	B
vascular	JJ	I-NP	I
accident	NN	I-NP	I
(	(	O	O
CVA	NN	B-NP	B
)	)	O	O
or	CC	O	O
head	NN	B-NP	B
trauma	NN	I-NP	I
and	CC	O	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
developed	VBD	B-VP	O
seizures	NNS	B-NP	B
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
maximum	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
imipenem	NN	B-NP	O
/	SYM	B-NP	O
cilastatin	NN	I-NP	O
.	.	O	O

Neither	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
reported	VBN	I-VP	O
previous	JJ	B-NP	O
seizures	NNS	I-NP	B
or	CC	O	O
seizure	NN	B-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
activity	NN	B-NP	O
nor	CC	O	O
was	VBD	B-VP	O
receiving	VBG	I-VP	O
anticonvulsant	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
seizures	NNS	I-NP	B
were	VBD	B-VP	O
controlled	VBN	I-VP	O
with	IN	B-PP	O
therapeutic	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
.	.	O	O

Both	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
maximum	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
lactam	NN	I-NP	O
antibiotics	NNS	I-NP	O
without	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
activity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
insulin	NN	B-NP	O
treatment	NN	I-NP	O
to	TO	B-VP	O
reverse	VB	I-VP	O
or	CC	I-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
bladder	NN	I-NP	O
function	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NN	I-NP	B
mellitus	NN	I-NP	I
.	.	O	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
insulin	NN	B-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
and	CC	O	O
in	FW	B-NP	O
vitro	FW	I-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
diabetic	JJ	I-NP	B
rats	NNS	I-NP	O
were	VBD	B-VP	O
investigated.	RB	B-ADVP	O
num	CD	B-NP	O
.	.	O	O

Diabetes	NNS	B-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
duration	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
and	CC	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
fluid	NN	B-NP	O
consumption	NN	I-NP	O
,	,	O	O
urine	NN	B-NP	O
volume	NN	I-NP	O
,	,	O	O
frequency	NN	B-NP	O
of	IN	B-PP	O
micturition	NN	B-NP	O
,	,	O	O
and	CC	O	O
average	JJ	B-NP	O
volume	NN	I-NP	O
per	IN	B-PP	O
micturition	NN	B-NP	O
;	:	O	O
effects	NNS	B-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
insulin	NN	B-NP	O
treatment.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

Insulin	NN	B-NP	O
treatment	NN	I-NP	O
also	RB	B-ADVP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
contractile	JJ	B-NP	O
responses	NNS	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
body	NN	I-NP	O
strips	NNS	I-NP	O
from	IN	B-PP	O
diabetic	JJ	B-NP	B
rats	NNS	I-NP	O
to	TO	B-PP	O
nerve	NN	B-NP	O
stimulation	NN	I-NP	O
,	,	O	O
ATP	NN	B-NP	O
,	,	O	O
and	CC	O	O
bethanechol.	RB	B-NP	O
num	CD	I-NP	O
.	.	O	O

Diabetes	NNS	B-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
duration	NN	I-NP	O
also	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
and	CC	O	O
increases	NNS	B-NP	O
in	IN	B-PP	O
fluid	NN	B-NP	O
consumption	NN	I-NP	O
,	,	O	O
urine	NN	B-NP	O
volume	NN	I-NP	O
,	,	O	O
frequency	NN	B-NP	O
of	IN	B-PP	O
micturition	NN	B-NP	O
,	,	O	O
and	CC	O	O
average	JJ	B-NP	O
volume	NN	I-NP	O
per	IN	B-PP	O
micturition	NN	B-NP	O
,	,	O	O
effects	NNS	B-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
insulin	NN	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
final	JJ	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

Insulin	NN	B-NP	O
treatment	NN	I-NP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
contractile	JJ	B-NP	O
responses	NNS	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
body	NN	I-NP	O
strips	NNS	I-NP	O
from	IN	B-PP	O
diabetic	JJ	B-NP	B
rats	NNS	I-NP	O
to	TO	B-PP	O
nerve	NN	B-NP	O
stimulation	NN	I-NP	O
,	,	O	O
ATP	NN	B-NP	O
,	,	O	O
and	CC	O	O
bethanechol.	RB	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NNS	I-NP	B
on	IN	B-PP	O
urinary	JJ	B-NP	O
bladder	NN	I-NP	O
function	NN	I-NP	O
are	VBP	B-VP	O
both	CC	I-VP	O
prevented	VBN	I-VP	O
and	CC	O	O
reversed	VBN	B-VP	O
by	IN	B-PP	O
insulin	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Delayed	VBN	B-NP	O
institution	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
during	IN	B-PP	O
focal	JJ	B-NP	O
cerebral	JJ	I-NP	B
ischemia	NN	I-NP	I
:	:	O	O
effect	NN	B-NP	O
on	IN	B-PP	O
brain	NN	B-NP	B
edema	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
instituted	VBN	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
delay	NN	I-NP	O
following	VBG	B-PP	O
middle	JJ	B-NP	B
cerebral	JJ	I-NP	I
artery	NN	I-NP	I
occlusion	NN	I-NP	I
(	(	O	O
MCAO	NN	B-NP	B
)	)	O	O
on	IN	B-PP	O
brain	NN	B-NP	B
edema	NN	I-NP	I
formation	NN	I-NP	O
and	CC	O	O
histochemical	JJ	B-NP	O
injury	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

Under	IN	B-PP	O
isoflurane	NN	B-NP	O
anesthesia	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
MCA	NNP	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
spontaneously	RB	I-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
was	VBD	B-VP	O
occluded	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
not	RB	I-VP	O
manipulated	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
MAP	NN	I-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
beginning	VBG	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
MCAO	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
MCAO	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
brains	NNS	I-NP	O
harvested	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
brains	NNS	I-NP	O
were	VBD	B-VP	O
sectioned	VBN	I-VP	O
along	IN	B-PP	O
coronal	JJ	B-NP	O
planes	NNS	I-NP	O
spanning	VBG	B-VP	O
the	DT	B-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
ischemia	NN	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
MCAO	NN	B-NP	B
.	.	O	O

Specific	JJ	B-NP	O
gravity	NN	I-NP	O
(	(	O	O
SG	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
subcortex	NN	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
sites	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
(	(	O	O
core	NN	B-NP	O
and	CC	O	O
periphery	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ischemic	JJ	I-NP	B
territory	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
neuronal	JJ	B-NP	B
injury	NN	I-NP	I
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
triphenyltetrazolium	NN	I-NP	O
staining	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
ischemic	JJ	I-NP	B
core	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
SG	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
subcortex	NN	I-NP	O
and	CC	I-NP	O
cortex	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
periphery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ischemic	JJ	I-NP	B
territory	NN	I-NP	O
,	,	O	O
SG	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
(	(	O	O
less	JJR	B-NP	O
edema	NN	I-NP	B
accumulation	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
histochemical	JJ	B-NP	O
injury	NN	I-NP	O
(	(	O	O
as	IN	B-PP	O
a	DT	B-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hemisphere	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
phenylephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
instituted	VBN	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-SBAR	O
MCAO	NN	B-NP	B
does	VBZ	B-VP	O
not	RB	I-VP	O
aggravate	VB	I-VP	O
edema	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
ischemic	JJ	I-NP	B
core	NN	I-NP	O
,	,	O	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
improves	VBZ	B-VP	O
edema	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
periphery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ischemic	JJ	I-NP	B
territory	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
histochemical	JJ	B-NP	O
neuronal	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Amiodarone	NN	B-NP	O
pulmonary	JJ	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

Amiodarone	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
antiarrhythmic	JJ	I-NP	O
agent	NN	I-NP	O
whose	WP$	B-NP	O
utility	NN	I-NP	O
is	VBZ	B-VP	O
limited	VBN	I-VP	O
by	IN	B-PP	O
many	JJ	B-NP	O
side	NN	I-NP	O
-	HYPH	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
problematic	JJ	I-NP	O
being	VBG	I-NP	O
pneumonitis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
pulmonary	JJ	I-NP	B
toxicity	NN	I-NP	I
of	IN	B-PP	O
amiodarone	NN	B-NP	O
is	VBZ	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
direct	JJ	B-NP	O
injury	NN	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
intracellular	JJ	I-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
phospholipid	NN	B-NP	O
and	CC	O	O
T	NN	B-NP	O
cell	NN	I-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
hypersensitivity	NN	I-NP	B
pneumonitis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
radiographic	JJ	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
pulmonary	JJ	I-NP	B
toxicity	NN	I-NP	I
are	VBP	B-VP	O
characteristic	JJ	B-ADJP	O
but	CC	I-ADJP	O
nonspecific	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
depends	VBZ	B-VP	O
on	IN	B-PP	O
exclusion	NN	B-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
entities	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
,	,	O	O
infection	NN	B-NP	B
,	,	O	O
and	CC	O	O
malignancy	NN	B-NP	B
.	.	O	O

While	IN	B-SBAR	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
clinical	JJ	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
majority	NN	B-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
always	RB	B-ADVP	O
possible	JJ	B-ADJP	O
or	CC	I-ADJP	O
advisable	JJ	I-ADJP	O
.	.	O	O

Dose	NN	B-NP	O
reduction	NN	I-NP	O
or	CC	O	O
concomitant	JJ	B-NP	O
steroid	NN	I-NP	O
therapy	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
selected	VBN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Light	NN	B-NP	O
chain	NN	I-NP	O
proteinuria	NN	I-NP	B
and	CC	O	O
cellular	JJ	B-NP	O
mediated	VBN	I-NP	O
immunity	NN	I-NP	O
in	IN	B-PP	O
rifampin	NN	B-NP	O
treated	VBN	B-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
tuberculosis	NN	B-NP	B
.	.	O	O

Light	NN	B-NP	O
chain	NN	I-NP	O
proteinuria	NN	I-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
tuberculosis	NN	I-NP	B
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
rifampin	NN	B-NP	O
.	.	O	O

Concomitant	JJ	B-NP	O
assay	NN	I-NP	O
of	IN	B-PP	O
cellular	JJ	B-NP	O
mediated	VBN	I-NP	O
immunity	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
using	VBG	B-VP	O
skin	NN	B-NP	O
test	NN	I-NP	O
antigen	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
lymphokine	NN	I-NP	O
in	FW	B-NP	O
vitro	FW	I-NP	O
test	NN	I-NP	O
provided	VBD	B-VP	O
results	NNS	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
different	JJ	B-ADJP	O
.	.	O	O

Response	NN	B-NP	O
to	TO	B-PP	O
Varidase	NN	B-NP	O
skin	NN	I-NP	O
test	NN	I-NP	O
antigen	NN	I-NP	O
was	VBD	B-VP	O
negative	JJ	B-ADJP	O
for	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
tuberculosis	NN	I-NP	B
patients	NNS	I-NP	O
tested	VBN	B-VP	O
,	,	O	O
but	CC	O	O
there	EX	B-NP	O
occurred	VBD	B-VP	O
a	DT	B-NP	O
hyper	NN	I-NP	O
-	HYPH	B-NP	O
responsiveness	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lymphocytes	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
to	TO	B-PP	O
phytomitogen	NN	B-NP	O
(	(	O	O
PHA	NN	B-NP	O
-	HYPH	O	O
P	NN	B-NP	O
)	)	O	O
.	.	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
of	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
other	JJ	I-NP	O
tuberculous	JJ	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
last	JJ	I-NP	O
finding	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
time	NN	B-NP	O
of	IN	B-PP	O
testing	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
endogenous	JJ	B-NP	O
serum	NN	I-NP	O
binding	NN	I-NP	O
of	IN	B-PP	O
rifampin	NN	B-NP	O
which	WDT	B-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
inhibited	VBN	I-VP	O
mitogen	NN	B-NP	O
activity	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
lymphocyte	NN	I-NP	O
.	.	O	O

Initial	JJ	B-NP	O
potassium	NN	I-NP	O
loss	NN	I-NP	O
and	CC	I-NP	O
hypokalaemia	NN	I-NP	B
during	IN	B-PP	O
chlorthalidone	NN	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
essential	JJ	B-NP	O
hypertension	NN	I-NP	B
:	:	O	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
dietary	JJ	B-NP	O
sodium	NN	I-NP	O
restriction	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
potassium	NN	I-NP	O
loss	NN	I-NP	O
and	CC	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hypokalaemia	NN	B-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
oral	JJ	I-NP	O
diuretic	JJ	I-NP	O
,	,	I-NP	O
metabolic	JJ	I-NP	O
balance	NN	I-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
essential	JJ	B-NP	O
hypertension	NN	I-NP	B
who	WP	B-NP	O
had	VBD	B-VP	O
shown	VBN	I-VP	O
hypokalaemia	NN	B-NP	B
under	IN	B-PP	O
prior	JJ	B-NP	O
oral	JJ	I-NP	O
diuretic	JJ	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Chlorthalidone	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
-	HYPH	I-NP	O
sodium	NN	I-NP	O
diet	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
a	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
sodium	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
mmol	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
)	)	O	O
diet	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
initial	JJ	I-NP	O
total	JJ	I-NP	O
body	NN	I-NP	O
potassium	NN	I-NP	O
(	(	O	O
40K	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
electrolyte	NN	I-NP	O
balances	NNS	I-NP	O
,	,	O	O
weight	NN	B-NP	O
,	,	O	O
bromide	NN	B-NP	O
space	NN	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
renin	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
and	CC	O	O
aldosterone	NN	B-NP	O
secretion	NN	I-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
a	DT	B-NP	O
potassium	NN	I-NP	O
deficit	NN	I-NP	O
developed	VBD	B-VP	O
,	,	O	O
with	IN	B-PP	O
proportionally	RB	B-NP	O
larger	JJR	I-NP	O
losses	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
extracellular	JJ	I-NP	O
than	IN	B-PP	O
from	IN	B-PP	O
the	DT	B-NP	O
intracellular	JJ	I-NP	O
compartment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
-	HYPH	I-NP	O
sodium	NN	I-NP	O
group	NN	I-NP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
mean	JJ	I-NP	O
potassium	NN	I-NP	O
deficit	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mmol	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
which	WDT	B-NP	O
some	DT	B-NP	O
potassium	NN	I-NP	O
was	VBD	B-VP	O
regained	VBN	I-VP	O
;	:	O	O
in	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
sodium	NN	I-NP	O
group	NN	I-NP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
deficit	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mmol	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
normal	JJ	I-NP	O
-	HYPH	I-NP	O
sodium	NN	I-NP	O
group	NN	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
immediate	JJ	I-NP	O
but	CC	I-NP	O
temporary	JJ	I-NP	O
rise	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
and	CC	I-NP	O
aldosterone	NN	I-NP	O
levels	NNS	I-NP	O
;	:	O	O
in	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
sodium	NN	I-NP	O
group	NN	I-NP	O
renin	NN	I-NP	O
and	CC	I-NP	O
aldosterone	NN	I-NP	O
increased	VBD	B-VP	O
more	RBR	B-ADVP	O
slowly	RB	I-ADVP	O
but	CC	O	O
remained	VBD	B-VP	O
elevated	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
dietary	JJ	B-NP	O
sodium	NN	I-NP	O
restriction	NN	I-NP	O
increases	VBZ	B-VP	O
diuretic	JJ	B-ADJP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
potassium	NN	I-NP	O
loss	NN	I-NP	O
,	,	O	O
presumably	RB	B-ADVP	O
by	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
-	HYPH	B-NP	O
angiotensin	NN	I-NP	O
-	HYPH	I-NP	O
aldosterone	NN	I-NP	O
system	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
sodium	NN	B-NP	O
delivery	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
distal	JJ	I-NP	O
renal	JJ	I-NP	O
tubules	NNS	I-NP	O
remains	VBZ	B-VP	O
sufficiently	RB	B-ADJP	O
high	JJ	I-ADJP	O
to	TO	B-VP	O
allow	VB	I-VP	O
increased	VBN	B-NP	O
potassium	NN	I-NP	O
secretion	NN	I-NP	O
.	.	O	O

Dynamic	JJ	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessel	NN	I-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
postulated	VBD	B-VP	O
that	IN	B-SBAR	O
during	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
gentamicin	NN	B-NP	O
the	DT	B-NP	O
transient	JJ	I-NP	O
or	CC	I-NP	O
dynamic	JJ	I-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessels	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
affected	VBN	I-VP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
antioxidants	NNS	B-NP	O
can	MD	B-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
dynamic	JJ	B-NP	O
responses	NNS	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
new	JJ	I-NP	O
approach	NN	I-NP	O
to	TO	B-PP	O
ex	FW	B-NP	O
vivo	FW	I-NP	O
blood	NN	I-NP	O
vessel	NN	I-NP	O
experiments	NNS	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
the	DT	B-NP	O
end	NN	I-NP	O
points	NNS	I-NP	O
of	IN	B-PP	O
vessels	NNS	B-NP	O
response	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
interval	NN	I-NP	O
is	VBZ	B-VP	O
considered	VBN	I-VP	O
,	,	O	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
dynamics	NNS	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
response	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
paper	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
confirm	VBP	B-VP	O
the	DT	B-NP	O
alteration	NN	I-NP	O
in	IN	B-PP	O
dynamic	JJ	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessels	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
change	NN	I-NP	O
of	IN	B-PP	O
pressure	NN	B-NP	O
in	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
C	NN	I-NP	O
administration	NN	I-NP	O
to	TO	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
are	VBP	B-VP	O
also	RB	I-VP	O
confirmed	VBN	I-VP	O
through	IN	B-PP	O
:	:	O	O
lower	JJR	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
urea	NN	I-NP	O
and	CC	I-NP	O
creatinine	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
potassium	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
pressure	NN	I-NP	O
dynamic	JJ	I-NP	O
responses	NNS	I-NP	O
of	IN	B-PP	O
isolated	VBN	B-NP	O
blood	NN	I-NP	O
vessels	NNS	I-NP	O
show	VBP	B-VP	O
a	DT	B-NP	O
faster	JJR	I-NP	O
pressure	NN	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

Vitamin	NN	B-NP	O
C	NN	I-NP	O
administration	NN	I-NP	O
induced	VBD	B-VP	O
slowdown	NN	B-NP	O
of	IN	B-PP	O
pressure	NN	B-NP	O
change	NN	I-NP	O
back	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
values	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
pressure	NN	I-NP	O
dynamic	JJ	I-NP	O
properties	NNS	I-NP	O
,	,	O	O
quantitatively	RB	B-VP	O
defined	VBN	I-VP	O
by	IN	B-PP	O
comparative	JJ	B-NP	O
pressure	NN	I-NP	O
dynamic	JJ	I-NP	O
and	CC	I-NP	O
total	JJ	I-NP	O
pressure	NN	I-NP	O
dynamic	JJ	B-ADJP	O
,	,	O	O
confirm	VBP	B-VP	O
the	DT	B-NP	O
alteration	NN	I-NP	O
in	IN	B-PP	O
dynamic	JJ	B-NP	O
response	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessels	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
change	NN	I-NP	O
of	IN	B-PP	O
pressure	NN	B-NP	O
in	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
and	CC	O	O
beneficial	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
C	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hemodynamics	NNS	I-NP	O
of	IN	B-PP	O
oxytocin	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
vasoactive	JJ	I-NP	O
agents	NNS	I-NP	O
during	IN	B-PP	O
neuraxial	JJ	B-NP	O
anesthesia	NN	I-NP	O
for	IN	B-PP	O
cesarean	JJ	B-NP	O
delivery	NN	I-NP	O
:	:	O	O
findings	NNS	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Oxytocin	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
uterotonic	JJ	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
significant	JJ	B-NP	O
and	CC	I-NP	O
even	RB	I-NP	O
fatal	JJ	I-NP	O
hypotension	NN	I-NP	B
,	,	O	O
particularly	RB	B-ADVP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
bolus	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
resulting	VBG	I-NP	O
hypotension	NN	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
or	CC	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
through	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
venous	JJ	B-NP	O
return	NN	I-NP	O
.	.	O	O

Parturients	NNS	B-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
volume	NN	I-NP	O
status	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
valves	NNS	I-NP	O
and	CC	O	O
pulmonary	JJ	B-NP	O
vasculature	NN	I-NP	O
most	RBS	B-ADVP	O
often	RB	I-ADVP	O
respond	VBP	B-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
hypotension	NN	I-NP	B
with	IN	B-PP	O
a	DT	B-NP	O
compensatory	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
stroke	NN	B-NP	B
volume	NN	I-NP	O
.	.	O	O

Oxytocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
at	IN	B-PP	O
cesarean	JJ	B-NP	O
delivery	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
incorrectly	RB	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
blood	NN	B-NP	B
loss	NN	I-NP	I
.	.	O	O

Pulse	NN	B-NP	O
power	NN	I-NP	O
analysis	NN	I-NP	O
(	(	O	O
also	RB	B-ADVP	O
called	VBN	B-VP	O
pulse	NN	B-NP	O
contour	NN	I-NP	O
analysis	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
an	DT	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
wave	NN	I-NP	O
form	NN	I-NP	O
allows	VBZ	B-VP	O
continuous	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
in	IN	B-PP	O
real	JJ	B-NP	O
time	NN	I-NP	O
,	,	O	O
thereby	RB	B-VP	O
elucidating	VBG	I-VP	O
the	DT	B-NP	O
causative	JJ	I-NP	O
factors	NNS	I-NP	O
behind	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

Pulse	NN	B-NP	O
power	NN	I-NP	O
analysis	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
cesarean	JJ	B-NP	O
delivery	NN	I-NP	O
performed	VBN	B-VP	O
under	IN	B-PP	O
neuraxial	JJ	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
oxytocin	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
compensatory	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
stroke	NN	B-NP	B
volume	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
.	.	O	O

Pulse	NN	B-NP	O
power	NN	I-NP	O
analysis	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
helpful	JJ	B-ADJP	O
in	IN	B-PP	O
determining	VBG	B-VP	O
the	DT	B-NP	O
etiology	NN	I-NP	O
of	IN	B-PP	O
and	CC	O	O
treating	VBG	B-VP	O
hypotension	NN	B-NP	B
during	IN	B-PP	O
cesarean	JJ	B-NP	O
delivery	NN	I-NP	O
under	IN	B-PP	O
neuraxial	JJ	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

Exaggerated	VBN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
mediators	NNS	I-NP	O
in	IN	B-PP	O
vasoactive	JJ	B-NP	O
intestinal	JJ	I-NP	O
polypeptide	NN	I-NP	O
knockout	NN	I-NP	O
(	(	O	O
VIP	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	SYM	O	O
)	)	O	O
mice	NNS	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CYP	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
.	.	O	O

Vasoactive	JJ	B-NP	O
intestinal	JJ	I-NP	O
polypeptide	NN	I-NP	O
(	(	O	O
VIP	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
immunomodulatory	JJ	I-NP	O
neuropeptide	NN	I-NP	O
distributed	VBN	B-VP	O
in	IN	B-PP	O
micturition	NN	B-NP	O
pathways	NNS	I-NP	O
.	.	O	O

VIP	NN	B-NP	O
mice	NNS	I-NP	O
exhibit	VBP	B-VP	O
altered	VBN	I-VP	O
bladder	NN	B-NP	O
function	NN	I-NP	O
and	CC	O	O
neurochemical	JJ	B-NP	O
properties	NNS	I-NP	O
in	IN	B-PP	O
micturition	NN	B-NP	O
pathways	NNS	I-NP	O
after	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CYP	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
.	.	O	O

Given	VBN	B-NP	O
VIP	NN	I-NP	O
s	VBZ	B-VP	O
role	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
mediator	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
VIP	NN	B-NP	O
mice	NNS	I-NP	O
would	MD	B-VP	O
exhibit	VB	I-VP	O
enhanced	VBN	I-VP	O
inflammatory	JJ	B-NP	O
mediator	NN	I-NP	O
expression	NN	I-NP	O
after	IN	B-PP	O
cystitis	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
mouse	NN	I-NP	O
inflammatory	JJ	I-NP	O
cytokine	NN	I-NP	O
and	CC	I-NP	O
receptor	NN	I-NP	O
RT2	NN	I-NP	O
profiler	NN	I-NP	O
array	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
regulated	JJ	B-NP	O
transcripts	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
of	IN	B-PP	O
wild	JJ	B-NP	O
type	NN	I-NP	O
(	(	O	O
WT	NN	B-NP	O
)	)	O	O
and	CC	O	O
VIP	NN	B-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
CYP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
binary	JJ	I-NP	O
comparisons	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
:	:	O	O
WT	JJ	B-NP	O
control	NN	I-NP	O
versus	CC	O	O
CYP	NN	B-NP	O
treatment	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
h	NN	I-NP	O
)	)	O	O
,	,	O	O
VIP	NN	B-NP	O
control	NN	I-NP	O
versus	IN	B-PP	O
CYP	NN	B-NP	O
treatment	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
h	NN	I-NP	O
)	)	O	O
,	,	O	O
WT	NN	B-NP	O
control	NN	I-NP	O
versus	IN	B-PP	O
VIP	NN	B-NP	O
control	NN	I-NP	O
,	,	O	O
and	CC	O	O
WT	NN	B-NP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
treatment	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
h	NN	I-NP	O
)	)	O	O
versus	IN	B-PP	O
VIP	NN	B-NP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
treatment	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
h	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
genes	NNS	I-NP	O
presented	VBN	B-VP	O
represent	VBP	B-VP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
either	CC	O	O
direction	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
p	NN	I-NP	O
value	NN	I-NP	O
is	VBZ	B-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
comparison	NN	I-NP	O
being	VBG	B-VP	O
made	VBN	I-VP	O
.	.	O	O

Several	JJ	B-NP	O
regulated	VBN	I-NP	O
genes	NNS	I-NP	O
were	VBD	B-VP	O
validated	VBN	I-VP	O
using	VBG	B-VP	O
enzyme	NN	B-NP	O
-	HYPH	O	O
linked	VBN	B-NP	O
immunoassays	NNS	I-NP	O
including	VBG	B-PP	O
IL	NN	B-NP	O
-	HYPH	B-NP	O
1beta	NN	I-NP	O
and	CC	I-NP	O
CXCL1	NN	I-NP	O
.	.	O	O

CYP	NN	B-NP	O
treatment	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
expression	NN	B-NP	O
of	IN	B-PP	O
CXCL1	NN	B-NP	O
and	CC	I-NP	O
IL	NN	I-NP	O
-	HYPH	B-NP	O
1beta	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
of	IN	B-PP	O
WT	NN	B-NP	O
and	CC	I-NP	O
VIP	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
but	CC	O	O
expression	NN	B-NP	O
in	IN	B-PP	O
VIP	NN	B-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
increase	NN	I-NP	O
)	)	O	O
than	IN	B-PP	O
that	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
WT	JJ	B-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
increase	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
VIP	NN	B-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
bladder	NN	B-NP	B
inflammation	NN	I-NP	I
,	,	O	O
inflammatory	JJ	B-NP	O
mediators	NNS	I-NP	O
are	VBP	B-VP	O
increased	VBN	I-VP	O
above	IN	B-PP	O
that	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
WT	NN	B-NP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
shift	NN	I-NP	O
in	IN	B-PP	O
balance	NN	B-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
increased	VBN	B-NP	O
bladder	NN	I-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
VIP	NN	B-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
bladder	NN	B-NP	B
inflammation	NN	I-NP	I
and	CC	O	O
altered	VBD	B-VP	O
neurochemical	JJ	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
micturition	NN	B-NP	O
pathways	NNS	I-NP	O
.	.	O	O

Intraocular	JJ	B-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
uveitis	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
fluocinolone	NN	B-NP	O
acetonide	NN	I-NP	O
implants	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
elevated	JJ	B-NP	B
intraocular	JJ	I-NP	I
pressure	NN	I-NP	I
(	(	O	O
IOP	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
uveitis	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
fluocinolone	NN	I-NP	O
acetonide	NN	I-NP	O
(	(	O	O
FA	NN	B-NP	O
)	)	O	O
intravitreal	JJ	B-NP	O
implant	NN	I-NP	O
.	.	O	O

Pooled	VBN	B-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
multicenter	JJ	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
masked	VBN	B-VP	O
,	,	O	O
randomized	VBN	B-VP	O
,	,	O	O
controlled	VBN	B-VP	O
,	,	O	O
phase	NN	B-NP	O
2b	NN	I-NP	O
/	SYM	B-VP	O
num	CD	B-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
evaluating	VBG	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
FA	NN	I-NP	O
intravitreal	JJ	I-NP	O
implant	NN	I-NP	O
or	CC	O	O
standard	JJ	B-NP	O
therapy	NN	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
implanted	VBN	B-NP	O
eyes	NNS	I-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
IOP	NN	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
or	CC	O	O
more	JJR	B-ADJP	O
than	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
eyes	NNS	B-NP	O
reached	VBD	B-VP	O
an	DT	B-NP	O
IOP	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
,	,	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Topical	JJ	B-NP	O
IOP	NN	I-NP	O
-	HYPH	O	O
lowering	VBG	B-VP	O
medication	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
implanted	VBN	B-NP	O
eyes	NNS	I-NP	O
,	,	O	O
and	CC	O	O
IOP	NN	B-NP	O
-	HYPH	O	O
lowering	VBG	B-VP	O
surgeries	NNS	B-NP	O
,	,	O	O
most	JJS	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
trabeculectomies	NNS	B-NP	O
,	,	O	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
implanted	VBN	B-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Intraocular	JJ	B-NP	O
pressure	NN	I-NP	O
-	HYPH	B-VP	O
lowering	VBG	B-NP	O
surgeries	NNS	I-NP	O
were	VBD	B-VP	O
considered	VBN	I-VP	O
a	DT	B-NP	O
success	NN	I-NP	O
(	(	O	O
postoperative	JJ	B-NP	O
IOP	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
additional	JJ	B-NP	O
IOP	NN	I-NP	O
-	HYPH	O	O
lowering	VBG	B-VP	O
medication	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
eyes	NNS	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
hypotony	NN	B-NP	B
following	VBG	B-PP	O
IOP	NN	B-NP	O
-	HYPH	O	O
lowering	VBG	B-VP	O
surgery	NN	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
different	JJ	B-ADJP	O
from	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
implanted	VBN	B-NP	O
eyes	NNS	I-NP	O
not	RB	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
surgery	NN	B-NP	O
.	.	O	O

Elevated	JJ	B-NP	O
IOP	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
complication	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
FA	NN	I-NP	O
intravitreal	JJ	I-NP	O
implant	NN	I-NP	O
but	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
controlled	VBN	I-VP	O
with	IN	B-PP	O
medication	NN	B-NP	O
and	CC	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

Pallidal	JJ	B-NP	O
stimulation	NN	I-NP	O
:	:	O	O
an	DT	B-NP	O
alternative	NN	I-NP	O
to	TO	B-VP	O
pallidotomy	VB	I-VP	O
?	.	O	O
A	DT	B-NP	O
resurgence	NN	I-NP	O
of	IN	B-PP	O
interest	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
surgical	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
came	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
rediscovery	NN	I-NP	O
of	IN	B-PP	O
posteroventral	JJ	B-NP	O
pallidotomy	NN	I-NP	O
by	IN	B-PP	O
Laitinen	NNP	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

Laitinen	NNP	B-NP	O
s	NNS	I-NP	O
procedure	NN	I-NP	O
improved	VBD	B-VP	O
most	JJS	B-NP	O
symptoms	NNS	I-NP	O
in	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
resistant	JJ	I-NP	O
PD	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
engendered	VBD	B-VP	O
wide	JJ	B-NP	O
interest	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
neurosurgical	JJ	I-NP	O
community	NN	I-NP	O
.	.	O	O

Another	DT	B-NP	O
lesioning	VBG	I-NP	O
procedure	NN	I-NP	O
,	,	O	O
ventrolateral	JJ	B-NP	O
thalamotomy	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
become	VBN	I-VP	O
a	DT	B-NP	O
powerful	JJ	I-NP	O
alternative	NN	I-NP	O
to	TO	B-VP	O
stimulate	VB	I-VP	O
the	DT	B-NP	O
nucleus	NN	I-NP	O
ventralis	NN	I-NP	O
intermedius	NN	I-NP	O
,	,	O	O
producing	VBG	B-VP	O
high	JJ	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
success	NN	I-NP	O
rates	NNS	I-NP	O
and	CC	O	O
low	JJ	B-NP	O
morbidity	NN	I-NP	O
rates	NNS	I-NP	O
.	.	O	O

Pallidal	JJ	B-NP	O
stimulation	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
met	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
success	NN	I-NP	O
.	.	O	O

According	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
pallidotomy	NN	I-NP	O
improves	VBZ	B-VP	O
the	DT	O	O
on	IN	B-PP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
PD	NN	B-NP	B
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
dyskinesias	NNS	B-NP	B
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
off	JJ	I-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
rigidity	NN	B-NP	B
,	,	O	O
bradykinesia	NN	B-NP	B
,	,	O	O
and	CC	O	O
on	VB	B-VP	O
-	HYPH	B-NP	O
off	RP	I-NP	O
fluctuations	NNS	B-NP	O
.	.	O	O

Pallidal	JJ	B-NP	O
stimulation	NN	I-NP	O
improves	VBZ	B-VP	O
bradykinesia	NN	B-NP	B
and	CC	I-NP	O
rigidity	NN	I-NP	B
to	TO	B-PP	O
a	DT	B-NP	O
minor	JJ	I-NP	O
extent	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
its	PRP$	B-NP	O
strength	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
in	IN	B-PP	O
improving	VBG	B-VP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

Stimulation	NN	B-NP	O
often	RB	B-ADVP	O
produces	VBZ	B-VP	O
an	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hyper	NN	I-NP	B
-	HYPH	B-VP	I
or	CC	O	I
dyskinetic	JJ	B-NP	I
upper	JJ	I-NP	O
limbs	NNS	I-NP	O
,	,	O	O
but	CC	O	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
freezing	VBG	I-NP	O
phenomenon	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
limbs	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
.	.	O	O

Considering	VBG	B-VP	O
the	DT	B-NP	O
small	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
independence	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
high	JJ	I-NP	O
costs	NNS	I-NP	O
of	IN	B-PP	O
bilateral	JJ	B-NP	O
implants	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
difficulty	NN	I-NP	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
experience	VBP	B-VP	O
in	IN	B-PP	O
handling	VBG	B-VP	O
the	DT	B-NP	O
devices	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
question	NN	I-NP	O
arises	VBZ	B-VP	O
as	IN	B-PP	O
to	TO	B-PP	O
whether	IN	B-SBAR	O
bilateral	JJ	B-NP	O
pallidal	JJ	I-NP	O
stimulation	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
real	JJ	I-NP	O
alternative	NN	I-NP	O
to	TO	B-PP	O
pallidotomy	NN	B-NP	O
.	.	O	O

Case	NN	B-NP	O
report	NN	I-NP	O
:	:	O	O
Dexatrim	NN	B-NP	O
(	(	O	O
Phenylpropanolamine	NN	B-NP	O
)	)	O	O
as	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

Phenylpropanolamine	NN	B-NP	O
(	(	O	O
PPA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
sympathetic	JJ	I-NP	O
amine	NN	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
over	IN	B-PP	O
-	HYPH	B-NP	O
the	DT	B-NP	O
-	HYPH	I-NP	O
counter	NN	I-NP	O
cold	JJ	I-NP	O
remedies	NNS	I-NP	O
and	CC	O	O
weight	NN	B-NP	O
-	HYPH	I-NP	O
control	NN	I-NP	O
preparations	NNS	I-NP	O
worldwide	RB	B-ADVP	O
.	.	O	O

Its	PRP$	B-NP	O
use	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
hypertensive	JJ	B-NP	B
episodes	NNS	I-NP	O
and	CC	O	O
hemorrhagic	JJ	B-NP	B
strokes	NNS	I-NP	I
in	IN	B-PP	O
younger	JJR	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Several	JJ	B-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
linked	VBN	I-VP	O
the	DT	B-NP	O
abuse	NN	I-NP	O
of	IN	B-PP	O
PPA	NN	B-NP	O
with	IN	B-PP	O
myocardial	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
especially	RB	B-ADVP	O
when	WRB	B-ADVP	O
overdose	NN	B-NP	B
is	VBZ	B-VP	O
involved	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
here	RB	B-ADVP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
Dexatrim	NN	B-NP	O
(	(	O	O
PPA	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
young	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
using	VBG	I-VP	O
it	PRP	B-NP	O
at	IN	B-PP	O
recommended	VBN	B-NP	O
doses	NNS	I-NP	O
for	IN	B-PP	O
weight	NN	B-NP	O
control	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
review	VBP	B-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
other	JJ	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
PPA	NN	B-NP	O
related	JJ	I-NP	O
myocardial	JJ	I-NP	B
injury	NN	I-NP	I
that	WDT	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
so	RB	B-ADVP	O
far	RB	I-ADVP	O
.	.	O	O

Physicians	NNS	B-NP	O
and	CC	I-NP	O
patients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
alert	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
cardiac	JJ	I-NP	O
risk	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
PPA	NN	B-NP	O
,	,	O	O
even	RB	B-ADVP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
generally	RB	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
safe	JJ	B-ADJP	O
.	.	O	O

Risperidone	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
,	,	O	O
benign	JJ	B-NP	O
transient	JJ	I-NP	O
visual	JJ	I-NP	B
disturbances	NNS	I-NP	I
in	IN	B-PP	O
schizophrenic	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
past	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
LSD	NN	B-NP	O
abuse	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
schizophrenic	JJ	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
prior	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
LSD	NN	B-NP	O
abuse	NN	I-NP	O
and	CC	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
previously	RB	I-VP	O
developed	VBN	I-VP	O
EPS	NN	B-NP	B
with	IN	B-PP	O
classic	JJ	B-NP	O
antipsychotics	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
successfully	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

They	PRP	B-NP	O
both	DT	O	O
reported	VBD	B-VP	O
short	JJ	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
visual	JJ	I-NP	B
disturbances	NNS	I-NP	I
,	,	O	O
which	WDT	B-NP	O
appeared	VBD	B-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
imagery	NN	I-NP	O
resembled	VBD	B-VP	O
visual	JJ	B-NP	B
disturbances	NNS	I-NP	I
previously	RB	B-VP	O
experienced	VBN	I-VP	O
as	IN	B-PP	O
flashbacks	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
prior	JJ	B-NP	O
LSD	NN	I-NP	O
consumption	NN	I-NP	O
.	.	O	O

Risperidone	NN	B-NP	O
administration	NN	I-NP	O
was	VBD	B-VP	O
continued	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
visual	JJ	I-NP	B
disturbances	NNS	I-NP	I
gradually	RB	B-ADVP	O
wore	VBD	B-VP	O
off	RP	B-PRT	O
.	.	O	O

During	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
period	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	B
disturbances	NNS	I-NP	I
.	.	O	O

This	DT	B-NP	O
phenomenon	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
interpreted	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
benign	JJ	I-NP	O
,	,	I-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
and	CC	I-NP	O
self	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
side	NN	B-NP	O
effect	NN	I-NP	O
which	WDT	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
contraindicate	VB	I-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
or	CC	O	O
interfere	VB	B-VP	O
with	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Conclusions	NNS	B-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
taken	VBN	I-VP	O
with	IN	B-PP	O
appropriate	JJ	B-NP	O
caution	NN	I-NP	O
.	.	O	O

Activation	NN	B-NP	O
of	IN	B-PP	O
poly	NN	B-NP	O
(	(	O	O
ADP	NN	B-NP	O
-	HYPH	B-NP	O
ribose	NN	I-NP	O
)	)	O	O
polymerase	NN	B-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
.	.	O	O

Activation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nuclear	JJ	I-NP	O
enzyme	NN	I-NP	O
poly	NN	I-NP	O
(	(	O	O
ADP	NN	B-NP	O
-	HYPH	B-NP	O
ribose	NN	I-NP	O
)	)	O	O
polymerase	NN	B-NP	O
(	(	O	O
PARP	NN	B-NP	O
)	)	O	O
by	IN	B-PP	O
oxidant	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
DNA	NN	I-NP	O
damage	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
pathway	NN	I-NP	O
of	IN	B-PP	O
cell	NN	B-NP	O
dysfunction	NN	I-NP	O
and	CC	O	O
tissue	NN	B-NP	O
injury	NN	I-NP	O
in	IN	B-PP	O
conditions	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
factor	NN	I-NP	O
implicated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cardiotoxicity	NN	I-NP	B
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
antitumor	JJ	I-NP	O
anthracycline	NN	I-NP	O
antibiotic	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
PARP	NN	B-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
DOX	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Using	VBG	B-VP	O
a	DT	B-NP	O
dual	JJ	I-NP	O
approach	NN	I-NP	O
of	IN	B-PP	O
PARP	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
suppression	NN	I-NP	O
,	,	O	O
by	IN	B-PP	O
genetic	JJ	B-NP	O
deletion	NN	I-NP	O
or	CC	O	O
pharmacological	JJ	B-NP	O
inhibition	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
phenanthridinone	NN	I-NP	O
PARP	NN	I-NP	O
inhibitor	NN	I-NP	O
PJ34	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
now	RB	B-ADVP	O
demonstrate	VBP	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
PARP	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
DOX	NN	B-NP	O
.	.	O	O

PARP	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	B-NP	O
+	SYM	B-NP	O
and	CC	O	O
PARP	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
mice	NNS	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
DOX	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
performance	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
depressed	VBN	I-VP	O
in	IN	B-PP	O
PARP	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
+	SYM	B-NP	O
mice	NNS	I-NP	O
,	,	O	O
but	CC	O	O
only	RB	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
smaller	JJR	I-NP	O
extent	NN	I-NP	O
in	IN	B-PP	O
PARP	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
ones	NNS	B-NP	O
.	.	O	O

Similar	JJ	B-NP	O
experiments	NNS	I-NP	O
were	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
BALB	NN	B-NP	O
/	SYM	B-NP	O
c	NN	I-NP	O
mice	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
PJ34	NN	B-NP	O
or	CC	I-NP	O
vehicle	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
PJ34	NN	I-NP	O
significantly	RB	B-ADVP	O
improved	VBD	B-VP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
increased	VBD	B-VP	O
the	DT	B-NP	O
survival	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
PJ34	NN	I-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
DOX	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
lactate	NN	I-NP	O
dehydrogenase	NN	I-NP	O
and	CC	O	O
creatine	NN	B-NP	O
kinase	NN	I-NP	O
activities	NNS	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
metalloproteinase	NN	B-NP	O
activation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
PARP	NN	B-NP	O
activation	NN	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
cardiotoxicity	NN	I-NP	B
of	IN	B-PP	O
DOX	NN	B-NP	O
.	.	O	O

PARP	NN	B-NP	O
inhibitors	NNS	I-NP	O
may	MD	B-VP	O
exert	VB	I-VP	O
protective	JJ	B-NP	O
effects	NNS	I-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
cardiac	JJ	I-NP	B
complications	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
DOX	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Fluconazole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
.	.	O	O

To	TO	B-VP	O
present	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fluconazole	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
(	(	O	O
TDP	NN	B-NP	B
)	)	O	O
and	CC	O	O
discuss	NN	B-NP	O
fluconazole	NN	I-NP	O
s	VBZ	B-VP	O
role	NN	B-NP	O
in	IN	B-PP	O
causing	VBG	B-VP	O
TDP	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
white	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
Candida	NNP	B-NP	O
glabrata	NNS	I-NP	O
isolated	VBN	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
presacral	JJ	I-NP	O
abscess	NN	I-NP	O
developed	VBD	B-VP	O
TDP	NN	B-NP	B
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
commencing	VBG	B-VP	O
oral	JJ	B-NP	O
fluconazole	NN	I-NP	O
The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
other	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
TDP	NN	B-NP	B
,	,	O	O
including	VBG	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
cardiomyopathy	NN	B-NP	B
,	,	O	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
,	,	O	O
and	CC	O	O
electrolyte	NN	B-NP	O
abnormalities	NNS	I-NP	O
There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
temporal	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
fluconazole	NN	B-NP	O
and	CC	I-NP	O
TDP	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
TDP	NN	I-NP	B
resolved	VBN	B-VP	O
when	WRB	B-ADVP	O
fluconazole	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
continued	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
premature	JJ	B-NP	B
ventricular	JJ	I-NP	I
contractions	NNS	I-NP	I
and	CC	O	O
nonsustained	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
(	(	O	O
NSVT	NN	B-NP	B
)	)	O	O
until	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
cessation	NN	I-NP	O
DISCUSSION	NN	I-NP	O
:	:	O	O
Use	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
probability	NN	I-NP	O
scale	NN	I-NP	O
indicates	VBZ	B-VP	O
a	DT	B-NP	O
probable	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
fluconazole	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
TDP	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
mechanism	NN	I-NP	O
is	VBZ	B-VP	O
depression	NN	B-NP	B
of	IN	B-PP	O
rapidly	RB	B-VP	O
activating	VBG	I-VP	O
delayed	VBN	I-VP	O
rectifier	JJR	B-NP	O
potassium	NN	I-NP	O
currents	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
other	JJ	I-NP	O
etiology	NN	I-NP	O
identified	VBD	B-VP	O
that	WDT	B-NP	O
could	MD	B-VP	O
explain	VB	I-VP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
or	CC	O	O
TDP	NN	B-NP	B
The	DT	B-NP	O
complete	JJ	I-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
NSVT	NN	B-NP	B
and	CC	O	O
premature	JJ	B-NP	B
ventricular	JJ	I-NP	I
contractions	NNS	I-NP	I
followed	VBN	B-VP	O
by	IN	B-PP	O
normalization	NN	B-NP	O
of	IN	B-PP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
strongly	RB	B-ADVP	O
suggests	VBZ	B-VP	O
fluconazole	NN	B-NP	O
as	IN	B-SBAR	O
the	DT	B-NP	O
etiology	NN	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
that	IN	B-SBAR	O
fluconazole	NN	B-NP	O
,	,	O	O
even	RB	B-ADVP	O
at	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
may	MD	B-VP	O
cause	VB	I-VP	O
prolongation	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
QT	NN	I-NP	I
interval	NN	I-NP	I
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
TDP	NN	B-NP	B
.	.	O	O

Serial	JJ	B-NP	O
electrocardiographic	JJ	I-NP	O
monitoring	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
when	WRB	B-ADVP	O
fluconazole	NN	B-NP	O
is	VBZ	B-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
at	IN	B-PP	O
risk	NN	B-NP	O
for	IN	B-PP	O
ventricular	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methylprednisolone	NN	I-NP	O
may	MD	B-VP	O
do	VB	I-VP	O
more	JJR	B-NP	O
harm	NN	I-NP	O
for	IN	B-PP	O
spinal	JJ	B-NP	B
cord	NN	I-NP	I
injury	NN	I-NP	I
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
National	NNP	I-NP	O
Acute	NNP	I-NP	O
Spinal	NNP	I-NP	B
Cord	NNP	I-NP	I
Injury	NNP	I-NP	I
Studies	NNP	I-NP	O
(	(	O	O
NASCIS	NNP	B-NP	O
)	)	O	O
,	,	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methylprednisolone	NN	I-NP	O
became	VBD	B-VP	O
the	DT	B-NP	O
standard	NN	I-NP	O
of	IN	B-PP	O
care	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
spinal	JJ	I-NP	B
cord	NN	I-NP	I
injury	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
NASCIS	NNP	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
mention	NN	I-NP	O
regarding	VBG	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
corticosteroid	NN	I-NP	O
myopathy	NN	I-NP	B
that	IN	B-NP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methylprednisolone	NN	I-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
.	.	O	O

The	DT	B-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
methylprednisolone	NN	B-NP	O
recommended	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
NASCIS	NNP	I-NP	O
num	CD	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
steroids	NNS	B-NP	O
ever	RB	B-VP	O
being	VBG	I-VP	O
used	VBN	I-VP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
period	NN	I-NP	O
for	IN	B-PP	O
any	DT	B-NP	O
clinical	JJ	I-NP	O
condition	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
hypothesize	VBP	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
some	DT	B-NP	O
damage	NN	I-NP	B
to	TO	B-PP	I
the	DT	B-NP	I
muscle	NN	I-NP	I
of	IN	B-PP	O
spinal	JJ	B-NP	B
cord	NN	I-NP	I
injury	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

Further	RB	B-ADVP	O
,	,	O	O
steroid	NN	B-NP	O
myopathy	NN	I-NP	B
recovers	VBZ	B-VP	O
naturally	RB	B-ADVP	O
and	CC	O	O
the	DT	B-NP	O
neurological	JJ	I-NP	O
improvement	NN	I-NP	O
shown	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
NASCIS	NNP	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
just	RB	B-NP	O
a	DT	I-NP	O
recording	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
natural	JJ	I-NP	O
motor	NN	I-NP	O
recovery	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
steroid	NN	I-NP	O
myopathy	NN	I-NP	B
,	,	O	O
instead	RB	B-PP	O
of	IN	I-PP	O
any	DT	B-NP	O
protection	NN	I-NP	O
that	IN	B-SBAR	O
methylprednisolone	NN	B-NP	O
offers	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	B
cord	NN	I-NP	I
injury	NN	I-NP	I
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
discussion	NN	I-NP	O
considering	VBG	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
methylprednisolone	NN	I-NP	O
recommended	VBN	B-VP	O
by	IN	B-PP	O
NASCIS	NNP	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
acute	JJ	B-NP	O
corticosteroid	NN	I-NP	O
myopathy	NN	I-NP	B
.	.	O	O

Probing	VBG	B-VP	O
peripheral	JJ	B-NP	O
and	CC	I-NP	O
central	JJ	I-NP	O
cholinergic	JJ	I-NP	O
system	NN	I-NP	O
responses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
pharmacological	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
drugs	NNS	B-NP	O
that	WDT	B-NP	O
act	VBP	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
cholinergic	JJ	I-NP	O
system	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
iris	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
to	TO	I-VP	O
predict	VB	I-VP	O
deficits	NNS	B-NP	O
in	IN	B-PP	O
central	JJ	B-NP	O
cholinergic	JJ	I-NP	O
functioning	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
diseases	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
Alzheimer	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
yet	RB	B-ADVP	O
correlations	NNS	B-NP	O
between	IN	B-PP	O
central	JJ	B-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
responses	NNS	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
properly	RB	I-VP	O
studied	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
aging	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
tropicamide	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
pupil	NN	B-NP	O
diameter	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
effect	NN	I-NP	O
with	IN	B-PP	O
pilocarpine	NN	B-NP	O
.	.	O	O

Scopolamine	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
control	NN	I-NP	O
to	TO	B-VP	O
detect	VB	I-VP	O
age	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
central	JJ	B-NP	O
cholinergic	JJ	I-NP	O
functioning	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
.	.	O	O

Randomized	VBN	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
controlled	VBN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
elderly	JJ	I-NP	O
(	(	O	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
young	JJ	I-NP	O
(	(	O	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
volunteers	NNS	B-NP	O
.	.	O	O

Pupil	NN	B-NP	O
diameter	NN	I-NP	O
was	VBD	B-VP	O
monitored	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
computerized	JJ	I-NP	O
infrared	JJ	I-NP	O
pupillometer	NN	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
involved	VBD	B-VP	O
num	CD	B-NP	O
sessions	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
session	NN	I-NP	O
,	,	O	O
tropicamide	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microL	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
eye	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
.	.	O	O

In	IN	B-PP	O
another	DT	B-NP	O
session	NN	I-NP	O
,	,	O	O
tropicamide	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microL	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
,	,	O	O
followed	VBD	B-VP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
later	RB	B-ADVP	O
by	IN	B-PP	O
the	DT	B-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microL	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
eye	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
.	.	O	O

All	DT	B-NP	O
eye	NN	I-NP	O
drops	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
order	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
sessions	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
word	NN	B-NP	O
recall	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Buschke	NNP	I-NP	O
Selective	NNP	I-NP	O
Reminding	NNP	I-NP	O
Test	NNP	I-NP	O
over	IN	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

Pupil	NN	B-NP	O
size	NN	I-NP	O
at	IN	B-PP	O
time	NN	B-NP	O
points	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
tropicamide	NN	B-NP	O
and	CC	I-NP	O
pilocarpine	NN	I-NP	O
;	:	O	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
impairment	NN	I-NP	B
in	IN	B-PP	I
word	NN	B-NP	I
recall	NN	I-NP	I
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
elderly	JJ	B-NP	O
and	CC	I-NP	O
young	JJ	I-NP	O
volunteers	NNS	I-NP	O
in	IN	B-PP	O
pupillary	JJ	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
tropicamide	NN	B-NP	O
at	IN	B-PP	O
any	DT	B-NP	O
time	NN	I-NP	O
point	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
elderly	JJ	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
greater	JJR	I-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
net	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
pupil	NN	B-NP	O
size	NN	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
young	JJ	I-NP	O
group	NN	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
young	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
greater	JJR	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
impairment	NN	I-NP	B
in	IN	B-PP	I
word	NN	B-NP	I
recall	VBP	B-VP	I
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
age	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
pupillary	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
pilocarpine	NN	B-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
found	VBN	I-VP	O
with	IN	B-PP	O
tropicamide	NN	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
pilocarpine	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
to	TO	B-VP	O
assess	VB	I-VP	O
variations	NNS	B-NP	O
in	IN	B-PP	O
central	JJ	B-NP	O
cholinergic	JJ	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Acetazolamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
Gerstmann	NN	I-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Acute	JJ	B-NP	O
confusion	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
acetazolamide	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
known	VBN	I-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
impairment	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acetazolamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
Gerstmann	NN	I-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
highlight	VB	I-VP	O
predisposing	VBG	I-VP	O
factors	NNS	B-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
frequently	RB	I-VP	O
overlooked	VBN	I-VP	O
.	.	O	O

Hypomania	NN	B-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
syndrome	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
olanzapine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
female	JJ	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
a	DT	O	O
not	RB	O	O
otherwise	RB	B-ADVP	O
specified	VBD	B-VP	O
psychotic	JJ	B-NP	B
disorder	NN	I-NP	I
(	(	O	O
DSM	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
hypomania	NN	B-NP	B
shortly	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
olanzapine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Neutrophil	NN	B-NP	O
superoxide	NN	I-NP	O
and	CC	O	O
hydrogen	NN	B-NP	O
peroxide	NN	I-NP	O
production	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Defects	NNS	B-NP	O
in	IN	B-PP	O
superoxide	NN	B-NP	O
and	CC	I-NP	O
hydrogen	NN	I-NP	O
peroxide	NN	I-NP	O
production	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
bacterial	JJ	B-NP	B
infections	NNS	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
ALF	NN	B-NP	B
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
oxygen	NN	B-NP	O
radical	NN	I-NP	O
production	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
ALF	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
paracetamol	NN	B-NP	O
overdose	NN	I-NP	B
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
healthy	JJ	B-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

Neutrophils	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
ALF	NN	I-NP	B
patients	NNS	I-NP	O
were	VBD	B-VP	O
stimulated	VBN	I-VP	O
via	IN	B-PP	O
the	DT	B-NP	O
complement	NN	I-NP	O
receptors	NNS	I-NP	O
using	VBG	B-VP	O
zymosan	NN	B-NP	O
opsonized	VBN	B-VP	O
with	IN	B-PP	O
ALF	NN	B-NP	B
or	CC	I-NP	O
control	NN	I-NP	O
serum	NN	I-NP	O
.	.	O	O

Superoxide	NN	B-NP	O
and	CC	I-NP	O
hydrogen	NN	I-NP	O
peroxide	NN	I-NP	O
production	NN	I-NP	O
by	IN	B-PP	O
ALF	NN	B-NP	B
neutrophils	NNS	I-NP	O
stimulated	VBN	B-VP	O
with	IN	B-PP	O
zymosan	NN	B-NP	O
opsonized	VBN	B-VP	O
with	IN	B-PP	O
ALF	NN	B-NP	B
serum	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
control	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
defect	NN	I-NP	O
persisted	VBD	B-VP	O
when	WRB	B-ADVP	O
zymosan	NN	B-NP	O
opsonized	VBN	B-VP	O
by	IN	B-PP	O
control	NN	B-NP	O
serum	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

Superoxide	NN	B-NP	O
and	CC	I-NP	O
hydrogen	NN	I-NP	O
peroxide	NN	I-NP	O
production	NN	I-NP	O
in	IN	B-PP	O
neutrophils	NNS	B-NP	O
stimulated	VBN	B-VP	O
with	IN	B-PP	O
formyl	NN	B-NP	O
-	HYPH	B-NP	O
methionyl	NN	I-NP	O
-	HYPH	B-NP	O
leucyl	NN	I-NP	O
-	HYPH	O	O
phenylalanine	NN	B-NP	O
(	(	O	O
fMLP	NN	B-NP	O
)	)	O	O
from	IN	B-PP	O
a	DT	B-NP	O
further	JJ	I-NP	O
num	CD	I-NP	O
ALF	NN	I-NP	B
patients	NNS	I-NP	O
was	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
neutrophils	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
C3	NN	I-NP	O
complement	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
ALF	NN	B-NP	B
patients	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
a	DT	B-NP	O
neutrophil	NN	I-NP	O
defect	NN	I-NP	O
in	IN	B-PP	O
ALF	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
paracetamol	NN	B-NP	O
overdose	NN	I-NP	B
,	,	O	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
complement	NN	B-NP	O
dependent	JJ	I-NP	O
but	CC	I-ADJP	O
independent	JJ	I-ADJP	O
of	IN	B-PP	O
serum	NN	B-NP	O
complement	NN	I-NP	O
,	,	O	O
possibly	RB	B-VP	O
connected	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
complement	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

Absence	NN	B-NP	O
of	IN	B-PP	O
effect	NN	B-NP	O
of	IN	B-PP	O
sertraline	NN	B-NP	O
on	IN	B-PP	O
time	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
sensitization	NN	I-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
with	IN	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
study	NN	I-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
alone	RB	B-ADVP	O
and	CC	O	O
haloperidol	NN	B-NP	O
plus	CC	I-NP	O
sertraline	NN	I-NP	O
on	IN	B-PP	O
cognitive	JJ	B-NP	O
and	CC	I-NP	O
psychomotor	JJ	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
male	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
subjects	NNS	I-NP	O
received	VBD	B-VP	O
placebo	NN	B-NP	O
on	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
haloperidol	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
on	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

From	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
either	CC	O	O
sertraline	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
)	)	O	O
or	CC	O	O
placebo	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
)	)	O	O
;	:	O	O
the	DT	B-NP	O
sertraline	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
titrated	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
from	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	O	O
remained	VBD	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
final	JJ	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
administration	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Cognitive	JJ	B-NP	O
function	NN	I-NP	O
testing	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
before	IN	B-PP	O
dosing	NN	B-NP	O
and	CC	O	O
over	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
period	NN	I-NP	O
after	IN	B-PP	O
dosing	NN	B-NP	O
on	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
.	.	O	O

Impairment	NN	B-NP	B
of	IN	B-PP	I
cognitive	JJ	B-NP	I
function	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
on	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
but	CC	O	O
was	VBD	B-VP	O
not	RB	O	O
evident	JJ	B-ADJP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
dosing	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
haloperidol	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
again	RB	B-ADVP	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
greater	JJR	B-NP	O
impairment	NN	I-NP	O
with	IN	B-PP	O
earlier	JJR	B-NP	O
onset	NN	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
several	JJ	B-NP	O
tests	NNS	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
enhancement	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
indication	NN	I-NP	O
that	IN	B-SBAR	O
sertraline	NN	B-NP	O
exacerbated	VBD	B-VP	O
the	DT	B-NP	O
impairment	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
since	IN	B-PP	O
an	DT	B-NP	O
equivalent	JJ	I-NP	O
effect	NN	I-NP	O
also	RB	B-ADVP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
subjects	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
on	IN	B-PP	O
sertraline	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
on	IN	B-PP	O
placebo	NN	B-NP	O
)	)	O	O
withdrew	VBD	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
subjects	NNS	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
reported	VBD	B-VP	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
profiles	NNS	I-NP	O
of	IN	B-PP	O
sertraline	NN	B-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
placebo	NN	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
.	.	O	O

Haloperidol	NN	B-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
clear	JJ	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
that	WDT	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
worsened	VBN	I-VP	O
by	IN	B-PP	O
concomitant	JJ	B-NP	O
sertraline	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

Ciprofloxacin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cancer	NN	B-NP	B
.	.	O	O

Nephrotoxicity	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
is	VBZ	B-VP	O
uncommon	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cancer	NN	B-NP	B
who	WP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
that	WDT	B-NP	O
followed	VBD	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
are	VBP	B-VP	O
described	VBN	I-VP	O
and	CC	O	O
an	DT	B-NP	O
additional	JJ	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
reported	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

Other	JJ	B-ADJP	O
than	IN	B-PP	O
elevation	NN	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
characteristic	JJ	B-NP	O
clinical	JJ	I-NP	O
manifestations	NNS	I-NP	O
and	CC	O	O
abnormal	JJ	B-NP	O
laboratory	NN	I-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
not	RB	O	O
frequently	RB	B-ADJP	O
present	JJ	I-ADJP	O
.	.	O	O

Allergic	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
is	VBZ	B-VP	O
believed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
pathological	JJ	I-NP	O
-	HYPH	I-NP	O
process	NN	I-NP	O
.	.	O	O

Definitive	JJ	B-NP	O
diagnosis	NN	I-NP	O
requires	VBZ	B-VP	O
performance	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
biopsy	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
this	DT	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
always	RB	B-ADVP	O
feasible	JJ	B-ADJP	O
.	.	O	O

An	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
that	WDT	B-NP	O
followed	VBD	B-VP	O
the	DT	B-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
offending	VBG	I-NP	O
antibiotic	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
presumptive	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
ciprofloxacin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Case	NN	B-NP	O
report	NN	I-NP	O
:	:	O	O
pentamidine	NN	B-NP	O
and	CC	O	O
polymorphic	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
revisited	VBN	B-VP	O
.	.	O	O

Pentamidine	NN	B-NP	O
isethionate	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
ventricular	JJ	B-NP	B
tachyarrhythmias	NNS	I-NP	I
,	,	O	O
including	VBG	B-PP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
.	.	O	O

This	DT	B-NP	O
article	NN	I-NP	O
reports	VBZ	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
and	CC	O	O
reviews	VBZ	B-VP	O
all	DT	B-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
to	TO	B-PP	O
date	NN	B-NP	O
.	.	O	O

Pentamidine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	NNS	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
serum	NN	B-NP	O
magnesium	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
hypomagnesemia	NN	B-NP	B
may	MD	B-VP	O
synergistically	RB	I-VP	O
induce	VB	I-VP	O
torsade	NN	B-NP	O
.	.	O	O

Torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
occurred	VBD	B-VP	O
after	IN	B-PP	O
an	DT	B-NP	O
average	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
pentamidine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
no	DT	B-NP	O
other	JJ	I-NP	O
acute	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
pentamidine	NN	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Torsade	NNP	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
can	MD	B-VP	O
be	VB	I-VP	O
treated	VBN	I-VP	O
when	WRB	B-ADVP	O
recognized	VBN	B-VP	O
early	RB	B-ADVP	O
,	,	O	O
possibly	RB	B-ADVP	O
without	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
pentamidine	NN	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
QTc	NN	B-NP	B
interval	NN	I-NP	I
prolongation	NN	I-NP	I
is	VBZ	B-VP	O
observed	VBN	I-VP	O
,	,	O	O
early	JJ	B-NP	O
magnesium	NN	I-NP	O
supplementation	NN	I-NP	O
is	VBZ	B-VP	O
advocated	VBN	I-VP	O
.	.	O	O

Time	NN	B-NP	O
dependence	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
malondialdehyde	NN	I-NP	O
,	,	O	O
oxypurines	NNS	B-NP	O
,	,	O	O
and	CC	O	O
nucleosides	NNS	B-NP	O
during	IN	B-PP	O
incomplete	JJ	B-NP	O
cerebral	JJ	I-NP	B
ischemia	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Incomplete	JJ	B-NP	O
cerebral	JJ	I-NP	B
ischemia	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
min	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
by	IN	B-PP	O
bilaterally	RB	B-VP	O
clamping	VBG	I-VP	O
the	DT	B-NP	O
common	JJ	I-NP	O
carotid	NN	I-NP	O
arteries	NNS	I-NP	O
.	.	O	O

Peripheral	JJ	B-NP	O
venous	JJ	I-NP	O
blood	NN	I-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
withdrawn	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
femoral	JJ	I-NP	O
vein	NN	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
(	(	O	O
once	RB	B-ADVP	O
every	DT	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
)	)	O	O
before	IN	B-PP	O
ischemia	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
time	NN	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
ischemia	NN	B-NP	B
.	.	O	O

Plasma	NN	B-NP	O
extracts	NNS	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
highly	RB	I-NP	O
sensitive	JJ	I-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
performance	NN	I-NP	O
liquid	JJ	I-NP	O
chromatographic	JJ	I-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
direct	JJ	I-NP	O
determination	NN	I-NP	O
of	IN	B-PP	O
malondialdehyde	NN	B-NP	O
,	,	O	O
oxypurines	NNS	B-NP	O
,	,	O	O
and	CC	O	O
nucleosides	NNS	B-NP	O
.	.	O	O

During	IN	B-PP	O
ischemia	NN	B-NP	B
,	,	O	O
a	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
oxypurines	NNS	I-NP	O
and	CC	I-NP	O
nucleosides	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Plasma	NN	B-NP	O
malondialdehyde	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
minimal	JJ	B-NP	O
amount	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
time	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
mumol	NN	I-NP	O
/	SYM	B-NP	O
liter	NN	I-NP	O
plasma	NN	I-NP	O
;	:	O	O
SD	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
increased	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
ischemia	NN	B-NP	B
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
fivefold	JJ	I-NP	O
increase	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
carotid	NN	B-NP	O
occlusion	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
mumol	NN	I-NP	O
/	SYM	B-NP	O
liter	NN	I-NP	O
plasma	NN	I-NP	O
;	:	O	O
SD	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Increased	VBN	B-NP	O
plasma	NN	I-NP	O
malondialdehyde	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
recorded	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
other	JJ	I-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
subjected	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
b.w.	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cyclooxygenase	NN	I-NP	O
inhibitor	NN	I-NP	O
acetylsalicylate	NN	I-NP	O
intravenously	RB	B-ADVP	O
immediately	RB	I-ADVP	O
before	IN	B-PP	O
ischemia	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
b.w.	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
drug	NN	I-NP	O
nitroprusside	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
flow	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microliters	NNS	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
intravenously	RB	B-ADVP	O
during	IN	B-PP	O
ischemia	NN	B-NP	B
,	,	O	O
although	IN	B-SBAR	O
in	IN	B-PP	O
this	DT	B-NP	O
latter	JJ	I-NP	O
group	NN	I-NP	O
malondialdehyde	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
determination	NN	I-NP	O
of	IN	B-PP	O
malondialdehyde	NN	B-NP	O
,	,	O	O
oxypurines	NNS	B-NP	O
,	,	O	O
and	CC	O	O
nucleosides	NNS	B-NP	O
in	IN	B-PP	O
peripheral	JJ	B-NP	O
blood	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
monitor	VB	I-VP	O
the	DT	B-NP	O
metabolic	JJ	I-NP	O
alterations	NNS	I-NP	O
of	IN	B-PP	O
tissues	NNS	B-NP	O
occurring	VBG	B-VP	O
during	IN	B-PP	O
ischemic	JJ	B-NP	B
phenomena.	NN	I-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Cholinergic	JJ	B-NP	O
toxicity	NN	I-NP	B
resulting	VBG	B-VP	O
from	IN	B-PP	O
ocular	JJ	B-NP	O
instillation	NN	I-NP	O
of	IN	B-PP	O
echothiophate	NN	B-NP	O
iodide	NN	I-NP	O
eye	NN	I-NP	O
drops	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
cholinergic	JJ	I-NP	O
syndrome	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
echothiophate	NN	B-NP	O
iodide	NN	I-NP	O
ophthalmic	JJ	I-NP	O
drops	NNS	I-NP	O
,	,	O	O
presented	VBD	B-VP	O
with	IN	B-PP	O
profound	JJ	B-NP	O
muscle	NN	I-NP	B
weakness	NN	I-NP	I
and	CC	O	O
was	VBD	B-VP	O
initially	RB	I-VP	O
given	VBN	I-VP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
myasthenia	NN	B-NP	B
gravis	NN	I-NP	I
.	.	O	O

Red	JJ	B-NP	O
blood	NN	I-NP	O
cell	NN	I-NP	O
and	CC	I-NP	O
serum	NN	I-NP	O
cholinesterase	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
severely	RB	I-VP	O
depressed	VBN	I-VP	O
and	CC	O	O
symptoms	NNS	B-NP	O
resolved	VBN	B-VP	O
spontaneously	RB	I-VP	O
following	VBG	I-VP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
eye	NN	I-NP	O
drops	VBZ	B-VP	O
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
carboplatin	NN	I-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Carboplatin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
in	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
to	TO	B-PP	O
adult	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
girl	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
carboplatin	NN	I-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
parameningeal	JJ	I-NP	O
embryonal	JJ	I-NP	B
rhabdomyosarcoma	NN	I-NP	I
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
developed	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
slow	JJ	I-NP	O
partial	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Possible	JJ	B-NP	O
contributing	VBG	I-NP	O
factors	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Endometrial	JJ	B-NP	B
carcinoma	NN	I-NP	I
after	IN	B-PP	O
Hodgkin	NN	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
childhood	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
metastic	JJ	B-NP	O
endometrial	JJ	I-NP	B
carcinoma	NN	I-NP	I
after	IN	B-PP	O
Hodgkin	NN	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
childhood	NN	B-NP	O
.	.	O	O

She	PRP	B-NP	O
had	VBD	B-VP	O
ovarian	JJ	B-NP	B
failure	NN	I-NP	I
after	IN	B-PP	O
abdominal	JJ	B-NP	O
irradiation	NN	I-NP	O
and	CC	I-NP	O
chemotherapy	NN	I-NP	O
for	IN	B-PP	O
Hodgkin	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
received	VBD	B-VP	O
exogenous	JJ	B-NP	O
estrogens	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
treatment	NN	I-NP	O
implicated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
in	IN	B-PP	O
menopausal	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Young	JJ	B-NP	O
women	NNS	I-NP	O
on	IN	B-PP	O
replacement	NN	B-NP	O
estrogens	NNS	I-NP	O
for	IN	B-PP	O
ovarian	JJ	B-NP	B
failure	NN	I-NP	I
after	IN	B-PP	O
cancer	NN	B-NP	B
therapy	NN	I-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
have	VB	I-VP	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
carcinoma	NN	I-NP	I
and	CC	O	O
should	MD	B-VP	O
be	VB	I-VP	O
examined	VBN	I-VP	O
periodically	RB	B-ADVP	O
.	.	O	O

Induction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
obstructive	JJ	I-NP	B
sleep	NN	I-NP	I
apnea	NN	I-NP	I
syndrome	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
by	IN	B-PP	O
exogenous	JJ	B-NP	O
androgen	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
documented	VBD	B-VP	O
airway	NN	B-NP	O
occlusion	NN	I-NP	O
during	IN	B-PP	O
sleep	NN	B-NP	O
and	CC	O	O
an	DT	B-NP	O
abnormally	RB	I-NP	O
high	JJ	I-NP	O
supraglottic	JJ	I-NP	O
resistance	NN	I-NP	O
while	IN	B-SBAR	O
awake	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yr	NN	I-NP	O
-	HYPH	I-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
developed	VBN	I-VP	O
physical	JJ	B-NP	O
changes	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
syndrome	NN	I-NP	B
of	IN	B-PP	I
obstructive	JJ	B-NP	I
sleep	NN	I-NP	I
apnea	NN	I-NP	I
while	IN	B-SBAR	O
being	VBG	B-VP	O
administered	VBN	I-VP	O
exogenous	JJ	B-NP	O
androgens	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
the	DT	B-NP	O
androgens	NNS	I-NP	O
were	VBD	B-VP	O
withdrawn	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
physical	JJ	B-NP	O
changes	NNS	I-NP	O
,	,	O	O
symptoms	NNS	B-NP	O
,	,	O	O
sleep	NN	B-NP	O
study	NN	I-NP	O
,	,	O	O
and	CC	O	O
supraglottic	JJ	B-NP	O
resistance	NN	I-NP	O
all	DT	O	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
.	.	O	O

A	DT	B-NP	O
rechallenge	NN	I-NP	O
with	IN	B-PP	O
androgen	NN	B-NP	O
produced	VBD	B-VP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
obstructive	JJ	B-NP	B
sleep	JJ	I-NP	I
apnea	NN	I-NP	I
that	WDT	B-NP	O
abated	VBD	B-VP	O
upon	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hormone	NN	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
favored	VBN	I-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
androgens	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
sleep	NN	B-NP	B
apnea	NN	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
report	NN	I-NP	O
provides	VBZ	B-VP	O
direct	JJ	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
role	NN	I-NP	O
.	.	O	O

Structural	JJ	B-NP	O
and	CC	I-NP	O
functional	JJ	I-NP	O
measurements	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
androgens	NNS	B-NP	O
exert	VBP	B-VP	O
a	DT	B-NP	O
permissive	JJ	I-NP	O
or	CC	I-NP	O
necessary	JJ	I-NP	O
action	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
structural	JJ	I-NP	O
configuration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
oropharynx	NN	I-NP	O
that	WDT	B-NP	O
predisposes	VBZ	B-VP	O
to	TO	B-PP	O
obstruction	NN	B-NP	O
during	IN	B-PP	O
sleep	NN	B-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
obstructive	JJ	I-NP	B
sleep	NN	I-NP	I
apnea	NN	I-NP	I
syndrome	NN	I-NP	I
must	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
androgen	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
on	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
existing	VBG	I-NP	O
and	CC	I-NP	O
aminonucleoside	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
proteinuria	NN	I-NP	B
in	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

Proteinuria	NNP	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
side	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
hypertensive	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
reproducing	VBG	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
renal	JJ	I-NP	B
abnormality	NN	I-NP	I
with	IN	B-PP	O
captopril	NN	B-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
SHR	NN	B-NP	O
.	.	O	O

Oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
aggravate	VB	I-VP	O
proteinuria	NN	B-NP	B
pre	AFX	O	O
-	HYPH	O	O
existing	VBG	B-VP	O
in	IN	B-PP	O
SHR	NN	B-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
captopril	NN	B-NP	O
treatment	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
potentiate	VB	I-VP	O
or	CC	I-VP	O
facilitate	VB	I-VP	O
development	NN	B-NP	O
of	IN	B-PP	O
massive	JJ	B-NP	O
proteinuria	NN	I-NP	B
invoked	VBN	B-VP	O
by	IN	B-PP	O
puromycin	NN	B-NP	O
aminonucleoside	NN	I-NP	O
in	IN	B-PP	O
SHR	NN	B-NP	O
.	.	O	O

Captopril	NNP	B-NP	O
had	VBD	B-VP	O
little	JJ	B-NP	O
or	CC	I-NP	O
no	DT	I-NP	O
demonstrable	JJ	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
serum	NN	B-NP	O
electrolyte	NN	I-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
excretion	NN	B-NP	O
of	IN	B-PP	O
urine	NN	B-NP	O
,	,	I-NP	O
sodium	NN	I-NP	O
and	CC	I-NP	O
potassium	NN	I-NP	O
,	,	O	O
endogenous	JJ	B-NP	O
creatinine	NN	I-NP	O
clearance	NN	I-NP	O
,	,	O	O
body	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
and	CC	O	O
food	NN	B-NP	O
and	CC	I-NP	O
water	NN	I-NP	O
consumption	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
ketone	NN	B-NP	O
bodies	NNS	I-NP	O
were	VBD	B-VP	O
consistently	RB	B-ADJP	O
present	JJ	I-ADJP	O
in	IN	B-PP	O
urine	NN	B-NP	O
and	CC	O	O
several	JJ	B-NP	O
lethalities	NNS	I-NP	O
occurred	VBD	B-VP	O
during	IN	B-PP	O
multiple	JJ	B-NP	O
dosing	NN	I-NP	O
of	IN	B-PP	O
captopril	NN	B-NP	O
in	IN	B-PP	O
SHR	NN	B-NP	O
.	.	O	O

Epileptogenic	JJ	B-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
enflurane	NN	B-NP	O
and	CC	O	O
their	PRP$	B-NP	O
clinical	JJ	I-NP	O
interpretation	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
EEG	NN	B-NP	O
changes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
single	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
enflurane	NN	B-NP	O
anesthesia	NN	I-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
,	,	O	O
enflurane	NN	B-NP	O
administered	VBN	B-VP	O
during	IN	B-PP	O
a	DT	B-NP	O
donor	NN	I-NP	O
nephrectomy	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
unexpected	JJ	B-NP	O
partial	JJ	I-NP	O
motor	NN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Until	IN	B-PP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
was	VBD	B-VP	O
correctly	RB	I-VP	O
identified	VBN	I-VP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
inappropriately	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
anticonvulsants	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
other	JJ	I-NP	O
patients	NNS	I-NP	O
suffered	VBN	B-VP	O
from	IN	B-PP	O
partial	JJ	B-NP	O
,	,	I-NP	O
complex	JJ	I-NP	O
and	CC	I-NP	O
generalized	VBN	I-NP	O
seizures	NNS	I-NP	B
uncontrolled	JJ	B-ADJP	O
by	IN	B-PP	O
medication	NN	B-NP	O
.	.	O	O

Epileptic	JJ	B-NP	B
foci	NNS	I-NP	O
delineated	VBN	B-VP	O
and	CC	I-VP	O
activated	VBN	I-VP	O
by	IN	B-PP	O
enflurane	NN	B-NP	O
were	VBD	B-VP	O
surgically	RB	I-VP	O
ablated	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
now	RB	B-ADVP	O
seizure	NN	B-NP	B
-	HYPH	B-ADJP	O
free	JJ	I-ADJP	O
.	.	O	O

Previous	JJ	B-NP	O
exposures	NNS	I-NP	O
to	TO	B-VP	O
enflurane	VB	I-VP	O
have	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
disclosed	VBN	I-VP	O
to	TO	I-VP	O
avoid	VB	I-VP	O
mistakes	NNS	B-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
interpretation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
EEG	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
enflurane	NN	B-NP	O
may	MD	B-VP	O
prove	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
fast	JJ	I-NP	O
acting	VBG	I-NP	O
activator	NN	I-NP	O
of	IN	B-PP	O
epileptic	JJ	B-NP	B
foci	NNS	I-NP	O
during	IN	B-PP	O
corticography	NN	B-NP	O
or	CC	O	O
depth	JJ	B-NP	O
electrode	NN	I-NP	O
intraoperative	JJ	I-NP	O
recordings	NNS	I-NP	O
.	.	O	O

Reversible	JJ	B-NP	O
cerebral	JJ	I-NP	B
lesions	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
tiazofurin	NN	B-NP	O
usage	NN	I-NP	O
:	:	O	O
MR	NN	B-NP	O
demonstration	NN	I-NP	O
.	.	O	O

Tiazofurin	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
chemotherapeutic	JJ	I-NP	O
agent	NN	I-NP	O
currently	RB	B-VP	O
undergoing	VBG	I-VP	O
clinical	JJ	B-NP	O
evaluation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
our	PRP$	B-NP	O
results	NNS	I-NP	O
with	IN	B-PP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
(	(	O	O
MR	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
demonstrating	VBG	B-VP	O
reversible	JJ	B-NP	O
cerebral	JJ	I-NP	B
abnormalities	NNS	I-NP	I
concurrent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
abnormalities	NNS	I-NP	O
on	IN	B-PP	O
MR	NN	B-NP	O
were	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
findings	NNS	B-NP	O
on	IN	B-PP	O
CT	NN	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
with	IN	B-PP	O
cerebral	JJ	B-NP	O
angiography	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
MR	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
this	DT	B-NP	O
new	JJ	I-NP	O
agent	NN	I-NP	O
is	VBZ	B-VP	O
illustrated	VBN	I-VP	O
.	.	O	O

Antagonism	NN	B-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
sedative	JJ	I-NP	O
effects	NNS	I-NP	O
by	IN	B-PP	O
Ro15	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
under	IN	B-PP	O
lumbar	JJ	B-NP	O
epidural	JJ	I-NP	O
block	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
placebo	NN	I-NP	O
-	HYPH	B-VP	O
controlled	VBN	B-NP	O
investigation	NN	I-NP	O
of	IN	B-PP	O
efficacy	NN	B-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
Ro15	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
a	DT	B-NP	O
placebo	NN	I-NP	O
in	IN	B-PP	O
reversing	VBG	B-VP	O
diazepam	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
effects	NNS	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
under	IN	B-PP	O
epidural	JJ	B-NP	O
block	NN	I-NP	O
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
local	JJ	I-NP	O
tolerance	NN	I-NP	O
and	CC	O	O
general	JJ	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
Ro15	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
sedated	VBN	I-VP	O
with	IN	B-PP	O
diazepam	NN	B-NP	O
for	IN	B-PP	O
surgery	NN	B-NP	O
under	IN	B-PP	O
epidural	JJ	B-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

Antagonism	NN	B-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
effects	NNS	I-NP	O
by	IN	B-PP	O
Ro15	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
postoperatively	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
placebo	NN	I-NP	O
-	HYPH	B-VP	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
subjective	JJ	B-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
mood	NN	B-NP	O
rating	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
objective	JJ	I-NP	O
test	NN	I-NP	O
of	IN	B-PP	O
performance	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
amnesia	NN	B-NP	B
,	,	O	O
and	CC	O	O
vital	JJ	B-NP	O
signs	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
for	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
trial	NN	I-NP	O
drug	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
for	IN	B-PP	O
mood	NN	B-NP	O
rating	NN	I-NP	O
,	,	O	O
amnesia	NN	B-NP	B
,	,	O	O
or	CC	O	O
vital	JJ	B-NP	O
signs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
Ro15	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
group	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
performance	NN	I-NP	O
test	NN	I-NP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
reaction	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
site	NN	I-NP	O
.	.	O	O

Enhanced	VBN	B-NP	O
stimulus	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
neurotransmitter	NN	I-NP	O
overflow	NN	I-NP	O
in	IN	B-PP	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
prejunctional	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
activation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
examines	VBZ	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
epinephrine	NN	I-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
stimulus	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
(	(	O	O
num	CD	B-NP	O
Hz	NN	I-NP	O
)	)	I-NP	O
endogenous	JJ	I-NP	O
neurotransmitter	NN	I-NP	O
overflow	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
perfused	VBN	I-NP	O
kidney	NN	I-NP	O
of	IN	B-PP	O
vehicle	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
epinephrine	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
catecholamine	NN	I-NP	O
stores	NNS	I-NP	O
and	CC	I-NP	O
stimulus	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
overflow	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
vehicle	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
only	RB	B-ADVP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
epinephrine	NN	B-NP	O
treatment	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
incorporation	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
into	IN	B-PP	O
renal	JJ	B-NP	O
catecholamine	NN	I-NP	O
stores	NNS	I-NP	O
such	JJ	B-ADJP	O
that	IN	B-SBAR	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
catecholamine	NN	I-NP	O
present	NN	I-NP	O
was	VBD	B-VP	O
epinephrine	NN	B-NP	O
while	IN	B-SBAR	O
the	DT	B-NP	O
norepinephrine	NN	I-NP	O
content	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
degree	NN	I-NP	O
.	.	O	O

Total	JJ	B-NP	O
tissue	NN	I-NP	O
catecholamine	NN	I-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
molar	JJ	I-NP	O
basis	NN	I-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

Stimulus	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
fractional	JJ	I-NP	O
overflow	NN	I-NP	O
of	IN	B-PP	O
neurotransmitter	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
epinephrine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
kidneys	NNS	I-NP	O
was	VBD	B-VP	O
approximately	RB	B-ADVP	O
twice	RB	B-ADJP	O
normal	JJ	I-ADJP	O
and	CC	O	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
both	CC	O	O
norepinephrine	NN	B-NP	O
and	CC	I-NP	O
epinephrine	NN	I-NP	O
in	IN	B-PP	O
proportions	NNS	B-NP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
fractional	JJ	B-NP	O
overflow	NN	I-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
neuronal	JJ	B-NP	O
and	CC	I-NP	O
extraneuronal	JJ	I-NP	O
uptake	NN	I-NP	O
blockade	NN	I-NP	O
.	.	O	O

Propranolol	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
stimulus	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
overflow	NN	I-NP	O
in	IN	B-PP	O
either	DT	B-NP	O
group	NN	I-NP	O
.	.	O	O

Phentolamine	NN	B-NP	O
increased	VBD	B-VP	O
stimulus	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
overflow	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
although	IN	B-SBAR	O
the	DT	B-NP	O
increment	NN	I-NP	O
in	IN	B-PP	O
overflow	NN	B-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
epinephrine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
chronic	JJ	B-NP	O
epinephrine	NN	I-NP	O
treatment	NN	I-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
enhanced	VBN	B-NP	O
fractional	JJ	I-NP	O
neurotransmitter	NN	I-NP	O
overflow	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
neither	CC	O	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
prejunctional	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
influences	NNS	I-NP	O
nor	CC	O	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
neuronal	JJ	B-NP	O
and	CC	I-NP	O
extraneuronal	JJ	I-NP	O
uptake	NN	I-NP	O
mechanisms	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
this	DT	B-NP	O
alteration	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
data	NNS	B-NP	O
obtained	VBN	B-VP	O
with	IN	B-PP	O
phentolamine	NN	B-NP	O
alone	RB	B-ADVP	O
do	VBP	B-VP	O
not	RB	I-VP	O
suggest	VB	I-VP	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
adrenoceptor	NN	I-NP	O
desensitization	NN	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
enhanced	VBN	I-NP	O
neurotransmitter	NN	I-NP	O
overflow	NN	I-NP	O
after	IN	B-PP	O
epinephrine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Ocular	JJ	B-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
juvenile	JJ	B-NP	B
rheumatoid	JJ	I-NP	I
arthritis	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
followed	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
juvenile	JJ	B-NP	B
rheumatoid	JJ	I-NP	I
arthritis	NN	I-NP	I
closely	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
iridocyclitis	NN	B-NP	B
.	.	O	O

Iridocyclitis	NN	B-NP	B
was	VBD	B-VP	O
seen	VBN	I-VP	O
most	RBS	B-ADVP	O
frequently	RB	I-ADVP	O
in	IN	B-PP	O
young	JJ	B-NP	O
female	JJ	I-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
the	DT	B-NP	O
monoarticular	JJ	I-NP	O
or	CC	I-NP	O
pauciatricular	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arthritis	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
uveitis	NN	B-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
noncontributory	JJ	I-NP	O
ocular	JJ	I-NP	O
history	NN	I-NP	O
on	IN	B-PP	O
entry	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
active	JJ	B-NP	O
uveitis	NN	I-NP	B
on	IN	B-PP	O
entry	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
approach	NN	I-NP	O
was	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
detecting	VBG	B-VP	O
uveitis	NN	B-NP	B
in	IN	B-PP	O
new	JJ	B-NP	O
cases	NNS	I-NP	O
and	CC	I-NP	O
exacerbations	NNS	I-NP	O
of	IN	B-PP	O
uveitis	NN	B-NP	B
in	IN	B-PP	O
established	VBN	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
uveitis	NN	B-NP	B
had	VBD	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
identifiable	JJ	I-NP	O
signs	NNS	I-NP	O
or	CC	I-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
red	JJ	B-NP	O
eye	NN	I-NP	O
,	,	O	O
ocular	JJ	B-NP	B
pain	NN	I-NP	I
,	,	O	O
decreased	VBD	B-VP	B
visual	JJ	B-NP	I
acuity	NN	I-NP	I
,	,	O	O
or	CC	O	O
photophobia	NN	B-NP	B
,	,	O	O
in	IN	B-PP	O
order	NN	B-NP	O
of	IN	B-PP	O
decreasing	VBG	B-VP	O
frequency	NN	B-NP	O
.	.	O	O

Even	RB	B-ADVP	O
after	IN	B-PP	O
early	JJ	B-NP	O
detection	NN	I-NP	O
and	CC	O	O
prompt	JJ	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
uveitis	NN	B-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
respond	VB	I-VP	O
to	TO	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
intensive	JJ	B-NP	O
topical	JJ	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
corticosteroids	NNS	B-NP	O
and	CC	I-NP	O
mydriatics	NNS	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
this	DT	B-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
dramatic	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
blinding	VBG	B-VP	O
complications	NNS	B-NP	O
of	IN	B-PP	O
uveitis	NN	B-NP	B
cited	VBN	B-VP	O
in	IN	B-PP	O
earlier	JJR	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Cataract	NN	B-NP	B
and	CC	I-NP	O
band	NN	I-NP	B
keratopathy	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
group	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
chloroquine	NN	B-NP	O
or	CC	I-NP	O
hydroxychloroquine	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
found	VBN	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
chorioretinopathy	NN	B-NP	B
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Systemically	RB	B-NP	O
administered	VBN	I-NP	O
corticosteroids	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
;	:	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
posterior	JJ	B-NP	O
subcapsular	JJ	I-NP	O
cataracts	NNS	I-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Typical	JJ	B-NP	O
keratoconjunctivitis	NN	I-NP	B
sicca	NN	I-NP	O
developed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
uveitis	NN	I-NP	B
cases	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
uveitis	NN	B-NP	B
and	CC	I-NP	O
JRA	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
noted	VBN	I-VP	O
previously	RB	B-ADVP	O
.	.	O	O

Surgical	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
cataracts	NNS	B-NP	B
,	,	O	O
band	NN	B-NP	B
keratopathy	NN	I-NP	I
,	,	O	O
and	CC	O	O
glaucoma	NN	B-NP	B
achieved	VBD	B-VP	O
uniformly	RB	I-VP	O
discouraging	VBG	I-VP	O
results	NNS	B-NP	O
.	.	O	O

Water	JJ	B-NP	B
intoxication	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
oxytocin	NN	B-NP	O
administration	NN	I-NP	O
during	IN	B-PP	O
saline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
abortion	NN	I-NP	B
.	.	O	O
